PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Kinscherf, R; Deigner, HP; Usinger, C; Pill, J; Wagner, M; Kamencic, H; Hou, DM; Chen, M; Schmiedt, W; Schrader, M; Kovacs, G; Kato, K; Metz, J				Kinscherf, R; Deigner, HP; Usinger, C; Pill, J; Wagner, M; Kamencic, H; Hou, DM; Chen, M; Schmiedt, W; Schrader, M; Kovacs, G; Kato, K; Metz, J			Induction of mitochondrial manganese superoxide dismutase in macrophages by oxidized LDL: its relevance in atherosclerosis of humans and heritable hyperlipidemic rabbits	FASEB JOURNAL			English	Article						antioxidants; apoptosis; glutathione; p53	LOW-DENSITY-LIPOPROTEIN; TUMOR-NECROSIS-FACTOR; LIPID-PROTEIN ADDUCTS; ANTIOXIDANT ENZYMES; OXIDATIVE STRESS; INTRACELLULAR GLUTATHIONE; PROTECTIVE ROLE; HUMAN-MONOCYTES; FREE-RADICALS; VITAMIN-E	The objective of the study was to analyze the intracellular antioxidative response of macrophages (M Phi) exposed to increased levels of low density lipoprotein (LDL). We studied manganese superoxide dismutase (MnSOD) and, in part, GSH in cultured human and rabbit M Phi, and in atheromatous arterial tissue of humans and heritable hyperlipidemic (HHL) rabbits. Incubation of human M Phi with oxidized-LDL (ox-LDL) resulted in an induction of MnSOD mRNA production as shown by RT-PCR. MnSOD immunoreactivity (IR) was found to be located in the mitochondria of M Phi. In HHL rabbits, MnSOD activity and GSH concentration were significantly increased in atherosclerotic intima compared to the media of the aorta, but significantly decreased (P < 0.01) in larger plaques compared with smaller ones, resulting in a significant inverse correlation of MnSOD activity (r = -0.67, P < 0.001) and GSH concentration (r = -0.57, P < 0.01) with plaque size. Immunohistology of the atherosclerotic intima revealed MnSOD-IR in Mac-1 (CD 11b/CD 18)-immunoreactive (ir) M Phi of human arteries and, similarly, in RAM-11-ir M Phi, of rabbit ones. The relation of MnSOD-ir M Phi decreased with plaque advancement, which is consistent with biochemical finding. Most MnSOD-ir M Phi in atherosclerotic plaques revealed TUNEL-positive nuclei, indicating DNA strand breaks, and p53-1R. We conclude that mitochondrial antioxidants such as MnSOD are induced in M Phi in vitro and in atherosclerotic arteries as a reply to increased mitochondrial oxidation. As normal consequences of an increased oxidative stress due to the exposure to ox-LDL nuclear DNA strand breaks occur, which are suggested to be a signal to increase p53 protein levels. Reactive oxygen species-mediated mitochondrial-dependent pathways are suggested as major contributing pathomechanisms to nuclear damage, which eventually may result in apoptosis. A common response to increased oxidative stress due to modified LDL is presumed in rabbit and human atherosclerotic plaques.	Univ Heidelberg, Dept Anat & Cell Biol 3, D-69120 Heidelberg, Germany; Univ Heidelberg, Dept Anat & Cell Biol 2, D-69120 Heidelberg, Germany; Univ Heidelberg, Inst Pharmaceut Chem, D-69120 Heidelberg, Germany; Univ Heidelberg, Dept Urol, D-69120 Heidelberg, Germany; Dept Cardiothorac & Vasc Surg, D-55101 Mainz, Germany; Boehringer Mannheim GmbH, Dept Preclin Res, D-68298 Mannheim, Germany; Aichi Human Serv Ctr, Inst Dev Res, Dept Biochem, Kasugai, Aichi 48003, Japan	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Kinscherf, R (corresponding author), Univ Heidelberg, Dept Anat & Cell Biol 3, INF 307, D-69120 Heidelberg, Germany.		Kinscherf, Ralf/AAV-7164-2021					ASAYAMA K, 1985, AM J PHYSIOL, V249, pC393, DOI 10.1152/ajpcell.1985.249.5.C393; Bjorkerud S, 1996, AM J PATHOL, V149, P367; BOCCIO GD, 1990, ATHEROSCLEROSIS, V81, P127; COHN ZA, 1965, J EXP MED, V121, P153, DOI 10.1084/jem.121.1.153; DARLEYUSMAR VM, 1991, BIOCHEM J, V278, P429, DOI 10.1042/bj2780429; DAUGHERTY A, 1995, CARDIOVASC RES, V29, P297, DOI 10.1016/0008-6363(96)88585-3; DAUGHERTY A, 1988, ARTERIOSCLEROSIS, V8, P768, DOI 10.1161/01.ATV.8.6.768; DHAUNSI GS, 1994, CARCINOGENESIS, V15, P1923, DOI 10.1093/carcin/15.9.1923; ESTERBAUER H, 1989, FETT WISS TECHNOL, V91, P316, DOI 10.1002/lipi.19890910805; Gomez EO, 1996, BIOCHEM BIOPH RES CO, V228, P505, DOI 10.1006/bbrc.1996.1690; GOTOH N, 1993, BIOCHEM J, V296, P151, DOI 10.1042/bj2960151; GOTZ C, 1995, REV PHYSL BIOCH PHAR, V127, P64; GRECO AV, 1990, EXP PATHOL-JENA, V40, P19, DOI 10.1016/S0232-1513(11)80281-1; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; HAN DKM, 1995, AM J PATHOL, V147, P267; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HARRIS ED, 1992, FASEB J, V6, P2675, DOI 10.1096/fasebj.6.9.1612291; Henkart PA, 1996, J EXP MED, V183, P1293, DOI 10.1084/jem.183.4.1293; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; HOFFMAN R, 1992, ATHEROSCLEROSIS, V93, P105, DOI 10.1016/0021-9150(92)90204-T; HOSHIDA S, 1993, AM J PHYSIOL, V264, pH33, DOI 10.1152/ajpheart.1993.264.1.H33; JOSEPH BZ, 1993, INFLAMMATION, V17, P361, DOI 10.1007/BF00918997; Jovinge S, 1996, ARTERIOSCL THROM VAS, V16, P1573, DOI 10.1161/01.ATV.16.12.1573; KAESBERG B, 1993, ARTERIOSCLER THROMB, V13, P133, DOI 10.1161/01.ATV.13.1.133; KIKKAWA Y, 1984, LAB INVEST, V50, P62; KINSCHERF R, 1994, FASEB J, V8, P448, DOI 10.1096/fasebj.8.6.7909525; KINSCHERF R, 1995, HISTOCHEM CELL BIOL, V104, P295, DOI 10.1007/BF01464325; Kinscherf R, 1997, FEBS LETT, V405, P55, DOI 10.1016/S0014-5793(97)00157-9; KUZUYA M, 1989, BIOCHEM BIOPH RES CO, V163, P1466, DOI 10.1016/0006-291X(89)91144-3; MACHLIN LJ, 1987, FASEB J, V1, P441, DOI 10.1096/fasebj.1.6.3315807; MANTHA SV, 1993, ATHEROSCLEROSIS, V101, P135, DOI 10.1016/0021-9150(93)90110-G; MARKLUND SL, 1992, J BIOL CHEM, V267, P6696; MASUDA A, 1988, FASEB J, V2, P3087, DOI 10.1096/fasebj.2.15.3263930; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; METZ J, 1990, Z GERONTOL, V23, P140; Nakano T, 1996, CANCER RES, V56, P2771; Napoli C, 1994, Cardiologia, V39, P345; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PARATHASARATHY S, 1986, J CLIN INVEST, V77, P641; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POLIMENI PI, 1987, COMPUT BIOMED RES, V20, P113, DOI 10.1016/0010-4809(87)90039-5; Polla BS, 1996, FREE RADICAL RES, V25, P125, DOI 10.3109/10715769609149917; PORRECA E, 1993, ATHEROSCLEROSIS, V100, P141, DOI 10.1016/0021-9150(93)90200-E; REID VC, 1993, J PATHOL, V171, P321, DOI 10.1002/path.1711710413; Roma P, 1996, ATHEROSCLEROSIS, V127, P147, DOI 10.1016/S0021-9150(96)05952-7; ROSEN GM, 1995, FASEB J, V9, P200, DOI 10.1096/fasebj.9.2.7540156; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P680, DOI 10.1161/01.ATV.10.5.680; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; ROSENFELD ME, 1991, J CLIN INVEST, V87, P90, DOI 10.1172/JCI115006; SARAFIAN TA, 1994, FREE RADICAL RES, V21, P1, DOI 10.3109/10715769409056549; SCACCINI C, 1994, FREE RADICAL BIO MED, V16, P49, DOI 10.1016/0891-5849(94)90242-9; SCHRADER M, 1994, EUR J CELL BIOL, V64, P281; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SCHWARTZ SM, 1995, AM J PATHOL, V147, P229; SLOT JW, 1986, LAB INVEST, V55, P363; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; TSUKADA T, 1986, ARTERIOSCLEROSIS, V6, P601, DOI 10.1161/01.ATV.6.6.601; VISNER GA, 1990, J BIOL CHEM, V265, P2856; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	67	88	91	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1997	11	14					1317	1328		10.1096/fasebj.11.14.9409551	http://dx.doi.org/10.1096/fasebj.11.14.9409551			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YN210	9409551				2022-12-28	WOS:000071144100013
J	Ambs, S; Hussain, SP; Harris, CC				Ambs, S; Hussain, SP; Harris, CC			Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression	FASEB JOURNAL			English	Review						apoptosis; mutagenesis; DNA damage; molecular epidemiology	ENDOTHELIAL GROWTH-FACTOR; TATA-BINDING PROTEIN; C-TERMINAL DOMAIN; DNA-REPLICATION; IN-VITRO; TRANSCRIPTIONAL ACTIVATION; SYNTHASE ACTIVITY; WILD-TYPE; APOPTOSIS; DAMAGE	The tumor suppressor gene product p53 plays an important role in the cellular response to DNA damage, DNA damage can lead to p53-mediated growth arrest and apoptosis, High concentrations of nitric oxide (NO) and NO metabolites such as peroxynitrite and NO2 cause DNA damage and have been shown to be mutagenic. Furthermore, NO induces p53 accumulation and, as part of a feedback loop, p53 mediates transcriptional transrepression of inducible nitric oxide synthase. Recent studies have shown increased expression and activity of nitric oxide synthase isoforms in human cancer. NO has both genotoxic and angiogenic properties, so that increased NO production may select mutant p53 cells and contribute to human carcinogenesis and tumor progression.	NCI, HUMAN CARCINOGENESIS LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Ambs, Stefan/0000-0001-7651-9309; Hussain, S. Perwez/0000-0002-2294-522X				AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BILLIAR TR, 1990, J LEUKOCYTE BIOL, V48, P565, DOI 10.1002/jlb.48.6.565; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; COBBS CS, 1995, CANCER RES, V55, P727; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; Crow J P, 1995, Adv Pharmacol, V34, P17; DEROJASWALKER T, 1995, CHEM RES TOXICOL, V8, P473, DOI 10.1021/tx00045a020; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Edwards P, 1996, J SURG RES, V63, P49, DOI 10.1006/jsre.1996.0221; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEHSEL K, 1995, J IMMUNOL, V155, P2858; FELLEYBOSCO E, 1995, CARCINOGENESIS, V16, P2069, DOI 10.1093/carcin/16.9.2069; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; FORSTERMANN U, 1995, N-S ARCH PHARMACOL, V352, P351; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; Geng YJ, 1996, CANCER RES, V56, P866; GORSDORF S, 1990, CARCINOGENESIS, V11, P37, DOI 10.1093/carcin/11.1.37; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GUO FH, 1995, P NATL ACAD SCI USA, V92, P7809, DOI 10.1073/pnas.92.17.7809; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARRIS C, 1968, J ULTRA MOL STRUCT R, V22, P240, DOI 10.1016/S0022-5320(68)90018-X; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Ho YS, 1996, MOL CARCINOGEN, V16, P20, DOI 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.3.CO;2-I; Hoffman RA, 1997, AM J PHYSIOL-GASTR L, V272, pG383, DOI 10.1152/ajpgi.1997.272.2.G383; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; KASTAN MB, 1991, CANCER RES, V51, P6304; KIESER A, 1994, ONCOGENE, V9, P963; KO LJ, 1996, GENE DEV, V10, P1024; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LAVAL F, 1994, CARCINOGENESIS, V15, P443, DOI 10.1093/carcin/15.3.443; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MAEDA H, 1994, JPN J CANCER RES, V85, P331, DOI 10.1111/j.1349-7006.1994.tb02362.x; Maki CG, 1996, CANCER RES, V56, P2649; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MARLETTA MA, 1988, CHEM RES TOXICOL, V1, P249, DOI 10.1021/tx00005a001; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; MESSMER UK, 1994, FEBS LETT, V355, P23; MILLER SD, 1995, MOL CELL BIOL, V15, P6554; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MIYASHITA T, 1995, CELL, V80, P293; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; OHUE M, 1994, CANCER RES, V54, P4798; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Paraskeva E, 1996, FEBS LETT, V389, P40, DOI 10.1016/0014-5793(96)00574-1; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Rubbo H, 1995, BIOCHEM SOC SYMP, P33, DOI 10.1042/bss0610033; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; Tamir S, 1996, BBA-REV CANCER, V1288, pF31, DOI 10.1016/0304-419X(96)00021-2; TAMURA T, 1995, ONCOGENE, V11, P1939; THOMSEN LL, 1994, CANCER RES, V54, P1352; THOMSEN LL, 1995, BRIT J CANCER, V72, P41, DOI 10.1038/bjc.1995.274; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WINK DA, 1994, CARCINOGENESIS, V15, P2125, DOI 10.1093/carcin/15.10.2125; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; Wink DA, 1996, CURR TOP CELL REGUL, V34, P159, DOI 10.1016/S0070-2137(96)80006-9; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; WU YN, 1993, CARCINOGENESIS, V14, P7, DOI 10.1093/carcin/14.1.7; Xie KP, 1996, J LEUKOCYTE BIOL, V59, P797, DOI 10.1002/jlb.59.6.797; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333; YERMILOV V, 1995, CARCINOGENESIS, V16, P2045, DOI 10.1093/carcin/16.9.2045	89	193	203	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1997	11	6					443	448		10.1096/fasebj.11.6.9194524	http://dx.doi.org/10.1096/fasebj.11.6.9194524			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XE404	9194524				2022-12-28	WOS:A1997XE40400006
J	Brand, KA; Hermfisse, U				Brand, KA; Hermfisse, U			Aerobic glycolysis by proliferating cells: A protective strategy against reactive oxygen species	FASEB JOURNAL			English	Article						thymocytes; proliferation; reactive oxygen	TRICARBOXYLIC-ACID CYCLE; CANCER-CELLS; RAT THYMOCYTES; MAXIMUM ACTIVITIES; HUMAN-NEUTROPHILS; ENZYME-INDUCTION; MAMMALIAN-CELLS; T-LYMPHOCYTES; DNA-DAMAGE; METABOLISM	Our laboratory has reported that glucose is essential for glycolytic enzyme induction and proliferation of mitogen-activated rat thymocytes (41). Here we show that: 1) Resting thymocytes meet their ATP demand mainly by oxidative glucose breakdown (88%), whereas proliferating thymocytes produce 86% by glycolytic degradation of glucose to lactate and only 14% by oxidation to CO2 and water. 2) In contrast to nonstimulated resting thymocytes, production of PMA primed reactive oxygen species (ROS) II the proliferating cells is nearly abolished, 3) Consistent with this finding, no ROS formation is observed in proliferating human promyelocytic HL-60 cells, whereas differentiated, nonproliferating HL-60 cells exert a marked response upon priming with PMA. 4) The observed reduction of ROS formation by resting thymocytes incubated with pyruvate suggests a function of pyruvate as an H2O2 scavenger. 5) The respiratory chain is a potential origin for ROS because inhibitors of tbe mitochondrial electron transport strongly reduce H2O2 production by resting thymocytes. The results are discussed in the contest of aerobic glycolysis by proliferating cells being a means to minimize oxidative stress during the phases of the cell cycle where maximally enhanced biosynthesis and cell division do occur.			Brand, KA (corresponding author), UNIV ERLANGEN NURNBERG,FAK MED,INST BIOCHEM,FAHRSTR 17,D-91054 ERLANGEN,GERMANY.							ANDRAE U, 1985, TOXICOL LETT, V28, P93, DOI 10.1016/0378-4274(85)90015-3; ARDAWI MSM, 1982, BIOCHEM J, V208, P743, DOI 10.1042/bj2080743; ARGILES JM, 1990, MED HYPOTHESES, V32, P151, DOI 10.1016/0306-9877(90)90039-H; ARORA KK, 1988, J BIOL CHEM, V263, P17422; BAGGETTO LG, 1992, BIOCHIMIE, V74, P959, DOI 10.1016/0300-9084(92)90016-8; BALINSKY D, 1983, CANCER RES, V43, P5895; BARRON JT, 1991, BIOCHIM BIOPHYS ACTA, V1093, P125, DOI 10.1016/0167-4889(91)90113-C; BAUMANN M, 1988, TUMOR BIOL, V9, P281, DOI 10.1159/000217573; Bergmeyer H. V., 1974, METHOD ENZYMAT AN, V2, P1196; BERGMEYER HU, 1983, METHOD ENZYMAT AN, V3, P146; BOARD M, 1990, BIOCHEM J, V265, P503, DOI 10.1042/bj2650503; BRAND K, 1988, EUR J BIOCHEM, V172, P695, DOI 10.1111/j.1432-1033.1988.tb13944.x; BRAND K, 1985, BIOCHEM J, V228, P353, DOI 10.1042/bj2280353; BRAND K, 1986, IMMUNOBIOLOGY, V173, P23, DOI 10.1016/S0171-2985(86)80086-9; BRAND MD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P128, DOI 10.1016/0005-2728(90)90232-S; BURK D, 1967, JNCI-J NATL CANCER I, V38, P839; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; Crabtree HG, 1929, BIOCHEM J, V23, P536, DOI 10.1042/bj0230536; DIAZESPADA F, 1982, IMMUNOLOGY, V46, P705; DROGE W, 1987, CELL IMMUNOL, V108, P405, DOI 10.1016/0008-8749(87)90223-1; DROGE W, 1994, METHOD ENZYMOL, V234, P135; EIGENBRODT E, 1980, TRENDS PHARMACOL SCI, V1, P240, DOI 10.1016/0165-6147(80)90009-7; EIGENBRODT E, 1985, BIOCH MOL ASPECTS SE, V2, P311; FUJII H, 1983, METHOD ENZYMAT AN, V3, P496; GAWEHN K, 1979, METHOD ENZYMAT AN, P1492; GILAT D, 1995, J EXP MED, V181, P1929, DOI 10.1084/jem.181.5.1929; GOLDSTONE SD, 1995, BBA-GENE STRUCT EXPR, V1263, P114, DOI 10.1016/0167-4781(95)00088-X; GREINER EF, 1994, J BIOL CHEM, V269, P31484; GUPPY M, 1993, EUR J BIOCHEM, V212, P95, DOI 10.1111/j.1432-1033.1993.tb17637.x; HAMMKUNZELMANN B, 1997, IN PRESS FEBS LETT; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; Krebs H A, 1972, Essays Biochem, V8, P1; Lamprecht W., 1988, METHOD ENZYMAT AN, VVI, P570; LANOUE KF, 1977, HORMONES CANCER, P131; LATOUR I, 1995, FEBS LETT, V373, P299, DOI 10.1016/0014-5793(95)01065-M; LOS M, 1995, EMBO J, V14, P3731, DOI 10.1002/j.1460-2075.1995.tb00043.x; MARJANOVIC S, 1988, BIOCHIM BIOPHYS ACTA, V970, P1, DOI 10.1016/0167-4889(88)90215-7; MARJANOVIC S, 1993, ARCH BIOCHEM BIOPHYS, V302, P398, DOI 10.1006/abbi.1993.1230; MARKERT M, 1984, METHOD ENZYMOL, V105, P358; MATHUPALA SP, 1995, J BIOL CHEM, V270, P16918, DOI 10.1074/jbc.270.28.16918; MCKEEHAN WL, 1982, CELL BIOL INT REP, V6, P635, DOI 10.1016/0309-1651(82)90125-4; MUJICA A, 1991, J REPROD FERTIL, V92, P75, DOI 10.1530/jrf.0.0920075; NELSON BD, 1984, BIOCHEM J, V219, P159, DOI 10.1042/bj2190159; NETZKER R, 1994, BBA-MOL CELL RES, V1224, P371, DOI 10.1016/0167-4889(94)90270-4; NETZKER R, 1992, J BIOL CHEM, V267, P6421; NISHIMURA J, 1975, BIOCHIM BIOPHYS ACTA, V396, P1, DOI 10.1016/0005-2728(75)90183-8; NOLL T, 1990, ADV EXP MED BIOL, V277, P467; ODONNELLTORMEY J, 1987, J EXP MED, V165, P500, DOI 10.1084/jem.165.2.500; PIKE SE, 1991, P NATL ACAD SCI USA, V88, P11081, DOI 10.1073/pnas.88.24.11081; RACKER E, 1976, J CELL PHYSIOL, V89, P697, DOI 10.1002/jcp.1040890429; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; REITZER LJ, 1980, J BIOL CHEM, V255, P5616; SALGO MG, 1995, ARCH BIOCHEM BIOPHYS, V322, P500, DOI 10.1006/abbi.1995.1493; SALISBURY JG, 1979, J BIOCHEM BIOPH METH, V1, P341, DOI 10.1016/0165-022X(79)90025-3; Schafer D, 1996, FEBS LETT, V391, P35, DOI 10.1016/0014-5793(96)00701-6; SCHOBITZ B, 1991, EUR J BIOCHEM, V199, P257, DOI 10.1111/j.1432-1033.1991.tb16118.x; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SENER A, 1988, J BIOL CHEM, V263, P1904; SESHAGIRI PB, 1991, MOL REPROD DEV, V30, P105, DOI 10.1002/mrd.1080300206; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; TOLLEFSBOL TO, 1985, J CELL PHYSIOL, V123, P417, DOI 10.1002/jcp.1041230318; TOLLEFSBOL TO, 1985, J CELL PHYSIOL, V122, P98, DOI 10.1002/jcp.1041220115; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Vassault A, 1984, METHODS ENZYM ANAL, V3, P118; WANG T, 1976, NATURE, V261, P702, DOI 10.1038/261702a0; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warburg O, 1924, BIOCHEM Z, V152, P309; Warburg O, 1929, BIOCHEM Z, V204, P482; WEBER G, 1977, NEW ENGL J MED, V296, P486, DOI 10.1056/NEJM197703032960905; WEBER G, 1977, NEW ENGL J MED, V296, P541, DOI 10.1056/NEJM197703102961005; WEBER G, 1963, CANCER RES, V23, P987; WEINHOUSE S, 1976, Z KREBSFORSCH KLIN O, V87, P115; YU H, 1995, J BIOL CHEM, V270, P15719, DOI 10.1074/jbc.270.26.15719	74	317	323	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1997	11	5					388	395		10.1096/fasebj.11.5.9141507	http://dx.doi.org/10.1096/fasebj.11.5.9141507			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WX156	9141507				2022-12-28	WOS:A1997WX15600013
J	Crouch, MF; Simson, L				Crouch, MF; Simson, L			The G-protein G(i) regulates mitosis but not DNA synthesis in growth factor-activated fibroblasts: A role for the nuclear translocation of G(i)	FASEB JOURNAL			English	Article						immunoprecipitation; nuclear fraction; EGF; cellular proliferation; beta-subunit	GTP-BINDING PROTEIN; RECEPTOR TYROSINE KINASES; ADENYLATE-CYCLASE; BALB/C3T3 CELLS; SUBCELLULAR-DISTRIBUTION; MAP-KINASE; ALPHA; COMPONENT; PURIFICATION; SUBSTRATE	GTP binding proteins, heterotrimeric molecules composed of alpha-, beta-, and gamma-subunits, are known to serve as transducers of information from seven-transmembrane receptors, Activation of G-proteins has been generally considered to involve subunit dissociation, with G(alpha) separating from G(beta gamma). However, we have found a receptor activation of G(i) in proliferating cells that differs from these models and involves the subcellular translocation of the alpha-subunit from the cell periphery to the nucleus where G(i alpha) binds to chromatin for the duration of mitosis, This report describes the mechanism of G(i) activation in Swiss 3T3 cells in response to serum, thrombin, and epidermal growth factor, and describes a role for G(i2) in the cell cycle, Agonists were found to be unable to induce the physical dissociation of G(i2) subunits, The alpha- and beta-subunits of G(i2) could be coimmunoprecipitated with a G(i alpha) antibody from both the membrane and nuclear fractions of long-term activated cultures, showing that G(i alpha 2) and G(i beta) are induced to comigrate to the nucleus in response to growth factor receptor activation, G(i2) appears to be activated in part by a postreceptor signal that carl be mimicked by protein kinase C activation; this signal may be responsible for the convergence of the signaling mechanisms of these distinct seven-transmembrane and tyrosine kinase receptors, mie suggest that translocation of G(i alpha) to the nucleus induced by either thrombin or EGF may occur without subunit dissociation, Functional studies of the role of G(i) showed that pertussis toxin does riot block DNA synthesis in Swiss 3T3 fibroblasts induced by serum or thrombin, but that cell proliferation is retarded to each, These results provide direct evidence for a novel mechanism of GTP binding protein activation and for an essential role of G(i) in the induction of cell division by a variety of growth factor receptors, G(i) can carry out this role in control of cellular proliferation through its translocation to the nucleus of mitotic cells.	AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, DIV NEUROSCI, CANBERRA, ACT 2600, AUSTRALIA	Australian National University; John Curtin School of Medical Research			Simson, Ljubov/C-2954-2009					BOKOCH GM, 1988, J CELL BIOL, V106, P1927, DOI 10.1083/jcb.106.6.1927; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CROUCH MF, 1993, MED RES REV, V13, P105, DOI 10.1002/med.2610130105; CROUCH MF, 1989, P NATL ACAD SCI USA, V86, P1776, DOI 10.1073/pnas.86.6.1776; CROUCH MF, 1993, CELL SIGNAL, V5, P41, DOI 10.1016/0898-6568(93)90006-8; CROUCH MF, 1991, FASEB J, V5, P200, DOI 10.1096/fasebj.5.2.1900794; CROUCH MF, 1988, J BIOL CHEM, V263, P3363; CROUCH MF, 1990, BIOCHEM BIOPH RES CO, V167, P1369, DOI 10.1016/0006-291X(90)90674-C; CROUCH MF, 1994, CELL SIGNAL, V6, P695, DOI 10.1016/0898-6568(94)90051-5; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; HANSKI E, 1981, J BIOL CHEM, V256, P2911; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; KATADA T, 1984, J BIOL CHEM, V259, P3578; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LEVITZKI A, 1993, INT ENCYCL PHARM TH, P47; LEWIS JM, 1991, CELL REGUL, V2, P1097, DOI 10.1091/mbc.2.12.1097; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIN CT, 1992, LAB INVEST, V67, P770; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; MURAYAMA T, 1987, J BIOL CHEM, V262, P12463; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RODBELL M, 1985, TRENDS BIOCHEM SCI, V10, P461, DOI 10.1016/0968-0004(85)90032-5; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SARNDAHL E, 1993, P NATL ACAD SCI USA, V90, P6552, DOI 10.1073/pnas.90.14.6552; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SPIEGEL AM, 1987, MOL CELL ENDOCRINOL, V49, P1, DOI 10.1016/0303-7207(87)90058-X; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; TAKUWA N, 1991, J BIOL CHEM, V266, P1403; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0	41	55	55	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1997	11	2					189	198		10.1096/fasebj.11.2.9039962	http://dx.doi.org/10.1096/fasebj.11.2.9039962			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK509	9039962				2022-12-28	WOS:A1997WK50900012
J	Damaj, BB; McColl, SR; Neote, K; Na, SQ; Ogborn, KT; Hebert, CA; Naccache, PH				Damaj, BB; McColl, SR; Neote, K; Na, SQ; Ogborn, KT; Hebert, CA; Naccache, PH			Identification of G-protein binding sites of the human interleukin-8 receptors by functional mapping of the intracellular loops	FASEB JOURNAL			English	Article						neutrophils; calcium mobilization; signal transduction; Gro-; NAP-2; C-X-C chemokines	FORMYL PEPTIDE RECEPTOR; SIGNAL-TRANSDUCTION; HUMAN-NEUTROPHILS; IL-8 RECEPTOR; A RECEPTOR; CHEMOTAXIS; MUTATION; AFFINITY; DOMAINS; CELLS	Interleukin 8 (IL-8) is considered to be a major mediator of the inflammatory response. Recent evidence indicates that a direct physical association occurs between IL-8 receptors and the alpha subunit of guanine nucleotide regulatory protein (G(i) alpha(2)) upon stimulation of human neutrophils by IL-8. In the present study, we identified by site-directed mutagenesis key residues within the three intracellular loops of the IL-8RA receptor involved in the interaction with G(i) alpha(2). We first systematically mutated, in groups of two to four, all the residues in the three intracellular loops of the IL-8 type A receptor to alanine and analyzed the mutant receptors transiently expressed in 293 cells. Four residues in the second intracellular loop (Y136, L137, I139, V140) and one residue in the third intracellular loop (M241) were shown to be crucial for mediating calcium signaling in response to IL-8. Other residues in the second and third intracellular loops were also found to affect IL-8RA-mediated signaling, but to a lesser extent. These effects were not due to lower expression or low IL-8 binding affinities to the mutated receptors. Mutagenesis of the residues in the first intracellular loop had only weak effects on the mobilization of calcium induced by IL-8. We then used a coimmunoprecipitation protocol with anti-G(i) alpha(2) antibodies to determine the involvement of the two regions defined above in G(i) alpha(2) coupling to IL-8 type A receptors. Whereas the anti-G(i) alpha(2) antibodies coimmunoprecipitated IL-8 receptors in the wild-type cells, this interaction was lost in cells expressing mutated receptors that affected intracellular calcium mobilization. The peptides corresponding to the regions of the type A receptor found to be critical for G(i) alpha(2) coupling and induction of intracellular calcium mobilization were next introduced into cells expressing wild-type IL-8RA or IL-8RB to assess their role in coupling G(i) alpha(2) to both IL-8 receptors. The results obtained in the latter experiments suggest that the same regions of the second intracellular loop (Y136, L137, I139, V140) and of the third intracellular loop (M241) are critically involved in the coupling of both IL-8RA and IL-8 RB to G(i) alpha(2) as well as to a downstream effector (or effecters) involved in calcium mobilization.	CHUL,CTR RECH RHUMATOL & IMMUNOL,ST FOY,PQ G1V 4G2,CANADA; UNIV LAVAL,FAC MED,DEPT MED,ST FOY,PQ G1K 7P4,CANADA; UNIV ADELAIDE,DEPT MICROBIOL & IMMUNOL,N TERR,SA,AUSTRALIA; GENENTECH INC,DEPT IMMUNOL,S SAN FRANCISCO,CA 94080; PFIZER INC,CENT RES,GROTON,CT 06340	Laval University; Laval University; University of Adelaide; Roche Holding; Genentech; Pfizer								BACON KB, 1995, J IMMUNOL, V154, P3654; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BARNETT ML, 1993, BIOCHIM BIOPHYS ACTA, V1177, P275, DOI 10.1016/0167-4889(93)90123-7; BENBARUCH A, 1995, J BIOL CHEM, V270, P9121, DOI 10.1074/jbc.270.16.9121; BIGNOLD LP, 1992, INT ARCH ALLERGY IMM, V97, P350, DOI 10.1159/000236144; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BOMMAKANTI RK, 1995, BIOCHEMISTRY-US, V34, P6720, DOI 10.1021/bi00020a017; CHUNTHARAPAI A, 1994, J IMMUNOL, V152, P1783; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; DAHINDEN CA, 1989, J EXP MED, V170, P1787, DOI 10.1084/jem.170.5.1787; DAMAJ BB, 1996, IN PRESS J BIOL CHEM; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; FAUCHER N, 1987, J CELL PHYSIOL, V132, P483, DOI 10.1002/jcp.1041320310; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HEBERT CA, 1993, CANCER INVEST, V11, P743, DOI 10.3109/07357909309046949; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; LEE J, 1992, J BIOL CHEM, V267, P16283; LEE J, 1992, J IMMUNOL, V148, P1261; LEONG SR, 1994, J BIOL CHEM, V269, P19343; LHEUREUX G, 1994, BLOOD, V85, P522; LOETSCHER P, 1994, FEBS LETT, V341, P187, DOI 10.1016/0014-5793(94)80454-0; Magazin M, 1992, Eur Cytokine Netw, V3, P461; MCCOLL SR, 1993, J IMMUNOL, V150, P4550; MICHEL G, 1992, FEBS LETT, V305, P241, DOI 10.1016/0014-5793(92)80677-9; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MORO O, 1993, J BIOL CHEM, V268, P22273; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEVE KA, 1991, MOL PHARMACOL, V39, P733; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; PETERSEN F, 1994, J IMMUNOL, V152, P2467; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P10686, DOI 10.1074/jbc.270.18.10686; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; ROLLET E, 1994, J IMMUNOL, V153, P353; SANDER B, 1991, IMMUNOL REV, V119, P65, DOI 10.1111/j.1600-065X.1991.tb00578.x; SCHREIBER RE, 1993, J LEUKOCYTE BIOL, V53, P470, DOI 10.1002/jlb.53.4.470; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; SEBOK K, 1993, J IMMUNOL, V150, P1524; TSIEN RY, 1982, J CELL BIOL, V94, P3325; VALIQUETTE M, 1993, BIOCHEMISTRY-US, V32, P4979, DOI 10.1021/bi00070a002; Watson S., 1994, G PROTEIN LINKED REC; WESTWICK J, 1989, IMMUNOL TODAY, V10, P146, DOI 10.1016/0167-5699(89)90164-3; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; XU LL, 1995, J LEUKOCYTE BIOL, V57, P335, DOI 10.1002/jlb.57.2.335	47	58	66	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1996	10	12					1426	1434		10.1096/fasebj.10.12.8903513	http://dx.doi.org/10.1096/fasebj.10.12.8903513			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VP485	8903513				2022-12-28	WOS:A1996VP48500008
J	Lee, WC; Lin, KY; Chiu, YT; Lin, JH; Cheng, HC; Huang, HC; Yang, PC; Liu, SK; Mao, SJT				Lee, WC; Lin, KY; Chiu, YT; Lin, JH; Cheng, HC; Huang, HC; Yang, PC; Liu, SK; Mao, SJT			Substantial decrease of heat shock protein 90 in ventricular tissues of two sudden-death pigs with hypertrophic cardiomyopathy	FASEB JOURNAL			English	Article						isoelectrofocusing; tissue homogenization; systolic anterior motion; HSP90; ischemia	GLUCOCORTICOID RECEPTOR; MYOCARDIAL-ISCHEMIA; STEROID-RECEPTORS; ACTIN-FILAMENTS; HSP90; STRESS; EXPRESSION; INDUCTION; BINDING; ASSOCIATION	We recently developed a pig model with naturally occurring hypertrophic cardiomyopathy (HCM). To further characterize the biochemical features of high frequency of sudden death affected by this disease, the protein profiles of ventricular tissues were analyzed on normal, HCM, and HCM with sudden-death pigs. By sodium dodecylsulfate-polyacrylamide gel electrophoresis, a protein corresponding to an apparent molecular mass of 90 kDa (p90) was found to be markedly decreased in the HCM-affected tissues of sudden-death pigs, but not in HCM or normal pigs. Further study showed that the primary decrease of p90 in HCM pigs with sudden death was located mainly in the interventricular septum. As determined by the molecular mass and isoelectric point on 2-dimensional gels and Western immunoblot with a specific 90 kDa heat shock protein (HSP90) monoclonal antibody, the unknown protein was identified as HSP90. Our findings indicate for the first time that substantially decreased heart HSP90 is associated with HCM pigs with sudden death. Although the role that HSP90 may play in protecting pigs with HCM from sudden death is still unclear, the model itself may provide further insight into understanding the role of heat shock proteins in cardiac sudden death.	ANIM MED CTR,NEW YORK,NY									ANDERSON KP, 1994, SUDDEN CARDIAC DEATH, P163; BENJAMIN IJ, 1994, BIOL HEAT SHOCK PROT, P533; BONNE G, 1995, NAT GENET, V11, P438, DOI 10.1038/ng1295-438; CANNON RO, 1985, CIRCULATION, V71, P234, DOI 10.1161/01.CIR.71.2.234; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CODD MB, 1989, CIRCULATION, V80, P564, DOI 10.1161/01.CIR.80.3.564; CUDA G, 1993, J CLIN INVEST, V91, P2861, DOI 10.1172/JCI116530; CURRIE RW, 1993, CIRCULATION, V87, P963, DOI 10.1161/01.CIR.87.3.963; CURRIE RW, 1988, CIRC RES, V63, P543, DOI 10.1161/01.RES.63.3.543; DAI KS, 1995, VET RES COMMUN, V19, P1635; DAI KS, 1995, IN PRESS BR VET J; FACTOR SM, 1991, J AM COLL CARDIOL, V17, P1343, DOI 10.1016/S0735-1097(10)80145-7; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; HADA Y, 1987, AM J CARDIOL, V59, P183, DOI 10.1016/S0002-9149(87)80107-8; HASEGAWA K, 1993, CIRCULATION, V88, P372, DOI 10.1161/01.CIR.88.2.372; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENGSTENBERG C, 1993, CARDIOSCIENCE, V4, P15; HOWARD KJ, 1988, J BIOL CHEM, V263, P3474; HUANG SY, 1996, IN PRESS LAB ANIM SC; HUTTER MM, 1994, CIRCULATION, V89, P355, DOI 10.1161/01.CIR.89.1.355; INANOBE A, 1994, J BIOCHEM, V115, P486, DOI 10.1093/oxfordjournals.jbchem.a124363; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; KELLERMAYER MSZ, 1995, BIOCHEM BIOPH RES CO, V211, P166, DOI 10.1006/bbrc.1995.1792; KNOWLTON AA, 1995, J MOL CELL CARDIOL, V27, P121, DOI 10.1016/S0022-2828(08)80012-0; KOGA Y, 1984, AM HEART J, V108, P351, DOI 10.1016/0002-8703(84)90624-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WC, 1991, J CELL PHYSIOL, V149, P66, DOI 10.1002/jcp.1041490110; LIAO F, 1994, J CLIN INVEST, V94, P877, DOI 10.1172/JCI117409; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LIU SK, 1993, AM J CARDIOL, V72, P944, DOI 10.1016/0002-9149(93)91112-U; LIU SK, 1983, VET CLIN N AM-SMALL, V13, P379, DOI 10.1016/S0195-5616(83)50036-3; LIU SK, 1994, CARDIOVASC PATHOL, V3, P261, DOI 10.1016/1054-8807(94)90012-4; LOUIE EK, 1994, PROG CARDIOVASC DIS, V36, P275, DOI 10.1016/S0033-0620(05)80036-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAILHOS C, 1994, J NEUROCHEM, V63, P1787; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; MARBER MS, 1993, CIRCULATION, V88, P1263; MARON BJ, 1982, CIRCULATION, V65, P1388, DOI 10.1161/01.CIR.65.7.1388; MARON BJ, 1978, AM J CARDIOL, V41, P1133, DOI 10.1016/0002-9149(78)90870-6; MARON BJ, 1986, J AM COLL CARDIOL, V8, P545, DOI 10.1016/S0735-1097(86)80181-4; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MCKENNA W, 1981, AM J CARDIOL, V47, P532, DOI 10.1016/0002-9149(81)90535-X; MESTRIL R, 1995, J MOL CELL CARDIOL, V27, P45, DOI 10.1016/S0022-2828(08)80006-5; MESTRIL R, 1994, J CLIN INVEST, V93, P759, DOI 10.1172/JCI117030; MINOWADA G, 1995, J CLIN INVEST, V95, P3, DOI 10.1172/JCI117655; MIYATA Y, 1991, J BIOL CHEM, V266, P8779; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; NADEAU K, 1993, J BIOL CHEM, V268, P1479; NISHIDA E, 1986, J BIOL CHEM, V261, P6033; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PLUMIER JCL, 1995, J CLIN INVEST, V95, P1854, DOI 10.1172/JCI117865; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; WALKER DM, 1993, CARDIOVASC RES, V27, P962, DOI 10.1093/cvr/27.6.962; WHITELAW ML, 1995, P NATL ACAD SCI USA, V92, P4437, DOI 10.1073/pnas.92.10.4437; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; YELLON DM, 1992, J MOL CELL CARDIOL, V24, P342; 1980, BRIT HEART J, V44, P672	62	39	45	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1996	10	10					1198	1204		10.1096/fasebj.10.10.8751722	http://dx.doi.org/10.1096/fasebj.10.10.8751722			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VD429	8751722				2022-12-28	WOS:A1996VD42900011
J	Chytil, F				Chytil, F			Retinoids in lung development	FASEB JOURNAL			English	Article						retinoic acid; retinol; fetal development; retinyl ester; gene expression	VITAMIN-A SUPPLEMENTATION; BINDING PROTEIN; RAT LUNG; BRONCHOPULMONARY DYSPLASIA; PERINATAL RAT; FETAL LUNG; POSTNATAL-DEVELOPMENT; ACID RECEPTORS; DEXAMETHASONE; EXPRESSION	The ''retinoid revolution'' has had considerable impact on research activity in the field of lung development, Postnatal lungs are very sensitive to dietary retinol (R) deprivation. The trachea and the bronchopulmonary tree in R-deficient animals show a striking change in morphology. The columnar epithelium undergoes keratinizing metaplasia, which is reversed when R is supplied. The fetal lung develops postnatally to become one of the most complex organs, characterized by 40 different cell types, The fetal lungs can accumulate retinyl esters, Before birth an unknown signal causes the lowering of these esters, which may be the source of retinoic acid (RA). The administration of glucocorticoids speeds up this process, which in turn is followed by acceleration of lung maturation, ending postnatally. It is not clear what role, if any, the cellular retinoid binding proteins play in this phenomenon, Fetal lung branching leading to the development of the alveolar tree is accelerated by RA, and so is the expression of some fetal genes coding for surfactant proteins and the enzymes that produce their lipid components, It is not clear whether RA influences the development of pulmonary epithelium by interacting directly with the epithelial cells or whether its effects require interaction with other cells like mesenchymal cells, Nuclear RA receptors are intimately involved in lung development, Despite the wealth of evidence on the effect of retinoids on lung development, the application of vitamin A to clinical work has been Limited to prematurely delivered infants who have immature lungs. Here attempts are made, by improving their R status, to aid in the development and healing of lungs injured by oxygen therapy.			Chytil, F (corresponding author), VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, 604 MRB I, NASHVILLE, TN 37232 USA.				NHLBI NIH HHS [HL-14214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAVIK CO, 1995, EXP CELL RES, V216, P358, DOI 10.1006/excr.1995.1045; BAVIK CO, 1992, J BIOL CHEM, V267, P23035; Bloch CE, 1921, J HYG-CAMBRIDGE, V19, P283, DOI 10.1017/S0022172400007865; Blomhoff R., 1994, Vitamin A in health and disease., P1; BOGUE CW, 1994, AM J PHYSIOL, V266, pL448, DOI 10.1152/ajplung.1994.266.4.L448; BURRI PH, 1974, ANAT REC, V178, P711, DOI 10.1002/ar.1091780405; CARDOSO WV, 1995, AM J RESP CELL MOL, V12, P464, DOI 10.1165/ajrcmb.12.5.7742011; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHYTIL F, 1992, AM J PHYSIOL, V262, pL517, DOI 10.1152/ajplung.1992.262.5.L517; CHYTIL F, 1990, Critical Reviews in Eukaryotic Gene Expression, V1, P61; DOLLE P, 1990, DEVELOPMENT, V110, P1133; FAWCETT D, 1995, DEVELOPMENT, V121, P671; FRASLON C, 1994, AM J PHYSIOL, V266, pL705, DOI 10.1152/ajplung.1994.266.6.L705; GEEVARGHESE SK, 1994, BIOCHEM BIOPH RES CO, V200, P529, DOI 10.1006/bbrc.1994.1480; GEORGIEFF MK, 1989, J PEDIATR-US, V114, P301, DOI 10.1016/S0022-3476(89)80801-7; GEORGIEFF MK, 1988, J PEDIATR GASTR NUTR, V7, P713, DOI 10.1097/00005176-198809000-00016; GORRY P, 1994, P NATL ACAD SCI USA, V91, P9032, DOI 10.1073/pnas.91.19.9032; GROSS I, 1990, AM J PHYSIOL, V259, pL337, DOI 10.1152/ajplung.1990.259.6.L337; GRUMMER MA, 1994, PEDIATR PULM, V17, P234, DOI 10.1002/ppul.1950170406; KAZZI NJ, 1990, PEDIATRICS, V86, P722; LAMPRON C, 1995, DEVELOPMENT, V121, P539; MASSARO D, 1986, AM J PHYSIOL, V251, pR218, DOI 10.1152/ajpregu.1986.251.2.R218; MASSARO D, 1985, J CLIN INVEST, V76, P1297, DOI 10.1172/JCI112103; Massaro GD, 1996, AM J PHYSIOL-LUNG C, V270, pL305, DOI 10.1152/ajplung.1996.270.2.L305; MCGOWAN SE, 1995, AM J PHYSIOL-LUNG C, V269, pL463, DOI 10.1152/ajplung.1995.269.4.L463; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; METZLER MD, 1993, ENDOCRINOLOGY, V133, P1990, DOI 10.1210/en.133.5.1990; NOGAWA H, 1995, DEVELOPMENT, V121, P1015; ONG DE, 1976, P NATL ACAD SCI USA, V73, P3976, DOI 10.1073/pnas.73.11.3976; ONG DE, 1988, J BIOL CHEM, V263, P5789; PEARSON E, 1992, J PEDIATR-US, V121, P420, DOI 10.1016/S0022-3476(05)81800-1; PECK GL, 1994, RETINOIDS BIOL CHEM; PFAHL M, 1996, IN PRESS ANN REV; PIJNAPPEL WWM, 1993, NATURE, V366, P340, DOI 10.1038/366340a0; POWELL JT, 1980, BIOCHEM J, V188, P1; RIAZULHAQ, 1991, P NATL ACAD SCI USA, V88, P8272, DOI 10.1073/pnas.88.18.8272; ROTHMAN KJ, 1995, NEW ENGL J MED, V333, P1369, DOI 10.1056/NEJM199511233332101; RUSH MG, 1991, ENDOCRINOLOGY, V129, P705, DOI 10.1210/endo-129-2-705; SCHUGER L, 1993, DEV BIOL, V159, P462, DOI 10.1006/dbio.1993.1256; SHENAI JP, 1981, J PEDIATR-US, V99, P302, DOI 10.1016/S0022-3476(81)80484-2; SHENAI JP, 1994, INT J VITAM NUTR RES, V64, P93; SHENAI JP, 1987, J PEDIATR-US, V111, P269, DOI 10.1016/S0022-3476(87)80086-0; SHENAI JP, 1990, BIOL NEONATE, V58, P318, DOI 10.1159/000243286; TAKAHASHI YI, 1977, AM J PHYSIOL, V233, pE263, DOI 10.1152/ajpendo.1977.233.4.E263; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; WILLIAMS MC, 1977, FED PROC, V36, P2653; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; Wolbach SB, 1933, J EXP MED, V57, P511, DOI 10.1084/jem.57.3.511; XU ZX, 1995, AM J PHYSIOL-LUNG C, V268, pL683, DOI 10.1152/ajplung.1995.268.4.L683; ZACHMAN RD, 1995, J NUTR, V125, pS1634; ZACHMAN RD, 1984, PEDIATR RES, V18, P1297, DOI 10.1203/00006450-198412000-00015	53	117	118	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1996	10	9					986	992		10.1096/fasebj.10.9.8801181	http://dx.doi.org/10.1096/fasebj.10.9.8801181			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801181				2022-12-28	WOS:A1996UY93200008
J	Napoli, JL				Napoli, JL			Retinoic acid biosynthesis and metabolism	FASEB JOURNAL			English	Article						retinoid; cellular retinol binding protein; cellular retinoic acid binding protein; retinol dehydrogenase; retinal dehydrogenase; retinol	LIVER ALDEHYDE DEHYDROGENASES; BINDING PROTEINS; RAT-LIVER; IDENTIFICATION; OXIDATION; CELLS; ACYLTRANSFERASE; DIFFERENTIATION; RETINALDEHYDE; REDUCTION	Metabolic activation of retinol into the hormone retinoic acid and metabolism of retinoic acid entail essential aspects of retinoid biology that seem interdependent with functions of retinoid binding-proteins, Cellular retinol binding protein and cellular retinoic acid binding protein enjoy widespread expression and, where expressed, their liganded forms represent the major physiological forms of retinol and retinoic acid, respectively, These retinoid binding proteins may protect cells from the amphipathic properties of retinoids and protect the structurally sensitive retinoids from the cellular milieu. Starting from the perspective that the enzymes most likely to metabolize retinoids in vivo might recognize the major forms of retinoids that occur in vivo, several laboratories have produced results that support a model of retinoid metabolism with prominent roles for the cellular retinoid binding proteins, In this model, liganded cellular retinoid binding proteins serve as substrates for the metabolism of some retinoids (retinol, retinoic acid), restricting access to those enzymes that recognize both the binding protein and the retinoid, Other retinoids (3,4-didehydroretinol, 4-oxo-retinoic acid) liganded to binding-proteins have their metabolism arrested, In its unliganded form, at least one retinoid binding protein (cellular retinol binding protein) serves as a retinoid concentration-sensitive modulator of enzymes that catalyze retinol metabolism, This review will describe the model and the intrinsic relationships among retinoid-specific enzymes and retinoid binding proteins.			Napoli, JL (corresponding author), SUNY BUFFALO, SCH MED & BIOMED SCI, CTR MOL MECH DIS & AGING, 140 FARBER HALL, 3435 MAIN ST, BUFFALO, NY 14214 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013566] Funding Source: NIH RePORTER; NIA NIH HHS [AG13566] Funding Source: Medline; NIDDK NIH HHS [DK36870] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLOMHOFF R, 1991, PHYSIOL REV, V71, P951, DOI 10.1152/physrev.1991.71.4.951; BOERMAN MHEM, 1995, BIOCHEMISTRY-US, V34, P7027, DOI 10.1021/bi00021a014; Boerman MHEM, 1996, J BIOL CHEM, V271, P5610, DOI 10.1074/jbc.271.10.5610; BOERMAN MHEM, 1995, ARCH BIOCHEM BIOPHYS, V321, P434, DOI 10.1006/abbi.1995.1415; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; Chai XY, 1996, GENE, V169, P219, DOI 10.1016/0378-1119(95)00833-0; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; CHAI XY, 1995, J BIOL CHEM, V270, P28408, DOI 10.1074/jbc.270.47.28408; DEW SE, 1994, BIOCHEMISTRY-US, V33, P12340, DOI 10.1021/bi00206a042; DOCKHAM PA, 1992, BIOCHEM PHARMACOL, V43, P2453, DOI 10.1016/0006-2952(92)90326-E; DONOVAN M, 1995, J STEROID BIOCHEM, V53, P459, DOI 10.1016/0960-0760(95)00092-E; ELAKAWI Z, 1994, BIOCHEMISTRY-US, V33, P1938, DOI 10.1021/bi00173a042; FIORELLA PD, 1994, J BIOL CHEM, V269, P10538; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; HARRISON EH, 1987, J LIPID RES, V28, P973; LABRECQUE J, 1995, BIOCHEM J, V305, P681, DOI 10.1042/bj3050681; LAMPRON C, 1995, DEVELOPMENT, V121, P539; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; LI E, 1991, J BIOL CHEM, V266, P3622; LISSOOS TW, 1995, AM J PHYSIOL-GASTR L, V268, pG224, DOI 10.1152/ajpgi.1995.268.2.G224; MADEN M, 1994, NUTR REV, V52, P3; NAGAO A, 1994, FASEB J, V8, P968, DOI 10.1096/fasebj.8.12.8088462; NAPOLI JL, 1995, J STEROID BIOCHEM, V53, P497, DOI 10.1016/0960-0760(95)00096-I; NEBUTERNE X, 1995, J LIPID RES, V36, P1264; NEWCOMER ME, 1995, FASEB J, V9, P229, DOI 10.1096/fasebj.9.2.7781925; NEWCOMER ME, 1993, P NATL ACAD SCI USA, V90, P9223, DOI 10.1073/pnas.90.19.9223; NORRIS AW, 1994, BBA-PROTEIN STRUCT M, V1209, P10, DOI 10.1016/0167-4838(94)90130-9; ONG DE, 1994, RETINOIDS BIOL CHEM, P303; OTTONELLO S, 1993, J BIOL CHEM, V268, P27133; PIJNAPPEL WWM, 1993, NATURE, V366, P340, DOI 10.1038/366340a0; POSCH KC, 1992, BIOCHEM PHARMACOL, V43, P2296; POSCH KC, 1989, ARCH BIOCHEM BIOPHYS, V274, P171, DOI 10.1016/0003-9861(89)90428-1; RANDOLPH RK, 1991, J BIOL CHEM, V266, P16453; RANDOLPH RK, 1993, J BIOL CHEM, V268, P9198; SAARI JC, 1995, VISUAL NEUROSCI, V12, P263, DOI 10.1017/S095252380000794X; SHINGLETON JL, 1989, BIOCHEMISTRY-US, V28, P9641, DOI 10.1021/bi00451a015; THOMPSON JR, 1995, J MOL BIOL, V252, P433, DOI 10.1006/jmbi.1995.0509; WANG X, 1996, IN PRESS J BIOL CHEM; WEI LN, 1992, DEV GROWTH DIFFER, V34, P479; WILLIAMS JB, 1985, P NATL ACAD SCI USA, V82, P4658, DOI 10.1073/pnas.82.14.4658; YANG ZN, 1994, ALCOHOL CLIN EXP RES, V18, P587, DOI 10.1111/j.1530-0277.1994.tb00914.x; YOSHIDA A, 1993, ENZYMOL MOL BIOL CAR, V4, P37	43	312	326	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1996	10	9					993	1001		10.1096/fasebj.10.9.8801182	http://dx.doi.org/10.1096/fasebj.10.9.8801182			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801182				2022-12-28	WOS:A1996UY93200009
J	Kaufmann, WK; Paules, RS				Kaufmann, WK; Paules, RS			DNA damage and cell cycle checkpoints	FASEB JOURNAL			English	Review						mutation; cyclin-dependent kinase; carcinogenesis; DNA repair; DNA replication; mitosis	ATAXIA-TELANGIECTASIA; HUMAN FIBROBLASTS; REPAIR; REPLICATION; INHIBITION; INVITRO	DNA is prone to numerous forms of damage that can injure cells and impair fitness, Cells have evolved an array of mechanisms to repair these injuries, Proliferating cells are especially vulnerable to DNA damage due to the added demands of cellular growth and division. Cell cycle checkpoints represent integral components of DNA repair that coordinate cooperation between the machinery of the cell cycle and several biochemical pathways that respond to damage and restore DNA structure, By delaying progression through the cell cycle, checkpoints provide more time for repair before the critical phases of DNA replication, when the genome is replicated, and of mitosis, when the genome is segregated, Loss or attenuation of checkpoint function may increase spontaneous and induced gene mutations and chromosomal aberrations by reducing the efficiency of DNA repair, Defects in checkpoint control have been seen in certain hereditary cancer syndromes and at early stages of cell transformation, Mutations in checkpoint control genes therefore may contribute to the genetic instability that appears to drive neoplastic evolution.	UNIV N CAROLINA, DEPT PATHOL, CHAPEL HILL, NC 27599 USA; NIEHS, GROWTH CONTROL & CANC GRP, RES TRIANGLE PK, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kaufmann, WK (corresponding author), UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CB 7295, RM 351, CHAPEL HILL, NC 27599 USA.			Paules, Richard S/0000-0001-9106-7486	NCI NIH HHS [CA42765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOYER JC, 1991, CANCER RES, V51, P2960; CANMAN CE, 1994, CANCER RES, V54, P5054; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EJIMA Y, 1986, MUTAT RES, V159, P117, DOI 10.1016/0027-5107(86)90120-X; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FRIEDBERG EC, 1995, DNA REPAIR; GAUTSCHI JR, 1973, J MOL BIOL, V80, P393, DOI 10.1016/0022-2836(73)90411-7; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GRISHAM JW, 1983, SURV SYNTH PATHOL RE; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1990, MUTAT RES, V236, P107, DOI 10.1016/0921-8777(90)90038-7; KAUFMANN WK, 1995, CANCER METAST REV, V14, P31, DOI 10.1007/BF00690209; KAUFMANN WK, 1989, CARCINOGENESIS, V10, P1, DOI 10.1093/carcin/10.1.1; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LOCK RB, 1990, CANCER RES, V50, P3761; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MILLER EC, 1978, CANCER RES, V38, P1479; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; OLIVIERI G, 1983, MUTAT RES, V122, P65, DOI 10.1016/0165-7992(83)90144-6; PAINTER RB, 1985, MUTAT RES, V145, P63, DOI 10.1016/0167-8817(85)90041-0; PAULES RS, 1995, CANCER RES, V55, P1763; PHILLIPS JW, 1994, MOL CELL BIOL, V14, P5794, DOI 10.1128/MCB.14.9.5794; PINES J, 1990, New Biologist, V2, P389; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SASAKI MS, 1994, MUTAT RES, V307, P107, DOI 10.1016/0027-5107(94)90282-8; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCOTT D, 1994, INT J RADIAT BIOL, V66, pS157, DOI 10.1080/09553009414551991; SIROVER MA, 1976, SCIENCE, V194, P1434, DOI 10.1126/science.1006310; STEINMANN KE, 1994, ONCOGENE, V9, P387; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WATANABE M, 1985, MUTAT RES, V146, P285, DOI 10.1016/0167-8817(85)90070-7	44	247	256	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1996	10	2					238	247		10.1096/fasebj.10.2.8641557	http://dx.doi.org/10.1096/fasebj.10.2.8641557			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641557				2022-12-28	WOS:A1996TY96200008
J	Sei, Y; Whitesell, L; Kustova, Y; Paul, IA; Morse, HC; Skolnick, P; Basile, AS				Sei, Y; Whitesell, L; Kustova, Y; Paul, IA; Morse, HC; Skolnick, P; Basile, AS			Altered brain fyn kinase in a murine acquired immunodeficiency syndrome	FASEB JOURNAL			English	Article						AIDS; animal model; brain; dementia; fyn; glutamate; murine leukemia virus; tyrosine phosphorylation	RETROVIRUS-INDUCED IMMUNODEFICIENCY; LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; TYROSINE KINASES; RECEPTOR; ACTIVATION; AIDS; MICE; HIPPOCAMPUS; PROTEIN	Mice infected with the replication-defective virus (BM5def) in the LP-BM5 murine leukemia virus (MuLV) mixture develop an immune deficiency syndrome and encephalopathy characterized by impaired spatial learning and memory as demonstrated in the Morris water maze. However, the molecular mechanism (or mechanisms) underlying this cognitive deficit remains unknown. Here we report that brain fyn kinase, which has been proposed to be involved in spatial learning and memory, was unresponsive to glutamatergic stimulation in mice with MAIDS. Thus, whereas application of glutamate to hippocampal slices from control mice increased fyn protein tyrosine kinase (PTK) activity more than 2.5-fold, these changes were significantly impaired in LP-BM5 MuLV-infected mice. Moreover, mice with MAIDS exhibited an abnormal histological distribution of fyn PTK in the hippocampus, These findings suggest that virus-associated disruption of fyn kinase-mediated signaling contributes to the cognitive deficits observed in mice with MAIDS and other retrovirus-induced encephalopathies.	NIDDKD,NEUROSCI LAB,NIH,BETHESDA,MD 20892; NCI,CLIN PHARMACOL BRANCH,TUMOR CELL BIOL SECT,NIH,BETHESDA,MD 20892; NIAID,IMMUNOPATHOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Morse, Herbert/0000-0002-9331-3705	NIAID NIH HHS [N01 AI 45203] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; CHATTOPADHYAY SK, 1989, P NATL ACAD SCI USA, V86, P3862, DOI 10.1073/pnas.86.10.3862; COOKE M P, 1989, New Biologist, V1, P66; GAZZINELLI RT, 1992, J IMMUNOL, V148, P182; GELBARD HA, 1994, J VIROL, V68, P4628, DOI 10.1128/JVI.68.7.4628-4635.1994; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HA JH, 1995, J NEUROCHEM, V64, P1896; HEYES MP, 1989, ANN NEUROL, V26, P275; KLINKEN SP, 1988, J IMMUNOL, V140, P1123; KLINMAN DM, 1989, J IMMUNOL, V142, P1144; LIPTON SA, 1995, NEW ENGL J MED, V332, P934, DOI 10.1056/NEJM199504063321407; LIPTON SA, 1991, NEURON, V7, P111, DOI 10.1016/0896-6273(91)90079-F; MAKINO M, 1992, J IMMUNOL, V149, P1707; MCARTHUR JC, 1994, RES P ARNMD, V72, P251; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MORSE HC, 1992, AIDS, V6, P607, DOI 10.1097/00002030-199207000-00001; Nishida K, 1996, J NEUROCHEM, V66, P433; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PIANI D, 1994, J IMMUNOL, V152, P3578; SAITO K, 1993, BIOCHEM J, V291, P11, DOI 10.1042/bj2910011; SEI Y, 1992, FASEB J, V6, P3008, DOI 10.1096/fasebj.6.11.1644264; SEI Y, 1992, J NEUROIMMUNOL, V37, P131, DOI 10.1016/0165-5728(92)90164-G; SEI Y, J NEUROCHEM, V66, P296; SEI Y, AIDS RES HUM RETROV, V11, P753; SWOPE SL, 1993, J BIOL CHEM, V268, P25152; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; WHITESELL L, 1992, CANCER RES, V52, P1721; YAGI T, 1993, ONCOGENE, V8, P3343	32	12	12	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1996	10	2					339	344		10.1096/fasebj.10.2.8641568	http://dx.doi.org/10.1096/fasebj.10.2.8641568			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641568				2022-12-28	WOS:A1996TY96200019
J	Ludolph, DC; Konieczny, SF				Ludolph, DC; Konieczny, SF			Transcription factor families: Muscling in on the myogenic program	FASEB JOURNAL			English	Review						MyoD; bHLH; MEF2; myogenesis; regulatory pathways	LOOP-HELIX PROTEINS; ENHANCER-BINDING-FACTOR; DNA-BINDING; GENE MYF-5; DIFFERENTIATION; PHOSPHORYLATION; DOMAIN; MYOD; EMBRYOGENESIS; INACTIVATION	Embryonic skeletal muscle development has become a paradigm for understanding the molecular basis of how cell lineages are established and how cells differentiate into specialized structures. Most vertebrate muscles are derived from individual somites that produce two distinct muscle populations: the myotomal muscles that generate the axial and trunk musculature and a second migratory cell population that colonizes regions of the developing limbs. In both instances, muscle differentiation is accompanied by cell cycle arrest, fusion of individual myoblasts into multinucleate myotubes, and the transcriptional activation of muscle-specific genes. Recent experimental progress has led to greater understanding of the molecular mechanisms that control myogenesis in the embryo. Most of the advances have come from the identification and isolation of regulatory genes that are involved in controlling specific transcriptional events. In particular the muscle regulatory factor (MRF) and myocyte enhancer factor 2 (MEF2) families have been implicated in establishing the myogenic lineage as well as controlling terminal differentiation. Two additional transcription factors, Pax-3 and MLP, also appear to play a role in the production of a mature muscle cell. This review focuses on these four vertebrate transcription factor families and discusses the experimental evidence that these factors play important, non-overlapping roles in regulating skeletal muscle development.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus								ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; ATCHLEY WR, 1994, P NATL ACAD SCI USA, V91, P11522, DOI 10.1073/pnas.91.24.11522; BISCHOFF R, 1969, J CELL BIOL, V41, P188, DOI 10.1083/jcb.41.1.188; BOBER E, 1994, DEVELOPMENT, V120, P603; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1995, EMBO J, V14, P1176, DOI 10.1002/j.1460-2075.1995.tb07101.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BUCKINGHAM ME, 1994, CURR OPIN GENET DEV, V4, P745, DOI 10.1016/0959-437X(94)90142-P; BUCKLEY PA, 1974, DEV BIOL, V37, P193, DOI 10.1016/0012-1606(74)90179-1; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CHENG TC, 1995, P NATL ACAD SCI USA, V92, P561, DOI 10.1073/pnas.92.2.561; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FRANZ T, 1993, ANAT EMBRYOL, V187, P153; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9481; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GOLDHAMER DJ, 1995, DEVELOPMENT, V121, P637; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARDY S, 1993, MOL CELL BIOL, V13, P5943, DOI 10.1128/MCB.13.10.5943; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LI H, 1994, EMBO J, V13, P3580, DOI 10.1002/j.1460-2075.1994.tb06665.x; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MAK KL, 1992, MOL CELL BIOL, V12, P4334, DOI 10.1128/MCB.12.10.4334; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MITSUI K, 1993, J BIOL CHEM, V268, P24415; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NAIDU PS, 1995, MOL CELL BIOL, V15, P2707; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; RICHLER C, 1970, DEV BIOL, V23, P1, DOI 10.1016/S0012-1606(70)80004-5; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SASSOON DA, 1993, DEV BIOL, V156, P11, DOI 10.1006/dbio.1993.1055; SHIRAKATA M, 1993, GENE DEV, V7, P2456, DOI 10.1101/gad.7.12a.2456; STOCKDALE FE, 1992, DEV BIOL, V154, P284, DOI 10.1016/0012-1606(92)90068-R; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; WONG MW, 1994, DEV BIOL, V166, P683, DOI 10.1006/dbio.1994.1347; ZHANG W, 1995, GENE DEV, V9, P1388, DOI 10.1101/gad.9.11.1388	65	219	231	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1995	9	15					1595	1604		10.1096/fasebj.9.15.8529839	http://dx.doi.org/10.1096/fasebj.9.15.8529839			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TM761	8529839				2022-12-28	WOS:A1995TM76100013
J	GERRITSEN, ME; BLOOR, CM				GERRITSEN, ME; BLOOR, CM			ENDOTHELIAL-CELL GENE-EXPRESSION IN RESPONSE TO INJURY	FASEB JOURNAL			English	Review						CYTOKINES; GROWTH FACTORS; PRIMARY RESPONSE GENES; IMMEDIATE EARLY GENES; TRANSACTIVATING FACTORS; ATHEROSCLEROSIS; ARTHRITIS; ENDOTHELIUM; INTEGRINS; ADHESION; PLASMINOGEN ACTIVATOR	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; INTERCELLULAR-ADHESION MOLECULE-1; HUMAN-IMMUNODEFICIENCY-VIRUS; PROSTAGLANDIN-H SYNTHASE; FLUID SHEAR-STRESS; HUMAN VCAM1 GENE; MESSENGER-RNA; PHORBOL ESTER; CHROMOSOMAL LOCATION	Endothelial cells respond to injury with acute alterations in mediator generation and surface molecule expression. Endothelial cells may respond, depending on the stimulus, by altering the expression of various genes whose products are central to endothelial cell matrix remodeling, coagulation, and fibrinolysis, as well as interactions with polymorphonuclear leukocytes, platelets, and lymphocytes and in angiogenesis. These responses comprise endothelial activation or differentiation. The molecular events involved in endothelial perception of injury and in regulation of gene expression by cytokines, reactive oxygen intermediates, and mechanical forces are discussed. In addition, because endothelial cells from different sites exhibit heterogeneity regarding their injury responses, where possible this heterogencity in endothelial gene expression is highlighted.	UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego	GERRITSEN, ME (corresponding author), MILES INC, INST INFLAMMAT & AUTOIMMUN, West Haven, CT 06516 USA.				NHLBI NIH HHS [HL-35739, HL-32670] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035739, R01HL032670] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abate C, 1990, Semin Cancer Biol, V1, P19; ACEVEDO AD, 1992, FASEB J, V6, pA1600; ANDO J, 1987, MICROVASC RES, V33, P62, DOI 10.1016/0026-2862(87)90007-0; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAGBY GC, 1991, HEMATOL PATHOL, V5, P93; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BAND L, 1990, P CLIN BIOL RES, V353, P233; Blasi F, 1986, Horiz Biochem Biophys, V8, P377; BOCHNER BS, 1987, J IMMUNOL, V139, P2303; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BUGA GM, 1991, HYPERTENSION, V17, P187, DOI 10.1161/01.HYP.17.2.187; BURGUNDER JM, 1989, EUR J CLIN PHARMACOL, V36, P127, DOI 10.1007/BF00609183; CARSON W, 1991, AM COL RHEUM ABSTR, pA31; CARTER BZ, 1991, LAB INVEST, V65, P610; CLAESSON HE, 1989, ADV PROSTAGLANDINS T, V17, P115; COLLINS T, 1991, J BIOL CHEM, V266, P2466; COLOTTA F, 1988, BIOCHEM BIOPH RES CO, V152, P1104, DOI 10.1016/S0006-291X(88)80398-X; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; CYBULSKY MI, 1991, P NATL ACAD SCI USA, V88, P7859, DOI 10.1073/pnas.88.17.7859; DEFILIPPI P, 1991, J BIOL CHEM, V266, P7638; DEGITZ K, 1991, J BIOL CHEM, V266, P14024; DEWEY CF, 1981, J BIOMECH ENG-T ASME, V103, P177, DOI 10.1115/1.3138276; DIAMOND SL, 1989, SCIENCE, V243, P1483, DOI 10.1126/science.2467379; DOUKAS J, 1990, J IMMUNOL, V145, P1727; ESKIN SG, 1985, ASAIO J, V8, P109; FEINMARK SJ, 1986, J BIOL CHEM, V261, P6466; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; FREEMAN BA, 1982, LAB INVEST, V47, P412; FRIEDL HP, 1989, FASEB J, V3, P2512, DOI 10.1096/fasebj.3.13.2806779; GERRITSEN ME, 1987, BIOCHEM PHARMACOL, V36, P2701, DOI 10.1016/0006-2952(87)90252-8; GERRITSEN ME, 1993, IN PRESS BLOOD CELLS; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GIAVASSI R, 1990, CANCER RES, V52, P2628; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; GOTLIEB AI, 1990, TOXICOL PATHOL, V18, P603; HAJJAR DP, 1992, FASEB J, V6, P2933, DOI 10.1096/fasebj.6.11.1644257; HARLAN J, 1992, J CELL BIOCH A S, V16, pA008; HESSION C, 1991, J BIOL CHEM, V266, P6682; HLA T, 1990, J BIOL CHEM, V265, P9308; HLA T, 1990, BIOCHEM BIOPH RES CO, V167, P637, DOI 10.1016/0006-291X(90)92072-8; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; HSIEH HJ, 1992, C J CELL PHYSL, V150, P552; IBA T, 1991, J SURG RES, V50, P457, DOI 10.1016/0022-4804(91)90024-G; ISHII Y, 1992, J CLIN INVEST, V89, P794, DOI 10.1172/JCI115658; ISRAEL A, 1985, MOL CELL BIOL, V5, P2443, DOI 10.1128/MCB.5.9.2443; ISRAEL A, 1987, P NATL ACAD SCI USA, V84, P2653, DOI 10.1073/pnas.84.9.2653; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JEVNIKAR AM, 1990, KIDNEY INT, V38, P417, DOI 10.1038/ki.1990.221; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KLEBANOFF SJ, 1986, J IMMUNOL, V136, P4220; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LEE SW, 1988, P NATL ACAD SCI USA, V85, P1204, DOI 10.1073/pnas.85.4.1204; LEVESQUE MJ, 1990, BIOMATERIALS, V11, P702, DOI 10.1016/0142-9612(90)90031-K; LEWIS MS, 1988, J CLIN INVEST, V82, P2045, DOI 10.1172/JCI113825; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LIN AH, 1989, J BIOL CHEM, V264, P17379; MACKMAN N, 1989, BIOCHEMISTRY-US, V28, P1755, DOI 10.1021/bi00430a050; MADRI JA, 1988, MOL CELLULR BIOL WOU; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MARCHESI VT, 1961, Q J EXP PHYSIOL CMS, V46, P115, DOI 10.1113/expphysiol.1961.sp001522; MASINOVSKY B, 1990, J IMMUNOL, V145, P2886; MILHOAN KA, 1992, AM J PHYSIOL, V263, pH956, DOI 10.1152/ajpheart.1992.263.3.H956; MOATTER T, 1992, J CELL PHYSIOL, V151, P571, DOI 10.1002/jcp.1041510317; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; NIEDBALA MJ, 1992, BLOOD, V79, P678; NOVAK U, 1991, NUCLEIC ACIDS RES, V19, P3389, DOI 10.1093/nar/19.12.3389; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; PATEL KD, 1991, J CELL BIOL, V112, P749, DOI 10.1083/jcb.112.4.749; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; PHILLIPS PG, 1988, J APPL PHYSIOL, V64, P1196, DOI 10.1152/jappl.1988.64.3.1196; PHILLIPS PG, 1992, AM J PHYSIOL, V262, pL21, DOI 10.1152/ajplung.1992.262.1.L21; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; RAGHOW R, 1986, J BIOL CHEM, V261, P4677; RAGHOW R, 1987, TRENDS BIOCHEM SCI, V12, P358, DOI 10.1016/0968-0004(87)90165-4; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; ROSENBAUM RM, 1986, AM J PHYSIOL, V250, pC970, DOI 10.1152/ajpcell.1986.250.6.C970; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; RUBANYI GM, 1991, Z KARDIOL, V80, P91; RUBANYI GM, 1991, FASEB J, V5, P2713, DOI 10.1096/fasebj.5.12.1916094; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHATOS MA, 1992, J BIOL CHEM, V267, P597; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMPSON PJ, 1987, OXYGEN RADICALS TISS, P63; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STERN DM, 1991, DIABETES CARE, V14, P160, DOI 10.2337/diacare.14.2.160; STOLPEN AH, 1986, AM J PATHOL, V123, P16; SUZUKI Y, 1992, BIOCHEM BIOPH RES CO, V184, P1339, DOI 10.1016/S0006-291X(05)80029-4; SWERLICK RA, 1991, J INVEST DERMATOL, V97, P190, DOI 10.1111/1523-1747.ep12479643; THORNHILL MH, 1990, J IMMUNOL, V145, P865; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VANHOUTTE PM, 1991, J CARDIOVASC PHARM, V17, pS6; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WAAGE A, 1990, EUR J IMMUNOL, V20, P2439, DOI 10.1002/eji.1830201112; WARD PA, 1991, MOL ASPECTS MED, V12, P169, DOI 10.1016/0098-2997(91)90012-B; WEKSLER BB, 1990, J CELL PHYSIOL, V142, P514, DOI 10.1002/jcp.1041420310; WERTHEIMER SJ, 1992, J BIOL CHEM, V267, P12030; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; WOLF FW, 1992, J BIOL CHEM, V267, P1317; WONG WYL, 1989, MOL ENDOCRINOL, V3, P1714, DOI 10.1210/mend-3-11-1714; ZIMMERMAN GA, 1988, J CLIN INVEST, V81, P531, DOI 10.1172/JCI113351	115	159	163	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 1	1993	7	6					523	532		10.1096/fasebj.7.6.8472891	http://dx.doi.org/10.1096/fasebj.7.6.8472891			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KY009	8472891				2022-12-28	WOS:A1993KY00900005
J	KOLENBRANDER, PE; GANESHKUMAR, N; CASSELS, FJ; HUGHES, CV				KOLENBRANDER, PE; GANESHKUMAR, N; CASSELS, FJ; HUGHES, CV			COAGGREGATION - SPECIFIC ADHERENCE AMONG HUMAN ORAL PLAQUE BACTERIA	FASEB JOURNAL			English	Review						COAGGREGATION; DENTAL PLAQUE; ADHESINS RECEPTORS; ADHERENCE	PORPHYROMONAS BACTEROIDES GINGIVALIS; FIMBRIA-ASSOCIATED ADHESINS; STREPTOCOCCUS-SANGUIS; FUSOBACTERIUM-NUCLEATUM; ACTINOMYCES-VISCOSUS; CELL-SURFACE; FILAMENTOUS MICROORGANISMS; MONOCLONAL-ANTIBODIES; NUCLEOTIDE-SEQUENCE; APATITIC SURFACES	Nearly all human oral bacteria exhibit coaggregation, cell-to-cell recognition of genetically distinct cell types. Clumps or coaggregates composed of the two kinds of cells are formed immediately upon mixing two partner cell types. Members of all 18 genera tested exhibit lactose-reversible coaggregation. Many of these interactions appear to be mediated by a lectin on one cell type that interacts with a complementary carbohydrate receptor on the other cell type. A lactose-sensitive adhesin has, been isolated from Prevotella loescheii PK1295, and it exhibits the adherence properties observed with whole cells. Other adhesins have been identified and the genes for some of them have been cloned and sequenced. One Streptococcus sanguis adhesin is a lipoprotein that appears to have a dual function of recognizing both a bacterial carbohydrate receptor and a receptor in human saliva. Carbohydrate receptors for some adhesins have been purified from five oral streptococci, and they specifically block the coaggregations with the streptococcal partners that express the complementary adhesins. Coaggregation offers an explanation for the temporally related accretion of dental plaque and bacterial recognition of mucosal surfaces. Early colonizers of the tooth surface coaggregate with each other and late colonizers of the tooth surface coaggregate with each other, but with few exceptions, early colonizers do not recognize late colonizers. Furthermore, bacteria that colonize mucosal surfaces coaggregate with each other, indicating the high degree of specificity of coaggregation in the oral bacterial population.			KOLENBRANDER, PE (corresponding author), NIDR, MICROBIAL ECOL LAB, BLDG 30, ROOM 310, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.		Hughes, Christopher V./E-1438-2014					ABEYGUNAWARDANA C, 1991, BIOCHEMISTRY-US, V30, P8568, DOI 10.1021/bi00099a012; CASSELS FJ, 1990, J BIOL CHEM, V265, P14127; CASSELS FJ, 1989, J BACTERIOL, V171, P4019, DOI 10.1128/jb.171.7.4019-4025.1989; CISAR JO, 1983, INFECT IMMUN, V40, P759, DOI 10.1128/IAI.40.2.759-765.1983; DONKERSLOOT JA, 1985, J BACTERIOL, V162, P1075, DOI 10.1128/JB.162.3.1075-1078.1985; FENNO JC, 1989, INFECT IMMUN, V57, P3527, DOI 10.1128/IAI.57.11.3527-3533.1989; GANESHKUMAR N, 1991, INFECT IMMUN, V59, P1093, DOI 10.1128/IAI.59.3.1093-1099.1991; GIBBONS R J, 1970, Archives of Oral Biology, V15, P1397, DOI 10.1016/0003-9969(70)90031-2; GIBBONS RJ, 1988, INFECT IMMUN, V56, P2990, DOI 10.1128/IAI.56.11.2990-2993.1988; GIBBONS RJ, 1991, INFECT IMMUN, V59, P2948, DOI 10.1128/IAI.59.9.2948-2954.1991; GLUSKA J, 1992, IN PRESS BIOCHEMISTR; GOULBOURNE PA, 1991, J BACTERIOL, V173, P5266, DOI 10.1128/jb.173.17.5266-5274.1991; HASTY DL, 1992, INFECT IMMUN, V60, P2147, DOI 10.1128/IAI.60.6.2147-2152.1992; HUGHES CV, 1990, ARCH ORAL BIOL, V35, pS123, DOI 10.1016/0003-9969(90)90141-V; HUGHES CV, 1992, INFECT IMMUN, V60, P1178, DOI 10.1128/IAI.60.3.1178-1186.1992; HUGHES CV, 1988, APPL ENVIRON MICROB, V54, P1957, DOI 10.1128/AEM.54.8.1957-1963.1988; JENKINSON HF, 1992, INFECT IMMUN, V60, P1225, DOI 10.1128/IAI.60.3.1225-1228.1992; JENKINSON HF, 1990, INFECT IMMUN, V58, P3689, DOI 10.1128/IAI.58.11.3689-3697.1990; JONES SJ, 1972, ARCH ORAL BIOL, V17, P613, DOI 10.1016/0003-9969(72)90081-7; KAGERMEIER A, 1986, INFECT IMMUN, V51, P490, DOI 10.1128/IAI.51.2.490-494.1986; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KAUFMAN J, 1989, INFECT IMMUN, V57, P331, DOI 10.1128/IAI.57.2.331-337.1989; KILPPERBALZ R, 1985, INT J SYST BACTERIOL, V35, P482, DOI 10.1099/00207713-35-4-482; KOLENBRANDER PE, 1986, J BACTERIOL, V168, P851, DOI 10.1128/jb.168.2.851-859.1986; KOLENBRANDER PE, 1989, INFECT IMMUN, V57, P3204, DOI 10.1128/IAI.57.10.3204-3209.1989; KOLENBRANDER PE, 1990, INFECT IMMUN, V58, P3064, DOI 10.1128/IAI.58.9.3064-3072.1990; KOLENBRANDER PE, 1992, ADV MICROB ECOL, V12, P183; KOLENBRANDER PE, 1988, APPL ENVIRON MICROB, V54, P1046, DOI 10.1128/AEM.54.4.1046-1050.1988; KOLENBRANDER PE, 1989, CRIT REV MICROBIOL, V17, P137, DOI 10.3109/10408418909105746; KOLENBRANDER PE, 1985, INFECT IMMUN, V48, P741, DOI 10.1128/IAI.48.3.741-746.1985; KOLENBRANDER PE, 1990, APPL ENVIRON MICROB, V56, P3890, DOI 10.1128/AEM.56.12.3890-3894.1990; KOLENBRANDER PE, 1985, MOL BASIS ORAL MICRO, P164; LAI CH, 1990, INFECT IMMUN, V58, P3833, DOI 10.1128/IAI.58.12.3833-3839.1990; LISTGARTEN MA, 1973, ARCH ORAL BIOL, V18, P651, DOI 10.1016/0003-9969(73)90105-2; LONDON J, 1989, INFECT IMMUN, V57, P3940, DOI 10.1128/IAI.57.12.3940-3944.1989; LONDON J, 1990, J BACTERIOL, V172, P2527, DOI 10.1128/jb.172.5.2527-2534.1990; LONDON J, 1991, ANNU REP MED CHEM, V26, P239; MOORE LVH, 1987, J DENT RES, V66, P989, DOI 10.1177/00220345870660052401; MOORE WEC, 1985, INFECT IMMUN, V48, P507, DOI 10.1128/IAI.48.2.507-519.1985; NYVAD B, 1990, CARIES RES, V24, P267, DOI 10.1159/000261281; ROBRISH SA, 1987, J BACTERIOL, V169, P3891, DOI 10.1128/jb.169.9.3891-3897.1987; RUSSELL RRB, 1992, J BIOL CHEM, V267, P4631; STROMBERG N, 1992, INFECT IMMUN, V60, P3268; TEMPRO P, 1989, INFECT IMMUN, V57, P3418, DOI 10.1128/IAI.57.11.3418-3424.1989; THEILADE ELSE, 1966, J PERIODONTAL RES, V1, P1, DOI 10.1111/j.1600-0765.1966.tb01842.x; WEERKAMP AH, 1986, J BACTERIOL, V165, P746, DOI 10.1128/jb.165.3.746-755.1986; WEERKAMP AH, 1986, J BACTERIOL, V165, P756, DOI 10.1128/jb.165.3.756-762.1986; WEISS EI, 1990, ARCH ORAL BIOL, V35, pS127, DOI 10.1016/0003-9969(90)90142-W; WEISS EI, 1988, INFECT IMMUN, V56, P219, DOI 10.1128/IAI.56.1.219-224.1988; WEISS EI, 1989, INFECT IMMUN, V57, P2912, DOI 10.1128/IAI.57.9.2912-2913.1989; WEISS EI, 1987, J BACTERIOL, V169, P4215, DOI 10.1128/jb.169.9.4215-4222.1987; WEISS EI, 1988, J BACTERIOL, V170, P1123, DOI 10.1128/jb.170.3.1123-1128.1988; XIE H, 1991, ORAL MICROBIOL IMMUN, V6, P257, DOI 10.1111/j.1399-302X.1991.tb00488.x; YEUNG MK, 1992, INFECT IMMUN, V60, P1047, DOI 10.1128/IAI.60.3.1047-1054.1992; YEUNG MK, 1988, J BACTERIOL, V170, P3803, DOI 10.1128/jb.170.9.3803-3809.1988; [No title captured]	57	117	125	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1993	7	5					406	413		10.1096/fasebj.7.5.8462782	http://dx.doi.org/10.1096/fasebj.7.5.8462782			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KV351	8462782				2022-12-28	WOS:A1993KV35100004
J	HIROSE, K; LONGO, DL; OPPENHEIM, JJ; MATSUSHIMA, K				HIROSE, K; LONGO, DL; OPPENHEIM, JJ; MATSUSHIMA, K			OVEREXPRESSION OF MITOCHONDRIAL MANGANESE SUPEROXIDE-DISMUTASE PROMOTES THE SURVIVAL OF TUMOR-CELLS EXPOSED TO INTERLEUKIN-1, TUMOR-NECROSIS-FACTOR, SELECTED ANTICANCER DRUGS, AND IONIZING-RADIATION	FASEB JOURNAL			English	Note						MNSOD; IL-1; TNF; ANTICANCER DRUGS; IONIZING RADIATION	S-TRANSFERASE-PI; RADICAL FORMATION; GLUTATHIONE-PEROXIDASE; NADH DEHYDROGENASE; EXPRESSION VECTOR; OXIDATIVE DAMAGE; CYTO-TOXICITY; RESISTANCE; PARAQUAT; DNA	Interleukin-1 (IL-1) and tumor necrosis factor (TNF) selectively induce mitochondrial manganese superoxide dismutase (MnSOD) production in various cell types. We have evaluated the capacity of tumor cells that overexpress MnSOD to recover from the cytostatic and cytotoxic effects of cytokines (IL-1 and TNF), chemotherapeutic agents, and ionizing irradiation. Clones of human melanoma cell line, A375, which overexpressed MnSOD after sense MnSOD cDNA transfection, showed increased recovery from treatment with cytostatic and cytotoxic doses of IL-1alpha and TNFalpha, whereas clones of A375 cells that were transfected with anti-sense MnSOD cDNA recovered less well than normal cells from IL-1alpha and TNFalpha. In addition, Chinese hamster ovary (CHO) cells transfected with sense MnSOD cDNA showed increased survival after treatment with doxorubicin, mitomycin C, and gamma (gamma) radiation in vitro. It is hypothesized that mitochondrial MnSOD, by scavenging oxygen radicals induced by cytokines, some cytotoxic drugs, and ionizing radiation, is protective and promotes the survival of cells from the lethal effects of these treatments.	NCI,FREDERICK CANC RES & DEV CTR,DIV CANC TREATMENT,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Longo, Dan L./F-6022-2011					ADOLPHUS PGM, 1986, P NATL ACAD SCI USA, V83, P3820; BACKER JM, 1980, SCIENCE, V209, P297, DOI 10.1126/science.6770466; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BECK Y, 1987, NUCLEIC ACIDS RES, V15, P9076, DOI 10.1093/nar/15.21.9076; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CHABNER BA, 1982, CANCER PRINCIPLES PR, V1, P287; Crapo J D, 1978, Methods Enzymol, V53, P382; DAVIES KJA, 1986, J BIOL CHEM, V261, P3060; DAVIES KJA, 1983, FEBS LETT, V153, P227, DOI 10.1016/0014-5793(83)80153-7; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Doroshow J., 1982, PATHOLOGY OXYGEN, P245; DOROSHOW JH, 1986, P NATL ACAD SCI USA, V83, P4514, DOI 10.1073/pnas.83.12.4514; ELROYSTEIN O, 1986, EMBO J, V5, P615, DOI 10.1002/j.1460-2075.1986.tb04255.x; ENDO Y, 1988, J IMMUNOL, V141, P2342; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FORMAN HJ, 1982, FREE RADICAL BIO MED, V5, P65; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HALLIWELL B, 1988, FASEB J, V2, P2867, DOI 10.1096/fasebj.2.13.2844616; HASSAN HM, 1988, FREE RADICAL BIO MED, V5, P377, DOI 10.1016/0891-5849(88)90111-6; KAKO KJ, 1987, J MOL CELL CARDIOL, V19, P209, DOI 10.1016/S0022-2828(87)80563-1; KELNER MJ, 1990, J BIOL CHEM, V265, P10872; KLEBANOFF SJ, 1986, J IMMUNOL, V136, P4220; KRALL J, 1988, J BIOL CHEM, V263, P1910; MANIATIS T, 1982, MOL CLONING LABORATO, P309; MASUDA A, 1988, FASEB J, V2, P3087, DOI 10.1096/fasebj.2.15.3263930; McCord J. M, 1979, REV BIOCHEM TOXICOL, V1, P109; McCord JM, 1977, SUPEROXIDE SUPEROXID, P129; NAKAGAWA K, 1990, J BIOL CHEM, V265, P4296; NETA R, 1986, J IMMUNOL, V136, P2483; Oberley L.W., 1985, HDB METHODS OXYGEN R, P217; OBERLEY LW, 1987, ARCH BIOCHEM BIOPHYS, V254, P69, DOI 10.1016/0003-9861(87)90082-8; ONOZAKI K, 1985, J IMMUNOL, V135, P3962; PUCHALSKI RB, 1990, P NATL ACAD SCI USA, V87, P2443, DOI 10.1073/pnas.87.7.2443; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SCHNEIDER WC, 1948, J BIOL CHEM, V176, P259; SCHURIG JE, 1986, CANCER CHEMOTH PHARM, V16, P243, DOI 10.1007/BF00293985; SCOTT MD, 1989, J BIOL CHEM, V264, P2498; SINHA BK, 1989, CANCER RES, V49, P3844; WESLEY MB, 1979, P NATL ACAD SCI USA, V76, P1967; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; YAMAUCHI N, 1989, CANCER RES, V49, P1671; ZIMMERMAN RJ, 1989, CANCER RES, V49, P1644	46	329	341	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB 1	1993	7	2					361	368		10.1096/fasebj.7.2.8440412	http://dx.doi.org/10.1096/fasebj.7.2.8440412			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KN885	8440412				2022-12-28	WOS:A1993KN88500011
J	GRAY, MW; COVELLO, PS				GRAY, MW; COVELLO, PS			RNA EDITING IN PLANT-MITOCHONDRIA AND CHLOROPLASTS	FASEB JOURNAL			English	Article						RNA EDITING; FLOWERING PLANTS; ANGIOSPERMS; MITOCHONDRIA; CHLOROPLASTS	OXIDASE SUBUNIT-II; OENOTHERA MITOCHONDRIA; MESSENGER-RNAS; NADH-DEHYDROGENASE; WHEAT MITOCHONDRIA; MAIZE MITOCHONDRIA; TRANSCRIPTS; GENE; SITES; SEQUENCES	In the mitochondria and chloroplasts of flowering plants (angiosperms), transcripts of protein-coding genes are altered after synthesis so that their final primary nucleotide sequence differs from that of the corresponding DNA sequence. This posttranscriptional mRNA editing consists almost exclusively of C-to-U substitutions. Editing occurs predominantly within coding regions, mostly at isolated C residues, and usually at first or second positions of codons, thereby almost always changing the amino acid from that specified by the unedited codon. Editing may also create initiation and termination codons. The net effect of C-to-U RNA editing in plants is to make proteins encoded by plant organelles more similar in sequence to their nonplant homologs. In a few cases, a strong argument can be made that specific C-to-U editing events are essential for the production of functional plant mitochondrial proteins. Although the phenomenon of RNA editing in plants is now well documented, fundamental questions remain to be answered: What determines the specificity of editing? What is the biochemical mechanism (deamination, base exchange, or nucleotide replacement)? How did the system evolve? RNA editing in plants, as in other organisms, challenges our traditional notions of genetic information transfer.			GRAY, MW (corresponding author), DALHOUSIE UNIV,CANADIAN INST ADV RES,DEPT BIOCHEM,PROGRAM EVOLUT BIOL,HALIFAX B3H 4H7,NS,CANADA.			Gray, Michael/0000-0001-7125-2625				ARAYA A, 1992, P NATL ACAD SCI USA, V89, P1040, DOI 10.1073/pnas.89.3.1040; BEGU D, 1990, PLANT CELL, V2, P1283, DOI 10.1105/tpc.2.12.1283; BEIER H, 1992, NUCLEIC ACIDS RES, V20, P2679, DOI 10.1093/nar/20.11.2679; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BENNE R, 1990, TRENDS GENET, V6, P177, DOI 10.1016/0168-9525(90)90173-4; CATTANEO R, 1991, ANNU REV GENET, V25, P71, DOI 10.1146/annurev.ge.25.120191.000443; CHAPDELAINE Y, 1991, CELL, V65, P465, DOI 10.1016/0092-8674(91)90464-A; CONKLIN PL, 1991, GENE DEV, V5, P1407, DOI 10.1101/gad.5.8.1407; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; COVELLO PS, 1992, EMBO J, V11, P3815, DOI 10.1002/j.1460-2075.1992.tb05473.x; COVELLO PS, 1990, FEBS LETT, V268, P5, DOI 10.1016/0014-5793(90)80958-L; COVELLO PS, 1990, NUCLEIC ACIDS RES, V18, P5189, DOI 10.1093/nar/18.17.5189; DIAMOND AM, 1990, NUCLEIC ACIDS RES, V18, P6727, DOI 10.1093/nar/18.22.6727; FOX TD, 1981, CELL, V26, P315, DOI 10.1016/0092-8674(81)90200-2; GLAUBITZ JC, 1992, CURR GENET, V22, P163, DOI 10.1007/BF00351477; GRAY MW, 1992, ANNU REV PLANT PHYS, V43, P145, DOI 10.1146/annurev.pp.43.060192.001045; GRAY MW, 1992, INT REV CYTOL, V141, P233, DOI 10.1016/S0074-7696(08)62068-9; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; GUALBERTO JM, 1991, PLANT CELL, V3, P1109, DOI 10.1105/tpc.3.10.1109; GUALBERTO JM, 1990, NUCLEIC ACIDS RES, V18, P3771, DOI 10.1093/nar/18.13.3771; HAJDUK SL, 1993, FASEB J, V7, P54, DOI 10.1096/fasebj.7.1.8422975; HIESEL R, 1989, SCIENCE, V246, P1632, DOI 10.1126/science.2480644; HIESEL R, 1990, CURR GENET, V18, P371, DOI 10.1007/BF00318219; HOCH B, 1991, NATURE, V353, P178, DOI 10.1038/353178a0; HODGES P, 1992, TRENDS BIOCHEM SCI, V17, P77, DOI 10.1016/0968-0004(92)90506-5; KEMPKEN F, 1991, CURR GENET, V20, P417, DOI 10.1007/BF00317071; KNOOP V, 1991, EMBO J, V10, P3483, DOI 10.1002/j.1460-2075.1991.tb04912.x; KUDLA J, 1992, EMBO J, V11, P1099, DOI 10.1002/j.1460-2075.1992.tb05149.x; LAMATTINA L, 1991, NUCLEIC ACIDS RES, V19, P3275, DOI 10.1093/nar/19.12.3275; MAHENDRAN R, 1991, NATURE, V349, P434, DOI 10.1038/349434a0; MAIER RM, 1992, PLANT CELL, V4, P609, DOI 10.1105/tpc.4.5.609; MULLIGAN RM, 1991, PLANT CELL, V3, P327; NUGENT JM, 1991, CELL, V66, P473, DOI 10.1016/0092-8674(81)90011-8; ODA K, 1992, J MOL BIOL, V223, P1, DOI 10.1016/0022-2836(92)90708-R; SCHUSTER W, 1990, EMBO J, V9, P263, DOI 10.1002/j.1460-2075.1990.tb08104.x; SCHUSTER W, 1990, MOL CELL BIOL, V10, P2428, DOI 10.1128/MCB.10.5.2428; SCHUSTER W, 1990, NUCLEIC ACIDS RES, V18, P229, DOI 10.1093/nar/18.2.229; SCHUSTER W, 1991, FEBS LETT, V295, P97, DOI 10.1016/0014-5793(91)81394-N; SCHUSTER W, 1990, FEBS LETT, V268, P252, DOI 10.1016/0014-5793(90)81021-F; SCHUSTER W, 1991, CURR GENET, V20, P397, DOI 10.1007/BF00317068; SHAW JM, 1988, CELL, V53, P401, DOI 10.1016/0092-8674(88)90160-2; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; STUART K, 1991, TRENDS BIOCHEM SCI, V16, P68, DOI 10.1016/0968-0004(91)90027-S; SUTTON CA, 1991, MOL CELL BIOL, V11, P4274, DOI 10.1128/MCB.11.8.4274; WALBOT V, 1991, TRENDS GENET, V7, P37, DOI 10.1016/0168-9525(91)90225-F; WARD GC, 1991, PLANT MOL BIOL, V17, P1083, DOI 10.1007/BF00037148; WEINER AM, 1990, CELL, V61, P917, DOI 10.1016/0092-8674(90)90053-H; WINTZ H, 1991, CURR GENET, V19, P61, DOI 10.1007/BF00362089; WISSINGER B, 1990, MOL GEN GENET, V224, P389, DOI 10.1007/BF00262433; WISSINGER B, 1991, CELL, V65, P473, DOI 10.1016/0092-8674(91)90465-B; WISSINGER B, 1992, TRENDS GENET, V8, P322, DOI 10.1016/0168-9525(92)90265-6; YANG AJ, 1991, MOL CELL BIOL, V11, P4278, DOI 10.1128/MCB.11.8.4278	52	129	136	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					64	71		10.1096/fasebj.7.1.8422976	http://dx.doi.org/10.1096/fasebj.7.1.8422976			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422976				2022-12-28	WOS:A1993KH88000010
J	Rauhala, P; Lin, AMY; Chiueh, CC				Rauhala, P; Lin, AMY; Chiueh, CC			Neuroprotection by S-nitrosoglutathione of brain dopamine neurons from oxidative stress	FASEB JOURNAL			English	Article						hydroxyl radical; lipid peroxidation; nitric oxide; peroxynitrite; Parkinson's disease	LOW-DENSITY-LIPOPROTEIN; NITRIC-OXIDE RELEASE; GLUTATHIONE; NITROSOTHIOLS; NEUROTOXICITY; PEROXIDATION; ACTIVATION; SUPEROXIDE; INHIBITION; TOXICITY	The proposed anti- and prooxidant effects of nitric oxide (NO) derivatives, such as S-nitrosoglutathione (GSNO) and peroxynitrite, were investigated in the rat nigrostriatal dopaminergic system. Intranigal infusion of freshly prepared GSNO (0-16.8 nmol, i.n.) prevented iron-induced (4.2 nmol, i.n.) oxidative stress and nigral injury, reflected by a decrease in striatal dopamine levels. This neuroprotective effect of GSNO was verified by ex vivo imaging of brain dopamine uptake sites using I-125-labeled RTI-55. In addition, in vitro data indicate that GSNO concentration-dependently inhibited iron-evoked hydroxyl radical generation and brain lipid peroxidation. In this iron-induced oxidant stress model, GSNO was approximately 100-fold more potent than the antioxidant glutathione (GSH). Light-exposed, NO-exhausted GSNO produced neither antioxidative nor neuroprotective effects, which indicates that NO may mediate at least part of GSNO's effects. Moreover, GSNO completely (and GSH only partially) inhibited the weak pro-oxidant effect of peroxynitrite, which produced little injury to nigral neurons in vivo. This study provides relevant in vivo evidence suggesting that nanomol GSNO can protect brain dopamine neurons from iron-induced oxidative stress and degeneration. In conclusion, S-nitrosylation of GSH by NO and oxygen may be part of the antioxidative cellular defense system.	NIMH, Unit Neurodegenerat & Neuroprotect, Clin Sci Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Chiueh, CC (corresponding author), NIMH, Unit Neurodegenerat & Neuroprotect, Clin Sci Lab, NIH, Bldg 10,Rm 3D-41, Bethesda, MD 20892 USA.	chiueh@helix.nih.gov		Rauhala, Pekka/0000-0003-2036-3522	NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002648] Funding Source: NIH RePORTER; NIMH NIH HHS [Z01 MH 02648-04LCS] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BRUCKDORFER KR, 1990, BIOCHEM SOC T, V18, P285, DOI 10.1042/bst0180285; Casini A, 1997, HEPATOLOGY, V25, P361; Castagnoli K, 1997, CHEM RES TOXICOL, V10, P364, DOI 10.1021/tx970001d; Chang J, 1996, AM J PHYSIOL-LUNG C, V270, pL931, DOI 10.1152/ajplung.1996.270.6.L931; CHIUEH CC, 1983, J PHARMACOL EXP THER, V225, P529; CHIUEH CC, 1993, ADV NEUROL, V60, P251; CHIUEH CC, 1992, FREE RADICAL BIO MED, V13, P581, DOI 10.1016/0891-5849(92)90151-6; CHIUEH CC, 1995, ANN NY ACAD SCI, V738, P279; CHIUEH CC, 1997, ADV PHARMACOL, V42, P796; CHOI DW, 1993, P NATL ACAD SCI USA, V90, P9741, DOI 10.1073/pnas.90.21.9741; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; COOPER AJL, 1993, GLUTATHIONE BRAIN DI, P209; Dawson VL, 1996, J CHEM NEUROANAT, V10, P179, DOI 10.1016/0891-0618(96)00148-2; DILLARD CJ, 1973, LIPIDS, V8, P183, DOI 10.1007/BF02544632; Do KQ, 1996, NEUROCHEM INT, V29, P213; FAHN S, 1992, ANN NEUROL, V32, P804, DOI 10.1002/ana.410320616; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Gorren ACF, 1996, ARCH BIOCHEM BIOPHYS, V330, P219, DOI 10.1006/abbi.1996.0247; Gow AJ, 1997, J BIOL CHEM, V272, P2841, DOI 10.1074/jbc.272.5.2841; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Gutierrez HH, 1996, FREE RADICAL BIO MED, V21, P43, DOI 10.1016/0891-5849(95)02226-0; Hantraye P, 1996, NAT MED, V2, P1017, DOI 10.1038/nm0996-1017; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; HOGG N, 1993, FEBS LETT, V334, P170, DOI 10.1016/0014-5793(93)81706-6; KANNER J, 1991, ARCH BIOCHEM BIOPHYS, V289, P130, DOI 10.1016/0003-9861(91)90452-O; KIKUGAWA K, 1989, ADV EXP MED BIOL, V266, P345; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; KONOREV EA, 1995, J PHARMACOL EXP THER, V274, P200; Mackenzie GM, 1997, SYNAPSE, V26, P301, DOI 10.1002/(SICI)1098-2396(199707)26:3<301::AID-SYN11>3.0.CO;2-Y; MIKI N, 1977, BIOCHEM BIOPH RES CO, V75, P851, DOI 10.1016/0006-291X(77)91460-7; MOCHIZUKI H, 1994, NEUROSCI LETT, V168, P251, DOI 10.1016/0304-3940(94)90462-6; MOHANAKUMAR KP, 1994, ANN NY ACAD SCI, V738, P392; MONCADA S, 1991, PHARMACOL REV, V43, P109; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PLIUM RC, 1994, PROG INORG CHEM, V41, P599; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; RADOMSKI MW, 1992, BRIT J PHARMACOL, V107, P745, DOI 10.1111/j.1476-5381.1992.tb14517.x; Rauhala P, 1996, FREE RADICAL BIO MED, V21, P391, DOI 10.1016/0891-5849(96)00043-3; Rauhala P, 1996, SYNAPSE, V23, P58, DOI 10.1002/(SICI)1098-2396(199605)23:1<58::AID-SYN7>3.0.CO;2-G; ROTHMAN RB, 1995, J PHARMACOL EXP THER, V274, P385; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Sergent O, 1997, HEPATOLOGY, V25, P122, DOI 10.1002/hep.510250123; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; STRUCK AT, 1995, FEBS LETT, V361, P291, DOI 10.1016/0014-5793(95)00178-C; SUN CJ, 1988, J NEURAL TRANSM, V74, P75, DOI 10.1007/BF01245141; SZIRAKI I, 1998, IN PRESS NEUROSCIENC; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007; Wink DA, 1996, ARCH BIOCHEM BIOPHYS, V331, P241, DOI 10.1006/abbi.1996.0304; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813	53	146	148	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1998	12	2					165	173		10.1096/fasebj.12.2.165	http://dx.doi.org/10.1096/fasebj.12.2.165			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472981				2022-12-28	WOS:000071848400004
J	De Vries, HE; Ronken, E; Reinders, JH; Buchner, B; Van Berkel, TJC; Kuiper, J				De Vries, HE; Ronken, E; Reinders, JH; Buchner, B; Van Berkel, TJC; Kuiper, J			Acute effects of oxidized low density lipoprotein on metabolic responses in macrophages	FASEB JOURNAL			English	Article						microphysiometer; oxLDL; scavenger receptor; atheroclerosis	SCAVENGER RECEPTOR; POTENTIAL ROLE; LYSOPHOSPHATIDYLCHOLINE; ATHEROGENESIS; DEGRADATION; EXPRESSION; ACTIVATION; CELLS; LDL	The immediate effects of oxidized low density lipoprotein (OxLDL) on the metabolic activity of cultured macrophages (RAW 264.7) were studied using a microphysiometer. Administration of OxLDL acutely induced a concentration-dependent increase in metabolic activity, with an EC50 of 16 +/- 3 mu g/ml OxLDL and a maximal effect of 35% +/- 4% (mean +/- SEM; n=5). A biphasic response was measured after administration of 75 or 100 mu g/ml OxLDL consisting of an initial sharp increase, followed by the induction of a long-lasting hypoactivity of 80% of the control value. Incubation of cells with polyinosinic acid (polyI; 100 mu g/ml) for 30 min prior to OxLDL administration could completely block the effect of 25 mu g/ml OxLDL. In addition, polyI acted as a full antagonist on the decrease of the biphasic response of cells generated by 75 and 100 mu g/ml OxLDL. Macrophages used in this study possessed a specific binding site for OxLDL, with a dissociation constant (K-D) of 9 +/- 2 mu g/ml and a maximal binding of 610 +/- 32 ng I-125-OxLDL/mg cell protein. Binding of I-125-OxLDL to macrophages could be completely competed for by unlabeled OxLDL, by polyI for 58%, and by AcLDL for 46%. Tn conclusion, OxLDL can acutely activate the metabolic state of macrophages by a receptor-mediated process in a concentration-dependent fashion, which could be antagonized by polyI. Metabolic responses to OxLDL may underlie the changes observed in macrophages in the early atherosclerotic plaque.	Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands; Solway Duphar, CNS Pharmacol, Weesp, Netherlands	Leiden University; Leiden University - Excl LUMC	De Vries, HE (corresponding author), Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, POB 9503, NL-2300 RA Leiden, Netherlands.		Büchner, Bernd/E-2437-2016; Van Berkel, Theo/ABD-7677-2021	Büchner, Bernd/0000-0002-3886-2680; 				ACTON SL, 1994, J BIOL CHEM, V269, P21003; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; CHEN Y, 1995, ATHEROSCLEROSIS, V112, P69, DOI 10.1016/0021-9150(94)05400-D; DERIJKE YB, 1994, J BIOL CHEM, V269, P1; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; ESTERBAUER H, 1990, CHEM RES TOXICOL, V3, P77, DOI 10.1021/tx00014a001; Jovinge S, 1996, ARTERIOSCL THROM VAS, V16, P1573, DOI 10.1161/01.ATV.16.12.1573; KODAMA T, 1990, NATURE, V343, P1313; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; PARHAMI F, 1995, ARTERIOSCL THROM VAS, V15, P2019, DOI 10.1161/01.ATV.15.11.2019; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; Sakai M, 1996, J BIOL CHEM, V271, P27346, DOI 10.1074/jbc.271.44.27346; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; vanderKooij MA, 1996, ARTERIOSCL THROM VAS, V16, P106, DOI 10.1161/01.ATV.16.1.106; WEIS JR, 1991, FASEB J, V5, P2459, DOI 10.1096/fasebj.5.10.2065893; Yuan YP, 1996, J BIOL CHEM, V271, P27090, DOI 10.1074/jbc.271.43.27090	24	25	26	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1998	12	1					111	118		10.1096/fasebj.12.1.111	http://dx.doi.org/10.1096/fasebj.12.1.111			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YR723	9438416				2022-12-28	WOS:000071523800012
J	Loffreda, S; Yang, SQ; Lin, HZ; Karp, CL; Brengman, ML; Wang, DJ; Klein, AS; Bulkley, GB; Bao, C; Noble, PW; Lane, MD; Diehl, AM				Loffreda, S; Yang, SQ; Lin, HZ; Karp, CL; Brengman, ML; Wang, DJ; Klein, AS; Bulkley, GB; Bao, C; Noble, PW; Lane, MD; Diehl, AM			Leptin regulates proinflammatory immune responses	FASEB JOURNAL			English	Article						obesity; macrophage; cytokine; phagocytic function; TNF; lipopolysaccharide	TUMOR-NECROSIS-FACTOR; INSULIN-RESISTANCE; DIABETIC MICE; FACTOR-ALPHA; ZUCKER RAT; RECEPTOR; IDENTIFICATION; EXPRESSION; MUTATION; OBESITY	Obesity is associated with an increased incidence of infection, diabetes, and cardiovascular disease, which together account for most obesity-related morbidity and mortality. Decreased expression of leptin or of functional leptin receptors results in hyperphagia, decreased energy expenditure, and obesity. It is unclear, however, whether defective leptin-dependent signal transduction directly promotes any of the conditions that frequently complicate obesity. Abnormalities in tumor necrosis factor cc expression have been noted in each of the above comorbid conditions, so leptin deficiency could promote these complications if leptin had immunoregulatory activity. Studies of rodents with genetic abnormalities in leptin or leptin receptors revealed obesity-related deficits in macrophage phagocytosis and the expression of proinflammatory cytokines both in vivo and in vitro. Exogenous leptin up-regulated both phagocytosis and the production of proinflammatory cytokines. These results identify an important and novel function for leptin: up-regulation of inflammatory immune responses, which may provide a common pathogenetic mechanism that contributes to several of the major complications of obesity.	Johns Hopkins Univ, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Diehl, AM (corresponding author), Johns Hopkins Univ, Dept Med, 912 Ross Bldg,720 Rutland St, Baltimore, MD 21205 USA.			Karp, Christopher/0000-0002-0832-2659				Ahima RS, 1997, J CLIN INVEST, V99, P391, DOI 10.1172/JCI119172; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Gorsky RD, 1996, AM J PREV MED, V12, P388, DOI 10.1016/S0749-3797(18)30296-4; HALAAS JL, 1995, SCIENCE, V269, P544; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; JOUISLAHTI P, 1996, CIRCULATION, V93, P1372; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; KLEIN A, 1994, J LEUKOCYTE BIOL, V55, P248, DOI 10.1002/jlb.55.2.248; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; NATHAN CF, 1980, NEW ENGL J MED, V303, P622, DOI 10.1056/NEJM198009113031106; NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Plotkin BJ, 1996, J MED MICROBIOL, V44, P277, DOI 10.1099/00222615-44-4-277; Sarraf P, 1997, J EXP MED, V185, P171, DOI 10.1084/jem.185.1.171; Seidell JC, 1996, ARCH INTERN MED, V156, P958, DOI 10.1001/archinte.156.9.958; SOLBACH W, 1991, IMMUNOL TODAY, V12, P4, DOI 10.1016/0167-5699(91)90103-Z; Takao S, 1996, AM J PHYSIOL-CELL PH, V271, pC1278, DOI 10.1152/ajpcell.1996.271.4.C1278; TANAKA S, 1993, INT J OBESITY, V17, P631; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TRIENCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Ware C F, 1995, Curr Top Microbiol Immunol, V198, P175; WYSOCKA M, 1995, EUR J IMMUNOL, V25, P672, DOI 10.1002/eji.1830250307; YAMAKAWA T, 1995, CLIN IMMUNOL IMMUNOP, V75, P51, DOI 10.1006/clin.1995.1052; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557	37	1021	1074	0	35	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1998	12	1					57	65		10.1096/fasebj.12.1.57	http://dx.doi.org/10.1096/fasebj.12.1.57			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YR723	9438411				2022-12-28	WOS:000071523800007
J	Korchev, YE; Bashford, CL; Alder, GM; Apel, PY; Edmonds, DT; Lev, AA; Nandi, K; Zima, AV; Pasternak, CA				Korchev, YE; Bashford, CL; Alder, GM; Apel, PY; Edmonds, DT; Lev, AA; Nandi, K; Zima, AV; Pasternak, CA			A novel explanation for fluctuations of ion current through narrow pores	FASEB JOURNAL			English	Article						PETP membrane; alpha toxin channel; Staphylococcus aureus	AUREUS ALPHA-TOXIN; CONDUCTANCE STATES; DIVALENT-CATIONS; VOLUME CHANGES; CHANNEL; MEMBRANES; MODULATION; MECHANISM; TRANSPORT; BILAYERS	Fluctuation of ion current, between a high conductance and a low conductance state, through biological ion channels changes between an ''open'' and a ''closed'' configuration. Here we offer an additional mechanism that arises from changes in ionization of fixed charges within, or at the mouth of, a channel or pore. Our hypothesis, which is based on measurements of ion selectivity alongside ion current, applies to pores through some synthetic membranes and through channels--such as those created by certain toxins--that remain (at least partially) open in the low conductance state. It may also explain the phenomena of ''open channel noise'' and ''sub-state behavior'' that characterize several endogenous ion channels and should be considered when modeling the behavior of such channels.	UNIV LONDON, ST GEORGES MED SCH, DEPT CELLULAR & MOL SCI, LONDON SW17 0RE, ENGLAND; UNIV LONDON, CHARING CROSS & WESTMINSTER MED SCH, DEPT PHYSIOL, LONDON W6 8RF, ENGLAND; JOINT INST NUCL RES, DUBNA 141980, MOSCOW REGION, RUSSIA; RUSSIAN ACAD SCI, INST CYTOL, ST PETERSBURG 194064, RUSSIA; UNIV OXFORD, CLARENDON LAB, OXFORD OX1 3PU, ENGLAND	St Georges University London; University of London; Imperial College London; University of London; Joint Institute for Nuclear Research - Russia; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS; University of Oxford			Apel, Pavel Yu./D-4133-2009; babakinejad, babak/G-2674-2012; Korchev, Yuri/D-2498-2009	Apel, Pavel Yu./0000-0003-1259-163X; Korchev, Yuri/0000-0002-4872-8696	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APEL PY, 1985, COLLOID J USSR+, V47, P1; BASHFORD CL, 1986, J BIOL CHEM, V261, P9300; BASHFORD CL, 1988, J MEMBRANE BIOL, V103, P79, DOI 10.1007/BF01871934; BASHFORD CL, 1996, CELL MOL BIOL LETT, V1, P213; BEZRUKOV SM, 1993, PHYS REV LETT, V70, P2352, DOI 10.1103/PhysRevLett.70.2352; CESCATTI L, 1991, J MEMBRANE BIOL, V119, P53, DOI 10.1007/BF01868540; COLOMBO MF, 1992, SCIENCE, V256, P655, DOI 10.1126/science.1585178; DAWSON RMC, 1969, DATA BIOCH RES, P426; FOX JA, 1987, J MEMBRANE BIOL, V97, P1, DOI 10.1007/BF01869609; GUTMAN M, 1990, BIOCHIM BIOPHYS ACTA, V1015, P391, DOI 10.1016/0005-2728(90)90073-D; HILLE B, 1992, IONIC CHANNELS EXCIT, P472; HOWARD RE, 1986, SCIENCE, V231, P346, DOI 10.1126/science.231.4736.346; KORCHEV YE, 1995, J MEMBRANE BIOL, V147, P233; KRASILNIKOV OV, 1989, GEN PHYSIOL BIOPHYS, V8, P213; Lakshminarayanaiah N., 1969, TRANSPORT PHENOMENA; LEV AA, 1993, P ROY SOC B-BIOL SCI, V252, P187, DOI 10.1098/rspb.1993.0064; MEARES P, 1974, P ROY SOC LOND A MAT, V339, P513, DOI 10.1098/rspa.1974.0136; MENESTRINA G, 1986, J MEMBRANE BIOL, V90, P177, DOI 10.1007/BF01869935; MEVES H, 1989, BIOCHIM BIOPHYS ACTA, V988, P99, DOI 10.1016/0304-4157(89)90005-1; NISHIZAWA M, 1995, SCIENCE, V268, P700, DOI 10.1126/science.268.5211.700; PASTERNAK CA, 1995, RADIAT MEAS, V25, P675, DOI 10.1016/1350-4487(95)00220-9; PASTERNAK CA, 1993, COLLOID SURFACE A, V77, P119, DOI 10.1016/0927-7757(93)80108-Q; PENG S, 1992, BIOPHYS J, V62, P123, DOI 10.1016/S0006-3495(92)81799-X; ROSTOVTSEVA T, 1996, BIOPHYS J, V70, pA1; Rostovtseva TK, 1996, J MEMBRANE BIOL, V151, P29, DOI 10.1007/s002329900055; SACHS F, 1993, BIOPHYS J, V65, P1101, DOI 10.1016/S0006-3495(93)81149-4; SIGWORTH FJ, 1985, BIOPHYS J, V47, P709, DOI 10.1016/S0006-3495(85)83968-0; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; SPOHR R, 1990, ION TRACKERS MICROTE; STEIN WD, 1986, TRANSPORT DIFFUSION, P134; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; VLACHY V, 1986, J PHYS CHEM-US, V90, P3248, DOI 10.1021/j100405a039; WOLF A, 1995, GSI NACHR 5 OCT 1995; YEOMANS L, 1993, J CHEM PHYS, V98, P1436, DOI 10.1063/1.464308; ZAMBROWICZ EB, 1993, BIOPHYS J, V65, P1093, DOI 10.1016/S0006-3495(93)81148-2; ZIMMERBERG J, 1986, NATURE, V323, P36, DOI 10.1038/323036a0; ZIMMERBERG J, 1990, BIOPHYS J, V57, P1049, DOI 10.1016/S0006-3495(90)82623-0	37	59	60	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1997	11	7					600	608		10.1096/fasebj.11.7.9212084	http://dx.doi.org/10.1096/fasebj.11.7.9212084			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XH342	9212084				2022-12-28	WOS:A1997XH34200012
J	Prough, RA				Prough, RA			Basal and inducible expression of cytochromes P450 and related enzymes - Introduction	FASEB JOURNAL			English	Editorial Material							GENE-EXPRESSION; METABOLISM; SEQUENCE; RECEPTOR				Prough, RA (corresponding author), UNIV LOUISVILLE,SCH MED,DEPT BIOCHEM,LOUISVILLE,KY 40292, USA.		Russell A, Prough/AAH-5907-2020	Prough, Russell/0000-0001-8901-8490				ALVARES AP, 1967, BIOCHEM BIOPH RES CO, V29, P521, DOI 10.1016/0006-291X(67)90515-3; CONNEY AH, 1957, J BIOL CHEM, V228, P753; GONZALEZ FJ, 1984, GENE, V29, P281, DOI 10.1016/0378-1119(84)90057-X; HILDEBRANDT AG, 1969, MICROSOMES DRUG OXID, P331; HINES RN, 1985, ARCH BIOCHEM BIOPHYS, V237, P465, DOI 10.1016/0003-9861(85)90300-5; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; IVERSEN PL, 1987, ARCH BIOCHEM BIOPHYS, V256, P397, DOI 10.1016/0003-9861(87)90460-7; JAISWAL AK, 1985, NUCLEIC ACIDS RES, V13, P4503, DOI 10.1093/nar/13.12.4503; KAWAJIRI K, 1986, EUR J BIOCHEM, V159, P219, DOI 10.1111/j.1432-1033.1986.tb09857.x; LANDERS JP, 1992, P NATL ACAD SCI USA, V89, P8185; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; OMURA T, 1964, J BIOL CHEM, V239, P2370; POLAND AP, 1973, J BIOL CHEM, V249, P5599; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SLADEK NE, 1966, BIOCHEM BIOPH RES CO, V22, P668; WAXMAN DJ, 1988, BIOCHEM PHARMACOL, V37, P71, DOI 10.1016/0006-2952(88)90756-3; WHITLOCK JP, 1986, ANNU REV PHARMACOL, V26, P333	18	5	5	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1996	10	8					807	808		10.1096/fasebj.10.8.8666156	http://dx.doi.org/10.1096/fasebj.10.8.8666156			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UQ456	8666156				2022-12-28	WOS:A1996UQ45600001
J	Ayoubi, TAY; VanDeVen, WJM				Ayoubi, TAY; VanDeVen, WJM			Regulation of gene expression by alternative promoters	FASEB JOURNAL			English	Review						promoter; transcription; gene regulation	MESSENGER-RNAS; CELL-SURFACE; TRANSCRIPTION; MOUSE; LIVER; SEQUENCES; RECEPTOR; PROTEIN	Promoters have been defined as modulatory DNA structures containing a complex array of cis-acting regulatory elements required for accurate and efficient initiation of transcription and for controlling expression of a gene, It is becoming increasingly evident that they also constitute prime target elements through which diversity and flexibility in the complex patterns of gene expression in multicellular organisms are created. The nse of multiple promoters and transcription start sites is apparently a frequently used mechanism, whereas at the same time there is considerable variation and complexity in the patterns of alternative promoter usage, This review discusses the use of alternative promoters as a versatile mechanism to create diversity and flexibility in the regulation of gene expression, Alternative promoter usage can influence gene expression in very diverse ways, The level of transcription initiation can vary between alternative promoters, the turnover or translation efficiency of mRNA isoforms with different leader exons can differ, alternative promoters can have different tissue specificity and react differently to some signals, and finally, alternative promoter usage can lead to the generation of protein isoforms differing at the amino terminus.	UNIV LEUVEN, CTR HUMAN GENET, MOLEC ONCOL LAB, B-3000 LOUVAIN, BELGIUM; FLANDERS INTERUNIV INST BIOTECHNOL, B-3000 LOUVAIN, BELGIUM	KU Leuven								ATWATER JA, 1990, ANNU REV GENET, V24, P519; AYOUBI TAY, 1994, J BIOL CHEM, V269, P9298; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BORGESE N, 1993, FEBS LETT, V325, P70, DOI 10.1016/0014-5793(93)81416-W; CHRETIEN S, 1988, P NATL ACAD SCI USA, V85, P6, DOI 10.1073/pnas.85.1.6; CIANETTI L, 1990, NUCLEIC ACIDS RES, V18, P4361, DOI 10.1093/nar/18.15.4361; CRABTREE GR, 1992, TRANSCRIPTIONAL REGU, P1063; DOMENE HM, 1995, DNA CELL BIOL, V14, P195, DOI 10.1089/dna.1995.14.195; FISCHER G, 1993, BIOCHEM J, V292, P687, DOI 10.1042/bj2920687; GILMOUR RS, 1994, J ENDOCRINOL, V140, P1, DOI 10.1677/joe.0.1400001; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; JACOBS SM, 1994, ONCOGENE, V9, P227; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEMAIGRE FP, 1994, BIOCHEM J, V303, P1; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; McKnight S.L., 1992, TRANSCRIPTIONAL REGU; MCMAHON SB, 1992, FASEB J, V6, P2707, DOI 10.1096/fasebj.6.9.1612295; MEULIA T, 1992, MOL CELL BIOL, V12, P4590, DOI 10.1128/MCB.12.10.4590; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; NISHIO H, 1994, J CLIN INVEST, V94, P1037, DOI 10.1172/JCI117417; ODA T, 1990, J BIOL CHEM, V265, P7513; OGRAM SA, 1995, J BIOL CHEM, V270, P14235, DOI 10.1074/jbc.270.23.14235; RAJAGOPALAN S, 1993, P NATL ACAD SCI USA, V90, P6179, DOI 10.1073/pnas.90.13.6179; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SCHIBLER U, 1987, ANNU REV GENET, V21, P237, DOI 10.1146/annurev.ge.21.120187.001321; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STAPLETON G, 1993, NUCLEIC ACIDS RES, V21, P2465, DOI 10.1093/nar/21.10.2465; STROBL LJ, 1993, ONCOGENE, V8, P1437; TEERINK H, 1994, BIOCHEM J, V303, P547, DOI 10.1042/bj3030547; TENHUNEN J, 1993, DNA CELL BIOL, V12, P253, DOI 10.1089/dna.1993.12.253; THEIL EC, 1994, BIOCHEM J, V304, P1; TIMMUSK T, 1995, J CELL BIOL, V128, P185, DOI 10.1083/jcb.128.1.185; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VANDIJK MA, 1992, NUCLEIC ACIDS RES, V20, P3099, DOI 10.1093/nar/20.12.3099; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5	41	284	294	0	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1996	10	4					453	460		10.1096/fasebj.10.4.8647344	http://dx.doi.org/10.1096/fasebj.10.4.8647344			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UE557	8647344				2022-12-28	WOS:A1996UE55700009
J	King, J; HaasePettingell, C; Robinson, AS; Speed, M; Mitraki, A				King, J; HaasePettingell, C; Robinson, AS; Speed, M; Mitraki, A			Thermolabile folding intermediates: Inclusion body precursors and chaperonin substrates	FASEB JOURNAL			English	Review						inclusion body; protein folding; chaperones; aggregation	PHAGE-P22 TAILSPIKE PROTEIN; TAIL-SPIKE PROTEIN; RIBULOSE BISPHOSPHATE CARBOXYLASE; TEMPERATURE-SENSITIVE MUTATIONS; GENETIC-ANALYSIS; SALMONELLA PHAGE-P22; POLYPEPTIDE-CHAIN; ESCHERICHIA-COLI; COAT PROTEIN; IN-VITRO	An unexpected aspect of the expression of cloned genes is the frequent failure of newly synthesized polypeptide chains to reach their native state, accumulating instead as insoluble inclusion bodies, Amyloid deposits represent a related state associated with a variety of human diseases, The critical folding intermediates at the juncture of productive folding and the off-pathway aggregation reaction have been identified for the phage P22 tailspike and coat proteins, Though the parallel beta coil tailspike is thermostable, an early intracellular folding intermediate is thermolabile. As the temperature of intracellular folding is increased, this species partitions to inclusion bodies, a kinetic trap within the cell, The earliest intermediates along the in vitro aggregation pathway, sequential multimers of the thermolabile folding intermediates, have been directly identified by native gel electrophoresis, Temperature-sensitive folding (tsf) mutations identify sites in the beta coil domain, which direct the junctional intermediate down the productive pathway. Global suppressors of tsf mutants inhibit the pathway to inclusion bodies, rescuing the mutant chains, These mutants identify sites important for avoiding aggregation. Coat folding intermediates also partition to inclusion bodies as temperature is increased, Coat tsf mutants are suppressed by overexpression of the GroE chaperonin, indicating that the thermolabile intermediate is a physiological substrate for GroE. We suggest that many proteins are likely to have thermolabile intermediates in their intracellular folding pathways, which will be precursors to inclusion body formation at elevated temperatures and therefore substrates for heat shock chaperonins.			King, J (corresponding author), MIT, KING LAB, DEPT BIOL, 77 MASSACHUSETTS AVE, 68-330, CAMBRIDGE, MA 02139 USA.		MITRAKI, Anna/A-6034-2014; Robinson, Anne Skaja/H-7894-2012	Robinson, Anne Skaja/0000-0001-7235-1481; MITRAKI, Anna/0000-0001-5072-1939	NIGMS NIH HHS [F32 GM017538, F32 GM017538-02, GM17980, F32 GM017538-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017980, F32GM017980, F32GM017538, R37GM017980] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; BENSON MD, 1989, METABOLIC BASIS INHE; BOTSTEIN D, 1973, J MOL BIOL, V80, P669, DOI 10.1016/0022-2836(73)90204-0; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHEN BL, 1991, BIOCHEMISTRY-US, V30, P6260, DOI 10.1021/bi00239a026; CLELAND JL, 1991, ACS SYM SER, V470, P169; DANNER M, 1993, PROTEIN SCI, V2, P1869, DOI 10.1002/pro.5560021109; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FANE B, 1991, GENETICS, V127, P263; FANE B, 1991, J BIOL CHEM, V261, P11640; FUCHS A, 1991, BIOCHEMISTRY-US, V30, P6598, DOI 10.1021/bi00240a032; GALISTEO ML, 1993, BIOPHYS J, V65, P227, DOI 10.1016/S0006-3495(93)81073-7; GALISTEO ML, 1995, J BIOL CHEM, V270, P16595, DOI 10.1074/jbc.270.28.16595; GANONG WF, 1981, REV MED PHYSL, P549; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GOLDBERG M, 1980, PROTEIN FOLDING; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; GOLDENBERG DP, 1994, CURR BIOL, V4, P1026, DOI 10.1016/S0960-9822(00)00234-7; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GOLDENBERG DP, 1982, J BIOL CHEM, V257, P7864; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GORDON CL, 1994, J BIOL CHEM, V269, P27941; GORDON CL, 1993, J BIOL CHEM, V268, P9358; GORDON CL, 1994, GENETICS, V136, P427; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Jaenicke R, 1996, FASEB J, V10, P84, DOI 10.1096/fasebj.10.1.8566552; Jaenicke R, 1986, Methods Enzymol, V131, P218; KING J, 1986, BIO-TECHNOL, V4, P297, DOI 10.1038/nbt0486-297; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; MITRAKI A, 1993, J BIOL CHEM, V268, P20071; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; MYATT EA, 1994, P NATL ACAD SCI USA, V91, P3034, DOI 10.1073/pnas.91.8.3034; Neidhardt FC., 1987, ESCHERICHIA COLI SAL, V2nd ed, P3; PRASAD BVV, 1993, J MOL BIOL, V231, P65, DOI 10.1006/jmbi.1993.1257; PREVELIGE PE, 1988, J MOL BIOL, V202, P743, DOI 10.1016/0022-2836(88)90555-4; PREVELIGE PE, 1993, BIOPHYS J, V64, P824, DOI 10.1016/S0006-3495(93)81443-7; SATHER SK, 1994, J BIOL CHEM, V269, P25268; SAUER RT, 1982, BIOCHEMISTRY-US, V21, P5811, DOI 10.1021/bi00266a014; SCHEIN CH, 1988, BIO-TECHNOL, V6, P291, DOI 10.1038/nbt0388-291; SECKLER R, 1989, J BIOL CHEM, V264, P11750; SMITH DH, 1981, J MOL BIOL, V145, P653, DOI 10.1016/0022-2836(81)90308-9; SMITH DH, 1980, GENETICS, V96, P331; SPEED MA, 1995, PROTEIN SCI, V4, P900; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; STURTEVANT JM, 1989, J BIOL CHEM, V264, P10693; TESCHKE CM, 1995, BIOCHEMISTRY-US, V34, P6815, DOI 10.1021/bi00020a028; TESCHKE CM, 1993, BIOCHEMISTRY-US, V32, P10839, DOI 10.1021/bi00091a040; THATCHER DR, 1994, MECHANISMS PROTEIN F; THOMAS GJ, 1990, BIOCHEMISTRY-US, V29, P4181, DOI 10.1021/bi00469a022; VILLAFANE R, 1994, J BACTERIOL, V176, P137, DOI 10.1128/JB.176.1.137-142.1994; VILLAFANE R, 1988, J MOL BIOL, V204, P607, DOI 10.1016/0022-2836(88)90359-2; WETZEL R, 1994, TRENDS BIOTECHNOL, V12, P193, DOI 10.1016/0167-7799(94)90082-5; WETZEL R, 1992, STABILITY PROTEIN PH, P43; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994; YU MH, 1988, J BIOL CHEM, V263, P1424	63	131	135	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1996	10	1					57	66		10.1096/fasebj.10.1.8566549	http://dx.doi.org/10.1096/fasebj.10.1.8566549			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566549	Green Accepted			2022-12-28	WOS:A1996TR32800009
J	Miller, HI				Miller, HI			A need to ''reinvent'' the Clinton administration's approach to science and technology	FASEB JOURNAL			English	Article									INST INT STUDIES,STANFORD,CA 94305		Miller, HI (corresponding author), STANFORD UNIV,HOOVER INST,STANFORD,CA 94305, USA.							CORE A, 1993, EARTH BALANCE; GORE A, 1991, HARVARD J LAW TECHNO, V5; RIFKIN J, 1983, ALGENY	3	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1995	9	15					1509	1514		10.1096/fasebj.9.15.8529828	http://dx.doi.org/10.1096/fasebj.9.15.8529828			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TM761	8529828				2022-12-28	WOS:A1995TM76100002
J	KRUEGER, JM; OBAL, F				KRUEGER, JM; OBAL, F			GROWTH HORMONE-RELEASING HORMONE AND INTERLEUKIN-1 IN SLEEP REGULATION	FASEB JOURNAL			English	Article						REM SLEEP ELECTROENCEPHALOGRAM; SLEEP DEPRIVATION; FEVER	RAT; GRF; SOMATOSTATIN; TEMPERATURE; DEFICIENCY; CYTOKINES; SECRETION; PEPTIDES; DWARFISM	Growth hormone-releasing hormone (GHRH) and interleukin-1 (IL-1) are putative endogenous sleep-promoting substances. Evidence is reviewed showing that, 1) GHRH and IL-1 promote non-rapid eye movement sleep (NREMS); 2) if their production is enhanced, sleep is enhanced; and 3) if they are inhibited using either specific antibodies or peptide antagonists, sleep is reduced. Both are in the brain and both are also indirectly linked to sleep/wake cycles by various other evidence, e.g., growth hormone release and IL-1 plasma levels vary in phase with sleep/wake cycles. Finally, their actions are directly linked to each other; e.g., IL-1-induced growth hormone release is mediated via GHRH. The evidence reviewed strongly implicates both GHRH and IL-1 as key components in humoral sleep regulation. Humoral theories of sleep regulation are complementary to neural theories; both mechanisms affect each other and undoubtedly continuously interact to regulate sleep/wake cycles.	A SZENT GYORGYI MED UNIV,DEPT PHYSIOL,H-6720 SZEGED,HUNGARY	Szeged University	KRUEGER, JM (corresponding author), UNIV TENNESSEE CTR HLTH SCI,DEPT PHYSIOL & BIOPHYS,894 UNION AVE,MEMPHIS,TN 38163, USA.				NINDS NIH HHS [NS 27250, NS 25378] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027250, R01NS025378] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASTROM C, 1992, CLIN ENDOCRINOL, V36, P241, DOI 10.1111/j.1365-2265.1992.tb01439.x; ASTROM C, 1990, NEUROENDOCRINOLOGY, V51, P82, DOI 10.1159/000125320; BORBELY AA, 1989, PHYSIOL REV, V69, P605, DOI 10.1152/physrev.1989.69.2.605; BORN J, 1988, PSYCHONEUROENDOCRINO, V13, P233, DOI 10.1016/0306-4530(88)90021-2; CARLSON HE, 1972, J CLIN ENDOCR METAB, V34, P1102, DOI 10.1210/jcem-34-6-1102; DANGUIR J, 1986, BRAIN RES, V367, P26, DOI 10.1016/0006-8993(86)91574-X; DINARELLO CA, 1986, FASEB J, V45, P2545; DINARELLO CA, 1991, BLOOD, V77, P1627; DRUCKERCOLIN RR, 1975, NEUROENDOCRINOLOGY, V18, P1, DOI 10.1159/000122377; EHLERS CL, 1986, NEUROENDOCRINOLOGY, V42, P467, DOI 10.1159/000124489; Eisenman JS, 1982, PYRETICS ANTIPYRETIC, P187; GARRY P, 1985, ACTA ENDOCRINOL-COP, V110, P158, DOI 10.1530/acta.0.1100158; GEMMA C, 1991, EUR J PHARMACOL, V209, P139, DOI 10.1016/0014-2999(91)90026-M; GUDEWILL S, 1992, EUR ARCH PSY CLIN N, V242, P53, DOI 10.1007/BF02190343; GUILHAUME A, 1982, PEDIATR RES, V16, P299, DOI 10.1203/00006450-198204000-00011; HAYAISHI O, 1991, FASEB J, V5, P2575, DOI 10.1096/fasebj.5.11.1907936; HONEGGER J, 1991, ENDOCRINOLOGY, V129, P1275, DOI 10.1210/endo-129-3-1275; HOOPER SL, 1989, SCIENCE, V244, P1587, DOI 10.1126/science.2740903; INOUE S, 1989, BIOL SLEEP SUBSTANCE; JOUVET M, 1983, SLEEP 1982, P2; KERKHOFS M, 1992, J SLEEP RES S1, V1, P115; KRUEGER JM, 1990, YALE J BIOL MED, V63, P157; KRUEGER JM, 1990, CLIN IMMUNOL IMMUNOP, V57, P188, DOI 10.1016/0090-1229(90)90033-M; KRUEGER JM, 1992, PHYSIOL BEHAV, V51, P481, DOI 10.1016/0031-9384(92)90168-2; KRUEGER JM, 1984, AM J PHYSIOL, V246, pR994, DOI 10.1152/ajpregu.1984.246.6.R994; KRUEGER JM, IN PRESS SLEEP BREAT; KUPFER DJ, 1991, SLEEP, V14, P87; MARTIN JB, 1976, FRONT NEUROENDOCRIN, V4, P129; MENDELSON WB, 1980, BIOL PSYCHIAT, V15, P613; NISTICO G, 1987, NEUROPHARMACOLOGY, V26, P75, DOI 10.1016/0028-3908(87)90047-5; OBAL F, 1990, AM J PHYSIOL, V259, pR439, DOI 10.1152/ajpregu.1990.259.3.R439; OBAL F, 1991, BRAIN RES, V557, P149, DOI 10.1016/0006-8993(91)90128-I; OBAL F, 1986, CLIN NEUROPHARMACOL, V9, P459; OBAL F, 1988, AM J PHYSIOL, V255, pR310, DOI 10.1152/ajpregu.1988.255.2.R310; OBAL F, 1993, AM J PHYSIOL, V263, P1078; OPP MR, 1988, AM J PHYSIOL, V255, pR914, DOI 10.1152/ajpregu.1988.255.6.R914; OPP MR, 1993, INTERLEUKIN 1 BRAIN; OSWALD I, 1988, SLEEP 86, P23; PARKER DC, 1974, J CLIN ENDOCR METAB, V38, P496, DOI 10.1210/jcem-38-3-496; PARKER DC, 1969, J CLIN ENDOCR METAB, V29, P871, DOI 10.1210/jcem-29-6-871; PAYNE LC, 1992, NEUROENDOCRINOLOGY, V56, P118, DOI 10.1159/000126217; SALLANON M, 1988, NEUROSCI LETT, V88, P173, DOI 10.1016/0304-3940(88)90121-8; SASSIN JF, 1969, SCIENCE, V165, P513, DOI 10.1126/science.165.3892.513; SAWCHENKO PE, 1985, J COMP NEUROL, V237, P100, DOI 10.1002/cne.902370108; SILVA NL, 1984, AM J PHYSIOL, V247, pR335, DOI 10.1152/ajpregu.1984.247.2.R335; STEIGER A, 1992, NEUROENDOCRINOLOGY, V56, P566, DOI 10.1159/000126275; Sterman MB, 1985, BRAIN MECHANISMS SLE, P277; STERN WC, 1975, HORM BEHAV, V6, P189, DOI 10.1016/0018-506X(75)90035-5; TAKAHASHI Y, 1968, J CLIN INVEST, V47, P2079, DOI 10.1172/JCI105893; TOTH LA, 1990, DIENCEPHALON AND SLEEP, P331; VACCARINO FJ, 1985, NATURE, V314, P165; Valatx J L, 1975, Prog Brain Res, V42, P115; VANCAUTER E, 1990, HORM RES, V34, P45, DOI 10.1159/000181794; WOLFF G, 1973, PSYCHOL MED, V3, P18, DOI 10.1017/S0033291700046316; WU RH, 1988, SLEEP, V11, P425; ZHANG JX, 1988, BRAIN RES BULL, V21, P897; [No title captured]	57	78	78	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1993	7	8					645	652		10.1096/fasebj.7.8.8500689	http://dx.doi.org/10.1096/fasebj.7.8.8500689			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LE290	8500689				2022-12-28	WOS:A1993LE29000006
J	MACKRELL, AJ; KUSCHEGULLBERG, M; GARRISON, K; FESSLER, JH				MACKRELL, AJ; KUSCHEGULLBERG, M; GARRISON, K; FESSLER, JH			NOVEL DROSOPHILA LAMININ-A CHAIN REVEALS STRUCTURAL RELATIONSHIPS BETWEEN LAMININ SUBUNITS	FASEB JOURNAL			English	Note						DROSOPHILA; LAMININ-A CHAIN; EVOLUTION	NEUROMUSCULAR-JUNCTION; MULTIDOMAIN PROTEIN; SEQUENCE; DOMAINS; SECRETION; BIOSYNTHESIS; EXPRESSION; COLLAGEN; VARIANTS; HOMOLOGY	Laminins are trimeric glycoproteins composed of A, B1, and B2 chains that play important roles in cell adhesion and dffferentiation and in the assembly of basement membranes. There is evidence that multiple independent gene products can be used to supply the A, B1, and B2-like chains, thereby generating diverse laminin molecules. The set of A chain-like polypeptides are the most divergent. The amino-terminal portion of each chain, called the short arm, is composed of alternating cysteine-rich and globular domains. The amino-terminal two-thirds of the newly characterized Drosophila laminin A chain appears to encode a novel structure, but the analysis presented here shows that substantial portions of its amino acid sequence are related to sequences found in other A, B1, and B2 chains. A portion of the Drosophila A chain is composed of sequences like those found in B2 chains. These sequences parallel a portion of the vertebrate A chains, suggesting a structure for a shared ancestral A chain. However, unlike vertebrate A chains, the Drosophila A chain also contains sequences typical of B1 chains, suggesting that its gene must have arisen by recombination of segments from different primordial laminin genes.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,405 HILGARD AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Kusche-Gullberg, Marion/P-4466-2016	Kusche-Gullberg, Marion/0000-0002-5636-1695	NATIONAL INSTITUTE ON AGING [R01AG002128] Funding Source: NIH RePORTER; NIA NIH HHS [AG02128] Funding Source: Medline; NIGMS NIH HHS [GM07185] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARATANI Y, 1988, J BIOL CHEM, V263, P16163; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BECK K, 1991, PATTERNS PROTEIN SEQ, P231; CHI HC, 1989, J BIOL CHEM, V264, P1543; Dayhoff M. O., 1976, ATLAS PROTEIN SEQ S2, V5, P1; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; EDGAR D, 1988, J CELL BIOL, V106, P1299, DOI 10.1083/jcb.106.4.1299; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FESSLER LI, 1987, J CELL BIOL, V105, P2383, DOI 10.1083/jcb.105.5.2383; FRENETTE GP, 1988, CANCER RES, V48, P5193; GARRISON K, 1991, J BIOL CHEM, V266, P22899; GOAD WB, 1982, NUCLEIC ACIDS RES, V10, P247, DOI 10.1093/nar/10.1.247; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GREEN TL, 1992, J BIOL CHEM, V267, P2014; HAAPARANTA T, 1991, MATRIX, V11, P151, DOI 10.1016/S0934-8832(11)80153-8; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HUNTER I, 1992, J BIOL CHEM, V267, P6006; KANEHISA M, 1984, NUCLEIC ACIDS RES, V12, P417, DOI 10.1093/nar/12.1Part1.417; KLEIN G, 1988, CELL, V55, P331, DOI 10.1016/0092-8674(88)90056-6; KUSCHEGULLBERG M, 1992, EMBO J, V11, P4519, DOI 10.1002/j.1460-2075.1992.tb05553.x; MONTELL DJ, 1989, J CELL BIOL, V109, P2441, DOI 10.1083/jcb.109.5.2441; MONTELL DJ, 1988, CELL, V53, P463, DOI 10.1016/0092-8674(88)90166-3; MORITA A, 1985, BIOCHEM J, V229, P259, DOI 10.1042/bj2290259; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; PAULSSON M, 1991, J BIOL CHEM, V266, P17545; PAULSSON M, 1992, CRIT REV BIOCHEM MOL, V27, P93; PETERS BP, 1985, J BIOL CHEM, V260, P4732; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHITTNY J C, 1989, Journal of Cell Biology, V109, p44A; SCHITTNY JC, 1990, J CELL BIOL, V110, P825, DOI 10.1083/jcb.110.3.825; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119	37	19	19	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB 1	1993	7	2					375	381		10.1096/fasebj.7.2.8440414	http://dx.doi.org/10.1096/fasebj.7.2.8440414			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KN885	8440414				2022-12-28	WOS:A1993KN88500013
J	TAYLOR, A				TAYLOR, A			AMINOPEPTIDASES - STRUCTURE AND FUNCTION	FASEB JOURNAL			English	Review						AMINOPEPTIDASE; LEUCINE AMINOPEPTIDASE; BESTATIN; ZN2+	AMINO-ACID SEQUENCE; LEUCINE AMINOPEPTIDASE; BOVINE LENS; METHIONINE AMINOPEPTIDASE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; PROLYL AMINOPEPTIDASE; LEUCYL AMINOPEPTIDASE; VACUOLAR HYDROLASES	Aminopeptidases catalyze the cleavage of amino acids from the amino terminus of protein or peptide substrates. They are widely distributed throughout the animal and plant kingdoms and are found in many subcellular organelles, in cytoplasm, and as membrane components. Several aminopeptidases perform essential cellular functions. Many, but not all, of these peptidases are zinc metalloenzymes and are inhibited by the transition-state analog bestatin. Some are monomeric, and others are assemblies of relatively high mass (50 kDa) subunits. cDNA sequences are available for several aminopeptidases, and a 3-dimensional structure is available for the bovine lens enzyme. Crystallographic, electron micrographic, NMR, and photoaffinity labeling studies indicate that lens leucine aminopeptidase protomers are bilobal and that bestatin and substrates are bound in an active site, which is found in the larger lobe on each protomer. Zn2+ is involved in substrate liganding in most aminopeptidases. There is no evidence of an acyl-enzyme intermediate in hydrolysis. Amino acid sequences determined directly or deduced from cDNAs indicate some amino acid sequence homologies in organisms as diverse as Escherichia coli and mammals, particularly in catalytically important residues or in residues involved in metal ion binding.			TAYLOR, A (corresponding author), TUFTS UNIV,USDA,PULM RES CTR,NUTR & VIS RES LAB,BOSTON,MA 02111, USA.				PHS HHS [522361] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLEN MP, 1983, BIOCHEMISTRY-US, V22, P3778, DOI 10.1021/bi00285a010; ASANO Y, 1989, J BIOL CHEM, V264, P14233; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BARRETT AJ, 1979, PROTEINASES MAMMALIA; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BOTBOL V, 1991, J BIOL CHEM, V266, P2151; BRYCE GF, 1964, BIOCHEM J, V90, P513, DOI 10.1042/bj0900513; BURLEY SK, 1992, J MOL BIOL, V224, P113, DOI 10.1016/0022-2836(92)90580-D; CARPENTER FH, 1973, J BIOL CHEM, V248, P294; CHANG YH, 1989, J BIOL CHEM, V264, P6979; CHANG YH, 1992, J BIOL CHEM, V267, P8007; CUEVA R, 1989, FEBS LETT, V259, P125, DOI 10.1016/0014-5793(89)81510-8; CUYPERS HT, 1982, J BIOL CHEM, V257, P7077; Delange R. J., 1971, ENZYMES, VIII, P81; DIGREGORIO M, 1988, BIOCHEMISTRY-US, V27, P3613, DOI 10.1021/bi00410a013; FREITAS JO, 1985, INT J BIOCHEM, V17, P1285, DOI 10.1016/0020-711X(85)90049-7; GORDON EM, 1988, J MED CHEM, V31, P2199, DOI 10.1021/jm00119a023; GUENET C, 1992, J BIOL CHEM, V267, P8390; HANSON H, 1976, METHODS ENZYMOLOGY B, V45, P504; HARBESON SL, 1988, BIOCHEMISTRY-US, V27, P7301, DOI 10.1021/bi00419a019; JONES EW, 1982, GENETICS, V102, P665; JURNAK F, 1977, J MOL BIOL, V112, P149, DOI 10.1016/S0022-2836(77)80162-9; Kenny AJ, 1987, MAMMALIAN ECTOENZYME, P169; LIN WY, 1988, BIOCHEMISTRY-US, V27, P5062, DOI 10.1021/bi00414a017; LIN WY, 1988, BIOCHEMISTRY-US, V27, P5068, DOI 10.1021/bi00414a018; LINDERSTROMLANG YK, 1929, HOPPESEYLERS Z PHYSL, V182, P151; MALFROY B, 1989, BIOCHEM BIOPH RES CO, V161, P236, DOI 10.1016/0006-291X(89)91586-6; MATSUSHIMA M, 1991, BIOCHEM BIOPH RES CO, V178, P1459, DOI 10.1016/0006-291X(91)91057-J; MCDONALD JK, 1986, MAMMALIAN PROTEASES, V2; MCDONALD JK, 1986, MAMMALIAN PROTEASES, V2, P7; MILLER CG, 1975, ANNU REV MICROBIOL, V29, P485, DOI 10.1146/annurev.mi.29.100175.002413; MILLER CG, 1987, P NATL ACAD SCI USA, V84, P2718, DOI 10.1073/pnas.84.9.2718; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; NISHIMURA T, 1991, AGR BIOL CHEM TOKYO, V55, P1779, DOI 10.1080/00021369.1991.10870857; NISHIZAWA R, 1977, J MED CHEM, V20, P510, DOI 10.1021/jm00214a010; OCAIN TD, 1988, J MED CHEM, V31, P2193, DOI 10.1021/jm00119a022; PATTERSON EK, 1989, J BIOL CHEM, V264, P8004; PRESCOTT JM, 1985, BIOCHEMISTRY-US, V24, P5350, DOI 10.1021/bi00341a012; RICH DH, 1984, J MED CHEM, V27, P417, DOI 10.1021/jm00370a001; SANDERINK GJ, 1988, J CLIN CHEM CLIN BIO, V26, P795; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SQUIRE CR, 1991, J BIOL CHEM, V266, P22355; STIRLING CJ, 1989, EMBO J, V8, P1623, DOI 10.1002/j.1460-2075.1989.tb03547.x; SUDA H, 1976, ARCH BIOCHEM BIOPHYS, V177, P196, DOI 10.1016/0003-9861(76)90429-X; TAYLOR A, 1981, ARCH BIOCHEM BIOPHYS, V210, P90, DOI 10.1016/0003-9861(81)90167-3; TAYLOR A, 1979, J ULTRA MOL STRUCT R, V68, P92, DOI 10.1016/S0022-5320(79)90145-X; TAYLOR A, 1992, BIOCHEMISTRY-US, V31, P4141, DOI 10.1021/bi00131a034; TAYLOR A, 1984, J BIOL CHEM, V259, P4757; TAYLOR A, 1982, J BIOL CHEM, V257, P1571; TAYLOR A, 1984, EXP EYE RES, V38, P217, DOI 10.1016/0014-4835(84)90160-X; TAYLOR A, 1992, IN PRESS P INT C ANT, V8; TURZYNSKI A, 1990, EUR J BIOCHEM, V190, P509, DOI 10.1111/j.1432-1033.1990.tb15603.x; VANLOONKLAASSEN L, 1979, FEBS LETT, V107, P366, DOI 10.1016/0014-5793(79)80409-3; VANWART HE, 1981, BIOCHEMISTRY-US, V20, P5682, DOI 10.1021/bi00523a007; WATT VM, 1989, J BIOL CHEM, V264, P5480; WILKES SH, 1985, J BIOL CHEM, V260; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; 1978, ENZYME NOMENCLATURE	58	470	488	2	77	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB 1	1993	7	2					290	298		10.1096/fasebj.7.2.8440407	http://dx.doi.org/10.1096/fasebj.7.2.8440407			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KN885	8440407				2022-12-28	WOS:A1993KN88500004
J	MCCLAIN, WH				MCCLAIN, WH			TRANSFER-RNA IDENTITY	FASEB JOURNAL			English	Article						AMINOACYL-TRANSFER RNA SYNTHETASE; GENETIC CODE; PROTEIN SYNTHESIS; TRANSFER RNA IDENTITY AND RECOGNITION	PHENYLALANINE TRANSFER-RNA; ACCEPTOR IDENTITY; VARIABLE POCKET; NUCLEOTIDES; SPECIFICITY; SYNTHETASE; SITE; SEQUENCE; RESOLUTION; ANTICODON	Since its theoretical inception, the tRNA molecule has been identified and many of its functions have been described in terms of its structure. However, the molecular basis for the aminoacylation specificity of tRNA has remained largely unsolved until recently, when substantial progress has disclosed fundamental aspects of this process. What we know and would like to know about tRNA identity will be outlined, as will the experimental approaches used in this research.			MCCLAIN, WH (corresponding author), UNIV WISCONSIN, DEPT BACTERIOL, MADISON, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042123] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42123] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATILGAN T, 1986, NUCLEIC ACIDS RES, V14, P375, DOI 10.1093/nar/14.1.375; BJORK GR, 1987, ANNU REV BIOCHEM, V56, P263, DOI 10.1146/annurev.bi.56.070187.001403; CHATTAPADHYAY R, 1990, BIOCHEMISTRY-US, V29, P4263, DOI 10.1021/bi00470a001; CRICK F H, 1958, Symp Soc Exp Biol, V12, P138; CROTHERS DM, 1972, P NATL ACAD SCI USA, V69, P3063, DOI 10.1073/pnas.69.10.3063; DEDUVE C, 1988, NATURE, V333, P117, DOI 10.1038/333117a0; DOUDNA JA, 1989, P NATL ACAD SCI USA, V86, P7402, DOI 10.1073/pnas.86.19.7402; Ebel J P, 1979, TRANSFER RNA STRUCTU, P325; EDWARDS H, 1991, P NATL ACAD SCI USA, V88, P1153, DOI 10.1073/pnas.88.4.1153; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FRANCKLYN C, 1992, SCIENCE, V255, P1121, DOI 10.1126/science.1546312; FREIST W, 1989, BIOCHEMISTRY-US, V28, P6787, DOI 10.1021/bi00443a001; FRUGIER M, 1992, P NATL ACAD SCI USA, V89, P3990, DOI 10.1073/pnas.89.9.3990; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; LADNER JE, 1975, P NATL ACAD SCI USA, V72, P4414, DOI 10.1073/pnas.72.11.4414; MCCLAIN WH, 1987, J MOL BIOL, V194, P635, DOI 10.1016/0022-2836(87)90240-3; MCCLAIN WH, 1990, P NATL ACAD SCI USA, V87, P9260, DOI 10.1073/pnas.87.23.9260; MCCLAIN WH, 1988, SCIENCE, V242, P1681, DOI 10.1126/science.2462282; MCCLAIN WH, 1991, P NATL ACAD SCI USA, V88, P6147, DOI 10.1073/pnas.88.14.6147; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; MCCLAIN WH, 1988, SCIENCE, V241, P1804, DOI 10.1126/science.2459773; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; MCCLAIN WH, 1991, P NATL ACAD SCI USA, V88, P9272, DOI 10.1073/pnas.88.20.9272; MCCLAIN WH, 1988, J MOL BIOL, V202, P697, DOI 10.1016/0022-2836(88)90551-7; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; MUSIERFORSYTH K, 1992, NATURE, V357, P513, DOI 10.1038/357513a0; NAZARENKO IA, 1992, NUCLEIC ACIDS RES, V20, P475, DOI 10.1093/nar/20.3.475; NICHOLAS HB, 1987, COMPUT APPL BIOSCI, V3, P177; NICHOLAS HB, 1987, COMPUT APPL BIOSCI, V3, P53; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; NORMANLY J, 1990, J MOL BIOL, V213, P719, DOI 10.1016/S0022-2836(05)80258-X; PERRET V, 1990, NATURE, V344, P787, DOI 10.1038/344787a0; PRATHER NE, 1984, J MOL BIOL, V172, P177, DOI 10.1016/S0022-2836(84)80036-4; RENAUD M, 1981, P NATL ACAD SCI-BIOL, V78, P1606, DOI 10.1073/pnas.78.3.1606; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUDINGER J, 1992, P NATL ACAD SCI USA, V89, P5882, DOI 10.1073/pnas.89.13.5882; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHULMAN LH, 1968, P NATL ACAD SCI USA, V61, P308, DOI 10.1073/pnas.61.1.308; SCHULMAN LH, 1989, SCIENCE, V246, P1595, DOI 10.1126/science.2688091; SCHULMAN LH, 1988, SCIENCE, V240, P1591, DOI 10.1126/science.2454505; Tamura K, 1991, J Mol Recognit, V4, P129, DOI 10.1002/jmr.300040404; YARUS M, 1972, NATURE-NEW BIOL, V239, P106, DOI 10.1038/newbio239106a0	44	58	60	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1993	7	1					72	78		10.1096/fasebj.7.1.8422977	http://dx.doi.org/10.1096/fasebj.7.1.8422977			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422977				2022-12-28	WOS:A1993KH88000011
J	Seeger, M; Kraft, R; Ferrell, K; Bech-Otschir, D; Dumdey, R; Schade, R; Gordon, C; Naumann, M; Dubiel, W				Seeger, M; Kraft, R; Ferrell, K; Bech-Otschir, D; Dumdey, R; Schade, R; Gordon, C; Naumann, M; Dubiel, W			A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits	FASEB JOURNAL			English	Article						protein kinase complex; phosphorylation; signalosome	NF-KAPPA-B; C-JUN; UBIQUITIN LIGASE; LIGHT CONTROL; IN-VIVO; PHOSPHORYLATION; DEGRADATION; MITOSIS; KINASE; YEAST	A novel protein complex has been identified in human cells that has a molecular mass of approximately 450 kDa. It consists of at least eight different subunits including JAB1, the Jun activation-domain binding protein 1, and Trip15, the thyroid hormone receptor-interacting protein 15. The purified complex contains COP9 and COP11 protein homologs and is very similar, if not identical, to the plant COP9 complex involved in light-mediated signal transduction. The isolated JAB1-containing particle has kinase activity that phosphorylates I kappa B alpha, the carboxy terminus of p105, and Ser(63) and/or Ser(73) of the amino-terminal activation domain of c-Jun. The phosphorylation of c-Jun requires the carboxy terminus of the protein containing the DNA binding and dimerization domains. Three subunits of the new complex-Sgn3, Sgn5/JAB1, and Sgn6-exhibit sequence similarities to regulatory components of the 26S proteasome, which could indicate the existence of common substrate binding sites. Immunofluorescence staining reveals that the new complex shows a subcellular distribution similar to that of the 26S proteasome. The functional relationship of the two particles in regulating transcriptional activity is discussed. Considering the putative role of the complex in signal transduction and its widespread occurrence,we suggest the name JAB1-containing signalosome.	Humboldt Univ, Fac Med Charite, Inst Biochem, D-10117 Berlin, Germany; Humboldt Univ, Fac Med Charite, Inst Pharmacol & Toxicol, D-10117 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Max Planck Inst Infekt Biol, Mol Biol Abt, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Edinburgh; Max Planck Society	Dubiel, W (corresponding author), Humboldt Univ, Fac Med Charite, Inst Biochem, Monbijoustr 2, D-10117 Berlin, Germany.	wolfgang.dubiel@rz.hu-berlin.de	Naumann, Michael/B-5285-2011	Naumann, Michael/0000-0002-8060-2313; Dubiel, Wolfgang/0000-0002-3393-0701				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Chamovitz DA, 1996, CELL, V86, P115, DOI 10.1016/S0092-8674(00)80082-3; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DUBIEL W, 1995, FEBS LETT, V363, P97, DOI 10.1016/0014-5793(95)00288-K; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; Fuchs SY, 1996, ONCOGENE, V13, P1531; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; Kalderon D, 1996, CURR BIOL, V6, P662, DOI 10.1016/S0960-9822(09)00443-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Kominami K, 1997, MOL BIOL CELL, V8, P171, DOI 10.1091/mbc.8.1.171; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEWIS C, 1995, MICROBIOL-UK, V141, P1821, DOI 10.1099/13500872-141-8-1821; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P195, DOI 10.1016/S0968-0004(97)01058-X; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MANNING LS, 1991, INT J CANCER, V47, P285, DOI 10.1002/ijc.2910470219; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Seeger M, 1996, J MOL BIOL, V263, P423, DOI 10.1006/jmbi.1996.0586; Seeger M, 1997, MOL BIOL REP, V24, P83, DOI 10.1023/A:1006837600040; SHIMANUKI M, 1995, J CELL SCI, V108, P569; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; Spain BH, 1996, MOL CELL BIOL, V16, P6698; Spataro V, 1997, J BIOL CHEM, V272, P30470, DOI 10.1074/jbc.272.48.30470; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866	45	301	323	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1998	12	6					469	478		10.1096/fasebj.12.6.469	http://dx.doi.org/10.1096/fasebj.12.6.469			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZG118	9535219				2022-12-28	WOS:000072967300008
J	Cooper, S				Cooper, S			On the proposal of a G0 phase and the restriction point	FASEB JOURNAL			English	Article						cell cycle; cell division; G1 phase	CELL-PROLIFERATION; CONTINUUM MODEL; G1 PERIOD; EVENTS	Zetterberg and Larsson proposed that the restriction point divides the G1 phase into two parts. Cells before this point are able to leave the division cycle and enter a GO phase; cells past this point are unaffected by a short period of low serum. Additional results of Zetterberg and Larsson-1) cycloheximide treatment affects cells in the same way as low serum, and 2) a delay in the second division after serum starvation in the cells not initially affected in their first division-indicate that their experiments are consistent with serum removal affecting cells in all phases of the cell cycle equally. Their experiments are consistent with the continuum model of the mammalian division cycle. There is no need to postulate a restriction point or a GO phase to explain the serum starvation results.	Univ Michigan, Sch Med, Dept Immunol & Microbiol, Ann Arbor, MI 49109 USA	University of Michigan System; University of Michigan	Cooper, S (corresponding author), Univ Michigan, Sch Med, Dept Immunol & Microbiol, Ann Arbor, MI 49109 USA.							AUGENLICHT LH, 1974, EXP CELL RES, V89, P255, DOI 10.1016/0014-4827(74)90789-7; COOPER S, 1981, CELL BIOL INT REP, V5, P539, DOI 10.1016/S0309-1651(81)80002-1; COOPER S, 1979, NATURE, V280, P17, DOI 10.1038/280017a0; COOPER S, 1971, J BACTERIOL, V106, P709, DOI 10.1128/JB.106.2.709-711.1971; COOPER S, 1974, J THEOR BIOL, V46, P117, DOI 10.1016/0022-5193(74)90143-X; COOPER S, 1988, J THEOR BIOL, V135, P393, DOI 10.1016/S0022-5193(88)80253-4; COOPER S, 1982, J THEOR BIOL, V94, P783, DOI 10.1016/0022-5193(82)90078-9; COOPER S, 1981, CELL GROWTH DIFFER, P315; COOPER S, 1991, BACTERIAL GROWTH DIV; GUIGUET M, 1982, BIOSCIENCE REP, V2, P91, DOI 10.1007/BF01116174; HUTCHINSON C, 1995, CELL CYCLE CONTROL; LARK KG, 1969, J MOL BIOL, V42, P221, DOI 10.1016/0022-2836(69)90039-4; LARSSON O, 1985, J CELL SCI, V75, P259; LARSSON O, 1986, J CELL PHYSIOL, V127, P267, DOI 10.1002/jcp.1041270212; LISKAY RM, 1978, P NATL ACAD SCI USA, V75, P2873, DOI 10.1073/pnas.75.6.2873; MURRAY A, 1993, CELL CYCLE; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OKUDA A, 1989, EXP CELL RES, V185, P1, DOI 10.1016/0014-4827(89)90031-1; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; RUBIN H, 1975, J CELL PHYSIOL, V85, P261, DOI 10.1002/jcp.1040850213; ZETTERBERG A, 1991, COLD SH Q B, V56, P137; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365; ZETTERBERG A, 1995, CELL CYCLE CONTROL, P206	24	33	33	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1998	12	3					367	373		10.1096/fasebj.12.3.367	http://dx.doi.org/10.1096/fasebj.12.3.367			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YZ898	9506481				2022-12-28	WOS:000072305500026
J	Kim, MJC; Berdanier, CD				Kim, MJC; Berdanier, CD			Nutrient-gene interactions determine mitochondrial function: effect of dietary fat	FASEB JOURNAL			English	Article						dietary fat saturation; Arrhenius plot; mitochondrial respiration; BHE/cdb rats	RAT-LIVER MITOCHONDRIA; OXIDATIVE-PHOSPHORYLATION; THYROID-HORMONE; GLOBULAR PROTEINS; HYPOTHYROID RATS; ATP SYNTHASE; RESPIRATION; SUBUNITS; ACIDS	The effect on mitochondrial respiration of feeding hydrogenated coconut oil, corn oil, or menhaden oil (MO) to diabetes-prone BHE/cdb rats and normal Sprague Dawley (SD) rats was studied. Both fat source and strain affected the temperature dependence of succinate-supported respiration. The transition temperature was greater in BHE/cdb rats than in the SD rats. The efficiency of ATP synthesis as reflected by the ADP:O ratio was decreased in the BHE/cdb rats compared to SD rats, with the exception of the comparison made at 37 degrees C with the MO-fed rats; at this temperature, the ADP:O ratios were similar. The diet and strain differences suggest a dietary lipid-gene interaction with respect to the mobility of subunit 6 of the F(1)F(0)ATPase. This subunit has two errors in its gene: one that affects the proton channel and another that likely affects its mobility within the inner mitochondrial membrane.	Univ Georgia, Dept Foods & Nutr, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Berdanier, CD (corresponding author), Univ Georgia, Dept Foods & Nutr, Dawson Hall, Athens, GA 30602 USA.							BERDANIER CD, 1988, NUTRITION, V4, P293; BERDANIER CD, 1986, COMP BIOCHEM PHYS B, V85, P531, DOI 10.1016/0305-0491(86)90042-8; BERDANIER CD, 1993, J NUTR BIOCHEM, V4, P10, DOI 10.1016/0955-2863(93)90014-N; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; BURR GD, 1930, J BIOL CHEM, V82, P587; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; COX GB, 1986, BIOCHIM BIOPHYS ACTA, V849, P62, DOI 10.1016/0005-2728(86)90096-4; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; DEAVER OE, 1986, J NUTR, V116, P1148, DOI 10.1093/jn/116.7.1148; DIVAKARAN P, 1977, J NUTR, V107, P1621, DOI 10.1093/jn/107.9.1621; Fischer D, 1996, FASEB J, V10, P126, DOI 10.1096/fasebj.10.1.8566533; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GUERRIERI F, 1991, BIOCHIM BIOPHYS ACTA, V1059, P348, DOI 10.1016/S0005-2728(05)80220-8; HAFNER RP, 1990, BIOCHEM J, V265, P731, DOI 10.1042/bj2650731; HAYASHIDA T, 1963, J NUTR, V74, P103; HOCH FL, 1981, LIPIDS, V16, P328, DOI 10.1007/BF02534957; HOCH FL, 1981, J BIOENERG BIOMEMBR, V13, P25, DOI 10.1007/BF00744744; HOCH FL, 1968, POSTGRAD MED J, V44, P347, DOI 10.1136/pgmj.44.511.347; HULBERT AJ, 1976, BIOCHIM BIOPHYS ACTA, V455, P597, DOI 10.1016/0005-2736(76)90328-X; IOSSA S, 1991, MOL CELL ENDOCRINOL, V75, P15; ITO T, 1964, J BIOL CHEM, V239, P3201; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; KIM SB, 1996, THESIS U GEORGIA ATH; KIM SB, 1997, IN PRESS J BIOENERG; KLEMPERER HG, 1955, BIOCHEM J, V60, P122, DOI 10.1042/bj0600122; KUMAMOTO J, 1971, J THEOR BIOL, V31, P47, DOI 10.1016/0022-5193(71)90120-2; LEE YP, 1959, J BIOL CHEM, V234, P3051; LEHNINGER AL, 1975, BIOCHEMISTRY-US, P477; LEVIN E, 1957, J BIOL CHEM, V228, P15; LEVITT M, 1978, BIOCHEMISTRY-US, V17, P4277, DOI 10.1021/bi00613a026; MALEY GF, 1953, J BIOL CHEM, V204, P435; Mathews CE, 1995, FASEB J, V9, P1638, DOI 10.1096/fasebj.9.15.8529844; MCINTOSH MK, 1989, FASEB J, V3, P1734, DOI 10.1096/fasebj.3.6.2703106; MULLER MJ, 1981, LIFE SCI, V28, P2243, DOI 10.1016/0024-3205(81)90576-2; NISHIKI K, 1978, AM J PHYSIOL, V235, pC212, DOI 10.1152/ajpcell.1978.235.5.C212; Pedersen PL, 1996, J BIOENERG BIOMEMBR, V28, P389, DOI 10.1007/BF02113979; PEIFER JJ, 1968, J LIPID RES, V9, P193; RAFAEL J, 1984, J NUTR, V114, P255, DOI 10.1093/jn/114.2.255; RUZICKA FJ, 1981, ENDOCRINOLOGY, V109, P664, DOI 10.1210/endo-109-2-664; SEITZ HJ, 1985, BIOCHEM J, V227, P149, DOI 10.1042/bj2270149; STANCLIFF RC, 1969, ARCH BIOCHEM BIOPHYS, V131, P629, DOI 10.1016/0003-9861(69)90438-X; STERLING K, 1980, SCIENCE, V210, P340, DOI 10.1126/science.7423197; STOCKER WW, 1968, J BIOL CHEM, V234, P3051; WANDER RC, 1985, J NUTR, V115, P190, DOI 10.1093/jn/115.2.190; WILLIAMS MA, 1972, BIOCHIM BIOPHYS ACTA, V267, P444, DOI 10.1016/0005-2728(72)90172-7; WOOTEN WL, 1980, J BIOENERG BIOMEMBR, V12, P1, DOI 10.1007/BF00745009	46	13	14	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1998	12	2					243	248		10.1096/fasebj.12.2.243	http://dx.doi.org/10.1096/fasebj.12.2.243			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472989				2022-12-28	WOS:000071848400012
J	Strauss, O; Mergler, S; Wiederholt, M				Strauss, O; Mergler, S; Wiederholt, M			Regulation of L-type calcium channels by protein tyrosine kinase and protein kinase C in cultured rat and human retinal pigment epithelial cells	FASEB JOURNAL			English	Article						retinal pigment epithelium; L-type-channel; patch-clamp recording; PKC	SMOOTH-MUSCLE CELLS; PHOSPHORYLATION; MODULATION; PEPTIDE; ACTIVATION; RECEPTORS; INHIBITOR	The effect of protein tyrosine kinases (PTKs) on L-type calcium channel currents was studied in cultured rat and human retinal pigment epithelial cells, Barium currents through L-type channels were measured in the perforated patch-clamp technique and identified by using the L-type calcium channel opener Bay K8644 (10(-6) M), Application of the PTK blockers genistein (5x10(-6) M) or lavendustin A (5x10(-6) M) led to a decrease of L-type currents, The inactive genistein analog daidzein (10(-5) M) showed no effect on calcium channels, Intracellular application of pp60(c-src) (30 U/ml) via the patch-pipette during the conventional whole-cell configuration led to an increase of L-type currents, The protein kinase A and protein kinase G blocker H9 (10(-6) M) showed no effect on L-type currents; genistein reduced the current in the presence of H9, The protein kinase C (PKC) blocker chelerythrine (10(-5) M) reduced the G type current; additional inhibition of PTK by lavendustin showed an additional reduction of currents, Intracellular application of myristoylated PKC substrate (5x10(-5) M) for PKC inhibition led to a fast rundown of L-type current amplitudes, Intracellularly applied myristoylated PKC substrate (10(-4) M) together with pp60(c-src) showed no effect on L-type current, Up-regulation of PKC by 10(-6) M phorbol-12-myristate-13-acetate (PMA) had no effect on the L-type current amplitude, However, genistein in cells pretreated with PIMA led to an increase of the L-type currents, Intracellular application of pp60(c-src) in PMA-treated cells led to a reduction of L-type currents, We conclude that in the resting cell, PTK and PKC regulate L-type calcium channels in an additive manner, L-type channels appeared as a site of integration of PTK activation and of PKC-dependent pathways, The activity of PKC determines whether PTK decreases or increases L-type channel activity.			Strauss, O (corresponding author), FREE UNIV BERLIN,KLINIKUM BENJAMIN FRANKLIN,INST KLIN PHYSIOL,HINDENBURGDAMM 30,D-12200 BERLIN,GERMANY.		Strauss, Olaf/AAA-6485-2019	Mergler, Stefan/0000-0001-8608-648X; Strauss, Olaf/0000-0002-6272-8596				BOST LM, 1992, EXP EYE RES, V55, P727, DOI 10.1016/0014-4835(92)90177-T; Chik CL, 1996, FASEB J, V10, P1310, DOI 10.1096/fasebj.10.11.8836045; CLAPHAM DE, 1994, ANNU REV NEUROSCI, V17, P441; EDWARDS RB, 1977, IN VITRO CELL DEV B, V13, P301; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; GALLIZI JP, 1987, J BIOL CHEM, V262, P6947; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; Holmes TC, 1996, J NEUROSCI, V16, P1581; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HUANG XY, 1993, CELL, V80, P225; KOH SWM, 1992, CELL BIOL INT REP, V16, P1003, DOI 10.1016/S0309-1651(06)80053-6; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; STEELE FR, 1992, P NATL ACAD SCI USA, V90, P1526; STEINBERG RH, 1985, DOC OPHTHALMOL, V60, P327, DOI 10.1007/BF00158922; STRAUSS O, 1994, J CELL PHYSIOL, V160, P89, DOI 10.1002/jcp.1041600111; UEDA Y, 1993, INVEST OPHTH VIS SCI, V34, P3408; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WARD NE, 1993, BIOCHEMISTRY-US, V32, P11903, DOI 10.1021/bi00095a020; WILSON GF, 1993, NATURE, V366, P433, DOI 10.1038/366433a0; YOSHIDA M, 1992, BIOCHEM BIOPH RES CO, V189, P66, DOI 10.1016/0006-291X(92)91526-V; YOSHIMURA N, 1992, CURR EYE RES, V11, P997, DOI 10.3109/02713689209033498	23	71	74	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1997	11	11					859	867		10.1096/fasebj.11.11.9285484	http://dx.doi.org/10.1096/fasebj.11.11.9285484			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XT790	9285484				2022-12-28	WOS:A1997XT79000005
J	Arakaki, AK; Ceccarelli, EA; Carrillo, N				Arakaki, AK; Ceccarelli, EA; Carrillo, N			Plant-type ferredoxin-NADP(+) reductases: A basal structural framework and a multiplicity of functions	FASEB JOURNAL			English	Review						phylogenetic relationships; flavoprotein biogenesis; FAD assembly; structure-function relationships	SITE-DIRECTED MUTAGENESIS; AMINO-ACID-SEQUENCE; NADP+-REDUCTASE; ESCHERICHIA-COLI; ELECTRON-TRANSFER; BINDING-PROTEIN; CHLAMYDOMONAS-REINHARDTII; ANABAENA-VARIABILIS; SPINACH FERREDOXIN; GENE-PRODUCT	Ferredoxin-NADP(+) (oxido)reductase (EC 1.18.1.2, FNR) is an FAD-containing enzyme that catalyzes the reversible electron transfer between NADP(H) and electron carrier proteins such as ferredoxin and flavodoxin, Isoforms of this flavoprotein are present in chloroplasts, mitochondria, and bacteria ill which they participate in a,vide variety of redox metabolic pathways, Although ferrodoxin-NADP(+) reductases have been thoroughly investigated and their properties reviewed on several occasions, considerable advances in the understanding of these flavoenzymes have occurred in the last few years, including the characterization of cDNA and genomic clones encoding FNR proteins from plants, algae, vertebrates, and bacteria, determination of the atomic structure of a plant FNR at high resolution, and the expression of functional reductases in microorganisms like Escherichia coli and Saccharomyces cerevisiae. The aim of this article is to summarize information gained through these recent developments, including the phylogenetic relationships among ferredoxin reductases and the key structural features of the plant FNR family. Other aspects such as the catalytic mechanism of FNR and the molecular events underlying biogenesis, intracellular sorting, folding, and holoenzyme assembly of this important flavoenzyme are also discussed in some detail, Ferredoxin-NADP(+) reductases display several outstanding properties that make them excellent model proteins to address broad biological questions.	UNIV NACL ROSARIO, FAC CIENCIAS BIOQUIM & FARMACEUT, PROMUBIE, DIV MOL BIOL, RA-2000 ROSARIO, SANTA FE, ARGENTINA	National University of Rosario			Arakaki, Adrian K/C-6564-2008; Ceccarelli, Eduardo A./M-8699-2014	Ceccarelli, Eduardo A./0000-0001-5776-3306				ABRAMSKY MA, 1956, ARCH BIOCHEM BIOPHYS, V65, P475, DOI 10.1016/0003-9861(56)90207-7; ALIVERTI A, 1995, BIOCHEMISTRY-US, V34, P8371, DOI 10.1021/bi00026a019; ALIVERTI A, 1993, BIOCHEMISTRY-US, V32, P6374, DOI 10.1021/bi00076a010; AOKI H, 1995, BBA-BIOENERGETICS, V1229, P389, DOI 10.1016/0005-2728(95)00032-E; AOKI H, 1994, PLANT PHYSIOL, V104, P1473, DOI 10.1104/pp.104.4.1473; BATIE CJ, 1984, J BIOL CHEM, V259, P8832; BIANCHI V, 1995, J BACTERIOL, V177, P4528, DOI 10.1128/jb.177.15.4528-4531.1995; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; BOWSHER CG, 1993, PLANT J, V3, P463, DOI 10.1111/j.1365-313X.1993.tb00166.x; BRUNS CM, 1995, J MOL BIOL, V247, P125, DOI 10.1006/jmbi.1994.0127; CALCATERRA NB, 1995, BIOCHEMISTRY-US, V34, P12842, DOI 10.1021/bi00039a045; CARRILLO N, 1992, J BIOL CHEM, V267, P15537; CARRILLO N, 1985, EUR J BIOCHEM, V150, P469, DOI 10.1111/j.1432-1033.1985.tb09045.x; Carrillo N, 1987, TOPICS PHOTOSYNTHESI, V8, P527; CECCARELLI EA, 1991, J BIOL CHEM, V266, P14283; Ceccarelli EA, 1996, EUR J BIOCHEM, V238, P192, DOI 10.1111/j.1432-1033.1996.0192q.x; CECCARELLI EA, 1985, FEBS LETT, V190, P165, DOI 10.1016/0014-5793(85)80450-6; CHAN RL, 1987, ARCH BIOCHEM BIOPHYS, V253, P56, DOI 10.1016/0003-9861(87)90636-9; CHEN YP, 1989, J BACTERIOL, V171, P5012, DOI 10.1128/jb.171.9.5012-5016.1989; CHOI G, 1995, GENE BANK ACCESSION; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DECOTTIGNIES P, 1995, ARCH BIOCHEM BIOPHYS, V316, P249, DOI 10.1006/abbi.1995.1035; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FILLAT MF, 1991, BIOCHEM J, V274, P781, DOI 10.1042/bj2740781; FILLAT MF, 1993, PLANT MOL BIOL, V22, P725, DOI 10.1007/BF00047415; FORTI G, 1968, EUR J BIOCHEM, V3, P461, DOI 10.1111/j.1432-1033.1967.tb19553.x; GOMEZMORENO C, 1994, BIOCHEM SOC T, V22, P796, DOI 10.1042/bst0220796; GRAY JC, 1995, TRENDS CELL BIOL, V5, P243, DOI 10.1016/S0962-8924(00)89018-2; HANUKOGLU I, 1989, EUR J BIOCHEM, V180, P479, DOI 10.1111/j.1432-1033.1989.tb14671.x; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; JAKOWITSCH J, 1993, PLANT MOL BIOL, V21, P1023, DOI 10.1007/BF00023600; KARPLUS PA, 1994, J BIOENERG BIOMEMBR, V26, P89, DOI 10.1007/BF00763221; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARPLUS PA, 1984, BIOCHEMISTRY-US, V23, P6576, DOI 10.1021/bi00321a046; KEIRNS JJ, 1972, J BIOL CHEM, V247, P7374; KITAYAMA M, 1994, PLANT PHYSIOL, V106, P1715, DOI 10.1104/pp.106.4.1715; KRAKOW G, 1965, J BIOL CHEM, V240, P1820; KRAPP AR, 1995, ARCH BIOCHEM BIOPHYS, V317, P215, DOI 10.1006/abbi.1995.1156; LAX AR, 1994, GENE BANK ACCESSION; Massey V., 1970, PYRIDINE NUCLEOTIDE, P393; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; MICHALOWSKI CB, 1989, PLANT PHYSIOL, V89, P817, DOI 10.1104/pp.89.3.817; MORIGASAKI S, 1993, PLANT PHYSIOL, V103, P435, DOI 10.1104/pp.103.2.435; NEWMAN BJ, 1988, PLANT MOL BIOL, V10, P511, DOI 10.1007/BF00033606; OELMULLER R, 1993, MOL GEN GENET, V237, P261, DOI 10.1007/BF00282808; ORELLANO EG, 1993, J BIOL CHEM, V268, P19267; OTTADO J, 1994, EUR J BIOCHEM, V225, P677, DOI 10.1111/j.1432-1033.1994.00677.x; PIROLA MC, 1994, ARCH BIOCHEM BIOPHYS, V311, P480, DOI 10.1006/abbi.1994.1265; PSCHORN R, 1988, PHOTOSYNTH RES, V17, P217, DOI 10.1007/BF00035449; PUEYO JJ, 1991, EUR J BIOCHEM, V202, P1065, DOI 10.1111/j.1432-1033.1991.tb16471.x; RITCHIE SW, 1994, PLANT MOL BIOL, V26, P679, DOI 10.1007/BF00013753; SAIJO T, 1995, J BIOL CHEM, V270, P1899, DOI 10.1074/jbc.270.4.1899; SCHLUCHTER WM, 1992, BIOCHEMISTRY-US, V31, P3092, DOI 10.1021/bi00127a009; SCHRAUTEMIER B, 1985, FEBS LETT, V184, P304, DOI 10.1016/0014-5793(85)80627-X; SERRA EC, 1995, J BIOL CHEM, V270, P19930, DOI 10.1074/jbc.270.34.19930; SHIN M, 1965, J BIOL CHEM, V240, P1405; SONCINI FC, 1989, J BIOL CHEM, V264, P21112; VALLEJOS RH, 1984, J BIOL CHEM, V259, P8048; WALKER MC, 1991, ARCH BIOCHEM BIOPHYS, V287, P351, DOI 10.1016/0003-9861(91)90489-6; YAO Y, 1984, J BIOCHEM-TOKYO, V95, P1513, DOI 10.1093/oxfordjournals.jbchem.a134759; ZANETTI G, 1988, BIOCHEMISTRY-US, V27, P3753, DOI 10.1021/bi00410a035; ZANETTI G, 1996, IN PRESS FLAVINS FLA	63	139	146	2	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1997	11	2					133	140		10.1096/fasebj.11.2.9039955	http://dx.doi.org/10.1096/fasebj.11.2.9039955			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK509	9039955				2022-12-28	WOS:A1997WK50900005
J	Whitlock, JP; Okino, ST; Dong, LQ; Ko, HSP; ClarkeKatzenberg, R; Qiang, M; Li, H				Whitlock, JP; Okino, ST; Dong, LQ; Ko, HSP; ClarkeKatzenberg, R; Qiang, M; Li, H			Cytochromes P450 .5. Induction of cytochrome P4501A1: A model for analyzing mammalian gene transcription	FASEB JOURNAL			English	Review						dioxin; Ah receptor; chromatin structure; protein-DNA interactions; basic helix-loop-helix proteins	NUCLEAR TRANSLOCATOR PROTEIN; ARYL-HYDROCARBON RECEPTOR; LOOP-HELIX PROTEINS; HEAT-SHOCK PROTEIN; DNA-BINDING FORM; AH-RECEPTOR; DIOXIN RECEPTOR; AROMATIC-HYDROCARBONS; MECHANISM; ENZYMES	The induction of microsomal cytochrome PP501A1 by polycyclic aromatic hydrocarbons represents an interesting response by which mammalian cells adapt to xenobiotic exposure. Enzyme induction reflects increased transcription of the corresponding CYP1A1 gene. Analyses of the induction mechanism using genetic, biochemical, and molecular biological approaches have revealed a novel transcriptional regulatory pathway that involves ligand-dependent heterodimerization between two basic helix-loop-helix proteins (the Ah receptor and Arnt), interaction of the heterodimer with a xenobiotic-responsive enhancer, transmission of the induction signal from the enhancer to the CYP1A1 promoter, and alterations in chromatin structure. Current techniques permit examination of the induction mechanism in intact cells and analyses of the CYP1A1 gene in its native chromosomal configuration. Such experiments generate new insights into the control of mammalian transcription that are of relatively broad interest.			Whitlock, JP (corresponding author), STANFORD UNIV,SCH MED,DEPT MOLEC PHARMACOL,STANFORD,CA 94305, USA.				NATIONAL CANCER INSTITUTE [R35CA053887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003719] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA 53887] Funding Source: Medline; NIEHS NIH HHS [R01 ES 03719, ES 05598] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BACSI SG, 1995, MOL PHARMACOL, V47, P432; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; CARVER LA, 1994, J BIOL CHEM, V269, P30109; CONNEY AH, 1982, CANCER RES, V42, P4875; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FUJIIKURIYAMA Y, 1992, FASEB J, V6, P706, DOI 10.1096/fasebj.6.2.1537460; GELBOIN HV, 1980, PHYSIOL REV, V60, P1107, DOI 10.1152/physrev.1980.60.4.1107; GONZALEZ FJ, 1990, TRENDS GENET, V6, P182, DOI 10.1016/0168-9525(90)90174-5; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HENRY EC, 1993, BIOCHEM J, V294, P95, DOI 10.1042/bj2940095; HUFF J, 1994, ANNU REV PHARMACOL, V34, P343; JAIN S, 1994, J BIOL CHEM, V269, P31518; JERINA DM, 1974, SCIENCE, V185, P573, DOI 10.1126/science.185.4151.573; JONES KW, 1990, MOL CELL BIOL, V10, P5098, DOI 10.1128/MCB.10.10.5098; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; Ko HSP, 1996, MOL CELL BIOL, V16, P430; LI H, 1994, J BIOL CHEM, V269, P28098; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; MA Q, 1995, J BIOL CHEM, V270, P12697, DOI 10.1074/jbc.270.21.12697; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; MORGAN JE, 1992, P NATL ACAD SCI USA, V89, P11622, DOI 10.1073/pnas.89.23.11622; NEBERT DW, 1991, MOL ENDOCRINOL, V5, P1203, DOI 10.1210/mend-5-9-1203; OKEY AB, 1994, TRENDS PHARMACOL SCI, V15, P226, DOI 10.1016/0165-6147(94)90316-6; OKEY AB, 1990, PHARMACOL THERAPEUT, V45, P241, DOI 10.1016/0163-7258(90)90030-6; OKINO ST, 1995, MOL CELL BIOL, V15, P3714; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; PROBST MR, 1993, MOL PHARMACOL, V44, P511; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SHEN ES, 1992, J BIOL CHEM, V267, P6815; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WHITELAW ML, 1995, P NATL ACAD SCI USA, V92, P4437, DOI 10.1073/pnas.92.10.4437; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; WU L, 1992, P NATL ACAD SCI USA, V89, P4811, DOI 10.1073/pnas.89.11.4811; WU L, 1993, NUCLEIC ACIDS RES, V21, P119, DOI 10.1093/nar/21.1.119	44	222	224	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1996	10	8					809	818		10.1096/fasebj.10.8.8666157	http://dx.doi.org/10.1096/fasebj.10.8.8666157			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UQ456	8666157				2022-12-28	WOS:A1996UQ45600002
J	Sen, CK; Packer, L				Sen, CK; Packer, L			Antioxidant and redox regulation of gene transcription	FASEB JOURNAL			English	Review						reactive oxygen species; antioxidant therapy; human disease; thiols; nucleic acid; AIDS; atherosclerosis; NF-kappa B; AP-1	NF-KAPPA-B; DNA-BINDING ACTIVITY; GLUTATHIONE-S-TRANSFERASE; PROTEIN-TYROSINE KINASE; TUMOR-NECROSIS-FACTOR; C-JUN GENE; CIS-FOS; ACTIVATION; INDUCTION; OXYGEN	Reactive oxygen species (ROS) are implicated in the pathogenesis of a wide variety of human diseases, Recent evidence suggests that at moderately high concentrations, certain forms of ROS such as H2O2 may act as signal transduction messengers. To develop a better understanding of the exact mechanisms that underlie ROS-dependent disorders in biological systems, recent studies have investigated the regulation of gene expression by oxidants, antioxidants, and other determinants of the intracellular reduction-oxidation (redox) state, At least two well-defined transcription factors, nuclear factor (NF) kappa B and activator protein (AP)-1 have been identified to be regulated by the intracellular redox state, The regulation of gene expression by oxidants, antioxidants, and the redox state has emerged as a novel subdiscipline in molecular biology that has promising therapeutic implications, Binding sites of the redox-regulated transcription factors NF-kappa B and AP-1 are located in the promoter region of a large variety of genes that are directly involved in the pathogenesis of diseases, e.g., AIDS, cancer, atherosclerosis and diabetic complications. Biochemical and clinical studies have indicated that antioxidant therapy may be useful in the treatment of disease, Critical steps in the signal transduction cascade are sensitive to oxidants and antioxidants. Many basic events of cell regulation such as protein phosphorylation and binding of transcription factors to consensus sites on DNA are driven by physiological oxidant-antioxidant homeostasis, especially by the thiol-disulfide balance, Endogenous glutathione and thioredoxin systems, and the exogenous lipoate-dihydrolipoate couple may therefore be considered to be effective regulators of redox-sensitive gene expression, The efficacy of different antioxidants to favorably influence the molecular mechanisms implicated in human disease should be a critical determinant of its selection for clinical studies.	UNIV KUOPIO, FAC MED, DEPT PHYSIOL, SF-70211 KUOPIO, FINLAND	University of Eastern Finland	Sen, CK (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, MEMBRANE BIOENERGIES GRP, 251 LIFE SCI ADDIT, BERKELEY, CA 94720 USA.		Sen, Chandan K/A-8762-2013		NCI NIH HHS [CA 47597-07] Funding Source: Medline; NIGMS NIH HHS [GM 27345-15] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047597] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM027345] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AAGAARDTILLERY KM, 1995, J IMMUNOL, V155, P3297; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AMSTAD PA, 1992, CANCER RES, V52, P3952; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BAUR A, 1991, KLIN WOCHENSCHR, V69, P722, DOI 10.1007/BF01649442; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHEN CC, 1995, J IMMUNOL, V155, P3538; CHOI HS, 1993, MOL ENDOCRINOL, V7, P1596, DOI 10.1210/me.7.12.1596; COLLART FR, 1995, RADIAT RES, V142, P188, DOI 10.2307/3579028; COLLINS T, 1993, LAB INVEST, V68, P499; CRAWFORD D, 1988, ONCOGENE, V3, P27; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DROGE W, 1994, FASEB J, V8, P1131; FRAME MC, 1991, ONCOGENE, V6, P205; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; Galter Dagmar, 1994, European Journal of Biochemistry, V221, P639; GOLDMAN R, 1994, BBA-MOL CELL RES, V1222, P265, DOI 10.1016/0167-4889(94)90178-3; GOLDSTONE SD, 1995, BBA-GENE STRUCT EXPR, V1263, P114, DOI 10.1016/0167-4781(95)00088-X; GOPALAKRISHNA R, 1991, ARCH BIOCHEM BIOPHYS, V285, P382, DOI 10.1016/0003-9861(91)90377-U; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; HADARI YR, 1993, MOL CELL ENDOCRINOL, V97, P9, DOI 10.1016/0303-7207(93)90206-Y; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HUNT NH, 1994, MCBU, P237; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JANSSEN YMW, 1995, CANCER RES, V55, P2085; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LEGRANDPOELS S, 1995, J BIOL CHEM, V270, P6925, DOI 10.1074/jbc.270.12.6925; LIAO F, 1993, J CLIN INVEST, V91, P2572, DOI 10.1172/JCI116495; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; LOS M, 1995, EUR J IMMUNOL, V25, P159, DOI 10.1002/eji.1830250127; LOS M, 1995, EMBO J, V14, P3731, DOI 10.1002/j.1460-2075.1995.tb00043.x; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MITOMO K, 1994, GENE, V145, P197; NAKAMURA K, 1993, ONCOGENE, V8, P3133; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; NOVOGRODSKY A, 1982, P NATL ACAD SCI-BIOL, V79, P1171, DOI 10.1073/pnas.79.4.1171; OKAMOTO T, 1992, INT IMMUNOL, V4, P811, DOI 10.1093/intimm/4.7.811; OKUNO H, 1993, ONCOGENE, V8, P695; PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; PARHAMI F, 1993, J CLIN INVEST, V92, P471, DOI 10.1172/JCI116590; PENNYPACKER KR, 1994, FASEB J, V8, P475, DOI 10.1096/fasebj.8.8.8181665; PINKUS R, 1993, BIOCHEM J, V290, P637, DOI 10.1042/bj2900637; PURI PL, 1995, J BIOL CHEM, V270, P22129, DOI 10.1074/jbc.270.38.22129; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHIEVEN GL, 1993, J IMMUNOTHER, V14, P221, DOI 10.1097/00002371-199310000-00009; SCHIEVEN GL, 1993, J BIOL CHEM, V268, P16688; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SCHMIDT KN, 1995, IN PRESS J BIOL CHEM; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; Sen CK, 1996, BIOCHEM BIOPH RES CO, V218, P148, DOI 10.1006/bbrc.1996.0026; SHIBANUMA M, 1988, ONCOGENE, V3, P17; Sies, 1991, OXIDATIVE STRESS OXI, P245; Sies H., 1991, OXIDATIVE STRESS OXI, P650; STAUBLE B, 1994, EUR J BIOCHEM, V226, P393, DOI 10.1111/j.1432-1033.1994.tb20064.x; SULLIVAN SG, 1994, FREE RADICAL BIO MED, V16, P399, DOI 10.1016/0891-5849(94)90042-6; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI YJ, 1994, BIOCHEM MOL BIOL INT, V32, P299; Suzuki YJ, 1995, BIOCHEM MOL BIOL INT, V36, P241; SUZUKI YJ, 1993, BIOCHEM BIOPH RES CO, V193, P277, DOI 10.1006/bbrc.1993.1620; SUZUKI YJ, 1995, BIOCHEM BIOPH RES CO, V210, P537, DOI 10.1006/bbrc.1995.1693; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; SUZUKI YJ, 1993, BIOCHEM MOL BIOL INT, V31, P693; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; Treisman R, 1990, Semin Cancer Biol, V1, P47; TRUMP B F, 1992, Current Opinion in Cell Biology, V4, P227; VALLE A, 1995, FEBS LETT, V357, P41, DOI 10.1016/0014-5793(94)01329-Y; WATT F, 1993, NUCLEIC ACIDS RES, V21, P5092, DOI 10.1093/nar/21.22.5092; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; YAN SD, 1994, J BIOL CHEM, V269, P9889; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; ZOR U, 1993, BIOCHEM J, V295, P879, DOI 10.1042/bj2950879	94	1679	1722	2	81	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1996	10	7					709	720		10.1096/fasebj.10.7.8635688	http://dx.doi.org/10.1096/fasebj.10.7.8635688			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UN798	8635688	Bronze			2022-12-28	WOS:A1996UN79800005
J	Wilkinson, MF; Earle, ML; Triggle, CR; Barnes, S				Wilkinson, MF; Earle, ML; Triggle, CR; Barnes, S			Interleukin-1 beta, tumor necrosis factor-alpha, and LPS enhance calcium channel current in isolated vascular smooth muscle cells of rat tail artery	FASEB JOURNAL			English	Article						cytokine; calcium channel; immunomodulation; endotoxin; patch clamp	NITRIC-OXIDE SYNTHASE; RECEPTOR ANTAGONIST; SEPTIC SHOCK; ENDOTOXIN-SHOCK; INFLAMMATION; SURVIVAL; THERAPY; RABBITS; DISEASE	Cytokines, such as interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha), are thought to be responsible for the compromised blood pressure regulation after systemic infection or other antigenic challenge. Because Ca homeostasis is critical for the maintenance of vascular tone, we hypothesized that cytokines may contribute to alterations in blood pressure by a mechanism involving the voltage-sensitive Ca channel in vascular smooth muscle (VSM) cells. Using nystatin-permeabilized patch techniques we examined the effects of IL-1 beta, TNF-alpha, and lipopolysaccharide (LPS) on the Ca channel of VSM cells isolated from rat tail artery. Both IL-1 beta (0.05-1 nM) and TNF-alpha (0.1-1 nM) increased, dose-dependently, the Ba2+ current carried in VSM Ca channels, whereas heat-denatured IL-1 beta was without significant effect on the channel. LPS (0.01-1.0 ng/ml) also increased the Ba2+ current with onset kinetics similar to the two cytokines. Prostaglandins were ruled out as an intermediary in VSM Ca channel modulation, as prostaglandin E(2) had no effect and indomethacin (1 mu M) failed to block TNF-alpha-induced Ca channel enhancement. The role of cyclic nucleotides in mediating TNF-alpha-induced changes in Ca channel activity was also assessed. Increasing intracellular cAMP via forskolin (1 mu M) did not affect the response to TNF-alpha, but pretreatment with the membrane-permeant analog of cGMP, dibutyryl cGMP (100 mu M), inhibited the response to TNF-alpha. These data demonstrate that IL-1 beta, TNF-alpha, and LPS have immediate effects on VSM cells via an interaction with the voltage-sensitive Ca channel, and these effects may be regulated by intracellular cGMP. Immunomodulation of Ca channels may represent an early signaling step in VSM cells mediating kinetically slower events, such as changes in gene transcription.	UNIV CALGARY,FAC MED,SMOOTH MUSCLE RES GRP,CALGARY,AB T2N 4N1,CANADA	University of Calgary	Wilkinson, MF (corresponding author), UNIV CALGARY,FAC MED,NEUROSCI RES GRP,3330 HOSP DR NW,CALGARY,AB T2N 4N1,CANADA.			Triggle, Christopher/0000-0001-5307-0537				ALEXANDER HR, 1992, SURGERY, V112, P188; BATAAILLARD A, 1994, AM J PHYSIOL, V3, pR1148; BEASLEY D, 1994, AM J PHYSIOL, V266, pR1197, DOI 10.1152/ajpregu.1994.266.4.R1197; BEASLEY D, 1994, J EXP MED, V179, P71, DOI 10.1084/jem.179.1.71; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; CANNON JG, 1990, J INFECT DIS, V161, P79, DOI 10.1093/infdis/161.1.79; CLINTON SK, 1991, AM J PATHOL, V138, P1005; DERIJK R, 1992, AM J PHYSIOL, V263, pE1092; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; FISCHER E, 1992, BLOOD, V79, P2196; FISCHER E, 1992, J CLIN INVEST, V89, P1551, DOI 10.1172/JCI115748; FRENCH JF, 1993, EUR J PHARMACOL, V233, P109, DOI 10.1016/0014-2999(93)90355-L; FRENCH JF, 1991, J PHARMACOL EXP THER, V259, P260; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; HINSHAW LB, 1990, CIRC SHOCK, V30, P279; LEE HC, 1986, CIRC SHOCK, V18, P193; Loppnow H, 1994, Prog Clin Biol Res, V388, P309; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MARKS TN, 1990, PFLUG ARCH EUR J PHY, V417, P433, DOI 10.1007/BF00370664; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MIYOSHI H, 1994, J MOL CELL CARDIOL, V26, P1487, DOI 10.1006/jmcc.1994.1167; MORIMOTO K, 1992, J PHYSIOL-LONDON, V448, P307, DOI 10.1113/jphysiol.1992.sp019043; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; RUSSELL DA, 1995, J INFECT DIS, V171, P1528, DOI 10.1093/infdis/171.6.1528; SPINAS GA, 1991, J INFECT DIS, V163, P89, DOI 10.1093/infdis/163.1.89; STRIETER RM, 1993, CRIT CARE MED, V21, pS447, DOI 10.1097/00003246-199310001-00006; WAKABAYASHI GO, 1991, FASEB J, V5, P338, DOI 10.1096/fasebj.5.3.1825816; WANG R, 1989, AM J PHYSIOL, V256, pH1361, DOI 10.1152/ajpheart.1989.256.5.H1361; WARNER SJC, 1989, J IMMUNOL, V142, P100	32	46	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1996	10	7					785	791		10.1096/fasebj.10.7.8635696	http://dx.doi.org/10.1096/fasebj.10.7.8635696			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UN798	8635696				2022-12-28	WOS:A1996UN79800013
J	Parker, RS				Parker, RS			Carotenoids .4. Absorption, metabolism, and transport of carotenoids	FASEB JOURNAL			English	Review						beta-carotene; 9-cis m beta-carotene; vitamin A; retinoic acid	BETA-CAROTENE; RETINOIC ACID; VITAMIN-A; ENZYMATIC CONVERSION; EXCENTRIC CLEAVAGE; INTESTINAL-MUCOSA; HUMANS; PLASMA; ISOMERS; FERRET	Carotenoids are currently under intense scrutiny regarding their potential to modulate chronic disease risk and prevent vitamin A deficiency, and renewed emphasis has been placed on achieving a better understanding of the metabolic fate of these compounds in humans, The development of new animal models, and use of human metabolic studies and stable tracer methods have greatly improved our knowledge of how carotenoids are absorbed, metabolized, and transported to tissues; however, many important issues remain unresolved, For example, intestinal uptake of carotenoids occurs by passive diffusion, but the lumenal or intracellular factors limiting this process are obscure, The intestinal mucosa plays a key role in the metabolism of provitamin A carotenoids such as beta-carotene, thus greatly influencing their bioavailability, Most recent evidence supports a central oxidation mechanism of cleavage of beta-carotene to retinal in the intestinal mucosa, but the extent and site(s) of postabsorptive metabolism in the human is unknown, While the human and other species clearly absorb non-provitamin A carotenoids, little is known of the extent and pathways of their metabolism and elimination, The metabolic fate of cis isomers of beta-carotene is a subject of recent interest, since 9-cis retinoic acid can apparently be formed from 9-cis beta-carotene hl vitro and in vivo, Substantial cis-trans isomerization of at least small oral doses of 9-cis beta-carotene occurs in the human, although the site of isomerization is not yet known, Carotenoids are transported in plasma exclusively by lipoproteins, with the distribution among lipoprotein classes determined in large part by the physical properties of the carotenoid, The consequences of differential distribution in terms of tissue uptake and retention are not clear at present, Improved knowledge of the metabolic fate of carotenoids will assist in the development and testing of hypotheses regarding their potential to influence biological processes in the human.			Parker, RS (corresponding author), CORNELL UNIV,DIV NUTR SCI,113 SAVAGE HALL,NEW YORK,NY 14853, USA.							BLOMSTRA.R, 1967, SCAND J CLIN LAB INV, V19, P339, DOI 10.3109/00365516709090648; BOWEN PE, 1993, METHOD ENZYMOL, V214, P3; BROWN AJ, 1994, BBA-LIPID LIPID MET, V1210, P373, DOI 10.1016/0005-2760(94)90243-7; BROWN ED, 1989, AM J CLIN NUTR, V49, P1258, DOI 10.1093/ajcn/49.6.1258; BRUBACHER GB, 1985, INT J VITAM NUTR RES, V55, P5; CANFIELD LM, 1990, METHOD ENZYMOL, V189, P418; CHANDLER LA, 1987, J FOOD SCI, V52, P669, DOI 10.1111/j.1365-2621.1987.tb06700.x; CLEVIDENCE BA, 1993, METHOD ENZYMOL, V214, P33; CORNWELL DG, 1992, J LIPID RES, V3, P65; DEPEE S, 1995, LANCET, V346, P75, DOI 10.1016/S0140-6736(95)92111-7; DEVERY J, 1994, BRIT J NUTR, V72, P397, DOI 10.1079/BJN19940042; DOERING WV, 1995, J AM CHEM SOC, V117, P2747; DUEKER SR, 1994, ANAL CHEM, V66, P4177, DOI 10.1021/ac00095a011; ELGORAB MI, 1975, BIOCHIM BIOPHYS ACTA, V401, P265, DOI 10.1016/0005-2736(75)90310-7; ERDMAN JW, 1993, ANN NY ACAD SCI, V691, P76, DOI 10.1111/j.1749-6632.1993.tb26159.x; GAZIANO JM, 1995, AM J CLIN NUTR, V61, P1248, DOI 10.1093/ajcn/61.6.1248; GLOVER J, 1960, VITAM HORM, V18, P371; GOODMAN DS, 1965, SCIENCE, V149, P879, DOI 10.1126/science.149.3686.879; GOODMAN DWS, 1966, J CLIN INVEST, V45, P1615, DOI 10.1172/JCI105468; GREENBERG ER, 1990, NEW ENGL J MED, V323, P789, DOI 10.1056/NEJM199009203231204; HANDELMAN GJ, 1991, FREE RADICAL BIO MED, V10, P427, DOI 10.1016/0891-5849(91)90051-4; HANSEN S, 1988, BIOCHEMISTRY-US, V27, P200, DOI 10.1021/bi00401a030; HEBUTERNE X, 1995, J LIPID RES, V36, P1264; HERNELL O, 1990, BIOCHEMISTRY-US, V29, P2041, DOI 10.1021/bi00460a012; HOLLANDER D, 1978, AM J PHYSIOL, V235, pE686, DOI 10.1152/ajpendo.1978.235.6.E686; HUANG HS, 1965, J BIOL CHEM, V240, P2839; JOHNSON EJ, 1992, AM J CLIN NUTR, V56, P128, DOI 10.1093/ajcn/56.1.128; KOSTIC D, 1995, AM J CLIN NUTR, V62, P604, DOI 10.1093/ajcn/62.3.604; KRINSKY NI, 1990, J NUTR, V120, P81, DOI 10.1093/jn/120.1.81; KRINSKY NI, 1993, ANN NY ACAD SCI, V691, P167, DOI 10.1111/j.1749-6632.1993.tb26168.x; LAKSHMAN MR, 1989, P NATL ACAD SCI USA, V86, P9124, DOI 10.1073/pnas.86.23.9124; LAKSHMAN.MR, 1972, J LIPID RES, V13, P477; LAKSHMANAN MR, 1968, BIOCHEM BIOPH RES CO, V33, P347, DOI 10.1016/0006-291X(68)90791-2; MATHEWSROTH MM, 1992, METHOD ENZYMOL, V213, P265; MOBARHAN S, 1994, CANCER EPIDEM BIOMAR, V3, P501; NAGAO A, 1994, FASEB J, V8, P968, DOI 10.1096/fasebj.8.12.8088462; NAGAO A, 1993, ANN NY ACAD SCI, V691, P287, DOI 10.1111/j.1749-6632.1993.tb26198.x; NAGAO A, 1996, IN PRESS ARCH BIOCH; NAPOLI JL, 1988, J BIOL CHEM, V263, P17372; NOVOTNY JA, 1995, J LIPID RES, V36, P1825; OLSON JA, 1994, PURE APPL CHEM, V66, P1011, DOI 10.1351/pac199466051011; OLSON JA, 1965, P NATL ACAD SCI USA, V54, P1364, DOI 10.1073/pnas.54.5.1364; PARKER RS, 1993, ANN NY ACAD SCI, V691, P863; POOR CL, 1992, J NUTR, V122, P262, DOI 10.1093/jn/122.2.262; REDDY P P, 1989, FASEB Journal, V3, pA955; ROCK CL, 1992, AM J CLIN NUTR, V55, P96, DOI 10.1093/ajcn/55.1.96; Sauberlich H E, 1974, Vitam Horm, V32, P251; SCITA G, 1992, J NUTR BIOCHEM, V3, P118, DOI 10.1016/0955-2863(92)90103-P; SOLOMONS NW, 1993, ANN NY ACAD SCI, V691, P96, DOI 10.1111/j.1749-6632.1993.tb26161.x; STAHL W, 1995, J NUTR, V125, P2128, DOI 10.1093/jn/125.8.2128; STAHL W, 1992, J NUTR, V122, P2161, DOI 10.1093/jn/122.11.2161; SWANSON JE, 1993, FASEB J, V7, pA276; TANG GW, 1991, BIOCHEMISTRY-US, V30, P9829, DOI 10.1021/bi00105a003; TRABER MG, 1994, LIPIDS, V29, P665, DOI 10.1007/BF02538909; TRABER MG, 1985, J CLIN INVEST, V75, P1729, DOI 10.1172/JCI111883; VANVLIET T, 1993, ANN NY ACAD SCI, V691, P220, DOI 10.1111/j.1749-6632.1993.tb26176.x; VANVLIET T, 1995, AM J CLIN NUTR, V62, P110, DOI 10.1093/ajcn/62.1.110; VANVLIET T, 1992, NETH J NUTR, V53, P186; WANG XD, 1994, ARCH BIOCHEM BIOPHYS, V313, P150, DOI 10.1006/abbi.1994.1371; WANG XD, 1992, ARCH BIOCHEM BIOPHYS, V293, P298, DOI 10.1016/0003-9861(92)90399-H; WANG XD, 1991, ARCH BIOCHEM BIOPHYS, V285, P8, DOI 10.1016/0003-9861(91)90322-A; WANG XD, 1993, BIOCHIM BIOPHYS ACTA, V1167, P159, DOI 10.1016/0005-2760(93)90157-5; WANG XD, 1992, AM J PHYSIOL, V263, pG480, DOI 10.1152/ajpgi.1992.263.4.G480; WANG XD, 1994, J AM COLL NUTR, V13, P314, DOI 10.1080/07315724.1994.10718416; WEISER H, 1993, ANN NY ACAD SCI, V691, P223, DOI 10.1111/j.1749-6632.1993.tb26177.x; WESTSTRATE JA, 1995, AM J CLIN NUTR, V62, P591, DOI 10.1093/ajcn/62.3.591; WHITE WS, 1994, J AM COLL NUTR, V13, P665; WHITE WS, 1993, J NUTR, V123, P1129; WHITE WS, 1993, J NUTR, V123, P1405; WILLETT WC, 1983, AM J CLIN NUTR, V38, P559, DOI 10.1093/ajcn/38.4.559; XU MJ, 1992, J NATL CANCER I, V84, P1559, DOI 10.1093/jnci/84.20.1559; YOU CS, 1994, FASEB J, V8, pA192; ZECHMEISTER L, 1962, CIS T ISOMERIC CAROT, P118; ZENG SH, 1992, AM J CLIN NUTR, V56, P433, DOI 10.1093/ajcn/56.2.433	74	532	554	5	86	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1996	10	5					542	551		10.1096/fasebj.10.5.8621054	http://dx.doi.org/10.1096/fasebj.10.5.8621054			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UJ055	8621054				2022-12-28	WOS:A1996UJ05500003
J	Jaenicke, R				Jaenicke, R			Stability and folding of ultrastable proteins: Eye lens crystallins and enzymes from thermophiles	FASEB JOURNAL			English	Review						protein stability; oligomeric protein; chaperones; linkers; domains	EUBACTERIUM THERMOTOGA-MARITIMA; D-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; LACTATE-DEHYDROGENASE; ESCHERICHIA-COLI; RECONSTITUTION; ARCHAEBACTERIA; BIOMOLECULES; ASSOCIATION; TEMPERATURE; INVERTASE	Soluble globular proteins exhibit marginal stabilities, equivalent to only a few weak intermolecular interactions, Extreme conditions in the biosphere, as well as acute physiological stress, require either mutative adaptation or stabilization by accessory proteins or extrinsic factors such as metabolites, cofactors, or compatible solvent components. No general strategies of stabilization have yet been established. However, certain contributions to stability have been elucidated by analyzing extremely stable proteins, such as crystallins from the eye lens, or proteins from hyperthermophilic microorganisms, Relating the structure and stability of homologous proteins from mesophiles and extremophiles, it becomes clear that stability increments may accumulate from 1) local interactions, 2) secondary or supersecondary structure, 3) packing and docking of domains, 4) association of subunits, and 5) conjugation with prosthetic groups, carbohydrate moieties, or nucleic acids, etc, Single and multiple point mutations, nicking and swapping of folding units in domain proteins, grafting of linker peptides between domains, and dissociation-reassociation of oligomeric proteins give insight into the cumulative nature of protein stability and its relation to the hierarchy of protein structure and folding, In this review, beta gamma-crystallins and enzymes from hyperthermophilic microorganisms are used as models to discuss mechanisms of protein stabilization.			Jaenicke, R (corresponding author), UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,UNIV STR 31,D-93040 REGENSBURG,GERMANY.							BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BALDWIN RL, 1995, J BIOMOL NMR, V5, P103; BAX B, 1990, NATURE, V347, P776, DOI 10.1038/347776a0; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; BERNHARDT G, 1984, NATURWISSENSCHAFTEN, V71, P583, DOI 10.1007/BF01189186; BOHM G, 1994, INT J PEPT PROT RES, V43, P97; CARPENTER JF, 1993, CRYOBIOLOGY, V30, P2001; Creighton T. E., 1993, PROTEINS STRUCTURES; CREIGHTON TE, 1988, BIOPHYS CHEM, V311, P155; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DOBSON C, 1995, PHILOS T R SOC LOND, V348, P119; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; HECHT K, 1989, EUR J BIOCHEM, V183, P69, DOI 10.1111/j.1432-1033.1989.tb14897.x; HENSEL R, 1988, FEMS MICROBIOL LETT, V49, P75, DOI 10.1111/j.1574-6968.1988.tb02685.x; HUBER R, 1989, NATURE, V342, P833, DOI 10.1038/342833a0; JAENICKE R, 1981, ANNU REV BIOPHYS BIO, V10, P1, DOI 10.1146/annurev.bb.10.060181.000245; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; JAENICKE R, 1991, EUR J BIOCHEM, V202, P715, DOI 10.1111/j.1432-1033.1991.tb16426.x; JAENICKE R, 1995, PHILOS T ROY SOC B, V348, P97, DOI 10.1098/rstb.1995.0050; JAENICKE R, 1993, CHEMTRACTS BIOCH MOL, V4, P1; JAENICKE R, 1995, IN PRESS CURR TOP CE, V34; JAENICKE R, 1995, IN PRESS TM ADV PROT; KERN G, 1992, PROTEIN SCI, V1, P120; KERN G, 1993, PROTEIN SCI, V2, P1862, DOI 10.1002/pro.5560021108; KORNDORFER I, 1995, J MOL BIOL, V246, P511, DOI 10.1006/jmbi.1994.0103; MATTHEWS BW, 1995, ADV PROTEIN CHEM, V46, P249, DOI 10.1016/S0065-3233(08)60337-X; MAYR EM, 1994, J MOL BIOL, V235, P84, DOI 10.1016/S0022-2836(05)80017-8; OPITZ U, 1987, BIOCHEMISTRY-US, V26, P1399, DOI 10.1021/bi00379a028; OSTENDORP R, 1993, EUR J BIOCHEM, V216, P709, DOI 10.1111/j.1432-1033.1993.tb18190.x; PHIPPS BM, 1991, EMBO J, V10, P1711, DOI 10.1002/j.1460-2075.1991.tb07695.x; Privalov Peter L., 1992, P83; REHABER V, 1992, J BIOL CHEM, V267, P10999; RISSE B, 1992, PROTEIN SCI, V1, P1699, DOI 10.1002/pro.5560011218; RUDOLPH R, 1990, P NATL ACAD SCI USA, V87, P4625, DOI 10.1073/pnas.87.12.4625; SCHOLTZ JM, 1992, ANNU REV BIOPH BIOM, V21, P95, DOI 10.1146/annurev.bb.21.060192.000523; SCHULTES V, 1991, FEBS LETT, V290, P235, DOI 10.1016/0014-5793(91)81268-D; SCHUMANN J, 1993, PROTEIN SCI, V2, P1612, DOI 10.1002/pro.5560021007; SCHURIG H, 1995, EMBO J, V14, P442, DOI 10.1002/j.1460-2075.1995.tb07020.x; SCHURIG H, 1995, PROTEIN SCI, V4, P228; SECKLER R, 1992, FASEB J, V6, P2545, DOI 10.1096/fasebj.6.8.1592207; SOMERO GN, 1992, ANNU REV PHYSIOL, V54, P557, DOI 10.1146/annurev.ph.54.030192.003013; TOMSCHY A, 1993, EUR J BIOCHEM, V214, P43, DOI 10.1111/j.1432-1033.1993.tb17894.x; TRINKL S, 1994, PROTEIN SCI, V3, P1392, DOI 10.1002/pro.5560030905; VITA C, 1989, EUR J BIOCHEM, V183, P513, DOI 10.1111/j.1432-1033.1989.tb21079.x; WHITE RH, 1984, NATURE, V310, P430, DOI 10.1038/310430a0; WOESE CR, 1993, N COMP BIOC, V26, pR7; WRBA A, 1990, BIOCHEMISTRY-US, V29, P7584, DOI 10.1021/bi00485a007; WRBA A, 1990, EUR J BIOCHEM, V188, P195, DOI 10.1111/j.1432-1033.1990.tb15388.x	50	90	94	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1996	10	1					84	92		10.1096/fasebj.10.1.8566552	http://dx.doi.org/10.1096/fasebj.10.1.8566552			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566552				2022-12-28	WOS:A1996TR32800012
J	Shortle, D				Shortle, D			The denatured state (the other half of the folding equation) and its role in protein stability	FASEB JOURNAL			English	Review						protein folding; denaturants; folding intermediates	STAPHYLOCOCCAL NUCLEASE; THERMODYNAMIC STABILITY; RESIDUAL STRUCTURE; MUTANT FORMS; AMINO-ACIDS; MUTATIONS; LYSOZYME	Experimental studies of the physical interactions that stabilize protein structure are complicated by the fact that proteins do not unfold to a simple reference state, When their folded structure breaks down, protein chains do not become random coils, Instead, they enter a poorly understood ensemble of partially folded states known collectively as the denatured state, Although it has long been held that agents that promote protein unfolding act specifically on the denatured state, the idea that mutations can exert their destabilizing (or in some cases, stabilizing) effects directly on this state is nob widely accepted, A large body of thermodynamic data on mutant proteins plus a limited amount of structural information describing mutational effects on denatured states indicate that 1) the denatured state plays a central role in all aspects of protein stability, including mutant effects, and 2) a quantitative understanding of how amino acid sequence encodes protein structure will probably depend on a more complete picture of this complex, difficult-to-study state.			Shortle, D (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,725 N WOLFE ST,BALTIMORE,MD 21205, USA.							ALEXANDRESCU AT, 1995, J MOL BIOL, V250, P134, DOI 10.1006/jmbi.1995.0365; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DILL KA, 1995, PROTEIN SCI, V4, P561; FINK AL, 1994, BIOCHEMISTRY-US, V33, P12504, DOI 10.1021/bi00207a018; FLANAGAN JM, 1993, BIOCHEMISTRY-US, V32, P10359, DOI 10.1021/bi00090a011; GREEN SM, 1992, BIOCHEMISTRY-US, V31, P5717, DOI 10.1021/bi00140a005; GREEN SM, 1993, BIOCHEMISTRY-US, V32, P10131, DOI 10.1021/bi00089a032; HAWKES R, 1984, J MOL BIOL, V175, P195, DOI 10.1016/0022-2836(84)90474-1; HU CQ, 1992, BIOCHEMISTRY-US, V31, P1643, DOI 10.1021/bi00121a009; KATAOKA M, 1993, J MOL BIOL, V229, P591, DOI 10.1006/jmbi.1993.1064; KIMURA S, 1992, J BIOL CHEM, V267, P21535; LIM WA, 1992, BIOCHEMISTRY-US, V31, P4324, DOI 10.1021/bi00132a025; LOGAN TM, 1994, J MOL BIOL, V236, P637, DOI 10.1006/jmbi.1994.1173; LUMRY R, 1966, BIOPOLYMERS, V4, P917, DOI 10.1002/bip.1966.360040808; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; MILLER WG, 1968, BIOCHEMISTRY-US, V7, P3925, DOI 10.1021/bi00851a021; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; NERI D, 1992, SCIENCE, V257, P1559, DOI 10.1126/science.1523410; PEPYS MB, 1993, NATURE, V362, P553, DOI 10.1038/362553a0; SCHELLMAN JA, 1978, BIOPOLYMERS, V17, P1305, DOI 10.1002/bip.1978.360170515; SCHELLMAN JA, 1987, ANNU REV BIOPHYS BIO, V16, P115, DOI 10.1146/annurev.bb.16.060187.000555; SHORTLE D, 1993, STRUCTURE, V1, P121, DOI 10.1016/0969-2126(93)90027-E; SHORTLE D, 1992, Q REV BIOPHYS, V25, P205, DOI 10.1017/S0033583500004674; SHORTLE D, 1995, ADV PROTEIN CHEM, V46, P217, DOI 10.1016/S0065-3233(08)60336-8; SHORTLE D, 1988, BIOCHEMISTRY-US, V27, P4761, DOI 10.1021/bi00413a027; SHORTLE D, 1992, PROTEIN SCI, V1, P201; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; SHORTLE D, 1989, BIOCHEMISTRY-US, V28, P936, DOI 10.1021/bi00429a003; SHORTLE D, 1986, Proteins Structure Function and Genetics, V1, P81, DOI 10.1002/prot.340010113; SOSNICK TR, 1992, BIOCHEMISTRY-US, V31, P8329, DOI 10.1021/bi00150a029; STURTEVANT JM, 1994, CURR OPIN STRUC BIOL, V4, P69, DOI 10.1016/S0959-440X(94)90062-0; TANAKA A, 1993, PROTEIN SCI, V2, P567; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; TANFORD C, 1980, HYDROPHOBIC EFFECT; TIMASHEFF SN, 1992, BIOCHEMISTRY-US, V31, P9857, DOI 10.1021/bi00156a001; WANG Y, 1995, PHILOS T ROY SOC B, V348, P27, DOI 10.1098/rstb.1995.0042; WANG Y, 1995, IN PRESS BIOCHEMISTR, V34	39	350	358	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1996	10	1					27	34		10.1096/fasebj.10.1.8566543	http://dx.doi.org/10.1096/fasebj.10.1.8566543			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566543				2022-12-28	WOS:A1996TR32800005
J	FREY, PA				FREY, PA			LYSINE 2,3-AMINOMUTASE - IS ADENOSYLMETHIONINE A POOR MANS ADENOSYLCOBALAMIN	FASEB JOURNAL			English	Article						ADOCBL PREDECESSOR; PLP, NOVEL MECHANISM; RADICAL REARRANGEMENTS; [FES] CLUSTERS; COBALT ENZYME	ETHANOLAMINE AMMONIA-LYASE; BOND-DISSOCIATION ENERGY; S-ADENOSYLMETHIONINE; DEPENDENT ENZYME; LYSINE-2,3-AMINOMUTASE; COENZYME-B12; MECHANISM; RADICALS; COFACTOR	The interconversion of lysine and beta-lysine, which is catalyzed by lysine 2,3-aminomutase, is formally similar to the isomerization reactions catalyzed by adenosylcobalamin-dependent aminomutases. However, lysine 2,3-aminomutase is activated by S-adensoylmethionine and not by adenosylcobalamin. Lysine 2,3-aminomutase also contains [FeS] clusters, Co(II), and pyridoxal 5'-phosphate, all of which are required for maximum activity. Lysine 2,3-aminomutase acts through a mechanism akin to that of the adenosylcobalamin-dependent enzymes in which substrate radicals are intermediates. However, the 5'-deoxyadenosyl moiety of S-adenosylmethionine mediates hydrogen transfer in place of the 5'-deoxyadenosyl moiety of adenosylcobalamin. 5'-Deoxyadenosine is an intermediate in adenosylcobalamin-dependent reactions and in the reaction of lysine 2,3-aminomutase. The 5'-deoxyadenosyl radical, derived either from adenosylcobalamin or S-adenosylmethionine, appears to participate in these reactions. Similarly, the ribonucleotide reductase from Lactobacillus leichmanii is activated by adenosylcobalamin, whereas the ribonucleotide reductase from anaerobically grown Escherichia coli is activated by S-adenosylmethionine and an activating enzyme. The 5'-deoxyadenosyl radical seems to participate in the activation of both reductases. Therefore, both adenosylcobalamin and S-adenosylmethionine appear to serve as sources of 5'-deoxyadenosyl radicals in nature. S-Adenosylmethionine is not as chemically elegant a molecule as adenosylcobalamin, so it may be regarded as ''a poor man's adenosylcobalamin.''	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53705	University of Wisconsin System; University of Wisconsin Madison	FREY, PA (corresponding author), UNIV WISCONSIN,GRAD SCH,INST ENZYME RES,MADISON,WI 53705, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK028607, R01DK028607] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28607] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABELES RH, 1961, J BIOL CHEM, V236, P2347; ABERHART DJ, 1983, J AM CHEM SOC, V105, P5461, DOI 10.1021/ja00354a046; ASHLEY G, 1986, J BIOL CHEM, V260, P3958; BABIOR B, 1968, BIOCHIM BIOPHYS ACTA, V167, P456, DOI 10.1016/0005-2744(68)90225-8; BABIOR BM, 1974, J BIOL CHEM, V249, P1689; Baker J. J., 1982, B12, V2, P203; BALLINGER MD, 1992, BIOCHEMISTRY-US, V31, P10782, DOI 10.1021/bi00159a020; BANERJEE RV, 1990, FASEB J, V4, P1450, DOI 10.1096/fasebj.4.5.2407589; BARANIAK J, 1989, J BIOL CHEM, V264, P1357; BARKER HA, 1958, P NATL ACAD SCI USA, V44, P1093, DOI 10.1073/pnas.44.11.1093; BARKER HA, 1960, J BIOL CHEM, V235, P480; BARKER HA, 1967, BIOCHEM J, V105, P1; Blakley R L, 1978, Methods Enzymol, V51, P246, DOI 10.1016/S0076-6879(78)51034-3; BRADBEER C, 1965, J BIOL CHEM, V240, P4675; CHIRPICH TP, 1970, J BIOL CHEM, V245, P1778; COSTILOW RN, 1966, J BIOL CHEM, V241, P1573; DOWD P, 1989, J AM CHEM SOC, V111, P2313; ELIASSON R, 1990, P NATL ACAD SCI USA, V87, P3314, DOI 10.1073/pnas.87.9.3314; FINKE RG, 1984, INORG CHEM, V23, P3041, DOI 10.1021/ic00188a002; FREY PA, 1967, J BIOL CHEM, V242, P5369; FREY PA, 1990, CHEM REV, V90, P1343, DOI 10.1021/cr00105a014; HALPERN J, 1984, J AM CHEM SOC, V106, P8317, DOI 10.1021/ja00338a065; HAN O, 1990, J AM CHEM SOC, V112, P8982, DOI 10.1021/ja00180a054; LENHERT PG, 1961, NATURE, V192, P937, DOI 10.1038/192937a0; MOSS M, 1987, J BIOL CHEM, V262, P14859; MOSS ML, 1990, J BIOL CHEM, V265, P18112; OBRIEN RJ, 1985, J BIOL CHEM, V260, P6131; PETROVICH RM, 1992, BIOCHEMISTRY-US, V31, P10774, DOI 10.1021/bi00159a019; PETROVICH RM, 1991, J BIOL CHEM, V266, P7656; RETEY J, 1966, EXPERIENTIA, V22, P783, DOI 10.1007/BF01897408; RETEY J, 1966, EXPERIENTIA, V22, P502, DOI 10.1007/BF01898652; SONG KB, 1991, J BIOL CHEM, V266, P7651; STADTMAN ER, 1960, BIOCHEM BIOPH RES CO, V2, P1, DOI 10.1016/0006-291X(60)90252-7; TAN SL, 1986, J BIOL CHEM, V261, P3483; TSAI L, 1968, ARCH BIOCHEM BIOPHYS, V125, P210, DOI 10.1016/0003-9861(68)90656-5; TSAI L, 1967, BIOCHEM BIOPH RES CO, V28, P920; VALINSKY JE, 1974, J BIOL CHEM, V249, P2751; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WAGNER OW, 1966, J BIOL CHEM, V241, P1751; WOLLOWITZ S, 1988, J AM CHEM SOC, V110, P3112, DOI 10.1021/ja00218a020; ZAGALAK B, 1966, J BIOL CHEM, V241, P3028	41	72	72	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1993	7	8					662	670		10.1096/fasebj.7.8.8500691	http://dx.doi.org/10.1096/fasebj.7.8.8500691			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LE290	8500691				2022-12-28	WOS:A1993LE29000008
J	ZEISEL, SH				ZEISEL, SH			CHOLINE PHOSPHOLIPIDS - SIGNAL TRANSDUCTION AND CARCINOGENESIS	FASEB JOURNAL			English	Review						PHOSPHATIDYLCHOLINE; LYSOPHOSPHATIDYLCHOLINE; SPHINGOMYELIN; SPHINGOSINE; CERAMIDE; DIRADYLGLYCEROL; PROTEIN KINASE-C; RAT; HEPATOCARCINOMA	PROTEIN-KINASE-C; DEVOID DIET; RAT-LIVER; METHOTREXATE TREATMENT; LINKED DIGLYCERIDES; GROWTH-CONTROL; PHOSPHATIDYLCHOLINE; DIACYLGLYCEROL; DEFICIENT; ACTIVATION	Phospholipids act as vital elements in transmembrane signaling. Agonist-induced hydrolysis of phosphatidylinositides has been established as a major mechanism for transmitting messages into the interior of cells via protein phosphorylation cascades, ultimately regulating gene transcription. There is a growing body of evidence that choline phospholipids (phosphatidylcholine, sphingomyelin, and their metabolites) also are important mediators and modulators of transmembrane signaling. These functions may explain how choline phospholipids influence normal physiological processes as well as a diverse group of pathological processes.	UNIV N CAROLINA, SCH MED, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	ZEISEL, SH (corresponding author), UNIV N CAROLINA, SCH PUBL HLTH, DEPT NUTR, CHAPEL HILL, NC 27599 USA.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BASS DA, 1988, J BIOL CHEM, V263, P19610; Best CH, 1932, J PHYSIOL-LONDON, V75, P405, DOI 10.1113/jphysiol.1932.sp002899; Best CH, 1935, J PHYSIOL-LONDON, V83, P255, DOI 10.1113/jphysiol.1935.sp003227; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BLAIR R, 1985, J ANIM SCI, V60, P1508, DOI 10.2527/jas1985.6061508x; BLUSZTAJN JK, 1989, FEBS LETT, V243, P267, DOI 10.1016/0014-5793(89)80142-5; BUCHMAN AL, 1992, GASTROENTEROLOGY, V102, P1363; CABOT MC, 1984, BIOCHEM BIOPH RES CO, V125, P163, DOI 10.1016/S0006-291X(84)80349-6; CHANDAR N, 1987, CARCINOGENESIS, V8, P669, DOI 10.1093/carcin/8.5.669; CHANDAR N, 1988, CARCINOGENESIS, V9, P259, DOI 10.1093/carcin/9.2.259; CHANDAR N, 1989, P NATL ACAD SCI USA, V86, P2703, DOI 10.1073/pnas.86.8.2703; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DACOSTA KA, 1993, J BIOL CHEM, V268, P2100; DANIEL LW, 1988, BIOCHEM BIOPH RES CO, V151, P291, DOI 10.1016/0006-291X(88)90592-X; DAWSON WD, 1987, J CELL PHYSIOL, V132, P104, DOI 10.1002/jcp.1041320114; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; DIZIK M, 1991, CARCINOGENESIS, V12, P1307, DOI 10.1093/carcin/12.7.1307; EXTON JH, 1990, J BIOL CHEM, V265, P1; Fairbanks B. W., 1945, NORTH AMER VET, V26, P18; FINKELSTEIN JD, 1988, J BIOL CHEM, V263, P11750; FINKELSTEIN JD, 1982, ARCH BIOCHEM BIOPHYS, V218, P169, DOI 10.1016/0003-9861(82)90332-0; FORD DA, 1989, J BIOL CHEM, V264, P13818; GHOSHAL AK, 1983, AM J PATHOL, V113, P309; HANDLER P, 1949, P SOC EXP BIOL MED, V72, P569, DOI 10.3181/00379727-72-17502; HANNUN YA, 1989, CLIN CHIM ACTA, V185, P333, DOI 10.1016/0009-8981(89)90224-6; Hershey JM, 1931, AM J PHYSIOL, V93, P657; HEYMANS F, 1987, FEBS LETT, V218, P35, DOI 10.1016/0014-5793(87)81013-X; HOFFBAUER FW, 1965, ARCH PATHOL, V79, P364; HSIEH LL, 1989, CANCER RES, V49, P3795; HSIEH LL, 1989, J CELL BIOCHEM, V41, P179, DOI 10.1002/jcb.240410403; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KAIBUCHI K, 1986, J BIOL CHEM, V261, P1187; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KATO M, 1989, FEBS LETT, V247, P247, DOI 10.1016/0014-5793(89)81345-6; KETOLA HG, 1976, J ANIM SCI, V43, P474, DOI 10.2527/jas1976.432474x; KETOLA HG, 1973, POULTRY SCI, V52, P2362, DOI 10.3382/ps.0522362; KETOLA HG, 1974, J NUTR, V104, P1484, DOI 10.1093/jn/104.11.1484; KHAN WA, 1992, J BIOL CHEM, V267, P3605; KRAUSS RS, 1989, ONCOGENE, V4, P991; LENOX RH, 1992, BRAIN RES, V570, P333, DOI 10.1016/0006-8993(92)90598-4; LOCKER J, 1986, CARCINOGENESIS, V7, P1309, DOI 10.1093/carcin/7.8.1309; LOMBARDI B, 1971, FED PROC, V30, P139; LOMBARDI B, 1968, J LIPID RES, V9, P437; MARX J, 1992, SCIENCE, V257, P484, DOI 10.1126/science.1636083; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1992, NUTR REV, V50, P78; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; NEWBERNE PM, 1986, ANNU REV NUTR, V6, P407, DOI 10.1146/annurev.nu.06.070186.002203; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; POMFRET EA, 1990, J NUTR BIOCHEM, V1, P533, DOI 10.1016/0955-2863(90)90039-N; PRICE BD, 1989, J BIOL CHEM, V264, P16638; QIAN Z, 1990, J BIOL CHEM, V265, P3607; RIDER LG, 1988, J IMMUNOL, V140, P200; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RUSHMORE TH, 1984, CANCER LETT, V24, P251, DOI 10.1016/0304-3835(84)90020-X; SELHUB J, 1991, CANCER RES, V51, P16; SHINOZUKA H, 1980, CANCER RES, V40, P3846; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; TANI H, 1967, J NUTR, V92, P317, DOI 10.1093/jn/92.3.317; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; WAKELAM MJO, 1991, BIOCHEM SOC T, V19, P321, DOI 10.1042/bst0190321; WEINSTEIN IB, 1990, ADV SEC MESS PHOSPH, V24, P307; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; WILKISON WO, 1989, ONCOGENE, V4, P625; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1989, J BIOL CHEM, V264, P11373; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061; ZEISEL SH, 1990, J NUTR BIOCHEM, V1, P332, DOI 10.1016/0955-2863(90)90001-2	74	159	160	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 1	1993	7	6					551	557		10.1096/fasebj.7.6.8472893	http://dx.doi.org/10.1096/fasebj.7.6.8472893			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KY009	8472893				2022-12-28	WOS:A1993KY00900008
J	PUTNAM, FW				PUTNAM, FW			FROM ANTIGEN TO ANTIBODY	FASEB JOURNAL			English	Editorial Material											PUTNAM, FW (corresponding author), INDIANA UNIV,DEPT BIOL,JORDAN HALL 142,BLOOMINGTON,IN 47405, USA.							MARTIN DS, 1943, FED PROC, V2, P66; PUTNAM F. W., 1967, NOBEL SYMP, V3, P45; PUTNAM FW, 1967, COLD SPRING HARB SYM, V32, P9, DOI 10.1101/SQB.1967.032.01.006; PUTNAM FW, 1947, FED PROC, V6, P284; PUTNAM FW, 1943, FED PROC, V2, P68; WIKLER M, 1967, FED PROC, V26, P339	6	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB 1	1993	7	2					383	384		10.1096/fasebj.7.2.8440415	http://dx.doi.org/10.1096/fasebj.7.2.8440415			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KN885	8440415				2022-12-28	WOS:A1993KN88500015
J	Saier, MH; Paulsen, IT; Sliwinski, MK; Pao, SS; Skurray, RA; Nikaido, H				Saier, MH; Paulsen, IT; Sliwinski, MK; Pao, SS; Skurray, RA; Nikaido, H			Evolutionary origins of multidrug and drug-specific efflux pumps in bacteria	FASEB JOURNAL			English	Article						antimicrobial agents; drugs; antibiotics; resistance; transport; evolution; phylogenetic trees	GRAM-NEGATIVE BACTERIA; PROTEIN SEQUENCES; ESCHERICHIA-COLI; MEMBRANE-PROTEINS; TRANSPORT-SYSTEMS; RESISTANCE; TOPOLOGY; EXPORT; EMRE; INSERTION	The available genomic sequences of three pathogenic and three nonpathogenic: bacteria were analyzed to identify known and putative drug-specific and multidrug resistance transport systems, Escherichia coli was found to encode 29 such pumps, and with the exception of the archaebacterium Methanococcus jannaschii, the numbers of multidrug efflux pumps encoded within genomes of the other organisms were found to be approximately propertional to their total numbers of encoded transport systems as well as to total genome size, The similar numbers of chromosomally encoded multidrug efflux systems in pathogens and nonpathogens suggests that these transporters have not arisen recently in pathogens in response to antimicrobial chemotherapy, Phylogenetic analyses of the four transporter families that contain drug efflux permeases indicate that drug resistance arose rarely during the evolution of each family and that the diversity of current drug efflux pumps within each family arose from just one or a very few primordial systems, However, although the ability to confer drug efflux appears to have emerged on only a few occasions in evolutionary time and was stably maintained as an evolutionary trait, modulation of the substrate specificities of these systems has occurred repeatedly, A speculative model is presented that may explain the apparent capability of these multidrug transport systems to mediate drug transport from the cytoplasm or directly from the phospholipid bilayer.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Sydney, Sch Biol Sci, Sydney, NSW 2006, Australia; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California San Diego; University of Sydney; University of California System; University of California Berkeley	Saier, MH (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr,0116, La Jolla, CA 92093 USA.	msaier@ucsd.edu	Paulsen, Ian T/K-3832-2012	Paulsen, Ian T/0000-0001-9015-9418	NIAID NIH HHS [2RO1 AI14176] Funding Source: Medline; NIGMS NIH HHS [R01 GM55434] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055434] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLARD JD, 1992, J BIOL CHEM, V267, P17809; Arkin IT, 1996, BIOCHEMISTRY-US, V35, P7233, DOI 10.1021/bi960094i; Biaudet V, 1996, MICROBIOL-SGM, V142, P2669, DOI 10.1099/13500872-142-10-2669; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; DAVIES J, 1992, J GEN MICROBIOL, V138, P1553, DOI 10.1099/00221287-138-8-1553; DINH T, 1994, J BACTERIOL, V176, P3825, DOI 10.1128/JB.176.13.3825-3831.1994; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; FENG DF, 1990, METHOD ENZYMOL, V183, P375; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; George AM, 1996, FEMS MICROBIOL LETT, V139, P1, DOI 10.1016/0378-1097(96)00127-9; Goffeau A, 1997, YEAST, V13, P43, DOI 10.1002/(SICI)1097-0061(199701)13:1<43::AID-YEA56>3.0.CO;2-J; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; Gros P., 1996, HDB BIOL PHYS, V7, P137; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOLLAND IB, 1996, HDB BIOL PHYS, V2, P111; Kaneko T, 1996, DNA Res, V3, P109; KUAN G, 1995, RES MICROBIOL, V146, P271, DOI 10.1016/0923-2508(96)81050-3; LEWIS K, 1994, TRENDS BIOCHEM SCI, V19, P119, DOI 10.1016/0968-0004(94)90204-6; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; Nikaido H, 1996, J BACTERIOL, V178, P5853, DOI 10.1128/jb.178.20.5853-5859.1996; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; PAO SS, 1998, IN PRESS MICROBIOL M; PARR TR, 1992, RES MICROBIOL, V143, P443, DOI 10.1016/0923-2508(92)90089-7; PAULSEN IT, 1995, J BACTERIOL, V177, P2827, DOI 10.1128/jb.177.10.2827-2833.1995; PAULSEN IT, 1993, GENE, V124, P1, DOI 10.1016/0378-1119(93)90755-R; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Paulsen IT, 1997, FEMS MICROBIOL LETT, V156, P1, DOI 10.1111/j.1574-6968.1997.tb12697.x; Paulsen IT, 1996, MOL MICROBIOL, V19, P1167, DOI 10.1111/j.1365-2958.1996.tb02462.x; Paulsen IT, 1997, MICROBIOL-SGM, V143, P2685, DOI 10.1099/00221287-143-8-2685; Paulsen IT, 1996, P NATL ACAD SCI USA, V93, P3630, DOI 10.1073/pnas.93.8.3630; PAULSEN IT, 1998, IN PRESS J MOL BIOL; PIGEON RP, 1994, MOL MICROBIOL, V14, P871, DOI 10.1111/j.1365-2958.1994.tb01323.x; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; REIZER J, 1992, PROTEIN SCI, V1, P1326, DOI 10.1002/pro.5560011012; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Saier M H Jr, 1996, Microb Comp Genomics, V1, P129; SAIER MH, 1994, MOL MICROBIOL, V11, P841, DOI 10.1111/j.1365-2958.1994.tb00362.x; SAIER MH, 1994, MICROBIOL REV, V58, P71, DOI 10.1128/MMBR.58.1.71-93.1994; SALI A, 1990, TRENDS BIOCHEM SCI, V15, P235, DOI 10.1016/0968-0004(90)90036-B; SAURIN W, 1994, PROTEIN SCI, V3, P325; Schuldiner S, 1997, J EXP BIOL, V200, P335; SINGER SJ, 1990, TRENDS BIOCHEM SCI, V15, P369, DOI 10.1016/0968-0004(90)90230-9; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; Van Veen HW, 1996, HDB BIOL PHYS, V2, P165; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; VanVeen HW, 1996, P NATL ACAD SCI USA, V93, P10668, DOI 10.1073/pnas.93.20.10668; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; Yerushalmi H, 1996, J BIOL CHEM, V271, P31044, DOI 10.1074/jbc.271.49.31044	57	199	209	0	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1998	12	3					265	274		10.1096/fasebj.12.3.265	http://dx.doi.org/10.1096/fasebj.12.3.265			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YZ898	9506471				2022-12-28	WOS:000072305500015
J	Ferreira, F; Ebner, C; Kramer, B; Casari, G; Briza, P; Kungl, AJ; Grimm, R; Jahn-Schmid, B; Breiteneder, H; Kraft, D; Breitenbach, M; Rheinberger, H; Scheiner, O				Ferreira, F; Ebner, C; Kramer, B; Casari, G; Briza, P; Kungl, AJ; Grimm, R; Jahn-Schmid, B; Breiteneder, H; Kraft, D; Breitenbach, M; Rheinberger, H; Scheiner, O			Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy	FASEB JOURNAL			English	Article						major birch pollen allergen; Bet v 1 mutants; IgE binding epitopes; allergen-specific T cell clones; hypoallergens	BIRCH POLLEN ALLERGEN; T-CELL CLONES; BET-V-I; 4 RECOMBINANT ISOFORMS; MAJOR ALLERGEN; INTERLEUKIN-4 PRODUCTION; PROTEIN ANTIGENICITY; OVERLAPPING PEPTIDES; ESCHERICHIA-COLI; ATOPIC PATIENTS	Specific immunotherapy is an efficient treatment for patients suffering from type I allergy. The mechanisms underlying successful immunotherapy are assumed to operate at the level of T helper cells, leading to a modulation of the immune response to allergens. During immunotherapy, increasing doses of allergens are given on a regular basis, and the beneficial effects for the patient depend on the concentration of allergen used. On the other hand, the risk of IgE-mediated anaphylactic side effects also increase with the amount of allergen applied per injection. Therefore, we have proposed the use of hypoallergenic (low IgE binding activity) forms of allergens for immunotherapy. We evaluated by site-directed mutagenesis the contributions of individual amino acid residues/positions for IgE binding to Bet v 1, the major allergen of birch pollen. We found that IgE binding to Bet v 1 depended on at least six amino acid residues/positions. Immunoblot analyses and inhibition experiments showed that the multiple-point Bet v 1 mutant exhibited extremely low reactivity with serum IgE from birch pollen-allergic patients. In vivo (skin prick) tests showed that the potency of the multiple-point mutant to induce typical urticarial type I reactions in pollen-allergic patients was significantly lower than for wild-type Bet v 1. Proliferation assays of allergen-specific T cell clones demonstrated that these six amino acid exchanges in the Bet v 1 sequence did not influence T cell recognition. Thus, the Bet v I six-point mutant displayed significantly reduced IgE binding activity, but conserved T cell activating capacity, which is necessary for immunomodulation. The approach described here may be generally applied to produce allergen variants to be used in a safe therapy form of immediate-type allergies.	Salzburg Univ, Inst Genet & Allgemeine Biol, A-5020 Salzburg, Austria; European Mol Biol Lab, D-69012 Heidelberg, Germany; Novartis Forschungsinst, A-1235 Vienna, Austria; Hewlett Packard Analyt Grp, D-76337 Waldbronn, Germany; Univ Vienna, Inst Allgemeine & Expt Pathol, A-1090 Vienna, Austria	Salzburg University; European Molecular Biology Laboratory (EMBL); Novartis; Hewlett-Packard; University of Vienna	Ferreira, F (corresponding author), Salzburg Univ, Inst Genet & Allgemeine Biol, Hellbrunnerstr 34, A-5020 Salzburg, Austria.	fatima.ferreira@mh.sbg.ac.at	Briza, Peter/D-7309-2012; Ferreira, Fatima/E-4889-2011; Ferreira, Fatima/AAB-4321-2019	Briza, Peter/0000-0002-4941-6782; Ferreira, Fatima/0000-0003-0989-2335; Ferreira, Fatima/0000-0003-0989-2335; Kungl, Andreas/0000-0003-3362-797X				BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BREITENEDER H, 1992, J ALLERGY CLIN IMMUN, V90, P909, DOI 10.1016/0091-6749(92)90463-C; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CARBALLIDO JM, 1992, EUR J IMMUNOL, V22, P135; CASARI G, 1995, NAT STRUCT BIOL, V2, P171, DOI 10.1038/nsb0295-171; DREBORG S, 1985, ALLERGY S4, V40, P55; Duro G, 1997, INT ARCH ALLERGY IMM, V112, P348, DOI 10.1159/000237479; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1995, J IMMUNOL, V154, P1932; EBNER C, 1993, EUR J IMMUNOL, V23, P1523, DOI 10.1002/eji.1830230719; Faber C, 1996, J BIOL CHEM, V271, P19243, DOI 10.1074/jbc.271.32.19243; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; IPSEN H, 1989, EPITOPES ATOPIC ALLE, P3; JACOBS S, 1959, NATURE, V183, P262, DOI 10.1038/183262a0; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; JUTEL M, 1995, J IMMUNOL, V154, P4187; Kungl AJ, 1996, BIOCHEM BIOPH RES CO, V223, P187, DOI 10.1006/bbrc.1996.0867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laffer S, 1996, MOL IMMUNOL, V33, P417, DOI 10.1016/0161-5890(95)00152-2; LARSEN JN, 1992, MOL IMMUNOL, V29, P703, DOI 10.1016/0161-5890(92)90180-6; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; MARINI F, 1993, NUCLEIC ACIDS RES, V21, P2277, DOI 10.1093/nar/21.9.2277; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PETERSEN A, 1994, CLIN EXP ALLERGY, V24, P250, DOI 10.1111/j.1365-2222.1994.tb00227.x; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; Rothbard J B, 1989, Int Immunol, V1, P479, DOI 10.1093/intimm/1.5.479; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEINER O, 1995, ALLERGY, V50, P384, DOI 10.1111/j.1398-9995.1995.tb01167.x; SCHENK S, 1994, EUR J BIOCHEM, V224, P717, DOI 10.1111/j.1432-1033.1994.00717.x; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; SECRIST H, 1995, J EXP MED, V181, P1081, DOI 10.1084/jem.181.3.1081; SILVANOVICH A, 1991, J BIOL CHEM, V266, P1204; Smith AM, 1997, CLIN EXP ALLERGY, V27, P593, DOI 10.1111/j.1365-2222.1997.tb00750.x; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; Smith AM, 1997, INT ARCH ALLERGY IMM, V113, P99, DOI 10.1159/000237517; STAIGER CJ, 1993, PLANT J, V4, P631, DOI 10.1046/j.1365-313X.1993.04040631.x; STEWART GE, 1992, J ALLERGY CLIN IMMUN, V90, P567, DOI 10.1016/0091-6749(92)90129-P; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUPHIOGLU C, 1995, CLIN EXP ALLERGY, V25, P853, DOI 10.1111/j.1365-2222.1995.tb00028.x; SWOBODA I, 1995, J BIOL CHEM, V270, P2607, DOI 10.1074/jbc.270.6.2607; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; vanNeerven RJJ, 1996, IMMUNOL TODAY, V17, P526, DOI 10.1016/0167-5699(96)10058-X; VANREGENMORTEL MHV, 1989, IMMUNOL TODAY, V10, P266, DOI 10.1016/0167-5699(89)90140-0; VANREGENMORTEL MHV, 1986, TRENDS BIOCHEM SCI, V11, P36, DOI 10.1016/0968-0004(86)90230-6; Vrtala S, 1997, INT ARCH ALLERGY IMM, V113, P246, DOI 10.1159/000237560; WEISS C, 1993, J BIOL CHEM, V268, P19574; WESTHOF E, 1984, NATURE, V311, P123, DOI 10.1038/311123a0; WIERENGA EA, 1990, J IMMUNOL, V144, P4651	57	235	263	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1998	12	2					231	242		10.1096/fasebj.12.2.231	http://dx.doi.org/10.1096/fasebj.12.2.231			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472988	Bronze			2022-12-28	WOS:000071848400011
J	Wright, SC; Schellenberger, U; Ji, L; Wang, H; Larrick, JW				Wright, SC; Schellenberger, U; Ji, L; Wang, H; Larrick, JW			Calmodulin-dependent protein kinase II mediates signal transduction in apoptosis	FASEB JOURNAL			English	Article						tumor necrosis factor; PMSF; CaM-KII; AP24 activity	DNA FRAGMENTATION; T-LYMPHOCYTES; U937 CELLS; ACTIVATION; TNF; DEATH; RESISTANT; INHIBITOR; MECHANISM; PROTEASES	The present studies describe a new function for calmodulin-dependent protein kinase II (CaM-KII) in signal transduction leading to apoptosis, Both tumor necrosis factor a (TNF) and UV light rapidly stimulated Ca2+-independent activity of CaM-KII in the monocytic leukemia, U937, Two mechanistically different inhibitors of CaM-KII blocked activation of CaM-KII and prevented DNA fragmentation and death, Activation of CaM-KII during apoptosis and inhibition of DNA fragmentation by the two CaM-KII. inhibitors were reproduced in several other lines including KG1a, HL-60, and YAC-1. However, K562, which is relatively resistant to apoptosis induced by either TNF or UV light, did not activate CaM-KII in response to these stimuli, A variant derived from U937 that is resistant to TNF-or UV light-induced apoptosis also lacked a CaM-KII response, Activation of Cam-KII was blocked by two protease inhibitors, VAD-fmk and TPCK, but not by other inhibitors of serine proteases, Both inhibitors of CaM-KII and the protease inhibitors blocked activation of AP24, a serine protease originally isolated from apoptotic cells that induces DNA fragmentation in nuclei, Our evidence supports a model in which proteolytic activity functions upstream of CaM-KII. This kinase then leads to activation of AP24, which transmits signals to the nucleus to initiate DNA fragmentation.			Wright, SC (corresponding author), PALO ALTO INST MOL MED,2462 WYANDOTTE ST,MT VIEW,CA 94043, USA.				NCI NIH HHS [CA68223] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068223] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HASEGAWA Y, 1989, J IMMUNOL, V14, P2670; HASHIMOTO Y, 1991, BIOCHEM BIOPH RES CO, V181, P423, DOI 10.1016/S0006-291X(05)81436-6; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; TOKUMITSU H, 1990, J BIOL CHEM, V26, P4314; Whyte M, 1996, TRENDS CELL BIOL, V6, P245, DOI 10.1016/0962-8924(96)20025-X; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; WONG GHW, 1994, J IMMUNOL, V152, P1751; WRIGHT SC, 1992, J CELL BIOCHEM, V48, P344, DOI 10.1002/jcb.240480403; WRIGHT SC, 1993, J CELL BIOCHEM, V53, P222, DOI 10.1002/jcb.240530307; Wright SC, 1996, FASEB J, V10, P325, DOI 10.1096/fasebj.10.2.8641566; WRIGHT SC, 1994, J EXP MED, V180, P2113, DOI 10.1084/jem.180.6.2113; Wright SC, 1996, J EXP MED, V183, P463, DOI 10.1084/jem.183.2.463	27	79	81	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1997	11	11					843	849		10.1096/fasebj.11.11.9285482	http://dx.doi.org/10.1096/fasebj.11.11.9285482			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XT790	9285482				2022-12-28	WOS:A1997XT79000003
J	Tripiciano, A; Palombi, F; Ziparo, E; Filippini, A				Tripiciano, A; Palombi, F; Ziparo, E; Filippini, A			Dual control of seminiferous tubule contractility mediated by ET(A) and ET(B) endothelin receptor subtypes	FASEB JOURNAL			English	Article						endothelin receptors; signal transduction; myoid cells; peritubular contractility	CYCLIC ADP-RIBOSE; CA2+ RELEASE; SIGNAL-TRANSDUCTION; INTRACELLULAR CA-2+; PHOSPHOLIPASE-C; SMOOTH-MUSCLE; MYOID CELLS; RAT; CLONING; CALCIUM	Testicular myoid cells surrounding the seminiferous tubule are contractile cells responsible for peritubular contractility and for the propulsion of tubular fluid and spermatozoa. We have investigated the contractile response of rat myoid cells to endothelins (ETs) in cell and organ culture and analyzed the cell signaling involved. ET-2, ET-3, and IRL 1620, a highly selective agonist of ET(B) receptor, elicit [Ca2+](i) increases, though with dissimilar potencies and kinetics. Competition binding assays using [I-125]ET-1, [I-125]ET-3 and [I-125]IRL 1620 show that myoid cells express both ET(A) and ET(B) receptors with high affinity for ET-1 and ET-1/ET-3, respectively. All endothelin isoforms activate phosphoinositide (PI) turnover, but only stimulation of the ET(A) receptor mediates both PI turnover and mobilization of [Ca2+](i). Although stimulation of the ET(B) receptor with IRL 1620 fails to produce a significant effect on inositol phosphate (IF) production, it induces mobilization of a thapsigargin-sensitive intracellular Ca2+ pool in the absence of any measurable IP production. We also studied the effect of U-73122 [1-(6-[17-beta-3-methoxyestra-1,3,5 (10)-trien-17-yl] amino/hexyl)-H-1-pirrole-2,5-dione] and its inactive analog, U-73343, on Ca2+ mobilization and IP production after selective stimulation of ET receptors. U-73122 (1 mu M) completely inhibited the effect of ET(A)-mediated ET-1 stimulation of IP production, whereas U-73343 was inactive. However, in the presence of U-73122, the selective stimulation of ET(B) receptors induced the mobilization of a thapsigargin-sensitive and inositol phosphate-independent intracellular Ca2+ pool. The ET(B) receptor-dependent mobilization of [Ca2+](i) resulted mainly from Ca2+ release from intracellular Ca2+ stores. This paper illustrates contraction of myoid cells in the seminiferous tubule in response to selective activation of either ET receptor. Scanning electron microscopy of the peritubular tissue demonstrates that the contractile response to ET was inhibited by a combination of BQ-123 and BQ-788, but not by either antagonist alone. Moreover, the observation that selective stimulation of ET(B) receptor with IRL 1620 also resulted in cell contraction strongly suggests that stimulation of either ET(A) or ET(B) receptors alone may be sufficient to elicit seminiferous tubule contractility, Two types of receptors account for the actions of endothelin on contractile activity of seminiferous tubule: 1) an ET(A) receptor that is positively coupled to phospholipase C (PLC) and Ca2+ mobilization; and 2) an ET(B) receptor that induces title mobilization of a thapsigargin-sensitive intracellular Ca2+ pool in a manner independent of the formation of inositol phosphates. ET may play a complex role in regulating the flux of spermatozoa along the seminiferous tubule through its contractile effect on peritubular myoid cells.-Tripiciano, A., Palombi, F., Ziparo, E., Filippini, A. Dual control of seminiferous tubule contractility mediated by ET(A) and ET(B) endothelin receptor subtypes.	UNIV ROMA LA SAPIENZA,INST HISTOL & GEN EMBRYOL,SCH MED,IST PASTEUR FDN CENCI BOLOGNETTI,I-00161 ROME,ITALY	Fondazione Cenci Bolognetti; Sapienza University Rome			Tripiciano, Antonella/K-4635-2016	Tripiciano, Antonella/0000-0001-7814-984X; filippini, antonio/0000-0001-8453-287X; Ziparo, Elio/0000-0002-8776-3515				ADAMO S, 1985, FEBS LETT, V190, P161, DOI 10.1016/0014-5793(85)80449-X; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; CLOZEL M, 1992, BIOCHEM BIOPH RES CO, V186, P867, DOI 10.1016/0006-291X(92)90826-7; EMORI T, 1990, FEBS LETT, V263, P261, DOI 10.1016/0014-5793(90)81388-5; FANTONI G, 1993, AM J PHYSIOL, V265, pE267, DOI 10.1152/ajpendo.1993.265.2.E267; FILIPPINI A, 1993, ENDOCRINOLOGY, V133, P1789, DOI 10.1210/en.133.4.1789; FILIPPINI A, 1995, ENDOTHELINS ENDOCRIN, P219; FRELIN C, 1993, J BIOL CHEM, V268, P8787; Galione Antony, 1994, Trends in Cell Biology, V4, P431, DOI 10.1016/0962-8924(94)90104-X; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALLAM TJ, 1989, BIOCHEM J, V259, P125, DOI 10.1042/bj2590125; HARGROVE JL, 1977, FERTIL STERIL, V28, P1146; HOUSSET C, 1993, P NATL ACAD SCI USA, V90, P9266, DOI 10.1073/pnas.90.20.9266; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; IHARA M, 1995, EUR J PHARMACOL, V274, P1, DOI 10.1016/0014-2999(94)00670-3; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISHIKAWA K, 1994, P NATL ACAD SCI USA, V91, P4892, DOI 10.1073/pnas.91.11.4892; ITOH S, 1993, BIOCHEM BIOPH RES CO, V195, P969, DOI 10.1006/bbrc.1993.2139; KARNE S, 1993, J BIOL CHEM, V268, P19126; KESTER M, 1995, ENDOTHELINS ENDOCRIN, P67; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; LEVIN ER, 1995, NEW ENGL J MED, V333, P357; LITTLE PJ, 1992, BIOCHEM BIOPH RES CO, V183, P694, DOI 10.1016/0006-291X(92)90538-V; MAGGI M, 1995, J ANDROL, V16, P213; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MATSUMOTO H, 1989, BIOCHEM BIOPH RES CO, V164, P74, DOI 10.1016/0006-291X(89)91684-7; MCCANN JD, 1989, AM J PHYSIOL, V257, pL116, DOI 10.1152/ajplung.1989.257.2.L116; MCMURDO L, 1993, BRIT J PHARMACOL, V108, P557, DOI 10.1111/j.1476-5381.1993.tb12840.x; MICHEL MC, 1989, J BIOL CHEM, V264, P4986; MORELAND S, 1992, BIOCHEM BIOPH RES CO, V184, P100, DOI 10.1016/0006-291X(92)91163-K; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PALOMBI F, 1988, BIOL REPROD, V39, P1101, DOI 10.1095/biolreprod39.5.1101; PALOMBI F, 1988, MOL CELL ENDOCRINOL, V50, P311; POLLOCK DM, 1995, FASEB J, V9, P1196, DOI 10.1096/fasebj.9.12.7672512; RUDGE SA, 1995, MOL CELL BIOCHEM, V149, P161, DOI 10.1007/BF01076574; SAKAGUCHI H, 1992, AM J PHYSIOL, V263, pR15, DOI 10.1152/ajpregu.1992.263.1.R15; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAKURAI T, 1991, BIOCHEM BIOPH RES CO, V175, P44, DOI 10.1016/S0006-291X(05)81197-0; SAMLER DE, 1995, J PHARMACOL EXP THER, V272, P1052; Santiemma V, 1996, BIOL REPROD, V54, P583, DOI 10.1095/biolreprod54.3.583; Simonson M S, 1992, Adv Nephrol Necker Hosp, V21, P177; SITSAPESAN R, 1995, TRENDS PHARMACOL SCI, V16, P386, DOI 10.1016/S0165-6147(00)89080-X; SOKOLOVSKY M, 1992, J BIOL CHEM, V267, P20551; STOJILKOVIC SS, 1992, ENDOCRINOLOGY, V130, P465, DOI 10.1210/en.130.1.465; TAKAI M, 1992, BIOCHEM BIOPH RES CO, V184, P953, DOI 10.1016/0006-291X(92)90683-C; TAKAYANAGI R, 1991, FEBS LETT, V282, P103, DOI 10.1016/0014-5793(91)80454-B; TATRAI A, 1994, BBA-MOL CELL RES, V1224, P575, DOI 10.1016/0167-4889(94)90296-8; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Tripiciano A, 1996, BIOL REPROD, V55, P25, DOI 10.1095/biolreprod55.1.25; VASSAUX G, 1992, J BIOL CHEM, V267, P11092; VIGNE P, 1991, J BIOL CHEM, V266, P5925; VOGL AW, 1985, ANAT REC, V213, P63, DOI 10.1002/ar.1092130109; WARNER TD, 1992, AM J PHYSIOL, V262, pH1600, DOI 10.1152/ajpheart.1992.262.5.H1600; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YULE DI, 1992, J BIOL CHEM, V267, P13830	56	25	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1997	11	4					276	286		10.1096/fasebj.11.4.9068617	http://dx.doi.org/10.1096/fasebj.11.4.9068617			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WM850	9068617				2022-12-28	WOS:A1997WM85000010
J	Che, MX; Gatmaitan, Z; Arias, IM				Che, MX; Gatmaitan, Z; Arias, IM			Hepatic canalicular membrane .2. Ectonucleotidases, purine nucleoside transporter, and function of the bile canalicular plasma membrane of the hepatocyte	FASEB JOURNAL			English	Review						cCAM105; apyrase; extracellular nucleotide; ATP metabolism	CELL-ADHESION MOLECULE; EPIDERMAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; ATP-DEPENDENT TRANSPORT; BILIARY GLYCOPROTEIN-I; SMOOTH-MUSCLE CELLS; LIVER ECTO-ATPASE; RAT-LIVER; CARCINOEMBRYONIC ANTIGEN; INSULIN-RECEPTOR	Ectonucleotidases are enzymes that degrade extracellular nucleotides, Extracellular nucleotides (especially ATP) and their degradation products (particularly adenosine) have multiple effects on cell functions by acting through purinergic receptors, Adenosine nucleotides are present in bile, which suggests that hepatocytes may release nncleotides into the canaliculus where they are promptly degraded into adenosine by ecto-ATPase and 5'-nucleotidase, which have been identified in the canalicular plasma membrane. Adenosine is then transported into hepatocytes by a Na+-dependent nucleoside transporter that is present in the canalicular plasma membrane, Purification and molecular cloning of ecto-ATPase and other canalicular proteins are complicated by all abundant canalicular plasma membrane protein, cCAM 105. However, the recent cloning of all ecto-ATPase (apyrase) from potato tubers provides a ne cv opportunity to identify the canalicular ecto-ATPase. The canalicular Na+-dependent purine nucleoside transporter has been cloned from rat liver, Study of its expression during development and other physiological circumstances suggests that the transporter may play an important role in maintaining hepatic purine levels that are essential for the Liver to serve as a major source of purines for tissues (i.e., brain, muscle) that lack pathways for de novo purine biosynthesis.	TUFTS UNIV,SCH MED,DEPT CELLULAR & MOL PHYSIOL,BOSTON,MA 02111	Tufts University								ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ACCILI D, 1986, ENDOCRINOLOGY, V119, P3137; ARIAS IM, 1993, HEPATOLOGY, V17, P318, DOI 10.1002/hep.1840170225; AURIVILLIUS M, 1990, FEBS LETT, V264, P267, DOI 10.1016/0014-5793(90)80264-J; BECKER A, 1986, BIOL CHEM H-S, V367, P681, DOI 10.1515/bchm3.1986.367.2.681; BECKER A, 1993, EUR J BIOCHEM, V214, P539, DOI 10.1111/j.1432-1033.1993.tb17952.x; BECKER A, 1989, HISTOCHEMISTRY, V93, P55, DOI 10.1007/BF00266847; BELT JA, 1983, MOL PHARMACOL, V24, P479; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BLITZER BL, 1978, J CLIN INVEST, V62, P1104, DOI 10.1172/JCI109216; CHARI RS, 1996, IN PRESS HEPATOLOGY; CHE MX, 1992, J BIOL CHEM, V267, P9684; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; CRAWFORD CR, 1990, J BIOL CHEM, V265, P9732; CRAWFORD CR, 1991, BIOCHEM BIOPH RES CO, V175, P846, DOI 10.1016/0006-291X(91)91642-P; CULIC O, 1992, BIOCHEM J, V285, P47, DOI 10.1042/bj2850047; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; EDELMAN GM, 1984, P NATL ACAD SCI-BIOL, V81, P1460, DOI 10.1073/pnas.81.5.1460; FORRESTER T, 1977, J PHYSIOL-LONDON, V268, P371, DOI 10.1113/jphysiol.1977.sp011862; FOX IH, 1978, ANNU REV BIOCHEM, V47, P655, DOI 10.1146/annurev.bi.47.070178.003255; GAO JP, 1993, ARCH BIOCHEM BIOPHYS, V303, P90, DOI 10.1006/abbi.1993.1259; GATI WP, 1989, RED BLOOD CELL MEMBR, P635; GATMAITAN Z, 1993, HEPATOLOGY, V18, pA143, DOI 10.1016/0270-9139(93)92101-5; GATMAITAN ZC, 1995, PHYSIOL REV, V75, P261, DOI 10.1152/physrev.1995.75.2.261; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Handa M, 1996, BIOCHEM BIOPH RES CO, V218, P916, DOI 10.1006/bbrc.1996.0162; HENDERSON JF, 1959, J BIOL CHEM, V234, P3219; HINODA Y, 1989, P NATL ACAD SCI USA, V86, P1668; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; INOUE M, 1983, J BIOL CHEM, V258, P5183; JAVIS SM, 1987, PHARMACOL THERAPEUT, V32, P339; JAVIS SM, 1989, BIOCHIM BIOPHYS ACTA, V979, P132; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KAST C, 1994, J BIOL CHEM, V269, P5179; KITAMURA T, 1991, HEPATOLOGY, V14, P640, DOI 10.1016/0270-9139(91)90051-V; KNOWLES AF, 1995, BIOCHEM BIOPH RES CO, V207, P529, DOI 10.1006/bbrc.1995.1220; LAJTHA LG, 1958, NATURE, V182, P191, DOI 10.1038/182191a0; LIN SH, 1985, J BIOL CHEM, V260, P7850; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; LIN SH, 1989, J BIOL CHEM, V264, P14408; LIN SH, 1984, J BIOL CHEM, V259, P3016; LIN SH, 1989, J BIOL CHEM, V264, P14403; LIN SH, 1985, J BIOL CHEM, V260, P976; LIN SH, 1990, ANN NY ACAD SCI, V603, P394; MARGOLIS RN, 1990, BIOCHEM BIOPH RES CO, V166, P562, DOI 10.1016/0006-291X(90)90845-E; MARGOLIS RN, 1988, P NATL ACAD SCI USA, V85, P7256, DOI 10.1073/pnas.85.19.7256; MAYER D, 1990, J CANCER RES CLIN, V116, P251, DOI 10.1007/BF01612899; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MOWERY J, 1991, HEPATOLOGY, V13, P47; MULLER M, 1991, J BIOL CHEM, V266, P18920; MURRAY AW, 1971, ANNU REV BIOCHEM, V40, P811, DOI 10.1146/annurev.bi.40.070171.004115; NAJJAR SM, 1995, BIOCHEMISTRY-US, V34, P9341, DOI 10.1021/bi00029a009; NATSUMEDA Y, 1984, CANCER RES, V44, P2475; Nies AT, 1996, J LIPID RES, V37, P1125; NOVIKOFF AB, 1960, AM J MED, V29, P102, DOI 10.1016/0002-9343(60)90011-5; OCKLIND C, 1982, J BIOL CHEM, V257, P6788; ODIN P, 1988, J HISTOCHEM CYTOCHEM, V36, P729, DOI 10.1177/36.7.3290331; OIKAWA S, 1991, J BIOL CHEM, V266, P7995; PAJOR AM, 1992, J BIOL CHEM, V267, P3357; PEARSON JD, 1979, NATURE, V281, P384, DOI 10.1038/281384a0; PEARSON JD, 1980, BIOCHEM J, V190, P421, DOI 10.1042/bj1900421; PERROTTI N, 1987, P NATL ACAD SCI USA, V84, P3137, DOI 10.1073/pnas.84.10.3137; PHILLIPS SA, 1987, FEBS LETT, V212, P141, DOI 10.1016/0014-5793(87)81573-9; PLAGEMANN PGW, 1990, BIOCHIM BIOPHYS ACTA, V1028, P289, DOI 10.1016/0005-2736(90)90178-Q; PLAGEMANN PGW, 1984, BIOCHIM BIOPHYS ACTA, V773, P39, DOI 10.1016/0005-2736(84)90548-0; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; PLAGEMANN PGW, 1985, BIOCHIM BIOPHYS ACTA, V816, P387, DOI 10.1016/0005-2736(85)90506-1; PLESNER L, 1995, INT REV CYTOL, V158, P141; Reddy MM, 1996, SCIENCE, V271, P1876, DOI 10.1126/science.271.5257.1876; REESJONES RW, 1985, J BIOL CHEM, V260, P4461; RICHARDSON PJ, 1987, NATURE, V327, P232, DOI 10.1038/327232a0; RODEN M, 1991, GASTROENTEROLOGY, V100, P1554; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SCHACHTER D, 1988, LIVER BIOL PATHOBIOL, P131; SHIVELY JE, 1985, CRC CR REV ONCOL-HEM, V2, P355, DOI 10.1016/S1040-8428(85)80008-1; SIPPEL CJ, 1993, J BIOL CHEM, V267, P9684; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TUCKER AL, 1994, J BIOL CHEM, V269, P27900; VIJAYALAKSHMI D, 1988, J BIOL CHEM, V263, P19419; WANG TF, 1996, IN PRESS J BIOL CHEM; WILLIAMS TC, 1991, BIOCHEM J, V274, P27, DOI 10.1042/bj2740027; WISHER MH, 1975, BIOCHEM J, V146, P375, DOI 10.1042/bj1460375; WU XC, 1992, J BIOL CHEM, V267, P8813; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345; Zoeteweij JP, 1996, HEPATOLOGY, V23, P858, DOI 10.1002/hep.510230429	87	42	42	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1997	11	2					101	108		10.1096/fasebj.11.2.9039951	http://dx.doi.org/10.1096/fasebj.11.2.9039951			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK509	9039951				2022-12-28	WOS:A1997WK50900001
J	Hegde, SS; Eglen, RM				Hegde, SS; Eglen, RM			Peripheral 5-HT4 receptors	FASEB JOURNAL			English	Review						gastrointestinal tract; urinary bladder; adrenal cortex; myocardium; 5-HT4	GUINEA-PIG ILEUM; SHORT-CIRCUIT CURRENT; ISOLATED DETRUSOR MUSCLE; ISOLATED VAGUS NERVE; IN-VITRO; ALDOSTERONE SECRETION; RIGHT ATRIUM; PHARMACOLOGICAL CHARACTERIZATION; 5-HYDROXYTRYPTAMINE-4 RECEPTORS; CHOLINERGIC TRANSMISSION	The 5-HT4 receptor is a member of the seven transmembrane spanning G-protein-coupled family of receptors. The receptor is positively coupled to adenylate cyclase and exists in two isoforms (5-HT4S and 5-HT4L) that differ in the length and sequence of their carboxy termini. The 5-HT4. receptor is pharmacologically defined by selective agonists such as SC 53116 and RS 67506, and selective antagonists such as GR 113808, SB 204070, and RS 39604. The receptor is widely distributed in the central nervous system and peripheral tissues. In the periphery, the receptor plays an important role in the function of several organ responses including the alimentary tract, urinary bladder, heart and adrenal gland. In the alimentary tract, stimulation of 5-HT4 receptors has a pronounced effect on smooth muscle tone, mucosal electrolyte secretion, and the peristaltic reflex. In the urinary bladder, activation of 5-HT4 receptors modulates cholinergic/purinergic transmission. In the heart, stimulation of atrial 5-HT4. receptors produces positive inotropy and tachycardia that can precipitate arrythmias. In the adrenal gland, agonism of 5-HT4 receptors stimulates release of cortisol, corticosterone, and aldosterone. Since its discovery in 1988, significant advances have been made in our understanding of the physiology and pharmacology of the 5-HT4 receptor. These advances have led to the development of several selective 5-HT4 receptor agonists and antagonists that may have therapeutic utility in the treatment of peripheral disorders such as irritable bowel syndrome, gastroparesis, urinary incontinence and cardiac arrhythmias.			Hegde, SS (corresponding author), ROCHE BIOSCI, INST PHARMACOL, NEUROBIOL UNIT, R2-101, 3401 HILLVIEW AVE, PALO ALTO, CA 94304 USA.							BANNER SE, 1993, BRIT J PHARMACOL, V110, pP16; BAXTER GS, 1991, N-S ARCH PHARMACOL, V343, P439; BHANDARI P, 1991, EUR J PHARMACOL, V204, P273, DOI 10.1016/0014-2999(91)90852-H; BINGHAM S, 1995, J PHARM PHARMACOL, V47, P219, DOI 10.1111/j.2042-7158.1995.tb05782.x; BLEY KR, 1994, EUR J PHARMACOL, V260, P139, DOI 10.1016/0014-2999(94)90330-1; BOYD IW, 1994, MED J AUSTRALIA, V160, P579; Briejer MR, 1995, PHARMACOL REV, V47, P631; BUCHHEIT KH, 1994, EUR J PHARMACOL, V262, P91, DOI 10.1016/0014-2999(94)90031-0; BUCHHEIT KH, 1991, EUR J PHARMACOL, V205, P203, DOI 10.1016/0014-2999(91)90821-7; BUCHHEIT KH, 1995, J MED CHEM, V38, P2331, DOI 10.1021/jm00013a010; BUDHOO MR, 1994, SURGERY, V116, P396; BURLEIGH DE, 1993, EUR J PHARMACOL, V241, P125, DOI 10.1016/0014-2999(93)90943-C; CLARK RD, 1995, BIOORG MED CHEM LETT, V5, P2119, DOI 10.1016/0960-894X(95)00358-Z; COCKS TM, 1992, BRIT J PHARMACOL, V107, P591, DOI 10.1111/j.1476-5381.1992.tb12788.x; Cohen ML, 1996, J PHARMACOL EXP THER, V277, P97; CONTESSE V, 1994, EUR J PHARMACOL, V265, P27, DOI 10.1016/0014-2999(94)90219-4; CRAIG DA, 1991, BRIT J PHARMACOL, V102, P563, DOI 10.1111/j.1476-5381.1991.tb12211.x; CRAIG DA, 1990, J PHARMACOL EXP THER, V252, P1378; EGLEN RM, 1990, BRIT J PHARMACOL, V101, P513, DOI 10.1111/j.1476-5381.1990.tb14113.x; EGLEN RM, 1995, TRENDS PHARMACOL SCI, V16, P391, DOI 10.1016/S0165-6147(00)89081-1; ELSWOOD CJ, 1991, EUR J PHARMACOL, V196, P149, DOI 10.1016/0014-2999(91)90421-L; FORD APD, 1992, BRIT J PHARMACOL, V211, P117; FORD APDW, 1993, MED RES REV, V13, P633, DOI 10.1002/med.2610130603; FOXXORENSTEIN AE, 1995, GASTROENTEROLOGY, V108, pA600; FRANKS CM, 1995, J PHARM PHARMACOL, V47, P213, DOI 10.1111/j.2042-7158.1995.tb05781.x; FUKUI H, 1994, EUR J PHARMACOL, V257, P47, DOI 10.1016/0014-2999(94)90692-0; GALE JD, 1993, J GASTROINTEST MOTIL, V5, P192; GERALD C, 1995, EMBO J, V14, P2806, DOI 10.1002/j.1460-2075.1995.tb07280.x; Grossman C. J., 1994, British Journal of Pharmacology, V112, p176P; GULLIKSON GW, 1993, J PHARMACOL EXP THER, V264, P240; HANSEN MB, 1994, J SURG RES, V56, P277, DOI 10.1006/jsre.1994.1044; HANSEN MB, 1994, CAN J PHYSIOL PHARM, V72, P227, DOI 10.1139/y94-035; HEGDE SS, 1995, BRIT J PHARMACOL, V115, P1087, DOI 10.1111/j.1476-5381.1995.tb15922.x; HEGDE SS, 1994, J PHARMACOL EXP THER, V271, P741; HEGDE SS, 1995, N-S ARCH PHARMACOL, V351, P589; HEGDE SS, 1994, BRIT J PHARMACOL, V112, pU67; IDRES S, 1991, MOL BRAIN RES, V10, P251, DOI 10.1016/0169-328X(91)90068-9; JOHNSON PJ, 1994, BRIT J PHARMACOL, V111, P1240, DOI 10.1111/j.1476-5381.1994.tb14878.x; KAUMANN AJ, 1994, N-S ARCH PHARMACOL, V349, P331, DOI 10.1007/BF00170877; KAUMANN AJ, 1994, TRENDS PHARMACOL SCI, V15, P451, DOI 10.1016/0165-6147(94)90058-2; KAUMANN AJ, 1991, N-S ARCH PHARMACOL, V344, P150, DOI 10.1007/BF00167212; KAUMANN AJ, 1995, BRIT J PHARMACOL, V115, P933, DOI 10.1111/j.1476-5381.1995.tb15900.x; KILBINGER H, 1995, N-S ARCH PHARMACOL, V351, P229; KILBINGER H, 1992, N-S ARCH PHARMACOL, V345, P270; KING BF, 1992, BRIT J PHARMACOL, V107, pP313; KOJIMA S, 1995, BRIT J PHARMACOL, V114, P73, DOI 10.1111/j.1476-5381.1995.tb14907.x; LEFEBVRE H, 1993, J CLIN ENDOCR METAB, V77, P1662, DOI 10.1210/jc.77.6.1662; LEFEBVRE H, 1992, NEUROSCIENCE, V47, P999, DOI 10.1016/0306-4522(92)90047-6; LEFEBVRE H, 1995, J CLIN ENDOCR METAB, V80, P504, DOI 10.1210/jc.80.2.504; LEUNG E, 1995, N-S ARCH PHARMACOL, V351, P596; McLean PG, 1996, BRIT J PHARMACOL, V117, P238, DOI 10.1111/j.1476-5381.1996.tb15182.x; MESSORI E, 1995, BRIT J PHARMACOL, V115, P677, DOI 10.1111/j.1476-5381.1995.tb14986.x; MIYAHARA H, 1994, J PHARMACOL EXP THER, V271, P379; NESTLER JE, 1983, CLIN PHARMACY, V2, P83; OLSSON S, 1992, BRIT MED J, V305, P748, DOI 10.1136/bmj.305.6856.748-a; OUADID H, 1992, MOL PHARMACOL, V41, P346; PAN H, 1994, AM J PHYSIOL, V266, pG230, DOI 10.1152/ajpgi.1994.266.2.G230; QIN XY, 1993, BRIT J PHARMACOL, V108, P44, DOI 10.1111/j.1476-5381.1993.tb13437.x; RAMIREZ MJ, 1994, BRIT J PHARMACOL, V111, P419, DOI 10.1111/j.1476-5381.1994.tb14751.x; REEVES JJ, 1991, BRIT J PHARMACOL, V103, P1067, DOI 10.1111/j.1476-5381.1991.tb12301.x; RHODES KF, 1992, N-S ARCH PHARMACOL, V346, P496; RIZZI CA, 1994, N-S ARCH PHARMACOL, V349, P338, DOI 10.1007/BF00170878; SANDERS L, 1992, N-S ARCH PHARMACOL, V345, P382; SANDERS L, 1995, CIRCULATION, V92, P2526, DOI 10.1161/01.CIR.92.9.2526; SCHOEMAKER RG, 1993, EUR J PHARMACOL, V230, P103; SCHOEMAKER RG, 1992, N-S ARCH PHARMACOL, V346, P486; SCOTT CM, 1992, BRIT J PHARMACOL, V106, P877, DOI 10.1111/j.1476-5381.1992.tb14428.x; SOMMERS DK, 1993, EUR J CLIN PHARMACOL, V44, P337; TAM FSF, 1995, BRIT J PHARMACOL, V115, P172; TAM FSF, 1994, BRIT J PHARMACOL, V113, P143, DOI 10.1111/j.1476-5381.1994.tb16186.x; TONINI M, 1994, BRIT J PHARMACOL, V113, P1; TONINI M, 1992, LIFE SCI, V50, pPL173, DOI 10.1016/0024-3205(92)90453-V; Tuladhar B. R., 1994, British Journal of Pharmacology, V112, p560P; TULADHAR BR, 1994, BRIT J PHARMACOL, V113, pP172; ULLMER C, 1995, FEBS LETT, V370, P215, DOI 10.1016/0014-5793(95)00828-W; VILLALON CM, 1991, BRIT J PHARMACOL, V102, P107, DOI 10.1111/j.1476-5381.1991.tb12140.x; WAIKAR MV, 1994, BRIT J PHARMACOL, V111, P213, DOI 10.1111/j.1476-5381.1994.tb14046.x; WARDLE KA, 1993, BRIT J PHARMACOL, V110, P1593, DOI 10.1111/j.1476-5381.1993.tb14006.x; Wardle KA, 1996, BRIT J PHARMACOL, V117, pP126; YUAN SY, 1994, BRIT J PHARMACOL, V112, P1095, DOI 10.1111/j.1476-5381.1994.tb13196.x	80	123	136	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1996	10	12					1398	1407		10.1096/fasebj.10.12.8903510	http://dx.doi.org/10.1096/fasebj.10.12.8903510			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VP485	8903510				2022-12-28	WOS:A1996VP48500005
J	Roberts, MF				Roberts, MF			Phospholipases: Structural and functional motifs for working at an interface	FASEB JOURNAL			English	Review						lipolytic enzymes; interfacial activation; lipid second messengers; phosphatidylinositols; protein structure; signal transduction	PLATELET-ACTIVATING-FACTOR; BACILLUS-CEREUS; FACTOR ACETYLHYDROLASE; TRYPANOSOMA-BRUCEI; CRYSTAL-STRUCTURE; SUBSTRATE-ANALOG; A(2); DOMAIN; BINDING; PROTEIN	Phospholipases form a ubiquitous class of enzymes optimized to catalyze the hydrolysis of phospholipids. Because their products are often second messengers, they are highly regulated by the cell. For a given ester bond, there are separate secreted as well as cytoplasmic phospholipases with different substrate specificities and. modes of regulation. As it becomes available, structural information provides a view of interfacial catalysis for several of these phospholipases on a molecular level, Recent structural advances include solution structures of a pancreatic phospholipase A(2) in the absence and presence of a micellar interface, crystal structures of a bacterial phosphatidylinosiol-phospholipase C whose active site is reminiscent of ribonuclease, and a Ca2+ Lipid binding domain with high homology to regions in several cytoplasmic phospholipases that can model the way those proteins interact with the membrane surface. Phospholipases also have a wide and complex array of regulatory mechanisms involving cytoplasmic proteins, notably G-proteins, as well as different effector lipids (e.g., phosphatidylinositol-4,5-biphosphate, or PIP2) or Ca2+. Deconvolution of these interactions is necessary to understand their roles in different signal transduction pathways.			Roberts, MF (corresponding author), BOSTON COLL,MERKERT CHEM CTR,2609 BEACON ST,CHESTNUT HILL,MA 02167, USA.							ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; AMIDON B, 1995, BIOCHEMISTRY-US, V34, P5554, DOI 10.1021/bi00016a029; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BURGOYNE RD, 1994, TRENDS BIOCHEM SCI, V19, P55, DOI 10.1016/0968-0004(94)90032-9; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DUA R, 1995, J BIOL CHEM, V270, P263, DOI 10.1074/jbc.270.1.263; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; HANSEN S, 1992, J MOL BIOL, V225, P543, DOI 10.1016/0022-2836(92)90938-G; HANSEN S, 1993, J MOL BIOL, V234, P179, DOI 10.1006/jmbi.1993.1572; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; HAZEN SL, 1993, J BIOL CHEM, V268, P9892; HEINZ DW, 1995, EMBO J, V14, P3855, DOI 10.1002/j.1460-2075.1995.tb00057.x; HOENER MC, 1993, LIPID METABOLISM SIG, P3; HUANG PS, 1995, FEBS LETT, V358, P287, DOI 10.1016/0014-5793(94)01453-8; KOBLAN KS, 1995, BIOCHEM J, V305, P745, DOI 10.1042/bj3050745; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LEWIS KA, 1993, BIOCHEMISTRY-US, V32, P8836, DOI 10.1021/bi00085a014; LI JY, 1994, J BIOL CHEM, V269, P28963; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; MENSAWILMOT K, 1992, MOL BIOCHEM PARASIT, V56, P311, DOI 10.1016/0166-6851(92)90180-R; MORRIS JC, 1995, J BIOL CHEM, V270, P2517, DOI 10.1074/jbc.270.6.2853; MUNFORD RS, 1992, J BIOL CHEM, V267, P10116; MUNFORD RS, 1995, J LIPID RES, V36, P1653; REISFELD N, 1993, FEBS LETT, V315, P267, DOI 10.1016/0014-5793(93)81176-Z; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; SHARP JD, 1994, J BIOL CHEM, V269, P23250; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; VANDENBERG B, 1995, J BIOMOL NMR, V5, P110, DOI 10.1007/BF00208802; VANDENBERG B, 1995, EMBO J, V14, P4123, DOI 10.1002/j.1460-2075.1995.tb00086.x; VOLWERK JJ, 1990, BIOCHEMISTRY-US, V29, P8056, DOI 10.1021/bi00487a010; WU L, 1995, NATURE, V373, P216, DOI 10.1038/373216a0; ZHU HX, 1995, BIOCHEMISTRY-US, V34, P15307, DOI 10.1021/bi00046a040	41	74	76	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1996	10	10					1159	1172		10.1096/fasebj.10.10.8751718	http://dx.doi.org/10.1096/fasebj.10.10.8751718			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VD429	8751718				2022-12-28	WOS:A1996VD42900007
J	Antolin, I; Rodriguez, C; Sainz, RM; Mayo, JC; Uria, H; Kotler, MI; RodriguezColunga, MJ; Tolivia, D; MenendezPelaez, A				Antolin, I; Rodriguez, C; Sainz, RM; Mayo, JC; Uria, H; Kotler, MI; RodriguezColunga, MJ; Tolivia, D; MenendezPelaez, A			Neurohormone melatonin prevents cell damage: Effect on gene expression for antioxidant enzymes	FASEB JOURNAL			English	Article						antioxidative protection; melatonin; Harderian glands; porphyrin synthesis	CONTAINING SUPEROXIDE-DISMUTASE; HAMSTER HARDERIAN-GLAND; SYNTHASE MESSENGER-RNA; MAMMALIAN-TISSUES; SYRIAN-HAMSTERS; GOLDEN-HAMSTER; RAT-LIVER; PORPHYRINS; ACID; PROTOPORPHYRIN	It is well known that porphyrins cause a toxic light-mediated effect due to their capability to generate free radicals. Several reports have proved that melatonin is a potent free radical scavenger. The aim of this work has been to study the ability of melatonin to prevent the cell damage caused by porphyrins in the Harderian gland of female Syrian hamsters. Cell injury was evaluated estimating the percentage of damaged cells found in the gland and analyzing the degree of this damage at ultrastructural level. To explain the mechanism by which this hormone could prevent the cell damage caused by porphyrins, its capability to both decrease porphyrin synthesis and increase the mRNA levels for antioxidant enzymes was evaluated. Our results demonstrate that melatonin administration decreases the percentage of damaged cells, porphyrin synthesis, and aminolevulinate synthase (ALA-S) mRNA levels and increases the mRNA levels for manganese superoxide-dismutase and copper-zinc superoxide dismutase. When observed under an electron microscope, the lesions in the clear cells of the treated females were much less severe than in the corresponding cells of the control animals. Melatonin exerts a cytoprotective effect by inhibiting the ALA-S gene expression (and so porphyrin synthesis) and by raising the mRNA levels for several antioxidant enzymes.			Antolin, I (corresponding author), UNIV OVIEDO, DEPT MORFOL & BIOL CELULAR, E-33006 OVIEDO, ASTURIAS, SPAIN.		Mayo, Juan Carlos/H-3435-2011; Sainz, Rosa M./N-5885-2014; Antolin, Isaac/L-6210-2014	Mayo, Juan Carlos/0000-0002-0882-2047; Sainz, Rosa M./0000-0003-3048-5582; Antolin, Isaac/0000-0002-4232-9248; Kotler, Monica Lidia/0000-0002-3555-7621; Rodriguez, Carmen/0000-0002-3203-4753				ACUNACASTROVIEJO D, 1993, RES COMMUN CHEM PATH, V82, P253; ANTOLIN I, 1994, ANAT REC, V239, P349, DOI 10.1002/ar.1092390402; ANTOLIN I, 1996, IN PRESS J STRUCT BI; AVNER DL, 1983, GASTROENTEROLOGY, V85, P700; AVRAHAM KB, 1988, CELL, V54, P823, DOI 10.1016/S0092-8674(88)91153-1; BARLOWWALDEN LR, 1995, NEUROCHEM INT, V26, P497, DOI 10.1016/0197-0186(94)00154-M; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; BLOOMER JR, 1988, HEPATOLOGY, V8, P402, DOI 10.1002/hep.1840080235; BUETTNER GR, 1979, FEBS LETT, V98, P18, DOI 10.1016/0014-5793(79)80141-6; BUZZELL GR, 1989, J EXP ZOOL, V249, P172, DOI 10.1002/jez.1402490209; CALBERG C, 1995, J PINEAL RES, V18, P171; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIVARIS DXG, 1990, AM J PATHOL, V136, P891; EMILIANI C, 1983, PHOTOCHEM PHOTOBIOL, V37, P487, DOI 10.1111/j.1751-1097.1983.tb04505.x; FREEMAN BA, 1983, J BIOL CHEM, V258, P2534; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HARDELAND R, 1993, NEUROSCI BIOBEHAV R, V17, P347, DOI 10.1016/S0149-7634(05)80016-8; Hardeland R., 1993, CHRONOBIOLOGY CHRONO, P113; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; HO YS, 1987, NUCLEIC ACIDS RES, V15, P10070, DOI 10.1093/nar/15.23.10070; HO YS, 1987, NUCLEIC ACIDS RES, V15, P6746, DOI 10.1093/nar/15.16.6746; HOFFMAN RA, 1971, AM J ANAT, V132, P463, DOI 10.1002/aja.1001320405; HURT J, 1992, NUCLEIC ACIDS RES, V20, P2985, DOI 10.1093/nar/20.12.2985; JONAS SK, 1989, BIOCHEM J, V264, P651, DOI 10.1042/bj2640651; KRALL J, 1988, J BIOL CHEM, V263, P1910; MAGNUS IA, 1969, J INVEST DERMATOL, V53, P400, DOI 10.1038/jid.1969.167; MENENDEZPELAEZ A, 1993, J PINEAL RES, V15, P59, DOI 10.1111/j.1600-079X.1993.tb00511.x; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; MENENDEZPELAEZ A, 1991, MOL CELL ENDOCRINOL, V80, P177, DOI 10.1016/0303-7207(91)90154-K; MENENDEZPELAEZ A, 1993, J PINEAL RES, V14, P34, DOI 10.1111/j.1600-079X.1993.tb00482.x; MOAN J, 1984, PHOTOCHEM PHOTOBIOL, V39, P445; PAYNE AP, 1977, J ENDOCRINOL, V75, P73, DOI 10.1677/joe.0.0750073; PAYNE AP, 1994, J ANAT, V185, P1; PIERI C, 1994, LIFE SCI, V55, pPL271, DOI 10.1016/0024-3205(94)00666-0; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; POHFITZPATRICK MB, 1986, PHOTODERMATOLOGY, V3, P148; REITER RJ, 1993, NEUROENDOCRINOL LETT, V15, P103; RIMINGTON C, 1967, Q J MED, V36, P29; RODRIGUEZ C, 1994, ENDOCRINE, V2, P863; RODRIGUEZCOLUNGA MJ, 1991, J PINEAL RES, V11, P42, DOI 10.1111/j.1600-079X.1991.tb00825.x; RODRIGUEZCOLUNGA MJ, 1992, ANAT REC, V232, P293, DOI 10.1002/ar.1092320214; SANDBERG S, 1982, ACTA DERM-VENEREOL, P75; SLATER TF, 1984, BIOCHEM J, V222, P1; SPIKE RC, 1985, J ANAT, V142, P59; SPIKES JD, 1975, ANN NY ACAD SCI, V244, P496, DOI 10.1111/j.1749-6632.1975.tb41550.x; SRIVASTAVA G, 1988, J BIOL CHEM, V263, P5202; STANKOV B, 1992, J PINEAL RES, V13, P20, DOI 10.1111/j.1600-079X.1992.tb00050.x; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; STRAKA JG, 1990, ANNU REV MED, V41, P457; STRUM JM, 1982, TISSUE CELL, V14, P149, DOI 10.1016/0040-8166(82)90014-3; URIA H, 1994, CELL BIOL PROBLEMS C, P89; VANSTEVENINCK J, 1986, PHOTOCHEM PHOTOBIOL, V44, P711; WARNER B, 1993, AM J PHYSIOL, V264, pL598, DOI 10.1152/ajplung.1993.264.6.L598; YOSHIMURA S, 1988, BIOCHEM BIOPH RES CO, V154, P1024, DOI 10.1016/0006-291X(88)90242-2; ZEEVI M, 1982, MOL CELL BIOL, V2, P517, DOI 10.1128/MCB.2.5.517	56	421	431	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1996	10	8					882	890		10.1096/fasebj.10.8.8666165	http://dx.doi.org/10.1096/fasebj.10.8.8666165			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UQ456	8666165				2022-12-28	WOS:A1996UQ45600010
J	Dragani, TA; Canzian, F; Pierotti, MA				Dragani, TA; Canzian, F; Pierotti, MA			Polygenic model of inherited predisposition to cancer	FASEB JOURNAL			English	Review						disease models; animal/disease susceptibility/linkage; genetics/mice, inbred strains/models	INTESTINAL NEOPLASIA; CARCINOGENESIS; MOUSE; GENE; LOCUS; MICE	Polygenic inheritance of predisposition to cancer is demonstrated in experimental animals for different tumor types, Genetic susceptibility to hepatocarcinogenesis, lung tumorigenesis, skin and intestine carcinogenesis, and plasmacytomagenesis is determined by inheritance of multiple cancer predisposition and resistance alleles, whose chromosomal locations have been found by genetic linkage analysis, In some of these experimental models, genetic heterogeneity has also been reported, In humans, increased risk of lung cancer associated with multiple genes coding for drug metabolizing enzymes, increased risk of cancer in relatives of cancer patients, and genetic heterogeneity are compatible with polygenic inheritance of cancer predisposition. Polygenic inheritance based on the combination of multiple alleles that give predisposition and resistance to cancer would predict a very high risk of cancer in carrier individuals and a marginal increase in the relative risk of cancer in the progeny of the cancer patients, Therefore, predisposition to cancer may be genetically determined even in the absence of familial clustering of cases.			Dragani, TA (corresponding author), IST NAZL TUMORI,DIV EXPTL ONCOL A,VIA VENEZIAN 1,I-20133 MILAN,ITALY.		Pierotti, Marco Alessandro/AAC-4728-2022; Canzian, Federico/I-2804-2014; Dragani, Tommaso A./K-4493-2016	Pierotti, Marco Alessandro/0000-0002-7431-8332; Dragani, Tommaso A./0000-0001-5915-4598; Canzian, Federico/0000-0002-4261-4583				AMOS CI, 1992, CANCER EPIDEM BIOMAR, V1, P505; ATCHLEY WR, 1991, SCIENCE, V254, P554, DOI 10.1126/science.1948030; BANGRAZI C, 1990, CARCINOGENESIS, V11, P1711, DOI 10.1093/carcin/11.10.1711; BULOW S, 1987, DAN MED BULL, V34, P1; CANZIAN F, 1995, MAMM GENOME, V6, P231, DOI 10.1007/BF00352406; CAPORASO N, 1995, PHARMACOGENETICS, V5, P59, DOI 10.1097/00008571-199504000-00001; CARTER BS, 1993, J UROLOGY, V150, P797, DOI 10.1016/S0022-5347(17)35617-3; CORDELL HJ, 1995, TRENDS GENET, V11, P499, DOI 10.1016/S0168-9525(00)89160-X; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DELCHAPELLE A, 1995, ANNU REV GENET, V29, P329; DELLAPOR.G, 1967, TUMORI, V53, P81; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; Dragani TA, 1995, ADV CANCER RES, V67, P83, DOI 10.1016/S0065-230X(08)60711-3; DRAGANI TA, 1995, GENETICS CANC, P111; EWENS WJ, 1995, AM J HUM GENET, V57, P455; FERNANDEZ E, 1994, CANCER EPIDEM BIOMAR, V3, P209; Festing M. F. W., 1993, Mouse Genome, V91, P393; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; FORD D, 1995, AM J HUM GENET, V57, P1457; FUCHS CS, 1994, NEW ENGL J MED, V331, P1669, DOI 10.1056/NEJM199412223312501; GARIBOLDI M, 1993, CANCER RES, V53, P209; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; GOLDSTEIN AM, 1994, AM J HUM GENET, V54, P489; HARTL DL, 1968, J THEOR BIOL, V20, P129, DOI 10.1016/0022-5193(68)90186-0; HSU LC, 1994, CANCER RES, V54, P2765; JACOBY RF, 1994, GENOMICS, V22, P381, DOI 10.1006/geno.1994.1399; JORDE LB, 1995, AM J HUM GENET, V56, P11; KNUDSON AG, 1993, NAT GENET, V5, P103, DOI 10.1038/ng1093-103; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LEAHY MG, 1995, HUM MOL GENET, V4, P1551, DOI 10.1093/hmg/4.9.1551; LEE GH, 1995, GENETICS, V139, P387; LIFTON RP, 1995, P NATL ACAD SCI USA, V92, P8545, DOI 10.1073/pnas.92.19.8545; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Manenti G, 1996, NAT GENET, V12, P455, DOI 10.1038/ng0496-455; MANENTI G, 1994, GENOMICS, V23, P118, DOI 10.1006/geno.1994.1466; MOCK BA, 1993, P NATL ACAD SCI USA, V90, P9499, DOI 10.1073/pnas.90.20.9499; MOEN CJA, 1992, ONCOGENE, V7, P563; NAGASE H, 1995, NAT GENET, V10, P424, DOI 10.1038/ng0895-424; NAROD S, 1995, AM J HUM GENET, V57, P957; PALLI D, 1994, CANCER EPIDEM BIOMAR, V3, P15; PARAZZINI F, 1994, INT J CANCER, V59, P460, DOI 10.1002/ijc.2910590404; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PERICAKVANCE MA, 1995, TRENDS GENET, V11, P504, DOI 10.1016/S0168-9525(00)89161-1; PIEROTTI M A, 1992, Current Opinion in Oncology, V4, P127, DOI 10.1097/00001622-199202000-00017; POTTER M, 1994, CANCER RES, V54, P969; RAUNIO H, 1995, GENE, V159, P113, DOI 10.1016/0378-1119(94)00448-2; SEARLE AG, 1994, J MED GENET, V31, P1, DOI 10.1136/jmg.31.1.1; SELLERS TA, 1992, CANCER RES, V52, pS2694; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; THOMSON G, 1995, AM J HUM GENET, V57, P487; WU JS, 1994, NAT GENET, V7, P541, DOI 10.1038/ng0894-541; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413	56	36	36	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1996	10	8					865	870		10.1096/fasebj.10.8.8666163	http://dx.doi.org/10.1096/fasebj.10.8.8666163			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UQ456	8666163				2022-12-28	WOS:A1996UQ45600008
J	Medof, ME; Nagarajan, S; Tykocinski, ML				Medof, ME; Nagarajan, S; Tykocinski, ML			Cell-surface engineering with GPI-anchored proteins	FASEB JOURNAL			English	Review						cellular engineering; protein transfer; erythrocyte protein; endoplasmic reticulum	DECAY-ACCELERATING FACTOR; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; MAJOR HISTOCOMPATIBILITY COMPLEX; RAPID LATERAL DIFFUSION; HIGH-LEVEL EXPRESSION; HAMSTER OVARY CELLS; LIPID-LINKED FORM; HUMAN-ERYTHROCYTES; PHOSPHOLIPASE-C	Protein engineering of cell surfaces is a potentially powerful technology through which the surface protein composition of cells can be manipulated without gene transfer, This technology exploits the fact that proteins that are anchored by glycoinositol phospholipids (GPIs), when purified and added to cells in vitro, incorporate into their surface membranes and are fully functional, By substituting 3'-mRNA end sequence of naturally GPI-anchored proteins (i.e., a sequence that contains the signals that direct GPI anchoring) for endogenous 3'-mRNA end sequence, virtually any protein of interest can be expressed as a GPI-anchored derivative, The GPI-anchored product then can be purified from tranfectants and the purified protein used to ''paint'' any target cell, Such protein engineering or ''painting'' of the cell surface offers several advantages over conventional gene transfer, Among these advantages are that 1) GPI-anchored proteins can be painted onto cells that are difficult to transfect, 2) cells can be altered immediately without previous culturing, 3) the amount of protein added to the surface can be precisely controlled, and 4) multiple GPI-anchored proteins can be sequentially or concurrently inserted into the same cells, Emerging applications for the technology include its nse for the analysis of complex cell-surface interactions, the engineering of antigen presenting cells, the development of cancer vaccines, and possibly the protection against graft rejection.			Medof, ME (corresponding author), CASE WESTERN RESERVE UNIV, INST PATHOL, 2085 ADELBERT RD, CLEVELAND, OH 44106 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031044, R21AI131044, R01AI023598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038181] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31044, AI23598] Funding Source: Medline; NIDDK NIH HHS [DK38181] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brodbeck WG, 1996, J IMMUNOL, V156, P2528; BRODSKY RA, 1994, HUM GENE THER, V5, P1231, DOI 10.1089/hum.1994.5.10-1231; Brown Deborah A., 1992, Trends in Cell Biology, V2, P338; BRUNSCHWIG E, 1995, J IMMUNOL, V55, P5498; BULOW R, 1988, BIOCHEMISTRY-US, V27, P2384; CAPEDEVILLE Y, 1987, BIOCHEM BIOPH RES CO, V147, P1219; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CARAS IW, 1987, NATURE, V325, P545, DOI 10.1038/325545a0; CARAS IW, 1989, SCIENCE, V243, P1196, DOI 10.1126/science.2466338; CHEN LP, 1994, J EXP MED, V179, P523, DOI 10.1084/jem.179.2.523; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; COCKETT MI, 1990, BIO-TECHNOL, V8, P662, DOI 10.1038/nbt0790-662; DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637; DAVIS SJ, 1990, J BIOL CHEM, V265, P10410; DAVITZ MA, 1987, SCIENCE, V238, P81, DOI 10.1126/science.2443973; DEALMEIDA MLC, 1988, BIOCHEM BIOPH RES CO, V150, P476; DELAHUNTY MD, 1993, J BIOL CHEM, V268, P12017; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FERRELL JE, 1985, BIOCHEMISTRY-US, V24, P2849, DOI 10.1021/bi00333a006; FERRELL JE, 1985, BIOCHEMISTRY-US, V24, P2857, DOI 10.1021/bi00333a007; FUTERMAN AH, 1983, NEUROSCI LETT, V40, P85, DOI 10.1016/0304-3940(83)90097-6; GERBER LD, 1992, J BIOL CHEM, V267, P12168; HAMBOR JE, 1990, J IMMUNOL, V145, P1646; HANNAN LA, 1993, J CELL BIOL, V120, P353, DOI 10.1083/jcb.120.2.353; HARRISON PT, 1994, NUCLEIC ACIDS RES, V22, P3813, DOI 10.1093/nar/22.18.3813; HEMPERLY JJ, 1986, P NATL ACAD SCI USA, V83, P9822, DOI 10.1073/pnas.83.24.9822; HERBERT WJ, 1973, T ROY SOC TROP MED H, V67, P268, DOI 10.1016/0035-9203(73)90174-0; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; HUANG JH, 1994, IMMUNITY, V1, P607, DOI 10.1016/1074-7613(94)90050-7; HUANG JH, 1994, MOL IMMUNOL, V31, P1017; IKEHARA Y, 1987, EMBO WORKSH POSTTR A, V24; ISHIHARA A, 1987, P NATL ACAD SCI USA, V84, P1290, DOI 10.1073/pnas.84.5.1290; JACOBSON K, 1987, ANNU REV PHYSIOL, V49, P163, DOI 10.1146/annurev.ph.49.030187.001115; JARVINEN JA, 1977, EXP PARASITOL, V43, P203, DOI 10.1016/0014-4894(77)90024-8; KAM W, 1985, P NATL ACAD SCI USA, V82, P8715, DOI 10.1073/pnas.82.24.8715; KOOYMAN DL, 1995, SCIENCE, V269, P89, DOI 10.1126/science.7541557; LEWIS SM, 1965, BRIT J HAEMATOL, V11, P549, DOI 10.1111/j.1365-2141.1965.tb00099.x; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LOW MG, 1985, NATURE, V318, P62, DOI 10.1038/318062a0; LOW MG, 1988, P NATL ACAD SCI USA, V85, P980, DOI 10.1073/pnas.85.4.980; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MCHUGH RS, 1995, P NATL ACAD SCI USA, V92, P8059, DOI 10.1073/pnas.92.17.8059; MEDOF ME, 1990, UCLA SYM BI, V111, P17; MEDOF ME, 1985, P NATL ACAD SCI USA, V82, P2980, DOI 10.1073/pnas.82.9.2980; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; MEDOF ME, 1987, P NATL ACAD SCI USA, V84, P2007, DOI 10.1073/pnas.84.7.2007; MEDOF ME, 1987, J CLIN INVEST, V80, P165, DOI 10.1172/JCI113043; MICANOVIC R, 1988, P NATL ACAD SCI USA, V85, P1398, DOI 10.1073/pnas.85.5.1398; MORAN P, 1991, J BIOL CHEM, V266, P1250; NAGARAJAN S, 1995, J IMMUNOL METHODS, V184, P241, DOI 10.1016/0022-1759(95)00095-R; OKADA N, 1989, J IMMUNOL, V143, P2262; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; PEARCE EJ, 1990, J IMMUNOL, V144, P2751; PUKLAVEC M, 1988, POSTTRANSLATIONAL MO, P51; REISER H, 1986, CELL, V47, P365, DOI 10.1016/0092-8674(86)90593-3; RIFKIN MR, 1990, P NATL ACAD SCI USA, V87, P801, DOI 10.1073/pnas.87.2.801; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; SEED B, 1987, NATURE, V313, P812; SELVARAJ P, 1988, NATURE, V333, P565, DOI 10.1038/333565a0; SELVARAJ P, 1987, J EXP MED, V166, P1011, DOI 10.1084/jem.166.4.1011; SIMMONS D, 1988, NATURE, V333, P568, DOI 10.1038/333568a0; SLECKMAN BP, 1991, J IMMUNOL, V147, P428; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STRAUS DS, 1985, P NATL ACAD SCI USA, V82, P6245, DOI 10.1073/pnas.82.18.6245; SUGITA Y, 1988, J BIOCHEM-TOKYO, V104, P633, DOI 10.1093/oxfordjournals.jbchem.a122524; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; THOMPSON LF, 1979, J IMMUNOL, V123, P2475; TSE AGD, 1985, SCIENCE, V230, P1003, DOI 10.1126/science.2865810; TYKOCINSKI ML, 1988, P NATL ACAD SCI USA, V85, P3555, DOI 10.1073/pnas.85.10.3555; Tykocinski ML, 1996, AM J PATHOL, V148, P1; TYKOCINSKI ML, 1993, KIDNEY INT       S39, V43, P5120; WALTER EI, 1990, J IMMUNOL, V144, P1030; WALTER EI, 1992, J BIOL CHEM, V261, P356; WANECK GL, 1987, J EXP MED, V165, P1358, DOI 10.1084/jem.165.5.1358; WANECK GL, 1988, P NATL ACAD SCI USA, V85, P577, DOI 10.1073/pnas.85.2.577; WEBER MC, 1994, EXP CELL RES, V210, P107, DOI 10.1006/excr.1994.1016; WEISS MJ, 1986, P NATL ACAD SCI USA, V83, P7182, DOI 10.1073/pnas.83.19.7182; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219; YEH ET, 1987, J IMMUNOL, V131, P91; ZALMAN LS, 1987, J EXP MED, V165, P572, DOI 10.1084/jem.165.2.572; ZHANG F, 1992, P NATL ACAD SCI USA, V89, P5231, DOI 10.1073/pnas.89.12.5231	82	164	193	1	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1996	10	5					574	586		10.1096/fasebj.10.5.8621057	http://dx.doi.org/10.1096/fasebj.10.5.8621057			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UJ055	8621057				2022-12-28	WOS:A1996UJ05500006
J	Patel, T; Gores, GJ; Kaufmann, SH				Patel, T; Gores, GJ; Kaufmann, SH			The role of proteases during apoptosis	FASEB JOURNAL			English	Review						calpains; granzymes; interleukin-1 beta converting enzyme; programmed cell death; serine protease inhibitors; ubiquitin	PROGRAMMED CELL-DEATH; INTERLEUKIN-1-BETA CONVERTING ENZYME; C-ELEGANS; POLY(ADP-RIBOSE) POLYMERASE; SERINE PROTEASES; CYTO-TOXICITY; GENE CED-3; INHIBITORS; CLEAVAGE; PURIFICATION	The importance of proteases during apoptosis is becoming increasingly apparent, Because apoptosis contributes to a diverse variety of disease processes, understanding the roles played by proteases and their inhibitors might provide insight into the pathogenesis of these conditions and suggest novel therapeutic: strategies, In this review, we discuss the involvement and role of specific proteases, substrates, and protease inhibitors that appear to participate in the apoptotic process.	MAYO CLIN & MAYO FDN,MAYO MED SCH,CTR BASIC RES DIGEST DIS,DIV GASTROENTEROL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DIV ONCOL RES,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic			patel, tushar/A-6382-2008; patel, tushar/J-3976-2013	patel, tushar/0000-0001-7021-9532; Kaufmann, Scott/0000-0002-4900-7145	NATIONAL CANCER INSTITUTE [R01CA069008] Funding Source: NIH RePORTER; NCI NIH HHS [CA69008, R01 CA069008] Funding Source: Medline; NIDDK NIH HHS [DK14876] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BROWNE SJ, 1994, INT J CANCER, V59, P56, DOI 10.1002/ijc.2910590113; BRUNO S, 1992, LEUKEMIA, V6, P1113; CASCIOLAROSEN L, 1994, J BIOL CHEM, V8269, P30757; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DARMON AJ, 1994, J BIOL CHEM, V269, P32043; DELIC J, 1993, MOL CELL BIOL, V13, P4875, DOI 10.1128/MCB.13.8.4875; DING RC, 1992, J BIOL CHEM, V267, P12804; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FEARNHEAD HO, 1995, FEBS LETT, V357, P242, DOI 10.1016/0014-5793(94)01367-A; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FESUS L, 1991, EUR J CELL BIOL, V56, P170; GAZIEV AI, 1992, INT J RADIAT BIOL, V61, P169, DOI 10.1080/09553009214550781; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HEBERT L, 1994, EXP CELL RES, V210, P10, DOI 10.1006/excr.1994.1002; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P475, DOI 10.1016/0006-291X(73)90736-5; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; HOUENOU LJ, 1995, P NATL ACAD SCI USA, V92, P895, DOI 10.1073/pnas.92.3.895; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KAUFMANN SH, 1996, IN PRESS MOL MED TOD, V2; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUMAR S, 1991, J BIOL CHEM, V266, P20960; KWO P, 1995, AM J PHYSIOL-GASTR L, V268, pG613, DOI 10.1152/ajpgi.1995.268.4.G613; KYPRIANOU N, 1988, PROSTATE, V13, P103, DOI 10.1002/pros.2990130203; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LAZEBNIK YA, 1995, IN PRESS P NATL ACAD; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MILLER TE, 1994, APOPTOSIS, V2, P357; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NEAMATI N, 1995, J IMMUNOL, V154, P3788; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; PASTERNACK MS, 1991, J BIOL CHEM, V266, P14703; PHILLIPS ME, 1994, GEN COMP ENDOCR, V95, P409, DOI 10.1006/gcen.1994.1140; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; REALINI CA, 1992, J BIOL CHEM, V267, P18858; RUGGIERO V, 1987, CELL IMMUNOL, V107, P317, DOI 10.1016/0008-8749(87)90240-1; SARIN A, 1994, J IMMUNOL, V153, P862; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SMITH GK, 1992, CANCER RES, V52, P4895; SMYTH MJ, 1995, IMMUNOL TODAY, V16, P202, DOI 10.1016/0167-5699(95)80122-7; SQUIER A, 1994, J IMMUNOL, V159, P229; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUFFYS P, 1988, EUR J BIOCHEM, V178, P257, DOI 10.1111/j.1432-1033.1988.tb14451.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; THORNBERRY NA, 1994, NATURE, V370, P251, DOI 10.1038/370251a0; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; VOELKELJOHNSON C, 1995, J IMMUNOL, V154, P1707; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1995, J BIOL CHEM, V270, P18044, DOI 10.1074/jbc.270.30.18044; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WARRENER P, 1991, BIOCHEM BIOPH RES CO, V180, P716, DOI 10.1016/S0006-291X(05)81124-6; WEAVER VM, 1993, BIOCHEM CELL BIOL, V71, P488, DOI 10.1139/o93-071; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; WRIGHT S, 1995, J EXP MED, V180, P2113; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; XU C, 1995, P NATL ACAD SCI USA, V92, P7829, DOI 10.1073/pnas.92.17.7829; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHIVOTOVSKY B, 1994, FEBS LETT, V351, P150, DOI 10.1016/0014-5793(94)00827-2	97	530	546	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1996	10	5					587	597		10.1096/fasebj.10.5.8621058	http://dx.doi.org/10.1096/fasebj.10.5.8621058			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UJ055	8621058				2022-12-28	WOS:A1996UJ05500007
J	Lee, CP; Gu, Q; Xiong, Y; Mitchell, RA; Ernster, L				Lee, CP; Gu, Q; Xiong, Y; Mitchell, RA; Ernster, L			P/O ratios reassessed: Mitochondrial P/O ratios consistently exceed 1.5 with succinate and 2.5 with NAD-linked substrates	FASEB JOURNAL			English	Article						mitochondria; oxidative phosphorylation; ATP synthesis	ATP-SITE RATIOS; OXIDATIVE-PHOSPHORYLATION; MECHANISTIC STOICHIOMETRY; PROTON TRANSLOCATION; ELECTRON-TRANSPORT; CHARGE-SITE; H+-SITE; GRADIENT; COMPLEX	The efficiency of ATP synthesis coupled to cell respiration, commonly referred to as the P/O ratio, has been the subject of extensive studies for more than 50 years. The general conclusion from these studies is that respiring mitochondria can convert external ADP to ATP at a maximal P/O ratio of 3 for NAD-linked substrates and 2 for succinate. However, in recent years the validity of these ''integral'' values has been questioned on both mechanistic and thermodynamic grounds, and a mechanistic P/O ratio of 2.5 for NAD-linked substrates and 1.5 for succinate have been concluded on the basis of experiments with isolated mitochondria. These values have been widely adopted in the scientific literature, including several recent textbooks. In this paper we report that under optimal conditions with respect to preparation and assay procedures, the P/O ratios obtained with isolated rat liver mitochondria consistently exceed 2.5 with NAD-linked substrates and 1.5 with succinate. These results, although not excluding ''nonintegral'' P/O ratios due to various energy-dissipating side reactions, warrant caution in accepting the reported lower values and, in general, in referring to mechanistic considerations unless the underlying molecular mechanisms are understood.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, DETROIT, MI 48201 USA; UNIV STOCKHOLM, ARRHENIUS LABS NAT SCI, DEPT BIOCHEM, S-10691 STOCKHOLM, SWEDEN	Wayne State University; Stockholm University				Xiong, Ye/0000-0001-9770-6031	NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005384] Funding Source: NIH RePORTER; NCRR NIH HHS [S07-RR05384-30] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALEXANDRE A, 1978, P NATL ACAD SCI USA, V75, P5296, DOI 10.1073/pnas.75.11.5296; AZZONE GF, 1994, BBA-BIOENERGETICS, V1187, P140, DOI 10.1016/0005-2728(94)90100-7; AZZONE GF, 1979, J BIOL CHEM, V254, P206; AZZONE GF, 1971, EUR J BIOCHEM, V19, P97, DOI 10.1111/j.1432-1033.1971.tb01292.x; BEATTIE DS, 1993, J BIOENERG BIOMEMBR, V25, P233, DOI 10.1007/BF00762585; BEATTIE DS, 1993, J BIOENERG BIOMEMBR, V25, P191, DOI 10.1007/BF00762581; BEAVIS AD, 1986, EUR J BIOCHEM, V158, P315, DOI 10.1111/j.1432-1033.1986.tb09753.x; BERRY EA, 1983, J BIOL CHEM, V258, P1474; BOYER PD, 1977, ANNU REV BIOCHEM, V46, P955, DOI 10.1146/annurev.bi.46.070177.004515; BOYER PD, 1965, OXIDASES RELATED RED, P994; BRAND MD, 1994, BIOCHEM J, V297, P27, DOI 10.1042/bj2970027; BRAND MD, 1994, BBA-BIOENERGETICS, V1187, P132, DOI 10.1016/0005-2728(94)90099-X; Brand MD, 1994, BIOCH LOND, V16, P20; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; ERNSTER L, 1993, FASEB J, V7, P1520, DOI 10.1096/fasebj.7.15.8262336; ERNSTER L, 1994, BIOCHEM SOC T, V22, P253, DOI 10.1042/bst0220253; ERNSTER L, 1984, S BIOL HUNGARICA, V26, P13; ERNSTER L, 1992, NEW COMPREHENSIVE BI, V23; Ernster L., 1995, BIOCHIM BIOPHYS ACTA, V1271, P195; FERGUSON SJ, 1986, TRENDS BIOCHEM SCI, V11, P351, DOI 10.1016/0968-0004(86)90197-0; FERGUSONMILLER S, 1993, J BIOENERG BIOMEMBR, V25, P69, DOI 10.1007/BF00762848; Hinkle P.C., 1981, CHEMIOSMOTIC PROTON, P49; HINKLE PC, 1991, BIOCHEMISTRY-US, V30, P3576, DOI 10.1021/bi00228a031; HOEK JB, 1992, NEW COMPR BIOCH, V23, P421; HOGEBOOM GH, 1946, J BIOL CHEM, V165, P615; HOGEBOOM GH, 1948, J BIOL CHEM, V172, P619; KENNEDY EP, 1949, J BIOL CHEM, V179, P957; KLINGENBERG M, 1977, EUR J BIOCHEM, V73, P125, DOI 10.1111/j.1432-1033.1977.tb11298.x; LARDY HA, 1952, J BIOL CHEM, V195, P215; LEE CP, 1979, MUSCLE NERVE, V2, P340, DOI 10.1002/mus.880020504; LEE CP, 1989, BIOCHIM BIOPHYS ACTA, V1000, P371, DOI 10.1016/S0006-3002(89)80032-0; LEE CP, 1968, EUR J BIOCHEM, V3, P385, DOI 10.1111/j.1432-1033.1967.tb19541.x; LEHNINGER AL, 1949, J BIOL CHEM, V181, P415; LEMASTERS JJ, 1984, J BIOL CHEM, V259, P3123; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; Moran LA, 1994, BIOCHEMISTRY; NEDERGAARD J, 1992, NEW COMPREHENSIVE BI, V23, P385; NICHOLLS B, 1984, NEW COMPR BIOCH, V9, P29; NICHOLS DG, 1992, BIOENERGETICS, V2; Ochoa S, 1943, J BIOL CHEM, V151, P493; OHNISHI T, 1993, J BIOENERG BIOMEMBR, V25, P325, DOI 10.1007/BF00762457; PALMIERI F, 1992, NEW COMPREHENSIVE BI, V23, P359; Pedersen P L, 1978, Methods Cell Biol, V20, P411, DOI 10.1016/S0091-679X(08)62030-0; PEDERSEN PL, 1993, J BIOENERG BIOMEMBR, V25, P431, DOI 10.1007/BF01108400; POZZAN T, 1979, J BIOL CHEM, V254, P200; REYNAFARJE B, 1976, J BIOL CHEM, V251, P7442; ROSSI E, 1969, EUR J BIOCHEM, V7, P418, DOI 10.1111/j.1432-1033.1969.tb19626.x; SLATER EC, 1953, NATURE, V172, P975, DOI 10.1038/172975a0; Sottocasa G. L., 1967, METHOD ENZYMOL, V10, P448; STONER CD, 1987, J BIOL CHEM, V262, P10445; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; VERCESI A, 1978, J BIOL CHEM, V253, P6379; WESTERHOFF HV, 1992, NEW COMPREHENSIVE BI, V23, P2; WIKSTROM MKF, 1977, NATURE, V266, P271, DOI 10.1038/266271a0; Zubay G., 1993, BIOCHEMISTRY	57	47	47	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1996	10	2					345	350		10.1096/fasebj.10.2.8641569	http://dx.doi.org/10.1096/fasebj.10.2.8641569			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641569				2022-12-28	WOS:A1996TY96200020
J	Lee, B; Kurochkina, N; Kang, HS				Lee, B; Kurochkina, N; Kang, HS			Protein folding by a biased Monte Carlo procedure in the dihedral angle space	FASEB JOURNAL			English	Review						conformational search; hydrophobic potential	SECONDARY STRUCTURE; GLOBULAR-PROTEINS; HELIX; MODEL; PREDICTION; CRAMBIN; PEPTIDE	A straightforward method for predicting the protein structure is to find conformations that have the lowest energy along a chosen folding pathway, One approach in this direction is to produce a large number of structures by varying the dihedral angles of the molecule more or less randomly and then to screen each one using a suitable energy function, This procedure is computationally demanding, but by using a more realistic model, one hopes that the folding behavior one observes in calculations may better mimic the actual folding process in nature, The method is beginning to yield interesting results, thanks to the increase in the computational power but also to the intelligent selection of the folding pathway, This article reviews general features of this method, some important highlights of the particular procedure we used, and some of the more significant results obtained to date in our laboratory, The results are highly encouraging and indicate the direction of future effort that is most likely to be fruitful.			Lee, B (corresponding author), NCI, DIV BASIC SCI,MOLEC BIOL LAB,RM 4B15,BLDG 37, 37 CONVENT DR, MSC 4255, BETHESDA, MD 20892 USA.							BIERZYNSKI A, 1982, P NATL ACAD SCI-BIOL, V79, P2470, DOI 10.1073/pnas.79.8.2470; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; CHAN HS, 1990, P NATL ACAD SCI USA, V87, P6388, DOI 10.1073/pnas.87.16.6388; COVELL DG, 1994, J MOL BIOL, V235, P1032, DOI 10.1006/jmbi.1994.1055; COVELL DG, 1990, BIOCHEMISTRY-US, V29, P3287, DOI 10.1021/bi00465a020; DEFAY T, 1995, PROTEINS, V23, P431, DOI 10.1002/prot.340230317; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; Fischer D, 1996, FASEB J, V10, P126, DOI 10.1096/fasebj.10.1.8566533; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GO N, 1970, MACROMOLECULES, V3, P628, DOI 10.1021/ma60017a603; GRAHAMLORENCE S, 1995, PROTEIN SCI, V4, P1065, DOI 10.1002/pro.5560040605; HENDRICKSON WA, 1981, NATURE, V290, P107, DOI 10.1038/290107a0; HINDS DA, 1994, J MOL BIOL, V243, P668, DOI 10.1016/0022-2836(94)90040-X; HOLMES MA, 1991, J MOL BIOL, V220, P723, DOI 10.1016/0022-2836(91)90113-K; HONIG B, 1995, ADV PROTEIN CHEM, V46, P27, DOI 10.1016/S0065-3233(08)60331-9; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KANG HS, 1993, J MOL BIOL, V229, P448, DOI 10.1006/jmbi.1993.1045; KNAPP EW, 1993, J COMPUT CHEM, V14, P19, DOI 10.1002/jcc.540140106; KOLINSKI A, 1994, PROTEINS, V18, P353, DOI 10.1002/prot.340180406; KOLINSKI A, 1994, PROTEINS, V18, P338, DOI 10.1002/prot.340180405; KUROCHKINA N, 1995, PROTEIN ENG, V8, P437, DOI 10.1093/protein/8.5.437; KUROCHKINA NA, 1994, NATO ADV SCI INST SE, V325, P147; LEE B, 1991, P NATL ACAD SCI USA, V88, P5154, DOI 10.1073/pnas.88.12.5154; LEVITT M, 1977, J MOL BIOL, V114, P181, DOI 10.1016/0022-2836(77)90207-8; LIWO A, 1993, PROTEIN SCI, V2, P1715, DOI 10.1002/pro.5560021016; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; MIYAZAWA S, 1985, MACROMOLECULES, V18, P534, DOI 10.1021/ma00145a039; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; PARK BH, 1995, J MOL BIOL, V249, P493, DOI 10.1006/jmbi.1995.0311; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; SALI A, 1994, NATURE, V369, P248, DOI 10.1038/369248a0; SHIRLEY BA, 1992, BIOCHEMISTRY-US, V31, P725, DOI 10.1021/bi00118a013; SHRAKE A, 1973, J MOL BIOL, V79, P351, DOI 10.1016/0022-2836(73)90011-9; SRINIVASAN R, 1995, PROTEINS, V22, P81, DOI 10.1002/prot.340220202; SUN SJ, 1995, BIOPHYS J, V69, P340, DOI 10.1016/S0006-3495(95)79906-4; SUN SJ, 1993, PROTEIN SCI, V2, P762, DOI 10.1002/pro.5560020508; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WILSON C, 1989, PROTEINS, V6, P193, DOI 10.1002/prot.340060208; WLODAWER A, 1988, BIOCHEMISTRY-US, V27, P2705, DOI 10.1021/bi00408a010; YUE K, 1995, P NATL ACAD SCI USA, V92, P146, DOI 10.1073/pnas.92.1.146; [No title captured]	43	16	17	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1996	10	1					119	125		10.1096/fasebj.10.1.8566532	http://dx.doi.org/10.1096/fasebj.10.1.8566532			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566532				2022-12-28	WOS:A1996TR32800016
J	Ding, XZ; Tsokos, GC; Kiang, JG				Ding, XZ; Tsokos, GC; Kiang, JG			Overexpression of HSP-70 inhibits the phosphorylation of HSF1 by activating protein phosphatase and inhibiting protein kinase C activity	FASEB JOURNAL			English	Article						gene transfection; heat shock protein; gene transcription; PP activity; PKC activity	HEAT-SHOCK FACTOR; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; CELLULAR-REGULATION; A-431 CELLS; HT-29 CELLS; IN-VIVO; HSP70; STRESS; HSP90	This laboratory reported previously that overexpressed heat shock protein 70 kDa (HSP-70) inhibited the activation of its transcriptional factor, HSF1. We had conducted experiments to understand the mechanisms whereby HSP-70 down-regulated the activation of HSF1. Genetically overexpressed HSP-70 had no effects on the HSF1 level in cytosol, but significantly inhibited phosphorylation of HSF1 in the nucleus. Transfection of cells with HSF1 cDNA resulted in increases in the unphosphorylated, but not phosphorylated, HSF1 levels in both the cytosol and nucleus. Because serine phosphorylation of various proteins was reduced in HSP-70 cDNA-transfected cells, we measured the activity of enzymes involved in serine phosphorylation. Overexpressed HSP-70 significantly inhibited the enzymatic activities of protein kinase A (PKA. by 73 and 62% in the cytosol and membrane-bound fraction, respectively) and protein kinase C (PKC by 61% in membrane-bound fraction), whereas it activated that of protein phosphatase (PP by 33 and 86% in the cytosol and the membrane-bound fraction, respectively). Forskolin (a PKA stimulator), PMA (a PKC stimulator), and okadaic acid (an inhibitor of PP) were used to investigate whether HSP-70-induced changes in PKA, PKC, and IPP were responsible for the HSF1 dephosphorylation. Forskolin did not change nuclear HSF1 phosphorylation, suggesting that decreases in PKA activity in HSP-70 overexpressing cells is not associated with HSF1 phosphorylation. PMA and okadaic acid induced an increase in HSF1 phosphorylation in both vector-and HSP-70 cDNA-transfected cells, although levels of phosphorylated HSF1 in HSP-70 cDNA-transfected cells were lower than those in vector-transfected cells. The PMA-induced increase in HSF1 phosphorylation in HSP-70 cDNA-transfected cells was blocked by pretreatment with staurosporine, a PKC inhibitor. These results suggest that overexpression of HSP-70 inhibits phosphorylation of HSF1 at serine residues by activating PP and inhibiting PKC activity.	Walter Reed Army Med Ctr, Dept Clin Physiol, Div Med, Washington, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Kiang, JG (corresponding author), Walter Reed Army Med Ctr, Dept Clin Physiol, Div Med, Bldg 40, Washington, DC 20307 USA.		tsokos, george C/O-3360-2013	tsokos, george C/0000-0001-9589-2360				ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; BAXTER GD, 1992, J IMMUNOL, V148, P1949; CHANG NT, 1993, J BIOL CHEM, V268, P1436; COHEN P, 1989, J BIOL CHEM, V264, P21435; DEWJI NN, 1995, MOL BRAIN RES, V33, P245, DOI 10.1016/0169-328X(95)00131-B; Ding XZ, 1996, J INVEST MED, V44, P144; Ding XZ, 1997, J CLIN INVEST, V99, P136, DOI 10.1172/JCI119124; Ding XZ, 1997, MOL CELL BIOCHEM, V167, P145, DOI 10.1023/A:1006833522418; DING XZ, 1996, MOL CELL BIOCHEM, V158, P48; ERDOS G, 1994, BIOCHEM BIOPH RES CO, V202, P476, DOI 10.1006/bbrc.1994.1953; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; GAESTEL M, 1992, J BIOL CHEM, V267, P21607; GUESDON F, 1993, J BIOL CHEM, V268, P4236; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; JACQUIERSARLIN MR, 1995, J BIOL CHEM, V270, P14094, DOI 10.1074/jbc.270.23.14094; Jurivich D.A., 1994, BIOL HEAT SHOCK PROT, P417; KAUFMANN SHE, 1994, HEAT SHOCK PROTEINS, P1; KEMP BE, 1988, METHOD ENZYMOL, V159, P173; KHANNA A, 1995, ENDOCRINOLOGY, V136, P1775, DOI 10.1210/en.136.4.1775; Kiang JG, 1996, J INVEST MED, V44, P53; KIANG JG, 1998, IN PRESS TOXICOL APP; KIANG JG, 1998, IN PRESS PHARM THER; Kiang Juliann Gong, 1996, Journal of Biomedical Science, V3, P379, DOI 10.1007/BF02258043; KIM DH, 1995, P NATL ACAD SCI USA, V92, P2126, DOI 10.1073/pnas.92.6.2126; KIM SH, 1993, BIOCHEM BIOPH RES CO, V193, P759, DOI 10.1006/bbrc.1993.1690; KREBS EG, 1989, JAMA-J AM MED ASSOC, V262, P1815, DOI 10.1001/jama.262.13.1815; KROEGER PE, 1993, MOL CELL BIOL, V13, P3370, DOI 10.1128/MCB.13.6.3370; LANDRY J, 1992, J BIOL CHEM, V267, P794; Liossis SNC, 1997, J IMMUNOL, V158, P5668; MAILHOS C, 1994, J NEUROCHEM, V63, P1787; MIMNAUGH EG, 1995, J BIOL CHEM, V270, P28654, DOI 10.1074/jbc.270.48.28654; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; Newton EM, 1996, MOL CELL BIOL, V16, P839; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PARKER PJ, 1995, BIOCHEM SOC T, V23, P153, DOI 10.1042/bst0230153; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1994, MOL CELL BIOL, V14, P6552, DOI 10.1128/MCB.14.10.6552; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; SANTELL L, 1992, BIOCHEM J, V284, P705, DOI 10.1042/bj2840705; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SONG QZ, 1993, BIOCHEM BIOPH RES CO, V190, P47, DOI 10.1006/bbrc.1993.1009; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; VARELA JCS, 1995, MOL CELL BIOL, V15, P6232; WALKER PR, 1993, EXP CELL RES, V207, P142, DOI 10.1006/excr.1993.1173; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; WHY SKV, 1994, J CLIN INVEST, V94, P1518; Wu C., 1994, BIOL HEAT SHOCK PROT, P395; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; YAMAMOTO N, 1994, KIDNEY INT, V45, P1093, DOI 10.1038/ki.1994.146; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z; ZIMARINO V, 1990, MOL CELL BIOL, V10, P752, DOI 10.1128/MCB.10.2.752	59	73	77	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1998	12	6					451	459		10.1096/fasebj.12.6.451	http://dx.doi.org/10.1096/fasebj.12.6.451			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZG118	9535217				2022-12-28	WOS:000072967300006
J	Myllarniemi, M; Calderon, L; Lemstrom, K; Buchdunger, E; Hayry, P				Myllarniemi, M; Calderon, L; Lemstrom, K; Buchdunger, E; Hayry, P			Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation	FASEB JOURNAL			English	Article						PDGF receptor; ballooning injury; cell proliferation; SMC migration	SIGNAL-TRANSDUCTION; ARTERIAL INJURY; PORCINE ARTERIES; GENE-EXPRESSION; FACTOR-BETA; FACTOR-I; B GENE; PDGF; PROTEIN; INVIVO	Platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) have been linked to vascular smooth muscle cell (SMC) migration and proliferation leading to atherosclerosis, restenosis, and chronic allograft rejection. This study describes the effect of CGP 53716, a specific PDGFR tyrosine kinase inhibitor on SMC proliferation and migration in vitro and in neointimal formation in vivo. CGP 53716 inhibited dose dependently tyrosine phosphorylation of both the known PDGFRs: the PDGFR-alpha and PDGFR-beta. In primary rat SMC cultures, a dose-dependent inhibition of PDGF-AA and PDGF-BB induced migration, and tritiated thymidine incorporation of SMC was seen at nontoxic concentrations. After rat carotid artery ballooning injury in vivo, the migration of alpha-actin-positive cells on the luminal side of internal elastic lamina was decreased with 50 mg.kg(-1).day(-1) of CGP 53716 from 38 +/- 10 (control group) to 4 +/- 2 (P < 0.0001, Mann-Whitney U test, N = 18). CGP 53716 did not inhibit the number of replicating bromodeoxyuridine (BrdU)-incorporating cells in the intima, media, or adventitia during BrdU labeling at 0-96 postoperative h, though it inhibited significantly (P < 0.01) the replication of medial and intimal cells from 93 h onward. Intima/ media ratio was inhibited by 40% after 14 days in the CGP 53716-treated group (P = 0.028) after rat aortic denudation. The results indicate that inhibition of the PDGFR tyrosine kinase inhibits SMC migration and proliferation in vitro, SMC migration, and, to a lesser extent, proliferation after ballooning injury in vivo, confirming a causal role for activation of the PDGFR and the formation of neointimal lesions.	UNIV HELSINKI,CENT HOSP,HELSINKI,FINLAND; NOVARTIS PHARMACEUT DIV,BASEL,SWITZERLAND	University of Helsinki; Helsinki University Central Hospital; Novartis	Myllarniemi, M (corresponding author), UNIV HELSINKI,TRANSPLANTAT LAB,POB 21,FIN-00014 HELSINKI,FINLAND.		Lemström, Karl B/J-8885-2016	Lemström, Karl B/0000-0001-6920-4093; Myllarniemi, L Marjukka/0000-0001-9343-0867				Bendeck MP, 1996, CIRC RES, V78, P38, DOI 10.1161/01.RES.78.1.38; BILDER GE, 1992, CIRCULATION, V86, P169; Bornfeldt KE, 1995, ANN NY ACAD SCI, V766, P416, DOI 10.1111/j.1749-6632.1995.tb26691.x; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; Casscells W, 1991, Prog Growth Factor Res, V3, P177, DOI 10.1016/0955-2235(91)90006-P; CERCEK B, 1991, AM J CARDIOL, V68, pC24; CLOWES AW, 1983, LAB INVEST, V49, P327; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GOLDEN MA, 1991, J CLIN INVEST, V87, P406, DOI 10.1172/JCI115011; GORDON D, 1992, J HEART LUNG TRANSPL, V11, P57; GRONWALD RGK, 1989, J BIOL CHEM, V264, P8120; GROTENDORST GR, 1982, J CELL PHYSIOL, V113, P261, DOI 10.1002/jcp.1041130213; HAUDENSCHILD CC, 1993, AM J MED, V94, pS40; HAYRY P, 1995, FASEB J, V9, P1336; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; KOYAMA N, 1994, CIRC RES, V75, P682, DOI 10.1161/01.RES.75.4.682; KOYAMA N, 1992, J BIOL CHEM, V267, P22806; Levitzki A, 1996, CURR OPIN CELL BIOL, V8, P239, DOI 10.1016/S0955-0674(96)80071-8; LIBBY P, 1992, CIRCULATION, V86, P47; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; NABEL EG, 1993, J CLIN INVEST, V91, P1822, DOI 10.1172/JCI116394; POMPILI VJ, 1995, ARTERIOSCL THROM VAS, V15, P2254, DOI 10.1161/01.ATV.15.12.2254; POWELL JS, 1991, J AM COLL CARDIOL, V17, pB137; RECHTER MD, 1994, CIRC RES, V75, P410; ROSS R, 1991, TRENDS CARDIOVAS MED, V1, P277, DOI 10.1016/1050-1738(91)90043-E; ROSS R, 1995, ANN NY ACAD SCI, V748, P1; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; Scott NA, 1996, CIRCULATION, V93, P2178, DOI 10.1161/01.CIR.93.12.2178; SHIMOKADO K, 1995, ANN NY ACAD SCI, V748, P171; THYBERG J, 1983, DIFFERENTIATION, V25, P156; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; Waltenberger J, 1996, ARTERIOSCL THROM VAS, V16, P1516, DOI 10.1161/01.ATV.16.12.1516; Zempo N, 1996, ARTERIOSCL THROM VAS, V16, P28, DOI 10.1161/01.ATV.16.1.28	39	104	106	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1997	11	13					1119	1126		10.1096/fasebj.11.13.9367346	http://dx.doi.org/10.1096/fasebj.11.13.9367346			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367346				2022-12-28	WOS:A1997YE98300009
J	Wick, G; Romen, M; Amberger, A; Metzler, B; Mayr, M; Falkensammer, G; Xu, Q				Wick, G; Romen, M; Amberger, A; Metzler, B; Mayr, M; Falkensammer, G; Xu, Q			Atherosclerosis, autoimmunity, and vascular-associated lymphoid tissue	FASEB JOURNAL			English	Article							HEAT-SHOCK PROTEIN; SMOOTH-MUSCLE CELLS; HUMAN AORTIC INTIMA; MAST-CELLS; ADHESION MOLECULES; LYMPHOCYTES-T; CHLAMYDIA-PNEUMONIAE; ENDOTHELIAL-CELLS; SERUM ANTIBODIES; DENDRITIC CELLS		UNIV INNSBRUCK, SCH MED, INST GEN & EXPT PATHOL, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck	Wick, G (corresponding author), AUSTRIAN ACAD SCI, INST BIOMED AGING RES, RENNWEG 10, A-6020 INNSBRUCK, AUSTRIA.			Mayr, Manuel/0000-0002-0597-829X				Amberger A, 1997, CELL STRESS CHAPERON, V2, P94, DOI 10.1379/1466-1268(1997)002<0094:CEOIVE>2.3.CO;2; Bobryshev YV, 1996, PATHOL RES PRACT, V192, P462; BOBRYSHEV YV, 1995, ARCH HISTOL CYTOL, V58, P307, DOI 10.1679/aohc.58.307; BOBRYSHEV YV, 1995, CARDIOVASC RES, V29, P689, DOI 10.1016/0008-6363(96)88642-1; CESARE SD, 1992, IMMUNOLOGY, V76, P341; DANIELI MG, 1992, J AUTOIMMUN, V5, P443, DOI 10.1016/0896-8411(92)90004-A; Dansky HM, 1997, P NATL ACAD SCI USA, V94, P4642, DOI 10.1073/pnas.94.9.4642; ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576; EMESON EE, 1988, AM J PATHOL, V130, P369; FOX CC, 1994, CELL IMMUNOL, V158, P253, DOI 10.1006/cimm.1994.1272; HAJJAR DP, 1986, AM J PATHOL, V122, P62; HANSSON GK, 1993, LANCET, V341, P278, DOI 10.1016/0140-6736(93)92621-Y; HANSSON GK, 1989, ARTERIOSCLEROSIS, V9, P567, DOI 10.1161/01.ATV.9.5.567; Hoppichler F, 1996, ATHEROSCLEROSIS, V126, P333, DOI 10.1016/0021-9150(96)05931-X; Inoue Y, 1996, AM J PATHOL, V149, P2037; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; JONES DB, 1993, IMMUNOL TODAY, V14, P115, DOI 10.1016/0167-5699(93)90210-C; KAARTINEN M, 1994, ARTERIOSCLER THROMB, V14, P966, DOI 10.1161/01.ATV.14.6.966; KIESSLING R, 1991, IMMUNOL REV, V121, P91, DOI 10.1111/j.1600-065X.1991.tb00824.x; KLEINDIENST R, 1993, AM J PATHOL, V142, P1927; KOKKONEN JO, 1993, ARTERIOSCLER THROMB, V13, P276, DOI 10.1161/01.ATV.13.2.276; KOVANEN PT, 1995, CHEM IMMUNOL, V62, P132; KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841; LABERGE S, 1995, J IMMUNOL, V155, P2902; LIBBY P, 1988, NEW ENGL J MED, V318, P1493, DOI 10.1056/NEJM198806093182303; LIBBY P, 1991, LAB INVEST, V64, P5; LINDSTEDT KA, 1993, ARTERIOSCLER THROMB, V13, P23, DOI 10.1161/01.ATV.13.1.23; Metzler B, 1997, ARTERIOSCL THROM VAS, V17, P536, DOI 10.1161/01.ATV.17.3.536; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; RES PCM, 1988, LANCET, V2, P478, DOI 10.1016/S0140-6736(88)90123-7; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schett G, 1997, ATHEROSCLEROSIS, V128, P27, DOI 10.1016/S0021-9150(96)05975-8; Schett G, 1995, J CLIN INVEST, V96, P2569, DOI 10.1172/JCI118320; Seitz CS, 1996, LAB INVEST, V74, P241; Soltys BJ, 1996, EXP CELL RES, V222, P16, DOI 10.1006/excr.1996.0003; STEINBERG D, 1990, JAMA-J AM MED ASSOC, V264, P3047, DOI 10.1001/jama.264.23.3047; STEMME S, 1991, LAB INVEST, V65, P654; STULNIG TM, 1995, ARTERIOSCL THROM VAS, V15, P872, DOI 10.1161/01.ATV.15.7.872; THOM DH, 1992, JAMA-J AM MED ASSOC, V268, P68, DOI 10.1001/jama.268.1.68; TOKUNAGA O, 1995, ANN NY ACAD SCI, V748, P498; VANDERWAL AC, 1992, AM J PATHOL, V141, P1427; VANEDEN W, 1988, NATURE, V331, P171, DOI 10.1038/331171a0; VLAICU R, 1985, ATHEROSCLEROSIS, V57, P163, DOI 10.1016/0021-9150(85)90030-9; WANDWURTTENBERGER A, 1991, EUR J IMMUNOL, V21, P1089, DOI 10.1002/eji.1830210437; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; WICK G, 1989, ADV IMMUNOL, V47, P433, DOI 10.1016/S0065-2776(08)60666-5; WICK G, 1995, IMMUNOL TODAY, V16, P27, DOI 10.1016/0167-5699(95)80067-0; WICK G, 1987, IMMUNOL LETT, V16, P249, DOI 10.1016/0165-2478(87)90154-4; WICK G, 1991, ANN NY ACAD SCI, V621, P277; Wick G., 1992, TRENDS FOOD SCI TECH, V3, P114; WICK G, 1996, IMMUNOLOGY METHODS M, P2271; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9; WOOD KM, 1993, HISTOPATHOLOGY, V22, P437, DOI 10.1111/j.1365-2559.1993.tb00157.x; XU QB, 1993, ARTERIOSCLER THROMB, V13, P1763, DOI 10.1161/01.ATV.13.12.1763; XU QB, 1994, CIRC RES, V75, P1078, DOI 10.1161/01.RES.75.6.1078; Xu QB, 1996, MOL MED TODAY, V2, P372, DOI 10.1016/S1357-4310(96)10034-4; XU QB, 1990, CLIN IMMUNOL IMMUNOP, V56, P344, DOI 10.1016/0090-1229(90)90155-J; XU QB, 1993, J CLIN INVEST, V91, P2693, DOI 10.1172/JCI116508; XU QB, 1993, LANCET, V341, P255, DOI 10.1016/0140-6736(93)92613-X; XU QB, 1992, ARTERIOSCLER THROMB, V12, P789, DOI 10.1161/01.ATV.12.7.789; Xu QB, 1996, ATHEROSCLEROSIS, V123, P145, DOI 10.1016/0021-9150(96)05800-5; XU QB, 1994, PTERIDINES, V5, P139; YOUNG RA, 1989, CELL, V59, P5, DOI 10.1016/0092-8674(89)90861-1	64	170	183	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1997	11	13					1199	1207		10.1096/fasebj.11.13.9367355	http://dx.doi.org/10.1096/fasebj.11.13.9367355			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367355				2022-12-28	WOS:A1997YE98300018
J	VonKnethen, A; Brune, B				VonKnethen, A; Brune, B			Cyclooxygenase-2: an essential regulator of NO-mediated apoptosis	FASEB JOURNAL			English	Article						macrophage; interferon; nitric oxide; LDH; transfection	NF-KAPPA-B; OXIDE-INDUCED APOPTOSIS; RAT MESANGIAL CELLS; NITRIC-OXIDE; PERITONEAL-MACROPHAGES; MESSENGER-RNA; PROSTAGLANDIN SYNTHASE; IFN-GAMMA; IN-VITRO; DEATH	Lipopolysaccharide/interferon gamma upregulated inducible nitric oxide synthase and caused nitric oxide generation and concomitant apoptotic cell death in RAW 264.7 macrophages. Exogenously supplied nitric oxide donors such as S-nitrosoglutathione produced equivalent alterations, Preactivation of macrophages with a combination of lipopolysaccharide/interferon gamma under conditions of blocked NO synthase-N-G-monomethyl-L-arginine addition-or stimulation with a low, nondestructive dose of S-nitrosoglutathione conferred protection against high and thus apoptotic NO concentrations, Here we report that induction of cyclooxygenase-2 during the preactivation period is a critical regulator of macrophage apoptosis, Under resting conditions, macrophages do not express cyclooxygenase-2, whereas lipopolysaccharide/interferon gamma/N-G-monomethyl-L-arginine prestimulation for 12-15 h caused protein expression, In parallel, preactivation of RAW cells with a low, nontoxic dose of S-nitrosoglutathione promoted protection and cyclooxygenase-2 up-regulation, To prove cyclooxygenase-2 involvement during protection, we stably transfected RAW 264.7 macrophages with a rat cyclooxygenase-2 expression vector, Cyclooxygenase-2 overexpressing macrophages, preactivated with the calcium liberating and thus phopholipase A(2)-activating agent A23187, revealed protection against exogenously supplied NO, Protection afforded by lipopolysaccharide/interferon gamma/N-G-monomethyl-L-arginine prestimulation was completely reversed by the addition of the cyclooxygenase-2 selective inhibitor NS-398 or in macrophages stably transfected with an antisense cyclooxygegase-2 expression vector, Our results point to cyclooxygenase-2 induction by lipopolysaccharide/interferon gamma/N-G-monomethyl-L-arginine or low-dose nitric oxide pretreatment conferring macrophage protection to the apoptotic action of nitric oxide.	UNIV ERLANGEN NURNBERG,FAC MED,DEPT MED 4,DIV EXPT,D-91054 ERLANGEN,GERMANY	University of Erlangen Nuremberg								Albina JE, 1996, J IMMUNOL, V157, P279; ALBINA JE, 1993, J IMMUNOL, V150, P5080; ANKARCRONA M, 1994, EXP CELL RES, V213, P172, DOI 10.1006/excr.1994.1187; APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bellmann K, 1996, FEBS LETT, V391, P185, DOI 10.1016/0014-5793(96)00730-2; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; Brune B, 1995, TOXICOL LETT, V82-3, P233, DOI 10.1016/0378-4274(95)03481-1; BRUNE B, 1996, BIOCHEM BIOPH RES CO, V299, P396; BUCHMULLERROUILLER Y, 1992, J IMMUNOL, V148, P1171; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; Corbett JA, 1996, AM J PHYSIOL-CELL PH, V270, pC1581, DOI 10.1152/ajpcell.1996.270.6.C1581; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DEAKIN AM, 1995, CYTOKINE, V7, P408, DOI 10.1006/cyto.1995.0056; FEHSEL K, 1995, J IMMUNOL, V155, P2858; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GENG Y, 1995, J IMMUNOL, V155, P796; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; IKEDA M, 1994, CYTOKINE, V6, P602, DOI 10.1016/1043-4666(94)90047-7; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; KANETO H, 1995, DIABETES, V44, P733, DOI 10.2337/diabetes.44.7.733; KIM YM, 1995, FEBS LETT, V374, P228, DOI 10.1016/0014-5793(95)01115-U; Kitade H, 1996, HEPATOLOGY, V23, P797, DOI 10.1002/hep.510230421; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; LEE JM, 1995, CANCER METAST REV, V14, P149, DOI 10.1007/BF00665797; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU XJ, 1995, P NATL ACAD SCI USA, V92, P7961, DOI 10.1073/pnas.92.17.7961; MAGNELLI L, 1995, BIOCHEM BIOPH RES CO, V215, P641, DOI 10.1006/bbrc.1995.2512; MARNETT LJ, 1992, CANCER RES, V52, P5575; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Messmer UK, 1996, FEBS LETT, V384, P162; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; Messmer UK, 1996, J BIOL CHEM, V271, P20192, DOI 10.1074/jbc.271.33.20192; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171, DOI 10.1002/jlb.54.2.171; OBANION MK, 1991, J BIOL CHEM, V266, P23261; Packham G, 1996, J IMMUNOL, V156, P2792; QIU ZH, 1993, J BIOL CHEM, V268, P24506; RIDGWAY WM, 1994, CURR OPIN IMMUNOL, V6, P946, DOI 10.1016/0952-7915(94)90018-3; Salvemini D, 1996, J CLIN INVEST, V97, P2562, DOI 10.1172/JCI118704; Sandau K, 1996, CELL SIGNAL, V8, P173, DOI 10.1016/0898-6568(95)02051-9; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SCHWARZ MA, 1995, P NATL ACAD SCI USA, V92, P4452, DOI 10.1073/pnas.92.10.4452; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TESUKA T, 1996, BIOCHEM BIOPH RES CO, V218, P808; Tetsuka T, 1996, J CLIN INVEST, V97, P2051, DOI 10.1172/JCI118641; TORDJMAN C, 1995, BBA-LIPID LIPID MET, V1256, P249, DOI 10.1016/0005-2760(95)00026-9; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Weisz A, 1996, BIOCHEM J, V316, P209, DOI 10.1042/bj3160209; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	69	118	121	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1997	11	11					887	895						9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XT790	9285487				2022-12-28	WOS:A1997XT79000008
J	NegreSalvayre, A; Hirtz, C; Carrera, G; Cazenave, R; Troly, M; Salvayre, R; Penicaud, L; Casteilla, L				NegreSalvayre, A; Hirtz, C; Carrera, G; Cazenave, R; Troly, M; Salvayre, R; Penicaud, L; Casteilla, L			Role for uncoupling protein-2 as a regulator of mitochondrial hydrogen peroxide generation	FASEB JOURNAL			English	Article						mitochondria; inflammation; monocyte/macrophage; adipose tissue; rhodamine 123; UCP	BROWN ADIPOSE-TISSUE; LIVER-MITOCHONDRIA; H2O2; NUCLEOTIDES; EVOLUTION; CELLS	According to the state of mitochondrial respiration, the respiratory chain generates superoxide anions converted into hydrogen peroxide. Two uncoupling proteins (UCP) able to modulate the coupling between the respiratory chain and ATP synthesis are now identified and could be involved in mitochondrial H2O2 generation. UCP1 is specific to brown adipose tissue (BAT) whereas UCP2 is expressed in numerous tissues, particularly in monocytes/macrophages. Preincubation of BAT mitochondrial fractions with GDP, an inhibitor of UCP1, induced a rise in mitochondrial membrane potential (assessed by rhodamine 123 uptake) and H2O2 production. An uncoupling agent reversed this effect. Liver mitochondria exhibited a similar phenotype. CDP was also able to raise membrane potential and H2O2 production of the mitochondria from nonparenchymal cells expressing UCP2, but was completely ineffective on mitochondria from hepatocytes deprived of UCP2. The GDP effect was also observed with mitochondrial fractions of the spleen or thymus, which highly expressed UCP2. Altogether, these results strongly suggest that UCP2 is sensitive to GDP and that the UCPs, particularly UCP2, are able to modulate H2O2 mitochondrial generation. This supports a role for UCP2 in cellular (patho-) physiological processes involving free radicals generated by mitochondria, such as oxidative damage, inflammation, or apoptosis.	CHU RANGUEIL, CNRS, UPRESA 5018, IFR L BUGNARD, F-31054 TOULOUSE, FRANCE; CHU RANGUEIL, EA 824, F-31054 TOULOUSE, FRANCE; CHU RANGUEIL, INSERM U466, IFR L BUGNARD, F-31054 TOULOUSE, FRANCE	Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse; CHU de Toulouse; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)			Hirtz, Christophe/AAD-1662-2022; Hirtz, Christophe/R-9255-2017	Hirtz, Christophe/0000-0002-7313-0629; Hirtz, Christophe/0000-0002-7313-0629; Casteilla, Louis/0000-0001-9647-3248; Negre-Salvayre, Anne/0000-0003-2136-5706				APRILLE JR, 1980, ARCH BIOCHEM BIOPHYS, V201, P564, DOI 10.1016/0003-9861(80)90546-9; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BOUILLAUD F, 1994, EMBO J, V13, P1990, DOI 10.1002/j.1460-2075.1994.tb06468.x; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; BRAND MD, 1991, BIOCHEM J, V275, P81, DOI 10.1042/bj2750081; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; FORMAN HJ, 1982, FREE RADICAL BIO MED, V5, P65; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LARROUY D, IN PRESS BIOCH BIOPH; LOSCHEN G, 1974, FEBS LETT, V42, P68, DOI 10.1016/0014-5793(74)80281-4; LOSCHEN G, 1973, FEBS LETT, V33, P84, DOI 10.1016/0014-5793(73)80165-6; LOSCHEN G, 1971, FEBS LETT, V18, P261, DOI 10.1016/0014-5793(71)80459-3; LUFT R, 1994, P NATL ACAD SCI USA, V91, P8731, DOI 10.1073/pnas.91.19.8731; MABILE L, 1997, IN PRESS ARTERIOSCLE; MUKHERJEE SP, 1980, BIOCHEM PHARMACOL, V29, P1239; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798; PORTER RK, 1993, NATURE, V362, P628, DOI 10.1038/362628a0; PORTER RK, 1995, AM J PHYSIOL-REG I, V269, pR1213, DOI 10.1152/ajpregu.1995.269.5.R1213; RICQUIER D, 1991, FASEB J, V5, P2237, DOI 10.1096/fasebj.5.9.1860614; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; VERCESI AE, 1995, NATURE, V375, P24, DOI 10.1038/375024a0; ViguerieBascands N, 1996, J CLIN ENDOCR METAB, V81, P368, DOI 10.1210/jc.81.1.368; Wharton DC., 1967, METHOD ENZYMOL, P245	32	648	661	1	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1997	11	10					809	815		10.1096/fasebj.11.10.9271366	http://dx.doi.org/10.1096/fasebj.11.10.9271366			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XR105	9271366				2022-12-28	WOS:A1997XR10500011
J	Brenner, MK				Brenner, MK			Hematological malignancies	FASEB JOURNAL			English	Review						hemopoietic stem cell; gene transfer; tumor vaccine; bone marrow transplantation; gene therapy	BONE-MARROW TRANSPLANTATION; GENE-TRANSFER; MULTIDRUG RESISTANCE; TUMOR-THERAPY; CELLS; CANCER; EXPRESSION; MARKING; COSTIMULATION; ANTISENSE	The present cure rate for leukemia and lymphoma represents one of the success stories of modern cancer therapy. However, treatments remain toxic, expensive, and ineffective for many patients. There is therefore considerable interest in exploring gene therapies for these disorders. To date, four major strategies have been adopted: 1) modifying the tumor cell itself either by ''repairing'' one or more genetic defect associated with the malignant process, introducing a gene that will trigger an anti-tumor immune response, or delivering a prodrug metabolizing enzyme that will render the tumor sensitive to the corresponding cytotoxic agent; 2) modifying the immune response to the tumor by altering the specificity or effector function of immune system cells; 3) decreasing the sensitivity of normal host tissue by delivering cytotoxic drug resistance genes to marrow precursor cells and thereby increasing the therapeutic index of cytotoxic agents; and 4) marking normal and malignant hemopoietic cells in order to more closely monitor the efficacy of conventional therapies. Given the current ''state of the art,'' all these approaches have significant limitations, but each has had its successes, offering encouragement for future applications in clinical practice.			Brenner, MK (corresponding author), ST JUDE CHILDRENS RES HOSP, CELL & GENE THERAPY PROGRAM, 332 N LAUDERDALE ST, MEMPHIS, TN 38105 USA.		Brenner, Malcolm/Y-2509-2019		NCI NIH HHS [CA 20180, CA 61384] Funding Source: Medline; NHLBI NIH HHS [HL 55703] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061384, P01CA020180, U01CA061384] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055703] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BI WL, 1993, HUM GENE THER, V4, P725, DOI 10.1089/hum.1993.4.6-725; BRENNER MK, 1993, LANCET, V342, P1134, DOI 10.1016/0140-6736(93)92122-A; BRENNER MK, 1991, CURR OPIN IMMUNOL, V3, P752, DOI 10.1016/0952-7915(91)90108-D; BRENNER MK, 1993, LANCET, V341, P85, DOI 10.1016/0140-6736(93)92560-G; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; COLOMBO MP, 1994, IMMUNOL TODAY, V15, P48, DOI 10.1016/0167-5699(94)90131-7; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DEFABRITIIS P, 1989, BONE MARROW TRANSPL, V4, P660; DEISSEROTH AB, 1994, BLOOD, V83, P3068, DOI 10.1182/blood.V83.10.3068.3068; Dilloo D, 1996, NAT MED, V2, P1090, DOI 10.1038/nm1096-1090; DILLOO D, 1996, IN PRESS BLOOD; DUNBAR CE, 1994, ANN NY ACAD SCI, V716, P216, DOI 10.1111/j.1749-6632.1994.tb21714.x; FREEMAN SM, 1993, CANCER RES, V53, P5274; FUJIWARA T, 1993, CANCER RES, V53, P4129; GANSBACHER B, 1990, J EXP MED, V172, P1217, DOI 10.1084/jem.172.4.1217; GRIBBEN JG, 1991, NEW ENGL J MED, V325, P1525, DOI 10.1056/NEJM199111283252201; Heslop HE, 1996, NAT MED, V2, P551, DOI 10.1038/nm0596-551; HOCK H, 1993, CANCER RES, V53, P714; HUBER BE, 1994, P NATL ACAD SCI USA, V91, P8302, DOI 10.1073/pnas.91.17.8302; KNOX RJ, 1993, CANCER METAST REV, V12, P195, DOI 10.1007/BF00689810; LANZAVECCHIA A, 1993, SCIENCE, V260, P937, DOI 10.1126/science.8493532; MCLACHLIN JR, 1990, J NATL CANCER I, V82, P1260, DOI 10.1093/jnci/82.15.1260; MELIEF CJM, 1993, CURR OPIN IMMUNOL, V5, P709, DOI 10.1016/0952-7915(93)90125-C; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; MORITZ T, 1993, BLOOD, V82, pA118; MURPHY D, 1993, ANN ONCOL, V4, P377, DOI 10.1093/oxfordjournals.annonc.a058516; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.med.42.1.277; Riddell SR, 1996, NAT MED, V2, P216, DOI 10.1038/nm0296-216; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; ROSENBERG SA, 1992, JAMA-J AM MED ASSOC, V268, P2416, DOI 10.1001/jama.268.17.2416; ROSSI JJ, 1995, BRIT MED BULL, V51, P217, DOI 10.1093/oxfordjournals.bmb.a072948; TAHARA H, 1994, SOMATIC GENE THERAPY, P263; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; WANG JX, 1995, CANCER GENE THER, V2, P9; WEI MX, 1994, HUM GENE THER, V5, P969, DOI 10.1089/hum.1994.5.8-969; ZHANG YJ, 1993, HUM GENE THER, V4, P451, DOI 10.1089/hum.1993.4.4-451	39	8	8	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1997	11	8					640	648		10.1096/fasebj.11.8.9240966	http://dx.doi.org/10.1096/fasebj.11.8.9240966			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XN027	9240966				2022-12-28	WOS:A1997XN02700005
J	Gath, I; Closs, EI; GodtelArmbrust, U; Schmitt, S; Nakane, M; Wessler, I; Forstermann, U				Gath, I; Closs, EI; GodtelArmbrust, U; Schmitt, S; Nakane, M; Wessler, I; Forstermann, U			Inducible NO synthase II and neuronal NO synthase I are constitutively expressed in different structures of guinea pig skeletal muscle: Implications for contractile function	FASEB JOURNAL			English	Article						NO synthase mRNA; anti-NO synthase antibodies; Ca2+-dependent and -independent NO synthase activity; muscle contraction; N-G-nitro-L-arginine; S-nitroso-N-acetyl-D,L-penicillamine	NITRIC-OXIDE SYNTHASE; NITROPRUSSIDE; SARCOLEMMA; INHIBITION; ISOFORMS; RELEASE; FIBERS; CELLS	The expression of NOS isoforms was studied in guinea pig skeletal muscle at the mRNA and protein level, and the effect of NO on contractile response was examined, Ribonuclease protection analyses demonstrated NOS I and NOS II mRNAs in diaphragm and gastrocnemius muscle, In Western blots, NOS I and NOS II immunoreactivities were found in the particulate but not the soluble fraction of skeletal muscle, NOS activity was found almost exclusively in the particulate fraction, About 50% of this activity was Ca2+ independent, In immunohistochemistry, the anti-NOS I antibody stained distinct membrane regions of muscle fibers, The most intense staining was seen in neuromuscular endplates identified by labeling with a-bungarotoxin, The anti-NOS II antibody labeled muscle fibers that contained alkalilabile myosin ATPase (type I fibers), NOS II was located to intracellular structures and was also seen in ''specific pathogen-free'' animals. Pretreatment of guinea pigs with bacterial lipopolysaccharide (LPS) markedly intensified NOS II staining, Significant NOS III immunoreactivity was detected only in vascular endothelium. In functional experiments, tetanic muscle contractions were induced in diaphragm and gastrocnemius muscle by electrical stimulation of the innervating nerves, Pretreatment of guinea pigs with LPS or addition of S-nitroso-N-acetyl-D,L-penicillamine to the organ bath markedly decreased tetanic contractions, N-G-nitro-L-arginine, on the other hand, increased contractile force and reversed the effect of LPS, Our data indicate that NOS II and NOS I are expressed in different structures of skeletal muscle and are involved in the regulation of contractile response.	UNIV MAINZ,DEPT PHARMACOL,D-55101 MAINZ,GERMANY; ABBOTT LABS,DEPT 4NB,ABBOTT PK,IL 60064	Johannes Gutenberg University of Mainz; Abbott Laboratories			Closs, Ellen/ABD-5217-2020	Closs, Ellen/0000-0002-9505-2289				BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; CLOSE RI, 1972, PHYSIOL REV, V52, P129, DOI 10.1152/physrev.1972.52.1.129; Forstermann U, 1996, METHOD ENZYMOL, V268, P334; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FORSTERMANN U, 1995, BIOCHEM PHARMACOL, V50, P1321, DOI 10.1016/0006-2952(95)00181-6; GERSHONI JM, 1983, P NATL ACAD SCI-BIOL, V80, P4973, DOI 10.1073/pnas.80.16.4973; GROZDANOVIC Z, 1995, CELL TISSUE RES, V281, P493; ISHII K, 1991, AM J PHYSIOL, V261, pH598, DOI 10.1152/ajpheart.1991.261.2.H598; KING CE, 1994, J APPL PHYSIOL, V76, P1166, DOI 10.1152/jappl.1994.76.3.1166; KOBZIK L, 1995, BIOCHEM BIOPH RES CO, V211, P375, DOI 10.1006/bbrc.1995.1824; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; LINDGREN CA, 1994, NEUROREPORT, V5, P2205, DOI 10.1097/00001756-199410270-00054; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MORRISSEY JJ, 1994, KIDNEY INT, V45, P998, DOI 10.1038/ki.1994.135; MURRANT CL, 1994, CAN J PHYSIOL PHARM, V72, P1089, DOI 10.1139/y94-152; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NAKANE M, 1995, BIOCHEM BIOPH RES CO, V206, P511, DOI 10.1006/bbrc.1995.1073; PADYKULA HA, 1955, J HISTOCHEM CYTOCHEM, V3, P161, DOI 10.1177/3.3.161; POLLOCK JS, 1993, AM J PHYSIOL, V265, pC1379, DOI 10.1152/ajpcell.1993.265.5.C1379; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; Sambrook J., 1989, MOL CLONING; SCHMIDT HHHW, 1992, J HISTOCHEM CYTOCHEM, V40, P1439, DOI 10.1177/40.10.1382087; SCHWEIZER M, 1994, BIOCHEM BIOPH RES CO, V204, P169, DOI 10.1006/bbrc.1994.2441; STEVENS DL, 1994, HARRISONS PRINCIPLES, P561; WANG T, 1995, NATURE, V374, P262, DOI 10.1038/374262a0; WESSLER I, 1986, N-S ARCH PHARMACOL, V334, P365, DOI 10.1007/BF00569371	27	115	117	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1996	10	14					1614	1620		10.1096/fasebj.10.14.9002553	http://dx.doi.org/10.1096/fasebj.10.14.9002553			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WC869	9002553				2022-12-28	WOS:A1996WC86900007
J	Sincoff, R; Tanguy, J; Hamilton, B; Carter, D; Brunner, EA; Yeh, JZ				Sincoff, R; Tanguy, J; Hamilton, B; Carter, D; Brunner, EA; Yeh, JZ			Halothane acts as a partial agonist of the alpha 6 beta 2 gamma 2S GABA(A) receptor	FASEB JOURNAL			English	Article						volatile anesthetics; HEK 293 cells	GAMMA-AMINOBUTYRIC-ACID; RAT HIPPOCAMPAL-NEURONS; SUBUNIT MESSENGER-RNAS; ROOT GANGLION NEURONS; VOLATILE ANESTHETICS; PYRAMIDAL NEURONS; CHANNEL COMPLEX; A RECEPTORS; PROPOFOL; ENHANCEMENT	Whole-cell patch clamp recording was performed on human embryonic kidney 293 cells stably transfected with rat cDNAs for the alpha 6, beta 2, and gamma 2S subunits of the GABA(A) receptor, The volatile anesthetic halothane directly activated a current in the absence of the ligand gamma-aminobutyric acid (GABA), Both the current amplitude and the rate of desensitization increased in a dose-dependent manner with an EC(50) of 1.0+/-0.2 mM and a Hill coefficient (n(h)) of 1.5+/-0.1, The EC(50) and n(h) for GABA to activate the receptor were 1.0+/-0.3 mu M and 1.4+/-0.2, respectively, The peak amplitude of the halothane-activated current was about 4% of the maximal GABA response, which was not changed when the concentration of Ca2+ in the external solution was decreased from 2 mM to 0.2 mM. The reversal potential of both halothane- and GABA-activated currents changed with the external Cl- concentration as predicted by the Nernst equation for chloride ions, The halothane- and GABA-activated currents were blocked by both the noncompetitive GABA(A) receptor antagonist picrotoxin and the competitive GABA(A) receptor antagonist bicuculline. Schild plots revealed that the K(i)s for bicuculline to competitively antagonize the currents activated by halothane and GABA are similar (0.69 and 0.72 mu M, respectively), These results indicate that halothane activates the alpha 6 beta 2 gamma 2S GABA(A) receptor to induce a current similar to the GABA-induced current.	NORTHWESTERN UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT ANESTHESIOL,CHICAGO,IL 60611; UPJOHN CO,CNS DIS RES,KALAMAZOO,MI 49001	Northwestern University; Northwestern University; Pfizer								ADODRA S, 1995, BRIT J PHARMACOL, V115, P953, DOI 10.1111/j.1476-5381.1995.tb15903.x; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; HALES TG, 1991, BRIT J PHARMACOL, V104, P619, DOI 10.1111/j.1476-5381.1991.tb12479.x; HALL AC, 1994, BRIT J PHARMACOL, V112, P906, DOI 10.1111/j.1476-5381.1994.tb13166.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAMILTON BJ, 1993, NEUROSCI LETT, V153, P206, DOI 10.1016/0304-3940(93)90323-D; HARA M, 1994, ANESTHESIOLOGY, V81, P988, DOI 10.1097/00000542-199410000-00026; HARA M, 1993, ANESTHESIOLOGY, V79, P781, DOI 10.1097/00000542-199310000-00021; IM WB, 1991, MOL PHARMACOL, V39, P394; JONES MV, 1995, J PHARMACOL EXP THER, V274, P962; JONES MV, 1992, J PHYSIOL-LONDON, V449, P279, DOI 10.1113/jphysiol.1992.sp019086; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; LONGONI B, 1993, J PHARMACOL EXP THER, V266, P153; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MALHERBE P, 1990, FEBS LETT, V260, P261, DOI 10.1016/0014-5793(90)80118-3; MOODY EJ, 1988, J NEUROCHEM, V51, P1386, DOI 10.1111/j.1471-4159.1988.tb01102.x; NAKAHIRO M, 1989, FASEB J, V3, P1850, DOI 10.1096/fasebj.3.7.2541038; NICOLL RA, 1980, BRAIN RES, V191, P225, DOI 10.1016/0006-8993(80)90325-X; ORSER BA, 1994, J NEUROSCI, V14, P7747; PERSOHN E, 1991, NEUROSCIENCE, V42, P497, DOI 10.1016/0306-4522(91)90392-2; ROBERTSON B, 1989, BRIT J PHARMACOL, V98, P167, DOI 10.1111/j.1476-5381.1989.tb16878.x; SANNA E, 1995, J PHARMACOL EXP THER, V274, P353; SANNA E, 1995, MOL PHARMACOL, V47, P213; SCHULZ DW, 1981, BRAIN RES, V209, P177, DOI 10.1016/0006-8993(81)91179-3; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SETO T, 1992, J PHARMACEUT BIOMED, V10, P1, DOI 10.1016/0731-7085(92)80003-6; SIVILOTTI L, 1991, PROG NEUROBIOL, V36, P35, DOI 10.1016/0301-0082(91)90036-Z; TANGUY J, 1995, PROG ANESTH MECH, V3, P82; VALEYEV AY, 1993, NEUROSCI LETT, V155, P199, DOI 10.1016/0304-3940(93)90707-R; WAKAMORI M, 1991, J NEUROPHYSIOL, V66, P2014, DOI 10.1152/jn.1991.66.6.2014; Winters W D, 1982, Prog Drug Res, V26, P225; WISDEN W, 1992, J NEUROSCI, V12, P1040; YANG J, 1992, FASEB J, V6, P914, DOI 10.1096/fasebj.6.3.1740240; YEH JZ, 1994, ANESTHESIOLOGY, V81, pA800	36	16	16	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1996	10	13					1539	1545		10.1096/fasebj.10.13.8940300	http://dx.doi.org/10.1096/fasebj.10.13.8940300			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VU982	8940300				2022-12-28	WOS:A1996VU98200011
J	Prough, RA; Linder, MW; Pinaire, JA; Xiao, GH; Falkner, KC				Prough, RA; Linder, MW; Pinaire, JA; Xiao, GH; Falkner, KC			Cytochromes P450 .8. Hormonal regulation of hepatic enzymes involved in foreign compound metabolism	FASEB JOURNAL			English	Review						Ah receptor; aldehyde dehydrogenase class 3; cytochrome P4501A1; glucocorticoid receptor; glutathione S-transferase; NAD(P)H: quinone oxidoreductase	POLYCYCLIC AROMATIC-HYDROCARBONS; CLASS-3 ALDEHYDE DEHYDROGENASE; ADULT-RAT HEPATOCYTES; GENE-EXPRESSION; GLUCOCORTICOID REGULATION; INDUCIBLE EXPRESSION; INDUCTION; IDENTIFICATION; ELEMENTS; TRANSCRIPTION	The regulation of hepatic P450s has been the focus of numerous studies because of the importance of these proteins in endocrinology, oncology, and toxicology, as well as drug development. Considerable evidence exists demonstrating that many hepatic P450s are regulated by developmental, sex, or hormonal factors in addition to receptors that interact with foreign chemicals. The focus of work in our laboratory has been on the effects of steroid hormones, especially glucocorticoids, on expression of genes regulated by the Ah receptor. We have shown that most rat hepatic genes of the Ah receptor gene battery are regulated by glucocorticoids. We have used glucocorticoid-deficient animal models to demonstrate that these steroids do modulate the expression (basal and inducible) of these genes in vivo. Using cultured rat hepatocytes, we have demonstrated that polycyclic aromatic hydrocarbon (PAH) induction of cytochrome P4501A1, glutathione S-transferase Ya(1), and UDP-glucuronosyl-transferase 1*6 are apparently potentiated two- to fourfold upon inclusion of glucocorticoids in the media to activate the glucocorticoid receptor and further, that the receptor antagonist RU 38486 reverses these phenomenon. NAD(P)H:quinone oxidoreductase and aldehyde dehydrogenase 3 gene expression were repressed 70-80% by glucocorticoids in cultured hepatocytes through a glucocorticoid receptor-mediated process as well. The effect of glucocorticoid concentration on PAH induction of glutathione S-transferase Ya(1) subunit for glucocorticoids was biphasic, but at physiological concentrations gene expression was repressed to similar to 20-40% of control. At supraphysiological concentrations, glucocorticoids alone induced expression two- to threefold and potentiated the PAH-inducible expression of the Ya(1) subunit gene. Subsequent work in our laboratory has focused on defining the molecular basis of this hormonal regulation, specifically elucidating responsive elements responsible for the action of the glucocorticoid receptor and the mechanisms by which some of these genes are positively regulated and others are negatively regulated.			Prough, RA (corresponding author), UNIV LOUISVILLE,SCH MED,DEPT BIOCHEM,319 ABRAHAM FLEXNER WAY,LOUISVILLE,KY 40292, USA.		Russell A, Prough/AAH-5907-2020	Prough, Russell/0000-0001-8901-8490	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004244] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES04244] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABRAMOVITZ M, 1988, XENOBIOTICA, V18, P1249, DOI 10.3109/00498258809042248; ALDRIDGE TC, 1995, BIOCHEM J, V306, P473, DOI 10.1042/bj3060473; ASMAN DC, 1993, J BIOL CHEM, V268, P12530; BRASIER AR, 1990, MOL ENDOCRINOL, V4, P1921, DOI 10.1210/mend-4-12-1921; CARR BR, 1980, J CLIN ENDOCR METAB, V50, P870, DOI 10.1210/jcem-50-5-870; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; GREENGARD O, 1975, J STEROID BIOCHEM, V6, P639, DOI 10.1016/0022-4731(75)90045-X; HARDWICK JP, 1983, J BIOL CHEM, V258, P8081; HASSELMEYER EG, 1979, SMOKING HLTH REPORT, P1; HAWKINS JM, 1987, DRUG METAB REV, V18, P441, DOI 10.3109/03602538708994130; HESS P, 1992, J BIOL CHEM, V267, P1; HINES RN, 1988, CARCINOGENESIS, V9, P1599, DOI 10.1093/carcin/9.9.1599; HINES RN, 1985, ARCH BIOCHEM BIOPHYS, V237, P465, DOI 10.1016/0003-9861(85)90300-5; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JANECZKO R, 1990, MOL ENDOCRINOL, V4, P295, DOI 10.1210/mend-4-2-295; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KOCAREK TA, 1994, BIOCHEM PHARMACOL, V48, P1815, DOI 10.1016/0006-2952(94)90468-5; LINDER MW, 1993, ARCH BIOCHEM BIOPHYS, V302, P92, DOI 10.1006/abbi.1993.1185; MATHIS JM, 1986, ARCH BIOCHEM BIOPHYS, V244, P650, DOI 10.1016/0003-9861(86)90633-8; MATHIS JM, 1989, ARCH BIOCHEM BIOPHYS, V269, P93, DOI 10.1016/0003-9861(89)90090-8; MATHIS JM, 1986, ARCH BIOCHEM BIOPHYS, V246, P439, DOI 10.1016/0003-9861(86)90490-X; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; RAM PA, 1992, J BIOL CHEM, V267, P3294; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SCHUETZ EG, 1984, J BIOL CHEM, V259, P2007; SHERRATT AJ, 1989, J PHARMACOL EXP THER, V249, P667; SHERRATT AJ, 1990, MOL PHARMACOL, V37, P198; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3907; Takimoto K, 1992, Arch Biochem Biophys, V298, P493; TAKIMOTO K, 1994, ARCH BIOCHEM BIOPHYS, V312, P539, DOI 10.1006/abbi.1994.1343; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; WAXMAN DJ, 1988, BIOCHEM PHARMACOL, V37, P71, DOI 10.1016/0006-2952(88)90756-3; WAXMAN DJ, 1990, MOL ENDOCRINOL, V4, P447, DOI 10.1210/mend-4-3-447; WAXMAN DJ, 1995, MOL PHARMACOL, V5, P790; WESTIN S, 1990, MOL PHARMACOL, V38, P192; WHITLOCK JP, 1986, ANNU REV PHARMACOL, V26, P333; WRIGHT K, 1991, MOL PHARMACOL, V39, P468; XIAO GH, 1995, DRUG METAB DISPOS, V23, P642	39	58	58	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1996	10	12					1369	1377		10.1096/fasebj.10.12.8903507	http://dx.doi.org/10.1096/fasebj.10.12.8903507			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VP485	8903507				2022-12-28	WOS:A1996VP48500002
J	Bellamacina, CR				Bellamacina, CR			Protein motifs .9. The nicotinamide dinucleotide binding motif: A comparison of nucleotide binding proteins	FASEB JOURNAL			English	Article						nicotinamide adenine dinucleotide binding protein; beta alpha beta alpha beta unit; fingerprint region; phosphate binding consensus sequence; phosphate binding helix	REFINED CRYSTAL-STRUCTURE; LIVER ALCOHOL-DEHYDROGENASE; 3-DIMENSIONAL STRUCTURE; LACTATE-DEHYDROGENASE; CATALYTIC MECHANISM; ESCHERICHIA-COLI; 3-ISOPROPYLMALATE DEHYDROGENASE; TRYPANOTHIONE REDUCTASE; MALATE-DEHYDROGENASE; HELIX DIPOLE	Classical nicotinamide adenine dinucleotide (NAD(+)) binding proteins contain a beta alpha beta alpha beta unit. By comparing 14 such proteins, it is observed that an additional beta strand associates with this unit to form the ''core'' topology, the minimum structure necessary to bind cofactor. Although the overall topologies of the cofactor binding domains of nicotinamide binding proteins vary, they all contain at least the core topology, The first 30-35 amino acids of the core topology, called the ''fingerprint'' region, are diagnostic for the presence of a dinucleotide binding fold, There are four characteristics of this fingerprint region: 1) a phosphate binding consensus sequence, GXGXXG, 2) six positions usually occupied by small hydrophobic amino acids, 3) a conserved, negatively charged residue (Glu or Asp) at the end of the second beta strand of the fingerprint region, and 4) a conserved positively charged residue (Arg or Lys) at the beginning of the first beta strand of the fingerprint region, The core topologies of the classical nicotinamide binding proteins overlap well with root mean squared deviations of main chain atoms ranging from 0.7 to 4.7 Angstrom. A conserved interaction (found in 8 of the 12 classical nicotinamide binding proteins studied) between the cofactor and the protein is a hydrogen bond between the pyrophosphate oxygen of NAD(P)(+) and the carboxy-terminal glycine of the phosphate binding helix, the first alpha helix of the beta alpha beta alpha beta unit. The classical nicotinamide binding proteins all bind their cofactor in the same location and orientation, with the cofactor itself adopting a similar extended conformation in every structure. Although observed less frequently than the classical fold, numerous nonclassical folding patterns are also used by proteins that bind NAD(P)(+).	BRANDEIS UNIV,BIOPHYS PROGRAM,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02554	Brandeis University					NIGMS NIH HHS [GM-26788] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026788] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABADZAPATERO C, 1987, J MOL BIOL, V198, P445, DOI 10.1016/0022-2836(87)90293-2; ADAMS MJ, 1970, NATURE, V227, P1098, DOI 10.1038/2271098a0; AL-KARADAGHI S, 1994, ACTA CRYSTALLOGR D, V50, P793, DOI 10.1107/S0907444994005263; ALBER T, 1981, PHILOS T ROY SOC B, V293, P159, DOI 10.1098/rstb.1981.0069; BAILEY S, 1993, EUR J BIOCHEM, V213, P67, DOI 10.1111/j.1432-1033.1993.tb17734.x; BAUER AJ, 1992, PROTEINS, V12, P372, DOI 10.1002/prot.340120409; BLAGDON DE, 1975, BIOPOLYMERS, V14, P241, DOI 10.1002/bip.1975.360140118; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; COFFIN L, RAYSHADE; COLONNACESARI F, 1986, J BIOL CHEM, V261, P5273; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; DRENTH J, 1971, COLD SPRING HARB SYM, V36, P107, DOI 10.1101/SQB.1972.036.01.016; DRENTH J, 1976, BIOCHEMISTRY-US, V15, P3731, DOI 10.1021/bi00662a014; DUNN CR, 1991, PHILOS T ROY SOC B, V332, P177, DOI 10.1098/rstb.1991.0047; EKLUND H, 1984, BIOCHEMISTRY-US, V23, P5982, DOI 10.1021/bi00320a014; FITA I, 1985, P NATL ACAD SCI USA, V82, P1604, DOI 10.1073/pnas.82.6.1604; FONTANO E, RAYSCRIPT PROGRAM UT; HALL MD, 1992, J MOL BIOL, V226, P867, DOI 10.1016/0022-2836(92)90637-Y; HARRISON DH, 1994, BIOCHEMISTRY-US, V33, P2011, DOI 10.1021/bi00174a006; HILL E, 1972, J MOL BIOL, V72, P577, DOI 10.1016/0022-2836(72)90176-3; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; HURLEY JH, 1994, STRUCTURE, V2, P1007, DOI 10.1016/S0969-2126(94)00104-9; IMADA K, 1991, J MOL BIOL, V222, P725, DOI 10.1016/0022-2836(91)90508-4; JOHNSON LN, 1980, J MOL BIOL, V140, P565, DOI 10.1016/0022-2836(80)90271-5; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KIRSCH JF, 1984, J MOL BIOL, V174, P497, DOI 10.1016/0022-2836(84)90333-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURIYAN J, 1991, P NATL ACAD SCI USA, V88, P8764, DOI 10.1073/pnas.88.19.8764; LAMZIN VS, 1992, EUR J BIOCHEM, V206, P441, DOI 10.1111/j.1432-1033.1992.tb16945.x; MATTEVI A, 1992, PROTEINS, V13, P336, DOI 10.1002/prot.340130406; MORAS D, 1975, J BIOL CHEM, V250, P9137; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; REARDON D, 1995, FASEB J, V9, P497, DOI 10.1096/fasebj.9.7.7737457; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SCHIERING N, 1991, NATURE, V352, P168, DOI 10.1038/352168a0; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SHERIDAN RP, 1980, BIOPHYS CHEM, V11, P133, DOI 10.1016/0301-4622(80)80015-9; SHERIFF S, 1981, J MOL BIOL, V145, P441, DOI 10.1016/0022-2836(81)90214-X; STEHLE T, 1991, J MOL BIOL, V221, P1325, DOI 10.1016/0022-2836(91)90936-Z; VARUGHESE KI, 1992, P NATL ACAD SCI USA, V89, P6080, DOI 10.1073/pnas.89.13.6080; WADA A, 1976, ADV BIOPHYS, V79, P1; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; 1983, EUR J BIOCHEM, V131, P9	46	213	217	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1996	10	11					1257	1269		10.1096/fasebj.10.11.8836039	http://dx.doi.org/10.1096/fasebj.10.11.8836039			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VJ717	8836039				2022-12-28	WOS:A1996VJ71700005
J	Aschner, M				Aschner, M			The functional significance of brain metallothioneins	FASEB JOURNAL			English	Review						zinc; induction; nitric oxide; glutathione	TRANSCRIPTION FACTOR MTF-1; PRIMARY ASTROCYTE CULTURES; NITRIC-OXIDE; GENE-EXPRESSION; RAT-BRAIN; OXIDATIVE STRESS; HEAVY-METALS; II GENES; CONSTITUTIVE EXPRESSION; TRANSGENIC MICE	Metallothioneins (MTs) are ubiquitous low molecular weight proteins characterized by their abundant content of cysteines, Two MT isoforms, MT-I and MT-II, are expressed coordinately in all mammalian tissues, In the CNS, MT-I and MT-II are conspicuously absent from neuronal populations, yet abundant in fibrous and protoplasmic astrocytes. A newly identified brain-specific MT gene, MT-III, is predominantly expressed in zinc-containing neurons of the hippocampus and absent from glial elements, MTs have been implicated as regulator molecules in gene expression, homeostatic control of cellular metabolism of metals, and cellular adaptation to stress. MTs store and release essential metals, such as zinc and copper, maintaining the low intracellular concentration of free essential metals. Thus, MTs fulfill a regulatory capacity and influence transcription, replication, protein synthesis, metabolism, as well as other zinc-dependent biological processes, Because MT-III is particularly abundant in zinc-containing neurons of the hippocampus, it is likely to play an important role in neuromodulation by zinc-containing neurons and to act as a sink for free zinc, It may also play an etiologic role in various pathophysiological conditions associated with increased extracellular zinc, Studies demonstrating that MT-III prevents neuronal sprouting in vitro, appears to be downregulated in Alzheimer's disease, and that MT-III ''knockout'' mice appear highly sensitive to kainate-induced seizures have focused growing attention on the etiologic role of MT-III in neurodegeneration.			Aschner, M (corresponding author), WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT PHYSIOL & PHARMACOL, WINSTON SALEM, NC 27103 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES005223] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05223] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABEL J, 1989, TOXICOL LETT, V47, P191, DOI 10.1016/0378-4274(89)90075-1; ANDREWS GK, 1990, PROG FOOD NUTR SCI, V14, P193; ASCHNER M, 1996, IN PRESS NEUROTOXICO; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; BLAAUWGEERS HGT, 1993, GLIA, V8, P62, DOI 10.1002/glia.440080108; BREMNER I, 1987, PROG FOOD NUTR SCI, V11, P1; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; BUSH AI, 1996, TOXICOLOGIST, V30, P43; CHOUDHURI S, 1995, TOXICOL APPL PHARM, V131, P144, DOI 10.1006/taap.1995.1056; COOGAN TP, 1994, J TOXICOL ENV HEALTH, V41, P233, DOI 10.1080/15287399409531839; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DALTON T, 1995, NEUROCHEM INT, V27, P59, DOI 10.1016/0197-0186(94)00168-T; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DAWSON TM, 1994, PROG BRAIN RES, V103, P365; DUNN MA, 1987, P SOC EXP BIOL MED, V185, P107; DURNAM DM, 1984, MOL CELL BIOL, V4, P484, DOI 10.1128/MCB.4.3.484; EBADI M, 1995, NEUROCHEM INT, V27, P1, DOI 10.1016/0197-0186(94)00164-P; ERICKSON JC, 1995, NEUROCHEM INT, V27, P35, DOI 10.1016/0197-0186(94)00166-R; ERICKSON JC, 1994, BRAIN RES, V649, P297, DOI 10.1016/0006-8993(94)91076-6; Frederickson C. J., 1994, Biological Signals, V3, P127; HAGER LJ, 1981, NATURE, V291, P340, DOI 10.1038/291340a0; HAINAUT P, 1993, CANCER RES, V53, P4469; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; HIDALGO J, 1994, CHEM-BIOL INTERACT, V93, P197, DOI 10.1016/0009-2797(94)90020-5; ITANO Y, 1991, NEUROSCI LETT, V124, P13, DOI 10.1016/0304-3940(91)90811-7; Kagi J H, 1987, Experientia Suppl, V52, P25; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; KARIN M, 1985, CELL, V41, P9, DOI 10.1016/0092-8674(85)90051-0; KILLE P, 1994, BBA-PROTEIN STRUCT M, V1205, P151, DOI 10.1016/0167-4838(94)90228-3; KUFFLER SW, 1966, J NEUROPHYSIOL, V29, P768; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; MARET W, 1994, P NATL ACAD SCI USA, V91, P237, DOI 10.1073/pnas.91.1.237; MARGOSHES M, 1957, J AM CHEM SOC, V79, P4813, DOI 10.1021/ja01574a064; MASTERS BA, 1994, J NEUROSCI, V14, P5844; MIYAMOTO M, 1989, J PHARMACOL EXP THER, V250, P1132; MONTAGUE PR, 1994, SCIENCE, V263, P973, DOI 10.1126/science.7508638; MURPHY BJ, 1994, CANCER RES, V54, P5808; NISHIMURA N, 1992, J HISTOCHEM CYTOCHEM, V40, P309, DOI 10.1177/40.2.1552172; Palmiter R.D., 1996, TOXICOLOGIST, V30, P43; PALMITER RD, 1995, TOXICOL APPL PHARM, V135, P139, DOI 10.1006/taap.1995.1216; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; PENKOWA M, 1995, GLIA, V13, P217, DOI 10.1002/glia.440130308; POHLE W, 1994, BRAIN RES, V644, P297, DOI 10.1016/0006-8993(94)91693-4; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; RADI R, 1991, J BIOL CHEM, V266, P4244; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RHEE SJ, 1989, CHEM-BIOL INTERACT, V72, P347, DOI 10.1016/0009-2797(89)90009-4; RISING L, 1995, J NEUROCHEM, V65, P1562; RISING L, 1995, BRAIN RES, V678, P91, DOI 10.1016/0006-8993(95)00170-U; SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T; SCHWARZ MA, 1994, J BIOL CHEM, V269, P15238; SCHWARZ MA, 1995, P NATL ACAD SCI USA, V92, P4452, DOI 10.1073/pnas.92.10.4452; Searle P F, 1987, Experientia Suppl, V52, P407; SEARLE PF, 1984, MOL CELL BIOL, V4, P1221, DOI 10.1128/MCB.4.7.1221; SHIRAGA H, 1993, NEUROCHEM INT, V23, P561, DOI 10.1016/0197-0186(93)90104-D; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; SUZUKI K, 1992, ACTA HISTOCHEM CYTOC, V25, P617, DOI 10.1267/ahc.25.617; TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013; TAMAI KT, 1994, MOL CELL BIOL, V14, P8155, DOI 10.1128/MCB.14.12.8155; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; VALLEE BL, 1993, METALLOTHIONEIN, V3, P1; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; YAGLE MK, 1985, MOL CELL BIOL, V5, P291, DOI 10.1128/MCB.5.2.291; YOUNG JK, 1991, GLIA, V4, P602, DOI 10.1002/glia.440040607; Young John K., 1994, Biological Signals, V3, P169	70	168	171	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1996	10	10					1129	1136		10.1096/fasebj.10.10.8751715	http://dx.doi.org/10.1096/fasebj.10.10.8751715			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VD429	8751715				2022-12-28	WOS:A1996VD42900004
J	Goldsmith, EJ				Goldsmith, EJ			Allosteric enzymes as models for chemomechanical energy transducing assemblies	FASEB JOURNAL			English	Review						conformational change; phosphorylation; energy coupling; ATP hydrolysis	GLYCOGEN-PHOSPHORYLASE; ASPARTATE CARBAMOYLTRANSFERASE; MUSCLE-CONTRACTION; CRYSTAL-STRUCTURES; ESCHERICHIA-COLI; BINDING; ATP; ACTIVATION; ACTIN; PHOSPHOFRUCTOKINASE	In chemomechanical energy transducing assemblies such as muscle and ATP synthase, substrates and macromolecules are locked together as partners where energy available from (or required for) a chemical transformation is exchanged with protein conformational changes, Allosteric binding proteins and enzymes are also chemomechanical energy transducers, using binding energy to generate protein conformational changes, and transduce energy in amounts almost as large as those used to drive muscle contraction and the synthesis of ATP, The recently determined structure of the F1-ATPase reveals a direct correspondence between the types of conformational changes in this transducer and simpler allosteric binding proteins and enzymes. Therefore, we can examine the structural and energetic data available on allosteric proteins to under stand the linkage between ligand binding and global conformational changes in more complex energy transducing assemblies.			Goldsmith, EJ (corresponding author), UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.							ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; Baldwin J.M., 1975, Progress Biophys Molec Biol, V29, P225; BENNETT WS, 1978, P NATL ACAD SCI USA, V75, P4848, DOI 10.1073/pnas.75.10.4848; BLANGY D, 1968, J MOL BIOL, V31, P13, DOI 10.1016/0022-2836(68)90051-X; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BROWNER MF, 1992, TRENDS BIOCHEM SCI, V17, P66, DOI 10.1016/0968-0004(92)90504-3; CHOTHIA C, 1985, J MOL BIOL, V182, P151, DOI 10.1016/0022-2836(85)90033-6; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DILL KA, 1989, BIOCHEMISTRY-US, V28, P5439, DOI 10.1021/bi00439a019; EISENBERG E, 1985, SCIENCE, V227, P999, DOI 10.1126/science.3156404; Evans PR, 1991, CURR OPIN STRUC BIOL, V1, P773, DOI 10.1016/0959-440X(91)90178-V; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOLDENBERG EP, 1989, PROCEEDINGS - NATIONAL EDUCATIONAL COMPUTING CONFERENCE 1989, P87; GOLDSMITH EJ, 1989, SCIENCE, V245, P528, DOI 10.1126/science.2756432; GOUAUX JE, 1990, BIOCHEMISTRY-US, V29, P7702, DOI 10.1021/bi00485a020; HIBBERD MG, 1985, SCIENCE, V228, P1317, DOI 10.1126/science.3159090; HOLT JM, 1995, FASEB J, V9, P210, DOI 10.1096/fasebj.9.2.7781923; HOWLETT GJ, 1977, BIOCHEMISTRY-US, V16, P5091, DOI 10.1021/bi00642a023; HURLEY JH, 1993, SCIENCE, V259, P673, DOI 10.1126/science.8430315; JANSONIUS JN, 1984, BIOCHEM SOC T, V12, P424, DOI 10.1042/bst0120424; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; KUO LC, 1989, SCIENCE, V245, P522, DOI 10.1126/science.2667139; LAU FTK, 1987, NATURE, V326, P811; LIPSCOMB WN, 1994, ADV ENZYMOL RAMB, V68, P67; MADSEN NB, 1986, ENZYMES, V17, P366; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NASSAR N, 1995, IN PRESS NATURE LOND; NIENABER VL, 1993, BIOCHEMISTRY-US, V32, P11469, DOI 10.1021/bi00094a001; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RAYMENT I, 1994, TRENDS BIOCHEM SCI, V19, P129, DOI 10.1016/0968-0004(94)90206-2; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; Schulz GE, 1991, CURR OPIN STRUC BIOL, V1, P883, DOI 10.1016/0959-440X(91)90082-5; SCHUMACHER MA, 1995, NATURE, V375, P84, DOI 10.1038/375084a0; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SCHUTT CE, 1992, P NATL ACAD SCI USA, V89, P319, DOI 10.1073/pnas.89.1.319; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; SHRIVER JW, 1981, BIOCHEMISTRY-US, V20, P2004, DOI 10.1021/bi00510a041; SPRANG S, 1987, SCIENCE, V237, P1012, DOI 10.1126/science.3616621; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; SPRANG SR, 1992, PROTEIN SCI, V1, P1100, DOI 10.1002/pro.5560010904; STEVENS RC, 1990, BIOCHEMISTRY-US, V29, P7691, DOI 10.1021/bi00485a019; WIEGAND G, 1986, ANNU REV BIOPHYS BIO, V15, P97; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5	50	21	21	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1996	10	7					702	708		10.1096/fasebj.10.7.8635687	http://dx.doi.org/10.1096/fasebj.10.7.8635687			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UN798	8635687				2022-12-28	WOS:A1996UN79800004
J	Schonfelder, G; John, M; Hopp, H; Fuhr, N; vanderGiet, M; Paul, M				Schonfelder, G; John, M; Hopp, H; Fuhr, N; vanderGiet, M; Paul, M			Expression of inducible nitric oxide synthase in placenta of women with gestational diabetes	FASEB JOURNAL			English	Article						human placenta; RT-PCR	PROTEINS	Gestational diabetes is one of the most prevalent medical complications of pregnancy and causes increased fetal wastage, Investigation of placentas from diabetic mothers indicate chronic: disturbances in intervillous circulation, dilatation of capillaries, and a relatively immature villous structure, Abnormal levels of nitric oxide (NO) may contribute to maternal disorders such as the pathogenesis of diabetic: vascular complications, In the normal placenta NO is generated only by endothelial NOS, which apparently serves to regulate vascular tone in the fetoplacental circulation, In contrast, studies have reported the absence of inducible nitric oxide synthase (iNOS) in human placentas under normal conditions, The aim of our study was to investigate whether iNOS is expressed in placentas from patients with gestational diabetes, Reverse transcription-polymerase chain reaction and Western blot analysis demonstrated iNOS mRNA and protein expression in placental tissue only from patients with gestational diabetes, Immunohistochemistry localized iNOS staining to endothelial cells and trophoblasts, We conclude that iNOS can be expressed in human placenta, Its expression might play an important role in placental pathophysiology.	FREE UNIV BERLIN,KLINIKUM BENJAMIN FRANKLIN,DEPT CLIN PHARMACOL,D-12200 BERLIN,GERMANY; FREE UNIV BERLIN,KLINIKUM BENJAMIN FRANKLIN,DEPT GASTROENTEROL,D-12200 BERLIN,GERMANY; FREE UNIV BERLIN,KLINIKUM BENJAMIN FRANKLIN,DEPT OBSTET & GYNECOL,D-12200 BERLIN,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin			Paul, Martin/K-5425-2015	Schonfelder, Gilbert/0000-0001-6134-1990				ANKARCRONA M, 1994, EXP CELL RES, V213, P172, DOI 10.1006/excr.1994.1187; BACKE E, 1991, J CLIN PATHOL, V44, P936, DOI 10.1136/jcp.44.11.936; BARON AD, 1994, AM J PHYSIOL, V267, pE187, DOI 10.1152/ajpendo.1994.267.2.E187; BENIRSCHKE K, 1990, PATHOLOGY HUMAN PLAC, P475; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN R, 1963, AM J OBSTET GYNECOL, V86, P66, DOI 10.1016/0002-9378(63)90077-2; BUTTERY LDK, 1994, PLACENTA, V15, P257, DOI 10.1016/0143-4004(94)90017-5; CETKOVICCVRLJE M, 1994, CYTOKINE, V6, P399, DOI 10.1016/1043-4666(94)90064-7; CONRAD KP, 1993, FASEB J, V7, P1269, DOI 10.1096/fasebj.7.13.7691671; CORBETT JA, 1995, J EXP MED, V181, P559, DOI 10.1084/jem.181.2.559; DIKRANIAN K, 1994, ACTA HISTOCHEM, V96, P145, DOI 10.1016/S0065-1281(11)80170-4; EIS ALW, 1995, PLACENTA, V16, P113, DOI 10.1016/0143-4004(95)90000-4; EMMRICH P, 1968, PATHOL MICROBIOL, V32, P285, DOI 10.1159/000162069; FOX H, 1969, OBSTET GYNECOL, V34, P792; GARVEY EP, 1994, ARCH BIOCHEM BIOPHYS, V311, P235, DOI 10.1006/abbi.1994.1232; HARTY JR, 1992, J CLIN ENDOCR METAB, V75, P947, DOI 10.1210/jc.75.3.947; Haust M D, 1981, Monogr Pathol, P201; HOLEBERG G, 1995, AM J OBSTET GYNECOL, V172, P71; HOPP H, 1995, GEBURTSH FRAUENHEILK, V55, P28, DOI 10.1055/s-2007-1022769; HU XL, 1992, J REPROD IMMUNOL, V22, P257, DOI 10.1016/0165-0378(92)90047-8; KOLB H, 1991, LIFE SCI, V49; KRISTOFFERSEN EK, 1994, APMIS, V102, P509, DOI 10.1111/j.1699-0463.1994.tb05198.x; KRONCKE KD, 1994, IMMUNOBIOLOGY, V19, P267; Kukor Z., 1994, Acta Physiologica Hungarica, V82, P313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBRACH CL, 1994, J BIOL CHEM, V269, P17125; LINDSAY RM, 1995, DIABETES, V44, P365, DOI 10.2337/diabetes.44.3.365; LUKIC ML, 1991, BIOCHEM BIOPH RES CO, V178, P913, DOI 10.1016/0006-291X(91)90978-G; MOHR H, 1950, Zentralbl Gynakol, V72, P1530; MYATT L, 1993, PLACENTA, V14, P487, DOI 10.1016/S0143-4004(05)80202-4; MYATT L, 1993, PLACENTA, V14, P373, DOI 10.1016/S0143-4004(05)80459-X; MYATT L, 1991, AM J OBSTET GYNECOL, V164, P687, DOI 10.1016/S0002-9378(11)80047-5; Nagy G, 1993, Zentralbl Gynakol, V115, P450; REILING N, 1994, EUR J IMMUNOL, V24, P1941, DOI 10.1002/eji.1830240836; SHARMA K, 1995, BIOCHEM BIOPH RES CO, V207, P80, DOI 10.1006/bbrc.1995.1156; SPRINGALL DR, 1992, HISTOCHEMISTRY, V98, P259, DOI 10.1007/BF00271040; THOMSEN K, 1958, ACTA ENDOCRINOL-COP, V29, P602, DOI 10.1530/acta.0.0290602; VOGEL M, 1967, VIRCHOWS ARCH A, V343, P51, DOI 10.1007/BF00959345; 1979, DIABETES, V28, P1039	39	64	67	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1996	10	7					777	784		10.1096/fasebj.10.7.8635695	http://dx.doi.org/10.1096/fasebj.10.7.8635695			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UN798	8635695				2022-12-28	WOS:A1996UN79800012
J	Kornblihtt, AR; Pesce, CG; Alonso, CR; Cramer, P; Srebrow, A; Werbajh, S; Muro, AF				Kornblihtt, AR; Pesce, CG; Alonso, CR; Cramer, P; Srebrow, A; Werbajh, S; Muro, AF			The fibronectin gene as a model for splicing and transcription studies	FASEB JOURNAL			English	Review						alternative splicing; cell binding; extra domain I; transcriptional regulation	PRE-MESSENGER-RNA; AMP RESPONSE ELEMENT; GROWTH-FACTOR-BETA; III CONNECTING SEGMENT; CELLULAR FIBRONECTIN; SERUM STIMULATION; FACTOR ATF-2; CDNA CLONES; DNA-BINDING; CCAAT BOX	The fibronectin (FN) gene has become paradigmatic to illustrate genome evolution by exon shuffling, generation of protein diversity by alternative mRNA splicing, and topological coordination between transcription and splicing, Alternative splicing in three sites of the primary transcript gives rise to multiple FN polypeptides. This process is cell type-, development- and age-regulated, The different FN variants seem to play specific roles in FN dimer secretion, blood clotting, adhesion to lymphoid cells, skin wound healing, atherosclerosis, and liver fibrosis, This review focuses on function assignment to the alternatively spliced segments, as well as on the external signals and cis-acting sequences that control the mechanisms of alternative splicing, We also discuss FN transcriptional regulation in response to viral transformation, growth factors, and cyclic AMP in the light of promoter architecture and its interaction with specific transcription factors, The relevance of FN RNA ''tracks'' as assembly lines of coordinated transcription and RNA processing is also addressed.	UNIV BUENOS AIRES,FAC CIENCIAS EXACTAS & NAT,DEPT CIENCIAS BIOL,RA-1428 BUENOS AIRES,DF,ARGENTINA	University of Buenos Aires	Kornblihtt, AR (corresponding author), INST INVEST INGN GENET & BIOL MOLEC,VUELTA OBLIGADO 2490,2 PISO,RA-1428 BUENOS AIRES,DF,ARGENTINA.		Muro, Andrés F/K-3156-2016	Muro, Andrés F/0000-0002-9628-0494; Kornblihtt, Alberto/0000-0003-4322-0831				ANDRISANI O, 1990, J BIOL CHEM, V265, P3112; BARNES JL, 1994, AM J PATHOL, V145, P585; BARONE MV, 1989, EMBO J, V8, P1079, DOI 10.1002/j.1460-2075.1989.tb03476.x; BERNATH VA, 1990, J BIOL CHEM, V265, P18219; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; BORSI L, 1990, FEBS LETT, V261, P175, DOI 10.1016/0014-5793(90)80664-5; BROWN LF, 1993, AM J PATHOL, V142, P793; BURKE EM, 1991, BIOCHEM BIOPH RES CO, V178, P620, DOI 10.1016/0006-291X(91)90153-X; CAPUTI M, 1994, NUCLEIC ACIDS RES, V22, P1018, DOI 10.1093/nar/22.6.1018; DEAN DC, 1988, J CELL BIOL, V106, P2159, DOI 10.1083/jcb.106.6.2159; DEAN DC, 1987, P NATL ACAD SCI USA, V84, P1876, DOI 10.1073/pnas.84.7.1876; DEAN DC, 1989, MOL CELL BIOL, V9, P1498, DOI 10.1128/MCB.9.4.1498; DEAN DC, 1990, J BIOL CHEM, V265, P3522; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; EPERON LP, 1988, CELL, V54, P393, DOI 10.1016/0092-8674(88)90202-4; FFRENCHCONSTANT C, 1989, J CELL BIOL, V109, P903, DOI 10.1083/jcb.109.2.903; GARDELLA R, 1993, CELL BIOL INT, V17, P989, DOI 10.1006/cbir.1993.1027; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GLUKHOVA MA, 1989, J CELL BIOL, V109, P357, DOI 10.1083/jcb.109.1.357; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; GUTMAN A, 1987, P NATL ACAD SCI USA, V84, P7179, DOI 10.1073/pnas.84.20.7179; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HUH GS, 1994, GENE DEV, V8, P1561, DOI 10.1101/gad.8.13.1561; HUH GS, 1993, MOL CELL BIOL, V13, P5301, DOI 10.1128/MCB.13.9.5301; HUMPHRIES MJ, 1988, J CELL BIOL, V106, P1289, DOI 10.1083/jcb.106.4.1289; Hynes RO, 1990, FIBRONECTINS; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KORNBLIHTT AR, 1983, P NATL ACAD SCI-BIOL, V80, P3218, DOI 10.1073/pnas.80.11.3218; KORNBLIHTT AR, 1984, NUCLEIC ACIDS RES, V12, P5853, DOI 10.1093/nar/12.14.5853; KORNBLIHTT AR, 1984, EMBO J, V3, P221, DOI 10.1002/j.1460-2075.1984.tb01787.x; KUHN C, 1989, AM REV RESPIR DIS, V140, P1693, DOI 10.1164/ajrccm/140.6.1693; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAGNUSON VL, 1991, J BIOL CHEM, V266, P14654; MARDON HJ, 1992, J CELL SCI, V103, P423; MARDON HJ, 1987, NUCLEIC ACIDS RES, V15, P7725, DOI 10.1093/nar/15.19.7725; MIAO S, 1993, HEPATOLOGY, V17, P882, DOI 10.1002/hep.1840170519; Mosher DF, 1989, FIBRONECTIN; MOULD AP, 1990, J BIOL CHEM, V265, P4020; MURO AF, 1992, J BIOL CHEM, V267, P12767; NAKAMURA T, 1992, J VIROL, V66, P6436, DOI 10.1128/JVI.66.11.6436-6450.1992; NORTON PA, 1987, MOL CELL BIOL, V7, P4297, DOI 10.1128/MCB.7.12.4297; OYAMA F, 1989, J BIOL CHEM, V264, P10331; PAGANI F, 1991, J CELL BIOL, V113, P1223, DOI 10.1083/jcb.113.5.1223; PAGANI F, 1993, BIOCHIM BIOPHYS ACTA, V1173, P172, DOI 10.1016/0167-4781(93)90178-G; PATEL RS, 1987, EMBO J, V6, P2565, DOI 10.1002/j.1460-2075.1987.tb02545.x; PAUL JI, 1986, J BIOL CHEM, V261, P2258; PETERS JH, 1986, J CLIN INVEST, V78, P1596, DOI 10.1172/JCI112752; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; POLLY P, 1993, GENE, V137, P353, DOI 10.1016/0378-1119(93)90036-3; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; RYSECK RP, 1989, EXP CELL RES, V180, P537, DOI 10.1016/0014-4827(89)90080-3; SCHWARZBAUER JE, 1989, J CELL BIOL, V109, P3445, DOI 10.1083/jcb.109.6.3445; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SREBROW A, 1993, FEBS LETT, V327, P25, DOI 10.1016/0014-5793(93)81031-T; VARTIO T, 1987, J CELL SCI, V88, P419; VIBEPEDERSEN K, 1984, EMBO J, V3, P2511, DOI 10.1002/j.1460-2075.1984.tb02165.x; VIBEPEDERSEN K, 1987, FEBS LETT, V207, P287; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WANG A, 1991, J BIOL CHEM, V266, P15598; WEINTRAUB SJ, 1992, MOL CELL BIOL, V12, P512, DOI 10.1128/MCB.12.2.512; WILSON CL, 1992, J CELL BIOL, V119, P923, DOI 10.1083/jcb.119.4.923; XIA P, 1994, EXP CELL RES, V213, P253, DOI 10.1006/excr.1994.1197; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; Xing Yigong, 1993, Trends in Cell Biology, V3, P346, DOI 10.1016/0962-8924(93)90105-A; ZARDI L, 1987, EMBO J, V6, P2337, DOI 10.1002/j.1460-2075.1987.tb02509.x	76	169	177	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1996	10	2					248	257		10.1096/fasebj.10.2.8641558	http://dx.doi.org/10.1096/fasebj.10.2.8641558			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641558				2022-12-28	WOS:A1996TY96200009
J	Matthews, BW				Matthews, BW			Structural and genetic analysis of the folding and function of T4 lysozyme	FASEB JOURNAL			English	Review						protein stability; hydrophobicity cavities; alanine	PROTEIN STABILITY; BACTERIOPHAGE-T4 LYSOZYME; AMINO-ACIDS; ENERGETICS; MUTATION; PACKING; MUTANT	The combination of directed mutagenesis with high-resolution structure analysis has made it possible to systematically address fundamental questions of protein folding and stability, Here we briefly review some recent results in this area based on studies of the lysozyme of bacteriophage T4. Extended segments of the polypeptide chain can be substituted with alanine, suggesting that about 50%, or perhaps less, of the overall amino acid sequence protein is necessary to define the 3-dimensional structure of the protein. It is the internal residues that seem to be most important for folding and stability (although not necessarily for function). Substitutions within the core of the protein of large nonpolar side chains with smaller ones have been used to better understand the nature of hydrophobic stabilization. Mutants that produce the largest cavities within the protein tend to be most destabilizing, allowing the energy cost of cavity formation to be estimated, Small, nonpolar ligands bind within such cavities and restore some stability to the protein. Analogous, nonpolar ligands do not bind, however, providing evidence that water molecules do not bind with high occupancy within nonpolar cavities. In a further series of studies it has been possible to re-engineer the active site region of TL4 lysozyme to change the catalytic mechanism of the enzyme.	UNIV OREGON, DEPT PHYS, EUGENE, OR 97403 USA	University of Oregon	Matthews, BW (corresponding author), UNIV OREGON, HOWARD HUGHES MED INST, INST MOLEC BIOL, EUGENE, OR 97403 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021967] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21967] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANAND NN, 1988, BIOCHEM BIOPH RES CO, V153, P862, DOI 10.1016/S0006-291X(88)81175-6; BLABER M, 1995, J MOL BIOL, V246, P317, DOI 10.1006/jmbi.1994.0087; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; DAHLQUIS.FW, 1969, BIOCHEMISTRY-US, V8, P694, DOI 10.1021/bi00830a035; ERIKSSON AE, 1992, NATURE, V355, P371, DOI 10.1038/355371a0; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; HARDY LW, 1991, BIOCHEMISTRY-US, V30, P9457, DOI 10.1021/bi00103a010; HEINZ DW, 1992, P NATL ACAD SCI USA, V89, P3751, DOI 10.1073/pnas.89.9.3751; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; KELLIS JT, 1989, BIOCHEMISTRY-US, V28, P4914, DOI 10.1021/bi00437a058; KUROKI R, 1995, NAT STRUCT BIOL, V2, P1007, DOI 10.1038/nsb1195-1007; KUROKI R, 1993, SCIENCE, V262, P2030, DOI 10.1126/science.8266098; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; MATTHEWS BW, 1987, BIOCHEMISTRY-US, V26, P6885, DOI 10.1021/bi00396a001; MORTON A, 1995, BIOCHEMISTRY-US, V34, P8564, DOI 10.1021/bi00027a006; MORTON A, 1995, BIOCHEMISTRY-US, V34, P8576, DOI 10.1021/bi00027a007; PACE CN, 1992, J MOL BIOL, V226, P29, DOI 10.1016/0022-2836(92)90121-Y; Pauling L, 1943, PHYSIOL REV, V23, P0203, DOI 10.1152/physrev.1943.23.3.203; REIDHAAROLSON JF, 1988, SCIENCE, V241, P53, DOI 10.1126/science.3388019; RENNELL D, 1991, J MOL BIOL, V222, P67, DOI 10.1016/0022-2836(91)90738-R; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; SANDBERG WS, 1991, P NATL ACAD SCI USA, V88, P1706, DOI 10.1073/pnas.88.5.1706; SHOICHET BK, 1995, P NATL ACAD SCI USA, V92, P452, DOI 10.1073/pnas.92.2.452; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; WARSHEL A, 1987, NATURE, V330, P15, DOI 10.1038/330015a0; XU J, 1995, AM CRYST ASS ABSTR, V23, P154; ZHANG XJ, 1992, PROTEIN SCI, V1, P761, DOI 10.1002/pro.5560010608; ZHANG XJ, 1991, BIOCHEMISTRY-US, V30, P2012, DOI 10.1021/bi00222a001	29	127	132	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1996	10	1					35	41		10.1096/fasebj.10.1.8566545	http://dx.doi.org/10.1096/fasebj.10.1.8566545			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566545				2022-12-28	WOS:A1996TR32800006
J	Rudolph, R; Lilie, H				Rudolph, R; Lilie, H			In vitro folding of inclusion body proteins	FASEB JOURNAL			English	Review						protein folding; disulfide bond formation	CHEMICALLY SYNTHESIZED GENE; ESCHERICHIA-COLI EXPRESSION; DISULFIDE BOND FORMATION; RECOMBINANT PROTEINS; FAB-FRAGMENTS; GROWTH-FACTOR; PURIFICATION; BODIES; REACTIVATION; AGGREGATION	Insoluble, inactive inclusion bodies are frequently formed upon recombinant protein production in transformed microorganisms. These inclusion bodies, which contain the recombinant protein in an highly enriched form, can be isolated by solid/liquid separation, After solubilization, native proteins can be generated from the inactive material by using in vitro folding techniques. New folding procedures have been developed for efficient in vitro reconstitution of complex hydrophobic, multidomain, oligomeric, or highly disulfide-bonded proteins. These protocols take into account process parameters such as protein concentration, catalysis of disulfide bond formation, temperature, pH, and ionic strength, as well as specific solvent ingredients that reduce unproductive side reactions, Modification of the protein sequence has been exploited to improve in vitro folding.			Rudolph, R (corresponding author), UNIV HALLE WITTENBERG, INST BIOTECHNOL, WEINBERGWEG 16A, D-06120 HALLE, GERMANY.							AHMED AK, 1975, J BIOL CHEM, V250, P8477; ALEXANDER DM, 1992, PROTEIN EXPRES PURIF, V3, P204, DOI 10.1016/1046-5928(92)90016-P; ALLEN SP, 1992, J BACTERIOL, V174, P6938, DOI 10.1128/JB.174.21.6938-6947.1992; AMBROSIUS D, 1992, Patent No. 9622; AMBROSIUS D, 1992, Patent No. 500108; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BRINKMANN U, 1992, P NATL ACAD SCI USA, V89, P3075, DOI 10.1073/pnas.89.7.3075; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; BUILDER SE, 1986, Patent No. 4620948; CABILLY S, 1989, GENE, V85, P553, DOI 10.1016/0378-1119(89)90451-4; CARDAMONE M, 1995, BIOCHEMISTRY-US, V34, P5773, DOI 10.1021/bi00017a009; CARLSON JD, 1992, BIO-TECHNOL, V10, P86, DOI 10.1038/nbt0192-86; CARTER P, 1992, BIO-TECHNOL, V10, P163, DOI 10.1038/nbt0292-163; CERLETTI N, 1990, Patent No. 433225; CLELAND JL, 1992, J BIOL CHEM, V267, P13327; COOPER A, 1992, J AM CHEM SOC, V114, P9208, DOI 10.1021/ja00049a074; DABORA JM, 1991, J BIOL CHEM, V266, P23637; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; DIAZCOLLIER JA, 1994, THROMB HAEMOSTASIS, V71, P339; DIBELLA EE, 1995, J BIOL CHEM, V270, P163, DOI 10.1074/jbc.270.1.163; FAHEY RC, 1977, J MOL EVOL, V10, P155, DOI 10.1007/BF01751808; FISCHER B, 1993, BIOTECHNOL BIOENG, V41, P3, DOI 10.1002/bit.260410103; FISCHER S, 1986, Patent No. 393725; FORCINITI D, 1994, J CHROMATOGR A, V668, P95, DOI 10.1016/0021-9673(94)80096-0; GARZARAMOS G, 1992, EUR J BIOCHEM, V208, P389, DOI 10.1111/j.1432-1033.1992.tb17199.x; GOEDDEL DV, 1979, P NATL ACAD SCI USA, V76, P106, DOI 10.1073/pnas.76.1.106; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRIBSKOV M, 1983, GENE, V26, P109, DOI 10.1016/0378-1119(83)90180-4; HAGEL P, 1971, BIOCHIM BIOPHYS ACTA, V243, P366, DOI 10.1016/0005-2795(71)90003-1; HAGEN AJ, 1990, BIOTECHNOL BIOENG, V35, P955, DOI 10.1002/bit.260351002; HART RA, 1994, BIO-TECHNOL, V12, P1113, DOI 10.1038/nbt1194-1113; HART RA, 1990, J BIOL CHEM, V265, P12728; HEJNAES KR, 1992, PROTEIN ENG, V5, P797, DOI 10.1093/protein/5.8.797; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; ITAKURA K, 1977, SCIENCE, V198, P1056, DOI 10.1126/science.412251; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JAENICKE R, 1981, BIOCHEM INT, V2, P23; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KANE JF, 1988, TRENDS BIOTECHNOL, V6, P95, DOI 10.1016/0167-7799(88)90065-0; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; KOPETZKI E, 1989, MOL GEN GENET, V216, P149, DOI 10.1007/BF00332244; KUHELJ R, 1995, EUR J BIOCHEM, V229, P533, DOI 10.1111/j.1432-1033.1995.0533k.x; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIN WJ, 1993, PROTEIN EXPRES PURIF, V4, P256, DOI 10.1006/prep.1993.1033; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MICHAELIS U, 1994, Patent No. 586872; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; OBERG K, 1994, BIOCHEMISTRY-US, V33, P2628, DOI 10.1021/bi00175a035; ORSINI G, 1978, J BIOL CHEM, V253, P3453; PLUCKTHUN A, 1991, BIO-TECHNOL, V9, P545, DOI 10.1038/nbt0691-545; PRZYBYCIEN TM, 1994, PROTEIN ENG, V7, P131, DOI 10.1093/protein/7.1.131; PURI NK, 1992, BIOCHEM J, V285, P871, DOI 10.1042/bj2850871; RISCHER B, 1992, PROTEIN ENG, V6, P593; ROZEMA D, 1995, J AM CHEM SOC, V117, P2373, DOI 10.1021/ja00113a036; RUDOLPH R, 1983, H-S Z PHYSIOL CHEM, V364, P813, DOI 10.1515/bchm2.1983.364.2.813; RUDOLPH R, 1990, MODERN METHOD IN PROTEIN- AND NUCLEIC ACID RESEARCH, P149; Rudolph R, 1990, U.S. Patent, Patent No. [4,933,434, 4933434]; Rudolph R, 1995, PROTEIN ENG PRINCIPL, P283; SAMUELSSON E, 1991, BIO-TECHNOL, V9, P363, DOI 10.1038/nbt0491-363; SCHEIN CH, 1988, BIO-TECHNOL, V6, P291, DOI 10.1038/nbt0388-291; SCHEIN CH, 1990, BIO-TECHNOL, V8, P308, DOI 10.1038/nbt0490-308; SCHOEMAKER JM, 1985, EMBO J, V4, P775, DOI 10.1002/j.1460-2075.1985.tb03696.x; SCHUMANN J, 1993, PROTEIN SCI, V2, P1612, DOI 10.1002/pro.5560021007; SELA M, 1957, SCIENCE, V125, P691, DOI 10.1126/science.125.3250.691; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; SMITH AT, 1990, J BIOL CHEM, V265, P13335; STEMPFER G, 1996, IN PRESS BIOTECHNOLO; TANDON S, 1987, J BIOL CHEM, V262, P4486; TANEJA S, 1994, BIOCHEM J, V303, P147, DOI 10.1042/bj3030147; TAYLOR G, 1986, BIO-TECHNOL, V4, P553, DOI 10.1038/nbt0686-553; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; WERNER MH, 1994, FEBS LETT, V345, P125, DOI 10.1016/0014-5793(94)00401-3; WETLAUFER DB, 1987, PROTEIN ENG, V1, P141, DOI 10.1093/protein/1.2.141; WETZEL R, 1981, GENE, V16, P63, DOI 10.1016/0378-1119(81)90061-5; WILKINSON DL, 1991, BIO-TECHNOL, V9, P443, DOI 10.1038/nbt0591-443; ZARDENETA G, 1994, ANAL BIOCHEM, V218, P392, DOI 10.1006/abio.1994.1197; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007	80	554	623	2	78	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1996	10	1					49	56		10.1096/fasebj.10.1.8566547	http://dx.doi.org/10.1096/fasebj.10.1.8566547			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566547				2022-12-28	WOS:A1996TR32800008
J	ZeilstraRyalls, J; Fayet, O; Georgopoulos, C				ZeilstraRyalls, J; Fayet, O; Georgopoulos, C			In vivo protein folding: Suppressor analysis of mutations in the groES cochaperone gene of Escherichia coli	FASEB JOURNAL			English	Article						multicopy suppression; GroES; GroEL; dnaA46; heat shock; groES; intra- and extragenic suppression	BACTERIOPHAGE MORPHOGENESIS; HOST-CELL; PRODUCTS; MUTANTS; LAMBDA; GROWTH; DNA	Our previous work has shown that the Escherichia coli groES14 and groES15 mutations result in reduced GroE chaperone machine function. By selecting for restoration of the ability of those mutant groES alleles to suppress the thermosensitivity of bacteria bearing the dnaA46 mutation, we isolated a number of intra- and extragenic suppressors that increase in vivo GroE chaperone function. One of the intragenic suppressors has been mapped to a segment that codes for the GroES mobile loop, previously shown to be indispensable for proper GroES/GroEL interaction, Two extragenic suppressors have been mapped to a groEL segment, previously identified by mutational analysis as coding for an important functional region of the GroEL protein. Our results should contribute to our eventual understanding of the structure-function relationships of the universally conserved GroE chaperone machine.	CNRS,F-31062 TOULOUSE,FRANCE; CTR MED UNIV GENEVA,DEPT BIOCHIM MED,CH-1211 GENEVA 4,SWITZERLAND	Centre National de la Recherche Scientifique (CNRS); University of Geneva	ZeilstraRyalls, J (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL & MOLEC GENET,POB 20708,HOUSTON,TX 77225, USA.				NIAID NIH HHS [AI121029] Funding Source: Medline; NIGMS NIH HHS [GM23917] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023917, R01GM023917] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; COPPO A, 1973, J MOL BIOL, V76, P61, DOI 10.1016/0022-2836(73)90081-8; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GEORGOPOULOS CP, 1972, NATURE-NEW BIOL, V239, P38, DOI 10.1038/newbio239038a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HUMPHREYS GO, 1976, MOL GEN GENET, V145, P101, DOI 10.1007/BF00331564; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; JENKINS AJ, 1986, MOL GEN GENET, V202, P446, DOI 10.1007/BF00333275; Jessee J., 1986, FOCUS, V8, P9; KEPPEL F, 1990, GENE, V86, P19, DOI 10.1016/0378-1119(90)90109-5; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; Miller J.H., 1972, EXPT MOL GENETICS; REVEL HR, 1980, J VIROL, V33, P366, DOI 10.1128/JVI.33.1.366-376.1980; STERNBERG N, 1973, J MOL BIOL, V76, P1, DOI 10.1016/0022-2836(73)90078-8; TAKANO T, 1972, NATURE-NEW BIOL, V239, P34, DOI 10.1038/newbio239034a0; TILLY K, 1982, J BACTERIOL, V149, P1082, DOI 10.1128/JB.149.3.1082-1088.1982; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; VANDERVIES SM, 1994, NATURE, V368, P654, DOI 10.1038/368654a0; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; ZAHN R, 1993, J MOL BIOL, V229, P579, DOI 10.1006/jmbi.1993.1062; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505; ZEILSTRARYALLS J, 1993, J BACTERIOL, V175, P1134, DOI 10.1128/JB.175.4.1134-1143.1993; ZEILSTRARYALLS J, 1994, J BACTERIOL, V176, P6558, DOI 10.1128/JB.176.21.6558-6565.1994	32	6	6	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1996	10	1					148	152		10.1096/fasebj.10.1.8566535	http://dx.doi.org/10.1096/fasebj.10.1.8566535			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566535				2022-12-28	WOS:A1996TR32800019
J	RAJ, NBK; PITHA, PM				RAJ, NBK; PITHA, PM			65-KDA PROTEIN BINDS TO DESTABILIZING SEQUENCES IN THE IFN-BETA MESSENGER-RNA CODING AND 3' UTR	FASEB JOURNAL			English	Article						IFN-BETA MESSENGER RNA; INSTABILITY DOMAINS; RNA BINDING PROTEINS	INTERFERON GENE-EXPRESSION; AU-RICH SEQUENCES; UNTRANSLATED REGION; DEGRADATION; TURNOVER; CELLS; IDENTIFICATION; DECAY; LYMPHOKINE; INDUCTION	The transient expression of human interferon (IFN-beta) gene in response to viral induction is regulated both at the transcriptional and posttranscriptional levels. The decrease in levels of IFN-beta mRNA, which requires protein synthesis, is due to transcriptional repression as well as a rapid turnover of beta mRNA. Previous studies have shown the presence of two destabilizing sequences, one in the 3' untranslated region (UTR) and the other in the coding region. We have shown in this study that the coding region destabilizing element resides in the 3' end of the coding region (+538 to +637) and that the degradation does not require the translation of IFN-beta mRNA through its coding region. In addition, we have identified three domains of 19, 20, and 29 nucleotides long that specifically bind a 65-kilodalton (kDa) cytoplasmic protein. One of the binding sites is in the 3' end of the coding region and the other two in the 3' UTR. All these regions are AU-rich and show considerable homology to each other. Interestingly, the levels of the 65-kDa protein was increased after poly rI.rC induction. We suggest that this 65-kDa protein is a component of the IFN-beta mRNA destabilizing complex or plays a role in the degradation of IFN-beta mRNA.	JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21231 USA	Johns Hopkins University	RAJ, NBK (corresponding author), JOHNS HOPKINS UNIV, SCH MED, CTR ONCOL, BALTIMORE, MD 21231 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI019737, R01AI019737] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19737] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BONNIEU A, 1988, ONCOGENE RES, V3, P155; BONNIEU A, 1990, ONCOGENE, V5, P1585; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CAVALIERI RL, 1977, P NATL ACAD SCI USA, V74, P4415, DOI 10.1073/pnas.74.10.4415; CHEN CYA, 1992, MOL CELL BIOL, V12, P5748, DOI 10.1128/MCB.12.12.5748; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND D W, 1989, New Biologist, V1, P121; Demaeyer E., 1988, INTERFERONS OTHER RE; GILLIS P, 1991, J BIOL CHEM, V266, P3172; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRUYS V, 1990, ENZYME, V44, P193, DOI 10.1159/000468757; LAIRDOFFRINGA IA, 1991, NUCLEIC ACIDS RES, V19, P2387, DOI 10.1093/nar/19.9.2387; LIEBERMAN AP, 1992, J BIOL CHEM, V267, P2123; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MOSCA JD, 1985, J VIROL, V56, P867, DOI 10.1128/JVI.56.3.867-878.1985; MOSCA JD, 1986, MOL CELL BIOL, V6, P2279, DOI 10.1128/MCB.6.6.2279; MOSCA JD, 1992, J VIROL, V66, P3811, DOI 10.1128/JVI.66.6.3811-3822.1992; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; PEPPEL K, 1991, J BIOL CHEM, V266, P6663; PITHA PM, 1983, A BENZON S GENE EXPR, V19, P477; RAJ NBK, 1985, J INTERFERON RES, V5, P493, DOI 10.1089/jir.1985.5.493; RAJ NBK, 1981, P NATL ACAD SCI-BIOL, V78, P7426, DOI 10.1073/pnas.78.12.7426; RAJ NBK, 1991, J BIOL CHEM, V266, P11360; RAJ NBK, 1983, P NATL ACAD SCI-BIOL, V80, P3923, DOI 10.1073/pnas.80.13.3923; RAJ NBK, 1988, J INTERFERON RES, V8, P179, DOI 10.1089/jir.1988.8.179; REEVES R, 1990, PROG NUCLEIC ACID RE, V38, P241; SEHGAL PB, 1979, VIROLOGY, V92, P240, DOI 10.1016/0042-6822(79)90230-7; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SORENSON CM, 1991, NUCLEIC ACIDS RES, V19, P4459, DOI 10.1093/nar/19.16.4459; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WHITTEMORE LA, 1990, MOL CELL BIOL, V10, P1329, DOI 10.1128/MCB.10.4.1329; WHITTEMORE LA, 1990, P NATL ACAD SCI USA, V87, P7799, DOI 10.1073/pnas.87.20.7799; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931	47	28	29	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1993	7	8					702	710		10.1096/fasebj.7.8.8500695	http://dx.doi.org/10.1096/fasebj.7.8.8500695			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LE290	8500695				2022-12-28	WOS:A1993LE29000013
J	MARCUS, AJ; SAFIER, LB				MARCUS, AJ; SAFIER, LB			THROMBOREGULATION - MULTICELLULAR MODULATION OF PLATELET REACTIVITY IN HEMOSTASIS AND THROMBOSIS	FASEB JOURNAL			English	Review						PLATELET ACTIVATION AND RECRUITMENT; TRANSCELLULAR METABOLISM; ENDOTHELIAL CELL-PLATELET INTERACTIONS; ERYTHROCYTE-PLATELET INTERACTIONS; NEUTROPHIL-PLATELET INTERACTIONS; ENDOTHELIAL ECTO-ADPASE; EDRF NO	ENDOTHELIAL-CELLS; UNSTIMULATED NEUTROPHILS; ATP-DIPHOSPHOHYDROLASE; BOVINE AORTA; NITRIC-OXIDE; INHIBITION; ACID; ENDOPEROXIDES; ERYTHROCYTES; RECRUITMENT	Blood platelets represent the first line of host defense when normal vessels are injured. Platelet adhesion to subendothelium, aggregation, and further platelet recruitment culminate in hemostatic plug formation, which is accompanied by the consolidating effect of fibrin deposition on and between platelets. The process is multicellular in that erythrocytes promote and neutrophils inhibit platelet plug formation. Endothelial cells in proximity possess three protective mechanisms (thromboregulators) for limiting the size of the hemostatic plug-ADPase, eicosanoids, endothelium-dependent relaxing factor/NO. We propose that in advanced atherosclerotic blood vessels such as coronary arteries, an ulcer or fissure in the fibrous cap of the atheroma serves as an agonist that transforms the platelet into a major prothrombotic offender. Induction of excessive platelet activation overcomes the normal thromboregulatory mechanisms. Erythrocytes further activate platelets, even in the presence of aspirin, and neutrophil blockage of platelet reactivity is insufficient to prevent impending vascular occlusion. Appreciating that multiple cell types and metabolic pathways are involved in modulation of platelet reactivity in vascular occlusion is a relatively recent concept. Strategies designed to restore processes such as thromboregulation may serve to improve therapeusis in thrombosis, which at present is far from optimal.	DEPT VET AFFAIRS MED CTR,DEPT PATHOL,NEW YORK,NY 10010; CORNELL UNIV,MED CTR,COLL MED,DEPT MED,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,DEPT PATHOL,NEW YORK,NY 10021	Cornell University; Cornell University	MARCUS, AJ (corresponding author), DEPT VET AFFAIRS MED CTR,DEPT MED,DIV HEMATOL ONCOL,THROMBOSIS RES LAB,ROOM 13028W,423 E 23RD ST,NEW YORK,NY 10010, USA.				NHLBI NIH HHS [HL-47073, HL-18828, HL-46403] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046403, R01HL047073, P50HL018828, R37HL047073] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASSENGE E, 1992, BRIT J CLIN PHARMACO, V34, pS37, DOI 10.1111/j.1365-2125.1992.tb04147.x; Brass LF, 1991, HEMATOLOGY BASIC PRI, P1176; BREZINSKI DA, 1992, CIRCULATION, V86, P56, DOI 10.1161/01.CIR.86.1.56; BROEKMAN MJ, 1991, BLOOD, V78, P1033, DOI 10.1182/blood.V78.4.1033.bloodjournal7841033; COTE YP, 1991, BIOCHIM BIOPHYS ACTA, V1078, P187, DOI 10.1016/0167-4838(91)99008-G; COTE YP, 1992, BIOCHIM BIOPHYS ACTA, V1139, P133, DOI 10.1016/0925-4439(92)90092-2; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; DAVIES MJ, 1990, CIRCULATION, V82, P38; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; KROLL MH, 1989, BLOOD, V74, P1181; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; MACLOUF J, 1989, PHARMACOL RES, V21, P1, DOI 10.1016/1043-6618(89)90115-1; MARCUS AJ, 1987, J CLIN INVEST, V79, P179, DOI 10.1172/JCI112781; MARCUS AJ, 1984, P NATL ACAD SCI-BIOL, V81, P903, DOI 10.1073/pnas.81.3.903; MARCUS AJ, 1990, BLOOD, V76, P1903; MARCUS AJ, 1988, J BIOL CHEM, V263, P2223; MARCUS AJ, 1991, J CLIN INVEST, V88, P1690, DOI 10.1172/JCI115485; MARCUS AJ, 1980, J CLIN INVEST, V66, P979, DOI 10.1172/JCI109967; MARCUS AJ, 1982, BIOCHEM BIOPH RES CO, V109, P130, DOI 10.1016/0006-291X(82)91575-3; MARCUS AJ, 1992, CLIN RES, V40, pA226; MARCUS AJ, 1990, DISORDERS HEMOSTASIS, P75; MCEVER RP, 1991, THROMB HAEMOSTASIS, V66, P80; MONCADA S, 1991, PHARMACOL REV, V43, P109; MYLER RK, 1990, J INVASIVE CARDIOL, V2, P117; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; SANTOS MT, 1991, J CLIN INVEST, V87, P571, DOI 10.1172/JCI115032; SANTOS MT, 1991, CLIN RES, V39, pA254; SCHAFER AI, 1984, J CLIN INVEST, V73, P1105, DOI 10.1172/JCI111296; STARY HC, 1989, ARTERIOSCLEROSIS, V9, pI19; SZCZEKLIK A, 1992, ARTERIOSCLER THROMB, V12, P548, DOI 10.1161/01.ATV.12.5.548; VALLES J, 1991, BLOOD, V78, P154; WOOLF N, 1992, OXFORD TXB PATHOLOGY, P509; YAGI K, 1991, BIOCHEM BIOPH RES CO, V180, P1200, DOI 10.1016/S0006-291X(05)81323-3	35	238	246	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR 1	1993	7	6					516	522		10.1096/fasebj.7.6.8472890	http://dx.doi.org/10.1096/fasebj.7.6.8472890			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KY009	8472890				2022-12-28	WOS:A1993KY00900004
J	Hoyer, J; Kohler, R; Distler, A				Hoyer, J; Kohler, R; Distler, A			Mechanosensitive Ca2+ oscillations and STOC activation in endothelial cells	FASEB JOURNAL			English	Article						shear stress; spontaneous transient outward currents; intracellular calcium; ryanodine; bovine aortic endothelial cells	INDUCED CALCIUM TRANSIENTS; FLUID SHEAR-STRESS; INTRACELLULAR CALCIUM; ION CHANNELS; CURRENTS; STRETCH; MOBILIZATION; INCREASES; INFLUX	Activation of ion channels and the increase in intracellular Ca2+ concentration [Ca2+](i) play a key role in endothelial responses to hemodynamic forces and subsequent vasoregulation. In bovine aortic endothelial cells subjected to shear stress in a parallel flow chamber, we demonstrate shear stress activation of hyperpolarizing K+ currents that occur simultaneously with oscillating increases of [Ca2+](i). Oscillating K+ currents, also known as spontaneous transient outward currents (STOC), were regulated in frequency and amplitude by the rate of shear stress in a range from 5 to 18 dyn/cm(2). Activation of STOC depended on Ca2+ influx; current depended on the extracellular Ca2+ concentration and was blocked by 50 mu M Gd3+, Emptying of Ca2+ stores by BHQ abolished current responses to shear stress, STOC activation was significantly reduced by cell dialysis with ryanodine (20 mu M), but not heparin (200 mu g/ml). Shear stress-induced STOC activation was also observed in the intact endothelium. The endothelial response to shear stress involves oscillating [Ca2+](i) increase and STOC activation, which depend on Ca2+ influx-induced Ca2+ release from ryanodine-sensitive stores, demonstrating a new signaling pathway in endothelial mechanotransduction.	Free Univ Berlin, Hosp Benjamin Franklin, Dept Internal Med, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hoyer, J (corresponding author), Free Univ Berlin, Hosp Benjamin Franklin, Dept Internal Med, D-12200 Berlin, Germany.		Hoyer, Joachim/GQB-1090-2022	Kohler, Ralf/0000-0001-9563-2913				ALEVRIADOU BR, 1993, ANN BIOMED ENG, V21, P1, DOI 10.1007/BF02368159; ANDO J, 1988, IN VITRO CELL DEV B, V24, P871; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DIAMOND SL, 1994, ARTERIOSCLER THROMB, V14, P2000, DOI 10.1161/01.ATV.14.12.2000; DULL RO, 1991, AM J PHYSIOL, V261, pH149, DOI 10.1152/ajpheart.1991.261.1.H149; FALCONE JC, 1993, AM J PHYSIOL, V264, pH653, DOI 10.1152/ajpheart.1993.264.2.H653; FRANGOS JA, 1988, BIOTECHNOL BIOENG, V32, P1053, DOI 10.1002/bit.260320812; FRANZIUS D, 1994, PFLUG ARCH EUR J PHY, V428, P433, DOI 10.1007/BF00374562; GEIGER RV, 1992, AM J PHYSIOL, V262, pC1411, DOI 10.1152/ajpcell.1992.262.6.C1411; Helmlinger G, 1996, J VASC RES, V33, P360, DOI 10.1159/000159164; HIMMEL HM, 1993, HYPERTENSION, V21, P112, DOI 10.1161/01.HYP.21.1.112; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Hoyer J, 1996, P NATL ACAD SCI USA, V93, P11253, DOI 10.1073/pnas.93.20.11253; HOYER J, 1994, P NATL ACAD SCI USA, V91, P2367, DOI 10.1073/pnas.91.6.2367; JACOB R, 1991, CELL CALCIUM, V12, P127, DOI 10.1016/0143-4160(91)90014-6; LANSMAN JB, 1987, NATURE, V325, P811, DOI 10.1038/325811a0; LUCKHOFF A, 1990, PFLUG ARCH EUR J PHY, V416, P305, DOI 10.1007/BF00392067; MO M, 1991, AM J PHYSIOL, V260, pH1698, DOI 10.1152/ajpheart.1991.260.5.H1698; NARUSE K, 1993, AM J PHYSIOL, V264, pC1037, DOI 10.1152/ajpcell.1993.264.4.C1037; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Nilius B, 1997, ANNU REV PHYSIOL, V59, P145, DOI 10.1146/annurev.physiol.59.1.145; NITSCHKE R, 1991, PFLUG ARCH EUR J PHY, V417, P622, DOI 10.1007/BF00372961; NOLLERT MU, 1990, BIOCHEM BIOPH RES CO, V170, P281, DOI 10.1016/0006-291X(90)91271-S; ONEILL WC, 1995, AM J PHYSIOL-CELL PH, V269, pC863, DOI 10.1152/ajpcell.1995.269.4.C863; RUSKO J, 1995, BRIT J PHARMACOL, V115, P133, DOI 10.1111/j.1476-5381.1995.tb16330.x; SCHWARZ G, 1992, J PHYSIOL-LONDON, V458, P527, DOI 10.1113/jphysiol.1992.sp019432; SHEN J, 1992, AM J PHYSIOL, V262, pC384, DOI 10.1152/ajpcell.1992.262.2.C384; VACA L, 1995, AM J PHYSIOL, V267, pC920; Ying XY, 1996, CIRC RES, V79, P898, DOI 10.1161/01.RES.79.4.898; ZIEGELSTEIN RC, 1994, CIRC RES, V74, P151, DOI 10.1161/01.RES.74.1.151	30	41	45	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1998	12	3					359	366		10.1096/fasebj.12.3.359	http://dx.doi.org/10.1096/fasebj.12.3.359			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YZ898	9506480				2022-12-28	WOS:000072305500025
J	Hellbach, S; Gartner, P; Deicke, J; Fischer, D; Hassan, AHS; Almeida, OFX				Hellbach, S; Gartner, P; Deicke, J; Fischer, D; Hassan, AHS; Almeida, OFX			Inherent glucocorticoid response potential of isolated hypothalamic neuroendocrine neurons	FASEB JOURNAL			English	Article						corticotropin-releasing hormone; arginine vasopressin; beta-endorphin; dexamethasone; glucocorticoid feedback	CORTICOTROPIN-RELEASING HORMONE; FACTOR GENE-EXPRESSION; CENTRAL-NERVOUS-SYSTEM; PARAVENTRICULAR NUCLEUS; MESSENGER-RNA; RAT-BRAIN; VASOPRESSIN EXPRESSION; ARGININE-VASOPRESSIN; FACTOR SECRETION; INHIBITION	Within the broader framework of facilitating investigations into the inherent responses of restricted neuronal phenotypes devoid of their in vivo afferents, serum- and steroid-free cultures enriched in corticotropin-releasing hormone (CRH), arginine vasopressin (AVP), and beta-endorphin (beta-END) peptidergic neurons were prepared from the hypothalamic paraventricular (PVN: CRH and AVP) and/or arcuate (ARC: beta-END) nuclei of juvenile male rats, The functional viability of these ARC/PVN cultures was verified by their ability to synthesize and secrete CRH, AVP, and beta-END under basal and depolarizing (veratridine) conditions in vitro. Peptide secretion was shown to be Ca2+ and Na+ dependent in that it was blocked in the presence of veraspamil and tetrodotoxin, respectively. Exposure of ARC/PVN cocultures to the glucocorticoid dexamethasone (DEX) resulted in a dose-dependent increase of CRH secretion and an inhibition of AVP and beta-END; the CRH responses deviated strikingly from predictions based on in vivo experiments. Steroid withdrawal or treatment with the glucocorticoid receptor antagonist RU38486 reversed these trends. Opposite effects of DEX on CRH secretion were observed in cultures consisting of PVN cells only. Supported by studies using an opioid receptor agonist (morphine) and antagonist (naloxone), these observations demonstrate that ARC-derived (beta-END) neurons modulate the responses of PVN neurons to DEX.	Max Planck Inst Psychiat, Dept Neuroendocrinol, Neuroadaptat Grp, D-80804 Munich, Germany	Max Planck Society	Almeida, OFX (corresponding author), Max Planck Inst Psychiat, Dept Neuroendocrinol, Neuroadaptat Grp, Kraepelinstr 2-10, D-80804 Munich, Germany.	osa@mpipsykl.mpg.de	Almeida, Osborne F.X. F/E-8402-2010	Almeida, Osborne F.X. F/0000-0001-7331-6928				AHIMA RS, 1991, ENDOCRINOLOGY, V129, P226, DOI 10.1210/endo-129-1-226; ALMEIDA OFX, 1992, BRAIN RES, V571, P189, DOI 10.1016/0006-8993(92)90654-R; ALMEIDA OFX, 1993, CIBA F SYMP, V172, P151; ANTONI FA, 1993, FRONT NEUROENDOCRIN, V14, P76, DOI 10.1006/frne.1993.1004; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEAULIEU S, 1988, MOL ENDOCRINOL, V2, P727, DOI 10.1210/mend-2-8-727; BERTINI LT, 1991, NEUROSCIENCE, V42, P237, DOI 10.1016/0306-4522(91)90161-G; BERTINI LT, 1993, NEUROENDOCRINOLOGY, V57, P716, DOI 10.1159/000126430; BRADY LS, 1992, NEUROENDOCRINOLOGY, V55, P121, DOI 10.1159/000126107; BUCKINGHAM JC, 1986, NEUROENDOCRINOLOGY, V42, P148, DOI 10.1159/000124266; CALOGERO AE, 1988, J CLIN INVEST, V82, P767, DOI 10.1172/JCI113677; Calogero AE, 1995, ANN NY ACAD SCI, V771, P31, DOI 10.1111/j.1749-6632.1995.tb44668.x; DALLMAN MF, 1994, ANN NY ACAD SCI, V746, P22; DAVIS LG, 1986, P NATL ACAD SCI USA, V83, P1145, DOI 10.1073/pnas.83.4.1145; DEKLOET ER, 1993, CELL MOL NEUROBIOL, V13, P433, DOI 10.1007/BF00711582; FELDMAN S, 1995, NEUROSCI BIOBEHAV R, V19, P235, DOI 10.1016/0149-7634(94)00062-6; FINK G, 1988, J PHYSIOL-LONDON, V401, P329, DOI 10.1113/jphysiol.1988.sp017165; HERMAN JP, 1995, J COMP NEUROL, V363, P15, DOI 10.1002/cne.903630103; HERMAN JP, 1995, J NEUROENDOCRINOL, V7, P475, DOI 10.1111/j.1365-2826.1995.tb00784.x; IMAKI T, 1995, J CLIN INVEST, V96, P231, DOI 10.1172/JCI118026; IXART G, 1991, EXP BRAIN RES, V87, P153; JOELS M, 1991, J STEROID BIOCHEM, V40, P83, DOI 10.1016/0960-0760(91)90170-A; JONES MT, 1988, PHYSIOL REV, V68, P743, DOI 10.1152/physrev.1988.68.3.743; Karalis K, 1996, NAT MED, V2, P556, DOI 10.1038/nm0596-556; KOVACS KJ, 1987, NEUROENDOCRINOLOGY, V46, P365, DOI 10.1159/000124846; LEVINE S, 1994, ANN NY ACAD SCI, V76, P275; LIPOSITS Z, 1990, PROG HISTOCHEM CYTOC, V21, P1; Liu X, 1995, NEUROENDOCRINOLOGY, V62, P628, DOI 10.1159/000127059; Malkoski SP, 1997, MOL CELL ENDOCRINOL, V127, P189, DOI 10.1016/S0303-7207(96)04004-X; MCDOWELL J, 1987, BRAIN RES REV, V12, P397, DOI 10.1016/0165-0173(87)90006-3; NIKOLARAKIS KE, 1987, NEUROSCIENCE, V23, P143, DOI 10.1016/0306-4522(87)90278-8; NORDEEN SK, 1993, MOL ENDOCRINOL, V7, P731, DOI 10.1210/me.7.6.731; ORCHINIK M, 1994, ANN NY ACAD SCI, V746, P101; PATCHEV VK, 1995, FASEB J, V9, P419, DOI 10.1096/fasebj.9.5.7896013; Patchev VK, 1996, J NEUROSCI, V16, P7077; PATCHEV VK, 1991, NEUROENDOCRINOLOGY, V54, P111, DOI 10.1159/000125859; PICH EM, 1993, NEUROSCIENCE, V55, P695, DOI 10.1016/0306-4522(93)90435-I; PLOTSKY PM, 1986, REGUL PEPTIDES, V16, P235, DOI 10.1016/0167-0115(86)90022-4; PLOTSKY PM, 1991, J NEUROENDOCRINOL, V3, P1, DOI 10.1111/j.1365-2826.1991.tb00231.x; ROSENFELD P, 1993, CELL MOL NEUROBIOL, V13, P295, DOI 10.1007/BF00711575; RUNDLE SE, 1988, NEUROENDOCRINOLOGY, V47, P374, DOI 10.1159/000124941; SAPOLSKY RM, 1990, BIOL PSYCHIAT, V27, P937, DOI 10.1016/0006-3223(90)90032-W; SAWCHENKO PE, 1992, CIBA F SYMP, V168, P16; SAWCHENKO PE, 1987, BRAIN RES, V403, P213, DOI 10.1016/0006-8993(87)90058-8; SCHILLING K, 1991, NEUROENDOCRINOLOGY, V53, P528, DOI 10.1159/000125768; Schmidt ED, 1997, J NEUROENDOCRINOL, V9, P69, DOI 10.1046/j.1365-2826.1997.00618.x; SPENCER RL, 1990, BRAIN RES, V514, P37, DOI 10.1016/0006-8993(90)90433-C; SZE PY, 1995, J STEROID BIOCHEM, V55, P185, DOI 10.1016/0960-0760(95)00178-3; SZOT P, 1993, DEV BRAIN RES, V73, P177, DOI 10.1016/0165-3806(93)90136-X; TIXIERVIDAL A, 1994, ANN NY ACAD SCI, V733, P56, DOI 10.1111/j.1749-6632.1994.tb17256.x; TSAGARAKIS S, 1990, NEUROENDOCRINOLOGY, V51, P599, DOI 10.1159/000125397; Walker CD, 1997, J NEUROENDOCRINOL, V9, P25, DOI 10.1046/j.1365-2826.1997.00544.x; Wang GJ, 1996, ENDOCRINOLOGY, V137, P379, DOI 10.1210/en.137.1.379; WHITNALL MH, 1993, PROG NEUROBIOL, V40, P573, DOI 10.1016/0301-0082(93)90035-Q	54	13	14	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1998	12	2					199	207		10.1096/fasebj.12.2.199	http://dx.doi.org/10.1096/fasebj.12.2.199			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472985				2022-12-28	WOS:000071848400008
J	Mandeville, R; Franco, E; SidracGhali, S; ParisNadon, L; Rocheleau, N; Mercier, G; Desy, M; Gaboury, L				Mandeville, R; Franco, E; SidracGhali, S; ParisNadon, L; Rocheleau, N; Mercier, G; Desy, M; Gaboury, L			Evaluation of the potential carcinogenicity of 60 Hz linear sinusoidal continuous-wave magnetic fields in Fischer F344 rats	FASEB JOURNAL			English	Article						carcinogenesis; solid tumor; mononuclear cell leukemia; tumor incidence	FREQUENCY ELECTROMAGNETIC-FIELDS; TUMOR PROMOTION; MAMMARY CARCINOGENESIS; EPIDEMIOLOGIC EVIDENCE; LIVER FOCI; EXPOSURE; CANCER; SURVIVAL; 50-HZ; MICE	Electric and magnetic fields (EMFs) associated with the production, transmission, and use of electricity are ubiquitous in industrialized societies. These fields are predominantly of low frequency (50/60 Hz) and are generally of low intensity. Review of the epidemiological evidence shows that the association between exposure to EMFs and cancer is weak and inconsistent, and generally fails to show a dose-response relationship. Moreover, in view of the methodological problems of these epidemiological studies, animal and laboratory studies are urgently needed to determine whether EMFs could be initiators and/or promoters of cancers. The objective of the present study was to determine whether chronic exposure to 60 Hz linear (single axis) sinusoidal, continuous-wave magnetic fields (MFs) of different intensities might increase the risk of leukemia and solid tumor development in rodents born and raised under these fields. Five groups of 50 female F344 rats were exposed for 20 h/day to 60 Hz MFs at intensities of <0.02 (sham controls), 2, 20, 200, and 2000 mu T. Full body exposure to the different fields was administered for 104 wk starting from the prenatal period (2 days before birth) and continuing during lactation and weaning until late adult Life. Body weight, survival, and clinical observations were evaluated in all groups of animals during in-life exposure. Necropsy was performed on all exposed and control animals that died, were found moribund, or were killed at termination of the study. To preserve and demonstrate the absence of any experimental bias, all clinical observations and pathological evaluations were conducted under ''blinded'' conditions. Fifty organs and tissues were evaluated in each animal, with special attention to the incidence of mononuclear cell leukemia, brain tumors, and mammary tumors. The findings from this chronic carcinogenicity study dem onstrate that, under our defined experimental conditions, exposure to 60 Hz linear (single axis) sinusoidal, continuous wave MFs did not affect animal survival, solid tumor, or mononuclear cell leukemia development in female F344 rats. No statistically significant, consistent, positive dose-related trends with the number of tumor-bearing animals per study group could be attributed to MF exposure.	MCGILL UNIV, DEPT ONCOL, DIV EPIDEMIOL, MONTREAL, PQ H3G 1Y6, CANADA; UNIV MONTREAL, DEPT PATHOL, MONTREAL, PQ H3C 3J7, CANADA	McGill University; Universite de Montreal	Mandeville, R (corresponding author), UNIV QUEBEC, INST ARMAND FRAPPIER, IMMUNOL RES CTR, 531 BOUL PRAIRES, LAVAL, PQ H7N 4Z3, CANADA.		Franco, Eduardo/C-6445-2014	Franco, Eduardo/0000-0002-4409-8084				ALDRICH TE, 1992, ELECTRO MAGNETOBIOL, V11, P127, DOI 10.3109/15368379209009822; ANDERSON LE, 1993, AM IND HYG ASSOC J, V54, P186, DOI 10.1202/0002-8894(1993)054<0186:BEOELE>2.0.CO;2; [Anonymous], PATHOLOGY F344 RAT; BATES MN, 1991, ENVIRON HEALTH PERSP, V95, P147, DOI 10.2307/3431121; BAUM A, 1995, CARCINOGENESIS, V16, P119, DOI 10.1093/carcin/16.1.119; BELLOSSI A, 1986, RADIAT ENVIRON BIOPH, V25, P75, DOI 10.1007/BF01209687; BENIASHVILI DS, 1991, CANCER LETT, V61, P75, DOI 10.1016/0304-3835(91)90079-W; Boorman G.A., 1985, HDB CARCINOGEN TESTI, P345; FAIRBAIRN DW, 1994, CELL MOL BIOL, V40, P561; Feldman D.B., 1988, NECROPSY GUIDE RODEN; FIORANI M, 1992, MUTAT RES, V282, P25, DOI 10.1016/0165-7992(92)90069-T; GART JJ, 1986, DESIGN ANAL LONG TER, V3; Haseman JK, 1996, MUTAT RES-FUND MOL M, V350, P131, DOI 10.1016/0027-5107(95)00098-4; HENDEE WR, 1994, HEALTH PHYS, V66, P127, DOI 10.1097/00004032-199402000-00001; HUFF J, 1982, ENVIRON HEALTH PERSP, V45, P185, DOI 10.2307/3429406; JUUTILAINEN J, 1986, HEREDITAS, V104, P145, DOI 10.1111/j.1601-5223.1986.tb00527.x; KAICER EK, 1997, IN PRESS MAGNETISM E; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAUNE KT, 1990, EXTREMELY LOW FREQUE, P17; LOSCHER W, 1994, LIFE SCI, V54, P1531, DOI 10.1016/0024-3205(94)90024-8; LOSCHER W, 1993, CANCER LETT, V71, P75, DOI 10.1016/0304-3835(93)90100-N; LOSCHER W, 1994, ONCOLOGY-BASEL, V51, P288; LOSCHER W, 1996, ANN REV RES BIOL EFF, P7; MANDEVILLE R, 1993, ELECTRICITY AND MAGNETISM IN BIOLOGY AND MEDICINE, P419; MANDEVILLE R, 1991, AIR WASTE MANAGEMENT, V5, P1; MANDEVILLE R, 1992, AIR WASTE MANAGEMENT, V1, P1; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MCCORMICK DL, 1996, ANN REV RES BIOL EFF, P7; MEVISSEN M, 1993, BIOELECTROMAGNETICS, V14, P131, DOI 10.1002/bem.2250140206; NAFZIGER J, 1993, BIOELECTROCH BIOENER, V30, P133, DOI 10.1016/0302-4598(93)80071-2; Percy C., 1990, INT CLASSIFICATION D; PORTIER CJ, 1986, CANCER RES, V46, P4372; RANNUG A, 1993, BIOELECTROMAGNETICS, V14, P17, DOI 10.1002/bem.2250140105; RANNUG A, 1994, CARCINOGENESIS, V15, P153, DOI 10.1093/carcin/15.2.153; RANNUG A, 1993, ENVIRON RES, V62, P223, DOI 10.1006/enrs.1993.1107; RAO GN, 1990, TOXICOL PATHOL, V18, P61, DOI 10.1177/019262339001800109; SAGAN LA, 1992, JAMA-J AM MED ASSOC, V268, P625, DOI 10.1001/jama.268.5.625; SAVITZ DA, 1993, ENVIRON HEALTH PERSP, V101, P83, DOI 10.2307/3431664; STUCHLY MA, 1992, CANCER LETT, V65, P1, DOI 10.1016/0304-3835(92)90205-A; Tremblay L, 1996, BIOELECTROMAGNETICS, V17, P373, DOI 10.1002/(SICI)1521-186X(1996)17:5<373::AID-BEM4>3.0.CO;2-0; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681; YASUI M, 1993, BIOELECTROMAGNETICS, V14, P535, DOI 10.1002/bem.2250140605	42	42	42	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1997	11	13					1127	1136		10.1096/fasebj.11.13.9367347	http://dx.doi.org/10.1096/fasebj.11.13.9367347			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367347				2022-12-28	WOS:A1997YE98300010
J	Walzog, B; Jeblonski, F; Zakrzewicz, A; Gaehtgens, P				Walzog, B; Jeblonski, F; Zakrzewicz, A; Gaehtgens, P			beta(2) integrins (CD11/CD18) promote apoptosis of human neutrophils	FASEB JOURNAL			English	Article						PMN; signal transduction; inflammation; DNA fragmentation assay; cell morphology; migration	PROTEIN-TYROSINE PHOSPHORYLATION; PROGRAMMED CELL-DEATH; TUMOR-NECROSIS-FACTOR; RESPIRATORY BURST; NONADHERENT NEUTROPHILS; MOLECULAR MECHANISMS; AGING NEUTROPHILS; CROSS-LINKING; ACTIVATION; RECEPTOR	Apoptosis of human polymorphonuclear neutrophils (PMN) is thought to be critical for the control of the inflammatory process, but the mechanisms underlying its regulation in physiological settings are still incompletely understood, This study was undertaken to test the hypothesis that the beta(2) integrin (CD11/CD18) family of leukocyte adhesion molecules contributes to the control of activated PMN by up-regulating apoptosis, Apoptosis of isolated human PMN was investigated by 1) analysis of DNA content, 2) detection of DNA degradation, 3) morphological studies, and 4) measurement of CD16 expression on the cell surface, We found that beta(2) integrins potentiated the tumor necrosis factor alpha (TNF-alpha) -induced apoptosis within 4 and 8 h after stimulation, The effect required aggregation of the beta(2) integrin Mac-1 (CD11b/CD18), which was induced by antibody cross-linking, and was independent of Fc receptors, An enhancement of apoptosis was also observed after migration of PMN through an endothelial cell monolayer, TNF-alpha-induced apoptosis as well as potentiation' by beta(2) integrins was prevented by inhibition of tyrosine kinases with herbimycin A or genistein, The present study provides a new model for the regulation of PMN apoptosis by a functional cross-talk between beta(2) integrins and TNF-alpha with a promoting role for the beta(2) integrins, This mechanism, which allows enhanced elimination of previously emigrated PMN, may be critical to abate local inflammatory processes in vivo.			Walzog, B (corresponding author), FREE UNIV BERLIN,DEPT PHYSIOL,ARNIMALLEE 22,D-14195 BERLIN,GERMANY.							ARNAOUT MA, 1990, BLOOD, V75, P1037; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BAGGIOLINI M, 1993, FASEB J, V7, P1004, DOI 10.1096/fasebj.7.11.8396540; BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; Chitnis D, 1996, J LEUKOCYTE BIOL, V59, P835, DOI 10.1002/jlb.59.6.835; COX G, 1992, AM J RESP CELL MOL, V7, P507, DOI 10.1165/ajrcmb/7.5.507; Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; DRANSFIELD I, 1994, J IMMUNOL, V153, P1254; Dusi S, 1996, J IMMUNOL, V157, P4615; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; HALL SE, 1994, J IMMUNOL, V153, P3218; HJORTH R, 1981, J IMMUNOL METHODS, V43, P95, DOI 10.1016/0022-1759(81)90040-5; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Ley K, 1996, CARDIOVASC RES, V32, P733, DOI 10.1016/0008-6363(96)00066-1; Liles WC, 1995, J LEUKOCYTE BIOL, V58, P690, DOI 10.1002/jlb.58.6.690; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; OHATA H, 1994, FEBS LETT, V355, P267; PAYNE CM, 1994, MICROSC RES TECHNIQ, V28, P327, DOI 10.1002/jemt.1070280408; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SQUIER MKT, 1995, J LEUKOCYTE BIOL, V57, P2, DOI 10.1002/jlb.57.1.2; TAKAHASHI K, 1990, IN VITRO CELL DEV, V25, P265; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TSUCHIDA H, 1995, J IMMUNOL, V154, P2403; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; Walzog B, 1996, J LEUKOCYTE BIOL, V59, P747, DOI 10.1002/jlb.59.5.747; WALZOG B, 1994, J LEUKOCYTE BIOL, V56, P625, DOI 10.1002/jlb.56.5.625; Watson RWG, 1997, J IMMUNOL, V158, P945; WHYTE MKB, 1993, J IMMUNOL, V150, P5124; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yan SR, 1995, J INFLAMM, V45, P297; Yan SR, 1997, J IMMUNOL, V158, P1902; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868; Zheng LM, 1996, P NATL ACAD SCI USA, V93, P8431, DOI 10.1073/pnas.93.16.8431	42	81	83	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1997	11	13					1177	1186		10.1096/fasebj.11.13.9367353	http://dx.doi.org/10.1096/fasebj.11.13.9367353			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367353				2022-12-28	WOS:A1997YE98300016
J	Kohn, DB; Parkman, R				Kohn, DB; Parkman, R			Gene therapy for newborns	FASEB JOURNAL			English	Review						neonate; umbilical cord blood; cystic fibrosis; bone marrow; stem cell; hematopoiesis	IMMUNODEFICIENCY-VIRUS TYPE-1; BONE-MARROW; CORD-BLOOD; ADENOSINE-DEAMINASE; TRANSPLANTATION; EXPRESSION; DISEASES; CELLS	Application of gene therapy to treat genetic and infectious diseases may have several advantages if performed in newborns. Because of the minimal adverse effect of the underlying disease on cells of the newborn, the relatively small size of infants, and the large amount of future growth, gene therapy may be more successful in newborns than in older children or adults. The presence of umbilical cord blood from newborns provides a unique and susceptible target for the genetic modification of hematopoietic stem cells. In our first trial of gene therapy in newborns, we inserted a normal adenosine deaminase gene into umbilical cord blood cells of three neonates with a congenital immune deficiency. The trial demonstrated the successful transduction and engraftment of stem cells, which continue to contribute to leukocyte production more than 3 years later. A similar approach may be taken to insert genes that inhibit replication of HIV-1 into umbilical cord blood cells of HIV-1-infected neonates. Many other metabolic and infectious disorders could be treated by gene therapy during the neonatal period if prenatal diagnoses are made and the appropriate techical and regulatory requirements have been met.	UNIV SO CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT MOL MICROBIOL & IMMUNOL,LOS ANGELES,CA 90027	University of Southern California; University of Southern California	Kohn, DB (corresponding author), UNIV SO CALIF,CHILDRENS HOSP LOS ANGELES,SCH MED,DIV RES IMMUNOL BONE MARROW TRANSPLANTAT,LOS ANGELES,CA 90027, USA.		Kohn, Donald/N-5085-2016	Kohn, Donald/0000-0003-1840-6087	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054850] Funding Source: NIH RePORTER; NHLBI NIH HHS [1P50 HL54850] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bahner I, 1996, J VIROL, V70, P4352, DOI 10.1128/JVI.70.7.4352-4360.1996; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; GILBOA E, 1994, TRENDS GENET, V10, P139, DOI 10.1016/0168-9525(94)90216-X; HAO QL, 1995, BLOOD, V86, P3745, DOI 10.1182/blood.V86.10.3745.bloodjournal86103745; Hirschhorn R, 1996, NAT GENET, V13, P290, DOI 10.1038/ng0796-290; HOCK RA, 1989, BLOOD, V74, P876; KEARNS K, 1997, HUM GENE THER, V8, P310; Kohn DB, 1996, ADV EXP MED BIOL, V394, P421; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; Kohn Donald B., 1995, Current Opinion in Pediatrics, V7, P56, DOI 10.1097/00008480-199502000-00011; KURTZBERG J, 1996, NEW ENGL J MED, V335, P137; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; PARKMAN R, 1986, SCIENCE, V232, P1373, DOI 10.1126/science.3520819; Stephan V, 1996, NEW ENGL J MED, V335, P1563, DOI 10.1056/NEJM199611213352104; WAGNER JE, 1995, LANCET, V346, P214, DOI 10.1016/S0140-6736(95)91268-1; Weinberg K, 1995, Biol Blood Marrow Transplant, V1, P18; YU M, 1993, P NATL ACAD SCI USA, V90, P6340, DOI 10.1073/pnas.90.13.6340	20	14	14	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1997	11	8					635	639		10.1096/fasebj.11.8.9240965	http://dx.doi.org/10.1096/fasebj.11.8.9240965			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XN027	9240965				2022-12-28	WOS:A1997XN02700004
J	Wolman, SR; Heppner, GH; Wolman, E				Wolman, SR; Heppner, GH; Wolman, E			New directions in breast cancer research	FASEB JOURNAL			English	Article						molecular genetics; cellular models for preneoplastic disease; tumor environment; hormonal risk; chemoprevention	OVARIAN-CANCER; GROWTH-FACTOR; RISK; EPIDEMIOLOGY; PREVENTION; ESTROGENS; PROLIFERATION; SUPPRESSION; CARCINOMAS; TUMORS	Research in breast cancer extends in many directions, stimulated by concerns related to the high incidence of the disease and the relative unpredictability of its clinical course. Examples of work in several directions are presented here arranged by four levels of analysis. 1) Molecular, intracellular events (molecular genetics). Recent identification of genes that predispose to breast cancer, and the isolation of those genes and their protein products, permit investigations of the most critical issues: the roles of these genes in normal development and breast differentiation, and how their alteration permits or contributes to tumor initiation. Thus, we expect that understanding the functions of the genes involved in inherited susceptibility to breast cancer will also be informative for sporadic breast cancers. 2) Cellular biology (cellular models for preneoplastic disease). We examine models of breast cancer development and ask how they help to validate a morphologic sequence for human breast neoplasia and whether they permit investigation of how to modify disease progression. Two useful models, one in transgenic mice and the other using human breast stem cells capable of culture and xenograft growth, are now available. 3) Tissue and organ (the tumor and its local environment). We look at the relationship of the tumor cell population to its local environment (stroma, blood vessels, etc.). This leads naturally to questions of how neighboring tissues and cytokines may modify tumor growth. 4) The individual as an organism and member of a population (hormonal rise and chemoprevention). We address identification of the primarily hormonal risk factors and a possible related mode of cancer prevention.	WAYNE STATE UNIV, DEPT PATHOL, DETROIT, MI 48202 USA; GEORGE WASHINGTON UNIV, DEPT PATHOL, WASHINGTON, DC 20052 USA; UNIFORMED SERV UNIV HLTH SCI, DEPT PATHOL, BETHESDA, MD 20814 USA; WAYNE STATE UNIV, SCH MED, DEPT MED, DETROIT, MI 48201 USA; KARMANOS CANC INST, BREAST CANC PROGRAM, DETROIT, MI 48201 USA; GEORGE MASON UNIV, DEPT OPERAT RES & ENGN, FAIRFAX, VA 22030 USA	Wayne State University; George Washington University; Uniformed Services University of the Health Sciences - USA; Wayne State University; Barbara Ann Karmanos Cancer Institute; George Mason University					NATIONAL CANCER INSTITUTE [R01CA028366, R01CA070923, R01CA061217] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA28366, CA70923, CA61217] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amundadottir LT, 1996, BREAST CANCER RES TR, V39, P119, DOI 10.1007/BF01806083; Bissell M J, 1987, Prog Clin Biol Res, V249, P251; BRINTON LA, 1993, EPIDEMIOL REV, V15, P66, DOI 10.1093/oxfordjournals.epirev.a036117; BRINTON LA, 1995, J NATL CANCER I, V87, P827, DOI 10.1093/jnci/87.11.827; Cardiff RD, 1996, J MAMMARY GLAND BIOL, V1, P61, DOI 10.1007/BF02096303; Cauley JA, 1996, JAMA-J AM MED ASSOC, V276, P1404, DOI 10.1001/jama.276.17.1404; Chambers AF, 1995, CANCER METAST REV, V14, P279, DOI 10.1007/BF00690599; CHEN C, 1995, CANCER RES, V55, P4230; Clark GJ, 1996, ONCOGENE, V12, P169; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; CROPP CS, 1994, CANCER RES, V54, P2548; Dawson PJ, 1996, AM J PATHOL, V148, P313; DEOME KB, 1959, CANCER RES, V19, P515; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; INAVANI S, 1996, FASEB J, V10, P2406; KELSEY JL, 1993, EPIDEMIOL REV, V15, P256, DOI 10.1093/oxfordjournals.epirev.a036112; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; KVALE G, 1992, ACTA ONCOL, V31, P187, DOI 10.3109/02841869209088901; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; MEDINA D, 1996, MAMMARY TUMOR CELL C, P36; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILLER FR, 1996, P AM ASSOC CANC RES, V37, P3879; NAROD S, 1993, CLIN INVEST MED, V16, P314; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Page DL, 1987, DIAGNOSTIC HISTOPATH, P120; Phelan CM, 1996, NAT GENET, V12, P309, DOI 10.1038/ng0396-309; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; PIKE MC, 1987, J CHRON DIS, V40, pS59, DOI 10.1016/S0021-9681(87)80009-7; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; ROSNER B, 1994, AM J EPIDEMIOL, V139, P819, DOI 10.1093/oxfordjournals.aje.a117079; RUSSO J, 1994, CANCER EPIDEM BIOMAR, V3, P353; SHEKHAR PVM, 1996, P AM ASSOC CANC RES, V37, P4026; SHEKHAR PVM, 1995, P AM ASSOC CANC RES, V36, P1523; SHENG ZM, 1988, ONCOGENE RES, V2, P245; SINGER C, 1995, CANCER RES, V55, P2448; SOULE HD, 1990, CANCER RES, V50, P6075; SPICER DV, 1995, CANCER INVEST, V13, P495, DOI 10.3109/07357909509024914; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Tait L, 1996, INT J ONCOL, V9, P263; WHELAN EA, 1994, AM J EPIDEMIOL, V140, P1081, DOI 10.1093/oxfordjournals.aje.a117208; WOLMAN SR, 1993, ADV MOL CEL, V7, P1; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Ziegler RG, 1996, J NATL CANCER I, V88, P650, DOI 10.1093/jnci/88.10.650	47	12	14	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1997	11	7					535	543		10.1096/fasebj.11.7.9212077	http://dx.doi.org/10.1096/fasebj.11.7.9212077			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XH342	9212077				2022-12-28	WOS:A1997XH34200005
J	Klaassen, CD; Boles, JW				Klaassen, CD; Boles, JW			Sulfation and sulfotransferases .5. The importance of 3'-phosphoadenosine 5'-phosphosulfate (PAPS) in the regulation of sulfation	FASEB JOURNAL			English	Review						acetaminophen; sulfate; ATP-sulfurylase; APS-kinase; glutathione	ADENOSINE 3'-PHOSPHATE 5'-PHOSPHOSULFATE; BORDER MEMBRANE-VESICLES; PERFUSED-RAT-LIVER; INCREASED INORGANIC SULFATE; ANION TRANSPORT INHIBITORS; DEFICIENT DIETARY-INTAKE; STEADY-STATE KINETICS; ATP-SULFURYLASE; PENICILLIUM-CHRYSOGENUM; SACCHAROMYCES-CEREVISIAE	Sulfation is the transfer of a sulfate group from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to a substrate that is catalyzed by a family of sulfotransferase enzymes. Many different endogenous and xenobiotic molecules are substrates for the sulfotransferases; sulfation affects many different physiological processes, including: I) deactivation and bioactivation of xenobiotics, 2) inactivation of hormones and catecholamines, 3) structure and function of macromolecules, and 4) elimination of end products of catabolism. PAPS is the obligate cosubstrate that is synthesized in tissues to make available an ''activated form'' of sulfate for the sulfation reaction. PAPS participation in the reaction is dependent on its availability, which in turn is dependent on its synthesis, degradation, and ultimately its utilization in the sulfation reaction itself. PAPS synthesis is dependent on the availability of sulfate and on the activity of the two enzymes of its synthesis, ATP-sulfurylase and APS-kinase. Although the kinetic properties of these two enzymes are well described, their in vivo regulation is not fully understood. Sulfation is a high-affinity, low-capacity enzymatic process in which the entire liver content of PAPS can be consumed in less than 2 min. ATP-sulfurylase and APS-kinase can rapidly synthesize additional PAPS. The low capacity of sulfation in rats is due to the Limited availability of sulfate, whereas in mice the sulfotransferases appear to limit sulfation capacity. Sulfation rates are not readily enhanced, but they can be decreased. 2,6-Dichloro-4-nitrophenol inhibits phenolsulfotransferases, but not hydroxysteroid-sulfotransferases. However, the sulfation of phenols and hydroxysteroids can be decreased by factors that decrease sulfate availability such as a low-sulfate diet, other xenobiotics that are sulfated, and molybdate, which inhibits sulfate intestinal absorption, renal reabsorption, and sulfate incorporation into PAPS.			Klaassen, CD (corresponding author), UNIV KANSAS,MED CTR,DEPT PHARMACOL TOXICOL & THERAPEUT,CTR ENVIRONM & OCCUPAT HLTH,KANSAS CITY,KS 66160, USA.							ADACHI T, 1975, J BACTERIOL, V121, P29, DOI 10.1128/JB.121.1.29-35.1975; ANDERSON LM, 1978, J NATL CANCER I, V61, P1405; ARZ HE, 1994, BBA-GENE STRUCT EXPR, V1218, P447, DOI 10.1016/0167-4781(94)90203-8; AW TY, 1982, J BIOL CHEM, V257, P8997; AW TY, 1985, AM J PHYSIOL, V249, pC385, DOI 10.1152/ajpcell.1985.249.5.C385; AZAKAMI H, 1992, J BACTERIOL, V174, P2344, DOI 10.1128/JB.174.7.2344-2351.1992; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BAKHTIAN S, 1993, MECH AGEING DEV, V66, P257, DOI 10.1016/0047-6374(93)90013-H; BANDURSKI RS, 1956, J AM CHEM SOC, V78, P6408, DOI 10.1021/ja01605a028; BENINCOSA LJ, 1995, LIFE SCI, V57, P1497; BENINCOSA LJ, 1995, J PHARMACOL EXP THER, V272, P248; BERGLUND F, 1960, ACTA PHYSL SCAN S172, V49, P1; BISSIG M, 1994, J BIOL CHEM, V269, P3017; BRADLEY H, 1994, J RHEUMATOL, V21, P1192; BRION F, 1987, J NEUROCHEM, V48, P1171, DOI 10.1111/j.1471-4159.1987.tb05643.x; BRZEZNICKA EA, 1987, DRUG METAB DISPOS, V15, P133; CAPASSO JM, 1984, J BIOL CHEM, V259, P4263; CAPPIELLO M, 1989, EUR J CLIN PHARMACOL, V37, P317, DOI 10.1007/BF00679793; CAPPIELLO M, 1990, DEV PHARMACOL THERAP, V14, P62, DOI 10.1159/000480940; CASTRANOVA V, 1979, J MEMBRANE BIOL, V49, P57, DOI 10.1007/BF01871039; CHEREST H, 1985, GENE, V34, P269; CHIBA H, 1995, P NATL ACAD SCI USA, V92, P8176, DOI 10.1073/pnas.92.18.8176; COLE DEC, 1992, J PERINAT MED, V20, P443, DOI 10.1515/jpme.1992.20.6.443; COLE DEC, 1986, CLIN CHIM ACTA, V155, P237, DOI 10.1016/0009-8981(86)90243-3; COLE DEC, 1982, CLIN CHIM ACTA, V120, P153, DOI 10.1016/0009-8981(82)90086-9; COLE DEC, 1985, OBSTET GYNECOL, V66, P485; COLE DEC, 1984, AM J OBSTET GYNECOL, V148, P596, DOI 10.1016/0002-9378(84)90755-5; COLE DEC, 1985, CLIN CHEM, V31, P866; COLE DEC, 1980, CLIN CHIM ACTA, V107, P135, DOI 10.1016/0009-8981(80)90423-4; CURTIS CG, 1982, SULFATE METABOLISM S; DARLING IM, 1991, PHARMACEUT RES, V8, P376, DOI 10.1023/A:1015805918168; DARLING IM, 1994, DRUG METAB DISPOS, V22, P318; DAWSON JR, 1983, BIOCHEM PHARMACOL, V32, P1789, DOI 10.1016/0006-2952(83)90126-0; DEVRIES BJ, 1985, ARTHRITIS RHEUM, V28, P922, DOI 10.1002/art.1780280812; DIBBELT L, 1991, BIOL CHEM H-S, V372, P173, DOI 10.1515/bchm3.1991.372.1.173; DILLS RL, 1986, DRUG METAB DISPOS, V14, P190; DILLS RL, 1986, J PHARMACOL EXP THER, V238, P463; DOMIANO SSR, 1982, J NEUROCHEM, V48, P1411; ELGAVISH A, 1991, AM J PHYSIOL, V260, pL450, DOI 10.1152/ajplung.1991.260.6.L450; FARLEY JR, 1976, J BIOL CHEM, V251, P4389; FOSTER BA, 1994, J BIOL CHEM, V269, P19777; FRICK A, 1986, PFLUG ARCH EUR J PHY, V407, P541, DOI 10.1007/BF00657513; FRICK A, 1984, PFLUG ARCH EUR J PHY, V402, P433, DOI 10.1007/BF00583944; GALINSKY RE, 1986, J PHARMACOL EXP THER, V236, P133; GLAZENBURG EJ, 1983, J NUTR, V113, P1363, DOI 10.1093/jn/113.7.1363; GLAZENBURG EJ, 1984, BIOCHEM PHARMACOL, V33, P625, DOI 10.1016/0006-2952(84)90318-6; GOON D, 1991, DRUG METAB DISPOS, V19, P340; GOON D, 1990, J PHARMACOL EXP THER, V252, P201; GREGUS Z, 1994, DRUG METAB DISPOS, V22, P725; GREGUS Z, 1988, BIOCHEM PHARMACOL, V37, P4307, DOI 10.1016/0006-2952(88)90611-9; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HJELLE JJ, 1986, J PHARMACOL EXP THER, V236, P526; HJELLE JJ, 1985, DRUG METAB DISPOS, V13, P35; HJELLE JJ, 1984, J PHARMACOL EXP THER, V228, P407; JOHNSON GA, 1982, BIOCHEM PHARMACOL, V31, P2949, DOI 10.1016/0006-2952(82)90268-4; JOHNSON GA, 1980, LIFE SCI, V26, P1591, DOI 10.1016/0024-3205(80)90362-8; KIM HJ, 1995, J PHARMACOL EXP THER, V275, P654; KIM HJ, 1992, J PHARMACOL EXP THER, V261, P1015; Kim HJ, 1995, J PHARMACOL EXP THER, V275, P1506; KIM HJ, 1995, DRUG METAB DISPOS, V23, P840; KLONUS D, 1994, PLANT J, V6, P105, DOI 10.1046/j.1365-313X.1994.6010105.x; KNOWLES FC, 1986, ARCH BIOCHEM BIOPHYS, V251, P767, DOI 10.1016/0003-9861(86)90388-7; KOMATSU K, 1994, BIOCHEM BIOPH RES CO, V204, P1178, DOI 10.1006/bbrc.1994.2587; KORCH C, 1991, MOL GEN GENET, V229, P96, DOI 10.1007/BF00264218; KRIJGSHELD KR, 1981, BIOCHIM BIOPHYS ACTA, V677, P7, DOI 10.1016/0304-4165(81)90139-2; KRIJGSHELD KR, 1979, BIOCHIM BIOPHYS ACTA, V586, P492, DOI 10.1016/0304-4165(79)90039-4; KRIJGSHELD KR, 1982, BIOCHEM PHARMACOL, V31, P3997, DOI 10.1016/0006-2952(82)90646-3; KRIJGSHELD KR, 1981, BIOCHEM PHARMACOL, V30, P1973, DOI 10.1016/0006-2952(81)90208-2; LAKSHMANAN FL, 1976, AM J CLIN NUTR, V29, P1367, DOI 10.1093/ajcn/29.12.1367; LEUSTEK T, 1994, PLANT PHYSIOL, V105, P897, DOI 10.1104/pp.105.3.897; LEYH TS, 1988, J BIOL CHEM, V263, P2409; Liu L, 1996, TOXICOL APPL PHARM, V139, P128, DOI 10.1006/taap.1996.0151; LUCKE H, 1981, GASTROENTEROLOGY, V80, P22; LYLE S, 1994, BIOCHEMISTRY-US, V33, P5920, DOI 10.1021/bi00185a032; LYLE S, 1995, BIOCHEMISTRY-US, V34, P940, DOI 10.1021/bi00003a028; MANDON EC, 1994, P NATL ACAD SCI USA, V91, P10707, DOI 10.1073/pnas.91.22.10707; MARKOVICH D, 1994, J BIOL CHEM, V269, P3022; MASON J, 1977, RES VET SCI, V22, P313, DOI 10.1016/S0034-5288(18)33254-5; MAZIASZ TJ, 1991, TOXICOL APPL PHARM, V110, P365, DOI 10.1016/0041-008X(91)90039-H; MEERMAN JHN, 1980, CANCER RES, V40, P3772; MEERMAN JHN, 1983, BIOCHEM PHARMACOL, V32, P1587, DOI 10.1016/0006-2952(83)90332-5; MOHAPATRA NK, 1995, PEDIATR RES, V38, P42, DOI 10.1203/00006450-199507000-00008; MORRIS ME, 1988, J PHARMACOL EXP THER, V244, P945; Mulder G.J., 1990, CONJUGATION REACTION, P107; MULDER GJ, 1978, BIOCHEM J, V172, P247, DOI 10.1042/bj1720247; NEIBERGER RE, 1991, CHILD NEPHROL UROL, V11, P61; NEIBERGER RE, 1992, PEDIATR NEPHROL, V6, P65, DOI 10.1007/BF00856839; OGURO T, 1994, J PHARMACOL EXP THER, V270, P1145; Oguro T, 1996, TOXICOL APPL PHARM, V136, P354, DOI 10.1006/taap.1996.0043; PANG KS, 1981, J PHARMACOL EXP THER, V219, P134; PANG KS, 1978, J PHARMACOL EXP THER, V207, P178; PENA DR, 1992, PEDIATR NEPHROL, V6, P532, DOI 10.1007/BF00866495; PRITCHARD JB, 1987, AM J PHYSIOL, V252, pF346, DOI 10.1152/ajprenal.1987.252.2.F346; RENOSTO F, 1984, J BIOL CHEM, V259, P2113; RENOSTO F, 1991, ARCH BIOCHEM BIOPHYS, V284, P30, DOI 10.1016/0003-9861(91)90258-K; REUVENY Z, 1977, P NATL ACAD SCI USA, V74, P619, DOI 10.1073/pnas.74.2.619; Rossi A, 1996, J BIOL CHEM, V271, P18456, DOI 10.1074/jbc.271.31.18456; Roth J. A., 1982, SULFATE METABOLISM S, P107; ROZMAN P, 1992, DRUG METAB DISPOS, V20, P374; SCHNEIDER EG, 1984, J BIOL CHEM, V259, P4591; SEAH VMY, 1994, BIOCHEM PHARMACOL, V47, P1743, DOI 10.1016/0006-2952(94)90301-8; SEUBERT PA, 1985, ARCH BIOCHEM BIOPHYS, V240, P509, DOI 10.1016/0003-9861(85)90057-8; SMITH JT, 1983, ANN NUTR METAB, V27, P345, DOI 10.1159/000176698; SUGAHARA K, 1982, ARCH BIOCHEM BIOPHYS, V214, P589, DOI 10.1016/0003-9861(82)90064-9; SUGAHARA K, 1982, ARCH BIOCHEM BIOPHYS, V214, P602, DOI 10.1016/0003-9861(82)90065-0; TEMPLETON DM, 1992, CAN J PHYSIOL PHARM, V70, P843, DOI 10.1139/y92-113; TOGAWA T, 1990, J PHARMACOBIO-DYNAM, V13, P83, DOI 10.1248/bpb1978.13.83; VANDERKRAAN PM, 1990, J ORTHOPAED RES, V8, P565, DOI 10.1002/jor.1100080413; VANDERKRAAN PM, 1988, BIOCHEM PHARMACOL, V37, P3683, DOI 10.1016/0006-2952(88)90401-7; WALMSLEY MIB, 1995, MOL GEN GENET, V247, P423; WHITTEMORE RM, 1985, BIOCHEM PHARMACOL, V34, P3853, DOI 10.1016/0006-2952(85)90434-4; WIEBKIN P, 1979, BIOCHEM PHARMACOL, V28, P3315, DOI 10.1016/0006-2952(79)90127-8; WONG BK, 1986, TOXICOL APPL PHARM, V86, P421, DOI 10.1016/0041-008X(86)90369-8; WONG KP, 1991, BIOCHEM PHARMACOL, V41, P63; YU M, 1989, ARCH BIOCHEM BIOPHYS, V269, P156, DOI 10.1016/0003-9861(89)90096-9; ZARUBA ME, 1988, BIOCHEM BIOPH RES CO, V155, P1271, DOI 10.1016/S0006-291X(88)81278-6	116	241	254	2	48	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1997	11	6					404	418		10.1096/fasebj.11.6.9194521	http://dx.doi.org/10.1096/fasebj.11.6.9194521			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XE404	9194521				2022-12-28	WOS:A1997XE40400003
J	LazarovSpiegler, O; Solomon, AS; ZeevBrann, AB; Hirschberg, DL; Lavie, V; Schwartz, M				LazarovSpiegler, O; Solomon, AS; ZeevBrann, AB; Hirschberg, DL; Lavie, V; Schwartz, M			Transplantation of activated macrophages overcomes central nervous system regrowth failure	FASEB JOURNAL			English	Article						CNS; immunosuppression; inflammation; regeneration	RETINAL GANGLION-CELLS; AXONAL REGENERATION; NEURITE GROWTH; SPINAL-CORD; ADULT-RATS; INJURY; OLIGODENDROCYTES; DEGENERATION; MICROGLIA; TRANSGLUTAMINASE	Macrophages have long been known to play a key role in the healing processes of tissues that regenerate after injury; however, the nature of their involvement in healing of the injured central nervous system (CNS) is still a subject of controversy, Here we show that the absence of regrowth in transected rat optic nerve (which, like all other CNS nerves in mammals, cannot regenerate after injury) can be overcome by local transplantation of macrophages preincubated ex vivo with segments of a nerve (e.g., sciatic nerve) that can regenerate after injury, The observed effect of the transplanted macrophages was found to be an outcome of their stimulated activity, as indicated by phagocytosis, Thus, macrophage phagocytic activity was stimulated by their preincubation with sciatic nerve segments but inhibited by their preincubation with optic nerve segments. We conclude that the inability of nerves of the mammalian CNS to regenerate is related to the failure of their macrophages recruited after injury to acquire growth-supportive activity. We attribute this failure to the presence of a CNS resident macrophage inhibitory activity, which may be the biochemical basis underlying the immune privilege of the CNS, The transplantation of suitably activated macrophages into injured nerves may overcome multiple malfunctioning aspects of the CNS response to trauma, and thus may be developed into a novel, practical, and multipotent therapy for CNS injuries.	WEIZMANN INST SCI, DEPT NEUROBIOL, IL-76100 REHOVOT, ISRAEL; TEL AVIV UNIV, SACKLER SCH MED, SHEBA MED CTR, GOLDSCHLEGER EYE RES INST, TEL HASHOMER, ISRAEL	Weizmann Institute of Science; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine			Solomon, Arieh/AAF-4361-2021; Lazarov, Orly/F-9406-2015	Lazarov, Orly/0000-0002-5887-948X				ANDREESEN R, 1983, J IMMUNOL METHODS, V56, P295, DOI 10.1016/S0022-1759(83)80019-2; [Anonymous], 1959, DEGENERATION REGENER; BANDTLOW C, 1990, J NEUROSCI, V10, P3837, DOI 10.1523/JNEUROSCI.10-12-03837.1990; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; CADELLI DS, 1992, EXP NEUROL, V115, P189, DOI 10.1016/0014-4886(92)90246-M; CHEN DF, 1995, P NATL ACAD SCI USA, V92, P7287, DOI 10.1073/pnas.92.16.7287; COLOTTA F, 1984, J IMMUNOL, V132, P936; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; EITAN S, 1992, P NATL ACAD SCI USA, V89, P5442, DOI 10.1073/pnas.89.12.5442; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; FABERELMAN A, 1995, J NEUROCHEM, V65, P1524; GARCIAVALENZUELA E, 1994, J NEUROBIOL, V25, P431, DOI 10.1002/neu.480250408; GEORGE R, 1994, EXP NEUROL, V129, P225, DOI 10.1006/exnr.1994.1164; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; HAREL A, 1989, J NEUROCHEM, V52, P1218, DOI 10.1111/j.1471-4159.1989.tb01869.x; HEUMANN R, 1987, P NATL ACAD SCI USA, V84, P8735, DOI 10.1073/pnas.84.23.8735; HIRSCHBERG DL, 1994, J NEUROIMMUNOL, V50, P9, DOI 10.1016/0165-5728(94)90209-7; HIRSCHBERG DL, 1995, J NEUROIMMUNOL, V61, P89, DOI 10.1016/0165-5728(95)00087-I; LAVIE V, 1992, BRAIN RES, V575, P1, DOI 10.1016/0006-8993(92)90415-6; LOTAN M, 1994, EXP NEUROL, V126, P284, DOI 10.1006/exnr.1994.1066; LOTAN M, 1994, FASEB J, V8, P1026, DOI 10.1096/fasebj.8.13.7926367; MERRILL JE, 1995, FASEB J, V9, P611, DOI 10.1096/fasebj.9.8.7768352; MULLER HW, 1985, SCIENCE, V228, P499, DOI 10.1126/science.3983637; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHWARTZ M, 1989, FASEB J, V3, P2371, DOI 10.1096/fasebj.3.12.2676680; SMITH GM, 1987, ANN NY ACAD SCI, V495, P185, DOI 10.1111/j.1749-6632.1987.tb23675.x; STOLL G, 1986, NEUROSCI LETT, V72, P233, DOI 10.1016/0304-3940(86)90519-7; STREILEIN JW, 1993, CURR OPIN IMMUNOL, V5, P428, DOI 10.1016/0952-7915(93)90064-Y; THANOS S, 1991, EUR J NEUROSCI, V3, P1189, DOI 10.1111/j.1460-9568.1991.tb00054.x; THANOS S, 1993, J NEUROSCI, V13, P455; THOMAS WE, 1992, BRAIN RES REV, V17, P61; VANFURTH R, 1985, COMP IMMUNOL MICROB, V8, P205, DOI 10.1016/0147-9571(85)90045-1; VIDALSANZ M, 1988, EXP NEUROL, V102, P92, DOI 10.1016/0014-4886(88)90081-7; VILLEGASPEREZ MP, 1988, J NEUROSCI, V8, P265	38	214	228	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1996	10	11					1296	1302		10.1096/fasebj.10.11.8836043	http://dx.doi.org/10.1096/fasebj.10.11.8836043			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VJ717	8836043				2022-12-28	WOS:A1996VJ71700009
J	Conrad, KP; Benyo, DF; WesterhausenLarsen, A; Miles, TM				Conrad, KP; Benyo, DF; WesterhausenLarsen, A; Miles, TM			Expression of erythropoietin by the human placenta	FASEB JOURNAL			English	Article						syncytiotrophoblast; cytotrophoblast; JAR choriocarcinoma cells; hypoxia; pregnancy; preeclampsia	COLONY-STIMULATING FACTOR; CONSCIOUS RATS; INSITU HYBRIDIZATION; GENE-EXPRESSION; CELLS; MACROPHAGE; PREGNANCY; DIFFERENTIATION; HEMODYNAMICS; TROPHOBLAST	Circulating levels of maternal erythropoietin (EPO) rise during gestation due to increased biosynthesis of the hormone, Our objective was to investigate the human placenta as a potential extrarenal site of EPO production, Using two monoclonal antibodies recognizing different antigenic determinants, we identified immunoreactive EPO associated with villous cytotrophoblast, endovascular and intravascular cytotrophoblast, cytotrophoblast cell colunms, and syncytiotrophoblast of first and second-trimester placenta as well as syncytiotrophoblast and extravillous cytotrophoblast of normal third-trimester and preeclamptic placenta, In addition, cultured JAR (trophoblast-derived) choriocarcinoma cells, cytotrophoblasts isolated from term placenta, villous core cells, and possibly other nontrophoblast cells within the decidual basal plate expressed immunoreactive EPO, Using reverse transcription-polymerase chain reaction and EPO-specific primers, a 378 bp DNA product was amplified from placental tissues of various gestational ages, cytotrophoblasts isolated from term placenta, and JAR choriocarcinoma cells, The amplified product yielded restriction enzyme fragments of predicted sizes, On Southern analysis, hybridization was observed for two of these fragments in which the radiolabeled EPO cDNA probe did not overlap with the primer sequences, Finally, the JAR choriocarcinoma cells elaborated EPO into the culture medium as determined by enzyme-linked immunosorbant assay and expressed EPO mRNA as determined by Northern analysis, both of which were stimulated by hypoxia (15-20 torr), Taken together, these results suggest a new site of EPO expression: the trophoblast cell of the human placenta.	UNIV PITTSBURGH,DEPT OBSTET GYNECOL & REPROD SCI,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Conrad, KP (corresponding author), MAGEE WOMENS RES INST,204 CRAFT AVE,PITTSBURGH,PA 15213, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030325, K04HD001098] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD30325, K04 HD01098] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANAGNOSTOU A, 1990, P NATL ACAD SCI USA, V87, P5978, DOI 10.1073/pnas.87.15.5978; BACHMANN S, 1993, J HISTOCHEM CYTOCHEM, V41, P335, DOI 10.1177/41.3.8429197; BONDURANT MC, 1991, SEMIN HEMATOL, V28, P20; CARLINI RG, 1995, KIDNEY INT, V47, P740, DOI 10.1038/ki.1995.113; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CONRAD KP, 1984, KIDNEY INT, V26, P24, DOI 10.1038/ki.1984.129; CONRAD KP, 1992, UROL ANN, V6, P313; DELVALLE GO, 1993, AM J PHYSIOL, V265, pR399, DOI 10.1152/ajpregu.1993.265.2.R399; FRANDREY J, 1993, BLOOD, V81, P617; GARCIALLORET MI, 1994, EXP CELL RES, V214, P46, DOI 10.1006/excr.1994.1232; GILSON GJ, 1992, AM J PHYSIOL, V263, pH1911, DOI 10.1152/ajpheart.1992.263.6.H1911; GOUGH SR, 1995, AM J PHYSIOL-REG I, V268, pR1117, DOI 10.1152/ajpregu.1995.268.5.R1117; GUILBERT L, 1993, IMMUNOL CELL BIOL, V71, P49, DOI 10.1038/icb.1993.5; HERMINE O, 1991, BLOOD, V78, P2253; HUCH R, 1993, ANN MED, V25, P289; JELKMANN W, 1994, CLIN INVESTIGATOR, V72, pS3; KLIMAN HJ, 1986, ENDOCRINOLOGY, V118, P1567, DOI 10.1210/endo-118-4-1567; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; KOURY ST, 1993, MICROSC RES TECHNIQ, V25, P29, DOI 10.1002/jemt.1070250106; LONGO LD, 1983, AM J PHYSIOL, V245, pR720, DOI 10.1152/ajpregu.1983.245.5.R720; MASUDA S, 1994, J BIOL CHEM, V269, P19488; *NAT HIGH BLOOD PR, 1991, 913029 NIH; OHLS RK, 1994, PEDIATR RES, V35, P169, DOI 10.1203/00006450-199402000-00008; PEKONEN F, 1987, ACTA ENDOCRINOL-COP, V116, P561, DOI 10.1530/acta.0.1160561; PRITCHARD JA, 1960, AM J OBSTET GYNECOL, V79, P750, DOI 10.1016/0002-9378(60)90633-5; SAITO S, 1993, GROWTH FACTORS, V9, P11, DOI 10.3109/08977199308991578; SAITO S, 1991, BIOCHEM BIOPH RES CO, V178, P1099, DOI 10.1016/0006-291X(91)91005-W; SAWYER ST, 1989, BLOOD, V74, P103; SHIRAMIZU M, 1994, EXP CELL RES, V215, P249, DOI 10.1006/excr.1994.1340; UENO M, 1989, AM J PHYSIOL, V257, pC743, DOI 10.1152/ajpcell.1989.257.4.C743; VOGT C, 1989, EXP HEMATOL, V17, P391; WIDNESS JA, 1991, J DEV PHYSIOL, V15, P139; WOGNUM AW, 1990, EXP HEMATOL, V18, P228; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223; ZANJANI ED, 1974, J LAB CLIN MED, V83, P281; ZANJANI ED, 1977, J LAB CLIN MED, V89, P640	37	106	111	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1996	10	7					760	768		10.1096/fasebj.10.7.8635693	http://dx.doi.org/10.1096/fasebj.10.7.8635693			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UN798	8635693				2022-12-28	WOS:A1996UN79800010
J	RUGGERI, ZM; WARE, J				RUGGERI, ZM; WARE, J			VONWILLEBRAND-FACTOR	FASEB JOURNAL			English	Review						MOLECULAR CLONING; GENE STRUCTURE; A-DOMAIN; LIGAND; MEGAKARYOCYTE	VON-WILLEBRAND FACTOR; PLATELET GLYCOPROTEIN-IB; WEIBEL-PALADE BODIES; FACTOR-VIII; FACTOR BINDING; IIB-IIIA; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; FACTOR MULTIMERS; FACTOR GENE	von Willebrand factor is a multimeric glycoprotein essential for the normal arrest of bleeding after tissue injury (hemostasis). The molecule is present in blood, both in plasma and inside platelets, as well as in endothelial cells and the subendothelial matrix of the vessel wall. Through multiple functional domains, von Willebrand factor mediates the attachment of platelets to exposed tissues, where discontinuity of the vascular endothelium occurs, and the subsequent platelet aggregation leading to the formation of platelet thrombi. The crucial role of von Willebrand factor in platelet function is particularly apparent when hemodynamic conditions create blood flow with high shear stress, as in capillaries under physiologic conditions or in stenosed and partially occluded arteries in disease states. The involvement of von Willebrand factor in the processes that lead to acute thrombosis has attracted considerable interest on the molecular and functional biology of the protein. Indeed, understanding the mechanisms and structural bases for von Willebrand factor function may result in new and effective approaches to anti-thrombotic intervention.	SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	RUGGERI, ZM (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV EXPTL THROMBOSIS & HEMOSTASIS, LA JOLLA, CA 92037 USA.				NHLBI NIH HHS [R01 HL050545-06, R01 HL050545] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050545] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAHOU WF, 1989, J CLIN INVEST, V84, P56, DOI 10.1172/JCI114169; BERLINER S, 1988, J BIOL CHEM, V263, P7500; BERNDT MC, 1991, THROMB HAEMOSTASIS, V65, P748; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; CAREW JA, 1990, BLOOD, V76, P2530; CHRISTOPHE O, 1991, BLOOD, V78, P2310; COLOMBATTI A, 1991, BLOOD, V77, P2305; CRAMER EM, 1985, BLOOD, V66, P710; DENT JA, 1991, J CLIN INVEST, V88, P774, DOI 10.1172/JCI115376; FAUVEL F, 1983, P NATL ACAD SCI-BIOL, V80, P551, DOI 10.1073/pnas.80.2.551; FAY PJ, 1986, SCIENCE, V232, P995, DOI 10.1126/science.3486471; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FOWLER WE, 1985, J CLIN INVEST, V76, P1491, DOI 10.1172/JCI112129; FOWLER WE, 1989, COAGULATION BLEEDING, P181; GAUCHER C, 1991, BRIT J HAEMATOL, V78, P506, DOI 10.1111/j.1365-2141.1991.tb04480.x; GINSBURG D, 1985, SCIENCE, V228, P1401, DOI 10.1126/science.3874428; HADA M, 1986, BLOOD, V68, P95; HANDIN RI, 1989, PROG HEMOST THROMB, V9, P233; HANTGAN RR, 1990, BLOOD, V76, P345; HILLEUBANKS DC, 1990, J BIOL CHEM, V265, P17854; HUNT LT, 1987, BIOCHEM BIOPH RES CO, V144, P876, DOI 10.1016/S0006-291X(87)80046-3; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; LEYTE A, 1991, BIOCHEM J, V274, P257, DOI 10.1042/bj2740257; LOSCALZO J, 1986, J CLIN INVEST, V78, P1112, DOI 10.1172/JCI112668; MANCUSO DJ, 1991, BIOCHEMISTRY-US, V30, P253, DOI 10.1021/bi00215a036; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MAYADAS TN, 1991, ANN NY ACAD SCI, V614, P153, DOI 10.1111/j.1749-6632.1991.tb43700.x; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MOHRI H, 1988, J BIOL CHEM, V263, P17901; PARETI FI, 1987, J BIOL CHEM, V262, P13835; PARKER RI, 1987, BLOOD, V70, P1589; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; RAND JH, 1991, J CLIN INVEST, V88, P253, DOI 10.1172/JCI115285; RIBES JA, 1990, BLOOD, V75, P1460; ROBERTS DD, 1986, J BIOL CHEM, V261, P3306; ROTH GJ, 1986, BIOCHEMISTRY-US, V25, P8357, DOI 10.1021/bi00374a004; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SHELTONINLOES BB, 1986, BIOCHEMISTRY-US, V25, P3164, DOI 10.1021/bi00359a014; SUGIMOTO M, 1991, BIOCHEMISTRY-US, V30, P5202, DOI 10.1021/bi00235a013; SUGIMOTO M, 1991, J BIOL CHEM, V266, P18172; TAKAGI J, 1991, J BIOL CHEM, V266, P5575; TANNENBAUM SH, 1990, BLOOD, V75, P2177; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; TSAI HM, 1989, BIOCHEM BIOPH RES CO, V158, P980, DOI 10.1016/0006-291X(89)92818-0; TURITTO VT, 1985, BLOOD, V65, P823; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; VOORBERG J, 1991, THROMB HAEMOSTASIS, V65, P969; WAGNER DD, 1991, CELL, V64, P403, DOI 10.1016/0092-8674(91)90648-I; WAGNER DD, 1989, COAGULATION BLEEDING, P161; WARE J, 1991, P NATL ACAD SCI USA, V88, P2946, DOI 10.1073/pnas.88.7.2946; WEINSTEIN MJ, 1989, BRIT J HAEMATOL, V72, P68, DOI 10.1111/j.1365-2141.1989.tb07654.x; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; WION KL, 1985, NATURE, V317, P726, DOI 10.1038/317726a0; WISE RJ, 1991, J BIOL CHEM, V266, P21948; WISE RJ, 1988, CELL, V52, P229, DOI 10.1016/0092-8674(88)90511-9	59	251	264	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB 1	1993	7	2					308	316		10.1096/fasebj.7.2.8440408	http://dx.doi.org/10.1096/fasebj.7.2.8440408			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KN885	8440408				2022-12-28	WOS:A1993KN88500006
J	Suzuki, N; Mihara, S; Sakane, T				Suzuki, N; Mihara, S; Sakane, T			Development of pathogenic anti-DNA antibodies in patients with systemic lupus erythematosus	FASEB JOURNAL			English	Article						cationic; somatic mutation; germline V kappa gene	GERM-LINE; B-CELLS; NUCLEOTIDE-SEQUENCE; NEGATIVE SELECTION; CROSS-REACTIVITY; SOMATIC MUTATION; VARIABLE REGIONS; ESCAPE TOLERANCE; AUTOIMMUNE MICE; MURINE MODELS	The anti-DNA response is a hallmark of systemic lupus erythematosus (SLE). The precise mechanisms leading to anti-DNA antibody (Ab) production remain to be studied. Nonetheless, it is becoming clear that anti-DNA Abs cause inflammatory lesions not only via deposition of circulating immune complexes (IC) consisting of anti-DNA Ab and antigens (Ags), but also via in situ IC formation by cationic anti-DNA Abs. It is intriguing that cationic anti-DNA Abs are encoded by a unique germline V kappa gene, A30, which encodes an extraordinary cationic light chain, whereas somatic mutations did not induce a cationic shift of electrical charge in human lupus nephritis, suggesting that the usage of a specific germline gene may confer the cationic charge (or pathogenicity) on anti-DNA Abs and that somatic mutations induce the affinity maturation of Abs. Whether cationic anti-DNA Abs will develop depends at least partly on the presence or absence of the germline A30 gene, since patients who lack this gene in the germline V kappa repertoire did not develop severe lupus nephritis. Receptor editing, a mechanism for changing the affinity of the B cell Ag receptor [surface immunoglobulin (Ig) receptor] to avoid self-reactivity actually seems defective in patients with SLE because normal B cells edited the A30 mRNA. Thus, along with the importance of somatic mutations, polymorphisms of Ig V kappa locus, and genetic predisposition, the failure of receptor editing may contribute to the development of pathogenic anti-DNA responses in humans.	ST MARIANNA UNIV,SCH MED,DEPT MED,MIYAMAE KU,KAWASAKI,KANAGAWA 216,JAPAN	Saint Marianna University	Suzuki, N (corresponding author), ST MARIANNA UNIV,SCH MED,DEPT IMMUNOL,MIYAMAE KU,2-16-1 SUGAO,KAWASAKI,KANAGAWA 216,JAPAN.							ANDRZEJEWSKI C, 1981, J IMMUNOL, V126, P226; BACCALA R, 1989, P NATL ACAD SCI USA, V86, P4624, DOI 10.1073/pnas.86.12.4624; BEHAR SM, 1991, J EXP MED, V173, P731, DOI 10.1084/jem.173.3.731; BENSIMON C, 1994, EMBO J, V13, P2951, DOI 10.1002/j.1460-2075.1994.tb06593.x; BRINKMAN K, 1990, IMMUNOL TODAY, V11, P232, DOI 10.1016/0167-5699(90)90095-Q; BRUNEAU C, 1979, J CLIN INVEST, V64, P191, DOI 10.1172/JCI109439; Chen C, 1995, IMMUNITY, V3, P747, DOI 10.1016/1074-7613(95)90064-0; Cyster JG, 1996, NATURE, V381, P325, DOI 10.1038/381325a0; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DATTA SK, 1987, J EXP MED, V165, P1252, DOI 10.1084/jem.165.5.1252; DECKMYN H, 1994, BLOOD, V84, P1968; DIAMOND B, 1992, ANNU REV IMMUNOL, V10, P731, DOI 10.1146/annurev.iy.10.040192.003503; EBLING F, 1980, ARTHRITIS RHEUM, V23, P392, DOI 10.1002/art.1780230402; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; FAABER P, 1986, J CLIN INVEST, V77, P1824, DOI 10.1172/JCI112508; Fanning LJ, 1996, CLIN IMMUNOL IMMUNOP, V79, P1, DOI 10.1006/clin.1996.0044; GAUTHIER VJ, 1990, J IMMUNOL, V145, P3348; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; GHIA P, 1995, EUR J IMMUNOL, V25, P3108, DOI 10.1002/eji.1830251118; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HARADA T, 1994, J IMMUNOL, V153, P4806; HUBER C, 1993, EUR J IMMUNOL, V23, P2868, DOI 10.1002/eji.1830231121; HUBER C, 1993, EUR J IMMUNOL, V23, P2860, DOI 10.1002/eji.1830231120; ISENBERG DA, 1994, ARTHRITIS RHEUM-US, V37, P169, DOI 10.1002/art.1780370204; JACOB L, 1985, J CLIN INVEST, V75, P315, DOI 10.1172/JCI111692; KAUSHIK A, 1988, SCAND J IMMUNOL, V27, P461, DOI 10.1111/j.1365-3083.1988.tb02372.x; KLEIN R, 1993, EUR J IMMUNOL, V23, P3248, DOI 10.1002/eji.1830231231; KRAMERS C, 1994, J CLIN INVEST, V94, P568, DOI 10.1172/JCI117371; KUNICKI TJ, 1991, J AUTOIMMUN, V4, P433, DOI 10.1016/0896-8411(91)90157-8; LAFER EM, 1981, J EXP MED, V153, P897, DOI 10.1084/jem.153.4.897; Lang J, 1996, J EXP MED, V184, P1685, DOI 10.1084/jem.184.5.1685; LAUTNERRIESKE A, 1992, EUR J IMMUNOL, V22, P1023, DOI 10.1002/eji.1830220422; MADAIO MP, 1987, J IMMUNOL, V138, P2883; MANSER T, 1987, J EXP MED, V166, P1456, DOI 10.1084/jem.166.5.1456; MARION TN, 1992, IMMUNOL REV, V128, P123, DOI 10.1111/j.1600-065X.1992.tb00835.x; MELCHERS F, 1995, CURR OPIN IMMUNOL, V7, P214, DOI 10.1016/0952-7915(95)80006-9; MOHAN C, 1993, J EXP MED, V177, P1367, DOI 10.1084/jem.177.5.1367; NAPARSTEK Y, 1985, J EXP MED, V161, P1525, DOI 10.1084/jem.161.6.1525; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; OKEEFE TL, 1992, EUR J IMMUNOL, V22, P619, DOI 10.1002/eji.1830220302; PARGENT W, 1991, EUR J IMMUNOL, V21, P1829, DOI 10.1002/eji.1830210808; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; PISETSKY DS, 1982, MOL IMMUNOL, V19, P645, DOI 10.1016/0161-5890(82)90364-9; POLYMENIS M, 1995, J IMMUNOL, V154, P2198; PRAK EL, 1994, J EXP MED, V180, P1805, DOI 10.1084/jem.180.5.1805; RADA C, 1991, P NATL ACAD SCI USA, V88, P5508, DOI 10.1073/pnas.88.13.5508; RADIC MZ, 1994, ANNU REV IMMUNOL, V12, P487, DOI 10.1146/annurev.iy.12.040194.002415; RADIC MZ, 1993, J EXP MED, V177, P1165, DOI 10.1084/jem.177.4.1165; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RAZ E, 1989, J IMMUNOL, V142, P3076; RIOUX JD, 1995, MOL IMMUNOL, V32, P683, DOI 10.1016/0161-5890(95)00045-G; Rothfield Naomi F., 1993, P1155; SCHOENFELD Y, 1983, NEW ENGL J MED, V308, P414; SHEFNER R, 1991, J EXP MED, V173, P287, DOI 10.1084/jem.173.2.287; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; SMITH HR, 1983, ANNU REV IMMUNOL, V1, P175, DOI 10.1146/annurev.iy.01.040183.001135; SUZUKI N, 1993, J IMMUNOL, V151, P1128; Suzuki N, 1996, J CLIN INVEST, V98, P1843, DOI 10.1172/JCI118985; Tan Eng M., 1993, P1179; THEOFILOPOULOS AN, 1985, ADV IMMUNOL, V37, P269, DOI 10.1016/S0065-2776(08)60342-9; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TILLMAN DM, 1992, J EXP MED, V176, P761, DOI 10.1084/jem.176.3.761; VANES JH, 1991, J EXP MED, V173, P461, DOI 10.1084/jem.173.2.461; WOODS VL, 1989, TXB RHEUMATOLOGY, V2, P1077; ZOUALI M, 1989, EUR J IMMUNOL, V19, P1757, DOI 10.1002/eji.1830190934	66	31	33	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1997	11	12					1033	1038		10.1096/fasebj.11.12.9337156	http://dx.doi.org/10.1096/fasebj.11.12.9337156			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YA724	9337156				2022-12-28	WOS:A1997YA72400013
J	Node, K; Kitakaze, M; Kosaka, H; Minamino, T; Sato, H; Kuzuya, T; Hori, M				Node, K; Kitakaze, M; Kosaka, H; Minamino, T; Sato, H; Kuzuya, T; Hori, M			Roles of NO and Ca2+-activated K+ channels in coronary vasodilation induced by 17 beta-estradiol in ischemic heart failure	FASEB JOURNAL			English	Article						nitric oxide; myocardial ischemia; coronary blood flow	NITRIC-OXIDE; POSTMENOPAUSAL WOMEN; MYOCARDIAL-ISCHEMIA; SMOOTH-MUSCLE; ESTROGEN; ARTERY; RELEASE; CONDUCTANCE; ENDOTHELIUM; RELAXATION	Estrogen induces the generation of nitric oxide (NO) and produces coronary vasodilation by opening the Ca2+-activated K+ (K-Ca) channels, The hypothesis that 17 beta-estradiol produces NO and activates K-Ca channels during coronary hypoperfusion was investigated, In open-chest dogs, the left anterior descending coronary artery was perfused through an extracorporeal bypass tube from the left carotid artery, 17 beta-Estradiol was infused into the bypass tube for 20 min after coronary blood flow was reduced by partial occlusion of the bypass tube, 17 beta-Estradiol increased the difference in NO concentrations between the coronary venous and arterial blood as well as coronary blood flow, The lactate extraction ratio and pH of coronary venous blood were both also increased by 17 beta-estradiol, indicating a reduction in myocardial anaerobic metabolism, Whereas the increase in the coronary arteriovenous difference in NO concentration was completely attenuated by N-G-nitro-L-arginine methyl ester (L-NAME, an inhibitor of NO synthase), the increase in coronary blood flow induced by 17 beta-estradiol was only partially attenuated by L-NAME. The combination of L-NAME and iberiotoxin (a blocker of high-conductance K-Ca channels) completely abolished the coronary vasodilatory effect of 17 beta-estradiol, The data indicate that during coronary hypoperfusion in canine hearts, 17 beta-estradiol increases coronary blood flow and improves metabolic dysfunction by increasing NO release and opening K-Ca channels.	OSAKA UNIV,SCH MED,DEPT MED 1,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT PHYSIOL 1,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University			Kuzuya, Teiji/ABG-8786-2021					ABRAHAM GE, 1972, J CLIN ENDOCR METAB, V34, P312, DOI 10.1210/jcem-34-2-312; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; COLLINS P, 1994, CIRCULATION, V90, P1964, DOI 10.1161/01.CIR.90.4.1964; COWAN CL, 1991, AM J PHYSIOL, V261, pH830, DOI 10.1152/ajpheart.1991.261.3.H830; GILLIGAN DM, 1994, CIRCULATION, V89, P2545, DOI 10.1161/01.CIR.89.6.2545; HAN SZ, 1995, CIRCULATION, V91, P2619, DOI 10.1161/01.CIR.91.10.2619; HARDER DR, 1979, J CELL PHYSIOL, V100, P375, DOI 10.1002/jcp.1041000218; HAYASHI T, 1995, BIOCHEM BIOPH RES CO, V214, P847, DOI 10.1006/bbrc.1995.2364; HUTCHESON IR, 1994, AM J PHYSIOL, V266, pH590, DOI 10.1152/ajpheart.1994.266.2.H590; IVERSEN LL, 1973, BRIT MED BULL, V29, P130, DOI 10.1093/oxfordjournals.bmb.a070982; JIANG C, 1992, BRIT J PHARMACOL, V106, P739, DOI 10.1111/j.1476-5381.1992.tb14403.x; KOHNO Y, 1993, HYPERTENSION, V22, P34; MA XL, 1993, CIRC RES, V72, P403, DOI 10.1161/01.RES.72.2.403; MORI H, 1992, AM J PHYSIOL, V263, pH1946, DOI 10.1152/ajpheart.1992.263.6.H1946; NAGAO T, 1992, J PHYSIOL-LONDON, V445, P355, DOI 10.1113/jphysiol.1992.sp018928; Node K, 1997, CIRCULATION, V95, P1560; Node K, 1996, CIRCULATION, V93, P356, DOI 10.1161/01.CIR.93.2.356; NODE K, 1995, BIOCHEM BIOPH RES CO, V211, P370, DOI 10.1006/bbrc.1995.1823; ROSANO GMC, 1993, LANCET, V342, P133, DOI 10.1016/0140-6736(93)91343-K; RUSKO J, 1995, BIOCHEM BIOPH RES CO, V214, P367, DOI 10.1006/bbrc.1995.2297; SACK MN, 1994, LANCET, V343, P269, DOI 10.1016/S0140-6736(94)91117-7; SAKUMA I, 1992, CIRC RES, V70, P607, DOI 10.1161/01.RES.70.3.607; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; SUDHIR K, 1995, J AM COLL CARDIOL, V26, P807, DOI 10.1016/0735-1097(95)00248-3; VARGAS R, 1993, BRIT J PHARMACOL, V109, P612, DOI 10.1111/j.1476-5381.1993.tb13616.x; WADA A, 1995, N-S ARCH PHARMACOL, V352, P545; WHITE RE, 1995, CIRC RES, V77, P936, DOI 10.1161/01.RES.77.5.936; YAO SK, 1995, CIRCULATION, V92, P1005, DOI 10.1161/01.CIR.92.4.1005	28	59	62	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1997	11	10					793	799		10.1096/fasebj.11.10.9271364	http://dx.doi.org/10.1096/fasebj.11.10.9271364			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XR105	9271364				2022-12-28	WOS:A1997XR10500009
J	Lubec, B; Marx, M; HerreraMarschitz, M; Labudova, O; Hoeger, H; Gille, L; Nohl, H; Mosgoeller, W; Lubec, G				Lubec, B; Marx, M; HerreraMarschitz, M; Labudova, O; Hoeger, H; Gille, L; Nohl, H; Mosgoeller, W; Lubec, G			Decrease of heart protein kinase C and cyclin-dependent kinase precedes death in perinatal asphyxia of the rat	FASEB JOURNAL			English	Article						neonatal; oxidative stress; antioxidant enzymes; superoxide dismutase; catalase; glutathione peroxidase; lipid peroxidation; malondialdehyde; protein carbonyls; electron spin resonance	TRANSIENT FOREBRAIN ISCHEMIA; CEREBRAL-ISCHEMIA; NEURONAL DAMAGE; BRAIN ISCHEMIA; IN-VITRO; PHOSPHORYLATION; OXIDATION; ACIDOSIS; CELL; DYSFUNCTION	Acidosis, energy depletion, overstimulation by excitatory amino acids, and free radical-mediated reactions are the major current concepts for the explanation of damage and death resulting from asphyxia. Impaired phosphorylation by protein kinase C (PKC) represents another mechanism incriminated for cell death. We used an unsophisticated perinatal asphyxia model to study heart protein kinases PKC and cyclin dependent kinase (CDK). Tissue pH, ATP, the antioxidant enzymes superoxide dismutase, catalase, and glutathion peroxidase, Lipid peroxidation products, carbonyls, and aromatic hydroxylation were also tested. Electron spin resonance was applied to demonstrate the possible presence of radical adducts. An ELISA method was used to determine cell death. PKC activity and mRNA decreased with the length of the asphyctic periods and were paralleled by CDK and pH, whereas cell death gradually increased. No evidence was found for the involvement of active oxygen species or a radical adduct, and no energy depletion was observed. We conclude that impaired protein phosphorylation and/or acidosis may play a role in the pathobiochemistry of death from perinatal asphyxia in the rat.	UNIV VIENNA,DEPT PEDIAT,DIV NEONATOL,A-1090 VIENNA,AUSTRIA; KAROLINSKA INST,DEPT PHARMACOL,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST ANIM BREEDING,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DEPT PHARMACOL,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DEPT HISTOL,A-1090 VIENNA,AUSTRIA	University of Vienna; University of Vienna; University of Vienna; University of Vienna				Lubec, Gert/0000-0002-6333-9461; Mosgoller, Wilhelm/0000-0003-1436-1504				ARONOWSKI J, 1992, J NEUROCHEM, V58, P1743, DOI 10.1111/j.1471-4159.1992.tb10049.x; Baran H, 1996, LIFE SCI, V58, P1891, DOI 10.1016/0024-3205(96)00173-7; BARKS JDE, 1992, BRAIN PATHOL, V2, P235, DOI 10.1111/j.1750-3639.1992.tb00697.x; BATIST G, 1989, CIRCULATION, V80, P10; BJELKE B, 1991, BRAIN RES, V543, P1, DOI 10.1016/0006-8993(91)91041-X; BOLLI R, 1987, AM J PHYSIOL, V253, pH1372, DOI 10.1152/ajpheart.1987.253.6.H1372; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; BUSTO R, 1994, J NEUROCHEM, V63, P1095; CARDELL M, 1990, NEUROSCI LETT, V119, P228, DOI 10.1016/0304-3940(90)90840-6; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Cohen MV, 1996, ANNU REV MED, V47, P21, DOI 10.1146/annurev.med.47.1.21; COVA D, 1992, FREE RADICAL RES COM, V15, P353, DOI 10.3109/10715769209049151; DELLANNA E, 1995, EXP NEUROL, V131, P279, DOI 10.1016/0014-4886(95)90050-0; DELLANNA E, IN PRESS EXP BRAIN R; DELLANNA ME, 1995, EXP NEUROL, V131, P144, DOI 10.1016/0014-4886(95)90016-0; DOMANSKAJANIK K, 1992, J NEUROCHEM, V58, P1432, DOI 10.1111/j.1471-4159.1992.tb11360.x; ERECINSKA M, 1989, J CEREBR BLOOD F MET, V9, P2, DOI 10.1038/jcbfm.1989.2; GOPLERUD JM, 1995, BRAIN RES, V696, P161, DOI 10.1016/0006-8993(95)00861-J; HARA H, 1990, NEUROSCI LETT, V120, P120, DOI 10.1016/0304-3940(90)90183-A; Hayn M, 1996, LIFE SCI, V59, P537, DOI 10.1016/0024-3205(96)00334-7; Henry P, 1996, CIRC RES, V78, P161, DOI 10.1161/01.RES.78.1.161; HERRERAMARSCHITZ M, 1994, MOL NEUROBIOL, V9, P171, DOI 10.1007/BF02816117; Hu KL, 1996, CIRC RES, V78, P492, DOI 10.1161/01.RES.78.3.492; HU YRF, 1993, NEUROCHEM RES, V18, P1003; INGWALL JS, 1975, P NATL ACAD SCI USA, V72, P2809, DOI 10.1073/pnas.72.7.2809; JAHNEL U, 1992, N-S ARCH PHARMACOL, V346, P665; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; Kwak BR, 1996, MOL CELL BIOCHEM, V157, P93; LEIST M, 1994, J IMMUNOL, V153, P1778; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LEVINE RL, 1993, FASEB J, V7, P1242, DOI 10.1096/fasebj.7.13.8405809; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LOUIS JC, 1988, J BIOL CHEM, V263, P19282; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lubec B, 1996, FREE RADICAL BIO MED, V21, P219, DOI 10.1016/0891-5849(96)00018-4; Lubec B, 1996, CIRCULATION, V94, P2620, DOI 10.1161/01.CIR.94.10.2620; LUBEC G, 1994, FASEB J, V8, P1166, DOI 10.1096/fasebj.8.14.7958623; Lubec G, 1996, J INVEST MED, V44, P324; MAYER RJ, 1987, CELL MOL BIOL, P259; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MELLONI E, 1985, P NATL ACAD SCI USA, V82, P6435, DOI 10.1073/pnas.82.19.6435; MITCHELL MB, 1995, CIRC RES, V76, P73, DOI 10.1161/01.RES.76.1.73; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ODONNELL BR, 1994, STROKE, V25, P171, DOI 10.1161/01.STR.25.1.171; PAIN VM, 1986, BIOCHEM J, V235, P625, DOI 10.1042/bj2350625; PUCEAT M, 1996, MOL CELL BIOCHEM, V157, P655; QU Y, 1992, CAN J PHYSIOL PHARM, V70, P1230, DOI 10.1139/y92-171; REHNCRONA S, 1980, ACTA PHYSIOL SCAND, V110, P435, DOI 10.1111/j.1748-1716.1980.tb06692.x; Rehring TF, 1996, J SURG RES, V63, P324, DOI 10.1006/jsre.1996.0269; RICHARDSON RM, 1992, J BIOL CHEM, V267, P10127; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; Shuba LM, 1996, BRIT J PHARMACOL, V117, P1395, DOI 10.1111/j.1476-5381.1996.tb15298.x; SIESJO BK, 1988, CRIT CARE MED, V16, P954, DOI 10.1097/00003246-198810000-00006; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIESJO BK, 1990, STROKE, V21, P194; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPEECHLYDICK ME, 1995, CIRC RES, V77, P1030, DOI 10.1161/01.RES.77.5.1030; SWANSON RA, 1995, J CEREBR BLOOD F MET, V15, P417, DOI 10.1038/jcbfm.1995.52; TSAO PS, 1990, AM J PHYSIOL, V259, pH1660, DOI 10.1152/ajpheart.1990.259.6.H1660; WALTHER FJ, 1985, J PEDIATR-US, V107, P781, DOI 10.1016/S0022-3476(85)80417-0; WHITE BA, 1982, J BIOL CHEM, V257, P8569; WIELOCH T, 1991, J NEUROCHEM, V56, P1227, DOI 10.1111/j.1471-4159.1991.tb11415.x; WONG SHY, 1987, CLIN CHEM, V33, P214	65	29	29	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1997	11	6					482	492		10.1096/fasebj.11.6.9194529	http://dx.doi.org/10.1096/fasebj.11.6.9194529			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XE404	9194529				2022-12-28	WOS:A1997XE40400011
J	Bork, P; Hofmann, K; Bucher, P; Neuwald, AF; Altschul, SF; Koonin, EV				Bork, P; Hofmann, K; Bucher, P; Neuwald, AF; Altschul, SF; Koonin, EV			A superfamily of conserved domains in DNA damage responsive cell cycle checkpoint proteins	FASEB JOURNAL			English	Article						BRCT domain; database search; PARP; profile; motif	REPLICATION FACTOR-C; SACCHAROMYCES-CEREVISIAE; POLY(ADP-RIBOSE) POLYMERASE; FISSION YEAST; TRANSCRIPTIONAL ACTIVATION; RETINOBLASTOMA PROTEIN; SEQUENCE SIMILARITY; SECONDARY STRUCTURE; MULTIPLE ALIGNMENT; FEEDBACK CONTROLS	Computer analysis of a conserved domain, BRCT, first described at the carboxyl terminus of the breast cancer protein BRCA1, a p53 binding protein (53BP1), and the yeast cell cycle checkpoint protein RAD9 revealed a large superfamily of domains that occur predominantly in proteins involved in cell cycle checkpoint functions responsive to DNA damage. The BRCT domain consists of similar to 95 amino acid residues and occurs as a tandem repeat at the carboxyl terminus of numerous proteins, but has been observed also as a tandem repeat at the amino terminus or as a single copy. The BRCT superfamily presently includes similar to 40 nonorthologous proteins, namely, BRCA1, 53BP1, and RAD9; a protein family that consists of the fission yeast replication checkpoint protein Rad4, the oncoprotein ECT2, the DNA repair protein XRCC1, and yeast DNA polymerase subunit DPB11; DNA binding enzymes such as terminal deoxynucleotidyltransferases, deoxycytidyl transferase involved in DNA repair, and DNA-ligases III and IV; yeast multifunctional transcription factor RAP1; and several uncharacterized gene products. Another previously described domain that is shared by bacterial NAD-dependent DNA-ligases, the large subunits of eukaryotic replication factor C, and poly(ADP-ribose) polymerases appears to be a distinct version of the BRCT domain. The retinoblastoma protein (a universal tumor suppressor) and related proteins may contain a distant relative of the BRCT domain. Despite the functional diversity of all these proteins, participation in DNA damage-responsive checkpoints appears to be a unifying theme. Thus, the BRCT domain is likely to perform critical, yet uncharacterized, functions in the cell cycle control of organisms from bacteria to humans. The carboxyterminal BRCT domain of BRCA1 corresponds precisely to the recently identified minimal transcription activation domain of this protein, indicating one such, function.	EUROPEAN MOL BIOL LAB, D-69012 HEIDELBERG, GERMANY; MAX DELBRUCK CTR MOL MED, BERLIN, GERMANY; SWISS INST EXPT CANC RES, CH-1066 EPALINGES, SWITZERLAND	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Swiss Institute Experimental Cancer Research	Bork, P (corresponding author), NATL LIB MED, NATL CTR BIOTECHNOL INFORMAT, NIH, BETHESDA, MD 20894 USA.		Bork, Peer/F-1813-2013; Altschul, Stephen/R-4000-2019	Bork, Peer/0000-0002-2627-833X; 				Aboussekhra A, 1996, EMBO J, V15, P3912, DOI 10.1002/j.1460-2075.1996.tb00765.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; Birney E, 1996, NUCLEIC ACIDS RES, V24, P2730, DOI 10.1093/nar/24.14.2730; Bork P, 1996, CURR OPIN STRUC BIOL, V6, P366, DOI 10.1016/S0959-440X(96)80057-1; Bork P, 1996, METHOD ENZYMOL, V266, P162; BRIDGES BA, 1995, BIOESSAYS, V17, P63, DOI 10.1002/bies.950170112; Brown M, 1993, Proc Int Conf Intell Syst Mol Biol, V1, P47; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURBELO PD, 1993, P NATL ACAD SCI USA, V90, P11543, DOI 10.1073/pnas.90.24.11543; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Caldecott KW, 1995, NUCLEIC ACIDS RES, V23, P4836, DOI 10.1093/nar/23.23.4836; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; DEMURCIA G, 1994, MOL CELL BIOCHEM, V138, P15, DOI 10.1007/BF00928438; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; Eddy S R, 1995, J Comput Biol, V2, P9, DOI 10.1089/cmb.1995.2.9; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P946, DOI 10.1093/nar/22.6.946; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; HOWELL EA, 1994, MOL CELL BIOL, V14, P255, DOI 10.1128/MCB.14.1.255; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; KARLIN S, 1990, P NATL ACAD SCI USA, V87, P2264, DOI 10.1073/pnas.87.6.2264; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; KHANNA KK, 1995, ONCOGENE, V11, P609; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Konig P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; Koonin EV, 1996, METHOD ENZYMOL, V266, P295; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; LANDAU NR, 1987, MOL CELL BIOL, V7, P3237, DOI 10.1128/MCB.7.9.3237; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; LEE EYHP, 1995, SEMIN CANCER BIOL, V6, P119, DOI 10.1006/scbi.1995.0019; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEHMANN AR, 1993, NUCLEIC ACIDS RES, V21, P5274, DOI 10.1093/nar/21.22.5274; LI JJ, 1993, CELL, V74, P223, DOI 10.1016/0092-8674(93)90413-K; LJUNGQUIST S, 1994, MUTAT RES, V314, P177, DOI 10.1016/0921-8777(94)90081-7; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; LUTHY R, 1994, PROTEIN SCI, V3, P139; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; MASUTANI M, 1995, BIOCHIMIE, V77, P462, DOI 10.1016/0300-9084(96)88161-2; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MONTEIRO ANA, 1996, IN PRESS P NATL ACAD; MULLER T, 1994, J STRUCT BIOL, V113, P1, DOI 10.1006/jsbi.1994.1027; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NEFF MW, 1992, MOL CELL BIOL, V12, P3857, DOI 10.1128/MCB.12.9.3857; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; NEUWALD AF, 1995, PROTEIN SCI, V4, P1618, DOI 10.1002/pro.5560040820; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; SAKA Y, 1994, EMBO J, V13, P5319, DOI 10.1002/j.1460-2075.1994.tb06866.x; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SHALL S, 1994, MOL CELL BIOCHEM, V138, P71, DOI 10.1007/BF00928445; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; SIBBALD PR, 1990, J MOL BIOL, V216, P813, DOI 10.1016/S0022-2836(99)80003-5; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SUBLER MA, 1994, ONCOGENE, V9, P1351; TATUSOV RL, 1994, P NATL ACAD SCI USA, V91, P12091, DOI 10.1073/pnas.91.25.12091; THOMPSON JD, 1994, COMPUT APPL BIOSCI, V10, P19; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1992, RADIAT RES, V132, P141, DOI 10.2307/3578518; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WHYTE P, 1995, SEMIN CANCER BIOL, V6, P83, DOI 10.1006/scbi.1995.0011; WIMAN KG, 1993, FASEB J, V7, P841, DOI 10.1096/fasebj.7.10.8393817; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; YODER BL, 1991, J BIOL CHEM, V266, P22689	95	637	655	0	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1997	11	1					68	76		10.1096/fasebj.11.1.9034168	http://dx.doi.org/10.1096/fasebj.11.1.9034168			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK147	9034168				2022-12-28	WOS:A1997WK14700010
J	Taipale, J; KeskiOja, J				Taipale, J; KeskiOja, J			Growth factors in the extracellular matrix	FASEB JOURNAL			English	Review						heparan sulfate; FGF; TGF-beta	HEPARAN-SULFATE PROTEOGLYCANS; ENDOTHELIAL-CELLS; BINDING-PROTEIN; FACTOR-BETA; PROTEOLYTIC CLEAVAGE; SIGNAL-TRANSDUCTION; PERICELLULAR MATRIX; MOLECULAR-CLONING; PLATELET FACTOR-4; SCATTER FACTOR	Much recent research has focused on the study of the expression of growth factor genes and on the identification of growth factor signaling mechanisms inside cells, However, growth factor signaling can also be regulated outside of cells by extracellular matrix proteins and proteolytic enzymes, The ability of extracellular proteins to process complex information in the absence of new protein synthesis is illustrated in blood clotting and complement pathways. An increasing number of growth factors, including IGFs, FGFs, TGF-P's, and HGF, have been found to associate with the extracellular matrix proteins or with heparan sulfate, Rapid and localized changes in the activity of these factors call he induced by release from matrix storage and/or by activation of latent forms, These growth factors, in turn, control cell proliferation, differentiation, and synthesis and remodeling of the extracellular matrix. It is therefore likely that much of the information processing necessary for construction of complex multicellular organisms occurs in the extracellular environment. This suggests that extracellular matrix plays a major role in the control of growth factor signaling.	UNIV HELSINKI, DEPT DERMATOL & VENEROL, FIN-00014 HELSINKI, FINLAND	University of Helsinki	Taipale, J (corresponding author), UNIV HELSINKI, DEPT VIROL, POB 21, FIN-00014 HELSINKI, FINLAND.							ALON R, 1994, J IMMUNOL, V152, P1304; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BENEZRA M, 1993, BLOOD, V81, P3324; BROWN KJ, 1994, BIOCHEMISTRY-US, V33, P13918, DOI 10.1021/bi00250a047; BUMCROT DA, 1995, MOL CELL BIOL, V15, P2294; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; BUTZOW R, 1993, J CELL BIOL, V122, P721, DOI 10.1083/jcb.122.3.721; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FALCONE DJ, 1993, J BIOL CHEM, V268, P11951; FLAUMENHAFT R, 1992, MOL BIOL CELL, V3, P1057, DOI 10.1091/mbc.3.10.1057; FLAUMENHAFT R, 1992, J CELL BIOL, V118, P901, DOI 10.1083/jcb.118.4.901; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; GOTZ R, 1994, NATURE, V372, P266, DOI 10.1038/372266a0; HAN EKH, 1993, J CELL BIOL, V122, P461, DOI 10.1083/jcb.122.2.461; HANNEKEN A, 1995, J CELL BIOL, V128, P1221, DOI 10.1083/jcb.128.6.1221; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HECHT P M, 1992, Trends in Cell Biology, V2, P197, DOI 10.1016/0962-8924(92)90246-J; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; INGBER DE, 1993, CELL, V75, P1249, DOI 10.1016/0092-8674(93)90612-T; JONES CA, 1995, BIOL REPROD, V52, P839, DOI 10.1095/biolreprod52.4.839; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; KINASHI T, 1995, BLOOD, V86, P2086, DOI 10.1182/blood.V86.6.2086.bloodjournal8662086; KLEIN G, 1995, MATRIX BIOL, V14, P457, DOI 10.1016/0945-053X(95)90003-9; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; LYON M, 1994, J BIOL CHEM, V269, P11216; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MCCAFFREY TA, 1992, J CELL PHYSIOL, V152, P430, DOI 10.1002/jcp.1041520226; MEREAU A, 1993, J CELL BIOL, V122, P713, DOI 10.1083/jcb.122.3.713; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; Miyazawa K, 1996, J BIOL CHEM, V271, P3615; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; Olofsson A, 1995, J BIOL CHEM, V270, P31294, DOI 10.1074/jbc.270.52.31294; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PARTENHEIMER A, 1995, J IMMUNOL, V155, P5557; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; PORTER PL, 1995, J HISTOCHEM CYTOCHEM, V43, P791, DOI 10.1177/43.8.7622842; RAINES EW, 1992, P NATL ACAD SCI USA, V89, P1281, DOI 10.1073/pnas.89.4.1281; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RICHARD C, 1995, J BIOL CHEM, V270, P24188, DOI 10.1074/jbc.270.41.24188; ROBERTS AB, 1996, MOL CELLULAR BIOL WO, P275; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; ROSENBLOOM J, 1993, FASEB J, V7, P1208, DOI 10.1096/fasebj.7.13.8405806; RUOSLAHTI E, 1992, COLD SPRING HARB SYM, V57, P309, DOI 10.1101/SQB.1992.057.01.035; Saharinen J, 1996, EMBO J, V15, P245, DOI 10.1002/j.1460-2075.1996.tb00355.x; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; SHIMOMURA T, 1995, EUR J BIOCHEM, V229, P257, DOI 10.1111/j.1432-1033.1995.0257l.x; SOYOMBO AA, 1994, J BIOL CHEM, V269, P17734; Taipale J, 1996, J BIOL CHEM, V271, P4342; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; Taipale J, 1996, J HISTOCHEM CYTOCHEM, V44, P875, DOI 10.1177/44.8.8756760; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; TSUTSUI J, 1991, BIOCHEM BIOPH RES CO, V176, P792, DOI 10.1016/S0006-291X(05)80255-4; VUKICEVIC S, 1994, BIOCHEM BIOPH RES CO, V198, P693, DOI 10.1006/bbrc.1994.1100; WAHLCHECK B, 1996, NATURE, V380, P720; WANG TY, 1995, EXP HEMATOL, V23, P26	74	718	754	2	43	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1997	11	1					51	59		10.1096/fasebj.11.1.9034166	http://dx.doi.org/10.1096/fasebj.11.1.9034166			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK147	9034166				2022-12-28	WOS:A1997WK14700008
J	Bussolati, O; Uggeri, J; Belletti, S; Dallasta, V; Gazzola, GC				Bussolati, O; Uggeri, J; Belletti, S; Dallasta, V; Gazzola, GC			The stimulation of Na,K,Cl cotransport and of system A for neutral amino acid transport is a mechanism for cell volume increase during the cell cycle	FASEB JOURNAL			English	Article						glutamine; cell proliferation; hypertonic stress; potassium; cell water	SENSITIVE NA+/K+/CL COTRANSPORT; SACCHAROMYCES-CEREVISIAE; QUIESCENT FIBROBLASTS; CULTURED FIBROBLASTS; 3T3 FIBROBLASTS; K+-TRANSPORT; SERUM; GROWTH; GLUTAMINE; INFLUX	It has been known for several years that the triggering of cell proliferation is associated with an increase of the activity of Na,K,CI cotransport and of transport system A for neutral amino acids. These systems are also enhanced during the volume recovery of hypertonically shrunk cells. We demonstrate here that during the cell cycle of NIH3T3 cells, an increase in cell volume is associated with an enhanced cell content of potassium and amino acids. Bumetanide delays cell cycle progression and hampers volume increase. The nonmetabolizable analog 2-methylamino-isobutpric acid, a specific substrate of system A, can partially substitute natural amino acids accumulated during the cell cycle as intracellular osmolytes. It is therefore proposed that the stimulation of Na,K,CL cotransport and of system A, observed in proliferating cells, causes an expansion of cell volume through an enhanced intracellular accumulation of both inorganic and organic osmolytes and the concurrent, osmotically obliged uptake of water.	UNIV PARMA,IST PATOL GEN,I-43100 PARMA,ITALY	University of Parma			Dall'Asta, Valeria/M-6698-2015; Bussolati, Ovidio/B-7589-2013	Dall'Asta, Valeria/0000-0001-8540-0916; Bussolati, Ovidio/0000-0002-4301-2939; BELLETTI, Silvana/0000-0003-0262-4485				AMSLER K, 1985, J CELL PHYSIOL, V123, P257, DOI 10.1002/jcp.1041230216; BANNAI S, 1988, J CELL PHYSIOL, V137, P360, DOI 10.1002/jcp.1041370221; BASERGA R, 1985, BIOL CELL REPROD, P103; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BUSSOLATI O, 1993, BIOCHIM BIOPHYS ACTA, V1151, P153, DOI 10.1016/0005-2736(93)90099-L; CHEN JG, 1994, AM J PHYSIOL, V267, pC529, DOI 10.1152/ajpcell.1994.267.2.C529; DALLASTA V, 1990, BIOCHIM BIOPHYS ACTA, V1052, P106, DOI 10.1016/0167-4889(90)90063-J; DALLASTA V, 1994, J BIOL CHEM, V269, P10485; DARMAUN D, 1988, J CELL PHYSIOL, V134, P143, DOI 10.1002/jcp.1041340118; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DEMAUREX N, 1994, J EXP BIOL, V196, P389; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GAZZOLA G, 1991, Cellular Physiology and Biochemistry, V1, P131, DOI 10.1159/000154601; GUIDOTTI GG, 1992, MAMMALIAN AMINO ACID TRANSPORT, P3; GULCHEVACARGOVA Z, 1994, SCIENCE, V265, P806; HAAS M, 1994, AM J PHYSIOL-CELL PH, V267, pC869, DOI 10.1152/ajpcell.1994.267.4.C869; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; JOHNSTON GC, 1977, J BACTERIOL, V132, P738, DOI 10.1128/JB.132.2.738-739.1977; KLIP A, 1986, J CELL PHYSIOL, V127, P244, DOI 10.1002/jcp.1041270209; LAW RO, 1987, J PHYSIOL-LONDON, V386, P45, DOI 10.1113/jphysiol.1987.sp016521; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; MEYER M, 1991, J BIOL CHEM, V266, P8230; MOOLENAAR WH, 1981, CELL, V23, P789, DOI 10.1016/0092-8674(81)90443-8; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; PANET R, 1994, J CELL PHYSIOL, V158, P121, DOI 10.1002/jcp.1041580115; PANET R, 1986, BIOCHIM BIOPHYS ACTA, V859, P117, DOI 10.1016/0005-2736(86)90325-1; PANET R, 1991, J CELL BIOL, V114, P337, DOI 10.1083/jcb.114.2.337; PANET R, 1982, J MEMBRANE BIOL, V70, P165, DOI 10.1007/BF01870226; PANET R, 1985, BIOCHIM BIOPHYS ACTA, V813, P141, DOI 10.1016/0005-2736(85)90355-4; PARIS S, 1986, J BIOL CHEM, V261, P6177; POUYSSEGUR J, 1982, P NATL ACAD SCI-BIOL, V79, P3935, DOI 10.1073/pnas.79.13.3935; ROZENGURT E, 1975, P NATL ACAD SCI USA, V72, P4992; RUIZMONTASELL B, 1994, P NATL ACAD SCI USA, V91, P9569, DOI 10.1073/pnas.91.20.9569; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; SCHULDINER S, 1982, P NATL ACAD SCI-BIOL, V79, P7778, DOI 10.1073/pnas.79.24.7778; SMITH JB, 1978, P NATL ACAD SCI USA, V75, P5560, DOI 10.1073/pnas.75.11.5560; SOLER C, 1993, BIOCHEM J, V289, P653, DOI 10.1042/bj2890653; SPRING KR, 1992, KIDNEY PHYSL PATHOPH, P120; TERADA Y, 1994, J BIOL CHEM, V269, P31296; TRAMACERE M, 1984, EXP CELL RES, V151, P70, DOI 10.1016/0014-4827(84)90356-2; UGGERI J, 1995, BIOCHEM BIOPH RES CO, V211, P878, DOI 10.1006/bbrc.1995.1894; YAMAUCHI A, 1994, AM J PHYSIOL-CELL PH, V267, pC1493, DOI 10.1152/ajpcell.1994.267.5.C1493; YAN MH, 1994, NATURE, V372, P798; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	49	72	73	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1996	10	8					920	926		10.1096/fasebj.10.8.8666170	http://dx.doi.org/10.1096/fasebj.10.8.8666170			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UQ456	8666170				2022-12-28	WOS:A1996UQ45600015
J	Garbuglia, M; Verzini, M; Giambanco, I; Spreca, A; Donato, R				Garbuglia, M; Verzini, M; Giambanco, I; Spreca, A; Donato, R			Effects of calcium-binding proteins (S-100a(o), S-100a, S-100b) on desmin assembly in vitro	FASEB JOURNAL			English	Article						S-100 proteins; desmin intermediate filaments; calcium	INTERMEDIATE FILAMENT NETWORKS; FIBRILLARY ACIDIC PROTEIN; CONSENSUS SEQUENCE MOTIF; VIMENTIN FILAMENTS; TYROSINE PHOSPHORYLATION; S100 PROTEIN; CALPACTIN-I; ANNEXIN-II; MITOSIS; CELLS	S-100a(o), the alpha alpha isoform of a subfamily of Ca2+-binding proteins of the EF-hand type expressed in cardiac and skeletal muscle cells, is reported to inhibit the assembly of the intermediate filament subunit desmin and to stimulate the disassembly of desmin intermediate filaments in the presence of micromolar levels of free Ca2+, These effects are dose-dependent with respect to the S-100a(o) concentration and maximal at a desmin/S-100a(o) (dimer) molar ratio of similar to 2, Other members of the S-100 subfamily [S-100a (alpha beta) and S-100b (beta beta)] and the unfractionated mixture of S-100a plus S-100b produce qualitatively similar effects on desmin assembly, with a potency that depends on the fraction of S-100 alpha subunit (the most potent) or S-100 beta subunit (the least potent) present in the S-100 isoforms tested, A binding stoichiometry of 2 mol of desmin/mol of S-100a(o) (dimer) and an affinity in the submicromolar range are calculated, The S-100 beta subunit also interacts with desmin, but with a lower affinity compared with S-100 alpha. By contrast, the S-100-like proteins calcyclin and p11 neither interact with desmin nor affect desmin assembly, The present data suggest that S-100a(o) might play a role in the regulation of the state of assembly of desmin intermediate filaments.	UNIV PERUGIA,DEPT EXPTL MED & BIOCHEM SCI,SECT ANAT,I-06126 PERUGIA,ITALY	University of Perugia				Giambanco, Ileana/0000-0003-0286-6302	Telethon [591] Funding Source: Medline; Fondazione Telethon Funding Source: Custom	Telethon(Fondazione Telethon); Fondazione Telethon(Fondazione Telethon)		ALBERS K, 1992, INT REV CYTOL, V134, P243, DOI 10.1016/S0074-7696(08)62030-6; ANGELIDES KJ, 1989, J CELL BIOL, V108, P1495, DOI 10.1083/jcb.108.4.1495; AUBIN JE, 1980, EXP CELL RES, V129, P149, DOI 10.1016/0014-4827(80)90340-7; BENNETT GS, 1979, J CELL BIOL, V82, P577, DOI 10.1083/jcb.82.2.577; BIANCHI R, 1992, BIOCHIM BIOPHYS ACTA, V1160, P67, DOI 10.1016/0167-4838(92)90039-G; BIANCHI R, 1993, J BIOL CHEM, V268, P12669; BIANCHI R, 1994, BBA-MOL CELL RES, V1223, P354, DOI 10.1016/0167-4889(94)90095-7; BIANCHI R, 1994, BBA-MOL CELL RES, V1223, P361, DOI 10.1016/0167-4889(94)90096-5; BIANCHI R, 1995, BIOCHEM BIOPH RES CO, V209, P910; BURWINKEL F, 1994, HISTOCHEMISTRY, V101, P113, DOI 10.1007/BF00269357; CELIS JE, 1983, J CELL BIOL, V97, P1429, DOI 10.1083/jcb.97.5.1429; CHOU YH, 1989, P NATL ACAD SCI USA, V86, P1885, DOI 10.1073/pnas.86.6.1885; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; COOPER JA, 1982, METHOD ENZYMOL, V85, P182; DONATO R, 1991, CELL CALCIUM, V12, P713, DOI 10.1016/0143-4160(91)90040-L; DONATO R, 1988, J BIOL CHEM, V263, P106; DONATO R, 1989, CELL CALCIUM, V10, P81, DOI 10.1016/0143-4160(89)90048-1; DONATO R, 1984, BIOCHEM BIOPH RES CO, V124, P850, DOI 10.1016/0006-291X(84)91035-0; EVANS RM, 1982, CELL, V29, P43, DOI 10.1016/0092-8674(82)90088-5; FRANKE WW, 1984, EXP CELL RES, V154, P567, DOI 10.1016/0014-4827(84)90181-2; FREEMAN MR, 1989, EXP CELL RES, V182, P370, DOI 10.1016/0014-4827(89)90242-5; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GARBUGLIA M, 1995, BIOCHEM BIOPH RES CO, V208, P901, DOI 10.1006/bbrc.1995.1420; GARD DL, 1980, CELL, V19, P263, DOI 10.1016/0092-8674(80)90408-0; GEISLER N, 1980, EUR J BIOCHEM, V111, P425, DOI 10.1111/j.1432-1033.1980.tb04957.x; GEORGATOS SD, 1993, FEBS LETT, V318, P101, DOI 10.1016/0014-5793(93)80001-B; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GERKE V, 1985, J BIOL CHEM, V260, P1688; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; GLENNEY JR, 1989, J CELL BIOL, V108, P569, DOI 10.1083/jcb.108.2.569; GLENNEY JR, 1986, J BIOL CHEM, V261, P485; HAGIWARA M, 1988, J BIOL CHEM, V263, P6438; HAIMOTO H, 1988, EUR J BIOCHEM, V171, P409, DOI 10.1111/j.1432-1033.1988.tb13805.x; HARAFUJI H, 1980, J BIOCHEM, V87, P1305, DOI 10.1093/oxfordjournals.jbchem.a132868; HATZFELD M, 1992, J CELL BIOL, V116, P157, DOI 10.1083/jcb.116.1.157; HEXHAM JM, 1986, BIOCHEM BIOPH RES CO, V134, P248, DOI 10.1016/0006-291X(86)90554-1; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3393; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; IVANENKOV VV, 1995, J BIOL CHEM, V270, P14651, DOI 10.1074/jbc.270.24.14651; KOUKLIS PD, 1992, J CELL SCI, V102, P31; KUZNICKI J, 1989, FEBS LETT, V254, P141, DOI 10.1016/0014-5793(89)81026-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; LI SH, 1994, J CELL BIOL, V124, P827; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER RK, 1991, J CELL BIOL, V113, P843, DOI 10.1083/jcb.113.4.843; NAKAMURA Y, 1991, GLIA, V4, P101, DOI 10.1002/glia.440040112; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; PARRY D A D, 1992, Current Opinion in Cell Biology, V4, P94, DOI 10.1016/0955-0674(92)90064-J; Pendergast F. G., 1983, J BIOL CHEM, V258, P7541; QUINLAN RA, 1991, BIOESSAYS, V13, P597, DOI 10.1002/bies.950131110; RAMBOTTI MG, 1990, J HISTOCHEM CYTOCHEM, V38, P1583, DOI 10.1177/38.11.2212618; ROTH J, 1993, BLOOD, V82, P1875; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Stewart M, 1993, CURR OPIN CELL BIOL, V5, P3, DOI 10.1016/S0955-0674(05)80002-X; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; THIEL C, 1992, J CELL SCI, V103, P733; TOKUMITSU H, 1992, J BIOL CHEM, V267, P8919; TOKUYASU KT, 1984, J CELL BIOL, V98, P1961, DOI 10.1083/jcb.98.6.1961; VIKSTROM KL, 1989, P NATL ACAD SCI USA, V86, P549, DOI 10.1073/pnas.86.2.549; VIKSTROM KL, 1992, J CELL BIOL, V118, P121, DOI 10.1083/jcb.118.1.121	64	44	44	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1996	10	2					317	324		10.1096/fasebj.10.2.8641565	http://dx.doi.org/10.1096/fasebj.10.2.8641565			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641565				2022-12-28	WOS:A1996TY96200016
J	RAY, SD; KAMENDULIS, LM; GURULE, MW; YORKIN, RD; CORCORAN, GB				RAY, SD; KAMENDULIS, LM; GURULE, MW; YORKIN, RD; CORCORAN, GB			CA2+ ANTAGONISTS INHIBIT DNA FRAGMENTATION AND TOXIC CELL-DEATH INDUCED BY ACETAMINOPHEN	FASEB JOURNAL			English	Article						ACETAMINOPHEN; APOPTOSIS; CA2+ ANTAGONISTS; DNA FRAGMENTATION; NECROSIS (TOXIC CELL DEATH)	CHANNEL BLOCKING-AGENTS; INDUCED LIVER NECROSIS; CALCIUM CHANNELS; RAT HEPATOCYTES; CA-2+ INFLOW; INDUCED CYTOTOXICITY; N-ACETYLCYSTEINE; CYTOSOLIC CA-2+; PLASMA-MEMBRANE; MICE	Ca2+ accumulates in the nucleus and DNA undergoes enzymatic cleavage into internucleosome-length fragments before acetaminophen and dimethylnitrosamine produce hepatic necrosis in vivo and toxic cell death in vitro. However, Ca2+-endonuclease fragmentation of DNA is characteristic of apoptosis, a type of cell death considered biochemically and functionally distinct from toxic cell death. The present studies investigate DNA fragmentation as a critical event in toxic cell death by testing whether die Ca2+-calmodulin antagonist chlorpromazine and the Ca2+ channel blocker verapamil prevent acetaminophen-induced hepatic necrosis by inhibiting Ca2+ deregulation and DNA damage. Acetaminophen overdose in mice produced accumulation of Ca2+ in the nucleus (358% of control) and fragmentation of DNA (250% of control) by 6 h, with peak release of ALT occurring at 12-24 h (38,000 U/1). Pretreatment with chlorpromazine prevented increases in nuclear Ca2+ and DNA fragmentation and nearly abolished biochemical evidence of toxic cell death. Verapamil pretreatment also decreased Ca2+ accumulation and DNA damage while attenuating liver injury. The Ca2+ antagonists did not protect against toxic cell death through hypothermia because neither produced the delay in toxicity that is customarily associated with hypothermia. Nor did chlorpromazine or verapamil protect through inhibiting acetaminophen bioactivation. Chlorpromazine failed to diminish glutathione depletion in whole liver and isolated nuclei. Verapamil (250 muM) also failed to alter glutathione depletion in whole liver and had no effect on acetaminophen-glutathione adduct formation by mouse liver microsomes and by cultured mouse hepatocytes. Collectively, these results support the hypothesis that Ca2+-induced DNA fragmentation plays a significant role in cell necrosis produced by acetaminophen and may contribute to toxic cell death caused by other alkylating hepatotoxins.	UNIV NEW MEXICO, COLL PHARM, TOXICOL PROGRAM, ALBUQUERQUE, NM 87131 USA	University of New Mexico			Ray, Sidhartha/AAE-9879-2021	Corcoran, George/0000-0002-4816-8836				BAGINSKI ES, 1973, CLIN CHIM ACTA, V46, P49, DOI 10.1016/0009-8981(73)90101-0; BEALES D, 1985, BIOCHEM PHARMACOL, V34, P19, DOI 10.1016/0006-2952(85)90094-2; BEAN BP, 1985, J GEN PHYSIOL, V86, P1, DOI 10.1085/jgp.86.1.1; BEATRICE MC, 1984, J BIOL CHEM, V259, P1279; BLAZKA ME, 1991, TOXICOL APPL PHARM, V110, P355, DOI 10.1016/S0041-008X(05)80018-3; BOOBIS AR, 1989, TRENDS PHARMACOL SCI, V10, P275, DOI 10.1016/0165-6147(89)90027-8; BURCHAM PC, 1988, TOXICOL LETT, V44, P91, DOI 10.1016/0378-4274(88)90134-8; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHAUVEAU J, 1956, EXP CELL RES, V11, P317, DOI 10.1016/0014-4827(56)90107-0; CHIEN KR, 1979, AM J PATHOL, V97, P505; CORCORAN GB, 1992, TOXICOL APPL PHARM, V113, P167, DOI 10.1016/0041-008X(92)90112-6; CORCORAN GB, 1988, TOXICOLOGY, V50, P157, DOI 10.1016/0300-483X(88)90088-1; CORCORAN GB, 1987, RES COMMUN CHEM PATH, V58, P291; CORCORAN GB, 1985, J PHARMACOL EXP THER, V232, P857; CORCORAN GB, 1980, MOL PHARMACOL, V18, P536; CORCORAN GB, 1991, TOXICOLOGIST, V11, P102; CROFTS JN, 1990, BIOCHEM J, V269, P579, DOI 10.1042/bj2690579; DEFERREYRA EC, 1985, RES COMMUN CHEM PATH, V47, P289; FARBER JL, 1990, CHEM RES TOXICOL, V3, P503, DOI 10.1021/tx00018a003; FAWTHROP DJ, 1991, ARCH TOXICOL, V65, P437, DOI 10.1007/BF01977355; FOX AP, 1987, J PHYSIOL-LONDON, V394, P173, DOI 10.1113/jphysiol.1987.sp016865; GALIZZI JP, 1986, P NATL ACAD SCI USA, V83, P7513, DOI 10.1073/pnas.83.19.7513; GOULD RJ, 1983, P NATL ACAD SCI-BIOL, V80, P5122, DOI 10.1073/pnas.80.16.5122; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HALLIWELL G, 1964, BRIT J PHARM CHEMOTH, V23, P330, DOI 10.1111/j.1476-5381.1964.tb01590.x; HAMANN SR, 1983, PHARMACOLOGY, V27, P1, DOI 10.1159/000137823; HARTMANN F, 1983, DRUG METAB DISPOS, V11, P244; Heilmann C, 1990, Prog Liver Dis, V9, P261; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P475, DOI 10.1016/0006-291X(73)90736-5; HIKADA H, 1981, P NATL ACAD SCI USA, V78, P4354; HUGHES BP, 1989, BIOCHIM BIOPHYS ACTA, V1013, P197, DOI 10.1016/0167-4889(89)90135-3; ITOH S, 1988, RES COMMUN CHEM PATH, V60, P133; JEWELL SA, 1982, SCIENCE, V217, P1257, DOI 10.1126/science.7112127; JOHNSON JD, 1983, J PHARMACOL EXP THER, V226, P330; KASS GEN, 1990, J BIOL CHEM, V265, P17486; KOBUSCH AB, 1990, RES COMMUN CHEM PATH, V68, P143; KRAUSFRIEDMANN N, 1990, CELL CALCIUM, V11, P625, DOI 10.1016/0143-4160(90)90017-O; LAMB RG, 1984, TOXICOL APPL PHARM, V75, P510, DOI 10.1016/0041-008X(84)90187-X; LANDON EJ, 1986, BIOCHEM PHARMACOL, V35, P697, DOI 10.1016/0006-2952(86)90369-2; LAUTERBURG BH, 1987, HEPATOLOGY, V7, P1179, DOI 10.1002/hep.1840070602; LOH SN, 1990, RADIAT RES, V121, P98, DOI 10.2307/3577570; LONG RM, 1988, J BIOCHEM TOXICOL, V3, P353, DOI 10.1002/jbt.2570030412; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARZI A, 1980, TOXICOL APPL PHARM, V52, P82, DOI 10.1016/0041-008X(80)90250-1; MASINI A, 1986, BIOCHIM BIOPHYS ACTA, V852, P19, DOI 10.1016/0005-2728(86)90051-4; mclean a. e. m., 1965, INT REV EXP PATHOL, V4, P127; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P211; MOORE M, 1985, J BIOL CHEM, V260, P3035; NAKAE D, 1990, AM J PATHOL, V136, P787; NELSON SD, 1990, ANNU REV PHARMACOL, V30, P169; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; NICOTERA P, 1986, J BIOL CHEM, V261, P4628; NICOTERA P, 1990, CHEM RES TOXICOL, V3, P484, DOI 10.1021/tx00018a001; NILIUS B, 1985, NATURE, V316, P443, DOI 10.1038/316443a0; OGATA N, 1990, J PHARMACOL EXP THER, V252, P1142; PECK RC, 1981, AGENTS ACTIONS, V11, P421, DOI 10.1007/BF01982481; PROZIALECK WC, 1982, J PHARMACOL EXP THER, V222, P509; PUMFORD NR, 1989, J PHARMACOL EXP THER, V248, P190; RAY SD, 1990, TOXICOL APPL PHARM, V106, P346, DOI 10.1016/0041-008X(90)90254-R; RAY SD, 1992, J PHARMACOL EXP THER, V263, P387; REED DJ, 1990, CHEM RES TOXICOL, V3, P495, DOI 10.1021/tx00018a002; REES KR, 1961, NATURE, V190, P821, DOI 10.1038/190821a0; RENTON KW, 1985, BIOCHEM PHARMACOL, V34, P2549, DOI 10.1016/0006-2952(85)90541-6; Sambrook J, 1989, MOL CLONING LABORATO; SARKAR BCR, 1967, ANAL BIOCHEM, V20, P155, DOI 10.1016/0003-2697(67)90273-4; SAVILLE JG, 1988, BIOCHEM PHARMACOL, V37, P2467, DOI 10.1016/0006-2952(88)90375-9; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; SCHATZMAN RC, 1981, BIOCHEM BIOPH RES CO, V98, P669, DOI 10.1016/0006-291X(81)91166-9; SEEMAN P, 1980, PHARMACOL REV, V32, P229; SHEN W, 1991, TOXICOL APPL PHARM, V111, P242, DOI 10.1016/0041-008X(91)90028-D; THIBAULT N, 1991, J BIOCHEM TOXICOL, V6, P237, DOI 10.1002/jbt.2570060310; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TIRMENSTEIN MA, 1989, J BIOL CHEM, V264, P9814; TSOKOSKUHN JO, 1989, BIOCHEM PHARMACOL, V38, P3061, DOI 10.1016/0006-2952(89)90016-6; TSOKOSKUHN JO, 1988, BIOCHEM PHARMACOL, V37, P2125, DOI 10.1016/0006-2952(88)90570-9; WALKER RM, 1981, TOXICOL APPL PHARM, V59, P500, DOI 10.1016/0041-008X(81)90303-3; WEI S, 1992, TOXICOL APPL PHARM, V112, P32, DOI 10.1016/0041-008X(92)90276-X; WROBLEWSKI F, 1956, P SOC EXP BIOL MED, V91, P569; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAMAGUCHI M, 1991, MOL CELL ENDOCRINOL, V75, P65; YAMAMOTO H, 1990, PHARMACOL TOXICOL, V67, P115, DOI 10.1111/j.1600-0773.1990.tb00795.x; Zar J.H., 1999, ZAR KUHR 5 2019, V4th	82	195	205	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1993	7	5					453	463		10.1096/fasebj.7.5.8462787	http://dx.doi.org/10.1096/fasebj.7.5.8462787			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KV351	8462787				2022-12-28	WOS:A1993KV35100010
J	Lacy-Hulbert, A; Metcalfe, JC; Hesketh, R				Lacy-Hulbert, A; Metcalfe, JC; Hesketh, R			Biological responses to electromagnetic fields	FASEB JOURNAL			English	Review						ELF-EMFs; protein kinase C; tumor development; growth factors; cell proliferation; geomagnetic field	FREQUENCY MAGNETIC-FIELDS; ELECTRIC UTILITY WORKERS; ORNITHINE DECARBOXYLASE ACTIVITY; HUMAN PERIPHERAL LYMPHOCYTES; BRAIN-TISSUE INVITRO; SALIVARY-GLAND CELLS; HUMAN LYMPHOID-CELLS; HUMAN AMNIOTIC CELLS; VOLTAGE POWER-LINES; CYCLOTRON-RESONANCE	Electrification in developed countries has progressively increased the mean level of extremely low-frequency electromagnetic fields (ELF-EMFs) to which populations are exposed; these humanmade fields are substantially above the naturally occurring ambient electric and magnetic fields of similar to 10(-4) Vm(-1) and similar to 10(-13) T, respectively, Several epidemiological studies have concluded that ELF-EMFs may be linked to an increased risk of cancer, particularly childhood leukemia, These observations have been reinforced by cellular studies reporting EMF-induced effects on biological systems, most notably on the activity of components of the pathways that regulate cell proliferation, However, time limited number of attempts to directly replicate these experimental findings have been almost uniformly unsuccessful, and no EMF-induced biological response has yet been replicated in independent laboratories, Many of the most well-defined effects have come from gene expression studies; several attempts have been made recently to repeat these key findings, This review analyses these studies and summarizes other reports of major cellular responses to EMFs and the published attempts at replication, The opening sections discuss quantitative aspects of exposure to EMFs and the incidence of cancers that have been correlated with such fields, The concluding section considers the problems that confront research in this area and suggests feasible strategies.	Univ Cambridge, Dept Biochem, Cambridge CB2 1TP, England	University of Cambridge	Lacy-Hulbert, A (corresponding author), Univ London Univ Coll, Rayne Inst, Dept Med, 5 Univ St, London WC1E 6JJ, England.	a.lacy-hulbert@ucl.ac.uk		Lacy-Hulbert, Adam/0000-0003-2162-0156				AHLBOM A, 1993, LANCET, V342, P1295, DOI 10.1016/0140-6736(93)92384-6; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; AZADNIV M, 1992, BIOCHEM BIOPH RES CO, V189, P437, DOI 10.1016/0006-291X(92)91577-D; AZADNIV M, 1995, BIOCHEM BIOPH RES CO, V214, P627, DOI 10.1006/bbrc.1995.2332; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Barbier E, 1996, BIOELECTROMAGNETICS, V17, P303, DOI 10.1002/(SICI)1521-186X(1996)17:4<303::AID-BEM6>3.0.CO;2-7; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BASSETT CAL, 1993, J CELL BIOCHEM, V51, P387, DOI 10.1002/jcb.2400510402; BATCHELOR SN, 1993, J PHYS CHEM-US, V97, P4570, DOI 10.1021/j100120a002; BATCHELOR SN, 1993, J PHYS CHEM-US, V97, P13250, DOI 10.1021/j100152a032; BATCHELOR SN, 1992, MOL PHYS, V77, P75, DOI 10.1080/00268979200102331; BAWIN SM, 1976, P NATL ACAD SCI USA, V73, P1999, DOI 10.1073/pnas.73.6.1999; BLACKMAN CF, 1985, BIOELECTROMAGNETICS, V6, P327, DOI 10.1002/bem.2250060402; BLACKMAN CF, 1982, RADIAT RES, V92, P510, DOI 10.2307/3575923; BLACKMAN CF, 1993, FASEB J, V7, P801, DOI 10.1096/fasebj.7.9.8330687; BLANCHARD JP, 1994, BIOELECTROMAGNETICS, V15, P217, DOI 10.1002/bem.2250150306; BLANK M, 1992, FASEB J, V6, P2434, DOI 10.1096/fasebj.6.7.1314204; BLANK M, 1995, SCIENCE, V270, P1104; BLANK M, 1993, BIOELECTROCH BIOENER, V31, P27; BLANK M, 1987, BIOCHIM BIOPHYS ACTA, V906, P277, DOI 10.1016/0304-4157(87)90014-1; BROUDE N, 1994, BIOELECTROCH BIOENER, V33, P19, DOI 10.1016/0302-4598(94)87028-4; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; BYUS CV, 1987, CARCINOGENESIS, V8, P1385, DOI 10.1093/carcin/8.10.1385; CADOSSI R, 1992, FASEB J, V6, P2667, DOI 10.1096/fasebj.6.9.1612290; CAIN CD, 1993, CARCINOGENESIS, V14, P955, DOI 10.1093/carcin/14.5.955; CHIABRERA A, 1992, ACTA PHARMACEUT, V42, P315; COHEN MM, 1986, BIOELECTROMAGNETICS, V7, P415, DOI 10.1002/bem.2250070409; COHEN MM, 1986, MUTAT RES, V172, P177, DOI 10.1016/0165-1218(86)90073-X; COLEMAN MP, 1989, BRIT J CANCER, V60, P793, DOI 10.1038/bjc.1989.362; CONTI P, 1985, FEBS LETT, V181, P28, DOI 10.1016/0014-5793(85)81107-8; CONTI P, 1983, FEBS LETT, V162, P156, DOI 10.1016/0014-5793(83)81069-2; CONTI P, 1985, J BIOELECTRICITY, V4, P227, DOI 10.3109/15368378509040375; COSSARIZZA A, 1989, BIOCHEM BIOPH RES CO, V160, P692, DOI 10.1016/0006-291X(89)92488-1; COULTON LA, 1993, PHYS MED BIOL, V38, P347, DOI 10.1088/0031-9155/38/3/002; COULTON LA, 1997, BIOCH BIOPHYS RES CO; DAVIES M, 1993, UPTAKE CALCIUM INDIC; DAVIES M, 1994, UPTAKE CALCIUM INDIC; DEIBERT MC, 1994, J ORTHOPAED RES, V12, P875; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEYCHTING M, 1994, EPIDEMIOLOGY, V5, P501; FEYCHTING M, 1993, AM J EPIDEMIOL, V138, P467, DOI 10.1093/oxfordjournals.aje.a116881; FITZSIMMONS RJ, 1994, CALCIFIED TISSUE INT, V55, P376, DOI 10.1007/BF00299318; FLODERUS B, 1993, CANCER CAUSE CONTROL, V4, P465, DOI 10.1007/BF00050866; FRAZIER ME, 1984, 232 HANF LIF SCI S, P255; FULTON JP, 1980, AM J EPIDEMIOL, V111, P292, DOI 10.1093/oxfordjournals.aje.a112899; GALT S, 1993, BIOELECTROMAGNETICS, V14, P315, DOI 10.1002/bem.2250140404; GALT S, 1995, BIOELECTROCH BIOENER, V36, P1, DOI 10.1016/0302-4598(93)01702-O; GOLD S, 1994, BIOELECTROMAGNETICS, V15, P329, DOI 10.1002/bem.2250150407; GOODMAN EM, 1993, BIOCHIM BIOPHYS ACTA, V1202, P107, DOI 10.1016/0167-4838(93)90070-8; GOODMAN EM, 1994, BIOELECTROMAGNETICS, V15, P77, DOI 10.1002/bem.2250150111; GOODMAN R, 1986, BIOELECTROMAGNETICS, V7, P23, DOI 10.1002/bem.2250070104; GOODMAN R, 1991, BIOELECTROCH BIOENER, V25, P335, DOI 10.1016/0302-4598(91)80001-J; GOODMAN R, 1988, P NATL ACAD SCI USA, V85, P3928, DOI 10.1073/pnas.85.11.3928; GOODMAN R, 1994, BIOELECTROCH BIOENER, V33, P115, DOI 10.1016/0302-4598(94)85002-X; GOODMAN R, 1992, BIOELECTROCH BIOENER, V29, P185, DOI 10.1016/0302-4598(92)80066-P; GOODMAN R, 1992, ELECTRO MAGNETOBIOL, V11, P19; GOODMAN R, 1989, BIOCHIM BIOPHYS ACTA, V1009, P219; GREENE JJ, 1991, BIOCHEM BIOPH RES CO, V174, P742, DOI 10.1016/0006-291X(91)91480-Z; Guenel P, 1996, AM J EPIDEMIOL, V144, P1107, DOI 10.1093/oxfordjournals.aje.a008889; Gurney JG, 1996, AM J EPIDEMIOL, V143, P120; HAMILTON CA, 1988, MOL PHYS, V65, P423, DOI 10.1080/00268978800101141; HARKINS TT, 1994, SCIENCE, V263, P958, DOI 10.1126/science.8310292; HARLAND JD, 1994, ANN REV RES BIOL EFF; Harrington JM, 1997, OCCUP ENVIRON MED, V54, P7, DOI 10.1136/oem.54.1.7; Hendee SP, 1996, BIOPHYS J, V70, P2915, DOI 10.1016/S0006-3495(96)79861-2; Henshaw DL, 1996, INT J RADIAT BIOL, V69, P25, DOI 10.1080/095530096146156; HESKETH R, 1994, ONCOGENES; HINTENLANG DE, 1993, BIOELECTROMAGNETICS, V14, P545, DOI 10.1002/bem.2250140606; HOJEVIK P, 1995, BIOELECTROMAGNETICS, V16, P33, DOI 10.1002/bem.2250160109; HSU CY, 1994, SCIENCE, V265, P95, DOI 10.1126/science.265.5168.95; JACKSON JD, 1992, P NATL ACAD SCI USA, V89, P3508, DOI 10.1073/pnas.89.8.3508; JENROW KA, 1995, BIOELECTROMAGNETICS, V16, P106, DOI 10.1002/bem.2250160206; JOHANSEN T, 1994, MOL CELL BIOL, V14, P646, DOI 10.1128/MCB.14.1.646; KARABAKHTSIAN R, 1994, FEBS LETT, V349, P1, DOI 10.1016/0014-5793(94)00618-0; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; KOBAYASHI AK, 1995, NATURE, V374, P123, DOI 10.1038/374123a0; KORZHSLEPTSOVA IL, 1995, FEBS LETT, V359, P151, DOI 10.1016/0014-5793(95)00031-4; LACYHULBERT A, 1995, NATURE, V375, P23, DOI 10.1038/375023a0; LACYHULBERT A, 1995, RADIAT RES, V144, P8; Lawrence A F, 1982, Neurol Res, V4, P115; LEDNEV VV, 1991, BIOELECTROMAGNETICS, V12, P71, DOI 10.1002/bem.2250120202; LERCHL A, 1991, NEUROSCI LETT, V124, P213, DOI 10.1016/0304-3940(91)90096-C; Li CY, 1996, OCCUP ENVIRON MED, V53, P505, DOI 10.1136/oem.53.8.505; LIBOFF AR, 1987, J BIOELECTRICITY, V6, P13; LIBURDY RP, 1993, FEBS LETT, V334, P301, DOI 10.1016/0014-5793(93)80699-U; LIBURDY RP, 1993, J PINEAL RES, V14, P89, DOI 10.1111/j.1600-079X.1993.tb00491.x; LIN H, 1994, J CELL BIOCHEM, V54, P281, DOI 10.1002/jcb.240540304; LIN H, 1995, BIOELECTROCH BIOENER, V36, P33, DOI 10.1016/0302-4598(94)05012-J; LIN SR, 1989, EPIDEMIOLOGIC STUDY; LINDSTROM E, 1993, J CELL PHYSIOL, V156, P395, DOI 10.1002/jcp.1041560223; Linet MS, 1997, NEW ENGL J MED, V337, P1, DOI 10.1056/NEJM199707033370101; LITOVITZ TA, 1994, BIOELECTROMAGNETICS, V15, P399, DOI 10.1002/bem.2250150504; LITOVITZ TA, 1991, BIOCHEM BIOPH RES CO, V178, P862, DOI 10.1016/0006-291X(91)90970-I; LIVINGSTONE GK, 1986, REPRODUCTIVE INTEGRI; LONDON SJ, 1991, AM J EPIDEMIOL, V134, P923, DOI 10.1093/oxfordjournals.aje.a116176; MANIMNEH S, 1996, BIOELECTROMAGNETICS, V17, P519; MARINO AA, 1993, BIOELECTROCH BIOENER, V29, P255, DOI 10.1016/0302-4598(93)85002-B; MARKOV MS, 1993, BIOELECTROCH BIOENER, V30, P119, DOI 10.1016/0302-4598(93)80069-7; MARTIN SP, 1996, AM J EPIDEMIOL, V143, P105; MCLAUCHLAN K, 1992, PHYSICS WORLD, V92, P41; MCLEAN JRN, 1991, BIOELECTROMAGNETICS, V12, P273, DOI 10.1002/bem.2250120503; Merchant C. J., 1994, Journal of Radiological Protection, V14, P77, DOI 10.1088/0952-4746/14/1/008; MEVISSEN M, 1993, BIOELECTROMAGNETICS, V14, P131, DOI 10.1002/bem.2250140206; Miller AB, 1996, AM J EPIDEMIOL, V144, P150, DOI 10.1093/oxfordjournals.aje.a008902; MINNA JD, 1988, LUNG CANCER, V4, P6; MOONEY NA, 1986, BIOELECTROMAGNETICS, V7, P387, DOI 10.1002/bem.2250070406; MORRIS JDH, 1984, THESIS U CAMBRIDGE C; MYERS A, 1989, BRIT J CANCER, V63, P977; NAFZIGER J, 1993, BIOELECTROCH BIOENER, V30, P133, DOI 10.1016/0302-4598(93)80071-2; NAKANISHI O, 1993, J BIOL CHEM, V268, P10754; *NAT RAD PROT BOAR, 1994, DOC NRPB, V5, P77; *NAT RAD PROT BOAR, 1992, DOCUMENTS NRPB, V3, P1; NORDENSON I, 1994, BIOELECTROMAGNETICS, V15, P293, DOI 10.1002/bem.2250150404; OLSEN JH, 1993, BRIT MED J, V307, P891, DOI 10.1136/bmj.307.6909.891; PARKINSON WC, 1992, RADIAT RES, V130, P319, DOI 10.2307/3578377; PARKINSON WC, 1989, BIOELECTROMAGNETICS, V10, P129, DOI 10.1002/bem.2250100203; PETRINI M, 1990, J BIOELECTRICITY, V9, P159, DOI 10.3109/15368379009119803; PHILLIPS JL, 1991, CANCER BIOCHEM BIOPH, V12, P1; PHILLIPS JL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P140, DOI 10.1016/0167-4781(92)90004-J; POOL R, 1990, SCIENCE, V249, P1096, DOI 10.1126/science.2204111; PRASAD AV, 1994, HEALTH PHYS, V66, P305, DOI 10.1097/00004032-199403000-00011; PRASAD AV, 1991, RADIAT ENVIRON BIOPH, V30, P305, DOI 10.1007/BF01210515; RANNUG A, 1994, CARCINOGENESIS, V15, P153, DOI 10.1093/carcin/15.2.153; RANNUG A, 1993, CARCINOGENESIS, V14, P573, DOI 10.1093/carcin/14.4.573; REESE JA, 1991, BIOELECTROMAGNETICS, V12, P21, DOI 10.1002/bem.2250120104; Reipert BM, 1996, GROWTH FACTORS, V13, P205, DOI 10.3109/08977199609003222; Reipert BM, 1997, LIFE SCI, V61, P1571, DOI 10.1016/S0024-3205(97)00736-4; ROSENTHAL M, 1989, MUTAT RES, V210, P329, DOI 10.1016/0027-5107(89)90094-8; ROY S, 1995, FEBS LETT, V376, P164, DOI 10.1016/0014-5793(95)01266-X; ROZEK RJ, 1987, CELL CALCIUM, V8, P413, DOI 10.1016/0143-4160(87)90025-X; SAALMAN E, 1991, BIOELECTROCH BIOENER, V26, P335, DOI 10.1016/0302-4598(91)80034-Z; SAFFER JD, 1995, RADIAT RES, V144, P18, DOI 10.2307/3579231; SAFFER JD, 1995, NATURE, V375, P22, DOI 10.1038/375022a0; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; SAVITZ DA, 1995, AM J EPIDEMIOL, V141, P123, DOI 10.1093/oxfordjournals.aje.a117400; SEVERSON RK, 1988, AM J EPIDEMIOL, V128, P10, DOI 10.1093/oxfordjournals.aje.a114932; SHUVALOVA LA, 1991, DOKL AKAD NAUK SSSR+, V317, P227; SMITH SD, 1987, BIOELECTROMAGNETICS, V8, P215, DOI 10.1002/bem.2250080302; STUCHLY MA, 1992, CANCER LETT, V65, P1, DOI 10.1016/0304-3835(92)90205-A; SWANSON J, 1994, ENG SCI ED J     APR, P71; TABRAH FL, 1994, BIOELECTROMAGNETICS, V15, P85, DOI 10.1002/bem.2250150112; THERIAULT G, 1994, AM J EPIDEMIOL, V139, P1053; THERIAULT G, 1994, AM J EPIDEMIOL, V139, P550, DOI 10.1093/oxfordjournals.aje.a117046; THOMAS JR, 1986, BIOELECTROMAGNETICS, V7, P349, DOI 10.1002/bem.2250070402; TOFANI S, 1995, BIOELECTROCH BIOENER, V36, P9, DOI 10.1016/0302-4598(94)01722-D; TOMENIUS L, 1986, BIOELECTROMAGNETICS, V7, P191, DOI 10.1002/bem.2250070209; Tomlinson IPM, 1996, P NATL ACAD SCI USA, V93, P14800, DOI 10.1073/pnas.93.25.14800; TSONG TY, 1992, BIOCHIM BIOPHYS ACTA, V1113, P53, DOI 10.1016/0304-4157(92)90034-8; Tynes T, 1997, AM J EPIDEMIOL, V145, P219, DOI 10.1093/oxfordjournals.aje.a009094; UCKUN FM, 1995, J BIOL CHEM, V270, P27666, DOI 10.1074/jbc.270.46.27666; VERKASALO PK, 1993, BRIT MED J, V307, P895, DOI 10.1136/bmj.307.6909.895; WALLECZEK J, 1992, FASEB J, V6, P3177, DOI 10.1096/fasebj.6.13.1397839; WALLECZEK J, 1990, FEBS LETT, V271, P157, DOI 10.1016/0014-5793(90)80396-Z; WALLECZEK J, 1994, 16 ANN M BIOEL SOC C; WANG KW, 1994, BIOPHYS J, V67, P1473, DOI 10.1016/S0006-3495(94)80621-6; WANG KW, 1994, BBA-BIOMEMBRANES, V1195, P218, DOI 10.1016/0005-2736(94)90259-3; WEI LX, 1990, BIOELECTROMAGNETICS, V11, P269, DOI 10.1002/bem.2250110403; WEISBROT DR, 1993, BIOELECTROCH BIOENER, V31, P167, DOI 10.1016/0302-4598(93)80005-F; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681; WERTHEIMER N, 1986, BIOELECTROMAGNETICS, V7, P13, DOI 10.1002/bem.2250070103; WERTHEIMER N, 1982, INT J EPIDEMIOL, V11, P345, DOI 10.1093/ije/11.4.345; YOST MG, 1992, FEBS LETT, V296, P117, DOI 10.1016/0014-5793(92)80361-J; YOUNGSON JHAM, 1991, BRIT J CANCER, V63, P977, DOI 10.1038/bjc.1991.214; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041	164	277	302	1	54	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1998	12	6					395	420		10.1096/fasebj.12.6.395	http://dx.doi.org/10.1096/fasebj.12.6.395			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZG118	9535213				2022-12-28	WOS:000072967300002
J	Barabe, F; Gilbert, C; Liao, N; Bourgoin, SG; Naccache, PH				Barabe, F; Gilbert, C; Liao, N; Bourgoin, SG; Naccache, PH			Crystal-induced neutrophil activation VI. Involvement of Fc gamma RIIIB (CD16) and CD11b in response to inflammatory microcrystals	FASEB JOURNAL			English	Article						tyrosine phosphorylation; inflammation; gout; signal transduction; opsonin receptors	MONOSODIUM URATE CRYSTALS; PROTEIN-TYROSINE KINASE; C-CBL PROTOONCOGENE; CALCIUM PYROPHOSPHATE CRYSTALS; RECEPTOR-MEDIATED PHAGOCYTOSIS; PHOSPHATIDYLINOSITOL 3-KINASE; COMPLEMENT RECEPTOR-TYPE-3; SIGNALING PATHWAYS; RESPIRATORY BURST; EGF STIMULATION	The inflammatory reaction associated with the deposition of monosodium urate (MSU) crystals in synovial spaces is known to be due to interactions with polymorphonuclear neutrophils mediated by presently unidentified surface structures. In this study, we have observed that antibodies directed against CD16 (VIFcRIII) and CD11b (VIM12) selectively and potently inhibit the activation of neutrophils by MSU crystals. The responses affected include the stimulation of tyrosine phosphorylation, activation of the tyrosine kinase syk, tyrosine phosphorylation of the proto-oncogene Cbl, mobilization of calcium, and stimulation of the activity of phospholipase D and of the production of superoxide anions, Tyrosine phosphorylation responses to MSU crystals develop during the Me2SO4-induced differentiation of HC-60 cells in parallel with the surface expression of CD16, These data strongly support the hypothesis that inflammatory microcrystals interact opportunistically with CD16 initially, and that the signal transduction pathways activated thereby depend on CD11b, An examination of the relevance of the hypothesis that an uncontrolled activation of CD16/CD11b may play a role in inflammatory reactions associated with a dysregulation of neutrophil function (other than crystal arthropathies) appears warranted on the basis of the present results.	CHUL, Ctr Rech, Ctr Rech Rhumatol & Immunol, Ste Foy, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Med, Ste Foy, PQ G1K 7P4, Canada; Univ Laval, Fac Med, Dept Physiol, Ste Foy, PQ G1K 7P4, Canada	Laval University; Laval University; Laval University	Naccache, PH (corresponding author), CHUL, Ctr Rech, Ctr Rech Rhumatol & Immunol, Room T1-49,2705 Blvd Laurier, Ste Foy, PQ G1V 4G2, Canada.	paul.naccache@crchul.ulaval.ca		Bourgoin, Sylvain/0000-0001-9779-0368; Gilbert, Caroline/0000-0003-2722-1180				ABRAMSON S, 1982, ARTHRITIS RHEUM, V25, P174, DOI 10.1002/art.1780250210; AlShami A, 1997, BLOOD, V89, P1035, DOI 10.1182/blood.V89.3.1035; AlShami A, 1997, J IMMUNOL METHODS, V202, P183, DOI 10.1016/S0022-1759(97)00004-5; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOMALASKI JS, 1990, J IMMUNOL, V145, P3391; BURT HM, 1993, MOL PHARMACOL, V43, P30; BURT HM, 1994, J LEUKOCYTE BIOL, V55, P112, DOI 10.1002/jlb.55.1.112; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DEMEDICIS R, 1983, EUR J RHEUMATOL INFL, V6, P143; DIGIOVINE FS, 1991, J CLIN INVEST, V87, P1375, DOI 10.1172/JCI115142; DIGIOVINE FS, 1987, J IMMUNOL, V138, P3213; EDBERG JC, 1994, J IMMUNOL, V152, P5826; FAIRES JS, 1962, LANCET, V2, P682; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Galon J, 1996, J IMMUNOL, V157, P1184; GAUDRY M, 1993, J CLIN INVEST, V91, P1649, DOI 10.1172/JCI116373; GINSBERG MH, 1977, ARTHRITIS RHEUM, V20, P1538, DOI 10.1002/art.1780200815; GORDON TP, 1988, INFLAMMATION BASIC P, P775; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUERNE PA, 1989, ARTHRITIS RHEUM-US, V32, P1443, DOI 10.1002/anr.1780321114; HACHICHA M, 1995, J EXP MED, V182, P2019, DOI 10.1084/jem.182.6.2019; HOFFMEYER F, 1995, J IMMUNOL, V155, P4016; HULETT MD, 1995, ADV IMMUNOL, V57, P1; INDIK ZK, 1995, BLOOD, V85, P1175, DOI 10.1182/blood.V85.5.1175.bloodjournal8551175; INDIK ZK, 1995, BLOOD, V86, P4389, DOI 10.1182/blood.V86.12.4389.bloodjournal86124389; JAQUES BC, 1982, ARTHRITIS RHEUM-US, V25, P508, DOI 10.1002/art.1780250504; KOBAYASHI K, 1995, J BIOCHEM, V117, P1156, DOI 10.1093/oxfordjournals.jbchem.a124838; KRAUSS JC, 1994, J IMMUNOL, V153, P1769; KUSUNOKI T, 1994, J LEUKOCYTE BIOL, V55, P735, DOI 10.1002/jlb.55.6.735; Langdon WY, 1995, AUST NZ J MED, V25, P859, DOI 10.1111/j.1445-5994.1995.tb02892.x; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; MACKENZIE SJ, 1995, BIOCHEM J, V306, P519, DOI 10.1042/bj3060519; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; Matsuo T, 1996, FEBS LETT, V382, P11, DOI 10.1016/0014-5793(96)00122-6; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MILLER EJ, 1993, J RHEUMATOL, V20, P1250; NACCACHE PH, 1993, ARTHRITIS RHEUM, V36, P117, DOI 10.1002/art.1780360119; NACCACHE PH, 1990, BLOOD, V76, P2098; NACCACHE PH, 1991, ARTHRITIS RHEUM, V34, P333, DOI 10.1002/art.1780340311; ONELLO E, 1991, J IMMUNOL, V146, P4289; ORTIZBRAVO E, 1993, ARTHRITIS RHEUM-US, V36, P1274, DOI 10.1002/art.1780360912; PETTY HR, 1993, J LEUKOCYTE BIOL, V54, P492, DOI 10.1002/jlb.54.5.492; POO H, 1995, J MOL BIOL, V247, P597; POUBELLE PE, 1987, BIOCHEM BIOPH RES CO, V149, P649, DOI 10.1016/0006-291X(87)90417-7; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Ribon V, 1996, MOL CELL BIOL, V16, P45; ROBERGE CJ, 1993, J CLIN INVEST, V92, P1722, DOI 10.1172/JCI116759; Roberge CJ, 1996, J LEUKOCYTE BIOL, V59, P864, DOI 10.1002/jlb.59.6.864; ROBERGE CJ, 1994, J IMMUNOL, V152, P5485; ROCHARVEILLER M, 1990, BIOMED PHARMACOTHER, V44, P467, DOI 10.1016/0753-3322(90)90207-P; ROLLET E, 1994, J IMMUNOL, V153, P353; SALMON JE, 1995, J CLIN INVEST, V95, P2877, DOI 10.1172/JCI117994; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SCHUMACHER HR, 1975, ARTHRITIS RHEUM, V18, P783, DOI 10.1002/art.1780180723; SEEGMILLER JE, 1962, JAMA-J AM MED ASSOC, V180, P125; SEHGAL G, 1993, J IMMUNOL, V150, P4571; SERHAN CN, 1984, PROSTAG OTH LIPID M, V27, P563, DOI 10.1016/0090-6980(84)90092-3; SIMCHOWITZ L, 1982, ARTHRITIS RHEUM, V25, P181, DOI 10.1002/art.1780250211; STOCKL J, 1995, J IMMUNOL, V154, P5452; STROHMEIER GR, 1995, J LEUKOCYTE BIOL, V58, P415, DOI 10.1002/jlb.58.4.415; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TERKELTAUB R, 1991, ARTHRITIS RHEUM, V34, P894, DOI 10.1002/art.1780340716; TERKELTAUB RA, 1990, J IMMUNOL, V144, P2719; TERKELTAUB RA, 1995, ANN RHEUM DIS, V54, P79, DOI 10.1136/ard.54.2.79; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; Uddin S, 1996, BIOCHEM BIOPH RES CO, V225, P833, DOI 10.1006/bbrc.1996.1259; Unkeless J C, 1995, Semin Immunol, V7, P37, DOI 10.1016/1044-5323(95)90006-3; ZHOU MJ, 1994, J CELL BIOL, V125, P1407, DOI 10.1083/jcb.125.6.1407; ZHOU MJ, 1993, J IMMUNOL, V150, P3030	72	71	72	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1998	12	2					209	220		10.1096/fasebj.12.2.209	http://dx.doi.org/10.1096/fasebj.12.2.209			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472986				2022-12-28	WOS:000071848400009
J	English, JA; Hemphill, KM; Paul, IA				English, JA; Hemphill, KM; Paul, IA			LP-BM5 infection impairs acquisition, but not performance, of active avoidance responding in C57B1/6 mice	FASEB JOURNAL			English	Article						animal model; AIDS; dementia; learning; memory; retention	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; AIDS DEMENTIA COMPLEX; IMMUNE-DEFICIENCY-SYNDROME; QUINOLINIC ACID; HIV-1 INFECTION; BRAIN; VIRUS; NEUROPATHOLOGY; LOCALIZATION; EXPRESSION	LP-BM5 murine leukemia virus infection causes an AIDS-like syndrome-murine acquired immunodeficiency syndrome-in C57Bl/6 mice and impairs spatial learning in the Morris water maze without gross motor impairment. We used a shuttle shock-avoidance procedure to examine the effects of LP-BM5 infection on learning and retention of avoidance behavior. Thirty mice were inoculated with LP-BM5; 30 received vehicle (DMEM) injections. Fifteen LP-BM5 and 15 DMEM mice were trained in avoidance 7 wk after inoculation; retention of the avoidance response was tested 4 wk later. The remaining mice were trained 11 wk after inoculation, In animals trained 7 wk after inoculation, the groups performed similarly, with a marginally significant tendency for LP-BM5-infected animals to make more avoidance responses. This group difference was sig nificant when animals were retested at 11 wk. However, LP-BM5 animals trained 11 wk after inoculation made significantly fewer avoidance responses than controls trained at the same time. We conclude that in later stages of disease, LP-BM5 impairs response acquisition, but not performance, in the active avoidance procedure. Results extend the use of the LP-BM5-infected mouse as a model of AIDS dementia complex.	Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center	English, JA (corresponding author), Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, Box 127,2500 N State St, Jackson, MS 39216 USA.				NIMH NIH HHS [MH53228] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH053228] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDERS KH, 1986, AM J PATHOL, V124, P537; DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646; EPSTEIN L G, 1984, AIDS Research, V1, P447; HA JH, 1995, J NEUROCHEM, V64, P1896; HARTLEY JW, 1989, J VIROL, V63, P1223, DOI 10.1128/JVI.63.3.1223-1231.1989; HEYES MP, 1991, ANN NEUROL, V29, P202, DOI 10.1002/ana.410290215; HO DD, 1989, ANN INTERN MED, V111, P400, DOI 10.7326/0003-4819-111-5-400; HOLSCHER C, 1994, BEHAV BRAIN RES, V63, P187, DOI 10.1016/0166-4328(94)90090-6; JOHNSON RT, 1988, FASEB J, V2, P2970, DOI 10.1096/fasebj.2.14.2846395; KESEBERG U, 1995, BEHAV BRAIN RES, V67, P255, DOI 10.1016/0166-4328(94)00156-A; KLINKEN SP, 1988, J IMMUNOL, V140, P1123; KLINMAN DM, 1989, J IMMUNOL, V142, P1144; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; Nishida K, 1996, J NEUROCHEM, V66, P433; PAUL IA, 1993, AM COL NEUROPSYCHOPH, P139; POPOLI P, 1994, BRAIN RES BULL, V35, P329, DOI 10.1016/0361-9230(94)90109-0; POWER C, 1993, ANN NEUROL, V34, P339, DOI 10.1002/ana.410340307; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; Sei Y, 1996, J NEUROCHEM, V66, P296; SEI Y, 1992, FASEB J, V6, P3008, DOI 10.1096/fasebj.6.11.1644264; SHUSTER GM, 1992, EUR J PHARMACOL, V224, P97; TYOR WR, 1992, ANN NEUROL, V31, P349, DOI 10.1002/ana.410310402; WEINBERGER SB, 1992, BEHAV GENET, V22, P177, DOI 10.1007/BF01066996; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089	28	11	11	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1998	12	2					175	179		10.1096/fasebj.12.2.175	http://dx.doi.org/10.1096/fasebj.12.2.175			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472982				2022-12-28	WOS:000071848400005
J	Hicke, L				Hicke, L			Ubiquitin-dependent internalization and down-regulation of plasma membrane proteins	FASEB JOURNAL			English	Review						ubiquitination; alpha-factor receptor; uracil permease; yeast protein; internalization; endocytosis	GROWTH-FACTOR RECEPTOR; CELL ANTIGEN RECEPTOR; YEAST URACIL PERMEASE; FACTOR BETA-RECEPTOR; LIGAND-INDUCED POLYUBIQUITINATION; PROTEASOME PROTEOLYTIC PATHWAY; TYROSINE KINASE SUBSTRATE; ANGIOTENSIN-II RECEPTOR; SACCHAROMYCES-CEREVISIAE; MULTIUBIQUITIN-CHAIN	The modification of cytosolic proteins with polyubiquitin chains targets them for recognition and degradation by the multisubunit proteolytic particle, the 26S proteasome. Membrane proteins are also substrates for ubiquitination. Integral membrane proteins of the endoplasmic reticulum are ubiquitinated and destroyed by the proteasome (reviewed in refs 1, 2), However, it has been shown recently that the ubiquitination of Saccharomyces cerevisiae plasma membrane proteins signals their degradation by the proteolytic system in the lysosome-like vacuole, Ubiquitination of several different classes of cell surface proteins serves as a signal for their entry into the endocytic pathway; this leads to their transport to the vacuole, where they are permanently inactivated by degradation, In yeast, ubiquitin has been implicated as an internalization signal for most, if not all, endogenous plasma membrane proteins that are known to be endocytosed, Ubiquitin-dependent internalization has been best characterized for two proteins: the mating pheromone a-factor receptor and the uracil permease. Some mammalian cell surface receptors are also ubiquitinated at the plasma membrane, Ubiquitination machinery is required for ligand-induced endocytosis of the growth hormone receptor, suggesting that ubiquitin-dependent endocytosis and sorting is also an important regulatory process in mammalian cells, Mammalian receptors may also be down-regulated through the degradation of their cytosolic domains by a proteasome-dependent pathway.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Hicke, L (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.							ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; BERKOWER C, 1994, MOL BIOL CELL, V5, P1185, DOI 10.1091/mbc.5.11.1185; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Bukusoglu G, 1996, MOL CELL BIOL, V16, P4818; Cenciarelli C, 1996, J BIOL CHEM, V271, P8709, DOI 10.1074/jbc.271.15.8709; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Dunbar JD, 1997, J IMMUNOL, V158, P4252; EGNER R, 1995, MOL CELL BIOL, V15, P5879; Egner R, 1996, FEBS LETT, V378, P177, DOI 10.1016/0014-5793(95)01450-0; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; GALAN JM, 1994, BIOCHEM BIOPH RES CO, V201, P769, DOI 10.1006/bbrc.1994.1767; Galan JM, 1996, J BIOL CHEM, V271, P10946, DOI 10.1074/jbc.271.18.10946; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; Garnier C, 1996, MOL MICROBIOL, V21, P1061, DOI 10.1046/j.1365-2958.1996.621430.x; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; HEIN L, 1994, J BIOL CHEM, V269, P27719; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Horak J, 1997, J BACTERIOL, V179, P1541, DOI 10.1128/jb.179.5.1541-1549.1997; HOU D, 1994, J BIOL CHEM, V269, P14244; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Kolling R, 1997, EMBO J, V16, P2251, DOI 10.1093/emboj/16.9.2251; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOETSCHER H, 1990, J BIOL CHEM, V265, P20131; Lucero P, 1997, FEMS MICROBIOL LETT, V147, P273, DOI 10.1016/S0378-1097(96)00538-1; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Medintz I, 1996, J BACTERIOL, V178, P2245, DOI 10.1128/jb.178.8.2245-2254.1996; MIYAZAWA K, 1994, BLOOD, V83, P137; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1995, BIOCHEM BIOPH RES CO, V213, P32, DOI 10.1006/bbrc.1995.2094; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; MORI S, 1993, J BIOL CHEM, V268, P577; NICKEL BE, 1989, BIOCHEMISTRY-US, V28, P958, DOI 10.1021/bi00429a006; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; Panek HR, 1997, EMBO J, V16, P4194, DOI 10.1093/emboj/16.14.4194; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; ROHRER J, 1993, MOL BIOL CELL, V4, P511, DOI 10.1091/mbc.4.5.511; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; STANBROUGH M, 1995, J BACTERIOL, V177, P94, DOI 10.1128/jb.177.1.94-102.1995; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Tan PK, 1996, J CELL BIOL, V135, P1789, DOI 10.1083/jcb.135.6.1789; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; TERELL J, 1997, IN PRESS MOL CELL; THOMAS WG, 1995, J BIOL CHEM, V270, P22153, DOI 10.1074/jbc.270.38.22153; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; vanDelft S, 1997, J BIOL CHEM, V272, P14013, DOI 10.1074/jbc.272.22.14013; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; Wendland B, 1996, J CELL BIOL, V135, P1485, DOI 10.1083/jcb.135.6.1485; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YEE NS, 1994, J BIOL CHEM, V269, P31991; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; [No title captured]	90	224	225	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1997	11	14					1215	1226		10.1096/fasebj.11.14.9409540	http://dx.doi.org/10.1096/fasebj.11.14.9409540			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YN210	9409540				2022-12-28	WOS:000071144100002
J	Pickart, CM				Pickart, CM			Targeting of substrates to the 268 proteasome	FASEB JOURNAL			English	Article						ubiquitination; polyubiquitin chains; ornithine decarboxylase; protein turnover	ORNITHINE DECARBOXYLASE ANTIZYME; UBIQUITIN-MEDIATED PROTEOLYSIS; DEGRADATION IN-VIVO; KAPPA-B-ALPHA; MULTIUBIQUITIN-CHAIN; SACCHAROMYCES-CEREVISIAE; PROTEIN-DEGRADATION; REGULATORY SUBUNIT; GENE ENCODES; INTRACELLULAR DEGRADATION	The ubiquitin-proteasome pathway is the principal mechanism for the turnover of short-lived proteins in eukaryotic cells, In this pathway, the covalent ligation of ubiquitin to the substrate is a signal for recognition by the 26S proteasome, Recent studies indicate that targeting of substrates of the ubiquitin pathway to the proteasome is usually accomplished by the Ligation of a polyubiquitin chain assembled through K48-G76 isopeptide bonds, rather than by Ligation of monoubiquitin. In addition to providing benefits in signal generation, recognition, and persistence, assigning the proteolytic targeting function to a specific specific type of polyubiquitin chain may allow monoubiquitin or polyubiquitin chains of novel structures to serve distinct targeting functions, Besides polyubiquitinated substrates, the proteasome also degrades an unknown number of proteins that are recognized without undergoing ubiquitination. Ornithine decarboxylase is the prototype ubiquitin-independent substrate; it is targeted to the proteasome through noncovalent interaction with a specific protein factor known as antizyme, The existence of ubiquitin-independent substrates of the proteasome raises important questions about the nature of the substrate-and proteasome-based elements that cooperate to bring about the targeting of substrates to this novel proteolytic complex.			Pickart, CM (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT BIOCHEM, 615 N WOLFE ST, BALTIMORE, MD 21205 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046984] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46984] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Amerik AY, 1997, EMBO J, V16, P4826; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Bercovich B, 1997, J BIOL CHEM, V272, P9002; BUSCH H, 1981, MOL CELL BIOCHEM, V40, P173; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEMARINI DJ, 1995, MOL CELL BIOL, V15, P6311; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DEVERAUX Q, 1990, J BIOL CHEM, V265, P6323; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Ferrell K, 1996, FEBS LETT, V381, P143, DOI 10.1016/0014-5793(96)00101-9; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; GALAN JM, 1997, IN PRESS EMBO J; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1992, MOL CELL BIOL, V12, P2178, DOI 10.1128/MCB.12.5.2178; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; GREGORI L, 1990, J BIOL CHEM, V265, P8354; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GROPPER R, 1991, J BIOL CHEM, V266, P3602; GUARINO LA, 1995, CELL, V80, P301, DOI 10.1016/0092-8674(95)90413-1; HADARI T, 1992, J BIOL CHEM, V267, P719; HARACSKA L, 1995, EUR J BIOCHEM, V231, P720, DOI 10.1111/j.1432-1033.1995.0720d.x; Hayashi S, 1996, TRENDS BIOCHEM SCI, V21, P27, DOI 10.1016/0968-0004(96)80882-6; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; HELLER JS, 1976, P NATL ACAD SCI USA, V73, P1858, DOI 10.1073/pnas.73.6.1858; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P1619, DOI 10.1073/pnas.81.6.1619; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOUGH R, 1986, J BIOL CHEM, V261, P2400; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; KOMINAMI K, 1995, EMBO J, V14, P3105, DOI 10.1002/j.1460-2075.1995.tb07313.x; KOMINAMI K, 1995, J BIOL CHEM, V270, P29660; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; Li XQ, 1996, J BIOL CHEM, V271, P4441; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1994, J BIOL CHEM, V269, P3539; MA CP, 1992, BIOCHIM BIOPHYS ACTA, V1119, P303, DOI 10.1016/0167-4838(92)90218-3; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1985, BIOCHEM J, V226, P893, DOI 10.1042/bj2260893; MURAKAMI Y, 1992, BIOCHEM J, V283, P661, DOI 10.1042/bj2830661; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; PICKART CM, 1998, IN PRESS UBIQUITIN B; PIOTROWSKI J, 1997, IN PRESS J BIOL CHEM, V272; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROM E, 1994, P NATL ACAD SCI USA, V91, P3959, DOI 10.1073/pnas.91.9.3959; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHIMKE RT, 1973, ADV ENZYMOL RAMB, V37, P135; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SHAEFFER JR, 1995, BIOCHEMISTRY-US, V34, P4015, DOI 10.1021/bi00012a020; SHAEFFER JR, 1994, J BIOL CHEM, V269, P29530; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856; WANG W, 1996, P NATL ACAD SCI USA, V93, P8326; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; Yokota K, 1996, MOL BIOL CELL, V7, P853, DOI 10.1091/mbc.7.6.853	98	298	302	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1997	11	13					1055	1066		10.1096/fasebj.11.13.9367341	http://dx.doi.org/10.1096/fasebj.11.13.9367341			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367341				2022-12-28	WOS:A1997YE98300004
J	DelBufalo, D; Biroccio, A; Leonetti, C; Zupi, G				DelBufalo, D; Biroccio, A; Leonetti, C; Zupi, G			Bcl-2 overexpression enhances the metastatic potential of a human breast cancer line	FASEB JOURNAL			English	Article						breast carcinoma; metastases; invasion; migration	CELL-DEATH; C-MYC; ANTICANCER DRUGS; PROSTATE CANCERS; TUMOR INVASION; EXPRESSION; APOPTOSIS; CARCINOMA; PROTEIN; GENE	Bcl-2 protein has been shown to contribute to oncogenesis because it can transform and immortalize cells in cooperation with c-myc, ras, or viral genes, However, in vivo studies have not yet established whether bcl-2 can play a role in metastasis, Here we investigate the potential metastatic role off bcl-2, We introduced the human bcl-2 gene into a low bcl-2 expressing human breast cancer cell line MCF7 ADR, We demonstrate that two bcl-2 overexpressing clones injected intravenously or intramuscularly into nude mice induce a significantly higher number of experimental and spontaneous lung metastases compared to the control transfectant clone, We demonstrate that bcl-2 overexpressing clones are more invasive and migratory in response to chemotactic stimuli than the control transfectant clone, Furthermore, zymographic analysis shows that secretion of 72 and 92 kDa gelatinases increases in the two bcl-2 overexpressing transfectants, Tumors originating from bcl-2 overexpressing clones also show a decrease in the latency period of tumor appearance, In conclusion, our data show that bcl-2 overexpression enhances both tumorigenicity and metastatic potential of MCF7 ADR cells by inducing metastasis-associated properties.	REGINA ELENA INST CANC RES,EXPT CHEMOTHERAPY LAB,ROME,ITALY	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena			Leonetti, Carlo/B-2860-2018; Del Bufalo, Donatella/K-8673-2016; Biroccio, Annamaria/B-2861-2018; Del Bufalo, Donatella/AAC-1594-2021	Leonetti, Carlo/0000-0002-3526-7827; Del Bufalo, Donatella/0000-0002-3148-6096; Biroccio, Annamaria/0000-0003-3198-3532; Del Bufalo, Donatella/0000-0002-3148-6096				ALBINI A, 1987, J CELL BIOL, V105, P1867, DOI 10.1083/jcb.105.4.1867; ALBINI A, 1987, CANCER RES, V47, P3239; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CAMPOS L, 1993, BLOOD, V81, P3091; CHAN WK, 1993, J PATHOL S, V169, P138; CHAOYING Y, 1997, NATURE, V385, P637; COLOMBEL M, 1993, AM J PATHOL, V143, P390; DAWSON CW, 1995, ONCOGENE, V10, P69; DelBufalo D, 1996, J CLIN INVEST, V98, P1165, DOI 10.1172/JCI118900; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHER TC, 1993, CANCER RES, V53, P3321; Furuya Y, 1996, CLIN CANCER RES, V2, P389; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Krajewska M, 1996, AM J PATHOL, V148, P1567; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; LEEK RD, 1994, BRIT J CANCER, V69, P1135; Leonetti C, 1996, JNCI-J NATL CANCER I, V88, P419, DOI 10.1093/jnci/88.7.419; LIOTTA LA, 1986, CANCER RES, V46, P1; LU QL, 1993, INT J CANCER, V53, P29, DOI 10.1002/ijc.2910530107; McConkey DJ, 1996, CANCER RES, V56, P5594; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MENSING H, 1984, INT J CANCER, V33, P43, DOI 10.1002/ijc.2910330109; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; NAKJIMA M, 1989, CANCER RES, V49, P1698; Nicolson GL, 1989, CURR OPIN CELL BIOL, V1, P1009, DOI 10.1016/0955-0674(89)90073-2; OLTAVI ZN, 1993, CELL, V74, P609; PIGNATELLI M, 1991, J PATHOL, V165, P25, DOI 10.1002/path.1711650106; PONTA H, 1994, BBA-REV CANCER, V1198, P1, DOI 10.1016/0304-419X(94)90002-7; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; REED JC, 1990, MOL CELL BIOL, V10, P4370, DOI 10.1128/MCB.10.8.4370; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; SATO H, 1992, ONCOGENE, V7, P77; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SIERRA A, 1995, INT J CANCER, V60, P54, DOI 10.1002/ijc.2910600108; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; ZUTTER MM, 1990, AM J PATHOL, V137, P863	44	111	113	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1997	11	12					947	953		10.1096/fasebj.11.12.9337147	http://dx.doi.org/10.1096/fasebj.11.12.9337147			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YA724	9337147				2022-12-28	WOS:A1997YA72400004
J	Manton, KG; Corder, LS; Stallard, E				Manton, KG; Corder, LS; Stallard, E			Monitoring changes in the health of the US elderly population: Correlates with biomedical research and clinical innovations	FASEB JOURNAL			English	Article							VITAMIN-E CONSUMPTION; UNITED-STATES ADULTS; ALZHEIMERS-DISEASE; CANCER MORTALITY; VASCULAR-DISEASE; LUNG-CANCER; RISK; AGE; THERAPY; VIRUS				Manton, KG (corresponding author), DUKE UNIV, CTR DEMOG STUDIES, 2117 CAMPUS DR, BOX 90408, DURHAM, NC 27708 USA.							ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Bailar JC, 1997, NEW ENGL J MED, V336, P1569, DOI 10.1056/NEJM199705293362206; BAILAR JC, 1986, NEW ENGL J MED, V314, P1226, DOI 10.1056/NEJM198605083141905; BODE L, 1995, NAT MED, V1, P232, DOI 10.1038/nm0395-232; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Capron L, 1996, NAT MED, V2, P856, DOI 10.1038/nm0896-856; Carabello BA, 1997, NEW ENGL J MED, V337, P32, DOI 10.1056/NEJM199707033370107; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; Chylack LT, 1997, NEW ENGL J MED, V337, P46, DOI 10.1056/NEJM199707033370110; Cohn JN, 1997, CIRCULATION, V95, P766; Cole P, 1996, CANCER, V78, P2045, DOI 10.1002/(SICI)1097-0142(19961115)78:10<2045::AID-CNCR3>3.0.CO;2-N; Crisby M, 1997, ATHEROSCLEROSIS, V130, P17, DOI 10.1016/S0021-9150(96)06037-6; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; DAVIS DL, 1994, JAMA-J AM MED ASSOC, V271, P431, DOI 10.1001/jama.271.6.431; ELAYDA MA, 1993, CIRCULATION, V88, P11; Flowers CR, 1997, NAT MED, V3, P136, DOI 10.1038/nm0297-136; FOGEL RW, 1994, AM ECON REV, V84, P369; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIES JF, 1989, ARCH INTERN MED, V149, P1002, DOI 10.1001/archinte.149.5.1002; GAUNTT C, 1995, NAT MED, V1, P405, DOI 10.1038/nm0595-405; Gottlieb S, 1997, CIRCULATION, V95, P342; GRAYSTON JT, 1993, CIRCULATION, V87, P1408, DOI 10.1161/01.CIR.87.4.1408; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; HALPERN MT, 1993, JNCI-J NATL CANCER I, V85, P457, DOI 10.1093/jnci/85.6.457; Hansson LE, 1996, NEW ENGL J MED, V335, P242, DOI 10.1056/NEJM199607253350404; HARRIS JE, 1983, JNCI-J NATL CANCER I, V71, P473; HITCHINGS GH, 1950, J BIOL CHEM, V183, P1; Hoeksema MJ, 1996, J NATL CANCER I, V88, P1706, DOI 10.1093/jnci/88.23.1706; HOSKING MP, 1989, JAMA-J AM MED ASSOC, V261, P1909; Howard BV, 1997, CIRCULATION, V95, P2591, DOI 10.1161/01.CIR.95.11.2591; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; Knox JB, 1997, CIRCULATION, V95, P205, DOI 10.1161/01.CIR.95.1.205; LANSKA DJ, 1993, STROKE, V24, P1382, DOI 10.1161/01.STR.24.9.1382; LEWIS T, 1975, LIVES CELL; LICHTIGER S, 1994, NEW ENGL J MED, V330, P1841, DOI 10.1056/NEJM199406303302601; LOWY DR, 1995, NAT MED, V1, P747, DOI 10.1038/nm0895-747; MANTON KG, 1993, J GERONTOL, V48, pS153, DOI 10.1093/geronj/48.4.S153; MANTON KG, 1995, J GERONTOL B-PSYCHOL, V50, pS194, DOI 10.1093/geronb/50B.4.S194; MANTON KG, 1995, NEW ENGL J MED, V333, P1232, DOI 10.1056/NEJM199511023331824; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593; Manton KG, 1997, DEMOGRAPHY, V34, P135, DOI 10.2307/2061664; MANTON KG, 1997, IN PRESS J GERONTOL; MCCULLY KS, 1983, ATHER REV, V11, P157; McCully KS, 1996, NAT MED, V2, P386, DOI 10.1038/nm0496-386; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; Meydani SN, 1997, JAMA-J AM MED ASSOC, V277, P1380, DOI 10.1001/jama.277.17.1380; Minna JD, 1996, NAT MED, V2, P974, DOI 10.1038/nm0996-974; PAOLISSO G, 1993, AM J CLIN NUTR, V57, P650, DOI 10.1093/ajcn/57.5.650; Parsonnet J, 1996, NEW ENGL J MED, V335, P278, DOI 10.1056/NEJM199607253350411; PAUL SD, 1994, ARCH INTERN MED, V154, P1143, DOI 10.1001/archinte.154.10.1143; *PHS, 1996, NAT CTR HLTH STAT HL; PRASAD KN, 1992, J AM COLL NUTR, V11, P487; PRESTON SH, 1993, FORECASTING HLTH ELD; PYPER JM, 1995, NAT MED, V1, P209, DOI 10.1038/nm0395-209; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Saraste A, 1997, CIRCULATION, V95, P320; Sayers BM, 1997, EUR J PUBLIC HEALTH, V7, P113, DOI 10.1093/eurpub/7.1.113; SEMPOS CT, 1993, JAMA-J AM MED ASSOC, V269, P3009, DOI 10.1001/jama.269.23.3009; SHINTON R, 1993, BMJ-BRIT MED J, V307, P231, DOI 10.1136/bmj.307.6898.231; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STERN Y, 1994, JAMA-J AM MED ASSOC, V271, P1004, DOI 10.1001/jama.271.13.1004; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; TAYLOR A, 1993, J AM COLL NUTR, V12, P138; Tolley HD, 1996, SOC SECUR BULL, V59, P71; Topol EJ, 1997, CIRCULATION, V95, P1072; Tosteson ANA, 1997, CIRCULATION, V95, P24, DOI 10.1161/01.CIR.95.1.24; WAIDMANN T, 1995, MILBANK Q, V73, P253, DOI 10.2307/3350259; WEISBROD BA, 1991, J ECON LIT, V29, P523; Weiss RB, 1997, SEMIN ONCOL, V24, P153; WURTMAN RJ, 1995, NAT MED, V1, P1122, DOI 10.1038/nm1195-1122; Zuckerman AJ, 1997, NEW ENGL J MED, V336, P1906, DOI 10.1056/NEJM199706263362610	74	21	22	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1997	11	12					923	930		10.1096/fasebj.11.12.9337144	http://dx.doi.org/10.1096/fasebj.11.12.9337144			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YA724	9337144				2022-12-28	WOS:A1997YA72400001
J	Drab, M; Haller, H; Bychkov, R; Erdmann, B; Lindschau, C; Haase, H; Morano, I; Luft, FC; Wobus, AM				Drab, M; Haller, H; Bychkov, R; Erdmann, B; Lindschau, C; Haase, H; Morano, I; Luft, FC; Wobus, AM			From totipotent embryonic stem cells to spontaneously contracting smooth muscle cells: a retinoic acid and db-cAMP in vitro differentiation model	FASEB JOURNAL			English	Article						vascular smooth muscle cells; myosin heavy chain; retinoic acid receptors; oligonucleotide; intracellular calcium; immunocytochemistry; embryoid body	CARDIAC-SPECIFIC GENES; CENTRAL-NERVOUS-SYSTEM; IN-VITRO; CARCINOMA-CELLS; PHENOTYPIC CHANGES; XENOPUS EMBRYOS; IONIC CURRENTS; F9 CELLS; EXPRESSION; MYOSIN	Vascular smooth muscle cell (VSMC) differentiation is important in understanding vascular disease; however, no in vitro model is available. Totipotent mouse embryonic stem (ES) cells were used to establish such a model. To test whether the ES cell-derived smooth muscle cells expressed VSMC-specific properties, the differentiated cells were characterized by 1) morphological analysis, 2) gene expression, 3) immunostaining for VSMC-specific proteins, 4) expression of characteristic VSMC ion channels, and 5) formation of [Ca2+](i) transients in response to VSMC-specific agonists. Treatment of embryonic stem cell-derived embryoid bodies with retinoic acid and dibutyryl-cyclic adenosine monophosphate (db-cAMP) induced differentiation of spontaneously contracting cell clusters in 67% of embryoid bodies compared with 10% of untreated controls. The highest differentiation rate was observed when retinoic acid and db-cAMP were applied to the embryoid bodies between days 7 and 11 in combination with frequent changes of culture medium. Other protocols with retinoic acid and db-cAMP, as well as single or combined treatment with VEGF, ECGF, bFGF, aFGF, fibronectin, matrigel, or hypoxia did not influence the differentiation rate. Single-cell RTPCR and sequencing of the PCR products identified myosin heavy chain (MHC) splice variants distinguishing: between gut and VSMC isoforms. RT-PCR with VSMC-specific MHC primers and immunostaining confirmed the presence of VSMC transcripts and MHC protein. Furthermore, VSMC expressing MHC had typical ion channels and responded to specific agonists with an increased [Ca2+](i). Here we present a retinoic acid + dbcAMP-inducible embryonic stem cell model of in vitro vasculogenesis. ES cell-derived cells expressing VSMC-specific MHC and functional VSMC properties may be a suitable system to study mechanisms of VSMC differentiation.	HUMBOLDT UNIV BERLIN,FRANZ VOLHARD CLIN,MAX DELBRUCK CTR MOL MED,D-13122 BERLIN,GERMANY; INST PLANT GENET & CROP PLANT RES,GATERSLEBEN,GERMANY; MAX DELBRUCK CTR MOL MED,BERLIN,GERMANY	Franz-Volhard Clinical Research Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Drab, Marek/J-5196-2013; Drab, Marek/AAQ-1892-2020; Lindschau, Carsten/G-1798-2011; Lindschau, Carsten/AAE-6721-2020	Drab, Marek/0000-0002-2771-1692; Lindschau, Carsten/0000-0003-1960-099X; Luft, Friedrich/0000-0002-8635-1199				AIKAWA M, 1993, CIRC RES, V73, P1000, DOI 10.1161/01.RES.73.6.1000; Bagutti C, 1996, DEV BIOL, V179, P184, DOI 10.1006/dbio.1996.0250; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; BLANK RS, 1995, CIRC RES, V76, P742, DOI 10.1161/01.RES.76.5.742; CALOVINI T, 1995, J CELL BIOCHEM, V59, P69, DOI 10.1002/jcb.240590109; CARNEGIE JA, 1994, BIOL REPROD, V50, P413, DOI 10.1095/biolreprod50.2.413; CHAMLEY JH, 1977, CELL TISSUE RES, V177, P503; CHYTIL F, 1990, Critical Reviews in Eukaryotic Gene Expression, V1, P61; Colbert MC, 1996, CIRC RES, V78, P790, DOI 10.1161/01.RES.78.5.790; CURIEL OA, 1993, DIFFERENTIATION, V52, P201; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FRAICHARD A, 1995, J CELL SCI, V108, P3181; FRID MG, 1992, DEV BIOL, V153, P185, DOI 10.1016/0012-1606(92)90104-O; GIANNI M, 1995, BLOOD, V85, P3619, DOI 10.1182/blood.V85.12.3619.bloodjournal85123619; GLUKHOVA MA, 1991, AM J PHYSIOL, V261, P78, DOI 10.1152/ajpheart.1991.261.4.78; Gollasch M, 1996, CIRC RES, V78, P676, DOI 10.1161/01.RES.78.4.676; GOLLASCH M, 1991, P NATL ACAD SCI USA, V88, P10262, DOI 10.1073/pnas.88.22.10262; GROSCHELSTEWART U, 1989, CELL TISSUE RES, V257, P137; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; Haase H, 1996, J CELL BIOCHEM, V60, P521, DOI 10.1002/(SICI)1097-4644(19960315)60:4<521::AID-JCB8>3.0.CO;2-U; HALEVY O, 1993, J CELL PHYSIOL, V154, P566, DOI 10.1002/jcp.1041540315; HALLER H, 1995, CIRC RES, V76, P21, DOI 10.1161/01.RES.76.1.21; HALLER H, 1994, KIDNEY INT, V46, P1653, DOI 10.1038/ki.1994.465; HAMADA Y, 1990, BIOCHEM BIOPH RES CO, V170, P53, DOI 10.1016/0006-291X(90)91239-O; HOGAN BLM, 1981, NATURE, V291, P235, DOI 10.1038/291235a0; HOGAN BLM, 1992, NATURE, V359, P237, DOI 10.1038/359237a0; JOHANSEN FF, 1995, NEUROCHEM INT, V26, P239, DOI 10.1016/0197-0186(94)00129-I; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KELLEY CA, 1993, J BIOL CHEM, V268, P12848; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; MALTSEV VA, 1994, CIRC RES, V75, P233, DOI 10.1161/01.RES.75.2.233; MARTIN CA, 1990, P NATL ACAD SCI USA, V87, P4804, DOI 10.1073/pnas.87.12.4804; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; MIKAWA T, 1992, P NATL ACAD SCI USA, V89, P9504, DOI 10.1073/pnas.89.20.9504; Morano I, 1997, J CELL BIOCHEM, V64, P171, DOI 10.1002/(SICI)1097-4644(199702)64:2<171::AID-JCB1>3.0.CO;2-U; MUMMERY CL, 1990, CELL DIFFER DEV, V30, P195, DOI 10.1016/0922-3371(90)90139-N; NELSON MT, 1990, AM J PHYSIOL, V259, pC3; OWENS GK, 1995, PHYSIOL REV, V75, P487; PAPALOPULU N, 1991, DEVELOPMENT, V113, P1145; PAPALOPULU N, 1991, NUCLEIC ACIDS RES, V19, P5497, DOI 10.1093/nar/19.20.5497; PAULETTO P, 1994, CIRC RES, V74, P774, DOI 10.1161/01.RES.74.5.774; PRICE RJ, 1994, CIRC RES, V75, P520, DOI 10.1161/01.RES.75.3.520; RISAU W, 1988, DEVELOPMENT, V102, P471; ROHWEDEL J, 1995, EXP CELL RES, V220, P92, DOI 10.1006/excr.1995.1295; ROHWEDEL J, 1994, DEV BIOL, V164, P87, DOI 10.1006/dbio.1994.1182; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; SIMEONE A, 1995, MECH DEVELOP, V51, P83, DOI 10.1016/0925-4773(95)96241-M; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; STRUBING C, 1995, MECH DEVELOP, V53, P275, DOI 10.1016/0925-4773(95)00446-8; Suzuki T, 1996, CIRC RES, V78, P395, DOI 10.1161/01.RES.78.3.395; WANG R, 1992, DEVELOPMENT, V114, P303; WHEELER MB, 1994, REPROD FERT DEVELOP, V6, P563, DOI 10.1071/RD9940563; WHITE S, 1993, AM J PHYSIOL, V264, pC1252, DOI 10.1152/ajpcell.1993.264.5.C1252; WOBUS AM, 1995, ANN NY ACAD SCI, V752, P460, DOI 10.1111/j.1749-6632.1995.tb17456.x; WOBUS AM, 1991, DIFFERENTIATION, V48, P173, DOI 10.1111/j.1432-0436.1991.tb00255.x; WOBUS AM, 1994, ROUX ARCH DEV BIOL, V204, P36, DOI [10.1007/BF00744871, 10.1007/BF00189066]; Wright G, 1996, AM J PHYSIOL-HEART C, V270, pH1363, DOI 10.1152/ajpheart.1996.270.4.H1363; XIAO YH, 1995, J CELL BIOL, V129, P1345, DOI 10.1083/jcb.129.5.1345	61	179	207	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1997	11	11					905	915		10.1096/fasebj.11.11.9285489	http://dx.doi.org/10.1096/fasebj.11.11.9285489			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XT790	9285489				2022-12-28	WOS:A1997XT79000010
J	Maecker, HT; Todd, SC; Levy, S				Maecker, HT; Todd, SC; Levy, S			The tetraspanin superfamily: Molecular facilitators	FASEB JOURNAL			English	Review						TM4SF; adhesion; integrins; gene families; membrane proteins	DOMINANT RETINITIS-PIGMENTOSA; INTEGRAL MEMBRANE-PROTEIN; DIPHTHERIA-TOXIN RECEPTOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; SPAN-TRANSMEMBRANE PROTEIN; HERMANSKY-PUDLAK SYNDROME; MONOCLONAL-ANTIBODY ALB6; TUMOR-ASSOCIATED ANTIGEN; HUMAN B-LYMPHOCYTES; MRC OX-44 ANTIGEN	A legacy of molecular evolution is the formation of gene families encoding proteins that often serve related functions. One such family gaining recent attention is the tetraspanin superfamily, whose membership has grown to nearly 20 known genes since its discovery in 1990. All encode cell-surface proteins that span the membrane four times, forming two extracellular loops. Some of these genes are found in organisms as primitive as schistosomes and nematodes. Alternately known as the transmembrane 4 (TM4) superfamily or the TM4SF, 4TM, or tetraspan family, we propose here that the name tetraspanins be used for the purpose of standardization. What do the tetraspanins do? Awaiting definitive functional studies, we can only put together pieces of a puzzle that has been built by raising antibodies against these proteins and looking at their distribution, associations, and functions. A brief overview indicates that some tetraspanins are found in virtually all tissues (CD81, CD82, CD9, CD63), whereas others are highly restricted, such as CD37 (B cells) or CD53 (lymphoid and myeloid cells). Many of these proteins have a flair for promiscuous associations with other molecules, including lineage-specific proteins, integrins, and other tetraspanins. Zn terms of function, they are involved in diverse processes such as cell activation and proliferation, adhesion and motility, differentiation, and cancer. We propose that these functions may all relate to their ability to act as ''molecular facilitators,'' grouping specific cell-surface proteins and thus increasing the formation and stability of functional signaling complexes.	STANFORD UNIV,MED CTR,DEPT MED ONCOL,STANFORD,CA 94305	Stanford University								ABE J, 1989, ACTA HAEMATOL JAPON, V52, P712; ABE J, 1989, CLIN IMMUNOL IMMUNOP, V51, P13, DOI 10.1016/0090-1229(89)90202-X; ANDRIA ML, 1991, J IMMUNOL, V147, P1030; ANDRIA ML, 1992, BIOCHEM BIOPH RES CO, V186, P1201, DOI 10.1016/S0006-291X(05)81533-5; ANGELISOVA P, 1990, IMMUNOGENETICS, V32, P281, DOI 10.1007/BF00187099; ANGELISOVA P, 1994, IMMUNOGENETICS, V39, P249; ANTON ES, 1995, J NEUROSCI, V15, P584; ATKINSON B, 1984, CANCER RES, V44, P2577; BARRETT TB, 1991, J IMMUNOL, V146, P1722; BASCOM RA, 1993, HUM MOL GENET, V2, P385, DOI 10.1093/hmg/2.4.385; BEHR S, 1995, J EXP MED, V182, P1191, DOI 10.1084/jem.182.5.1191; BELL GM, 1992, J EXP MED, V175, P527, DOI 10.1084/jem.175.2.527; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; Boismenu R, 1996, SCIENCE, V271, P198, DOI 10.1126/science.271.5246.198; BOSCA L, 1994, J EXP MED, V179, P1119, DOI 10.1084/jem.179.4.1119; BOUCHEIX C, 1985, ANN GENET-PARIS, V28, P19; BOUCHEIX C, 1983, FEBS LETT, V161, P289, DOI 10.1016/0014-5793(83)81027-8; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; BRIERE N, 1990, ACTA HISTOCHEM, V89, P157; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CARMO AM, 1995, EUR J IMMUNOL, V25, P2090, DOI 10.1002/eji.1830250743; CLASSON BJ, 1990, J EXP MED, V172, P1007, DOI 10.1084/jem.172.3.1007; CLASSON BJ, 1989, J EXP MED, V169, P1497, DOI 10.1084/jem.169.4.1497; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; CRAMER EM, 1994, BLOOD, V84, P1722; DEBLANDRE GA, 1995, J BIOL CHEM, V270, P23860, DOI 10.1074/jbc.270.40.23860; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; FITTER S, 1995, BLOOD, V86, P1348, DOI 10.1182/blood.V86.4.1348.bloodjournal8641348; FORSYTH KD, 1991, IMMUNOLOGY, V72, P292; FUKAI K, 1995, HUM MOL GENET, V4, P1665, DOI 10.1093/hmg/4.9.1665; GAUGITSCH HW, 1991, EUR J IMMUNOL, V21, P377, DOI 10.1002/eji.1830210219; Geisert EE, 1996, J NEUROSCI, V16, P5478; GIL ML, 1992, J IMMUNOL, V148, P2826; GONZALEZ ME, 1993, GENOMICS, V18, P725; GORIN MB, 1995, OPHTHALMOLOGY, V102, P246; GRIFFITH L, 1991, BLOOD, V78, P1753; Gwynn B, 1996, GENOMICS, V35, P389, DOI 10.1006/geno.1996.0375; Hadjiargyrou M, 1996, J NEUROCHEM, V67, P2505; HADJIARGYROU M, 1995, J NEUROSCI, V15, P574; Hasegawa H, 1996, J VIROL, V70, P3258, DOI 10.1128/JVI.70.5.3258-3263.1996; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; HOREJSI V, 1991, FEBS LETT, V288, P1, DOI 10.1016/0014-5793(91)80988-F; HOTTA H, 1992, BIOCHEM BIOPH RES CO, V185, P436, DOI 10.1016/S0006-291X(05)81004-6; HOTTA H, 1988, CANCER RES, V48, P2955; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; IMAI T, 1992, J IMMUNOL, V149, P2879; IMAI T, 1993, J IMMUNOL, V151, P6470; IMAI T, 1995, J IMMUNOL, V155, P1229; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; JANKOWSKI SA, 1994, ONCOGENE, V9, P1205; JANKOWSKI SA, 1995, GENOMICS, V25, P501, DOI 10.1016/0888-7543(95)80051-M; JENNINGS LK, 1990, J BIOL CHEM, V265, P3815; JORDAN SA, 1992, AM J HUM GENET, V50, P634; KALLIN B, 1991, MOL CELL BIOL, V11, P5338, DOI 10.1128/MCB.11.10.5338; KAO PN, 1986, J BIOL CHEM, V261, P8085; KAPRIELIAN Z, 1993, J NEUROSCI, V13, P2495, DOI 10.1523/JNEUROSCI.13-06-02495.1993; KAWAKATSU T, 1993, THROMB RES, V70, P245, DOI 10.1016/0049-3848(93)90131-7; KIKAWA E, 1994, GENOMICS, V20, P137, DOI 10.1006/geno.1994.1142; KIM RY, 1995, ARCH OPHTHALMOL-CHIC, V113, P451, DOI 10.1001/archopht.1995.01100040067029; KITANI S, 1991, J BIOL CHEM, V266, P1903; KNOL EF, 1991, J ALLERGY CLIN IMMUN, V88, P328, DOI 10.1016/0091-6749(91)90094-5; KONCZYNSKI CC, 1996, SCIENCE, V271, P1867; LEBELBINAY S, 1995, J IMMUNOL, V155, P101; LEBELBINAY S, 1995, J LEUKOCYTE BIOL, V57, P956, DOI 10.1002/jlb.57.6.956; LEDBETTER JA, 1987, LEUKOCYTE TYPING, V3, P339; LEE KW, 1995, EXP PARASITOL, V80, P155, DOI 10.1006/expr.1995.1018; LeNaour F, 1996, ONCOGENE, V13, P481; LEVY S, 1991, J BIOL CHEM, V266, P14597; LEVY S, 1997, IN PRESS ANN REV IMM; LIN SL, 1992, J IMMUNOL, V149, P2549; Loffler S, 1997, J VIROL, V71, P42; Maecker HT, 1997, J EXP MED, V185, P1505, DOI 10.1084/jem.185.8.1505; Mannion BA, 1996, J IMMUNOL, V157, P2039; MARKEN JS, 1992, P NATL ACAD SCI USA, V89, P3503, DOI 10.1073/pnas.89.8.3503; MARTINALONSO JM, 1992, J BIOCHEM-TOKYO, V112, P63, DOI 10.1093/oxfordjournals.jbchem.a123866; Maruyama M, 1996, GENE, V168, P273, DOI 10.1016/0378-1119(95)00716-4; MASELLISSMITH A, 1994, J IMMUNOL, V152, P2768; MASELLISSMITH A, 1990, J IMMUNOL, V144, P1607; MATSUMOTO AK, 1993, J EXP MED, V178, P1407, DOI 10.1084/jem.178.4.1407; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MIYAKE M, 1995, CANCER RES, V55, P4127; Miyake M, 1996, CANCER RES, V56, P1244; Moritz OL, 1996, INVEST OPHTH VIS SCI, V37, P352; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Nakazawa M, 1996, ARCH OPHTHALMOL-CHIC, V114, P72, DOI 10.1001/archopht.1996.01100130068011; NISHIBORI M, 1993, J CLIN INVEST, V91, P1775, DOI 10.1172/JCI116388; NISHIKATA H, 1992, J IMMUNOL, V149, P862; NOJIMA Y, 1993, CELL IMMUNOL, V152, P249, DOI 10.1006/cimm.1993.1285; OLIGINO LD, 1988, MOL BIOCHEM PARASIT, V28, P95, DOI 10.1016/0166-6851(88)90056-4; OLWEUS J, 1993, J IMMUNOL, V151, P707; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; OZAKI Y, 1995, J BIOL CHEM, V270, P15119, DOI 10.1074/jbc.270.25.15119; PATERSON DJ, 1987, J EXP MED, V165, P1, DOI 10.1084/jem.165.1.1; Radford KJ, 1996, BIOCHEM BIOPH RES CO, V222, P13, DOI 10.1006/bbrc.1996.0690; RASMUSSEN AM, 1994, J IMMUNOL, V153, P4997; REYNOLDS SR, 1992, J IMMUNOL, V149, P3995; ROBERTS JJ, 1995, BRIT J HAEMATOL, V89, P853; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; SCHICK MR, 1993, J IMMUNOL, V151, P4090; SCHICK MR, 1993, J IMMUNOL, V151, P1918; SCHWARTZ R, 1986, LEUCOCYTE TYPING 2, V2, P527; SCHWARTZALBIEZ R, 1988, J IMMUNOL, V140, P905; Secrist H, 1996, EUR J IMMUNOL, V26, P1435, DOI 10.1002/eji.1830260706; SEEHAFER JG, 1988, BIOCHIM BIOPHYS ACTA, V957, P399, DOI 10.1016/0167-4838(88)90231-2; SEEHAFER JG, 1991, BIOCHEM BIOPH RES CO, V179, P401, DOI 10.1016/0006-291X(91)91384-O; SELA BA, 1989, HYBRIDOMA, V8, P481, DOI 10.1089/hyb.1989.8.481; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; SI ZY, 1993, INT J CANCER, V54, P37, DOI 10.1002/ijc.2910540107; Skubitz KM, 1996, J IMMUNOL, V157, P3617; SLUPSKY JR, 1989, J BIOL CHEM, V264, P12289; Smith DA, 1995, MOL IMMUNOL, V32, P1339, DOI 10.1016/0161-5890(95)00113-1; SOHMA Y, 1994, CELL STRUCT FUNCT, V19, P219, DOI 10.1247/csf.19.219; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; Tai XG, 1996, J EXP MED, V184, P753, DOI 10.1084/jem.184.2.753; TAKAGI S, 1995, INT J CANCER, V61, P706, DOI 10.1002/ijc.2910610519; TAKAHASHI N, 1991, JPN J CANCER RES, V82, P1239, DOI 10.1111/j.1349-7006.1991.tb01787.x; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; Todd SC, 1996, J EXP MED, V184, P2055, DOI 10.1084/jem.184.5.2055; TOLE S, 1993, DEV DYNAM, V197, P94, DOI 10.1002/aja.1001970203; TOMLINSON MG, 1995, EUR J IMMUNOL, V25, P2201, DOI 10.1002/eji.1830250813; Tomlinson MG, 1996, J MOL EVOL, V43, P312; TOMLINSON MG, 1993, EUR J IMMUNOL, V23, P136, DOI 10.1002/eji.1830230122; TOOTHILL VJ, 1990, J IMMUNOL, V145, P283; VISCHER UM, 1993, BLOOD, V82, P1184, DOI 10.1182/blood.V82.4.1184.1184; WICE BM, 1995, J BIOL CHEM, V270, P21907, DOI 10.1074/jbc.270.37.21907; WILLETT BJ, 1994, IMMUNOLOGY, V81, P228; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WRIGHT MD, 1990, J IMMUNOL, V144, P3195; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; WRIGHT MD, 1993, INT IMMUNOL, V5, P209, DOI 10.1093/intimm/5.2.209; WROBLEWSKI JJ, 1994, OPHTHALMOLOGY, V101, P12; WROBLEWSKI JJ, 1994, BRIT J OPHTHALMOL, V78, P831, DOI 10.1136/bjo.78.11.831; WU XR, 1995, J BIOL CHEM, V270, P29752; YU J, 1994, J CELL BIOL, V125, P171, DOI 10.1083/jcb.125.1.171	140	786	840	1	67	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1997	11	6					428	442		10.1096/fasebj.11.6.9194523	http://dx.doi.org/10.1096/fasebj.11.6.9194523			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XE404	9194523	Bronze			2022-12-28	WOS:A1997XE40400005
J	Rhoads, AR; Friedberg, F				Rhoads, AR; Friedberg, F			Sequence motifs for calmodulin recognition	FASEB JOURNAL			English	Review						calmodulin binding region; MLCK; IQ motif; CaM binding motif; calmodulin binding proteins; myosin	PROTEIN-KINASE-C; NITRIC-OXIDE SYNTHASE; VASOACTIVE INTESTINAL PEPTIDE; PERTUSSIS ADENYLATE-CYCLASE; RABBIT SKELETAL-MUSCLE; AMINO-ACID-SEQUENCE; LIGHT-CHAIN KINASE; HEAT-SHOCK PROTEIN; BINDING DOMAIN; PHOSPHORYLASE-KINASE	Calmodulin (CaM) is recognized as a major calcium sensor and orchestrator of regulatory events through its interaction with a diverse group of cellular proteins. Many investigations have focused on defining the region of interaction between CaM and its cellular targets and the action of CaM on target protein function, Because CaM can bind with high affinity to a relatively small alpha-helical region of many proteins, success in clearly defining the essential elements of CaM binding motifs seems feasible and should provide a means of identifying CaM binding proteins. Three recognition motifs for CaM interaction are discussed in the context of experimental investigations of a variety of CaM target proteins. A modified version of the IQ motif as a consensus for Ca2+-independent binding and two related motifs for Ca2+-dependent binding, termed 1-8-14 and 1-5-10 based on the position of conserved hydrophobic residues, are proposed. Although considerable sequence diversity is observed among the different binding regions, these three classes of recognition motifs exist for many of the known CaM binding proteins.			Rhoads, AR (corresponding author), HOWARD UNIV, COLL MED, DEPT BIOCHEM & MOL BIOL, 520 W ST NW, WASHINGTON, DC 20059 USA.							ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; Anderson JT, 1996, J BIOL CHEM, V271, P6605, DOI 10.1074/jbc.271.12.6605; BAHLER M, 1994, J CELL BIOL, V126, P375, DOI 10.1083/jcb.126.2.375; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BOUHSS A, 1993, J BIOL CHEM, V268, P1690; BRENNEMAN DE, 1988, ANN NY ACAD SCI, V527, P595; BROCKERHOFF SE, 1994, J CELL BIOL, V124, P315, DOI 10.1083/jcb.124.3.315; BUELT MK, 1994, J BIOL CHEM, V269, P29367; Cali JJ, 1996, J BIOL CHEM, V271, P1089, DOI 10.1074/jbc.271.2.1089; CHEN SRW, 1994, J BIOL CHEM, V269, P22698; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; COMTE M, 1983, BIOCHEM J, V209, P269, DOI 10.1042/bj2090269; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FRIEDBERG F, 1990, Protein Sequences and Data Analysis, V3, P335; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; GARCIA A, 1989, J CELL BIOL, V109, P2895, DOI 10.1083/jcb.109.6.2895; GAUTEL M, 1995, EUR J BIOCHEM, V230, P752; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; GOMES AV, 1994, BIOESSAYS, V16, P853, DOI 10.1002/bies.950161113; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HARPER JF, 1991, SCIENCE, V252, P951, DOI 10.1126/science.1852075; HEIERHORST J, 1994, J BIOL CHEM, V269, P21086; Heiman RG, 1996, P NATL ACAD SCI USA, V93, P2420, DOI 10.1073/pnas.93.6.2420; HOUDUSSE A, 1995, P NATL ACAD SCI USA, V92, P10644, DOI 10.1073/pnas.92.23.10644; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JUMINAGA D, 1994, J BIOL CHEM, V269, P1660; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; KOBAYASHI T, 1989, J BIOL CHEM, V264, P1551; LADANT D, 1989, J BIOL CHEM, V264, P4015; LEE HC, 1995, J BIOL CHEM, V270, P9060, DOI 10.1074/jbc.270.16.9060; LETO TL, 1989, J BIOL CHEM, V264, P5826; LI ZP, 1991, J BIOL CHEM, V266, P1014; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; MADHAVAN R, 1992, BIOCHEM BIOPH RES CO, V185, P753, DOI 10.1016/0006-291X(92)91690-R; MALENCIK DA, 1983, BIOCHEM BIOPH RES CO, V114, P50, DOI 10.1016/0006-291X(83)91592-9; MANALAN AS, 1984, ADV CYCLIC NUCL PROT, V18, P227; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MINAMI Y, 1993, J BIOL CHEM, V268, P9604; MUNIER H, 1993, J BIOL CHEM, V268, P1695; NEWSHOLME P, 1992, J BIOL CHEM, V267, P810; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; PERSECHINI A, 1988, J CARDIOVASC PHARM, V12, pS1; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; PICTON C, 1980, EUR J BIOCHEM, V111, P553, DOI 10.1111/j.1432-1033.1980.tb04971.x; PORTER JA, 1995, EMBO J, V14, P4450, DOI 10.1002/j.1460-2075.1995.tb00124.x; ROBERTSON DL, 1988, GENE, V73, P363, DOI 10.1016/0378-1119(88)90501-X; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHLEMMER SR, 1995, J BIOL CHEM, V270, P11040, DOI 10.1074/jbc.270.19.11040; SEEHOLZER SH, 1987, CALCIUM BINDING PROT, P188; Slemmon JR, 1996, J BIOL CHEM, V271, P15911, DOI 10.1074/jbc.271.27.15911; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBUE K, 1980, BIOCHEM INT, V1, P561; Sonnenburg WK, 1995, J BIOL CHEM, V270, P30989, DOI 10.1074/jbc.270.52.30989; STALLWOOD D, 1992, J BIOL CHEM, V267, P19617; STEVENSON MA, 1990, MOL CELL BIOL, V10, P1234, DOI 10.1128/MCB.10.3.1234; STIRLING DA, 1994, EMBO J, V13, P4329, DOI 10.1002/j.1460-2075.1994.tb06753.x; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TAKAGI T, 1990, J BIOL CHEM, V265, P19721; TERWILLIGER TC, 1982, J BIOL CHEM, V257, P6016; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; Wang FS, 1996, SCIENCE, V273, P660, DOI 10.1126/science.273.5275.660; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; Wes PD, 1996, EMBO J, V15, P5839, DOI 10.1002/j.1460-2075.1996.tb00971.x; WINDER SJ, 1995, FEBS LETT, V357, P125, DOI 10.1016/0014-5793(94)01347-4; WOLENSKI JS, 1995, TRENDS CELL BIOL, V5, P310, DOI 10.1016/S0962-8924(00)89053-4; WU ZL, 1993, J BIOL CHEM, V268, P23766; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; ZHAN Q, 1991, J BIOL CHEM, V266, P21810; ZHANG MJ, 1994, J BIOL CHEM, V269, P981; ZHUANG SB, 1995, BIOCHEM BIOPH RES CO, V209, P12, DOI 10.1006/bbrc.1995.1463; ZIMMER DB, 1987, J BIOL CHEM, V262, P7751	95	729	760	1	38	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1997	11	5					331	340		10.1096/fasebj.11.5.9141499	http://dx.doi.org/10.1096/fasebj.11.5.9141499			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WX156	9141499				2022-12-28	WOS:A1997WX15600005
J	Goin, JC; Leiros, CP; Borda, E; SterinBorda, L				Goin, JC; Leiros, CP; Borda, E; SterinBorda, L			Interaction of human chagasic IgG with the second extracellular loop of the human heart muscarinic acetylcholine receptor: Functional and pathological implications	FASEB JOURNAL			English	Article						chagasic cardiomyopathy; mAChRs; 24-mer peptide; heart contractility; cAMP; cGMP; immunoblot; ELISA assay	TRYPANOSOMA-CRUZI; ANTIBODIES; DISEASE; CONTRACTILITY; LOCALIZATION; CARDIOPATHY; SYSTEM; SERA	Circulating antibodies from human and murine chagasic sera are able to interact with myocardium-activating neurotransmitter receptors. Here we reported the presence of autoantibodies against the second extracellular loop of the human heart muscarinic acetylcholine receptors (mAChR) in patients with Chagas' disease by using a synthetic 24-mer peptide in immunoblotting and enzyme immunoassay. Affinity-purified antipeptide IgG from chagasic patients, similar to monoclonal antihuman M-2 mAChR, recognized bands with a molecular weight corresponding to the cardiac mAChR. The binding was inhibited by the peptide, assessing the specificity of the interaction. The antipeptide autoantibody also displayed an ''agonist-like'' activity modifying the intracellular events associated with mAChR activation, i.e., decreased contractility, increased cGMP, and decreased cAMP production. All of these effects on rat atria by chagasic antipeptide autoantibodies resemble the effects of the authentic agonist and those of the total polyclonal chagasic IgG, being selectively blunted by atropine and neutralized by the synthetic peptide corresponding in amino acid sequence to the second extracellular loop of the human M-2 mAChR. A clinical relevance of these findings is demonstrated by a strong association between the existence of circulating antipeptide antoantibodies in chagasic patients and the presence of dysautonomic symptoms, making these antoantibodies a proper early marker of heart autonomic dysfunction.	CONSEJO NACL INVEST CIENT & TECN, CTR ESTUDIOS FARMACOL & BOT, RA-1414 BUENOS AIRES, DF, ARGENTINA; UNIV BUENOS AIRES, SCH MED & DENT, DEPT PHARMACOL, BUENOS AIRES, DF, ARGENTINA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires								ACOSTA AM, 1985, CIRCULATION, V71, P1255, DOI 10.1161/01.CIR.71.6.1255; BORDA E, 1984, CLIN EXP IMMUNOL, V57, P679; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; COSSIO PM, 1977, AM J PATHOL, V86, P533; COSSIO PM, 1974, CIRCULATION, V49, P13, DOI 10.1161/01.CIR.49.1.13; CUNNINGHAM DS, 1980, INFECT IMMUN, V30, P496; DEBRACCO MMD, 1984, CLIN EXP IMMUNOL, V55, P405; ECHAGUE AV, 1994, ACTA PHYSL PHARM LAT, V44, P100; FU LX, 1993, J CLIN INVEST, V91, P1964, DOI 10.1172/JCI116416; FU M, 1994, J HISTOCHEM CYTOCHEM, V42, P337, DOI 10.1177/42.3.8308250; FU MLX, 1994, CLIN IMMUNOL IMMUNOP, V72, P15, DOI 10.1006/clin.1994.1101; GOIN JC, 1994, J AUTONOM NERV SYST, V47, P45, DOI 10.1016/0165-1838(94)90064-7; GOIN JC, 1991, P SOC EXP BIOL MED, V197, P186, DOI 10.3181/00379727-197-43244; Goin Juan Carlos, 1994, Neuroimmunomodulation, V1, P284; Goin Juan Carlos, 1994, Molecular Neuropharmacology, V3, P189; GORELIK G, 1992, J MOL CELL CARDIOL, V24, P9, DOI 10.1016/0022-2828(92)91155-X; IOSA D, 1990, J AUTONOM NERV SYST, V30, pS83, DOI 10.1016/0165-1838(90)90107-T; KOBERLE F, 1961, Bol Oficina Sanit Panam, V51, P404; Koberle F., 1974, CIBA F SYMP, P137; LIANGXIONG F, 1995, J MOL CELL CARDIOL, V27, P427; MIRKIN GA, 1994, CLIN IMMUNOL IMMUNOP, V73, P69, DOI 10.1006/clin.1994.1171; PASCUAL J, 1986, BIOCHEM PHARMACOL, V35, P3839, DOI 10.1016/0006-2952(86)90673-8; Sterin-Borda Leonor J., 1994, Acta Physiologica Pharmacologica et Therapeutica Latinoamericana, V44, P109; STERINBORDA L, 1981, ARCH INT PHARMACOD T, V250, P93; STERINBORDA L, 1995, BRIT J PHARMACOL, V115, P1525, DOI 10.1111/j.1476-5381.1995.tb16646.x; STERINBORDA L, 1976, CARDIOVASC RES, V10, P613, DOI 10.1093/cvr/10.6.613; STERINBORDA L, 1981, EUR J PHARMACOL, V69, P1, DOI 10.1016/0014-2999(81)90596-3; STERINBORDA L, 1990, FASEB J, V4, P1661, DOI 10.1096/fasebj.4.6.2156743; STERINBORDA L, 1986, INT J IMMUNOPHARMACO, V8, P581, DOI 10.1016/0192-0561(86)90029-9; STERINBORDA L, 1991, CLIN IMMUNOL IMMUNOP, V61, P387, DOI 10.1016/S0090-1229(05)80010-8; STORINO R, 1986, MIOCARDIOPATIA CHAGA, P121; SZARFMAN A, 1982, J EXP MED, V155, P1161, DOI 10.1084/jem.155.4.1161	32	66	68	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1997	11	1					77	83		10.1096/fasebj.11.1.9034169	http://dx.doi.org/10.1096/fasebj.11.1.9034169			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK147	9034169				2022-12-28	WOS:A1997WK14700011
J	Doolittle, RF; Everse, SJ; Spraggon, G				Doolittle, RF; Everse, SJ; Spraggon, G			Human fibrinogen: Anticipating a 3-dimensional structure	FASEB JOURNAL			English	Article						fibrin; thrombin; factor XIII; plasmin; Gly-Pro-Arg	AMINO-ACID-SEQUENCE; GAMMA-CHAIN; ELECTRON-MICROSCOPY; ALPHA-CHAIN; POLYMERIZATION SITE; FRAGMENTS; DOMAINS; SUBUNIT; MODEL; CRYSTALLIZATION	The principal component of blood clots is a protein meshwork called fibrin. The precursor protein, fibrinogen, occurs in a soluble form in the blood plasma where it is activated by thrombin when and if the need arises. More than a century after first being purified, fibrinogen has yet to have its detailed 3-dimensional structure revealed. The situation is changing rapidly, however, and crystallographic studies in progress in several laboratories on a variety of fragments and complexes may soon reveal not only its structure but also the subtleties of how this large glycoprotein is transformed into a fibrin clot.			Doolittle, RF (corresponding author), UNIV CALIF SAN DIEGO, CTR MOL GENET, LA JOLLA, CA 92093 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026873, R37HL026873] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 26873] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bailey K, 1943, NATURE, V151, P716, DOI 10.1038/151716a0; BALE MD, 1985, P NATL ACAD SCI USA, V82, P1410, DOI 10.1073/pnas.82.5.1410; BLOMBACK B, 1957, ARK KEMI, V10, P415; BLUMENSTEIN M, 1992, BIOCHEMISTRY-US, V31, P10692, DOI 10.1021/bi00159a008; BOUMA H, 1978, THROMB RES, V13, P557, DOI 10.1016/0049-3848(78)90142-1; CHEN R, 1971, BIOCHEMISTRY-US, V10, P4486, DOI 10.1021/bi00800a021; COHEN C, 1974, NATURE, V251, P659, DOI 10.1038/251659a0; COHEN C, 1961, J POLYM SCI, V49, P144; DONAHUE JP, 1994, P NATL ACAD SCI USA, V91, P12178, DOI 10.1073/pnas.91.25.12178; Doolittle R F, 1973, Adv Protein Chem, V27, P1, DOI 10.1016/S0065-3233(08)60446-5; DOOLITTLE RF, 1992, PROTEIN SCI, V1, P1563, DOI 10.1002/pro.5560011204; DOOLITTLE RF, 1978, J MOL BIOL, V120, P311, DOI 10.1016/0022-2836(78)90070-0; DOOLITTLE RF, 1979, NATURE, V280, P464, DOI 10.1038/280464a0; DOOLITTLE RF, 1977, BIOCHEMISTRY-US, V16, P1710, DOI 10.1021/bi00627a029; ERICKSON HP, 1983, ANN NY ACAD SCI, V408, P146, DOI 10.1111/j.1749-6632.1983.tb23242.x; EVERSE SJ, 1995, PROTEIN SCI, V4, P1013; FOWLER WE, 1981, SCIENCE, V211, P287, DOI 10.1126/science.6108612; FU YP, 1992, BIOCHEMISTRY-US, V31, P11968, DOI 10.1021/bi00163a002; GARDLUND B, 1977, EUR J BIOCHEM, V77, P595, DOI 10.1111/j.1432-1033.1977.tb11704.x; GOLLWITZER R, 1983, THROMB RES, P41; GOLLWITZER R, 1986, EUR J BIOCHEM, V154, P437, DOI 10.1111/j.1432-1033.1986.tb09416.x; GORKUN OV, 1994, BIOCHEMISTRY-US, V33, P6986, DOI 10.1021/bi00188a031; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HAVERKATE F, 1977, THROMB RES, V10, P803, DOI 10.1016/0049-3848(77)90137-2; HAWIGER J, 1995, SEMIN HEMATOL, V32, P99; HENSCHEN A, 1964, ARK KEMI, V22, P355; HUANG SM, 1993, J BIOL CHEM, V268, P8919; HUDRYCLERGEON G, 1974, PATHOL BIOL, V22, P47; JAMNEY P, 1983, BIOCHEMISTRY-US, V22, P4336; KUYAS C, 1990, THROMB HAEMOSTASIS, V63, P439; LAUDANO AP, 1978, P NATL ACAD SCI USA, V75, P3085, DOI 10.1073/pnas.75.7.3085; MARDER VJ, 1970, THROMB DIATH HAEMOST, P187; MATSUDA M, 1991, BIOMED PROGR, V4, P51; Mayo KH, 1996, BIOCHEMISTRY-US, V35, P4434, DOI 10.1021/bi952485n; MCKEE PA, 1966, ARCH BIOCHEM BIOPHYS, V116, P271, DOI 10.1016/0003-9861(66)90033-6; MCKEE PA, 1970, P NATL ACAD SCI USA, V66, P738, DOI 10.1073/pnas.66.3.738; MOSESSON MW, 1981, J MOL BIOL, V153, P695, DOI 10.1016/0022-2836(81)90414-9; MURAKAWA M, 1993, THROMB HAEMOSTASIS, V69, P351; NUSSENZWEIG V, 1961, ANN I PASTEUR PARIS, V100, P377; PAN Y, 1992, P NATL ACAD SCI USA, V89, P2066, DOI 10.1073/pnas.89.6.2066; RAO SPS, 1991, J MOL BIOL, V222, P89, DOI 10.1016/0022-2836(91)90739-S; Rudchenko S, 1996, J BIOL CHEM, V271, P2523, DOI 10.1074/jbc.271.5.2523; SCHIELEN WJG, 1991, BIOCHEM J, V276, P655, DOI 10.1042/bj2760655; SHIMIZU A, 1992, P NATL ACAD SCI USA, V89, P2888, DOI 10.1073/pnas.89.7.2888; SOBEL JH, 1988, THROMB HAEMOSTASIS, V60, P153; SPRAGGON G, 1996, INT UN CRYST 17 C GE; TAKAGI T, 1975, BIOCHIM BIOPHYS ACTA, V386, P617, DOI 10.1016/0005-2795(75)90306-2; TOONEY NM, 1972, NATURE, V237, P23, DOI 10.1038/237023a0; TOONEY NM, 1977, J MOL BIOL, V110, P363, DOI 10.1016/S0022-2836(77)80077-6; WEISEL JW, 1981, NATURE, V289, P263, DOI 10.1038/289263a0; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058; WEISSBACH L, 1990, P NATL ACAD SCI USA, V87, P5198, DOI 10.1073/pnas.87.13.5198; WILLIAMS RC, 1981, J MOL BIOL, V150, P399, DOI 10.1016/0022-2836(81)90555-6; YAMAZUMI K, 1992, P NATL ACAD SCI USA, V89, P2893, DOI 10.1073/pnas.89.7.2893; YAMAZUMI K, 1992, PROTEIN SCI, V1, P1719, DOI 10.1002/pro.5560011220; YEE VC, 1996, INT UN CRYST 17 C GE	56	28	30	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1996	10	13					1464	1470		10.1096/fasebj.10.13.8940292	http://dx.doi.org/10.1096/fasebj.10.13.8940292			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VU982	8940292				2022-12-28	WOS:A1996VU98200003
J	Iida, N; Haisa, M; Igarashi, A; Pencev, D; Grotendorst, GR				Iida, N; Haisa, M; Igarashi, A; Pencev, D; Grotendorst, GR			Leukocyte-derived growth factor links the PDGF and CXC chemokine families of peptides	FASEB JOURNAL			English	Article						peptide growth factor; chemokines; wound healing	PLATELET BASIC-PROTEIN; SIMIAN SARCOMA-VIRUS; SMOOTH-MUSCLE CELLS; HUMAN WOUND FLUID; CONNECTIVE-TISSUE; BETA-THROMBOGLOBULIN; STIMULATORY ACTIVITY; MITOGENIC ACTIVITY; MESSENGER-RNA; GENE	Leukocytes produce many biological mediators that orchestrate the subsequent cellular events during wound healing, We have identified a novel cytokine, leukocyte-derived growth factor (LDGF), which is mitogenic for connective tissue cells, Sequence analysis of the LDGF peptide revealed that it is a precursor of other known peptides including platelet basic protein (PBP), connective tissue activating peptide III (CTAP-III), and neutrophil activating peptide 2 (NAP-2). None of these shorter peptides are active as mitogens for fibroblasts, LDGF appears to stimulate fibroblast growth by stimulation of tyrosine kinase activity of the PDGF receptors. One of the truncated products of LDGF, NAP-S, is a potent neutrophil chemoattractant, Peptides larger than NAP-2, such as PBP and CTAP-III, are not active as neutrophil chemoattractants, Collectively, these findings demonstrate that the LDGF peptide must remain intact in order to retain its fibroblast mitogenic activity, If the LDGF peptide is processed to release the carboxyl terminal half to generate NAP-S, a peptide with proinflammatory activity is generated, These results indicate that the multiple peptides produced from the LDGF-PBP gene posses divergent biological activities that could regulate different phases of the repair process.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT R124,MIAMI,FL 33136; UNIV S FLORIDA,DEPT BIOCHEM & MOL BIOL,COLL MED,TAMPA,FL 33612; UNIV S FLORIDA,DEPT MED,COLL MED,TAMPA,FL 33612	University of Miami; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida								ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; ANTONIADES HN, 1981, P NATL ACAD SCI-BIOL, V78, P7314, DOI 10.1073/pnas.78.12.7314; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; CASTOR CW, 1983, P NATL ACAD SCI-BIOL, V80, P765, DOI 10.1073/pnas.80.3.765; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIVELLI O, 1983, PEPTIDES, V4, P651, DOI 10.1016/0196-9781(83)90013-X; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLARK R. A. F., 1995, MOL CELLULAR BIOL WO; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; Cohen I. K., 1992, WOUND HEALING BIOCH; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; DEUEL TF, 1981, J BIOL CHEM, V256, P8896; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; GROTENDORST GR, 1981, P NATL ACAD SCI-BIOL, V78, P3669, DOI 10.1073/pnas.78.6.3669; GROTENDORST GR, 1991, J CELL PHYSIOL, V149, P235, DOI 10.1002/jcp.1041490209; GROTENDORST GR, 1990, ADV APPL BIOTECHNOLO, V8; GROTENDORST GR, 1991, MOL CELL BIOL CYTOKI, P381; HELDIN CH, 1981, P NATL ACAD SCI-BIOL, V78, P3664, DOI 10.1073/pnas.78.6.3664; HELDIN CH, 1981, BIOCHEM J, V193, P907, DOI 10.1042/bj1930907; HOLT JC, 1986, BIOCHEMISTRY-US, V25, P1988, DOI 10.1021/bi00356a023; INUI H, 1993, J BIOL CHEM, V268, P17045; KARTHA S, 1988, AM J PHYSIOL, V255, pF800, DOI 10.1152/ajprenal.1988.255.4.F800; KAZLAUSKAS A, 1988, EMBO J, V7, P3727, DOI 10.1002/j.1460-2075.1988.tb03256.x; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUOKA J, 1989, P NATL ACAD SCI USA, V86, P4416, DOI 10.1073/pnas.86.12.4416; MORNEX JF, 1986, J CLIN INVEST, V78, P61, DOI 10.1172/JCI112574; PAUL D, 1980, THROMB RES, V18, P883, DOI 10.1016/0049-3848(80)90210-8; PENCEV D, 1993, ONCOGENE RES, V268, P17045; PONCZ M, 1987, BLOOD, V69, P219; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SCHMID J, 1987, J IMMUNOL, V139, P250; SCHRODER JM, 1990, J EXP MED, V171, P1091, DOI 10.1084/jem.171.4.1091; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SOMA Y, 1992, FASEB J, V6, P2996, DOI 10.1096/fasebj.6.11.1644262; SPORN MB, 1986, J CLIN INVEST, V78, P329, DOI 10.1172/JCI112580; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; WALZ A, 1989, J EXP MED, V170, P1745, DOI 10.1084/jem.170.5.1745; WALZ A, 1990, J EXP MED, V171, P449, DOI 10.1084/jem.171.2.449; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WENGER RH, 1989, BLOOD, V73, P1498; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233	50	37	38	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1996	10	11					1336	1345		10.1096/fasebj.10.11.8836048	http://dx.doi.org/10.1096/fasebj.10.11.8836048			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VJ717	8836048				2022-12-28	WOS:A1996VJ71700014
J	Thorgeirsson, SS				Thorgeirsson, SS			Liver regeneration .9. Hepatic stem cells in liver regeneration	FASEB JOURNAL			English	Article						growth factors; liver stem cell biology; stem cell activation; hepatocytes; bile duct epithelial cells; liver parenchyma; oval cells; partial hepatectomy; proliferation; differentiation	GROWTH-FACTOR-ALPHA; CHOLINE-DEFICIENT DIET; BILIARY EPITHELIAL-CELLS; ADULT-RAT LIVER; OVAL CELLS; CHEMICAL HEPATOCARCINOGENESIS; FETOPROTEIN EXPRESSION; MONOCLONAL-ANTIBODIES; C-KIT; DIFFERENTIATION	The concept that the Liver contains epithelial cells that share some of the major properties of stem cells of the well-characterized, stem cell-fed lineages found in bone marrow, intestinal epithelium, and epidermis is now well supported, Nevertheless, the population dynamics of the major types of liver epithelial cells, hepatocytes, and bile epithelia display a striking difference from the population dynamics of the classic stem cell systems, The focus of this review is on recent studies of the activation and expansion of liver stem cells in vivo and the role these cells may play in regeneration of the liver. The requirement for a selective and sustained expression of growth factors during the early stages of stem cell activation is highlighted, In addition, results are presented supporting the hypothesis that after loss of liver mass, both the quiescent stem cells as well as the residual differentiated hepatocytes and bile duct epithelial cells are activated to proliferate, However, significant contribution of the stem cells to the regeneration process only occurs under circumstances in which the residual differentiated cells are functionally compromised and/or cannot proliferate.			Thorgeirsson, SS (corresponding author), NCI,NIH,EXPT CARCINOGENESIS LAB,DIV BASIC SCI,BLDG 37,ROOM 3C28,37 CONVENT DR MSC4255,BETHESDA,MD 20892, USA.							BISGAARD HC, 1994, J CELL PHYSIOL, V159, P475, DOI 10.1002/jcp.1041590312; Bisgaard HC, 1996, HEPATOLOGY, V23, P62, DOI 10.1002/hep.510230110; BISGAARD HC, 1994, J CELL PHYSIOL, V159, P485, DOI 10.1002/jcp.1041590313; DUNSFORD HA, 1989, CANCER RES, V49, P4887; ENGELHARDT NV, 1990, DIFFERENTIATION, V45, P29, DOI 10.1111/j.1432-0436.1990.tb00453.x; ENGELHARDT NV, 1993, DIFFERENTIATION, V55, P19, DOI 10.1111/j.1432-0436.1993.tb00029.x; EVARTS RP, 1992, MOL CARCINOGEN, V5, P25, DOI 10.1002/mc.2940050107; EVARTS RP, 1987, CARCINOGENESIS, V8, P1737, DOI 10.1093/carcin/8.11.1737; EVARTS RP, 1993, CELL GROWTH DIFFER, V4, P555; EVARTS RP, 1990, CANCER RES, V50, P3439; FACTOR VM, 1994, AM J PATHOL, V145, P409; FARBER E, 1984, CANCER RES, V44, P5463; FARBER E, 1956, CANCER RES, V16, P142; FARIS RA, 1991, CANCER RES, V51, P1308; FAUSTO N, 1990, PROG CLIN BIOL RES, V331, P325; Fujio K, 1996, EXP CELL RES, V224, P243, DOI 10.1006/excr.1996.0134; FUJIO K, 1994, LAB INVEST, V70, P511; GERBER MA, 1983, AM J PATHOL, V110, P70; GERMAIN L, 1988, CANCER RES, V48, P368; GERMAIN L, 1988, CANCER RES, V48, P4909; GERMAIN L, 1985, CANCER RES, V45, P673; GOLDING M, 1995, HEPATOLOGY, V22, P1243, DOI 10.1002/hep.1840220433; Grisham J W, 1980, Ann N Y Acad Sci, V349, P128, DOI 10.1111/j.1749-6632.1980.tb29521.x; GRISHAM JW, 1996, STEM CELL HDB; HAYNER NT, 1984, CANCER RES, V44, P332; HIXSON DC, 1990, PATHOBIOLOGY, V58, P65, DOI 10.1159/000163565; HIXSON DC, 1985, CANCER RES, V45, P3750; HSIA CC, 1994, J MED VIROL, V43, P216, DOI 10.1002/jmv.1890430304; HSIA CC, 1992, HEPATOLOGY, V16, P1327, DOI 10.1002/hep.1840160604; HU ZY, 1993, AM J PATHOL, V142, P1823; Hu ZY, 1996, CARCINOGENESIS, V17, P931, DOI 10.1093/carcin/17.5.931; INAOKA Y, 1967, GANN, V58, P355; Kinosita R., 1937, T JPN PATHOL SOC, V27, P665; LAJTHA LG, 1970, NOUV REV FR HEMATOL, V21, P59; LEMIRE JM, 1991, AM J PATHOL, V139, P535; LEMIRE JM, 1991, CANCER RES, V51, P4656; LENZI R, 1992, LAB INVEST, V66, P390; LESCH R, 1970, EXP MOL PATHOL, V12, P58, DOI 10.1016/0014-4800(70)90075-4; MARCEAU N, 1990, LAB INVEST, V63, P4; MARCEAU N, 1986, BIOCHEM CELL BIOL, V64, P788, DOI 10.1139/o86-107; MARCEAU N, 1992, ROLE CELL TYPES HEPA, P121; MARSDEN ER, 1992, LAB INVEST, V67, P427; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; METCALF D, 1991, P NATL ACAD SCI USA, V88, P11310, DOI 10.1073/pnas.88.24.11310; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MORRISONGRAHAM K, 1993, BIOESSAYS, V15, P77, DOI 10.1002/bies.950150202; NAGY P, 1994, J CELL BIOL, V126, P223, DOI 10.1083/jcb.126.1.223; Nagy P, 1996, HEPATOLOGY, V23, P71, DOI 10.1053/jhep.1996.v23.pm0008550051; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; PRICE JM, 1952, CANCER RES, V12, P192; RHIM JA, 1994, SCIENCE, V263, P1149, DOI 10.1126/science.8108734; SELL S, 1990, CANCER RES, V50, P3811; SELL S, 1984, AM J PATHOL, V114, P287; SHINOZUKA H, 1978, CANCER RES, V38, P1092; SHIOJIRI N, 1991, CANCER RES, V51, P2611; SIGAL SH, 1992, AM J PHYSIOL, V263, pG139, DOI 10.1152/ajpgi.1992.263.2.G139; TATEMATSU M, 1984, AM J PATHOL, V114, P418; TATEMATSU M, 1985, LAB INVEST, V52, P354; THORGEIRSSON CS, 1992, ROLE CELL TYPES HEPA, P100; THORGEIRSSON SS, 1993, AM J PATHOL, V142, P1331; THORGEIRSSON SS, 1994, NATO ADV SCI INST SE, V88, P129; THORGEIRSSON SS, 1995, P 25 INT S PRINC TAK, P163; VANEYKEN P, 1993, LIVER, V13, P113; VANEYKEN P, 1989, LIVER, V9, P372; VANEYKEN P, 1992, ROLE CELL TYPES HEPA, P227; VANTHIEL DH, 1989, GASTROENTEROLOGY, V93, P1414; WILSON JW, 1958, J PATHOL BACTERIOL, V76, P441, DOI 10.1002/path.1700760213; YANG L, 1993, P SOC EXP BIOL MED, V204, P280	68	266	287	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1996	10	11					1249	1256		10.1096/fasebj.10.11.8836038	http://dx.doi.org/10.1096/fasebj.10.11.8836038			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VJ717	8836038				2022-12-28	WOS:A1996VJ71700004
J	ZarainHerzberg, A; Rupp, H; Elimban, V; Dhalla, NS				ZarainHerzberg, A; Rupp, H; Elimban, V; Dhalla, NS			Modification of sarcoplasmic reticulum gene expression in pressure overload cardiac hypertrophy by etomoxir	FASEB JOURNAL			English	Article						pressure-overloaded heart; cardiac mRNA signals; SR gene expression; heart hypertrophy	THYROID-HORMONE RECEPTOR; STAGE HEART-FAILURE; DIABETIC RAT-HEART; NUCLEOTIDE-SEQUENCE; CA-2+-ATPASE GENE; CA2+-ATPASE GENE; MYOSIN; MUSCLE; ACID; MYOCYTES	Pressure overload on the heart is known to produce hypertrophy of cardiomyocytes and distinct changes in protein phenotype, including reduced expression of the gene for the sarcoplasmic reticulum (SR) Ca(2+)ATPase (SERCA2). In this study we have shown that the decrease in SERCA2 gene expression (normalized by poly(A)+ mRNA or 18 S rRNA) in rats with 8 wk of aortic constriction was prevented by treatment with etomoxir, an inhibitor of carnitine palmitoyltransferase 1. The reduction in steady-state mRNA levels for SR phospholamban (PLP) and Ca2+ release channel (CRC) in the pressure-overloaded animals was also prevented without any reduction in the extent of cardiac hypertrophy by treatment with etomoxir, Although no changes in mRNA levels for GAPDH were evident in rats with pressure overload, the expression of the alpha-skeletal actin was increased; this change was prevented by etomoxir. Similar beneficial effects of etomoxir treatment were also evident when the gene expression for SR SERCA2, PLP, and CRC in the hypertrophied heart was normalized with respect to mRNA for GAPDH, These results support the view that drugs such as etomoxir may increase the abundance of, the mRNA for SR proteins in the hypertrophied heart and thus may prevent the transition of cardiac hypertrophy into heart failure.	ST BONIFACE GEN HOSP, RES CTR, DIV CARDIOVASC SCI, WINNIPEG, MB R2H 2A6, CANADA; UNIV MANITOBA, FAC MED, DEPT PHYSIOL, WINNIPEG, MB R2H 2A6, CANADA	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba			Dhalla, Naranjan/C-8279-2014	Dhalla, Naranjan/0000-0002-4894-4727				ARAI M, 1993, CIRC RES, V72, P463, DOI 10.1161/01.RES.72.2.463; ARAI M, 1994, CIRC RES, V74, P555, DOI 10.1161/01.RES.74.4.555; BRILLANTES AM, 1992, CIRC RES, V71, P18, DOI 10.1161/01.RES.71.1.18; CHAN YL, 1984, J BIOL CHEM, V259, P224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELABASTIE D, 1990, CIRC RES, V66, P554, DOI 10.1161/01.RES.66.2.554; DHALLA N S, 1987, Canadian Journal of Cardiology, V3, P183; DOMDEY H, 1983, EUR J BIOCHEM, V131, P129, DOI 10.1111/j.1432-1033.1983.tb07239.x; GAY RG, 1988, AM J PHYSIOL, V255, pH801, DOI 10.1152/ajpheart.1988.255.4.H801; HARTONG R, 1994, J BIOL CHEM, V269, P13021; LEVITSKY D, 1991, AM J PHYSIOL, V261, P23, DOI 10.1152/ajplung.1991.261.4.L23; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; MEAROW KM, 1993, MOL CELL BIOCHEM, V121, P155, DOI 10.1007/BF00925975; MERCADIER JJ, 1990, J CLIN INVEST, V85, P305, DOI 10.1172/JCI114429; MORENHOUSE CA, 1975, STAT PRINCIPLES PROC; MORKIN E, 1993, CIRCULATION, V87, P1451, DOI 10.1161/01.CIR.87.5.1451; NAGAI R, 1989, P NATL ACAD SCI USA, V86, P2966, DOI 10.1073/pnas.86.8.2966; PENNOCK GD, 1993, CIRCULATION, V88, P1289, DOI 10.1161/01.CIR.88.3.1289; REINAUER H, 1990, J CLIN CHEM CLIN BIO, V28, P335; ROHRER D, 1988, J BIOL CHEM, V263, P6941; ROHRER DK, 1991, J BIOL CHEM, V266, P8638; RUPP H, 1992, J APPL PHYSIOL, V72, P352, DOI 10.1152/jappl.1992.72.1.352; RUPP H, 1994, MOL CELL BIOCHEM, V132, P69, DOI 10.1007/BF00925676; RUPP H, 1992, FASEB J, V6, P2349, DOI 10.1096/fasebj.6.6.1531968; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SCHWARTZ K, 1992, BASIC RES CARDIOL, V87, P285; SHEN H, 1991, AM J VET RES, V52, P1527; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SIMPSON PC, 1989, J MOL CELL CARDIOL, V21, P79, DOI 10.1016/0022-2828(89)90774-8; SIMPSON PC, 1991, MOL CELL BIOCHEM, V104, P35; Towbin H, 1992, Biotechnology, V24, P145; VETTER R, 1994, AM J PHYSIOL-HEART C, V267, pH2091, DOI 10.1152/ajpheart.1994.267.6.H2091; VETTER R, 1995, EUR HEART J, V16, P15, DOI 10.1093/eurheartj/16.suppl_C.15; ZAKUT R, 1982, NATURE, V298, P857, DOI 10.1038/298857a0; ZARAINHERZBERG A, 1994, BIOCHEM BIOPH RES CO, V203, P113, DOI 10.1006/bbrc.1994.2156; ZARAINHERZBERG A, 1994, J BIOL CHEM, V269, P1460	38	57	59	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1996	10	11					1303	1309		10.1096/fasebj.10.11.8836044	http://dx.doi.org/10.1096/fasebj.10.11.8836044			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VJ717	8836044				2022-12-28	WOS:A1996VJ71700010
J	Ahmad, A; Menezes, J				Ahmad, A; Menezes, J			Antibody-dependent cellular cytotoxicity in HIV infections	FASEB JOURNAL			English	Review						AIDS; ADCC; NK activity; HIV infection	IMMUNODEFICIENCY-VIRUS INFECTION; NATURAL-KILLER-CELLS; AIDS-RELATED COMPLEX; CYTO-TOXICITY ADCC; SEROPOSITIVE INDIVIDUALS; MEDIATED CYTOTOXICITY; DISEASE PROGRESSION; LYMPHOCYTES-T; TARGET-CELLS; INVIVO	ADCC is an important immune effector mechanism against tumor and virus-infected cells that can be destroyed by the combined action of specific antibodies of IgG isotype against cell surface-associated antigens and effector cells, predominantly of the NK phenotype, ADCC has been shown to function in vivo in several systems, With regard to HIV, it can be readily demonstrated in vitro against the viral envelope proteins with serum and/or effector cells obtained from HIV-infected subjects, Several studies have demonstrated that the titers of the env-specific ADCC-mediating antibodies decrease in the sera of HIV-infected individuals as the infection progresses toward AIDS, The cells that mediate ADCC also become functionally compromised in these individuals in early stages of the infection, thus depriving the host of the potential benefits of this process, Restoration of this process in the infected individuals by the administration of functionally competent effector cells (in vitro expanded and lymphokine-activated killer cells) and ADCC-mediating antibodies (hyperimmune serum or appropriate monoclonal antibodies), alone or in combination, may help slow the disease progress, Because of the multicomponent nature of the process, ADCC-mediating antibodies may prove a better correlate of protection and prognosis than the virus-specific neutralizing antibodies and cytotoxic T cells in assessing anti-HIV immunization and immunotherapy.	ST JUSTINE HOSP,LAB IMMUNOVIROL,MONTREAL,PQ H3T 1C5,CANADA; UNIV MONTREAL,PEDIAT RES CTR,LAB IMMUNOVIROL,MONTREAL,PQ H3T 1C5,CANADA; UNIV MONTREAL,DEPT MICROBIOL & IMMUNOL,MONTREAL,PQ H3T 1C5,CANADA	Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; Universite de Montreal				Ahmad, Ali/0000-0001-7689-7115				AHMAD A, 1994, J ACQ IMMUN DEF SYND, V7, P789; AHMAD A, 1994, J ACQ IMMUN DEF SYND, V7, P428; AHMAD A, 1995, J ACQ IMMUN DEF SYND, V10, P115, DOI 10.1097/00042560-199510020-00002; ALLEN JB, 1991, J CLIN INVEST, V87, P1773, DOI 10.1172/JCI115196; BERZOFSKY JA, 1991, J ACQ IMMUN DEF SYND, V4, P451; BONAVIDA B, 1986, J IMMUNOL, V137, P1157; BRENNER BG, 1991, J LEUKOCYTE BIOL, V50, P628, DOI 10.1002/jlb.50.6.628; BROLIDEN PA, 1990, J VIROL, V64, P936, DOI 10.1128/JVI.64.2.936-940.1990; Buijs L, 1993, Immunodeficiency, V5, P23; CLERICI M, 1994, IMMUNOL TODAY, V15, P575, DOI 10.1016/0167-5699(94)90220-8; COLLINS JJ, 1983, VIROLOGY, V126, P259, DOI 10.1016/0042-6822(83)90477-4; DALGLEISH A, 1990, CLIN EXP IMMUNOL, V81, P5, DOI 10.1111/j.1365-2249.1990.tb05283.x; EMSKOETTER T, 1989, J NEUROIMMUNOL, V24, P61, DOI 10.1016/0165-5728(89)90099-4; EVANS LA, 1989, AIDS, V3, P273, DOI 10.1097/00002030-198905000-00004; FERRARI G, 1994, J ACQ IMMUN DEF SYND, V7, P325; GOUDSMIT J, 1988, ARCH VIROL, V103, P189, DOI 10.1007/BF01311092; HANK JA, 1990, CANCER RES, V50, P5234; HERCEND T, 1988, IMMUNOL TODAY, V9, P291, DOI 10.1016/0167-5699(88)91317-5; HOFFENBACH A, 1989, J IMMUNOL, V142, P452; HOMSY J, 1989, SCIENCE, V244, P1357, DOI 10.1126/science.2786647; JENKINS M, 1993, PEDIATR RES, V33, P469, DOI 10.1203/00006450-199305000-00010; JEWETT A, 1990, J IMMUNOL, V145, P4065; KATZ JD, 1987, J IMMUNOL, V139, P55; KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330; KOHL S, 1982, J IMMUNOL, V129, P370; KOHL S, 1991, REV INFECT DIS, V13, P108; LEVY J, 1994, BLOOD, V84, P2130; LIOU RS, 1989, J IMMUNOL, V143; LJUNGGREN K, 1988, J IMMUNOL, V140, P602; LJUNGGREN K, 1988, CLIN EXP IMMUNOL, V73, P343; LJUNGGREN K, 1990, J INFECT DIS, V161, P198, DOI 10.1093/infdis/161.2.198; LYERLY HK, 1987, P NATL ACAD SCI USA, V84, P4601, DOI 10.1073/pnas.84.13.4601; LYERLY HK, 1987, AIDS RES HUM RETROV, V3, P409, DOI 10.1089/aid.1987.3.409; NIXON DF, 1992, IMMUNOLOGY, V76, P515; NORLEY SG, 1990, J IMMUNOL, V145, P1700; OJOAMAIZE E, 1989, J CLIN IMMUNOL, V9, P454, DOI 10.1007/BF00918014; OLSEN GP, 1984, NATURE, V309, P116; PEARSON GR, 1978, INT J CANCER, V22, P120, DOI 10.1002/ijc.2910220203; ROOK AH, 1987, J IMMUNOL, V138, P1064; SAWYER LA, 1990, AIDS RES HUM RETROV, V6, P341, DOI 10.1089/aid.1990.6.341; SINCLAIR AL, 1988, AIDS, V2, P465, DOI 10.1097/00002030-198812000-00009; SIRIANNI MC, 1988, J IMMUNOL, V140, P2565; SZELC C, 1992, J INFECT DIS, V166, P486, DOI 10.1093/infdis/166.3.486; TANNEAU F, 1990, J INFECT DIS, V162, P837, DOI 10.1093/infdis/162.4.837; TYLER DS, 1990, J IMMUNOL, V145, P3276; TYLER DS, 1990, J IMMUNOL, V144, P3375; TYLER DS, 1989, J IMMUNOL, V142, P1177; TYLER DS, 1989, AIDS RES HUM RETROV, V75, P557; VIVIER E, 1991, J IMMUNOL, V146, P206; VOLTARELLI JC, 1993, IMMUNOLOGY, V79, P509; VONGEGERFELT A, 1993, AIDS RES HUM RETROV, V9, P883, DOI 10.1089/aid.1993.9.883; WALKER BD, 1990, AIDS, V4, P177, DOI 10.1097/00002030-199003000-00001; WASIK M, 1991, TRANSPLANTATION, V51; WEINHOLD KJ, 1988, LANCET, V1, P902; WERSALL P, 1991, CANCER IMMUNOL IMMUN, V33, P45, DOI 10.1007/BF01742527; WINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215; ZINKERNAGEL RM, 1994, IMMUNOL TODAY, V15, P262, DOI 10.1016/0167-5699(94)90005-1	57	100	105	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1996	10	2					258	266		10.1096/fasebj.10.2.8641559	http://dx.doi.org/10.1096/fasebj.10.2.8641559			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641559				2022-12-28	WOS:A1996TY96200010
J	Wright, SC; Zheng, H; Zhong, J				Wright, SC; Zheng, H; Zhong, J			Tumor cell resistance to apoptosis due to a defect in the activation of sphingomyelinase and the 24 kDa apoptotic protease (AP24)	FASEB JOURNAL			English	Article						humor necrosis factor; IV light; sphingomyelinase; DNA fragmentation	NECROSIS-FACTOR; DNA FRAGMENTATION; SURFACE ANTIGEN; PHOSPHORYLATION; INHIBITORS; PHOSPHATASE; VARIANTS; CERAMIDE; DEATH; ACID	Signal transduction pathways involved in apoptotic cell death are poorly understood, although recent studies have implicated sphingomyelin hydrolysis and generation of the second messenger, ceramide, Previous work in this laboratory demonstrated that a serine protease termed AP24 was activated by TNF or UV light and induced DNA fragmentation in isolated nuclei, This study extended these findings to examine the role of these enzymes in apoptosis of the U937 cell line and the mechanism of resistance of its variant, U9-TR, Although this subclone was selected by growth in TNF, it was unexpectedly found to resist apoptosis induced by UV light, but was still sensitive to anti-Fas-induced DNA fragmentation, Here we show that in contrast to normal U937 cells, UV light and TNF both failed to activate neutral or acidic sphingomyelinase or AP24 in the U9-TR variant, However, anti-Fas activated both neutral and acidic sphingomyelinase in the variant comparable to that seen in parental U937, The U9-TR variant could be sensitized to TNF or UV light activation of both sphingomyelinase and DNA fragmentation by the protein phosphatase inhibitors okadaic acid and calyculin A, Furthermore, exogenous bacterial-derived sphingomyelinase caused U9-TR activation of AP24 and DNA fragmentation comparable to that in the parental U937, Exposure of permeabilized U937 cells to ceramide caused internucleosomal DNA cleavage that was blocked by an inhibitor of AP24, Taken altogether, these findings demonstrate that TNF or UV light activate sphingomyelinase that leads to generation of ceramide resulting in activation of AP24 and DNA fragmentation in sensitive cells, A selective defect in signals leading to sphingomyelinase activation can confer resistance to apoptosis even though the variant is still sensitive to downstream apoptotic signals such as nuclear DNA fragmentation by activated exogenous AP24.			Wright, SC (corresponding author), PALO ALTO INST MOLEC MED,2642 WYANDOTTE ST,MT VIEW,CA 94043, USA.				NATIONAL CANCER INSTITUTE [R01CA068223] Funding Source: NIH RePORTER; NCI NIH HHS [CA68223] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHARTIER L, 1991, CELL MOTIL CYTOSKEL, V18, P26, DOI 10.1002/cm.970180104; CIFONE MG, 1993, J EXP MED, V177, P1547; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HANNUN YA, 1993, ADV LIPID RES, V25, P43; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KINDER DH, 1985, J MED CHEM, V28, P1917, DOI 10.1021/jm00150a027; KINDER DH, 1992, INVAS METAST, V12, P309; LIU J, 1993, J BIOL CHEM, V268, P3047; MATHIAS S, 1993, ADV LIPID RES, V25, P65; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OEHM A, 1992, J BIOL CHEM, V267, P10709; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; Walker N I, 1988, Methods Achiev Exp Pathol, V13, P18; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WONG GHW, 1994, J IMMUNOL, V152, P1751; WRIGHT SC, 1992, J CELL BIOCHEM, V48, P344, DOI 10.1002/jcb.240480403; WRIGHT SC, 1993, J CELL BIOCHEM, V53, P222, DOI 10.1002/jcb.240530307; WRIGHT SC, 1992, CANCER IMMUNOL IMMUN, V34, P399, DOI 10.1007/BF01741751; WRIGHT SC, 1994, FASEB J, V8, P654, DOI 10.1096/fasebj.8.9.8005393; WRIGHT SC, 1994, J EXP MED, V180, P2113, DOI 10.1084/jem.180.6.2113	27	58	61	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1996	10	2					325	332		10.1096/fasebj.10.2.8641566	http://dx.doi.org/10.1096/fasebj.10.2.8641566			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641566				2022-12-28	WOS:A1996TY96200017
J	Carra, JH; Privalov, PL				Carra, JH; Privalov, PL			Thermodynamics of denaturation of staphylococcal nuclease mutants: An intermediate state in protein folding	FASEB JOURNAL			English	Review						protein folding; energetics; enthalpy; denaturation; molten globule	DIFFERENTIAL SCANNING CALORIMETRY; RESONANCE ENERGY-TRANSFER; AMINO-ACIDS; STABILITY; COMPACT; MUTATIONS; ENTHALPY	A valuable approach to understanding the forces that maintain protein structure is to analyze the thermodynamic effects of mutations on protein folding. The folding process is most often described using an energetic model that assumes a two-state transition between the native and denatured states, However, some results obtained using this approach for mutants of the protein staphylococcal nuclease have contradicted expectations from our current understanding of protein energetics, The application of differential scanning calorimetry to a set of mutant nuclease proteins allowed us to measure directly the effects of mutations on the enthalpy and heat capacity changes of unfolding, as well as on the cooperativity. We found that most of these effects can be understood with a three-state model of folding including a distinct intermediate, but not with the two-state model, Use of a three-state instead of a two-state model leads to large differences in conclusions about the stability effects of some mutations, suggesting that reevaluation of the effects of mutations on this and other proteins may be necessary to achieve an accurate description of folding energetics, The two-state assumption commonly used in protein stability studies may be an oversimplification in many cases.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; JOHNS HOPKINS UNIV, CTR BIOCALORIMETRY, BALTIMORE, MD 21218 USA	Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048036] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48036] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDRESCU AT, 1994, J MOL BIOL, V242, P527, DOI 10.1006/jmbi.1994.1598; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BILTONEN RL, 1978, CRC CR REV BIOCH MOL, V5, P85, DOI 10.3109/07388557809148191; CALDERON RO, 1985, BIOCHEMISTRY-US, V24, P6044, DOI 10.1021/bi00343a004; CARRA JH, 1994, PROTEIN SCI, V3, P952; CARRA JH, 1995, BIOCHEMISTRY-US, V34, P2034, DOI 10.1021/bi00006a025; CARRA JH, 1994, BIOCHEMISTRY-US, V33, P10842, DOI 10.1021/bi00201a035; CARRA JH, 1994, PROTEIN SCI, V3, P944; CHEN HM, 1994, BIOCHIMIE, V76, P384, DOI 10.1016/0300-9084(94)90112-0; CHEN YZ, 1994, BIOPHYS J, V66, P202, DOI 10.1016/S0006-3495(94)80766-0; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; EFTINK MR, 1991, BIOCHEMISTRY-US, V30, P8945, DOI 10.1021/bi00101a005; FINK AL, 1993, PROTEIN SCI, V2, P1155, DOI 10.1002/pro.5560020710; FLANAGAN JM, 1993, BIOCHEMISTRY-US, V32, P10359, DOI 10.1021/bi00090a011; FLANAGAN JM, 1992, P NATL ACAD SCI USA, V89, P748, DOI 10.1073/pnas.89.2.748; GITTIS AG, 1993, J MOL BIOL, V232, P718, DOI 10.1006/jmbi.1993.1425; GREEN SM, 1992, BIOCHEMISTRY-US, V31, P5717, DOI 10.1021/bi00140a005; GREEN SM, 1993, BIOCHEMISTRY-US, V32, P10131, DOI 10.1021/bi00089a032; GRIKO YV, 1994, BIOCHEMISTRY-US, V33, P1889, DOI 10.1021/bi00173a036; GRIKO YV, 1994, J MOL BIOL, V243, P93, DOI 10.1006/jmbi.1994.1632; JACOBS MD, 1994, P NATL ACAD SCI USA, V91, P449, DOI 10.1073/pnas.91.2.449; JAMES E, 1992, BIOCHEMISTRY-US, V31, P10217, DOI 10.1021/bi00157a008; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LADBURY JE, 1995, BIOCHEMISTRY-US, V34, P2148, DOI 10.1021/bi00007a007; LIN L, 1993, BIOCHEMISTRY-US, V32, P12638, DOI 10.1021/bi00210a011; LOH SN, 1994, BIOCHEMISTRY-US, V33, P1029, DOI 10.1021/bi00170a023; LOLL PJ, 1989, PROTEINS, V5, P183, DOI 10.1002/prot.340050302; MAKHATADZE GI, 1993, J MOL BIOL, V232, P639, DOI 10.1006/jmbi.1993.1416; MUCKE M, 1994, BIOCHEMISTRY-US, V33, P12930; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; Privalov Peter L., 1992, P83; Ptitsyn Oleg B., 1992, P243; RICHARDS FM, 1993, Q REV BIOPHYS, V26, P423, DOI 10.1017/S0033583500002845; ROSE GD, 1993, ANNU REV BIOPH BIOM, V22, P381, DOI 10.1146/annurev.bb.22.060193.002121; SHORTLE D, 1989, J BIOL CHEM, V264, P5315; SHORTLE D, 1993, STRUCTURE, V1, P121, DOI 10.1016/0969-2126(93)90027-E; SHORTLE D, 1988, BIOCHEMISTRY-US, V27, P4761, DOI 10.1021/bi00413a027; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; SHORTLE D, 1989, BIOCHEMISTRY-US, V28, P936, DOI 10.1021/bi00429a003; SHORTLE D, 1986, Proteins Structure Function and Genetics, V1, P81, DOI 10.1002/prot.340010113; STITES WE, 1994, J MOL BIOL, V235, P27, DOI 10.1016/S0022-2836(05)80008-7; STURTEVANT JM, 1994, CURR OPIN STRUC BIOL, V4, P69, DOI 10.1016/S0959-440X(94)90062-0; TANAKA A, 1993, PROTEIN SCI, V2, P567; WU LC, 1995, NAT STRUCT BIOL, V2, P281, DOI 10.1038/nsb0495-281; WU PG, 1993, BIOPHYS CHEM, V48, P123, DOI 10.1016/0301-4622(93)85004-2; WYNN R, 1993, PROTEIN SCI, V2, P395; XIE D, 1994, PROTEIN SCI, V3, P2175, DOI 10.1002/pro.5560031203; YAMAOTSU N, 1993, BIOCHIM BIOPHYS ACTA, V1163, P81, DOI 10.1016/0167-4838(93)90282-V	48	59	59	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1996	10	1					67	74		10.1096/fasebj.10.1.8566550	http://dx.doi.org/10.1096/fasebj.10.1.8566550			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566550				2022-12-28	WOS:A1996TR32800010
J	STROUD, RM; FINERMOORE, JS				STROUD, RM; FINERMOORE, JS			STEREOCHEMISTRY OF A MULTISTEP BIPARTITE METHYL TRANSFER-REACTION - THYMIDYLATE SYNTHASE	FASEB JOURNAL			English	Article						SITE-DIRECTED MUTAGENESIS; STRUCTURE; ENZYME MECHANISM; DCMP METHYLASE; CONFORMATION CHANGE; POLYGLUTAMATE; DRUG TARGET; METHYL TRANSFER; ATOMIC STRUCTURE	SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; LACTOBACILLUS-CASEI; SUBSTRATE-BINDING; ACTIVE-SITE; 5-FLUORO-2'-DEOXYURIDYLATE; SYNTHETASE; MECHANISM; 5,10-METHYLENETETRAHYDROFOLATE; 10-PROPARGYL-5,8-DIDEAZAFOLATE	Atomic structures of thymidylate synthase (TS) reveal key steps in a multi-step reaction and show quantitatively how conformation change is involved in mediating the methyl transfer reaction catalyzed by TS. Numerous alterations in TS produced by mutation, screened by complementation, and further characterized can be understood in terms of the structure and profound structure change required during the TS reaction.			STROUD, RM (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.				NATIONAL CANCER INSTITUTE [R01CA041323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024485, R37GM024485] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-41323] Funding Source: Medline; NIGMS NIH HHS [GM24485] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAUDETTE NV, 1980, ARCH BIOCHEM BIOPHYS, V200, P410, DOI 10.1016/0003-9861(80)90371-9; BENKOVIC SJ, 1973, PROGR BIOORG CHEM, V2, P133; CARRERAS CW, 1992, BIOCHEMISTRY-US, V31, P6038, DOI 10.1021/bi00141a012; CLIMIE S, 1990, P NATL ACAD SCI USA, V87, P633, DOI 10.1073/pnas.87.2.633; CLIMIE S, 1990, J BIOL CHEM, V265, P18776; CLIMIE SC, 1992, BIOCHEMISTRY-US, V31, P6032, DOI 10.1021/bi00141a011; DANENBERG PV, 1978, BIOCHEMISTRY-US, V17, P4018, DOI 10.1021/bi00612a022; DARON HH, 1978, J BIOL CHEM, V253, P940; DEV IK, 1988, P NATL ACAD SCI USA, V85, P1472, DOI 10.1073/pnas.85.5.1472; DEV IK, 1989, J BIOL CHEM, V264, P19132; FAUMAN EB, 1993, IN PRESS BIOCHEMISTR; FERONE R, 1986, J BIOL CHEM, V261, P6356; FINERMOORE J, 1993, IN PRESS J MOL BIOL; FINERMOORE JS, 1990, BIOCHEMISTRY-US, V29, P6977, DOI 10.1021/bi00482a005; GALIVAN JH, 1976, BIOCHEMISTRY-US, V15, P356, DOI 10.1021/bi00647a018; GHOSE C, 1990, CHEMISTRY AND BIOLOGY OF PTERIDINES 1989, P860; HARDY LW, 1992, P NATL ACAD SCI USA, V89, P9725, DOI 10.1073/pnas.89.20.9725; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; IVANETICH KM, 1990, EXP PARASITOL, V70, P367, DOI 10.1016/0014-4894(90)90119-W; JONES TR, 1981, EUR J CANCER, V17, P11, DOI 10.1016/0014-2964(81)90206-1; KAMB A, 1992, BIOCHEMISTRY-US, V31, P9883, DOI 10.1021/bi00156a005; KAMB A, 1992, BIOCHEMISTRY-US, V31, P12876, DOI 10.1021/bi00166a024; KIM CW, 1992, PROTEINS, V13, P352, DOI 10.1002/prot.340130407; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAPATPOLASKO L, 1990, BIOCHEMISTRY-US, V29, P9561, DOI 10.1021/bi00493a010; LIU L, 1992, BIOCHEMISTRY-US, V31, P5100, DOI 10.1021/bi00137a002; LOCKSHIN A, 1980, BIOCHEMISTRY-US, V19, P4244, DOI 10.1021/bi00559a016; LORENSON MY, 1967, J BIOL CHEM, V242, P3332; LU YZ, 1984, BIOCHEMISTRY-US, V23, P6870, DOI 10.1021/bi00321a091; MATTHEWS DA, 1990, J MOL BIOL, V214, P923, DOI 10.1016/0022-2836(90)90346-N; MATTHEWS DA, 1990, J MOL BIOL, V214, P937, DOI 10.1016/0022-2836(90)90347-O; MICHAELS ML, 1990, P NATL ACAD SCI USA, V87, P3957, DOI 10.1073/pnas.87.10.3957; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; PERRY KM, 1990, PROTEINS, V8, P315, DOI 10.1002/prot.340080406; PERRY KM, 1992, PROTEIN SCI, V1, P796, DOI 10.1002/pro.5560010611; PERRY KM, 1993, IN PRESS BIOCHEMISTR; POGOLOTTI AL, 1986, J MED CHEM, V29, P478, DOI 10.1021/jm00154a009; SANTI DV, 1990, J BIOL CHEM, V265, P6770; SANTI DV, 1987, BIOCHEMISTRY-US, V26, P8606, DOI 10.1021/bi00400a017; SANTI DV, 1984, FOLATES PTERINS, V1, P345; TATUM C, 1977, J CHEM SOC CHEM COMM, P218, DOI 10.1039/c39770000218; ZHANG HC, 1990, BIOCHEM BIOPH RES CO, V167, P869, DOI 10.1016/0006-291X(90)90604-L	42	45	45	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1993	7	8					671	677		10.1096/fasebj.7.8.8500692	http://dx.doi.org/10.1096/fasebj.7.8.8500692			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LE290	8500692				2022-12-28	WOS:A1993LE29000009
J	Gasparini, L; Racchi, M; Binetti, G; Trabucchi, M; Solerte, SB; Alkon, D; Etcheberrigaray, R; Gibson, G; Blass, J; Paoletti, R; Govoni, S				Gasparini, L; Racchi, M; Binetti, G; Trabucchi, M; Solerte, SB; Alkon, D; Etcheberrigaray, R; Gibson, G; Blass, J; Paoletti, R; Govoni, S			Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease	FASEB JOURNAL			English	Review						peripheral cells; CSF; plasma; diagnosis	AMYLOID-BETA-PROTEIN; CYTOSOLIC FREE-CALCIUM; CORTICOTROPIN-RELEASING HORMONE; APOLIPOPROTEIN-E EPSILON-4; CULTURED SKIN FIBROBLASTS; KETOGLUTARATE DEHYDROGENASE COMPLEX; CEREBROSPINAL-FLUID CONCENTRATIONS; SOMATOSTATIN-LIKE IMMUNOREACTIVITY; E ALLELE EPSILON-4; KINASE-C ACTIVITY	Alterations in amyloid precursor protein (APP) metabolism, calcium regulation, oxidative metabolism, and transduction systems have been implicated in Alzheimer's disease (AD). Limitations to the use of postmortem brain for examining molecular mechanisms underscore the need to develop a human tissue model representative of the pathophysiological processes that characterize AD. The use of peripheral tissues, particularly of cultured skin fibroblasts derived from AD patients, could complement studies of autopsy samples and provide a useful tool with which to investigate such dynamic processes as signal transduction systems, ionic homeostasis, oxidative metabolism, and APP processing. Peripheral cells as well as body fluids (i.e., plasma and CSF) could also provide peripheral biological markers for the diagnosis of AD. The criteria required for a definite diagnosis of AD presently include clinical criteria in association with histopathologic evidence obtained from biopsy or autopsy. Thus, the use of peripheral markers as a diagnostic tool, either to predict or at least to confirm a diagnosis, may be of great importance.	Univ Milan, Inst Pharmacol Sci, I-20133 Milan, Italy; Alzheimers Dis Unit Sacred Heart Hosp FBF, IRCCS San Giovanni Di Dio, Brescia, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Rome, Italy; Univ Pavia, Geriatr Clin, Dept Internal Med, I-27100 Pavia, Italy; NINDS, Lab Adapt Syst, NIH, Bethesda, MD 20892 USA; Georgetown Univ, Med Ctr, Inst Cognit & Computat Sci, Washington, DC 20007 USA; Cornell Univ, Coll Med, Burke Med Res Inst, New York, NY 10605 USA	University of Milan; IRCCS Fatebenefratelli; University of Rome Tor Vergata; University of Pavia; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Georgetown University; Cornell University	Govoni, S (corresponding author), Univ Milan, Inst Pharmacol Sci, Via Balzaretti 9, I-20133 Milan, Italy.	govonis@ipv36.unipv.it	Govoni, Stefano/K-2965-2015; Binetti, Giuliano/K-4519-2016; Gasparini, Laura/G-7711-2011; Racchi, Marco/G-6104-2018	Govoni, Stefano/0000-0002-7243-6837; Binetti, Giuliano/0000-0003-2759-5844; Gasparini, Laura/0000-0003-3894-9898; Racchi, Marco/0000-0002-7185-7808				ADLER MJ, 1991, P NATL ACAD SCI USA, V88, P16, DOI 10.1073/pnas.88.1.16; ADUNSKY A, 1991, J NEUROIMMUNOL, V33, P167, DOI 10.1016/0165-5728(91)90060-K; ALBERT M, 1993, BIOL PSYCHIAT, V33, P267, DOI 10.1016/0006-3223(93)90293-M; Almkvist O, 1997, ARCH NEUROL-CHICAGO, V54, P641, DOI 10.1001/archneur.1997.00550170111022; Alzheimer A., 1907, ALLGEMEINE Z PSYCHIA, V64, P146, DOI DOI 10.1002/CA.980080612; AMOUYEL P, 1994, LANCET, V344, P1315, DOI 10.1016/S0140-6736(94)90691-2; ARAI H, 1995, ANN NEUROL, V38, P649, DOI 10.1002/ana.410380414; BALIN AK, 1988, NEUROBIOL AGING, V9, P195, DOI 10.1016/S0197-4580(88)80050-2; BALL MJ, 1978, ACTA NEUROPATHOL, V42, P73, DOI 10.1007/BF00690970; BANKI CM, 1992, J AFFECT DISORDERS, V25, P39, DOI 10.1016/0165-0327(92)90091-J; BEAL MF, 1990, METABOLISM, V39, P116, DOI 10.1016/0026-0495(90)90226-3; Bergamaschi S, 1995, NEUROSCI LETT, V201, P1, DOI 10.1016/0304-3940(95)12168-4; BIERER LM, 1995, J NEUROCHEM, V64, P749; BISSETTE G, 1985, JAMA-J AM MED ASSOC, V254, P3067, DOI 10.1001/jama.254.21.3067; BLASS JP, 1997, IN PRESS INHERENT AB; BLASS JP, 1989, BIOL MARKERS ALZHEIM, P153; BLENNOW K, 1994, NEUROREPORT, V5, P2534, DOI 10.1097/00001756-199412000-00032; Blennow K, 1995, MOL CHEM NEUROPATHOL, V26, P231, DOI 10.1007/BF02815140; Blomberg M, 1996, NEUROSCI LETT, V214, P163, DOI 10.1016/0304-3940(96)12905-0; Blomberg M., 1996, Neurobiology of Aging, V17, pS167, DOI 10.1016/S0197-4580(96)80672-5; BONDY B, 1994, EUR ARCH PSY CLIN N, V243, P224, DOI 10.1007/BF02191578; BORDEN LA, 1992, NEUROBIOL AGING, V13, P33, DOI 10.1016/0197-4580(92)90005-I; BOSMAN GJCGM, 1992, NEUROBIOL AGING, V13, P711, DOI 10.1016/0197-4580(92)90094-E; BRUEL A, 1991, NEUROSCI LETT, V133, P89, DOI 10.1016/0304-3940(91)90064-Z; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CARMELIET G, 1990, MECH AGEING DEV, V53, P17, DOI 10.1016/0047-6374(90)90031-A; CARMELIET G, 1991, MUTAT RES, V256, P221, DOI 10.1016/0921-8734(91)90013-2; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; COLE G, 1988, BRAIN RES, V452, P165, DOI 10.1016/0006-8993(88)90021-2; COLEMAN PD, 1987, NEUROBIOL AGING, V8, P521, DOI 10.1016/0197-4580(87)90127-8; Cooper AJL, 1996, DEV NEUROSCI-BASEL, V18, P499, DOI 10.1159/000111446; DAI XY, 1994, NEUROSCI LETT, V175, P74, DOI 10.1016/0304-3940(94)91081-2; Davis RE, 1997, P NATL ACAD SCI USA, V94, P4526, DOI 10.1073/pnas.94.9.4526; DESOUZA EB, 1986, NATURE, V319, P593, DOI 10.1038/319593a0; DESOUZA EB, 1987, ANN NY ACAD SCI, V512, P237, DOI 10.1111/j.1749-6632.1987.tb24964.x; DICKSON DW, 1992, NEUROBIOL AGING, V13, P179, DOI 10.1016/0197-4580(92)90027-U; DiLuca M, 1996, ARCH NEUROL-CHICAGO, V53, P1162, DOI 10.1001/archneur.1996.00550110114019; DUNN JD, 1984, EXP BRAIN RES, V54, P1; DYSKEN MW, 1990, BIOL PSYCHIAT, V28, P144, DOI 10.1016/0006-3223(90)90631-B; ECKERT A, 1994, LIFE SCI, V55, P2019, DOI 10.1016/0024-3205(94)00382-3; ECKERT A, 1993, FEBS LETT, V330, P49, DOI 10.1016/0014-5793(93)80917-J; EDVINSSON L, 1993, DEMENTIA, V4, P167, DOI 10.1159/000107318; Eikelenboom P, 1996, NEUROBIOL AGING, V17, P673; ETCHEBERRIGARAY R, 1993, P NATL ACAD SCI USA, V90, P8209, DOI 10.1073/pnas.90.17.8209; ETCHEBERRIGARAY R, 1994, SCIENCE, V264, P276, DOI 10.1126/science.8146663; FACCHINETTI F, 1984, LIFE SCI, V35, P1691, DOI 10.1016/0024-3205(84)90181-4; FARLOW M, 1992, LANCET, V340, P453, DOI 10.1016/0140-6736(92)91771-Y; Feany MB, 1996, ANN NEUROL, V40, P139, DOI 10.1002/ana.410400204; FRISONI GB, 1994, DEMENTIA, V5, P240, DOI 10.1159/000106730; Frisoni GB, 1996, DEMENTIA, V7, P336, DOI 10.1159/000106900; Frisoni GB, 1996, J NEUROL NEUROSUR PS, V60, P699, DOI 10.1136/jnnp.60.6.699-a; FRISONI GB, 1995, ANN NEUROL, V37, P596, DOI 10.1002/ana.410370509; GABUZDA D, 1993, J NEUROCHEM, V61, P2326, DOI 10.1111/j.1471-4159.1993.tb07479.x; Galasko D, 1997, NEUROLOGY, V48, P632, DOI 10.1212/WNL.48.3.632; GARDELLA JE, 1992, LAB INVEST, V67, P303; GHIGO E, 1993, DEMENTIA, V4, P315, DOI 10.1159/000107339; Gibson G, 1996, LIFE SCI, V59, P477, DOI 10.1016/0024-3205(96)00327-X; GIBSON GE, 1988, ARCH NEUROL-CHICAGO, V45, P836, DOI 10.1001/archneur.1988.00520320022009; Gibson GE, 1996, BBA-MOL BASIS DIS, V1316, P71, DOI 10.1016/0925-4439(96)00002-6; GIBSON GE, 1992, MECH AGEING DEV, V63, P1, DOI 10.1016/0047-6374(92)90012-3; GILLESPIE SL, 1992, BIOCHEM BIOPH RES CO, V187, P1285, DOI 10.1016/0006-291X(92)90442-N; GLENNER GG, 1988, CELL, V52, P307, DOI 10.1016/S0092-8674(88)80021-7; GOMEZ JM, 1994, CLIN INVESTIGATOR, V72, P489; GOVONI S, 1993, NEUROLOGY, V43, P2581, DOI 10.1212/WNL.43.12.2581; Govoni S, 1996, NEUROLOGY, V47, P1069, DOI 10.1212/WNL.47.4.1069; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Hahne S, 1997, NEUROSCI LETT, V224, P99, DOI 10.1016/S0304-3940(97)13477-2; HARTIKAINEN P, 1992, J NEURAL TRANSM-PARK, V4, P53, DOI 10.1007/BF02257622; HARTMANN H, 1994, BIOCHEM BIOPH RES CO, V200, P1185, DOI 10.1006/bbrc.1994.1576; HATZINGER M, 1995, NEUROBIOL AGING, V16, P205, DOI 10.1016/0197-4580(94)00159-6; HEINONEN O, 1995, NEUROBIOL AGING, V16, P505, DOI 10.1016/0197-4580(95)00076-Q; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; HENRIKSSON T, 1991, J NEUROCHEM, V56, P1037, DOI 10.1111/j.1471-4159.1991.tb02026.x; HEUSER IJ, 1994, NEUROBIOL AGING, V15, P227, DOI 10.1016/0197-4580(94)90117-1; Hirashima N, 1996, NEUROBIOL AGING, V17, P549; Huang HM, 1996, LIFE SCI, V59, P1533, DOI 10.1016/0024-3205(96)00484-5; HUANG HM, 1991, NEUROBIOL AGING, V12, P469, DOI 10.1016/0197-4580(91)90075-U; HUANG HM, 1993, J BIOL CHEM, V268, P14616; HUANG HM, 1995, J NEUROCHEM, V64, P761; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; ITO E, 1994, P NATL ACAD SCI USA, V91, P534, DOI 10.1073/pnas.91.2.534; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JENSEN M, 1995, NEUROSCI LETT, V186, P189, DOI 10.1016/0304-3940(95)11297-A; Jensen M., 1995, Society for Neuroscience Abstracts, V21, P1501; Johnson GVW, 1997, J NEUROCHEM, V68, P430; Kalaria RN, 1996, NEUROBIOL AGING, V17, P687; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kennard ML, 1996, NAT MED, V2, P1230, DOI 10.1038/nm1196-1230; KOPONEN H, 1990, ACTA NEUROL SCAND, V82, P289; Kosaka T, 1997, NEUROLOGY, V48, P741, DOI 10.1212/WNL.48.3.741; KUMAR U, 1994, LIFE SCI, V54, P1855, DOI 10.1016/0024-3205(94)90142-2; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; Landen M, 1996, DEMENTIA, V7, P273, DOI 10.1159/000106892; LANNFELT L, 1995, NEUROSCI LETT, V199, P203, DOI 10.1016/0304-3940(95)12059-D; LANNFELT L, 1995, NAT MED, V1, P829, DOI 10.1038/nm0895-829; LEAKE A, 1993, DRUG AGING, V3, P408, DOI 10.2165/00002512-199303050-00003; LEAKE A, 1991, BIOL PSYCHIAT, V29, P357, DOI 10.1016/0006-3223(91)90221-7; LECHTIMAKI T, 1995, HUMAN GENET, V95, P39; LESCH KP, 1990, PSYCHIAT RES, V33, P107; LI QX, 1995, J BIOL CHEM, V270, P14140, DOI 10.1074/jbc.270.23.14140; LI QX, 1994, BLOOD, V84, P133, DOI 10.1182/blood.V84.1.133.133; LOFFLER J, 1993, BIOCHEM BIOPH RES CO, V195, P97, DOI 10.1006/bbrc.1993.2015; LORENS SA, 1990, NEUROBIOL AGING, V11, P139, DOI 10.1016/0197-4580(90)90047-4; MANN DMA, 1995, NEUROSCI LETT, V196, P105, DOI 10.1016/0304-3940(95)11860-Y; MATSUMOTO A, 1993, EUR J BIOCHEM, V217, P21, DOI 10.1111/j.1432-1033.1993.tb18213.x; MATSUMOTO A, 1991, BIOCHEM BIOPH RES CO, V175, P361, DOI 10.1016/0006-291X(91)91572-T; MATSUSHIMA H, 1994, NEUROBIOL AGING, V15, P671, DOI 10.1016/0197-4580(94)90047-7; MATSUYAMA SS, 1995, DEMENTIA, V6, P241, DOI 10.1159/000106953; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MATTSON MP, 1993, BRAIN RES, V621, P35, DOI 10.1016/0006-8993(93)90295-X; MAY C, 1987, NEUROLOGY, V37, P535, DOI 10.1212/WNL.37.3.535; MCCOY KR, 1993, NEUROBIOL AGING, V14, P447, DOI 10.1016/0197-4580(93)90103-I; Merched A, 1997, J NEUROL SCI, V145, P33, DOI 10.1016/S0022-510X(96)00234-1; Minthon L, 1990, J Neural Transm Suppl, V30, P57; MOLCHAN SE, 1993, PSYCHONEUROENDOCRINO, V18, P509, DOI 10.1016/0306-4530(93)90044-L; MOLINS A, 1991, J NEUROL, V238, P168, DOI 10.1007/BF00319684; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MOTTER R, 1995, ANN NEUROL, V38, P643, DOI 10.1002/ana.410380413; MUNROE WA, 1995, ANN CLIN LAB SCI, V25, P207; MURIALDO G, 1991, NEUROPSYCHOBIOLOGY, V24, P129, DOI 10.1159/000119475; NAKAMURA T, 1994, ANN NEUROL, V36, P903, DOI 10.1002/ana.410360616; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NITSCH RM, 1995, ANN NEUROL, V37, P512, DOI 10.1002/ana.410370414; PALMERT MR, 1990, NEUROLOGY, V40, P1028, DOI 10.1212/WNL.40.7.1028; PARKER WD, 1990, NEUROLOGY, V40, P1302, DOI 10.1212/WNL.40.8.1302; PEACOCK ML, 1994, NEUROLOGY, V44, P339, DOI 10.1212/WNL.44.2.339; PETERSON C, 1986, P NATL ACAD SCI USA, V83, P7999, DOI 10.1073/pnas.83.20.7999; PETERSON C, 1986, P NATL ACAD SCI USA, V83, P2758, DOI 10.1073/pnas.83.8.2758; PETERSON C, 1985, NEW ENGL J MED, V312, P1063; PETERSON C, 1988, NEUROBIOL AGING, V9, P261, DOI 10.1016/S0197-4580(88)80063-0; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Poirier J, 1995, P NATL ACAD SCI USA, V92, P12260, DOI 10.1073/pnas.92.26.12260; PRIOR R, 1991, NEUROSCI LETT, V124, P69, DOI 10.1016/0304-3940(91)90824-D; QUERFURTH HW, 1995, MOL BRAIN RES, V28, P319, DOI 10.1016/0169-328X(94)00224-3; RACCHI M, 1994, ARCH BIOCHEM BIOPHYS, V314, P107, DOI 10.1006/abbi.1994.1417; REINIKAINEN KJ, 1990, J NEUROSCI RES, V27, P576, DOI 10.1002/jnr.490270419; REINIKAINEN KJ, 1990, PSYCHIAT RES, V33, P307, DOI 10.1016/0165-1781(90)90047-9; REUL JMHM, 1991, J STEROID BIOCHEM, V40, P63, DOI 10.1016/0960-0760(91)90168-5; REUL JMHM, 1988, NEUROBIOL AGING, V9, P253, DOI 10.1016/S0197-4580(88)80062-9; Rogers J, 1996, NEUROBIOL AGING, V17, P681, DOI 10.1016/0197-4580(96)00115-7; ROHER AE, 1993, J BIOL CHEM, V268, P3072; Rosenberg RN, 1997, ARCH NEUROL-CHICAGO, V54, P139, DOI 10.1001/archneur.1997.00550140019007; ROSES AD, 1994, LANCET, V343, P1564, DOI 10.1016/S0140-6736(94)92960-2; Sandbrink R, 1996, MOL PSYCHIATR, V1, P27; SANG KHL, 1993, BIOL PSYCHIAT, V33, P391, DOI 10.1016/0006-3223(93)90330-G; SAPOLSKY RM, 1991, J NEUROSCI, V11, P3695; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Saunders AM, 1996, LANCET, V348, P90, DOI 10.1016/S0140-6736(96)01251-2; SCHENK D, 1996, NEUROBIOL AGING, V7, pS1; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHEU KFR, 1994, ANN NEUROL, V35, P312, DOI 10.1002/ana.410350311; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMS NR, 1987, ANN NEUROL, V21, P451, DOI 10.1002/ana.410210507; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SLACK BE, 1993, J BIOL CHEM, V268, P21097; SNIPS GJ, 1986, P NATL ACAD SCI USA, V83, P1130, DOI 10.1073/pnas.83.4.1130; Solerte S. B., 1996, Neurobiology of Aging, V17, pS169, DOI 10.1016/S0197-4580(96)80681-6; Solerte SB, 1996, DEMENTIA, V7, P343, DOI 10.1159/000106901; SOLERTE SB, 1996, J ENDOCRINOL INVE S5, V19, P52; Song X.-H., 1995, Society for Neuroscience Abstracts, V21, P1501; SORBI S, 1995, ALZ DIS ASSOC DIS, V9, P73, DOI 10.1097/00002093-199509020-00003; SORBI S, 1994, NEUROSCI LETT, V177, P100, DOI 10.1016/0304-3940(94)90054-X; Southwick PC, 1996, J NEUROCHEM, V66, P259; Stanbury B., 1983, METABOLIC BASIS INHE; STCLAIR D, 1994, NEUROSCI LETT, V176, P45, DOI 10.1016/0304-3940(94)90867-2; Steinberg D., 1983, METABOLIC BASIS INHE, P731; STRITTMATTER MM, 1992, NEUROREPORT, V3, P413, DOI 10.1097/00001756-199205000-00009; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SUEMARU S, 1991, LIFE SCI, V48, P1871, DOI 10.1016/0024-3205(91)90243-5; SUEMARU S, 1993, LIFE SCI, V53, P697, DOI 10.1016/0024-3205(93)90246-Y; TABATON M, 1994, BIOCHEM BIOPH RES CO, V200, P1598, DOI 10.1006/bbrc.1994.1634; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; TATEBAYASHI Y, 1995, DEMENTIA, V6, P9, DOI 10.1159/000106916; TATO RE, 1995, J NEUROL NEUROSUR PS, V59, P280, DOI 10.1136/jnnp.59.3.280; TESCO G, 1993, EXP GERONTOL, V28, P51, DOI 10.1016/0531-5565(93)90019-A; TOFELGREHL B, 1992, MOL BIOL CELL, V35, P1898; TSAL MS, 1994, AM J HUM GENET, V54, P643; UEKI A, 1993, NEUROSCI LETT, V163, P166, DOI 10.1016/0304-3940(93)90373-S; VANDERMEEREN M, 1993, J NEUROCHEM, V61, P1828, DOI 10.1111/j.1471-4159.1993.tb09823.x; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74; VANGOOL WA, 1995, ANN NEUROL, V38, P225, DOI 10.1002/ana.410380215; VANGOOL WA, 1995, ANN NEUROL, V37, P277, DOI 10.1002/ana.410370221; VANHUYNH T, 1989, ARCH NEUROL-CHICAGO, V46, P1195, DOI 10.1001/archneur.1989.00520470049026; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VANNOSTRAND WE, 1989, NATURE, V341, P546; VANNOSTRAND WE, 1992, ANN NY ACAD SCI, V674, P243; VANNOSTRAND WE, 1992, P NATL ACAD SCI USA, V89, P2551, DOI 10.1073/pnas.89.7.2551; Vestling M, 1997, NEUROREPORT, V8, P2031, DOI 10.1097/00001756-199705260-00045; VESTLING M, 1995, SOC NEUR ABSTR, V21; VIGOPELFREY C, 1995, NEUROLOGY, V45, P788, DOI 10.1212/WNL.45.4.788; Wallin A, 1991, Eur Neuropsychopharmacol, V1, P165, DOI 10.1016/0924-977X(91)90718-A; WANG HY, 1994, NEUROBIOL AGING, V15, P293, DOI 10.1016/0197-4580(94)90023-X; Weisgraber Karl H., 1994, Current Opinion in Lipidology, V5, P110, DOI 10.1097/00041433-199404000-00007; WHITEHOUSE PJ, 1987, NEUROLOGY, V37, P905, DOI 10.1212/WNL.37.6.905; WIKKELSO C, 1991, EUR NEUROL, V31, P88, DOI 10.1159/000116653; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YASUDA M, 1993, JPN J PSYCHIAT NEUR, V47, P85; Younkin L. H., 1996, Neurobiology of Aging, V17, pS167, DOI 10.1016/S0197-4580(96)80675-0	210	160	178	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1998	12	1					17	34		10.1096/fasebj.12.1.17	http://dx.doi.org/10.1096/fasebj.12.1.17			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YR723	9438407				2022-12-28	WOS:000071523800003
J	Mochly-Rosen, D; Gordon, AS				Mochly-Rosen, D; Gordon, AS			Anchoring proteins for protein kinase C: a means for isozyme selectivity	FASEB JOURNAL			English	Review						PKC; RACK; RICK; localization	PHORBOL ESTER; IN-VIVO; SUBCELLULAR-LOCALIZATION; INTRACELLULAR RECEPTORS; CARDIAC MYOCYTES; BINDING-PROTEINS; BETA-SUBUNIT; CELLS; IDENTIFICATION; ACTIVATION	Protein kinase C (PKC) isozymes comprise a family of related enzymes, There are only limited differences between these isozymes in substrate specificity or sensitivity to activators, However, there are multiple isozymes within a cell mediating isozyme-specific functions, Differential subcellular localization has been proposed to explain this specificity, When members of the PKC family are activated by lipid-derived second messengers, they translocate from one cell compartment to another. Isozyme specificity appears to be mediated in part by association of each PKC isozyme with specific anchoring proteins, This review will cover the proteins involved in the anchoring of PKC isozymes at specific subcellular sites, the domains in the PKC isozymes that mediate protein-protein interaction with isozyme-specific anchoring proteins, and identification of peptides that interfere with or promote these protein-protein interactions, thus altering the localization and function of individual isozymes.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Univ Calif San Francisco, Ctr Neurobiol Addict, San Francisco, CA 94110 USA; Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, San Francisco, CA 94110 USA; Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Cellular & Mol Pharmacol, San Francisco, CA 94110 USA	Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center	Mochly-Rosen, D (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.			Mochly-Rosen, Daria/0000-0002-6691-8733	NHLBI NIH HHS [R01 HL-43380, R01 HL-52141] Funding Source: Medline; PHS HHS [R01 10039] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043380, R01HL052141] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; Chalfant CE, 1996, MOL ENDOCRINOL, V10, P1273, DOI 10.1210/me.10.10.1273; Chapline C, 1996, J BIOL CHEM, V271, P6417, DOI 10.1074/jbc.271.11.6417; CSKAI M, 1997, J BIOL CHEM, V272, P29200; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; DISATNIK MH, 1995, J MOL CELL CARDIOL, V27, P2473, DOI 10.1006/jmcc.1995.0235; DONG LQ, 1993, CELL GROWTH DIFFER, V4, P793; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P6438; Gordon AS, 1997, MOL PHARMACOL, V52, P554, DOI 10.1124/mol.52.4.554; GOSH S, 1994, J BIOL CHEM, V269, P10000; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Hundle B, 1997, J BIOL CHEM, V272, P15028, DOI 10.1074/jbc.272.23.15028; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; Izumi Y, 1997, J BIOL CHEM, V272, P7381, DOI 10.1074/jbc.272.11.7381; JAKEN S, 1992, PROTEIN KINASE C CUR, P237; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LEHEL C, 1995, J BIOL CHEM, V270, P19651, DOI 10.1074/jbc.270.33.19651; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; MURRAY NR, 1994, J BIOL CHEM, V269, P21385; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Newton AC, 1996, CURR BIOL, V6, P806, DOI 10.1016/S0960-9822(02)00600-0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; RON D, 1994, J BIOL CHEM, V269, P21395; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SHOJI M, 1986, BIOCHEM BIOPH RES CO, V135, P1144, DOI 10.1016/0006-291X(86)91047-8; SOSSIN WS, 1993, TRENDS BIOCHEM SCI, V18, P207, DOI 10.1016/0968-0004(93)90189-T; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; VALVERDE MA, 1994, P NATL ACAD SCI USA, V91, P5572; WOLF M, 1986, J BIOL CHEM, V261, P3327; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417; Zhang ZH, 1997, CIRC RES, V80, P720, DOI 10.1161/01.RES.80.5.720; Zhou LY, 1996, J INVEST DERMATOL, V107, P248, DOI 10.1111/1523-1747.ep12329733	56	497	506	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1998	12	1					35	42						8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YR723	9438408				2022-12-28	WOS:000071523800004
J	Haas, AL				Haas, AL			Introduction: Evolving roles for ubiquitin in cellular regulation	FASEB JOURNAL			English	Editorial Material							ATP-DEPENDENT PROTEOLYSIS; PROTEIN-DEGRADATION; CONJUGATION; POLYPEPTIDE; ENZYME				Haas, AL (corresponding author), MED COLL WISCONSIN, DEPT BIOCHEM, 8701 WATERTOWN PLANK RD, MILWAUKEE, WI 53226 USA.							BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOUGH R, 1987, J BIOL CHEM, V262, P8303; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; SCHIMKE RT, 1970, ANNU REV BIOCHEM, V39, P929, DOI 10.1146/annurev.bi.39.070170.004433; Schoenheimer R., 1942, DYNAMIC STATE BODY C; SEGAL HL, 1965, J CELL COMPAR PHYSL, V66, P11, DOI 10.1002/jcp.1030660404; SIMPSON MV, 1953, J BIOL CHEM, V201, P143; WILKINSON KD, 1980, J BIOL CHEM, V255, P7529	17	14	14	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1997	11	13					1053	1054		10.1096/fasebj.11.13.9367340	http://dx.doi.org/10.1096/fasebj.11.13.9367340			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367340				2022-12-28	WOS:A1997YE98300003
J	Chen, XG; Brining, SK; Nguyen, VQ; Yergey, AL				Chen, XG; Brining, SK; Nguyen, VQ; Yergey, AL			Simultaneous assessment of conformation and aggregation of beta-amyloid peptide using electrospray ionization mass spectrometry	FASEB JOURNAL			English	Article						protein conformation; protein aggregation; Alzheimer disease	AMINO-TERMINAL FRAGMENT; ALZHEIMERS-DISEASE; SECONDARY STRUCTURE; SENILE PLAQUES; CORE PROTEIN; IN-VITRO; DEPOSITION; DETERMINANTS; TRANSITION; PATHOLOGY	Electrospray ionization mass spectrometry was used to study conformation and aggregation of the synthetic beta-amyloid peptide, residues 140 (beta A4), as a function of concentration and sample aging, All mass spectra showed a major envelope of peaks corresponding to charge states of 7-3 of the monomeric form of beta A4, In addition, weaker envelopes of peaks corresponding to charge states of dimeric, trimeric, and tetrameric beta A4 species were seen under gentle ionization conditions, The average charge state of the envelope associated with the monomeric form decreased by ca. 0.5 z as samples were aged, indicating that the relatively open form (likely random coil) of the peptide was modified into the more compact form (likely beta-sheet) as a function of sample aging, The aggregate forms became weaker and ultimately were absent both in the more dilute solutions and in aged aliquots of the concentrated sample, These aggregates were interpreted as assemblies of the random coil form, We interpret our inability to see an ion envelope that can be associated with aggregates of the beta-sheet form to be a consequence of the presumed very compact nature of this form, A model for the formation of beta A4 fibrils is proposed and discussed.	NICHHD,BETHESDA,MD 20892; NIA,NEUROSCI LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)								BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BURDICK D, 1992, J BIOL CHEM, V267, P546; CAMILLERI P, 1994, FEBS LETT, V341, P256, DOI 10.1016/0014-5793(94)80467-2; DOWNARD KM, 1995, INT J MASS SPECTROM, V148, P191, DOI 10.1016/0168-1176(95)04295-V; ELHADDAOUI A, 1995, J MOL STRUCT, V347, P363, DOI 10.1016/0022-2860(95)08558-D; FENN JB, 1993, J AM SOC MASS SPECTR, V4, P524, DOI 10.1016/1044-0305(93)85014-O; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; GLENNER GG, 1974, J HISTOCHEM CYTOCHEM, V22, P1141, DOI 10.1177/22.12.1141; HALVERSON K, 1990, BIOCHEMISTRY-US, V29, P2639, DOI 10.1021/bi00463a003; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JARRETT JT, 1994, J AM CHEM SOC, V116, P9741, DOI 10.1021/ja00100a046; JARRETT JT, 1992, BIOCHEMISTRY-US, V31, P12345, DOI 10.1021/bi00164a008; LACZKOHOLLOSI I, 1992, EUR BIOPHYS J BIOPHY, V21, P345, DOI 10.1007/BF00188347; LANSBURY PT, 1995, EUR J MED CHEM, V30, pS621; LANSBURY PT, 1992, BIOCHEMISTRY-US, V31, P6865, DOI 10.1021/bi00145a001; LEE JP, 1995, BIOCHEMISTRY-US, V34, P5191, DOI 10.1021/bi00015a033; LI C, 1992, P NATL ACAD SCI USA, V89, P9885, DOI 10.1073/pnas.89.20.9885; LIGHTWAHL KJ, 1994, J AM CHEM SOC, V116, P5271, DOI 10.1021/ja00091a035; Maggio JE, 1996, BRAIN PATHOL, V6, P147, DOI 10.1111/j.1750-3639.1996.tb00797.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; Naslund J, 1996, J NEUROCHEM, V67, P294; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; ROGERS J, 1985, J NEUROSCI, V5, P2801; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J BIOL CHEM, V268, P3072; ROZEMULLER JM, 1989, J NEUROPATH EXP NEUR, V48, P674, DOI 10.1097/00005072-198911000-00009; Schnier PD, 1996, J AM SOC MASS SPECTR, V7, P972, DOI 10.1016/1044-0305(96)00071-2; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SHEN CL, 1994, BIOPHYS J, V67, P1238, DOI 10.1016/S0006-3495(94)80593-4; SHEN CL, 1995, BIOPHYS J, V69, P640, DOI 10.1016/S0006-3495(95)79940-4; SHEN CL, 1993, BIOPHYS J, V65, P2383, DOI 10.1016/S0006-3495(93)81312-2; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; SIUZDAK G, 1996, MASS SPECTROMETRY BI, P89; SMITH DL, 1994, MASS SPECTROM REV, V13, P411, DOI 10.1002/mas.1280130503; SMITH RD, 1993, BIOL MASS SPECTROM, V22, P493, DOI 10.1002/bms.1200220902; SOTO C, 1994, J NEUROCHEM, V63, P1191; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; SPENCER RGS, 1991, BIOCHEMISTRY-US, V30, P10382, DOI 10.1021/bi00107a004; TALAFOUS J, 1994, BIOCHEMISTRY-US, V33, P7788, DOI 10.1021/bi00191a006; TERRY RD, 1964, AM J PATHOL, V44, P269; TERZI E, 1994, BIOCHEMISTRY-US, V33, P1345, DOI 10.1021/bi00172a009; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; TERZI E, 1994, BIOCHEMISTRY-US, V33, P7434, DOI 10.1021/bi00189a051; Xu YD, 1996, J AM SOC MASS SPECTR, V7, P25, DOI 10.1016/1044-0305(95)00625-7; YAMAGUCHI H, 1988, ACTA NEUROPATHOL, V77, P113; ZAGORSKI MG, 1992, BIOCHEMISTRY-US, V31, P5621, DOI 10.1021/bi00139a028	51	20	22	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1997	11	10					817	823		10.1096/fasebj.11.10.9271367	http://dx.doi.org/10.1096/fasebj.11.10.9271367			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XR105	9271367				2022-12-28	WOS:A1997XR10500012
J	Malinda, KM; Goldstein, AL; Kleinman, HK				Malinda, KM; Goldstein, AL; Kleinman, HK			Thymosin beta(4) stimulates directional migration of human umbilical vein endothelial cells	FASEB JOURNAL			English	Article						migration; angiogenesis; human umbilical vein endothelial cells; T beta(4)	DEOXYNUCLEOTIDYL TRANSFERASE-ACTIVITY; DIFFERENTIAL EXPRESSION; BASEMENT-MEMBRANE; LIVING CELLS; BETA-4 GENE; IN-VITRO; ACTIN; ANGIOGENESIS; LAMININ; PEPTIDE	Thymosin beta(4) (T beta(4)) is a 4.9 kDa polypeptide that interacts with G-actin and is thought to be an important mediator in cell proliferation, migration, and differentiation. T beta(4) has been identified as a factor involved in the differentiation of human umbilical vein endothelial cells (HUVECs) cultured on Matrigel, Here we have used various in vitro and in vivo migration assays to demonstrate the role of T beta(4) in endothelial cell migration, Our results demonstrate that T beta(4) acts as a chemoattractant for endothelial cells, stimulating the migration of HUVECs in Boyden chambers four- to sixfold over that observed with media alone, Of the primary cell types tested, only human coronary artery cells responded to T beta(4) treatment, suggesting that the migration activity of T beta(4) was endothelial cell-specific, T beta(4) significantly accelerated the rate of migration into the scratch wounded area of a HUVEC monolayer, T beta(4) treatment also increased the production of matrix metalloproteinases that may degrade the basement membrane during angiogenesis, Additional experiments using subcutaneously implanted Matrigel showed that T beta(4) stimulated cell migration in vivo. These results provide the first direct evidence that T beta(4) has chemoattractive activity and promotes angiogenesis by stimulating the migration of endothelial cells.	NIDR,NIH,BETHESDA,MD 20892; GEORGE WASHINGTON UNIV,SCH MED & HLTH SCI,DEPT BIOCHEM & MOL BIOL,WASHINGTON,DC 20037	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); George Washington University								CARPINTERO P, 1995, NEUROSCI LETT, V184, P63, DOI 10.1016/0304-3940(94)11169-J; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; COCKERILL GW, 1995, INT REV CYTOL, V159, P113, DOI 10.1016/S0074-7696(08)62106-3; CODON MR, 1992, J MOL NEUROSCI, V3, P165; Frohm M, 1996, EUR J BIOCHEM, V237, P86, DOI 10.1111/j.1432-1033.1996.0086n.x; GOMEZMARQUEZ J, 1989, J IMMUNOL, V143, P2740; GONDO H, 1987, J IMMUNOL, V139, P3840; GRANT DS, 1992, J CELL PHYSIOL, V153, P614, DOI 10.1002/jcp.1041530324; GRANT DS, 1995, J CELL SCI, V108, P3685; HALL AK, 1991, INT J CANCER, V48, P672, DOI 10.1002/ijc.2910480507; HU GF, 1993, P NATL ACAD SCI USA, V90, P1217, DOI 10.1073/pnas.90.4.1217; HU SK, 1981, MOL CELL BIOCHEM, V41, P49; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KIBBEY MC, 1994, J CELL PHYSIOL, V160, P185, DOI 10.1002/jcp.1041600121; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Lafrenie RM, 1996, J IMMUNOL, V157, P974; LIN SC, 1990, J MOL NEUROSCI, V2, P35, DOI 10.1007/BF02896924; LOW TLK, 1981, P NATL ACAD SCI-BIOL, V78, P1162, DOI 10.1073/pnas.78.2.1162; LOW TLK, 1982, J BIOL CHEM, V257, P1000; MIHELIC M, 1994, AMINO ACIDS, V6, P1, DOI 10.1007/BF00808118; NAYLOR PH, 1984, IMMUNOPHARMACOLOGY, V7, P9, DOI 10.1016/0162-3109(84)90003-1; NAYLOR PH, 1986, INT J IMMUNOPHARMACO, V8, P667, DOI 10.1016/0192-0561(86)90001-9; OATES KK, 1995, BIOL THERAPY CANC, P841; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PASSANITI A, 1992, LAB INVEST, V67, P519; SAFER D, 1994, BIOESSAYS, V16, P473, DOI 10.1002/bies.950160706; SANDERS MC, 1992, P NATL ACAD SCI USA, V89, P4678, DOI 10.1073/pnas.89.10.4678; SANGER JM, 1995, CELL MOTIL CYTOSKEL, V31, P307, DOI 10.1002/cm.970310407; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; SHAHABUDDIN N, 1994, AIDS RES HUM RETROV, V10, P1525; Sun HQ, 1996, J BIOL CHEM, V271, P9223, DOI 10.1074/jbc.271.16.9223; THURMAN GB, 1981, LYMPHOKINES THYMIC H, P145; WELLER FE, 1988, J BIOL RESP MODIF, V7, P91; YAMAMOTO M, 1992, BIOCHEM BIOPH RES CO, V184, P93, DOI 10.1016/0006-291X(92)91162-J; YAMAMOTO T, 1993, BIOCHEM BIOPH RES CO, V193, P706, DOI 10.1006/bbrc.1993.1682; YU FX, 1994, CELL MOTIL CYTOSKEL, V27, P13, DOI 10.1002/cm.970270103; YU FX, 1993, J BIOL CHEM, V268, P502	39	197	213	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1997	11	6					474	481		10.1096/fasebj.11.6.9194528	http://dx.doi.org/10.1096/fasebj.11.6.9194528			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XE404	9194528				2022-12-28	WOS:A1997XE40400010
J	Goldberg, B; Yarlett, N; Sufrin, J; Lloyd, D; Bacchi, CJ				Goldberg, B; Yarlett, N; Sufrin, J; Lloyd, D; Bacchi, CJ			A unique transporter of S-adenosylmethionine in African trypanosomes	FASEB JOURNAL			English	Article						purine uptake; S-adenosylmethionine metabolism; trypanocidal agents	DL-ALPHA-DIFLUOROMETHYLORNITHINE; ADENOSYL-L-METHIONINE; BRUCEI-BRUCEI; LEISHMANIA-DONOVANI; RHODESIENSE; METABOLISM; ANALOGS; SYNTHETASE; AFFINITY; INVITRO	African trypanosomes are pathogens of humans and livestock in equatorial Africa, There is a great deal of resistance tea present front line drugs for treating African trypanosomiasis such as melarsoprol (Arsobal) and pentamidine. In the search for new and novel drugs against this disease, we have found a unique transporter of S-adenosylmethionine (AdoMet), a metabolite used in transmethylation reactions and polyamine synthesis, This transporter is distinct from those for methionine and adenosine, since AdoMet uptake was not inhibited by trypanocidal drugs, which compete with adenosine for transport, AdoMet analogs competing with [methyl-H-3]AdoMet for uptake required a positively charged sulfonium group on the 5' position of the ribose, Since transport of AdoMet does not normally occur to a significant extent in mammalian cells, the parasite transporter provides a selective and novel route to deliver new chemotherapeutic agents against these organisms, Goldberg, B., Yarlett N., Sufrin, J., Lloyd, D., Baechi, C. J. A unique transporter of S-adenosyhmethionine in African trypanosomes.	PACE UNIV,HASKINS LABS,NEW YORK,NY 10038; PACE UNIV,DEPT CHEM & PHYS SCI,NEW YORK,NY 10038; PACE UNIV,DEPT BIOL,NEW YORK,NY 10038; UNIV WALES COLL CARDIFF,CARDIFF CF1 3TL,S GLAM,WALES; ROSWELL PK CANC INST,GRACE CANC DRUG CTR,BUFFALO,NY 14263	Pace University; Pace University; Pace University; Cardiff University; Roswell Park Cancer Institute			Yarlett, Nigel/B-3523-2009; Lloyd, David/D-2483-2010					Alleman MM, 1995, EXP PARASITOL, V81, P519, DOI 10.1006/expr.1995.1145; ARONOW B, 1987, MOL BIOCHEM PARASIT, V22, P29, DOI 10.1016/0166-6851(87)90066-1; BACCHI CJ, 1980, SCIENCE, V210, P332, DOI 10.1126/science.6775372; BACCHI CJ, 1990, ANTIMICROB AGENTS CH, V34, P1183, DOI 10.1128/AAC.34.6.1183; BACCHI CJ, 1991, ANTIMICROB AGENTS CH, V35, P1315, DOI 10.1128/AAC.35.7.1315; BACCHI CJ, 1995, BIOCHEM J, V309, P737, DOI 10.1042/bj3090737; BARRETT MP, 1995, MOL BIOCHEM PARASIT, V73, P223, DOI 10.1016/0166-6851(95)00120-P; Berens Randolph L., 1995, P89, DOI 10.1016/B978-012473345-9/50007-6; BITONTI AJ, 1989, P NATL ACAD SCI USA, V86, P651, DOI 10.1073/pnas.86.2.651; BITONTI AJ, 1990, ANTIMICROB AGENTS CH, V34, P1485, DOI 10.1128/AAC.34.8.1485; CANTONI GL, 1953, J BIOL CHEM, V204, P403; CARTER NS, 1995, J BIOL CHEM, V270, P28153, DOI 10.1074/jbc.270.47.28153; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; CLARKSON AB, 1989, J BIOL CHEM, V264, P17770; CORNFORTH JN, 1979, TRASMETHYLATION, P19; DELAHABA G, 1959, J AM CHEM SOC, V81, P3975, DOI 10.1021/ja01524a039; DUCE AM, 1988, HEPATOLOGY, V8, P65, DOI 10.1002/hep.1840080113; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; JAMES DM, 1980, PARASITOLOGY, V81, P383, DOI 10.1017/S0031182000056110; KUZOE F, 1993, AFRICAN TRYPANOSOMIA, P115; LHOSTIS C, 1993, BIOCHEM J, V291, P297, DOI 10.1042/bj2910297; MOZIER NM, 1990, FASEB J, V4, P3329, DOI 10.1096/fasebj.4.15.2253846; PEZZOLI C, 1978, BIOCHEM BIOPH RES CO, V85, P1031, DOI 10.1016/0006-291X(78)90646-0; PHELOUZAT MA, 1995, BIOCHEM J, V305, P133, DOI 10.1042/bj3050133; STRAMENTINOLI G, 1987, AM J MED, V83, P35, DOI 10.1016/0002-9343(87)90849-7; STRAMENTINOLI G, 1978, BIOCHEM PHARMACOL, V27, P323; SUFRIN JR, 1991, J MED CHEM, V34, P2600, DOI 10.1021/jm00112a039; YARLETT N, 1993, BIOCHIM BIOPHYS ACTA, V1181, P68, DOI 10.1016/0925-4439(93)90092-F; YARLETT N, 1991, EXP PARASITOL, V72, P205, DOI 10.1016/0014-4894(91)90138-M; YARLETT N, 1991, J GEN MICROBIOL, V137, P717, DOI 10.1099/00221287-137-3-717	30	30	30	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1997	11	4					256	260		10.1096/fasebj.11.4.9068614	http://dx.doi.org/10.1096/fasebj.11.4.9068614			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WM850	9068614				2022-12-28	WOS:A1997WM85000007
J	Schmitt, DA; Hatton, JP; Emond, C; Chaput, D; Paris, H; Levade, T; Cazenave, JP; Schaffar, L				Schmitt, DA; Hatton, JP; Emond, C; Chaput, D; Paris, H; Levade, T; Cazenave, JP; Schaffar, L			The distribution of protein kinase C in human leukocytes is altered in microgravity	FASEB JOURNAL			English	Article						spaceflight; monocytes; signal transduction; PKC	SIGNAL-TRANSDUCTION; GRAVITY; ACTIVATION; PHORBOL; CELLS; PHOSPHORYLATION; TRANSLOCATION; FILAMENTS; ISOZYMES; FLIGHT	Protein kinase C (PKC) is an ubiquitous enzyme that mediates intracellular signal transduction in eukaryotes. Jurkat and U931 cells were exposed to microgravity during a Space Shuttle flight and stimulated with a radiolabeled phorbol ester (H-3-PDBu) that specifically activates and labels several PKC isoforms, Both the total amount of H-3-PDBu labeling per cell and the relative distribution of labeling between subcellular compartments were altered in microgravity compared to onboard and ground 1 g control samples, The amount of total phorbol ester labeling per cell was increased approximately twofold in microgravity samples when compared with onboard Ig samples for both cell lines, The subcellular distribution of PKC in the cytosol and nuclear fractions appeared to be correlated with the applied acceleration, In both cell types the relative amount of phorbol ester labeling in the nuclear fraction decreased with applied acceleration, whereas the labeling in cytosolic fraction increased with g level, No significant differences were observed between labeling levels in the membrane fraction in both cell types, Interleukin-1 beta Synthesis by U931 cells was markedly decreased in microgravity when compared to the onboard 1 g control, suggesting that the observed alterations in PKC distribution may have functional consequences, The results may have important implications for the effect of gravity on cellular signal transduction.	ETAB TRANSFUS SANGUINE STRASBOURG, INSERM U311, F-67065 STRASBOURG, FRANCE; HOP & FAC MED TOULOUSE RANGUEIL, IMMUNOL LAB, F-31054 TOULOUSE, FRANCE; CTR NATL ETUD SPATIALES, F-31055 TOULOUSE, FRANCE; CHU RANGUEIL, INSERM U317, F-31054 TOULOUSE, FRANCE; CHU RANGUEIL, INSERM CJF 9206, F-31054 TOULOUSE, FRANCE; INSERM, SERV ICAR, F-75654 PARIS 13, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Schmitt, DA (corresponding author), INT SPACE UNIV, BLVD GONTHIER ANDERNACH, STRASBOURG CENT CAMPUS, F-67400 ILLKIRCH GRAFFENSTADEN, FRANCE.		Cazenave, Jean-Pierre/AAE-2935-2019; Levade, Thierry/O-8948-2014					BJORKMAN T, 1988, ADV BOT RES, V15, P1; BRIARTY LG, 1995, BIORACK SPACELAB IML, V1, P141; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; Cogoli A, 1991, Adv Space Biol Med, V1, P183; DEGROOT RP, 1991, EXP CELL RES, V197, P87, DOI 10.1016/0014-4827(91)90483-B; FLEMING SD, 1991, J LEUKOCYTE BIOL, V50, P69, DOI 10.1002/jlb.50.1.69; GENZEL P, 1988, ESA, P21; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUGHESFULFORD M, 1993, ASGSB B, V7, P31; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; KILEY SC, 1995, J CELL SCI, V108, P1003; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LIMOUSE M, 1991, EXP CELL RES, V197, P82, DOI 10.1016/0014-4827(91)90482-A; LORENZI G, 1990, BIOL CELL, V68, P259, DOI 10.1016/0248-4900(90)90317-V; MAHONEY CW, 1994, PROTEIN KINASE C, P16; MALVIYA AN, 1993, RECEPTOR, V3, P257; MANDELKOW E, 1989, SCIENCE, V246, P1291, DOI 10.1126/science.2588005; MEEK DW, 1992, BIOCHEM J, V287, P1; MORRISON D, 1995, POSTFL M ESTEC NOORD; MURTI KG, 1992, EXP CELL RES, V202, P36, DOI 10.1016/0014-4827(92)90401-S; OFLAHERTY JT, 1990, J BIOL CHEM, V265, P9146; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; OKADA S, 1969, SCIENCE, V165, P698, DOI 10.1126/science.165.3894.698; PARKER PJ, 1994, PROTEIN KINASE C, P3; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; Pippia P, 1996, J BIOTECHNOL, V47, P215, DOI 10.1016/0168-1656(96)01387-9; PRIGOGINE I, 1984, ORDER OUT CHAOS, P40; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SCHMITT DA, 1993, J CELL SCI, V104, P805; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SHOYAB M, 1980, NATURE, V288, P451, DOI 10.1038/288451a0; SPOONER BS, 1990, AVIAT SPACE ENVIR MD, V61, P725; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TABONY J, 1994, SCIENCE, V264, P245, DOI 10.1126/science.8146654; TAKAI Y, 1979, BIOCHEM BIOPH RES CO, V91, P1218, DOI 10.1016/0006-291X(79)91197-5; TSUTSUMI A, 1993, J IMMUNOL, V150, P1746; WOODS KM, 1994, EXP CELL RES, V211, P171, DOI 10.1006/excr.1994.1074	37	70	73	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1996	10	14					1627	1634		10.1096/fasebj.10.14.9002555	http://dx.doi.org/10.1096/fasebj.10.14.9002555			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WC869	9002555				2022-12-28	WOS:A1996WC86900009
J	Kessler, N; PerlTreves, D; Addadi, L				Kessler, N; PerlTreves, D; Addadi, L			Monoclonal antibodies that specifically recognize crystals of dinitrobenzene	FASEB JOURNAL			English	Article						immunogenicity; cholesterol; crystal; dinitrobenzene; monoclonal antibodies	3-DIMENSIONAL STRUCTURE; ANTIGEN; COMPLEX; AUTOANTIBODIES; CHOLESTEROL; ADSORPTION; HAPTEN	Monoclonal antibodies have been elicited and selected after injection of crystals of 1,4-dinitrobenzene (1,4-DNB) and cholesterol monohydrate in mice. The reactivity of some of these antibodies to 1,4-DNB crystals, cholesterol monohydrate crystals, and other solid substrates has been characterized. Two of the antibodies selectively recognize 1,4-DNB crystal surfaces in an appropriately modified ELISA. They do not interact either with 1,4-DNB/BSA conjugates or with polystyrene and cholesterol monohydrate surfaces. They do interact with 1,2-DNB crystal surfaces, albeit with much lower reactivity. It is consequently suggested that these antibodies are not specific to the DNB molecule but rather to a repetitive motif of molecular moieties exposed at the crystal surfaces. Characterization of their binding regions may help to elucidate the interactions of antibodies with solid substrates and, in general, with antigens exposed on biological and artificial surfaces.	WEIZMANN INST SCI,DEPT BIOL STRUCT,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science				Perl-Treves, Daniele/0000-0001-6312-4092				AIZENBERG J, 1994, J CRYST GROWTH, V142, P156, DOI 10.1016/0022-0248(94)90283-6; ALVING CR, 1989, BIOCHEM SOC T, V17, P637, DOI 10.1042/bst0170637; AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; BRUNGER AT, 1991, J MOL BIOL, V221, P239, DOI 10.1016/0022-2836(91)90817-P; CHITARRA V, 1993, P NATL ACAD SCI USA, V90, P7711, DOI 10.1073/pnas.90.16.7711; CHOTHIA C, 1991, CURR OPIN STRUC BIOL, V1, P43; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DINTZIS RZ, 1989, J IMMUNOL, V143, P1239; DIRIENZO F, 1980, ACTA CRYSTALLOGR B, V36, P586, DOI 10.1107/S056774088000386X; Engvall E, 1980, Methods Enzymol, V70, P419; Eshhar Z., 1985, HYBRIDOMA TECHNOLOGY, P3; GARCIA KC, 1992, SCIENCE, V257, P502, DOI 10.1126/science.1636085; GOLDBLUM RM, 1992, LANCET, V340, P510, DOI 10.1016/0140-6736(92)91710-P; GREENSPAN NS, 1992, IMMUNOL TODAY, V13, P164, DOI 10.1016/0167-5699(92)90120-V; Guyton John R., 1994, Current Opinion in Lipidology, V5, P376, DOI 10.1097/00041433-199410000-00010; JAMES RW, 1935, P ROY SOC LOND A MAT, V153, P225; KAM M, 1992, FASEB J, V6, P2608, DOI 10.1096/fasebj.6.8.1592211; KAM M, 1995, NATURE, V273, P105; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOZIN F, 1982, J COLLOID INTERF SCI, V88, P326, DOI 10.1016/0021-9797(82)90262-4; LIN JN, 1991, J CHROMATOGR, V542, P41; LIN JN, 1989, J IMMUNOL METHODS, V125, P67, DOI 10.1016/0022-1759(89)90079-3; MICHAELIDES MC, 1974, J EXP MED, V140, P687, DOI 10.1084/jem.140.3.687; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.iy.13.040195.003255; PerlTreves D, 1996, MOL CRYST LIQ CRYS A, V278, P1, DOI 10.1080/10587259608033652; PERLTREVES D, 1996, IN PRESS CHEM BIO, V3; SEEGMILLER JE, 1962, JAMA-J AM MED ASSOC, V180, P125; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; URBAIN J, 1993, J AUTOIMMUN, V6, P663, DOI 10.1006/jaut.1993.1054; WASSEF NM, 1989, J IMMUNOL, V143, P2990; WISSLER RW, 1993, ARTERIOSCLER THROMB, V13, P1291; ZIEGLER M, 1994, BIOMATERIALS, V15, P859, DOI 10.1016/0142-9612(94)90043-4	33	22	22	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1996	10	12					1435	1442		10.1096/fasebj.10.12.8903514	http://dx.doi.org/10.1096/fasebj.10.12.8903514			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VP485	8903514				2022-12-28	WOS:A1996VP48500009
J	Hooper, LV; Manzella, SM; Baenziger, JU				Hooper, LV; Manzella, SM; Baenziger, JU			From legumes to leukocytes: Biological roles for sulfated carbohydrates	FASEB JOURNAL			English	Review						glycoprotein; sulfotransferase; luteinizing hormone; nod factor; selectin	N-LINKED OLIGOSACCHARIDES; SIALYL-LEWIS-X; HUMAN CHORIONIC-GONADOTROPIN; SYMBIOTIC HOST-SPECIFICITY; ENDOTHELIAL-DERIVED LIGAND; RHIZOBIUM-MELILOTI; L-SELECTIN; P-SELECTIN; GLYCOPROTEIN HORMONES; TYROSINE SULFATION	Carbohydrates attached to proteins and lipids characteristically display complex and heterogeneous structures. However, it is becoming increasingly clear that carbohydrates with definite biological functions also exhibit unique structural features. A number of glycoproteins and glycolipids have been shown to bear oligosaccharides containing sulfate, Often, addition of a sulfate moiety turns a relatively common structural motif into a unique carbohydrate with the potential to be recognized by a specific receptor or lectin. This is clearly the case in three systems in which sulfated oligosaccharides have been shown to play a well-defined biological role: 1) control of the circulatory half-life of luteinizing hormone, 2) symbiotic interactions be tween leguminous plants and nitrogen-fixing bacteria, and 3) homing of lymphocytes to lymph nodes. The rapidly growing list of glycoproteins and glycolipids identified as bearing sulfated oligosaccharides suggests that sulfated carbohydrates play important biological roles in numerous other systems as well.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Baenziger, Jacques U/E-9430-2012		NCI NIH HHS [CA-21923] Funding Source: Medline; PHS HHS [OK-41738] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA021923, R56CA021923, R01CA021923] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASCOLI M, 1975, MOL CELL ENDOCRINOL, V3, P21, DOI 10.1016/0303-7207(75)90029-5; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BAENZIGER JU, 1991, BIOL CARBOHYDRATES, V3, P1; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BERGWERFF AA, 1995, EUR J BIOCHEM, V228, P1009; BURGER D, 1990, J NEUROCHEM, V54, P1569, DOI 10.1111/j.1471-4159.1990.tb01206.x; CHOU DKH, 1993, J BIOL CHEM, V268, P330; CHOU KH, 1985, BIOCHEM BIOPH RES CO, V128, P383, DOI 10.1016/0006-291X(85)91690-0; COOKE RM, 1994, BIOCHEMISTRY-US, V33, P10591, DOI 10.1021/bi00201a004; CROWLEY WF, 1985, EPISODIC SECRETION H, P121; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEBELLE F, 1986, J BACTERIOL, V168, P1075, DOI 10.1128/jb.168.3.1075-1086.1986; DEWAARD P, 1991, J BIOL CHEM, V266, P4237; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; DIAZ CL, 1989, NATURE, V338, P579, DOI 10.1038/338579a0; EVANS WS, 1992, ENDOCR REV, V13, P81, DOI 10.1210/er.13.1.81; FAUCHER C, 1988, J BACTERIOL, V170, P5489, DOI 10.1128/jb.170.12.5489-5499.1988; FIELD MC, 1992, J NEUROCHEM, V58, P993, DOI 10.1111/j.1471-4159.1992.tb09353.x; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; FREEZE HH, 1986, J BIOL CHEM, V261, P127; GREEN ED, 1984, P NATL ACAD SCI-BIOL, V81, P5320, DOI 10.1073/pnas.81.17.5320; HALL H, 1993, EUR J NEUROSCI, V5, P34, DOI 10.1111/j.1460-9568.1993.tb00202.x; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; HARTREE AS, 1992, BIOCHEM J, V287, P665, DOI 10.1042/bj2870665; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HOOPER LV, 1995, J BIOL CHEM, V270, P5985, DOI 10.1074/jbc.270.11.5985; HOOPER LV, 1995, J BIOL CHEM, V270, P16327, DOI 10.1074/jbc.270.27.16327; HORVATH B, 1986, CELL, V46, P335, DOI 10.1016/0092-8674(86)90654-9; IMAI Y, 1993, NATURE, V361, P555; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; JACOB GS, 1995, BIOCHEMISTRY-US, V34, P1210, DOI 10.1021/bi00004a014; KAMERLING JP, 1988, FEBS LETT, V241, P246, DOI 10.1016/0014-5793(88)81070-6; KANSAS GS, 1994, J CELL BIOL, V124, P609, DOI 10.1083/jcb.124.4.609; KATO Y, 1989, J BIOL CHEM, V264, P3364; KAWASHIMA C, 1992, GLYCOCONJUGATE J, V9, P307, DOI 10.1007/BF00731091; KONDOROSI E, 1984, MOL GEN GENET, V193, P445, DOI 10.1007/BF00382082; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LONG SR, 1989, CELL, V56, P203, DOI 10.1016/0092-8674(89)90893-3; MENGELING BJ, 1995, P NATL ACAD SCI USA, V92, P502, DOI 10.1073/pnas.92.2.502; NEEDHAM LK, 1993, J CELL BIOL, V121, P397, DOI 10.1083/jcb.121.2.397; NEEDHAM LK, 1991, ANN NY ACAD SCI, V633, P553; NELSON RM, 1993, J CLIN INVEST, V91, P1157, DOI 10.1172/JCI116275; NIEHRS C, 1994, CHEM-BIOL INTERACT, V92, P257, DOI 10.1016/0009-2797(94)90068-X; OKA S, 1992, J BIOL CHEM, V267, P22711; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; ROCHE P, 1991, J BIOL CHEM, V266, P10933; ROSEN SD, 1993, RES IMMUNOL, V144, P699, DOI 10.1016/S0923-2494(93)80054-3; ROSEN SD, 1993, HISTOCHEMISTRY, V100, P185, DOI 10.1007/BF00269091; ROUX L, 1988, J BIOL CHEM, V263, P8879; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SANJUAN J, 1992, P NATL ACAD SCI USA, V89, P8789, DOI 10.1073/pnas.89.18.8789; SCHWARZ JK, 1984, J BIOL CHEM, V259, P3554; SCHWEDOCK J, 1990, NATURE, V348, P644, DOI 10.1038/348644a0; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SHILATIFARD A, 1993, J VIROL, V67, P943, DOI 10.1128/JVI.67.2.943-952.1993; SICILIANO RA, 1993, GLYCOBIOLOGY, V3, P225, DOI 10.1093/glycob/3.3.225; SICILIANO RA, 1994, J BIOL CHEM, V269, P910; SKELTON TP, 1991, J BIOL CHEM, V266, P17142; SKELTON TP, 1992, J BIOL CHEM, V267, P12998; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SMITH PL, 1990, P NATL ACAD SCI USA, V87, P7275, DOI 10.1073/pnas.87.18.7275; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; SPIRO RG, 1988, J BIOL CHEM, V263, P14351; STOCKERT RJ, 1980, J BIOL CHEM, V255, P3830; SUNDBLAD G, 1988, J BIOL CHEM, V263, P8890; TRUCHET G, 1991, NATURE, V351, P670, DOI 10.1038/351670a0; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; VELDHUIS JD, 1984, J CLIN ENDOCR METAB, V58, P1050, DOI 10.1210/jcem-58-6-1050; VELDHUIS JD, 1987, P NATL ACAD SCI USA, V84, P7686, DOI 10.1073/pnas.84.21.7686; WANG H, 1991, J BIOL CHEM, V266, P780; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; YAMASHITA K, 1983, J BIOL CHEM, V258, P4144; YUEN CT, 1994, J BIOL CHEM, V269, P1595; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003; ZHENG YQ, 1994, J BIOL CHEM, V269, P30313; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	87	77	79	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1996	10	10					1137	1146		10.1096/fasebj.10.10.8751716	http://dx.doi.org/10.1096/fasebj.10.10.8751716			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VD429	8751716				2022-12-28	WOS:A1996VD42900005
J	Whelan, WJ				Whelan, WJ			Scientist and statesman: Ephraim Katchalski-Katzir at 80	FASEB JOURNAL			English	Item About an Individual											Whelan, WJ (corresponding author), UNIV MIAMI,SCH MED,POB 016129 M823,MIAMI,FL 33101, USA.								0	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1996	10	10					1233	1234		10.1096/fasebj.10.10.8786036	http://dx.doi.org/10.1096/fasebj.10.10.8786036			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VD429	8786036				2022-12-28	WOS:A1996VD42900016
J	Berard, J; Laboune, F; Mukuna, M; Masse, S; Kothary, R; Bradley, WEC				Berard, J; Laboune, F; Mukuna, M; Masse, S; Kothary, R; Bradley, WEC			Lung tumors in mice expressing an antisense RAR beta 2 transgene	FASEB JOURNAL			English	Article						retinoic acid receptor beta 2; lung tumors; tumor suppressor gene; antisense RNA; transgenic nice	RETINOIC ACID RECEPTORS; CARCINOMA CELL-LINES; RAR DOUBLE MUTANTS; EPITHELIAL-CELLS; CANCER CELLS; BETA; ABNORMALITIES; BREAST; GENES; RNA	Retinoic acid has been shown to be an anticancer agent, and a growing literature suggests that it is the nuclear retinoic acid receptor beta 2 (RAR beta 2) that is primarily responsible for mediating this effect, at least in some systems, To determine whether partial inactivation of RAR beta 2 would predispose to lung cancer in mice, we generated three transgenic lines expressing antisense sequences. When killed at 13-3/4-18 months of age, 21/36 animals had a total of 43 pulmonary tumors superficially visible upon necropsy, whereas among 23 nontransgenic mice, only 1 had a single visible lung tumor, A twofold higher incidence of lung tumors was seen in homozygous vs, hemizygous antisense mice, The endogenous RAR beta 2 message level was reduced in transgenic lung tissue and further reduced in the tumors, RAR beta 4, a truncated isoform derived from the same transcript as RAR beta 2, does not carry the sequence identified by the antisense construct and its message was not as strongly affected, Immunofluorescence studies showed that RAR beta was virtually undetectable in the tumors, but present in normal tissue, We conclude that RAR beta 2, but probably not RAR beta 4, plays an important role in suppression of murine lung tumorigenesis.	UNIV SHERBROOKE,FAC MED,DEPT PATHOL,SHERBROOKE,PQ J1H 5N4,CANADA; INST CANC MONTREAL,CTR RECH LOUIS CHARLES SIMARD,MONTREAL,PQ H2L 4M1,CANADA; UNIV MONTREAL,DEPT MED,MONTREAL,PQ H3C 3J7,CANADA	University of Sherbrooke; Universite de Montreal; Universite de Montreal	Berard, J (corresponding author), UNIV SHERBROOKE,FAC MED,DEPT ANAT & CELLULAR BIOL,SHERBROOKE,PQ J1H 5N4,CANADA.			Kothary, Rashmi/0000-0002-9239-7310				BERARD J, 1994, EMBO J, V13, P5570, DOI 10.1002/j.1460-2075.1994.tb06894.x; CARNEY DN, 1988, SEMIN ONCOL, V15, P199; CHAMBON P, 1991, RETINOIDS : 10 YEARS ON, P10; DE LUCA LM, 1991, FASEB J, V5, P2924; DOUGHERTY WG, 1995, CURR OPIN CELL BIOL, V7, P399, DOI 10.1016/0955-0674(95)80096-4; GERBERT JF, 1991, ONCOGENE, V6, P1859; GRAHAM S, 1984, JNCI-J NATL CANCER I, V73, P1423; HARRIS CC, 1973, JNCI-J NATL CANCER I, V51, P1059, DOI 10.1093/jnci/51.3.1059; Hong Waun Ki, 1994, P597; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; HU L, 1991, CANCER RES, V51, P3972; IZANT JG, 1985, SCIENCE, V229, P345, DOI 10.1126/science.2990048; LI XS, 1995, J CELL PHYSIOL, V165, P449, DOI 10.1002/jcp.1041650302; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; LUO JM, 1995, MECH DEVELOP, V53, P61, DOI 10.1016/0925-4773(95)00424-6; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; MENDELSOHN C, 1994, DEV BIOL, V166, P246, DOI 10.1006/dbio.1994.1311; NAPGAL S, 1992, P NATL ACAD SCI USA, V89, P2718; NERVI C, 1991, EXP CELL RES, V195, P163, DOI 10.1016/0014-4827(91)90512-S; Roberts A, 1984, RETINOIDS; ROMAN SD, 1992, CANCER RES, V52, P2236; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Si SP, 1996, EXP CELL RES, V223, P102, DOI 10.1006/excr.1996.0062; STEWART TA, 1988, MOL CELL BIOL, V8, P473, DOI 10.1128/MCB.8.1.473; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; VALERA A, 1994, J BIOL CHEM, V269, P28543; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x	30	102	104	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1996	10	9					1091	1097		10.1096/fasebj.10.9.8801172	http://dx.doi.org/10.1096/fasebj.10.9.8801172			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801172				2022-12-28	WOS:A1996UY93200021
J	Chevalier, S; Ferland, G; Tuchweber, B				Chevalier, S; Ferland, G; Tuchweber, B			Lymphatic absorption of retinol in young, mature, and old rats: Influence of dietary restriction	FASEB JOURNAL			English	Article						retinoids; aging; AL rats; dietary-restricted rats	VITAMIN-A; INTESTINAL-ABSORPTION; MEMBRANE FLUIDITY; FOOD RESTRICTION; AGING RATS; LIVER; TRANSPORT; METABOLISM; STORAGE; MICE	Earlier studies have shown that hepatic vitamin A stores increase with age and that rats subjected to life-long dietary restriction (DR) have greater hepatic retinoid concentrations than ad libitum-fed rats, It was suggested that these changes may be attributed to altered intestinal absorption, and so we measured retinol absorption in 3, 12, and 22 month-old female Sprague-Dawley rats fed ad libitum (AL) or a restricted diet (40%) enriched (DR(+)) or not (DR) with vitamins and minerals, An in vivo model was used and lymph collected from the mesenteric duct while rats were infused a micellar solution containing [H-3]retinol into the proximal duodenum, Aging significantly decreased lymph flow, and at all ages DR and DR(+) rats exhibited a higher flow than age-matched AL rats, Absorption of retinol was not significantly modified by age in AL and DR(+) rats, However, in the DR group, there was a marked decrease in absorption between 3 and 12 months of age, Retinol absorption was significantly higher in 12 and 22 month-old DR(+) rats than in age-matched AL rats, a finding that may be explained by both higher lymph flow rate and higher long-term vitamin A intake per body weight, In conclusion, the increased content of vitamin A in the livers of older AL rats is not associated with changes in intestinal absorption, In DR rats, however, retinoid accumulation in the liver may be explained by increased intestinal absorption of the vitamin, though other mechanisms may be involved, A possible explanation may be a decreased output of retinol from the liver as a result of lower metabolic needs, The lower serum vitamin A concentrations observed in DR rats would tend to support this hypothesis.	UNIV MONTREAL,DEPT NUTR,MONTREAL,PQ H3C 3J7,CANADA	Universite de Montreal								AHN JJ, 1995, J NUTR BIOCHEM, V6, P595, DOI 10.1016/0955-2863(95)00127-L; BLOMHOFF R, 1991, FASEB J, V5, P271, DOI 10.1096/fasebj.5.3.2001786; BLOMHOFF R, 1991, PHYSIOL REV, V71, P951, DOI 10.1152/physrev.1991.71.4.951; BOUCHARD G, 1995, GASTROENTEROLOGY, V108, pA717; BRASITUS TA, 1984, BIOCHIM BIOPHYS ACTA, V778, P341, DOI 10.1016/0005-2736(84)90378-X; BYUN DS, 1995, AGING-CLIN EXP RES, V7, P40, DOI 10.1007/BF03324291; Chevalier S., 1996, FASEB Journal, V10, pA524; CHEVALIER S, 1995, NUTR RES, V15, P859, DOI 10.1016/0271-5317(95)00051-J; DEW SE, 1994, BIOCHEMISTRY-US, V33, P12340, DOI 10.1021/bi00206a042; FERLAND G, 1992, J GERONTOL, V47, pB3, DOI 10.1093/geronj/47.1.B3; FERNANDEZ E, 1990, LIPIDS, V25, P549, DOI 10.1007/BF02537163; FLEMING BB, 1982, EXP GERONTOL, V17, P115, DOI 10.1016/0531-5565(82)90044-4; HOLLANDER D, 1980, AM J PHYSIOL, V239, pG210, DOI 10.1152/ajpgi.1980.239.3.G210; HOLLANDER D, 1990, EXP GERONTOL, V25, P61, DOI 10.1016/0531-5565(90)90010-Y; HOLLANDER D, 1986, AGE, V9, P57, DOI 10.1007/BF02432262; LAGANIERE S, 1989, MECH AGEING DEV, V48, P207, DOI 10.1016/0047-6374(89)90083-3; LEVIN G, 1992, MECH AGEING DEV, V62, P137, DOI 10.1016/0047-6374(92)90050-N; ROBERTS D, 1994, AM J PHYSIOL-GASTR L, V267, pG515, DOI 10.1152/ajpgi.1994.267.4.G515; SCARPACE PJ, 1987, J GERONTOL, V42, P442, DOI 10.1093/geronj/42.4.442; SUNDBOOM J, 1984, EXP GERONTOL, V19, P257, DOI 10.1016/0531-5565(84)90021-4; SWEDA LI, 1994, J BIOL CHEM, V269, P8712; UNDERWOOD BA, 1970, AM J CLIN NUTR, V23, P1037; WARSHAW AL, 1972, GUT, V13, P66, DOI 10.1136/gut.13.1.66; YOST RW, 1988, J BIOL CHEM, V263, P18693; YU BP, 1994, P SOC EXP BIOL MED, V205, P97, DOI 10.3181/00379727-205-43684; YU BP, 1992, MECH AGEING DEV, V65, P17, DOI 10.1016/0047-6374(92)90123-U; YU BP, 1985, J GERONTOL, V40, P657, DOI 10.1093/geronj/40.6.657; YU BP, 1990, REV BIOL RES AGING, V4, P349	28	24	24	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1996	10	9					1085	1090		10.1096/fasebj.10.9.8801171	http://dx.doi.org/10.1096/fasebj.10.9.8801171			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801171				2022-12-28	WOS:A1996UY93200020
J	Repa, JJ; Plum, LA; Tadikonda, PK; ClagettDame, M				Repa, JJ; Plum, LA; Tadikonda, PK; ClagettDame, M			All-trans 3,4-didehydroretinoic acid equals all-trans retinoic acid in support of chick neuronal development	FASEB JOURNAL			English	Article						sympathetic neuron; nerve growth factor; retinoic acid receptor; didehydroretinoic acid; baculovirus expression system	RESPONSE ELEMENT; TRANSACTIVATION PROPERTIES; POLARIZING ACTIVITY; LIGAND-BINDING; X-RECEPTORS; LIMB-BUDS; IDENTIFICATION; EXPRESSION; EMBRYO; GENE	All-trans 3,4-didehydroretinoic acid (at-ddRA) has been identified as a biologically important retinoid in avian, but not mammalian, embryonic development, In this report, we show that at-ddRA, like ah-trans retinoic acid (atRA), supports the survival and differentiation of sympathetic neurons of the embryonic chick, Furthermore, the expression of the retinoid-responsive gene RAR beta 2 is increased in neurons exposed to either at-ddRA or atRA, The mechanism whereby at-ddRA exerts its effects in chick neurons may involve binding to and activation of nuclear retinoid receptors, For this reason, the binding of recombinant chick RAR beta 2 to at-ddRA and to receptor-specific DNA response elements was examined and compared with the binding characteristics of recombinant murine RAR beta 2, The chick RAR beta 2, like the mammalian RAR, binds to [H-3]atRA with high affinity (k(d) = 0.7-2 nM), Furthermore, both chick and murine RAR beta 2 bind equally web to at-ddRA, atRA, and 9-cis RA, but neither receptor shows appreciable binding to 13-cis RA, The chick RAR beta 2 recognizes previously described retinoic: acid response elements of mammalian gene promoters and, Like mammalian RAR beta 2, shows enhanced binding in the presence of RXR, This study provides evidence that at-ddRA., like atRA, supports neuronal development in the thick by its interaction with nuclear retinoid receptors.	UNIV WISCONSIN, SCH PHARM, INTERDEPT GRAD PROGRAM NUTR SCI, MADISON, WI 53706 USA; UNIV WISCONSIN, SCH PHARM, DEPT BIOCHEM, MADISON, WI 53706 USA; UNIV WISCONSIN, SCH PHARM, DIV PHARMACEUT SCI, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Repa, Joyce/0000-0001-5740-1954	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK014881] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-14881] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAME MC, 1985, P NATL ACAD SCI USA, V82, P7825, DOI 10.1073/pnas.82.23.7825; DERSCH H, 1993, DEV BIOL, V160, P424, DOI 10.1006/dbio.1993.1318; Dong D, 1995, BIOCHEM BIOPH RES CO, V217, P1026, DOI 10.1006/bbrc.1995.2872; DTHE H, 1990, NATURE, V343, P177; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Hofmann Clementine, 1994, P387; HOGAN BLM, 1992, NATURE, V359, P237, DOI 10.1038/359237a0; HORTON C, 1995, DEV DYNAM, V202, P312, DOI 10.1002/aja.1002020310; HUSMANN M, 1992, BIOCHEM BIOPH RES CO, V187, P1558, DOI 10.1016/0006-291X(92)90480-9; KIM YW, 1994, J BIOCHEM TOXICOL, V9, P225, DOI 10.1002/jbt.2570090502; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LOPEZ SL, 1995, DEV DYNAM, V204, P457, DOI 10.1002/aja.1002040411; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; LUO JM, 1995, MECH DEVELOP, V53, P61, DOI 10.1016/0925-4773(95)00424-6; MADEN M, 1992, BIOESSAYS, V14, P431, DOI 10.1002/bies.950140702; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MANGELSDORF DJ, 1991, RETINOIDS BIOL CHEM, P319; MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7194, DOI 10.1073/pnas.91.15.7194; MICHAILLE JJ, 1995, INT J DEV BIOL, V39, P587; MICHAILLE JJ, 1994, DEV DYNAM, V201, P334, DOI 10.1002/aja.1002010405; MOTTO MG, 1989, J CHROMATOGR, V481, P255, DOI 10.1016/S0021-9673(01)96769-X; MUNDER M, 1995, P NATL ACAD SCI USA, V92, P2795, DOI 10.1073/pnas.92.7.2795; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NOHNO T, 1991, BIOCHIM BIOPHYS ACTA, V1089, P273, DOI 10.1016/0167-4781(91)90024-G; NOJI S, 1991, NATURE, V350, P83, DOI 10.1038/350083a0; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Plum LA, 1996, DEV DYNAM, V205, P52, DOI 10.1002/(SICI)1097-0177(199601)205:1<52::AID-AJA5>3.0.CO;2-4; QUICK TC, 1994, RECEPTOR, V4, P65; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; REPA JJ, 1993, P NATL ACAD SCI USA, V90, P7293, DOI 10.1073/pnas.90.15.7293; RODRIGUEZTEBAR A, 1991, DEVELOPMENT, V112, P813; SANI BP, 1990, ARCH BIOCHEM BIOPHYS, V283, P107, DOI 10.1016/0003-9861(90)90619-A; SATRE MA, 1989, DEV BIOL, V133, P529, DOI 10.1016/0012-1606(89)90055-9; SCOTT WJ, 1994, DEV BIOL, V165, P397, DOI 10.1006/dbio.1994.1262; SMITH SM, 1991, DEVELOPMENT, V111, P245; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; THOMPSON JN, 1964, PROC R SOC SER B-BIO, V159, P510, DOI 10.1098/rspb.1964.0017; THOMPSON JN, 1969, BRIT J NUTR, V23, P471, DOI 10.1079/BJN19690056; TINI M, 1994, MOL ENDOCRINOL, V8, P1494, DOI 10.1210/me.8.11.1494; TORMA H, 1994, J INVEST DERMATOL, V102, P49, DOI 10.1111/1523-1747.ep12371731; VONHOLST A, 1995, MOL CELL NEUROSCI, V6, P185; VONSCHWEITER U, 1962, HELV CHIM ACTA, V45, P541; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WARKANY J, 1954, J CELL COMPAR PHYSL, V43, pA207, DOI 10.1002/jcp.1030430410; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	51	17	17	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1996	10	9					1078	1084		10.1096/fasebj.10.9.8801170	http://dx.doi.org/10.1096/fasebj.10.9.8801170			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801170				2022-12-28	WOS:A1996UY93200019
J	Cummings, RD; Nyame, AK				Cummings, RD; Nyame, AK			Glycobiology of schistosomiasis	FASEB JOURNAL			English	Review						Lewis x antigens; glycoprotein; glycolipid; autoimmunity; oligosaccharides	ASPARAGINE-LINKED OLIGOSACCHARIDES; MANSONI SYNTHESIZES GLYCOPROTEINS; CIRCULATING CATHODIC ANTIGEN; KEYHOLE LIMPET HEMOCYANIN; MONOCLONAL-ANTIBODY; CARBOHYDRATE EPITOPES; N-ACETYLGALACTOSAMINE; CERCARIAL GLYCOCALYX; HUMAN-NEUTROPHILS; DOWN-REGULATION	Schistosomiasis is a helminthic parasitic disease that results in a wide-ranging pathology in the approximately 200 million infected people worldwide, Much of the immunity to the parasite is directed against carbohydrate determinants in both glycoproteins and glycolipids from the adult worms and their eggs, Circulating glycoproteins derived from the parasite may be diagnostic for the disease, Recent studies of the structures of schistosome-derived glycoconjugates reveal that they exhibit several interesting and novel moths, Many schistosome glycans are rich in fucose and devoid of sialic acid, It is surprising that some of the fucosylated schistosome glycans contain the Lewis x (Le(x)) antigen that is also found on human leukocytes and other tissues, These Le(x)-containing glycans elicit autoantibodies, and the glycans mag. affect lymphocyte functions, This review highlights recent progress in sehistosome research in terms of structure, function, and biosynthesis of glycoconjugates. It is hoped that the deeper understanding being gained about glycoconjugates will foster innovative new strategies for lessening the mortality and morbidity caused by these parasites.			Cummings, RD (corresponding author), UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, 941 SL YOUNG BLVD, BSEV ROOM 325, OKLAHOMA CITY, OK 73190 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026725, R22AI026725] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26725] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALVESBRITO CF, 1992, T ROY SOC TROP MED H, V86, P53, DOI 10.1016/0035-9203(92)90439-J; BARSOUM IS, 1991, J INFECT DIS, V164, P1010, DOI 10.1093/infdis/164.5.1010; BERGWERFF AA, 1994, J BIOL CHEM, V269, P31510; BOROJEVIC R, 1983, J INFECT DIS, V148, P422, DOI 10.1093/infdis/148.3.422; BRINDLEY PJ, 1989, MOL BIOCHEM PARASIT, V34, P99, DOI 10.1016/0166-6851(89)90001-7; BRINDLEY PJ, 1994, ADV PARASIT, V34, P133, DOI 10.1016/S0065-308X(08)60138-4; BUTTERWORTH AE, 1994, PARASITOL TODAY, V10, P378, DOI 10.1016/0169-4758(94)90225-9; CAPRON A, 1987, SCIENCE, V238, P1065, DOI 10.1126/science.3317823; CARTER CE, 1979, J IMMUNOL, V122, P2204; CAULFIELD JP, 1988, EXP PARASITOL, V65, P10, DOI 10.1016/0014-4894(88)90102-6; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; CRINNELL BW, 1994, GLYCOBIOLOGY, V4, P221; CRZYCH JM, 1984, J IMMUNOL, V133, P998; DALTON JP, 1987, EXP PARASITOL, V63, P215, DOI 10.1016/0014-4894(87)90164-0; DAMIAN RT, 1989, CURR TOP MICROBIOL, V145, P101; DeBoseBoyd R, 1996, EXP PARASITOL, V82, P1, DOI 10.1006/expr.1996.0001; DEELDER AM, 1980, EXP PARASITOL, V50, P16, DOI 10.1016/0014-4894(80)90004-1; DISSOUS C, 1986, NATURE, V323, P443, DOI 10.1038/323443a0; DUNNE DW, 1990, PARASITOL TODAY, V6, P45, DOI 10.1016/0169-4758(90)90068-F; ESPINOZA B, 1988, MOL BIOCHEM PARASIT, V29, P171, DOI 10.1016/0166-6851(88)90072-2; FATIMA M, 1991, J EXP MED, V174, P1399, DOI 10.1084/jem.174.6.1399; FILE S, 1995, J PARASITOL, V81, P234, DOI 10.2307/3283925; FOLEY M, 1988, PARASITOLOGY, V96, P85, DOI 10.1017/S0031182000081671; GILBERT B, 1972, PARASITOLOGY, V64, P333, DOI 10.1017/S0031182000029760; GOLDRING OL, 1976, CLIN EXP IMMUNOL, V26, P181; GRZYCH JM, 1987, J EXP MED, V165, P865, DOI 10.1084/jem.165.3.865; HALL TMT, 1995, EXP PARASITOL, V80, P242, DOI 10.1006/expr.1995.1030; HAM DA, 1984, J EXP MED, V159, P1371; HAMBURGER J, 1982, J IMMUNOL, V128, P1864; HARNETT W, 1986, PARASITOLOGY, V93, P401, DOI 10.1017/S0031182000051568; HASSAN MM, 1992, AM J TROP MED HYG, V46, P737, DOI 10.4269/ajtmh.1992.46.737; HAWN TR, 1993, MOL BIOCHEM PARASIT, V59, P73, DOI 10.1016/0166-6851(93)90008-L; HICKSTEIN DD, 1986, BLOOD, V67, P1054; JAMES SL, 1990, CURR TOP MICROBIOL, V155, P21; Jordan P., 1993, HUMAN SCHISTOSOMIASI; KANG S, 1993, J PARASITOL, V79, P815, DOI 10.2307/3283717; KHOO KH, 1995, J BIOL CHEM, V270, P17114, DOI 10.1074/jbc.270.29.17114; KO AI, 1990, P NATL ACAD SCI USA, V87, P4159, DOI 10.1073/pnas.87.11.4159; KOSTER B, 1994, PARASITOLOGY, V108, P433, DOI 10.1017/S0031182000075995; KOSTER B, 1994, ARCH BIOCHEM BIOPHYS, V310, P108, DOI 10.1006/abbi.1994.1146; KUBA NOBORU, 1963, JAP J VETERINARY SCI, V25, P289; LANGLEY JG, 1992, PARASITE IMMUNOL, V14, P185, DOI 10.1111/j.1365-3024.1992.tb00460.x; LEVERY SB, 1992, J BIOL CHEM, V267, P5542; LUNDJOHANSEN F, 1992, J IMMUNOL, V148, P3221; MAKAARU CK, 1992, J BIOL CHEM, V267, P2251; MANSOUR MH, 1995, MOL BIOCHEM PARASIT, V69, P173, DOI 10.1016/0166-6851(94)00188-S; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MCLAREN DJ, 1977, NATURE, V269, P147, DOI 10.1038/269147a0; MCLAREN DJ, 1984, PARASITOLOGY, V88, P597, DOI 10.1017/S0031182000085516; MENGELING BJ, 1995, P NATL ACAD SCI USA, V92, P502, DOI 10.1073/pnas.92.2.502; MULDER H, 1995, EUR J BIOCHEM, V227, P175, DOI 10.1111/j.1432-1033.1995.tb20374.x; NANDURI J, 1991, J BIOL CHEM, V266, P1341; NASH TE, 1978, AM J TROP MED HYG, V27, P944, DOI 10.4269/ajtmh.1978.27.944; NEELEMAN AP, 1994, GLYCOBIOLOGY, V4, P641, DOI 10.1093/glycob/4.5.641; NORDEN AP, 1984, EXP PARASITOL, V58, P333, DOI 10.1016/0014-4894(84)90050-X; NYAME AK, 1996, IN PRESS EXP PARASIT; NYAME K, 1987, J BIOL CHEM, V262, P7990; NYAME K, 1988, MOL BIOCHEM PARASIT, V28, P265, DOI 10.1016/0166-6851(88)90011-4; NYAME K, 1989, J BIOL CHEM, V264, P3235; NYAME K, 1988, J PARASITOL, V74, P562, DOI 10.2307/3282171; OMERALI P, 1988, J IMMUNOL, V140, P258; OMERALI P, 1986, J IMMUNOL, V137, P3601; PAPPAS PW, 1975, EXP PARASITOL, V37, P469, DOI 10.1016/0014-4894(75)90016-8; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; RICHTER D, 1995, PARASITOL TODAY, V11, P288, DOI 10.1016/0169-4758(95)80041-7; RIVERAMARRERO CA, 1990, MOL BIOCHEM PARASIT, V43, P59, DOI 10.1016/0166-6851(90)90130-E; SAMUELSON JC, 1986, INFECT IMMUN, V51, P181, DOI 10.1128/IAI.51.1.181-186.1986; SAUMA SY, 1991, MOL BIOCHEM PARASIT, V46, P73, DOI 10.1016/0166-6851(91)90200-P; SCHMIDT CD, 1996, FDN PARASITOLOGY; SHER A, 1991, J IMMUNOL, V147, P2713; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; SKUBITZ KM, 1985, BLOOD, V65, P333; SKUBITZ KM, 1987, J IMMUNOL, V139, P1631; Smithers S. R., 1982, Immunology of parasitic infections.  2nd edition., P527; SMITHERS SR, 1969, ANN NY ACAD SCI, V160, P826, DOI 10.1111/j.1749-6632.1969.tb15904.x; SRIVATSAN J, 1994, J PARASITOL, V80, P884, DOI 10.2307/3283435; SRIVATSAN J, 1992, GLYCOBIOLOGY, V2, P445, DOI 10.1093/glycob/2.5.445; SRIVATSAN J, 1992, J BIOL CHEM, V267, P20196; VANDAM GJ, 1993, EUR J IMMUNOL, V23, P2807, DOI 10.1002/eji.1830231113; VANDAM GJ, 1994, EUR J BIOCHEM, V225, P467, DOI 10.1111/j.1432-1033.1994.00467.x; VANDENEIJNDEN DH, 1995, BIOCHEM SOC T, V23, P175, DOI 10.1042/bst0230175; VANKUIK JA, 1987, EUR J BIOCHEM, V169, P399; VANLIESHOUT L, 1995, ACTA TROP, V59, P19, DOI 10.1016/0001-706X(94)00084-E; VANTWOUT AB, 1995, PARASITOL RES, V81, P434, DOI 10.1007/BF00931506; VELUPILLAI P, 1994, P NATL ACAD SCI USA, V91, P18, DOI 10.1073/pnas.91.1.18; VERWEIJ JJ, 1995, T ROY SOC TROP MED H, V89, P48, DOI 10.1016/0035-9203(95)90654-1; WARREN KS, 1967, AM J PATHOL, V51, P735; WEISS JB, 1986, J IMMUNOL, V136, P4275; WEISS JB, 1985, J IMMUNOL, V135, P1421; WIRGUIN I, 1995, CANCER IMMUNOL IMMUN, V40, P307, DOI 10.1007/BF01519630; XU XF, 1994, EXP PARASITOL, V79, P399, DOI 10.1006/expr.1994.1102; ZANETTI M, 1993, INT IMMUNOL, V5, P113, DOI 10.1093/intimm/5.2.113	92	71	74	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1996	10	8					838	848		10.1096/fasebj.10.8.8666160	http://dx.doi.org/10.1096/fasebj.10.8.8666160			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UQ456	8666160				2022-12-28	WOS:A1996UQ45600005
J	Domingo, E; Escarmis, C; Sevilla, N; Moya, A; Elena, SF; Quer, J; Novella, IS; Holland, JJ				Domingo, E; Escarmis, C; Sevilla, N; Moya, A; Elena, SF; Quer, J; Novella, IS; Holland, JJ			Basic concepts in RNA virus evolution	FASEB JOURNAL			English	Review						genetic bottleneck; Red Queen hypothesis; population equilibrium; quasispecies; competitive exclusion principle; RNA genome replication	VESICULAR STOMATITIS-VIRUS; MOUTH-DISEASE VIRUS; SPONTANEOUS MUTATION; MULLER RATCHET; FITNESS; HETEROGENEITY; POPULATIONS; SELECTION; ECOLOGY	A hallmark of RNA genomes is the error-prone nature of their replication and retrotranscription. The major biochemical basis of the limited replication fidelity is the absence of proofreading/repair and postreplicative error correction mechanisms that normally operate during replication of cellular DNA, In spite of this unique feature of RNA replicons, the dynamics of viral populations seems to follow the same basic principles that classical population genetics has established for higher organisms. Here we review recent evidence of the profound effects that genetic bottlenecks have in enhancing the deleterious effects of Muller's ratchet during RNA virus evolution, The validity of the Red Queen hypothesis and of the competitive exclusion principle for RNA viruses are viewed as the expected result of the highly variable and adaptable nature of viral quasispecies. Viral fitness, or ability to replicate infectious progeny, can vary a million-fold within short time intervals. Paradoxically, functional and structural studies suggest extreme limitations to virus variation, Adaptability of RNA viruses appears to be based on the occupation of very narrow portions of sequence space at any given time.	FAC BIOL,DEPT GENET,E-46100 BURJASSOT,VALENCIA,SPAIN; FAC BIOL,SERV BIOINFORMAT,E-46100 BURJASSOT,VALENCIA,SPAIN; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR GENET MOLEC,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego	Domingo, E (corresponding author), UNIV AUTONOMA MADRID,CTR BIOL MOL SEVERO OCHOA,E-28049 MADRID,SPAIN.		Elena, Santiago F./A-4191-2011; Quer, Josep/A-6741-2012; Sevilla, Noemi/K-8648-2014; Moya, Andrés/A-8190-2008; Domingo, Esteban/K-3937-2014	Elena, Santiago F./0000-0001-8249-5593; Quer, Josep/0000-0003-0014-084X; Sevilla, Noemi/0000-0003-0118-0376; Moya, Andrés/0000-0002-2867-1119; Domingo, Esteban/0000-0002-0573-1676	NIAID NIH HHS [AI-14627] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI014627, R01AI014627] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Avise John C., 1994, pi; AYALA FJ, 1971, SCIENCE, V171, P820, DOI 10.1126/science.171.3973.820; BECKMAN RA, 1993, Q REV BIOPHYS, V26, P255; BORREGO B, 1993, J VIROL, V67, P6071, DOI 10.1128/JVI.67.10.6071-6079.1993; BRANCH P, 1995, CANCER RES, V55, P2305; CATLANEO R, 1988, CELL, V56, P759; CHAO L, 1990, NATURE, V348, P454, DOI 10.1038/348454a0; CLARKE DK, 1994, P NATL ACAD SCI USA, V91, P4821, DOI 10.1073/pnas.91.11.4821; DELASSUS S, 1992, J VIROL, V66, P5642, DOI 10.1128/JVI.66.9.5642-5645.1992; DOMINGO E, 1978, CELL, V13, P735, DOI 10.1016/0092-8674(78)90223-4; Domingo E, 1992, Genet Eng (N Y), V14, P13; Domingo Esteban, 1994, P161; DRAKE JW, 1993, P NATL ACAD SCI USA, V90, P4171, DOI 10.1073/pnas.90.9.4171; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; DUARTE E, 1992, P NATL ACAD SCI USA, V89, P6015, DOI 10.1073/pnas.89.13.6015; DUARTE EA, 1994, J VIROL, V68, P4295, DOI 10.1128/JVI.68.7.4295-4301.1994; Eigen M., 1992, STEPS LIFE; Eigen M, 1979, THE HYPERCYCLE, P60; Eigen M., 1988, RNA GENETICS, V3, P211; ELANA SF, 1996, GENETICS, V142, P673; FRIEDBERG EC, 1995, DNA REPAIR; Gause G, 1971, STRUGGLE EXISTENCE; Hoffmann A.A., 1991, EVOLUTIONARY GENETIC; HOLLAND JJ, 1990, J VIROL, V64, P3960, DOI 10.1128/JVI.64.8.3960-3962.1990; HOLLAND JJ, 1992, CURR TOP MICROBIOL, V176, P1; KEESE P, 1993, CURR OPIN GENET DEV, V3, P873, DOI 10.1016/0959-437X(93)90007-C; KILBOURNE ED, 1991, CURR OPIN IMMUNOL, V3, P518, DOI 10.1016/0952-7915(91)90014-R; Kimura M., 1983, NEUTRAL THEORY MOL E; LANDE R, 1994, EVOLUTION, V48, P1460, DOI [10.2307/2410240, 10.1111/j.1558-5646.1994.tb02188.x]; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; MARTINEZ MA, 1991, J VIROL, V65, P3954; MATEU MG, 1994, J VIROL, V68, P1407, DOI 10.1128/JVI.68.3.1407-1417.1994; MEYERHANS A, 1989, CELL, V58, P910; MOYA A, 1995, MOL BASIS VIRUS EVOL, P213; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8; NOVELLA IS, 1995, P NATL ACAD SCI USA, V92, P5841, DOI 10.1073/pnas.92.13.5841; NOVELLA IS, 1995, J VIROL, V69, P6805, DOI 10.1128/JVI.69.11.6805-6809.1995; NOVELLA IS, 1995, J VIROL, V69, P2869, DOI 10.1128/JVI.69.5.2869-2872.1995; PATHAK VK, 1992, J VIROL, V66, P3093, DOI 10.1128/JVI.66.5.3093-3100.1992; RICCHETTI M, 1993, EMBO J, V12, P387, DOI 10.1002/j.1460-2075.1993.tb05670.x; STEINHAUER DA, 1989, J VIROL, V63, P2072, DOI 10.1128/JVI.63.5.2072-2080.1989; Van Valen L., 1973, EVOL THEORY REV, V1, P1, DOI DOI 10.1038/344864A0; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; Wain-Hobson Simon, 1994, P185; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033; Wright S, 1931, GENETICS, V16, P0097; [No title captured]	48	348	364	1	46	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1996	10	8					859	864		10.1096/fasebj.10.8.8666162	http://dx.doi.org/10.1096/fasebj.10.8.8666162			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UQ456	8666162				2022-12-28	WOS:A1996UQ45600007
J	Holman, RT				Holman, RT			How I got my start in lipids, and where it led me	FASEB JOURNAL			English	Item About an Individual											Holman, RT (corresponding author), UNIV MINNESOTA,HORMEL INST,801 16TH AVE NE,AUSTIN,MN 55912, USA.								0	1	1	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1996	10	8					931	934		10.1096/fasebj.10.8.8666172	http://dx.doi.org/10.1096/fasebj.10.8.8666172			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UQ456	8666172				2022-12-28	WOS:A1996UQ45600017
J	Saito, M; Sato, R; Hisatome, I; Narahashi, T				Saito, M; Sato, R; Hisatome, I; Narahashi, T			RANTES and platelet-activating factor open Ca2+-activated K+ channels in eosinophils	FASEB JOURNAL			English	Article						EoL-1; G-protein; PAF; Ca2+-activated K+ channel; RANTES	CELL-LINE; ION CHANNELS; PATCH-CLAMP; CONDUCTANCE; LEUKOCYTES; MUSCLE; EOL-1; ACID	RANTES is a member of the low molecular cytokines and appears to be strictly a chemotactic and activating factor for eosinophils, We studied the effect of RANTES on the channel activity of the eosinophilic cell line (EoL-1 cells) using patch clamp techniques, Under cell-attached patch conditions, RANTES (20 ng/ml) activated channels in EoL-1 cells when applied to the recording pipette or to the bath, This channel was permeable to K+ with a unit conductance of 14 pS, and the reversal potential was close to the equilibrium potential for K+, The current-voltage relationship for this K+ channel was almost linear, showing little or no rectification. The open time and closed time histograms could be fitted to a single exponential function with time constants of 6.4 and 2.7 ms, respectively, Extracellular application of the calcium ionophore A23187 (1 mu M) under cell-attached patch conditions or an increase in intracellular Ca2+ concentration under inside-out patch conditions increased K+ channel activity in a manner similar to that caused by RANTES, indicating that the RANTES-activated channel was the Ca2+-activated K+ channel, Intracellular application of GTP gamma S (10 mu M) opened the Ca2+-activated K+ channels under inside-out patch conditions, Furthermore, RANTES failed to activate the K+ channels after the cells had been treated with pertussis toxin (100 ng/ml) for 2 h at 37 degrees C, These results suggest that RANTES opens the Ca2+-activated K+ channels of EoL-1 cells through activation of G-proteins.	NORTHWESTERN UNIV, SCH MED, DEPT MOLEC PHARMACOL & BIOL CHEM, CHICAGO, IL 60611 USA; UNIV PENN, DEPT MED, PHILADELPHIA, PA 19104 USA	Northwestern University; University of Pennsylvania								ALAM R, 1993, J IMMUNOL, V150, P3442; BARNES PJ, 1990, EOSINOPHILS ALLERGY, P144; BLATZ AL, 1986, NATURE, V323, P718, DOI 10.1038/323718a0; BROWN AM, 1988, AM J PHYSIOL, V254, pH401, DOI 10.1152/ajpheart.1988.254.3.H401; GALLIN EK, 1991, PHYSIOL REV, V71, P775, DOI 10.1152/physrev.1991.71.3.775; GARDNER P, 1990, ANNU REV IMMUNOL, V8, P231, DOI 10.1146/annurev.iy.08.040190.001311; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; HAMIL OP, 1981, J PHYSL, V319, P97; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KAY AB, 1985, CLIN EXP IMMUNOL, V62, P1; KROEGEL C, 1989, J IMMUNOL, V142, P3518; LUX HD, 1981, PFLUG ARCH EUR J PHY, V389, P293, DOI 10.1007/BF00584792; MARTY A, 1981, NATURE, V291, P497, DOI 10.1038/291497a0; MCCLOSKEY MA, 1990, J GEN PHYSIOL, V95, P205, DOI 10.1085/jgp.95.2.205; MCLEAN A, 1994, LANCET, V343, P189, DOI 10.1016/S0140-6736(94)90985-7; NAKAJIMA T, 1991, FEBS LETT, V289, P239, DOI 10.1016/0014-5793(91)81079-N; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; PAGE CP, 1988, J ALLERGY CLIN IMMUN, V81, P144, DOI 10.1016/0091-6749(88)90233-3; PALLOTTA BS, 1981, NATURE, V293, P471, DOI 10.1038/293471a0; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SAITO H, 1985, BLOOD, V66, P1233; SATO R, 1990, AM J PHYSIOL, V259, pH1730, DOI 10.1152/ajpheart.1990.259.6.H1730; SATO R, 1994, J PHARMACOL EXP THER, V269, P1213; SHIKANO M, 1993, J IMMUNOL, V150, P3525; TORO L, 1993, HDB EXPT PHARM, P561; UI M, 1984, TRENDS PHARMACOL SCI, V5, P277, DOI 10.1016/0165-6147(84)90444-9; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; YOSHIE O, 1989, J LEUKOCYTE BIOL, V45, P10, DOI 10.1002/jlb.45.1.10	29	14	15	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1996	10	7					792	798		10.1096/fasebj.10.7.8635697	http://dx.doi.org/10.1096/fasebj.10.7.8635697			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UN798	8635697				2022-12-28	WOS:A1996UN79800014
J	Miller, RT; Jones, DT; Thornton, JM				Miller, RT; Jones, DT; Thornton, JM			Protein fold recognition by sequence threading: Tools and assessment techniques	FASEB JOURNAL			English	Article						protein folding; protein structure prediction; protein threading	GLOBULAR-PROTEINS; STRUCTURAL DOMAINS; PREDICTION; LOCATION	Protein fold recognition has been approached by threading an amino acid sequence onto a library of folds, calculating a sequence-structure compatibility score, and ranking these scores, Due to imperfections in the empirically derived pairwise potential functions and the necessarily heuristic approach to the sequence-structure alignment problem, the method benefits from the assessment of threaded models to evaluate the most probable structures among the list of possible folds, THREADER and ANALYST, software tools available through the Internet, facilitate the alignment and assessment steps of a threading prediction, No process has been found to be universally reliable for the detection of folds related to the structure of a known input sequence, but several useful steps and approaches are discussed.	UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOLEC BIOL,BIOMOLEC STRUCT & MODELLING UNIT,LONDON WC1E 6BT,ENGLAND; NATL INST MED RES,MATH BIOL LAB,LONDON NW7 7HX,ENGLAND	University of London; University College London; MRC National Institute for Medical Research				Thornton, Janet/0000-0003-0824-4096	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENNER SA, 1993, J MOL BIOL, V229, P1065, DOI 10.1006/jmbi.1993.1105; BENNER SA, 1992, CURR OPIN STRUC BIOL, V2, P402; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRYANT SH, 1995, CURR OPIN STRUC BIOL, V5, P236, DOI 10.1016/0959-440X(95)80082-4; BRYANT SH, 1993, PROTEINS, V16, P92, DOI 10.1002/prot.340160110; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; EISENHABER F, 1995, CRIT REV BIOCHEM MOL, V30, P1, DOI 10.3109/10409239509085139; GODZIK A, 1992, P NATL ACAD SCI USA, V89, P12098, DOI 10.1073/pnas.89.24.12098; JONES D, 1993, J COMPUT AID MOL DES, V7, P439, DOI 10.1007/BF02337560; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; JONES DT, IN RPESS PROTEIN SCI; JURNAK F, 1995, CURR OPIN STRUT BIOL, V5, P802; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIKUCHI T, 1988, J PROTEIN CHEM, V7, P427, DOI 10.1007/BF01024890; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LATHROP RH, 1994, PROTEIN ENG, V7, P1059, DOI 10.1093/protein/7.9.1059; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; MATSUO Y, 1994, PROTEIN SCI, V3, P2055, DOI 10.1002/pro.5560031118; MILLER RT, 1994, ADV MOL BIOINFORMATI, P9; ORENGO CA, 1993, PROTEIN ENG, V6, P485, DOI 10.1093/protein/6.5.485; PUSTERHOUT JK, 1994, TCL TK TOOLKIT; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SAYLE RA, E COMMUNICATION; SIPPL MJ, 1990, J MOL BIOL, V213, P859, DOI 10.1016/S0022-2836(05)80269-4; SOWDHAMINI R, 1995, PROTEIN SCI, V4, P506; TAYLOR WR, 1989, J MOL BIOL, V208, P1, DOI 10.1016/0022-2836(89)90084-3; WODAK SJ, 1981, BIOCHEMISTRY-US, V20, P6544, DOI 10.1021/bi00526a005; ZEHFUS MH, 1986, BIOCHEMISTRY-US, V25, P5759, DOI 10.1021/bi00367a062; [No title captured]	29	50	52	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1996	10	1					171	178		10.1096/fasebj.10.1.8566539	http://dx.doi.org/10.1096/fasebj.10.1.8566539			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566539				2022-12-28	WOS:A1996TR32800023
J	Moudrianakis, EN				Moudrianakis, EN			From protein coagulation and reversible denaturation to the protein folding problem: Chris Anfinsen defining the transition	FASEB JOURNAL			English	Item About an Individual											Moudrianakis, EN (corresponding author), JOHNS HOPKINS UNIV,DEPT BIOL,144 MUDD HALL,3400 N CHARLES ST,BALTIMORE,MD 21218, USA.							ANFINSEN CB, PUBLICATION LIST; Beadle GW, 1941, P NATL ACAD SCI USA, V27, P499, DOI 10.1073/pnas.27.11.499; CANFIELD RE, 6TH ANN M BIOPHYS SO; DINTZIS HM, 1961, P NATL ACAD SCI USA, V47, P247, DOI 10.1073/pnas.47.3.247; Edsall J.T., 1979, ANN NY ACAD SCI, V325, P53; EDSALL JT, 1992, PROTEIN SCI, V1, P1526, DOI 10.1002/pro.5560011114; MESELSON M, 1958, P NATL ACAD SCI USA, V44, P671, DOI 10.1073/pnas.44.7.671; SCHECHTER AN, 1995, NAT STRUCT BIOL, V2, P621, DOI 10.1038/nsb0895-621; Svedberg T, 1939, PROC R SOC SER B-BIO, V127, P1, DOI 10.1098/rspb.1939.0010; Svedberg T, 1939, PROC R SOC LON SER-A, V170, P0040, DOI 10.1098/rspa.1939.0018; TAYLOR JH, 1957, P NATL ACAD SCI USA, V43, P122, DOI 10.1073/pnas.43.1.122	11	3	3	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1996	10	1					179	183		10.1096/fasebj.10.1.8566540	http://dx.doi.org/10.1096/fasebj.10.1.8566540			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566540				2022-12-28	WOS:A1996TR32800025
J	Ptitsyn, OB				Ptitsyn, OB			A determinable but unresolved problem	FASEB JOURNAL			English	Editorial Material							CHYMOTRYPSIN INHIBITOR-2; PROTEIN CHAINS; PRINCIPLES; TRANSITION; STATE		NCI,MATH BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ptitsyn, OB (corresponding author), RUSSIAN ACAD SCI,INST PROT RES,PUSHCHINO 142292,RUSSIA.							ABKEVICH VI, 1994, BIOCHEMISTRY-US, V33, P10026, DOI 10.1021/bi00199a029; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BALDWIN RL, 1993, CURR OPIN STRUC BIOL, V3, P84, DOI 10.1016/0959-440X(93)90206-Z; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Carra JH, 1996, FASEB J, V10, P67, DOI 10.1096/fasebj.10.1.8566550; CLOTHIA C, 1992, NATURE, V357, P543; Creighton TE, 1996, FASEB J, V10, P110, DOI 10.1096/fasebj.10.1.8566531; DOLGIKH DA, 1984, FEBS LETT, V165, P88, DOI 10.1016/0014-5793(84)80020-4; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; FERSHT AR, 1993, FEBS LETT, V325, P5, DOI 10.1016/0014-5793(93)81405-O; FINKELSTEIN AV, 1987, PROG BIOPHYS MOL BIO, V50, P171, DOI 10.1016/0079-6107(87)90013-7; FINKELSTEIN AV, 1991, NATURE, V351, P497, DOI 10.1038/351497a0; Fischer D, 1996, FASEB J, V10, P126, DOI 10.1096/fasebj.10.1.8566533; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11270, DOI 10.1021/bi00093a002; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; JUENICKE R, 1996, FASEB J, V10, P84; King J, 1996, FASEB J, V10, P57, DOI 10.1096/fasebj.10.1.8566549; Kuwajima K, 1996, FASEB J, V10, P102, DOI 10.1096/fasebj.10.1.8566530; Lee B, 1996, FASEB J, V10, P119, DOI 10.1096/fasebj.10.1.8566532; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; Matthews BW, 1996, FASEB J, V10, P35, DOI 10.1096/fasebj.10.1.8566545; Miranker A, 1996, FASEB J, V10, P93, DOI 10.1096/fasebj.10.1.8566553; Pace CN, 1996, FASEB J, V10, P75, DOI 10.1096/fasebj.10.1.8566551; PENG ZY, 1994, BIOCHEMISTRY-US, V33, P2136, DOI 10.1021/bi00174a021; PTITSYN OB, 1980, Q REV BIOPHYS, V13, P339, DOI 10.1017/S0033583500001724; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; PTITSYN OB, 1973, DOKL AKAD NAUK SSSR+, V210, P1213; RICHARDSON JS, 1977, ADV PROTEIN CHEM, V343, P167; RODER H, 1994, FRONTIER MOL BIOL, P25; Rudolph R, 1996, FASEB J, V10, P49, DOI 10.1096/fasebj.10.1.8566547; Sauer RT, 1996, FASEB J, V10, P42, DOI 10.1096/fasebj.10.1.8566546; Shortle D, 1996, FASEB J, V10, P27, DOI 10.1096/fasebj.10.1.8566543; SVENSSON M, 1995, BIOCHEMISTRY-US, V34, P8606, DOI 10.1021/bi00027a010	34	11	12	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1996	10	1					3	4		10.1096/fasebj.10.1.8566544	http://dx.doi.org/10.1096/fasebj.10.1.8566544			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566544				2022-12-28	WOS:A1996TR32800001
J	RABIN, R; GORDON, SL; LYMN, RW; TODD, PW; FREY, MAB; SULZMAN, FM				RABIN, R; GORDON, SL; LYMN, RW; TODD, PW; FREY, MAB; SULZMAN, FM			EFFECTS OF SPACEFLIGHT ON THE MUSCULOSKELETAL SYSTEM - NIH AND NASA FUTURE-DIRECTIONS	FASEB JOURNAL			English	Article							MYOSIN HEAVY-CHAIN; MYOTENDINOUS JUNCTION; MUSCLE; EXPRESSION; DYSTROPHIN; ATROPHY; BONE	''The Effects of Space Travel on the Musculoskeletal System,'' a workshop held at the National Institutes of Health on October 3 and 4, 1990, was sponsored jointly by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Aeronautics and Space Administration (NASA) Attended by 80 invitees, it was chaired by Michael F. Holick, Boston University School of Medicine, and Kenneth M. Baldwin, University of California at Irvine. Participants reviewed the normal function and structure of bone and muscle, as well as independent and interactive responses of these tissues to activity and disuse on Earth and in the microgravity environment of space. They then focused on those future directions of research, summarized in this report, that are relevant to the missions and interests of both agencies. A comprehensive review of the presentations is available from NIAMS.2	NIAMSD,BETHESDA,MD 20892; LOCKHEED ENGN & SCI CO,DEPT LIFE SUPPORT,WASHINGTON,DC 20024; NASA,DIV LIFE SCI,WASHINGTON,DC 20546; UNIV COLORADO,DEPT CHEM ENGN,BOULDER,CO 80309	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Lockheed Martin; National Aeronautics & Space Administration (NASA); University of Colorado System; University of Colorado Boulder	RABIN, R (corresponding author), CTR SPACE & ADV TECHNOL,9302 LEE HWY,STE 400,FAIRFAX,VA 22031, USA.							ALBERTS B, 1989, MOL BIOL CELL, pCH11; ARNAUD SB, 1992, AVIAT SPACE ENVIR MD, V63, P14; Arnaud SB, 1989, ASGSB B, V2, P54; CERNY LC, 1986, J CELL BIOL, V103, P2153, DOI 10.1083/jcb.103.6.2153; EDGERTON VR, IN PRESS FUNDAMENTAL; HALL JA, 1988, DEV BIOL, V130, P591, DOI 10.1016/0012-1606(88)90354-5; HEUER AH, 1992, SCIENCE, V255, P1098, DOI 10.1126/science.1546311; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HYMER WC, 1992, J APPL PHYSIOL, V73, pS151, DOI 10.1152/jappl.1992.73.2.S151; JEE WS, 1990, BONE MORPHOMETRY, P284; LEBLANC AD, 1990, J BONE MINER RES, V5, P843; Nicogossian AE., 1989, SPACE PHYSL MED, V2nd/4th Edition; OHIRA Y, 1992, J APPL PHYSIOL, V73, pS51, DOI 10.1152/jappl.1992.73.2.S51; REISER PJ, 1987, J APPL PHYSIOL, V63, P2293, DOI 10.1152/jappl.1987.63.6.2293; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; Roy R R, 1991, Exerc Sport Sci Rev, V19, P269; ROY RR, 1992, J APPL PHYSL S, V73; RUBIN CT, 1989, J BONE JOINT SURG AM, V71A, P411, DOI 10.2106/00004623-198971030-00016; RUBIN CT, 1987, J ORTHOPAED RES, V5, P300, DOI 10.1002/jor.1100050217; SAMITT CE, 1990, MUSCLE NERVE, V13, P493, DOI 10.1002/mus.880130605; STOCKDALE FE, 1987, DEV BIOL, V123, P1, DOI 10.1016/0012-1606(87)90420-9; THOMASON DB, 1990, J APPL PHYSIOL, V68, P1, DOI 10.1152/jappl.1990.68.1.1; THOMASON DB, 1990, FASEB J, V4; TIDBALL JG, 1984, EXP MOL PATHOL, V40, P1, DOI 10.1016/0014-4800(84)90060-1; 1990, REPORT HHS WIDE RES; SPACELAB LIFE SCI, V1	26	18	18	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1993	7	5					396	398		10.1096/fasebj.7.5.8462780	http://dx.doi.org/10.1096/fasebj.7.5.8462780			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KV351	8462780				2022-12-28	WOS:A1993KV35100002
J	SUTTIE, JW				SUTTIE, JW			SYNTHESIS OF VITAMIN-K-DEPENDENT PROTEINS	FASEB JOURNAL			English	Article						VITAMIN-K; PROTHROMBIN; GAMMA-CARBOXYGLUTAMIC ACID; CLOTTING FACTORS	CARBOXYLATION RECOGNITION SITE; BOVINE PROTHROMBIN FRAGMENT-1; CARBOXYGLUTAMIC ACID DOMAIN; COAGULATION FACTOR-IX; CARBON-HYDROGEN BOND; MATRIX GLA PROTEIN; GAMMA-CARBOXYLATION; SUBSTRATE RECOGNITION; SECRETORY PATHWAY; PROPEPTIDE REGION	The unique and characteristic feature of vitamin K-dependent proteins is the presence of gamma-carboxyglutamyl (Gla) residues formed during the post-translational processing of these proteins. The energy needed to drive this microsomal carboxylation event comes from the reoxidation of the reduced, hydronaphthoquinone form of vitamin K to its 2,3-epoxide. Recent studies have suggested that an intermedite epoxide alkoxide is the strong base needed to abstract a proton from the relatively unreactive methylene carbon of the glutamyl residue. The primary gene product of the vitamin K-dependent proteins contains a homologous propeptide extension between the amino terminus of the mature protein and signal peptide. This region, which is cleaved before secretion of these proteins, serves to dock the protein substrate to the enzyme catalyzing the carboxylation event, and to also alter the apparent K(m) of the Glu binding site of the enzyme. The order in which the multiple Glu sites on the substrate proteins are carboxylated is unknown, but elucidation of this property of the enzyme and further details of the bioorganic mechanism should be aided by recent reports of purification of this unique carboxylase.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT NUTR SCI,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	SUTTIE, JW (corresponding author), UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706, USA.							ANTON DL, 1983, J BIOL CHEM, V258, P4084; BENTON ME, 1992, FASEB J, V6, pA1939; BERKNER KL, 1992, P NATL ACAD SCI USA, V89, P6242, DOI 10.1073/pnas.89.14.6242; BRINKHOUS KM, 1989, P NATL ACAD SCI USA, V86, P1382, DOI 10.1073/pnas.86.4.1382; CHARIFSON PS, 1991, P NATL ACAD SCI USA, V88, P424, DOI 10.1073/pnas.88.2.424; CHEUNG A, 1989, ARCH BIOCHEM BIOPHYS, V274, P574, DOI 10.1016/0003-9861(89)90472-4; CHEUNG A, 1990, BIOCHIM BIOPHYS ACTA, V1039, P90, DOI 10.1016/0167-4838(90)90230-D; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DAVIE EW, 1987, HEMOSTASIS THROMBOSI, P242; DECOTTIGNIESLEMARECHAL P, 1984, J BIOL CHEM, V259, P5010; DOWD P, 1991, J AM CHEM SOC, V113, P7734, DOI 10.1021/ja00020a041; DUBOIS J, 1983, J BIOL CHEM, V258, P7897; DUBOIS J, 1991, BIOCHEMISTRY-US, V30, P10506, DOI 10.1021/bi00107a020; DUCROCQ C, 1986, J CHEM SOC PERK T 1, P1323, DOI 10.1039/p19860001323; ENGELKE JA, 1991, BIOCHIM BIOPHYS ACTA, V1078, P31, DOI 10.1016/0167-4838(91)90088-H; FAIR DS, 1986, BLOOD, V67, P64; FOSTER DC, 1987, BIOCHEMISTRY-US, V26, P7003, DOI 10.1021/bi00396a022; FRIEDMAN EW, 1976, BLOOD, V48, P949; FRIEDMAN PA, 1987, INT J BIOCHEM, V19, P1, DOI 10.1016/0020-711X(87)90116-9; FRIEDMAN PA, 1979, P NATL ACAD SCI USA, V76, P3126, DOI 10.1073/pnas.76.7.3126; FUNG MR, 1988, CURRENT ADV VITAMIN, P143; FURIE B, 1990, BLOOD, V75, P1753; HAM SW, 1990, J AM CHEM SOC, V112, P1660, DOI 10.1021/ja00160a073; HANDFORD PA, 1991, PROTEIN ENG, V4, P319, DOI 10.1093/protein/4.3.319; HARBECK MC, 1989, THROMB RES, V56, P317, DOI 10.1016/0049-3848(89)90173-4; HUBBARD BR, 1989, J BIOL CHEM, V264, P14145; HUBBARD BR, 1989, P NATL ACAD SCI USA, V86, P6893, DOI 10.1073/pnas.86.18.6893; HUBER P, 1990, J BIOL CHEM, V265, P12467; JAMISON CS, 1992, THROMB HAEMOSTASIS, V68, P40; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; KARPATKIN M, 1979, P NATL ACAD SCI USA, V76, P491, DOI 10.1073/pnas.76.1.491; KARPATKIN S, 1987, BLOOD, V70, P773; KARPATKIN S, 1983, BRIT J HAEMATOL, V55, P673, DOI 10.1111/j.1365-2141.1983.tb02850.x; KAWABATA S, 1992, J BIOL CHEM, V267, P10331; KNOBLOCH JE, 1987, J BIOL CHEM, V262, P15334; LARSON AE, 1981, J BIOL CHEM, V256, P1032; LISKA DJ, 1988, BIOCHEMISTRY-US, V27, P8636, DOI 10.1021/bi00423a019; MACIK BG, 1989, AM J HEMATOL, V32, P232, DOI 10.1002/ajh.2830320315; Malhotra O P, 1981, Ann N Y Acad Sci, V370, P426, DOI 10.1111/j.1749-6632.1981.tb29754.x; MCTIGUE JJ, 1983, J BIOL CHEM, V258, P2129; MUNNS TW, 1976, P NATL ACAD SCI USA, V73, P2803, DOI 10.1073/pnas.73.8.2803; OWENS MR, 1983, THROMB RES, V31, P135, DOI 10.1016/0049-3848(83)90014-2; PRICE PA, 1987, P NATL ACAD SCI USA, V84, P8335, DOI 10.1073/pnas.84.23.8335; RABIET MJ, 1987, J BIOL CHEM, V262, P14895; SANFORD DG, 1991, BIOCHEMISTRY-US, V30, P9835, DOI 10.1021/bi00105a004; SESHADRI TP, 1991, J MOL BIOL, V220, P481, DOI 10.1016/0022-2836(91)90025-2; SHAH DV, 1984, THROMB RES, V35, P451, DOI 10.1016/0049-3848(84)90236-6; SHAH DV, 1980, THROMB RES, V19, P111, DOI 10.1016/0049-3848(80)90409-0; SHAH DV, 1993, IN PRESS THROMB HAEM; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; SOUTE BAM, 1989, THROMB HAEMOSTASIS, V61, P238; SOUTE BAM, 1992, IN PRESS THROMB HAEM; STANTON C, 1992, BIOCHEM J, V284, P25, DOI 10.1042/bj2840025; STANTON C, 1991, BIOCHEM J, V277, P59, DOI 10.1042/bj2770059; SUTTIE J W, 1988, Biofactors, V1, P55; SUTTIE JW, 1993, HEMOSTASIS THROMBOSI; SUTTIE JW, 1991, HDB VITAMINS, P145; ULRICH MMW, 1988, J BIOL CHEM, V263, P9697; ULRICH MMW, 1987, THROMB HAEMOSTASIS, V57, P17; UOTILA L, 1988, ARCH BIOCHEM BIOPHYS, V264, P135, DOI 10.1016/0003-9861(88)90578-4; VERMEER C, 1984, MOL CELL BIOCHEM, V61, P17; VIDALCROS A, 1990, BIOCHEM J, V266, P749, DOI 10.1042/bj2660749; WALLIN R, 1991, THROMB RES, V62, P235, DOI 10.1016/0049-3848(91)90144-L; WOOD GM, 1988, J BIOL CHEM, V263, P3234; WU SM, 1990, J BIOL CHEM, V265, P13124; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935; WU SM, 1991, P NATL ACAD SCI USA, V88, P2236, DOI 10.1073/pnas.88.6.2236; YAN SCB, 1989, TRENDS BIOCHEM SCI, V14, P264, DOI 10.1016/0968-0004(89)90060-1; ZHANG P, 1992, FASEB J, V6, pA1939	69	96	102	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1993	7	5					445	452		10.1096/fasebj.7.5.8462786	http://dx.doi.org/10.1096/fasebj.7.5.8462786			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KV351	8462786				2022-12-28	WOS:A1993KV35100009
J	MATTAJ, IW; TOLLERVEY, D; SERAPHIN, B				MATTAJ, IW; TOLLERVEY, D; SERAPHIN, B			SMALL NUCLEAR RNAS IN MESSENGER-RNA AND RIBOSOMAL-RNA PROCESSING	FASEB JOURNAL			English	Article						RNA PROCESSING; RIBONUCLEOPROTEINS; NUCLEOLAR RIBONUCLEOPROTEINS; NUCLEAR RNA; NUCLEOLAR RNA	EXTERNAL TRANSCRIBED SPACER; U5 SNRNP; YEAST; U3; RIBONUCLEOPROTEIN; DEPLETION; INVIVO; U1; U2; SPLICEOSOME	Ribonucleoproteins (RNPs) play essential roles in many aspects of gene expression. Two families of nuclear RNPs are involved in the processing of primary transcripts made by RNA polymerases I and II (pol I and II), two of the three polymerases present in the nuclei of eukaryotic cells. Ribosomal RNA precursor transcription by pol I, subsequent processing of the precursor, and the initial steps of ribosome assembly all take place in the nucleolus. A group of nucleolar RNPs containing small RNAs (small nucleolar RNAs or snoRNAs) are involved in the posttranscriptional nucleolar events of ribosome biosynthesis. Six members of a related family of small nuclear RNAs (snRNAs) are required for the processing of mRNA precursors in the nucleoplasm. Five of these snRNAs (U1, U2, U4-6) participate in the removal of intervening sequences while the sixth (U7) plays an essential role in the 3' processing of a subset of mRNA precursors, the histone pre-mRNAs. This is a review of structural and functional aspects of the U1-U7 snRNAs and of snoRNAs.			MATTAJ, IW (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY.		Tollervey, David/AAR-6662-2020	Tollervey, David/0000-0003-2894-2772; Mattaj, Iain/0000-0002-5537-8284; Seraphin, Bertrand/0000-0002-5168-1921				BARABINO SML, 1990, CELL, V63, P293, DOI 10.1016/0092-8674(90)90162-8; BASERGA SJ, 1992, IN PRESS GENES DEV; BEHRENS SE, 1991, GENE DEV, V5, P1439, DOI 10.1101/gad.5.8.1439; BELTRAME M, 1992, EMBO J, V11, P1531, DOI 10.1002/j.1460-2075.1992.tb05198.x; BIRNSTIEL ML, 1988, STRUCTURE FUNCTION M, P155; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; CLARKE MW, 1990, J CELL BIOL, V11, P1741; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; JAMISON SF, 1992, P NATL ACAD SCI USA, V89, P5482, DOI 10.1073/pnas.89.12.5482; JANSEN RP, 1991, J CELL BIOL, V113, P715, DOI 10.1083/jcb.113.4.715; KASS S, 1990, MOL CELL BIOL, V10, P4920, DOI 10.1128/MCB.10.9.4920; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; LAMM GM, 1991, NUCLEIC ACIDS RES, V19, P3193, DOI 10.1093/nar/19.12.3193; LEE SI, 1988, CELL, V54, P599, DOI 10.1016/S0092-8674(88)80004-7; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; LI HV, 1990, MOL CELL BIOL, V10, P1145, DOI 10.1128/MCB.10.3.1145; LI HV, 1992, EMBO J, V11, P683, DOI 10.1002/j.1460-2075.1992.tb05100.x; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MASER RL, 1989, P NATL ACAD SCI USA, V86, P6523, DOI 10.1073/pnas.86.17.6523; MELIN L, 1992, EMBO J, V11, P691, DOI 10.1002/j.1460-2075.1992.tb05101.x; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; MONTZKAWASSARMA.KM, 1992, MOL CELL BIOL, V12, P1276; MOWRY KL, 1987, MOL CELL BIOL, V7, P1663, DOI 10.1128/MCB.7.5.1663; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; PAN ZQ, 1988, SCIENCE, V241, P1328, DOI 10.1126/science.2970672; PATTERSON B, 1987, CELL, V49, P613, DOI 10.1016/0092-8674(87)90537-X; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SERAPHIN B, 1991, NUCLEIC ACIDS RES, V19, P3857, DOI 10.1093/nar/19.14.3857; SERAPHIN B, 1991, EMBO J, V10, P1209, DOI 10.1002/j.1460-2075.1991.tb08062.x; SMITH HO, 1991, P NATL ACAD SCI USA, V88, P9784, DOI 10.1073/pnas.88.21.9784; SMITH V, 1991, EMBO J, V10, P2627, DOI 10.1002/j.1460-2075.1991.tb07805.x; STROKE IL, 1989, J MOL BIOL, V210, P497, DOI 10.1016/0022-2836(89)90126-5; TANI T, 1991, GENE DEV, V5, P1022, DOI 10.1101/gad.5.6.1022; TOCZYSKI DPW, 1991, EMBO J, V10, P459, DOI 10.1002/j.1460-2075.1991.tb07968.x; TOLLERVEY D, 1987, J MOL BIOL, V196, P355, DOI 10.1016/0022-2836(87)90696-6; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; VANKAN P, 1992, EMBO J, V11, P335, DOI 10.1002/j.1460-2075.1992.tb05056.x; VASSEROT AP, 1989, P NATL ACAD SCI USA, V86, P4345, DOI 10.1073/pnas.86.12.4345; WASSARMAN DA, 1991, MOL CELL BIOL, V11, P3432, DOI 10.1128/MCB.11.7.3432; WOOLFORD JL, 1991, ADV GENET, V29, P63, DOI 10.1016/S0065-2660(08)60107-8; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; YUAN Y, 1989, J BIOL CHEM, V264, P14835	52	82	83	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					47	53		10.1096/fasebj.7.1.8422974	http://dx.doi.org/10.1096/fasebj.7.1.8422974			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422974				2022-12-28	WOS:A1993KH88000008
J	Zlatanova, J; Van Holde, K				Zlatanova, J; Van Holde, K			Binding to four-way junction DNA: A common property of architectural proteins?	FASEB JOURNAL			English	Review						HMG box; HU; IHF; linker histones; SWI/SNF	RNA-POLYMERASE-I; TRANSCRIPTION FACTORS; HMG-BOX; NUCLEOPROTEIN COMPLEXES; NONSPECIFIC DNA; LINKER HISTONES; GLOBULAR DOMAIN; SITE; RECOMBINATION; RECOGNITION	Proteins that can be shown to strongly bind in vitro to the four-way (Holliday) junction DNA include not only the obvious candidates such as enzymes involved in recombination, but also a remarkably diverse group of seemingly unrelated proteins, These include the HMG1 box proteins, members of the HMGI-Y family, winged helix proteins (including linker histones), the SWI/SNF complex, and some totally unrelated prokaryotic proteins, What these proteins seem to share is a propensity to bind to bent DNA, to bend DNA upon binding, and/or to preferentially interact with DNA crossings, Thus, they appear to be, in the main, architectural proteins, although some (like the SWI/SNF complex) have very specific functional roles as well, Perhaps because they bind to or promote the formation of particular DNA structures, the four-way junction binding proteins are frequently interchangeable in cellular function, Furthermore, since a given kind of structure can be recognized by many different protein motifs, it is not surprising that apparently unrelated proteins can fall into such a single functional class.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Bulgarian Acad Sci, Inst Genet, BU-1113 Sofia, Bulgaria	Oregon State University; Bulgarian Academy of Sciences	Zlatanova, J (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.		Zlatanova, Jordanka/B-3273-2009		NIGMS NIH HHS [GM50276] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050276] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P1604, DOI 10.1093/nar/23.9.1604; BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; BIANCHI ME, 1995, DNA PROTEIN STRUCTUR, P177; BONNEFOY E, 1994, J MOL BIOL, V242, P116, DOI 10.1006/jmbi.1994.1563; BOR YC, 1995, P NATL ACAD SCI USA, V92, P10334, DOI 10.1073/pnas.92.22.10334; BRENNAN RG, 1993, CELL, V74, P773, DOI 10.1016/0092-8674(93)90456-Z; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; CraneRobinson C, 1997, TRENDS BIOCHEM SCI, V22, P75, DOI 10.1016/S0968-0004(97)01013-X; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; Goytisolo FA, 1996, EMBO J, V15, P3421, DOI 10.1002/j.1460-2075.1996.tb00708.x; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; Hardman CH, 1995, BIOCHEMISTRY-US, V34, P16596, DOI 10.1021/bi00051a007; Hill DA, 1997, NUCLEIC ACIDS RES, V25, P3523, DOI 10.1093/nar/25.17.3523; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; Ivanchenko M, 1996, J BIOL CHEM, V271, P32580, DOI 10.1074/jbc.271.51.32580; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAVIGNE M, 1994, EMBO J, V13, P4983, DOI 10.1002/j.1460-2075.1994.tb06825.x; Lilley DMJ, 1997, P NATL ACAD SCI USA, V94, P9513, DOI 10.1073/pnas.94.18.9513; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; LILLEY DMJ, 1993, ANNU REV BIOPH BIOM, V22, P299, DOI 10.1146/annurev.bb.22.060193.001503; LILLEY DMJ, 1994, CURR BIOL, V4, P1152, DOI 10.1016/S0960-9822(00)00261-X; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; NER SS, 1994, TRENDS BIOCHEM SCI, V19, P185, DOI 10.1016/0968-0004(94)90017-5; Parekh BS, 1996, P NATL ACAD SCI USA, V93, P1173, DOI 10.1073/pnas.93.3.1173; PARVIN JD, 1995, NATURE, V373, P724, DOI 10.1038/373724a0; PEREZMARTIN J, 1994, MICROBIOL REV, V58, P268; PETERS R, 1995, BIOCHEMISTRY-US, V34, P4569, DOI 10.1021/bi00014a009; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; PETTIJOHN DE, 1990, NUCL ACIDS MOL BIOL, P153; Pruss D, 1996, SCIENCE, V274, P614, DOI 10.1126/science.274.5287.614; PUTNAM CD, 1994, MOL CELL BIOL, V14, P6476, DOI 10.1128/MCB.14.10.6476; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; READ CM, 1994, EMBO J, V13, P5639, DOI 10.1002/j.1460-2075.1994.tb06902.x; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SEGALL AM, 1994, EMBO J, V13, P4536, DOI 10.1002/j.1460-2075.1994.tb06775.x; SRINIVASAN AR, 1994, BIOCHEMISTRY-US, V33, P9389, DOI 10.1021/bi00198a004; Stefanovsky VY, 1996, NUCLEIC ACIDS RES, V24, P3208, DOI 10.1093/nar/24.16.3208; TEO SH, 1995, EUR J BIOCHEM, V230, P943, DOI 10.1111/j.1432-1033.1995.tb20640.x; TEO SH, 1995, EMBO J, V14, P3844, DOI 10.1002/j.1460-2075.1995.tb00054.x; VANDERVLIET PC, 1993, BIOESSAYS, V15, P25, DOI 10.1002/bies.950150105; VARGAWEISZ P, 1993, J BIOL CHEM, V268, P20699; VARGAWEISZ P, 1994, P NATL ACAD SCI USA, V91, P3525, DOI 10.1073/pnas.91.9.3525; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; Yaneva J, 1997, P NATL ACAD SCI USA, V94, P13448, DOI 10.1073/pnas.94.25.13448; Zlatanova J, 1996, PROG NUCLEIC ACID RE, V52, P217, DOI 10.1016/S0079-6603(08)60968-X	55	82	82	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1998	12	6					421	431		10.1096/fasebj.12.6.421	http://dx.doi.org/10.1096/fasebj.12.6.421			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZG118	9535214				2022-12-28	WOS:000072967300003
J	Scheibel, T; Bell, S; Walke, S				Scheibel, T; Bell, S; Walke, S			S-cerevisiae and sulfur: a unique way to deal with the environment	FASEB JOURNAL			English	Article						cysteine; methionine; toxicity; SOD; heat shock protein	CU,ZN SUPEROXIDE-DISMUTASE; SACCHAROMYCES-CEREVISIAE; TRIOSEPHOSPHATE ISOMERASE; CRYSTAL-STRUCTURE; AMINO-ACIDS; YEAST; METABOLISM; RESOLUTION; CYSTEINE	Saccharomyces cerevisiae is by far the best-studied unicellular eukaryote, Although yeast cells are very similar to higher eukaryotes in many respects, there is striking evidence that S, cerevisiae is not a perfect model for a eukaryotic cell (cf, 1), Here we report that yeast proteins contain a significantly lower amount of cysteine residues compared to other eukaryotes. Explanations for this phenomenon could not be found in the sulfur metabolism of yeast, which showed no major differences from other organisms (2-4), However, previous examinations could link a defect in sulfate uptake of S, cerevisiae to an increased resistance against toxic substances like selenate and chromate in the environment, which share the same permeases (5-7), This environmental problem might have caused S, cerevisiae to down-regulate its sulfate uptake and therefore lead to a lower amount of available sulfur in the cell, making it necessary to replace all dispensable sulfur amino acids in proteins, We show in two examples that S, cerevisiae proteins contain only such cysteine residues that are structurally or functionally needed, Therefore, we conclude that S. cerevisiae has solved a widespread environmental problem in a specific way which might be unique among eukaryotes.	MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	Scheibel, T (corresponding author), UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,UNIV STR 31,D-93040 REGENSBURG,GERMANY.		Scheibel, Thomas/I-1170-2014	Scheibel, Thomas/0000-0002-0457-2423				ANDERSON ME, 1987, METHOD ENZYMOL, V143, P313; BRETON A, 1977, J BACTERIOL, V132, P224, DOI 10.1128/JB.132.1.224-232.1977; CHEREST H, 1992, GENETICS, V130, P51; Creighton T.E., 1993, PROTEINS STRUCTURES, P2; CREIGHTON TE, 1993, PROTEINS, P316; DJINOVIC K, 1992, J MOL BIOL, V225, P791, DOI 10.1016/0022-2836(92)90401-5; Glick BS, 1996, CURR BIOL, V6, P1570, DOI 10.1016/S0960-9822(02)70774-4; GRIFFITH OW, 1987, METHOD ENZYMOL, V143, P366; HARRIS JI, 1976, ENZYMES, V13, P1; Lachance MA, 1997, YEAST, V13, P225, DOI 10.1002/(SICI)1097-0061(19970315)13:3<225::AID-YEA87>3.0.CO;2-I; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6609, DOI 10.1021/bi00480a009; MANDE SC, 1994, PROTEIN SCI, V3, P810, DOI 10.1002/pro.5560030510; MUDD SH, 1983, METABOLIC BASIS INHE, P522; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; PASZEWSKI A, 1992, CURR GENET, V22, P273, DOI 10.1007/BF00317920; ROSE AH, 1976, CHEM MICROBIOLOGY IN, P93; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCARINCI HE, 1990, ARCH LATINOAM NUTR, V40, P594; SMITH FW, 1995, MOL GEN GENET, V247, P709, DOI 10.1007/BF00290402; SODA K, 1987, METHOD ENZYMOL, V143, P453; STARMER WT, 1987, CAN J MICROBIOL, V33, P783, DOI 10.1139/m87-134; VanMantgem PJ, 1996, ECOTOX ENVIRON SAFE, V34, P228, DOI 10.1006/eesa.1996.0068	23	8	9	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1997	11	11					917	921		10.1096/fasebj.11.11.9285490	http://dx.doi.org/10.1096/fasebj.11.11.9285490			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XT790	9285490				2022-12-28	WOS:A1997XT79000011
J	Colman, RF				Colman, RF			Chemical arrows for enzymatic targets	FASEB JOURNAL			English	Article						affinity cleavage; isocitrate dehydrogenase; glutamate dehydrogenase; adenylosuccinate synthetase; enzyme	GLUTATHIONE-S-TRANSFERASE; LIVER GLUTAMATE-DEHYDROGENASE; BIFUNCTIONAL AFFINITY LABEL; BINDING-SITE; 3-DIMENSIONAL STRUCTURE; ADENYLOSUCCINATE LYASE; PYRUVATE-KINASE; REGULATORY SITE; ISOENZYME 3-3; IDENTIFICATION	Reactive analogs of substrates or allosteric regulators can be designed to bind reversibly to particular ligand sites of enzymes, Subsequently, these compounds can react covalently with amino acids accessible from the ligand site, thereby functioning as chemical arrows aimed at specific enzymatic target sites. The approach of affinity labeling can be used to identify amino acid participants in active or regulatory sites, to provide a rational choice of targets for site-directed muta-genesis experiments, or to monitor conformational changes in the region of a particular enzyme site. Illustrations of these approaches include: 1) the use of reactive nucleotide analogs directed to substrate sites in adenylosuccinate synthetase and adenylosuccinate lyase and to regulatory sites of glutamate dehydrogenase, 2) the use of affinity cleavage by Fe2+-isocitrate to locate the metal-substrate site of isocitrate dehydrogenase, and 3) the use of reactive peptides and aromatic compounds to target the glutathione and xenobiotic sites of glutathione S-transferases.-Colman, R. F. Chemical arrows for enzymatic targets.			Colman, RF (corresponding author), UNIV DELAWARE,DEPT CHEM & BIOCHEM,NEWARK,DE 19716, USA.				NATIONAL CANCER INSTITUTE [R01CA066561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039075] Funding Source: NIH RePORTER; NCI NIH HHS [CA 66561] Funding Source: Medline; NIDDK NIH HHS [DK 39075] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARYCKI JJ, 1993, BIOCHEMISTRY-US, V32, P13002, DOI 10.1021/bi00211a008; COLMAN RF, 1983, ANNU REV BIOCHEM, V52, P67, DOI 10.1146/annurev.bi.52.070183.000435; COLMAN RF, 1990, ENZYMES, V19, P283; DOMBROWSKI KE, 1992, BIOCHEMISTRY-US, V31, P3785, DOI 10.1021/bi00130a008; DOMBROWSKI KE, 1989, ARCH BIOCHEM BIOPHYS, V275, P302, DOI 10.1016/0003-9861(89)90377-9; Gite SU, 1996, BIOCHEMISTRY-US, V35, P2658, DOI 10.1021/bi952640y; HASELBECK RJ, 1992, BIOCHEMISTRY-US, V31, P6219, DOI 10.1021/bi00142a007; HU LQ, 1995, J BIOL CHEM, V270, P21875, DOI 10.1074/jbc.270.37.21875; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KAPETANOVIC E, 1985, BIOCHEMISTRY-US, V24, P7586, DOI 10.1021/bi00347a013; KATUSZ RM, 1991, BIOCHEMISTRY-US, V30, P11230, DOI 10.1021/bi00111a006; KATUSZ RM, 1992, ARCH BIOCHEM BIOPHYS, V298, P667, DOI 10.1016/0003-9861(92)90464-8; LEE TT, 1996, FASEB J, V10, pA1101; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Moe OA, 1996, BIOCHEMISTRY-US, V35, P9024, DOI 10.1021/bi960426j; PATTHY L, 1975, J BIOL CHEM, V250, P557; POLAND BW, 1993, J BIOL CHEM, V268, P25334; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; SAENGER W, 1984, PRINCIPLES NUCLEIC A, pCH4; SIGMAN DS, 1990, ANNU REV BIOCHEM, V59, P207, DOI 10.1146/annurev.biochem.59.1.207; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; SOUNDAR S, 1993, J BIOL CHEM, V268, P5264; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; STONE RL, 1993, J BIOL CHEM, V268, P19710; STONE RL, 1992, NAT GENET, V1, P59, DOI 10.1038/ng0492-59; VOLLMER SH, 1994, J BIOL CHEM, V269, P8082; WRZESZCZYNSKI KO, 1994, BIOCHEMISTRY-US, V33, P11544, DOI 10.1021/bi00204a017	27	16	16	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1997	11	4					217	226		10.1096/fasebj.11.4.9068610	http://dx.doi.org/10.1096/fasebj.11.4.9068610			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WM850	9068610				2022-12-28	WOS:A1997WM85000003
J	Desmet, J; Wilson, IA; Joniau, M; DeMaeyer, M; Lasters, I				Desmet, J; Wilson, IA; Joniau, M; DeMaeyer, M; Lasters, I			Computation of the binding of fully flexible peptides to proteins with flexible side chains	FASEB JOURNAL			English	Article						docking; peptide binding; MHC structures; dead-end elimination; rotamer library	DEAD-END ELIMINATION; MOLECULAR RECOGNITION; DOCKING; COMPLEX; COMPLEMENTARITY; CALMODULIN; ALGORITHM; THEOREM; DESIGN; SEARCH	Docking algorithms play an important role in the process of rational drug design and in understanding the mechanism of molecular recognition, Au important determinant for successful docking is the extent to which the configurational space (including conformational changes) of the ligand/receptor system is searched, Here we describe a new, combinatorial method for flexible docking of peptides to proteins that allows full rotation around all single bonds of the peptide Ligand and around those of a large set of receptor side chains, We have simulated the binding of several viral peptides to murine major histocompatibility complex class I H-2K(b). In addition, we have explored the Limits of our by simulating a complex between calmodulin and an 18-residue long helical peptide from calmodulin-dependent protein kinase II alpha. The calculated peptide conformations generally matched well with the X-ray structures, Essential information about local flexibility and about residues that are responsible for strong binding was obtained, We have frequently observed considerable side-chain flexibility during the simulations, showing the need for a flexible treatment of the receptor, Our method may also be useful whenever the receptor side-chain conformation is not available or uncertain, as illustrated by the docking of an H-SKb binding nonapeptide to the receptor structure taken from an octapeptide/H-2K(b) complex.	Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; FLANDERS INTERUNIV INST BIOTECHNOL, CTR TRANSGENE TECHNOL & GENE THERAPY, B-3000 LOUVAIN, BELGIUM	Scripps Research Institute	Desmet, J (corresponding author), KATHOLIEKE UNIV LEUVEN, INTERDISCIPLINARY RES CTR, CAMPUS KORTRIJK, UNIV CAMPUS, B-8500 KORTRIJK, BELGIUM.							BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUCCOLERI RE, 1994, PROTEIN FOLDING PROB, P125; CAFLISCH A, 1992, PROTEINS, V13, P223, DOI 10.1002/prot.340130305; CHAMBERS JL, 1979, ACTA CRYSTALLOGR B, V35, P1861, DOI 10.1107/S0567740879007925; CRAIG JJ, 1986, INTRO ROBOTICS, P15; DELHAISE P, 1984, J MOL GRAPHICS, V2, P103, DOI 10.1016/0263-7855(84)80002-8; DESJARLAIS RL, 1988, J MED CHEM, V31, P722, DOI 10.1021/jm00399a006; DESMET J, 1992, NATURE, V356, P539, DOI 10.1038/356539a0; DESMET J, 1994, PROTEIN FOLDING PROB, P307; DUNBRACK RL, 1994, NAT STRUCT BIOL, V1, P334, DOI 10.1038/nsb0594-334; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FISCHER D, 1995, J MOL BIOL, V248, P459, DOI 10.1006/jmbi.1995.0234; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; GOLDSTEIN RF, 1994, BIOPHYS J, V66, P1335, DOI 10.1016/S0006-3495(94)80923-3; JONES G, 1995, J MOL BIOL, V245, P43, DOI 10.1016/S0022-2836(95)80037-9; JORGENSEN WL, 1991, SCIENCE, V254, P954, DOI 10.1126/science.1719636; KOSHLAND D E JR, 1971, Pure and Applied Chemistry, V25, P119, DOI 10.1351/pac197125010119; KUNTZ ID, 1994, ACCOUNTS CHEM RES, V27, P117, DOI 10.1021/ar00041a001; KUNTZ ID, 1982, J MOL BIOL, V161, P269, DOI 10.1016/0022-2836(82)90153-X; LASTERS I, 1993, PROTEIN ENG, V6, P717, DOI 10.1093/protein/6.7.717; LASTERS I, 1995, PROTEIN ENG, V8, P815, DOI 10.1093/protein/8.8.815; LEACH AR, 1994, J MOL BIOL, V235, P345, DOI 10.1016/S0022-2836(05)80038-5; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MOON JB, 1991, PROTEINS, V11, P314, DOI 10.1002/prot.340110409; PEARL J, 1987, ANNU REV COMPUT SCI, V2, P451, DOI 10.1146/annurev.cs.02.060187.002315; PELLEGRINI M, 1993, PROTEINS, V15, P436, DOI 10.1002/prot.340150410; ROSENFELD R, 1995, ANNU REV BIOPH BIOM, V24, P677, DOI 10.1146/annurev.bb.24.060195.003333; Rosenfeld R, 1995, GENET ANAL-BIOMOL E, V12, P1, DOI 10.1016/1050-3862(95)00107-7; ROSENFELD R, 1993, J MOL BIOL, V234, P515, DOI 10.1006/jmbi.1993.1607; SAITO Y, 1993, J BIOL CHEM, V268, P21309; SANDAK B, 1995, COMPUT APPL BIOSCI, V11, P87; SAWYER TK, 1992, INT J PEPT PROT RES, V40, P274; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; SEZERMAN U, 1993, PROTEIN SCI, V2, P1827, DOI 10.1002/pro.5560021105; SHOICHET BK, 1991, J MOL BIOL, V221, P327, DOI 10.1016/0022-2836(91)80222-G; STANFIELD RL, 1995, CURR OPIN STRUC BIOL, V5, P103, DOI 10.1016/0959-440X(95)80015-S; WODAK SJ, 1978, J MOL BIOL, V124, P323, DOI 10.1016/0022-2836(78)90302-9	41	49	58	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1997	11	2					164	172		10.1096/fasebj.11.2.9039959	http://dx.doi.org/10.1096/fasebj.11.2.9039959			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK509	9039959				2022-12-28	WOS:A1997WK50900009
J	Simpson, ER; Michael, MD; Agarwal, VR; Hinshelwood, MM; Bulun, SE; Zhao, Y				Simpson, ER; Michael, MD; Agarwal, VR; Hinshelwood, MM; Bulun, SE; Zhao, Y			Expression of the CYP19 (aromatase) gene: An unusual case of alternative promoter usage	FASEB JOURNAL			English	Review						gene; estrogen formation; splicing; tissue-specific expression; phylogeny; ontogeny	POLYMERASE CHAIN-REACTION; HUMAN ADIPOSE-TISSUE; BREAST-CANCER CELLS; STROMAL CELLS; ESTROGEN BIOSYNTHESIS; CYTOCHROME-P450 TRANSCRIPTS; REVERSE TRANSCRIPTION; MONOLAYER-CULTURE; FETAL HEPATOCYTES; INTERFERON-ALPHA	Family 19 of the P450 super family is responsible for the conversion of C-19 androgenic steroids to the corresponding estrogens, a reaction known as aromatization because it involves conversion of the Delta(4)-3-one A-ring of the androgens to the corresponding phenolic A-ring characteristic of estrogens. The gene encoding human aromatase has been cloned and characterized and shown to be unusual compared to genes encoding other P450 enzymes, because there are numerous untranslated first exons that occur in aromatase transcripts in a tissue-specific fashion due to differential splicing as a consequence of the nse of tissue-specific promoters. Thus, expression hu the ovary uses a proximal promoter that is regulated primarily by cAMP. On the other hand, expression ill the placenta uses a distal promoter located at least 40 kb upstream of the start of transcription that is regulated by retinoids. Other promoters are used in brain and adipose tissue. In the latter case, class I cytokines such as IL-6 and IL-11, as well as TNF-alpha, are important regulatory factors. A common 3'-splice junction located upstream of the start of translation is used in all of the splicing events involved in the use of these various promoters. Thus, the coding region of the transcripts, and hence the protein, ape identical regardless of the tissue site of expression; what differs in a tissue-specific fashion is the 5'-end of the transcripts. This pattern of expression has great significance both from a phylogenetic and ontogenetic standpoint, as well as for the physiology and pathophysiology of estrogen formation, as will be discussed in thie review.			Simpson, ER (corresponding author), UNIV TEXAS, SW MED CTR, CTR REPRODUCT BIOL SCI, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.			Michael, Mervyn/0000-0002-0224-1065	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013234, T32HD007190] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG008174] Funding Source: NIH RePORTER; NIA NIH HHS [R37-AG08174] Funding Source: Medline; NICHD NIH HHS [5-T 32-HD07190, HD 13234] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACKERMAN GE, 1981, J CLIN ENDOCR METAB, V53, P412, DOI 10.1210/jcem-53-2-412; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; BERKOVITZ GD, 1989, J STEROID BIOCHEM, V33, P341, DOI 10.1016/0022-4731(89)90322-1; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1622, DOI 10.1210/jc.77.6.1622; BULUN SE, 1994, TRENDS ENDOCRIN MET, V5, P113, DOI 10.1016/1043-2760(94)90092-2; BULUN SE, 1994, J CLIN ENDOCR METAB, V78, P428, DOI 10.1210/jc.78.2.428; CALLARD GV, 1978, ENDOCRINOLOGY, V103, P2283, DOI 10.1210/endo-103-6-2283; CALLARD GV, 1981, BRAIN RES, V204, P461, DOI 10.1016/0006-8993(81)90609-0; CALLARD GV, 1980, GEN COMP ENDOCR, V42, P155, DOI 10.1016/0016-6480(80)90181-1; CALLARD GV, 1984, GEN COMP ENDOCR, V56, P53, DOI 10.1016/0016-6480(84)90060-1; CALLARD GV, 1996, P 4 INT AR C TAH CIT, P20; CORBIN CJ, 1995, MOL CELL ENDOCRINOL, V113, P29, DOI 10.1016/0303-7207(95)03607-9; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; EDMAN CD, 1976, ENDOCRINE FUNCTION H, P135; FITZPATRICK SL, 1993, MOL ENDOCRINOL, V7, P341, DOI 10.1210/me.7.3.341; FRANCE JT, 1969, J CLIN ENDOCR METAB, V29, P138, DOI 10.1210/jcem-29-1-138; GRODIN JM, 1973, J CLIN ENDOCR METAB, V36, P207, DOI 10.1210/jcem-36-2-207; HARADA N, 1992, BIOCHEM BIOPH RES CO, V189, P1001, DOI 10.1016/0006-291X(92)92303-F; HARADA N, 1993, P NATL ACAD SCI USA, V90, P11312, DOI 10.1073/pnas.90.23.11312; HARADA N, 1990, BIOCHEM BIOPH RES CO, V166, P365, DOI 10.1016/0006-291X(90)91954-Q; HEMSELL DL, 1974, J CLIN ENDOCR METAB, V38, P476, DOI 10.1210/jcem-38-3-476; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HONDA S, 1994, BIOCHEM BIOPH RES CO, V198, P1153, DOI 10.1006/bbrc.1994.1163; Hutchison J B, 1991, Curr Opin Neurobiol, V1, P562, DOI 10.1016/S0959-4388(05)80029-7; IKEDA Y, 1994, MOL ENDOCRINOL, V8, P654, DOI 10.1210/me.8.5.654; JENKINS C, 1993, MOL CELL ENDOCRINOL, V97, pR1, DOI 10.1016/0303-7207(93)90227-B; KELLER DC, 1993, BLOOD, V82, P1428; KELLIS JT, 1987, J BIOL CHEM, V262, P4413; KILGORE MW, 1992, MOL CELL ENDOCRINOL, V83, pR9, DOI 10.1016/0303-7207(92)90202-H; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; LANOUX MJ, 1985, ENDOCRINOLOGY, V117, P361, DOI 10.1210/endo-117-1-361; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MAHENDROO MS, 1993, J BIOL CHEM, V268, P19463; MAHENDROO MS, 1991, J BIOL CHEM, V266, P11276; MEANS GD, 1991, MOL ENDOCRINOL, V5, P2005, DOI 10.1210/mend-5-12-2005; MEANS GD, 1989, J BIOL CHEM, V264, P19385; MENDELSON CR, 1985, ARCH BIOCHEM BIOPHYS, V243, P480, DOI 10.1016/0003-9861(85)90525-9; MICHAEL MD, 1995, J BIOL CHEM, V270, P13561, DOI 10.1074/jbc.270.22.13561; MILLER W R, 1987, Steroids, V50, P537, DOI 10.1016/0039-128X(87)90037-7; NAKAJIN S, 1986, BIOCHEM BIOPH RES CO, V134, P704, DOI 10.1016/S0006-291X(86)80477-6; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NICHOLS JE, 1995, J SOC GYNECOL INVEST, V2, P45, DOI 10.1016/1071-5576(94)00047-5; ONEILL JS, 1988, BRIT MED J, V296, P741, DOI 10.1136/bmj.296.6624.741; PRICE T, 1992, J CLIN ENDOCR METAB, V74, P1247, DOI 10.1210/jc.74.6.1247; PRICE T, 1992, P SOC GYNECOLOGIC IN, P179; REED MJ, 1993, J STEROID BIOCHEM, V44, P589, DOI 10.1016/0960-0760(93)90264-W; REED MJ, 1992, J ENDOCRINOL, V132, pR5, DOI 10.1677/joe.0.132R005; SASANO H, 1994, HUM PATHOL, V25, P530, DOI 10.1016/0046-8177(94)90127-9; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHMIDT M, 1994, EUR J CELL BIOL, V63, P96; SIMPSON ER, 1981, P NATL ACAD SCI-BIOL, V78, P5690, DOI 10.1073/pnas.78.9.5690; SIMPSON ER, 1994, ENDOCR REV, V15, P342, DOI 10.1210/er.15.3.342; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TANAKA M, 1995, J BIOCHEM-TOKYO, V117, P719, DOI 10.1093/oxfordjournals.jbchem.a124768; THOMPSON EA, 1974, J BIOL CHEM, V249, P5364; THOMPSON EA, 1974, J BIOL CHEM, V249, P5373; TODA K, 1994, MOL ENDOCRINOL, V8, P210, DOI 10.1210/me.8.2.210; TODA K, 1993, EUR J BIOCHEM, V213, P383, DOI 10.1111/j.1432-1033.1993.tb17772.x; TODA K, 1990, EUR J BIOCHEM, V193, P559, DOI 10.1111/j.1432-1033.1990.tb19372.x; ZHAO Y, 1995, MOL ENDOCRINOL, V9, P340, DOI 10.1210/me.9.3.340; ZHAO Y, 1995, J BIOL CHEM, V270, P16449, DOI 10.1074/jbc.270.27.16449; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	67	171	186	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1997	11	1					29	36		10.1096/fasebj.11.1.9034163	http://dx.doi.org/10.1096/fasebj.11.1.9034163			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK147	9034163				2022-12-28	WOS:A1997WK14700005
J	Weinshilboum, RM; Otterness, DM; Aksoy, IA; Wood, TC; Her, C; Raftogianis, RB				Weinshilboum, RM; Otterness, DM; Aksoy, IA; Wood, TC; Her, C; Raftogianis, RB			Sulfotransferase molecular biology: cDNAs and genes	FASEB JOURNAL			English	Review						sulfation; sulfonation; sulfate conjugation; gene structure; chromosomal localization; molecular regulation	LIVER DEHYDROEPIANDROSTERONE SULFOTRANSFERASE; THERMOLABILE PHENOL SULFOTRANSFERASE; RAT-LIVER; ESTROGEN SULFOTRANSFERASE; ARYL SULFOTRANSFERASE; HYDROXYSTEROID SULFOTRANSFERASE; COMPLEMENTARY-DNA; SEQUENCE-ANALYSIS; SULFATING FORM; MOUSE-LIVER	Sulfotransferase (ST) enzymes catalyze the sulfate conjugation of many hormones, neurotransmitters, drugs, and xenobiotic compounds. These reactions result hi enhanced renal excretion of the sulfate-conjugated reaction products, but they call also lead to the formation of ''bioactivated'' metabolites. ST enzymes are members of an emerging gene superfamily that presently includes phenol ST (PST), hydroxysteroid ST (HSST), and, in plants, flavonol ST (FST) ''families,'' members of which share at least 45% amino acid sequence identity. These families can be further subdivided into ''subfamilies'' that are at least 60% identical in amino acid sequence. For example, the PST family includes both PST and estrogen ST (EST) subfamilies. Amino acid sequence motifs exist within ST enzymes that are conserved throughout phylogeny. These signature sequences may be involved in the binding of 3'-phosphoadenosine-5'-phosphosulfate, the cosubstrate for the sulfonation reaction. There are presently five known human cytosolic ST enzymes: an EST, an HSST, and three PSTs. cDNAs and genes for all of these enzymes have been cloned, and chromosomal localizations have been reported for all five genes. Genes for these human enzymes, as well as those of other mammalian cytosolic ST enzymes that have been cloned, show a high degree of structural homology, with conservation of the locations of most intron/exon splice junctions. Human ST enzyme expression varies among individuals. Functionally significant genetic polymorphisms for ST enzymes in humans have been reported, and other molecular genetic mechanisms that might be involved in the regulation of the expression of these enzymes are being explored. Knowledge of the molecular biology of cytosolic ST enzymes, when placed within a context provided by decades of biochemical research, promises to significantly enhance our understanding of the regulation of the sulfate conjugation of hormones, neurotransmitters, and drugs.			Weinshilboum, RM (corresponding author), MAYO CLIN & MAYO FDN,MAYO MED SCH,DEPT PHARMACOL,ROCHESTER,MN 55905, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028157, R01GM035720] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 35720, R01 GM 28157] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKSOY IA, 1994, BIOCHEM BIOPH RES CO, V200, P1621, DOI 10.1006/bbrc.1994.1637; AKSOY IA, 1993, DRUG METAB DISPOS, V21, P268; AKSOY IA, 1994, GENOMICS, V23, P275, DOI 10.1006/geno.1994.1494; AKSOY IA, 1993, CLIN PHARMACOL THER, V54, P498, DOI 10.1038/clpt.1993.181; AKSOY IA, 1995, BIOCHEM BIOPH RES CO, V208, P786, DOI 10.1006/bbrc.1995.1406; ANANVORANICH S, 1994, PLANT PHYSIOL, V106, P485, DOI 10.1104/pp.106.2.485; ANANVORANICH S, 1995, PLANT PHYSIOL, V107, P1019, DOI 10.1104/pp.107.3.1019; Baumann E, 1876, DTSCH CHEM GES, P54; BERNIER F, 1994, MOL CELL ENDOCRINOL, V99, pR11, DOI 10.1016/0303-7207(94)90159-7; BERNIER F, 1994, J BIOL CHEM, V269, P28200; Bernier F, 1996, DNA CELL BIOL, V15, P367, DOI 10.1089/dna.1996.15.367; CHATTERJEE B, 1987, J BIOL CHEM, V262, P822; CHEN X, 1992, PROTEIN EXPRES PURIF, V3, P421, DOI 10.1016/S1046-5928(05)80045-2; CHIBA H, 1995, P NATL ACAD SCI USA, V92, P8176, DOI 10.1073/pnas.92.18.8176; COMER KA, 1993, BIOCHEM J, V289, P233, DOI 10.1042/bj2890233; CRUICKSHANK D, 1993, BIOCHEM BIOPH RES CO, V191, P295, DOI 10.1006/bbrc.1993.1216; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DEMYAN WF, 1992, MOL ENDOCRINOL, V6, P589, DOI 10.1210/me.6.4.589; DOOLEY TP, 1993, GENOMICS, V18, P440, DOI 10.1006/geno.1993.1494; DOOLEY TP, 1994, BIOCHEM BIOPH RES CO, V205, P482, DOI 10.1006/bbrc.1994.2691; DOOLEY TP, 1994, BIOCHEM BIOPH RES CO, V205, P1325, DOI 10.1006/bbrc.1994.2810; Dufort I, 1996, DNA CELL BIOL, V15, P481, DOI 10.1089/dna.1996.15.481; EVANS DAP, 1993, GENETIC FACTORS DRUG; FALANY CN, 1991, TRENDS PHARMACOL SCI, V12, P255, DOI 10.1016/0165-6147(91)90566-B; FALANY CN, 1995, J STEROID BIOCHEM, V52, P529, DOI 10.1016/0960-0760(95)00015-R; FALANY CN, 1989, BIOCHEM J, V260, P641, DOI 10.1042/bj2600641; FALANY JL, 1995, J STEROID BIOCHEM, V52, P35, DOI 10.1016/0960-0760(94)00147-E; FAROOQUI AA, 1980, INT J BIOCHEM, V12, P529, DOI 10.1016/0020-711X(80)90003-8; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FORBES KJ, 1995, MOL CELL ENDOCRINOL, V112, P53, DOI 10.1016/0303-7207(95)03585-U; GANGULY TC, 1995, DRUG METAB DISPOS, V23, P945; HART RF, 1979, LIFE SCI, V24, P125, DOI 10.1016/0024-3205(79)90121-8; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HENKEL RD, 1994, HUM MOL GENET, V3, P2264, DOI 10.1093/hmg/3.12.2264; HER C, 1995, GENOMICS, V29, P16, DOI 10.1006/geno.1995.1210; HER C, 1996, DRUG METAB DISPOS, V24, P1382; Her CT, 1996, GENOMICS, V33, P409, DOI 10.1006/geno.1996.0216; HERNANDEZ JS, 1992, DRUG METAB DISPOS, V20, P413; HIRSHEY SJ, 1992, MOL PHARMACOL, V42, P257; HUTTNER WB, 1982, NATURE, V299, P273, DOI 10.1038/299273a0; HWANG SR, 1995, BIOCHEM BIOPH RES CO, V207, P701, DOI 10.1006/bbrc.1995.1244; JARVELA IE, 1995, GENOMICS, V29, P478; JONES AL, 1995, BIOCHEM BIOPH RES CO, V208, P855, DOI 10.1006/bbrc.1995.1414; Kalow W., 1992, PHARMACOGENETICS DRU; KHAN AS, 1993, GENE, V137, P321, DOI 10.1016/0378-1119(93)90028-2; KHAN AS, 1995, GENOMICS, V26, P417, DOI 10.1016/0888-7543(95)80233-C; KIEHLBAUCH CC, 1995, J BIOL CHEM, V270, P18941, DOI 10.1074/jbc.270.32.18941; KOMATSU K, 1994, BIOCHEM BIOPH RES CO, V204, P1178, DOI 10.1006/bbrc.1994.2587; KONG ANT, 1993, BIOCHIM BIOPHYS ACTA, V1171, P315, DOI 10.1016/0167-4781(93)90073-M; KONG ANT, 1993, PHARMACEUT RES, V10, P627, DOI 10.1023/A:1018926825475; KONG ANT, 1994, CHEM-BIOL INTERACT, V92, P161, DOI 10.1016/0009-2797(94)90061-2; KONG ANT, 1992, BIOCHEM BIOPH RES CO, V187, P488; Lacomme C, 1996, PLANT MOL BIOL, V30, P995, DOI 10.1007/BF00020810; LEE YC, 1994, J BIOL CHEM, V269, P15838; LEITER EH, 1994, J CLIN INVEST, V93, P2007, DOI 10.1172/JCI117194; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Luu NX, 1995, BIOCHEM BIOPH RES CO, V217, P1078, DOI 10.1006/bbrc.1995.2879; Marsolais F, 1995, J BIOL CHEM, V270, P30458, DOI 10.1074/jbc.270.51.30458; Mulder G.J., 1990, CONJUGATION REACTION, P107; NAGATA K, 1993, J BIOL CHEM, V268, P24720; NASH AR, 1988, AUST J BIOL SCI, V41, P507; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; *NOM COMM INT UN B, 1992, ENZ NOM 1992, P299; OEDA T, 1992, MOL ENDOCRINOL, V6, P1216, DOI 10.1210/me.6.8.1216; OGURA K, 1989, BIOCHEM BIOPH RES CO, V165, P168, DOI 10.1016/0006-291X(89)91050-4; OGURA K, 1994, CHEM-BIOL INTERACT, V92, P129, DOI 10.1016/0009-2797(94)90059-0; OGURA K, 1990, BIOCHEM BIOPH RES CO, V166, P1494, DOI 10.1016/0006-291X(90)91036-R; OGURA K, 1996, CDNA CLONING BACTERI; OGURA K, 1996, MOL CLONING MONKEY L; OTTERNESS DM, 1995, CYTOGENET CELL GENET, V70, P45, DOI 10.1159/000133988; OTTERNESS DM, 1992, MOL PHARMACOL, V41, P865; OTTERNESS DM, 1995, DNA CELL BIOL, V14, P331, DOI 10.1089/dna.1995.14.331; OZAWA S, 1995, PHARMACOGENETICS, V5, pS135, DOI 10.1097/00008571-199512001-00015; OZAWA S, 1990, NUCLEIC ACIDS RES, V18, P4001, DOI 10.1093/nar/18.13.4001; PRICE RA, 1989, GENETICS, V122, P905; PRICE RA, 1988, GENET EPIDEMIOL, V5, P1, DOI 10.1002/gepi.1370050102; Raftogianis RB, 1996, PHARMACOGENETICS, V6, P473, DOI 10.1097/00008571-199612000-00001; Rikke BA, 1996, BBA-GENE STRUCT EXPR, V1307, P331, DOI 10.1016/0167-4781(96)00065-6; RUNGEMORRIS M, 1991, BIOCHEM BIOPH RES CO, V175, P1051, DOI 10.1016/0006-291X(91)91671-X; Sakakibara Y, 1995, J BIOL CHEM, V270, P30470, DOI 10.1074/jbc.270.51.30470; SCHAUSS SJ, 1995, BIOCHEM J, V311, P1; SONG CS, 1990, BIOCHEMISTRY-US, V29, P542, DOI 10.1021/bi00454a031; SONG WC, 1995, ENDOCRINOLOGY, V136, P2477, DOI 10.1210/en.136.6.2477; TAKIKAWA H, 1986, FEBS LETT, V207, P193, DOI 10.1016/0014-5793(86)81487-9; VARIN L, 1989, PLANT PHYSIOL, V90, P977, DOI 10.1104/pp.90.3.977; VARIN L, 1992, P NATL ACAD SCI USA, V89, P1286, DOI 10.1073/pnas.89.4.1286; WATABE T, 1994, CHEM-BIOL INTERACT, V92, P87, DOI 10.1016/0009-2797(94)90056-6; WEINSHILBOUM R, 1990, PHARMACOL THERAPEUT, V45, P93, DOI 10.1016/0163-7258(90)90010-Y; WEINSHILBOUM R, 1994, HDB EXPT PHARM CONJU, V112, P45; WEINSHILBOUM RM, 1986, FASEB J, V45, P2223; WILBORN TW, 1993, MOL PHARMACOL, V43, P70; WOOD TC, 1994, BIOCHEM BIOPH RES CO, V198, P1119, DOI 10.1006/bbrc.1994.1159; YAMAZOE Y, 1994, CHEM-BIOL INTERACT, V92, P107, DOI 10.1016/0009-2797(94)90057-4; YEROKUN T, 1992, CANCER RES, V52, P4779; Zhu XY, 1996, INT J BIOCHEM CELL B, V28, P565, DOI 10.1016/1357-2725(95)00164-6; ZHU XY, 1993, BIOCHEM BIOPH RES CO, V192, P671, DOI 10.1006/bbrc.1993.1467; ZHU XY, 1993, BIOCHEM BIOPH RES CO, V195, P120, DOI 10.1006/bbrc.1993.2018	97	377	394	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1997	11	1					3	14		10.1096/fasebj.11.1.9034160	http://dx.doi.org/10.1096/fasebj.11.1.9034160			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK147	9034160				2022-12-28	WOS:A1997WK14700002
J	Giusti, P; Lipartiti, M; Franceschini, D; Schiavo, N; Floreani, M; Manev, H				Giusti, P; Lipartiti, M; Franceschini, D; Schiavo, N; Floreani, M; Manev, H			Neuroprotection by melatonin from kainate-induced excitotoxicity in rats	FASEB JOURNAL			English	Article						glutamate; reactive oxygen species	KAINIC ACID; OXIDATIVE STRESS; GLUTAMATE; DAMAGE; BRAIN	In this study, we injected 10 mg/kg kainate i.p. into rats, This resulted in a brain injury, which we quantified in the hippocampus, the amygdala, and the pyriform cortex, Neuronal damage was preceded by a set of typical behavioral signs and by biochemical changes (noradrenaline decrease and 5-hydroxyindoleacetic acid increase) in the affected brain areas, Melatonin (2.5 mg/kg) was injected i.p. four times: 20 min before kainate, immediately after, and 1 and 2 h after the kainate, The cumulative dose of 10 mg/kg melatonin prevented kainate-induced neuronal death as well as behavioral and biochemical disturbances, A possible mechanism of melatonin-provided neuroprotection Lies in its antioxidant action, Our results suggest that melatonin holds potential for the treatment of pathologies such as epilepsy-associated brain damage, stroke, and brain trauma.	UNIV PADUA,DEPT PHARMACOL,I-35131 PADUA,ITALY; MED COLL PENN & HAHNEMANN UNIV,DEPT PSYCHIAT,PITTSBURGH,PA 15212; MED COLL PENN & HAHNEMANN UNIV,DEPT PHARMACOL,PITTSBURGH,PA 15212	University of Padua; Drexel University; Drexel University				GIUSTi, Pietro/0000-0001-9352-4046	NATIONAL INSTITUTE ON AGING [K07AG000532] Funding Source: NIH RePORTER; NIA NIH HHS [KO7AG00532] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMBROSINI A, 1995, MOL PHARMACOL, V47, P1057; Anton-Tay F, 1974, Adv Biochem Psychopharmacol, V11, P315; BENARI Y, 1979, BRAIN RES, V165, P362, DOI 10.1016/0006-8993(79)90571-7; BONDY SC, 1993, BRAIN RES, V610, P229, DOI 10.1016/0006-8993(93)91405-H; CADET JL, 1994, TRENDS NEUROSCI, V17, P192; CAGNOLI CM, 1995, J PINEAL RES, V18, P222, DOI 10.1111/j.1600-079X.1995.tb00163.x; CASTROVIEJO DA, 1986, NEUROENDOCRINOLOGY, V43, P24; CHUANG JI, 1994, J PINEAL RES, V17, P11, DOI 10.1111/j.1600-079X.1994.tb00107.x; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DYKENS JA, 1987, J NEUROCHEM, V49, P1222, DOI 10.1111/j.1471-4159.1987.tb10014.x; FILIPKOWSKI RK, 1994, NEUROREPORT, V5, P1538, DOI 10.1097/00001756-199407000-00032; GIUSTI P, 1995, EXP NEUROL, V131, P39, DOI 10.1016/0014-4886(95)90005-5; GOTZ ME, 1994, PHARMACOL THERAPEUT, V63, P37, DOI 10.1016/0163-7258(94)90055-8; LEBARS D, 1991, NUCL MED BIOL, V18, P357; LIPARTITI M, 1991, EXP NEUROL, V113, P301, DOI 10.1016/0014-4886(91)90019-9; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; MANEV H, 1994, NEUROREPORT, V5, P2661, DOI 10.1097/00001756-199412000-00064; Maney H., 1995, Society for Neuroscience Abstracts, V21, P1518; MELCHIORRI D, 1995, FASEB J, V9, P1205, DOI 10.1096/fasebj.9.12.7672513; MELCHIORRI D, 1994, LIFE SCI, V56, P83, DOI 10.1016/0024-3205(94)00928-7; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NORLUND JJ, 1977, J CLIN ENDOCR METAB, V45, P768; OHTA K, 1994, NEUROSCI RES, V21, P83, DOI 10.1016/0168-0102(94)90071-X; OLNEY JW, 1974, BRAIN RES, V77, P507, DOI 10.1016/0006-8993(74)90640-4; Paxinos G., 2004, J CHEM INF MODEL, V5th; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; PUTTFARCKEN PS, 1993, BRAIN RES, V624, P223, DOI 10.1016/0006-8993(93)90081-W; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P9525; SPERK G, 1983, NEUROSCIENCE, V10, P1301, DOI 10.1016/0306-4522(83)90113-6; SPERK G, 1994, PROG NEUROBIOL, V42, P1, DOI 10.1016/0301-0082(94)90019-1; Tan DX, 1993, ENDOCR J, V1, P57; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0	36	151	152	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1996	10	8					891	896		10.1096/fasebj.10.8.8666166	http://dx.doi.org/10.1096/fasebj.10.8.8666166			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UQ456	8666166				2022-12-28	WOS:A1996UQ45600011
J	Taub, R				Taub, R			Liver regeneration .4. Transcriptional control of liver regeneration	FASEB JOURNAL			English	Review						transcription factors; cell growth; immediate-early	ENHANCER-BINDING-PROTEIN; NF-KAPPA-B; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; STIMULATED H-35 CELLS; IMMEDIATE-EARLY GENES; EARLY-GROWTH-RESPONSE; 3 C/EBP ISOFORMS; PARTIAL-HEPATECTOMY; MESSENGER-RNA; 3T3 CELLS	Determining what factors are responsible for initiating regeneration following partial hepatectomy or toxic damage, and how the Liver maintains differentiated functions while the hepatocytes are undergoing cellular proliferation are central issues in understanding the molecular bases of liver regeneration. Examination of-the transcriptional milieu in the regenerating liver provides clues to the answers to these questions, Growth factor-generated intracellular signals that trigger Liver regeneration result in activation via posttranslational modifications of latent, normally inactive transcription factors that preexist in the liver. Two transcription factors that are activated by this mechanism include posthepatectomy factor/nuclear factor-kappa B (PHF/NF-kappa B) and Stat3, Because cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1), and IL-6 can induce these factors in the liver, the finding of activated Stat3 and PHF/NF-kappa B suggests that these cytokines may play a role ill some aspects of growth regulation during liver regeneration, Rapidly induced transcription factors, Stat3, PHF/NF-kappa B, and others are responsible for activation of the primary growth response or immediate-early genes, which play a role in regulating later phases of cell growth in regenerating liver and other mitogen-activated cells, Immediate-early genes encode many members of diverse transcription factor families including the Jun-Fos-LRF-1, nuclear receptor, and myc families to name a few, In this way a transcriptional cascade is established during the G1 phase of liver regeneration, Coexisting with these induced factors are liver-specific transcription factors such as the CAAT enhancer binding proteins and hepatocyte nuclear factors, which may interact with growth-induced factors to help the liver maintain metabolic homeostasis during regeneration. As a result the Liver is able to accomplish the goals of reestablishing its mass while it maintains its functional capacity during regeneration.			Taub, R (corresponding author), UNIV PENN,SCH MED,DEPT GENET & MED,PHILADELPHIA,PA 19104, USA.				NIDDK NIH HHS [DK44237] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044237] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; ALBRECHT JH, 1993, AM J PHYSIOL, V265, pG857, DOI 10.1152/ajpgi.1993.265.5.G857; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLOOMQUIST BT, 1994, J BIOL CHEM, V269, P9113; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; BRAUTIGAN DL, 1992, BIOCHIM BIOPHYS ACTA, V1114, P63, DOI 10.1016/0304-419X(92)90007-L; BUCHER NLR, 1975, P NATL ACAD SCI USA, V72, P1157, DOI 10.1073/pnas.72.3.1157; BUCHER NLR, 1978, CELL REPRODUCTION HO, P661; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; CRESSMAN DE, 1994, J BIOL CHEM, V269, P26594; CRILLI M, 1993, INT REV CYTOL, V143, P1; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DIAMOND RH, 1993, J BIOL CHEM, V268, P15185; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; DIEHL AM, 1994, HEPATOLOGY, V19, P447; DIEHL AM, 1994, AM J PHYSIOL-GASTR L, V267, pG552, DOI 10.1152/ajpgi.1994.267.4.G552; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; FAUSTO N, 1989, LAB INVEST, V60, P4; Fausto Nelson, 1994, P1059; FITZGERALD MJ, 1995, CELL GROWTH DIFFER, V6, P417; FLODBY P, 1993, EXP CELL RES, V208, P248, DOI 10.1006/excr.1993.1244; FONG Y, 1993, SURG FORUM, V49, P190; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; GHAHARY A, 1992, HEPATOLOGY, V15, P1125, DOI 10.1002/hep.1840150625; GLUCK U, 1992, EXP CELL RES, V202, P477, DOI 10.1016/0014-4827(92)90102-E; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; GREENBAUM LE, 1995, J CLIN INVEST, V96, P1351, DOI 10.1172/JCI118170; GRISHAM JW, 1962, CANCER RES, V22, P842; HABER B, 1995, HEPATOLOGY, V22, P906, DOI 10.1016/0270-9139(95)90314-3; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HSU JC, 1993, CANCER RES, V53, P3789; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; HUANG CS, 1993, J BIOL CHEM, V268, P20578; IRITANI N, 1993, J BIOCHEM, V113, P519, DOI 10.1093/oxfordjournals.jbchem.a124076; JOSHIBARVE SS, 1993, J BIOL CHEM, V268, P18018; KRUIJER W, 1986, J BIOL CHEM, V261, P7929; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEMAIRE L, 1993, LIFE SCI, V52, P917, DOI 10.1016/0024-3205(93)90526-9; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; MOHN KL, 1991, MOL CELL BIOL, V11, P1393, DOI 10.1128/MCB.11.3.1393; MOHN KL, 1990, J BIOL CHEM, V265, P21914; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MULLHAUPT B, 1994, J BIOL CHEM, V269, P19667; NELSON PA, 1991, GENE, V109, P255, DOI 10.1016/0378-1119(91)90617-K; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; RANA B, 1994, MOL CELL BIOL, V14, P5858, DOI 10.1128/MCB.14.9.5858; ROSA JL, 1992, BIOCHEM J, V287, P113, DOI 10.1042/bj2870113; ROSA JL, 1992, P NATL ACAD SCI USA, V89, P3746, DOI 10.1073/pnas.89.9.3746; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; RUPPERT S, 1992, GENE DEV, V6, P1430, DOI 10.1101/gad.6.8.1430; RUPPERT S, 1990, CELL, V61, P895, DOI 10.1016/0092-8674(90)90200-X; SCHNEIDERMAN J, 1993, AM J PATHOL, V143, P753; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TAKIGUCHI S, 1993, CYTOGENET CELL GENET, V64, P128, DOI 10.1159/000133568; TAUB R, 1987, J BIOL CHEM, V262, P10893; TAUB R, 1995, LIVER REGENERATION C, P71; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; THOMPSON NL, 1986, CANCER RES, V46, P3111; THORNTON AJ, 1994, CANCER RES, V54, P1337; TOHYAMA C, 1993, HEPATOLOGY, V18, P1193; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; UNTERMAN TG, 1990, ENDOCRINOLOGY, V126, P2614, DOI 10.1210/endo-126-5-2614; VARNUM BC, 1989, ONCOGENE, V4, P1263; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WU KJ, 1994, J BIOL CHEM, V269, P1177; Zaret Kenneth S., 1994, P53; ZARNEGAR R, 1991, BIOCHEM BIOPH RES CO, V177, P559, DOI 10.1016/0006-291X(91)92020-K; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041	95	311	324	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1996	10	4					413	427		10.1096/fasebj.10.4.8647340	http://dx.doi.org/10.1096/fasebj.10.4.8647340			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UE557	8647340				2022-12-28	WOS:A1996UE55700005
J	Cereghini, S				Cereghini, S			Liver-enriched transcription factors and hepatocyte differentiation	FASEB JOURNAL			English	Review						transcription factors; liver development; regulatory networks	ENHANCER-BINDING-PROTEIN; LEUCINE ZIPPER PROTEINS; NUCLEAR FACTOR-IV; FACTOR LFB1 HNF1; GENE FORK-HEAD; DNA-BINDING; ALBUMIN TRANSCRIPTION; EXPRESSION PATTERNS; TISSUE-SPECIFICITY; FACTOR HNF1/LFB1	Liver-specific gene expression in adult hepatocytes relies on four families of evolutionary conserved transcription factors that are liver-enriched but not restricted to this tissue, These factors function in unique combinations, often synergistically, to stimulate cell-specific transcription, Each family is composed of several members displaying similar, if not identical, DNA recognition properties and sharing structural homology in their DNA binding domains, The homo- and heterodimerization between members of a particular transcription factor family adds an additional level of complexity in gene regulation, The consequences of inactivating different family members in the mouse by homologous recombination, together with recent studies of their regulation, suggest a model for liver differentiation involving a regulatory network rather than a completely hierarchical genetic circuitry, These studies also indicate that individual regulators appear to serve multiple developmental functions, Their possible role in the progression through different stages of hepatic cell commitment and differentiation is discussed.			Cereghini, S (corresponding author), HOP NECKER ENFANTS MALAD, INSERM, UNITE 423, 149 RUE SEVRES, F-75743 PARIS 15, FRANCE.							AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BACH I, 1993, EMBO J, V12, P4229, DOI 10.1002/j.1460-2075.1993.tb06107.x; BARTKOWSKI S, 1993, MOL CELL BIOL, V13, P421, DOI 10.1128/MCB.13.1.421; BAUMHUETER S, 1988, EMBO J, V7, P2485, DOI 10.1002/j.1460-2075.1988.tb03095.x; BULLA GA, 1994, MOL CELL BIOL, V14, P7086, DOI 10.1128/MCB.14.11.7086; BURCH JBE, 1994, NUCLEIC ACIDS RES, V22, P4733, DOI 10.1093/nar/22.22.4733; CASCIO S, 1991, DEVELOPMENT, V113, P217; CEREGHINI S, 1992, DEVELOPMENT, V116, P783; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CEREGHINI S, 1990, EMBO J, V9, P2257, DOI 10.1002/j.1460-2075.1990.tb07396.x; CESKA TA, 1993, EMBO J, V12, P1805, DOI 10.1002/j.1460-2075.1993.tb05828.x; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COSTA RH, 1994, CELL, V57, P645; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; CUIF MH, 1992, MOL CELL BIOL, V12, P4852, DOI 10.1128/MCB.12.11.4852; De Simone V, 1991, CURR OPIN CELL BIOL, V3, P960, DOI 10.1016/0955-0674(91)90114-E; DEMARTIS A, 1994, MECH DEVELOP, V47, P19, DOI 10.1016/0925-4773(94)90092-2; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; DUNCAN SA, 1994, P NATL ACAD SCI USA, V91, P7598, DOI 10.1073/pnas.91.16.7598; EISENMANN DM, 1994, CURR OPIN GENET DEV, V4, P508, DOI 10.1016/0959-437X(94)90065-B; FLODBY P, 1993, EXP CELL RES, V208, P248, DOI 10.1006/excr.1993.1244; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; GE RW, 1994, J BIOL CHEM, V269, P13185; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HOSHIZAKI DK, 1994, DEVELOPMENT, V120, P2489; HOUSSAINT E, 1980, CELL DIFFER, V9, P69; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; IYER SV, 1991, MOL CELL BIOL, V11, P4863, DOI 10.1128/MCB.11.10.4863; JACOB A, 1994, NUCLEIC ACIDS RES, V22, P2126, DOI 10.1093/nar/22.11.2126; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JOHNSON PF, 1994, LIVER GENE TRANSCRIP; JONK LJC, 1994, MECH DEVELOP, V47, P81, DOI 10.1016/0925-4773(94)90098-1; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KELSEY G, 1994, LIVER GENE TRANSCRIP; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2718; KRITIS AA, 1993, NUCLEIC ACIDS RES, V21, P5882, DOI 10.1093/nar/21.25.5882; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; LAWSON KA, 1991, DEVELOPMENT, V113, P891; LAZZARO D, 1992, DEVELOPMENT, V114, P469; LEDOUARIN NM, 1975, MED BIOL, V53, P427; LEGRAVEREND C, 1993, NUCLEIC ACIDS RES, V21, P1735, DOI 10.1093/nar/21.8.1735; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; MAKOVER A, 1989, DIFFERENTIATION, V40, P17, DOI 10.1111/j.1432-0436.1989.tb00809.x; MALIK S, 1995, NUCLEIC ACIDS RES, V23, P1536, DOI 10.1093/nar/23.9.1536; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; MIURA N, 1993, NUCLEIC ACIDS RES, V21, P3731, DOI 10.1093/nar/21.16.3731; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; MUELLER CR, 1992, DNA CELL BIOL, V11, P559, DOI 10.1089/dna.1992.11.559; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; NICOSIA A, 1990, CELL, V61, P1225, DOI 10.1016/0092-8674(90)90687-A; OREILLY MAJ, 1995, DEVELOPMENT, V121, P1351; OTT MO, 1991, MECH DEVELOP, V36, P47, DOI 10.1016/0925-4773(91)90071-D; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PANI L, 1992, MOL CELL BIOL, V12, P552, DOI 10.1128/MCB.12.2.552; PIAGGIO G, 1994, NUCLEIC ACIDS RES, V22, P4284, DOI 10.1093/nar/22.20.4284; POGGEVONSTRANDM.P, 1995, DEVELOPMENT, V121, P1217; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POWER SC, 1996, IN PRESS MOL CELL BI; QIAN X, 1995, NUCLEIC ACIDS RES, V22, P1182; QIU YH, 1994, P NATL ACAD SCI USA, V91, P4451, DOI 10.1073/pnas.91.10.4451; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SADANI U, 1995, CELL GROWTH DIFFER, V6, P879; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SCHMIDT EE, 1995, J CELL BIOL, V128, P467, DOI 10.1083/jcb.128.4.467; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SLADEK FM, 1994, LIVER GENE TRANSCRIP; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; TONIATTI C, 1993, DNA CELL BIOL, V12, P199, DOI 10.1089/dna.1993.12.199; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WENCHEN Y, 1995, GENE DEV, V9, P168; ZAPP D, 1993, MOL CELL BIOL, V13, P6416, DOI 10.1128/MCB.13.10.6416; ZHONG WM, 1994, MOL CELL BIOL, V14, P7276, DOI 10.1128/MCB.14.11.7276; ZHONG WM, 1993, EMBO J, V12, P537, DOI 10.1002/j.1460-2075.1993.tb05685.x	102	465	472	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1996	10	2					267	282		10.1096/fasebj.10.2.8641560	http://dx.doi.org/10.1096/fasebj.10.2.8641560			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641560				2022-12-28	WOS:A1996TY96200011
J	Hynes, G; Sutton, CW; U, S; Willison, KR				Hynes, G; Sutton, CW; U, S; Willison, KR			Peptide mass fingerprinting of chaperonin-containing TCP-1 (CCT) and copurifying proteins	FASEB JOURNAL			English	Article						peptide mass fingerprinting; CCT theta; adenylylation	T-COMPLEX POLYPEPTIDE-1; MOLECULAR CHAPERONE; THERMOPHILIC ARCHAEBACTERIUM; CYTOPLASMIC CHAPERONIN; GLUTAMINE-SYNTHETASE; TUBULIN; IDENTIFICATION; EXPRESSION; PARTICLE; SUBUNITS	The chaperonin-containing TCP-1 (CCT), found in the eukaryotic cytosol, is currently the focus of extensive research, CCT isolated from mouse testis lysate sediments at 20S in a sucrose gradient and accounts for about 70% of the total protein in this fraction. We intend to identify all the other proteins that copurify with CCT and to compile a reference profile for future studies. Their identification can be accelerated by a combination of protease digestion, matrix-assisted laser desorption-mass spectrometry, and database matching known as peptide mass fingerprinting, We applied this strategy to 32 polypeptides resolved by 2-dimensional gel electrophoresis, and 23 known proteins and 6 novel proteins were identified, We analyzed isoelectric variants of the CCT subunits and differences in the peptide mass spectra of two CCT theta isoforms indicated a novel posttranslational modification of this subunit.	INST CANC RES,CHESTER BEATTY LABS,CRC CTR CELL & MOLEC BIOL,LONDON SW3 6JB,ENGLAND; FINNIGAN MAT LTD,HEMMEL HEMPSTEAD HP2 4TG,HERTS,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK				Sutton, Chris/0000-0002-1548-5093				CORBETT J, 1992, METHOD MOL BIOL, V19, P219; COTTRELL JS, 1994, PEPTIDE RES, V7, P115; CREUTZ CE, 1994, J BIOL CHEM, V269, P32035; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GOA Y, 1994, J CELL BIOL, V125, P989; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; HYNES G, 1995, FEBS LETT, V358, P129, DOI 10.1016/0014-5793(94)01408-S; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; KUBOTA H, 1995, GENE, V154, P231, DOI 10.1016/0378-1119(94)00880-2; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LINGAPPA JR, 1994, J CELL BIOL, V125, P99, DOI 10.1083/jcb.125.1.99; MAREO S, 1994, BIOPHYS J, V67, P364; MARTIN WH, 1990, J NEUROCHEM, V54, P612, DOI 10.1111/j.1471-4159.1990.tb01915.x; MELKI R, 1993, J CELL BIOL, V122, P1301, DOI 10.1083/jcb.122.6.1301; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; PATTERSON SD, 1994, ANAL BIOCHEM, V221, P1, DOI 10.1006/abio.1994.1371; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PHIPPS BM, 1993, NATURE, V361, P475, DOI 10.1038/361475a0; RHEE SG, 1984, METHOD ENZYMOL, V107, P183; SHAPIRO BM, 1967, P NATL ACAD SCI USA, V58, P642, DOI 10.1073/pnas.58.2.642; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; STREICHER SL, 1981, P NATL ACAD SCI-BIOL, V78, P229, DOI 10.1073/pnas.78.1.229; SUTTON CW, 1995, ELECTROPHORESIS, V16, P308, DOI 10.1002/elps.1150160151; SUTTON CW, 1994, ANAL BIOCHEM, V218, P34, DOI 10.1006/abio.1994.1138; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; WILLISON KR, 1990, GENET RES, V56, P193, DOI 10.1017/S0016672300035291; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZAKERI ZF, 1988, MOL CELL BIOL, V8, P2925, DOI 10.1128/MCB.8.7.2925; ZHANG WZ, 1994, PROTEIN SCI, V3, P677	37	29	30	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1996	10	1					137	147		10.1096/fasebj.10.1.8566534	http://dx.doi.org/10.1096/fasebj.10.1.8566534			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566534				2022-12-28	WOS:A1996TR32800018
J	Hendrick, JP; Hartl, FU				Hendrick, JP; Hartl, FU			The role of molecular chaperones in protein folding	FASEB JOURNAL			English	Review						Hsp70; chaperonin; GroEL; membrane translocation	HEAT-SHOCK PROTEINS; ATP HYDROLYSIS; BINDING-SPECIFICITY; CENTRAL CAVITY; GROEL; DNAK; HSP60; COOPERATIVITY; MITOCHONDRIA; FRAGMENT	Folding of newly synthesized polypeptides in the crowded cellular environment requires the assistance of so-called molecular chaperone proteins. Chaperones of the Hsp70 class and their partner proteins interact with nascent polypeptide chains on ribosomes and prevent their premature (mis)folding at least until a domain capable of forming a stable structure is synthesized. For many proteins, completion of folding requires the subsequent interaction with one of the large oligomeric ring-shaped proteins of the chaperonin family, which is composed of the GroEL-like proteins in eubacteria, mitochondria, and chloroplasts, and the TRiC family in eukaryotic cytosol and archaea. These proteins bind partially folded polypeptide in their central cavity and promote folding by ATP-dependent cycles of release and rebinding. In these reactions, molecular chaperones interact predominantly with the hydrophobic surfaces exposed by nonnative polypeptides, thereby preventing incorrect folding and aggregation.	MEM SLOAN KETTERING CANC CTR, HOWARD HUGHES MED INST, CELLULAR BIOCHEM BIOPHYS PROGRAM, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center			Hartl, F. Ulrich/Y-8206-2019					AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P18; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CORRALES FJ, 1995, P NATL ACAD SCI USA, V92, P5326, DOI 10.1073/pnas.92.12.5326; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ENGEL A, 1995, SCIENCE, V269, P832, DOI 10.1126/science.7638600; EPSTEIN CJ, 1963, COLD SPRING HARB SYM, V28, P439, DOI 10.1101/SQB.1963.028.01.060; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FISHER MT, 1994, J BIOL CHEM, V269, P29598; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAITANARIS GA, 1994, MOL MICROBIOL, V14, P861, DOI 10.1111/j.1365-2958.1994.tb01322.x; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GRAGEROV AI, 1991, FEBS LETT, V291, P222, DOI 10.1016/0014-5793(91)81289-K; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HANSEN WJ, 1994, J BIOL CHEM, V269, P26610; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HLODAN R, 1995, NAT STRUCT BIOL, V2, P587, DOI 10.1038/nsb0795-587; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; MARCO S, 1994, FEBS LETT, V341, P152, DOI 10.1016/0014-5793(94)80447-8; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MORSHAUSER RC, 1995, BIOCHEMISTRY-US, V34, P6261, DOI 10.1021/bi00019a001; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHMIDT M, 1994, J BIOL CHEM, V269, P27964; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VOOS W, 1994, MOL CELL BIOL, V14, P6627, DOI 10.1128/MCB.14.10.6627; WANG TF, 1993, J BIOL CHEM, V268, P26049; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; [No title captured]	76	183	187	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1995	9	15					1559	1569		10.1096/fasebj.9.15.8529835	http://dx.doi.org/10.1096/fasebj.9.15.8529835			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TM761	8529835				2022-12-28	WOS:A1995TM76100009
J	Woolley, M				Woolley, M			No more excuses! Turning quiet resistance into active advocacy for research	FASEB JOURNAL			English	Editorial Material									Res Amer, Alexandria, VA 22314 USA		Woolley, M (corresponding author), Res Amer, 908 King St,Suite 400 E, Alexandria, VA 22314 USA.								0	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1998	12	6					391	394		10.1096/fasebj.12.6.391	http://dx.doi.org/10.1096/fasebj.12.6.391			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZG118	9535212				2022-12-28	WOS:000072967300001
J	Liou, GI; Matragoon, S; Chen, DM; Gao, CL; Zhang, L; Fei, YJ; Katz, ML; Stark, WS				Liou, GI; Matragoon, S; Chen, DM; Gao, CL; Zhang, L; Fei, YJ; Katz, ML; Stark, WS			Visual sensitivity and interphotoreceptor retinoid binding protein in the mouse: regulation by vitamin A	FASEB JOURNAL			English	Article						vitamin A (retinol) deficiency and repletion; IRBP; photoreceptor; electroretinography	PIGMENT-EPITHELIUM; GENE-EXPRESSION; MESSENGER-RNA; BOVINE RETINA; DEPRIVED RATS; PHOTORECEPTOR; LIGHT; IRBP; RHODOPSIN; DROSOPHILA	Interphotoreceptor retinoid binding protein (IRBP) is a retinoid and fatty acid binding glycoprotein secreted by rod and cone photoreceptors in all vertebrates, IRBP is believed to serve as a carrier for retinoids in the bleaching and regeneration cycle of rhodopsin. IRBP protein has been found to be decreased in vitamin A-deprived rats; it is rapidly recovered after retinol repletion, To understand the mechanism for this recovery, we determined whether vitamin A affects transcription and translation of the IRBP gene, Wild-type and transgenic mice harboring the IRBP promoter-CAT reporter fusion gene were maintained on a retinol-deficient diet supplemented with retinoic acid (-A) or on a control diet (+A) for up to 60 wk postweaning, Some of the -A mice were given retinol repletion for 7 days (-A+A), Electroretinography analysis revealed alterations in waveform and a 2 log unit decrease in b-wave sensitivity in the -A mice over a broad range of stimulus wavelengths, Retinol repletion effected a full recovery, Immunochemistry showed a significant decrease in the immunogold-labeled IRBP between the retinal pigment epithelium and the outer segments of the -A mice compared with +A and -A+A mice, Northern blots showed no differences in the amounts of IRBP or CAT mRNA between these three treatment groups, These results suggest that the regulation of IRBP by retinol is not transcriptional.	St Louis Univ, Dept Biol, St Louis, MO 63103 USA; Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30912 USA; Univ Missouri, Sch Med, Mason Eye Inst, Columbia, MO 65212 USA; Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA	Saint Louis University; University System of Georgia; Augusta University; University of Missouri System; University of Missouri Columbia; University System of Georgia; Augusta University	Stark, WS (corresponding author), St Louis Univ, Dept Biol, St Louis, MO 63103 USA.				NEI NIH HHS [EY07192, EY08813, EY03829] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007192, R01EY003829, R01EY008813] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADLER AJ, 1991, EXP EYE RES, V53, P337, DOI 10.1016/0014-4835(91)90239-B; ADLER AJ, 1985, J BIOL CHEM, V260, P4850; BAZAN NG, 1985, J BIOL CHEM, V260, P3677; CARTERDAWSON L, 1986, DEV BIOL, V116, P431, DOI 10.1016/0012-1606(86)90144-2; Cochran W.G., 1957, EXPT DESIGN, V2nd ed.; DESJARDIN LE, 1993, J BIOL CHEM, V268, P6953; DONOSO LA, 1990, CURR EYE RES, V9, P357, DOI 10.3109/02713689008999623; DOWLING JE, 1960, P NATL ACAD SCI USA, V46, P587, DOI 10.1073/pnas.46.5.587; DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0; FARBER DB, 1991, EXP EYE RES, V53, P781, DOI 10.1016/0014-4835(91)90114-T; Fei Y., 1997, Investigative Ophthalmology and Visual Science, V38, pS699; Fei Y., 1996, Investigative Ophthalmology and Visual Science, V37, pS336; GONZALEZFERNANDEZ F, 1990, J CELL BIOL, V111, P2775, DOI 10.1083/jcb.111.6.2775; HAUSWIRTH WW, 1992, EXP EYE RES, V54, P661, DOI 10.1016/0014-4835(92)90021-J; HUSMANN M, 1992, BIOCHEM BIOPH RES CO, V187, P1558, DOI 10.1016/0006-291X(92)90480-9; JACOBS GH, 1991, NATURE, V353, P655, DOI 10.1038/353655a0; KATZ ML, 1987, BIOCHIM BIOPHYS ACTA, V924, P432, DOI 10.1016/0304-4165(87)90157-7; KATZ ML, 1991, INVEST OPHTH VIS SCI, V32, P1968; KATZ ML, 1993, EXP EYE RES, V56, P671, DOI 10.1006/exer.1993.1084; KATZ ML, 1993, EXP EYE RES, V57, P393, DOI 10.1006/exer.1993.1140; KURLANDSKY SB, 1995, J BIOL CHEM, V270, P17850, DOI 10.1074/jbc.270.30.17850; KUTTY G, 1994, EXP EYE RES, V58, P65, DOI 10.1006/exer.1994.1195; LIN ZS, 1989, VISION RES, V29, P1699, DOI 10.1016/0042-6989(89)90152-1; Liou G. I., 1997, Investigative Ophthalmology and Visual Science, V38, pS4; LIOU GI, 1990, J BIOL CHEM, V265, P8373; LIOU GI, 1994, DEV BIOL, V161, P345, DOI 10.1006/dbio.1994.1036; LIOU GI, 1982, VISION RES, V22, P1457, DOI 10.1016/0042-6989(82)90210-3; LIOU GI, 1992, BIOTECHNIQUES, V13, P719; LIOU GI, 1992, METHODS NEUROSCIENCE, V9, P101; Mangelsdorf David J., 1994, P319; OKAJIMA TIL, 1989, EXP EYE RES, V49, P629, DOI 10.1016/S0014-4835(89)80059-4; OKAJIMA TIL, 1990, P NATL ACAD SCI USA, V87, P6907, DOI 10.1073/pnas.87.17.6907; ORGANISCIAK DT, 1991, EXP EYE RES, V53, P772; PEPPERBERG DR, 1993, MOL NEUROBIOL, V7, P61, DOI 10.1007/BF02780609; Picking WL, 1996, EXP EYE RES, V63, P493, DOI 10.1006/exer.1996.0139; RAJAN N, 1990, J LIPID RES, V31, P821; Saari J.C., 1990, Progress in Retinal Research, V9, P363, DOI 10.1016/0278-4327(90)90011-6; SAARI JC, 1985, J BIOL CHEM, V260, P195; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWEMER J, 1992, COLLOQ INSE, V221, P277; SHIM K, 1997, IN PRESS EXP EYE RES; STARK WS, 1977, J COMP PHYSIOL, V121, P289, DOI 10.1007/BF00613010; SUN DX, 1993, EXP EYE RES, V57, P177, DOI 10.1006/exer.1993.1113; TTIMMERS AM, 1996, INVEST OPHTH VIS SCI, V37, pS693; Wagner E, 1997, FASEB J, V11, P271, DOI 10.1096/fasebj.11.4.9068616	46	6	6	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1998	12	1					129	138		10.1096/fasebj.12.1.129	http://dx.doi.org/10.1096/fasebj.12.1.129			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YR723	9438418				2022-12-28	WOS:000071523800014
J	Jacoby, RO; Lindsey, JR				Jacoby, RO; Lindsey, JR			Health care for research animals is essential and affordable	FASEB JOURNAL			English	Article									UNIV ALABAMA,DEPT COMPARAT MED,SCH MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT COMPARAT MED,SCH DENT,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Jacoby, RO (corresponding author), YALE UNIV,SCH MED,COMPARAT MED SECT,POB 208016,NEW HAVEN,CT 06520, USA.							BHATT PN, 1986, VIRAL MYCOPLASMAL IN; FOX JG, 1997, IN PRESS LAB ANIM SC; Jacoby RO, 1996, LAB ANIM SCI, V46, P370; Lindsey J.R, 1991, INFECT DIS MICE RATS; PERCY DH, 1993, PATHOLOGY LAB RATS M; SHAMES B, 1995, J CLIN MICROBIOL, V33, P2968, DOI 10.1128/JCM.33.11.2968-2972.1995	6	58	59	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1997	11	8					609	614		10.1096/fasebj.11.8.9240962	http://dx.doi.org/10.1096/fasebj.11.8.9240962			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XN027	9240962				2022-12-28	WOS:A1997XN02700001
J	VillarPalasi, C; Guinovart, JJ				VillarPalasi, C; Guinovart, JJ			The role of glucose 6-phosphate in the control of glycogen synthase	FASEB JOURNAL			English	Review						glucose transport; glucose phosphorylation; insulin	DEPENDENT PROTEIN-KINASE; RABBIT SKELETAL-MUSCLE; BC3H-1 CELL-LINE; RAT HEPATOCYTES; CYCLIC-AMP; INSULIN RESISTANCE; SIGNALING PATHWAYS; DIABETIC RATS; GLUCOSE-6-PHOSPHATE PLAYS; PHOSPHATASE INHIBITOR-1	Elevated blood glucose concentrations result in increased intracellular levels of glucose 6-phosphate in liver, skeletal muscle, and adipose tissue. In liver, blood glucose concentrations are the main factor in control of the synthesis of glycogen; insulin has only a potentiating effect. In skeletal muscle and adipocytes, glucose alone has little effect on the activity of glycogen synthase, the limiting enzyme in glycogen synthesis. However, insulin released as a result of elevated blood glucose stimulates the translocation of specific glucose transporters to the cell membrane, increases the uptake of glucose, and causes the covalent, dephosphorylation-mediated activation of glycogen synthase. We present evidence that elevated intracellular contents of glucose 6-phosphate provoke the activation of glycogen synthase in liver, muscle, and adipose tissue. In addition, glucose 6-phosphate may inhibit the phosphorylation of glycogen synthase by cyclic AMP-stimulated protein kinase. We show that the stimulated glucose uptake and phosphorylation appear to play a major role in the control by insulin of the enzymes involved in glycogen synthesis.	UNIV BARCELONA,DEPT BIOQUIM & BIOL MOL,E-08028 BARCELONA,SPAIN	University of Barcelona	VillarPalasi, C (corresponding author), UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908, USA.							AGIUS L, 1995, BIOCHEM J, V309, P711, DOI 10.1042/bj3090711; AGIUS L, 1993, BIOCHEM J, V296, P785, DOI 10.1042/bj2960785; Agius L, 1996, J BIOL CHEM, V271, P30479, DOI 10.1074/jbc.271.48.30479; AGIUS L, 1994, BIOCHEM J, V298, P237, DOI 10.1042/bj2980237; AHMAD Z, 1985, FEBS LETT, V179, P96, DOI 10.1016/0014-5793(85)80199-X; ALEMANY S, 1986, FEBS LETT, V198, P194, DOI 10.1016/0014-5793(86)80404-5; ARIZO J, 1985, BIOCHEM BIOPH RES CO, V130, P987; BARNARD RJ, 1992, FASEB J, V6, P3238, DOI 10.1096/fasebj.6.14.1426762; BOARD M, 1995, BIOCHEM J, V311, P845, DOI 10.1042/bj3110845; BOLLEN M, 1984, BIOCHEM J, V217, P427, DOI 10.1042/bj2170427; BONADONNA RC, 1993, J CLIN INVEST, V92, P486, DOI 10.1172/JCI116592; BURANT CF, 1984, AM J PHYSIOL, V247, pE657, DOI 10.1152/ajpendo.1984.247.5.E657; BURCELIN R, 1993, AM J PHYSIOL, V265, pE392, DOI 10.1152/ajpendo.1993.265.3.E392; Cadefau J, 1997, BIOCHEM J, V322, P745, DOI 10.1042/bj3220745; CARABAZA A, 1992, FEBS LETT, V296, P211, DOI 10.1016/0014-5793(92)80381-P; CARABAZA A, 1990, J BIOL CHEM, V265, P2724; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; CHANG LY, 1980, ACTA ENDOCRINOL-COP, V95, P427, DOI 10.1530/acta.0.0950427; CIUDAD CJ, 1986, BIOCHEM BIOPH RES CO, V141, P1195, DOI 10.1016/S0006-291X(86)80171-1; CIUDAD CJ, 1981, FEBS LETT, V129, P123, DOI 10.1016/0014-5793(81)80771-5; CRAIG JW, 1969, BIOCHIM BIOPHYS ACTA, V177, P213, DOI 10.1016/0304-4165(69)90130-5; DAS I, 1974, HORM METAB RES, V6, P40, DOI 10.1055/s-0028-1093901; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V281, P443, DOI 10.1042/bj2810443; FernandezNovell JM, 1997, BIOCHEM J, V321, P227, DOI 10.1042/bj3210227; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V288, P497, DOI 10.1042/bj2880497; FernandezNovell JM, 1996, EUR J BIOCHEM, V238, P570, DOI 10.1111/j.1432-1033.1996.0570z.x; FERNANDEZNOVELL JM, 1994, EUR J BIOCHEM, V226, P665, DOI 10.1111/j.1432-1033.1994.tb20094.x; FLORESRIVEROS JR, 1993, P NATL ACAD SCI USA, V90, P512, DOI 10.1073/pnas.90.2.512; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; FOULKES JG, 1980, FEBS LETT, V112, P21, DOI 10.1016/0014-5793(80)80117-7; FOULKES JG, 1982, J BIOL CHEM, V257, P2493; GLINSMANN W, 1970, BIOCHEM BIOPH RES CO, V39, P774, DOI 10.1016/0006-291X(70)90272-X; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; GUINOVART JJ, 1979, FEBS LETT, V106, P284, DOI 10.1016/0014-5793(79)80515-3; Guinovart JJ, 1997, BIOCHEM SOC T, V25, P157, DOI 10.1042/bst0250157; HENRIKSEN EJ, 1991, J APPL PHYSIOL, V70, P2322, DOI 10.1152/jappl.1991.70.5.2322; HIKEN JF, 1984, FEBS LETT, V175, P55, DOI 10.1016/0014-5793(84)80568-2; HIRSHMAN MF, 1993, AM J PHYSIOL, V264, pE882, DOI 10.1152/ajpendo.1993.264.6.E882; HOFMANN S, 1994, EUR J BIOCHEM, V219, P307, DOI 10.1111/j.1432-1033.1994.tb19942.x; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; JOSEPH PK, 1972, BIOCHEM J, V128, pP60; KHANDELWAL RL, 1979, ARCH BIOCHEM BIOPHYS, V197, P310, DOI 10.1016/0003-9861(79)90250-9; KONG XM, 1994, J BIOL CHEM, V269, P12963; KRAEGEN EW, 1993, BIOCHEM J, V295, P287, DOI 10.1042/bj2950287; KRUSZYNSKA YT, 1986, DIABETES, V35, P662, DOI 10.2337/diabetes.35.6.662; LANGDON DR, 1983, DIABETES, V32, P1134, DOI 10.2337/diabetes.32.12.1134; LARNER J, 1960, ARCH BIOCHEM BIOPHYS, V86, P56, DOI 10.1016/0003-9861(60)90367-2; LAWRENCE JC, 1978, J BIOL CHEM, V253, P2104; LAWRENCE JC, 1983, J BIOL CHEM, V258, P710; LAWRENCE JC, 1984, J BIOL CHEM, V259, P7975; LAWRENCE JC, 1977, J BIOL CHEM, V252, P444; LEMARCHANDBRUSTEL Y, 1981, BIOCHIM BIOPHYS ACTA, V677, P13; LIN JL, 1991, DIABETOLOGIA, V34, P477, DOI 10.1007/BF00403283; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; LUTTRELL L, 1986, ENDOCRINOLOGY, V119, P331, DOI 10.1210/endo-119-1-331; LUTTRELL LM, 1986, MOL PHARMACOL, V30, P624; MARCUS RG, 1994, AM J PHYSIOL-RENAL, V267, pF816, DOI 10.1152/ajprenal.1994.267.5.F816; MARETTE A, 1992, DIABETES, V41, P1562, DOI 10.2337/diabetes.41.12.1562; MASSILLON D, 1995, J BIOL CHEM, V270, P19351, DOI 10.1074/jbc.270.33.19351; MAYER D, 1989, CELL BIOCHEM FUNCT, V7, P243, DOI 10.1002/cbf.290070403; MEGLASSON MD, 1983, J BIOL CHEM, V258, P6705; MILLER TB, 1987, J BIOL CHEM, V262, P4000; MOR MA, 1981, FEBS LETT, V136, P131; MOULE SK, 1995, BIOCHEM J, V311, P595, DOI 10.1042/bj3110595; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; NAKAMURA T, 1984, J BIOCHEM-TOKYO, V95, P1691, DOI 10.1093/oxfordjournals.jbchem.a134782; NOGUCHI T, 1993, FEBS LETT, V328, P145, DOI 10.1016/0014-5793(93)80982-Z; NUTTALL FQ, 1994, ARCH BIOCHEM BIOPHYS, V311, P443, DOI 10.1006/abbi.1994.1260; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; OHTSUKA Y, 1988, J CLIN CHEM CLIN BIO, V26, P679; ORON Y, 1980, MOL CELL BIOCHEM, V32, P153; ORTMEYER HK, 1994, DIABETOLOGIA, V37, P127, DOI 10.1007/s001250050082; PANG L, 1993, BIOCHEM BIOPH RES CO, V196, P301, DOI 10.1006/bbrc.1993.2249; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; PIRAS R, 1968, BIOCHEMISTRY-US, V7, P56, DOI 10.1021/bi00841a009; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; POSTIC C, 1994, AM J PHYSIOL, V266, pE548, DOI 10.1152/ajpendo.1994.266.4.E548; REN JM, 1993, J BIOL CHEM, V268, P16113; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; ROSSETTI L, 1993, J CLIN INVEST, V92, P2963, DOI 10.1172/JCI116919; ROSSETTI L, 1990, J CLIN INVEST, V85, P1785, DOI 10.1172/JCI114636; ROTHMAN DL, 1992, J CLIN INVEST, V89, P1069, DOI 10.1172/JCI115686; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SALAVERT A, 1979, FEBS LETT, V106, P279, DOI 10.1016/0014-5793(79)80514-1; SCHALINJANTTI C, 1992, DIABETES, V41, P598, DOI 10.2337/diabetes.41.5.598; SCHULMAN GI, 1990, NEW ENGL J MED, V322, P223; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SENER A, 1985, BIOCHEM J, V230, P345, DOI 10.1042/bj2300345; Seoane J, 1996, J BIOL CHEM, V271, P23756, DOI 10.1074/jbc.271.39.23756; SHEN LC, 1970, PHYSIOL CHEM PHYS M, V2, P536; SHEORAIN VS, 1984, J BIOL CHEM, V259, P7024; SHULMAN RG, 1995, P NATL ACAD SCI USA, V92, P8535, DOI 10.1073/pnas.92.19.8535; SKURAT AV, 1994, J BIOL CHEM, V269, P25534; SMITH RL, 1988, J BIOL CHEM, V263, P658; SOBRINO F, 1986, BIOCHIM BIOPHYS ACTA, V885, P43, DOI 10.1016/0167-4889(86)90036-4; STALMANS W, 1974, EUR J BIOCHEM, V41, P117; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; VANDERCAMMEN A, 1990, EUR J BIOCHEM, V191, P483, DOI 10.1111/j.1432-1033.1990.tb19147.x; VILLAMORUZZI E, 1991, BIOCHEM BIOPH RES CO, V177, P1019, DOI 10.1016/0006-291X(91)90640-S; VILLARPALASI C, 1967, FED PROC, V26, P563; VILLARPALASI C, 1960, BIOCHIM BIOPHYS ACTA, V39, P171, DOI 10.1016/0006-3002(60)90142-6; VILLARPALASI C, 1994, BBA-PROTEIN STRUCT M, V1207, P88, DOI 10.1016/0167-4838(94)90055-8; VILLARPALASI C, 1994, DIABETOLOGIA, V37, P885; VILLARPALASI C, 1991, BIOCHIM BIOPHYS ACTA, V1095, P261, DOI 10.1016/0167-4889(91)90109-B; VILLARPALASI C, 1995, BBA-GEN SUBJECTS, V1244, P203, DOI 10.1016/0304-4165(95)00006-W; VILLARPALASI C, 1992, 8 INT C 2 MESS PHOSP; WALKENBACH RJ, 1980, BIOCHIM BIOPHYS ACTA, V629, P421, DOI 10.1016/0304-4165(80)90148-8; WALKENBACH RJ, 1978, MOL CELL BIOCHEM, V19, P31; WANG QM, 1995, J BIOL CHEM, V270, P18352, DOI 10.1074/jbc.270.31.18352; WANG YH, 1986, J BIOL CHEM, V261, P6909; WARDZALA LJ, 1981, J BIOL CHEM, V256, P7090; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WHITE MF, 1994, J BIOL CHEM, V269, P1; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; YANG SD, 1987, J BIOL CHEM, V262, P9421	121	150	158	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1997	11	7					544	558		10.1096/fasebj.11.7.9212078	http://dx.doi.org/10.1096/fasebj.11.7.9212078			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XH342	9212078				2022-12-28	WOS:A1997XH34200006
J	Glatt, H				Glatt, H			Sulfation and sulfotransferases .4. Bioactivation of mutagens via sulfation	FASEB JOURNAL			English	Review						allylic alcohols; aromatic hydroxylamines; benzylic alcohols; sulfotransferase	METABOLIC-ACTIVATION; BENZYLIC ALCOHOLS; V79 CELLS; HYDROXYSTEROID SULFOTRANSFERASE; HEPATIC SULFOTRANSFERASES; MEDIATED ACTIVATION; STABLE EXPRESSION; LIVER CARCINOGEN; CDNA CLONING; B6C3F1 MICE	Sulfation is a common final step in the biotransformation of xenobiotics and is traditionally associated with inactivation, However, the sulfate group is electron-withdrawing and may be cleaved off heterolytically in some molecules, leading to an electrophilic cation. The stable heterologous expression of sulfotransferases in indicator cells of standard mutagenicity tests has substantially improved the accessibility of this activation pathway. Sulfotransferase-mediated genotoxic effects have been demonstrated for numerous benzylic alcohols derived from polycyclic aromatic hydrocarbons and various aromatic hydroxylamines. Also, hycanthone (a benzylic alcohol), alpha-hydroxytamoxifen (an allylic alcohol), 1'-hydroxysafrole (an allylic/benzylic alcohol), and 2-nitropropane are activated to genotoxicants by sulfotransferases. Various reactive sulfate conjugates show strong mutagenic effects only when they are generated directly within the indicator cell, due to their inefficient penetration of cell membranes. In other cases, secondary membrane-penetrating reactive species are formed front sulfuric. acid esters by displacement reactions with medium components, such as chloride or amino acids. Reaction with water regenerates the alcohol, which becomes available for a new cycle of activation. Different sulfotransferases from the same species as well as related forms from rat and human differ iu their substrate specificities and tissue distributions. These characteristics and reactivities of the sulfate conjugates formed may explain organotropic effects of the compounds activated via sulfotransferases.			Glatt, H (corresponding author), GERMAN INST HUMAN NUTR,DIFE,DEPT TOXICOL,ARTHUR SCHEUNERT ALLEE 114-116,D-14558 POTSDAM,GERMANY.			Glatt, Hansruedi/0000-0001-6053-0562				ABUZEID M, 1992, CARCINOGENESIS, V13, P1307, DOI 10.1093/carcin/13.8.1307; BOBERG EW, 1986, CHEM-BIOL INTERACT, V59, P73, DOI 10.1016/S0009-2797(86)80056-4; CHOU HC, 1995, CANCER RES, V55, P525; CHOU HC, 1995, CARCINOGENESIS, V16, P413, DOI 10.1093/carcin/16.2.413; CZICH A, 1994, CHEM-BIOL INTERACT, V92, P119, DOI 10.1016/0009-2797(94)90058-2; DELCLOS KB, 1986, CARCINOGENESIS, V7, P277, DOI 10.1093/carcin/7.2.277; Enders N, 1993, POLYCYCL AROMAT COMP, V3, p887s; ENGST W, 1996, EXP TOXICOL PATHO S2, V48, P102; Falany JL, 1996, ENDOCRINOLOGY, V137, P1395, DOI 10.1210/en.137.4.1395; FENNELL TR, 1985, CANCER RES, V45, P5310; FORBES KJ, 1995, MOL CELL ENDOCRINOL, V112, P53, DOI 10.1016/0303-7207(95)03585-U; Glatt H, 1995, TOXICOL LETT, V82-3, P829, DOI 10.1016/0378-4274(95)03524-9; GLATT H, 1994, TOXICOL LETT, V72, P13, DOI 10.1016/0378-4274(94)90005-1; GLATT H, 1994, MUTAGENESIS, V9, P553, DOI 10.1093/mutage/9.6.553; GLATT H, 1990, ENVIRON HEALTH PERSP, V88, P43, DOI 10.2307/3431049; GLATT H, 1994, CARCINOGENESIS, V15, P2605, DOI 10.1093/carcin/15.11.2605; GLATT H, 1995, EUR J PHARM-ENVIRON, V293, P173, DOI 10.1016/0926-6917(95)90002-0; GLATT HR, 1996, CONTROL MECH CARCINO, P98; HAGEN M, 1997, IN PRESS CHEM BIOL I; HEFLICH RH, 1994, MUTAT RES-REV GENET, V318, P73, DOI 10.1016/0165-1110(94)90025-6; JONES AL, 1995, BIOCHEM BIOPH RES CO, V208, P855, DOI 10.1006/bbrc.1995.1414; LAI CC, 1985, CARCINOGENESIS, V6, P1037, DOI 10.1093/carcin/6.7.1037; Landsiedel R, 1996, POLYCYCL AROMAT COMP, V11, P341, DOI 10.1080/10406639608544685; LANDSIEDEL R, 1996, EXP TOXICOL PATHOL, V48, P366; LEE YC, 1995, BIOCHEM BIOPH RES CO, V209, P996, DOI 10.1006/bbrc.1995.1596; MCCOY EC, 1983, MUTAT RES, V121, P17, DOI 10.1016/0165-7992(83)90081-7; MILLER JA, 1994, CHEM-BIOL INTERACT, V92, P329, DOI 10.1016/0009-2797(94)90074-4; Monnerjahn S., 1993, POSTLABELLING METHOD, P189; NAGATA K, 1993, J BIOL CHEM, V268, P24720; OZAWA S, 1994, JPN J CANCER RES, V85, P1220, DOI 10.1111/j.1349-7006.1994.tb02933.x; PACIFICI GM, 1993, EUR J CLIN PHARMACOL, V45, P483, DOI 10.1007/BF00315522; PARKER CR, 1994, J CLIN ENDOCR METAB, V78, P234, DOI 10.1210/jc.78.1.234; RICE JE, 1987, J TOXICOL ENV HEALTH, V21, P525, DOI 10.1080/15287398709531040; Sasano H, 1995, MODERN PATHOL, V8, P891; SODUM RS, 1994, CHEM RES TOXICOL, V7, P344, DOI 10.1021/tx00039a011; SURH YJ, 1993, CANCER RES, V53, P1017; SURH YJ, 1995, CHEM RES TOXICOL, V8, P693, DOI 10.1021/tx00047a008; WATABE T, 1985, BIOCHEM BIOPH RES CO, V131, P694, DOI 10.1016/0006-291X(85)91293-8; WATABE T, 1982, SCIENCE, V215, P403, DOI 10.1126/science.6800033; WILLIAMS GM, 1993, CARCINOGENESIS, V14, P315; WISEMAN RW, 1985, CANCER RES, V45, P3096	41	172	177	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1997	11	5					314	321		10.1096/fasebj.11.5.9141497	http://dx.doi.org/10.1096/fasebj.11.5.9141497			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WX156	9141497				2022-12-28	WOS:A1997WX15600003
J	Wess, J				Wess, J			G-protein-coupled receptors: Molecular mechanisms involved in receptor activation and selectivity of G-protein recognition	FASEB JOURNAL			English	Review						signal transduction; receptor structure; receptor/G-protein interactions	MUSCARINIC ACETYLCHOLINE-RECEPTOR; BETA-ADRENERGIC RECEPTORS; HETEROTRIMERIC G-PROTEINS; 3RD INTRACELLULAR LOOP; INTRAMOLECULAR INTERACTIONS; ELECTRON CRYOMICROSCOPY; CONFORMATIONAL-CHANGES; PROJECTION STRUCTURE; SIGNAL-TRANSDUCTION; SYNTHETIC PEPTIDES	G-protein-coupled receptors (GPCRs) play fundamental roles in regulating the activity of virtually every body cell, Upon binding of extracellular ligands, GPCRs interact with a specific subset of heterotrimeric G-proteins that can then, in their activated forms, inhibit or activate various effector enzymes and/or ion channels. Molecular cloning studies have shown that GPCRs form one of the largest protein families found in nature, and it is estimated that approximately 1000 different such receptors exist in mammals. The molecular mechanisms involved in GPCR function, particularly the molecular modes of receptor activation and G-protein recognition and activation, have therefore become the research focus of an ever increasing number of laboratories. This review Trill summarize and attempt to integrate recent data derived from structural, molecular genetic, biochemical, and biophysical studies that have shed new light on these processes.			Wess, J (corresponding author), NIDDKD,BIOORGAN CHEM LAB,NIH,BLDG 8A,RM B1A-09,BETHESDA,MD 20892, USA.							Acharya S, 1996, J BIOL CHEM, V271, P25406, DOI 10.1074/jbc.271.41.25406; Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; ARNIS S, 1994, J BIOL CHEM, V269, P23879; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; BLUML K, 1994, J BIOL CHEM, V269, P402; BLUML K, 1994, P NATL ACAD SCI USA, V91, P7980, DOI 10.1073/pnas.91.17.7980; BLUML K, 1994, J BIOL CHEM, V269, P11537; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BOURNE HR, 1997, IN PRESS CURR OPIN C; Bukusoglu G, 1996, MOL CELL BIOL, V16, P4818; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; Evans PD, 1995, PROG BRAIN RES, V106, P259; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; GETHER U, 1995, J BIOL CHEM, V270, P28268; Gilchrist RL, 1996, J BIOL CHEM, V271, P19283, DOI 10.1074/jbc.271.32.19283; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HEDIN KE, 1993, CELL SIGNAL, V5, P505, DOI 10.1016/0898-6568(93)90046-O; HillEubanks D, 1996, J BIOL CHEM, V271, P3058, DOI 10.1074/jbc.271.6.3058; HOGGER P, 1995, J BIOL CHEM, V270, P7405; Hwa J, 1996, J BIOL CHEM, V271, P7956, DOI 10.1074/jbc.271.14.7956; JONES PG, 1995, EUR J PHARM-MOLEC PH, V288, P251, DOI 10.1016/0922-4106(95)90036-5; JUNG H, 1995, FEBS LETT, V358, P133, DOI 10.1016/0014-5793(94)01409-T; Jung H, 1996, BIOCHEMISTRY-US, V35, P6399, DOI 10.1021/bi952575s; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; Kudo M, 1996, J BIOL CHEM, V271, P22470, DOI 10.1074/jbc.271.37.22470; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; Lin SW, 1996, BIOCHEMISTRY-US, V35, P11149, DOI 10.1021/bi960858u; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; LIU J, 1995, J BIOL CHEM, V270, P19532, DOI 10.1074/jbc.270.33.19532; Mazzoni MR, 1996, J BIOL CHEM, V271, P30034, DOI 10.1074/jbc.271.47.30034; Mizobe T, 1996, J BIOL CHEM, V271, P2387, DOI 10.1074/jbc.271.5.2387; MUNCH G, 1991, EUR J BIOCHEM, V198, P357, DOI 10.1111/j.1432-1033.1991.tb16023.x; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; OLIVEIRA L, 1994, TRENDS PHARMACOL SCI, V15, P170, DOI 10.1016/0165-6147(94)90137-6; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Perez DM, 1996, MOL PHARMACOL, V49, P112; PITTEL Z, 1994, MOL PHARMACOL, V45, P61; Porter JE, 1996, J BIOL CHEM, V271, P28318, DOI 10.1074/jbc.271.45.28318; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; RAYMOND JR, 1995, AM J PHYSIOL-RENAL, V269, pF141, DOI 10.1152/ajprenal.1995.269.2.F141; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; ROSENTHAL W, 1993, J BIOL CHEM, V268, P13030; SAVARESE TM, 1992, BIOCHEM J, V283, P1; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Schwartz TW, 1996, TRENDS PHARMACOL SCI, V17, P213, DOI 10.1016/0165-6147(96)10017-1; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUBRAMANIAM S, 1993, EMBO J, V12, P1; SURPRENANT A, 1992, SCIENCE, V257, P977, DOI 10.1126/science.1354394; SURYANARAYANA S, 1992, J BIOL CHEM, V267, P21991; Taylor JM, 1996, J BIOL CHEM, V271, P3336; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; TSUTSUMI M, 1992, MOL ENDOCRINOL, V6, P1163, DOI 10.1210/me.6.7.1163; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WATSON S, 1994, G PROTEIN LINKED REC, P1; Wess J, 1997, LIFE SCI, V60, P1007, DOI 10.1016/S0024-3205(97)00041-6; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; WONG SKF, 1994, J BIOL CHEM, V269, P18968; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YANG K, 1996, IN PRESS BIOCHEMISTR; YEAGLE PL, 1996, IN PRESS MOL VISION; ZHOU W, 1994, MOL PHARMACOL, V45, P165; ZHU SZ, 1994, MOL PHARMACOL, V45, P517	87	490	507	2	42	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1997	11	5					346	354		10.1096/fasebj.11.5.9141501	http://dx.doi.org/10.1096/fasebj.11.5.9141501			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WX156	9141501				2022-12-28	WOS:A1997WX15600007
J	Mundlos, S; Olsen, BR				Mundlos, S; Olsen, BR			Heritable diseases of the skeleton .1. Molecular insights into skeletal development-transcription factors and signaling pathways	FASEB JOURNAL			English	Review						bone; chondrodysplasia; growth plate; mutation	GROWTH-FACTOR RECEPTOR-3; TGF-BETA-SUPERFAMILY; SPLIT FOOT LOCUS; CROUZON-SYNDROME; TRANSMEMBRANE DOMAIN; WAARDENBURG SYNDROME; PAIRED BOX; GENE CAUSE; LIMB BUD; MUTATIONS	The recent identification of the genetic basis of hereditary skeletal disorders is providing important insights into the intricate processes of skeletal formation, growth, and homeostasis. These processes include patterning events during condensation and differentiation of mesenchymal cells to form cartilage precursors of the future bones, the replacement of cartilage by bones through endochondral ossification, the growth of long bones through proliferation and differentiation of chondrocytes in growth plates, and bone formation through differentiation of osteoblasts from mesenchymal cells in areas of intramembranous ossification, Defects in any of these processes can give rise to skeletal abnormalities, Mutations in transcription factors such as HOX and PAX and members of the transforming growth factor-beta superfamily cause disorders associated with abnormal mesenchymal condensation, whereas defects in the transcription factor SOX-9 lead to abnormalities in chondrocyte differentiation. Abnormal growth plate function, resulting in dwarfism, is the consequence of mutations in receptors for fibroblast growth factors and parathyroid hormone-related peptide, Premature closure of cranial sutures in intramembranous ossification is a feature of syndromes due to mutations in fibroblast growth factor receptors.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School			Mundlos, Stefan/ABH-9585-2020		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR036820, R56AR036819, R37AR036819, R01AR036819, R01AR036820] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR36820, AR36819] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BASSON CT, 1994, NEW ENGL J MED, V330, P885, DOI 10.1056/NEJM199403313301302; BELLUS GA, 1995, NAT GENET, V10, P357, DOI 10.1038/ng0795-357; Bonaventure J, 1996, AM J MED GENET, V63, P148, DOI 10.1002/(SICI)1096-8628(19960503)63:1<148::AID-AJMG26>3.0.CO;2-N; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DEVLIN CJ, 1988, DEVELOPMENT, V103, P111; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GODFREY P, 1993, NAT GENET, V4, P227, DOI 10.1038/ng0793-227; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; JABS EW, 1994, NAT GENET, V8, P275, DOI 10.1038/ng1194-275; JOHNSON KR, 1995, GENOMICS, V29, P457, DOI 10.1006/geno.1995.9981; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LEE K, 1993, BONE, V14, P341, DOI 10.1016/8756-3282(93)90162-4; LEE KC, 1995, ENDOCRINOLOGY, V136, P453, DOI 10.1210/en.136.2.453; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MCKUSICK VA, 1973, J MED GENET, V10, P11, DOI 10.1136/jmg.10.1.11; MEYERS GA, 1995, NAT GENET, V11, P462, DOI 10.1038/ng1295-462; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; MUNDLOS S, 1995, HUM MOL GENET, V4, P71, DOI 10.1093/hmg/4.1.71; MUNDLOS S, 1994, PROGR HISTOCHEM CYTO, V28; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NUNES ME, 1995, HUM MOL GENET, V4, P2165, DOI 10.1093/hmg/4.11.2165; OHLSSON C, 1992, P NATL ACAD SCI USA, V89, P9826, DOI 10.1073/pnas.89.20.9826; PETERS KG, 1993, DEVELOPMENT, V114, P232; Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; RIJII FM, 1993, CELL, V75, P1333; ROUSSEAU F, 1995, NAT GENET, V10, P11, DOI 10.1038/ng0595-11; RUTLAND P, 1995, NAT GENET, V9, P173, DOI 10.1038/ng0295-173; SCHERER SW, 1994, AM J HUM GENET, V55, P12; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; SILLENCE DO, 1987, AM J MED GENET, V27, P75, DOI 10.1002/ajmg.1320270109; SPRANGER J, 1992, EUR J PEDIATR, V151, P407; STANESCU R, 1990, AM J MED GENET, V27, P412; STOILOV I, 1995, J MED GENET, V45, P492; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; SUPERTIFURGA A, 1995, EUR J PEDIATR, V154, P215, DOI 10.1007/BF01954274; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; Thomas JT, 1996, NAT GENET, V12, P315, DOI 10.1038/ng0396-315; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Wajnrajch MP, 1996, NAT GENET, V12, P88, DOI 10.1038/ng0196-88; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15; ZLOTOGORA J, 1995, AM J HUM GENET, V56, P1173	60	132	139	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1997	11	2					125	132		10.1096/fasebj.11.2.9039954	http://dx.doi.org/10.1096/fasebj.11.2.9039954			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK509	9039954				2022-12-28	WOS:A1997WK50900004
J	Keppler, D; Arias, IM				Keppler, D; Arias, IM			Introduction: Transport across the hepatocyte canalicular membrane	FASEB JOURNAL			English	Review							ATP-DEPENDENT TRANSPORT; RESISTANCE GENE-PRODUCT; BILE-SALT TRANSPORT; RAT-LIVER; PLASMA-MEMBRANE; TAUROCHOLATE TRANSPORT; FUNCTIONAL POLARITY; P-GLYCOPROTEIN; VESICLES; SYSTEM		TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111	Tufts University	Keppler, D (corresponding author), GERMAN CANC RES CTR,DIV TUMOR BIOCHEM,NEUENHEIMER FELD 280,D-69120 HEIDELBERG,GERMANY.		Keppler, Dietrich/A-5528-2013	Keppler, Dietrich/0000-0003-2964-2333				ADACHI Y, 1991, HEPATOLOGY, V14, P655, DOI 10.1016/0270-9139(91)90053-X; ARIAS IM, 1993, HEPATOLOGY, V17, P318, DOI 10.1002/hep.1840170225; BECKER A, 1986, BIOL CHEM H-S, V367, P681, DOI 10.1515/bchm3.1986.367.2.681; BLOUIN A, 1977, J CELL BIOL, V72, P441, DOI 10.1083/jcb.72.2.441; BOHME M, 1994, GASTROENTEROLOGY, V107, P255; BOYER JL, 1992, ANNU REV PHYSIOL, V54, P415, DOI 10.1146/annurev.ph.54.030192.002215; BRADBURY NA, 1994, AM J PHYSIOL, V267, pC1, DOI 10.1152/ajpcell.1994.267.1.C1; Buchler M, 1996, J BIOL CHEM, V271, P15091; BUSCHMAN E, 1992, J BIOL CHEM, V267, P18093; CHE MX, 1992, J BIOL CHEM, V267, P9684; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; Childs S, 1994, Important Adv Oncol, P21; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DENZLINGER C, 1985, SCIENCE, V230, P330, DOI 10.1126/science.4048937; ELFERINK RPJO, 1995, BBA-REV BIOMEMBRANES, V1241, P215, DOI 10.1016/0304-4157(95)00006-D; EVANS WH, 1980, BIOCHIM BIOPHYS ACTA, V604, P27, DOI 10.1016/0005-2736(80)90584-2; GATMAITAN ZC, 1995, PHYSIOL REV, V75, P261, DOI 10.1152/physrev.1995.75.2.261; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Hubbard Ann L., 1994, P189; HUBER M, 1987, HEPATOLOGY, V7, P224, DOI 10.1002/hep.1840070204; INOUE M, 1984, J CLIN INVEST, V73, P659, DOI 10.1172/JCI111257; INOUE M, 1983, J BIOL CHEM, V258, P5183; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KEPPLER D, 1996, PROGR LIVER DIS, P55; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; MAYER R, 1995, J CELL BIOL, V131, P137, DOI 10.1083/jcb.131.1.137; MEIER PJ, 1990, METHOD ENZYMOL, V192, P534; MEIER PJ, 1984, J BIOL CHEM, V259, P614; Meier PJ, 1995, AM J PHYSIOL-GASTR L, V269, pG801, DOI 10.1152/ajpgi.1995.269.6.G801; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MULLER M, 1991, J BIOL CHEM, V266, P18920; Nies AT, 1996, J LIPID RES, V37, P1125; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; PLESNER L, 1995, INT REV CYTOL, V158, P141; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; RUETZ S, 1988, P NATL ACAD SCI USA, V85, P6147, DOI 10.1073/pnas.85.16.6147; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; STPIERRE MV, 1994, P NATL ACAD SCI USA, V88, P6590; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; Tommasini R, 1996, P NATL ACAD SCI USA, V93, P6743, DOI 10.1073/pnas.93.13.6743; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; WATANABE N, 1991, J CELL BIOL, V113, P1069, DOI 10.1083/jcb.113.5.1069; WISHER MH, 1975, BIOCHEM J, V146, P375, DOI 10.1042/bj1460375	46	88	89	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1997	11	1					15	18		10.1096/fasebj.11.1.9034161	http://dx.doi.org/10.1096/fasebj.11.1.9034161			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK147	9034161				2022-12-28	WOS:A1997WK14700003
J	Mufson, RA				Mufson, RA			The role of serine/threoaine phosphorylation in hematopoietic cytokine receptor signal transduction	FASEB JOURNAL			English	Review						protein kinase C; tyrosine phosphorylation; STATS; calmodulin	PROTEIN-KINASE-C; COLONY-STIMULATING FACTOR; MYELOID CELL-LINE; NIH 3T3 CELLS; INTERLEUKIN-3 RECEPTOR; TYROSINE KINASE; SERINE PHOSPHORYLATION; PLASMA-MEMBRANE; IL-3 RECEPTOR; ACTIVATION	The hematopoietic cytokine receptors rapidly activate tyrosine phosphorylation after Ligand engagement, In addition, however, serine/ threonine phosphorylation of important effector molecules also icreases, Interleukins 2-5 and granulocyte-macrophage colony stimulating factor all activate protein kinase C. This results in serine/threonine phosphorylation of such important regulatory molecules as Raf-1 kinase, myristoylated alanine-rich C kinase substrate, and SOS, These phosphorylated effector molecules are regulators of important genes related to cell survival and proliferation, In addition, as yet uncharacterized serine/ threonine kinases associate directly with the hematopoietic receptor subunits themselves, These kinases may contribute to the phosphorylation of the STAT family of transcription factors that is important in regulating cytokine-specific gene inductions. Thus, it is time to begin integrating serine/threonine kinases into the postulated signaling pathways activated by hematopoietic cytokine receptors.			Mufson, RA (corresponding author), AMER RED CROSS,DEPT IMMUNOL,JEROME H HOLLAND LAB,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855, USA.				NATIONAL CANCER INSTITUTE [R01CA053609] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA 53609] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEREM A, 1995, BIOCHEM SOC T, V23, P587, DOI 10.1042/bst0230587; ADNUYAH S, 1991, J BIOL CHEM, V266, P5670; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARRUDA S, 1992, J IMMUNOL, V149, P1258; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BAXTER GT, 1992, BIOCHEMISTRY-US, V31, P10920; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; BOSWELL HS, 1989, LEUKEMIA, V3, P662; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BROXMEYER HE, 1991, CANCER CELL-MON REV, V3, P480; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; COOPER JA, 1992, MOL BIOL CELL, V3, P583; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; FARRAR WL, 1985, NATURE, V315, P235, DOI 10.1038/315235a0; FARRAR WL, 1985, NATURE, V315, P233, DOI 10.1038/315233a0; FUNG MR, 1991, J IMMUNOL, V147, P1253; GOLDSTEIN H, 1993, J IMMUNOL, V151, P6701; GOMEZ J, 1994, EXP CELL RES, V213, P178, DOI 10.1006/excr.1994.1188; HERGET T, 1994, EUR J BIOCHEM, V225, P549, DOI 10.1111/j.1432-1033.1994.t01-1-00549.x; HERGET T, 1994, EUR J BIOCHEM, V225, P539, DOI 10.1111/j.1432-1033.1994.00539.x; Ihle J N, 1993, Semin Immunol, V5, P375, DOI 10.1006/smim.1993.1043; KANAKURA Y, 1991, BLOOD, V77, P243; KATAYAMA N, 1990, BLOOD, V75, P1446; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LIU L, 1994, J BIOL CHEM, V269, P16774; LIU L, 1995, J BIOL CHEM, V270, P22422, DOI 10.1074/jbc.270.38.22422; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MASONGARCIA M, 1995, CELL PROLIFERAT, V28, P145, DOI 10.1111/j.1365-2184.1995.tb00063.x; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MUELLER M, 1993, EMBO J, V12, P4221; MUFSON RA, 1992, J IMMUNOL, V148, P1129; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OWEN PJ, 1993, J BIOL CHEM, V268, P15696; RAJOTTE D, 1992, J BIOL CHEM, V267, P9986; RAO P, 1994, CANCER RES, V54, P777; RAO P, 1995, J IMMUNOL, V154, P1664; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; REDDY GPV, 1992, BLOOD, V79, P1946; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; SATO N, 1994, CURR OPIN CELL BIOL, V6, P174, DOI 10.1016/0955-0674(94)90133-3; SCHREURS J, 1991, INT IMMUNOL, V3, P1231, DOI 10.1093/intimm/3.12.1231; SOZERI O, 1992, ONCOGENE, V7, P2259; SPANGLER R, 1992, BLOOD, V179, P52; STOCKOE D, 1994, SCIENCE, V264, P1463; WELHAM M, 1994, J BIOL CHEM, V26, P21165; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WHETTON AD, 1988, P NATL ACAD SCI USA, V85, P3284, DOI 10.1073/pnas.85.10.3284; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P98	56	37	39	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1997	11	1					37	44		10.1096/fasebj.11.1.9034164	http://dx.doi.org/10.1096/fasebj.11.1.9034164			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK147	9034164				2022-12-28	WOS:A1997WK14700006
J	Waterman, MR				Waterman, MR			Introduction: Transcription and regulation of activities of cytochromes P450 metabolizing endogenous substrates	FASEB JOURNAL			English	Editorial Material											Waterman, MR (corresponding author), VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232, USA.							ESTABROOK RW, 1963, BIOCHEM Z, V338, P741; HOLTON TA, 1993, NATURE, V366, P276, DOI 10.1038/366276a0; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; SCHLINGER BA, 1991, P NATL ACAD SCI USA, V88, P4191, DOI 10.1073/pnas.88.10.4191; Simpson E.R., 1995, ENDOCRINOLOGY, P1630; Stromstedt M, 1996, ARCH BIOCHEM BIOPHYS, V329, P73, DOI 10.1006/abbi.1996.0193; YOSHIKUNI M, 1994, DEV BIOL, V166, P615, DOI 10.1006/dbio.1994.1341	7	3	3	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1996	10	13					1455	1455		10.1096/fasebj.10.13.8940290	http://dx.doi.org/10.1096/fasebj.10.13.8940290			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VU982	8940290				2022-12-28	WOS:A1996VU98200001
J	deThe, H				deThe, H			Altered retinoic acid receptors	FASEB JOURNAL			English	Article						leukemia; dominant-negative; transcription nuclear bodies	ACUTE PROMYELOCYTIC LEUKEMIA; DOMINANT-NEGATIVE ACTIVITY; PML-RAR-ALPHA; NUCLEAR-BODIES; CELLS; PROTEINS; FUSION; FINGER; GENE; DIFFERENTIATION	Structurally and functionally altered retinoic acid receptors have been associated with rare human neoplasms: acute promyelocytic leukemia and hepatocellular carcinoma, Whereas the retinoic acid receptor beta (RAR beta) rearrangement in hepatocellular carcinoma is unique, in acute promyelocytic leukemia (APL), RAR alpha fusion to the promyelocytic leukemia (PML) gene by the t(15;11) translocation is a general feature of the disease, APL is an important model in cancer biology because retinoic acid induces complete remissions in this malignancy, providing the first example of differentiation therapy and of an antineoplastic drug directly targeted at the underlying genetic lesion, The molecular basis of PML/RAR alpha fusion leukemogenesis is discussed with respect to dominant negative inhibition of nuclear receptor and PML functions.	HOP ST LOUIS,SERV BIOCHIM,F-75475 PARIS 10,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	deThe, H (corresponding author), HOP ST LOUIS,CNRS UPR 9051,1 AV C VELLEFAUX,F-75475 PARIS 10,FRANCE.							ANESKIEVICH BJ, 1995, J CELL SCI, V108, P195; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Chomienne C, 1996, FASEB J, V10, P1025, DOI 10.1096/fasebj.10.9.8801163; DANIEL MT, 1993, BLOOD, V82, P1858; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DYEK JA, 1994, CELL, V76, P333; FAGIOLI M, 1992, ONCOGENE, V7, P1083; GODDARD AD, 1995, MAMM GENOME, V6, P732, DOI 10.1007/BF00354296; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; ISOMURA T, 1992, NUCLEIC ACIDS RES, V20, P5305, DOI 10.1093/nar/20.20.5305; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; ROBERTSON KA, 1992, BLOOD, V80, P1885; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; Stadler M, 1995, ONCOGENE, V11, P2565; STUURMAN N, 1992, J CELL SCI, V101, P773; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TSAI S, 1992, GENE DEV, V6, P2258, DOI 10.1101/gad.6.12a.2258; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; VHADAT L, 1994, BLOOD, V84, P3843; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7	43	47	48	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1996	10	9					955	960		10.1096/fasebj.10.9.8801177	http://dx.doi.org/10.1096/fasebj.10.9.8801177			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801177				2022-12-28	WOS:A1996UY93200004
J	Underwood, BA; Arthur, P				Underwood, BA; Arthur, P			The contribution of vitamin A to public health	FASEB JOURNAL			English	Article						WHO; vitamin A deficiency; blindness; diarrhea; iron-deficiency anemia; measles	A-DEFICIENCY; MILD VITAMIN; CHILDREN; MORBIDITY; DIARRHEA; SUPPLEMENTATION; RISK; MEASLES; BLINDNESS; PRESCHOOL	Vitamin A deficiency among children in developing countries remains the leading cause of preventable severe visual impairment and blindness, and is a significant contributor to severe infections and death, particularly from diarrhea and measles, Vitamin A deficiency is also likely to increase vulnerability To other illnesses in both women and children, such as iron-deficiency anemia, and may be an important factor contributing to poor maternal performance during pregnancy and lactation and to growth deficits in children, Benefits to public health can be expected by improving the vitamin A status of deficient populations through an appropriate mix of acceptable, affordable, and available programs including promotion of breast-feeding, control of infections, dietary diversification, food fortification, and supplementation. Benefits include not only improved health and welfare for individuals and their families, but also improved chances of survival for an estimated 254 million children.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND	University of London; London School of Hygiene & Tropical Medicine	Underwood, BA (corresponding author), WHO, 20 APPIA AVE, CH-1211 GENEVA, SWITZERLAND.							*ADM COMM COORD SU, 1994, STATE OF THE ART SER; ALVAREZ JO, 1995, AM J CLIN NUTR, V61, P1273, DOI 10.1093/ajcn/61.6.1273; BARRETO ML, 1994, LANCET, V344, P228, DOI 10.1016/S0140-6736(94)92998-X; BEACH RS, 1992, AIDS, V6, P701, DOI 10.1097/00002030-199207000-00013; BEATON GH, 1993, ACC SCN STATE OF THE; BHANDARI N, 1994, BRIT MED J, V309, P1404, DOI 10.1136/bmj.309.6966.1404; BINKA FN, 1995, AM J CLIN NUTR, V61, P853, DOI 10.1093/ajcn/61.4.853; BLOEM MW, 1995, P NUTR SOC, V54, P501, DOI 10.1079/PNS19950018; BLOEM MW, 1990, AM J EPIDEMIOL, V131, P332, DOI 10.1093/oxfordjournals.aje.a115502; BRILLIANT LB, 1985, B WORLD HEALTH ORGAN, V63, P375; CHANDRA RK, 1988, BRIT MED J, V297, P834, DOI 10.1136/bmj.297.6652.834; CHENG L, 1993, EUR J CLIN NUTR, V47, P88; CLASZIOU PP, 1993, BRIT MED J, V306, P366; Cohen N, 1985, World Health Stat Q, V38, P317; COURTRIGHT P, 1994, T ROY SOC TROP MED H, V88, P711, DOI 10.1016/0035-9203(94)90243-7; COUTSOUDIS A, 1991, AM J CLIN NUTR, V54, P890, DOI 10.1093/ajcn/54.5.890; COUTSOUDIS A, 1992, PEDIATR INFECT DIS J, V11, P203, DOI 10.1097/00006454-199203000-00006; DESOLE G, 1987, AM J CLIN NUTR, V45, P780, DOI 10.1093/ajcn/45.4.780; DOUER D, 1982, J CLIN INVEST, V69, P1039, DOI 10.1172/JCI110507; FAWZI WW, 1995, J NUTR, V125, P1211; FAWZI WW, 1993, JAMA-J AM MED ASSOC, V269, P898, DOI 10.1001/jama.269.7.898; FILTEAU SM, 1993, AM J CLIN NUTR, V58, P192, DOI 10.1093/ajcn/58.2.192; FOSTER A, 1992, T ROY SOC TROP MED H, V86, P454, DOI 10.1016/0035-9203(92)90268-H; Ghana VAST study Team, 1993, LANCET, V342, P7; MILTON RC, 1987, AM J CLIN NUTR, V46, P827, DOI 10.1093/ajcn/46.5.827; Nauss KM, 1986, VITAMIN A DEFICIENCY, P207; ROSS CA, 1994, NUTR REGULATION PREG, P187; ROSS DA, 1995, AM J PUBLIC HEALTH, V85, P1246, DOI 10.2105/AJPH.85.9.1246; SEMBA RD, 1993, ARCH INTERN MED, V153, P2149, DOI 10.1001/archinte.153.18.2149; SEMBA RD, 1994, LANCET, V343, P1593, DOI 10.1016/S0140-6736(94)93056-2; SMITASIRI S, 1992, ECOL FOOD NUTR, V28, P199, DOI 10.1080/03670244.1992.9991271; Sommer A, 1995, B WORLD HEALTH ORGAN, V73, P609; Sommer A, 1983, Trans Am Ophthalmol Soc, V81, P825; SOMMER A, 1984, AM J CLIN NUTR, V40, P1090, DOI 10.1093/ajcn/40.5.1090; Sommer A., 1995, VITAMIN A DEFICIENCY; SOMMER A, 1996, VITAMIN A DEFICIENCY, P71; STANTON BF, 1986, AM J DIS CHILD, V140, P584, DOI 10.1001/archpedi.1986.02140200094036; SUHARNO D, 1992, AM J CLIN NUTR, V56, P988, DOI 10.1093/ajcn/56.6.988; TANG AM, 1993, AM J EPIDEMIOL, V138, P937, DOI 10.1093/oxfordjournals.aje.a116814; TIELSCH JM, 1986, AM J EPIDEMIOL, V124, P561, DOI 10.1093/oxfordjournals.aje.a114428; TONASCIA JA, 1993, BELLAGIO M VIT A DEF; UNDERWOOD BA, 1994, AM J CLIN NUTR, V59, p517S, DOI 10.1093/ajcn/59.2.517S; UNDERWOOD BA, 1994, ADV EXP MED BIOL, V352, P201; Underwood BA, 1984, RETINOIDS, P281; Underwood Barbara A., 1994, P211; USHA N, 1991, J PEDIATR GASTR NUTR, V13, P168, DOI 10.1097/00005176-199108000-00009; WALLINGFORD JC, 1987, J NUTR, V117, P1410, DOI 10.1093/jn/117.8.1410; Wallingford JC, 1986, VITAMIN A DEFICIENCY, P101; WEST KP, 1995, AM J CLIN NUTR, V62, P143, DOI 10.1093/ajcn/62.1.143; *WHO, 1994, PREV CHILDH BLINDN; *WHO, 1995, 2 MDIS WHO; *WHO, 1982, TECH REP SER WHO, V672; *WHO, WHOEPIGEN949; *WHO, 1994, WHONUT941; *WHO FAO UN, 1992, INT C NUTR ROM; *WORLD SUMM CHILDR, 1990, UN CHILDR FUND	57	140	147	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1996	10	9					1040	1048		10.1096/fasebj.10.9.8801165	http://dx.doi.org/10.1096/fasebj.10.9.8801165			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801165				2022-12-28	WOS:A1996UY93200014
J	Mayne, ST				Mayne, ST			Beta-carotene, carotenoids, and disease prevention in humans	FASEB JOURNAL			English	Review						cancer prevention; cardiovascular disease	NUTRITION INTERVENTION TRIALS; LUNG-CANCER RISK; SERUM MICRONUTRIENTS; ORAL LEUKOPLAKIA; SUBSEQUENT RISK; SUPPLEMENTATION; VEGETABLES; DYSPLASIA; LINXIAN; MICRONUCLEI	A growing body of literature exists regarding the effects of beta-carotene and other carotenoids on chronic diseases in humans, This article reviews and critically evaluates this literature and identifies areas for further research, This review is restricted to studies in humans, with a major emphasis on the most recent literature in the area of carotenoids and selected cancers, Effects of carotenoids on cardiovascular diseases, photosensitivity diseases, cataracts, and age-related macular degeneration are also discussed briefly, Numerous observational studies have found that people who ingest more carotenoids in their diets have a reduced risk of several chronic diseases, However, intervention trials of supplemental beta-carotene indicate that supplements are of little or no value in preventing cardiovascular disease and the major cancers occurring in well-nourished populations, and may actually increase, rather than reduce, lung cancer incidence in smokers, As a consequence, of these findings, some of the ongoing trials of beta-carotene and disease prevention have been terminated or have dropped beta-carotene from their interventions, Researchers should now seek explanations for the apparently discordant findings of observational studies vs, intervention trials, The most pressing research issues include studies of interactions of carotenoids with themselves and with other phytochemicals and mechanistic studies of the actions of beta-carotene in lung carcinogenesis and cardiovascular disease, Paradoxically, the finding that lung carcinogenesis and cardiovascular disease can be enhanced by supplemental beta-carotene may ultimately lead to a clearer understanding of the role of diet in the etiology and prevention of these diseases, The conclusion that major public health benefits could be achieved by increasing consumption of carotenoid-rich fruits and vegetables still appears to stand; however, the pharmacological use of supplemental beta-carotene for the prevention of cardiovascular disease and lung cancer, particularly in smokers, can no longer be recommended.	YALE UNIV, CTR CANC, NEW HAVEN, CT 06520 USA	Yale University	Mayne, ST (corresponding author), YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, 60 COLL ST, POB 208034, NEW HAVEN, CT 06520 USA.				NATIONAL CANCER INSTITUTE [P01CA042101, R01CA064567] Funding Source: NIH RePORTER; NCI NIH HHS [CA42101, CA64567] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALAVANJA MCR, 1993, J NATL CANCER I, V85, P1906, DOI 10.1093/jnci/85.23.1906; BAIRATI I, 1994, 2 INT C ANT VIT BET; BATIEHA AM, 1993, CANCER EPIDEM BIOMAR, V2, P335; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; BLOT WJ, 1994, NEW ENGL J MED, V331, P614, DOI 10.1056/NEJM199409013310913; BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843; BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156; CAMPBELL DR, 1994, CANCER EPIDEM BIOMAR, V3, P493; DEVET HCW, 1991, J CLIN EPIDEMIOL, V44, P273, DOI 10.1016/0895-4356(91)90039-C; DRAGSTED LO, 1993, PHARMACOL TOXICOL, V72, pS116; FREEDMAN LS, 1992, AM J EPIDEMIOL, V136, P1148, DOI 10.1093/oxfordjournals.aje.a116581; GAREWAL H, 1995, P AN M AM SOC CLIN, V14, P496; GAREWAL HS, 1990, J CLIN ONCOL, V8, P1715, DOI 10.1200/JCO.1990.8.10.1715; GAZIANO JM, 1993, ANN NY ACAD SCI, V691, P148, DOI 10.1111/j.1749-6632.1993.tb26166.x; GAZIANO JM, 1994, AM J MED, V97, pS18, DOI 10.1016/0002-9343(94)90294-1; GEY KF, 1993, AM J CLIN NUTR, V57, P787; GEY KF, 1993, BRIT MED BULL, V49, P679, DOI 10.1093/oxfordjournals.bmb.a072640; GIOVANNUCCI E, 1995, J NATL CANCER I, V87, P1767, DOI 10.1093/jnci/87.23.1767; GOODMAN GE, 1994, CANCER EPIDEM BIOMAR, V3, P429; GOODMAN GE, 1993, CANCER EPIDEM BIOMAR, V2, P389; GREENBERG ER, 1990, NEW ENGL J MED, V323, P789, DOI 10.1056/NEJM199009203231204; GREENBERG ER, 1994, NEW ENGL J MED, V331, P141, DOI 10.1056/NEJM199407213310301; Handelman GJ, 1996, AM J CLIN NUTR, V63, P559, DOI 10.1093/ajcn/63.4.559; HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; INGRAM D, 1994, BRIT J CANCER, V69, P592, DOI 10.1038/bjc.1994.108; ISLER O, 1981, CAROTENOIDS COLORANT, pR13; JAIN M, 1994, J NATL CANCER I, V86, P1390, DOI 10.1093/jnci/86.18.1390; KARDINAAL AFM, 1993, LANCET, V342, P1379, DOI 10.1016/0140-6736(93)92751-E; KAUGARS GE, 1994, ORAL SURG ORAL MED O, V78, P462, DOI 10.1016/0030-4220(94)90039-6; KHACHIK F, 1992, J AGR FOOD CHEM, V40, P390, DOI 10.1021/jf00015a006; Kikendall JW, 1991, AM J GASTROENTEROL, V36, P1356; KOSTIC D, 1995, AM J CLIN NUTR, V62, P604, DOI 10.1093/ajcn/62.3.604; LEMARCHAND L, 1993, CANCER EPIDEM BIOMAR, V2, P183; LI JY, 1993, J NATL CANCER I, V85, P1492, DOI 10.1093/jnci/85.18.1492; MALAKER K, 1991, CANCER DETECT PREV, V15, P335; MANGELS AR, 1993, J AM DIET ASSOC, V93, P284, DOI 10.1016/0002-8223(93)91553-3; MATHEWSROTH MM, 1993, ANN NY ACAD SCI, V691, P127, DOI 10.1111/j.1749-6632.1993.tb26164.x; Mayne S.T., 1993, CURR OPIN OTOLARYNGO, V1, P126; MAYNE ST, 1991, CANCER CAUSE CONTROL, V2, P443, DOI 10.1007/BF00054305; MAYNE ST, 1992, ADV EXP MED BIOL, V320, P119; MAYNE ST, 1994, J NATL CANCER I, V86, P33, DOI 10.1093/jnci/86.1.33; MCLARTY JW, 1995, AM J CLIN NUTR S, V62, pS1413; MEYSKENS FL, 1995, AM J CLIN NUTR, V62, P1417, DOI 10.1093/ajcn/62.6.1417S; MICOZZI MS, 1990, JNCI-J NATL CANCER I, V82, P282, DOI 10.1093/jnci/82.4.282; MICOZZI MS, 1992, AM J CLIN NUTR, V55, P1120, DOI 10.1093/ajcn/55.6.1120; MOBARHAN S, 1994, CANCER EPIDEM BIOMAR, V3, P501; MORRIS DL, 1994, JAMA-J AM MED ASSOC, V272, P1439, DOI 10.1001/jama.272.18.1439; NEGRI E, 1993, CANCER EPIDEM BIOMAR, V2, P189; NIERENBERG DW, 1994, JNCI-J NATL CANCER I, V86, P117, DOI 10.1093/jnci/86.2.117; Olson JA, 1996, J NUTR, V126, pS1208, DOI 10.1093/jn/126.suppl_4.1208S; OLSON JA, 1994, NUTR REV, V52, P67, DOI 10.1111/j.1753-4887.1994.tb01389.x; PALOZZA P, 1995, FREE RADICAL BIO MED, V19, P887, DOI 10.1016/0891-5849(95)00094-E; Pocock SJ., 2013, CLIN TRIALS PRACTICA; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROUSSEAU A, 1983, J AM ACAD DERMATOL, V8, P123, DOI 10.1016/S0190-9622(83)80288-6; SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413; SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1246, DOI 10.1001/archopht.1993.01090090098027; STICH HF, 1988, INT J CANCER, V42, P195, DOI 10.1002/ijc.2910420209; TAYLOR A, 1993, J AM COLL NUTR, V12, P138; TOMA S, 1992, ONCOLOGY, V49, P77; TOMA S, 1994, 2 INT C ANT VIT BET; VANPOPPEL G, 1992, BRIT J CANCER, V66, P1164, DOI 10.1038/bjc.1992.428; WAHLQVIST ML, 1994, AM J CLIN NUTR, V60, P936, DOI 10.1093/ajcn/60.6.936; XU MJ, 1992, J NATL CANCER I, V84, P1559, DOI 10.1093/jnci/84.20.1559; Zaridze D, 1993, Ann Epidemiol, V3, P225; ZHENG W, 1993, CANCER RES, V53, P795; Ziegler RG, 1996, CANCER CAUSE CONTROL, V7, P157, DOI 10.1007/BF00115646; ZIEGLER RG, 1996, IN PRESS J NATL CANC	70	621	661	2	67	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1996	10	7					690	701		10.1096/fasebj.10.7.8635686	http://dx.doi.org/10.1096/fasebj.10.7.8635686			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UN798	8635686				2022-12-28	WOS:A1996UN79800003
J	Villalobos, C; Nunez, L; GarciaSancho, J				Villalobos, C; Nunez, L; GarciaSancho, J			Functional glutamate receptors in a subpopulation of anterior pituitary cells	FASEB JOURNAL			English	Article						hypothalamic releasing hormones; thyrotropin-releasing hormone; NMDA	AMINO-ACID RECEPTORS; PROLACTIN SECRETION; GROWTH-HORMONE; RAT; ANTAGONISTS; STIMULATION	We have studied the effects of glutamate receptor agonists on the cytosolic Ca2+ concentration ([Ca2+](i)) of single rat anterior pituitary (AP) cells, Ionotropic (NMDA and kainate/AMPA) and, to a smaller extent, metabotropic glutamate receptors were both present in all the five AP cell types, defined by the hormone they store, Cells within all the types responded also to thyrotropin-releasing hormone (TRH). Alternative typing by the response to four well-established hypothalamic releasing hormones (HRHs), GHRH, GnRH, CRH, and TRH, was performed, One-third of the cells were not sensitive to any HRH, another third were sensitive to only one HRH, and the last third were sensitive to more than one HRH, frequently to all four, Only the cells responding to TRH showed functional glutamate receptors, Superimposed to the above association, the strongest responses to glutamate were found in the cells responsive to multiple HRHs, These results suggest that glutamate may act, by a nonsynaptic mechanism, as a new releasing factor for one or, like TRH, several AIP hormones, Coexpression of glutamate and TRH receptors in the subpopulation of cells responsive to multiple HRHs might have a functional meaning, perhaps related to phenotypic plasticity and long-term regulation of hormone secretion by the anterior pituitary.	CSIC,DEPT BIOQUIM & BIOL MOLEC & FISIOL,FAC MED,E-47005 VALLADOLID,SPAIN; UNIV VALLADOLID,INST BIOL & GENET MOLEC,E-47005 VALLADOLID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid			nunez, lucia/AAG-8018-2019; Villalobos, Carlos/M-9839-2017; Garcia-Sancho, Javier/K-2975-2014	Villalobos, Carlos/0000-0002-0429-3846; Nunez, Lucia/0000-0002-9638-5747; Garcia-Sancho, Javier/0000-0003-4573-7930				BRANN DW, 1995, NEUROENDOCRINOLOGY, V61, P213, DOI 10.1159/000126843; CRONIN MJ, 1980, ENDOCRINOLOGY, V106, P718, DOI 10.1210/endo-106-3-718; DOBSON PRM, 1985, METHOD ENZYMOL, V109, P293; DONOSO AO, 1994, BRAZ J MED BIOL RES, V27, P921; FRAWLEY LS, 1991, ENDOCR REV, V12, P337, DOI 10.1210/edrv-12-4-337; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; GERSHENGORN MC, 1986, ANNU REV PHYSIOL, V48, P515; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERITIER AG, 1993, ENDOCRINOLOGY, V132, P634, DOI 10.1210/en.132.2.634; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; INAGAKI N, 1995, FASEB J, V9, P686, DOI 10.1096/fasebj.9.8.7768362; KASAHARA K, 1994, BIOCHEM BIOPH RES CO, V199, P1436, DOI 10.1006/bbrc.1994.1391; KATO M, 1992, J PHYSIOL-LONDON, V447, P171, DOI 10.1113/jphysiol.1992.sp018997; KEMP JA, 1987, TRENDS NEUROSCI, V10, P294, DOI 10.1016/0166-2236(87)90176-7; KIYAMA H, 1993, MOL BRAIN RES, V19, P262, DOI 10.1016/0169-328X(93)90039-R; LAMBERTS SWJ, 1990, PHYSIOL REV, V70, P279, DOI 10.1152/physrev.1990.70.2.279; LAUDER JM, 1993, TRENDS NEUROSCI, V16, P233, DOI 10.1016/0166-2236(93)90162-F; LINDSTROM P, 1992, ENDOCRINOLOGY, V131, P1903, DOI 10.1210/en.131.4.1903; LOGIN IS, 1990, LIFE SCI, V47, P2269, DOI 10.1016/0024-3205(90)90158-N; LOPEZ MG, 1995, J PHYSIOL-LONDON, V482, P15, DOI 10.1113/jphysiol.1995.sp020496; MASON GA, 1983, BRAIN RES, V289, P366, DOI 10.1016/0006-8993(83)90044-6; MEEKER RB, 1994, ENDOCRINOLOGY, V134, P621, DOI 10.1210/en.134.2.621; NIIMI M, 1994, NEUROENDOCRINOLOGY, V60, P173, DOI 10.1159/000126748; NUNEZ L, 1995, IN PRESS AM J PHYSL; OLEARY R, 1995, J NEUROCHEM, V65, P953; PALMER E, 1989, EUR J PHARMACOL, V166, P585, DOI 10.1016/0014-2999(89)90383-X; PREVARSKAYA N, 1994, MOL CELL NEUROSCI, V5, P699, DOI 10.1006/mcne.1994.1084; SCHALLY AV, 1978, ANNU REV BIOCHEM, V47, P89, DOI 10.1146/annurev.bi.47.070178.000513; SCHOEPP D, 1990, TRENDS PHARMACOL SCI, V11, P508, DOI 10.1016/0165-6147(90)90052-A; TERRY LC, 1981, BRAIN RES, V217, P129; VANDENPOL AN, 1990, SCIENCE, V250, P1276, DOI 10.1126/science.1978759; VILLALOBOS C, 1995, FASEB J, V9, P815, DOI 10.1096/fasebj.9.9.7601345; WATKINS JC, 1987, TRENDS NEUROSCI, V10, P265, DOI 10.1016/0166-2236(87)90171-8; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N; ZANISI M, 1994, P SOC EXP BIOL MED, V206, P431	35	64	65	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1996	10	5					654	660		10.1096/fasebj.10.5.8621065	http://dx.doi.org/10.1096/fasebj.10.5.8621065			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UJ055	8621065				2022-12-28	WOS:A1996UJ05500014
J	Joklik, VK				Joklik, VK			The story of penicillin: The view from Oxford in the early 1950s	FASEB JOURNAL			English	Article											Joklik, VK (corresponding author), DUKE UNIV, MED CTR, DEPT MICROBIOL, DURHAM, NC 27710 USA.							Dubos RJ, 1939, J EXP MED, V70, P1, DOI 10.1084/jem.70.1.11; Epstein LA, 1940, BRIT J EXP PATHOL, V21, P339; Fleming A, 1929, BRIT J EXP PATHOL, V10, P226; Goldsworthy NE, 1930, BRIT J EXP PATHOL, V11, P192; Hobby G., 1985, PENICILLIN M CHALLEN; Macfarlane G., 1979, H FLOREY MAKING GREA; WILLIAMS TI, 1984, H FLOREY PENICILLIN	7	5	6	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1996	10	4					525	528		10.1096/fasebj.10.4.8647352	http://dx.doi.org/10.1096/fasebj.10.4.8647352			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UE557	8647352				2022-12-28	WOS:A1996UE55700017
J	Sommerville, J; Ladomery, M				Sommerville, J; Ladomery, M			Masking of mRNA by Y-box proteins	FASEB JOURNAL			English	Review						Y-box promoter elements; polypyrimidine tracts stored mRNA; RNA-binding proteins; beta-barrel structures	RNA-BINDING-PROTEINS; MESSENGER-RIBONUCLEOPROTEIN PARTICLES; OOCYTE-SPECIFIC PROTEINS; COLD-SHOCK PROTEIN; XENOPUS-OOCYTES; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; TRANSLATION; LAEVIS; DOMAIN	The Y-box proteins are defined by their ability to bind to Y-box promoter elements and to help regulate transcription of a wide variety of genes. However, Y-box proteins are also identified as abundant proteins in the cytoplasm of germ cells, where they are found bound to stored mRNA molecules. Binding of Y-box proteins to mRNA sequences, both in vitro and in vivo, has been shown to effect their translational repression (''masking''). Here we discuss the ability of Y box proteins to recognize different nucleic acid structures and to become involved in regulation of both transcription and translation.			Sommerville, J (corresponding author), UNIV ST ANDREWS,SCH BIOL & MED SCI,BUTE MED BLDG,ST ANDREWS KY16 9TS,FIFE,SCOTLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BOUVET P, 1995, IN PRESS J BIOL CHEM; BRADDOCK M, 1990, CELL, V62, P1123, DOI 10.1016/0092-8674(90)90389-V; BRADDOCK M, 1994, NUCLEIC ACIDS RES, V22, P5255, DOI 10.1093/nar/22.24.5255; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; CUMMINGS A, 1988, J CELL BIOL, V107, P45, DOI 10.1083/jcb.107.1.45; CUMMINGS A, 1989, BIOCHIM BIOPHYS ACTA, V1014, P319, DOI 10.1016/0167-4889(89)90229-2; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DARNBROUGH CH, 1981, EUR J BIOCHEM, V113, P415, DOI 10.1111/j.1432-1033.1981.tb05081.x; DESCHAMPS S, 1992, J BIOL CHEM, V267, P13799; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; DONIGER J, 1992, NEW BIOL, V4, P389; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; GOLDEN BL, 1993, BIOCHEMISTRY-US, V32, P12812, DOI 10.1021/bi00210a033; GUNKEL N, 1995, NUCLEIC ACIDS RES, V23, P405, DOI 10.1093/nar/23.3.405; GURDON JB, 1971, NATURE, V233, P177, DOI 10.1038/233177a0; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HORWITZ EM, 1994, J BIOL CHEM, V269, P14130; ITO K, 1994, NUCLEIC ACIDS RES, V22, P2036, DOI 10.1093/nar/22.11.2036; JACQUEMINSABLON H, 1994, NUCLEIC ACIDS RES, V22, P2643, DOI 10.1093/nar/22.13.2643; JONES PG, 1992, J BACTERIOL, V174, P5798, DOI 10.1128/jb.174.18.5798-5802.1992; KANDALA JC, 1994, VIROLOGY, V198, P514, DOI 10.1006/viro.1994.1062; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KICK D, 1987, NUCLEIC ACIDS RES, V15, P4099, DOI 10.1093/nar/15.10.4099; KINNIBURGH AJ, 1994, GENE, V149, P93, DOI 10.1016/0378-1119(94)90416-2; KLEENE K, 1995, IN PRESS MOL REPROD; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; KWON YK, 1993, DEV BIOL, V158, P90, DOI 10.1006/dbio.1993.1170; LADOMERY M, 1994, NUCLEIC ACIDS RES, V22, P5582, DOI 10.1093/nar/22.25.5582; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; LATEANA A, 1991, P NATL ACAD SCI USA, V88, P10907, DOI 10.1073/pnas.88.23.10907; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MARELLO K, 1992, NUCLEIC ACIDS RES, V20, P5593, DOI 10.1093/nar/20.21.5593; MINICH WB, 1993, EUR J BIOCHEM, V212, P633, DOI 10.1111/j.1432-1033.1993.tb17701.x; MORGAN R, 1993, NUCLEIC ACIDS RES, V21, P4615, DOI 10.1093/nar/21.19.4615; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; MURRAY MT, 1991, J CELL BIOL, V112, P1, DOI 10.1083/jcb.112.1.1; MURRAY MT, 1994, BIOCHEMISTRY-US, V33, P13910, DOI 10.1021/bi00250a046; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; NEWKIRK K, 1994, P NATL ACAD SCI USA, V91, P5114, DOI 10.1073/pnas.91.11.5114; OBOKATA J, 1991, PLANT MOL BIOL, V17, P953, DOI 10.1007/BF00037080; RANJAN M, 1993, GENE DEV, V7, P1725, DOI 10.1101/gad.7.9.1725; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; SCHINDELIN H, 1994, P NATL ACAD SCI USA, V91, P5119, DOI 10.1073/pnas.91.11.5119; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHNUCHEL A, 1993, NATURE, V364, P169, DOI 10.1038/364169a0; SCHRODER K, 1995, MOL MICROBIOL, V16, P699, DOI 10.1111/j.1365-2958.1995.tb02431.x; SKEHEL PA, 1994, GENE, V145, P231, DOI 10.1016/0378-1119(94)90011-6; SOMMERVILLE J, 1992, BIOESSAYS, V14, P337, DOI 10.1002/bies.950140509; Sommerville J, 1990, J Reprod Fertil Suppl, V42, P225; SOMMERVILLE J, 1993, J CELL BIOL, V120, P227; SOMMERVILLE J, 1980, CELL NUCLEUS, V8, P1; SPIRIN AS, 1994, MOL REPROD DEV, V38, P107, DOI 10.1002/mrd.1080380117; SWIDERSKI RE, 1988, DEV BIOL, V128, P349, DOI 10.1016/0012-1606(88)90297-7; TAFURI SR, 1993, J BIOL CHEM, V268, P12213; TAFURI SR, 1993, J BIOL CHEM, V268, P24255; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TAFURI SR, 1992, NEW BIOL, V4, P1; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; WU ZG, 1991, J CELL BIOL, V113, P465, DOI 10.1083/jcb.113.3.465; ZOU YM, 1995, MOL CELL BIOL, V15, P2972	64	103	106	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1996	10	4					435	443		10.1096/fasebj.10.4.8647342	http://dx.doi.org/10.1096/fasebj.10.4.8647342			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UE557	8647342				2022-12-28	WOS:A1996UE55700007
J	Creighton, TE; Darby, NJ; Kemmink, J				Creighton, TE; Darby, NJ; Kemmink, J			The roles of partly folded intermediates in protein folding	FASEB JOURNAL			English	Review						BPTI; cooperativity; disulfide bonds; kinetic intermediates	PANCREATIC TRYPSIN-INHIBITOR; NUCLEAR-MAGNETIC-RESONANCE; DISULFIDE BONDS; KINETIC ROLE; PATHWAY; TRANSITION; BPTI; H-1; CONFORMATION; STATE	Proteins can fold very rapidly, undoubtedly because they do not do so simply by random searching. The stable, partly folded species that can be detected during protein refolding are, however, of uncertain kinetic significance, The available kinetic evidence indicates that the intermediates that are most responsible for the rapidity of folding are extremely unstable and not populated detectably; they are less extreme versions of the transition state for folding, Protein folding is most readily studied when it is coupled to disulfide formation, which has the advantages that the intermediates can be characterized in detail and their kinetic roles determined unambiguously, The most important aspects of the disulfide folding pathway of BPTI are understood to at least a first approximation, and several other protein disulfide folding pathways are known in outline, These pathways demonstrate that disulfide folding is not intrinsically different from that not involving disulfide formation, Pastry folded conformations can increase the rate of folding somewhat by causing productive disulfide bonds to be populated preferentially, bit the most important folding intermediates are not detectable. The essence of folding is to build up the cooperativity between the individual interactions that is necessary for a stable conformation.			Creighton, TE (corresponding author), EUROPEAN MOLEC BIOL LAB,POSTFACH 102209,D-69012 HEIDELBERG,GERMANY.							BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BALDWIN RL, 1995, J BIOMOL NMR, V5, P103; CREIGHTON T, 1995, PHILOS T ROY SOC B, V348, P5, DOI 10.1098/rstb.1995.0039; Creighton T E, 1986, Methods Enzymol, V131, P83; CREIGHTON TE, 1994, BIOCHEMISTRY-US, V33, P1534, DOI 10.1021/bi00172a033; CREIGHTON TE, 1988, P NATL ACAD SCI USA, V85, P5082, DOI 10.1073/pnas.85.14.5082; CREIGHTON TE, 1981, J MOL BIOL, V151, P211, DOI 10.1016/0022-2836(81)90230-8; CREIGHTON TE, 1994, J MOL BIOL, V242, P670, DOI 10.1006/jmbi.1994.1616; CREIGHTON TE, 1980, J MOL BIOL, V142, P43, DOI 10.1016/0022-2836(80)90205-3; CREIGHTON TE, 1977, J MOL BIOL, V113, P275, DOI 10.1016/0022-2836(77)90142-5; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1993, J MOL BIOL, V232, P1176, DOI 10.1006/jmbi.1993.1470; CREIGHTON TE, 1977, J MOL BIOL, V113, P313, DOI 10.1016/0022-2836(77)90144-9; CREIGHTON TE, 1995, CURR BIOL, V5, P353, DOI 10.1016/S0960-9822(95)00070-4; CREIGHTON TE, 1994, NAT STRUCT BIOL, V1, P135, DOI 10.1038/nsb0394-135; CREIGHTON TE, 1992, NATURE, V356, P194, DOI 10.1038/356194a0; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P162; CREIGHTON TE, 1977, J MOL BIOL, V96, P777; Creighton Thomas E., 1992, P301; DADLEZ M, 1995, NAT STRUCT BIOL, V2, P674, DOI 10.1038/nsb0895-674; DARBY NJ, 1995, J MOL BIOL, V249, P463, DOI 10.1006/jmbi.1995.0309; DARBY NJ, 1993, J MOL BIOL, V232, P873, DOI 10.1006/jmbi.1993.1437; EIGENBROT C, 1990, PROTEIN ENG, V3, P591, DOI 10.1093/protein/3.7.591; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3677, DOI 10.1021/bi00065a022; GOLDENBERG DP, 1993, PROTEINS, V15, P322, DOI 10.1002/prot.340150309; HUANG GS, 1995, P NATL ACAD SCI USA, V92, P6878, DOI 10.1073/pnas.92.15.6878; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; ITTAH V, 1995, BIOCHEMISTRY-US, V34, P4493, DOI 10.1021/bi00013a042; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; KEMMINK J, 1993, J MOL BIOL, V234, P861, DOI 10.1006/jmbi.1993.1631; KIPPEN AD, 1995, BIOCHEMISTRY-US, V34, P1464, DOI 10.1021/bi00004a042; Leventhal C, 1969, MOSSBAUER SPECTROSCO, P22; MATOUSCHEK A, 1994, PROTEIN ENG, V7, P1089, DOI 10.1093/protein/7.9.1089; MENDOZA JA, 1994, BIOCHEMISTRY-US, V33, P1142; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; OTZEN DE, 1994, P NATL ACAD SCI USA, V91, P10422, DOI 10.1073/pnas.91.22.10422; PENG ZY, 1994, BIOCHEMISTRY-US, V33, P2136, DOI 10.1021/bi00174a021; PENG ZY, 1995, BIOCHEMISTRY-US, V34, P3248, DOI 10.1021/bi00010a014; SEGAWA SI, 1984, BIOPOLYMERS, V23, P2473; SNYDER GH, 1981, BIOCHEMISTRY-US, V20, P6509, DOI 10.1021/bi00526a001; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; STATES DJ, 1984, J MOL BIOL, V174, P411, DOI 10.1016/0022-2836(84)90345-0; VANMIERLO CPM, 1994, J MOL BIOL, V235, P1044, DOI 10.1006/jmbi.1994.1056; VANMIERLO CPM, 1991, J MOL BIOL, V222, P373, DOI 10.1016/0022-2836(91)90217-T; VANMIERLO CPM, 1993, J MOL BIOL, V229, P1125, DOI 10.1006/jmbi.1993.1108; VANMIERLO CPM, 1991, J MOL BIOL, V222, P353, DOI 10.1016/0022-2836(91)90216-S; VINCENT JP, 1971, EUR J BIOCHEM, V23, P401, DOI 10.1111/j.1432-1033.1971.tb01634.x; WEISSMAN JS, 1992, P NATL ACAD SCI USA, V89, P9900, DOI 10.1073/pnas.89.20.9900; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WU LC, 1995, NAT STRUCT BIOL, V2, P281, DOI 10.1038/nsb0495-281; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P5202, DOI 10.1021/bi00183a025; ZHANG JX, 1993, BIOCHEMISTRY-US, V32, P14075, DOI 10.1021/bi00214a001	55	118	121	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1996	10	1					110	118		10.1096/fasebj.10.1.8566531	http://dx.doi.org/10.1096/fasebj.10.1.8566531			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566531				2022-12-28	WOS:A1996TR32800015
J	GomezGallego, F; GarridoPertierra, A; Mason, PJ; Bautista, JM				GomezGallego, F; GarridoPertierra, A; Mason, PJ; Bautista, JM			Unproductive folding of the human G6PD-deficient variant A(-)	FASEB JOURNAL			English	Article						G6PD deficiency; protein folding; protein disulfide isomerase; erythrocytes dimerization	PROTEIN DISULFIDE-ISOMERASE; HUMAN GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; CYSTIC-FIBROSIS; MUTATIONS; ENZYME	Human glucose-6-phosphate dehydrogenase (G6PD) deficiency almost invariably results from the presence of missense mutations in the X-Linked gene encoding G6PD. The common African deficient variant G6PD A(-) differs from the normal G6PD B by two amino acid substitutions. Only one of these mutations is found on its own, resulting in the nondeficient variant G6PD A, Deficiency is always associated with decreased G6PD activity in red cells, leading to a variety of clinical manifestations, A group of deficient variants, including A(-), have near-normal affinity for the substrates G6P and NADP. In these cases, deficiency is caused by a decreased number of catalytically active molecules per cell due to intracellular instability of the mutated G6PD, although the mechanism for this in vivo instability is unknown. Here we report that in vitro folding of the A(-) variant mainly renders partially folded polypeptides that do not undergo the dimerization required for activity, Under the same conditions, the nondeficient variants B and A undergo folding to produce active dimers with normal mobilities in native gels and normal kinetic properties. The loss of intrinsic folding determinants in the A(-) variant may underlie the mechanism of its in vivo instability.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HAEMATOL,LONDON W12 0NN,ENGLAND; UNIV COMPLUTENSE MADRID,FAC VET,DEPT BIOQUIM & BIOL MOLEC 4,E-28040 MADRID,SPAIN	Imperial College London; Complutense University of Madrid			Bautista, José M./B-7899-2013; Mason, Philip J/B-1087-2008; Gomez-Gallego, Felix/H-6925-2013	Bautista, José M./0000-0001-8926-881X; Gomez-Gallego, Felix/0000-0002-1968-1761				BABALOLA AOC, 1972, P NATL ACAD SCI USA, V69, P946; BAHALOLA AOG, 1976, J BIOL CHEM, V251, P2992; BAUTISTA JM, 1992, BIOCHIM BIOPHYS ACTA, V1119, P74, DOI 10.1016/0167-4838(92)90237-8; CAI H, 1994, J BIOL CHEM, V269, P24550; CRAIG S, 1985, J MOL BIOL, V185, P681, DOI 10.1016/0022-2836(85)90053-1; CREIGHTON TE, 1977, J MOL BIOL, V113, P329, DOI 10.1016/0022-2836(77)90145-0; GOMEZGALLEGO F, 1995, BIOCHEM SOC T, V23, pS82, DOI 10.1042/bst023082s; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; HIRONO A, 1988, P NATL ACAD SCI USA, V85, P3951, DOI 10.1073/pnas.85.11.3951; LUZZATTO L, 1971, BIOCHEMISTRY-US, V10, P420, DOI 10.1021/bi00779a010; MATOUSCHEK A, 1993, P NATL ACAD SCI USA, V90, P7814, DOI 10.1073/pnas.90.16.7814; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; PIOMELLI S, 1968, J CLIN INVEST, V47, P940, DOI 10.1172/JCI105786; PUG A, 1994, J BI OL CHEM, V269, P7764; RATTAZZI MC, 1967, NATURE, V213, P79, DOI 10.1038/213079b0; ROWLAND P, 1994, STRUCTURE, V2, P1073, DOI 10.1016/S0969-2126(94)00110-3; RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0; THOMAS PJ, 1992, FEBS LETT, V312, P7, DOI 10.1016/0014-5793(92)81399-7; TOWN M, 1992, HUM MOL GENET, V1, P171, DOI 10.1093/hmg/1.3.171; VULLIAMY T, 1992, TRENDS GENET, V8, P128; VULLIAMY TJ, 1988, P NATL ACAD SCI USA, V85, P5171, DOI 10.1073/pnas.85.14.5171; WANG CC, 1993, FASEB J, V7, P1515, DOI 10.1096/fasebj.7.15.7903263; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; YU MH, 1995, NAT STRUCT BIOL, V2, P363, DOI 10.1038/nsb0595-363	25	28	28	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1996	10	1					153	158		10.1096/fasebj.10.1.8566536	http://dx.doi.org/10.1096/fasebj.10.1.8566536			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566536				2022-12-28	WOS:A1996TR32800020
J	KIM, RY; WISTOW, GJ				KIM, RY; WISTOW, GJ			EXPRESSION OF THE DUCK ALPHA-ENOLASE/TAU-CRYSTALLIN GENE IN TRANSGENIC MICE	FASEB JOURNAL			English	Article						LENS; CRYSTALLIN; ENOLASE; EVOLUTION	LENS CRYSTALLINS; TAU-CRYSTALLIN; PROTEIN SUPERFAMILY; STRUCTURAL PROTEIN; GAMMA-CRYSTALLIN; TURTLE LENS; RECRUITMENT; EVOLUTION; ENZYME; PURIFICATION	In many vertebrates, metabolic enzymes have been directly recruited to an additional structural role as crystallins in the eye lens. In some species the glycolytic enzyme alpha-enolase. (AlphaENO) attains high concentrations in the lens, as tau-crystallin (tauCRY). A line of transgenic mice was constructed containing the entire duck alphaENO/tauCRY gene with 5'- and 3-flanking regions and all introns. Full-sized duck alphaENO mRNA was expressed in the transgenic mice with the same pattern as the endogenous mouse alphaENO isozyme. Although there was no evidence for tissue preference, the concentration of enolase increased markedly in transgenic lens as well as in other tissues. In spite of this, transgenic lenses were transparent and the animals were normal in appearance. The increase in enolase levels in the transgenic lens mimics the stepped increase that might occur in the early stages of enzyme crystallin recruitment. These results demonstrate that lens transparency is sufficiently robust to be refractory to some increase in metabolic enzyme concentration without the need for compensatory adaptation.	NEI,MOLEC & DEV BIOL LAB,MOLEC STRUCT & FUNCT SECT,BLDG 6,RM 222,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)								Battey, 1986, BASIC METHODS MOL BI; BERMAN ER, 1991, PERSPECTIVES VISION; Bloemendal H., 1981, MOL CELLULAR BIOL EY; CARPER D, 1987, FEBS LETT, V220, P209, DOI 10.1016/0014-5793(87)80905-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; De Jong W.W., 1981, MOL CELLULAR BIOL EY, P221, DOI DOI 10.1146/ANNUREV.ECOLSYS.33.020602.095451; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; FARNSWORTH PN, 1990, CURR EYE RES, V9, P819, DOI 10.3109/02713689008999554; GIALLONGO A, 1990, EUR J BIOCHEM, V190, P567, DOI 10.1111/j.1432-1033.1990.tb15611.x; GORING DR, 1987, SCIENCE, V235, P456, DOI 10.1126/science.3099390; Harding JJ, 1984, EYE B, V1b, P207; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; KAGHAD M, 1990, NUCLEIC ACIDS RES, V18, P3638, DOI 10.1093/nar/18.12.3638; KIM RY, 1991, GENE, V103, P193, DOI 10.1016/0378-1119(91)90273-E; OVERBEEK PA, 1985, P NATL ACAD SCI USA, V82, P7815, DOI 10.1073/pnas.82.23.7815; PIATIGORSKY J, 1991, SCIENCE, V252, P1078, DOI 10.1126/science.252.5009.1078; RUDNER G, 1990, CURR EYE RES, V9, P139, DOI 10.3109/02713689008995200; STAPEL SO, 1983, FEBS LETT, V162, P305, DOI 10.1016/0014-5793(83)80777-7; TANAKA M, 1985, J BIOCHEM-TOKYO, V98, P1527, DOI 10.1093/oxfordjournals.jbchem.a135421; TODHUNTER JA, 1979, METHOD ENZYMOL, V63, P388; WARWAR RE, 1992, INVEST OPHTH VIS SCI, V33, P794; WESTHEAD EW, 1967, METHOD ENZYMOL, V9, P670; WILLIAMS LA, 1985, EXP EYE RES, V40, P741, DOI 10.1016/0014-4835(85)90143-5; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; WISTOW G, 1990, P NATL ACAD SCI USA, V87, P6277, DOI 10.1073/pnas.87.16.6277; WISTOW G, 1990, J MOL EVOL, V30, P140, DOI 10.1007/BF02099940; WISTOW G, 1985, NATURE, V315, P771, DOI 10.1038/315771a0; WISTOW G, 1991, J MOL EVOL, V32, P262, DOI 10.1007/BF02342749; WISTOW GJ, 1987, NATURE, V326, P622, DOI 10.1038/326622a0; WISTOW GJ, 1988, J CELL BIOL, V107, P2729, DOI 10.1083/jcb.107.6.2729; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; Wold F., 1971, ENZYMES, P499; ZIESKE JD, 1991, DEV BIOL, V151, P18; ZOMZELYNEURATH CE, 1983, HDB NEUROCHEMISTRY, V4, P403	35	8	8	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1993	7	5					464	469		10.1096/fasebj.7.5.8462788	http://dx.doi.org/10.1096/fasebj.7.5.8462788			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KV351	8462788				2022-12-28	WOS:A1993KV35100011
J	KORETZKY, GA				KORETZKY, GA			ROLE OF THE CD45 TYROSINE PHOSPHATASE IN SIGNAL TRANSDUCTION IN THE IMMUNE-SYSTEM	FASEB JOURNAL			English	Review						TYROSINE PHOSPHATASE; SIGNAL TRANSDUCTION; CD45; T-CELL RECEPTOR; TYROSINE KINASE	CELL ANTIGEN RECEPTOR; LEUKOCYTE-COMMON ANTIGEN; HUMAN T-CELLS; PHOSPHOLIPASE-C ACTIVATION; PROTEIN-KINASE P56LCK; HUMAN LYMPHOCYTES-T; MONOCLONAL-ANTIBODIES; ISOFORM EXPRESSION; B-CELLS; PHOSPHORYLATION	CD45, a family of hematopoietic cell specific surface antigens, is the best characterized protein tyrosine phosphatase described to date. Considerable evidence from a number of laboratories suggests that surface expression of this molecule is required for normal signaling events to occur in T lymphocytes, B lymphocytes, and natural killer cells. In this paper, data supporting this contention are reviewed and a model proposing how CD45 may exert its regulatory function on signal transduction via the T cell antigen receptor is presented.	UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa	KORETZKY, GA (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,540 EMRB,IOWA CITY,IA 52242, USA.		Koretzky, Gary/AAU-5381-2021		NCI NIH HHS [R01 CA56050-01, R29 CA 56843-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056050, R29CA056843] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; AUTERO M, 1987, EUR J IMMUNOL, V17, P1503, DOI 10.1002/eji.1830171018; BELL G M, 1991, Arthritis and Rheumatism, V34, pS79; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIRKELAND ML, 1989, P NATL ACAD SCI USA, V86, P6734, DOI 10.1073/pnas.86.17.6734; BOTTOMLY K, 1989, EUR J IMMUNOL, V19, P617, DOI 10.1002/eji.1830190407; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2314; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHO HJ, 1992, BIOCHEMISTRY-US, V31, P133, DOI 10.1021/bi00116a019; COOK RG, 1987, J IMMUNOL, V139, P991; DEANS JP, 1992, EUR J IMMUNOL, V22, P661, DOI 10.1002/eji.1830220308; DIANZANI U, 1992, EUR J IMMUNOL, V22, P365, DOI 10.1002/eji.1830220212; DIANZANI U, 1990, EUR J IMMUNOL, V20, P2249, DOI 10.1002/eji.1830201014; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOLDMAN SJ, 1992, J BIOL CHEM, V267, P6197; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HARVATH L, 1991, J IMMUNOL, V146, P949; HASEGAWA K, 1990, INT IMMUNOL, V2, P367, DOI 10.1093/intimm/2.4.367; HSI ED, 1989, J BIOL CHEM, V264, P10836; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KIENER PA, 1989, J IMMUNOL, V143, P23; KORETZKY GA, 1992, J IMMUNOL, V149, P1138; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LEDBETTER JA, 1991, J IMMUNOL, V146, P1577; LEFRANCOIS L, 1985, J IMMUNOL, V135, P374; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MITTLER RS, 1991, J IMMUNOL, V147, P3434; MITTLER RS, 1987, J IMMUNOL, V138, P3159; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; MUSTELIN T, 1990, ONCOGENE, V5, P809; NEWMAN W, 1982, P NATL ACAD SCI-BIOL, V79, P3858, DOI 10.1073/pnas.79.12.3858; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PATEL MD, 1987, J BIOL CHEM, V262, P5831; PEYRON JF, 1991, INT IMMUNOL, V3, P1357, DOI 10.1093/intimm/3.12.1357; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SCHRAVEN B, 1990, NATURE, V345, P71, DOI 10.1038/345071a0; SCHRAVEN B, 1992, EUR J IMMUNOL, V22, P1857, DOI 10.1002/eji.1830220727; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SMELAND EB, 1990, SCAND J IMMUNOL, V31, P583, DOI 10.1111/j.1365-3083.1990.tb02809.x; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; STRAUS DB, 1992, CELL, V70, P583; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; THOMAS M, 1989, ANNU REV IMMUNOL, P339; THOMAS ML, 1988, IMMUNOL TODAY, V9, P320, DOI 10.1016/0167-5699(88)91326-6; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TROWBRIDGE IS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P46, DOI 10.1016/0167-4889(91)90043-W; VALENTINE MA, 1991, EUR J IMMUNOL, V21, P913, DOI 10.1002/eji.1830210409; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835; WEAVER CT, 1991, MOL CELL BIOL, V11, P4415, DOI 10.1128/MCB.11.9.4415; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WIRTHMUELLER U, 1992, J EXP MED, V175, P1381, DOI 10.1084/jem.175.5.1381; YAKURA H, 1983, J EXP MED, V157, P1077, DOI 10.1084/jem.157.4.1077; YAMADA A, 1990, EUR J IMMUNOL, V20, P1655, DOI 10.1002/eji.1830200806; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836	82	71	83	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1993	7	5					420	426		10.1096/fasebj.7.5.8462784	http://dx.doi.org/10.1096/fasebj.7.5.8462784			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KV351	8462784				2022-12-28	WOS:A1993KV35100006
J	Lombardi, AM; Moller, D; Loizeau, M; Girard, J; Leturque, A				Lombardi, AM; Moller, D; Loizeau, M; Girard, J; Leturque, A			Phenotype of transgenic mice overexpressing GLUT4 and hexokinase II in muscle	FASEB JOURNAL			English	Article						insulin stimulated level; skeletal muscle; insulin tolerance; hyperglycemia; hypoinsulinemia; glucose utilization index; gluteal muscle	RATE-LIMITING STEPS; GLUCOSE-TRANSPORT; SKELETAL-MUSCLE; INSULIN ACTION; ADIPOSE-TISSUE; MESSENGER-RNA; GENE; METABOLISM; PROTEIN; PHOSPHORYLATION	To optimize glucose utilization, double transgenic mice were created by crossing mice overexpressing glucose transporter GLUT4 with mice overexpressing hexokinase (HKII) in muscle. Transgenic mice overexpressing GLUT4 alone have exhibited improvements in glucose tolerance and insulin action. In vitro studies of hexose uptake in solens muscle from transgenic mice suggested that GLUT4 was limiting the glucose flux except at high glucose concentration, where hexokinase became the limiting step. In vivo, glucose tolerance was similar in GLUT4 and GLUT4/HKII mice, although stimulated plasma insulin values were significantly lower in the latter group. Insulin tolerance tests performed in diabetic GLUT4 vs. diabetic GLUT4/HKII transgenic mice yielded identical results. Again, endogenous insulin in GLUT4/HKII mice during a mild hyperglycemic clamp was stimulated by only two-vs. fourfold in GLUT4 mice. Although the overexpression of HKII alone resulted in increased glucose utilization in several muscles, the overexpression of GLUT4 plus HKII did not augment basal or stimulated in vivo glucose utilization compared to GLUT4 overexpression. In conclusion, GLUT4 is rate limiting for muscle glucose utilization but HKII might be important under hyperglycemia, The addition of HKII to GLUT4 overexpression is not sufficient to further augment glucose tolerance or insulin action, In GLUT4/HKII double transgenic mice, glucose clearance is tempered by a low insulin stimulated level.	CTR RECH ENDOCRINOL MOL & DEV,CNRS,UPR 1511,F-92190 MEUDON,FRANCE; UNIV PADUA,INST MED SEMEIOT,I-35123 PADUA,ITALY; MERCK & CO INC,RAHWAY,NJ 07065	Centre National de la Recherche Scientifique (CNRS); University of Padua; Merck & Company			Leturque, Armelle/Q-9437-2017	Leturque, Armelle/0000-0001-6570-6387				BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; Chang PY, 1996, J BIOL CHEM, V271, P14834, DOI 10.1074/jbc.271.25.14834; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CONCORDET JP, 1993, MOL CELL BIOL, V13, P9, DOI 10.1128/MCB.13.1.9; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; FERRE P, 1986, BIOCHEM J, V233, P249, DOI 10.1042/bj2330249; HENDERSON M, 1961, J BIOL CHEM, V236, P273; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; Katzen H M, 1967, Adv Enzyme Regul, V5, P335, DOI 10.1016/0065-2571(67)90025-8; KATZEN HM, 1966, BIOCHEM BIOPH RES CO, V24, P531, DOI 10.1016/0006-291X(66)90352-4; KUBO K, 1986, AM J PHYSIOL, V250, pE100, DOI 10.1152/ajpendo.1986.250.1.E100; LETURQUE A, 1981, BIOCHEM J, V200, P181, DOI 10.1042/bj2000181; Leturque A, 1996, DIABETES, V45, P23, DOI 10.2337/diabetes.45.1.23; MANCHESTER J, 1994, AM J PHYSIOL, V266, pE326, DOI 10.1152/ajpendo.1994.266.3.E326; Osawa H, 1996, J BIOL CHEM, V271, P16690, DOI 10.1074/jbc.271.28.16690; POSTIC C, 1993, DIABETES, V42, P922, DOI 10.2337/diabetes.42.6.922; PRINTZ RL, 1993, J BIOL CHEM, V268, P5209; SOMOGYI M, 1945, J BIOL CHEM, V160, P69; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; Tsao TS, 1996, J BIOL CHEM, V271, P14959, DOI 10.1074/jbc.271.25.14959; Tsao TS, 1996, DIABETES, V45, P28, DOI 10.2337/diabetes.45.1.28; ZIEL FH, 1988, DIABETES, V37, P885, DOI 10.2337/diabetes.37.7.885	25	25	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1997	11	13					1137	1144		10.1096/fasebj.11.13.9367348	http://dx.doi.org/10.1096/fasebj.11.13.9367348			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367348				2022-12-28	WOS:A1997YE98300011
J	Miller, RA; Chrisp, C; Galecki, A				Miller, RA; Chrisp, C; Galecki, A			CD4 memory T cell levels predict life span in genetically heterogeneous mice	FASEB JOURNAL			English	Article						T lymphocytes; memory T cells; aging; mice; longevity	PERIPHERAL-BLOOD; P-GLYCOPROTEIN; SUBSETS; AGE; LYMPHOCYTES; EXPRESSION; NUMBERS	Aging leads to changes in the relative proportions of several functionally distinct T cell subsets, including increases in the proportions of memory cells in the CD4 and CD8 subsets and in the proportion of T cells expressing the multiple-drug resistance pump P-glycoprotein. To see whether individual differences in T cell subset levels predict Life span, we measured the levels of five age-sensitive T cell subsets, at 8 and again at 18 months of age, in the peripheral blood of genetically heterogeneous mice bred as the progeny of CBGF1 females and C3D2F1 males. The strongest immunological predictor of Life span in univariate regression analyses was the proportion of CD4 memory cells measured at 18 months of age (P=0.003). CD4 memory cell levels remained strongly correlated with life span (P<0.0003) in a multiple regression analysis after adjustment for sex. The proportion of CD4 cells expressing P-glycoprotein was also correlated with life span (P<0.01), but only in male mice. Weaker relationships were observed between life span and 8-month tests of CD8 memory and CD8 P-glycoprotein levels, for CD4 naive cells at 18 months, and for the change in CD4 naive cells between 8 and 18 months of age; these were, however, near the margin of statistical significance and could reflect chance relationships. The relationship between CD4 memory cell levels and life span was similarly strong regardless of the cause of death in mice whose death was attributable to lymphoma, fibrosarcoma, mammary carcinoma, and other forms of terminal pathology. Additional work is needed to discriminate between two hypotheses: 1) that high levels of CD4 memory cell themselves predispose to disease and early death, particularly from neoplasia; or 2) that accumulation of CD4 memory cells is a biomarker of some underlying process process-perhaps accelerated aging-that itself leads to early mortality.	UNIV MICHIGAN,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,UNIT LAB ANIM MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,INST GERONTOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,ANN ARBOR DVA MED CTR,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE ON AGING [R01AG011687, P60AG008808, R01AG011067, P30AG008808] Funding Source: NIH RePORTER; NIA NIH HHS [AG08808, AG11067, AG11687] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAKER GT, 1988, EXP GERONTOL, V23, P223, DOI 10.1016/0531-5565(88)90025-3; Bining N, 1997, J GERONTOL A-BIOL, V52, pB137, DOI 10.1093/gerona/52A.3.B137; BOERSMA WJA, 1985, CELL IMMUNOL, V93, P417, DOI 10.1016/0008-8749(85)90146-7; Bronson R., 1990, GENETIC EFFECTS AGIN, VII, P279; Chrisp CE, 1996, VET PATHOL, V33, P735, DOI 10.1177/030098589603300620; COSTA PT, 1988, ARCH GERONTOL GERIAT, V7, P211, DOI 10.1016/0167-4943(88)90003-9; COSTA PT, 1995, HDB PHYSL 11; COVELLI V, 1989, J IMMUNOL, V142, P1224; ERNST DN, 1990, J IMMUNOL, V145, P1295; ERSHLER WB, 1993, J GERONTOL, V48, pB3, DOI 10.1093/geronj/48.1.B3; EVERITT JI, 1988, LAB ANIM SCI, V38, P609; FERGUSON FG, 1995, J GERONTOL A-BIOL, V50, pB378, DOI 10.1093/gerona/50A.6.B378; FLURKEY K, 1992, EUR J IMMUNOL, V22, P931, DOI 10.1002/eji.1830220408; GROSSMANN A, 1991, CELL IMMUNOL, V135, P118, DOI 10.1016/0008-8749(91)90259-E; HIROKAWA K, 1989, MECH AGEING DEV, V49, P49, DOI 10.1016/0047-6374(89)90067-5; LERNER A, 1989, EUR J IMMUNOL, V19, P977, DOI 10.1002/eji.1830190604; MASORO EJ, 1995, HDB PHYSL 11; MILLER RA, 1994, J GERONTOL, V49, pB255, DOI 10.1093/geronj/49.6.B255; MILLER RA, 1997, IN PRESS MECH AGEING; MILLER RA, 1996, J GERONTOL A-BIOL, V52, pB39; Miller Richard A., 1995, P555; MURASKO D M, 1988, Aging Immunology and Infectious Disease, V1, P1; NAKAMURA E, 1994, EXP GERONTOL, V29, P151, DOI 10.1016/0531-5565(94)90048-5; PILARSKI LM, 1991, J IMMUNOL, V147, P830; RAO CR, 1973, LINEAR STATISTICAL I; ROBERTST.IC, 1974, LANCET, V2, P368; SERRA HM, 1988, J IMMUNOL, V140, P1435; Short R, 1997, J GERONTOL A-BIOL, V52, pB26, DOI 10.1093/gerona/52A.1.B26; TUFFERY AA, 1966, J PATHOL BACTERIOL, V91, P301, DOI 10.1002/path.1700910203; UTSUYAMA M, 1992, MECH AGEING DEV, V63, P57, DOI 10.1016/0047-6374(92)90016-7; WAYNE SJ, 1990, J GERONTOL, V45, pM45, DOI 10.1093/geronj/45.2.M45; WITKOWSKI JM, 1994, J IMMUNOL, V153, P658; WITKOWSKI JM, 1993, J IMMUNOL, V150, P1296	33	53	53	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1997	11	10					775	783		10.1096/fasebj.11.10.9271362	http://dx.doi.org/10.1096/fasebj.11.10.9271362			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XR105	9271362	Green Submitted			2022-12-28	WOS:A1997XR10500007
J	Pollack, R				Pollack, R			Hard days on the endless frontier	FASEB JOURNAL			English	Article; Proceedings Paper	George-Washington-University Symposium on Science in Crisis at the Millennium	SEP   19, 1996	WASHINGTON, DC	George Washington Univ							Pollack, R (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.							POLLACK, 1994, SIGNS LIFE LANGUAGE; POLLACK, IN PRESS ITS TIME SC	2	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1997	11	10					725	731		10.1096/fasebj.11.10.9271357	http://dx.doi.org/10.1096/fasebj.11.10.9271357			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XR105	9271357				2022-12-28	WOS:A1997XR10500002
J	Eschenhagen, T; Fink, C; Remmers, U; Scholz, H; Wattchow, J; Weil, J; Zimmerman, W; Dohmen, HH; Schafer, H; Bishopric, N; Wakatsuki, T; Elson, EL				Eschenhagen, T; Fink, C; Remmers, U; Scholz, H; Wattchow, J; Weil, J; Zimmerman, W; Dohmen, HH; Schafer, H; Bishopric, N; Wakatsuki, T; Elson, EL			Three-dimensional reconstitution of embryonic cardiomyocytes in a collagen matrix: a new heart muscle model system	FASEB JOURNAL			English	Article						heart; cell culture; reconstituted tissue; adenovirus; transgenic model	CELLS; TISSUE; GEL; FIBROBLASTS; EXPRESSION; PROTEIN; INVITRO	A method has been developed for culturing cardiac myocytes in a collagen matrix to produce a coherently contracting 3-dimensional model heart tissue that allows direct measurement of isometric contractile force. Embryonic chick cardiomyocytes were mixed with collagen solution and allowed to gel between two Velcro-coated glass tubes. During culture, the cardiomyocytes formed spontaneously beating cardiac myocyte-populated matrices (CMPMs) anchored at opposite ends to the Velcro-covered tubes through which they could be attached to a force measuring system. Immunohistochemistry and electron microscopy revealed a highly organized tissue-like structure of alpha-actin and alpha-tropomyosin-positive cardiac myocytes exhibiting typical cross-striation, sarcomeric myofilaments, intercalated discs, desmosomes, and tight junctions. Force measurements off paced or unpaced CMPMs were performed in organ baths after 6-11 days of cultivation and were stable for up to 24 h. Force increased with frequency between 0.8 and 2.0 Hz (positive ''staircase''), increasing rest length (Starling mechanism), and increasing extracellular calcium. The utility of this system as a test bed for genetic manipulation was demonstrated by infecting the CMPMs with a recombinant beta-galactosidase-carrying adenovirus. Transduction efficiency increased from about 5% (MOI 0.1) to about 50% (MOI 100). CMPMs display more physiological characteristics of intact heart tissue than monolayer cultures. This approach, simpler and faster than generation of transgenic animals, should allow functional consequences of genetic or pharmacological manipulation of cardiomyocytes in vitro to be studied under highly controlled conditions.	UNIV HAMBURG, KRANKENHAUS EPPENDORF, INST PATHOL, D-20246 HAMBURG, GERMANY; SRI INT, MENLO PK, CA 94025 USA; WASHINGTON UNIV, SCH MED, DEPT MOL BIOPHYS & BIOCHEM, ST LOUIS, MO 63110 USA	University of Hamburg; SRI International; Washington University (WUSTL)	Eschenhagen, T (corresponding author), UNIV HAMBURG, KRANKENHAUS EPPENDORF, ABT ALLGEMEINE PHARMAKOL, MARTINISTR 52, D-20246 HAMBURG, GERMANY.		Zimmermann, Wolfram-Hubertus H/I-6838-2012	Zimmermann, Wolfram-Hubertus H/0000-0003-1190-4040				ACSADI G, 1995, J MOL MED, V73, P165; ALLEN IS, 1988, AM J PHYSIOL, V255, pC51, DOI 10.1152/ajpcell.1988.255.1.C51; BORZAK S, 1991, AM J PHYSIOL, V260, pH884, DOI 10.1152/ajpheart.1991.260.3.H884; Bowditch H.P., 1871, BER SACHS GES AKAD W, V23, P652; CAVANAUGH MW, 1955, J EXP ZOOL, V128, P573, DOI 10.1002/jez.1401280312; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER G, 1987, ANNU REV PHYSIOL, V49, P501, DOI 10.1146/annurev.ph.49.030187.002441; EPPENBERGEREBERHARDT M, 1990, DEV BIOL, V139, P269, DOI 10.1016/0012-1606(90)90296-U; Eschenhagen T, 1996, BASIC RES CARDIOL, V91, P41, DOI 10.1007/BF00795361; Eschenhagen T, 1996, CIRCULATION, V93, P763, DOI 10.1161/01.CIR.93.4.763; FITZGERALD M, 1994, J MOL CELL CARDIOL, V26, P1261, DOI 10.1006/jmcc.1994.1145; GIBSON GJ, 1982, J CELL BIOL, V93, P767, DOI 10.1083/jcb.93.3.767; GOLDNER JACQUES, 1938, AMER JOUR PATH, V14, P237; HASENFUSS G, 1994, BRIT HEART J, V72, P10; KOLODNEY MS, 1993, J BIOL CHEM, V268, P23850; Komuro I, 1996, FASEB J, V10, P631, DOI 10.1096/fasebj.10.5.8621062; Matsumoto T, 1996, J BIOMECH ENG-T ASME, V118, P420, DOI 10.1115/1.2796026; MAUCH C, 1988, EXP CELL RES, V178, P493, DOI 10.1016/0014-4827(88)90417-X; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; ROCHA V, 1985, EXP CELL RES, V159, P201, DOI 10.1016/S0014-4827(85)80049-5; SOUREN JEM, 1992, IN VITRO CELL DEV-AN, V28A, P199; TERRACIO L, 1988, IN VITRO CELL DEV B, V24, P53; VANDENBURGH HH, 1988, IN VITRO CELL DEV B, V24, P166, DOI 10.1007/BF02623542; VANDENBURGH HH, 1994, ANN NY ACAD SCI, V752, P19; VINCAN E, 1995, J MOL CELL CARDIOL, V27, P2393, DOI 10.1016/S0022-2828(95)92127-3; ZIEGLER T, 1994, J CELL BIOCHEM, V56, P204, DOI 10.1002/jcb.240560215	27	448	476	1	41	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1997	11	8					683	694		10.1096/fasebj.11.8.9240969	http://dx.doi.org/10.1096/fasebj.11.8.9240969			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XN027	9240969				2022-12-28	WOS:A1997XN02700008
J	Keppler, D; Konig, J				Keppler, D; Konig, J			Expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAT) gene in liver	FASEB JOURNAL			English	Review						ABC transporters; conjugate transport; Dubin-Johnson syndrome; bile flow; apical membrane; ATPase	RESISTANCE-ASSOCIATED PROTEIN; PLASMA-MEMBRANE VESICLES; ATP-DEPENDENT TRANSPORT; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; CYSTEINYL LEUKOTRIENES; CANALICULAR TRANSPORT; MUTANT RATS; GLUTATHIONE; SEQUENCE	The liver converts endogenous and xenobiotic lipophilic compounds into anionic conjugates with glutathione, glucuronate, or sulfate. These conjugates are transported across the canalicular (apical) membrane into bile by a 190 kDa membrane glycoprotein that has been cloned recently. This apical conjugate-transporting ATPase has been termed canalicular multidrug resistance protein (cMRP) because of the similarity in substrate specificity and sequence resistance protein canalicular multispecific organic anion transporter (cMOAT), or multidrug resistance protein 2 (MRP2). The amino acid sequence identity of human MRP2 and MRP1 is 49%. MRP2 is predominantly expressed in hepatocytes and localized to apical membrane domains, MRP2 is not expressed in the human Dubin-Johnson syndrome, which is therefore associated with an inherited deficiency in the secretion of amphiphilic anionic conjugates into the bile. The rat homolog Mrp2 is absent in two mutant strains of rats with different point mutations in the corresponding gene. These mutant rats are hyperbilirubinemic and deficient in the ATP-dependent transport of conjugates from hepatocytes into bile. Impairment of bile flow (cholestasis) can be associated with a down-regulation of the expression of the conjugate export pump, and MRP2 contributes to bile flow as an important driving force.			Keppler, D (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM, DIV TUMOR BIOCHEM, NEUENHEIMER FELD 280, D-69120 HEIDELBERG, GERMANY.		Keppler, Dietrich/A-5528-2013	Keppler, Dietrich/0000-0003-2964-2333; Koenig, Joerg/0000-0001-7016-5482				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; AKERBOOM TPM, 1991, J BIOL CHEM, V266, P13147; BOARD P, 1992, HEPATOLOGY, V15, P722, DOI 10.1002/hep.1840150428; Broeks A, 1996, EMBO J, V15, P6132, DOI 10.1002/j.1460-2075.1996.tb01001.x; BROWN PC, 1993, NUCLEIC ACIDS RES, V21, P3885, DOI 10.1093/nar/21.16.3885; Buchler M, 1996, J BIOL CHEM, V271, P15091; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Chowdhury Jayanta Roy, 1994, P471; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUBIN IN, 1954, MEDICINE, V33, P155, DOI 10.1097/00005792-195409000-00001; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; ELFERINK RPJO, 1995, BBA-REV BIOMEMBRANES, V1241, P215, DOI 10.1016/0304-4157(95)00006-D; FERNANDEZCHECA JC, 1992, J BIOL CHEM, V267, P1667; Flens MJ, 1996, AM J PATHOL, V148, P1237; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; GUHLMANN A, 1995, HEPATOLOGY, V21, P1568, DOI 10.1002/hep.1840210615; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIPFNER DR, 1994, CANCER RES, V54, P5788; HUBER M, 1987, HEPATOLOGY, V7, P224, DOI 10.1002/hep.1840070204; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; Ito K, 1997, AM J PHYSIOL-GASTR L, V272, pG16, DOI 10.1152/ajpgi.1997.272.1.G16; JANSEN PLM, 1985, HEPATOLOGY, V5, P573, DOI 10.1002/hep.1840050408; Jedlitschky G, 1996, CANCER RES, V56, P988; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; JEDLITSCHKY G, 1997, IN PRESS BIOCH J; JOHNSON M, 1997, IN PRESS NATURE LOND; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; JONES TR, 1989, CAN J PHYSIOL PHARM, V67, P17, DOI 10.1139/y89-004; Kartenbeck J, 1996, HEPATOLOGY, V23, P1061; Keppler D, 1996, ADV ENZYME REGUL, V36, P17, DOI 10.1016/0065-2571(95)00011-9; KEPPLER D, 1996, PROGR LIVER DIS, P55; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; KOBAYASHI K, 1988, FEBS LETT, V240, P55, DOI 10.1016/0014-5793(88)80339-9; Konig J, 1996, HEPATOLOGY, V24, P18; KRISHNAMACHARY N, 1994, ONCOL RES, V6, P119; Lee DW, 1996, EUR J CANCER, V32A, P945, DOI 10.1016/0959-8049(96)00046-9; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; MAYER R, 1995, J CELL BIOL, V131, P137, DOI 10.1083/jcb.131.1.137; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHAUB TP, 1997, IN PRESS J AM SOC NE, V8; SENGER M, 1995, COMPUT METH PROG BIO, V46, P131, DOI 10.1016/0169-2607(94)01610-R; SHUSTIK C, 1995, MOL ASPECTS MED, V16, P1, DOI 10.1016/0098-2997(94)00040-A; SILVERMAN JA, 1991, GENE, V106, P229, DOI 10.1016/0378-1119(91)90203-N; SPRINZ H, 1954, ANN INTERN MED, V41, P952, DOI 10.7326/0003-4819-41-5-952; Stride BD, 1996, MOL PHARMACOL, V49, P962; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; TAKIKAWA H, 1991, HEPATOLOGY, V14, P352, DOI 10.1002/hep.1840140223; Taniguchi K, 1996, CANCER RES, V56, P4124; Thomas PM, 1996, AM J HUM GENET, V59, P510; TRAUNER M, 1997, IN PRESS GASTROENTER, V113; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; vanKuijck MA, 1996, P NATL ACAD SCI USA, V93, P5401, DOI 10.1073/pnas.93.11.5401; ZAMAN GJR, 1993, CANCER RES, V53, P1747	59	234	239	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1997	11	7					509	516		10.1096/fasebj.11.7.9212074	http://dx.doi.org/10.1096/fasebj.11.7.9212074			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XH342	9212074				2022-12-28	WOS:A1997XH34200002
J	Hu, JS; Hastings, GA; Cherry, S; Gentz, R; Ruben, S; Coleman, TA				Hu, JS; Hastings, GA; Cherry, S; Gentz, R; Ruben, S; Coleman, TA			A novel regulatory function of proteolytically cleaved VEGF-2 for vascular endothelial and smooth muscle cells	FASEB JOURNAL			English	Article						COS-7 cells; vascular smooth muscle cells; PlGF; platelet-derived growth factor; VEGF-related protein	PLACENTA GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; PERMEABILITY FACTOR; MITOGEN; IDENTIFICATION; VASCULOGENESIS; BIOACTIVITY; PROTEIN; BINDING; FLT-1	By high throughput sequencing, we have identified a cDNA encoding a polypeptide related to vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) in the VEGF/PDGF PDGF gene family, It is designated vascular endothelial growth factor 2 (VEGF-2), Similar to VEGF, expression of VEGF-2 mRNA is abundant in vascular smooth muscle cells and several highly vascularized tissues, VEGF-2 protein is expressed as a secreted 52 kDa precursor as well as the 30 kDa amino-terminal and 27 kDa carboxy-terminal cleavage products, The latter two cleavage products are linked via a disulfide bridge (or bridges) and can be copurified, Using copurified 30 and 27 kDa proteins, the effect of VEGF-2 on growth of several cell types, including vascular endothelial and smooth muscle cells, was determined, Our results demonstrate that VEGF-2 protein stimulates the growth of human vascular endothelial cells but inhibits growth of human aortic smooth muscle cells induced by platelet-derived growth factor, These studies establish VEGF-2 as a novel regulator for growth of vascular endothelial and smooth muscle cells.	HUMAN GENOME SCI INC,DEPT PROT EXPRESS,ROCKVILLE,MD 20850	GlaxoSmithKline; Human Genome Sciences Inc	Hu, JS (corresponding author), HUMAN GENOME SCI INC,DEPT PROT THERAPEUT,9410 KEY W AVE,ROCKVILLE,MD 20850, USA.							ADAMS MD, 1995, NATURE, V377, P3; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIGNAM SS, 1990, GENE, V88, P133, DOI 10.1016/0378-1119(90)90024-L; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Joukov V, 1996, EMBO J, V15, P290; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PARK JE, 1994, J BIOL CHEM, V269, P25646; PAULSSON G, 1990, J MOL BIOL, V221, P331; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Sambrook J., 2002, MOL CLONING LAB MANU; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shibuya M, 1995, ADV CANCER RES, V67, P281, DOI 10.1016/S0065-230X(08)60716-2; SHIFREN JL, 1994, J CLIN ENDOCR METAB, V79, P316, DOI 10.1210/jc.79.1.316; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988	32	17	26	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1997	11	6					498	504		10.1096/fasebj.11.6.9194531	http://dx.doi.org/10.1096/fasebj.11.6.9194531			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XE404	9194531				2022-12-28	WOS:A1997XE40400013
J	Wada, T; Yokoyama, H; Furuichi, K; Kobayashi, KI; Harada, K; Naruto, M; Su, SB; Akiyama, M; Mukaida, N; Matsushima, K				Wada, T; Yokoyama, H; Furuichi, K; Kobayashi, KI; Harada, K; Naruto, M; Su, SB; Akiyama, M; Mukaida, N; Matsushima, K			Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1)	FASEB JOURNAL			English	Article						chemokine; glomerular base membrane; macrophage; proteinuria	INTERCELLULAR-ADHESION MOLECULE-1; CHEMOATTRACTANT PROTEIN-1; MESANGIAL CELLS; EXPRESSION; NEPHRITIS; RAT; INTERLEUKIN-8; PROLIFERATION; PURIFICATION; PEPTIDE-1	We investigated the pathophysiological cole of a potent macrophage (M phi) chemotactic cytokine (chemokine), monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 (MCAF/MCP-1), in an animal model of crescentic glomerulonephritis. Administration of a small dose of nephrotoxic sera induced severe proliferative and necrotizing glomerulonephritis, with crescentic formation in the early phase and glomerulosclerosis in the later phase, in Wistar-Kyoto rats. MCAF/MCP-1 protein was detected immunohistochemic ally in glomeruli, vascular endothelial cells, and tubular epithelial cells in the early phase of injured kidney tissues but not in normal ones. Anti-MCAF/MCP-1 antibodies decreased the number of M phi in glomeruli, and prevented crescentic formation and the fusion of epithelial cell foot process in nephritic rats, thereby decreasing the excreted amounts of protein to normal levels on days 3 and 6. Furthermore, anti-MCAF/MCP-1 antibodies remarkably reduced glomerulosclerosis and improved renal dysfunction as well as proteinuria in the later phase (56 days). These results indicate that MCAF/MCP-1 essentially participates in the impairment of renal functions associated with crescentic glomerulonephritis by recruiting and activating M phi.	KANAZAWA UNIV,CANC RES INST,DEPT PHARMACOL,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,SCH MED,DEPT INTERNAL MED 1,KANAZAWA,ISHIKAWA 920,JAPAN; TORAY INDUSTRIES LTD,BASIC RES LABS,KAMAKURA,KANAGAWA,JAPAN	Kanazawa University; Kanazawa University; Toray Industries, Inc.			Mukaida, Naofumi/D-7623-2011	Mukaida, Naofumi/0000-0002-4193-1851				BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BROWN Z, 1992, KIDNEY INT, V42, P95, DOI 10.1038/ki.1992.266; CAMUSSI G, 1990, KIDNEY INT, V38, P1047, DOI 10.1038/ki.1990.311; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; EGIDO J, 1993, KIDNEY INT, V43, pS59; JOHNSON RJ, 1987, J CLIN INVEST, V79, P1379, DOI 10.1172/JCI112965; JOHNSON RJ, 1991, J CLIN INVEST, V87, P847, DOI 10.1172/JCI115089; JONES ML, 1992, J IMMUNOL, V149, P2147; KAWASAKI K, 1992, KIDNEY INT, V41, P1517, DOI 10.1038/ki.1992.221; KRAKOWER CA, 1951, AMA ARCH PATHOL, V51, P629; KURKI P, 1986, EXP CELL RES, V166, P209, DOI 10.1016/0014-4827(86)90520-3; LAN HY, 1995, KIDNEY INT, V48, P753, DOI 10.1038/ki.1995.347; MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485; MULLIGAN MS, 1993, J CLIN INVEST, V91, P577, DOI 10.1172/JCI116237; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; NISHIKAWA K, 1993, J EXP MED, V177, P667, DOI 10.1084/jem.177.3.667; NOLASCO FEB, 1987, KIDNEY INT, V31, P1160, DOI 10.1038/ki.1987.123; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; ROVIN BH, 1993, KIDNEY INT, V43, P218, DOI 10.1038/ki.1993.35; ROVIN BH, 1994, LAB INVEST, V71, P536; SCHMOUDER RL, 1993, KIDNEY INT, V44, P43, DOI 10.1038/ki.1993.211; STAHL RAK, 1993, KIDNEY INT, V44, P1036, DOI 10.1038/ki.1993.346; TANG WW, 1994, LAB INVEST, V70, P631; WADA T, 1994, J EXP MED, V180, P1135, DOI 10.1084/jem.180.3.1135; WADA T, 1994, KIDNEY INT, V46, P455, DOI 10.1038/ki.1994.293; Wada T, 1996, KIDNEY INT, V49, P761, DOI 10.1038/ki.1996.105; YOSHIMURA T, 1991, BIOCHEM BIOPH RES CO, V174, P504, DOI 10.1016/0006-291X(91)91445-I; YOSHIMURA T, 1989, J IMMUNOL, V142, P1956	29	184	197	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1996	10	12					1418	1425		10.1096/fasebj.10.12.8903512	http://dx.doi.org/10.1096/fasebj.10.12.8903512			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VP485	8903512				2022-12-28	WOS:A1996VP48500007
J	DeLaAsuncion, JG; Millan, A; Pla, R; Bruseghini, L; Esteras, A; Pallardo, FV; Sastre, J; Vina, J				DeLaAsuncion, JG; Millan, A; Pla, R; Bruseghini, L; Esteras, A; Pallardo, FV; Sastre, J; Vina, J			Mitochondrial glutathione oxidation correlates with age-associated oxidative damage to mitochondrial DNA	FASEB JOURNAL			English	Article						free radicals; aging; oxidative stress; vitamins; antioxidants	PERFORMANCE LIQUID-CHROMATOGRAPHY; ASCORBIC-ACID; ANTIOXIDANTS; BLOOD	Mitochondria may be primary targets of free radical damage associated with aging. We have found that mitochondrial glutathione is markedly oxidized with aging in rats and mice. The oxidized to reduced glutathione ratio rises with aging in the liver, kidney, and brain. The magnitude of these changes is much higher than that previously found in whole cells of any species previously studied. In the liver, this ratio (expressing GSSG as a percent of GSH) changed from 0.77 +/- 0.19% (n=5) in young rats to 2.47 +/- 1.25% (n=5) in old ones, i.e., 320% of the controls. In the brain and kidney, values for old rats were, respectively, 600 and 540% higher than those of young rats. A marked oxidation of mitochondrial glutathione also occurred in mice. Aging also caused an increase in 8-oxo-7,8-dihydro-2'-dexoyguanosine levels in mtDNA in rats and mice. Oral antioxidant administration protected against both glutathione oxidation and mtDNA damage in rats and mice. Finally, we have found a direct relationship between mtDNA damage and mitochondrial glutathione oxidation. This occurs both in rats (r=0.95) and in mice (r=0.98). This relationship, which has been observed for the first time in these studies, underscores the role of glutathione in the protection against free radical damage that occurs upon aging.	UNIV VALENCIA, DEPT FISIOL, FAC MED, VALENCIA, SPAIN	University of Valencia			Vina, Jose/AAB-3069-2021; Pallardo, Federico V./T-1156-2017	Vina, Jose/0000-0001-9709-0089; Pallardo, Federico V./0000-0003-3715-1980				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ASENSI M, 1994, ANAL BIOCHEM, V217, P323, DOI 10.1006/abio.1994.1126; BRIGELIUS R, 1983, BIOCHEM PHARMACOL, V32, P2529, DOI 10.1016/0006-2952(83)90014-X; CUTLER RG, 1991, AM J CLIN NUTR, V53, pS373, DOI 10.1093/ajcn/53.1.373S; FRAGA CG, 1991, P NATL ACAD SCI USA, V88, P11003, DOI 10.1073/pnas.88.24.11003; GOHIL K, 1988, J APPL PHYSIOL, V64, P115, DOI 10.1152/jappl.1988.64.1.115; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; LATORRE A, 1986, P NATL ACAD SCI USA, V83, P8649, DOI 10.1073/pnas.83.22.8649; LOFT S, 1994, FASEB J, V8, P534, DOI 10.1096/fasebj.8.8.8181672; LOPEZTORRES M, 1993, MECH AGEING DEV, V70, P177, DOI 10.1016/0047-6374(93)90047-U; MEDVEDEV ZA, 1990, BIOL REV, V65, P375, DOI 10.1111/j.1469-185X.1990.tb01428.x; MEREDITH MJ, 1982, J BIOL CHEM, V257, P3747; MILLS BJ, 1990, ANAL BIOCHEM, V184, P263, DOI 10.1016/0003-2697(90)90678-3; MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8; MIQUEL J, 1979, EXP GERONTOL, V14, P279, DOI 10.1016/0531-5565(79)90039-1; OSHINO N, 1977, BIOCHEM J, V162, P509, DOI 10.1042/bj1620509; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; RICHIE JP, 1994, FASEB J, V8, P1302, DOI 10.1096/fasebj.8.15.8001743; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; RICKWOOD DW, 1987, MITOCHONDRIA PRACTIC, P4; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SHIGENAGA MK, 1990, METHOD ENZYMOL, V186, P521; SIES H, 1986, ANGEW CHEM INT EDIT, V25, P1058, DOI 10.1002/anie.198610581; SOHAL RS, 1994, FREE RADICAL BIO MED, V16, P621, DOI 10.1016/0891-5849(94)90062-0; TIMIRAS PS, 1988, PHYSL BASIS AGING GE, P1; VINA J, 1995, METHOD ENZYMOL, V251, P237, DOI 10.1016/0076-6879(95)51126-1; Vina J., 1990, GLUTATHIONE METABOLI; VINA J, 1992, FREE RADICALS AGING, P136; WAHLLANDER A, 1979, FEBS LETT, V97, P138, DOI 10.1016/0014-5793(79)80069-1; Weber H U, 1982, Arch Gerontol Geriatr, V1, P299, DOI 10.1016/0167-4943(82)90030-9; WLODEK L, 1993, BIOCHEM PHARMACOL, V46, P1917, DOI 10.1016/0006-2952(93)90632-7	32	211	220	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1996	10	2					333	338		10.1096/fasebj.10.2.8641567	http://dx.doi.org/10.1096/fasebj.10.2.8641567			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641567				2022-12-28	WOS:A1996TY96200018
J	Mazzanti, M; Assandri, R; Ferroni, A; Difrancesco, D				Mazzanti, M; Assandri, R; Ferroni, A; Difrancesco, D			Cytoskeletal control of rectification and expression of four substates in cardiac inward rectifier K+ channels	FASEB JOURNAL			English	Article						inward rectification; K channels; patch-clamp; calcium ions	GUINEA-PIG HEART; RECTIFYING POTASSIUM CHANNELS; VENTRICULAR CELLS; BLOCK; ACTIN; CYTOCHALASIN; MICROTUBULES; CONDUCTANCE; PHALLOIDIN; FILAMENTS	Cardiac inward rectifiers may have a three-barrel channel structure, based on evidence for three substates in single-channel recordings. However, some reports indicate four substates, a feature more compatible with the four-subunit structure for which there is evidence in cloned voltage-activated K+ channels. Here we show that although the fourth is easily missed, inward rectifier channels have four substates whose expression is controlled by intracellular Ca2+ ions. Fourth substate openings also appear after rectification loss in intracellular divalent cation-free solution. We find that this process is accelerated by cytochalasin, a microfilament disrupter. Cytochalasin also abolishes Ca2+, but not Mg2+, -induced rectification by restoring fourth substate openings. Thus, cytoskeletal elements control Ca2+-dependent substate expression and rectification in native inwardly rectifying K+ channels.-Mazzanti, M., Assandri, R., Ferroni, A., DiFrancesco, D. Cytoskeletal control of rectification and expression of four substrates in cardiac inward rectifier K+ channels.	UNIV MILAN,DIPARTIMENTO FISIOL & BIOCHIM GEN,I-20133 MILAN,ITALY	University of Milan			DiFrancesco, Dario/G-8408-2017; Mazzanti, Michele/A-8941-2011	DiFrancesco, Dario/0000-0002-7322-1790; Mazzanti, Michele/0000-0002-1819-3811				ALDRICH R, 1993, NATURE, V362, P107, DOI 10.1038/362107a0; BLACK MM, 1982, J CELL BIOL, V95, P379, DOI 10.1083/jcb.95.2.379; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; FAKLER B, 1994, FEBS LETT, V356, P199, DOI 10.1016/0014-5793(94)01258-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; FUKUDA J, 1981, NATURE, V294, P82, DOI 10.1038/294082a0; GALLI A, 1994, BIOPHYS J, V67, P2296, DOI 10.1016/S0006-3495(94)80715-5; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; JOHNSON BD, 1993, NEURON, V10, P797, DOI 10.1016/0896-6273(93)90196-X; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LETURNEAU PC, 1987, CELL MOTIL CYTOSKEL, V8, P193; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MATSUDA H, 1989, J PHYSIOL-LONDON, V413, P139, DOI 10.1113/jphysiol.1989.sp017646; MATSUDA H, 1988, J PHYSIOL-LONDON, V397, P237, DOI 10.1113/jphysiol.1988.sp016998; MATSUDA H, 1993, J PHYSIOL-LONDON, V470, P295, DOI 10.1113/jphysiol.1993.sp019859; MATSUMOTO G, 1984, J MEMBRANE BIOL, V77, P77; MAZZANTI M, 1989, PFLUG ARCH EUR J PHY, V413, P322, DOI 10.1007/BF00583549; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SAKMANN B, 1984, J PHYSIOL-LONDON, V347, P641, DOI 10.1113/jphysiol.1984.sp015088; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; STANFIELD PR, 1994, J PHYSIOL-LONDON, V475, P1; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0	26	37	39	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1996	10	2					357	361		10.1096/fasebj.10.2.8641571	http://dx.doi.org/10.1096/fasebj.10.2.8641571			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641571				2022-12-28	WOS:A1996TY96200022
J	Ellis, RJ; Hartl, FU				Ellis, RJ; Hartl, FU			Protein folding in the cell: Competing models of chaperonin function	FASEB JOURNAL			English	Review						molecular chaperones; protein folding; GroEL; GroES	RIBULOSE BISPHOSPHATE CARBOXYLASE; ATP HYDROLYSIS; CENTRAL CAVITY; GROEL; SUBUNITS; BINDING; CYCLE	The long-standing view that polypeptide chains newly synthesized inside cells fold spontaneously to their functional conformations in an energy-independent fashion derives from the observation that many pure denatured proteins will refold spontaneously in vitro when the denaturant is removed, This view is being challenged by the alternative proposal that in vivo many chains need to be helped to fold correctly by preexisting proteins acting as molecular chaperones, some of which hydrolyse ATP, The need for molecular chaperones arises because the high concentrations of transiently interacting protein surfaces inside cells permit the formation of incorrect nonfunctional structures, The best-studied family of molecular chaperones are called the chaperonins, the archetypal examples being the GroEL and GroES proteins of Escherichia coli, The chaperonins increase the yield of correctly refolded polypeptide chains, both by decreasing their propensity to aggregate with one another and by allowing polypeptides kinetically trapped in incorrect conformations to make fresh attempts to refold into the functional conformations, The mechanisms by which the chaperonins achieve these remarkable results are currently under debate, This review surveys competing models for chaperonin action, and emphasizes the importance when evaluating these models of considering the intracellular environment in which the chaperonins have evolved to function.	MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Ellis, RJ (corresponding author), UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND.		Hartl, F. Ulrich/Y-8206-2019					ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; BOCHKAREVA ES, 1994, J BIOL CHEM, V269, P23869; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; Ellis R. J., 1993, P1; ELLIS RJ, 1994, CURR BIOL, V4, P633; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; ELLIS RJ, 1996, IN PRESS CHAPERONINS; ENGEL A, 1995, SCIENCE, V269, P832, DOI 10.1126/science.7638600; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GIRSHOVICH AS, 1995, FEBS LETT, V366, P17, DOI 10.1016/0014-5793(95)00479-S; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; Hendrick JP, 1995, FASEB J, V9, P1559, DOI 10.1096/fasebj.9.15.8529835; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, V2, P1334; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PERALTA D, 1994, FEBS LETT, V339, P45, DOI 10.1016/0014-5793(94)80381-1; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1995, J BIOL CHEM, V270, P5388, DOI 10.1074/jbc.270.10.5388; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	43	200	204	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1996	10	1					20	26		10.1096/fasebj.10.1.8566542	http://dx.doi.org/10.1096/fasebj.10.1.8566542			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566542				2022-12-28	WOS:A1996TR32800004
J	HERSCOVICS, A; ORLEAN, P				HERSCOVICS, A; ORLEAN, P			GLYCOPROTEIN-BIOSYNTHESIS IN YEAST	FASEB JOURNAL			English	Review						GLYCOSYLPHOSPHOINOSITOL; GLYCOPROTEINS; DOLICHOL; YEAST; SACCHAROMYCES-CEREVISIAE	PHOSPHATE-MANNOSE SYNTHASE; ASPARAGINE-LINKED GLYCOSYLATION; SACCHAROMYCES-CEREVISIAE; PROTEIN GLYCOSYLATION; D-MANNOSYLTRANSFERASE; ALPHA-MANNOSIDASE; SECRETORY PATHWAY; MEMBRANE-PROTEIN; N-GLYCOSYLATION; PLASMA-MEMBRANE	Many proteins in the yeast Saccharomyces cerevisiae are modified by the attachment of N-linked saccharides to asparagine, of O-linked mannose glycans to serine or threonine, and of glycosylphosphoinositol membrane anchors. The biosynthetic events leading to these modifications are coupled to the secretory pathway. Early stages of N-linked glycosylation and the formation of glycosylphosphoinositol anchors have been conserved through evolution of eukaryotes. Studies of yeast offer a variety of genetic and molecular biological approaches, which have led to the isolation of different glycosylation mutants and of genes for enzymes involved in glycosylation. Yeast mutants are useful to identify biosynthetic intermediates, to establish whether a given enzyme is essential for viability, and to determine how cellular functions are affected when glycosylation is perturbed. Yeast glycosylation mutants and genes can be used to identify their counterparts in other eukaryotes.	UNIV ILLINOIS, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	HERSCOVICS, A (corresponding author), MCGILL UNIV, MCGILL CANC CTR, 3655 DRUMMOND ST, MONTREAL H3G 1Y6, QUEBEC, CANADA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046220] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-46220, GM-31265] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; ALBRIGHT CF, 1990, J BIOL CHEM, V265, P7042; ALBRIGHT CF, 1989, P NATL ACAD SCI USA, V86, P7366, DOI 10.1073/pnas.86.19.7366; ALVARADO E, 1990, BIOCHEMISTRY-US, V29, P2471, DOI 10.1021/bi00462a006; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BALLOU L, 1990, P NATL ACAD SCI USA, V87, P3368, DOI 10.1073/pnas.87.9.3368; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; BARNES G, 1984, MOL CELL BIOL, V4, P2381, DOI 10.1128/MCB.4.11.2381; BAUSE E, 1986, FEBS LETT, V206, P208, DOI 10.1016/0014-5793(86)80982-6; BECK PJ, 1990, MOL CELL BIOL, V10, P4612, DOI 10.1128/MCB.10.9.4612; BECK PJ, 1990, J CELL BIOL, V111, P378; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BERNSTEIN M, 1989, MOL CELL BIOL, V9, P1191, DOI 10.1128/MCB.9.3.1191; BYRD JC, 1982, J BIOL CHEM, V257, P4657; CAMIRAND A, 1991, J BIOL CHEM, V266, P15120; CAPPELLARO C, 1991, EMBO J, V10, P4081, DOI 10.1002/j.1460-2075.1991.tb04984.x; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; CONZELMANN A, 1992, EMBO J, V11, P457, DOI 10.1002/j.1460-2075.1992.tb05075.x; CONZELMANN A, 1990, EMBO J, V9, P653, DOI 10.1002/j.1460-2075.1990.tb08157.x; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; COUTO JR, 1984, J BIOL CHEM, V259, P378; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; DEVLIN C, 1990, MOL MICROBIOL, V4, P1993, DOI 10.1111/j.1365-2958.1990.tb02049.x; DICKSON RC, 1990, MOL CELL BIOL, V10, P2176, DOI 10.1128/MCB.10.5.2176; ESMON B, 1984, J BIOL CHEM, V259, P322; FERGUSON MAJ, 1992, BIOCHEM SOC T, V20, P243, DOI 10.1042/bst0200243; GERBER LD, 1992, J BIOL CHEM, V267, P12168; GRAHAM TR, 1992, YEAST, V8, pS458; Guthrie C, 1991, METHODS ENZYMOLOGY, V194; HASELBECK A, 1989, EUR J BIOCHEM, V181, P663, DOI 10.1111/j.1432-1033.1989.tb14774.x; HASELBECK A, 1982, P NATL ACAD SCI-BIOL, V79, P1520, DOI 10.1073/pnas.79.5.1520; HAUSLER A, 1992, GLYCOBIOLOGY, V2, P77, DOI 10.1093/glycob/2.1.77; HAUSLER A, 1992, P NATL ACAD SCI USA, V89, P6846, DOI 10.1073/pnas.89.15.6846; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HELLER L, 1992, P NATL ACAD SCI USA, V89, P7013, DOI 10.1073/pnas.89.15.7013; HERNANDEZ LM, 1989, J BIOL CHEM, V264, P13648; HERSCOVICS A, 1991, GLYCOCONJUGATE J, V8, P149; HILL K, 1992, GENETICS, V130, P273; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; JACKSON BJ, 1989, ARCH BIOCHEM BIOPHYS, V272, P203, DOI 10.1016/0003-9861(89)90211-7; JELINEKKELLY S, 1988, J BIOL CHEM, V263, P14757; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KEPES F, 1988, J BIOL CHEM, V263, P9155; KILKER RD, 1981, J BIOL CHEM, V256, P5299; KRUSIUS T, 1987, BIOCHEM J, V245, P229, DOI 10.1042/bj2450229; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LEHRMAN M A, 1991, Glycobiology, V1, P553, DOI 10.1093/glycob/1.6.553; LEWIS MS, 1991, J BIOL CHEM, V266, P8255; LIPKE PN, 1992, MICROBIOL REV, V56, P180, DOI 10.1128/MMBR.56.1.180-194.1992; MENON AK, 1992, J BIOL CHEM, V267, P15277; MOEHLE CM, 1987, MOL CELL BIOL, V7, P4390, DOI 10.1128/MCB.7.12.4390; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; ORLEAN P, 1991, METHOD ENZYMOL, V194, P682; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; PALAMARCZYK G, 1990, P NATL ACAD SCI USA, V87, P2666, DOI 10.1073/pnas.87.7.2666; PREUSS D, 1992, MOL BIOL CELL, V3, P789, DOI 10.1091/mbc.3.7.789; PREUSS D, 1991, YEAST, V7, P891, DOI 10.1002/yea.320070902; PUCCIA R, 1993, BIOCHEM J, V290, P21, DOI 10.1042/bj2900021; REASON A J, 1991, Glycobiology, V1, P387, DOI 10.1093/glycob/1.4.387; ROMERO PA, 1989, J BIOL CHEM, V264, P1946; ROMERO PA, 1992, J CELL BIOCHEM     S, V16, P175; SAUNIER B, 1982, J BIOL CHEM, V257, P4155; SCHUTZBACH JS, 1992, BIOCHEM CELL BIOL, V70, P460, DOI 10.1139/o92-070; SHARMA C B, 1991, Glycobiology, V1, P367, DOI 10.1093/glycob/1.4.367; SILBERSTEIN S, 1992, J BIOL CHEM, V267, P23658; SMITH DJ, 1992, MOL CELL BIOL, V12, P2924, DOI 10.1128/MCB.12.7.2924; STRAHLBOLSINGER S, 1991, EUR J BIOCHEM, V196, P185, DOI 10.1111/j.1432-1033.1991.tb15802.x; STRAHLBOLSINGER S, 1992, YEAST, V8, pS489; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; TRIMBLE RB, 1991, J BIOL CHEM, V266, P22807; TRIMBLE RB, 1992, GLYCOBIOLOGY, V2, P57, DOI 10.1093/glycob/2.1.57; TRIMBLE RB, 1993, IN PRESS GUIDEBOOK S; TRUEHEART J, 1989, P NATL ACAD SCI USA, V86, P9916, DOI 10.1073/pnas.86.24.9916; VAI M, 1991, J BIOL CHEM, V266, P12242; VEROSTEK MF, 1991, J BIOL CHEM, V266, P5547; WANG YC, 1992, J BIOL CHEM, V267, P2728; WATZELE G, 1989, J BIOL CHEM, V264, P8753; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; YANAGISAWA K, 1990, J BIOL CHEM, V265, P19351; ZIEGLER F D, 1991, Glycobiology, V1, P605, DOI 10.1093/glycob/1.6.605	89	451	474	1	38	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 1	1993	7	6					540	550		10.1096/fasebj.7.6.8472892	http://dx.doi.org/10.1096/fasebj.7.6.8472892			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KY009	8472892				2022-12-28	WOS:A1993KY00900007
J	GREENSPAN, NS; BONA, CA				GREENSPAN, NS; BONA, CA			IDIOTYPES - STRUCTURE AND IMMUNOGENICITY	FASEB JOURNAL			English	Article						IMMUNOGLOBULIN; T-CELL RECEPTOR; VARIABLE DOMAIN; HYPERVARIABLE REGION; IDIOTOPE; MOLECULAR MIMICRY; ANTIGEN PROCESSING; MAJOR HISTOCOMPATIBILITY COMPLEX ANTIGENS; ANTIBODY ENGINEERING	MONOCLONAL ANTIIDIOTYPIC ANTIBODIES; CROSS-REACTIVE IDIOTYPE; GROUP-A CARBOHYDRATE; 3RD HYPERVARIABLE REGION; T-CELL CLONES; HUMAN B-CELLS; INTERNAL IMAGE; ANTI-IDIOTYPE; IMMUNE-RESPONSE; BINDING-SPECIFICITY	Idiotopes are markers on the variable domains of antigen-specific immunological receptors recognized by anti-idiotypic antibodies or T cells. Therefore, a given antibody or T cell receptor can be identified on the basis of a characteristic idiotypic pattern. The structural correlates for idiotopes on antibodies have been studied by competitive binding assays, electron microscopy, site-directed mutagenesis, and X-ray crystallography. Immunoglobulin idiotopes, recognized by anti-idiotypic antibodies, can involve amino acid residues from several hypervariable or framework regions and from either or both of the heavy and light chain variable domains. Recent studies suggest that it may be possible to exploit structural knowledge of idiotopes and anti-idiotopes for the design of new ligands for immunological or other cell surface receptors. In one instance, it has been possible to use the inferred structural features of an anti-idiotope, which mimics a viral protein, to design a small organic molecule with functional properties approximating those of the antigen and the native anti-idiotope. An alternative strategy being explored for creating new vaccines or therapeutic agents involves engineering an amino acid sequence, corresponding to a segment of a selected nominal antigen, into an immunoglobulin variable domain.	CUNY MT SINAI SCH MED,DEPT MICROBIOL,BOX 1124,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029; CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Case Western Reserve University			Greenspan, Neil/AAJ-4795-2020					ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; ANDERS EM, 1989, J VIROL, V63, P2758, DOI 10.1128/JVI.63.6.2758-2767.1989; BAILEY NC, 1989, J CLIN INVEST, V84, P744, DOI 10.1172/JCI114232; BANIYASH M, 1987, EUR J IMMUNOL, V17, P1337, DOI 10.1002/eji.1830170918; BAXT B, 1989, Viral Immunology, V2, P103, DOI 10.1089/vim.1989.2.103; BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; BILETTA R, 1991, P NATL ACAD SCI USA, V88, P4713; BOGEN B, 1985, EUR J IMMUNOL, V15, P278, DOI 10.1002/eji.1830150313; BOGEN B, 1986, EUR J IMMUNOL, V16, P1373, DOI 10.1002/eji.1830161110; BONA C, 1978, J IMMUNOL, V120, P1436; BONA C, 1979, J EXP MED, V149, P815, DOI 10.1084/jem.149.4.815; BONILLA FA, 1983, IMMUNOBIOLOGY PROTEI, P123; BRACIALE TL, 1992, IMMUNOL TODAY, V12, P124; BRUCK C, 1986, P NATL ACAD SCI USA, V83, P6578, DOI 10.1073/pnas.83.17.6578; BRUGGEMANN M, 1986, EMBO J, V5, P1561, DOI 10.1002/j.1460-2075.1986.tb04397.x; CAMPBELL M, 1986, J IMMUNOL, V136, P2983; CHAKRABARTI D, 1992, CELL IMMUNOL, V142, P54, DOI 10.1016/0008-8749(92)90268-T; CHANH TC, 1990, J IMMUNOL, V144, P4721; CHEN PP, 1984, P NATL ACAD SCI-BIOL, V81, P1784, DOI 10.1073/pnas.81.6.1784; COSENZA H, 1976, EUR J IMMUNOL, V6, P114, DOI 10.1002/eji.1830060208; CZOP JK, 1990, J IMMUNOL, V145, P995; DAVIE JM, 1986, ANNU REV IMMUNOL, V4, P147, DOI 10.1146/annurev.immunol.4.1.147; DAVIS SJ, 1992, NATURE, V358, P76, DOI 10.1038/358076a0; ERTL HCJ, 1984, P NATL ACAD SCI-BIOL, V81, P2850, DOI 10.1073/pnas.81.9.2850; ERTL HCJ, 1984, J IMMUNOL, V153, P1778; FARID NR, 1985, ENDOCR REV, V6, P1; FEDERICO P, 1989, J CLIN INVEST, V84, P907; GLASEL JA, 1985, LIFE SCI, V36, P2523, DOI 10.1016/0024-3205(85)90149-3; Greenspan N S, 1987, Int Rev Immunol, V2, P391, DOI 10.3109/08830188709044764; GREENSPAN NS, 1992, B I PASTEUR, V90, P267; GREENSPAN NS, 1985, J IMMUNOL, V134, P1065; GREENSPAN NS, 1988, THEORETICAL IMMUNO 2, P215; GREENSPAN NS, 1992, STRUCTURE ANTIGENS, P55; GRIEDER FB, 1990, J IMMUNOL, V144, P2627; HALL BL, 1992, J IMMUNOL, V149, P1605; HASEMANN CA, 1991, J IMMUNOL, V147, P3170; HASSERMANN M, 1991, J IMMUNOL, V147, P3882; HUANG JH, 1986, J IMMUNOL, V137, P770; IRIBE H, 1988, J IMMUNOL, V140, P4151; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; JESKE D, 1986, J IMMUNOL, V136, P2568; KAUFMANN SHE, 1985, J IMMUNOL, V134, P4123; KENNEDY RC, 1984, J VIROL, V50, P951, DOI 10.1128/JVI.50.3.951-953.1984; KENNEDY RC, 1986, SCIENCE, V232, P220, DOI 10.1126/science.3952505; KRESINA TF, 1989, J CLIN INVEST, V83, P912, DOI 10.1172/JCI113976; KU HH, 1987, J IMMUNOL, V139, P2376; KUNKEL HG, 1963, SCIENCE, V140, P1218, DOI 10.1126/science.140.3572.1218; LAMARRE A, 1991, J IMMUNOL, V147, P4256; LAMBRIS JD, 1982, J EXP MED, V155, P1400, DOI 10.1084/jem.155.5.1400; LASSOUED K, 1991, EUR J IMMUNOL, V21, P1959, DOI 10.1002/eji.1830210826; LINDENMANN J, 1973, ANN INST PASTEUR IMM, VC124, P171; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LOMBES M, 1989, J IMMUNOL, V143, P4078; MARASCO WA, 1982, J IMMUNOL, V128, P963; MCMILLAN S, 1983, CELL, V35, P859, DOI 10.1016/0092-8674(83)90118-6; MCNAMARA MK, 1984, SCIENCE, V226, P1325, DOI 10.1126/science.6505692; MONAFO WJ, 1987, J IMMUNOL, V139, P2702; MOYLE WR, 1982, P NATL ACAD SCI-BIOL, V79, P2245, DOI 10.1073/pnas.79.7.2245; NISONOFF A, 1991, J IMMUNOL, V147, P2429; NOWELL J, 1985, J EXP MED, V162, P1371, DOI 10.1084/jem.162.4.1371; OLLIER P, 1985, EMBO J, V4, P3681, DOI 10.1002/j.1460-2075.1985.tb04135.x; OUDIN J, 1963, CR HEBD ACAD SCI, V257, P805; PARHAMISEREN B, 1990, J IMMUNOL, V145, P2340; PHILLIPS NJ, 1990, J IMMUNOL, V145, P915; RADBRUCH A, 1985, NATURE, V315, P506, DOI 10.1038/315506a0; REES ADM, 1987, EUR J IMMUNOL, V17, P197, DOI 10.1002/eji.1830170208; REGAN KJ, 1983, J VIROL, V48, P660; ROLF JM, 1989, P NATL ACAD SCI USA, V86, P2036, DOI 10.1073/pnas.86.6.2036; ROUX KH, 1987, P NATL ACAD SCI USA, V84, P4984, DOI 10.1073/pnas.84.14.4984; RUBINSTEIN LJ, 1983, J EXP MED, V158, P1129, DOI 10.1084/jem.158.4.1129; RUDENSKY AY, 1989, EUR J IMMUNOL, V19, P1677, DOI 10.1002/eji.1830190923; SACKS DL, 1982, J EXP MED, V155, P1108, DOI 10.1084/jem.155.4.1108; SARAGOVI HU, 1991, SCIENCE, V253, P792, DOI 10.1126/science.1876837; SASAKI T, 1988, J CLIN INVEST, V83, P748; SCHILLING J, 1980, NATURE, V283, P35, DOI 10.1038/283035a0; SCHREIBER AB, 1980, P NATL ACAD SCI-BIOL, V77, P7385, DOI 10.1073/pnas.77.12.7385; SCHREIBER JR, 1991, J IMMUNOL, V146, P188; SEGE K, 1978, NATURE, V271, P167, DOI 10.1038/271167a0; SEGE K, 1978, P NATL ACAD SCI USA, V75, P2443, DOI 10.1073/pnas.75.5.2443; SHARON J, 1990, J IMMUNOL, V144, P4863; SHEARER MH, 1990, J IMMUNOL, V145, P932; SPITSIN SV, 1991, J IMMUNOL, V147, P2001; STEIN KE, 1984, J EXP MED, V160, P1001, DOI 10.1084/jem.160.4.1001; STREICHER HZ, 1986, J IMMUNOL, V136, P1007; STRICKLAND FM, 1987, MOL IMMUNOL, V24, P631, DOI 10.1016/0161-5890(87)90044-7; SU S, 1992, J IMMUNOL, V148, P234; UYTDEHAAG FGCM, 1985, J IMMUNOL, V134, P1225; VELGEROUSSEL F, 1989, J IMMUNOL, V142, P2527; WASSERMANN NH, 1982, P NATL ACAD SCI-BIOL, V79, P4810, DOI 10.1073/pnas.79.15.4810; WATERS SJ, 1988, CELL IMMUNOL, V111, P87, DOI 10.1016/0008-8749(88)90053-6; WEISS S, 1991, CELL, V64, P767, DOI 10.1016/0092-8674(91)90506-T; WILSON A, 1990, J IMMUNOL, V145, P3937; WRIGHT A, 1989, J EXP MED, V169, P1557, DOI 10.1084/jem.169.5.1557; ZAGHOUANI H, 1993, SCIENCE, V259, P224, DOI 10.1126/science.7678469; ZAGHOUANI H, 1992, J IMMUNOL, V148, P3604; ZANETTI M, 1992, NATURE, V355, P476, DOI 10.1038/355476a0; ZENKE G, 1985, J IMMUNOL, V135, P4066	97	30	90	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1993	7	5					437	444		10.1096/fasebj.7.5.8462785	http://dx.doi.org/10.1096/fasebj.7.5.8462785			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KV351	8462785				2022-12-28	WOS:A1993KV35100008
J	Stadnicki, A; Sartor, RB; Janardham, R; Majluf-Cruz, A; Kettner, CA; Adam, AA; Colman, RW				Stadnicki, A; Sartor, RB; Janardham, R; Majluf-Cruz, A; Kettner, CA; Adam, AA; Colman, RW			Specific inhibition of plasma kallikrein modulates chronic granulomatous intestinal and systemic inflammation in genetically susceptible rats	FASEB JOURNAL			English	Article						kininogen; chronic enterocolitis; arthritis; protease inhibitor	PEPTIDOGLYCAN-INDUCED ARTHRITIS; FACTOR-XII; HUMAN-NEUTROPHILS; ACTIVATION; ENTEROCOLITIS; KININS; PREKALLIKREIN; INTERLEUKIN-1; PATHOGENESIS; COAGULATION	The kallilnein-kinin (K-K) (contact) system is activated during acute and chronic relapsing phases of enterocolitis induced in genetically susceptible Lewis rats by intramural injection of peptidoglycan-polysaccharide (PG-APS), Using the selective plasma kallikrein inhibitor P8720, we investigate whether activation of the K-K system plays a primary role in chronic granulomatous intestinal and systemic inflammation in this model, Group I (negative control) received human serum albumin intramurally. Group II (treatment) received PG-APS intramurally and P8720 orally, Group III (positive control) received PG-APS intramurally and albumin orally. P8720 attenuated the consumption of the contact proteins, high molecular weight kininogen (P<0.03), and factor XI (P<0.04) in group LI vs, group III. P8720 decreased chronic intestinal inflammation measured by blinded gross (P<0.01) and histologic (P<0.0005) scores as well as systemic complications (arthritis, splenomegaly, hepatomegaly, leukocytosis, and acute-phase reaction) (P<0.01) in group IT as compared with group m. We conclude that relapsing chronic enterocolitis and systemic complications are in part due to plasma K-K system activation, and that inhibition of this pathway is a potential therapeutic approach to human inflammatory bowel disease and associated extraintestinal manifestations.	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St, Philadelphia, PA 19140 USA; Univ N Carolina, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC 27599 USA; Dupont Merck Pharmaceut Co, Wilmington, DE 19880 USA; Univ Montreal, Dept Pharm, Montreal, PQ H3C 3J7, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of North Carolina; University of North Carolina Chapel Hill; DuPont; Universite de Montreal	Colman, RW (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St, Philadelphia, PA 19140 USA.	colmanr@astro.temple.edu		Stadnicki, Antoni/0000-0003-2675-3732				ADAM A, 1989, BIOCHEM PHARMACOL, V38, P1569, DOI 10.1016/0006-2952(89)90303-1; BERGMEYER HU, 1978, CLIN CHEM, V24, P58; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Blais C, 1997, ARTHRITIS RHEUM, V40, P1327, DOI 10.1002/1529-0131(199707)40:7<1327::AID-ART18>3.0.CO;2-B; COLMAN RW, 1975, J CLIN INVEST, V56, P1650, DOI 10.1172/JCI108247; de la Cadena RA, 1994, HEMOSTASIS THROMBOSI, P219; DELACADENA RA, 1995, FASEB J, V9, P446, DOI 10.1096/fasebj.9.5.7896018; DELACADENA RA, 1987, J LAB CLIN MED, V109, P601; DISCIPIO RG, 1982, IMMUNOLOGY, V45, P587; ELSON CO, 1995, GASTROENTEROLOGY, V109, P1344, DOI 10.1016/0016-5085(95)90599-5; GAGINELLA TS, 1989, AM J PHYSIOL, V256, pG1, DOI 10.1152/ajpgi.1989.256.1.G1; GHEBREHIWET B, 1981, J EXP MED, V153, P665, DOI 10.1084/jem.153.3.665; HANAUER S, 1995, NEW ENGL J MED, V331, P841; Herfarth HH, 1996, GUT, V39, P836, DOI 10.1136/gut.39.6.836; ICHINOSE A, 1986, J BIOL CHEM, V261, P3486; Jansen PM, 1996, BLOOD, V87, P2337, DOI 10.1182/blood.V87.6.2337.bloodjournal8762337; KAPLAN AP, 1972, J EXP MED, V135, P81, DOI 10.1084/jem.135.1.81; MCCALL RD, 1994, GASTROENTEROLOGY, V106, P960, DOI 10.1016/0016-5085(94)90755-2; MORRISON DC, 1974, J EXP MED, V140, P797, DOI 10.1084/jem.140.3.797; MURPHY EA, 1982, BIOSTATISTICS MED; PIXLEY RA, 1993, J CLIN INVEST, V91, P61, DOI 10.1172/JCI116201; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P928, DOI 10.1056/NEJM199109263251306; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; Raymond P, 1996, PEPTIDES, V17, P1171, DOI 10.1016/S0196-9781(96)00180-5; SARTOR RB, 1995, GASTROENTEROL CLIN N, V24, P475; Sartor RB, 1996, GASTROENTEROLOGY, V110, P1467, DOI 10.1053/gast.1996.v110.pm8613052; SARTOR RB, 1985, GASTROENTEROLOGY, V89, P587, DOI 10.1016/0016-5085(85)90455-X; SARTOR RB, 1994, INFLAMM BOWEL DIS, P210; SCHAPIRA M, 1982, J CLIN INVEST, V69, P1199, DOI 10.1172/JCI110557; SCHWAB JH, 1993, INFECT IMMUN, V61, P4535, DOI 10.1128/IAI.61.11.4535-4539.1993; SCOTT CF, 1986, ANN NY ACAD SCI, V485, P443, DOI 10.1111/j.1749-6632.1986.tb34612.x; SCOTT CF, 1988, J LAB CLIN MED, V111, P708; Stadnicki A, 1997, DIGEST DIS SCI, V42, P2356, DOI 10.1023/A:1018891323205; Stadnicki A, 1996, DIGEST DIS SCI, V41, P912, DOI 10.1007/BF02091530; Stadnicki A, 1996, J INVEST MED, V44, pA299; TOOSSI Z, 1992, P NATL ACAD SCI USA, V89, P11969, DOI 10.1073/pnas.89.24.11969; WACHTFOGEL YT, 1986, BLOOD, V67, P1731; WACHTFOGEL YT, 1983, J CLIN INVEST, V72, P1672, DOI 10.1172/JCI111126; WOOLVERTON CJ, 1989, AGENTS ACTIONS, V26, P301, DOI 10.1007/BF01967294; ZIMMERLI W, 1989, THROMB HAEMOSTASIS, V62, P1121; ZIMMERMANN EM, 1993, GASTROENTEROLOGY, V104, pA808	41	34	36	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1998	12	3					325	333		10.1096/fasebj.12.3.325	http://dx.doi.org/10.1096/fasebj.12.3.325			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YZ898	9506476				2022-12-28	WOS:000072305500021
J	Mallozzi, C; Di Stasi, AMM; Minetti, M				Mallozzi, C; Di Stasi, AMM; Minetti, M			Peroxynitrite modulates tyrosine-dependent signal transduction pathway of human erythrocyte band 3	FASEB JOURNAL			English	Article						nitric oxide; peroxynitrite; band 3; tyrosine phosphorylation; tyrosine nitration; GAPDH; glycolysis	RED BLOOD-CELL; NITRIC-OXIDE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; PROTEIN MODIFICATIONS; MEMBRANE-PROTEIN; PHOSPHORYLATION; SUPEROXIDE; BINDING; INACTIVATION; DEGRADATION	Peroxynitrite, the product of the reaction between nitric oxide and superoxide anion, is able to nitrate protein tyrosines. If this modification occurs on phosphotyrosine kinase substrates, it can down-regulate cell signaling, We investigated the effects of peroxynitrite on band 3-mediated signal transduction of human erythrocytes, Peroxynitrite treatment induced two different responses, At low concentrations (10-100 mu M) it stimulated a metabolic response, leading to 1) a reversible inhibition of phosphotyrosine phosphatase activity, 2) a rise of tyrosine phosphorylation in the 22K cytoplasmic domain of band 3, 3) the release of glyceraldehyde 3-phosphate dehydrogenase from the membrane, and 4) the enhancement of lactate production, At high concentrations (200-1000 mu M), peroxynitrite induced 1) cross-linking of membrane proteins, 2) inhibition of band 3 tyrosine phosphorylation, 3) nitration of tyrosines in the 22K cytoplasmic domain of band 3, 4) binding of hemoglobin to the membrane, 5) irreversible inhibition of phosphotyrosine kinase activity, 6) massive methemoglobin production, and 7) irreversible inhibition of lactate production, Our results demonstrate that at concentrations that could conceivably be achieved in vivo (10-100 mu M), peroxynitrite behaves like other oxidants, i.e., it stimulates band 3 tyrosine phosphorylation and increases glucose metabolism, Thus, one plausible physiologic effect of peroxynitrite is the up-regulation of signaling through the reversible inhibition of phosphotyrosine phosphatase activity, At high concentrations of peroxynitrite, the tyrosine phosphorylation ceases in parallel with the nitration of band 3 tyrosines, but at these concentrations phosphotyrosine kinase activity and glycolysis are also irreversibly inhibited, Thus, at least in red blood cells, the postulated down-regulation of signaling by peroxynitrite cannot merely be ascribed to the nitration of tyrosine kinase targets.	Ist Super Sanita, Dept Cell Biol, Lab Biol Cellulare, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Minetti, M (corresponding author), Ist Super Sanita, Dept Cell Biol, Lab Biol Cellulare, 299 Viale Regina Elena, I-00161 Rome, Italy.			MALLOZZI, CINZIA/0000-0002-6126-9500				Balagopalakrishna C, 1996, BIOCHEMISTRY-US, V35, P6393, DOI 10.1021/bi952875+; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; CASELLI A, 1994, J BIOL CHEM, V269, P24878; Chou SM, 1996, J NEUROL SCI, V139, P16, DOI 10.1016/0022-510X(96)00090-1; Epe B, 1996, NUCLEIC ACIDS RES, V24, P4105, DOI 10.1093/nar/24.21.4105; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; FUKUDA M, 1978, J BIOL CHEM, V253, P2419; Gow AJ, 1996, FEBS LETT, V385, P63, DOI 10.1016/0014-5793(96)00347-X; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; HARRISON ML, 1994, J BIOL CHEM, V269, P955; HARRISON ML, 1991, J BIOL CHEM, V266, P4106; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; ISCHIROPOULOS H, 1995, FEBS LETT, V364, P279, DOI 10.1016/0014-5793(95)00307-U; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; JENKINS JD, 1984, J BIOL CHEM, V259, P9374; KAUL R K, 1983, Journal of Biological Chemistry, V258, P7981; KEY MMB, 1996, CELL MOL BIOL, V42, P919; Kong SK, 1996, P NATL ACAD SCI USA, V93, P3377, DOI 10.1073/pnas.93.8.3377; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; LANDER HM, 1993, J IMMUNOL, V150, P1509; LOW PS, 1987, J BIOL CHEM, V262, P4592; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; LOW PS, 1993, J BIOL CHEM, V268, P14627; LOW PS, 1995, PROTOPLASMA, V184, P196, DOI 10.1007/BF01276920; MALLOZZI C, 1995, ARCH BIOCHEM BIOPHYS, V321, P345, DOI 10.1006/abbi.1995.1404; Minetti M, 1996, BIOCHEM J, V319, P369, DOI 10.1042/bj3190369; MINETTI M, 1986, J CELL BIOCHEM, V30, P361, DOI 10.1002/jcb.240300409; Mohr S, 1996, J BIOL CHEM, V271, P4209; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; Mondoro TH, 1997, FREE RADICAL BIO MED, V22, P1055, DOI 10.1016/S0891-5849(96)00510-2; Monteiro HP, 1996, FREE RADICAL BIO MED, V21, P323, DOI 10.1016/0891-5849(96)00051-2; MORENO JJ, 1992, CHEM RES TOXICOL, V5, P425, DOI 10.1021/tx00027a017; MORO MA, 1995, BRIT J PHARMACOL, V116, P1999, DOI 10.1111/j.1476-5381.1995.tb16404.x; MURTHY SNP, 1981, J BIOL CHEM, V256, P1203; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Pietraforte D, 1997, BIOCHEM J, V321, P743, DOI 10.1042/bj3210743; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RADI R, 1991, J BIOL CHEM, V266, P4244; ROGALSKI AA, 1989, J BIOL CHEM, V264, P6438; RUBBO H, 1994, J BIOL CHEM, V269, P26066; STECK TL, 1978, BIOCHEMISTRY-US, V17, P1216, DOI 10.1021/bi00600a013; STECK TL, 1973, METHOD ENZYMOL, V31, P178; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; TSAI IH, 1982, J BIOL CHEM, V257, P1438; WAUGH SM, 1985, BIOCHEMISTRY-US, V24, P34, DOI 10.1021/bi00322a006; WINTERBOURN CC, 1990, METHOD ENZYMOL, V186, P265; YANAGI S, 1995, CELL SIGNAL, V7, P185, DOI 10.1016/0898-6568(94)00088-S; Zipser Y, 1996, BIOCHEM J, V314, P881, DOI 10.1042/bj3140881	54	140	142	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1997	11	14					1281	1290		10.1096/fasebj.11.14.9409547	http://dx.doi.org/10.1096/fasebj.11.14.9409547			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YN210	9409547				2022-12-28	WOS:000071144100009
J	Muruganandam, A; Herx, LM; Monette, R; Durkin, JP; Stanimirovic, DB				Muruganandam, A; Herx, LM; Monette, R; Durkin, JP; Stanimirovic, DB			Development of immortalized human cerebromicrovascular endothelial cell line as an in vitro model of the human blood-brain barrier	FASEB JOURNAL			English	Article						SV40 large T antigen; proliferation; immortalization; human; brain endothelial cells	GLUTAMYL-TRANSFERASE TRANSPEPTIDASE; SV40 T-ANTIGEN; SV40-INDUCED IMMORTALIZATION; NEOPLASTIC TRANSFORMATION; EPITHELIAL-CELLS; INVIVO MODELS; INVITRO; ASSAY; IMPLANTATION; FIBROBLASTS	The objective of this study was to generate an immortal cell line representative of specialized human brain microvascular endothelia forming the blood-brain barrier (BBB) in vivo, Human capillary and microvascular endothelial cells (HCEC) were transfected with the plasmid pSV3-neo coding for the SV40 large T antigen and the neomycin gene, The neomycin-resistant transfected cells overcame proliferative senescence, and after a 6-8 wk period of crisis produced immortalization-competent cell colonies, Single-cell clones of near-diploid genotype were isolated from these colonies, propagated, and characterized, Immortalized HCEC (SV-HCEC) exhibited accelerated proliferation rates, but remained serum and anchorage dependent and retained the characteristic cobblestone morphology at confluence, SV-HCEC displayed a stable nuclear expression of SV40 large T antigen, lacked the invasiveness of transformed cells, and maintained major phenotypic properties of early passage control cells including expression of factor VIII-related antigen, uptake of acetylated low-density lipoprotein, binding of fluorescently labeled lectins, expression of transferrin receptor and transferrin receptor-mediated endocytosis, and high activities of the BBB-specific enzymes alkaline phosphatase and gamma-glutamyl transpeptidase, The diffusion of radiolabeled sucrose across SV-HCEC monolayers was fivefold lower than that observed with human lung microvascular endothelial cells, Furthermore, media conditioned by fetal human astrocytes increased the transendothelial electrical resistance of SV-HCEC monolayers by 2.5-fold, Therefore, this newly established human cell line expressing the specialized phenotype of BBB endothelium may serve as a readily available in vitro model for studying the properties of the human BBB.			Muruganandam, A (corresponding author), NATL RES COUNCIL CANADA, INST BIOL SCI, CELLULAR NEUROBIOL GRP, MONTREAL RD CAMPUS, BLDG M-54, OTTAWA, ON K1A 0R6, CANADA.							ABBOTT NJ, 1992, J CELL SCI, V103, P23; ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; AMBERGER A, 1993, MOL CHEM NEUROPATHOL, V20, P33, DOI 10.1007/BF03160068; Angelis E.D., 1996, ADV DRUG DELIVERY RE, V18, P193; ARTHUR FE, 1987, DEV BRAIN RES, V36, P155, DOI 10.1016/0165-3806(87)90075-7; BECK DW, 1986, BRAIN RES, V381, P131, DOI 10.1016/0006-8993(86)90700-6; BOREK C, 1980, NATURE, V283, P776, DOI 10.1038/283776a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN KA, 1993, J IMMUNOL METHODS, V163, P13, DOI 10.1016/0022-1759(93)90234-X; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; Conzen SD, 1995, ONCOGENE, V11, P2295; DEHOUCK MP, 1992, J NEUROCHEM, V58, P1790, DOI 10.1111/j.1471-4159.1992.tb10055.x; DIMRI GP, 1994, COLD SPRING HARB SYM, V59, P67, DOI 10.1101/SQB.1994.059.01.010; DOROVINIZIS K, 1991, LAB INVEST, V64, P425; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; FICKLING SA, 1992, EXP CELL RES, V201, P517, DOI 10.1016/0014-4827(92)90303-P; Frey Andreas, 1993, P339; GERHART DZ, 1988, BRAIN RES BULL, V21, P785, DOI 10.1016/0361-9230(88)90047-0; GIORDANO M, 1994, METH NEUROSCI, V21, P308; GOLDSTEIN GW, 1986, SCI AM, V255, P74, DOI 10.1038/scientificamerican0986-74; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Greenwood J, 1996, J NEUROIMMUNOL, V71, P51, DOI 10.1016/S0165-5728(96)00130-0; Hurst RD, 1996, J CELL PHYSIOL, V167, P81, DOI 10.1002/(SICI)1097-4652(199604)167:1<81::AID-JCP9>3.3.CO;2-F; Joo F, 1996, PROG NEUROBIOL, V48, P255, DOI 10.1016/0301-0082(95)00046-1; KAKUNAGA T, 1978, P NATL ACAD SCI USA, V75, P1334, DOI 10.1073/pnas.75.3.1334; KIRINAKA H, 1995, BIOSCI BIOTECH BIOCH, V59, P912, DOI 10.1271/bbb.59.912; LAL B, 1994, P NATL ACAD SCI USA, V91, P9695, DOI 10.1073/pnas.91.21.9695; LATTERA J, 1990, J CELL PHYSL, V144, P204; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAXWELL K, 1987, BRAIN RES, V410, P309, DOI 10.1016/0006-8993(87)90329-5; MISCHECK U, 1989, CELL TISSUE RES, V256, P221; Nagy Zoltan, 1996, Keio Journal of Medicine, V45, P200; PARDRIDGE WM, 1990, J PHARMACOL EXP THER, V253, P884; PRICE TNC, 1994, ONCOGENE, V9, P2897; Quinonero J, 1997, GENE THER, V4, P111, DOI 10.1038/sj.gt.3300360; REDDEL RR, 1995, INT J CANCER, V61, P199; ROUX F, 1993, ADV EXP MED BIOL, V331, P201; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SMITH JR, 1992, AM J CLIN NUTR, V55, P1215; SPATZ M, 1994, AM J PHYSIOL, V266, pC654, DOI 10.1152/ajpcell.1994.266.3.C654; Stanimirovic D, 1996, J CELL PHYSIOL, V169, P455; Stins MF, 1997, IN VITRO CELL DEV-AN, V33, P243; TAKAHASHI K, 1990, IN VITRO CELL DEV B, V26, P265; TRAUTMAN OD, 1993, FRONTIERS CEREBRAL V, P205; TRAUTMANN OD, 1991, IN VITRO CELL DEV-AN, V27, P771; WHUR P, 1980, BRIT J CANCER, V42, P305, DOI 10.1038/bjc.1980.231; WILSON JM, 1989, SCIENCE, V244, P1344, DOI 10.1126/science.2734614; WORTON RG, 1979, CULTURE ANIMAL CELLS, P165	49	111	119	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1997	11	13					1187	1197		10.1096/fasebj.11.13.9367354	http://dx.doi.org/10.1096/fasebj.11.13.9367354			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367354				2022-12-28	WOS:A1997YE98300017
J	Grune, T; Reinheckel, T; Davies, KJA				Grune, T; Reinheckel, T; Davies, KJA			Degradation of oxidized proteins in mammalian cells	FASEB JOURNAL			English	Review						protein degradation; proteasome complex; oxidation; protein repair mechanism; cellular organelle	OXIDATIVELY-DENATURED PROTEINS; MIXED-FUNCTION OXIDATION; LENS EPITHELIAL-CELLS; RED BLOOD-CELLS; OXYGEN RADICALS; GLUTAMINE-SYNTHETASE; MITOCHONDRIAL-MEMBRANE; SELECTIVE DEGRADATION; MODIFIED HEMOGLOBIN; AMINO-ACIDS	Protein oxidation in vivo is a natural consequence of aerobic life. Oxygen radicals and other activated oxygen species generated as by-products of cellular metabolism or from environmental sources cause modifications to the amino acids of proteins that generally result in loss of protein function/enzymatic activity. Oxidatively modified proteins can undergo direct chemical fragmentation or can form large aggregates due to covalent cross-linking reactions and increased surface hydrophobicity. Mammalian cells exhibit only limited direct repair mechanisms and most oxidized proteins undergo selective proteolysis. The proteasome appears to be largely responsible for the degradation of soluble intracellular proteins. In most cells, oxidized proteins are cleaved in an ATP-and ubiquitin-independent pathway by the 20 S ''core'' proteasome. The proteasome complex recognizes hydrophobic amino acid residues, aromatic residues, and bulky aliphatic residues that are exposed during the oxidative rearrangement of secondary and tertiary protein structure: increased surface hydrophobicity is a feature common to all oxidized proteins so far tested. The recognition of such (normally shielded) hydrophobic residues is the suggested mechanism by which proteasome catalyzes the selective removal of oxidatively modified cell proteins. By minimizing protein aggregation and cross-linking and by removing potentially toxic protein fragments, proteasome plays a key role in the overall antioxidant defenses that minimize the ravages of aging and disease.	UNIV SO CALIF, ETHEL PERCY ANDRUS GERONTOL CTR, LOS ANGELES, CA 90089 USA; HUMBOLDT UNIV BERLIN, FAC MED, D-10098 BERLIN, GERMANY; UNIV MAGDEBURG, DEPT CLIN BIOCHEM, D-39120 MAGDEBURG, GERMANY	University of Southern California; Humboldt University of Berlin; Otto von Guericke University			Reinheckel, Thomas/AAL-9761-2021	Reinheckel, Thomas/0000-0001-9866-9105; Grune, Tilman/0000-0003-4775-9973; Davies, Kelvin/0000-0001-7790-3003	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003598, R56ES003598, R23ES003598] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES-03598] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEPPU M, 1994, BBA-BIOMEMBRANES, V1196, P81, DOI 10.1016/0005-2736(94)90298-4; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; BUSS H, 1997, IN PRESS FREE RADICA; CERVERA J, 1988, FASEB J, V2, P2591, DOI 10.1096/fasebj.2.10.2898411; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAVIES K J A, 1986, Journal of Free Radicals in Biology and Medicine, V2, P155, DOI 10.1016/S0748-5514(86)80066-6; Davies KJA, 1995, BIOCHEM SOC SYMP, P1, DOI 10.1042/bss0610001; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1993, BIOCHEM SOC T, V21, P346, DOI 10.1042/bst0210346; DAVIES KJA, 1987, J BIOL CHEM, V262, P8220; DAVIES KJA, 1987, J BIOL CHEM, V262, P9908; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; DEAN RT, 1986, BIOCHEM J, V240, P489, DOI 10.1042/bj2400489; DEAN RT, 1993, TRENDS BIOCHEM SCI, V18, P437, DOI 10.1016/0968-0004(93)90145-D; GARRISON WM, 1962, RADIAT RES, V16, P483, DOI 10.2307/3571084; GIULIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329, DOI 10.1006/abbi.1994.1245; GIULIVI C, 1993, J BIOL CHEM, V268, P8752; GRANT AJ, 1993, FREE RADICAL RES COM, V18, P259, DOI 10.3109/10715769309147493; GRANT AJ, 1993, FREE RADICAL RES COM, V19, P125, DOI 10.3109/10715769309056507; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HUANG LL, 1995, EXP EYE RES, V61, P45, DOI 10.1016/S0014-4835(95)80057-3; IVY GO, 1984, SCIENCE, V226, P985, DOI 10.1126/science.6505679; JAHNGEN JH, 1986, J BIOL CHEM, V261, P3760; JAHNGENHODGE J, 1994, METHOD ENZYMOL, V233, P512; JESSUP W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P167, DOI 10.1016/0005-2760(92)90287-6; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; MARCILLAT O, 1988, BIOCHEM J, V254, P677, DOI 10.1042/bj2540677; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; MORTENSEN AM, 1991, TOXICOL APPL PHARM, V110, P435, DOI 10.1016/0041-008X(91)90045-G; MURAKAMI K, 1990, FREE RADICAL BIO MED, V8, P217, DOI 10.1016/0891-5849(90)90066-R; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2; PACIFICI RE, 1991, GERONTOLOGY, V37, P166; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PUIG A, 1994, J BIOL CHEM, V269, P7764; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROCK KL, 1993, BIOCHEM J, V291, P1; SALO DC, 1990, J BIOL CHEM, V265, P11919; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; STADTMAN ER, 1986, TRENDS BIOCHEM SCI, V11, P11, DOI 10.1016/0968-0004(86)90221-5; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; TAYLOR A, 1987, FREE RADICAL BIO MED, V3, P371, DOI 10.1016/0891-5849(87)90015-3; TOYOKUNI S, 1994, P NATL ACAD SCI USA, V91, P2616, DOI 10.1073/pnas.91.7.2616; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P8742, DOI 10.1073/pnas.90.18.8742; UCHIDA K, 1993, J BIOL CHEM, V268, P6388; UCHIDA K, 1994, BIOCHEMISTRY-US, V33, P12487, DOI 10.1021/bi00207a016; UCHIDA K, 1994, METHOD ENZYMOL, V233, P371; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; WOLFF SP, 1986, TRENDS BIOCHEM SCI, V11, P27, DOI 10.1016/0968-0004(86)90228-8; YOUNG J, 1993, J BIOL CHEM, V268, P19810	60	664	685	0	51	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1997	11	7					526	534		10.1096/fasebj.11.7.9212076	http://dx.doi.org/10.1096/fasebj.11.7.9212076			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XH342	9212076				2022-12-28	WOS:A1997XH34200004
J	Maruyama, K				Maruyama, K			Connectin/titin, giant elastic protein of muscle	FASEB JOURNAL			English	Review						muscle elasticity; passive tension; myosin filament; Z line; myofibrillogenesis; M line	RABBIT SKELETAL-MUSCLE; STRIATED-MUSCLE; IMMUNOELECTRON MICROSCOPY; MYOSIN-FILAMENTS; CARDIAC-MUSCLE; TITIN; EXTENDS; DOMAIN; ACTIN; LINE	The structure and function of the giant elastic protein connectin/titin are described on the basis of recent investigations. The 3000 kDa protein links the Z line to the myosin filament in striated muscle sarcomeres. The NH2-terminal region of connectin filament is involved in the Z line binding, and the COOP-terminal region is bound onto the myosin filament with an overlap between the counter-connectin filaments at the M line. The PEVK region in the I band is shown to be mainly responsible for passive tension generation. The longitudinal continuity of myosin-, actin-free sarcomeres is explained by the linkage of freed connectin filaments extending from both sides of the Z lines in a sarcomere. The role of connectin in myofibrillar differentiation and the biodiversity of connectin-related proteins in the animal kingdom are briefly reviewed.			Maruyama, K (corresponding author), CHIBA UNIV,OFF PRESIDENT,CHIBA 263,JAPAN.							Benian GM, 1996, ADV BIOPHYS, V33, P183; Bennett PM, 1996, J MOL BIOL, V259, P896, DOI 10.1006/jmbi.1996.0367; Bullard B, 1996, ADV BIOPHYS, V33, P211; CRAIG R, 1977, J MOL BIOL, V109, P69, DOI 10.1016/S0022-2836(77)80046-6; EINHEBER S, 1990, P NATL ACAD SCI USA, V87, P2157, DOI 10.1073/pnas.87.6.2157; FUNATSU T, 1993, J CELL BIOL, V120, P711, DOI 10.1083/jcb.120.3.711; FURST DO, 1988, J CELL BIOL, V106, P1563, DOI 10.1083/jcb.106.5.1563; Gautel M, 1996, J CELL SCI, V109, P2747; Gautel M, 1996, FEBS LETT, V385, P11, DOI 10.1016/0014-5793(96)00338-9; HIGUCHI H, 1988, J MUSCLE RES CELL M, V9, P491, DOI 10.1007/BF01738754; HOROWITS R, 1989, J CELL BIOL, V109, P2169, DOI 10.1083/jcb.109.5.2169; HOUMEIDA A, 1995, J CELL BIOL, V131, P1471, DOI 10.1083/jcb.131.6.1471; Improta S, 1996, STRUCTURE, V4, P323, DOI 10.1016/S0969-2126(96)00036-6; Kawamura Y, 1996, ADV BIOPHYS, V33, P175; KIMURA S, 1989, J BIOCHEM-TOKYO, V106, P952, DOI 10.1093/oxfordjournals.jbchem.a122979; LABEIT S, 1992, EMBO J, V11, P1711, DOI 10.1002/j.1460-2075.1992.tb05222.x; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; LABEIT S, 1996, IN PRESS CIRC RES; Linke WA, 1996, J MOL BIOL, V261, P62, DOI 10.1006/jmbi.1996.0441; LUTHER P, 1978, J MOL BIOL, V125, P313, DOI 10.1016/0022-2836(78)90405-9; MANABE T, 1993, J MUSCLE RES CELL M, V14, P654, DOI 10.1007/BF00141562; MARUYAMA K, 1986, INT REV CYTOL, V104, P81, DOI 10.1016/S0074-7696(08)61924-5; MARUYAMA K, 1977, J BIOCHEM, V82, P317; MARUYAMA K, 1994, BIOPHYS CHEM, V50, P73, DOI 10.1016/0301-4622(94)85021-6; MARUYAMA K, 1985, BIOMED RES-TOKYO, V6, P423, DOI 10.2220/biomedres.6.423; MARUYAMA K, 1995, CALCIUM CELL SIGNAL, P73; MARUYAMA K, 1996, MUSCLE ELASTIC PROTE; Obermann WMJ, 1996, J CELL BIOL, V134, P1441, DOI 10.1083/jcb.134.6.1441; Ohtsuka H, 1997, FEBS LETT, V401, P65, DOI 10.1016/S0014-5793(96)01432-9; Politou AS, 1995, BIOPHYS J, V69, P2601, DOI 10.1016/S0006-3495(95)80131-1; Schroeter JP, 1996, J CELL BIOL, V133, P571, DOI 10.1083/jcb.133.3.571; Shimada Y, 1996, ADV BIOPHYS, V33, P223; TAKANOOHMURO H, 1992, BIOCHEM BIOPH RES CO, V183, P31, DOI 10.1016/0006-291X(92)91604-O; TRINICK J, 1994, TRENDS BIOCHEM SCI, V19, P405, DOI 10.1016/0968-0004(94)90088-4; TROMBITAS K, 1993, J MUSCLE RES CELL M, V14, P416, DOI 10.1007/BF00121293; TROMBITAS K, 1995, CIRC RES, V77, P856, DOI 10.1161/01.RES.77.4.856; Turnacioglu KK, 1996, CELL MOTIL CYTOSKEL, V34, P108, DOI 10.1002/(SICI)1097-0169(1996)34:2<108::AID-CM3>3.0.CO;2-7; VANDERLOOP F, 1996, CELL BIOL ASPECTS MU; vanderLoop FTL, 1996, EUR J CELL BIOL, V69, P301; VINKEMEIER U, 1993, J CELL SCI, V106, P319; WANG K, 1993, BIOPHYS J, V64, P1161, DOI 10.1016/S0006-3495(93)81482-6; WANG K, 1979, P NATL ACAD SCI USA, V76, P3698, DOI 10.1073/pnas.76.8.3698; Yajima H, 1996, BIOCHEM BIOPH RES CO, V223, P160, DOI 10.1006/bbrc.1996.0862	43	195	199	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1997	11	5					341	345		10.1096/fasebj.11.5.9141500	http://dx.doi.org/10.1096/fasebj.11.5.9141500			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WX156	9141500				2022-12-28	WOS:A1997WX15600006
J	Varki, A				Varki, A			Sialic acids as ligands in recognition phenomena	FASEB JOURNAL			English	Review						lectins; recognition; binding proteins	CARBOHYDRATE BINDING-SPECIFICITY; ALTERNATIVE COMPLEMENT PATHWAY; ADHESION MOLECULE CD22-BETA; INFLUENZA-C VIRUS; SLUG LIMAX-FLAVUS; CELL-ADHESION; MAACKIA-AMURENSIS; IMMUNOGLOBULIN SUPERFAMILY; LINKED OLIGOSACCHARIDES; ENDOTHELIAL-CELLS	The sialic acids are acidic monosaccharides typically found at the outermost ends of the sugar chains of animal glycoconjugates. They potentially can inhibit intermolecular and intercellular interactions by virtue of their negative charge. However, they carl also act as critical components of ligands recognized by a variety of proteins of animal, plant, and microbial origin (sialic acid binding lectins), Recognition can be affected by specific structural variations and modifications of sialic acids,, their linkage to the underlying sugar chain, the structure of these chains, and the nature of the glycoconjugate to which they are attached, Presented here is a summary of the various proteins that can recognize and bind to this family of monosaccharides, comparing and contrasting the structural requirements and mechanisms involved iu binding, Particular attention is focused on the recently evolving information about sialic acid recognition by certain C-type lectins (the selectins), I-type lectins (e.g., CD22 and sialoadhesin), and a complement regulatory protein (the H protein), The last two instances are examples of the importance of the side chain of sialic acids and the effects of natural substitutions (e.g., 9-O-acetylation) of this part of the molecule.-Varki, A. Sialic acids as ligands in recognition phenomena.			Varki, A (corresponding author), UNIV CALIF SAN DIEGO, CTR CANC,GLYCOBIOL PROGRAM,DIV CELLULAR & MOL MED, CMM E BLDG, RM 1065, LA JOLLA, CA 92093 USA.							AHMED H, 1989, J BIOL CHEM, V264, P18673; Armstrong PB, 1996, J BIOL CHEM, V271, P14717, DOI 10.1074/jbc.271.25.14717; BEUTH J, 1995, GLYCOCONJUGATE J, V12, P1, DOI 10.1007/BF00731862; BROSSMER R, 1992, J BIOL CHEM, V267, P8752; Cohen E., 1984, Progress in Clinical and Biological Research, V157, P55; CROCKER PR, 1995, J CLIN INVEST, V95, P635, DOI 10.1172/JCI117708; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; DORAI DT, 1982, FEBS LETT, V148, P98, DOI 10.1016/0014-5793(82)81251-9; DRICKAMER K, 1995, CURR OPIN STRUC BIOL, V5, P612, DOI 10.1016/0959-440X(95)80052-2; Feizi Ten, 1993, Current Opinion in Structural Biology, V3, P701, DOI 10.1016/0959-440X(93)90053-N; FISCHER E, 1995, GLYCOCONJUGATE J, V12, P707, DOI 10.1007/BF00731268; FISHMAN PH, 1993, ADV LIPID RES, V25, P165; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; FRUTTIGER M, 1995, EUR J NEUROSCI, V7, P511, DOI 10.1111/j.1460-9568.1995.tb00347.x; GOLDHAR J, 1994, METHOD ENZYMOL, V236, P211; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HANASAKI K, 1995, J BIOL CHEM, V270, P7533, DOI 10.1074/jbc.270.13.7533; Harms G, 1996, GLYCOCONJUGATE J, V13, P621, DOI 10.1007/BF00731450; HENSLEY P, 1994, J BIOL CHEM, V269, P23949; HERRLER G, 1991, ADV VIRUS RES, V40, P213; Hirmo S, 1996, GLYCOCONJUGATE J, V13, P1005, DOI 10.1007/BF01053196; Iglesias MM, 1996, GLYCOCONJUGATE J, V13, P967, DOI 10.1007/BF01053192; Kaku H, 1996, J BIOL CHEM, V271, P1480, DOI 10.1074/jbc.271.3.1480; KAKU H, 1993, J BIOL CHEM, V268, P13237; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KARLSSON KA, 1995, CURR OPIN STRUC BIOL, V5, P622, DOI 10.1016/0959-440X(95)80054-9; KAZATCHKINE MD, 1979, J IMMUNOL, V122, P75; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; Kelm S, 1996, GLYCOCONJUGATE J, V13, P913, DOI 10.1007/BF01053186; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KELM S, 1997, IN PRES SURVEY CELL; Kitazume S, 1996, J BIOL CHEM, V271, P6694, DOI 10.1074/jbc.271.12.6694; KLEIN A, 1994, P NATL ACAD SCI USA, V91, P7782, DOI 10.1073/pnas.91.16.7782; KNIBBS RN, 1993, J BIOL CHEM, V268, P18524; KNIBBS RN, 1991, J BIOL CHEM, V266, P83; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; LI CM, 1994, NATURE, V369, P747, DOI 10.1038/369747a0; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; LOOMES LM, 1984, NATURE, V307, P560, DOI 10.1038/307560a0; MANDAL C, 1990, EXPERIENTIA, V46, P433, DOI 10.1007/BF01954221; MERCY PD, 1993, EUR J BIOCHEM, V215, P697, DOI 10.1111/j.1432-1033.1993.tb18081.x; MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982; MICHALEK MT, 1988, J IMMUNOL, V140, P1581; MICHALEK MT, 1988, J IMMUNOL, V140, P1588; MILLER RL, 1982, J BIOL CHEM, V257, P7574; MillerPodraza H, 1996, GLYCOCONJUGATE J, V13, P453, DOI 10.1007/BF00731478; MOCH T, 1987, P NATL ACAD SCI USA, V84, P3462, DOI 10.1073/pnas.84.10.3462; MONSIGNY M, 1980, EUR J BIOCHEM, V104, P147, DOI 10.1111/j.1432-1033.1980.tb04410.x; Mrkoci K, 1996, GLYCOCONJUGATE J, V13, P567, DOI 10.1007/BF00731444; NATH D, 1995, J BIOL CHEM, V270, P26184, DOI 10.1074/jbc.270.44.26184; NORGARD KE, 1993, P NATL ACAD SCI USA, V90, P1068, DOI 10.1073/pnas.90.3.1068; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; NYDEGGER UE, 1978, P NATL ACAD SCI USA, V75, P6078, DOI 10.1073/pnas.75.12.6078; Ofek I., 1990, CURR TOP MICROBIOL, V151, P91; ORLANDI PA, 1992, J CELL BIOL, V116, P901, DOI 10.1083/jcb.116.4.901; PERKINS ME, 1988, J IMMUNOL, V141, P3190; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1995, J BIOL CHEM, V270, P7523, DOI 10.1074/jbc.270.13.7523; POWELL LD, 1994, J BIOL CHEM, V269, P10628; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; POWELL LD, 1996, CURRENT PROTOCOLS MO; Puri KD, 1996, J BIOL CHEM, V271, P5404, DOI 10.1074/jbc.271.10.5404; RAVINDRANATH MH, 1985, J BIOL CHEM, V260, P8850; REUER G, 1996, BIOL CHEM HOPPESEYLE, V377, P325; ROELCKE D, 1990, VOX SANG, V59, P235, DOI 10.1111/j.1423-0410.1990.tb00244.x; ROGERS GN, 1983, NATURE, V304, P76, DOI 10.1038/304076a0; ROGERS GN, 1986, J BIOL CHEM, V261, P5947; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; SCHAUER R, 1991, Glycobiology, V1, P449, DOI 10.1093/glycob/1.5.449; Schauer R, 1995, BIOL SIALIC ACIDS, DOI [10.1007/978-1-4757-9504-2, DOI 10.1007/978-1-4757-9504-2]; SCHULTZE B, 1994, ARCH VIROL, P451; SEN GT, 1995, CARBOHYD RES, V268, P115, DOI 10.1016/0008-6215(94)00311-3; SGROI D, 1993, J BIOL CHEM, V268, P7011; SGROI D, 1995, P NATL ACAD SCI USA, V92, P4026, DOI 10.1073/pnas.92.9.4026; Shi WX, 1996, J BIOL CHEM, V271, P31526, DOI 10.1074/jbc.271.49.31526; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; SJOBERG ER, 1995, J BIOL CHEM, V270, P2921, DOI 10.1074/jbc.270.7.2921; SONG Y, 1995, GLYCOBIOLOGY, V5, P207, DOI 10.1093/glycob/5.2.207; STEHLE T, 1994, NATURE, V369, P160, DOI 10.1038/369160a0; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; VanDamme EJM, 1996, EUR J BIOCHEM, V235, P128, DOI 10.1111/j.1432-1033.1996.00128.x; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; VARKI A, 1997, IN PRESS J CLIN INVE; Vazquez L, 1996, COMP BIOCHEM PHYS B, V113, P355, DOI 10.1016/0305-0491(95)02039-X; Vestweber D, 1996, J CELL BIOCHEM, V61, P585, DOI 10.1002/(SICI)1097-4644(19960616)61:4<585::AID-JCB12>3.0.CO;2-F; WANG WC, 1988, J BIOL CHEM, V263, P4576; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WRIGHT CS, 1992, J BIOL CHEM, V267, P14345; YAMASHITA K, 1992, BIOCHEMISTRY-US, V31, P11647, DOI 10.1021/bi00161a052; YAMASHITA K, 1988, J BIOL CHEM, V263, P17482; Yang LJS, 1996, P NATL ACAD SCI USA, V93, P814, DOI 10.1073/pnas.93.2.814; ZENG FY, 1992, Z NATURFORSCH C, V47, P641	100	473	493	1	38	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1997	11	4					248	255		10.1096/fasebj.11.4.9068613	http://dx.doi.org/10.1096/fasebj.11.4.9068613			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WM850	9068613				2022-12-28	WOS:A1997WM85000006
J	Wang, HC; HarrisonShostak, DC; Lemasters, JJ; Herman, B				Wang, HC; HarrisonShostak, DC; Lemasters, JJ; Herman, B			Contribution of pH-dependent group II phospholipase A(2) to chemical hypoxic injury in rat hepatocytes	FASEB JOURNAL			English	Article						hypoxia; ischemia; phospholipase A(2); anti-sense; oligonucleotides; acidosis	PLASMA-MEMBRANE; ATP DEPLETION; CELL-DEATH; MYOCARDIAL-CELLS; CARDIAC MYOCYTES; ACIDOTIC PH; LIVER; ACIDOSIS; DEGRADATION; ACCUMULATION	Numerous studies have suggested that enhanced membrane phospholipid degradation contributes to hypoxic and ischemic injury, Recently, acidosis has been found to potently protect against hypoxic and ischemic injury, To investigate the interrelationships of these two events in hypoxic injury, we studied the role of a pH-dependent group II phospholipase A(2) (PLA(2), E.C. 3.1.1.4) in chemical hypoxic injury in rat hepatocytes, Northern blot analysis of RNA extracted from normoxic and hypoxic rat hepatocytes with group II rat liver PLA(2)-specific oligonucleotide cDNA probes revealed a 0.9 kb transcript whose abundance was significantly increased in rat hepatocytes within 15 min after initiation of chemical hypoxia and remained high until cells lost viability. Immunofluorescence staining of hepatocytes with polyclonal antibodies that recognize group II PLA(2) demonstrated a substantial increase in the level of PLA(2) protein in hypoxic rat hepatocytes within 30 min of initiation of hypoxic injury. Treatment of hepatocytes with group II PLA(2)-specific anti-sense DNA oligonucleotides: 1) abolished accumulation of PLA(2) protein in hypoxic rat hepatocytes as assessed by immunofluorescence staining with anti-PLA(2) antibodies; 2) decreased the enzymatic activity of PLA(2) manifested as decreased arachidonic acid release in hypoxic hepatocytes; and 3) significantly delayed cell death evoked by chemical hypoxia as indicated by a decrease in propidium iodide uptake, These findings suggest that pH-dependent group II PLA(2) plays an important role in chemical hypoxic injury of rat hepatocytes.	UNIV N CAROLINA, DEPT CELL BIOL & ANAT, SCH MED, CELL BIOL LABS, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Wang, Haichao/AAU-2237-2021; Wang, Haichao/K-6310-2012	Wang, Haichao/0000-0002-0211-9000; Wang, Haichao/0000-0002-0211-9000	NIA NIH HHS [AG07218] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG007218, R01AG007218] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARMSTRONG SC, 1991, AM J PATHOL, V138, P545; BING OHL, 1973, SCIENCE, V180, P1297, DOI 10.1126/science.180.4092.1297; BOND JM, 1991, BIOCHEM BIOPH RES CO, V179, P798, DOI 10.1016/0006-291X(91)91887-I; BONVENTRE JV, 1985, AM J PHYSIOL, V249, pC149, DOI 10.1152/ajpcell.1985.249.1.C149; BUJA LM, 1985, LAB INVEST, V53, P397; CHIARIELLO M, 1987, J PHARMACOL EXP THER, V241, P560; CHIEN KR, 1978, J BIOL CHEM, V253, P4809; CHIEN KR, 1985, J CLIN INVEST, V75, P1770, DOI 10.1172/JCI111889; CHIEN KR, 1977, AM J PATHOL, V88, P539; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROWL RM, 1991, J BIOL CHEM, V266, P2647; CURRIN RT, 1991, FASEB J, V5, P207, DOI 10.1096/fasebj.5.2.2004664; FARBER JL, 1981, ARCH BIOCHEM BIOPHYS, V211, P312, DOI 10.1016/0003-9861(81)90459-8; FLORINECASTEEL K, 1991, FASEB J, V5, P2078, DOI 10.1096/fasebj.5.7.2010060; GORES GJ, 1989, J CLIN INVEST, V83, P386, DOI 10.1172/JCI113896; GORES GJ, 1990, HEPATOLOGY, V11, P690, DOI 10.1002/hep.1840110425; GORES GJ, 1988, AM J PHYSIOL, V255, pC315, DOI 10.1152/ajpcell.1988.255.3.C315; GUNN MD, 1985, AM J PHYSIOL, V249, P1188, DOI 10.1152/ajpheart.1985.249.6.H1188; HARRISON DC, 1991, BIOCHEM BIOPH RES CO, V174, P654, DOI 10.1016/0006-291X(91)91467-Q; HERMAN B, 1988, FASEB J, V2, P146, DOI 10.1096/fasebj.2.2.3342967; KIKUCHIYANOSHITA R, 1993, J BIOCHEM-TOKYO, V114, P33, DOI 10.1093/oxfordjournals.jbchem.a124135; LEMASTERS JJ, 1983, J CELL BIOL, V97, P778, DOI 10.1083/jcb.97.3.778; LIU T, 1993, STROKE, V24, P1746, DOI 10.1161/01.STR.24.11.1746; LOFFLER BM, 1985, BIOCHIM BIOPHYS ACTA, V835, P448, DOI 10.1016/0005-2760(85)90114-6; LYONSGIORDANO B, 1989, BIOCHEM BIOPH RES CO, V164, P488, DOI 10.1016/0006-291X(89)91746-4; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; OTANI H, 1989, AM J PHYSIOL, V257, pH252, DOI 10.1152/ajpheart.1989.257.1.H252; PENTTILA A, 1974, SCIENCE, V185, P277, DOI 10.1126/science.185.4147.277; PRASAD MR, 1991, AM J PHYSIOL, V260, pH877, DOI 10.1152/ajpheart.1991.260.3.H877; SARGENT CA, 1992, J PHARMACOL EXP THER, V262, P1161; SEN A, 1988, J CLIN INVEST, V82, P1333, DOI 10.1172/JCI113735; STEENBERGEN C, 1984, J MOL CELL CARDIOL, V16, P605, DOI 10.1016/S0022-2828(84)80625-2; SUN FF, 1993, BIOCHEM PHARMACOL, V45, P1149, DOI 10.1016/0006-2952(93)90261-T; VANBILSEN M, 1990, J MOL CELL CARDIOL, V22, P155, DOI 10.1016/0022-2828(90)91112-K; VANSCHAIK RHN, 1993, BIOCHIM BIOPHYS ACTA, V1169, P1, DOI 10.1016/0005-2760(93)90075-K; Wang X. F., 1993, Bioimaging, V1, P30, DOI 10.1002/1361-6374(199303)1:1<30::AID-BIO6>3.3.CO;2-Q	37	17	19	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1996	10	11					1318	1325		10.1096/fasebj.10.11.8836046	http://dx.doi.org/10.1096/fasebj.10.11.8836046			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VJ717	8836046				2022-12-28	WOS:A1996VJ71700012
J	Hazen, SA; Waheed, A; Sly, WS; LaNoue, KF; Lynch, CJ				Hazen, SA; Waheed, A; Sly, WS; LaNoue, KF; Lynch, CJ			Differentiation-dependent expression of CA V and the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes	FASEB JOURNAL			English	Article						lipogenesis; pyruvate carboxylase; carbon fixation; trifluormethanesulfonamide; obesity	FATTY-ACID SYNTHESIS; GLUCOSE SYNTHESIS; RODENT TISSUES; UREA SYNTHESIS; ZUCKER RATS; INHIBITION; METABOLISM; LIVER; HEPATOCYTES; OBESITY	The incorporation of radioactivity from C-14-labeled compounds into metabolic intermediates and total lipids was examined in 3T3 adipocytes. The heterocyclic sulfonamide carbonic anhydrase inhibitor (SCAI) 6-ethoxyzolamide (ETZ) caused a decrease (42 +/- 7% of control, IC50 = 2.2 +/- 1.1 x 10(-7) M) in the incorporation of [C-14]bicarbonate into several Krebs cycle intermediates in 3T3-F442A adipocytes. This decrease in pyruvate carboxylase-mediated [C-14] carbon fixation was associated with a reduction in fluorometrically determined [citrate] and [malate]. The ability of ETZ to decrease both the incorporation of radioactivity into and the concentrations of Krebs cycle intermediates was not of sufficient magnitude to lower [ATP], but was associated with a decrease in de novo lipogenesis from [C-14]glucose, De novo lipogenesis was also inhibited to a similar extent by trifluormethanesulfonamide, an aliphatic SCAI, which suggests that the effects are mediated by carbonic anhydrase, ETZ did not inhibit de novo lipogenesis from [C-14]glutamine (12.38 +/- 1.068 nmol/mg protein, ETZ; 12.5 +/- 0.846 nmol/mg protein, DMSO). This suggests that ETZ inhibition of lipogenesis involves an inhibitory effect on pyruvate carboxylase as opposed to acetyl CoA carboxylase, because the incorporation of glutamine into lipids does not involve pyruvate carboxylase. Decreased de novo Lipogenesis was also observed by incubating cultures in media that contained 1 mM bicarbonate (atmosphere:100% humidified air) rather than 25 mM bicarbonate (atmosphere:95% humidified air/5% CO2). This suggests that exogenous CO2/bicarbonate may be required to sustain maximal rates of de novo lipogenesis. Because these results implied that CA V, the mitochondrial isoform of carbonic anhydrase, might be present in adipocytes, CA V levels were measured by immunoblotting, Mitochondrial preparations of adipocytes and liver were found to contain similar concentrations of CA V. Unlike adipocyte CA III, CA V concentrations were not significantly different in lean and obese Zucker rats, However, CA V levels were ninefold higher in differentiated 3T3-FP42A adipocytes compared to undifferentiated adipoblasts. Our data indicate that CA V is relatively abundant in adipocyte mitochondria and exhibits differentiation-dependent expression like pyruvate carboxylase and the cytosolic isozymes CA II and CA III. The possible roles of CA II and CA V in pyruvate carboxylation are discussed.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,DEPT CELLULAR & MOLEC PHYSIOL,COLL MED,HERSHEY,PA 17033; PENN STATE UNIV,CHILDRENS HOSP,HERSHEY,PA 17033; ST LOUIS UNIV,HLTH SCI CTR,EDWARD A DOISY DEPT BIOCHEM & MOLEC BIOL,ST LOUIS,MO 63104	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Saint Louis University			Lynch, Christopher J./E-6875-2010; Wahhed, Abdul/AAA-3099-2020	Lynch, Christopher J./0000-0003-2453-5838; 	NHLBI NIH HHS [HL49244] Funding Source: Medline; NIDDK NIH HHS [DK43402] Funding Source: Medline; NIGMS NIH HHS [GM34182] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL049244, R01HL049244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034182, R01GM034182] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGMEYER HU, 1974, METHODS ENZYMATIC AN; BODE AM, 1994, J BIOL CHEM, V269, P7879; BRAY GA, 1972, J CLIN INVEST, V51, P537, DOI 10.1172/JCI106842; CAO TP, 1978, LIFE SCI, V22, P2067, DOI 10.1016/0024-3205(78)90449-6; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; COULSON RA, 1984, ANN NY ACAD SCI, V429, P505, DOI 10.1111/j.1749-6632.1984.tb12379.x; DJIAN P, 1985, J CELL PHYSIOL, V124, P554, DOI 10.1002/jcp.1041240327; Dodgson S.J., 1991, CARBONIC ANHYDRASES, P3; DODGSON SJ, 1984, ANN NY ACAD SCI, V429, P516, DOI 10.1111/j.1749-6632.1984.tb12380.x; DODGSON SJ, 1991, BIOCHEM CELL BIOL, V69, P761, DOI 10.1139/o91-116; DODGSON SJ, 1989, AM J PHYSIOL, V257, pE791, DOI 10.1152/ajpendo.1989.257.6.E791; DODGSON SJ, 1986, ARCH BIOCHEM BIOPHYS, V251, P198, DOI 10.1016/0003-9861(86)90066-4; DODGSON SJ, 1986, J APPL PHYSIOL, V60, P646, DOI 10.1152/jappl.1986.60.2.646; DODGSON SJ, 1991, CARBONIC ANHYDRASES, P297; DOLE VP, 1960, J BIOL CHEM, V235, P2595; GLENN KC, 1992, ENDOCRINOLOGY, V131, P1115, DOI 10.1210/en.131.3.1115; HALL TJ, 1991, CALCIFIED TISSUE INT, V49, P328, DOI 10.1007/BF02556255; HAUSSINGER D, 1986, BIOCHEM PHARMACOL, V35, P3317, DOI 10.1016/0006-2952(86)90429-6; HAZEN SA, 1995, J LIPID RES, V36, P868; HECK RW, 1994, J BIOL CHEM, V269, P24742; HERBERT JD, 1984, ANN NY ACAD SCI, V429, P525, DOI 10.1111/j.1749-6632.1984.tb12381.x; Khalifah R. G., 1991, CARBONIC ANHYDRASES, P49, DOI DOI 10.1007/978-1-4899-0750-9_4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONGMUIR IS, 1966, NATURE, V209, P393, DOI 10.1038/209393a0; LOWENSTEIN JM, 1971, COMPREHENSIVE BIOCH, P31; LYNCH CJ, 1993, AM J PHYSIOL, V265, pC234, DOI 10.1152/ajpcell.1993.265.1.C234; LYNCH CJ, 1993, AM J PHYSIOL, V264, pE621, DOI 10.1152/ajpendo.1993.264.4.E621; LYNCH CJ, 1995, BIOCHEM J, V310, P197, DOI 10.1042/bj3100197; LYNCH CJ, 1992, AM J PHYSIOL, V262, pE608, DOI 10.1152/ajpendo.1992.262.5.E608; MACKALL JC, 1977, BIOCHEM BIOPH RES CO, V79, P720, DOI 10.1016/0006-291X(77)91171-8; MAREN TH, 1983, ANNU REV PHARMACOL, V23, P439, DOI 10.1146/annurev.pa.23.040183.002255; MAREN TH, 1980, HISTOCHEM J, V12, P183, DOI 10.1007/BF01024548; MAREN TH, 1993, J BIOL CHEM, V268, P26233; METCALFE HK, 1985, BIOCHEM SOC T, V13, P255, DOI 10.1042/bst0130255; NAGAO Y, 1993, P NATL ACAD SCI USA, V90, P7623, DOI 10.1073/pnas.90.16.7623; NAGAO Y, 1994, P NATL ACAD SCI USA, V91, P10330, DOI 10.1073/pnas.91.22.10330; RAMANADHAM M, 1984, ANN NY ACAD SCI, V429, P49; RUBIO V, 1986, BIOSCIENCE REP, V6, P335, DOI 10.1007/BF01116420; SCHNEIDER WC, 1950, J BIOL CHEM, V183, P123; SPENCER IM, 1988, BIOCHEM SOC T, V16, P973, DOI 10.1042/bst0160973; SPENCER IM, 1994, ISOZYME B, V27, P42; SPICER SS, 1990, AM J ANAT, V187, P55, DOI 10.1002/aja.1001870107; SPICER SS, 1979, J HISTOCHEM CYTOCHEM, V27, P820, DOI 10.1177/27.4.109495; STANTON LW, 1991, MOL ENDOCRINOL, V5, P860, DOI 10.1210/mend-5-6-860; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; VANNUCCI SJ, 1989, AM J PHYSIOL, V257, pE871, DOI 10.1152/ajpendo.1989.257.6.E871; WAHEED A, 1992, J BIOL CHEM, V267, P3308; WILLIAMSON JR, 1969, METHOD ENZYMOL, V13, P435	48	61	64	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1996	10	4					481	490		10.1096/fasebj.10.4.8647347	http://dx.doi.org/10.1096/fasebj.10.4.8647347			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UE557	8647347				2022-12-28	WOS:A1996UE55700012
J	VanDam, AM; DeVries, HE; Kuiper, J; Zijlstra, FJ; DeBoer, AG; Tilders, FJH; Berkenbosch, F				VanDam, AM; DeVries, HE; Kuiper, J; Zijlstra, FJ; DeBoer, AG; Tilders, FJH; Berkenbosch, F			Interleukin-1 receptors on rat brain endothelial cells: A role in neuroimmune interaction?	FASEB JOURNAL			English	Article						endothelium; brain; prostaglandin	HIGH-AFFINITY; MESSENGER-RNA; T-CELLS; NEURONAL LOCALIZATION; ENDOGENOUS PYROGEN; MOUSE-BRAIN; B-CELLS; BINDING; FEVER; PROSTAGLANDIN-E(2)	Inflammation following an infection induces a range of nonspecific symptoms of sickness in animals and humans. The cytokine interleukin-l (IL-1) mediates many of the brain-mediated symptoms of sickness. Binding sites for IL-1 have been found in mouse brain, but not in the brains of rats, This raises questions as to the involvement of these neuronally localized IL-1 binding sites in the induction of sickness symptoms. Based on observations of IL-1 receptor mRNA in close vicinity to the vasculature in the mouse and rat brain, we studied the possibility that endothelial cells in the rat brain exhibit IL-1 receptors to transduce information to the brain. Ligand binding studies reveal that cultured endothelial cells of adult rat brain exhibit specific binding sites for rat IL-1 beta. Polymerase chain reaction experiments demonstrated that mRNA of the type I but not that of the type II IL-1 receptor is present in rat brain endothelial cells. Incubation of these endothelial cells with recombinant rat IL-1 beta showed a dose-dependent increase in interleukin-6, prostaglandin E(2), and prostacyclin secretion. Intravenous administration of rat IL-1 beta to adult rats enhanced prostaglandin E(2) immnnoreactivity in endothelial cells of the brain microvasculature. These results indicate that functional type I IL-1 receptors are present on endothelial cells of adult rat brain, We postulate that circulating IL-1 can be translated by brain endothelial cells into other signals such as interleukin-6 or prostaglandins that have access to the brain and induce sickness symptoms.	LEIDEN UNIV,SYLVIUS LAB,LEIDEN AMSTERDAM CTR DRUG RES,DIV PHARMACOL,LEIDEN,NETHERLANDS; LEIDEN UNIV,DIV BIOPHARMACEUT,LEIDEN,NETHERLANDS; ERASMUS UNIV ROTTERDAM,DEPT PHARMACOL,3000 DR ROTTERDAM,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Erasmus University Rotterdam	VanDam, AM (corresponding author), FREE UNIV AMSTERDAM,FAC MED,DEPT PHARMACOL,NEUROSCI RES INST,VAN BOECHORSTSTRAAT 7,1081 BT AMSTERDAM,NETHERLANDS.							AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; AKAHOSHI T, 1988, J EXP MED, V167, P924, DOI 10.1084/jem.167.3.924; BAN E, 1991, NEUROSCIENCE, V43, P21, DOI 10.1016/0306-4522(91)90412-H; BERKENBOSCH F, 1987, SCIENCE, V238, P524, DOI 10.1126/science.2443979; BERKENBOSCH F, 1992, STRESS : NEUROENDOCRINE AND MOLECULAR APPROACHES, VOLS 1 AND 2, P623; BORASCHI D, 1991, BLOOD, V78, P1262; BRISTULF J, 1994, EUR CYTOKINE NETW, V5, P319; CANNON JG, 1990, J INFECT DIS, V161, P79, DOI 10.1093/infdis/161.1.79; CHANCE WT, 1991, BRAIN RES, V568, P261, DOI 10.1016/0006-8993(91)91406-Q; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCEANI F, 1986, YALE J BIOL MED, V59, P169; COCEANI F, 1992, CAN J PHYSIOL PHARM, V70, P1590, DOI 10.1139/y92-228; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; CRESTANI F, 1991, BRAIN RES, V542, P330, DOI 10.1016/0006-8993(91)91587-Q; CUNNINGHAM ET, 1992, J NEUROSCI, V12, P1101; DERIJK R, 1992, AM J PHYSIOL, V263, pE1092; DUBIUS JM, 1988, ENDOCRINOLOGY, V123, P2175; FARRAR WL, 1987, J IMMUNOL, V139, P459; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GOTTSCHALL PE, 1991, AM J PHYSIOL, V261, pE362, DOI 10.1152/ajpendo.1991.261.3.E362; GRANOWITZ EV, 1991, J BIOL CHEM, V266, P14147; HAOUR FG, 1990, PROG NEUROENDOCRINIM, V3, P196; HART RP, 1993, J NEUROIMMUNOL, V44, P49, DOI 10.1016/0165-5728(93)90267-3; KATSUKI H, 1990, EUR J PHARMACOL, V181, P323, DOI 10.1016/0014-2999(90)90099-R; KATSUURA G, 1988, BIOCHEM BIOPH RES CO, V156, P61, DOI 10.1016/S0006-291X(88)80805-2; KENT S, 1992, TRENDS PHARMACOL SCI, V13, P24, DOI 10.1016/0165-6147(92)90012-U; KLUGER MJ, 1991, PHYSIOL REV, V71, P93, DOI 10.1152/physrev.1991.71.1.93; KRUEGER JM, 1984, AM J PHYSIOL, V246, pR994, DOI 10.1152/ajpregu.1984.246.6.R994; LEE SC, 1993, J IMMUNOL, V150, P2659; LOWENTHAL JW, 1986, J EXP MED, V164, P1060, DOI 10.1084/jem.164.4.1060; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUMURA K, 1992, BRAIN RES, V581, P292, DOI 10.1016/0006-8993(92)90720-T; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; NAVARRA P, 1991, ENDOCRINOLOGY, V128, P37, DOI 10.1210/endo-128-1-37; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; RISAU W, 1990, J CELL BIOL, V110, P1757, DOI 10.1083/jcb.110.5.1757; RIVIER C, 1991, ENDOCRINOLOGY, V129, P384, DOI 10.1210/endo-129-1-384; RIVIER C, 1989, ENDOCRINOLOGY, V124, P2105, DOI 10.1210/endo-124-5-2105; ROTHWELL NJ, 1991, CAN J PHYSIOL PHARM, V69, P1465, DOI 10.1139/y91-219; SCAPIGLIATI G, 1989, FEBS LETT, V243, P394, DOI 10.1016/0014-5793(89)80169-3; SCHOBITZ B, 1993, EUR J NEUROSCI, V5, P1426, DOI 10.1111/j.1460-9568.1993.tb00210.x; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIRKO S, 1989, AM J PHYSIOL, V256, pR616, DOI 10.1152/ajpregu.1989.256.3.R616; TAKAO T, 1990, ENDOCRINOLOGY, V127, P3070, DOI 10.1210/endo-127-6-3070; TAKAO T, 1993, BRAIN RES, V623, P172, DOI 10.1016/0006-8993(93)90026-J; TORRE D, 1994, CLIN INFECT DIS, V18, P194, DOI 10.1093/clinids/18.2.194; VANDAM AM, 1993, BRAIN RES, V613, P331, DOI 10.1016/0006-8993(93)90922-A; VANDAM AM, 1995, NEUROSCIENCE, V65, P815, DOI 10.1016/0306-4522(94)00549-K; WELLER M, 1991, J NEUROL SCI, V104, P215, DOI 10.1016/0022-510X(91)90313-V; Wong Ma-Li, 1994, Neuroimmunomodulation, V1, P110, DOI 10.1159/000097143; ZIJLSTRA FJ, 1992, EUR J CLIN INVEST, V22, P301, DOI 10.1111/j.1365-2362.1992.tb01466.x	53	112	113	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1996	10	2					351	356		10.1096/fasebj.10.2.8641570	http://dx.doi.org/10.1096/fasebj.10.2.8641570			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641570				2022-12-28	WOS:A1996TY96200021
J	Kuwajima, K				Kuwajima, K			The molten globule state of alpha-lactalbumin	FASEB JOURNAL			English	Review						folding intermediate; protein folding; molecular chaperone	HYDROGEN-EXCHANGE; 2-DIMENSIONAL NMR; FOLDING REACTIONS; 3-STATE DENATURATION; MOLECULAR CHAPERONES; 1.7-A RESOLUTION; SMALL PROTEINS; COMPACT STATE; INTERMEDIATE; LYSOZYME	The molten globule state of alpha-lactalbumin is the best-characterized folding intermediate of globular proteins and has been studied intensively by various spectroscopic and physicochemical techniques, including stopped-flow CD and fluorescence spectroscopies, a hydrogen-exchange technique, H-1-NMR spectroscopy, disulfide-exchange chemistry, site-directed mutagenesis, and calorimetric techniques, This review summarizes recent studies, Major findings about the structure of the molten globule state are: 1) It is highly heterogeneous, having a highly structured alpha-helical domain with the beta-sheet domain being significantly unfolded; and 2) it is not a nonspecific, collapsed polypeptide but already has a native-like tertiary fold, These structural characteristics are essential to fully understand the thermodynamic properties of the molten globule state, which are described in connection with a recently proposed computational approach to predict the structure of the molten globule state of a protein, Mutant proteins in which the stability of the molten globule state was changed were constructed, Studies of the equilibrium unfolding and kinetic refolding of the mutant proteins will provide further insight into the molten globule state as a folding intermediate, In spite of an initial expectation that the structure recognized by an Escherichia coli chaperone, GroEL, is the molten globule, the interaction of GroEL with alpha-lactalbumin in the molten globule state is much weaker than the interaction with more unfolded states of alpha-lactalbumin, a disulfide-reduced form, and disulfide rearranged species.			Kuwajima, K (corresponding author), UNIV TOKYO, SCH SCI, DEPT PHYS, BUNKYO KU, 7-3-1 HONGO, TOKYO 113, JAPAN.							ACHARYA KR, 1989, J MOL BIOL, V208, P99, DOI 10.1016/0022-2836(89)90091-0; ACHARYA KR, 1991, J MOL BIOL, V221, P571; ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P7243, DOI 10.1021/bi00147a006; ALEXANDRESCU AT, 1993, BIOCHEMISTRY-US, V32, P1707, DOI 10.1021/bi00058a003; APENTEN RKO, 1995, FOOD CHEM, V52, P131, DOI 10.1016/0308-8146(94)P4191-H; BALACH J, 1995, NAT STRUCT BIOL, V2, P865; BALDWIN RL, 1995, J BIOMOL NMR, V5, P103; BALDWIN RL, 1993, CURR OPIN STRUC BIOL, V3, P84, DOI 10.1016/0959-440X(93)90206-Z; BALDWIN RL, 1994, BIOESSAYS, V16, P207, DOI 10.1002/bies.950160312; BARRICK D, 1993, PROTEIN SCI, V2, P869, DOI 10.1002/pro.5560020601; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; CHOTHIA C, 1992, NATURE, V357, P543, DOI 10.1038/357543a0; CHYAN CL, 1993, BIOCHEMISTRY-US, V32, P5681, DOI 10.1021/bi00072a025; CREIGHTON TE, 1994, BIOCHEMISTRY-US, V33, P1534, DOI 10.1021/bi00172a033; CREIGHTON TE, 1979, J MOL BIOL, V129, P235, DOI 10.1016/0022-2836(79)90279-1; DELAURETO PP, 1995, BIOCHEMISTRY-US, V34, P12596, DOI 10.1021/bi00039a015; Dobson CM, 1991, CURR OPIN STRUC BIOL, V1, P22, DOI 10.1016/0959-440X(91)90006-F; DOBSON CM, 1994, CURR BIOL, V4, P636, DOI 10.1016/S0960-9822(00)00141-X; Dobson CM., 1992, CURR OPIN STRUC BIOL, V2, P6; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; DOLGIKH DA, 1985, EUR BIOPHYS J BIOPHY, V13, P109, DOI 10.1007/BF00256531; ELLIS RJ, 1993, PHILOS T ROY SOC B, V339, P257, DOI 10.1098/rstb.1993.0023; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.biophys.21.1.243; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3694, DOI 10.1021/bi00065a023; EWBANK JJ, 1995, NAT STRUCT BIOL, V2, P10, DOI 10.1038/nsb0195-10a; EYNARD L, 1992, J AGR FOOD CHEM, V40, P1731, DOI 10.1021/jf00022a002; FINK AL, 1995, ANNU REV BIOPH BIOM, V24, P495, DOI 10.1146/annurev.bb.24.060195.002431; FREIRE E, 1994, BIOPHYS CHEM, V51, P243, DOI 10.1016/0301-4622(94)00045-X; GRIKO YV, 1994, BIOCHEMISTRY-US, V33, P1889, DOI 10.1021/bi00173a036; HAMADA S, 1994, J PROTEIN CHEM, V13, P423, DOI 10.1007/BF01901698; HARATA K, 1992, J BIOL CHEM, V267, P1419; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HILL RL, 1975, ADV ENZYMOL RAMB, V43, P411; HIRAOKA Y, 1985, INT J PEPT PROT RES, V26, P252; HIRAOKA Y, 1980, BIOCHEM BIOPH RES CO, V95, P1098, DOI 10.1016/0006-291X(80)91585-5; HUANG GS, 1995, P NATL ACAD SCI USA, V92, P6878, DOI 10.1073/pnas.92.15.6878; IKEGUCHI M, 1986, BIOCHEMISTRY-US, V25, P6965, DOI 10.1021/bi00370a034; IKEGUCHI M, 1992, BIOCHEMISTRY-US, V31, P12695, DOI 10.1021/bi00165a021; IMPROTA S, 1995, EUR J BIOCHEM, V227, P87, DOI 10.1111/j.1432-1033.1995.tb20362.x; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10436, DOI 10.1021/bi00107a011; JACOBS MD, 1994, P NATL ACAD SCI USA, V91, P449, DOI 10.1073/pnas.91.2.449; JENG MF, 1990, BIOCHEMISTRY-US, V29, P10433, DOI 10.1021/bi00498a001; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; JONES BE, 1995, PROTEIN SCI, V4, P167; KATSUMATA K, 1995, 10TH RINSH INT C STR, P59; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KRONMAN MJ, 1989, CRIT REV BIOCHEM MOL, V24, P565, DOI 10.3109/10409238909080054; KUSZEWSKI J, 1994, PROTEIN SCI, V3, P1945, DOI 10.1002/pro.5560031106; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KUWAJIMA K, 1985, BIOCHEMISTRY-US, V24, P874, DOI 10.1021/bi00325a010; KUWAJIMA K, 1976, J MOL BIOL, V106, P359, DOI 10.1016/0022-2836(76)90091-7; KUWAJIMA K, 1977, J MOL BIOL, V114, P241, DOI 10.1016/0022-2836(77)90208-X; KUWAJIMA K, 1995, PROTEIN STABILITY FO, V40, P115; KUWAJIMA K, 1995, CIRCULAR DICHROISM C; Kuwajima Kunihiro, 1992, Current Opinion in Biotechnology, V3, P462, DOI 10.1016/0958-1669(92)90072-Q; LALA AK, 1992, J BIOL CHEM, V267, P19914; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEVINTHAL C, 1968, J CHIM PHYS PCB, V65, P44, DOI 10.1051/jcp/1968650044; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; MOROZOVA L, 1993, EUR J BIOCHEM, V218, P303, DOI 10.1111/j.1432-1033.1993.tb18378.x; MULLINS LS, 1993, BIOCHEMISTRY-US, V32, P6152, DOI 10.1021/bi00075a006; NITTA K, 1989, EUR J BIOCHEM, V182, P111, DOI 10.1111/j.1432-1033.1989.tb14806.x; NITTA K, 1977, BIOCHIM BIOPHYS ACTA, V490, P200, DOI 10.1016/0005-2795(77)90120-9; NOLTING B, 1993, J AM CHEM SOC, V115, P9879, DOI 10.1021/ja00075a001; NOZAKA M, 1978, BIOCHEMISTRY-US, V17, P3753, DOI 10.1021/bi00611a013; OKAZAKI A, 1994, NAT STRUCT BIOL, V1, P439, DOI 10.1038/nsb0794-439; OKAZAKI A, 1995, NAT STRUCT BIOL, V2, P10, DOI 10.1038/nsb0195-10b; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; OTZEN DE, 1994, P NATL ACAD SCI USA, V91, P10422, DOI 10.1073/pnas.91.22.10422; PARDON E, 1995, J BIOL CHEM, V270, P10514, DOI 10.1074/jbc.270.18.10514; PENG ZY, 1995, PHILOS T ROY SOC B, V348, P43, DOI 10.1098/rstb.1995.0044; PENG ZY, 1994, BIOCHEMISTRY-US, V33, P2136, DOI 10.1021/bi00174a021; PENG ZY, 1995, BIOCHEMISTRY-US, V34, P3248, DOI 10.1021/bi00010a014; PFEIL W, 1986, FEBS LETT, V198, P287, DOI 10.1016/0014-5793(86)80422-7; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PTITSYN OB, 1980, Q REV BIOPHYS, V13, P339, DOI 10.1017/S0033583500001724; PTITSYN OB, 1994, PROTEIN ENG, V7, P593, DOI 10.1093/protein/7.5.593; PTITSYN OB, 1994, FEBS LETT, V341, P15, DOI 10.1016/0014-5793(94)80231-9; QASBA PK, 1984, NATURE, V308, P377, DOI 10.1038/308377a0; REN JS, 1993, J BIOL CHEM, V268, P19292; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; RODER H, 1994, MECHANISMS PROTEIN F, P26; SCHINDLER T, 1995, NAT STRUCT BIOL, V2, P663, DOI 10.1038/nsb0895-663; SCHULMAN BA, 1995, J MOL BIOL, V253, P651, DOI 10.1006/jmbi.1995.0579; SHIMIZU A, 1993, BIOCHEMISTRY-US, V32, P13198, DOI 10.1021/bi00211a031; SHIRAKI K, 1995, J MOL BIOL, V245, P180, DOI 10.1006/jmbi.1994.0015; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; SUGAI S, 1994, ADV BIOPHYS, V30, P37, DOI 10.1016/0065-227X(94)90010-8; UCHIYAMA H, 1995, IN PRESS PROTEIN ENG; VANDERHEEREN G, 1994, J BIOL CHEM, V269, P7090; WU LC, 1995, NAT STRUCT BIOL, V2, P281, DOI 10.1038/nsb0495-281; XIE D, 1994, J MOL BIOL, V242, P62, DOI 10.1006/jmbi.1994.1557; XIE D, 1994, PROTEIN SCI, V3, P2175, DOI 10.1002/pro.5560031203; XIE D, 1993, J MOL BIOL, V232, P5, DOI 10.1006/jmbi.1993.1364; XIE D, 1994, PROTEINS, V19, P291, DOI 10.1002/prot.340190404; XIE D, 1991, BIOCHEMISTRY-US, V30, P10673, DOI 10.1021/bi00108a010; YUTANI K, 1992, J MOL BIOL, V228, P347, DOI 10.1016/0022-2836(92)90824-4; [No title captured]	103	421	431	1	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1996	10	1					102	109		10.1096/fasebj.10.1.8566530	http://dx.doi.org/10.1096/fasebj.10.1.8566530			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566530	Green Submitted			2022-12-28	WOS:A1996TR32800014
J	Pitsillides, AA; Rawlinson, SCF; Suswillo, RFL; Bourrin, S; Zaman, G; Lanyon, LE				Pitsillides, AA; Rawlinson, SCF; Suswillo, RFL; Bourrin, S; Zaman, G; Lanyon, LE			Mechanical strain-induced NO production by bone cells: A possible role in adaptive bone (re)modeling?	FASEB JOURNAL			English	Article						bone; osteocytes; osteoblasts; nitric oxide; mechanical loading	NITRIC-OXIDE SYNTHASE; ENDOTHELIAL-CELLS; CANCELLOUS BONE; GAP-JUNCTIONS; CYCLIC-GMP; L-ARGININE; PROSTACYCLIN; RELEASE; STIMULATION; INVIVO	The structural competence of the skeleton is maintained by an adaptive mechanism in which resident bone cells respond to load-induced strains. To investigate the possible role of the messenger molecule nitric oxide (NO) in this response, we studied NO production in well-characterized organ culture systems, rat long bone-derived osteoblast-like (LOBs) cells, and embryonic chick osteocytes (LOCYs) in monolayer culture. In superfused cancellous bone cores, loading (for 15 min) produces increases in NO2- (stable NO metabolite) release during the loading period, which paralleled those in PGI(2) and PGE(2). Loading of rat vertebrae and ulnae produces increases in NO2- release, and in ulnae NO synthase inhibitors diminish these responses. Transient rapid increases in NO release are stimulated by strain hi both LOBs and LOCYs. Polymerase chain reaction amplification of extracted mRNA shows that rat ulnae, LOBs, and LOCYs express both the inducible anti neuronal (constitutive) isoforms of NO synthase. Adaptability to mechanical strain relies oil assessment of the strain environment followed by modification of bone architecture. Immediate increases in NO production induced by loading suggest the involvement of NO in strain measurement and cellular communication to establish strain distribution, as well as potentially in adaptive changes in bone cell behavior.			Pitsillides, AA (corresponding author), UNIV LONDON ROYAL VET COLL,DEPT VET BASIC SCI,32 BELGRAVE SQ,LONDON NW1 0TU,ENGLAND.			Rawlinson, Simon/0000-0003-2367-7391	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBINA JE, 1993, J IMMUNOL, V150, P5080; BARON R, 1993, PHYSL PHARM BONE, P111; BINDERMAN I, 1988, CALCIFIED TISSUE INT, V42, P261, DOI 10.1007/BF02553753; BINDERMAN I, 1984, CALCIFIED TISSUE INT, V36, pS82, DOI 10.1007/BF02406139; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BOURRIN S, 1994, J BONE MINER RES  S1, V9, pS255; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRIGHTON CT, 1991, J BONE JOINT SURG AM, V73A, P320, DOI 10.2106/00004623-199173030-00002; CHENG MZ, 1994, J BONE MINER RES, V9, P805; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW JWM, 1994, AM J PHYSIOL, V267, pE287, DOI 10.1152/ajpendo.1994.267.2.E287; DALLAS SL, 1993, J BONE MINER RES, V8, P251; DAMOULIS PD, 1994, BIOCHEM BIOPH RES CO, V201, P924, DOI 10.1006/bbrc.1994.1790; DAVIDOVITCH Z, 1977, CALC TISS RES, V24, P73, DOI 10.1007/BF02223299; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DODDS RA, 1994, J HISTOCHEM CYTOCHEM, V42, P599, DOI 10.1177/42.5.8157931; DONALDSON C L, 1970, Metabolism Clinical and Experimental, V19, P1071, DOI 10.1016/0026-0495(70)90032-6; DOTY SB, 1981, CALCIFIED TISSUE INT, V33, P509, DOI 10.1007/BF02409482; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; FUKISHIMA O, 1991, J HISTOCHEM CYTOCHEM, V39, P529; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; Howard G A, 1985, Prog Clin Biol Res, V187, P67; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; JEE WSS, 1987, BONE, V8, P171, DOI 10.1016/8756-3282(87)90017-2; JONES HH, 1977, J BONE JOINT SURG AM, V59, P204, DOI 10.2106/00004623-197759020-00012; JONES SJ, 1993, ANAT EMBRYOL, V187, P343; JONES SJ, 1977, CELL TISSUE RES, V184, P179; KASTEN TP, 1994, P NATL ACAD SCI USA, V91, P3569, DOI 10.1073/pnas.91.9.3569; KAWASE T, 1993, J BONE MINER RES, V8, pS372; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; LANYON LE, 1982, J BIOMECH, V15, P141, DOI 10.1016/0021-9290(82)90246-9; LANYON LE, 1993, CALCIFIED TISSUE INT, V53, pS102, DOI 10.1007/BF01673415; LINCOLN TM, 1989, PHARMACOL THERAPEUT, V41, P479, DOI 10.1016/0163-7258(89)90127-7; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LOWIK CWGM, 1994, J CLIN INVEST, V93, P1465, DOI 10.1172/JCI117124; MACINTYRE I, 1991, P NATL ACAD SCI USA, V88, P2936, DOI 10.1073/pnas.88.7.2936; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; MAYER B, 1986, BIOCHIM BIOPHYS ACTA, V875, P641, DOI 10.1016/0005-2760(86)90088-3; MESSMER UK, 1994, FEBS LETT, V355, P23; MONCADA S, 1991, PHARMACOL REV, V43, P109; MURRAY DW, 1990, CALCIFIED TISSUE INT, V47, P35, DOI 10.1007/BF02555863; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PEAD MJ, 1988, CALCIFIED TISSUE INT, V43, P92, DOI 10.1007/BF02555153; PEAD MJ, 1989, CALCIFIED TISSUE INT, V45, P34, DOI 10.1007/BF02556658; POHL U, 1991, AM J PHYSIOL, V261, pH2016, DOI 10.1152/ajpheart.1991.261.6.H2016; RALSTON SH, 1994, ENDOCRINOLOGY, V135, P330, DOI 10.1210/en.135.1.330; RAWLINSON SCF, 1993, CALCIFIED TISSUE INT, V53, P324, DOI 10.1007/BF01351837; RAWLINSON SCF, 1991, J BONE MINER RES, V6, P1345; RIANCHO JA, 1995, J BONE MINER RES, V10, P439; RUBIN CT, 1984, J BONE JOINT SURG AM, V66A, P397, DOI 10.2106/00004623-198466030-00012; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SHROR K, 1991, BASIC RES CARDIOL, V86, P117; SMITH EL, 1970, J BONE MINER RES, V6, P139; VANDERPLAS A, 1992, J BONE MINER RES, V7, P389; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; WALTER CL, 1987, FOOD ADDIT CONTAMIN, V6, P235; YEH CK, 1984, CALCIFIED TISSUE INT, V36, pS67, DOI 10.1007/BF02406136; ZAMAN G, 1994, J BONE MINER RES, V9, pS303	62	268	276	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1995	9	15					1614	1622		10.1096/fasebj.9.15.8529841	http://dx.doi.org/10.1096/fasebj.9.15.8529841			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TM761	8529841				2022-12-28	WOS:A1995TM76100015
J	Uz, T; Pesold, C; Longone, P; Manev, H				Uz, T; Pesold, C; Longone, P; Manev, H			Aging-associated up-regulation of neuronal 5-lipoxygenase expression: putative role in neuronal vulnerability	FASEB JOURNAL			English	Article						5-LO; aging; kainate; excitotoxicity; DNA damage; hippocampus; inflammation; caffeic acid; leukotriene	KAINIC ACID; NEURODEGENERATIVE DISEASES; ALZHEIMERS-DISEASE; RAT-BRAIN; INHIBITOR; SEIZURES; PROTEIN; KAINATE; AGE; MELATONIN	Aging is associated with neurodegenerative processes, 5-Lipoxygenase (5-LO), which is also expressed in neurons, is the key enzyme in the synthesis of leukotrienes, inflammatory eicosanoids that are capable of promoting neurodegeneration, We hypothesized that neuronal 5-LO expression can be up-regulated in aging and that this may increase the brain's vulnerability to neurodegeneration. We observed differences in the distribution of 5-LO-like immunoreactivity in various brain areas of adult young (2-month-old) vs, old (24-month-old) male rats, Greater 5-LO-like immunoreactivity was found in old vs, young rats, in particular in the dendrites of pyramidal neurons in limbic structures, including the hippocampus, and in layer V pyramidal cells of the frontoparietal cortex and their apical dendrites, The aging-increased expression of neuronal 5-LO protein appears to be due to increased 5-LO gene expression, Using a quantitative reverse transcription/polymerase chain reaction assay and 5-LO-specific oligonucleotide primers and their mutated internal standards, we observed about a 2.5-fold greater hippocampal 5-LO mRNA content in old rats, 5-LO-like immunoreactivity was also observed in small, nonpyramidal cells, which were positive for glutamic acid decarboxylase or glial fibrillary acid protein, This type of 5-LO immunostaining did not increase in the old rats, Hippocampal excitotoxic injury induced by systemic injection of kainate was greater in old rats, Neuroprotection was observed with the 5-LO inhibitor, caffeic acid, Together, these results suggest that aging increases both neuronal 5-LO expression and neuronal vulnerability to 5-LO inhibitor-sensitive excitotoxicity, and indicate that the 5-LO system might play a significant role in the pathobiology of aging-associated neurodegenerative diseases.	Univ Illinois, Inst Psychiat, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Manev, H (corresponding author), Univ Illinois, Inst Psychiat, 1601 W Taylor St,M-C 912, Chicago, IL 60612 USA.	HManev@psych.uic.edu	Longone, Patrizia/G-8428-2016	Longone, Patrizia/0000-0001-8964-1637	FOGARTY INTERNATIONAL CENTER [F05TW005271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG014630] Funding Source: NIH RePORTER; FIC NIH HHS [F05 TW/NS5271-02] Funding Source: Medline; NIA NIH HHS [R03 AG14630-01] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; Aisen PS, 1996, MOL CHEM NEUROPATHOL, V28, P83, DOI 10.1007/BF02815208; BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; BARAN H, 1994, BRAIN RES, V646, P201, DOI 10.1016/0006-8993(94)90078-7; Baskaya MK, 1996, J NEUROSURG, V85, P112, DOI 10.3171/jns.1996.85.1.0112; BIGNAMI A, 1974, J COMP NEUROL, V153, P27, DOI 10.1002/cne.901530104; Breitner JCS, 1996, NEUROBIOL AGING, V17, P789; BRUNGS M, 1994, BIOCHEM BIOPH RES CO, V205, P1572, DOI 10.1006/bbrc.1994.2846; BRUNGS M, 1995, P NATL ACAD SCI USA, V92, P107, DOI 10.1073/pnas.92.1.107; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLEMAN PD, 1988, BRAIN INJURY RECOVER, P235; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DAVIS M, 1995, STROKE, V26, P1072, DOI 10.1161/01.STR.26.6.1072; DAWSON R, 1995, TOXICOL APPL PHARM, V134, P1, DOI 10.1006/taap.1995.1163; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; Giusti P, 1996, FASEB J, V10, P891, DOI 10.1096/fasebj.10.8.8666166; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KADAR T, 1990, BRAIN RES, V512, P113, DOI 10.1016/0006-8993(90)91178-J; KESSLAK JP, 1995, NEUROSCI LETT, V188, P117, DOI 10.1016/0304-3940(95)11415-S; KOSHIHARA Y, 1984, BIOCHIM BIOPHYS ACTA, V792, P92; Lammers CH, 1996, J NEUROCHEM, V66, P147; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; Lu MC, 1996, AM J PHYSIOL-LUNG C, V271, pL547, DOI 10.1152/ajplung.1996.271.4.L547; Manev H, 1996, FASEB J, V10, P1546, DOI 10.1096/fasebj.10.13.8940301; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MEYDANI SN, 1995, CLIN GERIATR MED, V11, P567, DOI 10.1016/S0749-0690(18)30257-X; MOSKOWITZ MA, 1984, SCIENCE, V224, P886, DOI 10.1126/science.6719118; NICHOLS NR, 1993, NEUROBIOL AGING, V14, P421, DOI 10.1016/0197-4580(93)90100-P; Nogawa S, 1997, J NEUROSCI, V17, P2746; Obrenovitch TP, 1997, PROG NEUROBIOL, V51, P39, DOI 10.1016/S0301-0082(96)00049-4; OHTSUKI T, 1995, AM J PHYSIOL-HEART C, V268, pH1249, DOI 10.1152/ajpheart.1995.268.3.H1249; Paxinos G., 1996, RAT BRAIN STEREOTAXI; Pesold C, 1997, NEUROSCIENCE, V79, P477, DOI 10.1016/S0306-4522(96)00609-4; Pilegaard K, 1996, ANAL QUANT CYTOL, V18, P279; PIOMELLI D, 1994, CRIT REV NEUROBIOL, V8, P65; Reiter Russel J., 1994, Acta Neurobiologiae Experimentalis (Warsaw), V54, P31; Rogers J, 1996, NEUROBIOL AGING, V17, P681, DOI 10.1016/0197-4580(96)00115-7; Sambrook J., 2002, MOL CLONING LAB MANU; SANTI MR, 1994, J NEUROCHEM, V63, P1207; Schrader M, 1996, J BIOL CHEM, V271, P19732, DOI 10.1074/jbc.271.33.19732; SCHULZ JB, 1994, J CEREBR BLOOD F MET, V14, P1024, DOI 10.1038/jcbfm.1994.134; SHEPARD SR, 1990, ACT NEUR S, V51, P58; SIMMET T, 1990, PHARMACOL RES, V22, P667, DOI 10.1016/S1043-6618(05)80093-3; SIMMET T, 1990, BRAIN RES, V515, P79, DOI 10.1016/0006-8993(90)90579-Z; SPERK G, 1994, PROG NEUROBIOL, V42, P1, DOI 10.1016/0301-0082(94)90019-1; STEINHILBER D, 1995, J BIOL CHEM, V92, P107; Uz T, 1996, NEUROSCIENCE, V73, P631, DOI 10.1016/0306-4522(96)00155-8; Uz T, 1997, J NEUROCHEM, V69, P2220; Uz Tolga, 1997, Croatian Medical Journal, V38, P205; WALLIS RA, 1993, EUR J PHARMACOL, V238, P165, DOI 10.1016/0014-2999(93)90844-8; WOZNIAK DF, 1991, EXP NEUROL, V114, P250, DOI 10.1016/0014-4886(91)90042-B; ZAWIA N, 1992, BRAIN RES, V589, P333, DOI 10.1016/0006-8993(92)91295-P	53	103	115	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1998	12	6					439	449		10.1096/fasebj.12.6.439	http://dx.doi.org/10.1096/fasebj.12.6.439			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZG118	9535216				2022-12-28	WOS:000072967300005
J	Boss, O; Samec, S; Desplanches, D; Mayet, MH; Seydoux, J; Muzzin, P; Giacobino, JP				Boss, O; Samec, S; Desplanches, D; Mayet, MH; Seydoux, J; Muzzin, P; Giacobino, JP			Effect of endurance training on mRNA expression of uncoupling proteins 1, 2, and 3 in the rat	FASEB JOURNAL			English	Article						exercise training; uncoupling protein; skeletal muscle; heart; adipose tissue	BROWN ADIPOSE-TISSUE; INDUCED THERMOGENESIS; SKELETAL-MUSCLE; EXERCISE; DIET	Endurance exercise training has been shown to decrease diet-induced thermogenesis (DIT) in rats and humans, Zn rodents, most thermogenesis is thought to occur in brown adipose tissue via activation of the uncoupling protein-1 (UCP1) and in skeletal muscle, Since the level of UCP1 mRNA in rat BAT was reported to be unmodified by exercise training, the newly described uncoupling proteins UCP2 and UCP3 could be responsible for the decreased DIT in trained rats, UCP3 mRNA levels in endurance-trained rats were found to be reduced by 76% and 59% in tibialis anterior and soleus muscles, respectively, UCP2 mRNA levels were also decreased in tibialis anterior and in heart by 54% and 41%, respectively, Neither white adipose tissue UCP2 nor brown adipose tissue UCP1, UCP2, and UCP3 mRNA levels were modified, The results of this study show that a need for a higher metabolic efficiency is associated with decreased mRNA expression of the uncoupling proteins in skeletal and heart muscles, which would decrease energy dissipation in these tissues, The down-regulation of UCP3 and UCP2 expressions might also contribute to the rapid weight gain known to occur when exercise training ceased.	Univ Geneva, Fac Med, Dept Biochem Med, CH-1211 Geneva 4, Switzerland; Univ Geneva, Fac Med, Dept Physiol, CH-1211 Geneva, Switzerland; Univ Lyon 1, CNRS, UMR 5578, F-69373 Lyon 08, France	University of Geneva; University of Geneva; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Boss, O (corresponding author), Univ Geneva, Fac Med, Dept Biochem Med, 1 Michel Servet, CH-1211 Geneva 4, Switzerland.							Abdelmalki A, 1996, PFLUG ARCH EUR J PHY, V431, P671, DOI 10.1007/BF02253829; ASTRUP A, 1986, AM J PHYSIOL, V250, pE226, DOI 10.1152/ajpendo.1986.250.2.E226; BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P3097, DOI 10.1093/nar/21.13.3097; Boss O, 1997, FEBS LETT, V412, P111, DOI 10.1016/S0014-5793(97)00755-2; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; BOUILLAUD F, 1986, J BIOL CHEM, V261, P1487; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COYLE EF, 1984, J APPL PHYSIOL, V57, P1857, DOI 10.1152/jappl.1984.57.6.1857; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; LEBLANC J, 1984, CAN J PHYSIOL PHARM, V62, P334, DOI 10.1139/y84-052; LEBLANC J, 1982, J APPL PHYSIOL, V52, P556, DOI 10.1152/jappl.1982.52.3.556; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; LOWRY OH, 1973, FLEXIBLE SYSTEM ENZY, P93; NAGASAWA J, 1990, INT J SPORTS MED, V11, P107, DOI 10.1055/s-2007-1024772; Nakatani A, 1997, J APPL PHYSIOL, V82, P711, DOI 10.1152/jappl.1997.82.2.711; SCARPACE PJ, 1994, PHARMACOL BIOCHEM BE, V49, P1057, DOI 10.1016/0091-3057(94)90264-X; SIMONSEN L, 1993, INT J OBESITY, V17, pS47; THURLBY PL, 1986, CAN J PHYSIOL PHARM, V64, P1111, DOI 10.1139/y86-189; Tremblay A, 1997, METABOLISM, V46, P499, DOI 10.1016/S0026-0495(97)90184-0	22	124	134	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1998	12	3					335	339		10.1096/fasebj.12.3.335	http://dx.doi.org/10.1096/fasebj.12.3.335			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YZ898	9506477				2022-12-28	WOS:000072305500022
J	Dalton, ML; Gadson, PF; Wrenn, RW; Rosenquist, TH				Dalton, ML; Gadson, PF; Wrenn, RW; Rosenquist, TH			Homocysteine signal cascade: production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells	FASEB JOURNAL			English	Article						homocystinuria; PKC; cell proliferation; atherosclerosis	METHYL-D-ASPARTATE; RECEPTOR; ACID; ARTERIOSCLEROSIS; HOMOCYSTINURIA; INJURY; RAT; STIMULATION; METABOLISM; EXPRESSION	Hyperhomocysteinemia has been recognized as an independent risk factor far cerebral, coronary, and peripheral atherosclerosis, To examine the contribution of homocysteine (H[cys]) in the pathogenesis of vascular diseases, we sought to determine whether the H[cys] effect on vascular smooth muscle (VSMC) proliferation is mediated by a specific receptor/transporter or is due to an interaction with growth factors or cytokines. We show that H[cys] induced c-fos and c-myb and increased DNA synthesis and cell proliferation 12-fold in neural crest-derived VSMC (N-VSMC). The H[cys] effect on N-VSMC proliferation is inhibited by Mk-801, a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, a glutamate-gated calcium ion channel receptor, and CGS 19755, a competitive antagonist of NMDA-type glutamate receptor. H[cys] stimulates the synthesis of mass amounts of sn-1,2 diacylglycerol, and activates protein kinase C translocation from the nucleus and cytoplasm to cell membranes. Furthermore, protein kinase C inhibitors block the growth effect mediated by H[cys]. These findings indicate that H[cys]-mediated responses are coupled to diacylglycerol-dependent protein kinase C; activation. Our results suggest that homocysteine activates a receptor/transporter-like factor in neural crest derived smooth muscle.	UNIV NEBRASKA,MED CTR,DEPT CELL BIOL & ANAT,OMAHA,NE 68105; MED COLL GEORGIA,DEPT CELL BIOL & ANAT,AUGUSTA,GA 30912	University of Nebraska System; University of Nebraska Medical Center; University System of Georgia; Augusta University					NHLBI NIH HHS [HL-55940] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055940] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BASTA P, 1992, BIOCHIM BIOPHYS ACTA, V1132, P154, DOI 10.1016/0167-4781(92)90006-L; BILAH MM, 1990, BIOCHEM J, V269, P281; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BOSS V, 1992, J NEUROCHEM, V59, P2340; BOSS V, 1994, MOL PHARMACOL, V45, P1177; CURRAS MC, 1992, MOL PHARMACOL, V41, P520; DUDMAN NPB, 1991, ATHEROSCLEROSIS, V91, P77, DOI 10.1016/0021-9150(91)90189-A; GADSON P, 1990, J CELL BIOCHEM, V43, P185, DOI 10.1002/jcb.240430209; Gadson PF, 1997, EXP CELL RES, V230, P169, DOI 10.1006/excr.1996.3398; HARKER LA, 1983, CIRC RES, V53, P731, DOI 10.1161/01.RES.53.6.731; HARKER LA, 1976, J CLIN INVEST, V58, P731, DOI 10.1172/JCI108520; Kim W.-K., 1995, Society for Neuroscience Abstracts, V21, P521; MCCULLY KS, 1971, NATURE, V231, P391, DOI 10.1038/231391a0; MOELDERS H, 1987, Oncogene, V1, P377; MONAGHAN DT, 1991, EXCITATORY AMINO ACI, P33; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MUDD SH, 1985, AM J HUM GENET, V37, P1; OHMURI S, 1972, PHYSIOL CHEM PHYS M, V4, P286; PALMER E, 1990, DEV BRAIN RES, V51, P132, DOI 10.1016/0165-3806(90)90266-2; PREISS J, 1986, J BIOL CHEM, V261, P8597; SCHWARZ S, 1991, LANCET, V337, P1226, DOI 10.1016/0140-6736(91)92900-M; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; SVARDAL A, 1986, J BIOL CHEM, V261, P3156; Thieszen SL, 1996, EXP CELL RES, V227, P135, DOI 10.1006/excr.1996.0258; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; WILCKEN DEL, 1989, HAEMOSTASIS, V19, P14; WONG EHF, 1991, ANNU REV PHARMACOL, V31, P401; WRENN RW, 1993, IN VITRO CELL DEV-AN, V29A, P73, DOI 10.1007/BF02634374	30	107	123	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1997	11	8					703	711		10.1096/fasebj.11.8.9240971	http://dx.doi.org/10.1096/fasebj.11.8.9240971			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XN027	9240971				2022-12-28	WOS:A1997XN02700010
J	Su, Y; Shi, YF; Shi, YB				Su, Y; Shi, YF; Shi, YB			Cyclosporin A but not FK506 inhibits thyroid hormone-induced apoptosis in tadpole intestinal epithelium	FASEB JOURNAL			English	Article						metamorphosis; immunosuppressant; cell death	PROGRAMMED CELL-DEATH; GENE-EXPRESSION; AMPHIBIAN METAMORPHOSIS; MOLECULAR-BIOLOGY; CONNECTIVE-TISSUE; XENOPUS-LAEVIS; LARVAL; THYMOCYTES; RECEPTOR; INVITRO	Amphibian metamorphosis and mammalian T cell development represent two of the best known systems where developmental programmed cell death through apoptosis takes place. Two immunosuppressants, cyclosporin A (CsA) and FK506, have been demonstrated to inhibit activation-induced cell death in immature T cells and T cell hybridomas. In this study, we have established an in vitro system in which isolated primary tadpole intestinal epithelial cells undergo typical apoptosis upon treatment with thyroid hormone (T-3), the causative agent of metamorphosis. It is surprising that this T-3-induced apoptosis was found to be inhibited only by CsA but not by FK506, whereas both immunosuppressants block activation-induced apoptosis in T cells. Since T-3 exerts its effect primarily by regulating gene transcription through direct binding to nuclear thyroid hormone receptors, our results strongly suggest that except for their similarity in the T cell receptor-mediated signal transduction process, CsA, but not FK506, also blocks another yet-unidentified step during the induction of apoptosis. The identification of this novel function of CsA may provide an important clue toward the understanding of the mechanism of apoptosis and helps in designing better clinical applications of the immunosuppressants.	NICHHD, MOL EMBRYOL LAB, NIH, BETHESDA, MD 20892 USA; AMER RED CROSS, HOLLAND LAB, DEPT IMMUNOL, ROCKVILLE, MD 20855 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); American Red Cross				Shi, Yun-Bo/0000-0002-6330-0639				BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; Brown DD, 1996, P NATL ACAD SCI USA, V93, P1924, DOI 10.1073/pnas.93.5.1924; BUCKBINDER L, 1992, J BIOL CHEM, V267, P25786; Dauca M., 1985, METAMORPHOSIS, P36; Dodd M.H.I., 1976, P467; Gilbert L, 1981, METAMORPHOSIS PROBLE; Gilbert LI, 1996, METAMORPHOSIS POST E; HORNE SM, 1995, ARCH MICROBIOL, V163, P357, DOI 10.1007/s002030050215; ISHIZUYAOKA A, 1987, ANAT ANZEIGER, V164, P81; ISHIZUYAOKA A, 1992, J MORPHOL, V213, P185, DOI 10.1002/jmor.1052130205; ISHIZUYAOKA A, 1991, IN VITRO CELL DEV B, V27, P853; ISHIZUYAOKA A, 1992, ROUX ARCH DEV BIOL, V201, P322, DOI 10.1007/BF00592113; Izutsu Y, 1996, DIFFERENTIATION, V60, P277, DOI 10.1046/j.1432-0436.1996.6050277.x; IZUTSU Y, 1993, J EXP ZOOL, V266, P163, DOI 10.1002/jez.1402660211; KERR JFR, 1974, J CELL SCI, V14, P571; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARSHALL JA, 1978, J ANAT, V126, P133; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; MONTAGUE JW, 1994, J BIOL CHEM, V269, P18877; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; PAHL A, 1992, J BACTERIOL, V174, P5888, DOI 10.1128/jb.174.18.5888-5894.1992; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; SHI YB, 1994, DEV BIOL, V161, P48, DOI 10.1006/dbio.1994.1006; Shi YB, 1996, CURR TOP DEV BIOL, V32, P205, DOI 10.1016/S0070-2153(08)60429-9; SHI YB, 1993, J BIOL CHEM, V268, P20312; SHI YB, 1994, TRENDS ENDOCRIN MET, V5, P14, DOI 10.1016/1043-2760(94)90116-3; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; Shi Yun-Bo, 1996, Journal of Biomedical Science, V3, P307, DOI 10.1007/BF02257960; TATA JR, 1993, BIOESSAYS, V15, P239, DOI 10.1002/bies.950150404; TATA JR, 1991, DEV BIOL, V146, P72, DOI 10.1016/0012-1606(91)90447-B; TELFORD WG, 1991, CELL PROLIFERAT, V24, P447, DOI 10.1111/j.1365-2184.1991.tb01173.x; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WANG Z, 1993, J BIOL CHEM, V268, P16270; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAZDANBAKHSH K, 1995, P NATL ACAD SCI USA, V92, P437, DOI 10.1073/pnas.92.2.437; YOSHIZATO K, 1989, INT REV CYTOL, V119, P97	41	27	28	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1997	11	7					559	565		10.1096/fasebj.11.7.9212079	http://dx.doi.org/10.1096/fasebj.11.7.9212079			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XH342	9212079				2022-12-28	WOS:A1997XH34200007
J	Beck, L; DAmore, PA				Beck, L; DAmore, PA			Vascular development: Cellular and molecular regulation	FASEB JOURNAL			English	Review						endothelial cell; tissue factor; PDGF; TGF-beta; receptor	ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; SMOOTH-MUSCLE CELLS; ANGIOGENESIS IN-VITRO; INTEGRIN ALPHA(V)BETA(3); BLOOD-VESSELS; EMBRYONIC NEOVASCULARIZATION; BETA-RECEPTOR; MOUSE EMBRYO; EXPRESSION	The vascular system forms through a combination of vasculogenesis and angiogenesis. In vasculogenesis, vessels form de novo via the assembly of endothelial precursors called angioblasts, whereas in angiogenesis new vessels arise by migration and proliferation of endothelial cells from preexisting vessels. Although the two processes are distinct in some respects, recent evidence suggests that they share a number of regulatory mechanisms. The identification of a number of defined growth factors, observations of genetically manipulated mice, and the recognition of the importance of cell-cell interactions have greatly expanded our understanding of the regulation of vascularization. The paracrine actions of a variety of polypeptide growth factors, including platelet-derived growth factor, vascular endothelial growth factor, transforming growth factor-beta, and the angiopoietins, appear to be orchestrated in a complex sequence of steps that lead to the development of the adult vascular system, Thus, communication between the forming vasculature and the tissue parenchyma, as well as interactions among cells of the vascular wall, all appear to influence vascular development and growth.	CHILDRENS HOSP,SURG RES LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM BIOL & BIOMED SCI,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			D'Amore, Patricia/G-5660-2017	D'Amore, Patricia/0000-0001-9652-8974				ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; BASSON CT, 1992, J CELL PHYSIOL, V153, P118, DOI 10.1002/jcp.1041530116; BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Clark RAF, 1996, AM J PATHOL, V148, P1407; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; CORJAY MH, 1989, J BIOL CHEM, V264, P10501; Cui JS, 1996, NATURE, V384, P66, DOI 10.1038/384066a0; DAMORE PA, 1993, GROWTH FACTORS, V8, P61, DOI 10.3109/08977199309029135; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; DRAKE CJ, 1995, J CELL SCI, V108, P2655; DRAKE CJ, 1995, P NATL ACAD SCI USA, V92, P7657, DOI 10.1073/pnas.92.17.7657; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FLAMME I, 1992, DEVELOPMENT, V116, P435; FLAMME I, 1995, DEV BIOL, V171, P399, DOI 10.1006/dbio.1995.1291; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Hatva E, 1996, J NEUROPATH EXP NEUR, V55, P1124, DOI 10.1097/00005072-199611000-00003; HEIMARK RL, 1986, SCIENCE, V233, P1078, DOI 10.1126/science.3461562; HOLMGREN L, 1991, DEVELOPMENT, V113, P749; Hungerford JE, 1996, DEV BIOL, V178, P375, DOI 10.1006/dbio.1996.0225; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; KORHONEN J, 1994, ONCOGENE, V9, P395; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; MCLEOD DS, 1987, MICROVASC RES, V33, P257, DOI 10.1016/0026-2862(87)90021-5; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLER JW, 1994, AM J PATHOL, V145, P574; NICOSIA RF, 1995, LAB INVEST, V73, P658; NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; PARDANAUD L, 1989, DEVELOPMENT, V105, P473; Partanen J, 1996, DEVELOPMENT, V122, P3013; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Rohovsky Stephanie A., 1996, Surgical Forum, V47, P390; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SCHATTEMAN GC, 1995, TERATOLOGY, V51, P351, DOI 10.1002/tera.1420510602; SCHLONDORFF D, 1987, FASEB J, V1, P272, DOI 10.1096/fasebj.1.4.3308611; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHINBROT E, 1994, DEV DYNAM, V199, P169, DOI 10.1002/aja.1001990302; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; WALDO KL, 1994, ANAT RECORD, V239, P315, DOI 10.1002/ar.1092390310; ZHANG YM, 1994, J CLIN INVEST, V94, P1320, DOI 10.1172/JCI117451	67	415	449	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1997	11	5					365	373		10.1096/fasebj.11.5.9141503	http://dx.doi.org/10.1096/fasebj.11.5.9141503			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WX156	9141503				2022-12-28	WOS:A1997WX15600009
J	Bokoch, GM				Bokoch, GM			Interplay between Ras-related and heterotrimeric GTP binding proteins: Lifestyles of the BIG and little	FASEB JOURNAL			English	Article						G-protein; guanine nucleotide exchange factor; Pleckstrin homology; MAPK; PAK1	BETA-GAMMA-SUBUNITS; GUANINE-NUCLEOTIDE EXCHANGE; PLECKSTRIN HOMOLOGY DOMAINS; ADRENERGIC-RECEPTOR KINASE; MAP KINASE; LYSOPHOSPHATIDIC ACID; PH DOMAINS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PHOSPHOINOSITIDE-3 KINASE; TYROSINE PHOSPHORYLATION	Directed interactions of heterotrimeric G-proteins coupled to receptors responding to extracellular signals and small Res-related GTPases that control a variety of intracellular processes are being elucidated by recent work, We explore two of the most well-characterized pathways that couple big G-proteins to their smaller relatives.	SCRIPPS RES INST, DEPT CELL BIOL IMM14, LA JOLLA, CA 92037 USA	Scripps Research Institute	Bokoch, GM (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOKOCH GM, 1995, TRENDS CELL BIOL, V5, P109, DOI 10.1016/S0962-8924(00)88960-6; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; FAURE M, 1994, J BIOL CHEM, V269, P7851; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HOWE LR, 1993, J BIOL CHEM, V268, P20717; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; ITO A, 1995, FEBS LETT, V368, P183, DOI 10.1016/0014-5793(95)00643-N; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NIELSEN O, 1995, SEMIN CELL BIOL, V6, P95, DOI 10.1016/1043-4682(95)90006-3; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; QUI RG, 1995, NATURE, V374, P457; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; TIGYI G, 1994, P NATL ACAD SCI USA, V91, P1908, DOI 10.1073/pnas.91.5.1908; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WANG DS, 1994, BIOCHEM BIOPH RES CO, V203, P29, DOI 10.1006/bbrc.1994.2144; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; WINITZ S, 1993, J BIOL CHEM, V268, P19196; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246	71	31	31	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1996	10	11					1290	1295		10.1096/fasebj.10.11.8836042	http://dx.doi.org/10.1096/fasebj.10.11.8836042			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VJ717	8836042				2022-12-28	WOS:A1996VJ71700008
J	CORBETT, JA; SWEETLAND, MA; LANCASTER, JR; MCDANIEL, ML				CORBETT, JA; SWEETLAND, MA; LANCASTER, JR; MCDANIEL, ML			A 1-HOUR PULSE WITH IL-1-BETA INDUCES FORMATION OF NITRIC-OXIDE AND INHIBITS INSULIN-SECRETION BY RAT ISLETS OF LANGERHANS - EVIDENCE FOR A TYROSINE KINASE SIGNALING MECHANISM	FASEB JOURNAL			English	Note						NITRIC OXIDE; INTERLEUKIN-1; ISLET; IRONNITROSYL COMPLEX; TYROSINE KINASE	TUMOR-NECROSIS-FACTOR; REQUIRES GENE-TRANSCRIPTION; L-ARGININE; PANCREATIC-ISLETS; ACTIVATED MACROPHAGES; BETA-CELLS; INTERFERON-GAMMA; INTERLEUKIN-1; PROTEIN; COMPLEXES	Nitric oxide has been implicated as the effector molecule that mediates interleukin-1beta (IL-1beta)-induced inhibition of glucose-stimulated insulin secretion by rat islets. Brief exposures of islets (1 h) to IL-1beta have been shown to inhibit glucose-stimulated insulin secretion at 8 or 18 h after removal of this cytokine. The purpose of this investigation was to determine if brief exposures of islets to IL-1beta are sufficient to induce the formation of nitric oxide and to examine the signaling process associated with IL-1beta-induced expression of nitric oxide synthase. We demonstrate that a 1-h pretreatment of islets with IL-1beta followed by an 8-h incubation in the absence of this cytokine results in inhibition of glucose-stimulated insulin secretion (50%), which is completely prevented by pretreatment of islets with the nitric oxide synthase inhibitor N(G)-monomethyl-L-arginine (NMMA). The production of nitric oxide by islets under the se pulse conditions is demonstrated by IL-1beta-induced nitrite and electron paramagnetic resonance-detectable iron-nitrosyl complex formation, both of which are prevented by NMMA. IL-1beta initiates a signal transduction process resulting in the expression of nitric oxide synthase. The signaling process appears to require the activation of a tyrosine kinase, since the tyrosine kinase inhibitor genistein prevents both IL-1beta-induced inhibition of insulin secretion by islets and formation of nitric oxide by the insulinoma cell line RINm5F. These results show that short exposures of islets to IL-1beta are sufficient to induce the formation of nitric oxide resulting in inhibition of glucose-stimulated insulin secretion and that a tyrosine kinase may participate in the early signaling events required for IL-1beta to induce the expression of nitric oxide synthase.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, BOX 8118, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA; UTAH STATE UNIV, DEPT CHEM & BIOCHEM, LOGAN, UT 84322 USA	Washington University (WUSTL); Utah System of Higher Education; Utah State University					NIDDK NIH HHS [DK-06181, DK-08748] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK006181, R01DK006181, F32DK008748] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BENDTZEN K, 1986, SCIENCE, V232, P1545, DOI 10.1126/science.3086977; BERGMANN L, 1992, FEBS LETT, V299, P103, DOI 10.1016/0014-5793(92)80110-3; CHEDID M, 1989, J IMMUNOL, V142, P4301; COMENS PG, 1987, DIABETES, V36, P963, DOI 10.2337/diabetes.36.8.963; CORBETT JA, 1992, DIABETES, V41, P552, DOI 10.2337/diabetes.41.4.552; CORBETT JA, 1992, BIOCHEM J, V287, P229, DOI 10.1042/bj2870229; CORBETT JA, 1991, J BIOL CHEM, V266, P21351; CORBETT JA, 1992, DIABETES, V41, P897, DOI 10.2337/diabetes.41.8.897; CORBETT JA, 1992, J CLIN INVEST, V90, P2384, DOI 10.1172/JCI116129; COYNE DW, 1990, BIOCHEM BIOPH RES CO, V173, P718, DOI 10.1016/S0006-291X(05)80094-4; DOBSON PRM, 1989, J MOL ENDOCRINOL, V2, pR5, DOI 10.1677/jme.0.002R005; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; DRAPIER JC, 1988, EUR J IMMUNOL, V18, P1587, DOI 10.1002/eji.1830181018; EIZIRIK DL, 1992, FEBS LETT, V308, P249, DOI 10.1016/0014-5793(92)81285-T; EIZIRIK DL, 1991, DIABETOLOGIA, V34, P445, DOI 10.1007/BF00403185; EIZIRIK DL, 1992, AUTOIMMUNITY, V12, P127, DOI 10.3109/08916939209150319; FRENCH JF, 1991, J PHARMACOL EXP THER, V259, P260; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HAMMONDS P, 1990, FEBS LETT, V261, P97, DOI 10.1016/0014-5793(90)80645-Y; HELQVIST S, 1991, DIABETOLOGIA, V34, P150, DOI 10.1007/BF00418268; HIBBS JB, 1990, INT CONGR SER, V897, P189; HOFFMAN RA, 1990, J IMMUNOL, V145, P2220; HUGHES JH, 1990, J CLIN INVEST, V86, P856, DOI 10.1172/JCI114785; HUGHES JH, 1990, FEBS LETT, V266, P33, DOI 10.1016/0014-5793(90)81499-E; KILBOURN RG, 1990, J NATL CANCER I, V82, P772, DOI 10.1093/jnci/82.9.772; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LAYCHOCK SG, 1991, ENDOCRINOLOGY, V129, P3043, DOI 10.1210/endo-129-6-3043; MANDRUPPOULSEN T, 1986, ALLERGY, V41, P250, DOI 10.1111/j.1398-9995.1986.tb02025.x; MANDRUPPOULSEN T, 1990, CURR TOP MICROBIOL, V164, P169; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; MCDANIEL ML, 1988, DIABETES, V37, P1311, DOI 10.2337/diabetes.37.10.1311; MONCADA S, 1991, PHARMACOL REV, V43, P109; OLKEN NM, 1991, BIOCHEM BIOPH RES CO, V177, P828, DOI 10.1016/0006-291X(91)91864-9; PELLAT C, 1990, BIOCHEM BIOPH RES CO, V166, P119, DOI 10.1016/0006-291X(90)91919-J; PFEILSCHIFTER J, 1992, EUR J BIOCHEM, V203, P251, DOI 10.1111/j.1432-1033.1992.tb19854.x; SCHMIDT HHHW, 1992, SCIENCE, V255, P721, DOI 10.1126/science.1371193; SNYDER SH, 1992, SCI AM, V266, P68, DOI 10.1038/scientificamerican0592-68; SOUTHERN C, 1990, FEBS LETT, V276, P42, DOI 10.1016/0014-5793(90)80502-A; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; WELSH N, 1991, ENDOCRINOLOGY, V129, P3167, DOI 10.1210/endo-129-6-3167	42	79	79	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB 1	1993	7	2					369	374		10.1096/fasebj.7.2.8440413	http://dx.doi.org/10.1096/fasebj.7.2.8440413			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KN885	8440413				2022-12-28	WOS:A1993KN88500012
J	Holme, PA; Muller, F; Solum, NO; Brosstad, F; Froland, SS; Aukrust, P				Holme, PA; Muller, F; Solum, NO; Brosstad, F; Froland, SS; Aukrust, P			Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection	FASEB JOURNAL			English	Article						HIV; RANTES; platelets; antiretroviral therapy; P-selection	NF-KAPPA-B; PROTEIN-S; T-CELLS; CHEMOKINES; MICROPARTICLES; NEUTROPHILS; CYTOKINES; RECEPTOR; DISEASE; BLOOD	Besides their role in hemostasis, platelets are involved in inflammatory and immunological processes, and we hypothezise that platelet activation may play an immunopathogenetic role in HIV-1 infection. Blood was drawn from 15 controls and 20 HIV-1-infected patients with normal platelet counts, classified into groups of non-AIDS and AIDS. Platelet activation was detected using flow cytometry with mAbs against the release markers P-selectin and CD63, mAb against GPIb, and the probe annexin V detecting surface exposure of aminophospholipids. The amount of microvesicles was measured using mAb against GPIIIa. Compared to controls, blood samples from HIV-1-infected patients showed significantly enhanced levels of microvesicles and activated platelets as detected by their exposure of P-selectin, CD63, and aminophospholipids, as well as reduction in GPIb expression. Increased expression of P-selectin and amounts of microvesicles were most pronounced in advanced clinical and immunological disease. When studying the effect of HIV-1 protease inhibitor therapy (indinavir) on platelet activation, we found that concomitant with a profound decrease in plasma viral load, there was a near normalization of several of the parameters reflecting enhanced platelet activation. Finally, we demonstrated that platelets may be an important source of the chemokine RANTES in HIV-1-infected patients. Although both unstimulated and SFLLRN-stimulated platelets from asymptomatic patients had enhanced release of RANTES, platelets from AIDS patients were characterized by markedly enhanced spontaneous, but decreased SFLLRN-stimulated release of this chemokine. Taken together, these results, which demonstrate for the first time increased platelet activation in HIV-1-infected patients with normal platelet counts, may represent a previously unrecognized immunopathogenic factor in HIV-1 infection.	Univ Oslo, Natl Hosp, Dept Med A, Sect Clin Immunol & Infect Dis, Oslo, Norway; Univ Oslo, Natl Hosp, Internal Med Res Inst, Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway	Aukrust, P (corresponding author), Rikshosp, Dept Med A, Sect Clin Immunol & Infect Dis, N-0027 Oslo, Norway.	pal.aukrust@klinmed.uio.no						ABRAMS CS, 1990, BLOOD, V75, P128; AUKRUST P, 1994, J INFECT DIS, V169, P420, DOI 10.1093/infdis/169.2.420; Bacon KB, 1996, J EXP MED, V184, P873, DOI 10.1084/jem.184.3.873; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BIERLING P, 1995, SEMIN THROMB HEMOST, V21, P68, DOI 10.1055/s-2007-1000380; BISSUEL F, 1992, J ACQ IMMUN DEF SYND, V5, P484; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; CHIGNARD M, 1994, ANN NY ACAD SCI, V725, P309, DOI 10.1111/j.1749-6632.1994.tb39814.x; Clerici M, 1996, AIDS, V10, P1432, DOI 10.1097/00002030-199610000-00019; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DAMLE NK, 1992, EUR J IMMUNOL, V22, P1789, DOI 10.1002/eji.1830220718; ELBIM C, 1994, BLOOD, V84, P2759, DOI 10.1182/blood.V84.8.2759.bloodjournal8482759; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Gris JC, 1996, THROMB HAEMOSTASIS, V76, P38; HAWRYLOWICZ CM, 1989, J IMMUNOL, V143, P4015; Hedrick JA, 1996, CURR OPIN IMMUNOL, V8, P343, DOI 10.1016/S0952-7915(96)80123-3; HOLME PA, 1994, THROMB HAEMOSTASIS, V72, P666; Holme PA, 1997, ARTERIOSCL THROM VAS, V17, P646, DOI 10.1161/01.ATV.17.4.646; Holme PA, 1995, THROMB HAEMOSTASIS, V74, P1533; JANES SL, 1995, THROMB HAEMOSTASIS, V74, P1059; JY W, 1992, J LAB CLIN MED, V119, P334; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KLINGER MHF, 1995, INT ARCH ALLERGY IMM, V107, P541, DOI 10.1159/000237097; Lundahl TH, 1996, BLOOD COAGUL FIBRIN, V7, P218, DOI 10.1097/00001721-199603000-00027; MERINO J, 1992, J IMMUNOL METHODS, V153, P151, DOI 10.1016/0022-1759(92)90317-M; MICHELSON AD, 1991, BLOOD, V77, P770; Murakami T, 1996, EUR J CLIN INVEST, V26, P996, DOI 10.1046/j.1365-2362.1996.2360585.x; NAGATA K, 1993, J IMMUNOL, V151, P3267; ORYO M, 1996, J LEUKOCYTE BIOL, V60, P77; PAGE CP, 1989, IMMUNOPHARMACOLOGY, V17, P51, DOI 10.1016/0162-3109(89)90008-8; POWER CA, 1994, GENE, V151, P333, DOI 10.1016/0378-1119(94)90682-3; Rubbert A, 1997, AIDS RES HUM RETROV, V13, P63, DOI 10.1089/aid.1997.13.63; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Stein DS, 1996, AIDS, V10, P485, DOI 10.1097/00002030-199605000-00006; Strieter RM, 1996, J IMMUNOL, V156, P3583; Su SB, 1996, J LEUKOCYTE BIOL, V59, P420, DOI 10.1002/jlb.59.3.420; TAIT JF, 1989, J BIOL CHEM, V264, P7944; TAUB R, 1989, J BIOL CHEM, V264, P259; TODOROKI N, 1991, BIOCHEM BIOPH RES CO, V179, P756, DOI 10.1016/0006-291X(91)91881-C; TOULON P, 1993, THROMB HAEMOSTASIS, V70, P730; TSCHOEPE D, 1991, SEMIN THROMB HEMOST, V17, P433, DOI 10.1055/s-2007-1002650; WEKSLER B. B., 1992, INFLAMMATION BASIC P, P727; Weyrich AS, 1996, J CLIN INVEST, V97, P1525, DOI 10.1172/JCI118575; WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921; WIEDMER T, 1990, BIOCHEMISTRY-US, V29, P623, DOI 10.1021/bi00455a005; YAN ZQ, 1994, BLOOD, V84, P2329; Zalavary S, 1996, J LEUKOCYTE BIOL, V60, P58, DOI 10.1002/jlb.60.1.58; ZAULI G, 1992, BLOOD, V79, P2680; ZUCKERFRANKLIN D, 1990, BLOOD, V75, P120	52	137	141	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1998	12	1					79	89		10.1096/fasebj.12.1.79	http://dx.doi.org/10.1096/fasebj.12.1.79			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YR723	9438413				2022-12-28	WOS:000071523800009
J	Guerin, S; Mari, B; Fernandez, E; Belhacene, N; Toribio, ML; Auberger, P				Guerin, S; Mari, B; Fernandez, E; Belhacene, N; Toribio, ML; Auberger, P			CD10 is expressed on human thymic epithelial cell lines and modulates thymopentin-induced cell proliferation	FASEB JOURNAL			English	Article						thymic epithelial cell; peptidase; TP; proliferation	ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN-BONE MARROW; NEUTRAL ENDOPEPTIDASE; DIFFERENTIATION; THYMOPOIETIN; INDUCTION; INVITRO; HORMONE; ANTIGEN; MICE	Thymic hormones such as thymopoietin (TP) have been shown to regulate thymocyte differentiation and lymphocyte activation, However, it is not known whether thymopoietin affects thymic epithelial cell (TEC) functions, In this study we have examined the effect of a five amino acid active peptide (TP5), corresponding to amino acids 32-36 of TP, on the proliferation of nontransformed clones of human TEC, Our results indicate that TP5 induced reinitiation of DNA synthesis and potentiated fetal calf serum (FCS)-induced cell growth in postnatal and fetal-derived human TEC, We also found that TEC lines express high levels of endopeptidase 24.11, a cell-surface metallopeptidase also known as the CD10 antigen, We show that TP5 is cleaved by CD10 at the surface of TEC lines, indicating that this endopeptidase may regulate TP5-induced TEC proliferation, Phosphoramidon, a specific endopeptidase 24.11 inhibitor, consistently acts in synergy with TP5 to enhance FCS-induced TEC growth, Hence, we conclude that 1) TP5 alone or in combination with FCS supports the growth of TEC lines, and 2) TEC lines express high levels of CD10, which regulates TP5-induced TEC proliferation by acting as a thymic peptide degrading enzyme.	FAC MED, INSERM, CJF 9605, F-06107 NICE 2, FRANCE; UNIV AUTONOMA MADRID, CTR BIOL MOL, E-28049 MADRID, SPAIN	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Autonomous University of Madrid			Mari, Bernard/Q-5832-2019; AUBERGER, Patrick/G-1491-2013; Mari, Bernard P/GVS-3100-2022; Mari, Bernard P/D-7445-2015; Mari, Bernard P/F-8960-2013; Toribio, Maria L/C-2039-2017	Mari, Bernard/0000-0002-0422-9182; AUBERGER, Patrick/0000-0002-2481-8275; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Toribio, Maria L/0000-0002-8637-0373				BASCH RS, 1974, P NATL ACAD SCI USA, V71, P1474, DOI 10.1073/pnas.71.4.1474; BELHACENE N, 1993, EUR J IMMUNOL, V23, P1948, DOI 10.1002/eji.1830230833; BOYD RL, 1993, IMMUNOL TODAY, V14, P445, DOI 10.1016/0167-5699(93)90248-J; BROWN SB, 1994, J CELL BIOCHEM, V54, P320, DOI 10.1002/jcb.240540308; CHECLER F, 1992, BIOCHEM J, V286, P217, DOI 10.1042/bj2860217; CONANT MA, 1992, AIDS, V6, P1335, DOI 10.1097/00002030-199211000-00016; FALK W, 1989, J IMMUNOL, V143, P513; FERNANDEZ E, 1994, BLOOD, V83, P3245; GANJU RK, 1994, J CLIN INVEST, V94, P1784, DOI 10.1172/JCI117526; GOLDSTEIN G, 1979, SCIENCE, V204, P1309, DOI 10.1126/science.451537; GOLSTEIN G, 1974, NATURE, V247, P11; Guerin S, 1997, CELL IMMUNOL, V175, P85, DOI 10.1006/cimm.1996.1045; Guerin S, 1997, FASEB J, V11, P376, DOI 10.1096/fasebj.11.5.9141505; HADDEN EM, 1992, CELL IMMUNOL, V144, P228, DOI 10.1016/0008-8749(92)90239-L; HARRIS CA, 1995, GENOMICS, V28, P198, DOI 10.1006/geno.1995.1131; HARRIS CA, 1994, P NATL ACAD SCI USA, V91, P6283, DOI 10.1073/pnas.91.14.6283; Haynes B F, 1990, Semin Immunol, V2, P67; HIRAMINE C, 1990, LAB INVEST, V18, P821; HOKLAND P, 1984, BLOOD, V64, P662; ITOH T, 1988, EUR J IMMUNOL, V18, P821, DOI 10.1002/eji.1830180525; JANOSSY G, 1979, J IMMUNOL, V123, P1525; JENKINSON EJ, 1992, J EXP MED, V176, P845, DOI 10.1084/jem.176.3.845; KALLED SL, 1995, EUR J IMMUNOL, V25, P677, DOI 10.1002/eji.1830250308; MARGUET D, 1992, J BIOL CHEM, V267, P2200; MARI B, 1992, EMBO J, V11, P3875, DOI 10.1002/j.1460-2075.1992.tb05480.x; MARI B, 1994, IMMUNOLOGY, V82, P433; RANGES GE, 1982, J EXP MED, V156, P1057, DOI 10.1084/jem.156.4.1057; RITZ J, 1980, NATURE, V283, P583, DOI 10.1038/283583a0; ROQUES BP, 1993, PHARMACOL REV, V45, P87; SALLES G, 1993, P NATL ACAD SCI USA, V90, P7618, DOI 10.1073/pnas.90.16.7618; SALLES G, 1992, BLOOD, V80, P2021; SCHEID MP, 1978, J EXP MED, V147, P1727, DOI 10.1084/jem.147.6.1727; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; Small M, 1996, EUR J IMMUNOL, V26, P961, DOI 10.1002/eji.1830260438; SUNDAL E, 1994, ARZNEIMITTEL-FORSCH, V44-2, P1145; SUNSHINE GH, 1978, J IMMUNOL, V120, P1594; VANEWIJK W, 1991, ANNU REV IMMUNOL, V9, P591, DOI 10.1146/annurev.iy.09.040191.003111; WU Q, 1990, P NATL ACAD SCI USA, V87, P993, DOI 10.1073/pnas.87.3.993	38	13	15	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1997	11	12					1003	1011		10.1096/fasebj.11.12.9337153	http://dx.doi.org/10.1096/fasebj.11.12.9337153			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YA724	9337153				2022-12-28	WOS:A1997YA72400010
J	Steven, AC; Trus, BL; Booy, FP; Cheng, NQ; Zlotnick, A; Caston, JR; Conway, JF				Steven, AC; Trus, BL; Booy, FP; Cheng, NQ; Zlotnick, A; Caston, JR; Conway, JF			The making and breaking of symmetry in virus capsid assembly: glimpses of capsid biology from cryoelectron microscopy	FASEB JOURNAL			English	Review						procapsid; symmetry; bacteriophage; antiviral	STRUCTURAL TRANSITIONS; MOLECULAR COMPOSITION; ANGSTROM RESOLUTION; ICOSAHEDRAL VIRUS; CRYSTAL-STRUCTURE; SIMIAN VIRUS-40; RECONSTRUCTION; REPLICATION; MATURATION; PROTEIN	Virus capsids constitute a diverse and versatile family of protein-bound containers and compartments ranging in diameter from Angstrom 200 Angstrom (mass similar to 1 MDa) to >1500 Angstrom (mass>250 MDa). Cryoelectron microscopy of capsids, now attaining resolutions down to 10 Angstrom, is disclosing novel structural motifs, assembly mechanisms, and the precise locations of major epitopes. Capsids are essentially symmetric structures, and icosahedral surface lattices have proved to be widespread, However, many capsid proteins exhibit a remarkable propensity for symmetry breaking, whereby chemically identical subunits in distinct lattice sites have markedly different structures and packing relationships. Temporal differences in the conformation of a given subunit are also manifested in the large-scale conformational changes that accompany capsid maturation. Larger and more complex capsids, such as DNA bacteriophages and herpes simplex virus, are formed not by simple self-assembly, but under the control of tightly regulated programs that may include the involvement of viral scaffolding proteins and cellular chaperonins, maturational proteolysis, and conformational changes on an epic scale. In addition to its significance for virology, capsid-related research has implications for biology in general, relating to the still largely obscure assembly processes of macromolecular complexes that perform many important cellular functions.	NIAMSD, PROT EXPRESS LAB, NIH, BETHESDA, MD 20892 USA; NIH, COMPUTAT BIOL & ENGN LAB, DIV COMP RES & TECHNOL, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA	Steven, AC (corresponding author), NIAMSD, STRUCT BIOL LAB,NIH,BLDG 6,RM B2-34, 6 CENTER DR MSC 2717, BETHESDA, MD 20892 USA.		Conway, James F/A-2296-2010; Caston, Jose/AAB-8825-2021; Caston, Jose R/L-5896-2014	Conway, James F/0000-0002-6581-4748; Caston, Jose/0000-0003-2350-9048; Caston, Jose R/0000-0003-2350-9048; Zlotnick, Adam/0000-0001-9945-6267				ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Baker TS, 1996, CURR OPIN STRUC BIOL, V6, P585, DOI 10.1016/S0959-440X(96)80023-6; BAKER TS, 1991, BIOPHYS J, V60, P1445, DOI 10.1016/S0006-3495(91)82181-6; BAKER TS, 1988, P NATL ACAD SCI USA, V85, P422, DOI 10.1073/pnas.85.2.422; Baker TS, 1996, J STRUCT BIOL, V116, P120, DOI 10.1006/jsbi.1996.0020; BAN N, 1995, NAT STRUCT BIOL, V2, P882, DOI 10.1038/nsb1095-882; BANCROFT JB, 1967, VIROLOGY, V31, P354, DOI 10.1016/0042-6822(67)90180-8; Belnap DM, 1996, J MOL BIOL, V259, P249, DOI 10.1006/jmbi.1996.0317; BLACK LW, 1995, BIOESSAYS, V17, P1025, DOI 10.1002/bies.950171206; Bottcher B, 1996, STRUCTURE, V4, P387; Bottcher B, 1997, NATURE, V386, P88, DOI 10.1038/386088a0; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CHENG RH, 1994, J MOL BIOL, V244, P255, DOI 10.1006/jmbi.1994.1726; Conway JF, 1997, NATURE, V386, P91, DOI 10.1038/386091a0; CONWAY JF, 1995, J MOL BIOL, V253, P86, DOI 10.1006/jmbi.1995.0538; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; DARCY F, 1987, ANIMAL VIRUS STRUCTU, P407; DOKLAND T, 1993, J MOL BIOL, V233, P682, DOI 10.1006/jmbi.1993.1545; DUDA RL, 1995, J MOL BIOL, V247, P618, DOI 10.1016/S0022-2836(05)80143-3; ELLIOTT JP, 1984, SYMMETRY PHYSICS, V1, P85; Fields BN, 1996, VIROLOGY; Frank J., 1996, 3 DIMENSIONAL ELECT, Ved, ppp 54; Fry E, 1996, Methods Mol Biol, V56, P319; FULLER SD, 1987, CELL, V48, P923, DOI 10.1016/0092-8674(87)90701-X; GALISTEO ML, 1995, J BIOL CHEM, V270, P16595, DOI 10.1074/jbc.270.28.16595; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; Hashemolhosseini S, 1996, J BACTERIOL, V178, P6258, DOI 10.1128/jb.178.21.6258-6265.1996; HENDERSON CE, 1980, BIOCHEM J, V189, P161, DOI 10.1042/bj1890161; HENDRIX RW, 1978, P NATL ACAD SCI USA, V75, P4779, DOI 10.1073/pnas.75.10.4779; HENDRIX RW, 1994, SEMIN VIROL, V5, P15, DOI 10.1006/smvy.1994.1003; Hewat EA, 1996, EMBO J, V15, P1515, DOI 10.1002/j.1460-2075.1996.tb00495.x; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KELLENBERGER E, 1980, BIOSYSTEMS, V12, P201, DOI 10.1016/0303-2647(80)90018-0; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; Liljas L, 1996, CURR OPIN STRUC BIOL, V6, P151, DOI 10.1016/S0959-440X(96)80068-6; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; MARZEC CJ, 1993, BIOPHYS J, V65, P2559, DOI 10.1016/S0006-3495(93)81313-4; MCGEOCH DJ, 1995, J MOL BIOL, V247, P443, DOI 10.1006/jmbi.1995.0152; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; Nassal M, 1993, Trends Microbiol, V1, P221, DOI 10.1016/0966-842X(93)90136-F; Nermut M.V., 1987, ANIMAL VIRUS STRUCTU; Nermut MV, 1996, CURR TOP MICROBIOL, V214, P1; NEWCOMB WW, 1993, J MOL BIOL, V232, P499, DOI 10.1006/jmbi.1993.1406; Newcomb WW, 1996, J MOL BIOL, V263, P432, DOI 10.1006/jmbi.1996.0587; NIBERT ML, 1991, J CLIN INVEST, V88, P727, DOI 10.1172/JCI115369; PRASAD BVV, 1993, J MOL BIOL, V231, P65, DOI 10.1006/jmbi.1993.1257; RAO ZH, 1995, NATURE, V378, P743, DOI 10.1038/378743a0; RAYMENT I, 1982, NATURE, V295, P110, DOI 10.1038/295110a0; RITSERT K, 1995, J MOL BIOL, V253, P151, DOI 10.1006/jmbi.1995.0542; Rixon FJ, 1996, J GEN VIROL, V77, P2251, DOI 10.1099/0022-1317-77-9-2251; ROSS PD, 1985, J MOL BIOL, V183, P353, DOI 10.1016/0022-2836(85)90006-3; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SMITH TJ, 1993, P NATL ACAD SCI USA, V90, P7015, DOI 10.1073/pnas.90.15.7015; Spencer JV, 1997, VIROLOGY, V228, P229, DOI 10.1006/viro.1996.8392; STEVEN AC, 1991, J STRUCT BIOL, V106, P221, DOI 10.1016/1047-8477(91)90072-5; STEVEN AC, 1997, STRUCTURAL BIOL VIRU, P312; STRAUSS EG, 1996, FIELDS VIROLOGY, P153; Tamura T, 1996, SCIENCE, V274, P1385, DOI 10.1126/science.274.5291.1385; TESCHKE CM, 1993, BIOCHEMISTRY-US, V32, P10658, DOI 10.1021/bi00091a016; ThumanCommike PA, 1996, J MOL BIOL, V260, P85, DOI 10.1006/jmbi.1996.0383; Tong L, 1996, NATURE, V383, P272, DOI 10.1038/383272a0; Trus BL, 1997, NAT STRUCT BIOL, V4, P413, DOI 10.1038/nsb0597-413; TRUS BL, 1992, P NATL ACAD SCI USA, V89, P11508, DOI 10.1073/pnas.89.23.11508; Trus BL, 1996, J MOL BIOL, V263, P447, DOI 10.1016/S0022-2836(96)80018-0; TRUS BL, 1995, J VIROL, V69, P7362, DOI 10.1128/JVI.69.11.7362-7366.1995; Tuma R, 1996, BIOCHEMISTRY-US, V35, P4619, DOI 10.1021/bi952793l; VALPUESTA JM, 1994, Q REV BIOPHYS, V27, P107, DOI 10.1017/S0033583500004510; VANOOSTRUM J, 1985, J VIROL, V56, P439, DOI 10.1128/JVI.56.2.439-448.1985; WANG GJ, 1992, NATURE, V355, P275, DOI 10.1038/355275a0; WINGFIELD PT, 1995, BIOCHEMISTRY-US, V34, P4919, DOI 10.1021/bi00015a003; WISTOW G, 1993, TRENDS BIOCHEM SCI, V18, P301, DOI 10.1016/0968-0004(93)90041-K; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551; Zlotnick A, 1996, BIOCHEMISTRY-US, V35, P7412, DOI 10.1021/bi9604800	75	39	40	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1997	11	10					733	742		10.1096/fasebj.11.10.9271358	http://dx.doi.org/10.1096/fasebj.11.10.9271358			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XR105	9271358				2022-12-28	WOS:A1997XR10500003
J	Bellamy, COC; Clarke, AR; Wyllie, AH; Harrison, DJ				Bellamy, COC; Clarke, AR; Wyllie, AH; Harrison, DJ			p53 deficiency in liver reduces local control of survival and proliferation, but does not affect apoptosis after DNA damage	FASEB JOURNAL			English	Article						cell cycle; carcinogenesis; hepatocyte; wild-type cell; liver carcinoma	HEPATOCELLULAR-CARCINOMA; P53-DEFICIENT MICE; GAMMA-IRRADIATION; IN-VIVO; GROWTH; GENE; RAT; HEPATOCYTES; PROTEIN; HEPATOCARCINOGENESIS	Despite good evidence for p53 dysfunction in human hepatocellular carcinomas, little is known of the significance of p53 to normal hepatocytes and whether p53 dysfunction is relevant to early hepatocarcinogenesis. We have therefore examined the consequences of targeted p53 deficiency in hepatocytes for regulation of apoptosis, proliferation, and ploidy. p53 deficiency was silent in normal liver and did not affect progression from diploidy to polyploidy in the aging liver. However, in primary culture the absence of p53 resulted in increased hepatocyte proliferation indices and decreased sensitivity to proliferation inhibition by TGF beta. Moreover, p53-deficient cells continued to survive and proliferate under conditions of minimal trophic support that led to growth arrest and apoptosis of wild-type cells. In vivo, p53-deficient mice had enhanced proliferative responses to both xenobiotic hepatomitogen and CCl4-induced liver necrosis, although lack of persistent proliferation showed that other control mechanisms are important. There was no simple relationship between p53 and apoptosis after DNA damage because UV irradiation led to p53-independent apoptosis, even though p53 was stabilized. However, p53 did couple DNA damage to growth arrest, and abnormal mitoses after gamma-irradiation of regenerating p53 null livers demonstrated circumstances where loss of G(1) and G(2) checkpoints may generate abnormal ploidy. Thus p53 becomes important when hepatocytes are released from G(0) and stressed, sensitizing them to mitogen and cytokine regulators of cell cycle progression and apoptosis. Hence p53 deficiency is likely to be significant in an environment of persistent regenerative stimuli and unfavorable trophic support or in the presence of other enabling genetic lesions. This model is relevant to human hepatocarcinogenesis, which almost always occurs against a background of chronic hepatocellular destruction in hepatitis and cirrhosis. In that context, by reducing the need for cytokine support and disabling DNA damage-induced growth arrest, p53 deficiency should facilitate the expansion of preneoplastic clones in chronic liver disease.			Bellamy, COC (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PATHOL,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.			harrison, david/0000-0001-9041-9988; Clarke, Alan/0000-0002-4281-426X				AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284; BELLAMY COC, 1997, IN PRESS APOPTOSIS C; Brodsky W Y, 1977, Int Rev Cytol, V50, P275; CATER DB, 1956, ACTA RADIOL, V46, P655, DOI 10.3109/00016925609171460; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; FAUSTO N, 1989, LAB INVEST, V60, P4; Fausto N, 1986, Symp Fundam Cancer Res, V39, P69; Friedberg E. C., 1995, DNA REPAIR MUTAGENES, P1; FUKS Z, 1994, CANCER RES, V54, P2582; GERACI JP, 1994, RADIAT RES, V140, P249, DOI 10.2307/3578909; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GUIMARAES JP, 1966, EXPERIENTIA, V22, P661, DOI 10.1007/BF01902428; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Hayashi H, 1995, HEPATOLOGY, V22, P1702; HUANG SN, 1995, HEPATOLOGY, V21, P620, DOI 10.1002/hep.1840210303; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; KEMP CJ, 1995, MOL CARCINOGEN, V12, P132, DOI 10.1002/mc.2940120304; KREAMER BL, 1986, IN VITRO CELL DEV B, V22, P201; LIANG TJ, 1995, HEPATOLOGY, V22, P1330, DOI 10.1002/hep.1840220445; LIVNI N, 1995, CANCER, V75, P2420, DOI 10.1002/1097-0142(19950515)75:10<2420::AID-CNCR2820751006>3.0.CO;2-6; Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; ODA T, 1994, CANCER LETT, V83, P197, DOI 10.1016/0304-3835(94)90319-0; ODA T, 1992, CANCER RES, V52, P6358; POLAND A, 1980, MOL PHARMACOL, V18, P571; Rafferty JA, 1996, ONCOGENE, V12, P693; RENTON KW, 1978, MOL PHARMACOL, V14, P672; Romanowski P, 1996, TRENDS CELL BIOL, V6, P184, DOI 10.1016/0962-8924(96)10015-5; SELL C, 1995, CANCER RES, V55, P303; SHIMA A, 1985, INT J RADIAT BIOL, V47, P261, DOI 10.1080/09553008514550391; THOMPSON NL, 1986, CANCER RES, V46, P3111; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; TSUJI K, 1994, MOL CARCINOGEN, V9, P167, DOI 10.1002/mc.2940090308; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; ZHAO M, 1994, VIRCHOWS ARCH, V424, P613, DOI 10.1007/BF01069741	42	71	71	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1997	11	7					591	599		10.1096/fasebj.11.7.9212083	http://dx.doi.org/10.1096/fasebj.11.7.9212083			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XH342	9212083				2022-12-28	WOS:A1997XH34200011
J	Pozo, D; Delgado, M; FernandezSantos, JM; Calvo, JR; Gomariz, RP; MartinLacave, I; Ortiz, GG; Guerrero, JM				Pozo, D; Delgado, M; FernandezSantos, JM; Calvo, JR; Gomariz, RP; MartinLacave, I; Ortiz, GG; Guerrero, JM			Expression of the Mel(1a)-melatonin receptor mRNA in T and B subsets of lymphocytes from rat thymus and spleen	FASEB JOURNAL			English	Article						pineal gland; gene expression; RNA extraction; DNA sequencing	VASOACTIVE-INTESTINAL-PEPTIDE; CYCLIC-AMP PRODUCTION; BINDING-SITES; PINEAL-GLAND; MELATONIN RECEPTOR; HORMONE MELATONIN; NUCLEAR RECEPTOR; BRAIN; GENE; 2-<I-125>MELATONIN	In the present work we analyze by reverse transcription, polymerase chain reaction, cDNA cloning, and sequence analysis the expression of membrane melatonin receptors in rat thymus and spleen. Results show, for the first time, that the melatonin receptor mRNA is expressed in both the thymus and spleen. Moreover, the melatonin receptor mRNA was expressed in all the lymphocyte subpopulations (CD4(+),CD8(+), double positive, double negative, and B cells) studied from the rat thymus. The Southern blot analysis with the melatonin receptor probe and sequence data also showed the identity of the DNA fragments in thymus, spleen, and the lymphocyte subpopulations studied. The melatonin receptor fragments amplified from rat brain, thymus, and spleen share identical nucleotide sequences with the rat MeI1a-melatonin receptor subtype. No signal was obtained with primers used to amplify the rat Mel(1b)-melatonin receptor subtype in both thymus and spleen. Finally, the melatonin receptor mRNA transcript distribution throughout the rat thymus was examined. Using digoxigenin-labeled cRNA probe to the specific melatonin receptor mRNA, examination of the whole thymus revealed a clear hybridization signal in both cortex and medulla. Melatonin receptor gene expression in the thymus and spleen supports the notion of the immunomodulatory role of melatonin.	UNIV SEVILLE, SCH MED, DEPT MED BIOCHEM & MOL BIOL, SEVILLE 41009, SPAIN; UNIV SEVILLE, SCH MED, DEPT NORMAL & PATHOL CYTOL & HISTOL, SEVILLE 41009, SPAIN; VIRGEN MACARENA HOSP, SEVILLE, SPAIN; UNIV COMPLUTENSE MADRID, SCH BIOL, MADRID, SPAIN; INST MEXICANO SEGURO SOCIAL, CTR INVEST BIOMED OCCIDENTE, GUADALAJARA, SPAIN	University of Sevilla; University of Sevilla; Hospital Universitario Virgen Macarena; Complutense University of Madrid			Guerrero, Josep M./D-5519-2014; Pozo, David/C-2149-2017; Guerrero, Josep M./Y-2929-2019; Calvo, Juan R./A-7338-2017; IBIS, NEUROINMUNO/O-9306-2015; Delgado, Mario/P-1524-2016	Guerrero, Josep M./0000-0001-5236-4592; Pozo, David/0000-0002-3732-4960; Calvo, Juan R./0000-0002-4854-2963; Delgado, Mario/0000-0003-1893-5982; Martin-Lacave, Ines/0000-0003-4645-0755; Fernandez-Santos, Jose Maria/0000-0003-4541-1033; Guerrero, Juan Miguel/0000-0001-7553-0119				ACUNACASTROVIEJO D, 1994, J PINEAL RES, V16, P100, DOI 10.1111/j.1600-079X.1994.tb00089.x; AKANO SF, 1985, AM J PHYSIOL, V219, pR527; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; Berman L., 1921, GLANDS REGULATING PE; BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; CALVO JR, 1995, J PINEAL RES, V18, P119, DOI 10.1111/j.1600-079X.1995.tb00149.x; CARDARELLI NF, 1990, J THEOR BIOL, V145, P397, DOI 10.1016/S0022-5193(05)80118-3; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CSABA G, 1966, EXPERIENTIA, V22, P168, DOI 10.1007/BF01897715; DELGOBBO V, 1986, INT J IMMUNOPHARMACO, V5, P567; DEVECERSKI V, 1963, ACTA ANAT, V54, P352; EBISAWA T, 1994, P NATL ACAD SCI USA, V91, P6133, DOI 10.1073/pnas.91.13.6133; GIORDANO M, 1991, J PINEAL RES, V10, P117, DOI 10.1111/j.1600-079X.1991.tb00827.x; GONZALEZHABA MG, 1995, FASEB J, V9, P1331, DOI 10.1096/fasebj.9.13.7557023; GUERRERO JM, 1992, ENDOCR RES, V18, P91, DOI 10.1080/07435809209035401; ISAACSON PG, 1987, LANCET, V2, P1488; JANKOVIC BD, 1970, IMMUNOLOGY, V18, P1; KENDALL MD, 1991, J ANAT, V177, P1; Lopez-Gonzalez Miguel A., 1993, Biotechnology Therapeutics, V4, P253; LOPEZGONZALEZ MA, 1992, J PINEAL RES, V12, P97, DOI 10.1111/j.1600-079X.1992.tb00034.x; LOPEZGONZALEZ MA, 1993, J NEUROIMMUNOL, V45, P121, DOI 10.1016/0165-5728(93)90171-T; LOPEZGONZALEZ MA, 1992, J PINEAL RES, V12, P174, DOI 10.1111/j.1600-079X.1992.tb00045.x; MAESTRONI GJM, 1995, J PINEAL RES, V18, P84, DOI 10.1111/j.1600-079X.1995.tb00144.x; MAESTRONI GJM, 1988, IMMUNOLOGY, V63, P465; MAESTRONI GJM, 1993, J PINEAL RES, V14, P1, DOI 10.1111/j.1600-079X.1993.tb00478.x; MAESTRONI GJM, 1986, J NEUROIMMUNOL, V13, P19, DOI 10.1016/0165-5728(86)90047-0; MARTINCACAO A, 1993, IMMUNOL LETT, V36, P59, DOI 10.1016/0165-2478(93)90069-E; MILCU SM, 1943, ACTA ENDOCRINOL-BUCH, V9, P13; MORREY KM, 1994, J IMMUNOL, V153, P2671; PANG CS, 1992, J PINEAL RES, V12, P167, DOI 10.1111/j.1600-079X.1992.tb00044.x; PERSENGIEV S, 1991, INT J BIOCHEM, V23, P1487, DOI 10.1016/0020-711X(91)90292-U; PERSENGIEV S, 1991, INT J BIOCHEM, V23, P1483, DOI 10.1016/0020-711X(91)90291-T; POON AMS, 1992, LIFE SCI, V50, P1719, DOI 10.1016/0024-3205(92)90427-Q; POZO D, 1994, LIFE SCI, V55, pPL455, DOI 10.1016/0024-3205(94)00532-X; POZO D, 1996, IN PRESS J CELL BIOC; RAFIIELIDRISSI M, 1995, J NEUROIMMUNOL, V57, P171, DOI 10.1016/0165-5728(94)00182-N; REITER RJ, 1995, J PINEAL RES, V18, P1, DOI 10.1111/j.1600-079X.1995.tb00133.x; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; REPPERT SM, 1995, NEURON, V15, P1003, DOI 10.1016/0896-6273(95)90090-X; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SLAUGENHAUPT SA, 1995, GENOMICS, V27, P355, DOI 10.1006/geno.1995.1056; SPRENT J, 1989, LANCET, V2, P1488; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; YU ZH, 1991, NEUROSCI LETT, V125, P175, DOI 10.1016/0304-3940(91)90021-K	47	137	142	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1997	11	6					466	473		10.1096/fasebj.11.6.9194527	http://dx.doi.org/10.1096/fasebj.11.6.9194527			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XE404	9194527				2022-12-28	WOS:A1997XE40400009
J	Dessolin, S; Schalling, M; Champigny, O; Lonnqvist, F; Ailhaud, G; Dani, C; Ricquier, D				Dessolin, S; Schalling, M; Champigny, O; Lonnqvist, F; Ailhaud, G; Dani, C; Ricquier, D			Leptin gene is expressed in rat brown adipose tissue at birth	FASEB JOURNAL			English	Article						birth; brown adipose tissue; ob; suckling	OBESE GENE; UNCOUPLING PROTEIN; MESSENGER-RNA; OB GENE; MICE; CLONING; THERMOGENESIS; STEP; CDNA	The ob gene product leptin is secreted from adipose tissue, Leptin has dramatic effects on food intake and energy expenditure in rodents. Brown adipose tissue is the first form of adipose tissue to appear during development, and is present at birth in most species, The development of a leptin feedback system in early life and the relative role of the brown and white adipose tissues have not yet been revealed. We have investigated the expression of ob/leptin mRNA in brown adipose tissue around birth and with respect to feeding, Northern blotting analysis and in situ hybridization experiments demonstrated the presence of leptin mRNA in brown adipose tissue at 0, 18, and 24 h after birth, The leptin mRNA level was decreased at 8 h postpartum in fed animals and at 18 or 24 h in the absence of feeding. In addition, circulating leptin was detected in the plasma of newborn rats at 0, 10, or 24 h after birth, whereas it was not detectable in 10 h-old animals that did not suckle at their mother. The presence at birth of ob mRNA and circulating leptin, as web as the early effect of suckling on ob mRNA levels, suggests the precocious involvement of leptin in the control of food intake.	CEREMOD, CNRS, F-92190 MEUDON, FRANCE; UNIV NICE, FAC SCI, CTR BIOCHIM, UMR 134 CNRS, NICE, FRANCE; KAROLINSKA HOSP & INST, DEPT MOL MED, NEUROGENET UNIT, STOCKHOLM, SWEDEN; KAROLINSKA INST, DEPT MED, STOCKHOLM, SWEDEN; UNIV STOCKHOLM, HUDDINGE HOSP, RES CTR, STOCKHOLM, SWEDEN	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Stockholm University			DANI, Christian/G-3639-2014; Schalling, Martin/F-1518-2015	DANI, Christian/0000-0003-3228-0230; Schalling, Martin/0000-0001-5011-2922; Ailhaud, Gerard/0000-0003-0596-2906				Barnard T, 1970, BROWN ADIPOSE TISSUE, P33; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Collins S, 1996, J BIOL CHEM, V271, P9437, DOI 10.1074/jbc.271.16.9437; Collins S, 1996, NATURE, V380, P677, DOI 10.1038/380677a0; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HENNING SJ, 1979, AM J PHYSIOL, V237, pR187, DOI 10.1152/ajpregu.1979.237.3.R187; HIMMSHAGEN J, 1995, OBES RES, V3, P361, DOI 10.1002/j.1550-8528.1995.tb00162.x; HIMMSHAGEN J, 1997, IN PRESS HDB OBESITY; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; Lonnqvist F, 1996, QJM-MON J ASSOC PHYS, V89, P327; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; MOINAT M, 1995, FEBS LETT, V373, P131, DOI 10.1016/0014-5793(95)01030-I; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; OGAWA Y, 1995, J CLIN INVEST, V96, P1647, DOI 10.1172/JCI118204; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RICQUIER D, 1986, J BIOL CHEM, V261, P13905; RICQUIER D, 1991, FASEB J, V5, P2237, DOI 10.1096/fasebj.5.9.1860614; SCHALLING M, 1990, P NATL ACAD SCI USA, V87, P8427, DOI 10.1073/pnas.87.21.8427; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TRAYHURN P, 1995, FEBS LETT, V368, P488, DOI 10.1016/0014-5793(95)00719-P; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	24	73	74	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1997	11	5					382	387		10.1096/fasebj.11.5.9141506	http://dx.doi.org/10.1096/fasebj.11.5.9141506			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WX156	9141506				2022-12-28	WOS:A1997WX15600012
J	Silverman, JA; Schrenk, D				Silverman, JA; Schrenk, D			Hepatic canalicular membrane .4. Expression of the multidrug resistance genes in the liver	FASEB JOURNAL			English	Review						P-glycoprotein; liver; basal regulation; mdr	P-GLYCOPROTEIN GENE; CARCINOMA CELL-LINES; RAT-LIVER; MDR1 GENE; MESSENGER-RNA; TRANSCRIPTIONAL REPRESSOR; HEPATOCELLULAR CARCINOMAS; HOMOZYGOUS DISRUPTION; HEPATOCYTE CULTURES; PROMOTER	The liver is presented with a diverse set of nutrients, endogenous metabolites, and xenobiotics it must process for movement to their correct physiologic destinations. These compounds are transported by specific mechanisms that move their substrates, often against a concentration gradient. Several hepatic transporters have been identified such as the multispecific anion transporter, cMOAT, bile acid transporters, ion-motive ATPases, glutathione transporters, purine transporters, and the multidrug resistance-related protein, MRP. This review focuses on the hepatic regulation of the multidrug resistance genes that encode the P-glycoprotein transporters, P-glycoproteins are ATP-dependent integral membrane proteins that have diverse functions such as conferring resistance toward chemotherapeutic drugs and phospholipid movement. The expression of the multidrug resistance genes is regulated in a tissue-specific pattern and can be induced by exposure to chemotherapeutic drugs as well as cytotoxic xenobiotics. The specific molecular mechanisms that govern expression of these genes in normal and neoplastic cells are currently being unraveled.	UNIV TUBINGEN,INST TOXICOL,D-72074 TUBINGEN,GERMANY	Eberhard Karls University of Tubingen	Silverman, JA (corresponding author), AVMAX INC,890 HEINZ AVE,BERKELEY,CA 94710, USA.							ARIAS IM, 1991, XENOBIOTICS AND CANCER, P229; BORST P, 1993, PHARMACOL THERAPEUT, V60, P289, DOI 10.1016/0163-7258(93)90011-2; BRADLEY G, 1992, CANCER RES, V52, P5154; BROWN PC, 1993, NUCLEIC ACIDS RES, V21, P3885, DOI 10.1093/nar/21.16.3885; BURT RK, 1988, J NATL CANCER I, V80, P1381; BUSCHMAN E, 1992, J BIOL CHEM, V267, P18093; CHAPEKAR MS, 1991, BIOCHEM BIOPH RES CO, V181, P1524, DOI 10.1016/0006-291X(91)92112-W; CHENIVESSE X, 1993, J HEPATOL, V18, P168, DOI 10.1016/S0168-8278(05)80243-0; CHIN KV, 1990, J BIOL CHEM, V265, P221; COHEN D, 1991, J BIOL CHEM, V266, P2239; COMBATES NJ, 1994, J BIOL CHEM, V269, P29715; CROOP JM, 1989, MOL CELL BIOL, V9, P1345; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FAIRCHILD CR, 1987, P NATL ACAD SCI USA, V84, P7701, DOI 10.1073/pnas.84.21.7701; FARDEL O, 1993, CARCINOGENESIS, V14, P781, DOI 10.1093/carcin/14.4.781; FARDEL O, 1993, FEBS LETT, V327, P189, DOI 10.1016/0014-5793(93)80167-S; GANT TW, 1991, MOL CARCINOGEN, V4, P499, DOI 10.1002/mc.2940040614; GANT TW, 1992, NUCLEIC ACIDS RES, V20, P2841, DOI 10.1093/nar/20.11.2841; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOSLAND M, 1993, CANCER RES, V53, P5382; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Hill BA, 1996, CARCINOGENESIS, V17, P451, DOI 10.1093/carcin/17.3.451; HIRSCHERNST KI, 1995, BIOCHEM BIOPH RES CO, V215, P179, DOI 10.1006/bbrc.1995.2450; IKEGUCHI M, 1991, DNA CELL BIOL, V10, P639, DOI 10.1089/dna.1991.10.639; ITSUBO M, 1994, CANCER, V73, P298, DOI 10.1002/1097-0142(19940115)73:2<298::AID-CNCR2820730211>3.0.CO;2-4; KOHNO K, 1989, BIOCHEM BIOPH RES CO, V165, P1415, DOI 10.1016/0006-291X(89)92761-7; MARINO PA, 1990, CELL GROWTH DIFFER, V1, P57; MAUAD TH, 1994, AM J PATHOL, V145, P1237; MCCOY C, 1995, MOL CELL BIOL, V15, P6100; MIYAMOTO KI, 1992, ANTICANCER RES, V12, P649; MORROW CS, 1994, J BIOL CHEM, V269, P10739; NAKATSUKASA H, 1993, HEPATOLOGY, V18, P1202; NAKATSUKASA H, 1992, MOL CARCINOGEN, V6, P190, DOI 10.1002/mc.2940060304; PARK JG, 1994, J NATL CANCER I, V86, P700, DOI 10.1093/jnci/86.9.700; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SCHRENK D, 1993, HEPATOLOGY, V17, P854, DOI 10.1016/0270-9139(93)90162-G; SCHRENK D, 1994, CARCINOGENESIS, V15, P2541, DOI 10.1093/carcin/15.11.2541; SCHUETZ EG, 1995, MOL CARCINOGEN, V12, P61, DOI 10.1002/mc.2940120202; Schuetz EG, 1996, MOL PHARMACOL, V49, P311; SCHUETZ JD, 1995, J CELL PHYSIOL, V165, P261, DOI 10.1002/jcp.1041650207; SCHUETZ JD, 1995, CELL GROWTH DIFFER, V6, P1321; SHEN DW, 1991, J CELL SCI, V98, P317; SILVERMAN JA, 1995, MOL CARCINOGEN, V13, P50, DOI 10.1002/mc.2940130109; SILVERMAN JA, 1995, PROGR LIVER DIS, P101; SMIT JJM, 1995, BBA-GENE STRUCT EXPR, V1261, P44, DOI 10.1016/0167-4781(94)00214-N; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; TEETER LD, 1993, MOL CARCINOGEN, V8, P67, DOI 10.1002/mc.2940080202; TEETER LD, 1991, CELL GROWTH DIFFER, V2, P429; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; THORGEIRSSON SS, 1994, ANTICANCER DRUG RESI, P57; VOLM M, 1990, CARCINOGENESIS, V11, P169, DOI 10.1093/carcin/11.1.169; WACHER VJ, 1995, MOL CARCINOGEN, V13, P129, DOI 10.1002/mc.2940130302; YU LJ, 1995, CELL GROWTH DIFFER, V6, P1505	55	56	58	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1997	11	5					308	313		10.1096/fasebj.11.5.9141496	http://dx.doi.org/10.1096/fasebj.11.5.9141496			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WX156	9141496				2022-12-28	WOS:A1997WX15600002
J	Simantov, R; Tauber, M				Simantov, R; Tauber, M			The abused drug MDMA (Ecstasy) induces programmed death of human serotonergic cells	FASEB JOURNAL			English	Article						apoptosis; drug abuse; transporter; psychosis; nitric oxide; neurodegeneration	3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; NITRIC-OXIDE; RAT-BRAIN; METHYLENEDIOXYMETHAMPHETAMINE MDMA; CHORIOCARCINOMA CELLS; NEUROTOXICITY; DOPAMINE; TRANSPORTER; NEURONS; RELEASE	The widely abused amphetamine analog 3,4-methylenedioxymethamphetamine (MDMA, also called ''ecstasy'') induces hallucination and psychostimulation, as well as long-term neuropsychiatric behaviors such as panic and psychosis, In rodents and monkeys, MDMA is cytotoxic to serotonergic neurons, but this is less clear with humans. Herein, MDMA was cytotoxic to human serotonergic JAR cells; it altered the cell cycle, increased G2/M phase arrest, and induced DNA fragmentation in a cycloheximide-sensitive way. Tills apoptosis was not observed in nonserotonergic human NMB cells, The stereospecific effect of amphetamines in JAR cells, and the key role of NO and dopamine in MDMA-induced apoptosis were determined. The relevancy of MDMA-induced cell death to drug users is discussed.			Simantov, R (corresponding author), WEIZMANN INST SCI,DEPT MOL GENET,IL-76100 REHOVOT,ISRAEL.							AZMITIA EC, 1990, BRAIN RES, V510, P97, DOI 10.1016/0006-8993(90)90732-Q; BENAZZI F, 1991, LANCET, V338, P1520, DOI 10.1016/0140-6736(91)92332-V; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; BRODKIN J, 1993, PHARMACOL BIOCHEM BE, V45, P647, DOI 10.1016/0091-3057(93)90520-4; CALDWELL J, 1972, BIOCHEM J, V129, P11, DOI 10.1042/bj1290011; COMMINS DL, 1987, J PHARMACOL EXP THER, V241, P338; COOL DR, 1991, J BIOL CHEM, V266, P15750; CREIGHTON FJ, 1991, BRIT J PSYCHIAT, V159, P713, DOI 10.1192/bjp.159.5.713; FULLER RW, 1965, BIOCHEM PHARMACOL, V14, P483, DOI 10.1016/0006-2952(65)90221-2; GREEN AR, 1995, PSYCHOPHARMACOLOGY, V119, P247, DOI 10.1007/BF02246288; GUDELSKY GA, 1994, EUR J PHARMACOL, V264, P325, DOI 10.1016/0014-2999(94)90669-6; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; HUANG XM, 1993, EUR J PHARMACOL, V238, P291, DOI 10.1016/0014-2999(93)90859-G; INSEL TR, 1989, J PHARMACOL EXP THER, V249, P713; JOHNSON MP, 1986, EUR J PHARMACOL, V132, P268; KELLAND MD, 1989, EUR J PHARMACOL, V169, P11, DOI 10.1016/0014-2999(89)90812-1; KING SC, 1992, BIOCHEM BIOPH RES CO, V183, P487, DOI 10.1016/0006-291X(92)90508-I; LEONARDI ETK, 1994, NEUROPSYCHOPHARMACOL, V10, P231, DOI 10.1038/npp.1994.26; LORRAIN DS, 1993, NEUROREPORT, V5, P87, DOI 10.1097/00001756-199310000-00024; MCCANN UD, 1993, J CLIN PSYCHOPHARM, V13, P214; MCCANN UD, 1991, J CLIN PSYCHOPHARM, V11, P302; MCGUIRE P, 1991, BRIT MED J, V302, P697, DOI 10.1136/bmj.302.6778.697; MILLER KJ, 1994, J BIOL CHEM, V269, P27351; OCALLAGHAN JP, 1994, J PHARMACOL EXP THER, V270, P741; OHEARN E, 1988, J NEUROSCI, V8, P2788; POGUN S, 1994, BRAIN RES, V641, P83, DOI 10.1016/0006-8993(94)91818-X; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; RAMAMOORTHY S, 1993, J BIOL CHEM, V268, P21626; RIAD M, 1994, J NEUROCHEM, V62, P2224; RICAURTE G, 1985, SCIENCE, V229, P986, DOI 10.1126/science.4023719; RICAURTE GA, 1988, JAMA-J AM MED ASSOC, V260, P51, DOI 10.1001/jama.260.1.51; RICAURTE GA, 1988, BRAIN RES, V446, P165, DOI 10.1016/0006-8993(88)91309-1; RUDNICK G, 1993, MOL PHARMACOL, V43, P271; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; SCHIFANO F, 1991, LANCET, V338, P1335, DOI 10.1016/0140-6736(91)92633-D; SCHMIDT CJ, 1994, J NEUROCHEM, V62, P1382; SCHMIDT CJ, 1987, J PHARMACOL EXP THER, V240, P1; SCHMIDT CJ, 1992, EUR J PHARMACOL, V220, P151, DOI 10.1016/0014-2999(92)90743-N; SEIDEN LS, 1984, PHARMACOL BIOCHEM BE, V21, P29, DOI 10.1016/0091-3057(84)90125-4; Simantov R, 1996, NEUROSCIENCE, V74, P39, DOI 10.1016/0306-4522(96)00102-9; SIMANTOV R, 1995, BIOCHEM PHARMACOL, V50, P435, DOI 10.1016/0006-2952(95)00068-B; SLIKKER W, 1988, TOXICOL APPL PHARM, V94, P448, DOI 10.1016/0041-008X(88)90285-2; SPRAGUE JE, 1994, LIFE SCI, V55, P1193, DOI 10.1016/0024-3205(94)00658-X; STEELE TD, 1994, ADDICTION, V89, P539, DOI 10.1111/j.1360-0443.1994.tb03330.x; STONE DM, 1986, EUR J PHARMACOL, V128, P41, DOI 10.1016/0014-2999(86)90555-8; WHITE SR, 1994, NEUROSCIENCE, V62, P41, DOI 10.1016/0306-4522(94)90313-1; WILSON MA, 1989, NEUROSCIENCE, V28, P121, DOI 10.1016/0306-4522(89)90237-6	49	74	78	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1997	11	2					141	146		10.1096/fasebj.11.2.9039956	http://dx.doi.org/10.1096/fasebj.11.2.9039956			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK509	9039956				2022-12-28	WOS:A1997WK50900006
J	Bucala, R				Bucala, R			MIF rediscovered: Cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response	FASEB JOURNAL			English	Review						inflammation; steroids; sepsis; macrophage; T cells	MIGRATION INHIBITORY FACTOR; TUMOR NECROSIS FACTOR; ADRENAL AXIS; MACROPHAGE; CELLS; ENDOTOXIN; MOUSE; IMMUNOSUPPRESSION; INTERLEUKIN-1; LYMPHOCYTES	The protein that has been historically called macrophage migration inhibitory factor (MIF) was one of the first cytokine activities to be discovered and was originally described to be a T lymphocyte product that inhibited the random migration of macrophages, Over the years, additional molecules with MIF ''activity'' have been described and the precise role of the original MIF ''protein'' remained enigmatic, Recent studies have led to the discovery of a pituitary mediator that appears to act as the counterregulatory hormone for glucocorticoid action within the immune system, Isolated as a product of murine anterior pituitary cells, this peptide was sequenced and found to be the mouse homolog of MIF. MIF has the unique property of being released from macrophages and T cells in response to physiological concentrations of glucocorticoids. The secretion of MIF is tightly regulated and decreases at high, anti-inflammatory steroid concentrations. Once released, MIF ''overrides'' Or counterregulates the immunosuppressive effects of steroids on immune cell activation and cytokine production, These observations suggest that MIF fills an important gap in our understanding of how the host initiates and controls immunity, Because glucocorticoids are an integral part of the host's global response to infection or tissue invasion, the physiological role of MIF is to act at an;inflammatory site or lymph node to counterbalance the profound inhibitory effects of steroids on the immune response.			Bucala, R (corresponding author), PICOWER INST MED RES,MED BIOCHEM LAB,350 COMMUNITY DR,MANHASSET,NY 10030, USA.				NIAID NIH HHS [AI21359] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021359] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; Bernhagen J, 1996, J EXP MED, V183, P277, DOI 10.1084/jem.183.1.277; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BLOCKI FA, 1992, NATURE, V360, P269, DOI 10.1038/360269a0; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; BOZZA M, 1995, GENOMICS, V27, P412, DOI 10.1006/geno.1995.1071; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; DAVID JR, 1993, P NATL ACAD SCI USA, V90, P12056; DAVID JR, 1993, J IMMUNOL, V151, P1272; DINARELLO CA, 1991, CYTOKINE HDB, P47; FAGARASAN MO, 1990, P NATL ACAD SCI USA, V87, P7871, DOI 10.1073/pnas.87.20.7871; FANTUZZI G, 1995, J IMMUNOL, V155, P3552; GEORGE M, 1962, P SOC EXP BIOL MED, V111, P514; GOLDSTEIN RA, 1992, INFLAMMATION BASIC P, P1061; HAWES AS, 1992, INFECT IMMUN, V60, P2641, DOI 10.1128/IAI.60.7.2641-2647.1992; Kato Y, 1996, P NATL ACAD SCI USA, V93, P3007, DOI 10.1073/pnas.93.7.3007; KOSAK CA, 1995, GENOMICS, V27, P405; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; MCINNES A, 1988, J EXP MED, V167, P598, DOI 10.1084/jem.167.2.598; MIKAYAMA T, 1993, P NATL ACAD SCI USA, V90, P10056, DOI 10.1073/pnas.90.21.10056; MITCHELL R, 1995, J IMMUNOL, V154, P3863; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; NISHINO T, 1995, MOL MED, V1, P781, DOI 10.1007/BF03401892; Orth DN, 1992, WILLIAMS TXB ENDOCRI, P489; PARANT M, 1991, LYMPHOKINE CYTOK RES, V10, P265; PARKALKAR V, 1994, GENOMICS, V19, P48; PEARSON WR, 1994, PROTEIN SCI, V3, P525; Rosengren E, 1996, MOL MED, V2, P143, DOI 10.1007/BF03402210; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHERRY B, 1992, P NATL ACAD SCI USA, V89, P3511, DOI 10.1073/pnas.89.8.3511; Subramanya HS, 1996, BIOCHEMISTRY-US, V35, P792, DOI 10.1021/bi951732k; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; Suzuki M, 1996, NAT STRUCT BIOL, V3, P259, DOI 10.1038/nsb0396-259; SUZUKI M, 1994, J MOL BIOL, V235, P1141, DOI 10.1006/jmbi.1994.1063; THURMAN GB, 1985, J IMMUNOL, V134, P305; WISTOW GJ, 1993, P NATL ACAD SCI USA, V90, P1272, DOI 10.1073/pnas.90.4.1272; ZUCKERMAN SH, 1989, EUR J IMMUNOL, V19, P301, DOI 10.1002/eji.1830190213	46	174	195	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1996	10	14					1607	1613		10.1096/fasebj.10.14.9002552	http://dx.doi.org/10.1096/fasebj.10.14.9002552			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WC869	9002552				2022-12-28	WOS:A1996WC86900006
J	Burg, MB; Kwon, ED; Kultz, D				Burg, MB; Kwon, ED; Kultz, D			Osmotic regulation of gene expression	FASEB JOURNAL			English	Review						osmolytes; heat shock genes; hypertonicity; signaling pathway	ACTIVATED PROTEIN-KINASE; RENAL MEDULLARY CELLS; ALDOSE REDUCTASE GENE; MAP KINASE; SIGNAL-TRANSDUCTION; HIGH-OSMOLARITY; HYPERTONIC STRESS; ESCHERICHIA-COLI; TRANSPORTER GENE; MAMMALIAN-CELLS	Cells react to increased osmolality with numerous changes in gene expression, The specific genes affected differ between species, but the known osmoprotective effects of the gene products are remarkably similar, particularly with regard to cellular accumulation of compatible organic osmolytes, Here we concentrate on the molecular basis for osmotic regulation of gene expression, emphasizing certain genes expressed in bacteria, yeast, and the mammalian renal medulla because their expression is best understood, Thus, we emphasize I) bacterial and yeast two-component histidine kinase systems, each consisting of a membrane osmolality sensor and a separate cytoplasmic response regulator that, when phosphorylated, alters transcription, 2) volume regulatory increases in cellular K+ salts that can prompt increased gene transcription in bacteria through direct effects on DNA and that in mammalian renal cells increase transcription, seemingly via trans-activating proteins, 3) a yeast kinase cascade that transmits an osmotic signal to the gene regulating the level of glycerol, and 4) in mammalian cells, several homologous cascades that are activated by hypertonicity, but whose osmoregulatory targets are not yet known.	NHLBI,KIDNEY & ELECTROLYTE METAB LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			, DK/AAU-3163-2021					ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; ALTENDORF K, 1994, RES MICROBIOL, V145, P374, DOI 10.1016/0923-2508(94)90084-1; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; COHEN DM, 1994, J BIOL CHEM, V269, P25865; COHEN DM, 1993, AM J PHYSIOL, V264, pF593, DOI 10.1152/ajprenal.1993.264.4.F593; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FERRARIS JD, 1994, P NATL ACAD SCI USA, V91, P10742, DOI 10.1073/pnas.91.22.10742; Ferraris JD, 1996, J BIOL CHEM, V271, P18318, DOI 10.1074/jbc.271.31.18318; Ferraris JD, 1996, AM J PHYSIOL-CELL PH, V270, pC650, DOI 10.1152/ajpcell.1996.270.2.C650; FORST SA, 1994, RES MICROBIOL, V145, P363, DOI 10.1016/0923-2508(94)90083-3; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; GARNER MM, 1994, AM J PHYSIOL, V266, pC877, DOI 10.1152/ajpcell.1994.266.4.C877; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; KANEKO T, 1995, J AM SOC NEPHROL, V6, P363; KUMAR S, 1995, J BIOL CHEM, V270, P29043, DOI 10.1074/jbc.270.49.29043; KWON HM, 1995, CURR OPIN CELL BIOL, V7, P465, DOI 10.1016/0955-0674(95)80002-6; KWON HM, 1995, BIOCHEM BIOPH RES CO, V213, P975, DOI 10.1006/bbrc.1995.2224; LUCHT JM, 1994, FEMS MICROBIOL REV, V14, P3, DOI 10.1016/0168-6445(94)90008-6; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MCLAGGAN D, 1994, J BIOL CHEM, V269, P1; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; Pratt L., 1995, 2 COMPONENT SIGNAL T, P105; SCHLIESS F, 1995, BIOCHEM J, V309, P13, DOI 10.1042/bj3090013; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHEIKHHAMAD D, 1994, AM J PHYSIOL, V267, pF28, DOI 10.1152/ajprenal.1994.267.1.F28; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; TAKENAKA M, 1995, P NATL ACAD SCI USA, V92, P1072, DOI 10.1073/pnas.92.4.1072; TERADA Y, 1994, J BIOL CHEM, V269, P31296; UCHIDA S, 1989, AM J PHYSIOL, V256, pC614, DOI 10.1152/ajpcell.1989.256.3.C614; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; YANCEY PH, 1990, AM J PHYSIOL, V258, pC156, DOI 10.1152/ajpcell.1990.258.1.C156; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	39	148	151	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1996	10	14					1598	1606		10.1096/fasebj.10.14.9002551	http://dx.doi.org/10.1096/fasebj.10.14.9002551			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WC869	9002551				2022-12-28	WOS:A1996WC86900005
J	Han, IS; Ramamurthy, N; Yun, JH; Schaller, U; Meyerhoff, ME; Yang, VC				Han, IS; Ramamurthy, N; Yun, JH; Schaller, U; Meyerhoff, ME; Yang, VC			Selective monitoring of peptidase activities with synthetic polypeptide substrates and polyion-sensitive membrane electrode detection	FASEB JOURNAL			English	Article						polycationic sensor; electrochemical potential; chymotrypsin; renin	BIOANALYTICAL APPLICATIONS; ELECTROCHEMICAL SENSOR; HEPARIN	A novel method to monitor specific peptidase activities in biological samples as complex as undiluted plasma/blood is described. The approach is based on the design of synthetic polypeptide substrates in which di- or triarginine sequences are linked to each, other via one or more other amino acids recognized specifically by the peptidase to be determined. Detection of chymotrypsin and renin activities using synthetic substrates P4 (F-R-R-R-F-V-R-R-F-NH2) and P5 (R-R-R-L-L-R-R-L-L-R-R-R), respectively, serves to demonstrate the principles of this new assay system. A polyion-sensitive membrane electrode, prepared by doping polymer films with dinonyhlaphthalene-sulfonate (DNNS), is shown to exhibit significant nonequilibrium electromotive force (EMF) responses toward these and other polycationic substrates at er levels under physiological conditions: The same electrode, however, exhibits much smaller total EMF response toward the shorter fragments of the synthetic peptides generated by peptidase activity; hence, the addition of peptidase to a solution containing the synthetic substrate yields a change in electrode EMF response, the rate of which is proportional to the activity of peptidase present. Other synthetic polycationic peptides as ell as natural polycationic peptides (e.,., protamine) that lack specific cleavage sites for chymotrypsin and renin, yet are detected by the DNNS-based membrane electrode, do not elicit any significant change in EMF response in the presence of the peptidases, confirming the feasibility and utility of the proposed bioanalytical method.	UNIV MICHIGAN,COLL PHARM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055461, R01HL038353, R29HL038353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028882] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55461, HL38353] Funding Source: Medline; NIGMS NIH HHS [GM-28882] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrett A. J., 1980, MAMMALIAN PROTEASES, VI; BARRETT AJ, 1980, MAMMALIAN PROTEASES, V2; DUPONT, 1991, INSTRUCTION MANUAL; FU B, 1995, MACROMOLECULES, V28, P5834, DOI 10.1021/ma00121a021; FU B, 1994, ANAL CHEM, V66, P2250, DOI 10.1021/ac00086a009; HARRELL JB, 1969, ANAL CHEM, V41, P1459, DOI 10.1021/ac60280a026; MA SC, 1993, ANAL CHEM, V65, P2078, DOI 10.1021/ac00063a024; MA SC, 1992, ANAL CHEM, V64, P694, DOI 10.1021/ac00030a023; SCHALLER U, 1994, ANAL CHEM, V66, P391, DOI 10.1021/ac00075a013; SLATER EE, 1981, METHOD ENZYMOL, V80, P427; TELTINGDIAZ M, 1994, ANAL CHEM, V66, P576, DOI 10.1021/ac00076a025; Wahr JA, 1996, J CARDIOTHOR VASC AN, V10, P447, DOI 10.1016/S1053-0770(05)80002-3; YUN JH, 1995, ANAL BIOCHEM, V224, P212, DOI 10.1006/abio.1995.1032; YUN JH, 1995, ASAIO J, V41, P661; 1992, NOM COMM INT UN BIOC, P371	15	33	36	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1996	10	14					1621	1626		10.1096/fasebj.10.14.9002554	http://dx.doi.org/10.1096/fasebj.10.14.9002554			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WC869	9002554	Green Submitted			2022-12-28	WOS:A1996WC86900008
J	MorrissKay, GM; Sokolova, N				MorrissKay, GM; Sokolova, N			Embryonic development and pattern formation	FASEB JOURNAL			English	Article						retinoic acid; mouse embryo; neural crest; limb	RETINOIC ACID RECEPTORS; VITAMIN-A; MOUSE EMBRYOGENESIS; BINDING-PROTEINS; DIFFERENTIAL PATTERN; MORPHOGENESIS; EXPRESSION; RAT; GAMMA; CRABP	During embryogenesis, information encoded in the genome is translated into cell proliferation, morphogenesis, and early stages of differentiation, Embryonic pattern arises from the spatial and temporal regulation and coordination of these events, The vitamin A (retinol) derivative retinoic acid (RA) is essential for normal development, Mammalian embryos are protected against vitamin A deficiency by maternal retinoid homeostasis until stored retinoids fall to very low levels, Retinol binding protein, which is synthesized in the yolk sac placenta of rodent embryos and in the syncytiotrophoblast of the human placenta, is essential for access of retinol to the embryo, Synthesis and metabolism of RA may involve cytoplasmic binding proteins, but the observation that mutants lacking these proteins are normal or near-normal suggests that they are not essential, Severe congenital vitamin A deficiency results in a spectrum of malformations including defects of the eye, lungs, cardiovascular system, and urogenital system, Extreme deficiency results as well in forelimb abnormalities and cleft face, but the embryos are not viable, Similar abnormalities are observed in embryos lacking two retinoid receptors, but loss of one receptor results in either normal development or mild abnormalities. Two single-receptor null mutants, RAR gamma-/- and RXR alpha-/-, show regional pattern-specific resistance to teratogenic levels of RA, Mutations leading to abnormality of the structure or regulation of RA signaling pathway genes may be an important cause of human congenital abnormality.			MorrissKay, GM (corresponding author), DEPT HUMAN ANAT,S PARKS RD,OXFORD OX1 3QX,ENGLAND.							ABUD HE, IN PRESS DEV GENET; BAILEY JS, 1988, J BIOL CHEM, V263, P9326; BATES CJ, 1983, P NUTR SOC, V42, P65, DOI 10.1079/PNS19830008; Bavik C, 1996, P NATL ACAD SCI USA, V93, P3110, DOI 10.1073/pnas.93.7.3110; BRANSTETTER RF, 1973, INT J VITAM NUTR RES, V43, P142; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN WH, 1995, DEVELOPMENT, V121, P681; Chytil F, 1996, FASEB J, V10, P986, DOI 10.1096/fasebj.10.9.8801181; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; de Beer G., 1937, DEV VERTEBRATE SKULL; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DOLLE P, 1994, MECH DEVELOP, V45, P91, DOI 10.1016/0925-4773(94)90023-X; EVANS JA, 1994, AM J MED GENET, V49, P52, DOI 10.1002/ajmg.1320490111; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GORRY P, 1994, P NATL ACAD SCI USA, V90, P932; GRUNEBERG H, 1954, J GENET, V52, P52, DOI 10.1007/BF02981490; HOGAN BLM, 1992, NATURE, V359, P237, DOI 10.1038/359237a0; HORTON C, 1995, DEV DYNAM, V202, P312, DOI 10.1002/aja.1002020310; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KESSEL M, 1992, DEVELOPMENT, V115, P487; LAMPRON C, 1995, DEVELOPMENT, V121, P539; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; MADEN M, 1993, DEV BIOL, V159, P379, DOI 10.1006/dbio.1993.1249; Mangelsdorf David J., 1994, P319; Marshall H, 1996, FASEB J, V10, P969, DOI 10.1096/fasebj.10.9.8801179; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; MENDELSOHN C, 1991, DEVELOPMENT, V113, P723; MORRISS GM, 1972, J ANAT, V113, P241; MORRISSKAY G, 1991, J CRAN GENET DEV BIO, V11, P181; MORRISSKAY G, 1993, BIOESSAYS, V15, P9, DOI 10.1002/bies.950150103; MORRISSKAY G, 1994, CIBA F SYMP, V181, P51; NAPOLI JL, 1993, J NUTR, V123, P362, DOI 10.1093/jn/123.suppl_2.362; Napoli JL, 1996, FASEB J, V10, P993, DOI 10.1096/fasebj.10.9.8801182; ONG DE, 1978, J BIOL CHEM, V253, P4551; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROSS AC, 1994, ADV EXP MED BIOL, V352, P187; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUBERTE E, 1991, DEVELOPMENT, V111, P45; RUBERTE E, 1993, DEVELOPMENT, V118, P267; RUBERTE E, 1992, DEVELOPMENT, V115, P973; RUTLEDGE JC, 1994, P NATL ACAD SCI USA, V91, P5436, DOI 10.1073/pnas.91.12.5436; Shimamura K, 1995, DEVELOPMENT, V121, P3923; SOKOLOVA N, 1996, THESIS U OXFORD; SOPRANO DR, 1986, P NATL ACAD SCI USA, V83, P7330, DOI 10.1073/pnas.83.19.7330; SUKOV HM, 1995, DEVELOPMENT, V121, P3997; TICKLE C, 1994, ANNU REV CELL BIOL, V10, P121; Wake K, 1980, Int Rev Cytol, V66, P303; Wallingford JC, 1986, VITAMIN A DEFICIENCY, P101; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202; WOOD H, 1994, DEVELOPMENT, V120, P2279; WOOD HB, 1996, IN PRESS DEV GENET	55	150	163	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1996	10	9					961	968		10.1096/fasebj.10.9.8801178	http://dx.doi.org/10.1096/fasebj.10.9.8801178			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801178				2022-12-28	WOS:A1996UY93200005
J	Wilson, JE; Schwab, DA				Wilson, JE; Schwab, DA			Functional interaction of hexokinase with ATP requires participation by both small and large lobes of the enzyme: Implications for other proteins using the actin fold as a nucleotide binding motif	FASEB JOURNAL			English	Article						ATP; binding; hexokinase; binding of ATP	SHOCK COGNATE PROTEIN; RAT-BRAIN HEXOKINASE; AMINO-ACID SEQUENCE; YEAST HEXOKINASE; CLONED CDNA; FRAGMENT; DOMAIN	The actin fold is a structural motif involved in binding of ATP to an otherwise diverse family of proteins that includes hexokinase, actin, and the 70 kDa heat shock protein, Previous analyses have focused attention on a hydrophobic pocket within the large lobe of hexokinase (and analogous regions in other proteins possessing the actin fold motif) as the site for binding of the adenine moiety, However, there is reason to believe that binding of. the adenine moiety also involves a beta-sheet region located in the small lobe of hexokinase, It is postulated that functional interaction with ATP, required for catalysis, involves interactions with both regions, The expected structural consequences provide a basis for explaining the kinetic mechanism suggested for this enzyme, i.e., although both substrates can bind independently, the preferred kinetic pathway is not random but ordered, with glucose binding first, The structural features postulated to be involved in binding of ATP to hexokinase are also found in other proteins possessing the actin fold motif, Interaction of the nucleotide with the beta-sheet region, analogous to that found in the ''small lobe'' of hexokinase, may induce functionally important conformational changes in other proteins employing the actin fold as a nucleotide binding motif.			Wilson, JE (corresponding author), MICHIGAN STATE UNIV,DEPT BIOCHEM,301 BIOCHEM BLDG,E LANSING,MI 48824, USA.				NINDS NIH HHS [NS09910] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009910] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON CM, 1979, SCIENCE, V204, P375, DOI 10.1126/science.220706; ARORA KK, 1990, J BIOL CHEM, V265, P5324; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; HARRISON RW, 1985, THESIS YALE U NEW HA; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; JONES JP, 1991, BIOCHEMISTRY-US, V30, P3634, DOI 10.1021/bi00229a007; KABSCH W, 1995, FASEB J, V9, P167, DOI 10.1096/fasebj.9.2.7781919; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; SCHWAB DA, 1989, P NATL ACAD SCI USA, V86, P2563, DOI 10.1073/pnas.86.8.2563; SCHWAB DA, 1988, J BIOL CHEM, V263, P3220; SHOHAM M, 1980, J MOL BIOL, V140, P1, DOI 10.1016/0022-2836(80)90353-8; STEITZ TA, 1981, PHILOS T ROY SOC B, V293, P43, DOI 10.1098/rstb.1981.0058; TAYLOR KB, 1983, EUR J BIOCHEM, V134, P571, DOI 10.1111/j.1432-1033.1983.tb07604.x; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776	17	14	14	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1996	10	7					799	801		10.1096/fasebj.10.7.8635698	http://dx.doi.org/10.1096/fasebj.10.7.8635698			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UN798	8635698				2022-12-28	WOS:A1996UN79800015
J	Masters, BSS; McMillan, K; Sheta, EA; Nishimura, JS; Roman, LJ; Martasek, P				Masters, BSS; McMillan, K; Sheta, EA; Nishimura, JS; Roman, LJ; Martasek, P			Cytochromes P450 .3. Neuronal nitric oxide synthase, a modular enzyme formed by convergent evolution: Structure studies of a cysteine thiolate-liganded heme protein that hydroxylates L-arginine to produce NO center dot as a cellular signal	FASEB JOURNAL			English	Review						L-arginine; cysteine thiolate-bound heme; tetrahydrobiopterin; Ca2+-calmodulin; FAD and FMN; NO center dot; L-citrulline; modular structure	RELAXING FACTOR; BRAIN; RAT; TETRAHYDROBIOPTERIN; PURIFICATION; COFACTOR; IDENTIFICATION; EXPRESSION; RECEPTORS; NITRATE	The nitric oxide synthases (NOS-I, neuronal, NOS-II, inducible, and NOS-III, endothelial) are the most recent additions to the large number of heme proteins that contain cysteine thiolate-liganded protoporphyrin IX heme prosthetic groups. This group of oxygenating enzymes also includes one of the largest gene families, that of the cytochromes P450, which have been demonstrated to be involved in the hydroxylation of a variety of substrates, including endogenous compounds (steroids, fatty acids, and prostaglandins) and exogenous compounds (therapeutic drugs, environmental toxicants, and carcinogens). The substrates for cytochromes P450 are universally hydrophobic while the physiological substrate for the nitric oxide synthases is the amino acid. L-arginine, a hydrophilic compound. This review will discuss the approaches being used to study the structure and mechanism of neuronal nitric oxide synthase in the context of its known prosthetic groups and regulation by Ca2+-calmodulin and/or tetrahydrobiopterin (BH4).	PHARMACOPEIA,CRANBURY,NJ 08512; UNIV ALEXANDRIA,DEPT BIOCHEM,ALEXANDRIA,EGYPT	Egyptian Knowledge Bank (EKB); Alexandria University	Masters, BSS (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.		Martasek, Pavel/G-6622-2017	Martasek, Pavel/0000-0001-6165-4444				ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; AKGOREN N, 1994, P NATL ACAD SCI USA, V91, P5903, DOI 10.1073/pnas.91.13.5903; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; BUSCONI L, 1995, BIOCHEM PHARMACOL, V47, P655; CAMPOS KL, 1995, J BIOL CHEM, V270, P1721, DOI 10.1074/jbc.270.4.1721; CHARLES IG, 1993, BIOCHEM BIOPH RES CO, V196, P1481, DOI 10.1006/bbrc.1993.2419; CHEN PF, 1994, J BIOL CHEM, V269, P25062; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; FARACI FM, 1993, CIRC RES, V72, P476, DOI 10.1161/01.RES.72.2.476; FELDMAN PL, 1993, CHEM ENG NEWS, V71, P26; FURCHGOTT R F, 1988, P401; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; GERBER NC, 1995, J BIOL CHEM, V270, P17791, DOI 10.1074/jbc.270.30.17791; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GREEN LC, 1981, P NATL ACAD SCI-BIOL, V78, P7764, DOI 10.1073/pnas.78.12.7764; GREEN LC, 1981, SCIENCE, V212, P56, DOI 10.1126/science.6451927; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KLATT P, 1994, J BIOL CHEM, V269, P1674; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; KWON NS, 1989, J BIOL CHEM, V264, P20496; KWON NS, 1990, J BIOL CHEM, V265, P13442; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MASTERS BSS, 1996, 4 INT M BIOL NITR OX; MAYER B, 1995, J BIOL CHEM, V270, P655, DOI 10.1074/jbc.270.2.655; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; NARHI LO, 1987, J BIOL CHEM, V262, P6683; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NISHIMURA JS, 1995, BIOCHEM BIOPH RES CO, V210, P288, DOI 10.1006/bbrc.1995.1659; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PAPE HC, 1992, NEURON, V9, P441, DOI 10.1016/0896-6273(92)90182-D; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; PUFAHL RA, 1993, BIOCHEM BIOPH RES CO, V193, P963, DOI 10.1006/bbrc.1993.1719; PUFAHL RA, 1995, BIOCHEMISTRY-US, V34, P1930, DOI 10.1021/bi00006a014; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14723, DOI 10.1021/bi00253a010; ROMAN LJ, 1995, E COLI NATL ACAD SCI, V92, P8428; SALERNO JC, 1994, BIOCH MOL BIOL NITRI, P72; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SCOTTBURDEN T, 1993, BIOCHEM BIOPH RES CO, V196, P1261, DOI 10.1006/bbrc.1993.2388; SEO HG, 1995, BIOCHEM BIOPH RES CO, V208, P10, DOI 10.1006/bbrc.1995.1298; SHETA EA, 1994, J BIOL CHEM, V269, P15147; SOUTHAM E, 1991, J NEUROCHEM, V56, P2072, DOI 10.1111/j.1471-4159.1991.tb03468.x; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WANG ZZ, 1994, NEUROSCIENCE, V60, P275, DOI 10.1016/0306-4522(94)90221-6; WENDLAND B, 1994, P NATL ACAD SCI USA, V91, P2151, DOI 10.1073/pnas.91.6.2151; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; ZHANG MJ, 1994, J BIOL CHEM, V269, P981	70	185	190	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1996	10	5					552	558		10.1096/fasebj.10.5.8621055	http://dx.doi.org/10.1096/fasebj.10.5.8621055			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UJ055	8621055				2022-12-28	WOS:A1996UJ05500004
J	Frey, PA				Frey, PA			The Leloir pathway: A mechanistic imperative for three enzymes to change the stereochemical configuration of a single carbon in galactose	FASEB JOURNAL			English	Review						galactokinase; enzymatic catalysis; uridine nucleotide binding	GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE; ESCHERICHIA-COLI; URIDYLYL-ENZYME; ACTIVE-SITE; 4-EPIMERASE; IDENTIFICATION; SUBSTRATE; REDUCTION	The biological interconversion of galactose and glucose takes place only by way of the Leloir pathway and requires the three enzymes galactokinase, galactose-1-P uridylyltransferase, and UDP-galactose 4-epimerase. The only biological importance of these enzymes appears to be to provide for the interconversion of galactosyl and glucosyl groups. Galactose mutarotase also participates by producing the galactokinase substrate alpha-D-galactose from its beta-anomer, The galacto/gluco configurational change takes place at tbe level of the nucleotide sugar by an oxidation/reduction mechanism in the active site of the epimerase . NAD(+) complex, The nucleotide portion of UDP-galactose acid UDP-glucose participates in the epimerization process in two ways: 1) by serving as a binding anchor that allows epimerization to take place at glycosyl-C-4 through weak binding of the sugar, and 2) by inducing a conformational change in the epimerase that destabilizes NAD(+) and increases its reactivity toward substrates, Reversible hydride transfer is thereby facilitated between NAD(+) and carbon-4 of the weakly bound sugars, The structure of the enzyme reveals many details of the binding of NAD(+) and inhibitors at the active site, The essential roles of the kinase and transferase are to attach the UDP group to galactose, allowing for its participation in catalysis by the epimerase. The transferase is a Zn/Fe metalloprotein, in which the metal ions stabilize the structure rather than participating in catalysis, Tile structure is interesting in that it consists of a single beta-sheet with 13 antiparallel strands and 1 parallel strand connected by 6 helices. The mechanism of UMP attachment at the active site of the transferase is a double displacement, with the participation of a covalent UMP-His(166)-enzyme intermediate in the Escherichia coli enzyme. The evolution of this mechanism appears to have been guided by the principle of economy in the evolution of binding sites.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53705	University of Wisconsin System; University of Wisconsin Madison	Frey, PA (corresponding author), UNIV WISCONSIN,GRAD SCH,INST ENZYME RES,1710 UNIV AVE,MADISON,WI 53705, USA.				NIGMS NIH HHS [GM30480] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANKEL H, 1968, BIOCHEM BIOPH RES CO, V32, P526, DOI 10.1016/0006-291X(68)90694-3; ARABSHAHI A, 1986, BIOCHEMISTRY-US, V25, P5583, DOI 10.1021/bi00367a036; BAUER AJ, 1992, PROTEINS, V12, P372, DOI 10.1002/prot.340120409; BERTLAND AU, 1971, BIOCHEMISTRY-US, V10, P1545; BHADURI A, 1965, BIOCHEM BIOPH RES CO, V21, P631, DOI 10.1016/0006-291X(65)90533-4; BOUFFARD GG, 1994, J MOL BIOL, V244, P269, DOI 10.1006/jmbi.1994.1728; BURKE JR, 1993, BIOCHEMISTRY-US, V32, P13220, DOI 10.1021/bi00211a034; CAPUTTO R, 1949, J BIOL CHEM, V179, P497; CAPUTTO R, 1950, J BIOL CHEM, V184, P333; CARDINI C. E., 1950, NATURE [LONDON], V165, P191, DOI 10.1038/165191a0; CREVELING CR, 1965, BIOCHEM BIOPH RES CO, V21, P624, DOI 10.1016/0006-291X(65)90532-2; DARROW RA, 1968, BIOCHEMISTRY-US, V7, P1645, DOI 10.1021/bi00845a005; DAVIS JE, 1974, BIOCHIM BIOPHYS ACTA, V334, P442, DOI 10.1016/0005-2744(74)90189-2; ELSAS LJ, 1994, AM J HUM GENET, V54, P1030; FIELD TL, 1989, BIOCHEMISTRY-US, V28, P2094, DOI 10.1021/bi00431a019; Frey P. A., 1987, PYRIDINE NUCLEOTIDE, P461; FREY PA, 1982, METHOD ENZYMOL, V87, P20; FREY PA, 1992, J NUTR SCI VITAMINOL, P461; ISSELBACHER KJ, 1956, SCIENCE, V123, P635, DOI 10.1126/science.123.3198.635; KALCKAR HM, 1970, P NATL ACAD SCI USA, V65, P1113, DOI 10.1073/pnas.65.4.1113; KANG UG, 1975, J BIOL CHEM, V250, P7099; KIM JM, 1990, BIOCHEMISTRY-US, V29, P10590, DOI 10.1021/bi00499a003; KONOPKA JM, 1989, BIOCHEMISTRY-US, V28, P2645, DOI 10.1021/bi00432a043; LELOIR LF, 1951, ARCH BIOCHEM BIOPHYS, V33, P186, DOI 10.1016/0003-9861(51)90096-3; LELOIR LF, 1963, CIBA F S CONTROL GLY, P68; MAXWELL ES, 1957, J BIOL CHEM, V229, P139; NELSESTU.GL, 1971, J BIOL CHEM, V246, P7533; REICHARDT JKV, 1991, AM J HUM GENET, V49, P860; RUZICKA FJ, 1995, BIOCHEMISTRY-US, V34, P5610, DOI 10.1021/bi00016a036; SCHWARZ V, 1956, BIOCHEM J, V62, P34, DOI 10.1042/bj0620034; SWANSON BA, 1993, BIOCHEMISTRY-US, V32, P13231, DOI 10.1021/bi00211a035; TRUCCO RE, 1948, ARCH BIOCHEM, V18, P137; WEDEKIND JE, 1995, BIOCHEMISTRY-US, V34, P11049, DOI 10.1021/bi00035a010; WEE TG, 1973, J BIOL CHEM, V248, P33; WILKINSON JF, 1949, BIOCHEM J, V44, P460, DOI 10.1042/bj0440460; WILSON DB, 1964, J BIOL CHEM, V239, P2469; WONG LJ, 1977, BIOCHEMISTRY-US, V16, P1010, DOI 10.1021/bi00624a032; WONG SS, 1978, BIOCHEMISTRY-US, V17, P516, DOI 10.1021/bi00596a022; WONG SS, 1977, BIOCHEMISTRY-US, V16, P298, DOI 10.1021/bi00621a022; YANG SLL, 1979, BIOCHEMISTRY-US, V18, P2980, DOI 10.1021/bi00581a011	40	357	368	2	52	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1996	10	4					461	470		10.1096/fasebj.10.4.8647345	http://dx.doi.org/10.1096/fasebj.10.4.8647345			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UE557	8647345				2022-12-28	WOS:A1996UE55700010
J	Bouvier, SE; Poteete, AR				Bouvier, SE; Poteete, AR			Second-site eversion of a structural defect in bacteriophage T4 lysozyme	FASEB JOURNAL			English	Article						lysozyme; vector; mutation	GENETIC-ANALYSIS; RESOLUTION; PROTEIN; MUTANT; CORE	A plasmid-borne gene encoding bacteriophage T4 lysozyme with a structural mutation, Tyr(161)-Ala, was mutagenized by the use of polymerase chain reaction, The mutagenized gene was inserted into a specialized bacteriophage lambda cloning vector that must acquire a functional lysozyme gene in order to form plaques, Functional variants of the mutant lysozyme were selected. Three compensatory second-site revertants were obtained: Thr(152)-Met, Lys(43)-Ile, and Thr(151)-Ala. The effects of these mutations are interpreted in light of previous structural and genetic studies of T4 lysozyme.	UNIV MASSACHUSETTS,MED CTR,DEPT MOLEC GENET & MICROBIOL,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024083] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24083] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALDWIN EP, 1993, SCIENCE, V262, P1715, DOI 10.1126/science.8259514; BALDWIN EP, 1993, TECHNIQUES PROTEIN C, V4, P499; ECKERT KA, 1991, PCR PRACTICAL APPROA, P225; HARDY LW, 1991, BIOCHEMISTRY-US, V30, P9457, DOI 10.1021/bi00103a010; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; PJURA PE, 1990, BIOCHEMISTRY-US, V29, P2592, DOI 10.1021/bi00462a023; POTEETE AR, 1991, BIOCHEMISTRY-US, V30, P1425, DOI 10.1021/bi00219a037; POTEETE AR, 1994, J BACTERIOL, V176, P6783, DOI 10.1128/JB.176.22.6783-6788.1994; REMINGTON SJ, 1978, J MOL BIOL, V118, P81, DOI 10.1016/0022-2836(78)90245-0; RENNELL D, 1989, GENETICS, V123, P431; RENNELL D, 1991, J MOL BIOL, V222, P67, DOI 10.1016/0022-2836(91)90738-R; RENNELL D, 1985, VIROLOGY, V143, P280, DOI 10.1016/0042-6822(85)90115-1; ROSENBERG SM, 1985, GENE, V38, P165, DOI 10.1016/0378-1119(85)90215-X; Sambrook J, 1989, MOL CLONING LABORATO; SHORTLE D, 1985, GENETICS, V110, P539; Silhavy T. J., 1984, EXPT GENE FUSIONS; WEAVER LH, 1987, J MOL BIOL, V193, P189, DOI 10.1016/0022-2836(87)90636-X	19	5	5	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1996	10	1					159	163		10.1096/fasebj.10.1.8566537	http://dx.doi.org/10.1096/fasebj.10.1.8566537			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566537				2022-12-28	WOS:A1996TR32800021
J	Lorimer, GH				Lorimer, GH			A quantitative assessment of the role of chaperonin proteins in protein folding in vivo	FASEB JOURNAL			English	Review						GroEL; GroES; Rubisco; phage coat protein	RIBULOSE-BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI PROTEINS; LARGE SUBUNITS; PEA-CHLOROPLASTS; GROEL; AGGREGATION; PRODUCTS; PLANT	In vitro the chaperonin proteins, GroEL and GroES, facilitate the folding of some other proteins under conditions where that process does not occur spontaneously, Using values drawn from a number of such in vitro studies, together with the known rates of in vivo protein synthesis by Escherichia coli and the known quantities of GroEL and GroES in E. coli, an assessment of the general role of these proteins in protein folding in vivo has been made. Three specific eases are examined, where compelling evidence points to the involvement of the chaperonins; the in vivo folding of the bacteriophage coat protein during the burst phase of phage morphogenesis and of Rubisco during chloroplast development and during expression of recombinant Rubisco in E. coli. In each case the maximum in vitro rates are nearly sufficient to account for the observed in vivo rates of formation of the native protein, However, in general, there appears to be sufficient GroEL and GroES to facilitate the folding of no more than 5% of all of the proteins within E. coli.			Lorimer, GH (corresponding author), DUPONT CO INC,EXPTL STN,DEPT CENT RES & DEV,WILMINGTON,DE 19880, USA.							ANDREWS TJ, 1988, J BIOL CHEM, V263, P12213; ASHIUCHI M, 1995, J BIOCHEM, V117, P495, DOI 10.1093/oxfordjournals.jbchem.a124735; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; BATTISTONI A, FEBS LETT, V322, P6; BERRYLOWE SL, 1991, PLANT PHYSIOL, V99, P1597; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CARRILLO N, 1992, J BIOL CHEM, V267, P15537; DING YH, 1995, BIOCHEMISTRY-US, V34, P14918, DOI 10.1021/bi00045a037; DRAHOS DJ, 1982, J BACTERIOL, V149, P1050, DOI 10.1128/JB.149.3.1050-1063.1982; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FISHER MT, 1994, J BIOL CHEM, V269, P29598; GALISTEO ML, 1995, J BIOL CHEM, V270, P16595, DOI 10.1074/jbc.270.28.16595; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GOLOUBINOFF P, 1989, NATURE, V342, P884; GORDON CL, 1994, J BIOL CHEM, V269, P27941; GORDON CL, 1993, J BIOL CHEM, V268, P9358; HARRIS JR, 1994, J STRUCT BIOL, V112, P216, DOI 10.1006/jsbi.1994.1022; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; ITAYA M, 1995, FEBS LETT, V362, P257, DOI 10.1016/0014-5793(95)00233-Y; JENSEN RG, 1977, ANNU REV PLANT PHYS, V28, P379, DOI 10.1146/annurev.pp.28.060177.002115; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; KING J, 1974, NATURE, V251, P112, DOI 10.1038/251112a0; Kjeldgaard NO, 1974, RIBOSOMES, P369; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEE SC, 1992, J BIOL CHEM, V267, P2849; LLORCA O, 1994, FEBS LETT, V345, P2; MATTINGLY JR, 1995, J BIOL CHEM, V270, P1138, DOI 10.1074/jbc.270.3.1138; MUSGROVE JE, 1987, EUR J BIOCHEM, V163, P529, DOI 10.1111/j.1432-1033.1987.tb10900.x; Neidhardt FC., 1987, ESCHERICHIA COLI SAL, V2nd ed, P3; PICKERSGILL RW, 1986, BIOCHEM J, V236, P311, DOI 10.1042/bj2360311; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; ROY H, 1982, J CELL BIOL, V94, P20, DOI 10.1083/jcb.94.1.20; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SCHNEIDER G, 1992, ANNU REV BIOPH BIOM, V21, P119, DOI 10.1146/annurev.bb.21.060192.001003; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; TODD MJ, 1995, IN PRESS P NATL ACAD; VANBOGELEN RA, 1992, ELECTROPHORESIS, V13, P1014, DOI 10.1002/elps.11501301203; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VIITANEN PV, 1995, J BIOL CHEM, V270, P18158, DOI 10.1074/jbc.270.30.18158; WYNN RM, 1992, J BIOL CHEM, V267, P12400	43	184	187	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1996	10	1					5	9		10.1096/fasebj.10.1.8566548	http://dx.doi.org/10.1096/fasebj.10.1.8566548			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566548				2022-12-28	WOS:A1996TR32800002
J	FORSDYKE, DR				FORSDYKE, DR			ON GIRAFFES AND PEER-REVIEW	FASEB JOURNAL			English	Article											FORSDYKE, DR (corresponding author), QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ONTARIO,CANADA.		Forsdyke, Donald R/A-1182-2012	Forsdyke, Donald R/0000-0002-4844-1417				ANGIER N, 1988, NATURAL OBSESSIONS S, P1; APIRION D, 1979, FED PROC, V38, P2649; Chubin DE, 1990, PEERLESS SCI PEER RE, P83; COLE S, 1981, SCIENCE, V214, P881, DOI 10.1126/science.7302566; FORSDYKE DR, 1975, J THEOR BIOL, V52, P187, DOI 10.1016/0022-5193(75)90050-8; FORSDYKE DR, 1989, LANCET, V2, P1382; FORSDYKE DR, 1968, LANCET, V1, P281; FORSDYKE DR, 1983, MED HYPOTHESES, V11, P141, DOI 10.1016/0306-9877(83)90057-9; FORSDYKE DR, 1991, FASEB J, V5, P2313, DOI 10.1096/fasebj.5.9.1860622; FORSDYKE DR, 1992, ACCOUNTABILITY RES, V3, P1; GARFIELD RE, 1987, CLIN OBSTET GYNECOL, V30, P3, DOI 10.1097/00003081-198703000-00004; HARDEN V, 1986, INVENTING NIH; KIRSCHSTEIN RL, 1976, GRANTS PEER REV REPO; LEDERBERG J, 1989, CC/LIFE SCI, V32, P5; MANDEL HG, 1983, SCIENCE, V221, P338, DOI 10.1126/science.6867712; OSMOND DH, 1983, J NEUROBIOL, V14, P95, DOI 10.1002/neu.480140202; PRESCOTT DM, 1992, BIOESSAYS, V14, P317, DOI 10.1002/bies.950140505; SHARP PA, 1990, CELL, V62, P839, DOI 10.1016/0092-8674(90)90256-E; STRICKLAND SP, 1988, FASEB J, V2, P2439, DOI 10.1096/fasebj.2.9.3371591	19	13	13	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1993	7	8					619	621		10.1096/fasebj.7.8.8500686	http://dx.doi.org/10.1096/fasebj.7.8.8500686			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LE290	8500686				2022-12-28	WOS:A1993LE29000003
J	Prost, S; Bellamy, COC; Cunningham, DS; Harrison, DJ				Prost, S; Bellamy, COC; Cunningham, DS; Harrison, DJ			Altered DNA repair and dysregulation of p53 in IRF-1 null hepatocytes	FASEB JOURNAL			English	Article						liver; cell cycle; apoptosis; UV irradiation; cell proliferation	NUCLEOTIDE EXCISION-REPAIR; CELL-GROWTH INHIBITION; LI-FRAUMENI SYNDROME; TUMOR-SUPPRESSOR; UV; APOPTOSIS; DAMAGE; INDUCTION; PHOSPHORYLATION; RADIATION	The tumor suppressor proteins IRF-1 and p53 are involved in response pathways after DNA damage. In different cell types, IRF-1 and p53 can cooperate to produce cell cycle arrest (embryo fibroblasts) or can independently trigger apoptosis (lymphoid cells). p53 may also regulate DNA repair, but there is no information on IRF-1 and repair. The cell lineage dependency of these effects precludes extrapolation of findings to other tissues of relevance to human cancer. Here, we report the consequences of IRF-1 deficiency for apoptosis, cell cycle arrest, and DNA repair in primary hepatocytes after DNA damage and extend previous work on the role of p53 in hepatocytes. IRF-1-deficient hepatocytes showed reduced DNA repair activity compared with wild-type, as assessed by unscheduled DNA synthesis after UV irradiation (10J/m(2)) and by host reactivation of a UV-damaged reporter construct. p53-deficient hepatocytes also showed reduced unscheduled DNA synthesis after UV, but there was no impairment of specific repair in host reactivation assays. IRF-1 deficiency did not affect the p53-dependent G(1)/S arrest after UV irradiation. Hepatocyte apoptosis after UV treatment, previously reported to be independent of p53, was also independent of IRF-1. However, IRF-1 deficiency produced dysregulation of p53, manifested as increased transactivation of a p53-reporter plasmid in undamaged hepatocytes, and accelerated p53 stabilization after DNA damage. Hence, in hepatocytes, IRF-1 is not required for growth arrest or apoptosis after DNA damage, but the results suggest for the first time a role in DNA repair regulation.	Univ Edinburgh, Sch Med, Dept Pathol, CRC Labs, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh	Prost, S (corresponding author), Univ Edinburgh, Sch Med, Dept Pathol, CRC Labs, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	s.prost@ed.ac.uk		prost, sandrine/0000-0002-0140-7115; harrison, david/0000-0001-9041-9988				ABRAHAMS PJ, 1995, MUTAT RES-DNA REPAIR, V336, P169, DOI 10.1016/0921-8777(94)00049-C; Bellamy COC, 1997, J PATHOL, V183, P177, DOI 10.1002/(SICI)1096-9896(199710)183:2<177::AID-PATH909>3.0.CO;2-E; Bellamy COC, 1997, FASEB J, V11, P591, DOI 10.1096/fasebj.11.7.9212083; Bellamy COC, 1997, BRIT MED BULL, V53, P522; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; HARPER JW, 1993, CELL, V75, P805; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; Li G, 1996, AM J PATHOL, V148, P1113; Li G, 1997, AM J PATHOL, V150, P1457; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lohrum M, 1996, ONCOGENE, V13, P2527; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MacCallum DE, 1996, ONCOGENE, V13, P2575; MARX J, 1994, SCIENCE, V266, P1321, DOI 10.1126/science.7973719; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; McDonald E, 1996, CANCER RES, V56, P2250; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; Scheidtmann KH, 1996, INT J ONCOL, V9, P1277; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SHIVJI MK, 1995, CURR BIOL, V4, P1062; SMITH ML, 1995, ONCOGENE, V10, P1053; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TANIGUCHI T, 1995, J CANC RES CLIN ONCO, V121, P416; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; ZHANG W, 1994, CANCER RES, V54, P4448	38	28	29	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1998	12	2					181	188		10.1096/fasebj.12.2.181	http://dx.doi.org/10.1096/fasebj.12.2.181			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472983				2022-12-28	WOS:000071848400006
J	Biagioli, M				Biagioli, M			The instability of authorship: Credit and responsibility in contemporary biomedicine	FASEB JOURNAL			English	Review							MEDICAL-RESEARCH; COPYRIGHT; INTEGRITY; RIGHTS		Harvard Univ, Dept Hist Sci, Cambridge, MA 02138 USA	Harvard University	Biagioli, M (corresponding author), Harvard Univ, Dept Hist Sci, Cambridge, MA 02138 USA.		Biagioli, Mario/HGE-2809-2022	Biagioli, Mario/0000-0003-0271-2979				ALEXANDER RS, 1953, CIRC RES, V1, P281, DOI 10.1161/01.RES.1.4.281; ANGELL M, 1986, ANN INTERN MED, V104, P261, DOI 10.7326/0003-4819-104-2-261; Arendt Harry, 1969, ILLUMINATIONS, P217; BALTIMORE D, 1996, NEW YORKER      0527, P107; Barthes Roland., 1977, IMAGE MUSIC TEXT; BASKIN TI, COMMUNICATION; BERK RN, 1989, AM J ROENTGENOL, V152, P719, DOI 10.2214/ajr.152.4.719; Bhopal R, 1997, BRIT MED J, V314, P1009, DOI 10.1136/bmj.314.7086.1009; BIAGIOLI M, 1996, CRIT INQUIRY, V22, P193, DOI 10.1086/448789; Biagioli M., 1993, G COURTIER, P103; BIAGIOLI M, 1993, LANCET, V342, P315; BIAGIOLI M, 1982, LANCET, V2, P1199; BOURDIEU P, 1975, SOC SCI INFORM, V14, P19, DOI 10.1177/053901847501400602; BOYLE J, 1996, SHAMANS SOFTWARE SPL, P25; BOYLE J, 1996, SHAMANS SOFTWARE SPL, P35; BOYLE J, UNPUB POLITICS INTEL; BOYLE J, 1996, SHAMANS SOFTWARE SPL, P51; Boyle James, 1996, SHAMANS SOFTWARE SPL; BRAUNWALD E, 1987, NATURE, V325, P215, DOI 10.1038/325215a0; BROAD WJ, 1981, SCIENCE, V211, P1137, DOI 10.1126/science.7008199; CAELLEIGH AS, 1991, ACAD MED, V66, P676, DOI 10.1097/00001888-199111000-00007; CHUBIN DE, 1990, PEERLESS SCI; Cochrane L. G., 1994, ORDER BOOKS READERS, P25; CONRAD CC, 1990, AUTHORSHIP ACKNOWLED, P184; COURT C, 1994, BRIT MED J, V309, P1459, DOI 10.1136/bmj.309.6967.1459; CULLITON BJ, 1988, SCIENCE, V241, P525, DOI 10.1126/science.3399886; CULLITON BJ, 1988, SCIENCE, V242, P658, DOI 10.1126/science.3187511; DALTON R, 1997, SCIENCE, V385, P566; DARDIK H, 1977, SURG GYNECOL OBSTET, V145, P418; DEWEY ME, 1993, BRIT MED J, V306, P318, DOI 10.1136/bmj.306.6873.318; DEWEY ME, 1993, BRIT MED J, V306, P716; DINGELL JD, 1993, NEW ENGL J MED, V328, P1614; Eastwood Susan, 1996, Sci Eng Ethics, V2, P89, DOI 10.1007/BF02639320; ENGLER RL, 1987, NEW ENGL J MED, V317, P1383, DOI 10.1056/NEJM198711263172205; FIELDS KL, 1993, ACAD MED, V68, pS60, DOI 10.1097/00001888-199309000-00036; FOUCAULT M, 1977, WHAT IS AN AUTHOR, P124; FYE WB, 1990, ANN INTERN MED, V113, P324; FYE WB, 1990, ANN INTERN MED, V113, P320; GALISON P, 1997, C SCI AUTH MARCH 7 9; GARFIELD E, 1983, ESSAYS INFORMATION S, V5, P622; GARFIELD E, 1983, ESSAYS INFORMATION S, V2, P622; Godlee F, 1996, BRIT MED J, V312, P1501, DOI 10.1136/bmj.312.7045.1501a; GOEPFERT H, 1989, HEAD NECK        JUL, P293; GOLDSTEIN A, 1988, SCIENCE, V242, P1623; GOODMAN NW, 1994, BRIT MED J, V309, P1482, DOI 10.1136/bmj.309.6967.1482; GRANT IWB, 1989, BRIT MED J, V298, P386, DOI 10.1136/bmj.298.6670.386-d; GUENIN LM, 1996, ACAD MED, V71, P598; Hagstrom W. O., 1982, SCI CONTEXT READINGS, P21; HAMILTON DP, 1990, SCIENCE, V250, P1332; HESSE C, 1991, PUBLISHING CULTURAL, P1789; Horton R, 1997, LANCET, V350, P5, DOI 10.1016/S0140-6736(05)66236-8; HORTON R, BRIT MED J, V3112, P723; HORTON R, 1997, LANCET, V350, P6; HUTH EJ, 1986, ANN INTERN MED, V104, P266, DOI 10.7326/0003-4819-104-2-266; *ICMJE, 1997, JAMA-J AM MED ASSOC, V277, P928; JASZI P, 1991, DUKE LAW J, P455; KASSIRER JP, 1991, NEW ENGL J MED, V325, P1510, DOI 10.1056/NEJM199111213252112; Kevles Daniel J., 1998, BALTIMORE CASE TRIAL; Kevles DJ, 1996, NEW YORKER, P94; KLEIN DF, 1993, ACAD MED, V68, pS56, DOI 10.1097/00001888-199309000-00035; LaFollette MarcelC., 1992, STEALING PRINT FRAUD, DOI 10.1525/9780520917804; LAFOLLETTE MC, 1992, STEALING PRINT FRAUD, P156; LANGE D, 1981, LAW CONTEMP PROBL, V44, P147, DOI 10.2307/1191227; LASKIN DM, 1987, J ORAL MAXIL SURG, V45, P1, DOI 10.1016/0278-2391(87)90075-9; Leash E, 1997, J DENT RES, V76, P724, DOI 10.1177/00220345970760030101; LEASH E, 1997, J DENT RES, V76, P726; Litman Jessica, 1990, EMORY LAW J, V39, P999; Litman Jessica, 1990, EMORY LJ, V39, P965; MACAULEY D, 1992, BRIT MED J, V305, P6845; MADDOX J, 1988, NATURE, V333, P493, DOI 10.1038/333493a0; Marshall E, 1997, SCIENCE, V275, P780, DOI 10.1126/science.275.5301.780; MERTON RK, SOCIOLOGY SCI THEORE, P294; Merton Robert K., 1973, SOCIOLOGY SCI THEORE, P273; Nelkin D., 1984, SCI INTELLECTUAL PRO; Pasachoff JM, 1997, SCIENCE, V275, P14; PHILLIPS J, 1995, INTRO INTELLECTUAL P, P39; RELMAN AS, 1979, CLIN PAHRM THER, V25, P674; RELMAN AS, 1983, NEW ENGL J MED, V308, P1417; RENNIE D, 1994, JAMA-J AM MED ASSOC, V271, P469, DOI 10.1001/jama.271.6.469; RENNIE D, 1996, J AM MED ASS; RENNIE D, 1990, ETHICS POLICY SCI PU, P155; RIESENBERG D, 1990, JAMA-J AM MED ASSOC, V264, P1857, DOI 10.1001/jama.264.14.1857; Rose M., 1993, AUTHORS OWNERS; SCHECHTER AN, 1989, FASEB J, V3, P209, DOI 10.1096/fasebj.3.2.2914630; Scott PV, 1996, BRIT MED J, V313, P821; SHAPIN S, 1989, AM SCI, V77, P554; SHAPIN S, 1988, ISIS, V79, P373, DOI 10.1086/354773; SHAPIRO DW, 1994, JAMA-J AM MED ASSOC, V271, P438, DOI 10.1001/jama.271.6.438; SMITH J, 1994, BRIT MED J, V309, P1456, DOI 10.1136/bmj.309.6967.1456; Smith R, 1997, BRIT MED J, V314, P992, DOI 10.1136/bmj.314.7086.992; STEWART WW, 1987, NATURE, V325, P207, DOI 10.1038/325207a0; STRUB RL, 1976, LANCET, V2, P1090; WALKER PV, 1996, CHRONICLE HIGHE 0126, pA29; WALKER PV, 1997, CHRONICLE HIGHE 0606, pA27; WALKER PV, 1997, CHRONICLE HIGHE 0207, pA37; Willcox B L, 1992, Account Res, V2, P139, DOI 10.1080/08989629208573810; Woodmannsee M, 1984, EIGHTEENTH-CENT STUD, V17, P443; WOODMANSEE M, 1984, EIGHTEENTH-CENT STUD, V17, P425, DOI 10.2307/2738129; Woodmansee Martha, 1994, AUTHOR ART MARKET; ZUCKERMAN HA, 1988, SCI TECHNOL HUM VAL, V13, P7, DOI 10.1177/0162243988013001-203; 1989, JAMA, V262, P2005; 1997, SCIENCE, V275, P1055; 1985, LANCET, V2, P595; 1990, JAMA, V263; 1992, N ENGL J MED, V326, P1084	105	65	69	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1998	12	1					3	16		10.1096/fasebj.12.1.3	http://dx.doi.org/10.1096/fasebj.12.1.3			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YR723	9438406				2022-12-28	WOS:000071523800002
J	Nevalainen, MT; Valve, EM; Ahonen, T; Yagi, A; Paranko, J; Harkonen, PL				Nevalainen, MT; Valve, EM; Ahonen, T; Yagi, A; Paranko, J; Harkonen, PL			Androgen-dependent expression of prolactin in rat prostate epithelium in vivo and in organ culture	FASEB JOURNAL			English	Review						autocrine/paracrine; androgen; insulin; prostate; PRL	MESSENGER-RIBONUCLEIC-ACID; METHYL-N-NITROSOUREA; LATERAL PROSTATE; GENE-EXPRESSION; GROWTH-HORMONE; PRL STORAGE; CELL-DEATH; DEVELOPMENTAL ESTROGENIZATION; RECEPTOR EXPRESSION; SECRETORY GRANULES	Peptide hormones and growth factors are involved in the regulation of prostatic cell proliferation, differentiation, and programmed cell death, which functions are primarily controlled by androgen, In carcinogenesis, prostatic cancer cells often lose androgen dependence and become largely dependent on local growth factors, The prostatic cancer cells able to respond to factors other than androgen by proliferation and inhibition of apoptosis are possibly able to survive, We demonstrate that prostatic epithelium expresses prolactin mRNA and protein in a characteristic manner, By using in situ hybridization, an overall distribution of prolactin mRNA was demonstrated in the epithelium of rat dorsal and lateral prostate, whereas a very specific localization of prolactin protein to single cells was observed by immunohistochemistry in the same tissues, In these cells, immunoelectron microscopy showed that prolactin was primarily localized to the secretory granules, These data demonstrate a selective regulation of prostatic prolactin at least at the level of transcript processing/translation and/or protein accumulation and secretion, In addition, the expression of prolactin protein in rat dorsal and lateral prostate was found to be androgen dependent in vivo in castrated and in castrated, testosterone-treated rats, as well as in vitro in organ cultures, Our results support the concept of an autocrine/paracrine loop of prolactin action in prostate where it could mediate some of androgen actions, Also, locally synthesized prolactin might belong to the factors that take over androgen regulation of prostatic cancer cells during the development of androgen-independent growth.	Univ Turku, Inst Biomed, Dept Anat, FIN-20520 Turku, Finland; Univ Turku, Med Res Lab, FIN-20520 Turku, Finland; Univ Turku, Inst Biol, Physiol Anim Lab, FIN-20014 Turku, Finland	University of Turku; University of Turku; University of Turku	Harkonen, PL (corresponding author), Univ Turku, Inst Biomed, Dept Anat, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Abrahamsson PA, 1996, PROSTATE, P3; APRIKIAN AG, 1993, CANCER, V71, P3952, DOI 10.1002/1097-0142(19930615)71:12<3952::AID-CNCR2820711226>3.0.CO;2-X; ARRANDALE JM, 1994, MOL ENDOCRINOL, V8, P1083, DOI 10.1210/me.8.8.1083; BONKHOFF H, 1993, VIRCHOWS ARCH A, V423, P291, DOI 10.1007/BF01606893; BOSLAND MC, 1990, CANCER RES, V50, P691; BUJAN L, 1993, HUM REPROD, V8, P74, DOI 10.1093/oxfordjournals.humrep.a137878; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; COSTELLO LC, 1994, PROSTATE, V24, P162, DOI 10.1002/pros.2990240311; Culig Z, 1996, PROSTATE, V28, P392, DOI 10.1002/(SICI)1097-0045(199606)28:6<392::AID-PROS9>3.0.CO;2-C; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; Cunha GR, 1996, PROSTATE, P22; Denmeade SR, 1996, PROSTATE, V28, P251; DEVITO WJ, 1992, ENDOCRINOLOGY, V131, P2154, DOI 10.1210/en.131.5.2154; DIMATTIA GE, 1990, J BIOL CHEM, V265, P16412; DUNNING W. F., 1963, NATL CANCER INST MONOGR, V12, P351; EMANUELE NV, 1992, MOL ENDOCRINOL, V6, P35, DOI 10.1210/me.6.1.35; Farnsworth WE, 1996, PROSTATE, V28, P17; FIELDS K, 1993, LAB INVEST, V68, P354; GELLERSEN B, 1989, MOL CELL ENDOCRINOL, V64, P127, DOI 10.1016/0303-7207(89)90073-7; GELLERSEN B, 1995, MOL ENDOCRINOL, V9, P887, DOI 10.1210/me.9.7.887; GELLERSEN B, 1992, ENDOCRINOLOGY, V131, P1017, DOI 10.1210/en.131.3.1017; GELLERSEN B, 1994, MOL ENDOCRINOL, V8, P356, DOI 10.1210/me.8.3.356; GINSBURG E, 1995, CANCER RES, V55, P2591; Goffin V, 1996, ENDOCR REV, V17, P385, DOI 10.1210/er.17.4.385; Gothard LQ, 1996, MOL ENDOCRINOL, V10, P185, DOI 10.1210/me.10.2.185; GRECO TL, 1993, ENDOCR REV, V14, P59, DOI 10.1210/er.14.1.59; GUBBINS EJ, 1980, J BIOL CHEM, V255, P8655; GUYETTE WA, 1979, CELL, V17, P1013, DOI 10.1016/0092-8674(79)90340-4; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HIRAOKA Y, 1991, MOL CELL ENDOCRINOL, V75, P71; HO TWC, 1991, ENDOCRINOLOGY, V129, P184, DOI 10.1210/endo-129-1-184; HORSEMAN ND, 1994, ENDOCR REV, V15, P627, DOI 10.1210/er.15.5.627; IKONEN T, 1994, ENDOCRINOLOGY, V135, P1359, DOI 10.1210/en.135.4.1359; ISAACS JT, 1984, PROSTATE, V5, P545, DOI 10.1002/pros.2990050510; JESIK CJ, 1982, PROSTATE, V3, P81, DOI 10.1002/pros.2990030111; JOHANSSON R, 1975, THESIS U TURKU TURKU; JONES R, 1983, J ENDOCRINOL, V96, P407, DOI 10.1677/joe.0.0960407; KAIPIA A, 1992, ENDOCRINOLOGY, V131, P2703, DOI 10.1210/en.131.6.2703; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KEENAN EJ, 1981, ENDOCRINOLOGY, V109, P170, DOI 10.1210/endo-109-1-170; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; Kim IY, 1996, MOL ENDOCRINOL, V10, P107, DOI 10.1210/me.10.1.107; KLEIN G, 1990, BIOESSAYS, V12, P347, DOI 10.1002/bies.950120708; KURTZ A, 1993, BIOL REPROD, V48, P1095, DOI 10.1095/biolreprod48.5.1095; MANDAL A, 1991, INT J ANDROL, V14, P159, DOI 10.1111/j.1365-2605.1991.tb01077.x; MARTIKAINEN P, 1987, ANAT REC, V218, P166, DOI 10.1002/ar.1092180212; MARTIKAINEN P, 1990, ENDOCRINOLOGY, V127, P1268, DOI 10.1210/endo-127-3-1268; MARTIKAINEN PM, 1997, PROLACTIN DEATH ANTA; MASTRO RM, 1995, ENDOCRINOLOGY, V136, P69, DOI 10.1210/en.136.1.69; MAURER RA, 1981, J BIOL CHEM, V256, P524; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; Nevalainen MT, 1997, J CLIN INVEST, V99, P618, DOI 10.1172/JCI119204; Nevalainen MT, 1996, ENDOCRINOLOGY, V137, P3078, DOI 10.1210/en.137.7.3078; NEVALAINEN MT, 1991, ENDOCRINOLOGY, V129, P612, DOI 10.1210/endo-129-2-612; NEVALAINEN MT, 1993, CANCER RES, V53, P5199; NOWAK RA, 1993, J CLIN ENDOCR METAB, V76, P1308, DOI 10.1210/jc.76.5.1308; OETTING WS, 1986, J BIOL CHEM, V261, P1649; Peehl DM, 1996, PROSTATE, P74; PELLEGRINI I, 1988, ENDOCRINOLOGY, V122, P2667, DOI 10.1210/endo-122-6-2667; PELLEGRINI I, 1992, MOL ENDOCRINOL, V6, P1023, DOI 10.1210/me.6.7.1023; PELLEGRINI I, 1990, ENDOCRINOLOGY, V126, P1087; Perucho M, 1996, NAT MED, V2, P630, DOI 10.1038/nm0696-630; POWERS CA, 1990, ENDOCRINOLOGY, V127, P1916, DOI 10.1210/endo-127-4-1916; PRICE D, 1963, NATL CANCER I MONOGR, V12, P351; PRINS GS, 1995, ENDOCRINOLOGY, V136, P1303, DOI 10.1210/en.136.3.1303; PRINS GS, 1992, ENDOCRINOLOGY, V130, P2401, DOI 10.1210/en.130.4.2401; PYLKKANEN L, 1992, THESIS U TURKU TURKU; RAMBOURG A, 1992, ANAT RECORD, V232, P169, DOI 10.1002/ar.1092320202; Reinikainen P, 1996, ENDOCRINOLOGY, V137, P4351, DOI 10.1210/en.137.10.4351; RUI H, 1987, MOL CELL ENDOCRINOL, V52, P91, DOI 10.1016/0303-7207(87)90101-8; RUI H, 1987, THESIS U OSLO OSLO; SABHARWAL P, 1992, P NATL ACAD SCI USA, V89, P7713, DOI 10.1073/pnas.89.16.7713; SantAgnese P.A., 1992, HUM PATHOL, V23, P287, DOI 10.1016/0046-8177(92)90110-o; SANTTI R, 1994, PROSTATE, V24, P67, DOI 10.1002/pros.2990240204; SANTTI R, 1990, INT J ANDROL, V13, P77, DOI 10.1111/j.1365-2605.1990.tb00963.x; SCHACHT MJ, 1992, PROSTATE, V20, P51, DOI 10.1002/pros.2990200107; SCHACHTER BS, 1984, ENDOCRINOLOGY, V114, P1947, DOI 10.1210/endo-114-5-1947; Schleicher RL, 1996, PROSTATE, V28, P32, DOI 10.1002/(SICI)1097-0045(199601)28:1<32::AID-PROS5>3.0.CO;2-Q; SCOMMEGNA A, 1994, FERTIL STERIL, V61, P331; SINHA YN, 1992, TRENDS ENDOCRIN MET, V3, P100, DOI 10.1016/1043-2760(92)90021-R; SINHA YN, 1995, ENDOCR REV, V16, P354, DOI 10.1210/er.16.3.354; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STEINMETZ RW, 1993, J ENDOCRINOL, V136, P271, DOI 10.1677/joe.0.1360271; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Sun ZY, 1996, MOL ENDOCRINOL, V10, P265, DOI 10.1210/me.10.3.265; THOMAS JA, 1975, J ENDOCRINOL, V65, P149, DOI 10.1677/joe.0.0650149; TIMME TL, 1994, ENDOCRINOLOGY, V134, P1039, DOI 10.1210/en.134.3.1039; TORNER L, 1995, ENDOCRINOLOGY, V136, P5454, DOI 10.1210/en.136.12.5454; TOUGARD C, 1980, AM J ANAT, V158, P471, DOI 10.1002/aja.1001580409; TRICHE TJ, 1971, LAB INVEST, V25, P596; TROWELL OA, 1959, EXP CELL RES, V16, P118, DOI 10.1016/0014-4827(59)90201-0; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; Wallis M., 1988, Hormones and their actions. Part II. Specific actions of protein hormones., P295; WALVOORD DJ, 1976, INVEST UROL, V14, P60; WANG YF, 1993, ENDOCRINOLOGY, V133, P2156, DOI 10.1210/en.133.5.2156; Webber M M, 1981, Prog Clin Biol Res, V75B, P63; WILSON JD, 1980, AM J MED, V68, P745, DOI 10.1016/0002-9343(80)90267-3; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; ZELLER R, 1991, CURRENT PROTOCOLS MO, pCH14; Zhau HYE, 1996, P NATL ACAD SCI USA, V93, P15152, DOI 10.1073/pnas.93.26.15152	103	68	71	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1997	11	14					1297	1307		10.1096/fasebj.11.14.9409549	http://dx.doi.org/10.1096/fasebj.11.14.9409549			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YN210	9409549				2022-12-28	WOS:000071144100011
J	Sommer, T; Wolf, DH				Sommer, T; Wolf, DH			Endoplasmic reticulum degradation: reverse protein flow of no return	FASEB JOURNAL			English	Review						heavy chain; membrane protein; soluble protein; ER degradation	UBIQUITIN-PROTEASOME PATHWAY; ANTIGEN RECEPTOR CHAINS; PRE-GOLGI; CYSTIC-FIBROSIS; MEMBRANE; YEAST; TRANSLOCATION; CFTR; SUBUNITS; MUTANT	The endoplasmic reticulum (ER) is the site of entry of proteins into the secretory pathway, It is responsible for proper folding of the proteins before delivery to their site of action, Furthermore, proofreading to detect malfolded or unnecessary proteins that have to be eliminated and regulation of protein levels are crucial ER functions, The ubiquitin-proteasome system, located in the cytoplasm, has emerged as the major ER degradation machinery, A multitude of ER resident as well as membrane-bound and soluble proteolytic substrates of the secretory pathway are retained in the ER and destined for degradation via this pathway, Their actual proteolysis is preceded by a retrograde transport to the cytoplasm, A key component of the translocation apparatus, Sec61p, is also the central subunit of the retrogade transport system, Other components of the translocon such as Sec63p or the lumenal chaperone BiP may also be involved in export to the cytosol, Novel ER membrane proteins such as Der1p, Der3p/Hrd1p, or Hrd3p might reprogram the translocon for retrograde transport, As ubiquitination is a prerequisite for degradation by the proteasome, exported proteins are ubiquitinated, Representatives of ER membrane-bound ubiquitin-conjugating enzymes, Ubc6p and Cue1p/Ubc7p, have been identified in yeast, Retrograde transport and ubiquitination seem to be coupled processes.	Univ Stuttgart, Inst Biochem, D-70569 Stuttgart, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	University of Stuttgart; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Wolf, DH (corresponding author), Univ Stuttgart, Inst Biochem, Pfaffenwaldring 55, D-70569 Stuttgart, Germany.							AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BONIFACINO JS, 1994, CELLULAR PROTEOLYTIC, V15, P137; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; FINGER A, 1993, EUR J BIOCHEM, V215, P56; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Gaut JR, 1993, CURR OPIN CELL BIOL, V5, P589, DOI 10.1016/0955-0674(93)90127-C; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Kerkau T, 1997, J EXP MED, V185, P1295, DOI 10.1084/jem.185.7.1295; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Knop M, 1996, YEAST, V12, P1229, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1229::AID-YEA15>3.0.CO;2-H; LE A, 1992, J BIOL CHEM, V257, P1072; LEUSTEK T, 1992, CELL MOL BIOL, V38, P1; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LYKO F, 1995, J BIOL CHEM, V270, P19873, DOI 10.1074/jbc.270.34.19873; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; MULLINS C, 1995, J BIOL CHEM, V270, P1; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROEMISCH K, 1992, P NATL ACAD SCI USA, V89, P7227; Schlumpberger M, 1997, J BACTERIOL, V179, P1068, DOI 10.1128/jb.179.4.1068-1076.1997; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WOLF DH, 1975, J BACTERIOL, V123, P1150, DOI 10.1128/JB.123.3.1150-1156.1975	48	218	221	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1997	11	14					1227	1233		10.1096/fasebj.11.14.9409541	http://dx.doi.org/10.1096/fasebj.11.14.9409541			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YN210	9409541				2022-12-28	WOS:000071144100003
J	Tedone, T; Correale, M; Barbarossa, G; Casavola, V; Paradiso, A; Reshkin, SJ				Tedone, T; Correale, M; Barbarossa, G; Casavola, V; Paradiso, A; Reshkin, SJ			Release of the aspartyl protease cathepsin D is associated with and facilitates human breast cancer cell invasion	FASEB JOURNAL			English	Article						protease; proliferation; MCF-7	TRANSFORMED-CELLS; EXTRACELLULAR-MATRIX; GROWTH-FACTORS; TUMOR-CELLS; ACID; PH; INVITRO; DEGRADATION; METASTASIS; INHIBITION	Data concerning the hormone sensitivity of the release and role of the aspartyl protease cathepsin D in tumor proliferative and invasive processes have been contradictory. To clarify the mechanisms of its release and role we first studied the contribution of estradiol and stripped serum to the time course and kinetics of cathepsin D release, proliferation, and invasion in parallel in the MCF-7 in vitro breast cancer cell culture model. Both estradiol and stripped serum independently stimulated both proliferation and cathepsin D release. However, the dose-response of estradiol and stripped serum-dependent stimulated release were similar to those for invasion and differed from those for proliferation: cathepsin D release and invasion were first stimulated at a stripped serum concentration more than 10-fold lower than that which initiated proliferation and had half stimulation constants almost 10-fold lower than those for proliferation. These results demonstrate that cathepsin D release is not related in any direct way to proliferation. The effect of the reduction of cathepsin D activity or release on in vitro invasion was also measured: both the inhibition of secreted cathepsin D activity by a specific inhibitor, diazoacetyl-DL-Nle-OMe, and the reduction of cathepsin D release by antisense oligonucleotides against its translation start site reduced cellular in vitro invasion without affecting proliferation. Cathepsin D release and activity are concluded to be directly involved in the process of invasion.	UNIV BARI,INST GEN PHYSIOL,I-70126 BARI,ITALY; INST ONCOL,EXPT ONCOL LAB,I-70126 BARI,ITALY	Universita degli Studi di Bari Aldo Moro			Reshkin, Stephan/AAI-6680-2020; paradiso, angelo V/J-9457-2018	Reshkin, Stephan/0000-0001-9757-5908; CASAVOLA, Valeria/0000-0003-4471-4948				ALBINI A, 1987, CANCER RES, V47, P3239; AUGEREAU P, 1988, MOL ENDOCRINOL, V2, P186, DOI 10.1210/mend-2-2-186; AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; BRIOZZO P, 1991, EXP CELL RES, V194, P252, DOI 10.1016/0014-4827(91)90362-X; BRIOZZO P, 1988, CANCER RES, V48, P3688; CAPACCIOLI S, 1993, BIOCHEM BIOPH RES CO, V197, P818, DOI 10.1006/bbrc.1993.2552; CAVAILLES V, 1988, NUCLEIC ACIDS RES, V16, P1903, DOI 10.1093/nar/16.5.1903; CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552, DOI 10.1210/mend-3-3-552; CONOVER CA, 1994, J BIOL CHEM, V269, P7076; DUFFY MJ, 1992, CLIN EXP METASTAS, V10, P145, DOI 10.1007/BF00132746; FRELIN C, 1988, EUR J BIOCHEM, V174, P3, DOI 10.1111/j.1432-1033.1988.tb14055.x; GARCIA M, 1990, ONCOGENE, V5, P1809; *GEN COMP GROUP, 1994, PROGR MAN GSG PACK; GILLIES RJ, 1994, AM J PHYSIOL, V267, pC195, DOI 10.1152/ajpcell.1994.267.1.C195; HELSETH DL, 1984, P NATL ACAD SCI-BIOL, V81, P3302, DOI 10.1073/pnas.81.11.3302; Isidoro C, 1995, INT J CANCER, V63, P866, DOI 10.1002/ijc.2910630619; JOHNSON MD, 1993, CANCER RES, V53, P873; LOCKWOOD TD, 1977, NATURE, V267, P252, DOI 10.1038/267252a0; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; PAGLIACCI MC, 1991, ENDOCRINOLOGY, V129, P2555, DOI 10.1210/endo-129-5-2555; RAVDIN PM, 1993, BREAST CANCER RES TR, V24, P219, DOI 10.1007/BF01833262; RICHARDSON JM, 1988, J CELL BIOL, V107, P2097, DOI 10.1083/jcb.107.6.2097; ROCHEFORT H, 1992, ACTA ONCOL, V31, P125, DOI 10.3109/02841869209088891; ROZHIN J, 1994, CANCER RES, V54, P6517; SCHULTZ DC, 1994, CANCER RES, V54, P48; SLONE BF, 1990, SEMINARS CANC BIOL, V1, P137; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; TANAKA K, 1976, EXP CELL RES, V99, P1, DOI 10.1016/0014-4827(76)90672-8; TANNOCK IF, 1989, CANCER RES, V49, P4373; Tedone T, 1996, EUR J CANCER, V32A, P849, DOI 10.1016/0959-8049(95)00660-5; THOMPSON EW, 1993, CLIN EXP METASTAS, V11, P15, DOI 10.1007/BF00880062; VETVICKA V, 1994, CANCER LETT, V79, P131; VIGNON F, 1986, ENDOCRINOLOGY, V118, P1537, DOI 10.1210/endo-118-4-1537; WESTLEY B, 1979, BIOCHEM BIOPH RES CO, V90, P410, DOI 10.1016/0006-291X(79)91250-6; Westley BR, 1996, EUR J CANCER, V32A, P15, DOI 10.1016/0959-8049(95)00530-7	36	44	46	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1997	11	10					785	792		10.1096/fasebj.11.10.9271363	http://dx.doi.org/10.1096/fasebj.11.10.9271363			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XR105	9271363				2022-12-28	WOS:A1997XR10500008
J	Stadler, PJW				Stadler, PJW			Germany: New beginnings for biotechnology	FASEB JOURNAL			English	Editorial Material											Stadler, PJW (corresponding author), BAYER AG,DIV PHARMACEUT,D-5600 WUPPERTAL,GERMANY.							*GERM ASS CHEM ENG, 1996, C DECHEMA 1996; *MIN RES, 1996, DISC PAP SECT BIOT; MOORE SD, 1997, WALL STREET J E 0306; RUTTGERS J, 1997, COMMUNICATION   0211	4	0	0	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1997	11	7					505	508		10.1096/fasebj.11.7.9212073	http://dx.doi.org/10.1096/fasebj.11.7.9212073			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XH342	9212073				2022-12-28	WOS:A1997XH34200001
J	Rogers, PG				Rogers, PG			Biomedical research: A Louisiana purchase for the 21st century	FASEB JOURNAL			English	Article											Rogers, PG (corresponding author), RES AMER,1522 KING ST,ALEXANDRIA,VA 22314, USA.								0	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1997	11	5					305	307		10.1096/fasebj.11.5.9141495	http://dx.doi.org/10.1096/fasebj.11.5.9141495			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WX156	9141495				2022-12-28	WOS:A1997WX15600001
J	Kim, JH; Mynatt, RL; Moore, JW; Woychik, RP; Moustaid, N; Zemel, MB				Kim, JH; Mynatt, RL; Moore, JW; Woychik, RP; Moustaid, N; Zemel, MB			The effects of calcium channel blockade on agouti-induced obesity	FASEB JOURNAL			English	Article						intracellular Ca2+; fatty acid synthase; Ca-2+s channel blockade	FATTY-ACID SYNTHASE; DEHYDROEPIANDROSTERONE-SULFATE LEVELS; CYTOSOLIC FREE CALCIUM; INSULIN-RESISTANCE; RAT-LIVER; ECTOPIC EXPRESSION; GENE-TRANSCRIPTION; HYPERTENSIVE MEN; YELLOW MICE; TRIIODOTHYRONINE	We have previously observed that obese viable yellow (A(vy)/a) mice exhibit increased intracellular Ca2+ ([Ca2+](i)) and fatty acid synthase (FAS) gene expression; further, recombinant agouti protein increases in cultured adipocytes and these effects are inhibited by Ca2+ channel blockade, Accordingly, we determined the effect of Ca2+ channel blockade (nifedipine for 4 wk) on FAS and obesity in transgenic mice expressing the agouti gene in a ubiquitous manner, The transgenic mice initially were significantly heavier (30.5+/-0.6 vs, 27.3+/-0.3 g; P<0.001) and exhibited a 0.81 degrees C lower initial core temperature (B<0,0005), an approximately twofold increase in fat pad weights (P=0,002), a sevenfold increase in adipose FAS activity (P=0,009), and a twofold increase in plasma insulin level (P<0,05) compared to control mice. Nifedipine treatment resulted in an 18% decrease in fat pad weights (P<0.007) and a 74% decrease in adipose FAS activity (P=0.03), normalized circulating insulin levels and insulin sensitivity (P<0,05), and transiently elevated core temperature in the transgenic mice, but was without effect in the control mice, These data suggest that agouti regulates FAS, fat storage, and possibly thermogenesis, at least partially, via a [Ca2+](i)-dependent mechanism, and that Ca2+ channel blockade may partially attenuate agouti-induced obesity.	UNIV TENNESSEE, DEPT NUTR, KNOXVILLE, TN 37996 USA; OAK RIDGE NATL LAB, DIV BIOL, OAK RIDGE, TN 37831 USA	University of Tennessee System; University of Tennessee Knoxville; United States Department of Energy (DOE); Oak Ridge National Laboratory			Mynatt, Randall L/N-1980-2017; Moustaid-Moussa, Naima/B-9067-2014; Woychik, Richard P/C-8345-2019	Mynatt, Randall L/0000-0003-4399-0019; Moustaid-Moussa, Naima/0000-0002-7508-8030; Woychik, Richard P/0000-0001-8196-1732; Zemel, Michael/0000-0003-4104-5750				BARCELLINICOUGET S, 1994, BIOCHEM BIOPH RES CO, V199, P136, DOI 10.1006/bbrc.1994.1205; BEER NA, 1994, J CLIN ENDOCR METAB, V79, P1077, DOI 10.1210/jc.79.4.1077; BEER NA, 1993, J CLIN ENDOCR METAB, V76, P178, DOI 10.1210/jc.76.1.178; BLAKE WL, 1990, J NUTR, V120, P1727, DOI 10.1093/jn/120.12.1727; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; BYYNY RL, 1992, AM J HYPERTENS, V5, P459, DOI 10.1093/ajh/5.7.459; CHAKRABA.K, 1969, P SOC EXP BIOL MED, V131, P1051, DOI 10.3181/00379727-131-34038; CLARKE SD, 1990, J NUTR, V120, P218, DOI 10.1093/jn/120.2.218; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; DIAMANT S, 1972, EUR J BIOCHEM, V26, P553, DOI 10.1111/j.1432-1033.1972.tb01798.x; DRAZNIN B, 1988, J CLIN INVEST, V82, P1848, DOI 10.1172/JCI113801; DRAZNIN B, 1987, J BIOL CHEM, V262, P14385; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; FERRY WL, 1995, GENETICS, V140, P267; GIRARD J, 1994, FASEB J, V8, P36, DOI 10.1096/fasebj.8.1.7905448; GUICHARD C, 1992, J LIPID RES, V33, P679; JACKSON IJ, 1991, BIOESSAYS, V13, P439, DOI 10.1002/bies.950130903; Jones BH, 1996, AM J PHYSIOL-ENDOC M, V270, pE192, DOI 10.1152/ajpendo.1996.270.1.E192; KLEBIG ML, 1995, P NATL ACAD SCI USA, V92, P4728, DOI 10.1073/pnas.92.11.4728; LAKSHMAN.MR, 1972, P NATL ACAD SCI USA, V69, P3516, DOI 10.1073/pnas.69.12.3516; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU B, 1994, J BIOL CHEM, V269, P7443; MALAISSE WJ, 1981, BIOCHEM PHARMACOL, V30, P1039, DOI 10.1016/0006-2952(81)90439-1; MALAISSE WJ, 1973, DIABETOLOGIA, V9, P167, DOI 10.1007/BF01219778; MEYUHAS O, 1987, MOL CELL BIOL, V7, P2691, DOI 10.1128/MCB.7.8.2691; MICHAUD EJ, 1994, P NATL ACAD SCI USA, V91, P2562, DOI 10.1073/pnas.91.7.2562; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; MOUSTAID N, 1991, J BIOL CHEM, V266, P18550; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; MUSCH K, 1974, BIOCHIM BIOPHYS ACTA, V337, P343, DOI 10.1016/0005-2760(74)90109-X; NESTEL PJ, 1984, J CLIN INVEST, V74, P82, DOI 10.1172/JCI111422; ODIN RS, 1987, BIOCHIM BIOPHYS ACTA, V921, P378; Radin M J, 1993, Obes Res, V1, P433; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; VOLPE JJ, 1976, PHYSIOL REV, V56, P339, DOI 10.1152/physrev.1976.56.2.339; VOLPE JJ, 1974, P NATL ACAD SCI USA, V71, P889, DOI 10.1073/pnas.71.3.889; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WOLF SS, 1994, BIOCHEM BIOPH RES CO, V203, P943, DOI 10.1006/bbrc.1994.2273; YEN TT, 1994, FASEB J, V8, P479, DOI 10.1096/fasebj.8.8.8181666; YOSHIDA T, 1994, INT J OBESITY, V18, P776; ZEMEL MB, 1995, P NATL ACAD SCI USA, V92, P4733, DOI 10.1073/pnas.92.11.4733; ZEMEL MB, 1995, OBES RES, V3, pS338	42	74	80	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1996	10	14					1646	1652		10.1096/fasebj.10.14.9002558	http://dx.doi.org/10.1096/fasebj.10.14.9002558			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WC869	9002558				2022-12-28	WOS:A1996WC86900012
J	Timchenko, LT; Caskey, CT				Timchenko, LT; Caskey, CT			Trinucleotide repeat disorders in humans: Discussions of mechanisms and medical issues	FASEB JOURNAL			English	Review						myotonic dystrophy; ataxia; Huntington disease	FRAGILE-X SYNDROME; MYOTONIN-PROTEIN-KINASE; ANDROGEN RECEPTOR GENE; TISSUE-SPECIFIC EXPRESSION; HUNTINGTONS-DISEASE; MENTAL-RETARDATION; RNA-BINDING; CGG-REPEAT; CAG TRINUCLEOTIDE; SKELETAL-MUSCLE	Several human disorders are now known to be caused hy expansion of unstable trinucleotide repeat sequences, including fragile X syndrome (FRAX), myotonic dystrophy (DM), spinal and bulbar muscular atrophy (SBMA, also known as Kennedy disease), Huntington disease (HD), dentatorubral-pallidoluysian atrophy (DRPLA), spinocerebellar ataxia type 1 (SCA1), Machado-Joseph disease (MJD), and Friedreich ataxia, As these diseases are studied in more detail, important differences have emerged in the nature of the unstable repeats and the mechanism by which the repeat expansions cause disease symptoms. There are already animal models of some of these disorders, and these are important resources for studying pathology and therapeutic strategies, Diagnostic procedures for these disorders are only beginning to be standardized, and effective therapy will have to wait for further information on disease mechanisms, Much has been learned since discovery of the fragile X syndrome gene in 1991, but much remains to be done.	BAYLOR COLL MED,DEPT MED,CARDIOL SECT,HOUSTON,TX 77030	Baylor College of Medicine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054313] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL543-13] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHLEY CT, 1993, NAT GENET, V4, P244, DOI 10.1038/ng0793-244; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BINGHAM PM, 1995, NAT GENET, V9, P191, DOI 10.1038/ng0295-191; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; COBO A, 1993, HUM MOL GENET, V2, P711, DOI 10.1093/hmg/2.6.711; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; DUNNE PW, 1994, BIOCHEMISTRY-US, V33, P10809, DOI 10.1021/bi00201a031; *DUTCH BELG FRAG X, 1994, CELL, V78, P23; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; ETONGUEMAYER P, 1994, BIOCHEM BIOPH RES CO, V199, P89, DOI 10.1006/bbrc.1994.1198; FENG Y, 1995, SCIENCE, V268, P731, DOI 10.1126/science.7732383; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GACY AM, 1995, CELL, V81, P533; GUSELLA JF, 1985, NATURE, V318, P75, DOI 10.1038/318075a0; Harper P.S., 1989, MYOTONIC DYSTROPHY; HINDS HL, 1993, NAT GENET, V3, P36, DOI 10.1038/ng0193-36; HOFMANNRADVANYI H, 1993, NEUROMUSCULAR DISORD, V3, P497, DOI 10.1016/0960-8966(93)90104-R; HOUSMAN D, 1995, NAT GENET, V10, P3, DOI 10.1038/ng0595-3; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; *HUNT DIS COLL RES, 1993, CELL, V72, P971; HUNTER A, 1992, J MED GENET, V29, P774, DOI 10.1136/jmg.29.11.774; JANSEN G, 1995, HUM MOL GENET, V4, P843, DOI 10.1093/hmg/4.5.843; JANSEN G, 1995, THESIS U NIJMEGEN NE; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Khandjian EW, 1996, NAT GENET, V12, P91, DOI 10.1038/ng0196-91; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; MAEDA M, 1995, J BIOL CHEM, V270, P20246, DOI 10.1074/jbc.270.35.20246; MITAS M, 1995, NUCLEIC ACIDS RES, V23, P1050, DOI 10.1093/nar/23.6.1050; MONCKTON DG, 1995, CIRCULATION, V91, P1; MOUNSEY JP, 1995, J CLIN INVEST, V95, P2379, DOI 10.1172/JCI117931; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; OHOY KL, 1993, SCIENCE, V259, P809, DOI 10.1126/science.8094260; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; QUIGLEY CA, 1992, J CLIN ENDOCR METAB, V74, P927, DOI 10.1210/jc.74.4.927; REDDY S, 1996, IN PRESS NATURE GEN; REDMAN JB, 1993, JAMA-J AM MED ASSOC, V269, P1960, DOI 10.1001/jama.269.15.1960; SEQUEIROS J, 1993, ADV NEUROL, V61, P139; SHERMAN SL, 1985, HUM GENET, V69, P289, DOI 10.1007/BF00291644; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI MC, 1995, EMBO J, V14, P2401, DOI 10.1002/j.1460-2075.1995.tb07237.x; SUTHERLAND GR, 1977, SCIENCE, V197, P265, DOI 10.1126/science.877551; TAKAHASHI H, 1988, NEUROLOGY, V38, P1065, DOI 10.1212/WNL.38.7.1065; Tamanini F, 1996, HUM MOL GENET, V5, P809, DOI 10.1093/hmg/5.6.809; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; TIMCHENKO L, 1995, SEMIN CELL BIOL, V6, P13, DOI 10.1016/1043-4682(95)90010-1; TIMCHENKO L, 1995, P NATL ACAD SCI USA, V92, P5366, DOI 10.1073/pnas.92.12.5366; Timchenko LT, 1996, HUM MOL GENET, V5, P115, DOI 10.1093/hmg/5.1.115; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; TSILFIDIS C, 1992, NAT GENET, V1, P192, DOI 10.1038/ng0692-192; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; WANG JZ, 1995, HUM MOL GENET, V4, P599, DOI 10.1093/hmg/4.4.599; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; WARREN ST, 1994, JAMA-J AM MED ASSOC, V271, P536, DOI 10.1001/jama.271.7.536; WHITING EJ, 1995, HUM MOL GENET, V4, P1063, DOI 10.1093/hmg/4.6.1063; WIERINGA B, 1994, HUM MOL GENET, V3, P1, DOI 10.1093/hmg/3.1.1-a; ZHANG Y, 1995, EMBO J, V14, P5358, DOI 10.1002/j.1460-2075.1995.tb00220.x; ZOGHBI HY, 1991, CURRENT NEUROLOGY, P121	70	69	74	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1996	10	14					1589	1597		10.1096/fasebj.10.14.9002550	http://dx.doi.org/10.1096/fasebj.10.14.9002550			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WC869	9002550				2022-12-28	WOS:A1996WC86900004
J	Tate, BF; Allenby, G; Perez, JR; Levin, AA; Grippo, JF				Tate, BF; Allenby, G; Perez, JR; Levin, AA; Grippo, JF			Systematic analysis of the AF-2 domain of human retinoic acid receptor alpha reveals amino acids critical for transcriptional activation and conformational integrity	FASEB JOURNAL			English	Article						RARE; retinoic acids; plasmid mutants; transactivation; gel mobility shift assay	THYROID-HORMONE RECEPTOR; LIGAND-BINDING DOMAIN; 9-CIS-RETINOIC ACID; RESPONSIVE ELEMENT; NUCLEAR RECEPTORS; CRYSTAL-STRUCTURE; VITAMIN-D; V-ERBA; C-ERBA; IDENTIFICATION	We previously identified a carboxy-terminal transactivation function termed AF-2 within the last 15 amino acids of the ligand binding domain of the human retinoic acid receptor alpha (hRAR alpha). Truncation of this region abolished transcriptional activity, Here we provide a systematic analysis using alanine scanning mutagenesis of amino acids from Ser(405) to Gly(419) on a truncated hRAR alpha (Delta 419) to identify residues within this region that are responsible for transcriptional activity, Whereas mutations in positions 405, 408, 411, and 415-419 have little or no effect on the ability of modified receptors to activate a DR5 response element, mutations in positions 406, 407, 409, 410, and 412-413 modify either the potency or efficacy of all-trans retinoic acid (tRA) -induced gene transcription, Therefore, receptors with mutations in positions 409, 410, 413, and 414 have low transcriptional activity over a wide range of tRA concentrations, Receptors with mutations in positions 406, 407, and 412 exhibit a maximum transcriptional activity similar to wild-type hRAR alpha, but require higher concentrations of tRA, Replacing residues 405-419 on Delta 419 with the conserved AF-2 domain from the vitamin DQ receptor or the estrogen receptor results in a receptor with wild-type or low transcriptional activity, respectively, A full-length hRAR alpha mutant with an alanine substitution at position 406 (hRAR alpha M406A) binds tRA, but unlike the truncated M406A, which lacks the ''F'' region, it is not transcriptionally active, Protease mapping experiments detect a consistent difference in the conformation of hRAR alpha M406A compared to wild-type hRAR alpha, These data define amino acids from Ser(405) to Gly(419) on Delta 419 that are critical for transcriptional activity and point to the importance of the conformational integrity of receptor domains in maintaining ligand-induced transcriptional activation.	HOFFMANN LA ROCHE INC,DEPT METAB DIS,NUTLEY,NJ 07110; HOFFMANN LA ROCHE INC,DEPT ONCOL,NUTLEY,NJ 07110; UNIV LONDON ST BARTHOLOMEWS HOSP MED COLL,DEPT TOXICOL,LONDON EC1 7ED,ENGLAND; ISIS PHARMACEUT,DEPT PHARMACOKINET & TOXICOL,CARLSBAD RES CTR,CARLSBAD,CA 92008	Roche Holding; Roche Holding; University of London; Queen Mary University London; Isis Pharmaceuticals Inc								ALLAN GF, 1992, J BIOL CHEM, V267, P19513; ALLENBY G, 1994, J BIOL CHEM, V269, P16689; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; COSTAGIOMI MP, 1992, NUCLEIC ACIDS RES, V20, P3223, DOI 10.1093/nar/20.12.3223; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Kastner P., 1994, Vitamin A in health and disease., P189; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; Mangelsdorf David J., 1994, P319; MORRISSKAY G, 1992, RETINOIDS NORMAL DEV; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROSEN ED, 1993, J BIOL CHEM, V268, P11534; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; Sporn M.B., 1994, RETINOIDS BIOL CHEM; TATE BF, 1994, TRENDS ENDOCRIN MET, V5, P189, DOI 10.1016/1043-2760(94)90076-0; TATE BF, 1995, J BIOL CHEM, V270, P20258, DOI 10.1074/jbc.270.35.20258; TATE BF, 1994, MOL CELL BIOL, V14, P2323, DOI 10.1128/MCB.14.4.2323; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	33	10	11	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1996	10	13					1524	1531		10.1096/fasebj.10.13.8940298	http://dx.doi.org/10.1096/fasebj.10.13.8940298			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VU982	8940298				2022-12-28	WOS:A1996VU98200009
J	Kjeldgaard, M; Nyborg, J; Clark, BFC				Kjeldgaard, M; Nyborg, J; Clark, BFC			Protein motifs .10. The GTP binding motif: Variations on a theme	FASEB JOURNAL			English	Review						G-proteins; GTPase; structure and function; Rasp21; ARF; elongation factors; heterotrimeric	ELONGATION-FACTOR-TU; H-RAS P21; SIGNAL-RECOGNITION PARTICLE; AMINOACYL-TRANSFER-RNA; FACTOR-EF-TU; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURES; CATALYTIC DOMAIN; TRIPHOSPHATE CONFORMATION	GTP binding proteins (G-proteins) have wide-ranging functions in biology, being involved in cell proliferation, signal transduction, protein synthesis, and protein targeting. Common to their functioning is that they are active in the GTP-bound form and inactive in the GDP-bound form. The protein synthesis elongation factor EF-Tu was the first G-protein whose nucleotide binding domain was solved structurally by X-ray crystallography to yield a structural definition of the GDP-bound form, but a still increasing number of new structures of G-proteins are appearing in the literature, in both GDP and GTP bound forms. A common structural core for nucleotide binding is present in all these structures, and this core has long been known to include common consensus sequence elements involved in binding of the nucleotide. Nevertheless, subtle changes in the common sequences reflect functional differences. Therefore, it becomes increasingly important to focus on how these differences are reflected in the structures, and how these structural differences are related to function. The aim of this review is to describe to what extent this structural motif for GDP/GTP binding is common to other known structures of this class of proteins. We first describe the common structural core of the G-proteins. Next, examples are based on information available on the Ras protein superfamily, the targeting protein ARF, elongation factors EF-Tn and EF-G, and the heterotrimeric G-proteins. Finally, we discuss the important structures of complexes between GTP binding proteins and their substrates that have appeared in the literature recently.			Kjeldgaard, M (corresponding author), AARHUS UNIV, INST MOL & STRUCT BIOL, LANGELANDEGADE 140, DK-8000 AARHUS C, DENMARK.							Abel K, 1996, STRUCTURE, V4, P229, DOI 10.1016/S0969-2126(96)00027-5; AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; ANDERSEN C, 1994, EUR J BIOCHEM, V220, P739, DOI 10.1111/j.1432-1033.1994.tb18674.x; ARTYMIUK PJ, 1990, PROTEIN ENG, V4, P39, DOI 10.1093/protein/4.1.39; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRUNGER AT, 1990, P NATL ACAD SCI USA, V87, P4849, DOI 10.1073/pnas.87.12.4849; BURLEY SK, 1990, P NATL ACAD SCI USA, V87, P6878, DOI 10.1073/pnas.87.17.6878; COLEMAN DE, 1994, J MOL BIOL, V238, P630, DOI 10.1006/jmbi.1994.1320; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; FASANO O, 1982, J BIOL CHEM, V257, P3145; FRANKEN SM, 1993, BIOCHEMISTRY-US, V32, P8411, DOI 10.1021/bi00084a005; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; HALLIDAY KR, 1984, J CYCLIC NUCL PROT, V9, P435; HILGENFELD R, 1995, NAT STRUCT BIOL, V2, P3, DOI 10.1038/nsb0195-3; Hilgenfeld R, 1995, CURR OPIN STRUC BIOL, V5, P810, DOI 10.1016/0959-440X(95)80015-8; HUGHES SM, 1983, FEBS LETT, V164, P1, DOI 10.1016/0014-5793(83)80006-4; JONAK J, 1994, FEBS LETT, V343, P94, DOI 10.1016/0014-5793(94)80614-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JURNAK F, 1990, BIOCHIM BIOPHYS ACTA, V1050, P209, DOI 10.1016/0167-4781(90)90168-2; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; JURNAK F, 1994, STRUCTURE, V2, P785, DOI 10.1016/S0969-2126(94)00078-6; KAHN RA, 1993, GTPASES BIOL, V1; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; KNUDSEN CR, 1995, EUR J BIOCHEM, V228, P176; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEBERMAN R, 1984, EMBO J, V3, P339, DOI 10.1002/j.1460-2075.1984.tb01808.x; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MCCORMICK F, 1985, SCIENCE, V230, P78, DOI 10.1126/science.3898366; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; MOSS J, 1993, GTPASES BIOL, V1; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Nyborg J, 1996, TRENDS BIOCHEM SCI, V21, P81, DOI 10.1016/0968-0004(96)30008-X; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PARMEGGIANI A, 1987, P NATL ACAD SCI USA, V84, P3141, DOI 10.1073/pnas.84.10.3141; POLAND BW, 1993, J BIOL CHEM, V268, P25334; POLEKHINA G, 1996, IN PRESS STRUCTURE, V4; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SCHEIDIG AJ, 1994, ACTA CRYSTALLOGR D, V50, P512, DOI 10.1107/S090744499301443X; SCHEIDIG AJ, 1995, J MOL BIOL, V253, P132, DOI 10.1006/jmbi.1995.0541; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SCHWEINS T, 1994, CURR BIOL, V4, P547, DOI 10.1016/S0960-9822(00)00122-6; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOUTEN PFW, 1993, FEBS LETT, V320, P1, DOI 10.1016/0014-5793(93)81644-F; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SUAREZ HG, 1991, ONCOGENE, V6, P677; TONG L, 1989, SCIENCE, V245, P244, DOI 10.1126/science.2665078; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; VALENCIA A, 1991, P NATL ACAD SCI USA, V88, P5443, DOI 10.1073/pnas.88.12.5443; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012	82	232	235	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1996	10	12					1347	1368		10.1096/fasebj.10.12.8903506	http://dx.doi.org/10.1096/fasebj.10.12.8903506			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VP485	8903506				2022-12-28	WOS:A1996VP48500001
J	Ouellette, AJ; Selsted, ME				Ouellette, AJ; Selsted, ME			Paneth cell defensins: Endogenous peptide components of intestinal host defense	FASEB JOURNAL			English	Article						epithelium; secretory granules; antimicrobial peptides; mucosal immunity; mouse; gene	CYSTEINE-RICH PEPTIDES; ESCHERICHIA-COLI; MESSENGER-RNA; MEMBRANE PERMEABILIZATION; INTRACELLULAR DIGESTION; ANTIMICROBIAL PEPTIDES; CRYPTDIN LOCUS; GENE FAMILY; MOUSE; DIFFERENTIATION	Paneth cells are epithelial granulocytes at the base of the crypts of Lieberkuhn in the small intestine of many mammalian species, These secretory cells contribute to mucosal barrier function by the apical release of granules containing a variety of antimicrobial products, including peptides termed cryptdins, for crypt defensins. In mice, six Paneth cell defensins have been characterized at the peptide level that have potent antimicrobial activities equivalent to or greater than that of rabbit neutrophil defensin NP-1. Cryptdin peptides that differ only by single amino acid substitutions have been shown to exhibit a high degree of specificity against certain target microorganisms, Cryptdins are coded by separate, two-exon genes that are located on chromosome 8 in both mice and humans. Human Paneth cells contain high levels of two different defensin mRNAs, but in mice at least 19 cryptdin isoforms are predicted from cDNA sequencing data, The mouse cryptdin-4 gene is expressed with positional specificity along the longitudinal intestinal axis, and cryptdin genes are active in the intestinal epithelium prior to Paneth cell differentiation. Accordingly, Paneth cell defensins are early markers of crypt ontogeny and are therefore useful in studies of lineage determination in the intestinal epithelium, Because cryptdins mediate innate immunity in the hostile environment of the intestinal lumen, it should be of interest to define biochemical and biophysical attributes that adapt these peptides to barrier function of mucosal surfaces.	HARVARD UNIV,SCH MED,DEPT MED,CAMBRIDGE,MA 02138; UNIV CALIF IRVINE,COLL MED,DEPT PATHOL & MICROBIOL,IRVINE,CA 92717; UNIV CALIF IRVINE,COLL MED,DEPT MOL GENET,IRVINE,CA 92717	Harvard University; University of California System; University of California Irvine; University of California System; University of California Irvine	Ouellette, AJ (corresponding author), MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,MED SERV,JACKSON 711,50 FRUIT ST,BOSTON,MA 02114, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031852] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK044632, P01DK033506, R01DK044632] Funding Source: NIH RePORTER; NICHD NIH HHS [HD31852] Funding Source: Medline; NIDDK NIH HHS [DK44632, DK33506] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEY SB, 1994, INFECT IMMUN, V62, P5397, DOI 10.1128/IAI.62.12.5397-5403.1994; Bevins CL, 1996, GENOMICS, V31, P95, DOI 10.1006/geno.1996.0014; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; BRY L, 1994, P NATL ACAD SCI USA, V91, P10335, DOI 10.1073/pnas.91.22.10335; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1969, AM J ANAT, V126, P507, DOI 10.1002/aja.1001260409; DARMOUL D, 1994, GASTROENTEROLOGY, V106, pA603; DARMOUL D, 1996, AM J PHYSIOL, V34, pG68; EISENHAUER PB, 1992, INFECT IMMUN, V60, P3556, DOI 10.1128/IAI.60.9.3556-3565.1992; ERLANDSEN SL, 1972, J ULTRA MOL STRUCT R, V41, P296, DOI 10.1016/S0022-5320(72)90071-8; ERLANDSEN SL, 1972, J ULTRA MOL STRUCT R, V41, P319, DOI 10.1016/S0022-5320(72)90072-X; GANZ T, 1994, CURR OPIN IMMUNOL, V6, P584, DOI 10.1016/0952-7915(94)90145-7; GEYER G, 1973, ACTA HISTOCHEM, V45, P126; GHOOS Y, 1971, Histochemical Journal, V3, P175, DOI 10.1007/BF01002560; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; HUTTNER KM, 1994, GENOMICS, V19, P448, DOI 10.1006/geno.1994.1093; HUTTNER KM, 1994, GENOMICS, V24, P99, DOI 10.1006/geno.1994.1586; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; KAGAN BL, 1994, TOXICOLOGY, V87, P131, DOI 10.1016/0300-483X(94)90158-9; LACASSE J, 1992, J HISTOCHEM CYTOCHEM, V40, P1527, DOI 10.1177/40.10.1382091; LEHRER RI, 1983, INFECT IMMUN, V42, P10, DOI 10.1128/IAI.42.1.10-14.1983; LEHRER RI, 1988, J IMMUNOL METHODS, V108, P153, DOI 10.1016/0022-1759(88)90414-0; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; LEVY O, 1994, J CLIN INVEST, V94, P672, DOI 10.1172/JCI117384; LIN MY, 1992, GENOMICS, V14, P363, DOI 10.1016/S0888-7543(05)80227-7; LIU L, 1995, BLOOD, V85, P1095, DOI 10.1182/blood.V85.4.1095.bloodjournal8541095; Mallow EB, 1996, J BIOL CHEM, V271, P4038; MARSH J, 1994, CIBA FDN S, V186; MARTIN E, 1995, J LEUKOCYTE BIOL, V58, P128, DOI 10.1002/jlb.58.2.128; MICHAELSON D, 1992, J LEUKOCYTE BIOL, V51, P634, DOI 10.1002/jlb.51.6.634; MULHERKAR R, 1993, BIOCHEM BIOPH RES CO, V195, P1254, DOI 10.1006/bbrc.1993.2179; OUELLETTE AJ, 1989, GENOMICS, V5, P233, DOI 10.1016/0888-7543(89)90051-7; OUELLETTE AJ, 1994, INFECT IMMUN, V62, P5040, DOI 10.1128/IAI.62.11.5040-5047.1994; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; OUELLETTE AJ, 1990, J BIOL CHEM, V265, P9831; Paneth J., 1887, ARCH MIKROSK ANAT, V31, P113, DOI [10.1007/BF02955706, DOI 10.1007/BF02955706]; PARDI A, 1992, BIOCHEMISTRY-US, V31, P11357, DOI 10.1021/bi00161a013; PEETERS T, 1975, GUT, V16, P553, DOI 10.1136/gut.16.7.553; RUBIN DC, 1991, J CELL BIOL, V113, P1183, DOI 10.1083/jcb.113.5.1183; SATOH Y, 1988, CELL TISSUE RES, V251, P87, DOI 10.1007/BF00215451; SATOH Y, 1988, ACTA HISTOCHEM, V83, P185, DOI 10.1016/S0065-1281(88)80055-2; SCHWALBE G, 1872, ARCH MIKROSK ANAT, V8, P92; Selsted M E, 1993, Genet Eng (N Y), V15, P131; SELSTED ME, 1995, TRENDS CELL BIOL, V5, P114, DOI 10.1016/S0962-8924(00)88961-8; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; SELSTED ME, 1989, J BIOL CHEM, V264, P4003; SELZMAN HM, 1962, J HISTOCHEM CYTOCHEM, V10, P106, DOI 10.1177/10.1.106; SKALICKY JJ, 1994, PROTEINS, V20, P52, DOI 10.1002/prot.340200107; SPARKES RS, 1989, GENOMICS, V5, P240, DOI 10.1016/0888-7543(89)90052-9; TRIER JS, 1967, GASTROENTEROLOGY, V53, P240; TROUGHTON WD, 1969, J CELL BIOL, V41, P251, DOI 10.1083/jcb.41.1.251; VALORE EV, 1992, BLOOD, V79, P1538; WHITE SH, 1995, CURR OPIN STRUC BIOL, V5, P521, DOI 10.1016/0959-440X(95)80038-7; WIMLEY WC, 1994, PROTEIN SCI, V3, P1362, DOI 10.1002/pro.5560030902; WINTER HS, 1991, GASTROENTEROLOGY, V100, P89, DOI 10.1016/0016-5085(91)90587-B; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O	58	217	229	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1996	10	11					1280	1289		10.1096/fasebj.10.11.8836041	http://dx.doi.org/10.1096/fasebj.10.11.8836041			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VJ717	8836041				2022-12-28	WOS:A1996VJ71700007
J	Lotan, R				Lotan, R			Retinoids in cancer chemoprevention	FASEB JOURNAL			English	Article						retinoic acid; cancer prevention; premalignant lesion	TOPICAL TRETINOIN; DYSPLASTIC NEVI; VITAMIN-A; ACID; EXPRESSION; TRIAL; TRANSFORMATION; CARCINOMAS; PREVENTION; RECEPTORS	Naturally occurring and synthetic vitamin A metabolites and analogs (retinoids) inhibit tumor development in a variety of cellular, animal, and patient studies, They suppress transformation of cells in vitro and inhibit carcinogenesis in various organs in animal models. In a mouse skin carcinogenesis model, topical retinoids exhibit suppressive effects on tumor promotion, but have no effect on tumor initiation. In other models, retinoids administered in the diet suppress tumor development even in an adjuvant setting after excision of the first tumor. Retinoids suppress carcinogenesis in individuals with premalignant lesions and a high risk to develop cancer of the aerodigestive tract. Likewise, retinoids prevent the development of second primary cancers in head/neck and lung cancer patients who had been treated for the first primary, The mechanisms underlying the anticarcinogenic activity of retinoids appear to be associated with the ability of retinoids to modulate the growth, differentiation, and apoptosis of normal, premalignant, and malignant cells in vitro and in vivo. Most of these effects are mediated by nuclear retinoid receptors, but other mechanisms may also be involved, These studies indicate that retinoids are potentially useful agent for cancer chemoprevention.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT CLIN CANC PREVENT, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Lotan, R (corresponding author), UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT TUMOR BIOL 108, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.							ANZANO MA, 1994, CANCER RES, V54, P4614; ATHAR M, 1991, CARCINOGENESIS, V12, P2325, DOI 10.1093/carcin/12.12.2325; BAVINCK JNB, 1995, J CLIN ONCOL, V13, P1933, DOI 10.1200/JCO.1995.13.8.1933; BEENKEN SW, 1994, J CELL BIOCHEM, P270; BERTRAM JS, 1983, CANCER SURV, V2, P243; BOLLA M, 1994, EUR J CANCER, V30A, P767, DOI 10.1016/0959-8049(94)90290-9; CHIESA F, 1993, J CELL BIOCHEM, P255; COSTA A, 1994, CANCER RES, V54, pS2032; CREEK KE, 1994, ADV EXP MED BIOL, V354, P19; DARWICHE N, 1995, CANCER RES, V55, P2774; DE LUCA LM, 1994, NUTR REV, V52, P45; DEPALO G, 1995, J NATL CANCER I, V87, P146, DOI 10.1093/jnci/87.2.146; EDWARDS L, 1990, ARCH DERMATOL, V126, P494, DOI 10.1001/archderm.126.4.494; GREENWALD P, 1995, CA-CANCER J CLIN, V45, P31, DOI 10.3322/canjclin.45.1.31; HALPERN AC, 1994, J CLIN ONCOL, V12, P1028, DOI 10.1200/JCO.1994.12.5.1028; HAN J, 1993, PREV MED, V22, P712, DOI 10.1006/pmed.1993.1065; HARISIADIS L, 1978, NATURE, V174, P186; Hong Waun Ki, 1994, P597; Hong WK, 1995, CLIN CANCER RES, V1, P677; INOUE I, 1993, ORAL SURG ORAL MED O, V76, P608, DOI 10.1016/0030-4220(93)90070-K; KUMAR R, 1994, CARCINOGENESIS, V15, P701, DOI 10.1093/carcin/15.4.701; LEE JS, 1994, J CLIN ONCOL, V12, P937, DOI 10.1200/JCO.1994.12.5.937; Li JJ, 1996, CANCER RES, V56, P483; LIPPMAN SM, 1995, CANC PREVENTION CONT, P329; LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; LOTAN R, 1995, RETINOIDS ONCOLOGY, P27; MARKS SL, 1992, J AM ACAD DERMATOL, V27, P11, DOI 10.1016/0190-9622(92)70147-8; MEYSKENS FL, 1994, J NATL CANCER I, V86, P539, DOI 10.1093/jnci/86.7.539; Moon Richard C., 1994, P573; MOON TE, 1993, P AM SOC PREV ONCOL; MUTO Y, 1990, JPN J CLIN ONCOL, V20, P219; PASTORINO U, 1993, J CLIN ONCOL, V11, P1216, DOI 10.1200/JCO.1993.11.7.1216; Peck Gary L., 1994, P631; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; POLLARD M, 1991, CANCER RES, V51, P3610; PROUT GR, 1992, J CELL BIOCHEM, P148; ROOK AH, 1995, TRANSPLANTATION, V59, P714, DOI 10.1097/00007890-199503150-00013; SHINDOH M, 1995, OBSTET GYNECOL, V85, P721, DOI 10.1016/0029-7844(95)00043-Q; SHKLAR G, 1980, ORAL SURG ORAL MED O, V50, P45, DOI 10.1016/0030-4220(80)90330-8; SLAWIN K, 1993, CANCER RES, V53, P4461; STEELE VE, 1990, CANCER RES, V50, P2068; STUDER UE, 1995, EUR UROL, V28, P284; VERMA AK, 1992, CELLULAR AND MOLECULAR TARGETS FOR CHEMOPREVENTION, P207; WARGOVICH MJ, 1995, INT J CANCER, V60, P515, DOI 10.1002/ijc.2910600415; Xu X.-C., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P232; XU XC, 1994, CANCER RES, V54, P3580	47	388	404	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1996	10	9					1031	1039		10.1096/fasebj.10.9.8801164	http://dx.doi.org/10.1096/fasebj.10.9.8801164			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801164				2022-12-28	WOS:A1996UY93200013
J	Iozzo, RV; Murdoch, AD				Iozzo, RV; Murdoch, AD			Proteoglycans of the extracellular environment: Clues from the gene and protein side offer novel perspectives in molecular diversity and function	FASEB JOURNAL			English	Review						extracellular matrix; leucine-rich repeats; modular genes	HEPARAN-SULFATE PROTEOGLYCAN; EPIDERMAL GROWTH-FACTOR; MESSENGER-RNA LEVELS; CORE PROTEIN; CHROMOSOMAL LOCALIZATION; COLLAGEN FIBRILLOGENESIS; DIFFERENTIAL REGULATION; ARTICULAR-CARTILAGE; MULTIPLE DOMAINS; KERATAN SULFATE	This review focuses on the extracellular proteoglycans. Special emphasis is placed on the structural features of their protein cores, their gene organization, and their transcriptional control, A simplified nomenclature comprising two broad groups of extracellular proteoglycans is offered: the small leucine-rich proteoglycans or SLRPs, pronounced ''slurps,'' and the modular proteoglycans, The first group encompasses at least five distinct members of a gene family characterized by a central domain composed of leucine-rich repeats flanked by two cysteine-rich regions, The second group consists of those proteoglycans whose unifying feature is the assembly of various protein modules in a relatively elongated and often highly glycosylated structure, This group is quite heterogeneous and includes a distinct family of proteoglycans, the ''hyalectans,'' that bind hyaluronan and contain a C-type lectin motif that is likely to bind carbohydrates, and a less distinct group that contains structural homologies but lacks hyaluronan-binding properties or lectin-like domains.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107	Jefferson University	Iozzo, RV (corresponding author), THOMAS JEFFERSON UNIV,DEPT PATHOL ANAT & CELL BIOL,ROOM 249,JEFFERSON ALUMNI HALL,1020 LOCUST ST,PHILADELPHIA,PA 19107, USA.		Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NATIONAL CANCER INSTITUTE [R01CA047282, R01CA039481] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA47282, R01 CA39481] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADANY R, 1990, J BIOL CHEM, V265, P11389; ALLIEL PM, 1993, EUR J BIOCHEM, V214, P347, DOI 10.1111/j.1432-1033.1993.tb17930.x; ANTONSSON P, 1993, BIOCHIM BIOPHYS ACTA, V1174, P204, DOI 10.1016/0167-4781(93)90117-V; ASUNDI VK, 1992, EUR J CELL BIOL, V59, P314; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BATTAGLIA C, 1992, EUR J BIOCHEM, V208, P359, DOI 10.1111/j.1432-1033.1992.tb17195.x; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; BORK P, 1995, PROTEIN SCI, V4, P1421, DOI 10.1002/pro.5560040716; CHAKRAVARTI S, 1995, MAMM GENOME, V6, P367, DOI 10.1007/BF00364803; CHENG JF, 1994, GENOMICS, V23, P75, DOI 10.1006/geno.1994.1461; COHEN IR, 1993, P NATL ACAD SCI USA, V90, P10404, DOI 10.1073/pnas.90.21.10404; COPPOCK DL, 1993, CELL GROWTH DIFFER, V4, P483; CORNUET PK, 1994, INVEST OPHTH VIS SCI, V35, P870; COUCHMAN JR, 1995, J HISTOCHEM CYTOCHEM, V43, P955, DOI 10.1177/43.9.7543915; CROVER J, 1995, J BIOL CHEM, V270, P21942; DAMMER U, 1995, SCIENCE, V267, P1173, DOI 10.1126/science.7855599; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; DODGE GR, 1991, GENOMICS, V10, P673, DOI 10.1016/0888-7543(91)90451-J; DOEGE KJ, 1994, J BIOL CHEM, V269, P29232; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; FISHER LW, 1991, J BIOL CHEM, V266, P14371; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FULOP C, 1993, J BIOL CHEM, V268, P17377; GRASSEL S, 1995, MOL CELL BIOCHEM, V145, P61, DOI 10.1007/BF00925714; GROVER J, 1993, BIOCHEM J, V291, P361, DOI 10.1042/bj2910361; GUO BP, 1995, INFECT IMMUN, V63, P3467, DOI 10.1128/IAI.63.9.3467-3472.1995; HAGEN SG, 1993, J BIOL CHEM, V268, P7261; HAYASHI K, 1992, J CELL BIOL, V119, P945, DOI 10.1083/jcb.119.4.945; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HEDLUND H, 1994, MATRIX BIOL, V14, P227, DOI 10.1016/0945-053X(94)90186-4; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; HOCH W, 1994, J CELL BIOL, V126, P1, DOI 10.1083/jcb.126.1.1; IOZZO RV, 1993, EXPERIENTIA, V49, P447, DOI 10.1007/BF01923588; IOZZO RV, 1992, GENOMICS, V14, P845, DOI 10.1016/S0888-7543(05)80103-X; IOZZO RV, 1994, MATRIX BIOL, V14, P203, DOI 10.1016/0945-053X(94)90183-X; KAHARI VM, 1995, J INVEST DERMATOL, V104, P503, DOI 10.1111/1523-1747.ep12605969; KAHARI VM, 1991, J BIOL CHEM, V266, P10608; KLEIN G, 1995, MATRIX BIOL, V14, P457, DOI 10.1016/0945-053X(95)90003-9; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KORENBERG JR, 1993, GENOMICS, V16, P546, DOI 10.1006/geno.1993.1228; KRESSE H, 1993, EXPERIENTIA, V49, P403, DOI 10.1007/BF01923585; KRUMDIECK R, 1992, J IMMUNOL, V149, P3695; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LANDOLT RM, 1995, DEVELOPMENT, V121, P2303; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; MARGOLIS RU, 1994, METHOD ENZYMOL, V245, P105; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; MCBRIDE OW, 1990, GENOMICS, V6, P219, DOI 10.1016/0888-7543(90)90560-H; MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NASO MF, 1994, J BIOL CHEM, V269, P32999; NASO MF, 1995, GENOMICS, V29, P297, DOI 10.1006/geno.1995.1251; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; PATTHY L, 1994, NEUROCHEM INT, V24, P301, DOI 10.1016/0197-0186(94)90108-2; PEARSON D, 1992, J BIOL CHEM, V267, P25364; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; RAUCH U, 1995, GENOMICS, V28, P405, DOI 10.1006/geno.1995.1168; RAUCH U, 1992, J BIOL CHEM, V267, P19536; ROUGHLEY PJ, 1994, MICROSC RES TECHNIQ, V28, P385, DOI 10.1002/jemt.1070280505; RUPP F, 1992, J NEUROSCI, V12, P3535; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SANTRA M, 1994, J BIOL CHEM, V269, P579; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SCHOLZEN T, 1994, J BIOL CHEM, V269, P28270; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; SHINOMURA T, 1992, J BIOL CHEM, V267, P1265; SUNDARRAJ N, 1995, J CELL SCI, V108, P2601; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; SZTROLOVICS R, 1994, GENOMICS, V23, P715, DOI 10.1006/geno.1994.1567; TAKAHASHI T, 1993, J HISTOCHEM CYTOCHEM, V41, P1447, DOI 10.1177/41.10.8245404; TSEB G, 1995, J BIOL CHEM, V270, P3392; TSEN GS, 1995, J BIOL CHEM, V270, P15934, DOI 10.1074/jbc.270.27.15934; VALHMU WB, 1995, BIOCHEM J, V309, P535, DOI 10.1042/bj3090535; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WATANABE H, 1995, BIOCHEM J, V308, P433, DOI 10.1042/bj3080433; WATANABE H, 1994, NAT GENET, V7, P154, DOI 10.1038/ng0694-154; WEGROWSKI Y, 1995, GENOMICS, V30, P8, DOI 10.1006/geno.1995.0002; YAMADA H, 1994, J BIOL CHEM, V269, P10119; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817; ZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992	91	502	514	2	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1996	10	5					598	614		10.1096/fasebj.10.5.8621059	http://dx.doi.org/10.1096/fasebj.10.5.8621059			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UJ055	8621059				2022-12-28	WOS:A1996UJ05500008
J	Irwin, M; McClintick, J; Costlow, C; Fortner, M; White, J; Gillin, JC				Irwin, M; McClintick, J; Costlow, C; Fortner, M; White, J; Gillin, JC			Partial night sleep deprivation reduces natural killer and cellular immune responses in humans	FASEB JOURNAL			English	Article						immunity; natural killer cell activity; interleukin-2	SLOW-WAVE SLEEP; INFECTIOUS-DISEASE; CELLS; INTERLEUKIN-1; LYMPHOCYTE; SECRETION; CORTISOL	Prolonged and severe sleep deprivation is associated with alterations of natural and cellular immune function, To determine whether alterations of immune function also occur after even a modest loss of sleep, the effects of early-night partial sleep deprivation on circulating numbers of white blood cells, natural killer (NK) cell number and cytotoxicity, lymphokine-activated killer (LAK) cell number and activity, and stimulated interleukin-2 (IL-2) production were studied in 42 medically and psychiatrically healthy male volunteers, After a night of sleep deprivation between 10 P.M. and 3 A.M., a reduction of natural immune responses as measured by Nh cell activity, Ng activity per number of NI( cells, LAK activity, and LAK activity per number of LAK precursors (CD16,56, CD25) was found, In addition, concanavalin A-stimulated IL-2 production was suppressed after sleep deprivation due to changes in both adherent and nonadherent cell populations, After a night of recovery sleep, NK activity returned to baseline levels and IL-2 production remained suppressed, These data implicate sleep in the modulation of immunity and demonstrate that even a modest disturbance of sleep produces a reduction of natural immune responses and T cell cytokine production.	UNIV CALIF SAN DIEGO, DEPT PSYCHIAT, SAN DIEGO, CA USA	University of California System; University of California San Diego	Irwin, M (corresponding author), SAN DIEGO VA MED CTR, DEPT PSYCHIAT V116A, 3350 LA JOLLA VILLAGE DR, SAN DIEGO, CA 92161 USA.		Irwin, Michael R./H-4870-2013	Irwin, Michael R./0000-0002-1502-8431	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH030914, R01MH046867, P50MH030914] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00827] Funding Source: Medline; NIMH NIH HHS [MH46867, MH30914] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKERSTEDT T, 1980, SLEEP, V3, P23, DOI 10.1093/sleep/3.1.23; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P1; BENCA RM, 1992, ARCH GEN PSYCHIAT, V49, P651; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; BLOOM ET, 1983, J IMMUNOL METHODS, V58, P323, DOI 10.1016/0022-1759(83)90360-5; BORN J, 1988, PSYCHONEUROENDOCRINO, V13, P233, DOI 10.1016/0306-4530(88)90021-2; BROWN R, 1989, Regional Immunology, V2, P321; BROWN R, 1989, Brain Behavior and Immunity, V3, P320, DOI 10.1016/0889-1591(89)90031-7; COVER H, 1993, RES PERSPECT PSYCHON, V90; CROSS RJ, 1992, J IMMUNOL, V148, P1347; CURTI R, 1982, MED LAV, V6, P564; DEMENT W, 1966, ELECTROEN CLIN NEURO, V20, P523, DOI 10.1016/0013-4694(66)90110-6; DINGES DF, 1994, J CLIN INVEST, V93, P1930, DOI 10.1172/JCI117184; EVERSON CA, 1993, AM J PHYSIOL, V265, pR1148, DOI 10.1152/ajpregu.1993.265.5.R1148; FAWZY FI, 1993, ARCH GEN PSYCHIAT, V50, P681; GILLIS S, 1978, J IMMUNOL, V120, P2027; HEILIG M, 1993, BRAIN BEHAV IMMUN, V7, P154, DOI 10.1006/brbi.1993.1017; HOHAGEN F, 1993, NEUROPSYCHOBIOLOGY, V28, P9, DOI 10.1159/000118993; HORNE J, 1988, WHY WE SLEEP FUNCTIO, P1; IRWIN M, 1994, PSYCHOSOM MED, V56, P493, DOI 10.1097/00006842-199411000-00004; IRWIN M, 1992, PSYCHOSOM MED, V54, P10, DOI 10.1097/00006842-199201000-00002; JARRETT DB, 1990, BIOL PSYCHIAT, V27, P497, DOI 10.1016/0006-3223(90)90441-4; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; KOFF WC, 1985, J IMMUNOL, V135, P350; KORN EL, 1984, IMMUNOBIOLOGY, V167, P431, DOI 10.1016/S0171-2985(84)80075-3; KRUEGER JM, 1990, INT J NEUROSCI, V51, P359, DOI 10.3109/00207459008999744; KRUEGER JM, 1990, CLIN IMMUNOL IMMUNOP, V57, P188, DOI 10.1016/0090-1229(90)90033-M; LEVY SM, 1989, NAT IMMUN CELL GROW, V8, P173; LUE FA, 1988, INT J NEUROSCI, V42, P179; MOLDOFSKY H, 1986, PSYCHOSOM MED, V48, P309, DOI 10.1097/00006842-198605000-00001; MOLDOFSKY H, 1989, FASEB J, V3, P1972, DOI 10.1096/fasebj.3.8.2785942; MORREY KM, 1994, J IMMUNOL, V153, P2671; MURRAY DR, 1992, CIRCULATION, V86, P203, DOI 10.1161/01.CIR.86.1.203; Nakano Y, 1982, J Hum Ergol (Tokyo), V11 Suppl, P131; OPP MR, 1994, BRAIN RES, V639, P57, DOI 10.1016/0006-8993(94)91764-7; OPP MR, 1994, AM J PHYSIOL, V266, pR688, DOI 10.1152/ajpregu.1994.266.3.R688; PALMBLAD J, 1976, J PSYCHOSOM RES, V20, P193, DOI 10.1016/0022-3999(76)90020-9; PALMBLAD J, 1979, PSYCHOSOM MED, V41, P273, DOI 10.1097/00006842-197906000-00001; PARRY BL, 1990, ARCH GEN PSYCHIAT, V47, P1139; PHILLIPS JH, 1986, J EXP MED, V164, P814, DOI 10.1084/jem.164.3.814; RECHTSCHAFFEN A, 1968, MANUAL STANDARDIZED, P1; REYNOLDS CF, 1987, ARCH GEN PSYCHIAT, V44, P982; SOMERS VK, 1993, NEW ENGL J MED, V328, P303, DOI 10.1056/NEJM199302043280502; TOTH LA, 1993, P SOC EXP BIOL MED, V203, P179, DOI 10.3181/00379727-203-43590; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1	45	323	338	1	35	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1996	10	5					643	653		10.1096/fasebj.10.5.8621064	http://dx.doi.org/10.1096/fasebj.10.5.8621064			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UJ055	8621064				2022-12-28	WOS:A1996UJ05500013
J	Mari, B; Guerin, S; Far, DF; Breitmayer, JP; Belhacene, N; Peyron, JF; Rossi, B; Auberger, P				Mari, B; Guerin, S; Far, DF; Breitmayer, JP; Belhacene, N; Peyron, JF; Rossi, B; Auberger, P			Thrombin and trypsin-induced Ca2+ mobilization in human T cell lines through interaction with different protease-activated receptors	FASEB JOURNAL			English	Article						thrombin receptor; protease-activated receptor 2; T leukemic cell lines	STIMULATE PHOSPHOINOSITIDE HYDROLYSIS; PHOSPHOLIPASE-C; ALPHA-THROMBIN; RESPONSES; PEPTIDES; MECHANISM; CYCLASE; AGONIST	This study was conducted to determine whether serine proteinases may induce [Ca2+](i) mobilization in different hematopoietic cell lines and to analyze their mechanisms of action. We show that in addition to thrombin and thrombin receptor agonist peptide (TRP, SFLLRN), trypsin induced [Ca2+](i) mobilization in a highly thrombin-sensitive Jurkat T cell clone. Thrombin, TRP, and trypsin were found to induce [Ca2+](i) release in three different Jurkat T cell clones differing in the level of T cell receptor expression. Similar results were obtained with a prothymocytic leukemic cell line, MPB.ALL, although these cells were much more responsive to trypsin than to thrombin and TRP. Other cell types such as THP1, a myelomonocytic cell line, or CEM, a CD4(+) positive leukemic cell line, were unresponsive to thrombin, TRP, and trypsin. The effect of trypsin was mimicked by SLIGRL, a peptide corresponding to the cleaved amino-terminal sequence of the recently characterized murine trypsin-activated receptor (PAR2). At suboptimal concentrations, the effects of SFLLRN and SLIGRL were additive, whereas saturating doses of peptides did not further increase [Ca2+](i) mobilization in Jurkat T cells, indicating that both peptides were able to mobilize the same pool of calcium. Northern blot analysis of mRNAs from different leukemic cell lines indicated a remarkable correlation between PAR2 expression in different cell lines and SLIGRL or trypsin responses in the same cells. The expression of the ''trypsin receptor'' was also confirmed by polymerase chain reaction analysis. Moreover, a 24 h treatment of Jurkat cells by an anti-CDS monoclonal antibody, a condition known to down-regulate thrombin receptor expression, induced loss of thrombin and TRP responses but only partially affected trypsin stimulation of [Ca2+](i) release. Finally, after a first stimulation with either thrombin or trypsin, Jurkat cells were still able to respond to trypsin or thrombin, respectively, demonstrating that thrombin and trypsin essentially activated their own receptors. Our data provided evidence that 1) the human T leukemic cell line Jurkat and other T cell lines express at least two different functional protease-activated receptors, the thrombin receptor and a highly sensitive trypsin receptor, likely the human counterpart of the murine PAR2, and 2) at variance with the commonly accepted model, trypsin exerts most of its effect in T leukemic cell lines by thrombin receptor-independent mechanisms.	FAC MED NICE,INSERM,U364,F-06107 NICE 02,FRANCE; FAC MED NICE,INSERM,U343,F-06107 NICE 02,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur			Jean-Francois, Peyron/AAA-9496-2022; AUBERGER, Patrick/G-1491-2013; Mari, Bernard P/F-8960-2013; Mari, Bernard/Q-5832-2019; Mari, Bernard P/D-7445-2015; Mari, Bernard P/GVS-3100-2022; Peyron, Jean-Francois/M-5682-2016	Jean-Francois, Peyron/0000-0001-6113-916X; AUBERGER, Patrick/0000-0002-2481-8275; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Peyron, Jean-Francois/0000-0001-6113-916X				AUBERGER P, 1989, J IMMUNOL, V142, P289; BRASS LF, 1991, J BIOL CHEM, V266, P958; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUNG DT, 1992, J BIOL CHEM, V267, P20831; JAKOBS KH, 1988, BIOCHEM J, V249, P639, DOI 10.1042/bj2490639; JAKOBS KH, 1988, EUR J BIOCHEM, V172, P255, DOI 10.1111/j.1432-1033.1988.tb13881.x; JONES LG, 1989, MOL PHARMACOL, V36, P142; LAZAROWSKI ER, 1990, ARCH BIOCHEM BIOPHYS, V276, P265, DOI 10.1016/0003-9861(90)90037-Y; MARI B, 1992, EMBO J, V11, P3875, DOI 10.1002/j.1460-2075.1992.tb05480.x; MARI B, 1994, J BIOL CHEM, V269, P8517; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; RUGGIERO M, 1985, BIOCHEM BIOPH RES CO, V131, P1198, DOI 10.1016/0006-291X(85)90218-9; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SELAK MA, 1994, BIOCHEM J, V297, P269, DOI 10.1042/bj2970269; SUIDAN HS, 1994, P NATL ACAD SCI USA, V91, P8112, DOI 10.1073/pnas.91.17.8112; TORDAI A, 1993, J IMMUNOL, V150, P4876; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0	26	71	71	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1996	10	2					309	316		10.1096/fasebj.10.2.8641564	http://dx.doi.org/10.1096/fasebj.10.2.8641564			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641564				2022-12-28	WOS:A1996TY96200015
J	Benveniste, EN; Benos, DJ				Benveniste, EN; Benos, DJ			TNF-alpha and IFN-gamma-mediated signal transduction pathways: Effects on glial cell gene expression and function	FASEB JOURNAL			English	Review						cytokines; glial cells; central nervous system; HIV	TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; PROTEIN-KINASE-C; HUMAN-FETAL ASTROCYTES; INTERFERON-GAMMA; MULTIPLE-SCLEROSIS; ANTIGEN PRESENTATION; ENDOTHELIAL-CELLS; NUCLEAR FACTOR; ACTIVATION	Cytokines are a group of secreted proteins that display diverse biological activity. They are especially important in the body's response to injury. They subserve a variety of both autocrine and paracrine functions by activating numerous intracellular second-messenger signaling pathways. Cytokines are known to mediate many inflammatory processes, and the inappropriate presence of cytokines in the central nervous system (CNS) has been implicated in a number of disease states. This article focuses on the biological role of two cytokines, namely: tumor necrosis factor alpha (TNF-alpha), and interferon-gamma (IFN-gamma), in the progression of neurologic disorders such as multiple sclerosis (MS) and AIDS dementia complex (ADC), with an emphasis on cytokine effects on glial cells. We discuss the cellular source of each cytokine within the CNS, their receptors, and what signaling pathways are involved in mediating their actions. We also describe recent findings indicating that HIV viral proteins, i.e., gp120, can activate cells of the CNS in a comparable manlier as cytokines, and discuss the second messengers that mediate gp120-induced responses. We conclude by identifying potentially important areas of cytokine research in the context of neurologic disease.	UNIV ALABAMA, DEPT PHYSIOL & BIOPHYS, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Benveniste, EN (corresponding author), UNIV ALABAMA, DEPT CELL BIOL, BIRMINGHAM, AL 35294 USA.				NIMH NIH HHS [MH-50421] Funding Source: Medline; NINDS NIH HHS [NS-29719, NS-31096] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH050421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS029719, P20NS031096] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARANGUEZ I, 1995, GLIA, V13, P185, DOI 10.1002/glia.440130305; BALLESTAS ME, 1995, GLIA, V14, P267, DOI 10.1002/glia.440140404; BENOS DJ, 1994, P NATL ACAD SCI USA, V91, P494, DOI 10.1073/pnas.91.2.494; BENOS DJ, 1994, J BIOL CHEM, V269, P13811; BENVENISTE EN, 1991, J BIOL CHEM, V266, P18119; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; BENVENISTE EN, 1994, J IMMUNOL, V153, P5210; BENVENISTE EN, 1995, INT J DEV NEUROSCI, V13, P341, DOI 10.1016/0736-5748(94)00061-7; BENVENISTE EN, 1994, RES P ARNMD, V72, P71; BENVENISTE EN, 1990, J NEUROIMMUNOL, V30, P201, DOI 10.1016/0165-5728(90)90104-U; BENVENISTE EN, 1995, HUMAN CYTOKINES THEI, P195; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BUBIEN JK, 1995, AM J PHYSIOL-CELL PH, V37, pC1440; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FFRENCHCONSTANT C, 1994, LANCET, V343, P271, DOI 10.1016/S0140-6736(94)91118-5; FREI K, 1987, EUR J IMMUNOL, V17, P1271, DOI 10.1002/eji.1830170909; FROHMAN EM, 1989, J NEUROIMMUNOL, V23, P117, DOI 10.1016/0165-5728(89)90030-1; GENDELMAN HE, 1994, J LEUKOCYTE BIOL, V56, P389, DOI 10.1002/jlb.56.3.389; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P17; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; HERY C, 1995, J NEUROIMMUNOL, V57, P101, DOI 10.1016/0165-5728(94)00168-N; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; HURWITZ AA, 1992, J EXP MED, V176, P1631, DOI 10.1084/jem.176.6.1631; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LEE YJ, 1995, AM J PHYSIOL-CELL PH, V268, pC127; LEVI G, 1993, P NATL ACAD SCI USA, V90, P1541, DOI 10.1073/pnas.90.4.1541; LIPTON SA, 1995, NEW ENGL J MED, V332, P934, DOI 10.1056/NEJM199504063321407; MA MH, 1994, J VIROL, V68, P6824, DOI 10.1128/JVI.68.10.6824-6828.1994; MALIPIERO UV, 1990, J IMMUNOL, V144, P3816; MCCARRON RM, 1993, J NEUROIMMUNOL, V43, P23, DOI 10.1016/0165-5728(93)90071-6; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MOSES H, 1992, J IMMUNOL, V148, P3643; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NORRIS JG, 1994, J IMMUNOL, V152, P841; PANEK RB, 1994, J IMMUNOL, V153, P4555; PANITCH HS, 1987, NEUROLOGY, V37, P1097, DOI 10.1212/WNL.37.7.1097; PENEK RB, 1995, J IMMUNOL, V154, P610; PRPIC V, 1989, SCIENCE, V244, P469, DOI 10.1126/science.2541500; RAINE CS, 1990, CLIN IMMUNOL IMMUNOP, V57, P173, DOI 10.1016/0090-1229(90)90032-L; RAINE CS, 1984, LAB INVEST, V50, P608; ROBBINS DS, 1987, J IMMUNOL, V139, P2593; RODRIGUEZ M, 1994, J IMMUNOL, V153, P3811; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; RUDDLE NH, 1990, J EXP MED, V172, P1193, DOI 10.1084/jem.172.4.1193; SELMAJ K, 1995, J NEUROIMMUNOL, V56, P135, DOI 10.1016/0165-5728(94)00139-F; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; SELMAJ K, 1991, J IMMUNOL, V147, P1522; SELMAJ KW, 1990, J IMMUNOL, V144, P129; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SHARIEF MK, 1993, J NEUROIMMUNOL, V43, P15, DOI 10.1016/0165-5728(93)90070-F; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SHRIKANT P, 1994, J NEUROIMMUNOL, V51, P209, DOI 10.1016/0165-5728(94)90083-3; SHRIKANT P, 1995, IN PRESS J IMMUNOL; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SOBEL RA, 1990, AM J PATHOL, V136, P1309; SPARACIO SM, 1992, J NEUROIMMUNOL, V39, P231, DOI 10.1016/0165-5728(92)90257-L; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TWEARDY DJ, 1991, J NEUROIMMUNOL, V32, P269, DOI 10.1016/0165-5728(91)90197-F; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WILT SG, 1995, ANN NEUROL, V37, P381, DOI 10.1002/ana.410370315; WONG GHW, 1984, EUR J IMMUNOL, V14, P52, DOI 10.1002/eji.1830140110	68	141	145	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1995	9	15					1577	1584		10.1096/fasebj.9.15.8529837	http://dx.doi.org/10.1096/fasebj.9.15.8529837			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TM761	8529837				2022-12-28	WOS:A1995TM76100011
J	POTTER, VR				POTTER, VR			STUDIES ON ENZYME-INHIBITION - 50 YEARS AGO .24.	FASEB JOURNAL			English	Editorial Material											POTTER, VR (corresponding author), UNIV WISCONSIN, MCARDLE LAB CANC RES, MADISON, WI 53706 USA.							Albaum HG, 1943, CANCER RES, V3, P303; Bensley RR, 1934, ANAT REC, V60, P449, DOI 10.1002/ar.1090600408; Bensley RR, 1937, ANAT REC, V69, P341, DOI 10.1002/ar.1090690308; Claude A, 1940, SCIENCE, V91, P77, DOI 10.1126/science.91.2351.77; Elliott KAC, 1940, BIOCHEM J, V34, P1134, DOI 10.1042/bj0341134; HOGEBOOM GH, 1948, J BIOL CHEM, V172, P619; LEPAGE GA, 1946, AM J PHYSIOL, V146, P267, DOI 10.1152/ajplegacy.1946.146.2.267; LORING HUBERT S., 1942, JOUR GEN PHYSIOL, V25, P497, DOI 10.1085/jgp.25.3.497; MCSHAN WH, 1948, AM J PHYSIOL, V145, P93; Potter VR, 1943, J GEN PHYSIOL, V26, P391, DOI 10.1085/jgp.26.4.391; Potter VR, 1944, ADV ENZYMOL REL S BI, V4, P201; Potter VR, 1940, MEDICINE, V19, P441, DOI 10.1097/00005792-194012000-00001; Potter VR, 1943, J GEN PHYSIOL, V26, P443, DOI 10.1085/jgp.26.5.443; Potter VR, 1941, J BIOL CHEM, V141, P775; Potter VR, 1940, J BIOL CHEM, V134, P417; POTTER VR, 1943, FED PROC, V2, P68; SCHNEIDER WC, 1948, ANAT REC, V172, P451	17	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1993	7	5					486	487		10.1096/fasebj.7.5.8462790	http://dx.doi.org/10.1096/fasebj.7.5.8462790			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KV351	8462790				2022-12-28	WOS:A1993KV35100014
J	Galan, JM; Cantegrit, B; Garnier, C; Namy, O; Haguenauer-Tsapis, R				Galan, JM; Cantegrit, B; Garnier, C; Namy, O; Haguenauer-Tsapis, R			'ER degradation' of a mutant yeast plasma membrane protein by the ubiquitin-proteasome pathway	FASEB JOURNAL			English	Article						proteasome; ubiquitin; uracil permease	MAT-ALPHA-2 TRANSCRIPTIONAL REGULATOR; ENDOPLASMIC-RETICULUM; URACIL PERMEASE; SACCHAROMYCES-CEREVISIAE; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; MULTIUBIQUITIN-CHAIN; 26S PROTEASOME; GENE ENCODES; COMPONENT; TRANSLOCATION	The yeast plasma membrane, uracil permease, undergoes ubiquitin-dependent endocytosis and subsequent degradation in the vacuole via a process that does not involve the proteasome, Cell-surface ubiquitination of this protein is mediated by the ubiquitin-protein ligase Npi1p/Rsp5p and involves Lys(63)-linked ubiquitin chains, This report describes the intracellular fate of a mutant form of uracil permease carrying a three amino acid insertion in a cytoplasmic loop, Most of this protein is not deployed beyond the ER, and is degraded by the 26S proteasome, Mutant permease degradation is almost unaffected in cells with impaired Npilp/Rsp5p, but is dependent on the Ubc6p and Ubc7p ubiquitin-conjugating enzymes, suggesting that proteolysis of the protein requires its prior ubiquitination, Overproduction of a derivative of ubiquitin with a modified Lys(48) strongly impairs mutant permease degradation, This suggests that, Like other proteasome substrates, mutant permease might be polyubiquitinated with Lys(48)-linked ubiquitin chains, These findings provide an example of a yeast plasma membrane protein that is routed to the 'ER degradation' pathway, and highlight the versatility of the ubiquitin system.	Univ Paris 07, CNRS, Inst Jacques Monod, F-75251 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Haguenauer-Tsapis, R (corresponding author), Univ Paris 07, CNRS, Inst Jacques Monod, 2 Pl Jussieu, F-75251 Paris 05, France.	haguenauer@ijm.jussieu.fr	Namy, olivier/B-8906-2008; Haguenauer-Tsapis, Rosine/C-5446-2012; Namy, Olivier/ABD-4379-2020	Namy, Olivier/0000-0002-1143-5961				Amara J F, 1992, Trends Cell Biol, V2, P145, DOI 10.1016/0962-8924(92)90101-R; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Galan JM, 1996, J BIOL CHEM, V271, P10946, DOI 10.1074/jbc.271.18.10946; Garnier C, 1996, MOL MICROBIOL, V21, P1061, DOI 10.1046/j.1365-2958.1996.621430.x; GARNIER C, 1995, THESIS U PARIS 6; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HICKE L, 1997, IN PRESS FASEB J; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; MARCHAL C, IN PRESS MOL CELL BI; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PARLATI F, 1995, J BIOL CHEM, V270, P244, DOI 10.1074/jbc.270.1.244; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; PIND S, 1994, J BIOL CHEM, V269, P12784; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Rayner JC, 1997, EMBO J, V16, P1832, DOI 10.1093/emboj/16.8.1832; RICHTERRUOFF B, 1994, FEBS LETT, V354, P50, DOI 10.1016/0014-5793(94)01085-4; Roberg KJ, 1997, J CELL BIOL, V137, P1469, DOI 10.1083/jcb.137.7.1469; Roberts BJ, 1997, J BIOL CHEM, V272, P9771; SCHORK SM, 1995, J BIOL CHEM, V270, P26446, DOI 10.1074/jbc.270.44.26446; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SILVE S, 1991, MOL CELL BIOL, V11, P1114, DOI 10.1128/MCB.11.2.1114; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; VOLLAND C, 1992, J BIOL CHEM, V267, P23767; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	51	27	28	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1998	12	3					315	323		10.1096/fasebj.12.3.315	http://dx.doi.org/10.1096/fasebj.12.3.315			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YZ898	9506475				2022-12-28	WOS:000072305500020
J	Mironov, A; Luini, A; Mironov, A				Mironov, A; Luini, A; Mironov, A			A synthetic model of intra-Golgi traffic	FASEB JOURNAL			English	Article						intra-Golgi transport; cistern maturation; lateral diffusion; Golgi enzyme recycling	CYTOPLASMIC MEMBRANES; TRANSPORT VESICLES; APPARATUS; COMPLEX; PROTEIN; CELL; ELEMENTS	We present a hypothesis on the mechanisms used by cells to transport cargo through the secretory system. We propose that at least three basic processes coordinately participate in membrane traffic: cisternal maturation-progression, controlled cargo diffusion along transient membrane continuities between different compartments, and a mostly retrograde vesicle-mediated transport. A 'synthetic' model based on the combination of these mechanisms can explain both the progression of supramolecular aggregates through the secretory pathway and the fast intra-Golgi transport of conventional cargoes. Analysis of the existing literature shows that the available data are consistent with the proposed model.	Mario Negri Sud Inst, Mol Neurobiol Lab, I-66030 Chieti, Italy	Consorzio Mario Negri Sud	Luini, A (corresponding author), Mario Negri Sud Inst, Mol Neurobiol Lab, Via Nazl, I-66030 Chieti, Italy.	mironov@cmns.mnegri.it; luini@cmns.mnegri.it	Luini, Alberto/L-1372-2013	Luini, Alberto/0000-0002-8729-2549; Mironov, Aleksandr/0000-0002-1497-328X				Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; BERGMANN JE, 1989, METHOD CELL BIOL, V32, P85; CLAUDE A, 1970, J CELL BIOL, V47, P745, DOI 10.1083/jcb.47.3.745; CLERMONT Y, 1994, ANAT REC, V240, P469, DOI 10.1002/ar.1092400405; DAHAN S, 1994, J CELL BIOL, V127, P1859, DOI 10.1083/jcb.127.6.1859; LEBLOND CP, 1989, ANAT REC, V224, P123, DOI 10.1002/ar.1092240204; Mironov AA, 1997, J CELL BIOL, V138, P481, DOI 10.1083/jcb.138.3.481; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; RABOUILLE C, 1995, J CELL SCI, V108, P1617; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; ROTHMAN JE, 1984, J CELL BIOL, V99, P248, DOI 10.1083/jcb.99.1.248; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Sonnichsen B, 1996, J CELL BIOL, V134, P1411, DOI 10.1083/jcb.134.6.1411; STINCHCOMBE JC, 1995, J CELL BIOL, V131, P1387, DOI 10.1083/jcb.131.6.1387; Tanaka K, 1992, Hum Cell, V5, P211; TAYLOR TC, 1994, MOL BIOL CELL, V5, P237, DOI 10.1091/mbc.5.2.237; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39	17	29	32	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1998	12	2					249	252						4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472990				2022-12-28	WOS:000071848400013
J	Muciaccia, B; Uccini, S; Filippini, A; Ziparo, E; Paraire, F; Baroni, CD; Stefanini, M				Muciaccia, B; Uccini, S; Filippini, A; Ziparo, E; Paraire, F; Baroni, CD; Stefanini, M			Presence and cellular distribution of HIV in the testes of seropositive subjects: an evaluation by in situ PCR hybridization	FASEB JOURNAL			English	Article						testis; stem cell infection; AIDS; germ cell	HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY-SYNDROME; POLYMERASE CHAIN-REACTION; SERTOLI CELLS; ARTIFICIAL-INSEMINATION; HTLV-III; PREEJACULATORY FLUID; SEMINIFEROUS TUBULES; SEXUAL TRANSMISSION; TESTICULAR ATROPHY	Cellular distribution of HIV-1 proviral DNA has been studied, by in situ PCR hybridization, in the testes of infected men who died at various stages of the disease. In seropositive asymptomatic subjects, HIV-1 proviral DNA was present in the nuclei of germ cells at all stages of their differentiation. The presence of provirus did not induce germ cell damage, was associated with normal spermatogenesis, and was not accompanied by morphologic signs of immune response. The observed HIV hybridization pattern of germ cells suggests clonal infection. Mechanisms responsible for HIV penetration in testicular germ cells remain to be clarified; however, the possibility of a direct infection of the germ cells by cell-free virus is suggested. In the testes of AIDS-deceased men, histologic features of hypoplasia with arrested spermatogenesis were evident, and few infected spermatogonia and spermatocytes were observed. The whale of these data demonstrates that the testis is a site of early viral localization that fails to elicit an immunological response, and that HIV-seropositive men produce infected spermatozoa that are released in the genital tract.	Univ Roma La Sapienza, Dept Histol & Med Embryol, I-00161 Rome, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, Chair Pathol 2, I-00161 Rome, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, Immunopathol Sect, I-00161 Rome, Italy; Univ Roma La Sapienza, Ist Pasteur Fdn Cenci Bolognetti, I-00161 Rome, Italy; Hop Poincare, Lab Pathol & Forens Med, Garches, France	Sapienza University Rome; Sapienza University Rome; Sapienza University Rome; Fondazione Cenci Bolognetti; Sapienza University Rome; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP	Muciaccia, B (corresponding author), Univ Roma La Sapienza, Dept Histol & Med Embryol, Via Antonio Scarpa 14, I-00161 Rome, Italy.	mstefanini@axrma.uniromal.it		Ziparo, Elio/0000-0002-8776-3515; filippini, antonio/0000-0001-8453-287X				ANDERSON DJ, 1991, LANCET, V338, P573, DOI 10.1016/0140-6736(91)91139-L; ARANETA MRG, 1995, JAMA-J AM MED ASSOC, V273, P854, DOI 10.1001/jama.273.11.854; BACCETTI B, 1991, J SUBMICR CYTOL PATH, V23, P339; BACCETTI B, 1994, J CELL BIOL, V127, P903, DOI 10.1083/jcb.127.4.903; BAGASRA O, 1994, AIDS, V8, P1669, DOI 10.1097/00002030-199412000-00005; BAGASRA O, 1992, NEW ENGL J MED, V326, P1385, DOI 10.1056/NEJM199205213262103; BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BORZY MS, 1988, J ACQ IMMUN DEF SYND, V1, P419; Brogi A, 1996, AIDS RES HUM RETROV, V12, P483, DOI 10.1089/aid.1996.12.483; BROGI A, 1995, J SUBMICR CYTOL PATH, V27, P565; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; CHABON AB, 1987, UROLOGY, V29, P658, DOI 10.1016/0090-4295(87)90118-X; CHENGMAYER C, 1987, P NATL ACAD SCI USA, V84, P3526, DOI 10.1073/pnas.84.10.3526; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; DALTON ADA, 1991, J PATHOL, V163, P47, DOI 10.1002/path.1711630109; DASILVA M, 1990, AM J CLIN PATHOL, V93, P196, DOI 10.1093/ajcp/93.2.196; DECESARIS P, 1992, BIOCHEM BIOPH RES CO, V186, P1639; DEPAEPE ME, 1989, HUM PATHOL, V20, P210, DOI 10.1016/0046-8177(89)90125-1; DEPAEPE ME, 1989, HUM PATHOL, V20, P572, DOI 10.1016/0046-8177(89)90246-3; DUSSAIX E, 1993, RES VIROLOGY, V144, P487, DOI 10.1016/S0923-2516(06)80064-6; Dym M, 1970, Biology Reprod., V3, P308; FANTINI J, 1993, P NATL ACAD SCI USA, V90, P2700, DOI 10.1073/pnas.90.7.2700; FILIPPINI A, 1989, GAMETE RES, V23, P367, DOI 10.1002/mrd.1120230402; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; GRAY F, 1992, J NEUROPATH EXP NEUR, V51, P177, DOI 10.1097/00005072-199203000-00007; GUINAN ME, 1995, JAMA-J AM MED ASSOC, V273, P890; HAASE AT, 1990, P NATL ACAD SCI USA, V87, P4971, DOI 10.1073/pnas.87.13.4971; HAMED KA, 1993, J INFECT DIS, V167, P798, DOI 10.1093/infdis/167.4.798; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; HEAD JR, 1985, TRANSPLANTATION, V40, P269, DOI 10.1097/00007890-198509000-00010; HEAD JR, 1983, TRANSPLANTATION, V36, P423, DOI 10.1097/00007890-198310000-00014; HERMO L, 1976, AM J ANAT, V145, P467, DOI 10.1002/aja.1001450406; HERMO L, 1978, BIOL REPROD, V19, P92, DOI 10.1095/biolreprod19.1.92; HO DD, 1984, SCIENCE, V226, P451, DOI 10.1126/science.6208608; ILARIA G, 1992, LANCET, V340, P1469, DOI 10.1016/0140-6736(92)92658-3; JACKSON DP, 1991, PCR PRACTICAL APPROA, P29; KIESSLING AA, 1987, P NATL ACAD SCI USA, V84, P8667, DOI 10.1073/pnas.84.23.8667; KRIEGER JN, 1995, J UROLOGY, V154, P1035, DOI 10.1016/S0022-5347(01)66969-6; KRIEGER JN, 1991, J INFECT DIS, V163, P386, DOI 10.1093/infdis/163.2.386; LECATSAS G, 1985, P SOC EXP BIOL MED, V178, P653; MARX JL, 1989, SCIENCE, V245, P30, DOI 10.1126/science.2740912; Meistrich M., 1989, HISTONES OTHER BASIC, P165; MERMIN JH, 1991, J INFECT DIS, V164, P769, DOI 10.1093/infdis/164.4.769; Mostad SB, 1996, AIDS, V10, P1305, DOI 10.1097/00002030-199610000-00001; NUOVO GJ, 1994, AM J PATHOL, V144, P1142; NUOVO GJ, 1992, PCR IN SITU HYBRIDIZ; OLeary JJ, 1996, J PATHOL, V178, P11; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PORTIS JL, 1987, J VIROL, V61, P1037, DOI 10.1128/JVI.61.4.1037-1044.1987; PUDNEY J, 1991, AM J PATHOL, V139, P149; PUDNEY J, 1992, LANCET, V340, P1470, DOI 10.1016/0140-6736(92)92659-4; RICCIOLI A, 1995, P NATL ACAD SCI USA, V92, P5808, DOI 10.1073/pnas.92.13.5808; ROGERS C, 1988, HISTOPATHOLOGY, V12, P659, DOI 10.1111/j.1365-2559.1988.tb01990.x; Sanberg PR, 1996, NAT BIOTECHNOL, V14, P1692, DOI 10.1038/nbt1296-1692; SCOFIELD VL, 1994, AIDS, V8, P1733, DOI 10.1097/00002030-199412000-00018; Sewart G, 1996, LANCET, V347, P970, DOI 10.1016/S0140-6736(96)91457-9; SMABROOK J, 1989, MOL CLONING LAB MANU; STEWART GJ, 1985, LANCET, V2, P581; TATENO M, 1989, P NATL ACAD SCI USA, V86, P4287, DOI 10.1073/pnas.86.11.4287; TINDALL B, 1992, AIDS, V6, P949, DOI 10.1097/00002030-199209000-00006; TUNG KSK, 1980, IMMUNOLOGICAL ASPECT, P33; VANVOORHIS BJ, 1991, FERTIL STERIL, V55, P588; VERNAZZA PL, 1994, AIDS, V8, P1325, DOI 10.1097/00002030-199409000-00017; VIDAL F, 1993, HUM REPROD, V8, P1740, DOI 10.1093/oxfordjournals.humrep.a137926; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZAGURY D, 1984, SCIENCE, V226, P449, DOI 10.1126/science.6208607	68	46	52	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1998	12	2					151	163		10.1096/fasebj.12.2.151	http://dx.doi.org/10.1096/fasebj.12.2.151			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472980				2022-12-28	WOS:000071848400003
J	Rivera, DL; Olister, SM; Liu, X; Thompson, JH; Zhang, XJ; Pennline, K; Azuero, R; Clark, DA; Miller, MJS				Rivera, DL; Olister, SM; Liu, X; Thompson, JH; Zhang, XJ; Pennline, K; Azuero, R; Clark, DA; Miller, MJS			Interleukin-10 attenuates experimental fetal growth restriction and demise	FASEB JOURNAL			English	Article						TNF-alpha; nitric oxide; IL-10; TUNEL; placenta; cellular infiltration	TUMOR-NECROSIS-FACTOR; NITRIC-OXIDE SYNTHASE; FACTOR-ALPHA; AMNIOTIC-FLUID; CYTOKINE PRODUCTION; TROPHOBLAST CELLS; INTERFERON-GAMMA; PLACENTAL CELLS; T-CELLS; MACROPHAGES	Premature labor, fetal demise, and fetal growth restriction are accompanied by indices of inflammation or infection of the uteroplacental unit. To understand whether these events are causally related, we established an animal model of fetal demise and growth restriction and evaluated the potential utility of the anti-inflammatory cytokine interleukin-10 (IL-10). We administered low-dose endotoxin (lipopolysaccharide, or LPS, 100 mu g/kg, i.p.) to third trimester rats (gestational days 14-20). (Control rats received normal saline. A third group received IL-10 (100 mu g/kg; s.c.) concomitantly with LPS for 7 prenatal days. Cytokine gene expression (IL-10 and TNF-alpha) was evaluated by RT-PCR and tissue levels (TNF-alpha) were determined by ELISA. Apoptosis was evaluated by TdT-mediated dUTP nick end labeling immunohistochemistry, and nitric oxide (NO) levels were quantified by microelectrode electrochemical detection in explants in culture media. LPS exposure resulted in 43% fetal demise and reduced the size of the surviving fetuses. Placental weight was not altered by LPS. IL-10 attenuated the LPS-induced fetal death rate (to 22%) and growth restriction (P<0.05). in normal rats, IL-10 did not affect fetus size or the incidence of resorptions, although placental size was marginally smaller. Increased uterine TNF-alpha content and NO release and apoptosis of uterine epithelia and muscularis were hallmarks of the LPS model. All were normalized by IL-10. IL-10 may represent a new therapeutic option for the treatment of a variety of perinatal complications. Benefit may result from the suppression of TNF-a-and NO-mediated cell death.	Louisiana State Univ, Med Ctr, Dept Pediat, New Orleans, LA 70112 USA; Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA	Louisiana State University System; Merck & Company; Schering Plough Corporation	Miller, MJS (corresponding author), Louisiana State Univ, Med Ctr, Dept Pediat, 1542 Tulane Ave, New Orleans, LA 70112 USA.	mmiller@mail.peds.lsumc.edu			PHS HHS [R01 31885] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALBINA JE, 1993, J IMMUNOL, V150, P5080; ARAI T, 1995, BIOCHEM BIOPH RES CO, V213, P600, DOI 10.1006/bbrc.1995.2174; ATHANASSAKIS I, 1987, J IMMUNOL, V138, P37; BECHEREL PA, 1995, EUR J IMMUNOL, V25, P2992, DOI 10.1002/eji.1830251042; BERKOWITZ RS, 1988, AM J OBSTET GYNECOL, V158, P199, DOI 10.1016/0002-9378(88)90810-1; Bingisser P, 1996, AM J RESP CELL MOL, V15, P64, DOI 10.1165/ajrcmb.15.1.8679223; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; Bour ES, 1996, AM J PATHOL, V148, P485; CADET P, 1995, AM J OBSTET GYNECOL, V173, P25, DOI 10.1016/0002-9378(95)90164-7; CENDI E, 1993, EUR J IMMUNOL, V23, P1034; CHAOUAT G, 1995, J IMMUNOL, V154, P4261; CHEDA S, 1996, PEDIATR RES, V40, P475; CUI S, 1993, CANCER RES, V54, P2462; CUNHA FQ, 1992, BIOCHEM BIOPH RES CO, V182, P1155, DOI 10.1016/0006-291X(92)91852-H; DEKOSSODO S, 1992, J EXP MED, V176, P1259, DOI 10.1084/jem.176.5.1259; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; GENDRON RL, 1990, J REPROD FERTIL, V90, P395, DOI 10.1530/jrf.0.0900395; Geng YJ, 1996, CANCER RES, V56, P866; GREIG PC, 1995, AM J OBSTET GYNECOL, V173, P1223, DOI 10.1016/0002-9378(95)91358-0; HEYBORNE KD, 1992, AM J OBSTET GYNECOL, V167, P920, DOI 10.1016/S0002-9378(12)80012-3; HEYBORNE KD, 1994, AM J OBSTET GYNECOL, V171, P55, DOI 10.1016/S0002-9378(94)70077-X; HUNT JS, 1989, J REPROD IMMUNOL, V16, P1, DOI 10.1016/0165-0378(89)90002-8; HUNT JS, 1988, J IMMUNOL, V140, P1293; HUNZIKER RD, 1986, CRC CR REV IMMUNOL, V6, P245; INOUE T, 1994, HUM REPROD, V9, P2411, DOI 10.1093/oxfordjournals.humrep.a138460; JAATTELA M, 1988, LAB INVEST, V58, P48; LAHAM N, 1994, EUR J ENDOCRINOL, V131, P607, DOI 10.1530/eje.0.1310607; LIU XP, 1990, J ELECTROANAL CHEM, V295, P15; Lyall F, 1996, PLACENTA, V17, P165, DOI 10.1016/S0143-4004(96)80009-9; MACNEIL IA, 1990, J IMMUNOL, V145, P4167; MALEFYT RD, 1991, J EXP MED, V174, P1209; MARCHANT A, 1994, EUR J IMMUNOL, V24, P1167, DOI 10.1002/eji.1830240524; MCDUFFIE RS, 1992, AM J OBSTET GYNECOL, V167, P1583, DOI 10.1016/0002-9378(92)91745-V; Miller MJS, 1996, FREE RADICAL BIO MED, V21, P619, DOI 10.1016/0891-5849(96)00171-2; MOWBRAY J, 1993, IMMUNOLOGY PREGNANCY; MYERS SA, 1982, AM J PHYSIOL, V243, P4404; PAMPFER S, 1994, J REPROD FERTIL, V101, P199, DOI 10.1530/jrf.0.1010199; PENG TCC, 1992, P 39 ANN M SOC GYN I; PHILPOTT KL, 1988, IMMUNOLOGY, V64, P479; RANDOW F, 1995, J EXP MED, V181, P1887, DOI 10.1084/jem.181.5.1887; Ribbons KA, 1997, EUR J PHARMACOL, V323, P245, DOI 10.1016/S0014-2999(97)00017-4; SANDOVAL M, 1995, MEDIAT INFLAMM, V4, P248, DOI 10.1155/S0962935195000391; SILEN ML, 1989, AM J PATHOL, V135, P239; STALLMACH T, 1995, LAB INVEST, V73, P384; YELAVARTHI KK, 1991, J IMMUNOL, V146, P3840; YUI J, 1994, PLACENTA, V15, P819, DOI 10.1016/S0143-4004(05)80184-5	46	110	117	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1998	12	2					189	197		10.1096/fasebj.12.2.189	http://dx.doi.org/10.1096/fasebj.12.2.189			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472984	Bronze			2022-12-28	WOS:000071848400007
J	Wilkinson, KD				Wilkinson, KD			Regulation of ubiquitin-dependent processes by deubiquitinating enzymes	FASEB JOURNAL			English	Review						protease; hydrolase; proprotein processing; polyubiquitin degradation; DUB activity; oncogenesis	CARBOXYL-TERMINAL HYDROLASE; N-END RULE; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; FAT FACETS; FUNCTIONAL-ANALYSIS; CONJUGATING ENZYME; NUCLEAR-PROTEIN; DNA-REPAIR; KAPPA-B	An astounding number of important regulatory and structural proteins are subject to modification by the attachment of ubiquitin or ubiquitin-like proteins. This modification acts as a targeting signal, delivering the modified protein to different locations in the cell and modifying its activity, macromolecular interactions, or half-life, Deubiquitination, or the removal of this modification, is being recognized as an important regulatory strategy, This reaction is catalyzed by processing proteases known as deubiquitinating enzymes (DUBs), More than 60 DUEs are already known, although little is known about their biological roles, This review concentrates on recent findings and new insights into this fascinating class of enzymes.	Emory Univ, Dept Biochem, Atlanta, GA 30322 USA	Emory University	Wilkinson, KD (corresponding author), Emory Univ, Dept Biochem, 4017 Rollins Res Bldg, Atlanta, GA 30322 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030308] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30308] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 1997, EMBO J, V16, P4826; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; BAKER RT, 1994, J BIOL CHEM, V269, P25381; BAKER RT, 1992, J BIOL CHEM, V267, P23364; Biggins S, 1996, J CELL BIOL, V133, P1331, DOI 10.1083/jcb.133.6.1331; Boddy MN, 1996, ONCOGENE, V13, P971; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CIECHANOVER A, 1994, BIOL CHEM H-S, V375, P565; Dor Y, 1996, MOL MICROBIOL, V21, P1197, DOI 10.1046/j.1365-2958.1996.671433.x; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; GRAY DA, 1995, ONCOGENE, V10, P2179; GUPTA K, 1994, ONCOGENE, V9, P1729; Haas AL, 1996, BIOCHEMISTRY-US, V35, P5385, DOI 10.1021/bi9524981; HADARI T, 1992, J BIOL CHEM, V267, P719; Hegde AN, 1997, CELL, V89, P115, DOI 10.1016/S0092-8674(00)80188-9; Henchoz S, 1996, MOL CELL BIOL, V16, P5717; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Huang YZ, 1996, DEVELOPMENT, V122, P3207; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Isaksson A, 1996, BBA-REV CANCER, V1288, pF21, DOI 10.1016/0304-419X(96)00011-X; JarielEncontre I, 1997, MOL BIOL REP, V24, P51, DOI 10.1023/A:1006804723722; JAUNIAUX JC, 1987, EUR J BIOCHEM, V164, P601, DOI 10.1111/j.1432-1033.1987.tb11169.x; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Johnston SC, 1997, EMBO J, V16, P3787, DOI 10.1093/emboj/16.13.3787; Jones MH, 1996, HUM MOL GENET, V5, P1695, DOI 10.1093/hmg/5.11.1695; KANDA F, 1986, BIOCHIM BIOPHYS ACTA, V870, P64, DOI 10.1016/0167-4838(86)90009-9; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; KUMAR S, 1993, BIOCHEM BIOPH RES CO, V195, P393, DOI 10.1006/bbrc.1993.2056; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Lapenta V, 1997, GENOMICS, V40, P362, DOI 10.1006/geno.1996.4556; Larsen CN, 1996, BIOCHEMISTRY-US, V35, P6735, DOI 10.1021/bi960099f; LARSEN CN, 1996, THESIS EMORY U; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; LIU CC, 1989, J BIOL CHEM, V264, P20331; LOEB KR, 1994, MOL CELL BIOL, V14, P8408, DOI 10.1128/MCB.14.12.8408; Lucero P, 1997, FEMS MICROBIOL LETT, V147, P273, DOI 10.1016/S0378-1097(96)00538-1; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Maki CG, 1996, CANCER RES, V56, P2649; MARUSHIGE Y, 1995, ANTICANCER RES, V15, P267; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MILLER HI, 1989, BIO-TECHNOL, V7, P698, DOI 10.1038/nbt0789-698; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; MORI S, 1995, BIOCHEM BIOPH RES CO, V213, P32, DOI 10.1006/bbrc.1995.2094; Nakajima T, 1996, J BIOL CHEM, V271, P24842, DOI 10.1074/jbc.271.40.24842; Nakamura M, 1996, J Immunol, V156, P532; NAKAMURA T, 1992, ONCOGENE, V7, P733; OBIN M, 1994, BIOCHEM BIOPH RES CO, V200, P1169, DOI 10.1006/bbrc.1994.1574; Okura T, 1996, J IMMUNOL, V157, P4277; OLVERA J, 1993, J BIOL CHEM, V268, P17967; Pahl HL, 1996, CURR OPIN CELL BIOL, V8, P340, DOI 10.1016/S0955-0674(96)80007-X; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAPA FR, 1993, NATURE, V366, P315; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; PICKART CM, 1985, J BIOL CHEM, V260, P7903; Piotrowski J, 1997, J BIOL CHEM, V272, P23712, DOI 10.1074/jbc.272.38.23712; Riezman H, 1996, EXPERIENTIA, V52, P1033, DOI 10.1007/BF01952099; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; Singer JD, 1996, MOL CELL BIOL, V16, P1356; Srivenugopal KS, 1996, BIOCHEMISTRY-US, V35, P1328, DOI 10.1021/bi9518205; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; Udvardy A, 1996, EUR J BIOCHEM, V240, P307, DOI 10.1111/j.1432-1033.1996.0307h.x; vanDelft S, 1997, J BIOL CHEM, V272, P14013, DOI 10.1074/jbc.272.22.14013; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; WILKINSON KD, 1992, BIOCHEM SOC T, V20, P631, DOI 10.1042/bst0200631; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; WILKINSON KD, 1997, DEUBIQUITINATING ENZ; WILKINSON KD, 1997, HDB PROTOEOLYTIC ENZ; Wood SA, 1997, MECH DEVELOP, V63, P29, DOI 10.1016/S0925-4773(97)00672-2; YOON HJ, 1995, MOL CELL BIOL, V15, P4835; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275; Zhu YA, 1997, J BIOL CHEM, V272, P51	88	482	510	1	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1997	11	14					1245	1256		10.1096/fasebj.11.14.9409543	http://dx.doi.org/10.1096/fasebj.11.14.9409543			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YN210	9409543				2022-12-28	WOS:000071144100005
J	Bray, G; Bouchard, C				Bray, G; Bouchard, C			Genetics of human obesity: research directions	FASEB JOURNAL			English	Review						genome scanning; body fat; single gene defect; food intake; QTL; mendelian disorder; transgenic model; leptin	HUMAN OB GENE; TRANSGENIC MICE; LEPTIN RECEPTOR; ADIPOSE-TISSUE; BODY-WEIGHT; PHARMACOLOGICAL TREATMENT; NEUROPEPTIDE-Y; MOUSE MODEL; FOOD-INTAKE; GK RAT	Rapid strides in understanding the physiology controlling energy or nutrient intake and energy expenditure have complemented the search for the genetic basis of obesity, Several single gene defects are known that produce obesity in animals, All of these have been cloned within the past 4 years, providing a rich new base for understanding obesity, Since obesity is likely to be ''multifactorial,'' a number of laboratories have used the quantitative trait locus (QTL) technique of genome scanning to identify candidate genomic regions and, eventually, genes that may influence body weight and body fat, So far, 18 QTLs have been identified in association with crossbreeding strains of mice or rats with variable susceptibility to obesity, A number of mendelian disorders are known to exist in humans, but no specific genes have yet been identified for them, The potential for inserting new genetic material into mammals has produced numerous transgenic mice with increased or decreased quantities of body fat, These models will provide a continuing source of new insights into obesity, Several areas in the human genome have been linked to the development of obesity, Among the candidate genes with evidence of linkage to body fat are TNF-alpha, adenosine deaminase, and melanocortin-3 receptor, The new insights described above have invigorated the pharmaceutical industry to increase their efforts for new drug development aimed at the growing problem of obesity.			Bray, G (corresponding author), PENNINGTON BIOMED RES CTR, 6400 PERKINS RD, BATON ROUGE, LA 70808 USA.		Bouchard, Claude/A-7637-2009; Bouchard, Claude/AAE-2035-2019	Bouchard, Claude/0000-0002-0048-491X; 				Astrup A, 1995, OBES RES, V3, pS537, DOI 10.1002/j.1550-8528.1995.tb00224.x; Borecki I B, 1994, Obes Res, V2, P213; Bouchard C, 1996, OBES RES, V4, P81, DOI 10.1002/j.1550-8528.1996.tb00516.x; BOUCHARD C, 1997, IN PRESS DIABETOLOGI; BRAY GA, 1991, BRAIN RES BULL, V27, P517, DOI 10.1016/0361-9230(91)90152-A; Bray GA, 1996, LANCET, V348, P140, DOI 10.1016/S0140-6736(05)66103-X; BRAY GA, 1997, IN PRESS J CLIN ENDO; Campfield LA, 1995, OBES RES, V3, pS591, DOI 10.1002/j.1550-8528.1995.tb00231.x; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chagnon YC, 1996, TRENDS GENET, V12, P441, DOI 10.1016/0168-9525(96)30103-0; Chagnon YC, 1997, OBES RES, V5, P115, DOI 10.1002/j.1550-8528.1997.tb00651.x; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Cincotta AH, 1996, DIABETES CARE, V19, P667, DOI 10.2337/diacare.19.6.667; CLEMENT K, 1996, DIABETES, V45, P67; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; DRAGANI TA, 1995, MAMM GENOME, V6, P778, DOI 10.1007/BF00539002; DRENT ML, 1995, INT J OBESITY, V19, P221; Duggirala R, 1996, AM J HUM GENET, V59, P694; Dulloo AG, 1996, INT J OBESITY, V20, P393; Galli J, 1996, NAT GENET, V12, P31, DOI 10.1038/ng0196-31; Gauguier D, 1996, NAT GENET, V12, P38, DOI 10.1038/ng0196-38; GEARY N, 1990, NEUROSCI BIOBEHAV R, V14, P323, DOI 10.1016/S0149-7634(05)80042-9; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; GUYGRAND B, 1989, LANCET, V2, P1142; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; LANDER ES, 1989, GENETICS, V121, P185; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Leibowitz SF, 1995, OBES RES, V3, pS573, DOI 10.1002/j.1550-8528.1995.tb00230.x; Lembertas AV, 1997, J CLIN INVEST, V100, P1240, DOI 10.1172/JCI119637; LEVAKFRANK S, 1995, J CLIN INVEST, V96, P976, DOI 10.1172/JCI118145; LOWELL BB, 1993, CLIN RES, V41, pA260; Maffei M, 1996, DIABETES, V45, P679, DOI 10.2337/diabetes.45.5.679; MORAN TH, 1992, AM J CLIN NUTR, V55, P286; Niki T, 1996, DIABETES, V45, P675, DOI 10.2337/diabetes.45.5.675; NORMAN RA, 1995, J CLIN INVEST, V96, P158, DOI 10.1172/JCI118016; NORMAN RA, 1997, IN PRESS AM J HUMAN; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Reed DR, 1996, DIABETES, V45, P691, DOI 10.2337/diabetes.45.5.691; REED DR, 1995, INT J OBESITY, V19, P599; RICHARD D, 1993, AM J PHYSIOL, V265, pR146, DOI 10.1152/ajpregu.1993.265.1.R146; Rosmond R, 1996, OBES RES, V4, P245, DOI 10.1002/j.1550-8528.1996.tb00542.x; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; STENZELPOORE MP, 1992, ENDOCRINOLOGY, V130, P3378, DOI 10.1210/en.130.6.3378; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; WARDEN CH, 1995, J CLIN INVEST, V95, P1545, DOI 10.1172/JCI117827; WARDEN CH, 1992, MOL GENETICS CORONAR, P419; WEST DB, 1994, J CLIN INVEST, V94, P1410, DOI 10.1172/JCI117477; Yen TT, 1995, OBES RES, V3, pS531, DOI 10.1002/j.1550-8528.1995.tb00223.x; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	56	32	33	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1997	11	12					937	945		10.1096/fasebj.11.12.9337146	http://dx.doi.org/10.1096/fasebj.11.12.9337146			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YA724	9337146				2022-12-28	WOS:A1997YA72400003
J	Huang, MT; Lee, CF; Dobson, GP				Huang, MT; Lee, CF; Dobson, GP			Epinephrine enhances glycogen turnover and depresses glucose uptake in vivo in rat heart	FASEB JOURNAL			English	Article						skeletal muscle; liver; 2-deoxyglucose; [3-H-3]glucose	CONSCIOUS RATS; INSULIN; METABOLISM; INVIVO; LIVER; MYOCARDIUM; SYNTHASE; MUSCLE	In vivo effects of epinephrine on glucose uptake and glycogen turnover in rat heart were studied and compared to liver and skeletal muscle, Fasted ketamine-anesthetized rats were intravenously infused with saline or epinephrine. Both the low and high doses of epinephrine resulted in hyperglycemia (40-50%) and hyperlactemia (threefold) at the end of infusion, Glucose uptake, determined by the phosphorylation of the intravenously injected [C-14]2-deoxyglucose, was found to decrease in the heart and skeletal muscle of epinephrine-infused rats, Glycogen in livers, skeletal muscles, and hearts of the epinephrine-infused rats decreased to varying degrees relative to the saline-infused rats, indicating enhanced glycogenolysis in all three organs, Glycogen synthesis, determined by the incorporation of the co-infused [3-H-3]glucose into glycogen, was found to decrease in liver and skeletal muscle, However, glycogen synthesis in the heart was found to increase 50% in Epi-1 and 280% in Epi-2 compared to the saline-infused rats, We conclude that glucose utilization in the in vivo heart may be preferentially channeled through glycogen turnover in the presence of epinephrine, That both synthesis and degradation of glycogen can be simultaneously activated appears to be unique to the heart and is protective against a loss of glycogen art a time of enhanced glucose utilization.	JAMES COOK UNIV N QUEENSLAND,DEPT PHYSIOL & PHARMACOL,TOWNSVILLE,QLD 4811,AUSTRALIA	James Cook University	Huang, MT (corresponding author), CHANG GUNG COLL MED & TECHNOL,DEPT BIOCHEM,259 WEN HUA 1ST RD,TAYUAN,TAIWAN.							ARNALL DA, 1986, AM J PHYSIOL, V250, pE641, DOI 10.1152/ajpendo.1986.250.6.E641; Bergmeyer H.U., 1974, METHOD ENZYMAT AN, VVol. 3., P1196; CLARKE K, 1996, CIRCULATION, V91, P2299; COLINSNAKAI RL, 1994, AM J PHYSIOL, V267, pH1862; CRAIG JW, 1964, NATURE, V202, P971, DOI 10.1038/202971a0; Cross HR, 1996, CIRC RES, V78, P482, DOI 10.1161/01.RES.78.3.482; DOBSON GP, 1990, J BIOL CHEM, V265, P16350; FURNSINN C, 1994, AM J PHYSIOL, V267, pE300, DOI 10.1152/ajpendo.1994.267.2.E300; Goodwin GW, 1996, J CLIN INVEST, V97, P1409, DOI 10.1172/JCI118561; GOODWIN GW, 1995, J BIOL CHEM, V270, P9234, DOI 10.1074/jbc.270.16.9234; GREKINIS D, 1995, INT J BIOCHEM CELL B, V27, P565, DOI 10.1016/1357-2725(95)00029-O; GUTMANN I, 1974, METHOD ENZYMAT AN, P1465; HARIHARAN R, 1995, CIRCULATION, V91, P2435, DOI 10.1161/01.CIR.91.9.2435; Henning SL, 1996, CIRCULATION, V93, P1549, DOI 10.1161/01.CIR.93.8.1549; HUANG MT, 1988, J CLIN INVEST, V81, P872, DOI 10.1172/JCI113397; HUANG MT, 1991, J APPL PHYSIOL, V71, P359, DOI 10.1152/jappl.1991.71.1.359; JAMES DE, 1986, J BIOL CHEM, V261, P6366; JAMES DE, 1985, J MOL CELL CARDIOL, V17, P981, DOI 10.1016/S0022-2828(85)80078-X; Jensen J, 1997, AM J PHYSIOL-ENDOC M, V272, pE649, DOI 10.1152/ajpendo.1997.272.4.E649; Lang G., 1974, METHODS ENZYMATIC AN, P1238; LAUGHLIN MR, 1991, DIABETES, V40, P385, DOI 10.2337/diabetes.40.3.385; LAUGHLIN MR, 1992, AM J PHYSIOL, V262, pE875, DOI 10.1152/ajpendo.1992.262.6.E875; LAUGHLIN MR, 1994, AM J PHYSIOL, V267, pH217, DOI 10.1152/ajpheart.1994.267.1.H217; MACDONALD TF, 1971, PFLUGERS ARCH, V322, P95; NEELY JR, 1970, AM J PHYSIOL, V219, P1083; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; RALL TW, 1956, BIOCHIM BIOPHYS ACTA, V20, P69, DOI 10.1016/0006-3002(56)90264-5; RAMACHANDRAN C, 1982, J BIOL CHEM, V257, P1448; RATTIGAN S, 1991, BIOCHIM BIOPHYS ACTA, V1094, P217, DOI 10.1016/0167-4889(91)90012-M; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; WEISS J, 1985, J CLIN INVEST, V75, P436, DOI 10.1172/JCI111718; WEISS JN, 1987, SCIENCE, V238, P67, DOI 10.1126/science.2443972; WILLIAMS BJ, 1966, MOL PHARMACOL, V2, P454; WILLIAMSON JR, 1966, MOL PHARMACOL, V2, P206; WISNESKI JA, 1985, J CLIN INVEST, V76, P1819, DOI 10.1172/JCI112174	35	15	15	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1997	11	12					973	980		10.1096/fasebj.11.12.9337150	http://dx.doi.org/10.1096/fasebj.11.12.9337150			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YA724	9337150				2022-12-28	WOS:A1997YA72400007
J	Wellmann, A; Doseeva, V; Butscher, W; Raffeld, M; Fukushima, P; StetlerStevenson, M; Gardner, K				Wellmann, A; Doseeva, V; Butscher, W; Raffeld, M; Fukushima, P; StetlerStevenson, M; Gardner, K			The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat 1a fibroblasts	FASEB JOURNAL			English	Article						plasmid vector; gene expression; cytosolic membrane; antibody; PTK	NON-HODGKINS-LYMPHOMA; DNA-BINDING ACTIVITY; TRANSFORMING ACTIVITY; KI-1 LYMPHOMA; KAPPA-B; T-CELLS; PROTEIN; PHOSPHORYLATION; TRANSLOCATION; ONCOPROTEIN	More than 60% of anaplastic large-cell lymphomas (Ki-1 lymphoma) are associated with a t(2;5)(p23;q35) translocation that produces an 80 kDa hyperphosphorylated chimeric protein (p80) derived from the fusion of the anaplastic lymphoma kinase (ALK) with nucleophosmin (NPM). The NPM-ALK chimeric gene is an activated tyrosine kinase that has been shown to be a potent oncogene, We have developed a cellular model for the study of p80 action in rat 1a fibroblasts, Expression of cDNA's encoding NPM-ALK (p80) in rat 1a fibroblasts induces anchorage-independent growth in soft agar and promotes foci formation in culture, Cells expressing exogenous p80 showed significantly increased proliferation characterized by accelerated cell cycle entry into S-phase. Consistent with increased G(0)/G(1) to S-phase transition, there is also marked up-regulation of cyclin A and cyclin D1 expression, In addition, p80 transformed cells showed elevated expression of several immediate early genes involved in cellular proliferation, including fos, jun, and c-myc, DNA binding analysis of nuclear extracts prepared from p80 transformed cells reveal marked up-regulation of AP-1 DNA binding activity, Functional AP-1-specific transfection assays also show up-regulation of AP-1-dependent transcriptional activation, These finding demonstrate that p80 transformed rat 1a fibroblast can be a highly useful model system for the molecular and biochemical characterization of the mechanisms of action of this interesting new oncogene.	NIH, PATHOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA			Stetler-Stevenson, Maryalice/AAV-7393-2020					BARTKOVA J, 1995, ONCOGENE, V10, P775; BENNETT V, 1981, P NATL ACAD SCI-BIOL, V78, P7550, DOI 10.1073/pnas.78.12.7550; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; DEKAN R, 1993, NETH J MED, V43, P277; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FARINA AR, 1993, J BIOL CHEM, V268, P26466; FISCHER P, 1988, BLOOD, V72, P234; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; GARDNER K, 1994, J BIOL CHEM, V269, P32963; HERBER, 1994, ONCOGENE, V9, P2105; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; Hunter T, 1996, BIOCHEM SOC T, V24, P307, DOI 10.1042/bst0240307; HUNTER T, 1992, COLD SPRING HARB SYM, V57, P25, DOI 10.1101/SQB.1992.057.01.005; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Mathew P, 1997, BLOOD, V89, P1678, DOI 10.1182/blood.V89.5.1678.1678_1678_1685; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Powers C, 1996, J BIOL CHEM, V271, P30089, DOI 10.1074/jbc.271.47.30089; QUINN JP, 1991, FEBS LETT, V286, P225, DOI 10.1016/0014-5793(91)80979-D; SCHMIDT A, 1990, J VIROL, V64, P4037, DOI 10.1128/JVI.64.8.4037-4041.1990; Schulze A, 1996, MOL CELL BIOL, V16, P4632; SEYNAEVE CM, 1993, CANCER RES, V53, P2081; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIOTA M, 1994, BLOOD, V84, P3648, DOI 10.1182/blood.V84.11.3648.bloodjournal84113648; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	28	55	57	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1997	11	12					965	972		10.1096/fasebj.11.12.9337149	http://dx.doi.org/10.1096/fasebj.11.12.9337149			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YA724	9337149				2022-12-28	WOS:A1997YA72400006
J	Hofmann, J				Hofmann, J			The potential for isoenzyme-selective modulation of protein kinase C	FASEB JOURNAL			English	Review						substrate peptides; inhibitory peptides; isoenzyme-selective inhibitors	REVERSES MULTIDRUG-RESISTANCE; PROMOTING PHORBOL ESTERS; MULTIPLE-DRUG RESISTANCE; MYELIN BASIC-PROTEIN; NIH 3T3 FIBROBLASTS; T-CELL ACTIVATION; SUBSTRATE-SPECIFICITY; RAT-BRAIN; PHOSPHORYLATION SITES; SIGNAL-TRANSDUCTION	Protein kinase C (PKC) is a phospholipid-dependent serine/threonine kinase family consisting of at least 11 closely related isoenzymes. The different PKC isoenzymes play important roles in signal transduction pathways. The exact significance of each isoenzyme is not known at present; therefore, the elucidation of the roles of the various PKC isoenzymes is important. To explain the function of distinct PKC isoenzymes, the availability of isoenzyme-specific inhibibitors or activators would be an advantage. PKC inhibitors have been known for some time, but these compounds are not isoenzyme-specific and also inhibit other kinases. Recently, an inhibitor selective for PKC alpha and another one selective for PKC beta I and beta II were described. Both compounds compete with the ATP binding sites that exhibit high homologies among the different PKC isoenzymes. Among others, the phosporyl transfer region, the pseudosubstrate domain, the phorbolester binding sequences, and the phosphorylation sites may also be targets for modulation of isoenzyme-specific PKC activity. The question is whether the differences in these domains and the substrate specificity of the PKC isoenzymes will allow isoenzyme-specific inhibition. In this review the human sequences of these sites, isoenzyme-specific substrates, inhibitory compounds, and inhibitory peptides are summarized.			Hofmann, J (corresponding author), UNIV INNSBRUCK, INST MED CHEM & BIOCHEM, FRITZ PREGL STR 3, A-6020 INNSBRUCK, AUSTRIA.							ADAMS LM, 1993, P AM ASSOC CANC RES, V34, P2448; ADAMS LM, 1993, P AM ASSOC CANC RES, V34, P2447; AHMAD S, 1994, BIOCHEMISTRY-US, V33, P10313, DOI 10.1021/bi00200a011; AHMED S, 1993, J BIOL CHEM, V268, P10709; AIZU E, 1988, CARCINOGENESIS, V9, P309, DOI 10.1093/carcin/9.2.309; AKINAGA S, 1991, CANCER RES, V51, P4888; AMESS B, 1992, FEBS LETT, V297, P285; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; ARAUJO H, 1993, J BIOL CHEM, V268, P5911; ARCOLEO JP, 1985, CARCINOGENESIS, V6, P213, DOI 10.1093/carcin/6.2.213; ARIS JP, 1993, BIOCHIM BIOPHYS ACTA, V1174, P171, DOI 10.1016/0167-4781(93)90111-P; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BAIER G, 1993, J BIOL CHEM, V268, P4997; BAIER G, 1994, EUR J BIOCHEM, V225, P195, DOI 10.1111/j.1432-1033.1994.00195.x; BALBOA MA, 1994, J BIOL CHEM, V269, P10511; BARJA P, 1994, CELL IMMUNOL, V153, P28, DOI 10.1006/cimm.1994.1003; BASTA P, 1992, BIOCHIM BIOPHYS ACTA, V1132, P154, DOI 10.1016/0167-4781(92)90006-L; BASU A, 1995, INT J CANCER, V63, P597, DOI 10.1002/ijc.2910630422; BASU A, 1993, PHARMACOL THERAPEUT, V59, P257, DOI 10.1016/0163-7258(93)90070-T; BERG JM, 1990, J BIOL CHEM, V265, P6513; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Birch KA, 1996, DIABETES, V45, P642, DOI 10.2337/diabetes.45.5.642; BIRCHALL AM, 1994, J PHARMACOL EXP THER, V268, P922; BLAKE AD, 1987, BIOCHEM BIOPH RES CO, V147, P168, DOI 10.1016/S0006-291X(87)80102-X; Blobe GC, 1996, CANCER SURV, V27, P213; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; BLUMBERG PM, 1991, MOL CARCINOGEN, V4, P339, DOI 10.1002/mc.2940040502; BORNER C, 1989, J BIOL CHEM, V264, P13902; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; BOSCOBOINIK D, 1991, J BIOL CHEM, V266, P6188; BRACHWITZ H, 1995, PHARMACOL THERAPEUT, V66, P39, DOI 10.1016/0163-7258(95)00001-W; BRADSHAW D, 1993, AGENTS ACTIONS, V38, P135, DOI 10.1007/BF02027225; Budworth J, 1996, BRIT J CANCER, V73, P1063, DOI 10.1038/bjc.1996.205; CACACE AM, 1993, ONCOGENE, V8, P2095; CARAVATTI G, 1994, BIOORG MED CHEM LETT, V4, P399, DOI 10.1016/0960-894X(94)80004-9; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; CHAMBERS TC, 1995, BIOCHEMISTRY-US, V34, P14156, DOI 10.1021/bi00043a021; CHAN JA, 1994, J NAT PRODUCTS, V57, P1543, DOI 10.1021/np50113a011; CHAN KFJ, 1986, BIOCHEM BIOPH RES CO, V134, P1358, DOI 10.1016/0006-291X(86)90399-2; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; CHEN SJ, 1993, BIOCHEMISTRY-US, V32, P1032, DOI 10.1021/bi00055a006; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; CLARK KJ, 1995, J BIOL CHEM, V270, P7097, DOI 10.1074/jbc.270.13.7097; CLERK A, 1994, J BIOL CHEM, V269, P32848; COURAGE C, 1995, BRIT J CANCER, V71, P697, DOI 10.1038/bjc.1995.137; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; Craig KL, 1996, BIOCHEM J, V314, P937, DOI 10.1042/bj3140937; CZENDLIK C, 1996, ANN ONCOL         S1, V7, P264; Dean N, 1996, CANCER RES, V56, P3499; DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DEKKER LV, 1992, FEBS LETT, V312, P195, DOI 10.1016/0014-5793(92)80934-9; DEKKER LV, 1993, FEBS LETT, V329, P129, DOI 10.1016/0014-5793(93)80208-C; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DIETER P, 1991, BIOCHEM BIOPH RES CO, V181, P396, DOI 10.1016/S0006-291X(05)81432-9; DONG LQ, 1995, J BIOL CHEM, V270, P25534, DOI 10.1074/jbc.270.43.25534; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; EICHHOLTZ T, 1990, FEBS LETT, V261, P147, DOI 10.1016/0014-5793(90)80657-5; ENDO K, 1991, CANCER RES, V51, P1613; ETINDI RN, 1987, BIOCHIM BIOPHYS ACTA, V927, P345, DOI 10.1016/0167-4889(87)90098-X; FEINSTEIN DL, 1992, J NEUROSCI RES, V32, P1, DOI 10.1002/jnr.490320102; FERRARI S, 1987, EUR J BIOCHEM, V163, P481, DOI 10.1111/j.1432-1033.1987.tb10894.x; FERRARI S, 1985, FEBS LETT, V184, P72, DOI 10.1016/0014-5793(85)80656-6; FERRIOLA PC, 1989, BIOCHEM PHARMACOL, V38, P1617, DOI 10.1016/0006-2952(89)90309-2; FINKENZELLER G, 1990, NUCLEIC ACIDS RES, V18, P2183, DOI 10.1093/nar/18.8.2183; FINKENZELLER G, 1992, CELL SIGNAL, V4, P163, DOI 10.1016/0898-6568(92)90080-R; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; FROSCIO M, 1989, BIOCHEM PHARMACOL, V38, P2087, DOI 10.1016/0006-2952(89)90061-0; FUJIKI H, 1984, BIOCHEM BIOPH RES CO, V120, P339, DOI 10.1016/0006-291X(84)91259-2; FYFE D, 1996, ANN ONCOL         S1, V7, P263; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GEKELER V, 1995, BIOCHEM BIOPH RES CO, V206, P119, DOI 10.1006/bbrc.1995.1017; Gekeler V, 1996, BRIT J CANCER, V74, P897, DOI 10.1038/bjc.1996.454; GESCHER A, 1992, BRIT J CANCER, V66, P10, DOI 10.1038/bjc.1992.209; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GODSON C, 1993, J BIOL CHEM, V268, P11946; GOLDSTEIN DR, 1995, CARCINOGENESIS, V16, P1121, DOI 10.1093/carcin/16.5.1121; GONZALEZ A, 1993, ANAL BIOCHEM, V215, P184, DOI 10.1006/abio.1993.1574; Goodfellow HR, 1996, J BIOL CHEM, V271, P13668, DOI 10.1074/jbc.271.23.13668; GOSS VL, 1994, J BIOL CHEM, V269, P19074; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; GREIF H, 1992, MOL CELL BIOL, V12, P1304, DOI 10.1128/MCB.12.3.1304; GSCHWENDT M, 1991, TRENDS BIOCHEM SCI, V16, P167, DOI 10.1016/0968-0004(91)90064-3; GSCHWENDT M, 1983, BIOCHEM BIOPH RES CO, V117, P444, DOI 10.1016/0006-291X(83)91220-2; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gysin S, 1996, EUR J BIOCHEM, V240, P747, DOI 10.1111/j.1432-1033.1996.0747h.x; HA KS, 1993, J BIOL CHEM, V268, P10534; HANNUN YA, 1988, J BIOL CHEM, V263, P5124; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, CLIN CHIM ACTA, V185, P333, DOI 10.1016/0009-8981(89)90224-6; HANNUN YA, 1989, J BIOL CHEM, V264, P9960; HANNUN YA, 1993, ADV LIPID RES, V25, P43; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HERGET T, 1995, EUR J BIOCHEM, V233, P448, DOI 10.1111/j.1432-1033.1995.448_2.x; HERRMANN DBJ, 1990, CANCER TREAT REV, V17, P247, DOI 10.1016/0305-7372(90)90055-K; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HILGARD P, 1993, CANCER CHEMOTH PHARM, V32, P90, DOI 10.1007/BF00685608; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HOFMANN J, 1990, INT J CANCER, V45, P536, DOI 10.1002/ijc.2910450327; HOFMANN J, 1991, INT J CANCER, V47, P870, DOI 10.1002/ijc.2910470614; HOFMANN J, 1994, BIOCHEM BIOPH RES CO, V199, P937, DOI 10.1006/bbrc.1994.1319; HOFMANN J, 1992, J CANCER RES CLIN, V118, P361, DOI 10.1007/BF01294440; HOFMANN J, 1995, BIOCHEM PHARMACOL, V49, P603, DOI 10.1016/0006-2952(94)00479-6; HOFMANN J, 1989, LIPIDS, V24, P312, DOI 10.1007/BF02535169; HOFMANN J, 1988, INT J CANCER, V42, P382, DOI 10.1002/ijc.2910420313; HOUSE C, 1990, CELL SIGNAL, V2, P187, DOI 10.1016/0898-6568(90)90022-3; HOUSE C, 1987, J BIOL CHEM, V262, P772; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; Hu H, 1996, DRUG DISCOV TODAY, V1, P438, DOI 10.1016/S1359-6446(96)80010-9; HUANG KP, 1993, ARCH BIOCHEM BIOPHYS, V305, P570, DOI 10.1006/abbi.1993.1463; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; HVALBY O, 1994, P NATL ACAD SCI USA, V91, P4761, DOI 10.1073/pnas.91.11.4761; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; IKUTA T, 1994, CELL GROWTH DIFFER, V5, P943; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; INOUE M, 1977, J BIOL CHEM, V252, P7610; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; JACOBSON PB, 1995, J PHARMACOL EXP THER, V275, P995; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; JOHNSSON N, 1986, EMBO J, V5, P3455, DOI 10.1002/j.1460-2075.1986.tb04669.x; Jost M, 1996, BBA-MOL CELL RES, V1313, P283, DOI 10.1016/0167-4889(96)00101-2; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KERANEN LM, 1959, CURR BIOL, V5, P1393; Khuri FR, 1996, CELL GROWTH DIFFER, V7, P595; KIELBASSA K, 1995, J BIOL CHEM, V270, P6156, DOI 10.1074/jbc.270.11.6156; KIKKAWA U, 1988, COLD SPRING HARB SYM, V53, P97, DOI 10.1101/SQB.1988.053.01.015; Kiley S C, 1994, Trends Cell Biol, V4, P223, DOI 10.1016/0962-8924(94)90146-5; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOCHS G, 1993, EUR J BIOCHEM, V216, P597, DOI 10.1111/j.1432-1033.1993.tb18179.x; KONDO H, 1987, BIOCHEM BIOPH RES CO, V142, P155, DOI 10.1016/0006-291X(87)90464-5; KUBO K, 1987, FEBS LETT, V223, P138, DOI 10.1016/0014-5793(87)80524-0; KWON YG, 1994, J BIOL CHEM, V269, P4839; LAPORTA CAM, 1995, CARCINOGENESIS, V16, P1233; Lavin MF, 1996, EXPERIENTIA, V52, P979, DOI 10.1007/BF01920107; LEHEL C, 1995, J BIOL CHEM, V270, P19651, DOI 10.1074/jbc.270.33.19651; LESTER DS, 1991, EUR J PHARM-MOLEC PH, V206, P301, DOI 10.1016/0922-4106(91)90114-W; LEVENTHAL PS, 1993, J BIOL CHEM, V268, P13906; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Levitzki A, 1996, CURR OPIN CELL BIOL, V8, P239, DOI 10.1016/S0955-0674(96)80071-8; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1220; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Llosas MD, 1996, BIOCHEM J, V315, P1049; Logvinenko NS, 1996, P NATL ACAD SCI USA, V93, P9132, DOI 10.1073/pnas.93.17.9132; LOOMIS CR, 1988, J BIOL CHEM, V263, P1682; LOZANO J, 1994, J BIOL CHEM, V269, P19200; LUCAS M, 1995, GEN PHARMACOL, V26, P881, DOI 10.1016/0306-3623(94)00295-X; MAHONEY CW, 1990, J BIOL CHEM, V265, P5424; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; Manni A, 1996, CELL GROWTH DIFFER, V7, P1187; MAPELLI E, 1994, INT J CANCER, V57, P281, DOI 10.1002/ijc.2910570225; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MARAIS RM, 1990, FEBS LETT, V277, P151, DOI 10.1016/0014-5793(90)80831-3; MARKOVAC J, 1988, NATURE, V334, P71, DOI 10.1038/334071a0; MARTE BM, 1994, CELL GROWTH DIFFER, V5, P239; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MIYAKE R, 1984, BIOCHEM BIOPH RES CO, V121, P649, DOI 10.1016/0006-291X(84)90231-6; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOMOI T, 1986, BIOCHEM BIOPH RES CO, V138, P865, DOI 10.1016/S0006-291X(86)80576-9; MORI T, 1980, J BIOL CHEM, V255, P8378; MORUZZI M, 1987, BIOCHEM J, V247, P175, DOI 10.1042/bj2470175; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NAKADATE T, 1987, CANCER RES, V47, P6537; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1979, ADV CYCLIC NUCLEOTID, V9, P209; NOLAND TA, 1989, J BIOL CHEM, V264, P20778; OBRIAN CA, 1987, BIOCHEM PHARMACOL, V36, P1231, DOI 10.1016/0006-2952(87)90075-X; OBRIAN CA, 1984, BIOCHEM BIOPH RES CO, V124, P296, DOI 10.1016/0006-291X(84)90951-3; OBRIAN CA, 1990, BIOCHEM PHARMACOL, V39, P49, DOI 10.1016/0006-2952(90)90647-4; OBRIAN CA, 1990, J NATL CANCER I, V82, P1734, DOI 10.1093/jnci/82.22.1734; OBRIAN CA, 1989, MOL PHARMACOL, V36, P355; OHNO S, 1990, J BIOL CHEM, V265, P6296; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; ORR JW, 1994, J BIOL CHEM, V269, P27715; ORR JW, 1992, J BIOL CHEM, V267, P15263; PARKER PJ, 1987, ADV PROT PHOSPHATASE, V4, P363; PATEL G, 1989, CELL SIGNAL, V1, P227, DOI 10.1016/0898-6568(89)90040-5; PEARS C, 1991, BIOCHEM J, V276, P257, DOI 10.1042/bj2760257; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PRENDIVILLE J, 1993, BRIT J CANCER, V68, P418, DOI 10.1038/bjc.1993.352; RAMACHANDRAN C, 1984, J BIOL CHEM, V259, P3495; ROBINSON PJ, 1992, BIOCHEM PHARMACOL, V44, P1325, DOI 10.1016/0006-2952(92)90533-O; Rokaw MD, 1996, J BIOL CHEM, V271, P32468, DOI 10.1074/jbc.271.50.32468; Romanova LY, 1996, BIOCHEMISTRY-US, V35, P9900, DOI 10.1021/bi9525886; ROTENBERG SA, 1990, CANCER RES, V50, P677; SAEZ JC, 1990, EUR J BIOCHEM, V192, P263, DOI 10.1111/j.1432-1033.1990.tb19223.x; Sauma S, 1996, CELL GROWTH DIFFER, V7, P587; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SCHWARTZ GK, 1990, JNCI-J NATL CANCER I, V82, P1753, DOI 10.1093/jnci/82.22.1753; SCHWARTZ GK, 1995, J NATL CANCER I, V87, P1394, DOI 10.1093/jnci/87.18.1394; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SEYNAEVE CM, 1994, MOL PHARMACOL, V45, P1207; SILVER PJ, 1989, CARDIOVASC DRUG THER, V3, P675, DOI 10.1007/BF01857619; SINGH SS, 1994, CELL SIGNAL, V6, P345, DOI 10.1016/0898-6568(94)90039-6; SMITH CD, 1995, J BIOL CHEM, V270, P28145; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STABEL S, 1994, SEMIN CANCER BIOL, V5, P277; SU HD, 1985, BIOCHEM PHARMACOL, V34, P3649; SU HD, 1986, BIOCHEM BIOPH RES CO, V134, P78, DOI 10.1016/0006-291X(86)90529-2; SU HD, 1986, CANCER RES, V46, P3684; SULLIVAN JP, 1991, AGENTS ACTIONS, V34, P142, DOI 10.1007/BF01993261; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; Szallasi Z, 1996, CANCER RES, V56, P2105; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TAMAOKI T, 1990, ADV SEC MESS PHOSPH, V24, P497; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TURNER RS, 1985, J BIOL CHEM, V260, P1503; UBERALL F, 1991, CANCER RES, V51, P807; UBERALL F, 1991, CANCER RES, V51, P5821; Ukena D, 1995, CANCER CHEMOTH PHARM, V36, P160; UTZ I, 1994, INT J CANCER, V57, P104, DOI 10.1002/ijc.2910570119; VACCARINO F, 1987, P NATL ACAD SCI USA, V84, P8707, DOI 10.1073/pnas.84.23.8707; WARD NE, 1993, BIOCHEMISTRY-US, V32, P11903, DOI 10.1021/bi00095a020; WARD NE, 1995, J BIOL CHEM, V270, P8056, DOI 10.1074/jbc.270.14.8056; WARD NE, 1995, CANCER LETT, V88, P37, DOI 10.1016/0304-3835(94)03610-U; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WAYS KD, 1996, J CLIN INVEST, V95, P1906; WELLS NJ, 1995, J BIOL CHEM, V270, P28357; WINKELMANN M, 1992, J CANCER RES CLIN, V118, P405, DOI 10.1007/BF01629421; WISE BC, 1983, BIOCHEM PHARMACOL, V32, P1259, DOI 10.1016/0006-2952(83)90280-0; WISE BC, 1982, J BIOL CHEM, V257, P8489; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; YAMADA K, 1987, BIOCHEM BIOPH RES CO, V144, P35, DOI 10.1016/S0006-291X(87)80471-0; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z; Yazaki T, 1996, MOL PHARMACOL, V50, P236; Yeung JM, 1996, TOXICOL APPL PHARM, V141, P178, DOI 10.1016/S0041-008X(96)80023-8; ZHANG J, 1994, J BIOL CHEM, V269, P19578; Zimmermann J, 1996, ARCH PHARM, V329, P371, DOI 10.1002/ardp.19963290707; ZIMMERMANN J, 1994, INT M GROWTH CONTR T	257	307	337	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1997	11	8					649	669		10.1096/fasebj.11.8.9240967	http://dx.doi.org/10.1096/fasebj.11.8.9240967			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XN027	9240967				2022-12-28	WOS:A1997XN02700006
J	Nolan, JP; Hammerstedt, RH				Nolan, JP; Hammerstedt, RH			Regulation of membrane stability and the acrosome reaction in mammalian sperm	FASEB JOURNAL			English	Review						sperm maturation; capacitation; lipid asymmetry; polyunsaturated fatty acids; cholesterol	TRANSBILAYER PHOSPHOLIPID DISTRIBUTION; PROTEIN-TYROSINE PHOSPHORYLATION; RAM EPIDIDYMAL SPERMATOZOA; VESICULAR STOMATITIS-VIRUS; PLASMA-MEMBRANE; ZONA-PELLUCIDA; CELL-MEMBRANES; SURFACE MODIFICATIONS; BIOLOGICAL-MEMBRANES; ERYTHROCYTE-MEMBRANE	Membrane destabilization is an essential step in the process of membrane. fusion. In many cell types, exocytotic fusion may occur sporadically at microscopically localized sites on the surface of the cell, making it difficult to study the chemical and physical features of the membrane (or membranes) that promote fusion, In the sperm cell, exocytosis occurs synchronously at a distinct region on the sperm head. This localization of function makes the sperm cell a useful model to investigate the structural features of the bilayers that control membrane fusion, During sperm maturation, the anterior head membranes undergo a well-defined series of chemical, physical, and functional changes that are necessary to produce a fertile gamete. These changes include the addition of highly unsaturated phosphatidylcholine, a decrease in general membrane stability, and an increase in the ability to respond to physiological and pharmacological inducers of exocytosis. Concomitant addition of cholesterol and an actively maintained asymmetric transmembrane phospholipid distribution modulate these effects to stabilize the membrane of the mature sperm for storage, The environment of the female tract provides conditions that promote efflux of cholesterol from the sperm plasma membrane as well as the loss of membrane asymmetry. The cholesterol-poor, lipid-symmetric plasma membrane has a destabilized inner leaflet that facilitates membrane fusion upon binding of the sperm to the appropriate egg coat receptors, We summarize these features in a mechanistic model in which the sperm membrane contains destabilizing components to confer fusogenic potential as well as stabilizing components organized to maximize membrane integrity. This combination prevents premature fusion in the male tract, After deposition in the female tract and removal of the stabilizing components, followed by reorganization of the fusogenic components, the membrane becomes poised to fuse upon receipt of the final biological stimulus.	PENN STATE UNIV,DEPT BIOCHEM & MOL BIOL,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Nolan, JP (corresponding author), LOS ALAMOS NATL LAB,DIV LIFE SCI,LS-5,M-888,LOS ALAMOS,NM 87545, USA.				NCRR NIH HHS [RR-01315] Funding Source: Medline; NICHD NIH HHS [HD-13099] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013099] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001315] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AMANN RP, 1982, BIOL REPROD, V27, P723, DOI 10.1095/biolreprod27.3.723; AMANN RP, 1993, REPROD FERT DEVELOP, V5, P361, DOI 10.1071/RD9930361; AMANN RP, 1988, 11TH P INT C AN REPR, V5, P320; ARTS EGJM, 1994, BIOCHEM J, V304, P211, DOI 10.1042/bj3040211; AUSTIN CR, 1952, NATURE, V170, P326, DOI 10.1038/170326a0; BAENZIGER JE, 1992, BIOCHEMISTRY-US, V31, P3377, DOI 10.1021/bi00128a011; BAILEY AL, 1994, BIOCHEMISTRY-US, V33, P12573, DOI 10.1021/bi00208a007; Baker CS, 1993, BIOL REPROD S1, V48, P86; BENTZ J, 1992, BIOPHYS J, V63, P448, DOI 10.1016/S0006-3495(92)81622-3; BISHOP WR, 1985, CELL, V42, P51, DOI 10.1016/S0092-8674(85)80100-8; BLACKMORE PF, 1990, J BIOL CHEM, V265, P1376; BLACKMORE PF, 1991, J BIOL CHEM, V266, P18655; BRUMEN M, 1993, EUR BIOPHYS J BIOPHY, V22, P213, DOI 10.1007/BF00185783; CARDULLO RA, 1990, CILLIARY FLAGELLAR M; CHANG MC, 1951, NATURE, V168, P697, DOI 10.1038/168697b0; CHERNOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; CHERNOMORDIK LV, 1993, FEBS LETT, V318, P71, DOI 10.1016/0014-5793(93)81330-3; CLARK EN, 1993, J BIOL CHEM, V268, P5309; COHENDAYAG A, 1994, AM J PHYSIOL-CELL PH, V36, pC1167; Comfurius P, 1996, BIOCHEMISTRY-US, V35, P7631, DOI 10.1021/bi9606859; COX KJ, 1992, BIOCHEMISTRY-US, V31, P1112, DOI 10.1021/bi00119a020; CULLIS PR, 1987, MOL MECH MEMBRANE FU, P37; DEMEL RA, 1972, BIOCHIM BIOPHYS ACTA, V266, P26, DOI 10.1016/0005-2736(72)90116-2; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; DOSTALOVA Z, 1994, BBA-GEN SUBJECTS, V1200, P48, DOI 10.1016/0304-4165(94)90026-4; DRATZ EA, 1986, HLTH EFFECTS POLYUNS, P317; EDDY EM, 1985, AM J ANAT, V174, P225, DOI 10.1002/aja.1001740305; EDIDIN M, 1993, J CELL SCI S, V17, P165; EHRENWALD E, 1990, MOL REPROD DEV, V25, P195, DOI 10.1002/mrd.1080250213; EHRINGER W, 1990, CHEM PHYS LIPIDS, V54, P79, DOI 10.1016/0009-3084(90)90063-W; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FLEMING AD, 1981, GAMETE RES, V4, P253, DOI 10.1002/mrd.1120040402; FLORMAN HM, 1994, DEV BIOL, V165, P152, DOI 10.1006/dbio.1994.1242; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; FLORMAN HM, 1989, DEV BIOL, V135, P133, DOI 10.1016/0012-1606(89)90164-4; FLORMAN HM, 1992, DEV BIOL, V152, P304, DOI 10.1016/0012-1606(92)90137-6; FOURNIERDELPECH S, 1986, GAMETE RES, V14, P225, DOI 10.1002/mrd.1120140306; FOURNIERDELPECH S, 1982, GAMETE RES, V5, P403, DOI 10.1002/mrd.1120050410; FOURNIERDELPECH S, 1977, ANN BIOL ANIM BIOCH, V17, P987, DOI 10.1051/rnd:19770804; FOURNIERDELPECH S, 1979, ANN BIOL ANIM BIOCH, V19, P597, DOI 10.1051/rnd:19790505; GADELLA BM, 1994, J CELL SCI, V107, P2151; GADELLA BM, 1995, J CELL SCI, V108, P935; GELDWERTH D, 1993, J CLIN INVEST, V92, P308, DOI 10.1172/JCI116568; GRAHAM JK, 1991, BIOL REPROD, V44, P1092, DOI 10.1095/biolreprod44.6.1092; GUNTHERAUSBORN S, 1995, J BIOL CHEM, V270, P29279; Hammerstedt R H, 1987, J Reprod Fertil Suppl, V34, P133; HAMMERSTEDT RH, 1997, TISSUE BANKING REPRO; HELM CA, 1992, BIOCHEMISTRY-US, V31, P1794, DOI 10.1021/bi00121a030; HERRMANN A, 1990, BIOCHEMISTRY-US, V29, P4054, DOI 10.1021/bi00469a005; HO C, 1995, BIOCHEMISTRY-US, V34, P6188, DOI 10.1021/bi00018a023; Houslay M. D., 1982, DYNAMICS BIOL MEMBRA; KUMAR A, 1987, J BIOSCIENCE, V11, P543, DOI 10.1007/BF02704703; LANGLAIS J, 1985, GAMETE RES, V12, P183, DOI 10.1002/mrd.1120120209; LAX Y, 1994, FEBS LETT, V339, P234, DOI 10.1016/0014-5793(94)80422-2; LECKBAND DE, 1993, BIOCHEMISTRY-US, V32, P1127, DOI 10.1021/bi00055a019; LEE MA, 1992, MOL REPROD DEV, V31, P78, DOI 10.1002/mrd.1080310114; LEWIS RV, 1985, P NATL ACAD SCI USA, V82, P6490, DOI 10.1073/pnas.82.19.6490; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LLANOS MN, 1993, J EXP ZOOL, V267, P209, DOI 10.1002/jez.1402670214; LLANOS MN, 1982, J EXP ZOOL, V221, P107, DOI 10.1002/jez.1402210114; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MANJUNATH P, 1993, BIOL REPROD, V49, P27; MIDDLEKOOP E, 1985, BIOCHIM BIOPHYS ACTA, V855, P421; MITCHELL DC, 1992, BIOCHEMISTRY-US, V31, P332; MULLER K, 1994, BIOCHEMISTRY-US, V33, P9968; NIKOLOPOULOU M, 1985, BIOCHIM BIOPHYS ACTA, V815, P486, DOI 10.1016/0005-2736(85)90377-3; NOLAN JP, 1995, BIOCHEMISTRY-US, V34, P3907, DOI 10.1021/bi00012a006; NOLAN JP, 1992, ARCH BIOCHEM BIOPHYS, V292, P311, DOI 10.1016/0003-9861(92)90084-A; PARKS JE, 1985, BIOL REPROD, V32, P653, DOI 10.1095/biolreprod32.3.653; PARKS JE, 1987, BIOL REPROD, V37, P1249, DOI 10.1095/biolreprod37.5.1249; RAND RP, 1989, BIOCHIM BIOPHYS ACTA, V988, P351, DOI 10.1016/0304-4157(89)90010-5; SANKARAM MB, 1991, P NATL ACAD SCI USA, V88, P8686, DOI 10.1073/pnas.88.19.8686; SCHLEGEL RA, 1990, J BIOSCIENCE, V15, P187, DOI 10.1007/BF02703883; SCHWEISGUTH DC, 1992, J BIOCHEM BIOPH METH, V24, P81, DOI 10.1016/0165-022X(92)90049-G; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; SIEGEL DP, 1993, BIOPHYS J, V65, P2124, DOI 10.1016/S0006-3495(93)81256-6; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; SLATER SJ, 1993, BIOCHEMISTRY-US, V32, P3714, DOI 10.1021/bi00065a025; STILLWELL W, 1993, BIOCHIM BIOPHYS ACTA, V1146, P136, DOI 10.1016/0005-2736(93)90348-4; STRAUME M, 1987, BIOCHEMISTRY-US, V26, P5113, DOI 10.1021/bi00390a033; TENCHOV BG, 1985, BIOCHIM BIOPHYS ACTA, V815, P380, DOI 10.1016/0005-2736(85)90364-5; THOMAS P, 1989, BIOCHEM J, V264, P539, DOI 10.1042/bj2640539; THOMAS P, 1988, GAMETE RES, V20, P3957; TIGHE T, 1993, P 41 AM SOC MASS SPE; TULLIUS EK, 1989, BIOSCIENCE REP, V9, P623, DOI 10.1007/BF01119806; VISCONTI PE, 1995, DEVELOPMENT, V121, P1139; VISCONTI PE, 1995, DEVELOPMENT, V121, P1129; VOGEL SS, 1993, J BIOL CHEM, V268, P25764; VOGLMAYR JK, 1982, BIOL REPROD, V26, P483, DOI 10.1093/biolreprod/26.3.483; VOGLMAYR JK, 1980, BIOL REPROD, V22, P665; WARD CR, 1992, J BIOL CHEM, V267, P14061; WARD CR, 1994, J BIOL CHEM, V26, P13254; WASSARMAN PM, 1990, DEVELOPMENT, V108, P1; WILLIAMS RM, 1991, BIOL REPROD, V44, P1080, DOI 10.1095/biolreprod44.6.1080; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027; WILLIAMSON P, 1985, J CELL PHYSL, V128, P209; WOLF DE, 1984, J CELL BIOL, V98, P1678, DOI 10.1083/jcb.98.5.1678; WOLF DE, 1990, P NATL ACAD SCI USA, V87, P6893, DOI 10.1073/pnas.87.17.6893; WOLF DE, 1986, J CELL BIOL, V102, P1826, DOI 10.1083/jcb.102.5.1826; WOLF DE, 1987, SPECTROCOPIC MEMBRAN, P193; YAMADA S, 1986, BIOCHEMISTRY-US, V25, P3703, DOI 10.1021/bi00360a034	102	75	75	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1997	11	8					670	682		10.1096/fasebj.11.8.9240968	http://dx.doi.org/10.1096/fasebj.11.8.9240968			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XN027	9240968				2022-12-28	WOS:A1997XN02700007
J	Kirischuk, S; Kettenmann, H; Verkhratsky, A				Kirischuk, S; Kettenmann, H; Verkhratsky, A			Na+/Ca2+ exchanger modulates kainate-triggered Ca2+ signaling in Bergmann glial cells in situ	FASEB JOURNAL			English	Article						cerebellum; [Na+](i); [Ca2+](i); glutamate receptors	SODIUM-CALCIUM EXCHANGE; GLUTAMATE; ASTROCYTES; RECEPTORS; ENTRY	The role of sodium-calcium exchanger in calcium homeostasis in Bergmann glial cells in situ was investigated by monitoring cytoplasmic calcium ([Ca2+](i)) and sodium ([Na+](i)) concentrations. The [Ca2+](i) and [Na+](i) transients were measured either separately by using fluorescent indicators fura-2 and SBFI, respectively, or simultaneously using the indicators fluo-3 and SBFI. Since the removal of extracellular Na+ induced a relatively small (similar to 50 nM) elevation of [Ca2+](i), the Na+/Ca2+ exchanger seems to play a minor role in regulation of resting [Ca2+](i). In contrast, kainate-triggered [Ca2+](i) increase was significantly suppressed by lowering of the extracellular Na+ concentration ([Na+](o)). In addition, manipulations with [N-a+](o) dramatically affected the recovery of the kainate-induced [Ca2+](i) transients. Simultaneous recordings of [Ca2+](i) and [Na+](i) revealed that kainate-evoked [Ca2+](i) transients were accompanied with an increase in [Na+](i). Moreover, kainate induced significantly larger [Ca2+](i) and smaller [Na+](i) transients under current-clamp conditions as compared to those recorded when the membrane voltage was clamped at -70 mV. The above results demonstrate that the Na+-Ca2+ exchanger is operative in Bergmann glial cells in situ and is able to modulate dynamically the amplitude and kinetics of [Ca2+](i) signals associated with an activation of ionotropic glutamate receptors.			Kirischuk, S (corresponding author), MAX DELBRUCK CTR MOL MED, ROBERT ROSSLE STR 10, D-13122 BERLIN, GERMANY.		Verkhratsky, Alexei/J-4527-2013; Kettenmann, Helmut/AAJ-5142-2021	Verkhratsky, Alexei/0000-0003-2592-9898; Kettenmann, Helmut/0000-0001-8208-0291				BLAUSTEIN MP, 1991, ANN NY ACAD SCI, V639, P254, DOI 10.1111/j.1749-6632.1991.tb17315.x; CARAFOLI E, 1988, ANN NY ACAD SCI, V551, P147, DOI 10.1111/j.1749-6632.1988.tb22333.x; CHOI DW, 1994, ANN NY ACAD SCI, V747, P162; DIPOLO R, 1983, ANNU REV PHYSIOL, V45, P313, DOI 10.1146/annurev.ph.45.030183.001525; Finkbeiner Steven M., 1995, P273; GOLDMAN WF, 1994, J NEUROSCI, V14, P5834; Golovina VA, 1996, GLIA, V16, P296; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOLGADO A, 1995, GLIA, V14, P77, DOI 10.1002/glia.440140202; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; JONAS P, 1995, NEURON, V15, P987, DOI 10.1016/0896-6273(95)90087-X; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; Kirischuk S, 1996, PFLUG ARCH EUR J PHY, V431, P977, DOI 10.1007/BF02332186; Kirischuk S, 1996, EUR J NEUROSCI, V8, P1198, DOI 10.1111/j.1460-9568.1996.tb01288.x; Kirischuk S, 1995, J NEUROSCI, V15, P7861; MULLER T, 1992, SCIENCE, V256, P1563, DOI 10.1126/science.1317969; Otis TS, 1996, J NEUROSCI, V16, P1634, DOI 10.1523/jneurosci.16-05-01634.1996; Peters A., 1991, FINE STRUCTURE NERVO; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; TAKUMA K, 1994, GLIA, V12, P336, DOI 10.1002/glia.440120410; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; Verkhratsky A, 1996, TRENDS NEUROSCI, V19, P346, DOI 10.1016/0166-2236(96)10048-5	23	106	106	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1997	11	7					566	572		10.1096/fasebj.11.7.9212080	http://dx.doi.org/10.1096/fasebj.11.7.9212080			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XH342	9212080				2022-12-28	WOS:A1997XH34200008
J	Levy, GN				Levy, GN			Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer	FASEB JOURNAL			English	Review						prostaglandin synthase; cyclooxygenase; cancer chemoprevention; apoptosis	FAMILIAL ADENOMATOUS POLYPOSIS; HUMAN COLORECTAL ADENOMAS; ANTIINFLAMMATORY DRUGS; ASPIRIN USE; SELECTIVE-INHIBITION; DIFFERENTIAL INHIBITION; ENDOPEROXIDE SYNTHASE-2; BLADDER CARCINOGENESIS; INDOMETHACIN TREATMENT; EPITHELIAL-CELLS	Members of the structurally diverse class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs) have the ability to prevent or reduce the occurrence of colorectal, certain other gastrointestinal, and perhaps other cancers, The anticarcinogenic property of NSAIDs has been shown in epidemiological studies with humans and in experimental carcinogenesis studies with animals, In addition, clinical studies of the human disease familial adenomatous polyposis have demonstrated the efficacy of NSAIDs in mediating regression of colorectal adenomas, The mechanism of the anticarcinogenic effect of these drugs is not known, but most hypotheses have involved the common property of the NSAIDs to inhibit prostaglandin synthase (PHS) enzymes and thereby cause a subsequent reduction in levels of prostaglandins (PG) in tissue, Recent reports have questioned the role of PHS inhibition in the anticarcinogenic activity of NSAIDs by showing that some NSAID-related compounds that are not PHS inhibitors can induce the same anticarcinogenic changes in cell cycle and apoptotic response as the PHS inhibitors, In this review we will examine the evidence that NSAIDs are anticarcinogenic, the evidence supporting PBS as the target of NSAIDs, and the evidence for and against inhibition of PG synthesis as the mechanism of cancer prevention by NSAIDs.-Levy, G. N. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer.			Levy, GN (corresponding author), UNIV MICHIGAN, DEPT PHARMACOL, 1301 MSRB 3, ANN ARBOR, MI 48109 USA.				NATIONAL CANCER INSTITUTE [R01CA039018] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMSON SB, 1989, ARTHRITIS RHEUM, V32, P1, DOI 10.1002/anr.1780320102; ALBERTS DS, 1995, J CELL BIOCHEM, P18; ARAKAWA T, 1992, J BIOL CHEM, V267, P12188; BEDI A, 1995, CANCER RES, V55, P1811; BENNETT A, 1977, BRIT J SURG, V35, P882; Boolbol SK, 1996, CANCER RES, V56, P2556; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; Carabaza A, 1996, J CLIN PHARMACOL, V36, P505, DOI 10.1002/j.1552-4604.1996.tb05040.x; CARTER CA, 1989, CARCINOGENESIS, V10, P1369, DOI 10.1093/carcin/10.8.1369; CHAN CC, 1995, J PHARMACOL EXP THER, V274, P1531; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; CRAVEN PA, 1992, CARCINOGENESIS, V13, P541, DOI 10.1093/carcin/13.4.541; DEMELLO MCF, 1980, BIOCHEM PHARMACOL, V29, P311, DOI 10.1016/0006-2952(80)90506-7; DEWITT D, 1995, CELL, V83, P345, DOI 10.1016/0092-8674(95)90109-4; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; DUGGAN DE, 1977, J PHARMACOL EXP THER, V201, P8; EARNEST DL, 1992, J CELL BIOCHEM, P156; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; ELING TE, 1990, ANNU REV PHARMACOL, V30, P1, DOI 10.1146/annurev.pa.30.040190.000245; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FLAMMANG TJ, 1989, CANCER RES, V49, P1977; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Goldberg Y, 1996, ONCOGENE, V12, P893; GOPPELTSTRUEBE M, 1995, PROSTAG LEUKOTR ESS, V52, P213, DOI 10.1016/0952-3278(95)90039-X; GRIDLEY G, 1993, JNCI-J NATL CANCER I, V85, P307, DOI 10.1093/jnci/85.4.307; GustafsonSvard C, 1996, GUT, V38, P79, DOI 10.1136/gut.38.1.79; HAGUE A, 1994, ONCOGENE, V9, P3367; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; HIRST JJ, 1995, J CLIN ENDOCR METAB, V80, P517, DOI 10.1210/jc.80.2.517; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; HONN KV, 1983, BIOCHEM PHARMACOL, V32, P1, DOI 10.1016/0006-2952(83)90644-5; HUBBARD WC, 1988, CANCER RES, V48, P4770; Jacoby RF, 1996, CANCER RES, V56, P710; KARGMAN SL, 1995, CANCER RES, V55, P2556; KLAN R, 1993, J CANCER RES CLIN, V119, P482, DOI 10.1007/BF01215929; KLEIN T, 1994, BIOCHEM PHARMACOL, V48, P1605, DOI 10.1016/0006-2952(94)90205-4; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; Kraemer SA, 1996, ARCH BIOCHEM BIOPHYS, V330, P319, DOI 10.1006/abbi.1996.0259; KRAUSS RS, 1985, CANCER RES, V45, P1680; KUBOTA Y, 1992, DIS COLON RECTUM, V35, P645, DOI 10.1007/BF02053754; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LADENHEIM J, 1995, GASTROENTEROLOGY, V108, P1083, DOI 10.1016/0016-5085(95)90206-6; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; LEE DY, 1992, PROSTAGLANDINS, V43, P143, DOI 10.1016/0090-6980(92)90083-6; LEVY GN, 1992, CARCINOGENESIS, V13, P159, DOI 10.1093/carcin/13.2.159; LIU Y, 1995, BIOCHEM BIOPH RES CO, V215, P346, DOI 10.1006/bbrc.1995.2472; LIU Y, 1996, PROSTAGLANDINS, V53, P97; MARNETT LJ, 1990, ENVIRON HEALTH PERSP, V88, P5, DOI 10.1289/ehp.90885; MARNETT LJ, 1992, CANCER RES, V52, P5575; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; McCracken JD, 1996, J CLIN PHARMACOL, V36, P540, DOI 10.1002/j.1552-4604.1996.tb05043.x; MEADE EA, 1993, J BIOL CHEM, V268, P6610; METZGER U, 1984, DIS COLON RECTUM, V27, P366, DOI 10.1007/BF02553001; MIKKELSEN HB, 1991, HISTOCHEMISTRY, V96, P295, DOI 10.1007/BF00271349; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MOORGHEN M, 1988, J PATHOL, V156, P341, DOI 10.1002/path.1711560411; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MURASAKI G, 1984, CARCINOGENESIS, V5, P53, DOI 10.1093/carcin/5.1.53; NARISAWA T, 1990, DIS COLON RECTUM, V33, P840, DOI 10.1007/BF02051919; NARISAWA T, 1981, CANCER RES, V41, P1954; Nugent KP, 1996, DIS COLON RECTUM, V39, P659, DOI 10.1007/BF02056946; NUGENT KP, 1993, BRIT J SURG, V80, P1618, DOI 10.1002/bjs.1800801244; ONEILL GP, 1994, MOL PHARMACOL, V45, P245; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; PAGANINIHILL A, 1989, BRIT MED J, V299, P1247, DOI 10.1136/bmj.299.6710.1247; PASRICHA PJ, 1995, GASTROENTEROLOGY, V109, P994, DOI 10.1016/0016-5085(95)90411-5; Peleg II, 1996, DIGEST DIS SCI, V41, P1319, DOI 10.1007/BF02088554; PELEG II, 1994, ARCH INTERN MED, V154, P394, DOI 10.1001/archinte.154.4.394; PERI KG, 1995, J BIOL CHEM, V270, P24615, DOI 10.1074/jbc.270.41.24615; PIAZZA GA, 1995, CANCER RES, V55, P3110; POLLARD M, 1980, CANCER TREAT REP, V64, P1323; QIAO L, 1995, BBA-LIPID LIPID MET, V1258, P215, DOI 10.1016/0005-2760(95)00100-Q; Rao KVN, 1996, CARCINOGENESIS, V17, P1435, DOI 10.1093/carcin/17.7.1435; Reddy BS, 1996, CANCER RES, V56, P4566; REDDY BS, 1987, CANCER RES, V47, P5340; REED GA, 1988, ENVIRON CARCINOG REV, V6, P223; RIGAS B, 1993, J LAB CLIN MED, V122, P518; RIGAU J, 1991, ANN INTERN MED, V115, P952, DOI 10.7326/0003-4819-115-12-952; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; RUBIO CA, 1984, J NATL CANCER I, V72, P705; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SANO H, 1995, CANCER RES, V55, P3785; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Shiff SJ, 1996, EXP CELL RES, V222, P179, DOI 10.1006/excr.1996.0023; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; SMITH WL, 1995, SEMIN NEPHROL, V15, P179; SUH O, 1993, CANCER-AM CANCER SOC, V72, P1171, DOI 10.1002/1097-0142(19930815)72:4<1171::AID-CNCR2820720407>3.0.CO;2-D; TAKAHASHI M, 1990, CARCINOGENESIS, V11, P393, DOI 10.1093/carcin/11.3.393; TAZAWA R, 1994, BIOCHEM BIOPH RES CO, V203, P190, DOI 10.1006/bbrc.1994.2167; THOMPSON HJ, 1995, J NATL CANCER I, V87, P1259; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; THUN MJ, 1993, CANCER RES, V53, P1322; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VANE JR, 1995, ADV PROSTAG THROMB L, V23, P41; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5	109	270	292	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1997	11	4					234	247		10.1096/fasebj.11.4.9068612	http://dx.doi.org/10.1096/fasebj.11.4.9068612			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WM850	9068612	Green Submitted			2022-12-28	WOS:A1997WM85000005
J	Deltour, L; Ang, HL; Duester, G				Deltour, L; Ang, HL; Duester, G			Ethanol inhibition of retinoic acid synthesis as a potential mechanism for fetal alcohol syndrome	FASEB JOURNAL			English	Article						alcohol dehydrogenase; vitamin A; embryogenesis; cranial mesenchyme; retinol	RAR DOUBLE MUTANTS; RECEPTORS RARS; DEHYDROGENASE; CYTOCHROME-P-450; OXIDATION; ABNORMALITIES; EMBRYOGENESIS; METABOLISM; EXPRESSION; INDUCTION	Retinoic acid (RA) is known to act as a signaling molecule during embryonic: development, but little is known about the regulation of RA synthesis from retinol, The rate-limiting step in RA synthesis is the oxidation of retinol, a reaction that can be catalyzed by alcohol dehydrogenase (ADH), Ethanol is also a substrate for ADH, and high levels of ethanol inhibit ADH-catalyzed retinol oxidation, This has prompted us to hypothesize that ethanol-induced defects observed in fetal alcohol syndrome involve ethanol inhibition of ADH-catalyzed RA synthesis, Here, we have examined the effect of ethanol on RA levels in cultured mouse embryos by using a bioassay, Treatment with 100 mM ethanol, but not 10 mM, led to a significant decrease in RA detection in 7.5-day-old embryos, Using whole-mount in situ hybridization, we detected mRNA for class IV ADH, but not ethanol-active cytochrome P450 2E1, in 7.5- and 8.5-day-old embryos, indicating that an ADH-linked pathway exists at these stages for metabolizing retinol and ethanol. Thus, the observed ethanol-induced reduction in RA may be caused by ethanol. inhibition of retinol oxidation catalyzed by class IV ADH, in our postulated mechanism for fetal alcohol syndrome, this enzyme may well play a crucial role.	BURNHAM INST,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute				Duester, Gregg/0000-0003-4335-3650	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA007261, R01AA009731] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA09731, AA07261] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALGAR EM, 1983, EUR J BIOCHEM, V137, P139, DOI 10.1111/j.1432-1033.1983.tb07807.x; Blaner William S., 1994, P229; BLISS AF, 1951, ARCH BIOCHEM BIOPHYS, V31, P197, DOI 10.1016/0003-9861(51)90206-8; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; Cartwright MM, 1995, ALCOHOL CLIN EXP RES, V19, P1454, DOI 10.1111/j.1530-0277.1995.tb01007.x; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; CLARREN SK, 1978, NEW ENGL J MED, V298, P1063, DOI 10.1056/NEJM197805112981906; CONNOR MJ, 1987, BIOCHEM J, V244, P489, DOI 10.1042/bj2440489; DAVIS JF, 1993, J BIOL CHEM, V268, P16584; DERSCH H, 1993, DEV BIOL, V160, P424, DOI 10.1006/dbio.1993.1318; Duester G., 1994, Vitamin A in health and disease., P343; DUESTER G, 1991, ALCOHOL CLIN EXP RES, V15, P568, DOI 10.1111/j.1530-0277.1991.tb00562.x; Hofmann Clementine, 1994, P387; HOGAN BLM, 1992, NATURE, V359, P237, DOI 10.1038/359237a0; JONES KL, 1973, LANCET, V2, P999; JONES SM, 1992, BIOCHEM PHARMACOL, V43, P1876, DOI 10.1016/0006-2952(92)90726-Y; JULIA P, 1986, EXP EYE RES, V42, P305, DOI 10.1016/0014-4835(86)90023-0; Kastner P., 1994, Vitamin A in health and disease., P189; Kaufman M.H., 1992, ATLAS MOUSE DEV; KEDISHVILI NY, 1995, J BIOL CHEM, V270, P3625, DOI 10.1074/jbc.270.8.3625; KIM CI, 1992, ARCH BIOCHEM BIOPHYS, V294, P388, DOI 10.1016/0003-9861(92)90700-7; LIEBER CS, 1994, J TOXICOL-CLIN TOXIC, V32, P631, DOI 10.3109/15563659409017974; LIM K, 1989, BIOTECHNIQUES, V7, P576; LOHNES D, 1994, DEVELOPMENT, V120, P2723; Maden M., 1994, Vitamin A in health and disease., P289; Mangelsdorf David J., 1994, P319; MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7194, DOI 10.1073/pnas.91.15.7194; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; MEZEY E, 1971, EXP MOL PATHOL, V15, P148, DOI 10.1016/0014-4800(71)90095-5; MORRISSKAY G, 1993, BIOESSAYS, V15, P9, DOI 10.1002/bies.950150103; OHNISHI K, 1977, J BIOL CHEM, V252, P7124; OSUMIYAMASHITA N, 1994, DEV BIOL, V164, P409, DOI 10.1006/dbio.1994.1211; PERSSON B, 1991, EUR J BIOCHEM, V200, P537, DOI 10.1111/j.1432-1033.1991.tb16215.x; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; ROBERTS ES, 1992, MOL PHARMACOL, V41, P427; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; SERBEDZIJA GN, 1992, DEVELOPMENT, V116, P297; SONG BJ, 1986, J BIOL CHEM, V261, P6689; SULIK KK, 1981, SCIENCE, V214, P936, DOI 10.1126/science.6795717; VANTHIEL DH, 1974, SCIENCE, V186, P941, DOI 10.1126/science.186.4167.941; WAGNER M, 1992, DEVELOPMENT, V116, P55; WEBSTER WS, 1983, TERATOLOGY, V27, P231, DOI 10.1002/tera.1420270211; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202; YANG ZN, 1994, ALCOHOL CLIN EXP RES, V18, P587, DOI 10.1111/j.1530-0277.1994.tb00914.x; ZACHMAN RD, 1961, J BIOL CHEM, V236, P2309; ZAGOMBIEKNIGHT M, 1995, J BIOL CHEM, V270, P10868	47	141	143	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1996	10	9					1050	1057		10.1096/fasebj.10.9.8801166	http://dx.doi.org/10.1096/fasebj.10.9.8801166			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801166				2022-12-28	WOS:A1996UY93200015
J	THORPE, SR; BAYNES, JW; CHRONEOS, ZC				THORPE, SR; BAYNES, JW; CHRONEOS, ZC			THE DESIGN AND APPLICATION OF RESIDUALIZING LABELS FOR STUDIES OF PROTEIN CATABOLISM	FASEB JOURNAL			English	Review						PROTEIN TURNOVER; PROTEIN TURNOVER, TISSUE SITES; PROTEIN TURNOVER, CELLULAR SITES; TRAPPED LABELS; PLASMA PROTEINS; NONINVASIVE IMAGING; LOW DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN	LOW-DENSITY-LIPOPROTEIN; LIVER ENDOTHELIAL-CELLS; CHOLESTEROL-FED RABBITS; INTRACELLULAR-TRANSPORT; ATHEROSCLEROTIC LESIONS; RAT-LIVER; KUPFFER CELLS; INVIVO; SITES; LDL	Residualizing labels (R-labels) are chemical tags for proteins, originally designed for studies of the sites and mechanisms of plasma protein catabolism. The labels consist of oligosaccharides derivatized with radioactive, fluorescent, nuclear magnetic resonance (NMR), or positron emission tomography (PET) active reporter molecules. Because these glycoconjugates generally have molecular masses in excess of 500 daltons and are hydrophilic, they are relatively membrane impermeant. They are also designed to be resistant to lysosomal hydrolases and are therefore retained inside cells with half-lives of 2-5 days after endocytosis and degradation of the carrier protein. The R-labels thus provide a convenient means for following the cumulative uptake and catabolism of proteins by cells in vivo or in vitro. This review summarizes how R-labels have provided insights into the sites and regulation of the turnover of circulating proteins, and pathways for intracellular transport and degradation of endocytosed proteins. The potential use of R-labels for noninvasive studies of the distribution of protein pharmaceuticals in vivo is also discussed.	UNIV S CAROLINA, SCH MED, COLUMBIA, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	THORPE, SR (corresponding author), UNIV S CAROLINA, DEPT CHEM & BIOCHEM, COLUMBIA, SC 29208 USA.			, Zissis/0000-0002-9841-7917	NIDDK NIH HHS [DK25373] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025373] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AZHAR S, 1990, BIOCHIM BIOPHYS ACTA, V1047, P148, DOI 10.1016/0005-2760(90)90041-U; BERG T, 1985, EXP CELL RES, V161, P285, DOI 10.1016/0014-4827(85)90086-2; CAREW TE, 1984, ARTERIOSCLEROSIS, V4, P214, DOI 10.1161/01.ATV.4.3.214; CAREW TE, 1982, J BIOL CHEM, V257, P8001; CAREW TE, 1982, LIPOPROTEIN KINETICS, P169; CHRONEOS ZC, 1992, THESIS U S CAROLINA; DAUGHERTY A, 1985, J BIOL CHEM, V260, P4564; DAUGHERTY A, 1992, NUCL MED BIOL, V19, P411; DEMIGNOT S, 1991, CANCER IMMUNOL IMMUN, V33, P359, DOI 10.1007/BF01741595; ESKILD W, 1989, BIOCHEM J, V258, P511, DOI 10.1042/bj2580511; FRITZBERG AR, 1992, J NUCL MED, V33, P394; GLASS C, 1985, J BIOL CHEM, V260, P744; GLASS CK, 1983, J BIOL CHEM, V258, P7161; GOLDBERG IJ, 1990, J CLIN INVEST, V86, P463, DOI 10.1172/JCI114732; HENDERSON LA, 1982, ARCH BIOCHEM BIOPHYS, V215, P1, DOI 10.1016/0003-9861(82)90272-7; KAMPS JAAM, 1991, BIOCHEM J, V276, P135, DOI 10.1042/bj2760135; KINDBERG GM, 1990, BIOCHEM J, V270, P197, DOI 10.1042/bj2700197; KINDBERG GM, 1990, BIOCHEM J, V270, P205, DOI 10.1042/bj2700205; KLEINHERENBRINKSTINS MF, 1990, LAB INVEST, V63, P73; MAXWELL JL, 1988, J BIOL CHEM, V263, P14122; MAXWELL JL, 1990, BIOCHEM J, V267, P155, DOI 10.1042/bj2670155; MAXWELL JL, 1987, PHARM TOXICOLOGY PRO, P59; MEEH LA, 1992, IN PRESS BIOCH J, V286; MISQUITH S, 1988, EUR J BIOCHEM, V174, P691, DOI 10.1111/j.1432-1033.1988.tb14153.x; MOERLEIN SM, 1991, J NUCL MED, V32, P300; MOLDOVEANU Z, 1988, J IMMUNOL, V141, P208; NENSETER MS, 1988, BIOCHEM J, V254, P443, DOI 10.1042/bj2540443; ORD JM, 1992, CIRCULATION, V85, P288, DOI 10.1161/01.CIR.85.1.288; Pittman R C, 1986, Methods Enzymol, V129, P612; PITTMAN RC, 1983, BIOCHEM J, V212, P791, DOI 10.1042/bj2120791; SCHULTZE HE, 1966, MOLECULAR BIOLOGY HU, V1, P487; SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P895, DOI 10.1161/01.ATV.9.6.895; SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P908, DOI 10.1161/01.ATV.9.6.908; SCHWENKE DC, 1988, CIRC RES, V62, P699, DOI 10.1161/01.RES.62.4.699; SMEDSROD B, 1990, THROMB HAEMOSTASIS, V63, P60; SPADY DK, 1983, P NATL ACAD SCI-BIOL, V80, P3499, DOI 10.1073/pnas.80.11.3499; STEIN O, 1984, KLIN WOCHENSCHR, V62, P1151, DOI 10.1007/BF01712181; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; STROBEL JL, 1986, J BIOL CHEM, V261, P7989; STROBEL JL, 1985, ARCH BIOCHEM BIOPHYS, V240, P635, DOI 10.1016/0003-9861(85)90071-2; VALLABHAJOSULA S, 1990, SEMIN NUCL MED, V20, P68, DOI 10.1016/S0001-2998(05)80177-1; VALLABHAJOSULA S, 1988, J NUCL MED, V29, P1237; WARTY VS, 1989, J VASC SURG, V10, P392, DOI 10.1067/mva.1989.13732; WATERLOW JC, 1978, PROTEIN TURNOVER MAM, P482; WISHART R, 1990, BIOCHIM BIOPHYS ACTA, V1044, P382, DOI 10.1016/0005-2760(90)90084-B; YEDGAR S, 1983, AM J PHYSIOL, V244, pE101, DOI 10.1152/ajpendo.1983.244.1.E101	46	58	60	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1993	7	5					399	405		10.1096/fasebj.7.5.8462781	http://dx.doi.org/10.1096/fasebj.7.5.8462781			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KV351	8462781				2022-12-28	WOS:A1993KV35100003
J	Garrison, HH; Gerbi, SA				Garrison, HH; Gerbi, SA			Education and employment patterns of US PhD's in the biomedical sciences	FASEB JOURNAL			English	Article						predoctoral; postdoctoral; academia; unemployment; immigration; industry		During most of the 1970s and 1980s, the number of biomedical Ph.D.'s conferred in the United States was fairly constant, From 1987 to 1995, however, there was an increase of almost 50% in the number of biomedical Ph.D.'s awarded by U.S. institutions; nearly 70% of this increase can be accounted for by the increase in the number of noncitizens receiving a Ph.D. in the U.S. Although unemployment among U.S. citizens with biomedical Ph.D.'s is now extremely low-less than 2.0%-there have been some important changes in the job market for biomedical Ph.D.'s. The total number of biomedical scientists has grown, whereas the number of faculty positions has remained stable, causing a deline in faculty positions as a percentage of total employment for biomedical scientists. Jobs in industry have increased, and in the future might surpass academic jobs as the most prevalent form of employment for U.S. biomedical scientists.	Federat Amer Soc Expt Biol, Off Publ Affairs, Bethesda, MD 20814 USA; Brown Univ, Div Biol & Med, Providence, RI 02912 USA	Brown University	Garrison, HH (corresponding author), Federat Amer Soc Expt Biol, Off Publ Affairs, Bethesda, MD 20814 USA.			Garrison, Howard/0000-0001-9455-3527				Ammons SW, 1997, ACAD MED, V72, P820, DOI 10.1097/00001888-199709000-00020; AMMONS SW, 1996, OCT 1995 GREAT C FT; *COMM FUND YOUNG I, 1994, FUND YOUNG INV BIOL; *COMM NAT NEEDS BI, 1994, M NAT NEEDS BIOM BEH; *FED AM SOC EXP BI, 1997, GRAD ED CONS C REP; GOLDMAN CA, 1996, COMMUNICATION; HAYES SL, 1996, EDGE NEW FRONTIER PR; MASSEY W, 1995, PRODUCTION UTILIZATI; *NAT RES COUNC, 1996, SURV DOCT REC; *NAT RES COUNC, 1997, IN PRESS COMM TRENDS; *NAT RES COUNC, 1995, RESH GRAD ED SCI ENG; *NAT SCI BOARD, 1996, SCI ENG IND 1996; *NAT SCI FDN, 1996, NSF96302; PERKINS J, 1996, PHARMACOLOGIST, V38, P124	14	14	13	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1998	12	2					139	148		10.1096/fasebj.12.2.139	http://dx.doi.org/10.1096/fasebj.12.2.139			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472978				2022-12-28	WOS:000071848400001
J	Schmidt, M; Kloetzel, PM				Schmidt, M; Kloetzel, PM			Biogenesis of eukaryotic 20S proteasomes: the complex maturation pathway of a complex enzyme	FASEB JOURNAL			English	Review						catalytic mechanism; circular assemblies; crystal structure; protease maturation	MULTICATALYTIC PROTEINASE COMPLEX; MAJOR HISTOCOMPATIBILITY COMPLEX; THERMOPLASMA-ACIDOPHILUM; CRYSTAL-STRUCTURE; INTERFERON-GAMMA; SUBUNIT; DEGRADATION; LMP2; COMPONENTS; MECHANISM	Eukaryotic 20S proteasomes harbor a remarkably complex architecture and unique proteolytic properties. Its catalytic mechanism places this enzyme in a new kind of protease family, The recently solved crystal structure of the yeast 20S complex, along with elucidation of the maturation pathway of human proteasomes, has allowed insight into structure/function relationships, Although not all of the unusual enzymatic properties such as broad substrate specificity, predominant generation of peptides with a specific size, or susceptibility to activating complexes can be explained in detail, knowledge of the structure provides important hints for an explanation of underlying mechanisms, Except for ribosome biogenesis, the complexity of eukaryotic proteasome maturation is without precedence, It is a slow process that involves a series of precisely ordered events, Proteasome structure formation is characterized by an initial cooperative formation of an alpha ring matrix, providing docking sites for a defined subset of beta subunits, Subsequent structural rearrangement allows the residual subunits to bind, followed by dimerization of two half-proteasomes, The prosequences of beta subunits exert specific functions during this process and are removed by cis and trans-autocatalysis, most likely in the completely assembled proteasome cylinder.	Humboldt Univ Charite, Fak Med, Inst Biochem, Zentrum Expt Med, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Kloetzel, PM (corresponding author), Humboldt Univ Charite, Fak Med, Inst Biochem, Zentrum Expt Med, Monbijoustr 2A, D-10117 Berlin, Germany.							Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; Antson AA, 1996, CURR OPIN STRUC BIOL, V6, P142, DOI 10.1016/S0959-440X(96)80067-4; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; CHEN P, 1995, EMBO J, V14, P2620, DOI 10.1002/j.1460-2075.1995.tb07260.x; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Cruz M, 1997, GENE, V190, P251, DOI 10.1016/S0378-1119(97)00003-6; DAHLMANN B, 1992, EUR J BIOCHEM, V208, P789, DOI 10.1111/j.1432-1033.1992.tb17249.x; DAHLMANN B, 1991, BIOMED BIOCHIM ACTA, V50, P465; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; FRENTZEL S, 1994, J MOL BIOL, V236, P975, DOI 10.1016/0022-2836(94)90003-5; FRUH K, 1994, EMBO J, V13, P3236, DOI 10.1002/j.1460-2075.1994.tb06625.x; Gerards WLH, 1997, J BIOL CHEM, V272, P10080; Goldberg AL, 1997, BIOL CHEM, V378, P131; Groettrup M, 1996, EUR J IMMUNOL, V26, P863, DOI 10.1002/eji.1830260421; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; HENDIL KB, 1995, BIOCHEM J, V305, P245, DOI 10.1042/bj3050245; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; HILT W, 1995, MOL BIOL REP, V21, P3, DOI 10.1007/BF00990964; Hisamatsu H, 1996, J EXP MED, V183, P1807, DOI 10.1084/jem.183.4.1807; Kania MA, 1996, EUR J BIOCHEM, V236, P510, DOI 10.1111/j.1432-1033.1996.00510.x; Kopp F, 1997, P NATL ACAD SCI USA, V94, P2939, DOI 10.1073/pnas.94.7.2939; KOPP F, 1993, J MOL BIOL, V229, P14, DOI 10.1006/jmbi.1993.1003; KUCKELKORN U, 1995, EUR J IMMUNOL, V25, P2605, DOI 10.1002/eji.1830250930; LILLEY KS, 1990, FEBS LETT, V262, P327, DOI 10.1016/0014-5793(90)80220-D; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1994, J BIOL CHEM, V269, P3539; MAUPINFURLOW JA, 1995, J BIOL CHEM, V270, P28617, DOI 10.1074/jbc.270.48.28617; Mykles DL, 1997, MOL BIOL REP, V24, P133, DOI 10.1023/A:1006867825811; Nandi D, 1996, J IMMUNOL, V156, P2361; Nandi D, 1997, EMBO J, V16, P5363, DOI 10.1093/emboj/16.17.5363; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; PATEL SD, 1994, P NATL ACAD SCI USA, V91, P296, DOI 10.1073/pnas.91.1.296; PHILLIPS MA, 1992, CURR OPIN STRUC BIOL, V2, P713; Schmidt M, 1997, MOL BIOL REP, V24, P103, DOI 10.1023/A:1006826725056; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; Seeger M, 1997, MOL BIOL REP, V24, P83, DOI 10.1023/A:1006837600040; SEELIG A, 1993, J BIOL CHEM, V268, P25561; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; SHCMIDTKE G, 1997, J MOL BIOL, V268, P95; SHINDE U, 1993, P NATL ACAD SCI USA, V90, P6924, DOI 10.1073/pnas.90.15.6924; SHINDE U, 1994, J BIOCHEM, V115, P629, DOI 10.1093/oxfordjournals.jbchem.a124386; TAMURA T, 1995, CURR BIOL, V5, P766, DOI 10.1016/S0960-9822(95)00153-9; THOMSON S, 1993, FEBS LETT, V322, P135, DOI 10.1016/0014-5793(93)81553-C; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; WLODAWER A, 1995, STRUCTURE, V3, P417, DOI 10.1016/S0969-2126(01)00172-1; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687; Zuhl F, 1997, FEBS LETT, V400, P83, DOI 10.1016/S0014-5793(96)01403-2; ZWICKL P, 1994, STRUCT BIOL, V1, P765	59	40	40	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1997	11	14					1235	1243		10.1096/fasebj.11.14.9409542	http://dx.doi.org/10.1096/fasebj.11.14.9409542			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YN210	9409542				2022-12-28	WOS:000071144100004
J	Santella, L; Carafoli, E				Santella, L; Carafoli, E			Calcium signaling in the cell nucleus	FASEB JOURNAL			English	Review						nuclear envelope; gene transcription; proteolysis; pore gating; Ca2+ stores	PROTEIN-KINASE-C; RAT-LIVER NUCLEI; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CALMODULIN-BINDING PROTEINS; LYMPHOCYTE-T ACTIVATION; SMOOTH-MUSCLE CELLS; SWISS 3T3 CELLS; CYCLIC ADP-RIBOSE; GENE-EXPRESSION; INDUCED APOPTOSIS	Regulation of Ca2+ in the nucleus is a debated issue, essentially due to the presence in the envelope of the pores, which are large enough to permit the passive traffic of small molecules like Ca2+ Work with a number of cell systems has shown that Ca2+ diffuses freely in and out of the nucleus, whereas other studies have suggested instead that the nuclear envelope could become an efficient Ca2+ filter: electrophysiological work has shown that it could become impermeable to ions, and persistent nucleus cytoplasmic Ca2+ gradients have been documented in various cell types. The problem of the control of nuclear Ca2+ thus is still open: mechanisms for gating of the pores, based on the state of depletion of the cell Ca2+ stores, have been proposed, Irrespective of the mechanisms for possible pore gating, a final picture on the traffic of Ca2+ in and out of the nucleus must also include the Ca2+ pump as well as the InsP(3) and cyclic ADP ribose-modulated Ca2+ channels in the envelope, The channels can be activated by their ligands from inside the nucleus, producing Ca2+ transients in the nucleoplasm; the machinery for producing InsP(3) has been documented in the envelope. Most Ca2+-sensitive nuclear functions are jointly modulated by Ca2+ and calmodulin: calmodulin-dependent kinases and the calmodulin-dependent phosphatase calcineurin have been documented in the nucleus, An interesting case for the modulation of intranuclear processes by calmodulin-dependent kinases is that of immediate early genes, i.e., CREB, Other Ca2+-modulated nuclear processes are calmodulin independent: chief among them is the intranucleosomal cleavage of chromatin and the fragmentation of nuclear proteins during apoptosis.	ETH ZENTRUM, INST BIOCHEM 3, CH-8092 ZURICH, SWITZERLAND; Staz Zool Anton Dohrn, I-80121 NAPLES, ITALY	Swiss Federal Institutes of Technology Domain; ETH Zurich; Stazione Zoologica Anton Dohrn di Napoli			Carafoli, Ernesto/K-5192-2016; Santella, Luigia/AAM-3524-2020	Carafoli, Ernesto/0000-0002-7826-0094; Santella, Luigia/0000-0001-7159-0499				ABDELMAJID H, 1993, INT J DEV BIOL, V37, P279; ALLBRITTON NL, 1994, P NATL ACAD SCI USA, V91, P12458, DOI 10.1073/pnas.91.26.12458; ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; AMANKWAH KS, 1994, EXP CELL RES, V210, P315, DOI 10.1006/excr.1994.1044; ARENDS MJ, 1990, AM J PATHOL, V136, P593; ARIZONO K, 1993, LIFE SCI, V53, P1031, DOI 10.1016/0024-3205(93)90126-N; ASANO M, 1994, J BIOL CHEM, V269, P12360; BACHS O, 1990, J BIOL CHEM, V265, P18595; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Badminton MN, 1996, J BIOL CHEM, V271, P31210, DOI 10.1074/jbc.271.49.31210; BADMINTON MN, 1995, EXP CELL RES, V216, P236, DOI 10.1006/excr.1995.1030; BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; BELLOMO G, 1992, CANCER RES, V52, P1342; BENKE TA, 1993, P NATL ACAD SCI USA, V90, P7819, DOI 10.1073/pnas.90.16.7819; BILLIA F, 1991, J CELL SCI, V100, P219; BIRCH BD, 1992, P NATL ACAD SCI USA, V89, P7978, DOI 10.1073/pnas.89.17.7978; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BOSSER R, 1993, J BIOL CHEM, V268, P15477; BOUILLON M, 1994, CANCER RES, V54, P4144; BOUTILLIER AL, 1991, MOL ENDOCRINOL, V5, P1301, DOI 10.1210/mend-5-9-1301; BREMER JW, 1981, BIOCHEMISTRY-US, V20, P2013, DOI 10.1021/bi00510a042; BRINI M, 1993, EMBO J, V12, P4813, DOI 10.1002/j.1460-2075.1993.tb06170.x; BROWN DG, 1993, J BIOL CHEM, V268, P3037; BUCHNER K, 1995, EUR J BIOCHEM, V228, P211; BUSTAMANTE JO, 1993, BIOPHYS J, V64, P1735, DOI 10.1016/S0006-3495(93)81545-5; BUSTAMANTE JO, 1992, PFLUG ARCH EUR J PHY, V421, P473, DOI 10.1007/BF00370259; BUSTAMANTE JO, 1995, J MEMBRANE BIOL, V146, P239; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAPITANI S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P193, DOI 10.1016/0005-2760(90)90303-F; Carafoli E, 1996, EXPERIENTIA, V52, P1091, DOI 10.1007/BF01952107; CARAFOLI E, 1974, J MOL CELL CARDIOL, V6, P361, DOI 10.1016/0022-2828(74)90077-7; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHIBA K, 1993, MOL BIOL CELL, V4, P1027, DOI 10.1091/mbc.4.10.1027; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK TG, 1979, CELL, V18, P1101, DOI 10.1016/0092-8674(79)90223-X; CLAWSON GA, 1992, CELL GROWTH DIFFER, V3, P827; CLEMENS MJ, 1992, J CELL SCI, V103, P881; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; COHEN JJ, 1984, J IMMUNOL, V132, P38; COLAS P, 1992, BIOL CELL, V76, P217; COLOMER J, 1994, J CELL PHYSIOL, V159, P542, DOI 10.1002/jcp.1041590318; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; CONNOR JA, 1993, CELL CALCIUM, V14, P185, DOI 10.1016/0143-4160(93)90066-F; CORBETT AH, 1993, BIOCHEMISTRY-US, V32, P2090, DOI 10.1021/bi00059a029; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; DALE B, 1994, P ROY SOC B-BIOL SCI, V255, P119, DOI 10.1098/rspb.1994.0017; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DEBONI U, 1994, INT REV CYTOL, V150, P149; DEGUCHI R, 1994, DEV BIOL, V163, P162, DOI 10.1006/dbio.1994.1132; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; DENTON RM, 1980, FEBS LETT, V119, P1, DOI 10.1016/0014-5793(80)80986-0; DEVORE RF, 1992, CANCER RES, V52, P2156; DING R, 1992, J BIOL CHEM, V267, P12801; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DIVIRGILIO F, 1990, CELL CALCIUM, V11, P57, DOI 10.1016/0143-4160(90)90059-4; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; DOWD DR, 1992, MOL ENDOCRINOL, V6, P1843, DOI 10.1210/me.6.11.1843; DUBE F, 1990, J EXP ZOOL, V256, P323, DOI 10.1002/jez.1402560312; EGLY JM, 1984, EMBO J, V3, P2363, DOI 10.1002/j.1460-2075.1984.tb02141.x; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; Ferrier J, 1996, CELL CALCIUM, V20, P381, DOI 10.1016/S0143-4160(96)90000-7; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; FURUNO T, 1993, BIOPHYS J, V64, P665, DOI 10.1016/S0006-3495(93)81425-5; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GALLIN WJ, 1995, CURR OPIN NEUROBIOL, V5, P367, DOI 10.1016/0959-4388(95)80050-6; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GAZIEV AI, 1992, INT J RADIAT BIOL, V61, P169, DOI 10.1080/09553009214550781; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; HENNAGER DJ, 1995, J BIOL CHEM, V270, P4959, DOI 10.1074/jbc.270.10.4959; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hille B., 1991, IONIC CHANNELS EXCIT; HIMPENS B, 1994, FASEB J, V8, P879, DOI 10.1096/fasebj.8.11.8070638; HIMPENS B, 1992, AM J PHYSIOL, V263, pC95, DOI 10.1152/ajpcell.1992.263.1.C95; HIRAGA K, 1993, BIOCHIM BIOPHYS ACTA, V1177, P25, DOI 10.1016/0167-4889(93)90152-F; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HORIKOSHI Y, 1994, BIOCHEM J, V304, P57, DOI 10.1042/bj3040057; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; Humbert JP, 1996, J BIOL CHEM, V271, P478, DOI 10.1074/jbc.271.1.478; JARNIK M, 1991, J STRUCT BIOL, V107, P291, DOI 10.1016/1047-8477(91)90054-Z; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; KATAGIRI S, 1993, FEBS LETT, V334, P343, DOI 10.1016/0014-5793(93)80708-3; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KONISHI M, 1988, BIOPHYS J, V54, P1089, DOI 10.1016/S0006-3495(88)83045-5; KOPPLER P, 1993, J BIOL CHEM, V268, P26248; KREUDER V, 1984, EUR J BIOCHEM, V139, P389, DOI 10.1111/j.1432-1033.1984.tb08018.x; KUBO M, 1994, INT IMMUNOL, V6, P179, DOI 10.1093/intimm/6.2.179; KUMAR A, 1984, BIOCHEMISTRY-US, V23, P6753, DOI 10.1021/bi00321a072; LACKS SA, 1981, J BIOL CHEM, V256, P2644; LAHM A, 1991, J MOL BIOL, V222, P645, DOI 10.1016/0022-2836(91)90502-W; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE RD, 1992, EXP CELL RES, V203, P5, DOI 10.1016/0014-4827(92)90033-5; LANINI L, 1992, J BIOL CHEM, V267, P11548; LAREA LS, 1993, NEURON, V10, P31; LEACH KL, 1992, J BIOL CHEM, V267, P21816; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEFEBRE B, 1995, EMBO J, V10, P3207; LOEFFLER JP, 1989, J NEUROCHEM, V52, P1279, DOI 10.1111/j.1471-4159.1989.tb01876.x; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; MAK DOD, 1994, J BIOL CHEM, V269, P29375; MALVIYA AN, 1994, CELL CALCIUM, V16, P301, DOI 10.1016/0143-4160(94)90094-9; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; Marin MC, 1996, ONCOGENE, V12, P2259; MARMIROLI S, 1994, J BIOL CHEM, V269, P13; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MASMOUDI A, 1989, J BIOL CHEM, V264, P1172; MATHEOS P, 1997, 10 INT S CA BIND PRO; MATTER N, 1993, J BIOL CHEM, V268, P732; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MATZKE AJM, 1992, FEBS LETT, V302, P81, DOI 10.1016/0014-5793(92)80290-W; MAZZANTI M, 1990, NATURE, V343, P764, DOI 10.1038/343764a0; MAZZANTI M, 1991, J MEMBRANE BIOL, V121, P189, DOI 10.1007/BF01870532; MAZZANTI M, 1994, FASEB J, V8, P231, DOI 10.1096/fasebj.8.2.7509760; MELLGREN RL, 1994, BIOCHEM BIOPH RES CO, V204, P544, DOI 10.1006/bbrc.1994.2493; Mellgren RL, 1997, BIOCHEM BIOPH RES CO, V236, P555, DOI 10.1006/bbrc.1997.7003; MELLGREN RL, 1993, J BIOL CHEM, V268, P653; MELLGREN RL, 1991, J BIOL CHEM, V266, P13920; MIYAZAKI S, 1995, CURR OPIN CELL BIOL, V7, P190, DOI 10.1016/0955-0674(95)80027-1; Molinari M, 1997, J MEMBRANE BIOL, V156, P1, DOI 10.1007/s002329900181; MOLM M, 1997, 10 INT S CA BIND PRO; MONTAGUE JW, 1994, J BIOL CHEM, V269, P18877; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MORGAN JL, 1996, NATURE, V322, P552; NAIRN AC, 1985, P NATL ACAD SCI USA, V82, P7939, DOI 10.1073/pnas.82.23.7939; NAKAMURA Y, 1995, NEUROSCIENCE, V68, P181, DOI 10.1016/0306-4522(95)00092-W; NEAMATI N, 1995, J IMMUNOL, V154, P3788; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; NICOTERA P, 1993, APOPTOSIS, P97; NIKONOVA LV, 1993, EUR J BIOCHEM, V215, P893, DOI 10.1111/j.1432-1033.1993.tb18107.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OCHIISHI T, 1994, BRAIN RES, V659, P179, DOI 10.1016/0006-8993(94)90877-X; OHTA Y, 1990, P NATL ACAD SCI USA, V87, P5341, DOI 10.1073/pnas.87.14.5341; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; OMALLEY DM, 1994, J NEUROSCI, V14, P5741; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PARKER C, 1992, MELANOMA RES, V2, P337, DOI 10.1097/00008390-199212000-00007; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; PerezTerzic C, 1996, SCIENCE, V273, P1875, DOI 10.1126/science.273.5283.1875; PerezTerzic C, 1997, CELL CALCIUM, V21, P275, DOI 10.1016/S0143-4160(97)90115-9; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; PLANASSILVA MD, 1992, EMBO J, V11, P507, DOI 10.1002/j.1460-2075.1992.tb05081.x; PLEVIN R, 1990, BIOCHEM J, V268, P605, DOI 10.1042/bj2680605; POLZAR B, 1993, EUR J CELL BIOL, V62, P397; PRUSCHY M, 1994, J CELL BIOL, V127, P1527, DOI 10.1083/jcb.127.6.1527; PRZYWARA DA, 1991, FASEB J, V5, P227; PUJOL MJ, 1993, J NEUROCHEM, V60, P1422, DOI 10.1111/j.1471-4159.1993.tb03304.x; RAO A, 1991, CRIT REV IMMUNOL, V10, P495; RASSMUSSEN C, 1994, EMBO J, V13, P3917; RIBEIRO JM, 1993, BIOCHEMISTRY-US, V32, P9129, DOI 10.1021/bi00086a018; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; ROGUE P, 1990, J BIOL CHEM, V265, P4161; RYAZANOV A G, 1990, New Biologist, V2, P843; SAHLAS DJ, 1993, J CELL SCI, V105, P347; SAHYOUN N, 1984, P NATL ACAD SCI-BIOL, V81, P4311, DOI 10.1073/pnas.81.14.4311; SAHYOUN N, 1984, J BIOL CHEM, V259, P9341; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SANTELLA L, 1994, BIOCHEM BIOPH RES CO, V203, P674, DOI 10.1006/bbrc.1994.2235; SANTELLA L, 1997, IN PRESS BIOCH BIOPH; SANTELLA L, 1998, IN PRESS CALCIUM CEL; SANTELLA L, 1997, CELL CALCIUM, V22, P1; SCHINDLER M, 1986, J CELL BIOL, V102, P859, DOI 10.1083/jcb.102.3.859; SCHINDLER M, 1990, BIOCH STRUCTURAL DYN, P249; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; SEI CA, 1991, J BIOL CHEM, V266, P15910; SEILIEV AA, 1992, RADIAT ENVIRON BIOPH, V31, P123, DOI 10.1007/BF01211210; SHANKAR G, 1995, EXP CELL RES, V219, P364, DOI 10.1006/excr.1995.1240; SHANKAR G, 1993, J CELL SCI, V105, P61; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SIEGEL SJ, 1994, P NATL ACAD SCI USA, V91, P564, DOI 10.1073/pnas.91.2.564; SIKORSKA M, 1980, BIOCHEM BIOPH RES CO, V93, P1196, DOI 10.1016/0006-291X(80)90616-6; SIMMEN RCM, 1994, J CELL BIOL, V99, P588; SKALKA M, 1976, FEBS LETT, V72, P271, DOI 10.1016/0014-5793(76)80984-2; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; STEHNOBITTEL L, 1995, NEURON, V14, P163, DOI 10.1016/0896-6273(95)90250-3; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; SUN XM, 1994, BIOCHEM PHARMACOL, V47, P187; Sweitzer TD, 1996, P NATL ACAD SCI USA, V93, P14574, DOI 10.1073/pnas.93.25.14574; SWINGLE KF, 1967, RADIAT RES, V30, P81, DOI 10.2307/3572035; Takahashi K, 1990, INTRACELLULAR CALCIU, P55; TALLANT EA, 1988, BIOCHEMISTRY-US, V27, P2205, DOI 10.1021/bi00406a059; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; THORNBERRY NA, 1994, NATURE, V370, P251, DOI 10.1038/370251a0; TRAUB P, 1988, EUR J CELL BIOL, V46, P478; TSUBOI A, 1994, BIOCHEM BIOPH RES CO, V199, P1064, DOI 10.1006/bbrc.1994.1337; TSUBOI A, 1994, MOL BIOL CELL, V5, P119, DOI 10.1091/mbc.5.1.119; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; VASINGTON FD, 1962, J BIOL CHEM, V237, P2670; VOELKELJOHNSON C, 1995, J IMMUNOL, V154, P1707; WAKIM BT, 1990, BIOCHEM BIOPH RES CO, V171, P84, DOI 10.1016/0006-291X(90)91359-Z; WAKIM BT, 1994, J BIOL CHEM, V269, P2722; Wang XT, 1996, NATURE, V383, P434, DOI 10.1038/383434a0; WAYBILL MM, 1991, AM J PHYSIOL, V261, pE49, DOI 10.1152/ajpendo.1991.261.1.E49; WERLEN G, 1993, J BIOL CHEM, V268, P16596; WHITE BA, 1985, J BIOL CHEM, V260, P1213; WILLIAMS DA, 1987, SCIENCE, V235, P1644, DOI 10.1126/science.3103219; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0; WILLIAMSON JR, 1989, ANNU REV PHYSIOL, V51, P107, DOI 10.1146/annurev.ph.51.030189.000543; WU T, 1994, J CLIN INVEST, V93, P571, DOI 10.1172/JCI117009; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; YAMAMOTO M, 1989, J CLIN INVEST, V83, P1053, DOI 10.1172/JCI113946; YANO S, 1994, J BIOL CHEM, V269, P5428; YELAMARTY RV, 1990, J CLIN INVEST, V85, P1799, DOI 10.1172/JCI114638; YUAN J, 1993, CELL, V44, P817; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V233, P96, DOI 10.1006/bbrc.1997.6411; ZHIVOTOVSKY B, 1994, INT ARCH ALLERGY IMM, V105, P333, DOI 10.1159/000236778; ZHIVOTOVSKY B, 1995, EXP CELL RES, V221, P404, DOI 10.1006/excr.1995.1391; ZHIVOTOVSKY B, 1994, BIOCHEM BIOPH RES CO, V202, P120, DOI 10.1006/bbrc.1994.1901; ZHIVOTOVSKY BD, 1981, INT J RADIAT BIOL, V39, P437, DOI 10.1080/09553008114550531; ZINI N, 1993, EXP CELL RES, V208, P257, DOI 10.1006/excr.1993.1245	245	188	199	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1997	11	13					1091	1109		10.1096/fasebj.11.13.9367344	http://dx.doi.org/10.1096/fasebj.11.13.9367344			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367344				2022-12-28	WOS:A1997YE98300007
J	Maghazachi, AA; Skalhegg, BS; Rolstad, B; AlAoukaty, A				Maghazachi, AA; Skalhegg, BS; Rolstad, B; AlAoukaty, A			Interferon-inducible protein-10 and lymphotactin induce the chemotaxis and mobilization of intracellular calcium in natural killer cells through pertussis toxin-sensitive and -insensitive heterotrimeric G-proteins	FASEB JOURNAL			English	Article						NK cells; lymphotactin; CHAK; chemokine	RECEPTORS; ALPHA	We show here that interferon-inducible protein-10 (IP-10), an ELR lacking CXC chemokine, and the C chemokine lymphotactin (Ltn) induce the chemotaxis and calcium mobilization in IL-2-activated NK (IANK) and CC chemokine-activated NK (CHAK) cells. Cross-desensitization experiments show that IP-10 or Ltn use receptors not shared by other C, CC, or CXC chemokines. The chemotaxis induced by either IP-10 or Ltn for both cell types is inhibited upon pretreatment of these cells with pertussis toxin (PT), Also, Ltn-induced [Ca2+](i) in IANK but not in CHAK cells is inhibited upon pretreatment with PT, whereas IP-10-induced [Ca2+](i) in IANK and CHAK cells is inhibited upon pretreatment with this toxin, These results suggest important roles for PT-sensitive and -insensitive G-proteins in IP-10-induced and Ltn-induced chemotaxis and calcium fluxes in activated NK cells, This was further implicated after streptolysin O permeabilization of CHAK and IANK cells and after introduction of inhibitory antibodies to the PT-sensitive G(i) and G(o) or the PT-insensitive G(q). Our results suggest that IP-10 and Ltn receptors are coupled to G(i), G(o), and G(q) in IANK cells and to G(i) and G(q) in CHAX cells, with a possible low coupling of IP-10, but not of Ltn, receptors to G(o) in these cells, Together, these results show that IP-10 and Ltn-dependent chemotaxis and calcium mobilization may differentiate at the level of receptor coupling to the heterotrimeric G-proteins.	UNIV OSLO,DEPT BIOCHEM,INST BASIC MED SCI,N-0317 OSLO,NORWAY	University of Oslo	Maghazachi, AA (corresponding author), UNIV OSLO,DEPT ANAT,INST BASIC MED SCI,POSTBOKS 1105,N-0317 OSLO,NORWAY.		Skålhegg, Bjørn Steen/AAZ-2976-2021	Skålhegg, Bjørn Steen/0000-0002-3481-8084; Maghazachi, Azzam/0000-0002-3310-678X				AlAoukaty A, 1996, BLOOD, V87, P4255, DOI 10.1182/blood.V87.10.4255.bloodjournal87104255; ALLAVENA P, 1994, EUR J IMMUNOL, V24, P3233, DOI 10.1002/eji.1830241249; Bacon KB, 1996, INT ARCH ALLERGY IMM, V109, P97, DOI 10.1159/000237207; BIANCHI G, 1996, EUR J IMMUNOL, V26, P3238; Bluman EM, 1996, J CLIN INVEST, V97, P2722, DOI 10.1172/JCI118726; BYGRAVE FL, 1995, FASEB J, V9, P1297, DOI 10.1096/fasebj.9.13.7557019; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Dilloo D, 1996, NAT MED, V2, P1090, DOI 10.1038/nm1096-1090; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hedrick JA, 1996, CURR OPIN IMMUNOL, V8, P343, DOI 10.1016/S0952-7915(96)80123-3; Hedrick JA, 1997, J IMMUNOL, V158, P1533; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KENNEDY J, 1995, J IMMUNOL, V155, P203; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Loetscher P, 1996, J IMMUNOL, V156, P322; LUSTER AD, 1993, J EXP MED, V178, P1809; Maghazachi AA, 1996, EUR J IMMUNOL, V26, P315, DOI 10.1002/eji.1830260207; MAGHAZACHI AA, 1994, J IMMUNOL, V153, P4969; MAGHAZACHI AA, 1991, J LEUKOCYTE BIOL, V49, P302, DOI 10.1002/jlb.49.3.302; MAGHAZACHI AA, 1994, J BIOL CHEM, V269, P6796; MAGHAZACHI AA, 1993, INT IMMUNOL, V5, P825, DOI 10.1093/intimm/5.8.825; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; SEBOK K, 1993, J IMMUNOL, V150, P1524; Sgadari C, 1996, BLOOD, V87, P3877, DOI 10.1182/blood.V87.9.3877.bloodjournal8793877; TAUB DD, 1995, J IMMUNOL, V155, P3877; Taub DD, 1996, BLOOD, V87, P1423, DOI 10.1182/blood.V87.4.1423.bloodjournal8741423; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1	33	84	101	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1997	11	10					765	774		10.1096/fasebj.11.10.9271361	http://dx.doi.org/10.1096/fasebj.11.10.9271361			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XR105	9271361				2022-12-28	WOS:A1997XR10500006
J	Mansat, V; Bettaieb, A; Levade, T; Laurent, G; Jaffrezou, JP				Mansat, V; Bettaieb, A; Levade, T; Laurent, G; Jaffrezou, JP			Serine protease inhibitors block neutral sphingomyelinase activation, ceramide generation, and apoptosis triggered by daunorubicin	FASEB JOURNAL			English	Article						leukemia cells; chemotherapeutic drugs; serpins; sphingomyelin	FACTOR-KAPPA-B; PROGRAMMED CELL-DEATH; POLY(ADP-RIBOSE) POLYMERASE; SIGNAL-TRANSDUCTION; TNF-ALPHA; NECROSIS; CLEAVAGE; PATHWAY; KINASE; ACID	To address the role of a plausible protease cascade in daunorubicin-triggered apoptosis, we evaluated the effect of cell-permeant protease inhibitors on its signal transduction pathway. Treatment of U937 and HL-60 cells with 0.5-1. mu M of the chemotherapeutic drug daunorubicin induced a greater than 30% activation of neutral sphingomyelinase activity within 4-10 min with concomitant sphingomyelin hydrolysis and ceramide generation. DNA fragmentation and the classical morphological features of apoptosis were observed within 4-6 h. Pretreatment of cells with the serine protease inhibitors N-tosyl-L-phenylalanyl chloromethyl ketone (20 mu M) or dichloroisocoumarin (20 mu M) for 30 min inhibited daunorubicin-induced neutral sphingomyelinase activation, sphingomyelin hydrolysis, ceramide generation, and apoptosis. Other cell-permeant protease inhibitors such as pepstatin, leupeptin, and antipain had no such effect. The apoptotic response could be restored by the addition of 25 mu M cell-permeant C6-ceramide. Daunorubicin-induced NF-kappa B activation was inhibited by dichloroisocoumarin but not by N-tosyl-L-phenylalanyl chloromethyl ketone, suggesting that this transcription factor can be activated independently of ceramide and is not directly implicated in the apoptotic pathway. These results suggest that inhibitors of serine proteases can act upstream of ceramide in drug-triggered apoptosis and that neutral sphingomyelinase activation is either directly or indirectly serine protease dependent.	INSERM,CJF 9503,CTR CLAUDIUS REGAUD,F-31052 TOULOUSE,FRANCE; CHU PURPAN,SERV HEMATOL,F-31059 TOULOUSE,FRANCE; CHU RANGUEIL,INSERM 466,MED BIOCHEM LAB,F-31403 TOULOUSE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; CHU de Toulouse; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)			Levade, Thierry/O-8948-2014	Bettaieb, Ali/0000-0002-6018-9592				ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BETTS JC, 1994, J BIOL CHEM, V269, P8455; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DARMON AJ, 1994, J BIOL CHEM, V269, P32043; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; FOLCH J, 1957, J BIOL CHEM, V226, P497; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HARPER JW, 1985, BIOCHEMISTRY-US, V24, P1831, DOI 10.1021/bi00329a005; HIGUCHI M, 1995, BLOOD, V86, P2248, DOI 10.1182/blood.V86.6.2248.bloodjournal8662248; HIGUCHI M, 1996, J IMMUNOL, V156, P297; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Jarvis WD, 1996, CLIN CANCER RES, V2, P1; JOHNS LD, 1994, J IMMUNOL, V152, P5877; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; KUNO K, 1994, INT IMMUNOL, V6, P1269, DOI 10.1093/intimm/6.8.1269; LAHTI JM, 1996, MOL CELL BIOL, V15, P1; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEVADE T, 1993, FEBS LETT, V329, P306, DOI 10.1016/0014-5793(93)80243-N; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MARTHINUSS J, 1995, CELL GROWTH DIFFER, V6, P807; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, CELL DEATH DIFFER, V2, P253; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; MCCONKEY DJ, 1991, J IMMUNOL, V146, P1072; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; Rubin H, 1996, NAT MED, V2, P632, DOI 10.1038/nm0696-632; SCHOELLMANN G, 1963, BIOCHEMISTRY-US, V2, P252, DOI 10.1021/bi00902a008; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; STOFFEL W, 1980, H-S Z PHYSIOL CHEM, V361, P755, DOI 10.1515/bchm2.1980.361.1.755; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WEAVER VM, 1993, BIOCHEM CELL BIOL, V71, P488, DOI 10.1139/o93-071; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Wright SC, 1996, FASEB J, V10, P325, DOI 10.1096/fasebj.10.2.8641566; YANAGA F, 1994, BIOCHEM J, V298, P733, DOI 10.1042/bj2980733; YANG ZH, 1993, J BIOL CHEM, V268, P20520; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	61	66	66	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1997	11	8					695	702		10.1096/fasebj.11.8.9240970	http://dx.doi.org/10.1096/fasebj.11.8.9240970			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XN027	9240970				2022-12-28	WOS:A1997XN02700009
J	Shine, KI				Shine, KI			Continuing innovations for health	FASEB JOURNAL			English	Article											Shine, KI (corresponding author), NATL ACAD SCI,INST MED,WASHINGTON,DC 20418, USA.							*AAMC, 1996, FIN MED SCH REP AAMC, P34; *AAMC, 1996, FIN MED SCH REP AAMC, P31; AAMC [Association of American Medical Colleges], 1997, DAT BOOK STAT INF RE; *AS AM MED COLL, 1996, FIN MED SCH REP AAMC, P15; FEIN EB, 1997, NY TIMES        0215, P25; FOGELMAN AM, 1994, ANN INTERN MED, V120, P579, DOI 10.7326/0003-4819-120-7-199404010-00009; *I MED, 1994, CAREERS CLIN RES OBS; JONES RF, 1995, ACAD MED, V71, P300; LERNER J, 1996, WORKSH COMM SCI ENG; METHENY B, 1997, LIFE SCI; Shine KI, 1997, SCIENCE, V275, P9, DOI 10.1126/science.275.5296.9	11	1	1	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1997	11	6					398	403		10.1096/fasebj.11.6.9194520	http://dx.doi.org/10.1096/fasebj.11.6.9194520			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XE404	9194520				2022-12-28	WOS:A1997XE40400002
J	Guerin, S; Mari, B; Maulon, L; Belhacene, N; Marguet, D; Auberger, P				Guerin, S; Mari, B; Maulon, L; Belhacene, N; Marguet, D; Auberger, P			CD10 plays a specific role in early thymic development	FASEB JOURNAL			English	Article						flow cytometry; FTOC; thymopentin; thymic epithelial cells; endopeptidase 24.11	ENDOPEPTIDASE 24.11 ENKEPHALINASE; LEUKEMIA ANTIGEN CALLA; THYMOPOIETIN; PROGENITORS; ACTIVATION; INHIBITION; HORMONES; ENZYMES; MICE	Development of T lymphocyte is a complex process that depends on both thymocyte-stromal cell interactions and the production of soluble factors such as cytokines, peptides, and hormones. In many tissues, the concentration of active biological peptides is regulated locally by a specialized family of enzymes: the ectopeptidases. We show here that treatment of fetal thymic organ cultures (FTOC) with the specific CD10 (endopeptidase 24.11)inhibitors SCH 32615: (N-[L-(1-carboxy-2-phenyl)ethyl]-L-phenylalanyl-beta-alanine), RB25: (N-(3-[(hydroaxyamino)carbonyl]-2-benzylidene-1-oxopropyl]-N-glycine), and thymopentin (TP5) results in the inhibition of thymocyte differentiation. Each agent induces a significant decrease in the number of double positive (CD4(+) CD8(+)) cells in favor of the TN (TcR alpha beta(-)CD4(-)Cd8(-)) population. RB25 also blocks T lymphocyte differentiation in FTOC when preinjected into pregnant mice. Finally, RB25 and TP5 were also shown to reduce the number of CD44(+)CD25(-) and CD44(-)CD25(-) thymocytes both in vitro and after preinjection in vivo in day 2 FTOC. Thus, agents that affect endopeptidase 24.11 activity impair T cell development both in vitro and in vivo. Our results show that the CD10 molecule plays a specific role in promoting early T cell development.	FAC MED NICE,CJF INSERM 9605,F-06107 NICE 02,FRANCE; CIML,INSERM U136,F-13288 MARSEILLE 09,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			Marguet, Didier/B-9946-2008; Mari, Bernard P/GVS-3100-2022; Mari, Bernard/Q-5832-2019; Mari, Bernard P/F-8960-2013; Mari, Bernard P/D-7445-2015; Marguet, Didier/AGO-5421-2022; AUBERGER, Patrick/G-1491-2013	Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Marguet, Didier/0000-0003-3198-5095; AUBERGER, Patrick/0000-0002-2481-8275				AUDHYA T, 1984, P NATL ACAD SCI-BIOL, V81, P2847, DOI 10.1073/pnas.81.9.2847; DARDENNE M, 1994, IMMUNOL TODAY, V15, P518, DOI 10.1016/0167-5699(94)90207-0; ERDOS EG, 1989, FASEB J, V3, P145, DOI 10.1096/fasebj.3.2.2521610; GODFREY DI, 1993, J IMMUNOL, V150, P4244; GOLDSTEIN G, 1979, SCIENCE, V204, P1309, DOI 10.1126/science.451537; Guerin S, 1997, CELL IMMUNOL, V175, P85, DOI 10.1006/cimm.1996.1045; HARRIS CA, 1994, P NATL ACAD SCI USA, V91, P6283, DOI 10.1073/pnas.91.14.6283; HERNANDEZ JF, 1988, J MED CHEM, V31, P1825, DOI 10.1021/jm00117a025; KALLED SL, 1995, EUR J IMMUNOL, V25, P677, DOI 10.1002/eji.1830250308; Lalli E, 1996, EMBO J, V15, P528, DOI 10.1002/j.1460-2075.1996.tb00385.x; MARI B, 1992, EMBO J, V11, P3875, DOI 10.1002/j.1460-2075.1992.tb05480.x; MARI B, 1994, IMMUNOLOGY, V82, P833; MATTEI M, 1994, INT J IMMUNOPHARMACO, V16, P651, DOI 10.1016/0192-0561(94)90138-4; ROQUES BP, 1993, PHARMACOL REV, V45, P87; SALLES G, 1993, P NATL ACAD SCI USA, V90, P7618, DOI 10.1073/pnas.90.16.7618; SALLES G, 1992, BLOOD, V80, P2021; SCHEID MP, 1978, J EXP MED, V147, P1727, DOI 10.1084/jem.147.6.1727; SHIPP MA, 1988, P NATL ACAD SCI USA, V85, P4819, DOI 10.1073/pnas.85.13.4819; SHIPP MA, 1989, P NATL ACAD SCI USA, V86, P297, DOI 10.1073/pnas.86.1.297; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; Small M, 1996, EUR J IMMUNOL, V26, P961, DOI 10.1002/eji.1830260438; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1	22	19	19	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1997	11	5					376	381		10.1096/fasebj.11.5.9141505	http://dx.doi.org/10.1096/fasebj.11.5.9141505			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WX156	9141505				2022-12-28	WOS:A1997WX15600011
J	Mehta, K; Shahid, U; Malavasi, F				Mehta, K; Shahid, U; Malavasi, F			Human CD38, a cell-surface protein with multiple functions	FASEB JOURNAL			English	Review						enzyme; receptor; adhesion molecule; cyclic-ADP ribose; calcium	CYCLIC ADP-RIBOSE; TRANS-RETINOIC ACID; LEUKOCYTE ANTIGEN CD38; BRUTON TYROSINE KINASE; LEUKEMIC HL-60 CELLS; CYCLASE ACTIVITY; B-CELLS; BISPECIFIC ANTIBODIES; NAD GLYCOHYDROLASE; PROGNOSTIC VALUE	Human CD38 is a nonlineage-restricted type II transmembrane glycoprotein that has emerged as a multifunctional protein in recent years. It can serve as an ectoenzyme that catalyzes the synthesis and hydrolysis of cyclic ADP-ribose, a recently identified Ca2+ mobilizing agent that acts independently of inositol triphosphate. The enzymatic functions of CD38 probably contribute to an array of its immunoregulatory functions. The release of soluble CD38 and the ability of membrane-bound CD38 to become internalized in response to appropriate stimuli suggest that extracellular and intracellular roles for this protein are equally plausible. Ligation of CD38 with agonistic antibodies induces diverse effects in hematopoietic cells that range from growth stimulation to induction and prevention from apoptosis, induction of cytokines, activation of kinases, and phosphorylation of certain proteins. These observations suggest that CD38 may serve as receptor for an as yet unidentified ligand. Other molecules that share significant structural and functional homology to CD38 have been identified in humans and mice, suggesting that these molecules may represent a new family of proteins. Understanding the role of CD38 in certain pathological conditions such as myeloma, X-linked agammaglobulinemia, and HIV infection may provide insight into its physiological functions.	UNIV ANCONA,SCH MED,INST BIOL & GENET,ANCONA,ITALY	Marche Polytechnic University	Mehta, K (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOIMMUNOTHERAPY,BOX 60,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.			MALAVASI, Fabio/0000-0002-1844-174X	Telethon [E.0266] Funding Source: Medline; FDA HHS [FDR-000923] Funding Source: Medline	Telethon(Fondazione Telethon); FDA HHS		Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; AUSIELLO CM, 1995, EUR J IMMUNOL, V25, P1477, DOI 10.1002/eji.1830250554; BEERS KW, 1995, J CLIN INVEST, V95, P2385, DOI 10.1172/JCI117932; BOLEN JB, 1993, ONCOGENE, V8, P2025; CATERINA MJ, 1991, FASEB J, V5, P3078, DOI 10.1096/fasebj.5.15.1743439; COULEY ME, 1992, IMMUNOL REV, V138, P5; CUTRONA G, 1995, J EXP MED, V181, P699, DOI 10.1084/jem.181.2.699; Deaglio S, 1996, J IMMUNOL, V156, P727; DIANZANI U, 1994, J IMMUNOL, V153, P952; DONG C, 1994, INT IMMUNOL, V6, P1353, DOI 10.1093/intimm/6.9.1353; DRACH J, 1993, BIOCHEM BIOPH RES CO, V195, P545, DOI 10.1006/bbrc.1993.2080; DRACH J, 1994, CANCER RES, V54, P1746; ECHANIZ P, 1993, CELL IMMUNOL, V150, P72, DOI 10.1006/cimm.1993.1179; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; ELLIS JH, 1995, J IMMUNOL, V155, P925; FLAVELL DJ, 1995, INT J CANCER, V62, P337, DOI 10.1002/ijc.2910620318; FLAVELL DJ, 1992, BRIT J CANCER, V65, P545, DOI 10.1038/bjc.1992.112; FRENCH RR, 1995, BRIT J CANCER, V71, P986, DOI 10.1038/bjc.1995.190; FUNARO A, 1995, FUND CLIN IMMUNOL, V3, P101; FUNARO A, 1993, EUR J IMMUNOL, V23, P2407, DOI 10.1002/eji.1830231005; FUNARO A, 1990, J IMMUNOL, V145, P2390; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GIORGI JV, 1989, CLIN IMMUNOL IMMUNOP, V52, P10, DOI 10.1016/0090-1229(89)90188-8; GIORGI JV, 1993, J ACQ IMMUN DEF SYND, V6, P904; GOLDMACHER VS, 1994, BLOOD, V84, P3017; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; GRAEFF RM, 1994, BIOCHEM BIOPH RES CO, V205, P722, DOI 10.1006/bbrc.1994.2725; GRIMALDI JC, 1995, J IMMUNOL, V155, P811; GUIDA L, 1995, FEBS LETT, V368, P481, DOI 10.1016/0014-5793(95)00715-L; HARADA N, 1993, J IMMUNOL, V151, P3111; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; HO HN, 1993, J IMMUNOL, V150, P3070; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KAISHO T, 1994, P NATL ACAD SCI USA, V91, P5325, DOI 10.1073/pnas.91.12.5325; KATZ F, 1983, EUR J IMMUNOL, V13, P1008, DOI 10.1002/eji.1830131211; KIKUCHI Y, 1995, P NATL ACAD SCI USA, V92, P11814, DOI 10.1073/pnas.92.25.11814; KOGUMA T, 1994, BBA-MOL CELL RES, V1223, P160, DOI 10.1016/0167-4889(94)90087-6; KONTANI K, 1993, J BIOL CHEM, V268, P16895; Kontani K, 1996, J BIOL CHEM, V271, P1534; KRAMER G, 1995, J UROLOGY, V154, P1636, DOI 10.1016/S0022-5347(01)66733-8; KUMAGAI MA, 1995, J EXP MED, V181, P1101, DOI 10.1084/jem.181.3.1101; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; LEVACHER M, 1992, CLIN EXP IMMUNOL, V90, P376; LUND F, 1995, IMMUNOL TODAY, V16, P469, DOI 10.1016/0167-5699(95)80029-8; MALAVASI F, 1992, INT J CLIN LAB RES, V22, P73, DOI 10.1007/BF02591400; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; MALAVASI F, 1984, HUM IMMUNOL, V9, P9, DOI 10.1016/0198-8859(84)90003-X; Mehta K, 1996, CELL GROWTH DIFFER, V7, P179; MEHTA K, 1996, IN PRESS PRINCIPLES; MIZUGUCHI M, 1995, BRAIN RES, V697, P235, DOI 10.1016/0006-8993(95)00885-T; NAKAGAWARA K, 1995, CYTOGENET CELL GENET, V69, P38, DOI 10.1159/000133933; Otsuka K., 1994, BRAIN PATHOL, V4, P558; Ramaschi G, 1996, BLOOD, V87, P2308, DOI 10.1182/blood.V87.6.2308.bloodjournal8762308; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; SANTOSARGUMEDO L, 1995, INT IMMUNOL, V7, P163, DOI 10.1093/intimm/7.2.163; Silvennoinen O, 1996, J IMMUNOL, V156, P100; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; STEVENSON FK, 1991, BLOOD, V77, P1071; TAKAHASHI K, 1995, FEBS LETT, V371, P204, DOI 10.1016/0014-5793(95)00914-U; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TOHGO A, 1994, J BIOL CHEM, V269, P28555; Umar S, 1996, J BIOL CHEM, V271, P15922, DOI 10.1074/jbc.271.27.15922; WALKER CM, 1989, SCIENCE, V234, P1562; ZOCCHI E, 1995, FEBS LETT, V359, P35, DOI 10.1016/0014-5793(95)00005-T; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416; ZUPO S, 1994, EUR J IMMUNOL, V24, P1218, DOI 10.1002/eji.1830240532; ZUPO S, 1996, IN PRESS BLOOD	69	250	265	2	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1996	10	12					1408	1417		10.1096/fasebj.10.12.8903511	http://dx.doi.org/10.1096/fasebj.10.12.8903511			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VP485	8903511				2022-12-28	WOS:A1996VP48500006
J	DeSouza, SJ; Pereira, HM; Jacchieri, S; Brentani, RR				DeSouza, SJ; Pereira, HM; Jacchieri, S; Brentani, RR			Collagen/collagenase interaction: Does the enzyme mimic the conformation of its own substrate?	FASEB JOURNAL			English	Article						metalloproteinase; proline tipper; proline hinge region; collagen triple helix; serine protease; neutrophil collagenase	HUMAN FIBROBLAST COLLAGENASE; SITE	In this report, we present a hypothesis on the mechanism used by interstitial collagenases to cleave their natural substrate, interstitial collagens, The hypothesis is based on the assumption that the proline hinge domain of interstitial collagenase adopts a collagen-like conformation, With a collagen-like domain, the enzyme is able to disturb the quaternary organization of the triple helix in the collagenase-susceptible site. A modeling analysis suggests that interaction between prolines of both collagen and collagenase forming a kind of ''proline zipper'' is involved in the destabilization step, This destabilization makes the three-collagen helix susceptible to the catalytic cleft of the catalytic core.	UNIV FED MINAS GERAIS,DEPT BIOQUIM,INST CIENCIAS BIOL,LAB BIOL COMP,BR-01246902 SAO PAULO,BRAZIL; LUDWIG INST CANC RES,BR-01246902 SAO PAULO,BRAZIL; INST ADOLFO LUTS,DIV BIOL MED,BR-01246902 SAO PAULO,BRAZIL	Universidade Federal de Minas Gerais; Ludwig Institute for Cancer Research			de Souza, Sandro Jose/AAG-6270-2020; Pereira, Humberto M/J-7824-2016	Pereira, Humberto M/0000-0002-8652-6729				AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; BLUNDELL TL, 1981, P NATL ACAD SCI-BIOL, V78, P4175, DOI 10.1073/pnas.78.7.4175; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BORKAKOTI N, 1994, NAT STRUCT BIOL, V1, P106, DOI 10.1038/nsb0294-106; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; DARBON H, 1992, EUR J BIOCHEM, V209, P765, DOI 10.1111/j.1432-1033.1992.tb17346.x; DESOUZA SJ, 1992, J BIOL CHEM, V267, P13763; DESOUZA SJ, 1994, BIOCHEM J, V300, P605; FIELDS GB, 1990, BIOCHEMISTRY-US, V29, P6670, DOI 10.1021/bi00480a017; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; KNAUPER V, 1993, BIOCHEM J, V291, P847; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; Ramachandran G.N., 1967, TREATISE COLLAGEN, V1; SCHNIERER S, 1993, BIOCHEM BIOPH RES CO, V191, P319, DOI 10.1006/bbrc.1993.1220; TSU CA, 1994, J BIOL CHEM, V269, P19565; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	18	45	45	2	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1996	10	8					927	930		10.1096/fasebj.10.8.8666171	http://dx.doi.org/10.1096/fasebj.10.8.8666171			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UQ456	8666171				2022-12-28	WOS:A1996UQ45600016
J	Gofman, JW				Gofman, JW			Atherosclerotic heart disease and cancer: Looking for the ''smoking guns''	FASEB JOURNAL			English	Article											Gofman, JW (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,229 STANLEY HALL,BERKELEY,CA 94720, USA.							COFMAN JW, 1950, SCIENCE, V111, P166; DELALLA OF, 1954, AM J PHYSIOL, V179, P333; Glazier FW, 1954, J GERONTOL, V9, P395; GOFMAN JOHN W., 1954, PLASMA [MILAN], V2, P413; GOFMAN JW, 1966, CIRCULATION, V34, P679, DOI 10.1161/01.CIR.34.4.679; GOFMAN JW, 1949, J BIOL CHEM, V179, P973; GOFMAN JW, 1990, RAD INDUCED CANC LOW, pCH18; GOFMAN JW, 1959, CORONARY HEART DIS, P210; GOFMAN JW, 1995, PREVENTING BREAST CA; KOLB FO, 1955, METABOLISM, V4, P310; LINDGREN FT, 1949, J BIOL CHEM, V182, P1; PIERCE FT, 1952, CIRCULATION, V5, P401, DOI 10.1161/01.CIR.5.3.401; YOUNG W, 1960, AM J CARDIOL, V6, P287	13	2	2	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1996	10	5					661	663		10.1096/fasebj.10.5.8621066	http://dx.doi.org/10.1096/fasebj.10.5.8621066			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UJ055	8621066				2022-12-28	WOS:A1996UJ05500018
J	Stearns, DM; Belbruno, JJ; Wetterhahn, KE				Stearns, DM; Belbruno, JJ; Wetterhahn, KE			A prediction of chromium(III) accumulation in humans from chromium dietary supplements	FASEB JOURNAL			English	Article						chromium; supplementation; absorption; toxicity; picolinic acid	TRACE-ELEMENTS; HUMAN-BODY; LIVER; EXCRETION; TRIVALENT; RATS	It has been proposed that 90% of American's diets are deficient in the trace essential mineral chromium. Several chromium(III) dietary supplements are currently available to alleviate this deficiency. We show here that the same pharmacokinetic models that have been used to quantitate absorption of chromium(III) in humans predict that ingested chromium(III) will accumulate and be retained in human tissues for extended periods. Calculations were carried out with the popular supplement chromium picolinate as all example, but may be applied to any chromium(III) complex. Results from these calculations were compared to clinical data obtained from chromium(III) absorption/retention studies in humans, The models predict that chromium(III) can accumulate in human tissues to reach the levels at which DNA damage has been observed in animals and in vitro. The use of chromium supplements for extended periods or in excess dosages should be reevaluated in terms of these established models because the possible long-term biological effects of chromium accumulation in humans are poorly understood.			Stearns, DM (corresponding author), DARTMOUTH COLL,DEPT CHEM,6128 BURKE LAB,HANOVER,NH 03755, USA.				NIEHS NIH HHS [ES07167] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007167] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AITIO A, 1981, INT ARCH ENV HLTH, V54, P211; Aitio A., 1988, BIOL MONITORING TOXI, P369, DOI [10.1007/978-1-4613-0961-1_15, DOI 10.1007/978-1-4613-0961-1_15]; Anderson R A, 1993, Prog Clin Biol Res, V380, P221; ANDERSON RA, 1985, AM J CLIN NUTR, V41, P1177, DOI 10.1093/ajcn/41.6.1177; ANDERSON RA, 1983, J NUTR, V113, P276, DOI 10.1093/jn/113.2.276; ANDERSON RA, 1988, MODERN NUTRITION HLT, P268; BEYERSMANN D, 1984, TOXICOL ENVIRON CHEM, V8, P279, DOI 10.1080/02772248409357059; BOUGLE D, 1993, J PEDIATR GASTR NUTR, V17, P72, DOI 10.1097/00005176-199307000-00010; BRIDGEWATER LC, 1994, MOL CARCINOGEN, V9, P122, DOI 10.1002/mc.2940090304; BRYSON WG, 1983, CARCINOGENESIS, V12, P1535; BUNKER VW, 1984, AM J CLIN NUTR, V39, P797, DOI 10.1093/ajcn/39.5.797; CLANCY SP, 1994, INT J SPORT NUTR, V4, P142, DOI 10.1123/ijsn.4.2.142; Clarkson PM, 1991, J SPORT SCI, V9, P91, DOI 10.1080/02640419108729869; CUPO DY, 1985, CANCER RES, V45, P1146; EDWARDS C, 1961, P SOC EXP BIOL MED, V107, P94, DOI 10.3181/00379727-107-26546; FLATT PR, 1989, DIABETES METAB, V15, P93; FRIEDMAN J, 1987, MUTAT RES, V191, P207, DOI 10.1016/0165-7992(87)90155-2; GARGAS ML, 1994, DRUG METAB DISPOS, V22, P522; GIBB H, 1989, SCI TOTAL ENVIRON, V86, P181, DOI 10.1016/0048-9697(89)90204-0; HOPKINS L. L., 1965, AMER J PHYSIOL, V209, P731; ISHIKAWA Y, 1994, BRIT J CANCER, V70, P160, DOI 10.1038/bjc.1994.268; LEE NA, 1994, DIABETES CARE, V17, P1449, DOI 10.2337/diacare.17.12.1449; LEFAVI RG, 1992, INT J SPORT NUTR, V2, P111, DOI 10.1123/ijsn.2.2.111; LIM TH, 1983, AM J PHYSIOL, V244, pR445, DOI 10.1152/ajpregu.1983.244.4.R445; LODISH H, 1995, MOL CELL BIOL, P143; LYON TDB, 1992, FOOD CHEM, V43, P299, DOI 10.1016/0308-8146(92)90217-P; MERTZ W, 1965, AM J PHYSIOL, V209, P489, DOI 10.1152/ajplegacy.1965.209.3.489; NIELSEN FH, 1994, MODERN NUTR HLTH DIS, V1, P264; OFFENBACHER EG, 1986, AM J CLIN NUTR, V44, P77, DOI 10.1093/ajcn/44.1.77; OKADA S, 1983, J INORG BIOCHEM, V19, P95, DOI 10.1016/0162-0134(83)85015-6; OLIN KL, 1994, TRACE ELEM ELECTROLY, V11, P182; RANDALL JA, 1987, P SOC EXP BIOL MED, V185, P16, DOI 10.3181/00379727-185-42510; SANDERSON CJ, 1982, BIOL ENV ASPECTS CHR, P101; SCHROEDER HA, 1965, J NUTR, V86, P51, DOI 10.1093/jn/86.1.51; SCHROEDER HA, 1964, J NUTR, V83, P239, DOI 10.1093/jn/83.3.239; SCHROEDER HA, 1962, J CHRON DIS, V15, P941, DOI 10.1016/0021-9681(62)90114-5; SHAH BG, 1990, TRACE ELEM MED, V7, P11; SIMONOFF M, 1992, BIOL TRACE ELEM RES, V32, P25, DOI 10.1007/BF02784584; SMITH BSW, 1970, CLIN CHIM ACTA, V27, P105, DOI 10.1016/0009-8981(70)90381-5; SNOW ET, 1994, ENVIRON HEALTH PERSP, V102, P41, DOI 10.1289/ehp.94102s341; Stearns DM, 1995, FASEB J, V9, P1643, DOI 10.1096/fasebj.9.15.8529845; TANDON SK, 1978, ENVIRON RES, V15, P90, DOI 10.1016/0013-9351(78)90082-8; TERAOKA H, 1981, ARCH ENVIRON HEALTH, V36, P155, DOI 10.1080/00039896.1981.10667620; VERSIECK J, 1985, CRC CR REV CL LAB SC, V22, P97, DOI 10.3109/10408368509165788; VUORI E, 1987, TRACE ELEM MED, V4, P88; WELINDER H, 1983, SCAND J WORK ENV HEA, V9, P307; WILLIAMS PL, 1989, GRAYS ANATOMY, P1384; SYMBOLIC DIFFERENTIA; 1993, TOXICOLOGICAL PROFIL, P106; 1988, NUTR REV, V46, P17	50	113	115	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1995	9	15					1650	1657		10.1096/fasebj.9.15.8529846	http://dx.doi.org/10.1096/fasebj.9.15.8529846			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TM761	8529846				2022-12-28	WOS:A1995TM76100020
J	JOHNSON, AK; GROSS, PM				JOHNSON, AK; GROSS, PM			SENSORY CIRCUMVENTRICULAR ORGANS AND BRAIN HOMEOSTATIC PATHWAYS	FASEB JOURNAL			English	Article						AV3V REGION; SODIUM; OSMOREGULATION; HYPOTHALAMIC SUPRAOPTIC AND PARAVENTRICULAR NUCLEI; DIPSOGENESIS; HYPOVOLEMIA; PITUITARY GLAND	RAT AREA POSTREMA; ANGIOTENSIN-II; VASOPRESSIN RELEASE; SUBFORNICAL ORGAN; THIRST; RECEPTORS; LOCALIZATION; RESPONSES; PEPTIDES; DRINKING	Circumventricular organs (CVOs), small structures bordering the ventricular spaces in the midline of the brain, have common morphological and endocrine-like characteristics that distinguish them from the rest of the nervous system. Among their unique features are cellular contacts with two fluid phases - blood and cerebrospinal fluid - and neural connections with strategic nuclei establishing circuitry for communications throughout the neuraxis. A variety of additional morphological and functional characteristics of the CVOs implicates this group of structures in a wide array of homeostatic processes. For three of the circumventricular organs - the subfornical organ (SFO), the organum vasculosum of the lamina terminalis (OVLT), and the area postrema (AP) - recent findings demonstrate these structures as targets for blood-borne information reaching the brain. We propose that these three sensory CVOs interact with other nuclei in the maintenance of several homeostatic processes by way of neural and humoral links. We emphasize the collective role of brain CVOs in the maintenance of body fluid homeostasis as a model for the functional integration of these fascinating ''windows of the brain'' within central neurohumoral systems.	UNIV IOWA, DEPT PHARMACOL, IOWA CITY, IA 52242 USA; UNIV IOWA, CTR CARDIOVASC, IOWA CITY, IA 52242 USA; QUEENS UNIV, DEPT SURG, NEUROSURG RES UNIT, KINGSTON K7L 3N6, ONTARIO, CANADA; QUEENS UNIV, DEPT PHYSIOL, NEUROSURG RES UNIT, KINGSTON K7L 3N6, ONTARIO, CANADA; KINGSTON GEN HOSP, KINGSTON K7L 2V7, ONTARIO, CANADA	University of Iowa; University of Iowa; Queens University - Canada; Queens University - Canada; Queens University - Canada	JOHNSON, AK (corresponding author), UNIV IOWA, DEPT PSYCHOL, 11 SEASHORE HALL E, IOWA CITY, IA 52242 USA.							ANDERSSON B, 1971, AM SCI, V59, P408; AREVALO R, 1992, BRAIN RES BULL, V28, P599, DOI 10.1016/0361-9230(92)90109-B; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; Brody MJ, 1980, FRONT NEUROENDOCRIN, P249; BUGGY J, 1979, AM J PHYSIOL, V236, pR75, DOI 10.1152/ajpregu.1979.236.1.R75; BUGGY J, 1977, AM J PHYSIOL, V233, pR44, DOI 10.1152/ajpregu.1977.233.1.R44; CARPENTER DO, 1983, CELL MOL NEUROBIOL, V3, P113, DOI 10.1007/BF00735276; CLEMENTE CD, 1957, AM J PHYSIOL, V188, P193, DOI 10.1152/ajplegacy.1956.188.1.193; DIBONA GF, 1982, REV PHYSIOL BIOCH P, V94, P75, DOI 10.1007/BFb0031333; FERGUSON AV, 1991, CAN J PHYSIOL PHARM, V69, P1026, DOI 10.1139/y91-153; FERRARIO CM, 1972, CIRC RES, V30, P257, DOI 10.1161/01.RES.30.3.257; Gross P.M, 1987, CIRCUMVENTRICULAR OR, V1; Gross P.M, 1987, CIRCUMVENTRICULAR OR, VIII; Gross P.M, 1987, CIRCUMVENTRICULAR OR, VII; GROSS PM, 1992, PROG BRAIN RES, V91, P219; GROSS PM, 1990, AM J PHYSIOL, V258, pR788, DOI 10.1152/ajpregu.1990.258.3.R788; GROSS PM, 1987, J CEREBR BLOOD F MET, V7, P663, DOI 10.1038/jcbfm.1987.120; GROSS PM, 1991, ENDOCRINOLOGY, V129, P1110, DOI 10.1210/endo-129-2-1110; GRUBER KA, 1987, CIRCUMVENTRICULAR OR, V2, P137; HOFER H, 1958, DT ZOOL GES VERHANDL, V8, P202; IOVINO M, 1988, BRAIN RES, V447, P178, DOI 10.1016/0006-8993(88)90982-1; JEWELL PA, 1957, PHILOS T R SOC B, V240, P197, DOI 10.1098/rstb.1957.0002; Johnson A. K., 1991, THIRST PHYSL PSYCHOL, P149; JOHNSON AK, 1978, AM J PHYSIOL, V234, pR122, DOI 10.1152/ajpregu.1978.234.3.R122; JOHNSON AK, 1990, PERSPECTIVES EXERCIS, V3, P347; Johnson AK, 1990, CENTRAL REGULATION A, P247; JOHNSON AK, 1985, VASOPRESSIN, P319; JOY MD, 1970, NATURE, V228, P1303, DOI 10.1038/2281303a0; KADEKARO M, 1983, BRAIN RES, V275, P189, DOI 10.1016/0006-8993(83)90436-5; KILPATRICK GJ, 1989, EUR J PHARMACOL, V159, P157, DOI 10.1016/0014-2999(89)90700-0; KRISCH B, 1992, PROG BRAIN RES, V91, P247; LANCA AJ, 1985, NEUROSCIENCE, V14, P1117, DOI 10.1016/0306-4522(85)90281-7; LANDAS S, 1987, CIRCUMVENTRICULAR OR, V1, P131; LESLIE RA, 1986, CELL MOL NEUROBIOL, V6, P95, DOI 10.1007/BF00711065; LESLIE RA, 1992, NEUROANATOMY PHYSL A, P81; Lind R.W., 1990, HDB CHEM NEUROANATOM, V9, P165; Lind R. W, 1987, CIRCUMVENTRICULAR OR, VI, P27; Loewy A., 1990, CENTRAL REGULATION A, P1; LUITEN PGM, 1987, PROG NEUROBIOL, V28, P1, DOI 10.1016/0301-0082(87)90004-9; MCKINLEY MJ, 1990, FRONT NEUROENDOCRIN, V11, P91; MCKINLEY MJ, 1978, BRAIN RES, V141, P89, DOI 10.1016/0006-8993(78)90619-4; MENDELSOHN FAO, 1987, CAN J PHYSIOL PHARM, V65, P1517, DOI 10.1139/y87-239; Miselis R. R., 1987, CIRCUMVENTRICULAR OR, VIII, P144; MISELIS RR, 1986, PHYSL THIRST SODIUM, P345; MOREL F, 1979, OSMOREGULATION WATER, P125; NORGREN R, 1981, BRAIN MECH SENSATION, P143; PALKOVITS M, 1965, Prog Brain Res, V10, P627; PALKOVITS M, 1987, CIRCUMVENTRICULAR OR, V2, P209; PHILLIPS MI, 1987, CIRCUMVENTRICULAR OR, V1, P158; QUIRION R, 1986, P NATL ACAD SCI USA, V83, P174, DOI 10.1073/pnas.83.1.174; Rodriguez EM, 1987, CIRCUMVENTRICULAR OR, VII, P3; SAWCHENKO PE, 1984, P NATL ACAD SCI-BIOL, V81, P1883, DOI 10.1073/pnas.81.6.1883; Severs W.B, 1987, CIRCUMVENTRICULAR OR, VII, P43; SIMPSON JB, 1981, NEUROENDOCRINOLOGY, V32, P248, DOI 10.1159/000123167; SPETH RC, 1985, BRAIN RES, V326, P137, DOI 10.1016/0006-8993(85)91392-7; STUMPF WE, 1992, PROG BRAIN RES, V91, P271; SUMMYLONG JY, 1987, CIRCUMVENTRICULAR OR, V2, P161; SWANSON LW, 1981, BRAIN RES REV, V3, P1, DOI 10.1016/0165-0173(81)90010-2; THRASHER TN, 1980, AM J PHYSIOL, V238, pR333, DOI 10.1152/ajpregu.1980.238.5.R333; THRASHER TN, 1982, NEUROENDOCRINOLOGY, V35, P68, DOI 10.1159/000123357; THRASHER TN, 1987, AM J PHYSIOL, V253, pR108, DOI 10.1152/ajpregu.1987.253.1.R108; TSUNEKI K, 1986, J HIRNFORSCH, V27, P441; UNDESSER KP, 1985, CIRC RES, V56, P410, DOI 10.1161/01.RES.56.3.410; WEINDL A, 1992, PROG BRAIN RES, V91, P261; Weindl A, 1973, FRONT NEUROENDOCRIN, P3; WILKIN LD, 1989, NEUROSCIENCE, V28, P573, DOI 10.1016/0306-4522(89)90006-7; YOSHIZAWA T, 1990, SCIENCE, V247, P462, DOI 10.1126/science.2405487	67	404	414	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1993	7	8					678	686		10.1096/fasebj.7.8.8500693	http://dx.doi.org/10.1096/fasebj.7.8.8500693			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LE290	8500693				2022-12-28	WOS:A1993LE29000010
J	Garcia-Sanz, JA; Mikulits, W; Livingstone, A; Lefkovits, I; Mullner, EW				Garcia-Sanz, JA; Mikulits, W; Livingstone, A; Lefkovits, I; Mullner, EW			Translational control: a general mechanism for gene regulation during T cell activation	FASEB JOURNAL			English	Article						translation initiation; mRNP particles; polysome-bound mRNA	EUKARYOTIC PROTEIN-SYNTHESIS; MESSENGER-RNA; LYMPHOCYTES-T; INITIATION; EXPRESSION; ELONGATION; INSULIN; KINASE; MOUSE	Distributional changes of individual mRNAs between free ribonucleoprotein particles (mRNP) and ribosome-bound transcripts are used to assess translational control, Simultaneous analysis of many mRNA species is required to estimate the overall contribution of translation to the regulation of gene expression, To this purpose, total cytoplasmic RNA was fractionated in sucrose step gradients and poly(A)(+) RNA was prepared from mRNP and ribosome-bound fractions, Since direct, simultaneous analysis of a profusion of mRNAs is not feasible, distribution of their in vitro translation products was examined after separation in 2-dimensional gels, followed by computer-based analysis of autoradiogaphs. When this analysis was applied to antigenically stimulated T cells, 36% of in vitro translation products showed a greater than 10-fold increase in intensity, suggesting transcriptional activation of the corresponding mRNAs, In comparison, 7.9% of individual mRNAs (54 of 685 species) were translationally activated, They were redistributed from free mRNP to ribosome-associated fractions; 4.7% (32 species) were translationally repressed, as indicated by the opposite pattern, The differential recruitment of 12.6% of mRNA species demonstrates specificity and the general significance of translational control during T cell activation, which implies that translation may play a similar role in regulating gene expression in a variety of physiological processes.	Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; Basel Inst Immunol, CH-4005 Basel, Switzerland; Univ Vienna, Inst Mol Biol, Vienna Bioctr, A-1030 Vienna, Austria	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)	Garcia-Sanz, JA (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus de Cantoblanco, E-28049 Madrid, Spain.	jasanz@cnb.uam.es	Mikulits, Wolfgang/AAH-4043-2021; Garcia-Sanz, Jose A./AAA-2956-2019; Garcia-Sanz, Jose A/E-7684-2011; Lefkovits, Ivan/B-9777-2009	Garcia-Sanz, Jose A./0000-0002-1153-6025; Garcia-Sanz, Jose A/0000-0002-1153-6025; Lefkovits, Ivan/0000-0003-1783-8881; Mikulits, Wolfgang/0000-0003-4612-7106				AHERN T, 1975, EXP CELL RES, V92, P513, DOI 10.1016/0014-4827(75)90410-3; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ANDERSON NG, 1978, ANAL BIOCHEM, V85, P331, DOI 10.1016/0003-2697(78)90229-4; Belasco J.G., 2012, CONTROL MESSENGER RN; BOAL TR, 1993, BIOCHIM BIOPHYS ACTA, V1176, P257, DOI 10.1016/0167-4889(93)90053-R; CLEMENS M, 1992, NATURE, V360, P210, DOI 10.1038/360210a0; COHEN RB, 1990, EMBO J, V9, P3831, DOI 10.1002/j.1460-2075.1990.tb07601.x; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DEBENEDETTI A, 1986, J BIOL CHEM, V261, P5800; DUNCAN RF, 1996, TRANSLATIONAL CONTRO, P271; Frederickson R M, 1992, Semin Cell Biol, V3, P107; FREY JR, 1994, MOL IMMUNOL, V31, P1219, DOI 10.1016/0161-5890(94)90072-8; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; GarciaSanz JA, 1996, J EXP MED, V184, P159, DOI 10.1084/jem.184.1.159; GOODWIN EB, 1993, CELL, V75, P329, DOI 10.1016/0092-8674(93)80074-O; GROSS PR, 1963, BIOCHEM BIOPH RES CO, V10, P321, DOI 10.1016/0006-291X(63)90532-1; Hershey JWB, 1996, TRANSLATIONAL CONTRO; HULTIN T, 1961, EXP CELL RES, V25, P405, DOI 10.1016/0014-4827(61)90290-7; HUMPHREYS T, 1971, DEV BIOL, V26, P318; ILAN J, 1993, TRANSLATIONAL REGULA, V2; JEDLICKA P, 1991, J BIOL CHEM, V266, P15663; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P98; KNOFLER M, 1993, J BIOL CHEM, V268, P11409; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; MEHUHAS O, 1996, TRANSLATIONAL CONTRO, P363; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MOREL PA, 1987, J EXP MED, V166, P583, DOI 10.1084/jem.166.2.583; Mullner E. W., 1997, MANUAL IMMUNOLOGICAL, V1, P457; MULLNER EW, 1997, MANUAL IMMUNOLOGICAL, V1, P389; MULLNER EW, 1997, IMMUNOLOGY METHODS M, V1, P407; MULLNER EW, 1997, MANUAL IMMUNOLOGICAL, V1, P463; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Paulin FEM, 1996, ONCOGENE, V13, P505; REDPATH NT, 1994, BBA-MOL CELL RES, V1220, P147, DOI 10.1016/0167-4889(94)90130-9; Redpath NT, 1996, EMBO J, V15, P2291, DOI 10.1002/j.1460-2075.1996.tb00582.x; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; ROUAULT TA, 1996, TRANSLATIONAL CONTRO, P335; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WELSH M, 1986, BIOCHEM J, V235, P459, DOI 10.1042/bj2350459; WETTENHALL RE, 1974, BIOCHIM BIOPHYS ACTA, V349, P214, DOI 10.1016/0005-2787(74)90082-3; WICKENS M, 1993, NATURE, V363, P305, DOI 10.1038/363305a0; WORMINGTON M, 1994, BIOESSAYS, V16, P533, DOI 10.1002/bies.950160804	45	46	62	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1998	12	3					299	306		10.1096/fasebj.12.3.299	http://dx.doi.org/10.1096/fasebj.12.3.299			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YZ898	9506473				2022-12-28	WOS:000072305500018
J	Sachs, LM; Abdallah, B; Hassan, A; Levi, G; DeLuze, A; Reed, JC; Demeneix, BA				Sachs, LM; Abdallah, B; Hassan, A; Levi, G; DeLuze, A; Reed, JC; Demeneix, BA			Apoptosis in Xenopus tadpole tail muscles involves Bax-dependent pathways	FASEB JOURNAL			English	Article						thyroid hormone; metamorphosis; in vivo gene transfer	PROGRAMMED CELL-DEATH; THYROID-HORMONE; IN-VIVO; AMPHIBIAN METAMORPHOSIS; GENE-EXPRESSION; BCL-2; SURVIVAL; CLONING; INSITU; P53	Apoptosis is a fundamental mechanism implicated in normal development. One of the most spectacular developmental events involving apoptosis is tail regression during amphibian metamorphosis. We analyzed how thyroid hormone (3, 5, 3'-triiodothyronine, T-3), the orchestrator of metamorphosis, affects expression and function of the proapoptotic gene Bax in the tail muscle of free-living Xenopus tadpoles. During natural metamorphosis Bax mRNA was expressed in tail muscles and was spatially correlated with apoptosis, Precocious treatment of tadpoles with T-3 induced Bax expression and apoptosis. To verify that Bax expression was causally related to apoptosis we used a naked DNA gene transfer method to express Bax in the dorsal tail muscle. This induced apoptosis, and the process was exacerbated by T-3 treatment. To determine whether T-3 effects on Bax expression involved transcriptional regulation, we injected a Bax promoter sequence into dorsal and caudal tail muscles. In the dorsal muscle, T-3 treatment did not affect transcription from the Bax promoter. However, in the caudal muscle, T-3 treatment significantly increased Bax transcription. We conclude that T-3-induced apoptosis in Xenopus tadpole tail muscles involves Bax-activating and Bax-synergistic mechanisms, These programs are induced in spatially and temporally distinct manners.	MUSEUM NATL HIST NAT, LAB PHYSIOL GEN & COMPAREE, URA CNRS 90, F-75231 PARIS 5, FRANCE; IST, CBA, MOL BIOL LAB, GENOA, ITALY; BURNHAM INST, LA JOLLA, CA 92037 USA	Museum National d'Histoire Naturelle (MNHN); Sanford Burnham Prebys Medical Discovery Institute			Levi, Giovanni/B-4416-2013; Sachs, Laurent/AAE-1504-2020	Levi, Giovanni/0000-0002-7041-6787				CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CRUZREYES J, 1995, GENE, V158, P171, DOI 10.1016/0378-1119(95)00159-4; DELUZE A, 1993, P NATL ACAD SCI USA, V90, P7322, DOI 10.1073/pnas.90.15.7322; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HOCKENBERY DM, 1995, BIOESSAYS, V17, P631, DOI 10.1002/bies.950170709; KERR JFR, 1974, J CELL SCI, V14, P571; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; LELOUP J, 1977, CR ACAD SCI D NAT, V284, P2261; MACHUCA I, 1992, MOL CELL ENDOCRINOL, V87, P105, DOI 10.1016/0303-7207(92)90238-2; Middleton G, 1996, DEVELOPMENT, V122, P695; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; NIEUKOOP PD, 1975, NORMAL TABLE XENOPUS; NIKI K, 1982, DEV BIOL, V94, P116, DOI 10.1016/0012-1606(82)90074-4; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SACHS L, 1996, ENDOCRINOLOGY, V137, P1291; SAMBROOK J, 1989, MOL CLONIGN LAB MANU; Shi YB, 1996, BIOESSAYS, V18, P391, DOI 10.1002/bies.950180509; SOUSSI T, 1987, ONCOGENE, V1, P71; TATA JR, 1994, BIOCHEM CELL BIOL, V72, P581, DOI 10.1139/o94-077; TATA JR, 1993, BIOESSAYS, V15, P239, DOI 10.1002/bies.950150404; WANG Z, 1993, J BIOL CHEM, V268, P16270; Werner MH, 1996, STRUCTURE, V4, P879, DOI 10.1016/S0969-2126(96)00094-9; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHITFIELD HJ, 1990, CELL MOL NEUROBIOL, V10, P145, DOI 10.1007/BF00733641; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yaoita Y, 1997, J BIOL CHEM, V272, P5122, DOI 10.1074/jbc.272.8.5122	33	48	49	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1997	11	10					801	808		10.1096/fasebj.11.10.9271365	http://dx.doi.org/10.1096/fasebj.11.10.9271365			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XR105	9271365				2022-12-28	WOS:A1997XR10500010
J	Jackson, JR; Seed, MP; Kircher, CH; Willoughby, DA; Winkler, JD				Jackson, JR; Seed, MP; Kircher, CH; Willoughby, DA; Winkler, JD			The codependence of angiogenesis and chronic inflammation	FASEB JOURNAL			English	Review						steroids; rheumatoid arthritis; cytokine inhibitor; growth factor	ENDOTHELIAL GROWTH-FACTOR; CHRONIC GRANULOMATOUS INFLAMMATION; NECROSIS-FACTOR-ALPHA; CARTILAGE DEGRADATION; CELL-PROLIFERATION; FACTOR EXPRESSION; TYROSINE KINASE; IN-VITRO; INHIBITION; AGM-1470	Angiogenesis is the growth of new blood vessels from existing ones, It is an important aspect of new tissue development, growth, and tissue repair, It is also a component of many diseases including cancer, blindness, and chronic inflammation such as rheumatoid arthritis (RA) and psoriasis, There is considerable evidence to suggest that angiogenesis and chronic inflammation are codependent; recent studies have begun to reveal the nature of this link, which involves both augmentation of cellular infiltration and proliferation and overlapping roles of regulatory growth factors and cytokines. Through these studies, we have begun to understand the codependence of chronic inflammation and angiogenesis, the potential benefits of targeting angiogenesis in the treatment of chronic inflammation, and of targeting chronic inflammation to affect angiogenesis.	SMITHKLINE BEECHAM PHARMACEUT,DEPT IMMUNOPHARMACOL,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PATHOL TOXICOL,KING OF PRUSSIA,PA 19406; ST BARTHOLOMEWS HOSP,COLL MED,WILLIAM HARVEY RES INST,DEPT EXPT PATHOL,LONDON,ENGLAND	GlaxoSmithKline; GlaxoSmithKline; University of London; Queen Mary University London				Seed, Michael/0000-0001-7053-4743				ALAM CAS, 1995, J PHARM PHARMACOL, V47, P407, DOI 10.1111/j.2042-7158.1995.tb05820.x; ANTOINE N, 1995, J NATL CANCER I, V87, P136, DOI 10.1093/jnci/87.2.136; Appleton I, 1996, Adv Pharmacol, V35, P27, DOI 10.1016/S1054-3589(08)60274-4; APPLETON I, 1996, IN PRESS J PATHOL; AUERBACH W, 1994, PHARMACOL THERAPEUT, V63, P265, DOI 10.1016/0163-7258(94)90027-2; BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A; BenEzra D, 1996, INVEST OPHTH VIS SCI, V37, P4664; BERGER AE, 1993, AGENTS ACTIONS, V39, pC86, DOI 10.1007/BF01972729; BOTTOMLEY KMK, 1988, BRIT J PHARMACOL, V93, P627, DOI 10.1111/j.1476-5381.1988.tb10320.x; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; CAMUSSI G, 1995, J IMMUNOL, V154, P6492; COCKERILL GW, 1995, INT REV CYTOL, V159, P113, DOI 10.1016/S0074-7696(08)62106-3; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; COLVILLENASH PR, 1995, J PHARMACOL EXP THER, V274, P1463; COLVILLENASH PR, 1993, AGENTS ACTIONS, V38, P126, DOI 10.1007/BF02027224; COLVILLENASH PR, 1993, CURR OPIN INVEST DR, V2, P763; DIMARTINO MJ, 1994, ANN NY ACAD SCI, V732, P411, DOI 10.1111/j.1749-6632.1994.tb24769.x; DUNN CJ, 1991, DRUG DEVELOP RES, V23, P241; FAJARDO LF, 1992, AM J PATHOL, V140, P539; FAN TPD, 1995, TRENDS PHARMACOL SCI, V16, P57, DOI 10.1016/S0165-6147(00)88979-8; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J., 1992, INFLAMMATION BASIC P, P821; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FORM DM, 1983, P SOC EXP BIOL MED, V172, P214; FREEMANTLE C, 1996, INT J TISSUE REACT, V17, P157; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GALARDY RE, 1994, CANCER RES, V54, P4715; HIRATA S, 1989, ARTHRITIS RHEUM, V32, P1065, DOI 10.1002/anr.1780320903; Hori Y, 1996, BRIT J PHARMACOL, V118, P1584, DOI 10.1111/j.1476-5381.1996.tb15578.x; HU DE, 1995, BRIT J PHARMACOL, V114, P262; HU DE, 1994, INFLAMMATION, V18, P45, DOI 10.1007/BF01534597; HUDSON N, 1995, GUT, V37, P191, DOI 10.1136/gut.37.2.191; JACKSON JR, 1996, PHARM REV COMMUN, V8, P81; KIMURA M, 1986, J PHARMACOBIO-DYNAM, V9, P442, DOI 10.1248/bpb1978.9.442; KOCH AE, 1995, NATURE, V376, P517, DOI 10.1038/376517a0; KOCH AE, 1988, BIOCHEM BIOPH RES CO, V154, P205, DOI 10.1016/0006-291X(88)90671-7; KOCH AE, 1986, J LEUKOCYTE BIOL, V39, P233, DOI 10.1002/jlb.39.2.233; KUSAKA M, 1994, BRIT J CANCER, V69, P212, DOI 10.1038/bjc.1994.41; KUSAKA M, 1991, BIOCHEM BIOPH RES CO, V174, P1070, DOI 10.1016/0006-291X(91)91529-L; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MATSUBARA T, 1989, J CLIN INVEST, V83, P158, DOI 10.1172/JCI113853; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; NAGASHIMA M, 1995, J RHEUMATOL, V22, P1624; NICKOLOFF BJ, 1994, AM J PATHOL, V144, P820; NICOSIA RF, 1994, AM J PATHOL, V145, P1023; OLIVER SJ, 1995, CELL IMMUNOL, V166, P196, DOI 10.1006/cimm.1995.9978; OREILLY MS, 1995, MOL BIOL CELL, V6, P672; PEACOCK DJ, 1995, CELL IMMUNOL, V160, P178, DOI 10.1016/0008-8749(95)80025-E; PEACOCK DJ, 1992, J EXP MED, V175, P1135, DOI 10.1084/jem.175.4.1135; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; SLAVIN J, 1995, CELL BIOL INT, V19, P431, DOI 10.1006/cbir.1995.1087; SPISNI E, 1992, PROSTAG LEUKOTR ESS, V47, P111, DOI 10.1016/0952-3278(92)90146-A; STAN AC, 1995, J NEUROSURG, V82, P1044, DOI 10.3171/jns.1995.82.6.1044; Stjernschantz J, 1989, Prog Clin Biol Res, V312, P155; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410; TARABOLETTI G, 1995, J NATL CANCER I, V87, P293, DOI 10.1093/jnci/87.4.293; VILLASCHI S, 1994, LAB INVEST, V71, P291	61	575	608	1	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1997	11	6					457	465		10.1096/fasebj.11.6.9194526	http://dx.doi.org/10.1096/fasebj.11.6.9194526			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XE404	9194526				2022-12-28	WOS:A1997XE40400008
J	Falany, CN				Falany, CN			Sulfation and sulfotransferases .3. Enzymology of human cytosolic sulfotransferases	FASEB JOURNAL			English	Review						sulfation; xenobiotics; steroid; drug metabolism; human	LIVER DEHYDROEPIANDROSTERONE SULFOTRANSFERASE; HUMAN PHENOL SULFOTRANSFERASE; ESTROGEN SULFOTRANSFERASE; HYDROXYSTEROID SULFOTRANSFERASE; IMMUNOLOGICAL CHARACTERIZATION; HUMAN-PLATELET; CDNA CLONING; HUMAN-BRAIN; RAT-LIVER; FUNCTIONAL-CHARACTERIZATION	Conjugation of many xenobiotics, drugs, and endogenous compounds with a sulfonate moiety is an important reaction in their biotransformation. Sulfation of these compounds generally results in a decrease in biological activity and an increase in their urinary excretion. However, in certain instances, sulfation results in bioactivation to reactive electrophilic or therapeutically active forms. At least four cytosolic sulfotransferases (STs) have been identified and characterized from human tissues. These enzymes are two forms of phenol ST (PST), the phenol-sulfating and the monoamine-sulfating forms of PST (P-PST and M-PST, respectively), an estrogen sulfotransferase (EST), and a hydroxysteroid ST, dehydroepiandrosterone ST (DHEA-ST). Although four cytosolic STs have been well characterized in human tissues, evidence is accumulating for the presence of allelic forms or additional distinct forms of the STs in human tissues. The STs possess distinct but overlapping substrate specificities, and all of tile STs are capable of conjugating both xenobiotic and endogenous compounds. The individual forms of ST may display distinct patterns of tissue specific expression and different mechanisms of regulation. Although the role of sulfation in drug metabolism is well recognized, an increased understanding of the biochemistry and molecular biology of the STs should also provide additional information as to their functions in many normal physiologic processes.-Falany, C. N. Enzymology of human cytosolic sulfotransferases.			Falany, CN (corresponding author), UNIV ALABAMA, DEPT PHARMACOL & TOXICOL, 1670 UNIV BLVD, BIRMINGHAM, AL 35294 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038953, R29GM038953] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38953] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JB, 1979, BIOCHIM BIOPHYS ACTA, V567, P144, DOI 10.1016/0005-2744(79)90181-5; AKSOY IA, 1993, DRUG METAB DISPOS, V21, P268; AKSOY IA, 1993, CLIN PHARMACOL THER, V54, P498, DOI 10.1038/clpt.1993.181; AKSOY IA, 1993, BIOCHEM BIOPH RES CO, V4, P181; BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; BARKER EV, 1994, ENDOCRINOLOGY, V134, P982, DOI 10.1210/en.134.2.982; BARNES S, 1989, J LIPID RES, V30, P529; BARNES S, 1991, OXFORD TXB CLIN HEPA, P115; BARRETTCONNOR E, 1986, NEW ENGL J MED, V315, P1519, DOI 10.1056/NEJM198612113152405; Baumann E, 1876, DTSCH CHEM GES, P54; Baxter JD, 1987, ENDOCRINOL METAB, P511; BROOKS SC, 1983, STEROIDS ENDOMETRIAL, P145; CAMPBELL NRC, 1987, BIOCHEM PHARMACOL, V36, P1435, DOI 10.1016/0006-2952(87)90108-0; CASEY ML, 1983, J STEROID BIOCHEM, V19, P1403, DOI 10.1016/0022-4731(83)91114-7; CLARKE CL, 1982, J CLIN ENDOCR METAB, V55, P70, DOI 10.1210/jcem-55-1-70; COMER KA, 1993, BIOCHEM J, V289, P233, DOI 10.1042/bj2890233; COMER KA, 1992, MOL PHARMACOL, V41, P645; DOOLEY TP, 1993, GENOMICS, V18, P440, DOI 10.1006/geno.1993.1494; DOOLEY TP, 1994, BIOCHEM BIOPH RES CO, V205, P482, DOI 10.1006/bbrc.1994.2691; Falany CN, 1995, ANN NY ACAD SCI, V774, P59, DOI 10.1111/j.1749-6632.1995.tb17372.x; FALANY CN, 1995, J STEROID BIOCHEM, V52, P529, DOI 10.1016/0960-0760(95)00015-R; FALANY CN, 1990, BIOCHEM PHARMACOL, V40, P1027, DOI 10.1016/0006-2952(90)90489-8; FALANY CN, 1990, ARCH BIOCHEM BIOPHYS, V278, P312, DOI 10.1016/0003-9861(90)90265-Z; FALANY CN, 1989, BIOCHEM J, V260, P641, DOI 10.1042/bj2600641; FALANY CN, 1992, J BIOCHEM TOXICOL, V7, P241, DOI 10.1002/jbt.2570070407; FALANY CN, 1994, J STEROID BIOCHEM, V48, P369, DOI 10.1016/0960-0760(94)90077-9; Falany JL, 1996, ENDOCRINOLOGY, V137, P1395, DOI 10.1210/en.137.4.1395; Falany JL, 1996, CANCER RES, V56, P1551; FEHER T, 1975, CAN J BIOCHEM CELL B, V53, P215, DOI 10.1139/o75-030; FORBES KJ, 1995, MOL CELL ENDOCRINOL, V112, P53, DOI 10.1016/0303-7207(95)03585-U; FORBESBAMFORTH KJ, 1994, BIOCHEM BIOPH RES CO, V198, P707, DOI 10.1006/bbrc.1994.1102; GANGULY TC, 1995, DRUG METAB DISPOS, V23, P945; GLATT H, 1995, EUR J PHARM-ENVIRON, V293, P173, DOI 10.1016/0926-6917(95)90002-0; GLATT H, IN PRESS FASEB J, V11; GROSSO DS, 1984, J CLIN ENDOCR METAB, V59, P829, DOI 10.1210/jcem-59-5-829; GURPIDE E, 1982, AM J OBSTET GYNECOL, V144, P551, DOI 10.1016/0002-9378(82)90226-5; HART RF, 1979, LIFE SCI, V24, P125, DOI 10.1016/0024-3205(79)90121-8; HENDRIXTREACY S, 1986, EUR J CLIN PHARMACOL, V30, P273, DOI 10.1007/BF00541527; HER C, 1995, GENOMICS, V29, P16, DOI 10.1006/geno.1995.1210; HERNANDEZ JS, 1992, DRUG METAB DISPOS, V20, P413; HEROUX JA, 1988, MOL PHARMACOL, V34, P194; HEROUX JA, 1989, MOL PHARMACOL, V36, P29; HOBKIRK R, 1993, TRENDS ENDOCRIN MET, V4, P69, DOI 10.1016/S1043-2760(05)80018-9; HOMMA H, 1994, CHEM-BIOL INTERACT, V92, P15, DOI 10.1016/0009-2797(94)90049-3; Hornsby PJ, 1995, ANN NY ACAD SCI, V774, P29, DOI 10.1111/j.1749-6632.1995.tb17370.x; HUME R, 1994, HISTOCHEM J, V26, P850, DOI 10.1007/BF00162930; Hume R, 1996, HISTOCHEM CELL BIOL, V105, P147, DOI 10.1007/BF01696154; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P199; JONES AL, 1995, BIOCHEM BIOPH RES CO, V208, P855, DOI 10.1006/bbrc.1995.1414; KENNERSON AR, 1983, J CLIN ENDOCR METAB, V56, P786, DOI 10.1210/jcem-56-4-786; KIEHLBAUCH CC, 1995, J BIOL CHEM, V270, P18941, DOI 10.1074/jbc.270.32.18941; KONG ANT, 1992, BIOCHEM BIOPH RES CO, V187, P448, DOI 10.1016/S0006-291X(05)81514-1; KUDLACEK PE, 1995, BIOCHEM BIOPH RES CO, V210, P363, DOI 10.1006/bbrc.1995.1670; LIU HC, 1979, ENDOCRINOLOGY, V104, P1674, DOI 10.1210/endo-104-6-1674; Longcope C, 1995, ANN NY ACAD SCI, V774, P143, DOI 10.1111/j.1749-6632.1995.tb17378.x; Majewska MD, 1995, ANN NY ACAD SCI, V774, P111, DOI 10.1111/j.1749-6632.1995.tb17375.x; MATSUI M, 1994, INT J BIOCHEM, V26, P1237; MCALLISTER JM, 1988, ENDOCRINOLOGY, V122, P2012, DOI 10.1210/endo-122-5-2012; MCCALL JM, 1983, J MED CHEM, V26, P1791, DOI 10.1021/jm00366a030; MEISHERI KD, 1988, J PHARMACOL EXP THER, V245, P751; MILLER EC, 1985, CARCINOGENESIS LOND, V11, P93; MORRIS ME, 1983, CLIN PHARMACOL THER, V33, P529, DOI 10.1038/clpt.1983.72; MORTOLA JF, 1990, J CLIN ENDOCR METAB, V71, P696, DOI 10.1210/jcem-71-3-696; MOUELHI M E, 1986, Hepatology, V6, P450, DOI 10.1002/hep.1840060322; Mulder G.J., 1990, CONJUGATION REACTION, P107; MULDER GJ, 1984, PROG DRUG METAB, V8, P35; OBINATA K, 1994, SCAND J CLIN LAB INV, V54, P285, DOI 10.3109/00365519409087524; ORENTREICH N, 1984, J CLIN ENDOCR METAB, V59, P551, DOI 10.1210/jcem-59-3-551; OTTERNESS DM, 1995, CYTOGENET CELL GENET, V70, P45, DOI 10.1159/000133988; OTTERNESS DM, 1992, MOL PHARMACOL, V41, P865; OZAWA S, 1995, PHARMACOGENETICS, V5, pS135, DOI 10.1097/00008571-199512001-00015; PACK BA, 1979, J CLIN ENDOCR METAB, V48, P420, DOI 10.1210/jcem-48-3-420; PANG KS, 1990, CONJUGATION REACTION, P5; PARKER CR, 1994, J CLIN ENDOCR METAB, V78, P234, DOI 10.1210/jc.78.1.234; RADOMINSKA A, 1990, BIOCHEM J, V272, P597, DOI 10.1042/bj2720597; REITER C, 1983, N-S ARCH PHARMACOL, V324, P140, DOI 10.1007/BF00497020; REVELEY AM, 1983, J PSYCHIAT RES, V17, P303, DOI 10.1016/0022-3956(82)90009-7; ROBBINS PW, 1956, J AM CHEM SOC, V78, P2652, DOI 10.1021/ja01592a097; ROTH JA, 1982, BIOCHEM PHARMACOL, V31, P3017, DOI 10.1016/0006-2952(82)90073-9; ROTH JA, 1986, TRENDS PHARMACOL SCI, V7, P404, DOI 10.1016/0165-6147(86)90402-5; ROY AK, 1992, P SOC EXP BIOL MED, V199, P265; RUNGEMORRIS M, 1991, BIOCHEM BIOPH RES CO, V175, P1051, DOI 10.1016/0006-291X(91)91671-X; SCHWARTZ AG, 1988, ADV CANCER RES, V51, P391, DOI 10.1016/S0065-230X(08)60227-4; SPAULDING SW, 1992, J CLIN ENDOCR METAB, V74, P1062, DOI 10.1210/jc.74.5.1062; STIEHL A, 1977, LIVER BILE, P129; SUNDARAM RS, 1989, CLIN PHARMACOL THER, V46, P501, DOI 10.1038/clpt.1989.178; TSENG L, 1983, J STEROID BIOCHEM, V19, P1413, DOI 10.1016/0022-4731(83)91116-0; TYCE GM, 1980, J NEUROCHEM, V34, P210, DOI 10.1111/j.1471-4159.1980.tb04642.x; VERONESE ME, 1994, BIOCHEM J, V302, P497, DOI 10.1042/bj3020497; Visser TJ, 1996, EUR J ENDOCRINOL, V134, P12, DOI 10.1530/eje.0.1340012; WALDON DJ, 1989, J INVEST DERMATOL, V92, P538; WALLE T, 1992, DRUG METAB DISPOS, V20, P333; WALLE T, 1993, DRUG METAB DISPOS, V21, P76; WALLE T, 1994, CHEM-BIOL INTERACT, V92, P47, DOI 10.1016/0009-2797(94)90052-3; WANG DY, 1967, J ENDOCRINOL, V38, P307, DOI 10.1677/joe.0.0380307; WEINSHILBOUM R, 1988, CELL MOL NEUROBIOL, V8, P27, DOI 10.1007/BF00712908; WEINSHILBOUM R, 1990, PHARMACOL THERAPEUT, V45, P93, DOI 10.1016/0163-7258(90)90010-Y; WEINSHILBOUM RM, 1986, FASEB J, V45, P2223; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; WHITTEMORE RM, 1985, BIOCHEMISTRY-US, V24, P2477, DOI 10.1021/bi00331a013; WOOD TC, 1994, BIOCHEM BIOPH RES CO, V198, P1119, DOI 10.1006/bbrc.1994.1159; YOUNG WF, 1988, ENDOCRINOLOGY, V122, P1816, DOI 10.1210/endo-122-5-1816; YOUNG WF, 1985, J NEUROCHEM, V44, P1131, DOI 10.1111/j.1471-4159.1985.tb08734.x; ZHU XY, 1993, BIOCHEM BIOPH RES CO, V195, P120, DOI 10.1006/bbrc.1993.2018; ZOU JY, 1990, J NEUROCHEM, V55, P1154, DOI 10.1111/j.1471-4159.1990.tb03119.x	106	489	500	2	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1997	11	4					206	216		10.1096/fasebj.11.4.9068609	http://dx.doi.org/10.1096/fasebj.11.4.9068609			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WM850	9068609				2022-12-28	WOS:A1997WM85000002
J	Mundlos, S; Olsen, BR				Mundlos, S; Olsen, BR			Heritable diseases of the skeleton .3. Molecular insights into skeletal development-matrix components and their homeostasis	FASEB JOURNAL			English	Article						bone; chondrodysplasia; growth plate; mutation; skeletal development	MULTIPLE EPIPHYSEAL DYSPLASIA; LETHAL OSTEOGENESIS IMPERFECTA; SCHMID METAPHYSEAL CHONDRODYSPLASIA; ALPHA-1(II) COLLAGEN CHAINS; AGGRECAN CORE PROTEIN; II GENE COL2A1; SPONDYLOEPIPHYSEAL DYSPLASIA; MEDIATED RECOMBINATION; PERICENTROMERIC REGION; DIASTROPHIC DYSPLASIA	A range of osteochondrodysplasias is caused by mutations in components of the extracellular matrix in cartilage and bone and in molecules that are important for posttranslational processing of such components. Mutations in the genes encoding the two polypeptide subunits of collagen I cause defects iu the structure of bone matrix while mutations iu genes encoding cartilage-specific collagens are responsible for several chondrodysplasias. Abnormalities in cartilage structure and function can also be due to mutations in structural noncollagenous components such as aggrecan and cartilage oligomeric matrix protein. Finally, several cartilage and hone disorders are due to abnormalities in sulfate transport and regulation of bone matrix homeostasis.-Mundlos, S., Olsen, B. R. Heritable diseases of the skeleton. Part II: Molecular insights into skeletal development-matrix components and their homeostasis.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School			Mundlos, Stefan/ABH-9585-2020		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036820, R37AR036819, R37AR036820, R01AR036819] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR36819, AR36820] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AHMAD NN, 1991, P NATL ACAD SCI USA, V88, P6624, DOI 10.1073/pnas.88.15.6624; BARSH GS, 1985, P NATL ACAD SCI USA, V82, P2870, DOI 10.1073/pnas.82.9.2870; BATEMAN JF, 1992, BIOCHEM J, V288, P131, DOI 10.1042/bj2880131; BATEMAN JF, 1994, MATRIX BIOL, V14, P251, DOI 10.1016/0945-053X(94)90189-9; BONADIO J, 1990, P NATL ACAD SCI USA, V87, P7145, DOI 10.1073/pnas.87.18.7145; BRIGGS MD, 1993, GENOMICS, V18, P656, DOI 10.1016/S0888-7543(05)80369-6; BRIGGS MD, 1994, AM J HUM GENET, V55, P678; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; Byers Peter H., 1993, P317; BYERS PH, 1991, J MED GENET, V28, P433, DOI 10.1136/jmg.28.7.433; CHAN D, 1995, J BIOL CHEM, V270, P4558, DOI 10.1074/jbc.270.9.4558; CHAN D, 1993, J BIOL CHEM, V268, P15238; CHAN D, 1995, J BIOL CHEM, V270, P1747, DOI 10.1074/jbc.270.4.1747; CHAN D, 1991, J BIOL CHEM, V266, P12487; CHEAH KSE, 1991, DEVELOPMENT, V111, P945; CHIPMAN SD, 1993, P NATL ACAD SCI USA, V90, P1701, DOI 10.1073/pnas.90.5.1701; CHU ML, 1985, J BIOL CHEM, V260, P691; COHN DH, 1993, HUM MUTAT, V2, P21, DOI 10.1002/humu.1380020105; DEAK SB, 1983, J BIOL CHEM, V258, P5192; DEERE M, 1995, AM J HUM GENET, V56, P698; EYRE DR, 1986, AM J HUM GENET, V39, P52; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; Garnero P, 1996, J BONE MINER RES, V11, P827; GELB BD, 1995, NAT GENET, V10, P235, DOI 10.1038/ng0695-235; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; Gong YQ, 1996, AM J HUM GENET, V59, P146; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HASTBACKA J, 1992, NAT GENET, V2, P204, DOI 10.1038/ng1192-204; Hastbacka J., 1995, American Journal of Human Genetics, V57, pA48; HECHT JT, 1993, GENOMICS, V18, P661, DOI 10.1016/S0888-7543(05)80370-2; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; HORTON WA, 1979, PEDIATR RES, V13, P904, DOI 10.1203/00006450-197908000-00007; Houston LA, 1996, BONE, V18, P249, DOI 10.1016/8756-3282(95)00483-1; HUSTMYER FG, 1994, J CLIN INVEST, V94, P2130, DOI 10.1172/JCI117568; JACENKO O, 1993, NATURE, V365, P56, DOI 10.1038/365056a0; LI H, 1993, J BIOL CHEM, V268, P23504; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; LIM SK, 1995, J CLIN ENDOCR METAB, V80, P3677, DOI 10.1210/jc.80.12.3677; MAYNE R, 1993, J BIOL CHEM, V268, P9381; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; Mundlos S, 1996, AM J MED GENET, V63, P129; Mundlos S, 1997, FASEB J, V11, P125, DOI 10.1096/fasebj.11.2.9039954; Mundlos S, 1996, J BIOL CHEM, V271, P21068, DOI 10.1074/jbc.271.35.21068; MUNDLOS S, 1991, MATRIX, V11, P339, DOI 10.1016/S0934-8832(11)80205-2; Muragaki Y, 1996, NAT GENET, V12, P103, DOI 10.1038/ng0196-103; NAKATA K, 1993, P NATL ACAD SCI USA, V90, P2870, DOI 10.1073/pnas.90.7.2870; OEHLMANN R, 1994, AM J HUM GENET, V54, P3; OLSEN BR, 1995, CURR OPIN CELL BIOL, V7, P720, DOI 10.1016/0955-0674(95)80115-4; Pace JM, 1997, DEV DYNAM, V208, P25; PENNYPACKER JP, 1981, DEV BIOL, V81, P280, DOI 10.1016/0012-1606(81)90291-8; PIHLAJANIEMI T, 1984, J BIOL CHEM, V259, P2941; RINTALA M, 1993, J CRAN GENET DEV BIO, V13, P137; ROSATI R, 1994, NAT GENET, V8, P129, DOI 10.1038/ng1094-129; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; SCHNIEKE A, 1983, NATURE, V304, P315, DOI 10.1038/304315a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPRANGER J, 1994, EUR J PEDIATR, V153, P56, DOI 10.1007/BF01959208; STACEY A, 1988, NATURE, V332, P131, DOI 10.1038/332131a0; STANESCU R, 1993, AM J MED GENET, V45, P501, DOI 10.1002/ajmg.1320450420; STANESCU V, 1984, J BONE JOINT SURG AM, V66A, P817, DOI 10.2106/00004623-198466060-00002; SupertiFurga A, 1996, NAT GENET, V12, P100, DOI 10.1038/ng0196-100; VANDENBERG P, 1991, P NATL ACAD SCI USA, V88, P7640, DOI 10.1073/pnas.88.17.7640; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X; WANG Q, 1993, J BIOL CHEM, V268, P25162; WARMAN ML, 1993, NAT GENET, V5, P79, DOI 10.1038/ng0993-79; WATANABE H, 1994, NAT GENET, V7, P154, DOI 10.1038/ng0694-154; WENSTRUP RJ, 1991, J BIOL CHEM, V266, P2590; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; Willing MC, 1996, AM J HUM GENET, V59, P799; WILLING MC, 1988, J BIOL CHEM, V263, P8398; WINTERPACHT A, 1993, NAT GENET, V3, P323, DOI 10.1038/ng0493-323; Zabel B, 1996, AM J MED GENET, V63, P123	73	108	111	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1997	11	4					227	233		10.1096/fasebj.11.4.9068611	http://dx.doi.org/10.1096/fasebj.11.4.9068611			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WM850	9068611				2022-12-28	WOS:A1997WM85000004
J	VantHof, RJ; VonLindern, M; Nijweide, PJ; Beug, H				VantHof, RJ; VonLindern, M; Nijweide, PJ; Beug, H			Stem cell factor stimulates chicken osteoclast activity in vitro	FASEB JOURNAL			English	Article						osteoblast; RT-PCR; fibroblasts; bone marrow	OSTEOBLAST-LIKE CELLS; BONE-RESORPTION; PARATHYROID-HORMONE; GROWTH-FACTOR; KIT-LIGAND; DIFFERENTIATION; RELEASE; CULTURE; INTERLEUKIN-6; EXPRESSION	Stem cell factor (SCF) is a polypeptide growth factor active on multiple cell types, mainly of hematopoietic origin, We studied the effects of avian SCF on the differentiation of chicken osteoclasts from their putative progenitors as well as on the bone-resorbing activity of terminally differentiated osteoclasts, Osteoclast formation was analyzed in long-term cocultures of osteoblasts and nonadherent, osteoclast-depleted bone marrow cells, Osteoclast activity was studied in short-term (48 h) cultures of bone marrow cell populations enriched for osteoclasts, on dentine slices, SCF strongly enhanced osteoclast differentiation, The IL-6-related chicken myelomonocytic growth factor (cMGF) had a similar effect, and the effects of SCF and cMGF were additive, SCF, but not cMGF, also stimulated the bone-resorbing activity of existing osteoclasts, As osteoblasts have been found to regulate osteoclast activity and formation, chicken osteoblasts were tested for their ability to express and secrete SCF, Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis showed that osteoblasts express SCF mRNA and that parathyroid hormone increases expression levels about fourfold, SCF did not accumulate in the culture medium, but remained cell (osteoblasts) surface associated.-van 't Hof, R. J., von Lindern, M., Nijweide, P. J., Beug, H. Stem cell factor stimulates chicken osteoclast activity in vitro.	LEIDEN STATE UNIV,DEPT CELL BIOL,NL-2333 AL LEIDEN,NETHERLANDS; INST MOL PATHOL,A-1030 VIENNA,AUSTRIA	Leiden University; Leiden University - Excl LUMC; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)				van 't Hof, Rob/0000-0002-8193-6788				ALDINUCCI D, 1994, J CELL BIOCHEM, V18, P23; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BARKA T, 1962, J HISTOCHEM CYTOCHEM, V10, P741, DOI 10.1177/10.6.741; Bartunek P, 1996, CYTOKINE, V8, P14, DOI 10.1006/cyto.1996.0003; BEUG H, 1992, NUCLEAR PROCESSES ON, P53; BROXMEYER HE, 1991, CANCER CELL-MON REV, V3, P480; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLIN P, 1992, ENDOCRINOLOGY, V131, P1181, DOI 10.1210/en.131.3.1181; CORBOZ VA, 1992, ENDOCRINOLOGY, V130, P437, DOI 10.1210/en.130.1.437; DEMULDER A, 1992, J BONE MINER RES, V7, P1337; DICKSON IR, 1989, BIOCHEM BIOPH RES CO, V159, P1383, DOI 10.1016/0006-291X(89)92263-8; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; ELFORD PR, 1987, CALCIFIED TISSUE INT, V41, P151, DOI 10.1007/BF02563795; FELIX R, 1988, J BONE MINER RES, V3, P27; FELIX R, 1989, CALCIFIED TISSUE INT, V44, P356, DOI 10.1007/BF02556317; FELIX R, 1994, J CELL BIOCHEM, V55, P340, DOI 10.1002/jcb.240550311; FEYEN JHM, 1989, J BONE MINER RES, V4, P633, DOI 10.1002/jbmr.5650040422; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FULLER K, 1993, J EXP MED, V178, P1733, DOI 10.1084/jem.178.5.1733; FULLER K, 1991, BIOCHEM BIOPH RES CO, V181, P67, DOI 10.1016/S0006-291X(05)81382-8; GARRETT I R, 1990, Calcified Tissue International, V46, pA37; GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130; GREENFIELD EM, 1992, CALCIFIED TISSUE INT, V51, P317, DOI 10.1007/BF00334494; HAGENAARS CE, 1989, BONE MINER, V6, P179, DOI 10.1016/0169-6009(89)90049-4; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KODAMA H, 1991, J EXP MED, V173, P269, DOI 10.1084/jem.173.1.269; KODAMA H, 1991, J EXP MED, V173, P1291, DOI 10.1084/jem.173.5.1291; LEONARD MW, 1993, DEVELOPMENT, V119, P519; LEUTZ A, 1990, GROWTH FACTORS DIFFE, P215; LOWIK CWGM, 1989, BIOCHEM BIOPH RES CO, V162, P1546, DOI 10.1016/0006-291X(89)90851-6; MCNIECE IK, 1991, J IMMUNOL, V146, P3785; MCSHEEHY PMJ, 1987, J CLIN INVEST, V80, P425, DOI 10.1172/JCI113089; MODDERMAN WE, 1991, BONE, V12, P81, DOI 10.1016/8756-3282(91)90004-3; MUENCH MO, 1992, EXP HEMATOL, V20, P339; PERRY HM, 1992, CALCIFIED TISSUE INT, V50, P237, DOI 10.1007/BF00296288; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; SUDA T, 1992, J CELL BIOCHEM, V49, P53, DOI 10.1002/jcb.240490110; SZEBO KM, 1990, CELL, V63, P195; TETI A, 1991, BIOCHEM BIOPH RES CO, V179, P634, DOI 10.1016/0006-291X(91)91419-D; VANDERPLAS A, 1992, J BONE MINER RES, V7, P389; VANTHOF RJ, 1995, INT J EXP PATHOL, V76, P205; WILLIAMS DE, 1992, DEV BIOL, V151, P368, DOI 10.1016/0012-1606(92)90176-H	43	24	25	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1997	11	4					287	293						7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WM850	9068618				2022-12-28	WOS:A1997WM85000011
J	Agostinho, P; Duarte, CB; Oliveira, CR				Agostinho, P; Duarte, CB; Oliveira, CR			Impairment of excitatory amino acid transporter activity by oxidative stress conditions in retinal cells: Effect of antioxidants	FASEB JOURNAL			English	Article						D-[H-3]aspartate uptake; lipid peroxidation; antioxidants; melatonin; oxidation of proteins	OXYGEN-FREE RADICALS; HIGH-AFFINITY UPTAKE; ARACHIDONIC-ACID; GLUTAMATE TRANSPORTER; LIPID-PEROXIDATION; NEUROTRANSMITTER TRANSPORTERS; ASPARTATE TRANSPORTER; NERVOUS-SYSTEM; CYTO-TOXICITY; GLIAL-CELLS	In the present study we analyzed how oxidative stress conditions induced by ascorbate/Fe2+ affect the excitatory amino acid (EAA) transport systems in cultured chick retina cells, The uptake of D-[H-3]aspartate, which is transported by the same carrier as glutamate, was determined in control cells and in cells subjected to ascorbate/Fe2+. The uptake of this EAA was Na+ dependent and was inhibited by about 40% under oxidative stress conditions. To clarify the molecular mechanisms involved in the inhibition of D-[H-3]aspartate uptake by ascorbate/Fe2+, we investigated the effect of vitamin E (Vit E), melatonin, reduced glutathione (GSH), and dithiothreitol (DTT) on the uptake of D-[H-3]aspartate and on the extent of lipid peroxidation in control and in peroxidized cells, Preincubation with Vit E (100 mu M) abolished lipid peroxidation, but had no significant effect on the inhibition of D-[H-3]aspartate uptake evoked by ascorbate/Fe2+ Melatonin was more effective in reducing the formation of TEARS and conjugated dienes than in preventing the D-[H-3]aspartate uptake inhibition evoked by the oxidant pair, Conversely, GSH (4 mM) and DTT (41 mM) completely prevented the inhibition of D-[H-3]aspartate uptake in cells subjected to oxidative stress, but were without effect on the extent of peroxidation., Free fatty acids, such as arachidonic acid, seem not to be involved in reducing the activity of the D-[H-3]aspartate uptake system, whereas the reduction of the Na+ electrochemical gradient that occurs under oxidative stress was in part involved in the reduction of D-[H-3]aspartate uptake by the cells, The inhibition of D-[H-3]aspartate uptake by ascorbate/Fe2+ persisted for at least 1 h, but could be partially reverted by disulfide reducing agents, It is concluded that oxidative stress causes long-lasting modifications of the glutamate/D-[H-3]aspartate transport system (or systems), such as oxidation of protein sulfhydryl (SR) groups, which cll he recovered by some antioxidants.	UNIV COIMBRA, DEPT ZOOL, P-3000 COIMBRA, PORTUGAL; UNIV COIMBRA, FAC MED, P-3000 COIMBRA, PORTUGAL	Universidade de Coimbra; Universidade de Coimbra	Agostinho, P (corresponding author), UNIV COIMBRA, CTR NEUROSCI COIMBRA, P-3000 COIMBRA, PORTUGAL.		Oliveira, Catarina R./F-3685-2010; Agostinho, Paula/F-3748-2010; Duarte, Carlos B/K-6358-2013	Agostinho, Paula/0000-0001-5523-4945; Duarte, Carlos B/0000-0002-1474-0208; Oliveira, Catarina/0000-0001-6942-4328				Agostinho P, 1996, NEUROSCI RES, V25, P343; AGOSTINHO P, 1994, BRAIN RES, V655, P213, DOI 10.1016/0006-8993(94)91616-0; Agostinho P, 1996, J NEUROCHEM, V67, P1153; AGOSTINHO P, 1995, NEUROSCI LETT, V198, P193, DOI 10.1016/0304-3940(95)11996-A; ATTWELL D, 1993, SEMIN NEUROSCI, V5, P159, DOI 10.1016/S1044-5765(05)80049-1; BALEAR VJ, 1972, J NEUROCHEM, V19, P2657; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; BERGMEYER HU, 1974, METHOD ENZYMAT AN, P574; Buege J A, 1978, Methods Enzymol, V52, P302; CASADO M, 1991, J NEUROCHEM, V57, P1185, DOI 10.1111/j.1471-4159.1991.tb08278.x; CHAN PH, 1988, J NEUROCHEM, V50, P1185, DOI 10.1111/j.1471-4159.1988.tb10591.x; CHEN LD, 1995, NEUROSCI RES COMMUN, V17, P151; CHOI DW, 1987, J NEUROSCI, V7, P369; CLARK JA, 1993, BIOESSAYS, V15, P323, DOI 10.1002/bies.950150506; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DANBOLT NC, 1994, PROG NEUROBIOL, V44, P377, DOI 10.1016/0301-0082(94)90033-7; DEROUICHE A, 1995, J NEUROSCI RES, V42, P131, DOI 10.1002/jnr.490420115; Duarte CB, 1996, J NEUROSCI RES, V44, P363; FACCI L, 1990, J NEUROSCI RES, V27, P202, DOI 10.1002/jnr.490270210; Ferreira IL, 1996, EUR J PHARMACOL, V302, P153, DOI 10.1016/0014-2999(96)00044-1; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; HANDELMAN GJ, 1986, ADV FREE RADICAL BIO, V2, P1, DOI 10.1016/S8755-9668(86)80024-2; HARDELAND R, 1993, NEUROSCI BIOBEHAV R, V17, P347, DOI 10.1016/S0149-7634(05)80016-8; HUBA R, 1990, NEUROSCI LETT, V117, P37, DOI 10.1016/0304-3940(90)90116-Q; KANAI Y, 1993, FASEB J, V7, P1450, DOI 10.1096/fasebj.7.15.7903261; KATSUKI H, 1995, PROG NEUROBIOL, V46, P607, DOI 10.1016/0301-0082(95)00016-O; KELLEY EE, 1995, ARCH BIOCHEM BIOPHYS, V319, P102, DOI 10.1006/abbi.1995.1271; LITTLEFIELD LG, 1988, INT J RADIAT BIOL, V53, P875, DOI 10.1080/09553008814551241; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MIYAMOTO M, 1989, J PHARMACOL EXP THER, V250, P1132; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NEAL MJ, 1994, J NEUROCHEM, V62, P1025; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; PIERI C, 1994, LIFE SCI, V55, pPL271, DOI 10.1016/0024-3205(94)00666-0; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; RAUEN T, 1994, NEUROSCI LETT, V169, P137, DOI 10.1016/0304-3940(94)90375-1; REED CF, 1960, J LAB CLIN MED, V56, P281; Reed D.J., 1984, PHARMACOL REV, V36, p25S; Rego AC, 1996, J NEUROCHEM, V66, P2506; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; ROMANO C, 1995, J NEUROCHEM, V65, P59; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TROTTI D, 1995, J BIOL CHEM, V270, P9890, DOI 10.1074/jbc.270.17.9890; VOLTERRA A, 1994, J NEUROSCI, V14, P2924; VOLTERRA A, 1994, RENAL PHYSIOL BIOCH, V17, P165; WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447; WITTING LA, 1980, FREE RADICAL BIO MED, V4, P295; Yang CS, 1996, FREE RADICAL BIO MED, V20, P245, DOI 10.1016/0891-5849(95)02042-X; YIM MB, 1994, J BIOL CHEM, V269, P1621	56	57	58	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1997	11	2					154	163		10.1096/fasebj.11.2.9039958	http://dx.doi.org/10.1096/fasebj.11.2.9039958			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK509	9039958	Green Submitted			2022-12-28	WOS:A1997WK50900008
J	deSouza, AT; Yamada, T; Mills, JJ; Jirtle, RL				deSouza, AT; Yamada, T; Mills, JJ; Jirtle, RL			Imprinted genes in liver carcinogenesis	FASEB JOURNAL			English	Review						M6P/IGF2R; IGF2; genomic imprinting; tumor suppressor gene	GROWTH-FACTOR-II; MANNOSE 6-PHOSPHATE RECEPTOR; HUMAN-BREAST-CANCER; TGF-BETA RECEPTOR; MATERNAL-SPECIFIC METHYLATION; TUMOR-SUPPRESSOR ACTIVITY; MESSENGER-RNA EXPRESSION; CARRYING NULL MUTATIONS; FACTOR TYPE-2 RECEPTOR; HUMAN H19 GENE	Each cell contains both maternal and paternal copies of all genes except those that reside on the sex chromosomes, However, because of a phenomenon termed genomic imprinting, genes are biallelically expressed, Imprinted genes play an important role in embryogenesis and recently have also been shown to be mechanistically involved in carcinogenesis, The growing list of imprinted genes implicated in tumor formation includes both a growth factor gene, insulin-like growth factor 2 (IGF2), and a receptor gene, mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R). Elevated expression of IGF2 is often found in turners, and loss of imprinting is one mechanism by which its expression is deregulated, The M6P/IGF2R functions in the inactivation of the mitogen IGF2 and in the activation of the growth inhibitor, transforming growth factor beta, Recently, a high frequency of loss of heterozygosity with concomitant mutations in the remaining allele has been shown to occur at the M6P/IGF2R locus (i.e., 6q26-q27) in both human liver and breast tumors, suggesting that this gene functions as a tumor suppressor, Expression of the M6P/IGF2R gene is biallelic hi most humans but is monoallelic in mice, This species difference hi M6P/IGF2R gene imprinting provides one plausible explanation for the enhanced sensitivity of mice to tumor formation, Furthermore, these findings suggest that species differences in the imprinted status of genes mechanistically involved in tumor formation should be factored into human carcinogenesis risk assessment models when extrapolating results from mice to humans.	DUKE UNIV, MED CTR, DEPT RADIAT ONCOL, DURHAM, NC 27710 USA; SUMITOMO CHEM CO LTD, ENVIRONM HLTH SCI LAB, OSAKA, JAPAN; ZENECA PHARMACEUT, DEPT SAFETY MED, MACCLESFIELD SK10 4TG, CHESHIRE, ENGLAND	Duke University; Sumitomo Chem Co Ltd				Mills, Jeremy James/0000-0003-1719-9047; Yamada, Tomoya/0000-0002-9798-1049				Ahomadegbe J. C., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P598; ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; Barrois M., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P598; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; BRISSENDEN JE, 1984, NATURE, V310, P781, DOI 10.1038/310781a0; CASSIDY SB, 1995, ENVIRON MOL MUTAGEN, V25, P13, DOI 10.1002/em.2850250605; COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; Dahms NM, 1996, BIOCHEM SOC T, V24, P136, DOI 10.1042/bst0240136; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DAVIES SM, 1993, CANCER RES, V53, P4781; Deal Cheri L., 1995, Current Opinion in Pediatrics, V7, P445, DOI 10.1097/00008480-199508000-00018; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DEGROOT N, 1993, MOL REPROD DEV, V36, P390, DOI 10.1002/mrd.1080360316; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DESOUZA AT, 1995, ONCOGENE, V10, P1725; DEVILEE P, 1991, ONCOGENE, V6, P1705; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; EKSTROM TJ, 1994, HORM RES, V42, P176, DOI 10.1159/000184190; Fan HZ, 1996, CANCER RES, V56, P4366; FILSON AJ, 1993, DEVELOPMENT, V118, P731; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; GOLD JD, 1994, CURR TOP DEV BIOL, V29, P227; HAIG D, 1991, CELL, V64, P1045; HAN VKM, 1992, INSULIN LIKE GROWTH, P178; Hankins GR, 1996, ONCOGENE, V12, P2003; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HARPER ME, 1981, P NATL ACAD SCI-BIOL, V78, P4458, DOI 10.1073/pnas.78.7.4458; Hatada I, 1996, HUM MOL GENET, V5, P783, DOI 10.1093/hmg/5.6.783; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; HAVEMANN K, 1990, J STEROID BIOCHEM, V37, P877, DOI 10.1016/0960-0760(90)90436-O; HENDRICH BD, 1995, HUM MOL GENET, V4, P1765, DOI 10.1093/hmg/4.suppl_1.1765; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; IKEZU T, 1995, J BIOL CHEM, V270, P29224, DOI 10.1074/jbc.270.49.29224; JENNISCHE E, 1992, INSULIN LIKE GROWTH, P221; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JIRTLE RL, 1993, CANCER RES, V53, P3849; JIRTLE RL, 1994, CARCINOGENESIS, V15, P1473, DOI 10.1093/carcin/15.8.1473; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; KALSCHEUER VM, 1993, NAT GENET, V5, P74, DOI 10.1038/ng0993-74; KANEKOISHINO T, 1995, NAT GENET, V11, P52, DOI 10.1038/ng0995-52; KATZ F, 1992, BRIT J HAEMATOL, V80, P332, DOI 10.1111/j.1365-2141.1992.tb08141.x; KIESS W, 1987, P NATL ACAD SCI USA, V84, P7720, DOI 10.1073/pnas.84.21.7720; Kim IY, 1996, CANCER RES, V56, P44; KORNER C, 1995, J BIOL CHEM, V270, P287, DOI 10.1074/jbc.270.1.287; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KOVACINA KS, 1989, BIOCHEM BIOPH RES CO, V160, P393, DOI 10.1016/0006-291X(89)91669-0; Kuroiwa Y, 1996, NAT GENET, V12, P186, DOI 10.1038/ng0296-186; LAHM H, 1992, BRIT J CANCER, V65, P341, DOI 10.1038/bjc.1992.69; LAMBERT S, 1992, INT J CANCER, V52, P404, DOI 10.1002/ijc.2910520313; LAMBERT S, 1991, INT J CANCER, V48, P826, DOI 10.1002/ijc.2910480607; LAMBERT S, 1990, INT J CANCER, V46, P405, DOI 10.1002/ijc.2910460313; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; LATHAM KE, 1995, INT REV CYTOL, V160, P53, DOI 10.1016/S0074-7696(08)61553-3; LAUREYS G, 1988, GENOMICS, V3, P224, DOI 10.1016/0888-7543(88)90083-3; LEE JH, 1990, CANCER RES, V50, P2724; LEFF SE, 1992, NAT GENET, V2, P259, DOI 10.1038/ng1292-259; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; LI XR, 1995, ONCOGENE, V11, P221; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LINDER D, 1975, NEW ENGL J MED, V292, P63, DOI 10.1056/NEJM197501092920202; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LUDWIG T, 1993, EMBO J, V12, P5225, DOI 10.1002/j.1460-2075.1993.tb06218.x; MACDONALD RG, 1989, J BIOL CHEM, V264, P3256; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARS WM, 1990, CANCER METAST REV, V9, P35, DOI 10.1007/BF00047587; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1; MELINO G, 1992, NEUROSCI LETT, V144, P25, DOI 10.1016/0304-3940(92)90707-E; MILLIKIN D, 1991, CANCER RES, V51, P5449; MILLS JJ, 1995, CANCER RES, V55, P979; MILLS JJ, 1995, LIVER REGENERATION C, P199; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MORITA R, 1991, CANCER RES, V51, P5817; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; MOXHAM C, 1992, INSULIN LIKE GROWTH, P80; NICHOLLS RD, 1993, AM J MED GENET, V46, P16, DOI 10.1002/ajmg.1320460106; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; Nishita Y, 1996, GENOMICS, V36, P539, DOI 10.1006/geno.1996.0502; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OGAWA O, 1993, HUM MOL GENET, V2, P2163, DOI 10.1093/hmg/2.12.2163; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; OSBORNE CK, 1989, MOL ENDOCRINOL, V3, P1701, DOI 10.1210/mend-3-11-1701; Pearsall RS, 1996, BIOCHEM BIOPH RES CO, V222, P171, DOI 10.1006/bbrc.1996.0716; PEDONE PV, 1994, HUM MOL GENET, V3, P1117, DOI 10.1093/hmg/3.7.1117; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; PETTENATI MJ, 1986, HUM GENET, V74, P143, DOI 10.1007/BF00282078; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; Plass C, 1996, NAT GENET, V14, P106, DOI 10.1038/ng0996-106; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RAINIER S, 1995, CANCER RES, V55, P1836; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; RUMBSBY PC, 1996, HUM EXP TOXICOLL, V15, P539; SAITO S, 1992, CANCER RES, V52, P5815; SHAPIRO ET, 1990, J CLIN INVEST, V85, P1672, DOI 10.1172/JCI114619; SMITH GH, 1995, AM J PATHOL, V147, P1081; SMRZKA OW, 1995, HUM MOL GENET, V4, P1945, DOI 10.1093/hmg/4.10.1945; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SU TS, 1989, CANCER RES, V49, P1773; SUE SR, 1995, ANN SURG, V222, P171, DOI 10.1097/00000658-199508000-00009; SURANI MAH, 1984, NATURE, V308, P548, DOI 10.1038/308548a0; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; THORGEIRSSON SS, 1995, LIVER REGENERATION C; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; TYCKO B, 1994, AM J PATHOL, V144, P431; VU TH, 1995, J CLIN ENDOCR METAB, V80, P1670, DOI 10.1210/jc.80.5.1670; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; WAKE N, 1987, PLACENTA, V8, P319, DOI 10.1016/0143-4004(87)90056-7; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; WESTLEY BR, 1995, BRIT J CANCER, V72, P1065, DOI 10.1038/bjc.1995.465; Williamson CM, 1996, GENOMICS, V36, P280, DOI 10.1006/geno.1996.0463; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XU YQ, 1993, BIOCHEM BIOPH RES CO, V197, P747, DOI 10.1006/bbrc.1993.2542; Yamada T., 1996, Hepatology, V24, p358A; YEE D, 1988, CANCER RES, V48, P6691; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	136	89	91	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1997	11	1					60	67		10.1096/fasebj.11.1.9034167	http://dx.doi.org/10.1096/fasebj.11.1.9034167			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK147	9034167				2022-12-28	WOS:A1997WK14700009
J	Tucker, RM; Burke, DT				Tucker, RM; Burke, DT			Transgenic mice for the establishment of histidinol-resistant embryonic fibroblast feeder layers	FASEB JOURNAL			English	Article						embryonic stem cells; gene targeting; selectable marker	STEM ES CELLS; HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; GENE; LOCUS; SITE; ACTIVATION; SELECTIONS; MUTATIONS; STRATEGY	Gene targeting in mouse embryonic stem cells generates mutations by replacing an endogenous chromosomal region with a copy disrupted by a selectable genetic marker, The most commonly used selectable marker is the bacterial neo(r) gene, which confers resistance in mammalian cells to the antibiotic G418. Use of an alternative selectable marker, the Salmonella typhimurium gene hisD, should provide expanded applications for gene targeting, The hisD gene encodes the protein histidinol dehydrogenase, which catalyzes the conversion of histidinol to the amino acid histidine. Histidinol is toxic to mammalian cells, while histidine is an essential mammalian amino acid, Consequently, growth selection in cultures with media containing histidinol in place of histidine occurs by both histidine starvation and histidinol poisoning, The hisD selection is being tested for potential use in gene targeting experiments with mouse embryonic stem (ES) cells, Currently, most successful gene targeting experiments use primary embryonic fibroblast feeder layers, which assist in the maintenance of the pluripotential state of the embryonic stem cells, To support ES cell stability under histidinol selection, mice transgenic for the S, typhimurium hisD gene have been produced and used to generate embryonic fibroblast feeder cells, The transgenic embryonic fibroblasts survive under a wide range of histidinol-containing growth conditions and support growth of ES cell cultures.	UNIV MICHIGAN, SCH MED, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan				Burke, David/0000-0002-2564-7949				ASKEW GR, 1993, MOL CELL BIOL, V13, P4115, DOI 10.1128/MCB.13.7.4115; BAILEY JM, 1976, ANAL BIOCHEM, V70, P75, DOI 10.1016/S0003-2697(76)80049-8; BAUTISTA D, 1993, J IMMUNOL, V151, P1950; BROWN FL, 1993, MOL CELL BIOL, V13, P5245, DOI 10.1128/MCB.13.9.5245; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DETLOFF PJ, 1994, MOL CELL BIOL, V14, P6936, DOI 10.1128/MCB.14.10.6936; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; FARR C, 1991, P NATL ACAD SCI USA, V88, P7006, DOI 10.1073/pnas.88.16.7006; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HANSEN BS, 1972, J BIOL CHEM, V247, P3854; HANSON KD, 1995, MOL CELL BIOL, V15, P45, DOI 10.1128/MCB.15.1.45; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; HOGAN B, 1986, MANIPULATING MOUSE E; JOHNSON KA, 1995, NUCLEIC ACIDS RES, V23, P1273, DOI 10.1093/nar/23.7.1273; JOHNSON RS, 1989, SCIENCE, V245, P1234, DOI 10.1126/science.2506639; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; LI YP, 1993, MOL CELL BIOL, V13, P6064, DOI 10.1128/MCB.13.10.6064; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NEWMAN EM, 1983, CANCER RES, V43, P4703; PEASE S, 1990, DEV BIOL, V141, P344, DOI 10.1016/0012-1606(90)90390-5; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SCORNIK OA, 1980, J BIOL CHEM, V255, P6322; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VALANCIUS V, 1991, MOL CELL BIOL, V11, P1402, DOI 10.1128/MCB.11.3.1402; VONMELCHNER H, 1990, P NATL ACAD SCI USA, V87, P3733, DOI 10.1073/pnas.87.10.3733; WARBURTON D, 1990, GENOMICS, V6, P358, DOI 10.1016/0888-7543(90)90577-H; WARRINGTON RC, 1994, ANTICANCER RES, V14, P367; WARRINGTON RC, 1989, BRIT J CANCER, V60, P652, DOI 10.1038/bjc.1989.333; ZIMMER A, 1989, NATURE, V338, P150, DOI 10.1038/338150a0	32	3	5	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1996	10	14					1641	1645		10.1096/fasebj.10.14.9002557	http://dx.doi.org/10.1096/fasebj.10.14.9002557			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WC869	9002557	Green Submitted			2022-12-28	WOS:A1996WC86900011
J	Berthiaume, F; Moghe, PV; Toner, M; Yarmush, ML				Berthiaume, F; Moghe, PV; Toner, M; Yarmush, ML			Effect of extracellular matrix topology on cell structure, function, and physiological responsiveness: Hepatocytes cultured in a sandwich configuration	FASEB JOURNAL			English	Article						collagen; cell polarity; liver; 3-dimensional matrix; sandwich culture	ADULT-RAT HEPATOCYTES; POTENTIAL BIOARTIFICIAL LIVER; PRIMARY MONOLAYER-CULTURES; HOLLOW FIBER BIOREACTOR; ACUTE-PHASE-RESPONSE; LONG-TERM CULTURE; COLLAGEN GEL; DIFFERENTIATED FUNCTIONS; 3-DIMENSIONAL MATRIX; DIMETHYL-SULFOXIDE	Extracellular matrix (ECM) geometry is an important modulator of cell polarity and function, For example, 3-dimensional matrices often more effectively induce differentiated cell function than traditional 2-dimensional substrates, The effect of ECM topology can be investigated in a controlled fashion using a technique whereby cells cultured on a single surface are overlaid with a second layer of ECM, thereby creating a ''sandwich'' configuration, Confluent monolayers of epithelial or endothelial cells overlaid in this fashion often reorganize into structures that are reminiscent of their native tissue, In the case of hepatocytes, the overlay causes a dramatic reorganization of the cytoskeleton, adoption of in vivo-like morphology and polarity, and expression of a wide array of liver-specific functions. In this short review, we use the sandwiched hepatocyte culture system to illustrate the effect of ECM geometry on cellular function, Pertinent studies are summarized in the context of defining the parallels, strengths, and Limitations of this culture system as an in vitro model to study the physiology and morphogenesis of liver tissue, We also explore some of its a potential uses as a model to study liver pharmacology and toxicology, and for the development of Liver preservation techniques and liver-assist devices.	HARVARD UNIV,SCH MED,SHRINERS BURNS INST,DEPT SURG,BOSTON,MA 02114	Harvard University; Harvard Medical School	Berthiaume, F (corresponding author), MASSACHUSETTS GEN HOSP,CTR ENGN MED,SURG SERV,BIGALOW 1401,55 FRUIT ST,BOSTON,MA 02114, USA.		Berthiaume, Francois/ABD-2139-2020	Yarmush, Martin/0000-0003-4986-8444	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043371] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43371] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACOSTA D, 1978, IN VITRO CELL DEV B, V14, P428; BADER A, 1995, ARTIF ORGANS, V19, P368, DOI 10.1111/j.1525-1594.1995.tb02343.x; BADER A, 1992, BIOTECHNOL PROGR, V8, P219, DOI 10.1021/bp00015a007; BELLAMKONDA R, 1995, J BIOMED MATER RES, V29, P663, DOI 10.1002/jbm.820290514; BENZEEV A, 1988, P NATL ACAD SCI USA, V85, P2161, DOI 10.1073/pnas.85.7.2161; BHATIA SN, 1996, IN PRESS J BIOMED MA, V32; BISSELL DM, 1987, J CLIN INVEST, V79, P801, DOI 10.1172/JCI112887; Borel Rinkes IH, 1992, CELL TRANSPLANT, V1, P281; BOUDREAU N, 1995, TRENDS CELL BIOL, V5, P1, DOI 10.1016/S0962-8924(00)88924-2; BRENDEL MD, 1994, CELL TRANSPLANT, V3, P427, DOI 10.1177/096368979400300510; CARON JM, 1990, MOL CELL BIOL, V10, P1239, DOI 10.1128/MCB.10.3.1239; CASSERBETTE M, 1990, CALCIFIED TISSUE INT, V46, P46, DOI 10.1007/BF02555824; CHAMBARD M, 1981, J CELL BIOL, V91, P157, DOI 10.1083/jcb.91.1.157; CLAYTON DF, 1985, MOL CELL BIOL, V5, P2623, DOI 10.1128/MCB.5.10.2623; CONNER J, 1990, BIOCHEM J, V266, P683, DOI 10.1042/bj2660683; DELVOS U, 1982, LAB INVEST, V46, P61; DICH J, 1988, HEPATOLOGY, V8, P39, DOI 10.1002/hep.1840080109; DUNN JCY, 1989, FASEB J, V3, P174, DOI 10.1096/fasebj.3.2.2914628; DUNN JCY, 1991, BIOTECHNOL PROGR, V7, P237, DOI 10.1021/bp00009a007; DUNN JCY, 1992, J CELL BIOL, V116, P1043, DOI 10.1083/jcb.116.4.1043; EZZELL RM, 1993, EXP CELL RES, V208, P442, DOI 10.1006/excr.1993.1266; FRANGOS JA, 1993, PHYSICAL FORCES MAMM; FUJITA M, 1987, HEPATOLOGY, V7, pS1, DOI 10.1002/hep.1840070702; GUGUENGUILLOUZO C, 1983, EXP CELL RES, V143, P47, DOI 10.1016/0014-4827(83)90107-6; HALL HG, 1982, P NATL ACAD SCI-BIOL, V79, P4672, DOI 10.1073/pnas.79.15.4672; HOWARTH S, 1958, EXP CELL RES, V15, P613, DOI 10.1016/0014-4827(58)90110-1; ISOM HC, 1985, P NATL ACAD SCI USA, V82, P3252, DOI 10.1073/pnas.82.10.3252; JAUREGUI HO, 1986, IN VITRO CELL DEV B, V22, P13; KARLSSON JOM, 1993, BIOPHYS J, V65, P2524, DOI 10.1016/S0006-3495(93)81319-5; Koike M, 1996, ARTIF ORGANS, V20, P186; KONO Y, 1995, EXP CELL RES, V221, P478, DOI 10.1006/excr.1995.1399; KOST DP, 1991, J CELL PHYSIOL, V147, P274, DOI 10.1002/jcp.1041470212; KURIHARCUCH W, 1989, DIFFERENTIATION, V41, P148, DOI 10.1111/j.1432-0436.1989.tb00742.x; LANDRY J, 1985, J CELL BIOL, V101, P914, DOI 10.1083/jcb.101.3.914; LAZAR A, 1995, IN VITRO CELL DEV-AN, V31, P340, DOI 10.1007/BF02634282; LECLUYSE EL, 1994, AM J PHYSIOL, V266, pC1764, DOI 10.1152/ajpcell.1994.266.6.C1764; LECLUYSE EL, 1996, IN PRESS AM J PHYSL; LEE J, 1993, FASEB J, V7, P586, DOI 10.1096/fasebj.7.6.8472895; LEE JW, 1992, BIOTECHNOL BIOENG, V40, P298, DOI 10.1002/bit.260400214; LINDBLAD WJ, 1991, HEPATOLOGY, V13, P282, DOI 10.1002/hep.1840130213; LINDROOS P, 1993, CARCINOGENESIS, V14, P731, DOI 10.1093/carcin/14.4.731; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; MATTHEW HWT, 1996, IN PRESS BIOTECHNOL; MICHALOPOULOS G, 1975, EXP CELL RES, V94, P70, DOI 10.1016/0014-4827(75)90532-7; MICHALOPOULOS GK, 1993, J CELL PHYSIOL, V156, P443, DOI 10.1002/jcp.1041560303; Moghe PV, 1996, BIOMATERIALS, V17, P373, DOI 10.1016/0142-9612(96)85576-1; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MOONEY D, 1992, J CELL PHYSIOL, V151, P497, DOI 10.1002/jcp.1041510308; MORIN O, 1986, J CELL PHYSIOL, V129, P103, DOI 10.1002/jcp.1041290115; MUSAT AI, 1993, HEPATOLOGY, V18, P198, DOI 10.1002/hep.1840180129; NARITA M, 1985, GROWTH DIFFERENTIATI, P89; NYBERG SL, 1993, BIOTECHNOL BIOENG, V41, P194, DOI 10.1002/bit.260410205; REID LM, 1992, HEPATOLOGY, V15, P1198, DOI 10.1002/hep.1840150635; ROJKIND M, 1980, J CELL BIOL, V87, P255, DOI 10.1083/jcb.87.1.255; ROSE GG, 1962, J CELL BIOL, V13, P153, DOI 10.1083/jcb.13.1.153; ROTEM A, 1992, BIOTECHNOL BIOENG, V40, P1286, DOI 10.1002/bit.260401020; ROTEM A, 1995, TOXICOL IN VITRO, V9, P139, DOI 10.1016/0887-2333(94)00207-B; SHATFORD RA, 1992, J SURG RES, V53, P549, DOI 10.1016/0022-4804(92)90253-V; SIDHU JS, 1993, ARCH BIOCHEM BIOPHYS, V301, P103, DOI 10.1006/abbi.1993.1121; SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320; STEFANOVICH P, 1995, CRYOBIOLOGY, V23, P389; Taguchi K, 1996, ARTIF ORGANS, V20, P178	62	319	331	3	54	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1996	10	13					1471	1484		10.1096/fasebj.10.13.8940293	http://dx.doi.org/10.1096/fasebj.10.13.8940293			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VU982	8940293				2022-12-28	WOS:A1996VU98200004
J	Weisgraber, KH; Mahley, RW				Weisgraber, KH; Mahley, RW			Human apolipoprotein E: The Alzheimer's disease connection	FASEB JOURNAL			English	Article						neurite outgrowth; A beta peptide; cytoskeleton; microtubules; protein structure; neurodegenerative disease	CENTRAL-NERVOUS-SYSTEM; AMYLOID-BETA-PEPTIDE; REMNANT LIPOPROTEIN METABOLISM; HEPARAN-SULFATE PROTEOGLYCANS; HUMAN-PLASMA-LIPOPROTEINS; RECEPTOR-RELATED PROTEIN; NEURITE OUTGROWTH; AQUEOUS-SOLUTION; BINDING DOMAIN; TYPE-4 ALLELE	Human apolipoprotein (ape) E, long known for its prominent role in cholesterol transport and plasma lipoprotein metabolism, has recently emerged as a major genetic risk factor for Alzheimer's disease, a neurodegenerative disorder, In a variety of populations worldwide, one of the three common alleles of apoE, apoE4, is overrepresented in Alzheimer's subjects compared with age- and sex-matched controls, The genetic and epidemiologic evidence suggests that apoE is a major susceptibility gene for Alzheimer's disease; it likely accounts for a major portion of the genetic heterogeneity in the disease, Although its role in the development of Alzheimer's disease is unknown, biochemical and cell biology studies are providing important insights into how apoE may be involved in neurodegenerative disorders, Based on an understanding of the structure and function of apoE in Lipid transport and cellular metabolism, it is suggested that apoE is involved in a final common pathway of neuronal repair and remodeling: apoE3 (most common allele) supporting effective repair and remodeling after neuronal injury by noxious agents, and apoE4 being less effective in these processes.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes	Weisgraber, KH (corresponding author), UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,DEPT PATHOL,SAN FRANCISCO,CA 94141, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; *AM COLL MED GEN A, 1995, JAMA-J AM MED ASSOC, V270, P1627; ASKANAS V, 1994, LANCET, V343, P364, DOI 10.1016/S0140-6736(94)91208-4; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; BIRD TD, 1995, ANN NEUROL, V38, P2, DOI 10.1002/ana.410380103; CORDER EH, 1995, NEUROLOGY, V45, P1323, DOI 10.1212/WNL.45.7.1323; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CROWTHER RA, 1993, CURR OPIN STRUC BIOL, V3, P202, DOI 10.1016/S0959-440X(05)80153-8; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; DONG LM, 1994, J BIOL CHEM, V269, P22358; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; GREGG RE, 1986, J CLIN INVEST, V78, P815, DOI 10.1172/JCI112645; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HAN SH, 1994, J NEUROPATH EXP NEUR, V53, P535, DOI 10.1097/00005072-199409000-00013; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; Herz Joachim, 1995, Current Opinion in Lipidology, V6, P97, DOI 10.1097/00041433-199504000-00007; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JI ZS, 1994, J BIOL CHEM, V269, P13421; JI ZS, 1994, J BIOL CHEM, V269, P2764; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Mahley Robert W., 1995, Current Opinion in Lipidology, V6, P86, DOI 10.1097/00041433-199504000-00005; MAHLEY RW, 1994, ANN NY ACAD SCI, V737, P39, DOI 10.1111/j.1749-6632.1994.tb44300.x; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, IN PRESS MOL GENETIC; MASLIAH E, 1995, EXP NEUROL, V136, P107, DOI 10.1006/exnr.1995.1088; MAYEUX R, 1995, AM J PUBLIC HEALTH, V85, P1280, DOI 10.2105/AJPH.85.9.1280; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; Nathan B. P., 1995, Society for Neuroscience Abstracts, V21, P1009; NATHAN BP, 1995, J BIOL CHEM, V270, P19791, DOI 10.1074/jbc.270.34.19791; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; PITAS RE, 1987, J BIOL CHEM, V262, P14352; Poirier J, 1995, P NATL ACAD SCI USA, V92, P12260, DOI 10.1073/pnas.92.26.12260; ROSES AD, 1995, EXP NEUROL, V132, P149, DOI 10.1016/0014-4886(95)90019-5; ROSES AD, 1995, ANN NEUROL, V38, P6, DOI 10.1002/ana.410380105; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; STEINMETZ A, 1989, ARTERIOSCLEROSIS, V9, P405, DOI 10.1161/01.ATV.9.3.405; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; STRITTMATTER WJ, 1994, EXP NEUROL, V125, P163, DOI 10.1006/exnr.1994.1019; WEISGRABER KH, 1994, CURR OPIN STRUC BIOL, V4, P507, DOI 10.1016/S0959-440X(94)90212-7; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C	58	282	293	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1996	10	13					1485	1494		10.1096/fasebj.10.13.8940294	http://dx.doi.org/10.1096/fasebj.10.13.8940294			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VU982	8940294				2022-12-28	WOS:A1996VU98200005
J	Gonzalez, FJ; Lee, YH				Gonzalez, FJ; Lee, YH			Cytochromes P450 .6. Constitutive expression of hepatic cytochrome P450 genes	FASEB JOURNAL			English	Review						transcription; HNF-1 alpha; C/EBP beta; STAT; cPLA(2)	TRANSCRIPTION FACTOR GABP; GROWTH-HORMONE; AH-RECEPTOR; BINDING PROTEIN; RAT HEPATOCYTES; PROPOSED ROLE; CYP2E1 GENE; MOUSE-LIVER; PROMOTER; DNA	One of the more challenging areas for study of the regulation of P450s is understanding the constitutive regulation of hepatic P450s. In this article, Gonzalez and Lee provide insight into how unique tissue-enriched transcription factors regulate expression of many of the hepatic P450s that are not under direct control of the ''xenobiotic'' receptors described by others. These constitutively expressed P450s are principally responsible for eliminating various hydrophobic xenobiotics such as drugs and other man-made chemicals from the body by oxidation reactions that are necessary to make them more water soluble. in addition, these tissue-enriched transcription factors probably dictate the developmental and probably sex-specific expression of P450s in the liver. Many of the tissue-enriched transcription factors are most likely under the control of second message pathways, increasing the potential diversity of regulation of the unique hepatic P450s discussed.	NCI,MOL CARCINOGENESIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								CHEN D, 1994, J BIOL CHEM, V269, P5420; CHEN D, 1994, DNA CELL BIOL, V13, P771, DOI 10.1089/dna.1994.13.771; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FRIEDBERG T, 1986, BIOCHEMISTRY-US, V25, P7975, DOI 10.1021/bi00372a028; Genuario R. Robert, 1993, Gene Expression, V3, P279; GONZALEZ F J, 1992, Keio Journal of Medicine, V41, P68; GONZALEZ FJ, 1993, PHARMACOGENETICS, V3, P51, DOI 10.1097/00008571-199302000-00006; GONZALEZ FJ, 1990, TRENDS GENET, V6, P182, DOI 10.1016/0168-9525(90)90174-5; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; GUZELIAN PS, 1988, P NATL ACAD SCI USA, V85, P9783, DOI 10.1073/pnas.85.24.9783; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JOHNSON PF, 1990, CELL GROWTH DIFFER, V1, P47; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LEE YH, 1994, J BIOL CHEM, V269, P14681; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIU SY, 1995, DNA CELL BIOL, V14, P285, DOI 10.1089/dna.1995.14.285; Magelsdorf D. J., 1995, CELL, V83, P835; MATSUNAGA E, 1990, DNA CELL BIOL, V9, P443, DOI 10.1089/dna.1990.9.443; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MIZUNO K, 1991, MOL CELL BIOL, V11, P4927, DOI 10.1128/MCB.11.10.4927; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; MUERHOFF AS, 1992, ARCH BIOCHEM BIOPHYS, V296, P66, DOI 10.1016/0003-9861(92)90545-8; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; PFEIFER GP, 1983, METHOD ENZYMOL, V225, P567; QUATTROCHI LC, 1994, J BIOL CHEM, V269, P6949; SHAW PM, 1994, MOL PHARMACOL, V46, P79; SONG BJ, 1989, J BIOL CHEM, V264, P3568; SONG BJ, 1986, J BIOL CHEM, V261, P6689; SONG BJ, 1987, MOL ENDOCRINOL, V1, P542, DOI 10.1210/mend-1-8-542; SUBRAMANIAN A, 1995, MOL CELL BIOL, V15, P4672; SUEYOSHI T, 1995, MOL CELL BIOL, V15, P4158; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; TOLLET P, 1995, J BIOL CHEM, V270, P12569, DOI 10.1074/jbc.270.21.12569; UENO T, 1990, MOL CELL BIOL, V10, P4495, DOI 10.1128/MCB.10.9.4495; UMENO M, 1988, J BIOL CHEM, V263, P4956; VENEPALLY P, 1992, J BIOL CHEM, V267, P17333; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; YANO M, 1992, MOL CELL BIOL, V12, P2847, DOI 10.1128/MCB.12.6.2847; YOKOMORI N, 1995, P NATL ACAD SCI USA, V92, P1302, DOI 10.1073/pnas.92.5.1302; YOKOMORI N, 1995, MOL CELL BIOL, V15, P5355; YOSHIOKA H, 1990, J BIOL CHEM, V265, P14612; ZAPHIROPOULOS PG, 1989, TRENDS PHARMACOL SCI, V10, P149, DOI 10.1016/0165-6147(89)90167-3	49	116	118	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1996	10	10					1112	1117		10.1096/fasebj.10.10.8751713	http://dx.doi.org/10.1096/fasebj.10.10.8751713			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VD429	8751713				2022-12-28	WOS:A1996VD42900002
J	Horn, V; Minucci, S; Ogryzko, VV; Adamson, ED; Howard, BH; Levin, AA; Ozato, K				Horn, V; Minucci, S; Ogryzko, VV; Adamson, ED; Howard, BH; Levin, AA; Ozato, K			RAR and RXR selective ligands cooperatively induce apoptosis and neuronal differentiation in P19 embryonal carcinoma cells	FASEB JOURNAL			English	Article						retinoids; RAR; RXR	RETINOIC ACID; RECEPTOR; IDENTIFICATION	Retinoids cause differentiation in embryonal carcinoma (EC) cells, thus mimicking events in mammalian development, Here, we show that retinoids also cause apoptosis in P19 EC cells, Characteristic DNA fragmentation was observed within 36 h after addition of retinoic acid (RA), Synthetic retinoids that are selective for RA receptors (RAR) were also effective in inducing apoptosis, whereas RXR selective ligands were without effect, The combination of RAR and RXR ligands resulted in a synergistic increase in apoptotic cell death, As with apoptosis, neuronal differentiation of P19 cells was synergistically induced by the combination of RAR and RXR ligands. Data obtained with an RAR antagonist and with P19 cells carrying a dominant negative RXR indicate that the two processes are receptor mediated, Together, our results indicate that retinoid-induced apoptosis and neuronal differentiation are closely coupled, and that both RAR and RXR play a role in these processes as active receptors for their respective ligands.	NICHHD,LAB MOLEC GROWTH REGULAT,NIH,BETHESDA,MD 20892; LA JOLLA CANC RES FDN,LA JOLLA,CA 92037; ISIS PHARMACEUT,CARLSBAD,CA 92008	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Sanford Burnham Prebys Medical Discovery Institute; Isis Pharmaceuticals Inc			Minucci, Saverio/J-9669-2012; Ogryzko, Vasily/M-6665-2015	Ogryzko, Vasily/0000-0002-8548-1389				APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; Apfel CM, 1995, J BIOL CHEM, V270, P30765, DOI 10.1074/jbc.270.51.30765; ASTROM A, 1990, BIOCHEM BIOPH RES CO, V173, P339, DOI 10.1016/S0006-291X(05)81062-9; BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; BOLLAG W, 1994, LEUKEMIA, V8, P1453; Brooks SC, 1996, BLOOD, V87, P227; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KRANENBURG O, 1995, ONCOGENE, V10, P87; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; MADEN M, 1992, BIOESSAYS, V14, P431, DOI 10.1002/bies.950140702; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; Minucci S, 1996, P NATL ACAD SCI USA, V93, P1803, DOI 10.1073/pnas.93.5.1803; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; NAGY L, 1995, MOL CELL BIOL, V15, P3540; PONZONI M, 1995, CANCER RES, V55, P853; ROY DY, 1995, MOL CELL BIOL, V15, P6481; SLACK RS, 1995, J CELL BIOL, V129, P779, DOI 10.1083/jcb.129.3.779; STENBERGER LA, 1983, P NATL ACAD SCI USA, V80, P6126; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU JX, 1993, DEV BIOL, V159, P208, DOI 10.1006/dbio.1993.1234; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022	26	64	69	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1996	10	9					1071	1077		10.1096/fasebj.10.9.8801169	http://dx.doi.org/10.1096/fasebj.10.9.8801169			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801169				2022-12-28	WOS:A1996UY93200018
J	Green, KJ; Jones, JCR				Green, KJ; Jones, JCR			Desmosomes and hemidesmosomes: Structure and function of molecular components	FASEB JOURNAL			English	Review						cell junction; matrix connector; cytoskeleton	BULLOUS PEMPHIGOID ANTIGEN; INTERMEDIATE FILAMENT NETWORKS; CYTOPLASMIC DOMAIN; INTEGRIN SUBUNIT; CULTURED-CELLS; BETA-CATENIN; DESMOPLAKIN; PROTEIN; FAMILY; AUTOANTIBODIES	Desmosomes and hemidesmosomes ire the major cell surface attachment sites for intermediate filaments at cell-cell and cell-substrate contacts, respectively, The transmembrane molecules of the desmosome belong to the cadherin family of calcium-dependent adhesion molecules, whereas those in the hemidesmosome include the integrin class of cell matrix receptors, In each junction, the cytoplasmic domains of certain transmembrane junction components contain unusually long carboxy-terminal tails not found in those family members involved in linkage of actin to the cell surface, These domains are thought to be important for the regulation of junction assembly and specific attachment of intermediate filaments via associated adapter proteins. Recent developments have suggested the exciting possibility that these junctions, in addition to playing an important structural function in tissue integrity, are both acceptors and affectors of cell signaling pathways, Many desmosomal and hemidesmosomal constituents are phosphoproteins and in certain cases the function of specific phosphorylation sites in regulating protein-protein interactions is being uncovered, In addition, a more active role in transmitting signals that control morphogenesis during development and possibly even regulate cell growth and differentiation are being defined for cytoplasmic and membrane components of these junctions.	NORTHWESTERN UNIV,SCH MED,DEPT CELL & MOLEC BIOL,RH LURIE CANC CTR,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT PATHOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT DERMATOL,CHICAGO,IL 60611	Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Northwestern University			Jones, Jonathan C R/T-9467-2017	Jones, Jonathan C R/0000-0002-1496-4922	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041836, R01AR043380] Funding Source: NIH RePORTER; NCI NIH HHS [CB11OB] Funding Source: Medline; NIAMS NIH HHS [R01 AR41836, R01 AR 43380] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABERDAM D, 1994, NAT GENET, V6, P299, DOI 10.1038/ng0394-299; AMAGAI M, 1994, J INVEST DERMATOL, V102, P402, DOI 10.1111/1523-1747.ep12372164; AMAGAI M, 1992, J CLIN INVEST, V90, P919, DOI 10.1172/JCI115968; BRAKENHOFF RH, 1995, J CELL BIOL, V129, P1677, DOI 10.1083/jcb.129.6.1677; BROWN A, 1995, NAT GENET, V10, P301, DOI 10.1038/ng0795-301; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COLLINS JE, 1994, MOL BIOL DESMOSOME H; COWIN P, 1994, MOL BIOL DESMOSOMES, P1; DEMLEHNER MP, 1995, J CELL BIOL, V131, P745, DOI 10.1083/jcb.131.3.745; DOMLOGEHULTSCH N, 1992, J CLIN INVEST, V90, P1628, DOI 10.1172/JCI116033; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Garrod DR, 1993, CURR OPIN CELL BIOL, V5, P30, DOI 10.1016/S0955-0674(05)80005-5; GIANCOTTI FG, 1992, J CELL BIOL, V118, P951, DOI 10.1083/jcb.118.4.951; GIUDICE GJ, 1993, J IMMUNOL, V151, P5742; GREEN KJ, 1992, INT J BIOL MACROMOL, V14, P145, DOI 10.1016/S0141-8130(05)80004-2; GUIDICE GJ, 1991, J CLIN INVEST, V87, P734; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; HATZFELD M, 1994, J CELL SCI, V107, P2259; HEID HW, 1994, DIFFERENTIATION, V58, P113; HENNIES HC, 1995, HUM MOL GENET, V4, P1015, DOI 10.1093/hmg/4.6.1015; HIEDA Y, 1992, J CELL BIOL, V116, P1497, DOI 10.1083/jcb.116.6.1497; HOGERVORST F, 1993, J CELL BIOL, V121, P179, DOI 10.1083/jcb.121.1.179; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; HOPKINSON SB, 1992, J INVEST DERMATOL, V99, P264, DOI 10.1111/1523-1747.ep12616615; HOPKINSON SB, 1995, J CELL BIOL, V130, P117, DOI 10.1083/jcb.130.1.117; HOPKINSON SB, 1994, BIOCHEM J, V300, P851, DOI 10.1042/bj3000851; JONES JCR, 1994, EXP CELL RES, V213, P1, DOI 10.1006/excr.1994.1166; JONKMAN MF, 1995, J CLIN INVEST, V95, P1345, DOI 10.1172/JCI117785; KALLUNKI P, 1992, J CELL BIOL, V109, P3377; KARNOVSKY A, 1995, P NATL ACAD SCI USA, V92, P4522, DOI 10.1073/pnas.92.10.4522; KING IA, 1995, J INVEST DERMATOL, V105, P314, DOI 10.1111/1523-1747.ep12319935; KIVIRIKKO S, 1995, HUM MOL GENET, V4, P959, DOI 10.1093/hmg/4.5.959; KLATTE DH, 1994, J INVEST DERMATOL, V102, P39, DOI 10.1111/1523-1747.ep12371728; KLYMKOWSKY MW, 1995, CELL, V83, P5, DOI 10.1016/0092-8674(95)90226-0; KOCH PJ, 1994, CURR OPIN CELL BIOL, V6, P682, DOI 10.1016/0955-0674(94)90094-9; KOCH PJ, 1992, P NATL ACAD SCI USA, V89, P353, DOI 10.1073/pnas.89.1.353; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; KOWALCZYK AP, 1994, J BIOL CHEM, V269, P31214; KURPAKUS MA, 1991, J CELL BIOL, V115, P1737, DOI 10.1083/jcb.115.6.1737; LANGHOFER M, 1993, J CELL SCI, V105, P753; LIU Z, 1993, J CLIN INVEST, V92, P2480, DOI 10.1172/JCI116856; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MATHUR M, 1994, J BIOL CHEM, V269, P14075; MCGRATH JA, 1995, NAT GENET, V11, P83, DOI 10.1038/ng0995-83; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; OCHIAI A, 1994, BIOCHEM BIOPH RES CO, V205, P73, DOI 10.1006/bbrc.1994.2631; PASDAR M, 1995, CELL MOTIL CYTOSKEL, V30, P108, DOI 10.1002/cm.970300203; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; PULKKINEN L, 1994, NAT GENET, V6, P293, DOI 10.1038/ng0394-293; PULKKINEN L, 1994, GENOMICS, V24, P357, DOI 10.1006/geno.1994.1627; PYKE C, 1994, AM J PATHOL, V145, P782; RIDDELLE KS, 1991, J CELL BIOL, V112, P159, DOI 10.1083/jcb.112.1.159; ROH JY, 1995, J INVEST DERMATOL, V104, P720, DOI 10.1111/1523-1747.ep12606963; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RYAN MC, 1994, J BIOL CHEM, V269, P22779; SCHMIDT A, 1994, EUR J CELL BIOL, V65, P229; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SIMRAK D, 1995, GENOMICS, V25, P591, DOI 10.1016/0888-7543(95)80067-V; SKALLI O, 1994, J CELL BIOL, V125, P159, DOI 10.1083/jcb.125.1.159; SPINARDI L, 1993, MOL BIOL CELL, V4, P871, DOI 10.1091/mbc.4.9.871; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; STAPPENBECK TS, 1994, J BIOL CHEM, V269, P29351; STAPPENBECK TS, 1992, J CELL BIOL, V116, P1197, DOI 10.1083/jcb.116.5.1197; STAPPENBECK TS, 1993, J CELL BIOL, V123, P691, DOI 10.1083/jcb.123.3.691; SU KK, 1993, SCIENCE, V262, P1734; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TANAKA T, 1991, J BIOL CHEM, V266, P12555; TROYANOVSKY SM, 1994, J CELL BIOL, V127, P151, DOI 10.1083/jcb.127.1.151; TROYANOVSKY SM, 1993, CELL, V72, P561, DOI 10.1016/0092-8674(93)90075-2; TROYANOVSKY SM, 1994, P NATL ACAD SCI USA, V91, P10790, DOI 10.1073/pnas.91.23.10790; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; UEMATSU J, 1994, J BIOCHEM-TOKYO, V115, P469, DOI 10.1093/oxfordjournals.jbchem.a124361; VIDAL F, 1995, NAT GENET, V10, P229, DOI 10.1038/ng0695-229; WICHE G, 1993, J CELL BIOL, V121, P607, DOI 10.1083/jcb.121.3.607; YANG HY, 1985, J CELL BIOL, V100, P620, DOI 10.1083/jcb.100.2.620; YU KKM, 1995, J CELL SCI, V108, P2163	81	289	293	1	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1996	10	8					871	881		10.1096/fasebj.10.8.8666164	http://dx.doi.org/10.1096/fasebj.10.8.8666164			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UQ456	8666164				2022-12-28	WOS:A1996UQ45600009
J	Ponder, KP				Ponder, KP			Analysis of liver development, regeneration, and carcinogenesis by genetic marking studies	FASEB JOURNAL			English	Review						stem cell; oval cell; retroviral vector; transgenic mice	OVAL CELL-PROLIFERATION; RAT-LIVER; EPITHELIAL-CELLS; TRANSGENIC MICE; STEM-CELLS; HEPATOCELLULAR-CARCINOMA; LINEAGE RELATIONSHIPS; TREATED RATS; DIFFERENTIATION; EXPRESSION	The mechanism of generating new hepatocytes and bile ductule cells in the liver has been controversial, Oval cells are found in the periportal region under some circumstances and may represent multipotent stem cells. The role of stem eells in generating new liver eells in normal and pathological conditions is unclear, however, Genetic marking can be used to determine the ability of a particular cell to replicate and to migrate, Cells of known lineage are marked at an initial time point, and their developmental potential determined by the cluster size, position, and phenotype of marked cells at a later time point, Recently, genetic marking studies have demonstrated that the hepatocyte itself is the source of new hepatocytes in the normal postnatal liver and that daughter cells do not migrate. These studies have also demonstrated that the hepatocyte can replicate extensively when stimulated, Finally, genetic marking studies suggest that either hepatocytes or oval cells can develop into a hepatocellular carcinoma or cholangiocarcinoma if a sufficient number of genetic mutations accumulate, The implications of these results for hepatic gene therapy, treatment of liver insufficiency states, and liver cancer are discussed, Future genetic marking studies may help to address some remaining questions in liver biology.	WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	Ponder, KP (corresponding author), WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA.							ARBER N, 1988, LIVER, V8, P80; ATERMAN K, 1992, J CANCER RES CLIN, V118, P87, DOI 10.1007/BF01187498; BENNOUN M, 1993, AM J PATHOL, V143, P1326; BLIKKENDAALLIEFTINCK LF, 1977, EXP MOL PATHOL, V26, P184, DOI 10.1016/0014-4800(77)90048-X; BRALET MP, 1994, AM J PATHOL, V144, P896; BRAUN L, 1987, CANCER RES, V47, P4116; BRILL S, 1993, P SOC EXP BIOL MED, V204, P261; Bucher N.L.R., 1971, REGENERATION LIVER K; COLEMAN WB, 1993, AM J PATHOL, V142, P1373; DABEVA MD, 1993, P SOC EXP BIOL MED, V204, P242; EVARTS RP, 1989, CANCER RES, V49, P1541; FABRIKANT JI, 1968, J CELL BIOL, V36, P551, DOI 10.1083/jcb.36.3.551; FANG XJ, 1993, CARCINOGENESIS, V14, P669, DOI 10.1093/carcin/14.4.669; FANG XJ, 1992, CANCER RES, V52, P173; FAUSTO N, 1993, P SOC EXP BIOL MED, V204, P237; FAUSTO N, 1990, PROG CLIN BIOL RES, V331, P325; GARFIELD S, 1988, MOL CARCINOGEN, V1, P189, DOI 10.1002/mc.2940010307; GERMAIN L, 1988, CANCER RES, V48, P368; GERMAIN L, 1988, CANCER RES, V48, P4909; GOODMAN ZD, 1985, CANCER-AM CANCER SOC, V55, P124, DOI 10.1002/1097-0142(19850101)55:1<124::AID-CNCR2820550120>3.0.CO;2-Z; GOYETTE M, 1990, CANCER RES, V50, P4809; GRISHAM JW, 1962, CANCER RES, V22, P842; GRISHAM JW, 1994, AM J PATHOL, V144, P849; GRISHAM JW, 1969, CANCER RES, V17, P248; HEINIGER HJ, 1971, P SOC EXP BIOL MED, V137, P1381; IANNACCONE PM, 1987, DEVELOPMENT, V99, P187; INAOKA Y, 1967, GANN, V58, P355; ISOM HC, 1992, CANCER RES, V52, P940; KENNEDY S, 1995, HEPATOLOGY, V22, P160, DOI 10.1016/0270-9139(95)90369-0; LEDLEY FD, 1993, HEPATOLOGY, V18, P1263; LEMIRE JM, 1991, AM J PATHOL, V139, P535; LIN YZ, 1995, CANCER RES, V55, P5242; MACDONALD RA, 1961, ARCH INTERN MED, V107, P79; MARCEAU N, 1990, LAB INVEST, V63, P4; OVERBEEK PA, 1986, SCIENCE, V231, P1574, DOI 10.1126/science.3006249; PITOT HC, 1990, ANNU REV PHARMACOL, V30, P465; PONDER KP, 1991, P NATL ACAD SCI USA, V88, P1217, DOI 10.1073/pnas.88.4.1217; PONDER KP, 1996, IN PRESS GENE TRANSF; RETTINGER SD, 1994, P NATL ACAD SCI USA, V91, P1460, DOI 10.1073/pnas.91.4.1460; RHIM JA, 1994, SCIENCE, V263, P1149, DOI 10.1126/science.8108734; RHIM JA, 1995, P NATL ACAD SCI USA, V92, P4942, DOI 10.1073/pnas.92.11.4942; ROTH KA, 1991, P NATL ACAD SCI USA, V88, P9407, DOI 10.1073/pnas.88.21.9407; SCHIRMACHER P, 1991, AM J PATHOL, V139, P231; SCHULTZE B, 1960, SCIENCE, V131, P737, DOI 10.1126/science.131.3402.737; SELL S, 1994, MODERN PATHOL, V7, P105; SELL S, 1989, AM J PATHOL, V134, P1347; SELL S, 1993, ENVIRON HEALTH PERSP, V101, P15, DOI 10.2307/3431838; SHIOJIRI N, 1991, CANCER RES, V51, P2611; SIGAL SH, 1992, AM J PHYSIOL, V263, pG139, DOI 10.1152/ajpgi.1992.263.2.G139; SINHA S, 1988, P NATL ACAD SCI USA, V85, P3673, DOI 10.1073/pnas.85.11.3673; SIRICA AE, 1990, PATHOBIOLOGY, V58, P44, DOI 10.1159/000163564; SIRICA AE, 1984, CANCER RES, V44, P3454; SOLT DB, 1977, AM J PATHOL, V88, P595; STEINBERG P, 1994, LAB INVEST, V71, P700; THORGEIRSSON SS, 1993, AM J PATHOL, V142, P1331; TSAO MS, 1987, AM J PATHOL, V127, P168; URIEL J, 1976, CANCER RES, V36, P4269; WOODWORTH CD, 1988, MOL CELL BIOL, V8, P4492, DOI 10.1128/MCB.8.10.4492; ZAJICEK G, 1985, LIVER, V5, P293	59	59	62	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1996	10	7					673	682		10.1096/fasebj.10.7.8635684	http://dx.doi.org/10.1096/fasebj.10.7.8635684			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UN798	8635684				2022-12-28	WOS:A1996UN79800001
J	Farhat, MY; Lavigne, MC; Ramwell, PW				Farhat, MY; Lavigne, MC; Ramwell, PW			The vascular protective effects of estrogen	FASEB JOURNAL			English	Review						estrogen receptor; endothelium; vascular smooth muscle	SMOOTH-MUSCLE CELLS; BREAST-CANCER-CELLS; CORONARY-ARTERY; NITRIC-OXIDE; RAT AORTA; CELLULAR PROLIFERATION; POSTMENOPAUSAL WOMEN; GENDER DIFFERENCES; SEXUAL DIMORPHISM; UTERINE ARTERIES	There is now strong epidemiological evidence that estrogen replacement therapy has a protective effect in postmenopausal women, The cardiovascular protective action of estrogen is reported to be mediated indirectly by an effect on Lipoprotein metabolism and by a direct effect on the vessel wall itself, Estrogen is active both in vascular smooth muscle and endothelium. Functionally competent estrogen receptors have been identified in vascular smooth muscle cells, and specific binding sites have been demonstrated in endothelium. Estrogen administration promotes vasodilation both in human and experimental animals, in part by stimulating prostacyclin and nitric oxide synthesis. Both the prostaglandin synthase and the constitutive nitric oxide synthase were recently reported to be induced by estrogen treatment, In vitro, estrogen exerts a direct inhibitory effect on the smooth muscle by inhibiting calcium influx, In addition, estrogen inhibits vascular smooth muscle cell proliferation, In vivo, estradiol-17 beta prevents neointimal thickening after balloon injury and in rabbit cardiac transplant allografts, These data are consistent with in vitro studies wherein estrogen inhibits [H-3]thymidine uptake by arterial segments from porcine coronary artery as well as proliferation of rabbit aortic vascular smooth muscle cells induced by hyperlipedemic serum, Recent studies have also reported an effect of estrogen on directed vascular smooth muscle cell migration, Furthermore, like other steroids, the effect of estrogen on the vessel wall has a rapid nongenomic component involving membrane phenomena, such as alteration of membrane ionic permeability and activation of membrane-bound enzymes, as well as the classical genomic effect involving estrogen receptor activation and gene expression, The nature of these estrogen response genes in the vessel wall and their relation to vasodilation and antiproliferation remain to be determined.			Farhat, MY (corresponding author), GEORGETOWN UNIV, MED CTR, DEPT PHYSIOL & BIOPHYS, 3900 RESERVOIR RD NW, WASHINGTON, DC 20007 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040069] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 40069] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTURA BM, 1975, J PHARMACOL EXP THER, V193, P403; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BAYARD F, 1995, ENDOCRINOLOGY, V136, P1523, DOI 10.1210/en.136.4.1523; Bayard F, 1995, CIBA F SYMP, V191, P122; BERTHOIS Y, 1986, J STEROID BIOCHEM, V25, P963, DOI 10.1016/0022-4731(86)90330-4; BLACKMORE PF, 1990, J BIOL CHEM, V265, P1376; BRAWER JR, 1993, BIOL REPROD, V49, P647, DOI 10.1095/biolreprod49.4.647; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; CEMBRANO J, 1960, CIRC RES, V8, P527, DOI 10.1161/01.RES.8.3.527; CHAN CC, 1982, J PHARMACOL EXP THER, V222, P731; CHANG WC, 1980, BIOCHIM BIOPHYS ACTA, V620, P472; CHOBANIAN AV, 1968, J ATHEROSCLER RES, V8, P763, DOI 10.1016/S0368-1319(68)80039-0; CHOWIENCZYK PJ, 1994, LANCET, V344, P305, DOI 10.1016/S0140-6736(94)91342-0; CITIVELLI R, 1990, ENDOCRINOLOGY, V127, P2253; CLARKSON TB, 1990, OBSTET GYNECOL, V75, P217; CLARKSON TB, 1987, TRANSPLANT P, V19, P85; CLOWES AW, 1989, LAB INVEST, V60, P360; CLOWES AW, 1983, LAB INVEST, V49, P327; COLBURN P, 1978, SCIENCE, V201, P817, DOI 10.1126/science.684408; COLLINS P, 1995, CIRCULATION, V92, P24, DOI 10.1161/01.CIR.92.1.24; COLUCCI WS, 1982, CIRC RES, V50, P805, DOI 10.1161/01.RES.50.6.805; CONRAD KP, 1993, FASEB J, V7, P566, DOI 10.1096/fasebj.7.6.7682524; CONSTANTINIDES P, 1962, ARCH PATHOL, V73, P277; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CORMIER EM, 1989, CANCER RES, V49, P576; CORVAZIER E, 1984, THROMB RES, V34, P303, DOI 10.1016/0049-3848(84)90387-6; DEMEY JGR, 1991, AM J PHYSIOL, V260, pH1128, DOI 10.1152/ajpheart.1991.260.4.H1128; DUBIK D, 1987, CANCER RES, V47, P6517; ELAM MB, 1980, PROSTAGLANDINS, V20, P1039, DOI 10.1016/0090-6980(80)90058-1; FARHAT MY, 1992, J PHARMACOL EXP THER, V261, P686; FARHAT MY, 1992, BRIT J PHARMACOL, V107, P679, DOI 10.1111/j.1476-5381.1992.tb14506.x; FARHAT MY, 1993, BRIT J PHARMACOL, V110, P719, DOI 10.1111/j.1476-5381.1993.tb13871.x; FARHAT MY, 1996, IN PRESS ENDOTHELIUM; FISCHER GM, 1971, J APPL PHYSIOL, V31, P527, DOI 10.1152/jappl.1971.31.4.527; FISCHERDZOGA K, 1983, EXP MOL PATHOL, V39, P355, DOI 10.1016/0014-4800(83)90064-3; FOEGH ML, 1994, J VASC SURG, V19, P722, DOI 10.1016/S0741-5214(94)70047-8; FOEGH ML, 1987, TRANSPLANT P, V19, P90; FOGELBERG M, 1990, EUR J CLIN INVEST, V20, P105, DOI 10.1111/j.1365-2362.1990.tb01799.x; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FUCHS KI, 1982, J APPL PHYSIOL, V53, P703, DOI 10.1152/jappl.1982.53.3.703; GILLIGAN DM, 1994, CIRCULATION, V90, P786, DOI 10.1161/01.CIR.90.2.786; GILLIGAN DM, 1994, CIRCULATION, V89, P2545, DOI 10.1161/01.CIR.89.6.2545; GISCLARD V, 1987, J PHARMACOL EXP THER, V240, P466; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRAINGER DJ, 1993, BIOCHEM J, V294, P109, DOI 10.1042/bj2940109; GRINDLAY L, 1980, AM J PHYSIOL, V239, pH297, DOI 10.1152/ajpheart.1980.239.3.H297; HALLFRISCH J, 1985, ATHEROSCLEROSIS, V57, P179, DOI 10.1016/0021-9150(85)90031-0; HALLIWELL B, 1987, FEBS LETT, V213, P9, DOI 10.1016/0014-5793(87)81455-2; HARRISON DG, 1995, AM J CARDIOL, V75, pB75, DOI 10.1016/0002-9149(95)80018-N; HAYASHI T, 1992, P NATL ACAD SCI USA, V89, P11259, DOI 10.1073/pnas.89.23.11259; HENNEMAN DH, 1968, ENDOCRINOLOGY, V83, P678, DOI 10.1210/endo-83-4-678; HORWITZ KB, 1982, J CLIN INVEST, V69, P750, DOI 10.1172/JCI110513; JACOBSSON J, 1992, J HEART LUNG TRANSPL, V11, P1188; KANALEY JA, 1991, METABOLISM, V40, P88, DOI 10.1016/0026-0495(91)90197-5; KARAS RH, 1994, CIRCULATION, V89, P1943, DOI 10.1161/01.CIR.89.5.1943; KAUSER K, 1994, J AM COLL CARDIOL, pA295; KAUSER K, 1993, CIRCULATION, V88, P79; KEANEY JF, 1994, CIRCULATION, V89, P2251, DOI 10.1161/01.CIR.89.5.2251; KUSHWAHA RS, 1981, METABOLISM, V30, P359, DOI 10.1016/0026-0495(81)90116-5; LAN NC, 1990, EUR J PHARM-MOLEC PH, V188, P403, DOI 10.1016/0922-4106(90)90201-8; LANDERS J P, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P19; LANTTA M, 1983, AM J OBSTET GYNECOL, V147, P627, DOI 10.1016/0002-9378(83)90439-8; LAVIGNE MC, 1995, FASEB J, V9, pA315; LEIBERMAN JR, 1990, AM J OBSTET GYNECOL, V163, P1685, DOI 10.1016/0002-9378(90)90651-M; LIEBERHERR M, 1993, J BONE MINER RES, V8, P1365; LIEHR JG, 1990, FREE RADICAL BIO MED, V8, P415, DOI 10.1016/0891-5849(90)90108-U; LIN AL, 1986, ARTERIOSCLEROSIS, V6, P495, DOI 10.1161/01.ATV.6.5.495; LIN AL, 1985, ARTERIOSCLEROSIS, V5, P668, DOI 10.1161/01.ATV.5.6.668; LOSORDO DW, 1994, CIRCULATION, V89, P1501, DOI 10.1161/01.CIR.89.4.1501; Luscher T F, 1994, Blood Press Suppl, V1, P18; MADDOX YT, 1987, J PHARMACOL EXP THER, V240, P392; MALINOW MR, 1963, J CLIN ENDOCR METAB, V23, P306, DOI 10.1210/jcem-23-3-306; MCGILL HC, 1981, CIRC RES, V48, P238, DOI 10.1161/01.RES.48.2.238; MCNAMARA DB, 1993, BIOCHEM BIOPH RES CO, V193, P291, DOI 10.1006/bbrc.1993.1622; METCALFE JC, 1986, BRIT MED BULL, V42, P405, DOI 10.1093/oxfordjournals.bmb.a072159; MIKKOLA T, 1995, J CLIN ENDOCR METAB, V80, P1832, DOI 10.1210/jc.80.6.1832; MORALES DE, 1995, CIRCULATION, V91, P755, DOI 10.1161/01.CIR.91.3.755; MORLEY P, 1992, ENDOCRINOLOGY, V131, P1305, DOI 10.1210/en.131.3.1305; MOSKOWITZ MS, 1956, ARCH PATHOL, V61, P245; MOURA AM, 1984, HYPERTENSION, V6, P425, DOI 10.1161/01.HYP.6.3.425; NENCI I, 1981, J STEROID BIOCHEM, V14, P1139, DOI 10.1016/0022-4731(81)90043-1; OBERLEY TD, 1994, FREE RADICAL BIO MED, V16, P741, DOI 10.1016/0891-5849(94)90189-9; ORIMO A, 1993, BIOCHEM BIOPH RES CO, V195, P730, DOI 10.1006/bbrc.1993.2106; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; PERROTAPPLANAT M, 1988, ENDOCRINOLOGY, V123, P1511, DOI 10.1210/endo-123-3-1511; PIETRAS RJ, 1979, J CELL PHYSIOL, V98, P145, DOI 10.1002/jcp.1040980116; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; RADDINO R, 1986, ARCH INT PHARMACOD T, V281, P57; REIS SE, 1994, CIRCULATION, V89, P52, DOI 10.1161/01.CIR.89.1.52; RENAUD S, 1970, ATHEROSCLEROSIS, V38, P75; RHEE CY, 1977, J LAB CLIN MED, V90, P77; RORIE DK, 1979, BLOOD VESSELS, V16, P252; ROSANO GMC, 1993, LANCET, V342, P133, DOI 10.1016/0140-6736(93)91343-K; ROSS R, 1973, SCIENCE, V180, P1332, DOI 10.1126/science.180.4093.1332; SACK MN, 1994, LANCET, V343, P269, DOI 10.1016/S0140-6736(94)91117-7; SADLER SE, 1982, J BIOL CHEM, V257, P355; SALAS E, 1994, EUR J PHARMACOL, V258, P47, DOI 10.1016/0014-2999(94)90056-6; SALT PJ, 1972, EUR J PHARMACOL, V20, P329, DOI 10.1016/0014-2999(72)90194-X; SEKI J, 1994, RESTENOSIS SUMMIT, V6, P86; SHAN J, 1994, AM J PHYSIOL, V266, pH967, DOI 10.1152/ajpheart.1994.266.3.H967; SHAY J, 1994, LIFE SCI, V55, P1071, DOI 10.1016/0024-3205(94)00642-3; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; STALLONE JN, 1991, AM J PHYSIOL, V260, pH453, DOI 10.1152/ajpheart.1991.260.2.H453; STAMPFER MJ, 1990, ANN NY ACAD SCI, V592, P193; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STEINLEITNER A, 1989, AM J OBSTET GYNECOL, V161, P1677, DOI 10.1016/0002-9378(89)90949-6; SYLVESTER JT, 1985, CHEST, V88, pS252, DOI 10.1378/chest.88.4.252S; THAMPAN TNRV, 1981, NATURE, V290, P152, DOI 10.1038/290152a0; VANBREEMEN C, 1982, AM J CARDIOL, V49, P507, DOI 10.1016/S0002-9149(82)80003-9; VARGAS R, 1989, ADV PROSTAG THROMB L, V19, P277; VARGAS R, 1995, J CARDIOVASC PHARM, V25, P200, DOI 10.1097/00005344-199502000-00004; VARGAS R, 1993, BRIT J PHARMACOL, V109, P612, DOI 10.1111/j.1476-5381.1993.tb13616.x; WEHLING M, 1994, STEROIDS, V59, P160, DOI 10.1016/0039-128X(94)90095-7; WEIGT M, 1987, PFLUG ARCH EUR J PHY, V408, P609, DOI 10.1007/BF00581163; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; WETZEL RC, 1984, J APPL PHYSIOL, V56, P1199, DOI 10.1152/jappl.1984.56.5.1199; WILLIAMS JK, 1992, J AM COLL CARDIOL, V20, P452, DOI 10.1016/0735-1097(92)90116-5; WOLINSKY H, 1972, CIRC RES, V30, P341, DOI 10.1161/01.RES.30.3.341; ZHANG A, 1991, STEROIDS, V56, P524, DOI 10.1016/0039-128X(91)90118-F; ZHANG F, 1994, AM J PHYSIOL, V266, pC975, DOI 10.1152/ajpcell.1994.266.4.C975	122	526	543	1	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1996	10	5					615	624		10.1096/fasebj.10.5.8621060	http://dx.doi.org/10.1096/fasebj.10.5.8621060			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UJ055	8621060				2022-12-28	WOS:A1996UJ05500009
J	Shi, H; Severs, NJ; Robenek, H				Shi, H; Severs, NJ; Robenek, H			Effects of calcium on the migration and recruitment of macrophages and macrophage-derived foam cells	FASEB JOURNAL			English	Article						macrophage foam cell; atherosclerosis; lipoprotein; isradipine; Boyden chamber	LOW-DENSITY-LIPOPROTEIN; MOUSE PERITONEAL-MACROPHAGES; FAMILIAL HYPERCHOLESTEROLEMIA; CHANNEL BLOCKERS; ATHEROSCLEROSIS; ANTAGONISTS; ATHEROGENESIS; PATHOGENESIS; DEGRADATION; MECHANISMS	Calcium is thought to play an important role in the genesis of atherosclerotic lesions, but the precise mechanisms involved are unclear, In the present investigation, we have used in vitro systems to investigate the effects of calcium on one key aspect of lesion development: the migration of macrophages and macrophage/foam cells, Using agarose plate migration assays, the migratory characteristics of macrophages exposed to 1) no lipoprotein, 2) low density lipoprotein (LDL), 3) acetylated low density lipoprotein (acLDL), and) oxidized low density lipoprotein were examined. The most marked stimulatory effect on macrophage mobility was observed when freshly isolated cells were exposed to acLDL during the migration assay. High levels of exogenous calcium were found to suppress the stimulatory effect of acLDL on migration, As the responses of macrophages exposed to a uniform concentration of agents in the surrounding medium may differ from chemotactic responses to a concentration gradient, the migration of macrophages, with and without preexposure to acLDL or LDL, was studied using microchemotaxis Boyden chambers, Under these conditions, calcium acted as a highly potent chemoattractant, especially to cells that had been preincubated with acLDL. These results suggest how elevated external calcium concentration leads initially to macrophage recruitment, and subsequently to foam cell aggregation and lipid core formation, in association with calcification, in the developing atherosclerotic plaque.	UNIV MUNSTER,DEPT CELL BIOL & ULTRASTRUCT RES,INST ARTERIOSCLEROSIS RES,D-48149 MUNSTER,GERMANY; ROYAL BROMPTON HOSP,NATL HEART & LUNG INST,UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,LONDON SW3 6LY,ENGLAND	University of Munster; Imperial College London; Royal Brompton Hospital								BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BERNINI F, 1991, J CARDIOVASC PHARM, V18, pS42; Blumenthal Herman T., 1944, AMER JOUR PATH, V20, P665; BORN GVR, 1991, CALCIUM ANTAGONISM A, P1; Campbell A.K, 1983, INTRACELLULAR CALCIU; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; DAUGHERTY A, 1987, BRIT J PHARMACOL, V91, P113, DOI 10.1111/j.1476-5381.1987.tb08989.x; DUSHKIN MI, 1991, BIOCHEMISTRY-MOSCOW+, V56, P551; FALK E, 1992, CIRCULATION, V86, P30; FISHER M, 1991, CEREBROVAS BRAIN MET, V3, P114; FITZPATRICK LA, 1994, J CLIN INVEST, V94, P1597, DOI 10.1172/JCI117501; FLECKENSTEIN A, 1986, AM J CARDIOL, V57, pD1, DOI 10.1016/0002-9149(86)90798-8; FLECKENSTEIN A, 1983, CIRC RES, V52, P3; FLECKENSTEINGRUN G, 1991, ANN MED, V23, P589, DOI 10.3109/07853899109150522; GERRITY RG, 1981, AM J PATHOL, V103, P191; GERRITY RG, 1981, AM J PATHOL, V103, P181; HABIB JB, 1986, CIRC RES, V58, P305, DOI 10.1161/01.RES.58.2.305; HANDLEY DA, 1986, AM J PATHOL, V124, P88; HARA S, 1992, ARTERIOSCLER THROMB, V12, P593, DOI 10.1161/01.ATV.12.5.593; HENRIKSEN T, 1983, ARTERIOSCLEROSIS, V3, P149, DOI 10.1161/01.ATV.3.2.149; HENRY PD, 1991, J CARDIOVASC PHARM, V18, pS6, DOI 10.1097/00005344-199106181-00003; HENRY PD, 1990, ARTERIOSCLEROSIS, V10, P963, DOI 10.1161/01.ATV.10.6.963; HO YK, 1980, J LIPID RES, V21, P391; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; LICHTLEN PR, 1990, CARDIOVASC DRUG THER, V4, P1017; MALAYEV A, 1995, J MEMBRANE BIOL, V146, P101; Meyer W W, 1971, Monatsschr Kinderheilkd, V119, P298; NAYLER W, 1991, 2 GENERATION CALCIUM; NAYLER WG, 1992, J HUM HYPERTENS, V6, pS19; NAYLER WG, 1992, J CARDIOVASC PHARM, V19, pS17, DOI 10.1097/00005344-199219002-00005; NOMOTO A, 1987, ATHEROSCLEROSIS, V64, P255, DOI 10.1016/0021-9150(87)90253-X; OBRIEN ER, 1994, ARTERIOSCLER THROMB, V14, P1648, DOI 10.1161/01.ATV.14.10.1648; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PARTHASARATHY S, 1992, ANNU REV MED, V43, P219, DOI 10.1146/annurev.me.43.020192.001251; PATAKI M, 1992, ARTERIOSCLER THROMB, V12, P936, DOI 10.1161/01.ATV.12.8.936; PAULETTO P, 1992, J CARDIOVASC PHARM, V19, pS8, DOI 10.1097/00005344-199219002-00004; ROBENEK H, 1988, ARTERIOSCLEROSIS, V8, P57, DOI 10.1161/01.ATV.8.1.57; ROBENEK H, 1985, EUR J CELL BIOL, V39, P77; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; ROSS R, 1993, TRANSPLANT P, V25, P2041; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SARIG S, 1994, LAB INVEST, V71, P782; SCHMID K, 1980, ATHEROSCLEROSIS, V37, P199, DOI 10.1016/0021-9150(80)90005-2; SCHMITZ G, 1985, EMBO J, V4, P613, DOI 10.1002/j.1460-2075.1985.tb03674.x; SCHMITZ G, 1991, ATHEROSCLEROSIS, V88, P109, DOI 10.1016/0021-9150(91)90074-D; SCHMITZ G, 1988, ARTERIOSCLEROSIS, V8, P45; SCHUH J, 1978, P NATL ACAD SCI USA, V75, P3173, DOI 10.1073/pnas.75.7.3173; SCHWARTZ CJ, 1992, CIRCULATION, V86, P117; SHANAHAN CM, 1994, J CLIN INVEST, V93, P2393, DOI 10.1172/JCI117246; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; TAKEO S, 1989, ATHEROSCLEROSIS, V77, P175, DOI 10.1016/0021-9150(89)90079-8; TRIGGLE DJ, 1991, CALCIUM ANTAGONISM A, P27; WALERS D, 1992, CIRCULATION S, V86, P111; WEISSER B, 1992, ARTERIOSCLER THROMB, V12, P231, DOI 10.1161/01.ATV.12.2.231; WISSLER RW, 1992, ARCH PATHOL LAB MED, V116, P1281; WITTEMAN JCM, 1990, AM J CARDIOL, V66, P1060, DOI 10.1016/0002-9149(90)90505-U; WITZTUM JL, 1991, ADV EXP MED BIOL, V285, P353	60	14	14	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1996	10	4					491	501		10.1096/fasebj.10.4.8647348	http://dx.doi.org/10.1096/fasebj.10.4.8647348			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UE557	8647348				2022-12-28	WOS:A1996UE55700013
J	CHEN, XS; FUNK, CD				CHEN, XS; FUNK, CD			STRUCTURE-FUNCTION PROPERTIES OF HUMAN PLATELET 12-LIPOXYGENASE - CHIMERIC ENZYME AND INVITRO MUTAGENESIS STUDIES	FASEB JOURNAL			English	Note						LIPOXYGENASE; ARACHIDONIC ACID; MUTAGENESIS; IRON-BINDING DOMAIN	SITE-DIRECTED MUTAGENESIS; POLYMERASE CHAIN-REACTION; AMINO-ACID SEQUENCE; HUMAN 5-LIPOXYGENASE; MOLECULAR-CLONING; SOYBEAN LIPOXYGENASE-1; ARACHIDONATE 12-LIPOXYGENASE; POSITIONAL SPECIFICITY; ACTIVE-SITE; EXPRESSION	Mutant and chimeric lipoxygenases were expressed in human embryonal kidney 293 cells to assess the importance of amino acids and domains for catalytic activity and positional specificity of molecular oxygen insertion. Histidines 360, 365, and 540, when changed to glutamine residues, completely abolished human platelet 12-lipoxygenase activity. Altered histidines at positions 355, 383, and 392 retained enzymatic activity. The former three histidines could possibly serve as ligands for the catalytically essential non-heme iron atom. Amino acids adjacent (residues 398-417) to the five centrally located histidines conserved among all plant and animal lipoxygenases controlled to a limited extent the positional specificity of oxygenation of 12-lipoxygenase. Variant A417I and the triple variant K416Q/A417I/V418M, designed to introduce 15-lipoxygenase substitutions, transformed the platelet 12-lipoxygenase that synthesizes exclusively 12-hydro(pero)xy-eicosatetraenoic acid (12-H(P)ETE) to an enzyme capable of 10-20% 15-lipoxygenation. When all amino acids between positions 398-429 of 12-lipoxygenase had the corresponding 15-lipoxygenase sequence, the enzyme made 66% 15-lipoxygenase products. The latter enzyme had markedly reduced enzyme activity, though, indicating an apparent shift in the optimal alignment of substrate at the active site for hydrogen atom abstraction. The platelet enzyme could not be altered to form 5-lipoxygenase products by similar manipulations of sequence within this region. Chimeric enzymes consisting of an NH2-terminal segment from one lipoxygenase and the COOH terminus from another lipoxygenase or large substitutions resulted in nonfunctional enzymes. NH2-terminal extensions, but not short deletions, could be tolerated functionally. These studies provide some new insights into lipoxygenase structure-function in the absence of an unresolved three-dimensional structure.	VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232	Vanderbilt University			Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002710, R01HL046017] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46017, K04 HL02710] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; DEMARZO N, 1992, AM J PHYSIOL, V262, pL198; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; EALING PM, 1988, BIOCHEM J, V253, P915, DOI 10.1042/bj2530915; FUNK CD, 1992, P NATL ACAD SCI USA, V89, P3962, DOI 10.1073/pnas.89.9.3962; FUNK CD, 1991, ADV PROSTAG THROMB L, V21, P33; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2592, DOI 10.1073/pnas.86.8.2592; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; FUNK CD, 1991, PROSTAGLANDINS LEUKO, P97; GARDNER HW, 1989, BIOCHIM BIOPHYS ACTA, V1001, P274, DOI 10.1016/0005-2760(89)90111-2; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOUGHTON JE, 1989, NATURE, V338, P172, DOI 10.1038/338172a0; ISHII S, 1992, BIOCHEM BIOPH RES CO, V182, P1482, DOI 10.1016/0006-291X(92)91901-2; IZUMI T, 1990, P NATL ACAD SCI USA, V87, P7477, DOI 10.1073/pnas.87.19.7477; KUHN H, 1990, J BIOL CHEM, V265, P18351; KUHN H, 1990, J BIOL CHEM, V265, P16300; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P3406; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; NAVARATNAM S, 1988, BIOCHIM BIOPHYS ACTA, V956, P70, DOI 10.1016/0167-4838(88)90299-3; NGUYEN T, 1991, J BIOL CHEM, V266, P22057; NUGTEREN DH, 1975, BIOCHIM BIOPHYS ACTA, V380, P299, DOI 10.1016/0005-2760(75)90016-8; OPREY J, 1989, GENE, V84, P493, DOI 10.1016/0378-1119(89)90526-X; PERCIVAL MD, 1991, J BIOL CHEM, V266, P10058; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; SHIBATA D, 1987, J BIOL CHEM, V262, P10080; SHIBATA D, 1988, J BIOL CHEM, V263, P6816; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; SIGAL E, 1990, J BIOL CHEM, V265, P5113; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; STECZKO J, 1992, BIOCHEMISTRY-US, V31, P4053, DOI 10.1021/bi00131a022; STECZKO J, 1992, BIOCHEM BIOPH RES CO, V186, P686, DOI 10.1016/0006-291X(92)90801-Q; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; YENOFSKY RL, 1988, MOL GEN GENET, V211, P215, DOI 10.1007/BF00330597; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142; YOSHIMOTO T, 1990, BIOCHEM BIOPH RES CO, V172, P1230, DOI 10.1016/0006-291X(90)91580-L; ZHANG Y, 1991, J AM CHEM SOC, V113, P5162, DOI 10.1021/ja00014a004; ZHANG YY, 1992, P NATL ACAD SCI USA, V89, P485, DOI 10.1073/pnas.89.2.485	40	55	57	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1993	7	8					694	701		10.1096/fasebj.7.8.8500694	http://dx.doi.org/10.1096/fasebj.7.8.8500694			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LE290	8500694				2022-12-28	WOS:A1993LE29000012
J	HAJDUK, SL; HARRIS, ME; POLLARD, VW				HAJDUK, SL; HARRIS, ME; POLLARD, VW			RNA EDITING IN KINETOPLASTID MITOCHONDRIA	FASEB JOURNAL			English	Article						TRYPANOSOME; RNA PROCESSING	AUG INITIATION CODONS; B MESSENGER-RNA; TRYPANOSOMA-BRUCEI; GUIDE RNAS; LEISHMANIA-TARENTOLAE; CYTOCHROME-OXIDASE; URIDINE ADDITION; SUBUNIT-III; MURF3 GENE; TRANSCRIPTS	RNA editing in the mitochondrion of kinetoplastid protozoa results in the posttranscriptional addition and deletion of uridine residues in mRNAs. Editing of mRNAs can lead to the formation of initiation codons for mitochondrial translation, the correction of frame-shifted genes at the RNA level, and in extensively edited mRNAs, the formation of complete reading frames. Kinetoplastid RNA editing requires that genetic information from two or more separately transcribed genes be brought together to form the mature, edited mRNA. The information necessary for the proper insertion or deletion of uridines in the mRNA is present in small mitochondrial transcripts termed guide RNAs (gRNAs). Editing of mRNAs appears to be associated with a high molecular weight complex, called the editosome, containing specific gRNAs, unedited mRNAs, and proteins. Editing is likely a two-step process involving first the breakage of a phosphodiester bond at the editing site and formation of a chimeric molecule with a gRNA covalently joined to the 5' end of the 3' portion of an mRNA. The chimera is resolved by the rejoining of the 5' end of the mRNA to the 3' portion of the mRNA with the addition or deletion of a uridine at the junction point. Two models are proposed for the biochemical mechanism of RNA editing. The first is an enzymatic cascade of cleavage and ligation while the other supports successive rounds of transesterification. The obvious functional necessity for editing in kinetoplastid mitochondria is the formation of translatable mRNAs. Far less clear is the evolutionary origin of editing and the role editing plays in regulating mitochondrial gene expression.	UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham	HAJDUK, SL (corresponding author), UNIV ALABAMA,SCH MED,DEPT BIOCHEM,BIRMINGHAM,AL 35294, USA.				NIAID NIH HHS [AI 21401] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021401, R21AI021401] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; ADLER BK, 1991, MOL CELL BIOL, V11, P5878, DOI 10.1128/MCB.11.12.5878; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; BORST P, 1991, TRENDS GENET, V7, P139, DOI 10.1016/0168-9525(91)90374-Y; BOSTROM K, 1990, J BIOL CHEM, V265, P22446; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; FEAGIN JE, 1990, J BIOL CHEM, V265, P19373; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; FEAGIN JE, 1988, MOL CELL BIOL, V8, P1259, DOI 10.1128/MCB.8.3.1259; GRAY MW, 1993, FASEB J, V7, P64, DOI 10.1096/fasebj.7.1.8422976; HAJDUK S, 1992, AM J MED SCI, V303, P258, DOI 10.1097/00000441-199204000-00011; HAJDUK SL, 1986, MOL CELL BIOL, V6, P4372, DOI 10.1128/MCB.6.12.4372; HARRIS M, 1992, MOL CELL BIOL, V12, P2591, DOI 10.1128/MCB.12.6.2591; HARRIS ME, 1992, CELL, V68, P1091, DOI 10.1016/0092-8674(92)90080-V; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; JASMER DP, 1986, MOL BIOCHEM PARASIT, V18, P321, DOI 10.1016/0166-6851(86)90089-7; KOSLOWSKY DJ, 1991, CELL, V67, P537, DOI 10.1016/0092-8674(91)90528-7; KOSLOWSKY DJ, 1992, NATURE, V356, P807, DOI 10.1038/356807a0; KOSLOWSKY DJ, 1992, MOL CELL BIOL, V12, P2043, DOI 10.1128/MCB.12.5.2043; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; MAHENDRAN R, 1991, NATURE, V349, P434, DOI 10.1038/349434a0; MASLOV DA, 1992, MOL CELL BIOL, V12, P56, DOI 10.1128/MCB.12.1.56; MASLOV DA, 1992, CELL, V70, P459, DOI 10.1016/0092-8674(92)90170-H; MICHELOTTI EF, 1987, J BIOL CHEM, V262, P927; MICHELOTTI EF, 1992, MOL BIOCHEM PARASIT, V54, P31, DOI 10.1016/0166-6851(92)90092-X; POLLARD VW, 1991, MOL CELL BIOL, V11, P1668, DOI 10.1128/MCB.11.3.1668; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; POLLARD VW, 1992, EMBO J, V12, P4429; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; READ LK, 1992, J BIOL CHEM, V267, P1123; SHAW JM, 1989, P NATL ACAD SCI USA, V86, P6220, DOI 10.1073/pnas.86.16.6220; SHAW JM, 1988, CELL, V53, P401, DOI 10.1016/0092-8674(88)90160-2; SIMPSON AM, 1992, J BIOL CHEM, V267, P6782; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOUZA AE, 1992, MOL CELL BIOL, V12, P2100, DOI 10.1128/MCB.12.5.2100; STUART K, 1991, ANNU REV MICROBIOL, V45, P327, DOI 10.1146/annurev.mi.45.100191.001551; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; STURM NR, 1991, NUCLEIC ACIDS RES, V19, P6277, DOI 10.1093/nar/19.22.6277; VANDERSPEK H, 1988, EMBO J, V7, P2509, DOI 10.1002/j.1460-2075.1988.tb03098.x; VIDAL S, 1990, EMBO J, V9, P2017, DOI 10.1002/j.1460-2075.1990.tb08330.x	54	89	90	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					54	63		10.1096/fasebj.7.1.8422975	http://dx.doi.org/10.1096/fasebj.7.1.8422975			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422975				2022-12-28	WOS:A1993KH88000009
J	Cermak, JM; Holler, T; Jackson, DA; Blusztajn, JK				Cermak, JM; Holler, T; Jackson, DA; Blusztajn, JK			Prenatal availability of choline modifies development of the hippocampal cholinergic system	FASEB JOURNAL			English	Article						acetylcholine; acetylcholinesterase; acetylcholine release; choline acetyltransferase; cortex; development; high-affinity choline uptake; hippocampus; memory; pregnancy; rat	RAT SEPTOHIPPOCAMPAL NEURONS; BASAL FOREBRAIN LESIONS; ACETYLCHOLINE SYNTHESIS; EXCITOTOXIC LESIONS; DIETARY CHOLINE; GROWTH-FACTORS; FINE-STRUCTURE; CELL-LINE; BRAIN; SUPPLEMENTATION	Choline supplementation during fetal development [embryonic days (E) 11-17] permanently enhances memory performance in rats. To characterize the neurochemical mechanisms that may mediate this effect, we investigated the development of indices of the cholinergic system in the hippocampus: choline acetyltransferase (ChAT), acetylcholinesterase (AChE), synthesis of acetylcholine (ACh) from choline transported by high-affinity choline uptake (HACU), and potassium-evoked ACh release. During E11-E17, Sprague-Dawley pregnant rats consumed 0 [choline-deficient (ChD)], 1.3 [control(ChC)], and 4.6 [choline-supplemented (ChS)] mmol/(kg . day) of choline, respectively. On postnatal days 17 and 27, hippocampi of the ChD animals had the highest AChE and ChAT activities, and increased synthesis of ACh from choline transported by HACU, concomitant with reductions of tissue ACh content relative to the ChC and ChS rats and an inability to sustain depolarization-evoked ACh release relative to the ChS animals. In contrast, AChE and ChAT activities, and ACh synthesized from choline transported by HACU, were lowest in ChS rats whereas depolarization-evoked ACh release was the highest. This pattern of changes suggests that the hippocampus of the ChD animals is characterized by fast ACh recycling and efficient choline reutilization for ACh synthesis, presumably to maintain adequate ACh release despite the decrease of the ACh pool, whereas in the ChS animals ACh turnover and choline recycling is slower while the evoked release of ACh is high. Together, the data show a complex adaptive response of the hippocampal cholinergic system to prenatal choline availability and provide a novel example of developmental plasticity in the nervous system governed by the supply of a single nutrient.	Boston Univ, Sch Med, Dept Med Pathol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Lab Med, Boston, MA 02118 USA	Boston University; Boston University	Blusztajn, JK (corresponding author), Boston Univ, Sch Med, Dept Med Pathol, 85 E Newton St,Rm M1009, Boston, MA 02118 USA.			/0000-0001-8438-3122	NIA NIH HHS [AG09525] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Acquas E, 1996, J NEUROSCI, V16, P3089; Albright CD, 1996, FASEB J, V10, P510, DOI 10.1096/fasebj.10.4.8647350; ASHKENAZI A, 1989, NATURE, V340, P146, DOI 10.1038/340146a0; AUBERT I, 1994, J NEUROSCI, V14, P2476; Backman C, 1996, J NEUROSCI, V16, P5437; BAYER SA, 1979, J COMP NEUROL, V183, P89, DOI 10.1002/cne.901830108; BLUSZTAJN JK, 1983, SCIENCE, V221, P614, DOI 10.1126/science.6867732; BLUSZTAJN JK, 1987, P NATL ACAD SCI USA, V84, P5474, DOI 10.1073/pnas.84.15.5474; BRADY DR, 1989, DEV BRAIN RES, V47, P81, DOI 10.1016/0165-3806(89)90110-7; BUCHMAN AL, 1995, HEPATOLOGY, V22, P1399, DOI 10.1002/hep.1840220510; BURKE MA, 1994, EXP NEUROL, V128, P159, DOI 10.1006/exnr.1994.1124; BURKE MA, 1994, EXP NEUROL, V130, P178, DOI 10.1006/exnr.1994.1197; Charles V, 1996, BRAIN RES, V728, P193, DOI 10.1016/0006-8993(96)00398-8; CHIBA AA, 1995, J NEUROSCI, V15, P7315; COHEN EL, 1976, SCIENCE, V191, P561, DOI 10.1126/science.1251187; COYLE JT, 1976, BRAIN RES, V118, P429, DOI 10.1016/0006-8993(76)90310-3; Crawford M. A., 1993, Nutrition and Health (Bicester), V9, P81; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; CUADRADO A, 1993, ONCOGENE, V8, P2959; EAGLE H, 1955, J EXP MED, V102, P595, DOI 10.1084/jem.102.5.595; FIBIGER HC, 1991, TRENDS NEUROSCI, V14, P220, DOI 10.1016/0166-2236(91)90117-D; FINLAY BL, 1995, SCIENCE, V268, P1578, DOI 10.1126/science.7777856; FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x; GARNER SC, 1995, J NUTR, V125, P2851; GRIFFITH WENDELL H., 1939, JOUR BIOL CHEM, V131, P567; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Holler T, 1996, FASEB J, V10, P1653, DOI 10.1096/fasebj.10.14.9002559; HolmesMcNary MQ, 1997, DEV BRAIN RES, V101, P9, DOI 10.1016/S0165-3806(97)00044-8; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; JONES DNC, 1995, J NEUROSCI, V15, P7282; JOPE RS, 1979, J NEUROSCI RES, V4, P69, DOI 10.1002/jnr.490040110; KLEIN J, 1991, J NEUROCHEM, V57, P370, DOI 10.1111/j.1471-4159.1991.tb03762.x; LAPCHAK PA, 1991, J NEUROSCI, V11, P2821; LEE HC, 1993, P NATL ACAD SCI USA, V90, P10086, DOI 10.1073/pnas.90.21.10086; LOY R, 1991, ADV EXP MED BIOL, V295, P373; LOY R, 1987, DEV BRAIN RES, V34, P150; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; MECK WH, 1989, BEHAV NEUROSCI, V103, P1234, DOI 10.1037/0735-7044.103.6.1234; Meck WH, 1997, NEUROREPORT, V8, P3045, DOI 10.1097/00001756-199709290-00009; Meck WH, 1997, NEUROREPORT, V8, P2831, DOI 10.1097/00001756-199709080-00005; MORGANE PJ, 1993, NEUROSCI BIOBEHAV R, V17, P91, DOI 10.1016/S0149-7634(05)80234-9; MUIR JL, 1992, EXP BRAIN RES, V89, P611; MUIR JL, 1994, J NEUROSCI, V14, P2313; NADLER JV, 1974, DEV BIOL, V36, P142, DOI 10.1016/0012-1606(74)90197-3; NAUMANN T, 1992, J COMP NEUROL, V325, P219, DOI 10.1002/cne.903250207; NAUMANN T, 1994, J COMP NEUROL, V350, P161, DOI 10.1002/cne.903500202; Oh JD, 1996, EXP NEUROL, V140, P95, DOI 10.1006/exnr.1996.0119; POTTER PE, 1983, J NEUROCHEM, V41, P188, DOI 10.1111/j.1471-4159.1983.tb13668.x; RIEDER MJ, 1994, CLIN PERINATOL, V21, P483, DOI 10.1016/S0095-5108(18)30328-2; Schenk F, 1995, PSYCHOBIOLOGY, V23, P302; SEMBA K, 1988, J COMP NEUROL, V269, P87, DOI 10.1002/cne.902690107; SHELTON DL, 1979, BRAIN RES, V163, P263, DOI 10.1016/0006-8993(79)90354-8; SHERMAN KA, 1978, LIFE SCI, V23, P1863, DOI 10.1016/0024-3205(78)90119-4; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH PK, 1987, ANAL BIOCHEM, V163, P279; SOFRONIEW MV, 1990, SCIENCE, V247, P338, DOI 10.1126/science.1688664; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; ULUS IH, 1989, BRAIN RES, V484, P217, DOI 10.1016/0006-8993(89)90364-8; VanderZee CEEM, 1996, SCIENCE, V274, P1729, DOI 10.1126/science.274.5293.1729; VOYTKO ML, 1994, J NEUROSCI, V14, P167; WECKER L, 1989, J NEUROCHEM, V52, P568, DOI 10.1111/j.1471-4159.1989.tb09157.x; WECKER L, 1986, CAN J PHYSIOL PHARM, V64, P329, DOI 10.1139/y86-054; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413; ZEISEL SH, 1995, J NUTR, V125, P3049; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061	65	107	109	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1998	12	3					349	357		10.1096/fasebj.12.3.349	http://dx.doi.org/10.1096/fasebj.12.3.349			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YZ898	9506479				2022-12-28	WOS:000072305500024
J	Sela, M; Zisman, E				Sela, M; Zisman, E			Different roles of D-amino acids in immune phenomena	FASEB JOURNAL			English	Review						immunogenicity; antigenic specificity; T cell response; thymus independence	ANTIGEN-PRESENTING CELLS; HISTOCOMPATIBILITY COMPLEX-MOLECULES; RETRO-INVERSO PEPTIDOMIMETICS; REMITTING MULTIPLE-SCLEROSIS; CLASS-II MOLECULES; RHEUMATIC DISEASES; DIRECT BINDING; D-SERINE; T-CELLS; ANTIBODIES	Peptides and polypeptides either fully or partially built of D-amino acids interest researchers because of their advantages over all L peptides and polypeptides, In exploiting these characteristics, one should realize that the resulting molecules are nonetheless not inert, but rather may induce a unique immune response, which is hardly cross-reactive with the L-enantiomer, Moreover, cross-reaction between the L-and the D-sequences is limited also at the T cell level, probably due to different sterical conformations of the MHC-antigen-T cell receptor complexes formed, Polypeptides built exclusively of D-amino acids lead to antibody formation only at a relatively low concentration, otherwise they provoke immunological paralysis, The specificity of the immune response toward peptides containing D-amino acid residues is exquisite, and often D-amino acids play a dominant role in defining the specificity, Polypeptides composed exclusively of D-amino acids are thymus-independent antigens, Nevertheless, it is possible to prepare against them highly specific T cell hybridomas, In future plans for synthetic vaccines against infectious or autoimmune diseases, the inclusion of D-amino acids may be an advantage in terms of both specificity and efficacy, the latter because of longer persistence in an undigested form because they resist enzymatic degradation.			Sela, M (corresponding author), WEIZMANN INST SCI,DEPT IMMUNOL,IL-76100 REHOVOT,ISRAEL.							AHARONI R, 1997, IN PRESS IMMUNOL LET; ANANYEVA NM, 1988, IMMUNOL LETT, V18, P269, DOI 10.1016/0165-2478(88)90173-3; ARNON R, 1960, BIOCHEM J, V75, P103, DOI 10.1042/bj0750103; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BENKIRANE N, 1993, J BIOL CHEM, V268, P26279; BOEHM MF, 1984, P NATL ACAD SCI USA, V81, P5263, DOI 10.1073/pnas.81.16.5263; BORNSTEIN MB, 1987, NEW ENGL J MED, V317, P408, DOI 10.1056/NEJM198708133170703; BRIAND JP, 1995, J BIOL CHEM, V270, P20686, DOI 10.1074/jbc.270.35.20686; BROWN RK, 1963, J BIOL CHEM, V238, P3876; BRUNSWICK M, 1989, P NATL ACAD SCI USA, V86, P6724, DOI 10.1073/pnas.86.17.6724; CHIORAZZI N, 1976, P NATL ACAD SCI USA, V73, P2091, DOI 10.1073/pnas.73.6.2091; DANIELLO A, 1993, J BIOL CHEM, V268, P26941; DEMOTZ S, 1989, NATURE, V342, P682, DOI 10.1038/342682a0; DINTZIS HM, 1993, PROTEINS, V16, P306, DOI 10.1002/prot.340160309; ESHHAR Z, 1975, J IMMUNOL, V114, P872; FISHER GH, 1994, MOL CHEM NEUROPATHOL, V23, P115, DOI 10.1007/BF02815405; Fisher GH, 1995, CANCER BIOCHEM BIOPH, V15, P79; FRANKEN N, 1985, MOL IMMUNOL, V22, P573, DOI 10.1016/0161-5890(85)90181-6; FRANKEN N, 1984, INFECT IMMUN, V44, P182, DOI 10.1128/IAI.44.1.182-187.1984; FRIDKISHARELI M, 1995, CELL IMMUNOL, V163, P229, DOI 10.1006/cimm.1995.1121; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; GILL TJ, 1964, J BIOL CHEM, V239, P1107; GILL TJ, 1972, IMMUNOGENICITY, P1; GUICHARD G, 1994, P NATL ACAD SCI USA, V91, P9763; HAIMOVIC.J, 1969, EUR J BIOCHEM, V7, P537; IVANOVICS G, 1937, IMMUNITATSFORSCH, V91, P175; JACKSON S, 1984, J IMMUNOL, V133, P1553; JANEWAY CA, 1967, IMMUNOLOGY, V13, P29; JANEWAY CA, 1968, IMMUNOLOGY, V14, P225; JATON JC, 1968, J BIOL CHEM, V243, P5616; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; KATSUKI M, 1987, J IMMUNOL, V139, P3570; KONENWAISMAN S, 1995, J IMMUNOL, V154, P5977; KONENWAISMAN S, 1996, THESIS WEIZMANN I SC; KREIL G, 1994, J BIOL CHEM, V269, P10967; LAMB JR, 1986, IMMUNOLOGY, V57, P331; Maillere B, 1995, MOL IMMUNOL, V32, P1073, DOI 10.1016/0161-5890(95)00073-9; MARTIN MT, 1994, J AM CHEM SOC, V116, P6508, DOI 10.1021/ja00094a003; MEDLIN J, 1970, FOLIA BIOL-PRAGUE, V16, P145; MEDLIN J, 1970, FOLIA BIOL-PRAGUE, V16, P156; MILTON RCD, 1992, SCIENCE, V256, P1445, DOI 10.1126/science.1604320; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P666; MOR A, 1992, TRENDS BIOCHEM SCI, V17, P481, DOI 10.1016/0968-0004(92)90333-5; MOSIER DE, 1982, IMMUNOL TODAY, V3, P217, DOI 10.1016/0167-5699(82)90095-0; MOZES E, 1989, EMBO J, V8, P4049, DOI 10.1002/j.1460-2075.1989.tb08588.x; MOZES E, 1974, IMMUNOLOGY, V27, P641; MOZES E, 1973, EUR J IMMUNOL, V3, P1, DOI 10.1002/eji.1830030102; MULLER S, 1995, PEPTIDE RES, V8, P138; NAGATA Y, 1995, BRAIN RES BULL, V38, P181, DOI 10.1016/0361-9230(95)00087-U; PAPPENHEIMER JR, 1994, P NATL ACAD SCI USA, V91, P1942, DOI 10.1073/pnas.91.5.1942; POLLACK SJ, 1989, J AM CHEM SOC, V111, P5961, DOI 10.1021/ja00197a078; ROMAGNOLI P, 1992, J CLIN INVEST, V89, P254, DOI 10.1172/JCI115569; ROMAGNOLI P, 1991, EMBO J, V10, P1303, DOI 10.1002/j.1460-2075.1991.tb07648.x; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SAGE HJ, 1964, IMMUNOCHEMISTRY, V1, P133, DOI 10.1016/0019-2791(64)90077-1; SCHECHTE.I, 1967, BIOCHEMISTRY-US, V6, P897, DOI 10.1021/bi00855a034; SCHECHTER B, 1970, IMMUNOCHEMISTRY, V7, P587, DOI 10.1016/0019-2791(70)90279-X; SCHECHTER B, 1970, J BIOL CHEM, V245, P1438; SCHECHTER I, 1968, J EXP MED, V127, P237, DOI 10.1084/jem.127.2.237; SCHECHTER I, 1966, BIOCHIM BIOPHYS ACTA, V127, P438, DOI 10.1016/0304-4165(66)90398-9; SCHECHTER I, 1972, ANN NY ACAD SCI, V190, P394; SCHELL MJ, 1995, P NATL ACAD SCI USA, V92, P3948, DOI 10.1073/pnas.92.9.3948; Schlegel PG, 1996, P NATL ACAD SCI USA, V93, P5061, DOI 10.1073/pnas.93.10.5061; SCHMITTV.AM, 1974, IMMUNOGENETICS, V1, P357, DOI 10.1007/BF01564074; SELA M, 1960, BIOCHEM J, V75, P91, DOI 10.1042/bj0750091; SELA M, 1969, SCIENCE, V166, P1365, DOI 10.1126/science.166.3911.1365; SELA M, 1990, B I PASTEUR, V88, P303; SELA M, 1972, P NATL ACAD SCI USA, V69, P2696, DOI 10.1073/pnas.69.9.2696; SELA M, 1992, VACCINE, V10, P991, DOI 10.1016/0264-410X(92)90107-U; SELA M, 1965, P S MOL CELL BASIS A, P43; SELA MICHAEL, 1966, ADVANCE IMMUNOL, V5, P29, DOI 10.1016/S0065-2776(08)60272-2; SIMONIAN SJ, 1968, J IMMUNOL, V101, P730; STUPP Y, 1967, BIOCHIM BIOPHYS ACTA, V140, P349, DOI 10.1016/0005-2795(67)90475-8; TODOME Y, 1992, INT ARCH ALLERGY IMM, V97, P301, DOI 10.1159/000236137; VITETTA ES, 1987, IMMUNOL REV, V99, P193, DOI 10.1111/j.1600-065X.1987.tb01178.x; Waisman A, 1996, CELL IMMUNOL, V173, P7, DOI 10.1006/cimm.1996.0246; WEBB C, 1976, IMMUNOCHEMISTRY, V13, P333, DOI 10.1016/0019-2791(76)90344-X; ZISMAN E, 1993, P NATL ACAD SCI USA, V90, P994, DOI 10.1073/pnas.90.3.994; ZISMAN E, 1991, P NATL ACAD SCI USA, V88, P9738, DOI 10.1073/pnas.88.21.9738	79	73	115	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1997	11	6					449	456						8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XE404	9194525				2022-12-28	WOS:A1997XE40400007
J	Falany, CN				Falany, CN			Introduction: Changing view of sulfation and the cytosolic sulfotransferases	FASEB JOURNAL			English	Review											Falany, CN (corresponding author), UNIV ALABAMA, DEPT PHARMACOL & TOXICOL, 1670 UNIV BLVD, BIRMINGHAM, AL 35294 USA.							ADAMS JB, 1979, BIOCHIM BIOPHYS ACTA, V5267, P144; Bellino F. L., 1995, ANN NEW YORK ACAD SC, V774; BUHL AE, 1990, J INVEST DERMATOL, V95, P553, DOI 10.1111/1523-1747.ep12504905; GLOVER V, 1982, SULFATE METABOLISM S; HART RF, 1979, LIFE SCI, V24, P125, DOI 10.1016/0024-3205(79)90121-8; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P199; MICHEJDA CJ, 1994, CONJUGATION DEPENDEN, V27; MILLER EC, 1985, CARCINOGENESIS LOND, V11, P93; MILLER JA, 1969, PROG EXP TUMOR RES, V11, P273; ROBBINS PW, 1956, J AM CHEM SOC, V78, P2652, DOI 10.1021/ja01592a097	11	67	73	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1997	11	1					1	2						2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK147	9034159				2022-12-28	WOS:A1997WK14700001
J	Cao, MY; Dupriez, VJ; Rider, MH; Deggouj, N; Gersdorff, MCH; Rousseau, GG; Tomasi, JP				Cao, MY; Dupriez, VJ; Rider, MH; Deggouj, N; Gersdorff, MCH; Rousseau, GG; Tomasi, JP			Myelin protein Po as a potential autoantigen in autoimmune inner ear disease	FASEB JOURNAL			English	Article						autoimmunity; cochlea; MALDI-TOF; P zero	PERIPHERAL-NERVE MYELIN; GUILLAIN-BARRE-SYNDROME; MARIE-TOOTH DISEASE; AUDITORY EVOKED-POTENTIALS; SENSORINEURAL HEARING-LOSS; MAJOR STRUCTURAL PROTEIN; MOTOR-SENSORY NEUROPATHY; HEREDITARY MOTOR; POLYACRYLAMIDE GELS; DNA-SEQUENCE	We have previously shown that a 30,000 M(r) protein extracted from guinea pig inner ear tissue is recognized by autoantibodies present in the serum of patients suffering front autoimmune inner ear disease, This protein was localized in the modiolus and in the organ of Corti, We have now identified this protein by a combination of microsequencing and matrix-assisted laser desorption ionization time-of-flight mass spectrometry of its tryptic peptides, A partial sequence of the protein Tvas thereby determined, These data and 2-dimensional gel electrophoresis followed by immunoblotting experiments showed that the 30,000 M,inner ear antigen is the major peripheral myelin protein Po, This suggests that protein Po may be an important autoantigen in autoimmune inner ear disease.	UNIV LOUVAIN,SCH MED,LAB AUTOIMMUN,B-1200 BRUSSELS,BELGIUM; UNIV LOUVAIN,SCH MED,HORMONE & METAB RES UNIT,B-1200 BRUSSELS,BELGIUM; UNIV LOUVAIN,SCH MED,DEPT OTORHINOLARYNGOL,B-1200 BRUSSELS,BELGIUM; INT INST CELLULAR & MOL PATHOL,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel								ADELMANN M, 1992, NEUROCHEM RES, V17, P887, DOI 10.1007/BF00993264; BENJELLOUNDELLAGI S, 1992, ANN NEUROL, V32, P700; Cao MY, 1996, ANN OTO RHINOL LARYN, V105, P628; CAO MY, 1995, MOL CELL BIOCHEM, V146, P157, DOI 10.1007/BF00944608; CAO MY, 1995, J LARYNGOL OTOL, V109, P20; CELIS JE, 1991, FASEB J, V5, P2200, DOI 10.1096/fasebj.5.8.1827083; FILBIN MT, 1990, NATURE, V344, P871, DOI 10.1038/344871a0; GARG BP, 1982, NEUROLOGY, V32, P1017, DOI 10.1212/WNL.32.9.1017; GREENFIELD S, 1973, J NEUROCHEM, V20, P1207, DOI 10.1111/j.1471-4159.1973.tb00089.x; HARRIS JP, 1990, LARYNGOSCOPE, V100, P516; HAYASAKA K, 1991, BIOCHEM BIOPH RES CO, V180, P515, DOI 10.1016/S0006-291X(05)81094-0; Herinckx C., 1995, Acta Oto-Rhino-Laryngologica Belgica, V49, P63; HOJEBERG B, 1991, J NEUROL SCI, V106, P91, DOI 10.1016/0022-510X(91)90200-Q; HUGHES GB, 1984, LARYNGOSCOPE, V94, P758; KHALILISHIRAZI A, 1992, J NEUROL SCI, V111, P200, DOI 10.1016/0022-510X(92)90069-W; KULKENS T, 1993, NAT GENET, V5, P35, DOI 10.1038/ng0993-35; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMKE G, 1985, CELL, V40, P501, DOI 10.1016/0092-8674(85)90198-9; MCCABE BF, 1979, ANN OTO RHINOL LARYN, V88, P585, DOI 10.1177/000348947908800501; MILNER P, 1987, J NEUROL SCI, V79, P275, DOI 10.1016/0022-510X(87)90235-8; MOOS M, 1988, J BIOL CHEM, V263, P6005; MUSIEK FE, 1982, ARCH OTOLARYNGOL, V108, P595; NELSON KR, 1988, NEUROLOGY, V38, P1263, DOI 10.1212/WNL.38.8.1263; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; RAGLAN E, 1987, ACTA OTO-LARYNGOL, V103, P50, DOI 10.3109/00016488709134697; RIDER MH, 1995, EUR J BIOCHEM, V230, P258; ROPPER AH, 1986, NEUROLOGY, V36, P587, DOI 10.1212/WNL.36.4.587; SAKAMOTO Y, 1987, J BIOL CHEM, V262, P4208; SATYAMURTI S, 1979, ANN NEUROL, V5, P445, DOI 10.1002/ana.410050506; SCHIFF JA, 1985, NEUROLOGY, V35, P771, DOI 10.1212/WNL.35.5.771; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAKSMAN BH, 1955, J EXP MED, V102, P213, DOI 10.1084/jem.102.2.213; YOO TJ, 1982, SCIENCE, V217, P1153, DOI 10.1126/science.7112122; YOU KH, 1991, GENOMICS, V9, P751, DOI 10.1016/0888-7543(91)90370-T; YUKI N, 1993, ANN NEUROL, V33, P655, DOI 10.1002/ana.410330617	36	40	53	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1996	10	14					1635	1640		10.1096/fasebj.10.14.9002556	http://dx.doi.org/10.1096/fasebj.10.14.9002556			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WC869	9002556				2022-12-28	WOS:A1996WC86900010
J	Leaman, DW; Leung, S; Li, XX; Stark, GR				Leaman, DW; Leung, S; Li, XX; Stark, GR			Regulation of STAT-dependent pathways by growth factors and cytokines	FASEB JOURNAL			English	Review						JAK; transcriptional activation; receptor-STAT association	DNA-BINDING ACTIVITY; PROTEIN-TYROSINE KINASES; C-FOS PROMOTER; INSULIN-RECEPTOR SUBSTRATE-1; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; INTERFERON-ALPHA; HORMONE RECEPTOR; GENE-EXPRESSION; GAMMA RECEPTOR	Polypeptide growth factors and cytokines elicit their effects by activating specific cell-surface receptors, thereby initiating signaling cascades that culminate in the induction of specific subsets of genes, Initially identified as the primary mediators of interferon-dependent signaling, JAKs and STATs are now known to be utilized by many different extracellular signaling proteins, In this report we describe how JAK-STAT pathways transduce signals initiated by both cytokines and growth factors, focusing on how specificity is achieved through STAT-receptor interactions and on how receptor-associated kinases function in STAT activation, We also summarize current information on interactions between signaling pathways, particularly STAT-Ras cross-talk and the relative importance of these two Pathways in regulating the transcription of target genes.	CLEVELAND CLIN FDN,RES INST,DEPT MOL BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NCI NIH HHS [P01-CA62220] Funding Source: Medline; NIAID NIH HHS [F32-AI 08956] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008956] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; COFFER P, 1995, ONCOGENE, V10, P985; DALE TC, 1989, EMBO J, V8, P831, DOI 10.1002/j.1460-2075.1989.tb03444.x; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; David M, 1996, J BIOL CHEM, V271, P4585; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVID M, 1995, MOL CELL BIOL, V15, P7050; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; Flati V, 1996, EMBO J, V15, P1566, DOI 10.1002/j.1460-2075.1996.tb00501.x; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; HAQUE SJ, 1995, J BIOL CHEM, V270, P25709, DOI 10.1074/jbc.270.43.25709; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KITABAYASHI I, 1993, J BIOL CHEM, V268, P14482; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LI X, 1996, IN PRESS J BIOL CHEM, V271; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NAKAJIMA K, 1996, EMBO J, V15, P1557; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STARK GR, 1992, J INTERFERON RES, V12, P147, DOI 10.1089/jir.1992.12.147; SUBRAMANIAN A, 1995, MOL CELL BIOL, V15, P4672; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1995, EMBO J, V14, P854, DOI 10.1002/j.1460-2075.1995.tb07064.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; Winston LA, 1996, CURR BIOL, V6, P668, DOI 10.1016/S0960-9822(09)00445-X; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	105	263	266	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1996	10	14					1578	1588		10.1096/fasebj.10.14.9002549	http://dx.doi.org/10.1096/fasebj.10.14.9002549			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WC869	9002549				2022-12-28	WOS:A1996WC86900003
J	Vogt, PK				Vogt, PK			Peyton Rous: Homage and appraisal	FASEB JOURNAL			English	Biographical-Item											Vogt, PK (corresponding author), Scripps Res Inst, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ROUS P, PUBLICATION LIST	1	12	12	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1996	10	13					1559	1562		10.1096/fasebj.10.13.8940303	http://dx.doi.org/10.1096/fasebj.10.13.8940303			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VU982	8940303				2022-12-28	WOS:A1996VU98200014
J	Johnson, EF; Palmer, CNA; Griffin, KJ; Hsu, MH				Johnson, EF; Palmer, CNA; Griffin, KJ; Hsu, MH			Cytochromes P450 .7. Role of the peroxisome proliferator-activated receptor in cytochrome P450 4A gene regulation	FASEB JOURNAL			English	Article						CYP4A; fatty acid; omega-hydroxylase; PPAR	RETINOID-X-RECEPTOR; ACYL-COA OXIDASE; TISSUE-SPECIFIC EXPRESSION; GLAND HORMONE MELATONIN; BETA-OXIDATION PATHWAY; ACID-BINDING-PROTEIN; FATTY-ACIDS; NUCLEAR RECEPTOR; RESPONSE ELEMENT; DNA-BINDING	Cytochrome P450s of the 4A subfamily generally catalyze the <(omega)over bar>-hydroxylation of fatty acids. The induction of P450 PA enzymes by peroxisome proliferators or fatty acids is mediated by peroxisome proliferator-activated receptors (PPARs), which are members of the nuclear receptor family that regulates the expression of genes that control fatty acid synthesis, storage, and catabolism. PPARs bind as heterodimers with another member of the nuclear receptor family, the retinoid X receptor (RXR), to peroxisome proliferator response elements (PPREs) in the P450 4A1 and 4A6 genes, PPREs comprise two overlapping motifs for nuclear receptor binding, One motif consists of an imperfect, direct repeat of two copies of the nuclear receptor core binding site, AGGTCA, separated by a single nucleotide (a DR1 motif) that is recognized by other dimeric nuclear receptor complexes such as HNF-4 or ARP-1. A consensus sequence flanking the DR1 motif together with the 5' core binding site of the DR1 motif constitutes a second, overlapping moth resembling recognition elements for monomeric nuclear receptors, such as Rev-ErbA and the melatonin receptors, PPARs bind to the latter motif, The tripartite nature of PPREs together with imperfections in the core sites of DR1 motif confers specificity for PPAR alpha/RXR alpha binding to PPREs relative to other nuclear receptors.			Johnson, EF (corresponding author), Scripps Res Inst, DIV BIOCHEM, DEPT MOL & EXPT MED, NX-4, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Palmer, Colin NA/C-7053-2008	Palmer, Colin NA/0000-0002-6415-6560	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD004445] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD004445] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00833] Funding Source: Medline; NICHD NIH HHS [HD04445] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALDRIDGE TC, 1995, BIOCHEM J, V306, P473, DOI 10.1042/bj3060473; BARNETT CR, 1990, BIOCHEM J, V268, P765, DOI 10.1042/bj2680765; BECK F, 1992, P ROY SOC B-BIOL SCI, V247, P83, DOI 10.1098/rspb.1992.0012; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; BELL DR, 1992, EUR J BIOCHEM, V206, P979, DOI 10.1111/j.1432-1033.1992.tb17009.x; BELL DR, 1993, BIOCHEM J, V294, P173, DOI 10.1042/bj2940173; CASTELEIN H, 1994, J BIOL CHEM, V269, P26754; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FERGUSON NL, 1993, DRUG METAB DISPOS, V21, P745; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GIGUERE V, 1995, MOL CELL BIOL, V15, P2517; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GRONEMEYER H, 1995, NATURE, V375, P190, DOI 10.1038/375190a0; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HARDER DR, 1995, J VASC RES, V32, P79, DOI 10.1159/000159080; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; HARDWICK JP, 1987, J BIOL CHEM, V262, P80; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; HSU MH, 1995, MOL PHARMACOL, V48, P559; HUAN BF, 1995, J VIROL, V69, P547, DOI 10.1128/JVI.69.1.547-551.1995; IBRAHIMI A, 1994, MOL PHARMACOL, V46, P1070; IMAOKA S, 1988, BIOCHEM BIOPH RES CO, V152, P680, DOI 10.1016/S0006-291X(88)80092-5; ISSEMANN I, 1992, BIOCHEM SOC T, V20, P824, DOI 10.1042/bst0200824; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; JONES PS, 1995, EUR J BIOCHEM, V233, P219, DOI 10.1111/j.1432-1033.1995.219_1.x; KAIKAUS RM, 1993, J BIOL CHEM, V268, P9593; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KIMURA S, 1989, DNA-J MOLEC CELL BIO, V8, P517, DOI 10.1089/dna.1.1989.8.517; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KREY G, 1995, MOL ENDOCRINOL, V9, P219, DOI 10.1210/me.9.2.219; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; MORTENSEN PB, 1992, BIOCHIM BIOPHYS ACTA, V1124, P71, DOI 10.1016/0005-2760(92)90128-I; MUERHOFF AS, 1992, J BIOL CHEM, V267, P1905; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OKITA RT, 1994, PHARMACOL TOXICOL, P37; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; PALMER CNA, 1994, J BIOL CHEM, V269, P18083; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; ROMAN LJ, 1993, ARCH BIOCHEM BIOPHYS, V307, P57, DOI 10.1006/abbi.1993.1560; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; SHARMA R, 1988, BIOCHEM PHARMACOL, V37, P1203, DOI 10.1016/0006-2952(88)90771-X; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; WIESENBERG I, 1995, NUCLEIC ACIDS RES, V23, P327, DOI 10.1093/nar/23.3.327; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; YOKOTANI N, 1989, J BIOL CHEM, V264, P21665; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	67	157	161	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1996	10	11					1241	1248		10.1096/fasebj.10.11.8836037	http://dx.doi.org/10.1096/fasebj.10.11.8836037			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VJ717	8836037				2022-12-28	WOS:A1996VJ71700003
J	Wolf, G				Wolf, G			A history of vitamin A and retinoids	FASEB JOURNAL			English	Article											Wolf, G (corresponding author), UNIV CALIF BERKELEY,DEPT NUTR SCI,119 MORGAN HALL,BERKELEY,CA 94720, USA.							AYKROYD WR, 1928, IRISH J MED, V28, P161; Blaner William S., 1994, P229; Bloch CE, 1919, JB KINDERHEILK, V89, P405; Blomhoff R., 1994, Vitamin A in health and disease., P1; BUDD G, 1842, LONDON MED GAZ, V2, P632; Ebell B, 1937, PAPYRUS EBERS; Ewald A., 1877, CENTRALBL MED WISSEN, V15, P753; Fridericia LS, 1925, AM J PHYSIOL, V73, P63, DOI 10.1152/ajplegacy.1925.73.1.63; GOODMAN DS, 1984, RETINOIDS, P42; GUGGENHEIM KY, 1981, NUTR NUTR DIS, P265; HIRSCHBERG J, 1899, GRAEFESAEMISCH HDB G, V12, P98; HIRSHBERG J, 1915, GRAEFESAEMISCH HDB G, V14, P232; HOLM EJLER, 1929, ACTA OPHTHALMOL, V7, P146; Hopkins F., 1906, ANALYST, V31, p385b, DOI [10.1039/an906310385b, DOI 10.1039/AN906310385B]; HUSSAINI G, 1978, AM J CLIN NUTR, V31, P1489, DOI 10.1093/ajcn/31.9.1489; ISHIHARA S, 1913, MONATSH AUGENHEILK, V51, P596; ISLER O, 1947, HELV CHIM ACTA, V30, P1911, DOI 10.1002/hlca.19470300666; Karrer P, 1931, HELV CHIM ACTA, V14, P1431, DOI 10.1002/hlca.19310140622; Kastner P., 1994, Vitamin A in health and disease., P189; Lee T, 1967, DIS ANTIQUITY, P417; Lindeboom G A, 1984, Clio Med, V19, P40; Littre E, 1861, OEUVRES COMPLETES HI, VIX, P156; LUNIN G, 1881, HOPPESYELERS Z PHYSK, V5, P31; Mangelsdorf David J., 1994, P319; MANI N, 1953, Gesnerus, V10, P53; McCollum EV, 1913, J BIOL CHEM, V15, P167; MCCOLLUM EV, 1964, KANSAS BOY SCI, P114; Moore T, 1930, BIOCHEM J, V24, P692, DOI 10.1042/bj0240692; MOORE T, 1957, VITAMIN A, P263; MOORE T, 1957, VITAMIN A, P4; Mori M, 1904, JB KINDERHEILK, V51, P175; NUNN JF, 1996, IN PRESS ANCIENT EGY; Ong David E., 1994, P283; OSBORNE, 1914, J BIOL CHEM, V17, P401; Osborne TB, 1913, J BIOL CHEM, V15, P311; Palmer LS, 1919, J BIOL CHEM, V39, P299; PARINAUD M, 1881, CR HEBD ACAD SCI, V93, P286; SAFFIOTTI U, 1967, CANCER-AM CANCER SOC, V20, P857, DOI 10.1002/1097-0142(1967)20:5&lt;857::AID-CNCR2820200545&gt;3.0.CO;2-3; SCHWARZ E, 1861, REISE OESTERREICHISC, V1, P108; SPORN MB, 1983, CANCER RES, V43, P3034; Steenbock H, 1919, SCIENCE, V50, P352, DOI 10.1126/science.50.1293.352; Steenbock H, 1920, J BIOL CHEM, V41, P149; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; Wolf G., 1970, FAT SOLUBLE VITAMINS, P257; 1862, WOCHENBLATT Z KK GES, V18, P82	46	56	61	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1996	10	9					1102	1107		10.1096/fasebj.10.9.8801174	http://dx.doi.org/10.1096/fasebj.10.9.8801174			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801174				2022-12-28	WOS:A1996UY93200023
J	Annunziato, F; Manetti, R; Tomasevic, L; Giudizi, MG; Biagiotti, R; Gianno, V; Germano, P; Mavilia, C; Maggi, E; Romagnani, S				Annunziato, F; Manetti, R; Tomasevic, L; Giudizi, MG; Biagiotti, R; Gianno, V; Germano, P; Mavilia, C; Maggi, E; Romagnani, S			Expression and release of LAG-3-encoded protein by human CD4(+) T cells are associated with IFN-gamma production	FASEB JOURNAL			English	Article						membrane LAG-3; soluble LAG-3; human Th1/Th2 cells; IL-4; IFN-gamma	TUMOR-NECROSIS-FACTOR; CYTOKINE PRODUCTION; HUMAN TH1; HELPER; ACTIVATION; RECEPTOR; PROFILE; CLONES	The lymphocyte activation gene (LAG)-3 is a member of the immunoglobulin superfamily that is selectively transcribed in human activated T and NK cells, In this wort, the possibility that LAG-3 expression by human CD4(+) T cells was preferentially related to one or another phenotype of cytokine secretion was investigated, Surface LAG-3 expression correlated with IFN-gamma, but not IL-4, production in antigen-stimulated T cells and it was upregulated by IL-12, Most activated CD4(+) T cell clones with established Th1 or Th0 profiles of cytokine secretion expressed LAG-3 on their surface, whereas the great majority of Th2 clones showed neither surface LAG-3 nor LAG-3 mRNA expression, After activation, the majority of CD4+ T cell clones also released soluble LAG-3-related peptides, and such a release correlated positively with the production of IFN-gamma and inversely with the production of IL-4. Thus, LAG-3 expression by activated CD4+ human T cells appear to be preferentially associated with the differentiation/activation pathway leading to the production of IFN-gamma.	UNIV FLORENCE,IST CLIN MED 3,CATTEDRA IMMUNOL CLIN & ALLERGOL,SERV IMMUNOALLERGOL,I-50134 FLORENCE,ITALY	University of Florence			Annunziato, Francesco/C-1155-2013; Maggi, Enrico/AAA-8045-2019	Maggi, Enrico/0000-0002-1824-3583; Annunziato, Francesco/0000-0001-8798-7589				BAIXERAS E, 1992, J EXP MED, V176, P327, DOI 10.1084/jem.176.2.327; CAPPIO FC, 1995, CLIN EXP RHEUMATOL, V13, P339; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; DELPRETE G, 1995, J EXP MED, V182, P1655, DOI 10.1084/jem.182.6.1655; DELPRETE G, 1995, FASEB J, V9, P81, DOI 10.1096/fasebj.9.1.7821763; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; GRIFFIN DE, 1993, J INFECT DIS, V168, P275, DOI 10.1093/infdis/168.2.275; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HUARD B, 1995, EUR J IMMUNOL, V25, P2718, DOI 10.1002/eji.1830250949; HUARD B, 1994, IMMUNOGENETICS, V39, P213; HUARD B, 1994, EUR J IMMUNOL, V24, P3216, DOI 10.1002/eji.1830241246; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; MAGGI E, 1995, IMMUNITY, V3, P251, DOI 10.1016/1074-7613(95)90094-2; MAGGI E, 1992, J IMMUNOL, V148, P2142; MANETTI R, 1994, J EXP MED, V179, P1273, DOI 10.1084/jem.179.4.1273; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MILLS JA, 1994, NEW ENGL J MED, V330, P1871, DOI 10.1056/NEJM199406303302608; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PICCINNI MP, 1995, J IMMUNOL, V155, P128; PIZZOLO G, 1994, AIDS, V8, P741, DOI 10.1097/00002030-199406000-00003; ROMAGNANI S, 1995, J LEUKOCYTE BIOL, V57, P726, DOI 10.1002/jlb.57.5.726; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; SCHANDENE L, 1993, EUR J IMMUNOL, V23, P56, DOI 10.1002/eji.1830230110; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SWAIN SL, 1993, RES IMMUNOL, V144, P616, DOI 10.1016/S0923-2494(05)80013-6; TRIEBEL F, 1990, J EXP MED, V171, P1393, DOI 10.1084/jem.171.5.1393; VANDERHEIJDEN FL, 1991, J INVEST DERMATOL, V97, P389, DOI 10.1111/1523-1747.ep12480966	32	77	83	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1996	10	7					769	776		10.1096/fasebj.10.7.8635694	http://dx.doi.org/10.1096/fasebj.10.7.8635694			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UN798	8635694				2022-12-28	WOS:A1996UN79800011
J	Diehl, AM; Rai, RM				Diehl, AM; Rai, RM			Liver regeneration .3. Regulation of signal transduction during liver regeneration	FASEB JOURNAL			English	Review						hepatocyte proliferation; signal transduction; tyrosine kinases; organ regeneration	HEPATOCYTE GROWTH-FACTOR; RAT-LIVER; TGF-BETA; PARTIAL-HEPATECTOMY; FACTOR-ALPHA; INSULIN-RECEPTOR; PRIMARY CULTURE; DNA-SYNTHESIS; EXPRESSION; DIFFERENTIATION	The liver has a tremendous capacity to regenerate, For example, after extensive hepatic resection, remaining hepatocytes proliferate to restore the mass of the organ within days to weeks, This proliferative response is fascinating because hepatocytes rarely replicate in the healthy adult liver. Instead, these cells perform highly specialized functions and exemplify mature, terminally differentiated cells, Therefore it is somewhat surprising that the liver can repopulate while performing its many obligate, organ-specific functions, Study of the regenerating liver remnant after partial hepatectomy has helped to delineate mechanisms that regulate proliferation and liver-specific functions in individual hepatocytes, as well as those that coordinate the behaviors of different Liver cell populations to balance organ growth and tissue-specific gene expression, Hence, this review will focus on inter- and intracellular signals that regulate the hepatocyte phenotype after PH.	JOHNS HOPKINS UNIV, DIV GASTROINTESTINAL, BALTIMORE, MD 21205 USA	Johns Hopkins University								AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; ALBRECHT JH, 1994, ARCH BIOCHEM BIOPHYS, V314, P229, DOI 10.1006/abbi.1994.1434; ALISON MR, 1985, VIRCHOWS ARCH B, V48, P167, DOI 10.1007/BF02890125; AVRUCH J, 1982, J BIOL CHEM, V257, P5162; BAFFY G, 1992, J CELL PHYSIOL, V153, P332, DOI 10.1002/jcp.1041530213; BEAUCHAMP RD, 1992, MOL ENDOCRINOL, V6, P1789, DOI 10.1210/me.6.11.1789; BEYER HS, 1990, BIOCHEM INT, V22, P405; BUCHER NLR, 1991, J GASTROEN HEPATOL, V6, P615, DOI 10.1111/j.1440-1746.1991.tb00921.x; BUCHER NLR, 1973, CANCER RES, V33, P3189; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COLEMAN WB, 1993, AM J PATHOL, V142, P1373; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; CRUISE JL, 1991, DIGEST DIS SCI, V36, P485, DOI 10.1007/BF01298880; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESDOUETS C, 1994, HEPATOLOGY, V20, pA217; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; DIEHL AM, 1994, AM J PHYSIOL-GASTR L, V267, pG552, DOI 10.1152/ajpgi.1994.267.4.G552; DIEHL AM, 1995, HEPATOLOGY, V22, P252, DOI 10.1016/0270-9139(95)90379-8; DIEHL AM, 1992, J CLIN INVEST, V89, P1706, DOI 10.1172/JCI115771; DIEHL AM, 1992, HEPATOLOGY, V16, P1212, DOI 10.1002/hep.1840160518; DIEHL AM, 1995, IN PRESS J BIOL CHEM; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DUBOIS RN, 1994, HEPATOLOGY, V19, P788, DOI 10.1002/hep.1840190336; Fausto N, 1990, CURR OPIN CELL BIOL, V2, P1036, DOI 10.1016/0955-0674(90)90153-6; FRANCAVILLA A, 1992, HEPATOLOGY, V16, P1267, DOI 10.1016/0270-9139(92)90023-3; FUKAMI J, 1995, EXP CELL RES, V216, P107, DOI 10.1006/excr.1995.1014; GEBHARDT R, 1992, PHARMACOL THERAPEUT, V53, P275, DOI 10.1016/0163-7258(92)90055-5; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Higgins GM, 1931, ARCH PATHOL, V12, P186; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HORIKAWA S, 1986, BIOCHEM BIOPH RES CO, V140, P574, DOI 10.1016/0006-291X(86)90770-9; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JAMISON SR, 1994, J BIOL CHEM, V269, P21933; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Leffert H. L., 1978, CIBA F S, V55, P61; LIU YH, 1994, J BIOL CHEM, V269, P4152; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUMOTO K, 1992, P NATL ACAD SCI USA, V89, P3800, DOI 10.1073/pnas.89.9.3800; MEALY K, 1991, BRIT J SURG, V78, P331, DOI 10.1002/bjs.1800780320; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MULLHAUPT B, 1994, J BIOL CHEM, V269, P19667; NAKAMURA T, 1988, EXP CELL RES, V179, P488, DOI 10.1016/0014-4827(88)90286-8; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POST J, 1964, EXP CELL RES, V36, P111, DOI 10.1016/0014-4827(64)90165-X; RANA B, 1995, J BIOL CHEM, V270, P18123, DOI 10.1074/jbc.270.30.18123; REFNES M, 1992, J CELL PHYSL, V151, P164; RODLAND KD, 1990, J INVEST DERMATOL, V94, pS33, DOI 10.1111/1523-1747.ep12875031; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; SASAKI Y, 1993, J BIOL CHEM, V268, P3805; SATOH M, 1992, J CELL PHYSIOL, V150, P134, DOI 10.1002/jcp.1041500118; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SCHMIEDEBERG P, 1993, J CELL PHYSIOL, V154, P294, DOI 10.1002/jcp.1041540212; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SHORT J, 1973, BIOCHEM BIOPH RES CO, V50, P430, DOI 10.1016/0006-291X(73)90858-9; SIGAL SH, 1992, AM J PHYSIOL, V263, pG139, DOI 10.1152/ajpgi.1992.263.2.G139; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SORIANO HE, 1995, IN VITRO CELL DEV-AN, V31, P703, DOI 10.1007/BF02634092; STOLZ DB, 1994, J CELL BIOCHEM, V55, P445, DOI 10.1002/jcb.240550405; STROMBLAD S, 1993, EXP CELL RES, V204, P321, DOI 10.1006/excr.1993.1039; VESEY DA, 1992, GUT, V33, P831, DOI 10.1136/gut.33.6.831; WEBBER EM, 1994, AM J PATHOL, V145, P398; WEBBER EM, 1994, HEPATOLOGY, V19, P489; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WESTWICK JK, 1994, HEPATOLOGY, V20, pA483; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; XANTHOPOULOS KG, 1993, EUR J BIOCHEM, V216, P353, DOI 10.1111/j.1432-1033.1993.tb18152.x; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	77	205	208	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1996	10	2					215	227		10.1096/fasebj.10.2.8641555	http://dx.doi.org/10.1096/fasebj.10.2.8641555			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641555				2022-12-28	WOS:A1996TY96200006
J	GrahamLorence, S; Peterson, JA				GrahamLorence, S; Peterson, JA			P450s: Structural similarities and functional differences	FASEB JOURNAL			English	Review						molecular modeling; mammalian P450s; protein-protein interactions; substrate binding	PSEUDOMONAS-PUTIDA CYTOCHROME-P-450; FATTY-ACID MONOOXYGENATION; SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; AMINO-ACID; REDUCED PUTIDAREDOXIN; SUBSTRATE-SPECIFICITY; BACILLUS-MEGATERIUM; MOLECULAR-CLONING; HYDROXYLATION	More than 400 identified P450s are found in prokaryotes and eukaryotes, plants and animals, mitochondria and endoplasmic reticulum that function in areas such as xenobiotic metabolism and steroidogenesis. This superfamily of proteins has proved difficult to study because of the hydrophobic nature of their substrates, their various redox partners, and the membrane association of the eukaryotic proteins, To better understand the structure/function relationship of P450s-what determines substrate specificity and selectivity, what determines redox partner binding, and which regions are involved in membrane binding-we have compared the three crystallized, soluble bacterial P450s (two class I and one class II) and a model of a steroidogenic, eukaryotic P450 (P450arom) in order to define which structural elements form a conserved structural fold for P450s, what determines specificity of substrate binding and redox partner binding, and which regions are potentially involved in membrane association, We believe there is a conserved structural fold for all P450s that can be used to model those P450s that prove intransigent to structural determination. However, although there appears to be a conserved structural core among P450s, there is sufficient sequence variability that no two P450s are structurally identical.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050858, R01GM043479] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50858, GM43479] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINS WM, 1989, J AM CHEM SOC, V111, P2715, DOI 10.1021/ja00189a057; ATKINS WM, 1988, J BIOL CHEM, V263, P18842; BODDUPALLI SS, 1992, ARCH BIOCHEM BIOPHYS, V292, P20, DOI 10.1016/0003-9861(92)90045-X; BODDUPALLI SS, 1990, J BIOL CHEM, V265, P4233; BREWER CB, 1988, J BIOL CHEM, V263, P791; CRAHAMLORENCE S, 1995, PROTEIN SCI, V4, P1065; CUPPVICKERY JR, 1994, PROTEINS, V20, P197, DOI 10.1002/prot.340200210; CUPPVICKERY JR, 1995, STRUCT BIOL, V2, P144; FRUETEL JA, 1994, J BIOL CHEM, V269, P28815; GOTOH O, 1992, J BIOL CHEM, V267, P83; GRIFFIN BW, 1975, J BIOL CHEM, V250, P6445; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; HEDEGAARD J, 1965, J BIOL CHEM, V240, P4038; HINTZ MJ, 1981, J BIOL CHEM, V256, P6721; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; KATAGIRI M, 1968, J BIOL CHEM, V243, P3543; KRONBACH T, 1989, P NATL ACAD SCI USA, V86, P8262, DOI 10.1073/pnas.86.21.8262; KRONBACH T, 1991, BIOCHEMISTRY-US, V30, P6097, DOI 10.1021/bi00239a003; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; LOEW GH, 1980, J AM CHEM SOC, V102, P3655, DOI 10.1021/ja00530a073; LOIDA PJ, 1993, PROTEIN ENG, V6, P207, DOI 10.1093/protein/6.2.207; MIURA Y, 1975, BIOCHIM BIOPHYS ACTA, V388, P305, DOI 10.1016/0005-2760(75)90089-2; NARHI LO, 1987, J BIOL CHEM, V262, P6683; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OMURA T., 1965, FEDERATION PROC, V24, P1181; OMURA T, 1964, J BIOL CHEM, V239, P2370; PAULSEN MD, 1993, PROTEIN SCI, V2, P357; PAULSEN MD, 1991, J BIOMOL STRUCT DYN, V9, P187, DOI 10.1080/07391102.1991.10507906; PEISACH J, 1973, DRUG METAB DISPOS, V1, P45; PETERSON JA, 1992, ARCH BIOCHEM BIOPHYS, V294, P654, DOI 10.1016/0003-9861(92)90738-I; PINEAU T, 1995, P NATL ACAD SCI USA, V92, P5134, DOI 10.1073/pnas.92.11.5134; POULOS TL, 1991, METHOD ENZYMOL, V206, P11; POULOS TL, 1987, BIOCHEMISTRY-US, V26, P8165, DOI 10.1021/bi00399a022; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1985, J BIOL CHEM, V260, P6122; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; RAAG R, 1991, BIOCHEMISTRY-US, V30, P2674, DOI 10.1021/bi00224a016; RAAG R, 1989, BIOCHEMISTRY-US, V28, P7586, DOI 10.1021/bi00445a013; RAAG R, 1991, BIOCHEMISTRY-US, V30, P11420, DOI 10.1021/bi00112a008; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; SLIGAR SG, 1991, METHOD ENZYMOL, V206, P31; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; STAYTON PS, 1989, BIOCHEMISTRY-US, V28, P8201, DOI 10.1021/bi00446a035; STAYTON PS, 1990, BIOCHEMISTRY-US, V29, P7381, DOI 10.1021/bi00484a005; STRAUB P, 1993, BIOCHEM BIOPH RES CO, V197, P433, DOI 10.1006/bbrc.1993.2498; STRAUB P, 1993, J BIOL CHEM, V268, P21997; STRAUB P, 1993, ARCH BIOCHEM BIOPHYS, V306, P521, DOI 10.1006/abbi.1993.1547; TSUJITA M, 1993, BIOCHIM BIOPHYS ACTA, V1161, P124, DOI 10.1016/0167-4838(93)90205-6; YOKOYAMA C, 1991, BIOCHEM BIOPH RES CO, V178, P1479, DOI 10.1016/0006-291X(91)91060-P	50	124	150	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1996	10	2					206	214		10.1096/fasebj.10.2.8641554	http://dx.doi.org/10.1096/fasebj.10.2.8641554			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641554				2022-12-28	WOS:A1996TY96200005
J	Griendling, KK; Alexander, RW				Griendling, KK; Alexander, RW			Endothelial control of the cardiovascular system: Recent advances	FASEB JOURNAL			English	Review						endothelium-dependent relaxation; inflammation; thrombin receptor; shear stress; metalloproteinases	NITRIC-OXIDE SYNTHASE; CHOLESTEROL-FED RABBITS; SMOOTH-MUSCLE CELLS; MOLECULAR-CLONING; ADHESION MOLECULES; BINDING PROTEIN; EXPRESSION; ACTIVATION; PHOSPHORYLATION; ATHEROGENESIS	The endothelium is uniquely positioned at the interface between the blood and the vessel wall, As such, it performs multiple functions: It is involved in the regulation of coagulation, leukocyte adhesion in inflammation, vessel tone, and vascular smooth muscle cell growth, and also acts as a barrier to transvascular flux of liquids and solutes, Far from being a passive participant in these events, it is a dynamic tissue, secreting and modifying vasoactive substances, influencing the behavior of other cell types, and regulating extracellular matrix production and composition, During the past 20 years, the endothelium has been the focus of intense experimental work, resulting in the evolution of a new appreciation of its potential role in vascular disease, This review will concentrate on several areas of endothelial biology in which our knowledge of the molecular mechanisms regulating the function of the endothelium has expanded considerably, permitting new insights into the pathogenesis of vascular disease.			Griendling, KK (corresponding author), EMORY UNIV,DIV CARDIOL,POB LL,ATLANTA,GA 30322, USA.			Griendling, Kathy/0000-0002-9456-8582				ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; ALEXANDER RW, 1995, HYPERTENSION, V25, P155, DOI 10.1161/01.HYP.25.2.155; ARNAL JF, 1994, AM J PHYSIOL-CELL PH, V267, pC1381, DOI 10.1152/ajpcell.1994.267.5.C1381; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAFFY G, 1994, J BIOL CHEM, V269, P8483; BRASS LF, 1994, SEMIN HEMATOL, V31, P251; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; CHAIKOF EL, 1995, J BIOL CHEM, V270, P7431, DOI 10.1074/jbc.270.13.7431; COUGHLIN SR, 1994, J BIOL CHEM, V269, P1125; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DAVIES PF, 1993, CIRC RES, V72, P239, DOI 10.1161/01.RES.72.2.239; DAVIES PF, 1994, J CLIN INVEST, V93, P2031, DOI 10.1172/JCI117197; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GALIS ZS, 1994, CIRC RES, V75, P181, DOI 10.1161/01.RES.75.1.181; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GENG YJ, 1994, BBA-MOL CELL RES, V1223, P125, DOI 10.1016/0167-4889(94)90081-7; GERRITY RG, 1979, AM J PATHOL, V95, P775; GIRERD XJ, 1990, CIRC RES, V67, P1301, DOI 10.1161/01.RES.67.6.1301; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GRIENDLING KK, 1993, HURSTS HEART, P31; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; HANEMAAIJER R, 1993, BIOCHEM J, V296, P803, DOI 10.1042/bj2960803; Harrison D G, 1992, Heart Dis Stroke, V1, P95; HARRISON DG, 1987, J CLIN INVEST, V80, P1808, DOI 10.1172/JCI113276; HENRY PD, 1994, BASIC RES CARDIOL, V89, P107; HORVATH AR, 1990, ONCOGENE, V5, P1349; ISHII K, 1993, J BIOL CHEM, V268, P9780; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; LAN QX, 1994, BIOCHEM BIOPH RES CO, V201, P950, DOI 10.1006/bbrc.1994.1794; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MAGNALDO I, 1988, BIOCHEM J, V253, P711, DOI 10.1042/bj2530711; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; MUGGE A, 1991, CIRC RES, V69, P1293, DOI 10.1161/01.RES.69.5.1293; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; OHARA Y, 1995, HYPERTENSION, V25, P415, DOI 10.1161/01.HYP.25.3.415; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; POBER JS, 1991, LAB INVEST, V64, P301; RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; SATRIANO JA, 1993, J CLIN INVEST, V92, P1564, DOI 10.1172/JCI116737; Schini V. B., 1994, Arzneimittel-Forschung, V44, P432; SCHMIDT HHH, 1994, J CLIN INVEST, V78, P919; SESSA WC, 1993, CIRC RES, V72, P921, DOI 10.1161/01.RES.72.4.921; UNEMORI EN, 1990, J BIOL CHEM, V265, P445; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705; VENEMA RC, 1994, BBA-GENE STRUCT EXPR, V1218, P413, DOI 10.1016/0167-4781(94)90195-3; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WALPOLA PL, 1995, ARTERIOSCL THROM VAS, V15, P2, DOI 10.1161/01.ATV.15.1.2; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WILCOX JN, 1994, CIRC RES, V75, P1029, DOI 10.1161/01.RES.75.6.1029; ZACHARIAS U, 1995, J BIOL CHEM, V270, P545, DOI 10.1074/jbc.270.2.545	60	123	123	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1996	10	2					283	292		10.1096/fasebj.10.2.8641561	http://dx.doi.org/10.1096/fasebj.10.2.8641561			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641561				2022-12-28	WOS:A1996TY96200012
J	Buchner, J				Buchner, J			Supervising the fold: Functional principles of molecular chaperones	FASEB JOURNAL			English	Review						heat shock proteins; chaperonins; GroEL; Hsp90; Hsp70; BiP; sHsps; citrate synthase; antibody folding; thermal unfolding; aggregation	HEAT-SHOCK PROTEIN; ESCHERICHIA-COLI; ALPHA-CRYSTALLIN; BINDING-SPECIFICITY; AGGREGATION; GROE; INVITRO; HSP90; EXPRESSION; DOMAIN	Molecular chaperones are a set of conserved protein families that share the remarkable ability to recognize and selectively bind nonnative proteins under physiological and stress conditions. Thus, they prevent irreversible aggregation reactions and keep proteins on the productive folding pathway, Evidence suggests that the cell has developed several functionally distinct chaperone families to support protein folding, The importance of molecular chaperones under stress conditions is highlighted by the finding that all the major heat shock protein families (Hsp104, Hsp90, Hsp70, Hsp60/GroEL, and small Hsps) suppress irreversible unfolding reactions, Under heat shock, only the increased expression of a repertoire of different chaperones seems to convey thermotolerance and guarantee survival. The molecular mechanism by which chaperones in general influence protein folding processes is still far from clear. However, significant progress has been achieved in understanding some of the partial reactions of the chaperone folding cycles and in functionally differentiating between the different chaperone families.			Buchner, J (corresponding author), UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,UNIV STR 31,D-93040 REGENSBURG,GERMANY.		Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				ALLEN SP, 1992, J BACTERIOL, V174, P6938, DOI 10.1128/JB.174.21.6938-6947.1992; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; AZEM A, 1995, IN PRESS P NATL ACAD; BARDWELL JCA, 1988, J BACTERIOL, V170, P2977, DOI 10.1128/jb.170.7.2977-2983.1988; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; ENGEL A, 1995, SCIENCE, V269, P832, DOI 10.1126/science.7638600; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FISHER MT, 1994, J BIOL CHEM, V269, P29598; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRAGEROV AI, 1991, FEBS LETT, V291, P222, DOI 10.1016/0014-5793(91)81289-K; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAAS IG, 1994, EXPERIENTIA, V50, P1012, DOI 10.1007/BF01923455; HARRIS JR, 1994, J STRUCT BIOL, V112, P216, DOI 10.1006/jsbi.1994.1022; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HUNT JF, IN PRESS NATURE LOND; ISHII N, 1995, FEBS LETT, V362, P121, DOI 10.1016/0014-5793(95)00222-U; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; JAKOB U, 1995, J BIOL CHEM, V270, P18258; JAKOB U, 1993, J BIOL CHEM, V268, P7414; KAMPINGA HH, 1994, BIOCHEM BIOPH RES CO, V204, P1170, DOI 10.1006/bbrc.1994.2586; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LANGER T, 1992, EMBO J, V11, P455; LANGER T, 1994, BIOL HEAT SHOCK PROT, P53; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; LILIE H, 1995, P NATL ACAD SCI USA, V92, P8100, DOI 10.1073/pnas.92.18.8100; LILIE H, 1995, PROTEIN SCI, V4, P917; LILIE H, 1995, J MOL BIOL, V248, P190, DOI 10.1006/jmbi.1995.0211; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; LORIMER G, 1996, FASEB J, V10, P1; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MINAMI Y, 1993, J BIOL CHEM, V268, P9604; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; ROSPERT S, 1996, IN PRESS EMBO J; Rudolph R, 1996, FASEB J, V10, P49, DOI 10.1096/fasebj.10.1.8566547; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; SCHMIDT M, 1994, J BIOL CHEM, V269, P27964; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SMITH DF, 1993, STEROID HORMONE RECE, P247; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; WEI J, 1996, IN PRESS STRESS INDU; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; ZAHN R, 1994, J MOL BIOL, V242, P165, DOI 10.1006/jmbi.1994.1567; [No title captured]; [No title captured]; [No title captured]	73	363	395	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1996	10	1					10	19		10.1096/fasebj.10.1.8566529	http://dx.doi.org/10.1096/fasebj.10.1.8566529			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566529				2022-12-28	WOS:A1996TR32800003
J	Baltimore, D				Baltimore, D			Milestones in biological research - Discovery of the reverse transcriptase	FASEB JOURNAL			English	Article											Baltimore, D (corresponding author), MIT,DEPT BIOL,BLDG 68,RM 380,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.								0	7	7	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1995	9	15					1660	1663		10.1096/fasebj.9.15.8529847	http://dx.doi.org/10.1096/fasebj.9.15.8529847			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TM761	8529847				2022-12-28	WOS:A1995TM76100021
J	Galea, E; Reis, DJ; Xu, H; Feinstein, DL				Galea, E; Reis, DJ; Xu, H; Feinstein, DL			Transient expression of calcium-independent nitric oxide synthase in blood vessels during brain development	FASEB JOURNAL			English	Article						inducible nitric oxide synthase; development; endothelial cells; citrulline	NADPH DIAPHORASE; HISTOCHEMICAL-LOCALIZATION; MESSENGER-RNA; MACROPHAGES; INDUCTION; INVIVO; CELLS	The calcium-independent nitric oxide synthase, known as NOS-II or inducible NOS, is only present in adult brain during pathologies that involve inflammatory events. We sought to establish whether NOS-II tvas also expressed in the course of normal brain development, NOS-II mRNA, measured by quantitative polymerase chain reaction, appeared during the perinatal period in different brain areas. It was detected on embryonic day 14, the earliest time analyzed, and then levels decayed until the first postnatal week when a second, more robust phase of expression arose to peak around postnatal day 7. Expression then declined to negligible levels in adulthood, Immunohistology revealed translation of the NOS-II protein in both embryonic and postnatal animals, localized to parenchymal blood vessels, whereas no vessel staining was detected in adults. Furthermore, NOS-II mRNA and enzymatic activities were present in isolated brain microvessels from developing animals but not from adults, and P7 vessels contained a 125 kDa protein band detected with a monoclonal antibody raised against rat NOS-II protein, These results indicate that the calcium-independent NOS mRNA and functional protein are transiently expressed in vessels throughout the brain in the course of normal development.	CORNELL UNIV,COLL MED,DEPT NEUROL & NEUROSCI,DIV NEUROBIOL,NEW YORK,NY 10021	Cornell University			feinstein, doug/M-9414-2019; Galea, Elena/E-1362-2011	Galea, Elena/0000-0003-4537-9897				BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; CHUANFANG J, 1994, PCR METHODS APPLICA, V31, P252; CROSS AH, 1994, J CLIN INVEST, V93, P2684, DOI 10.1172/JCI117282; DORHEIM MA, 1994, BIOCHEM BIOPH RES CO, V205, P659, DOI 10.1006/bbrc.1994.2716; ENDOH M, 1993, NEUROSCI LETT, V154, P125, DOI 10.1016/0304-3940(93)90187-P; GABBOTT PLA, 1993, NEUROSCIENCE, V57, P79, DOI 10.1016/0306-4522(93)90113-T; GALEA E, 1991, J CEREBR BLOOD F MET, V11, P875, DOI 10.1038/jcbfm.1991.148; GALEA E, 1994, J NEUROSCI RES, V37, P406, DOI 10.1002/jnr.490370313; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GREEN IC, 1994, BIOCHEM SOC T, V22, P30, DOI 10.1042/bst0220030; HATTORI R, 1993, HYBRIDOMA, V12, P763, DOI 10.1089/hyb.1993.12.763; HEISS LN, 1994, P NATL ACAD SCI USA, V91, P267, DOI 10.1073/pnas.91.1.267; HUANG J, 1995, J LEUKOCYTE BIOL, V57, P27, DOI 10.1002/jlb.57.1.27; IADECOLA C, 1994, GALE ANN M SOC NEUR, P1479; KILBOURN RG, 1990, J NATL CANCER I, V82, P772, DOI 10.1093/jnci/82.9.772; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NIU XF, 1994, CIRC RES, V74, P1133, DOI 10.1161/01.RES.74.6.1133; PERRY VH, 1988, TRENDS NEUROSCI, V11, P273, DOI 10.1016/0166-2236(88)90110-5; PIPILISYNETOS E, 1994, BRIT J PHARMACOL, V111, P894, DOI 10.1111/j.1476-5381.1994.tb14822.x; RADOMSKI MW, 1993, CARDIOVASC RES, V27, P1380, DOI 10.1093/cvr/27.7.1380; REIS DJ, 1989, NEUROTRANSMISSION CE, V2, P369; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHMIDT HHHW, 1992, J HISTOCHEM CYTOCHEM, V40, P1439, DOI 10.1177/40.10.1382087; TOJO A, 1994, J AM SOC NEPHROL, V4, P1438; WALLACE MN, 1994, NEUROSCIENCE, V59, P905, DOI 10.1016/0306-4522(94)90294-1; WILLIAMS CV, 1994, J NEUROSCI, V14, P1746, DOI 10.1523/JNEUROSCI.14-03-01746.1994; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; Zheng Yong Mu, 1993, Journal of Virology, V67, P5786	34	41	42	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1995	9	15					1632	1637		10.1096/fasebj.9.15.8529843	http://dx.doi.org/10.1096/fasebj.9.15.8529843			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TM761	8529843				2022-12-28	WOS:A1995TM76100017
J	Karplus, PA; Fox, KM; Massey, V				Karplus, PA; Fox, KM; Massey, V			Flavoprotein structure and mechanism .8. Structure-function relations for old yellow enzyme	FASEB JOURNAL			English	Review						flavoenzyme; steroid binding; protein crystallography; NADH oxidase	CHARGE-TRANSFER INTERACTIONS; FLAVIN-PROTEIN; RESONANCE; CLONING; OXIDASE; GENE; EXPRESSION; RESOLUTION; NUCLEOTIDE; COMPLEXES	The past 5 years have seen tremendous progress in our know ledge of old yellow enzyme (OYE) as a number of OYEs have been cloned and expressed, a high-resolution crystal structure has been determined for one of these, and new substrates have been found that call he turned over by the enzyme. Together these studies do not yet define the physiological role of OYE, but they lead to significant new insights into the enzymatic properties and structure-function relations of OYE.	UNION COLL,DEPT CHEM,SCHENECTADY,NY 12308; UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	Union College; University of Michigan System; University of Michigan	Karplus, PA (corresponding author), CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,223 BIOTECHNOL BLDG,ITHACA,NY 14853, USA.			Karplus, Paul/0000-0001-8725-6292				ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5321; ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5327; ADACHI O, 1979, J BIOCHEM, V86, P699, DOI 10.1093/oxfordjournals.jbchem.a132574; BEINERT WD, 1985, EUR J BIOCHEM, V152, P573, DOI 10.1111/j.1432-1033.1985.tb09234.x; BIENSTOCK RJ, 1987, J RAMAN SPECTROSC, V18, P241, DOI 10.1002/jrs.1250180403; BOYD G, 1992, FEBS LETT, V308, P271, DOI 10.1016/0014-5793(92)81291-S; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; FOX KM, 1993, J MOL BIOL, V234, P502, DOI 10.1006/jmbi.1993.1604; FOX KM, 1991, FLAVINS AND FLAVOPROTEINS 1990, P353; FRANKLUND CV, 1993, J BACTERIOL, V175, P3002, DOI 10.1128/JB.175.10.3002-3012.1993; FRENCH CE, 1994, BIOCHEM J, V301, P97, DOI 10.1042/bj3010097; Haas E, 1938, BIOCHEM Z, V298, P378; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KITAGAWA T, 1979, J AM CHEM SOC, V101, P3376, DOI 10.1021/ja00506a042; KRUEGER MJ, 1992, BIOCHEMISTRY-US, V31, P5611, DOI 10.1021/bi00139a026; LINDQVIST Y, 1989, J MOL BIOL, V209, P151, DOI 10.1016/0022-2836(89)90178-2; LIU XL, 1993, BIOCHIM BIOPHYS ACTA, V1174, P187, DOI 10.1016/0167-4781(93)90113-R; MACHEROUX P, 1990, BIOCHEMISTRY-US, V29, P2670, DOI 10.1021/bi00463a008; MADANI ND, 1994, P NATL ACAD SCI USA, V91, P922, DOI 10.1073/pnas.91.3.922; MALLONEE DH, 1990, J BACTERIOL, V172, P7011, DOI 10.1128/jb.172.12.7011-7019.1990; MASSEY V, 1986, J BIOL CHEM, V261, P1215; Massey V, 1994, FLAVINS AND FLAVOPROTEINS 1993, P371; Massey V., 1984, FLAVINS FLAVOPROTEIN, P191; MASSEY V, 1979, J BIOL CHEM, V254, P9610; MIRANDA M, 1994, L37452 GEN ACC COD; MIURA R, 1986, J BIOCHEM-TOKYO, V99, P901, DOI 10.1093/oxfordjournals.jbchem.a135551; MIURA R, 1986, J BIOCHEM-TOKYO, V99, P907, DOI 10.1093/oxfordjournals.jbchem.a135552; NINO YS, 1995, J BIOL CHEM, V270, P1983; NISHINA Y, 1980, J BIOCHEM-TOKYO, V87, P831, DOI 10.1093/oxfordjournals.jbchem.a132813; SAITO K, 1991, J BIOL CHEM, V266, P20720; Schopfer L. M., 1991, STUDY ENZYMES, P247; STEWART RC, 1985, J BIOL CHEM, V260, P3639; STOTT K, 1993, J BIOL CHEM, V268, P6097; VAZ ADN, 1995, BIOCHEMISTRY-US, V34, P4246, DOI 10.1021/bi00013a014; Warburg O, 1933, BIOCHEM Z, V266, P377; WHITE SA, 1993, AM CRYSTALLOGRAPHIC; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M	39	92	95	4	36	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1995	9	15					1518	1526		10.1096/fasebj.9.15.8529830	http://dx.doi.org/10.1096/fasebj.9.15.8529830			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TM761	8529830	Green Submitted			2022-12-28	WOS:A1995TM76100004
J	Olson, JA; Krinsky, NI				Olson, JA; Krinsky, NI			The colorful, fascinating world of the carotenoids: Important physiologic modulators - Introduction	FASEB JOURNAL			English	Review							BETA-CAROTENE		TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111; TUFTS UNIV,JEAN MAYER HUMAN NUTR RES CTR AGING,BOSTON,MA 02111	Tufts University; Tufts University	Olson, JA (corresponding author), IOWA STATE UNIV,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011, USA.				NATIONAL CANCER INSTITUTE [R01CA049195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039733] Funding Source: NIH RePORTER; NCI NIH HHS [CA-49195] Funding Source: Medline; NIDDK NIH HHS [DK-39733] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMSTRONG GA, 1996, IN PRESS FASEB J; BERGEN HR, 1989, J LABELLED COMPD RAD, V27, P783, DOI 10.1002/jlcr.2580270707; BERZELIUS JJ, 1987, LIEBIGS ANN CHEM, V21, P257; BEUTNER S, 1994, PURE APPL CHEM, V66, P955, DOI 10.1351/pac199466050955; Britton G, 1995, FASEB J, V9, P1551, DOI 10.1096/fasebj.9.15.8529834; DEMMIGADAMS B, 1996, IN PRESS FASEB J; DEPEE S, 1995, LANCET, V346, P75, DOI 10.1016/S0140-6736(95)92111-7; FEINSTEIN AR, 1988, SCIENCE, V242, P1257, DOI 10.1126/science.3057627; Frank H. A., 1993, CAROTENOIDS PHOTOSYN, P252, DOI [10.1007/978-94-011-2124-8_8, DOI 10.1007/978-94-011-2124-8_8]; GAZIANO JM, 1995, AM J CLIN NUTR, V61, P1248, DOI 10.1093/ajcn/61.6.1248; KRINSKY NI, 1994, PURE APPL CHEM, V66, P1003, DOI 10.1351/pac199466051003; KRINSKY NI, 1992, P SOC EXP BIOL MED, V200, P248; KRINSKY NI, 1995, AM J CLIN NUTR S, V62, pS1299; MATHEWSROTH MM, 1993, ANN NY ACAD SCI, V691, P127, DOI 10.1111/j.1749-6632.1993.tb26164.x; MAYNE ST, 1996, IN PRESS FASEB J; MOORE TA, 1994, PURE APPL CHEM, V66, P1033, DOI 10.1351/pac199466051033; NAGAO A, 1994, FASEB J, V8, P968, DOI 10.1096/fasebj.8.12.8088462; NOVOTNY JA, 1995, J LIPID RES, V36, P1825; OLSON JA, 1995, IN PRESS J NUTR; PALMER LS, 1922, CAROTENOIDS RELATED, P1; PARKER RS, 1993, ANN NY ACAD SCI, V691, P86, DOI 10.1111/j.1749-6632.1993.tb26160.x; PARKER RS, 1996, IN PRESS FASEB J; PORTER JW, 1950, ARCH BIOCHEM, V27, P390; STAHL W, 1993, J NUTR, V123, P847, DOI 10.1093/jn/123.5.847; STRAUB O, 1987, KEY CAROTENOIDS, P1; Tswett M., 1911, BER DEUT BOT GES, V29, P630; WACHENRODER H, 1831, GEIGERS MAGAZ PHARM, V33, P144; WANG XD, 1994, ARCH BIOCHEM BIOPHYS, V313, P150, DOI 10.1006/abbi.1994.1371; YAMAMOTO HY, 1979, PURE APPL CHEM, V51, P639, DOI 10.1351/pac197951030639; ZENG SH, 1992, AM J CLIN NUTR, V56, P433, DOI 10.1093/ajcn/56.2.433; 1994, NEW ENGL J MED, V330, P1029	31	166	179	3	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1995	9	15					1547	1550		10.1096/fasebj.9.15.8529833	http://dx.doi.org/10.1096/fasebj.9.15.8529833			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TM761	8529833				2022-12-28	WOS:A1995TM76100007
J	GAILL, F				GAILL, F			ASPECTS OF LIFE DEVELOPMENT AT DEEP-SEA HYDROTHERMAL VENTS	FASEB JOURNAL			English	Review						CHEMOAUTOTROPHIC SYMBIOSIS; THERMAL ADAPTATION; EXTRACELLULAR MATRIX; SULFIDE; VESTIMENTIFERA	WORM RIFTIA-PACHYPTILA; TUBE WORM; GALAPAGOS RIFT; ANIMALS; JONES; VESTIMENTIFERA; SYMBIOSIS; BACTERIA; BIOLOGY; MUSSELS	Hydrothermal vent organisms are living in an unexpected deep-sea environment, several thousand meters below the surface, where the earth's crustal plates are spreading apart. The vent fluids are usually hot (350-degrees-C), anoxic, and contain high concentrations of hydrogen sulfide. This environment may be considered as extreme given the pressure, the high temperature, the chemical toxicity of the fluids, and the total lack of photosynthetic production for animal nutrition. The recent discovery of the unique fauna of the hydrothermal vent communities has brought an unexpected mode of animal nutrition in which chemoautotropic bacterial symbionts are maintained within specialized cells of the host animal. The bacterial symbionts obtain energy by oxidizing reduced sulfur compounds from the environment. A portion of this fixed carbon is used by the eukaryotic host. The present review will focus on four of the main topics studied on the paradigmatic vent organism Riftia pachyptila, a giant gutless tube worm: 1) the chemoautotrophic symbiosis, 2) the toxicity of hydrogen sulfide, 3) the characteristics of the extracellular matrices of the worms, especially data obtained on collagens, and 4) the influence of temperature and pressure on worm biology.	CTR BIOL CELLULAIRE,F-94205 IVRY,FRANCE									ALAYSEDANET AM, 1986, PSZNI MAR ECOL, V7, P233; ARP AJ, 1983, SCIENCE, V219, P295, DOI 10.1126/science.219.4582.295; BLUM J, 1984, ARCH BIOCHEM BIOPHYS, V228, P617, DOI 10.1016/0003-9861(84)90030-4; CARY SC, 1989, MAR ECOL PROG SER, V52, P89, DOI 10.3354/meps052089; CARY SC, 1988, SCIENCE, V240, P78, DOI 10.1126/science.240.4848.78; CAVANAUGH CM, 1981, SCIENCE, V213, P340, DOI 10.1126/science.213.4505.340; CAVANAUGH CM, 1987, NATURE, V325, P346, DOI 10.1038/325346a0; CHEVALDONNE P, 1992, NATURE, V359, P593, DOI 10.1038/359593b0; CHILDRESS JJ, 1992, OCEANOGR MAR BIOL, V30, P337; CHILDRESS JJ, 1986, SCIENCE, V233, P1306, DOI 10.1126/science.233.4770.1306; CORLISS JB, 1979, SCIENCE, V203, P1073, DOI 10.1126/science.203.4385.1073; DAHLHOFF E, 1991, J EXP BIOL, V159, P473; DAHLOFF E, 1991, PHYSIOL ZOOL, V64, P490; DESBRUYERES D, 1983, MAR BIOL, V75, P201, DOI 10.1007/BF00406003; DISTEL DL, 1988, J BACTERIOL, V170, P2506, DOI 10.1128/jb.170.6.2506-2510.1988; FELBECK H, 1981, NATURE, V293, P291, DOI 10.1038/293291a0; FELBECK H, 1985, PHYSIOL ZOOL, V58, P272, DOI 10.1086/physzool.58.3.30155998; FELBECK H, 1981, SCIENCE, V213, P336, DOI 10.1126/science.213.4505.336; FIALAMEDIONI A, 1990, ANIMAL NUTRITION TRA, V1, P49; FISCHER C, 1990, REV AQUAT SCI, V2, P399; FRY B, 1983, NATURE, V306, P51, DOI 10.1038/306051a0; GAILL F, 1991, J MOL BIOL, V221, P209, DOI 10.1016/0022-2836(91)80215-G; GAILL F, 1992, ADVANCES IN CHITIN AND CHITOSAN, P232; GAILL F, 1986, MAR ECOL PROG SER, V34, P267, DOI 10.3354/meps034267; GAILL F, 1992, ADVANCES IN CHITIN AND CHITOSAN, P225; GAILL F, 1991, REV AQUAT SCI, V4, P107; GAILL F, 1992, IN PRESS J STRUCT BI; JONES ML, 1989, BIOL BULL, V177, P254, DOI 10.2307/1541941; JONES ML, 1981, SCIENCE, V213, P333, DOI 10.1126/science.213.4505.333; MANN K, 1992, EUR J BIOCHEM, V210, P839, DOI 10.1111/j.1432-1033.1992.tb17487.x; POWELL MA, 1983, SCIENCE, V219, P297, DOI 10.1126/science.219.4582.297; RAU GH, 1981, NATURE, V289, P484, DOI 10.1038/289484a0; RAU GH, 1981, SCIENCE, V213, P338, DOI 10.1126/science.213.4505.338; SOMERO GN, 1992, ANNU REV PHYSIOL, V54, P557, DOI 10.1146/annurev.ph.54.030192.003013; SOMERO GN, 1989, CRC CRIT REV AQUAT S, V1, P591; SOUTHWARD EC, 1988, J MAR BIOL ASSOC UK, V68, P465, DOI 10.1017/S0025315400043344; SUZUKI T, 1990, BIOCHEM J, V266, P221, DOI 10.1042/bj2660221; TERWILLIGER RC, 1985, B BIOL SOC WASH, V6, P273; TOULMOND A, 1991, BIOL BULL, V179, P366; TUNNICLIFFE V, 1991, OCEANOGR MAR BIOL AN, V29, P1991	40	57	60	4	48	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR 1	1993	7	6					558	565		10.1096/fasebj.7.6.8472894	http://dx.doi.org/10.1096/fasebj.7.6.8472894			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KY009	8472894				2022-12-28	WOS:A1993KY00900009
J	ZAKERI, ZF; QUAGLINO, D; LATHAM, T; LOCKSHIN, RA				ZAKERI, ZF; QUAGLINO, D; LATHAM, T; LOCKSHIN, RA			DELAYED INTERNUCLEOSOMAL DNA FRAGMENTATION IN PROGRAMMED CELL-DEATH	FASEB JOURNAL			English	Article						APOPTOSIS; PROGRAMMED CELL DEATH; ENDONUCLEASE; MANDUCA SEXTA; DNA	RAT VENTRAL PROSTATE; GENE-EXPRESSION; APOPTOSIS; ACTIVATION; INDUCTION; ENDONUCLEASE; INVOLVEMENT; TRANSCRIPTS; LYMPHOCYTES; REGRESSION	DNA fragmentation was evaluated in three instances of programmed cell death, interdigital cell death in embryonic mouse limbs, and metamorphic death of both the labial glands and intersegmental muscle in the tobacco hornworm Manduca sexta. In the mouse, we evaluated both developmental cell death and expanded-range cell death induced by retinoic acid. The status of DNA was examined in several ways. Nuclei were examined by electron microscopy and Feulgen staining. Quantitative assessment of total DNA content in Feulgen-stained degenerating nuclei was made for the gland. In the labial gland, DNA content does not drop during the early phases of cell death; nor is an endonucleolytic ladder seen when DNA was examined by ethidium bromide staining or prelabeling with [H-3]thymidine. Only by using end labeling of DNA could we detect DNA fragmentation at a very late stage in cell death, day 4 of the collapse of the gland. In contrast, WEHI 7.1 lymphoma cells display an early and extensive ladder after treatment with glucocorticoids. In mouse limb, for which cell death follows a more classic apoptotic morphology, a ladder is likewise not seen. We conclude that activation of an endonuclease is neither a trigger nor a necessary or defining component of the early phases of developmental programmed cell death, and that reported failure by others to find such a ladder may depend on limitations in the system that is under investigation.	ST JOHNS UNIV, DEPT BIOL SCI, JAMAICA, NY 11439 USA; CUNY QUEENS COLL, DEPT BIOL, FLUSHING, NY 11367 USA; UNIV MODENA, DEPT PATHOL, I-41100 MODENA, ITALY; CUNY, GRAD CTR, FLUSHING, NY 11367 USA	Saint John's University; City University of New York (CUNY) System; Queens College NY (CUNY); Universita di Modena e Reggio Emilia; City University of New York (CUNY) System			Quaglino, Daniela/A-9381-2010	Quaglino, Daniela/0000-0002-4302-5078	NIA NIH HHS [R01 AG-10101] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG010101] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akai H., 1984, P323; ALLES AJ, 1989, TERATOLOGY, V40, P163, DOI 10.1002/tera.1420400210; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BEAULATION J, 1977, J MORPHOL, V154, P39, DOI 10.1002/jmor.1051540104; BEAULATON J, 1982, INT REV CYTOL, V79, P215, DOI 10.1016/S0074-7696(08)61675-7; BRIEHL MM, 1991, MOL ENDOCRINOL, V5, P1381, DOI 10.1210/mend-5-10-1381; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CARONLESLIE LAM, 1991, J STEROID BIOCHEM, V40, P661, DOI 10.1016/0960-0760(91)90288-G; CARSON DA, 1988, ADV ENZYME REGUL, V27, P395, DOI 10.1016/0065-2571(88)90028-3; CARSON DA, 1986, EXP CELL RES, V164, P273, DOI 10.1016/0014-4827(86)90028-5; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; COHEN JJ, 1984, J IMMUNOL, V132, P38; Cope FO., 1991, APOPTOSIS MOL BASIS, P47; DOWD DR, 1991, J BIOL CHEM, V266, P18423; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GOLDMAN AS, 1983, P SOC EXP BIOL MED, V174, P239; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KERR JFR, 1991, MOL BASIS CELL DEATH, P5; Lockshin R A, 1965, J Insect Physiol, V11, P803, DOI 10.1016/0022-1910(65)90159-9; LOCKSHIN RA, 1990, J GERONTOL, V45, pB135, DOI 10.1093/geronj/45.5.B135; LOCKSHIN RA, 1974, J ULTRA MOL STRUCT R, V46, P43, DOI 10.1016/S0022-5320(74)80021-3; LOCKSHIN RA, 1979, TISSUE CELL, V11, P803, DOI 10.1016/0040-8166(79)90033-8; LOCKSHIN RA, 1964, J INSECT PHYSIOL, V10, P643, DOI 10.1016/0022-1910(64)90034-4; LOCKSHIN RA, 1965, J INSECT PHYSL, V11, P605; LOCKSHIN RICHARD A., 1965, J INSECT PHYSIOL, V11, P831, DOI 10.1016/0022-1910(65)90186-1; LOCKSHIN RICHARD A., 1965, J INSECT PHYSIOL, V11, P123, DOI 10.1016/0022-1910(65)90099-5; MONTEMAYOR ME, 1990, FEBS LETT, V276, P219, DOI 10.1016/0014-5793(90)80546-U; NAEGELE JR, 1991, P NATL ACAD SCI USA, V88, P330, DOI 10.1073/pnas.88.2.330; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; PIACENTINI M, 1991, CELL TISSUE RES, V263, P227, DOI 10.1007/BF00318764; PRICE JM, 1977, AM J ANAT, V149, P353, DOI 10.1002/aja.1001490304; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; SCHWARTZ LM, 1990, NEURON, V5, P411, DOI 10.1016/0896-6273(90)90080-Y; SENSIBAR JA, 1990, PROSTATE, V16, P263, DOI 10.1002/pros.2990160310; TASHIRO Y, 1968, J CELL BIOL, V38, P574, DOI 10.1083/jcb.38.3.574; TILLY JL, 1991, ENDOCRINOLOGY, V129, P2799, DOI 10.1210/endo-129-5-2799; UMANSKY SR, 1991, APOPTOSIS MOL BASIS, P193; WYLLIE AH, 1987, J PATHOL, V153, P313, DOI 10.1002/path.1711530404; ZAKERI Z, 1990, Cell Biology International Reports, V14, P171, DOI 10.1016/0309-1651(90)90786-X	42	188	189	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1993	7	5					470	478		10.1096/fasebj.7.5.8462789	http://dx.doi.org/10.1096/fasebj.7.5.8462789			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KV351	8462789				2022-12-28	WOS:A1993KV35100012
J	Pooga, M; Hallbrink, M; Zorko, M; Langel, U				Pooga, M; Hallbrink, M; Zorko, M; Langel, U			Cell penetration by transportan	FASEB JOURNAL			English	Article						peptide synthesis; Bowes' melanoma cells; endocytosis; GTPase activity	CHIMERIC PEPTIDE; ANTENNAPEDIA HOMEODOMAIN; CEREBROSPINAL-FLUID; GALANIN RECEPTOR; G-PROTEINS; 3RD HELIX; MASTOPARAN; MEMBRANES; BINDING; PERMEABILITY	Transportan is a 27 amino acid-long peptide containing 12 functional amino acids from the amino terminus of the neuropeptide galanin and mastoparan in the carboxyl terminus, connected via a lysine. Transportan is a cell-penetrating peptide as judged by indirect immunofluorescence using N-epsilon 13-biotinyl-transportan. The internalization of biotinyl-transportan is energy independent and takes place efficiently at 37 degrees, 4 degrees, and 0 degrees C, Cellular uptake of transportan is probably not mediated by endocytosis, since it cannot be blocked by treating the cells with phenylarsine oxide or hyperosmolar sucrose solution and is nonsaturable, The kinetics of internalization was studied with the aid of the I-125-labeled peptide. At 37 degrees C, the maximal intracellular concentration is reached in about 20 min, The internalized transportan is protected from trypsin. The cell-penetrating ability of transportan is not restricted by cell type, but seems to be a general feature of this peptide, In Bowes' melanoma cells, transportan first localizes in the outer membrane and cytoplasmatic membrane structures, This is followed by a redistribution into the nuclear membrane and uptake into the nuclei where transportan concentrates in distinct substructures, probably the nucleoli.	Univ Stockholm, Arrhenius Lab, Dept Neurochem & Neurotoxicol, S-10691 Stockholm, Sweden; Estonian Bioctr, EE-2400 Tartu, Estonia; Univ Ljubljana, Fac Med, Inst Biochem, Ljubljana 1000, Slovenia	Stockholm University; Estonian Biocentre; University of Ljubljana	Langel, U (corresponding author), Univ Stockholm, Arrhenius Lab, Dept Neurochem & Neurotoxicol, S-10691 Stockholm, Sweden.	ulo@neurochem.su.se	Pooga, Margus/A-8575-2011	Pooga, Margus/0000-0003-4532-4087; Langel, Ulo/0000-0001-6107-0844				AHREN B, 1986, BIOCHEM BIOPH RES CO, V140, P1059, DOI 10.1016/0006-291X(86)90742-4; BEDECS K, 1995, NEUROPEPTIDES, V29, P137, DOI 10.1016/0143-4179(95)90015-2; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; Consolo S, 1997, BRAIN RES, V756, P174, DOI 10.1016/S0006-8993(97)00146-7; DANILENKO M, 1993, BIOCHEM BIOPH RES CO, V196, P1296, DOI 10.1006/bbrc.1993.2393; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; FROST SC, 1985, J BIOL CHEM, V260, P2646; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; ILLINGER D, 1994, J CELL BIOL, V125, P783, DOI 10.1083/jcb.125.4.783; Jureus A., 1996, ACTA CHIM SLOV, V43, P51, DOI DOI 10.1007/S008940100045; Kask K, 1996, EMBO J, V15, P236, DOI 10.1002/j.1460-2075.1996.tb00354.x; KASK K, 1995, REGUL PEPTIDES, V59, P341, DOI 10.1016/0167-0115(95)00089-T; LAND T, 1991, INT J PEPT PROT RES, V38, P267; LAND T, 1991, METHODS NEUROSCIENCE, V5, P225; LANGEL U, 1992, INT J PEPT PROT RES, V39, P516; Langel U, 1996, REGUL PEPTIDES, V62, P47, DOI 10.1016/0167-0115(96)00002-X; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P8450, DOI 10.1021/bi960342a; MCKENZIE FR, 1992, SIGNAL TRANSDUCTION, P31; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; Ostenson CG, 1997, ENDOCRINOLOGY, V138, P3308, DOI 10.1210/en.138.8.3308; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PFEIFFER DR, 1995, J BIOL CHEM, V270, P4923, DOI 10.1074/jbc.270.9.4923; PROCHIANTZ A, 1995, BIOESSAYS, V17, P39, DOI 10.1002/bies.950170109; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SODERQVIST H, 1994, EUR J CELL BIOL, V64, P183; STOJAN J, 1997, IN PRESS J CHEM INF; TAM JP, 1986, J AM CHEM SOC, V108, P5242, DOI 10.1021/ja00277a031; TANIMURA A, 1991, BIOCHEM BIOPH RES CO, V177, P802, DOI 10.1016/0006-291X(91)91860-F; WEIDMAN PJ, 1994, J CELL BIOL, V127, P1815, DOI 10.1083/jcb.127.6.1815	32	519	596	3	85	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1998	12	1					67	77		10.1096/fasebj.12.1.67	http://dx.doi.org/10.1096/fasebj.12.1.67			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YR723	9438412				2022-12-28	WOS:000071523800008
J	Armstead, VE; Minchenko, AG; Campbell, B; Lefer, AM				Armstead, VE; Minchenko, AG; Campbell, B; Lefer, AM			P-selectin is up-regulated in vital organs during murine traumatic shock	FASEB JOURNAL			English	Article						adhesion molecules; endothelium; RNase protection assay; splanchnic organs; immunohistochemistry; NF-kappa B	NF-KAPPA-B; ENDOTHELIAL-CELL-ADHESION; GRANULE MEMBRANE-PROTEIN; TUMOR-NECROSIS-FACTOR; LOWER TORSO ISCHEMIA; NEUTROPHIL ADHERENCE; REPERFUSION INJURY; LUNG INJURY; ACTIVATION; EXPRESSION	Murine traumatic shock is associated with increased adherence of neutrophils to the vascular endothelium resulting in neutrophil infiltration and tissue damage. We examined the effects of trauma on the expression of the adhesion molecule P-selectin in several vital organs (i.e., heart, lungs, liver, kidneys, and small intestine) 2 h after induction of Noble-Collip drum trauma in anesthetized rats. Total RNA was extracted from these organs and P-selectin mRNA was quantified by RNase protection assays. P-selectin mRNA was significantly increased over control nontraumatized, anesthetized rats in all vital organs (P<0.05 or less), with the largest increase occurring in the lung (P<0.01). Immunohistochemical analysis showed increased expression of P-selectin protein in postcapillary venules of all vital organs after trauma. To further investigate the possible mechanisms of increased P-selectin mRNA transcription promoter activity during trauma, we quantified binding of proteins from nuclear extracts to the KB site ((-218)GGGGGTGACCC(-207)) Of the P-selectin gene by electrophoretic mobility shift assay, We confirmed the results of NF-kappa B binding by demonstrating increases in p50 and p52, as well as decreases in I kappa B in cytoplasmic and nuclear extracts from the lungs of trauma rats by Western blotting. Increased activity of the transcription factor, nuclear factor kappa B (NF-kappa B), occurred in all vital organs of the trauma rats compared to sham-operated controls. Our findings suggest that severe trauma results in up-regulation of P-selectin at the transcriptional level, which is partly controlled by an NF-kappa B-responsive element in the region of the P-selectin promoter. This increased activation of NF-kappa B binding may contribute to the widespread increases in P-selectin expression observed in several vital organs 2 h after trauma, which in turn may play a key role in the pathogenesis of traumatic shock.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Physiol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Anesthesiol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Lefer, AM (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Physiol, 1020 Locust St, Philadelphia, PA 19107 USA.		Minchenko, Oleksandr/AAV-5742-2020	Minchenko, Oleksandr/0000-0002-7093-5173	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045434] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45434] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Armstead VE, 1997, AM J PHYSIOL-HEART C, V273, pH740, DOI 10.1152/ajpheart.1997.273.2.H740; BAUE AE, 1992, ARCH SURG-CHICAGO, V127, P1451; BECKSTEAD JH, 1986, BLOOD, V67, P285; BOLDT J, 1995, CHEST, V107, P787, DOI 10.1378/chest.107.3.787; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS T, 1993, LAB INVEST, V68, P499; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; DAVENPECK KL, 1994, GASTROENTEROLOGY, V107, P1050, DOI 10.1016/0016-5085(94)90229-1; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; GAUTHIER TW, 1995, ARTERIOSCL THROM VAS, V15, P1652, DOI 10.1161/01.ATV.15.10.1652; Gibbs SAL, 1996, SURGERY, V119, P652, DOI 10.1016/S0039-6060(96)80189-9; GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662, DOI 10.1002/jlb.55.5.662; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HILL J, 1993, J APPL PHYSIOL, V74, P659, DOI 10.1152/jappl.1993.74.2.659; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KHACHIGIAN LM, 1995, J CLIN INVEST, V96, P1169, DOI 10.1172/JCI118106; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; LEFER AM, 1987, AM J PHYSIOL, V252, pR193, DOI 10.1152/ajpregu.1987.252.2.R193; LEFER AM, 1993, ANNU REV PHARMACOL, V33, P71, DOI 10.1146/annurev.pa.33.040193.000443; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; Noble RL, 1942, Q J EXP PHYSIOL CMS, V31, P187, DOI 10.1113/expphysiol.1942.sp000856; PAN JL, 1995, J BIOL CHEM, V270, P23077, DOI 10.1074/jbc.270.39.23077; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; Rong YQ, 1996, J NEUROCHEM, V67, P662; SANDERS WE, 1992, BLOOD, V80, P795; Scalia R, 1996, SHOCK, V6, P177, DOI 10.1097/00024382-199609000-00004; Shono T, 1996, MOL CELL BIOL, V16, P4231; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIMMONS RK, 1996, J TRAUMA INJURY INF, V41, P653; SKURK C, 1995, SHOCK, V3, P13; SKURK C, 1994, AM J PHYSIOL-HEART C, V267, pH2124, DOI 10.1152/ajpheart.1994.267.6.H2124; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; SUGAMA Y, 1992, J CELL BIOL, V119, P935, DOI 10.1083/jcb.119.4.935; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Weiser MR, 1996, J EXP MED, V183, P2343, DOI 10.1084/jem.183.5.2343; WELBOURN R, 1991, J APPL PHYSIOL, V70, P2645, DOI 10.1152/jappl.1991.70.6.2645; WELBOURN R, 1992, CIRC RES, V71, P82, DOI 10.1161/01.RES.71.1.82; WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921; WEYRICH AS, 1993, J CLIN INVEST, V91, P2620, DOI 10.1172/JCI116501	41	25	29	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1997	11	14					1271	1279		10.1096/fasebj.11.14.9409546	http://dx.doi.org/10.1096/fasebj.11.14.9409546			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YN210	9409546				2022-12-28	WOS:000071144100008
J	Ames, BN; Gold, LS				Ames, BN; Gold, LS			Environmental pollution, pesticides, and the prevention of cancer: Misconceptions	FASEB JOURNAL			English	Article						synthetic chemical; fruits and vegetables; rodent carcinogen; natural chemical; mutagen; carcinogenesis	LOW-INCOME HOUSEHOLDS; UNITED-STATES; HEMATOLOGICAL FINDINGS; RODENT CARCINOGENS; OXIDATIVE EVENTS; BREAST-CANCER; IRON STATUS; DNA DAMAGE; INJURY; SPERM	The major causes of cancer are: 1) smoking, which accounts for about a third of U.S. cancer and 90% of lung cancer; 2) dietary imbalances: lack of sufficient amounts of dietary fruits and vegetables. The quarter of the population eating the fewest fruits and vegetables has double the cancer rate for most types of cancer than the quarter eating the most; 3) chronic infections, mostly in developing countries; and 4) hormonal factors, influenced primarily by lifestyle. There is no cancer epidemic except for cancer of the lung due to smoking, Cancer mortality rates have declined by 16% since 1950 (excluding lung cancer). Regulatory policy that focuses on traces of synthetic chemicals is based on misconceptions about animal cancer tests. Recent research indicates that rodent carcinogens are not rare. Half of all chemicals tested in standard high-dose animal cancer tests, whether occurring naturally or produced synthetically, are ''carcinogens''; there are high-dose effects in rodent cancer tests that are not relevant to low-dose human exposures and which contribute to the high proportion of chemicals that test positive, The focus of regulatory policy is on synthetic chemicals, although 99.9% of the chemicals humans ingest are natural. More than 1000 chemicals have been described in coffee: 28 have been tested and 19 are rodent carcinogens. Plants in the human diet contain thousands of natural ''pesticides'' produced by plants to protect themselves from insects and other predators: 63 have been tested and 35 are rodent carcinogens. There is no convincing evidence that synthetic chemical pollutants are important as a cause of human cancer. Regulations targeted to eliminate minuscule levels of synthetic chemicals are enormously expensive: the Environmental Protection Agency has estimated that environmental regulations cost society $140 billion/year. Others have estimated that the median toxic control program costs 146 times more per hypothetical life-year saved than the median medical intervention. Attempting to reduce tiny hypothetical risks has other costs as well: if reducing synthetic pesticides makes fruits and vegetables more expensive, thereby decreasing consumption, then the cancer rate will increase, especially for the poor. The prevention of cancer will come from knowledge obtained from biomedical research, education of the public, and lifestyle changes made by individuals. A reexamination of priorities in cancer prevention, both public and private, seems called for.	UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, BERKELEY, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Ames, BN (corresponding author), UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, BARKER HALL MCB BMB, BERKELEY, CA 94720 USA.				NATIONAL CANCER INSTITUTE [R35CA039910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NCI NIH HHS [CA39910] Funding Source: Medline; NIEHS NIH HHS [ESO1896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADACHI Y, 1995, GASTROENTEROLOGY, V108, P218, DOI 10.1016/0016-5085(95)90027-6; AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258; AMES BN, 1993, ENVIRON HEALTH PERSP, V101, P35, DOI 10.2307/3431840; Ames BN, 1996, RISK ANAL, V16, P613, DOI 10.1111/j.1539-6924.1996.tb00810.x; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7772, DOI 10.1073/pnas.87.19.7772; AMES BN, 1987, SCIENCE, V236, P271, DOI 10.1126/science.3563506; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7782, DOI 10.1073/pnas.87.19.7782; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; AMES BN, 1994, REPROD BIOL, P243; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7777, DOI 10.1073/pnas.87.19.7777; Bailar JC, 1997, NEW ENGL J MED, V336, P1569, DOI 10.1056/NEJM199705293362206; BAILEY LB, 1982, AM J CLIN NUTR, V35, P1023, DOI 10.1093/ajcn/35.5.1023; BAILEY LB, 1979, AM J CLIN NUTR, V32, P2346, DOI 10.1093/ajcn/32.11.2346; BLOCK G, 1992, NUTR REV, V50, P207, DOI 10.1111/j.1753-4887.1992.tb01329.x; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BUTTERWORTH BE, 1995, CANCER LETT, V93, P129, DOI 10.1016/0304-3835(95)03794-W; CHRISTEN S, 1997, IN PRESS MICROBES MA; COLBURN T, 1996, OUR STOLEN FUTURE AR; Contrera JF, 1997, REGUL TOXICOL PHARM, V25, P130, DOI 10.1006/rtph.1997.1085; CZAJA MJ, 1994, HEPATOLOGY, V19, P1282, DOI 10.1016/0270-9139(94)90878-8; DAVIES TS, 1995, J AM COLL TOXICOL, V14, P90, DOI 10.3109/10915819509008684; DEVESA SS, 1995, JNCI-J NATL CANCER I, V87, P175, DOI 10.1093/jnci/87.3.175; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; Feigelson HS, 1996, CARCINOGENESIS, V17, P2279, DOI 10.1093/carcin/17.11.2279; Fraga CG, 1996, MUTAT RES-FUND MOL M, V351, P199, DOI 10.1016/0027-5107(95)00251-0; FRAGA CG, 1991, P NATL ACAD SCI USA, V88, P11003, DOI 10.1073/pnas.88.24.11003; Gold L.S., 1997, HDB CARCINOGENIC POT; GOLD LS, 1992, SCIENCE, V258, P261, DOI 10.1126/science.1411524; GOLD LS, 1994, CHEM RISK ASSESSMENT, P91; GOLD LS, 1997, IN PRESS DRUG METAB; GOLD LS, 1997, IN PRESS FOOD CHEM R; GOUGH M, 1990, RISK ANAL, V10, P1, DOI 10.1111/j.1539-6924.1990.tb01011.x; Graham JD, 1995, RISK VS RISK TRADEOF, P2; Gribble GW, 1996, PURE APPL CHEM, V68, P1699, DOI 10.1351/pac199668091699; GUNAWARDHANA L, 1993, TOXICOL APPL PHARM, V119, P205, DOI 10.1006/taap.1993.1061; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; Hahn R, 1996, RISKS COSTS LIVES SA; HART RW, 1995, FUND APPL TOXICOL, V25, P184, DOI 10.1006/faat.1995.1054; HELBOCK HJ, 1997, IN PRESS P NATL ACAD; HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166; Herbert V., 1996, PRESENT KNOWLEDGE NU, V7th ed, pp. 191; Hill M. J, 1994, EPIDEMIOLOGY DIET CA; HUNTER DJ, 1993, EPIDEMIOL REV, V15, P110, DOI 10.1093/oxfordjournals.epirev.a036096; INNES JRM, 1969, JNCI-J NATL CANCER I, V42, P1101; JACOBSON EL, 1993, J AM COLL NUTR, V12, P412, DOI 10.1080/07315724.1993.10718330; KEENEY RL, 1990, RISK ANAL, V10, P147, DOI 10.1111/j.1539-6924.1990.tb01029.x; KOLATA G, 1996, NY TIMES        0504, pE4; KrebsSmith SM, 1995, AM J PUBLIC HEALTH, V85, P1623, DOI 10.2105/AJPH.85.12.1623; KrebsSmith SM, 1996, ARCH PEDIAT ADOL MED, V150, P81, DOI 10.1001/archpedi.1996.02170260085014; LASKIN DL, 1988, HEPATOLOGY, V8, P1051, DOI 10.1002/hep.1840080512; LASKIN DL, 1995, ANNU REV PHARMACOL, V35, P655, DOI 10.1146/annurev.pharmtox.35.1.655; *NAT AC SCI US, 1970, LIF SCI REC PROGR AP; National Cancer Institute, 1996, J NATL CANCER I, V88, P1314; National Research Council, 1996, CARC ANT HUM DIET CO; OMENN GS, 1995, MOL CARCINOGEN, V14, P37, DOI 10.1002/mc.2940140108; PETO R, 1994, MORTALITY SMOKING; Pisani P, 1997, CANCER EPIDEM BIOMAR, V6, P387; REINLI K, 1996, NUTR CANC, V26, P1996; RiceEvans CA, 1997, FREE RADICAL RES, V26, P381, DOI 10.3109/10715769709097818; RIES LAG, 1997, SEER CANC STAT REV 1; Safe SH, 1997, ENVIRON HEALTH PERSP, V105, P675, DOI 10.2307/3433388; SAFE SH, 1995, ENVIRON HEALTH PERSP, V103, P346, DOI 10.2307/3432287; Safe Stephen H., 1994, Environmental Science and Pollution Research International, V1, P29, DOI 10.1007/BF02986921; SENTI FR, 1985, J NUTR, V115, P1398, DOI 10.1093/jn/115.11.1398; SHACTER E, 1988, CARCINOGENESIS, V9, P2297, DOI 10.1093/carcin/9.12.2297; SHACTER E, 1989, CARCINOGENESIS, V10, P628; Steinmetz KA, 1996, J AM DIET ASSOC, V96, P1027, DOI 10.1016/S0002-8223(96)00273-8; SUBAR AF, 1989, AM J CLIN NUTR, V50, P508, DOI 10.1093/ajcn/50.3.508; TENGS TO, 1995, RISK ANAL, V15, P369, DOI 10.1111/j.1539-6924.1995.tb00330.x; Turturro A, 1996, TOXICOL PATHOL, V24, P769, DOI 10.1177/019262339602400621; *US EPA, 1991, ENV INV COST CLEAN E; VISCUSI WK, 1992, FATAL TRADE OFFS; Wallock L., 1997, FASEB Journal, V11, pA184; WEI HC, 1993, CARCINOGENESIS, V14, P1195, DOI 10.1093/carcin/14.6.1195; WEI LH, 1993, CARCINOGENESIS, V14, P841, DOI 10.1093/carcin/14.5.841; WICKRAMASINGHE SN, 1994, BLOOD, V83, P1656; Wildavsky A., 1995, IS IT TRUE CITIZENS; Wildavsky AaronB., 1988, SEARCHING SAFETY; Woodall A. A., 1997, Vitamin C in health and disease., P193; WYROBEK AJ, 1995, AM J HUM GENET, V57, P737; YAMASHINA K, 1986, CANCER RES, V46, P2396; Zeiger E., 1997, HDB CARCINOGENIC POT, P661; ZHANG JZ, 1993, J NUTR, V123, P1349	87	102	106	0	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1997	11	13					1041	1052		10.1096/fasebj.11.13.9367339	http://dx.doi.org/10.1096/fasebj.11.13.9367339			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367339				2022-12-28	WOS:A1997YE98300002
J	Lin, MCM; Li, JJ; Wang, EJ; Princler, GL; Kauffman, FC; Kung, HF				Lin, MCM; Li, JJ; Wang, EJ; Princler, GL; Kauffman, FC; Kung, HF			Ethanol down-regulates the transcription of microsomal triglyceride transfer protein gene	FASEB JOURNAL			English	Article						MTP; gene expression; HepG2; rats	MODERATE ALCOHOL-CONSUMPTION; B-CONTAINING LIPOPROTEINS; CORONARY HEART-DISEASE; APOLIPOPROTEIN-B; HEPG2 CELLS; SECRETION; ABETALIPOPROTEINEMIA; EXPRESSION; RISK; MEN	Microsomal triglyceride transfer protein (MTP) plays a central role in the assembly and secretion of apoB-containing lipoproteins. In this study, we investigated the effect of ethanol on the expression of the large subunit of MTP in a human liver hepatoma cell line, the HepG2 cells, Exposure of HepG2 cells to low concentrations of ethanol reduced MTP mRNA levels in a concentration-and time-dependent manner, The level of MTP mRNA decreased significantly (P < 0.05, -26% relative to pretreatment control) when the concentration of ethanol in the culture medium was 50 ppm (0.005%, v/v), Maximal suppression (-50%) was observed at 100 ppm ethanol; the MTP mRNA levels remained at 50% of control when the ethanol concentration was raised to 10,000 ppm, Furthermore, a 10-day ethanol treatment caused a significant 50% decrease in the MTP activity and apoB secretion rate in HepG2 cells. To investigate the molecular mechanisms underlying this phenomenon, we examined the effect of ethanol on the promoter activity of the MTP gene. Transient transfection analysis of human MTP promoter-driven luciferase gene expression showed that ethanol down-regulates MTP promoter activity in a manner parallel to that observed for mRNA levels, Deletion analysis suggested that the MTP promoter sequence contains a negative ethanol response element -612 to -142 bp upstream of the transcription start site, To evaluate the in vivo relevance of the effect of ethanol on MTP mRNA levels, rats were given a single oral dose of ethanol, with hepatic and intestinal MTP mRNA measured 3 h after dosing, Rats receiving 1 or 3 g/kg of ethanol exhibited substantially lower hepatic and intestinal MTP mRNA levels, Taken together, these results strongly suggest that ethanol can modulate the secretion of apoB-containing lipoproteins by down-regulating the expression of MTP large subunit, primarily through inhibiting the transcription of the MTP gene.	NCI,FREDERICK CANC RES & DEV CTR,LAB BIOCHEM PHYSIOL,NIH,FREDERICK,MD 21702; RUTGERS STATE UNIV,DEPT PHARMACOL & TOXICOL,PISCATAWAY,NJ 08855	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Rutgers State University New Brunswick	Lin, MCM (corresponding author), UNIV MED & DENT NEW JERSEY,SCH OSTEOPATH MED,DEPT CELL BIOL,STRATFORD,NJ 08084, USA.			Li, Jian Jian/0000-0003-3694-9675				BARAONA E, 1979, J LIPID RES, V20, P289; Bartek W, 1996, FASEB J, V10, P4617; BENNETT AJ, 1995, BIOCHEM BIOPH RES CO, V212, P473, DOI 10.1006/bbrc.1995.1994; BRETT DJ, 1995, BIOCHEM J, V310, P11, DOI 10.1042/bj3100011; CASTELLI WP, 1977, LANCET, V2, P153; CONTALDO F, 1989, METABOLISM, V38, P166, DOI 10.1016/0026-0495(89)90257-6; CRIQUI MH, 1987, EUR HEART J, V8, P19, DOI 10.1093/eurheartj/8.suppl_B.19; Dashti N, 1996, J LIPID RES, V37, P810; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; HAGAN DL, 1994, J BIOL CHEM, V269, P28737; HOJNACKI JL, 1994, NUTR RES, V14, P1241, DOI 10.1016/S0271-5317(05)80250-7; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; Kuske T, 1996, FASEB J, V10, P4615; LANGER RD, 1992, CIRCULATION, V85, P910, DOI 10.1161/01.CIR.85.3.910; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; LIEBER CS, 1984, ALCOHOL CLIN EXP RES, V8, P409, DOI 10.1111/j.1530-0277.1984.tb05689.x; Liesen T, 1996, MOL MICROBIOL, V21, P621, DOI 10.1111/j.1365-2958.1996.tb02570.x; LIN MCM, 1994, J BIOL CHEM, V269, P29138; LIN MCM, 1995, J LIPID RES, V36, P1073; NEUMAN MG, 1993, BIOCHEM BIOPH RES CO, V197, P932, DOI 10.1006/bbrc.1993.2569; PATEL SB, 1994, CIRCULATION, V90, P1186; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHARP D, 1994, BIOCHEMISTRY-US, V33, P9057, DOI 10.1021/bi00197a005; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; VALIMAKI M, 1988, EUR J CLIN INVEST, V18, P472, DOI 10.1111/j.1365-2362.1988.tb01042.x; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3	35	32	32	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1997	11	13					1145	1152		10.1096/fasebj.11.13.9367349	http://dx.doi.org/10.1096/fasebj.11.13.9367349			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367349				2022-12-28	WOS:A1997YE98300012
J	Ehrhart, EJ; Segarini, P; Tsang, MLS; Carroll, AG; BarcellosHoff, MH				Ehrhart, EJ; Segarini, P; Tsang, MLS; Carroll, AG; BarcellosHoff, MH			Latent transforming growth factor beta 1 activation in situ: quantitative and functional evidence after low-dose gamma-irradiation	FASEB JOURNAL			English	Article						ionizing radiation; reactive oxygen species; mammary gland; extracellular matrix; collagen; gene expression	MOLECULAR-WEIGHT COMPLEX; MATRIX GENE-EXPRESSION; MOUSE MAMMARY-GLAND; TGF-BETA; EXTRACELLULAR-MATRIX; IONIZING-RADIATION; PLASMINOGEN-ACTIVATOR; PULMONARY FIBROSIS; COLLAGEN-SYNTHESIS; BINDING-PROTEIN	The biological activity of transforming growth factor beta 1 (TCF-beta) is controlled by its secretion as a latent complex in which it is noncovalently associated with latency-associated peptide (LAP). Activation is the extracellular process in which TGF-beta is released from LAP, and is considered to be a primary regulatory control, We recently reported rapid and persistent changes in TGF-beta immunoreactivity in conjunction with extracellular matrix remodeling in gamma-irradiated mouse mammary gland, Our hypothesis is that these specific changes in immunoreactivity are indicative of latent TGF-beta activation, In the present study, we determined the radiation dose response and tested whether a functional relationship exists between radiation-induced TGF-beta and collagen type III remodeling, After radiation exposures as low as 0.1 Gy, we detected increased TGF-beta immunoreactivity in the mammary epithelium concomitant with decreased LAP immunostaining, which are events consistent with activation, Quantitative image analysis demonstrated a significant (P=0.0005) response at 0.1 Gy without an apparent threshold and a linear dose response to 5 Gy, However, in the adipose stroma, loss of LAP demonstrated a qualitative threshold at 0.5 Gy, Loss of LAP paralleled induction of collagen III immunoreactivity in this tissue compartment, We tested whether TGF-beta mediates collagen III expression by treating animals with TGF-beta panspecific monoclonal antibody, 1D11.16, administered i.p. shortly before irradiation, Radiation-induced collagen III staining in the adipose stroma was blocked in an antibody dose-dependent manner, which persisted through 7 days postirradiation, RNase protection assay revealed that radiation-induced elevation of total gland collagen III mRNA was also blocked by neutralizing antibody treatment, These data provide functional confirmation of the hypothesis that radiation exposure leads to latent TGF-beta activation, support our interpretation of the reciprocal shift in immunoreactivity as evidence of activation, and implicate TGF-beta as a mediator of tissue response to ionizing radiation, The sensitivity of activation to low radiation doses points to a potential role for TGF-beta in orchestrating tissue response to oxidative stress, As such, radiation may be useful as a probe to delineate the consequences of latent TGF-beta 1 activation in situ.	UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV LIFE SCI, BERKELEY, CA 94720 USA; COLORADO STATE UNIV, FT COLLINS, CO 80523 USA; CELTRIX PHARMACEUT INC, SANTA CLARA, CA 95050 USA; R&D SYST INC, MINNEAPOLIS, MN 55413 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Colorado State University								ANSCHER MS, 1990, RADIAT RES, V122, P77, DOI 10.2307/3577586; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; BAHADORI L, 1995, AM J PATHOL, V146, P1140; Barcellos-Hoff MH, 1996, J MAMMARY GLAND BIOL, V1, P353, DOI 10.1007/BF02017391; BARCELLOSHOFF MH, 1994, J CLIN INVEST, V93, P892, DOI 10.1172/JCI117045; BARCELLOSHOFF MH, 1993, CANCER RES, V53, P3880; BarcellosHoff MH, 1996, MOL ENDOCRINOL, V10, P1077, DOI 10.1210/me.10.9.1077; BARCELLOSHOFF MH, 1995, AM J PATHOL, V147, P1228; BOOTHMAN DA, 1991, CANCER RES, V51, P5587; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; Brownh PD, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037500; CANNEY PA, 1990, BRIT J RADIOL, V63, P620, DOI 10.1259/0007-1285-63-752-620; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CREELY JJ, 1992, AM J PATHOL, V140, P45; DALLAS SL, 1995, J CELL BIOL, V131, P539, DOI 10.1083/jcb.131.2.539; DASCH JR, 1989, J IMMUNOL, V142, P1536; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DIMARI SJ, 1991, AM J RESP CELL MOL, V4, P455, DOI 10.1165/ajrcmb/4.5.455; Ehrhart EJ, 1996, RADIAT RES, V145, P157, DOI 10.2307/3579170; FLANDERS KC, 1989, J CELL BIOL, V108, P653, DOI 10.1083/jcb.108.2.653; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; FLAUMENHAFT R, 1992, MOL BIOL CELL, V3, P1057, DOI 10.1091/mbc.3.10.1057; FLAUMENHAFT R, 1992, J CELL BIOL, V118, P901, DOI 10.1083/jcb.118.4.901; Franko AJ, 1997, RADIAT RES, V147, P245, DOI 10.2307/3579426; FREEMAN BA, 1982, LAB INVEST, V47, P412; FUKUNAGA N, 1992, INT J RADIAT ONCOL, V24, P949, DOI 10.1016/0360-3016(92)90479-2; GROTENDORST GR, 1989, J CELL PHYSIOL, V140, P396, DOI 10.1002/jcp.1041400226; HAINAUT P, 1993, CANCER RES, V53, P4469; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HOYT DG, 1988, J PHARMACOL EXP THER, V246, P765; KENNEY NJ, 1995, MOL REPROD DEV, V41, P277, DOI 10.1002/mrd.1080410302; KHALIL N, 1991, AM J RESP CELL MOL, V5, P155, DOI 10.1165/ajrcmb/5.2.155; LAIHO M, 1992, Critical Reviews in Oncogenesis, V3, P1; MAASILTA P, 1991, INT J RADIAT ONCOL, V20, P973, DOI 10.1016/0360-3016(91)90193-8; MARTIN M, 1993, RADIAT RES, V134, P63, DOI 10.2307/3578502; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; METSARANTA M, 1989, BIOCHIM BIOPHYS ACTA, P241; MIYAZONO K, 1993, GROWTH FACTORS, V8, P11, DOI 10.3109/08977199309029130; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; NUNES I, 1995, J IMMUNOL, V155, P1450; PANIZZON RG, 1988, RADIAT RES, V116, P145, DOI 10.2307/3577485; PIERCE DF, 1993, GENE DEV, V7, P2308, DOI 10.1101/gad.7.12a.2308; PIRCHER R, 1986, BIOCHEM BIOPH RES CO, V136, P30, DOI 10.1016/0006-291X(86)90872-7; RAGHU G, 1989, AM REV RESPIR DIS, V140, P95, DOI 10.1164/ajrccm/140.1.95; REISS M, 1997, IN PRESS BR CANC RES; RHOADS DD, 1986, MOL CELL BIOL, V6, P2774, DOI 10.1128/MCB.6.8.2774; RILEY PA, 1994, INT J RADIAT BIOL, V65, P27, DOI 10.1080/09553009414550041; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; SHENKAR R, 1994, AM J RESP CELL MOL, V11, P351, DOI 10.1165/ajrcmb.11.3.8086171; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TSAO CH, 1985, RADIAT RES, V103, P393, DOI 10.2307/3576761; VOLLBERG TM, 1991, EXP CELL RES, V193, P93, DOI 10.1016/0014-4827(91)90542-3; WAHL SM, 1994, J EXP MED, V180, P1587, DOI 10.1084/jem.180.5.1587; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646; WESTERGRENTHORSSON G, 1990, EXP CELL RES, V186, P192, DOI 10.1016/0014-4827(90)90227-2; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	64	191	196	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1997	11	12					991	1002		10.1096/fasebj.11.12.9337152	http://dx.doi.org/10.1096/fasebj.11.12.9337152			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YA724	9337152				2022-12-28	WOS:A1997YA72400009
J	RungeMorris, MA				RungeMorris, MA			Sulfation and sulfotransferases .2. Regulation of expression of the rodent cytosolic sulfotransferases	FASEB JOURNAL			English	Review						gene expression; NIDDM; growth hormone; androgen; cytochrome P450	HEPATIC CORTISOL SULFOTRANSFERASE; PROTEIN-KINASE-C; RAT-LIVER; ESTROGEN SULFOTRANSFERASE; ARYL SULFOTRANSFERASE; GENE-EXPRESSION; ENZYMATIC SULFATION; MESSENGER-RNA; STEROID SULFOTRANSFERASES; GUINEA-PIG	Understanding the molecular regulation of the sulfotransferases is important because these enzymes are essential to a number of critical biological processes, Sulfotransferase expression clearly plays a role in xenobiotic detoxication, carcinogen activation, prodrug processing, cellular signaling pathways, and the regulation of intratissue active androgen and estrogen levels, Although cytosolic sulfotransferases are present in the gut, adrenal, kidney, lung, skin, brain, and other extrahepatic tissues, the basis for the molecular regulation of this complicated gene family has been best characterized in the rat liver, where sulfotransferase levels are relatively abundant, Advances in genomic cloning and in the molecular characterization of individual sulfotransferase cDNAs have inspired new insights into the mechanisms involved in sulfotransferase gene regulation. In particular, the hypothalamic-pituitary-gonadal-adrenocortical axis appears to play a significant role in the regulation of individual sulfotransferase genes, The molecular signals that fluctuate with developmental age, gender, and the occurrence of systemic endocrinopathies also influence sulfotransferase gene expression, For example, diabetes, which disrupts glucose and ketone homeo-stasis, insulin sensitivity, gonadal and neuroendocrine hormone balance, protein kinase C isoform expression, and P450 metabolism, also disturbs hepatic sulfotransferase gene expression, What role does sulfotransferase expression play in target organ toxicity? Do xenobiotic-mediated changes in sulfotransferase expression compromise detoxication? Does deregulated sulfotransferase expression during development lead to birth defects by perturbing the delicate balance of active hormone levels in fetal tissues? Do conditions of glucocorticoid excess, such as stress or high-dose glucocorticoid therapy induce sulfotransferase expression and place toxicant and carcinogen bioactivation systems in overdrive? This review will summarize our current understanding of the molecular and cellular regulation of the major rodent cytosolic sulfotransferases, Only by thoroughly dissecting the regulation of this important multigene family in rodent Liver, where sulfotransferase expression is most abundant, can we begin to focus ore more pressing questions concerning the role of the sulfotransferases in the genesis of endocrinopathies and cancer in humans.			RungeMorris, MA (corresponding author), WAYNE STATE UNIV,INST CHEM TOXICOL,2727 2ND AVE,DETROIT,MI 48201, USA.				NIEHS NIH HHS [ES06639, ES05823] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES005823, P30ES006639, R01ES005823] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALKHALAF M, 1989, J ENDOCRINOL, V122, P439, DOI 10.1677/joe.0.1220439; BARNETT CR, 1993, BIOCHEM PHARMACOL, V45, P313, DOI 10.1016/0006-2952(93)90066-6; BECKMANN JD, 1994, J CELL PHYSIOL, V160, P603, DOI 10.1002/jcp.1041600324; BORTHWICK EB, 1995, J STEROID BIOCHEM, V55, P255, DOI 10.1016/0960-0760(95)00173-W; BUHL AE, 1990, J INVEST DERMATOL, V95, P553, DOI 10.1111/1523-1747.ep12504905; CHATTERJEE B, 1994, CHEM-BIOL INTERACT, V92, P273, DOI 10.1016/0009-2797(94)90069-8; Chatterjee B, 1996, P NATL ACAD SCI USA, V93, P728, DOI 10.1073/pnas.93.2.728; CHATTERJEE B, 1989, FASEB J, V3, P169, DOI 10.1096/fasebj.3.2.2464518; CHEN C, 1995, DRUG METAB DISPOS, V23, P1346; CHIDA K, 1995, CANCER RES, V55, P4865; COUGHTRIE MWH, 1990, BIOCHEM PHARMACOL, V40, P2180, DOI 10.1016/0006-2952(90)90252-G; DAVIES MH, 1994, J HEPATOL, V21, P1127, DOI 10.1016/S0168-8278(05)80630-0; DEMYAN WF, 1992, MOL ENDOCRINOL, V6, P589, DOI 10.1210/me.6.4.589; DRISCOLL WJ, 1993, J BIOL CHEM, V268, P23496; DUFFEL MW, 1991, MOL PHARMACOL, V40, P36; FALANY CN, 1991, TRENDS PHARMACOL SCI, V12, P255, DOI 10.1016/0165-6147(91)90566-B; FAUSTMAN DL, 1993, BIOMED PHARMACOTHER, V47, P3, DOI 10.1016/0753-3322(93)90030-O; GILGOMEZ G, 1993, EUR J BIOCHEM, V213, P773, DOI 10.1111/j.1432-1033.1993.tb17819.x; GILISSEN RAHJ, 1992, LIFE SCI, V51, P1255, DOI 10.1016/0024-3205(92)90014-G; GILL AM, 1994, DIABETES, V43, P999, DOI 10.2337/diabetes.43.8.999; GONZALEZ FJ, 1984, MOL PHARMACOL, V26, P117; HOBKIRK R, 1993, TRENDS ENDOCRIN MET, V4, P69, DOI 10.1016/S1043-2760(05)80018-9; HOMMA H, 1992, BIOCHEM BIOPH RES CO, V183, P872, DOI 10.1016/0006-291X(92)90564-2; ISRAEL DI, 1984, J BIOL CHEM, V259, P5400; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, P199; KAHN BB, 1990, J CLIN INVEST, V84, P401; KIRKPATRICK RB, 1984, AM J PHYSIOL, V247, pG226, DOI 10.1152/ajpgi.1984.247.3.G226; KRAKOWER GR, 1993, AM J PHYSIOL, V264, pE342, DOI 10.1152/ajpendo.1993.264.3.E342; KWON NS, 1994, FASEB J, V8, P529, DOI 10.1096/fasebj.8.8.8181671; LABRIE Y, 1994, ENDOCRINOLOGY, V134, P1693, DOI 10.1210/en.134.4.1693; LEITER EH, 1993, CRIT REV FOOD SCI, V33, P333, DOI 10.1080/10408399309527629; LEITER EH, 1994, J CLIN INVEST, V93, P2007, DOI 10.1172/JCI117194; LEITER EH, 1991, DIABETES, V40, P1360, DOI 10.2337/diabetes.40.10.1360; LEITER EH, 1989, ENDOCRINOLOGY, V124, P912, DOI 10.1210/endo-124-2-912; MCCALL JM, 1983, J MED CHEM, V26, P1791, DOI 10.1021/jm00366a030; NASH AR, 1988, AUST J BIOL SCI, V41, P507; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OGURA K, 1990, MOL PHARMACOL, V37, P848; OHL VS, 1977, ARCH BIOCHEM BIOPHYS, V180, P186, DOI 10.1016/0003-9861(77)90024-8; OZAWA S, 1990, NUCLEIC ACIDS RES, V18, P4001, DOI 10.1093/nar/18.13.4001; PAUL SM, 1992, FASEB J, V6, P2311, DOI 10.1096/fasebj.6.6.1347506; QUATTROCHI LC, 1995, J BIOL CHEM, V270, P28917, DOI 10.1074/jbc.270.48.28917; RINGER DP, 1994, CHEM-BIOL INTERACT, V92, P343, DOI 10.1016/0009-2797(94)90075-2; ROY AK, 1992, P SOC EXP BIOL MED, V199, P265; RUNGEMORRIS M, 1995, DRUG METAB DISPOS, V23, P455; RUNGEMORRIS M, 1994, TOXICOL APPL PHARM, V125, P133, DOI 10.1006/taap.1994.1057; RUNGEMORRIS M, 1994, FASEB J, V8, pA1251; RUNGEMORRIS M, 1991, BIOCHEM BIOPH RES CO, V175, P1051, DOI 10.1016/0006-291X(91)91671-X; RUNGEMORRIS M, 1996, IN PRESS DRUG METAB; RUNGEMORRIS MA, 1994, CHEM-BIOL INTERACT, V92, P67, DOI 10.1016/0009-2797(94)90054-X; Safe S, 1995, Arch Toxicol Suppl, V17, P99; SCHAUSS SJ, 1995, BIOCHEM J, V311, P209, DOI 10.1042/bj3110209; SCHUETZ EG, 1984, J BIOL CHEM, V259, P2007; SHINOMIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P1346, DOI 10.1073/pnas.81.5.1346; SINGER SS, 1976, ENDOCRINOLOGY, V99, P1346, DOI 10.1210/endo-99-5-1346; SINGER SS, 1976, ENDOCRINOLOGY, V98, P963, DOI 10.1210/endo-98-4-963; SINGER SS, 1978, ENDOCRINOLOGY, V103, P66, DOI 10.1210/endo-103-1-66; SINGER SS, 1978, EXP GERONTOL, V13, P425, DOI 10.1016/0531-5565(78)90053-0; SONG CS, 1990, BIOCHEMISTRY-US, V29, P542, DOI 10.1021/bi00454a031; SONG CS, 1991, ENDOCRINOLOGY, V128, P349, DOI 10.1210/endo-128-1-349; SONG WC, 1995, ENDOCRINOLOGY, V136, P2477, DOI 10.1210/en.136.6.2477; SURH YJ, 1989, CARCINOGENESIS, V10, P1519, DOI 10.1093/carcin/10.8.1519; TANG EY, 1993, FEBS LETT, V326, P117, DOI 10.1016/0014-5793(93)81774-T; Tosh D, 1996, BIOCHEM PHARMACOL, V51, P369, DOI 10.1016/0006-2952(95)02163-9; URABE M, 1993, STEROIDS, V58, P209, DOI 10.1016/0039-128X(93)90020-N; Waxman David J., 1995, P391; WERLESCHNEIDER G, 1993, CARCINOGENESIS, V14, P2267, DOI 10.1093/carcin/14.11.2267; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; YAMAZOE Y, 1994, CHEM-BIOL INTERACT, V92, P107, DOI 10.1016/0009-2797(94)90057-4; YAMAZOE Y, 1989, MOL PHARMACOL, V35, P707; YEROKUN T, 1992, CANCER RES, V52, P4779; YEROKUN T, 1994, CHEM-BIOL INTERACT, V92, P363, DOI 10.1016/0009-2797(94)90077-9; YEROKUN T, 1991, CANCER RES, V51, P504	73	34	35	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1997	11	2					109	117		10.1096/fasebj.11.2.9039952	http://dx.doi.org/10.1096/fasebj.11.2.9039952			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK509	9039952				2022-12-28	WOS:A1997WK50900002
J	Roenneberg, T; Rehman, J				Roenneberg, T; Rehman, J			Nitrate, a nonphotic signal for the circadian system	FASEB JOURNAL			English	Article						dinoflagellates; nitrate metabolism; circadian rhythms; multioscillator model; algal blooms	GONYAULAX-POLYEDRA; ACTIVITY RHYTHMS; PHASE RESPONSES; HOUSE SPARROWS; CLOCK; LIGHT; FREQUENCY; PERIOD; AUTOREGULATION; OSCILLATORS	Recent advances in circadian biology have brought insights into the molecular mechanisms involved in the generation of circadian rhythmicity. However, Little is known about the relationship between these molecular oscillators and the organism's temporal adaptation to complex daily environmental changes. We have studied the effects of nutrients on the circadian system of a marine unicellular alga and found that nitrate influences all three canonical properties of circadian rhythmicity: amplitude, phase, and period. The effects of nitrate are part of a complex feedback loop involving both circadian input and output. These new aspects of circadian nutrient metabolism have important implications for our understanding of the ecological significance of circadian programs.			Roenneberg, T (corresponding author), UNIV MUNICH,INST MED PSYCHOL,D-80336 MUNICH,GERMANY.		Rehman, Jalees/J-8258-2012; Rehman, Jalees/B-8064-2009; Rehman, Jalees/GVU-1981-2022	Rehman, Jalees/0000-0002-2787-9292; Rehman, Jalees/0000-0002-2787-9292				ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; ASCHOFF J, 1987, COMP ASPECTS CIRCADI, P19; Broda H., 1986, Journal of Biological Rhythms, V1, P251, DOI 10.1177/074873048600100307; BYRNE TE, 1992, PLANT PHYSIOL, V98, P879, DOI 10.1104/pp.98.3.879; CHABOT CC, 1992, J BIOL RHYTHM, V7, P287, DOI 10.1177/074873049200700403; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; DAAN S, 1984, J COMP PHYSIOL A, V154, P669; EBIHARA S, 1992, J COMP PHYSIOL A, V171, P63; EPPLEY RW, 1968, J PHYCOL, V4, P333, DOI 10.1111/j.1529-8817.1968.tb04704.x; FLEISSNER G, 1996, IN PRESS SCORPION BI; GUILLARD RR, 1962, CAN J MICROBIOL, V8, P229, DOI 10.1139/m62-029; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; HARRISON PJ, 1979, J EXP MAR BIOL ECOL, V21, P199; HASTINGS JW, 1961, J GEN PHYSIOL, V45, P69, DOI 10.1085/jgp.45.1.69; HASTINGS JW, 1958, BIOL BULL, V115, P440, DOI 10.2307/1539108; HASTINGS JW, 1964, PHOTOPHYSIOLOGY, P333; HAU M, 1992, J COMP PHYSIOL A, V170, P403; JILGE B, 1991, PHYSIOL BEHAV, V51, P157; JOHNSON CH, 1989, J BIOL RHYTHM, V4, P417, DOI 10.1177/074873048900400403; KENNEDY GA, 1991, AM J PHYSIOL, V261, pR819, DOI 10.1152/ajpregu.1991.261.4.R819; Kleinhofs A., 1990, BIOCH PLANTS, P89, DOI [DOI 10.1016/B978-0-08-092616-2.50009-7, 10.1016/B978-0-08-092616-2.50009-7]; MORSE D, 1994, J BIOL RHYTHM, V9, P263, DOI 10.1177/074873049400900307; MROSOVSKY N, 1992, J BIOL RHYTHM, V7, P41, DOI 10.1177/074873049200700104; PILGRIM ML, 1993, PLANT MOL BIOL, V23, P349, DOI 10.1007/BF00029010; RAMALHO CB, 1995, PLANT PHYSIOL, V107, P225, DOI 10.1104/pp.107.1.225; ROENNEBERG T, 1989, J BIOL RHYTHM, V4, P201, DOI 10.1177/074873048900400208; ROENNEBERG T, 1991, PHOTOCHEM PHOTOBIOL, V53, P525, DOI 10.1111/j.1751-1097.1991.tb03665.x; ROENNEBERG T, 1988, NATURWISSENSCHAFTEN, V75, P206, DOI 10.1007/BF00735584; ROENNEBERG T, 1993, NATURE, V362, P362, DOI 10.1038/362362a0; ROENNEBERG T, 1994, J BIOL RHYTHM, V9, P1, DOI 10.1177/074873049400900101; ROENNEBERG T, 1994, NATURWISSENSCHAFTEN, V81, P343; ROENNEBERG T, 1992, OSCILLATIONS MORPHOG, P399; Roenneberg T, 1994, EVOLUTION CIRCADIAN, P3; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; STEPHAN FK, 1992, PHYSIOL BEHAV, V52, P997, DOI 10.1016/0031-9384(92)90382-C; STEPHAN FK, 1992, PHYSIOL BEHAV, V52, P985, DOI 10.1016/0031-9384(92)90381-B; SWEENEY BM, 1984, PLANT PHYSIOL, V75, P242, DOI 10.1104/pp.75.1.242; VANREETH O, 1994, AM J PHYSIOL, V266, pE964, DOI 10.1152/ajpendo.1994.266.6.E964; WEAVER DR, 1989, DEV BRAIN RES, V46, P291, DOI 10.1016/0165-3806(89)90292-7	39	45	45	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1996	10	12					1443	1447		10.1096/fasebj.10.12.8903515	http://dx.doi.org/10.1096/fasebj.10.12.8903515			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VP485	8903515				2022-12-28	WOS:A1996VP48500010
J	Ferre, T; Riu, E; Bosch, F; Valera, A				Ferre, T; Riu, E; Bosch, F; Valera, A			Evidence from transgenic mice that glucokinase is rate limiting for glucose utilization in the liver	FASEB JOURNAL			English	Article						P-enolpyruvate carboxykinase gene promoter; bu glycolysis	PYRUVATE-KINASE GENE; CARBOHYDRATE RESPONSE ELEMENT; DEPENDENT DIABETES-MELLITUS; TRANSCRIPTIONAL CONTROL; MAMMALIAN GLUCOKINASE; ADIPOSE-TISSUE; CYCLIC-AMP; INSULIN; EXPRESSION; DEFINITION	To study the role of glucokinase (GK) in the control of glucose metabolism in the liver, transgenic mice were generated in which GK was overexpressed under control of the P-enolpyruvate carboxykinase gene promoter, Whereas the expression of the GK gene in starved control mice was blocked, this promoter was able to direct the expression of the enzyme to the liver of starved transgenic mice, Furthermore, starved transgenic mice showed levels of GK activity fourfold higher than those of starved control and similar to those of fed control, This activation of GEC led to an increase in the intracellular concentration. of glucose 6-phosphate, which was also related ito an induction of glycogen accumulation, In addition, L-pyruvate kinase (L-PK) activity increased in transgenic mice, which when starved showed similar levels of activity to control fed mice, The induction of L-PK caused an increase in the hepatic lactate concentration, Furthermore, hepatocytes in primary culture from transgenic mice incubated with 20 mM glucose produced levels of lactate threefold higher than controls, but no difference was noted when the hepatocytes from control and transgenic mice were incubated with 2 mM glucose. These results demonstrated in vivo that the activation of GK is a rate-limiting step in the induction of glycolysis and glycogen synthesis. These changes in liver glucose metabolism led to a marked reduction in blood glucose (30%) and insulin (40%) concentrations. Furthermore, transgenic mice showed lower levels of blood glucose after an intraperitoneal glucose tolerance test, indicating that GK overexpression caused an increase in blood glucose disposal by the Liver, All these findings show the key role of liver GK in the control of whole-body glucose homeostasis.	UNIV AUTONOMA BARCELONA, FAC VET, DEPT BIOQUIM & BIOL MOL, BELLATERRA 08193, SPAIN; UNIV AUTONOMA BARCELONA, FAC VET, SERV BIOTECNOL ANIM, BELLATERRA 08193, SPAIN	Autonomous University of Barcelona; Autonomous University of Barcelona				BOSCH, FATIMA/0000-0002-7705-5515; Ferre, Tura/0000-0001-9713-0829; Riu, Efren/0000-0002-2574-3578				BALI D, 1995, J BIOL CHEM, V270, P21464, DOI 10.1074/jbc.270.37.21464; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIDSON AL, 1987, ARCH BIOCHEM BIOPHYS, V253, P156, DOI 10.1016/0003-9861(87)90648-5; DOIRON B, 1994, J BIOL CHEM, V269, P10213; EFRAT S, 1994, P NATL ACAD SCI USA, V91, P2051, DOI 10.1073/pnas.91.6.2051; FELIU JE, 1977, EUR J BIOCHEM, V81, P609, DOI 10.1111/j.1432-1033.1977.tb11988.x; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; GIRARD J, 1994, FASEB J, V8, P36, DOI 10.1096/fasebj.8.1.7905448; HOGAN B, 1986, MANIPULATING MOUSE E; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; Keppler D., 1984, METHOD ENZYMAT AN, V6, P11; LARNER J, 1990, ADV ENZYMOL RAMB, V63, P173; LECAM A, 1976, EXP CELL RES, V98, P382, DOI 10.1016/0014-4827(76)90448-1; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; LEMAIGRE FP, 1994, BIOCHEM J, V303, P1; LIU ML, 1993, P NATL ACAD SCI USA, V90, P11346, DOI 10.1073/pnas.90.23.11346; MARSHALL BA, 1993, J BIOL CHEM, V268, P18442; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MICHAL G, 1981, METHOD ENZYMAT AN, V6, P185; MUNNICH A, 1987, J BIOL CHEM, V262, P17065; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; PRINTZ RL, 1993, ANNU REV NUTR, V13, P463, DOI 10.1146/annurev.nu.13.070193.002335; ROTHMAN DL, 1992, J CLIN INVEST, V89, P1069, DOI 10.1172/JCI115686; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SHIH HM, 1992, J BIOL CHEM, V267, P13222; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; VALERA A, 1995, FASEB J, V9, P1067, DOI 10.1096/fasebj.9.11.7649406; VALERA A, 1994, FASEB J, V8, P440, DOI 10.1096/fasebj.8.6.8168695; VALERA A, 1994, EUR J BIOCHEM, V222, P533, DOI 10.1111/j.1432-1033.1994.tb18895.x; VALERA A, 1994, P NATL ACAD SCI USA, V91, P9151, DOI 10.1073/pnas.91.19.9151; VANSCHAFTINGEN E, 1994, FASEB J, V8, P414, DOI 10.1096/fasebj.8.6.8168691; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0	35	162	179	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1996	10	10					1213	1218		10.1096/fasebj.10.10.8751724	http://dx.doi.org/10.1096/fasebj.10.10.8751724			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VD429	8751724				2022-12-28	WOS:A1996VD42900013
J	Jing, YK; Zhang, J; Bleiweiss, IJ; Waxman, S; Zelent, A; MiraYLopez, R				Jing, YK; Zhang, J; Bleiweiss, IJ; Waxman, S; Zelent, A; MiraYLopez, R			Defective expression of cellular retinol binding protein type I and retinoic acid receptors alpha 2, beta 2, and gamma 2 in human breast cancer cells	FASEB JOURNAL			English	Article						RXR; breast cancer	MAMMARY EPITHELIAL-CELLS; HUMAN LUNG-CANCER; RESPONSE ELEMENT; GROWTH-INHIBITION; LINES; GENE; ABNORMALITIES; SENSITIVITY; METABOLISM; ISOFORMS	Because the retinoic acid (RA) signaling pathway regulates cell proliferation and differentiation, inactivation of genes integral to the pathway represents a potential mechanism of carcinogenesis. We have studied in human breast cancer cells (T47D, MCF-7, ZR75-1, MDA-MB-231, and BT20) the expression of a subset of retinoid signaling genes that are themselves transcriptionally up-regulated by RA, the cellular retinol binding protein type I (CRBPI) and the RA receptors (RARs) alpha 2, beta 2, and gamma 2. We find that constitutive expression of these genes is low or undetectable, and that expression levels are seldom responsive to 24 h treatment with 1 mu M all-trans or 9-cis RA (Northern blot analysis). This is in contrast to breast fibroblasts, which show RA-dependent expression of all four genes under the same conditions. Moreover, normal human breast epithelial cells express CRBPI and RAR beta 2 at the mRNA level, suggesting that loss of expression of these genes is tied to malignant transformation. RAR beta 2, but not CRBPI, was also expressed in RA-treated MTSV1-7 cells, an immortalized but nontumorigenic luminal epithelial cell Line. Lack of CRBPI and RAR beta 2 expression in cancer cells was not due to general impairment of RA signaling, as shown by RA activation of a RARE(3)-tk-CAT reporter in a subclone of MDA-MB-231 cells that did not express either CRBPI or RAR beta 2. These results suggest that at least two independent defects in the expression of proteins that function in retinoid signaling may be involved in breast carcinogenesis.	MT SINAI MED CTR,DEPT MED,NEW YORK,NY 10029; MT SINAI MED CTR,DEPT PATHOL,NEW YORK,NY 10029; INST CANC RES,CHESTER BEATTY LABS,LEUKAEMIA RES FUND CTR,LONDON SW3 6JB,ENGLAND	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			Zelent, Arthur/B-3532-2009	Zelent, Arthur/0000-0002-7968-9888	NCI NIH HHS [R29 CA54273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA054273] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; ESKILD W, 1991, BIOL REPROD, V44, P55; GEBERT JF, 1991, ONCOGENE, V6, P1859; Gudas Lorraine J., 1994, P443; HU L, 1991, CANCER RES, V51, P3972; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KRUYT FAE, 1991, MECH DEVELOP, V33, P171, DOI 10.1016/0925-4773(91)90025-2; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LEVIN MS, 1993, J BIOL CHEM, V268, P8267; LISSOOS TW, 1995, AM J PHYSIOL-GASTR L, V268, pG224, DOI 10.1152/ajpgi.1995.268.2.G224; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; MADER S, 1993, J BIOL CHEM, V268, P591; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; MOGHAL N, 1995, MOL CELL BIOL, V17, P3945; NAPOLI JL, 1993, J NUTR, V123, P362, DOI 10.1093/jn/123.suppl_2.362; NILSSON MHL, 1988, EUR J BIOCHEM, V173, P35, DOI 10.1111/j.1432-1033.1988.tb13963.x; Ong David E., 1994, P283; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; ROMAN SD, 1992, CANCER RES, V52, P2236; Sambrook J., 2002, MOL CLONING LAB MANU; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STAMPFER M, 1980, IN VITRO CELL DEV B, V16, P415; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403; VALCARCEL R, 1994, GENE DEV, V8, P3068, DOI 10.1101/gad.8.24.3068; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; VANDERLEEDE BJM, 1995, MOL CELL ENDOCRINOL, V109, P77, DOI 10.1016/0303-7207(95)03487-R; VANDERLEEDE BJM, 1995, INT J ONCOL, V6, P391; WAN YJY, 1995, EXP CELL RES, V219, P392, DOI 10.1006/excr.1995.1244; XIAO JH, 1995, J BIOL CHEM, V270, P3001, DOI 10.1074/jbc.270.7.3001; XU XC, 1994, CANCER RES, V54, P3580; ZELENT A, 1994, BRIT J HAEMATOL, V86, P451, DOI 10.1111/j.1365-2141.1994.tb04773.x; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZHANG XK, 1994, CANCER RES, V54, P5663	46	33	34	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1996	10	9					1064	1070		10.1096/fasebj.10.9.8801168	http://dx.doi.org/10.1096/fasebj.10.9.8801168			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801168				2022-12-28	WOS:A1996UY93200017
J	Albright, CD; Liu, R; Bethea, TC; DaCosta, KA; Salganik, RI; Zeisel, SH				Albright, CD; Liu, R; Bethea, TC; DaCosta, KA; Salganik, RI; Zeisel, SH			Choline deficiency induces apoptosis in SV40-immortalized CWSV-1 rat hepatocytes in culture	FASEB JOURNAL			English	Article						p53; hepatocytes; PCNA expression; cell proliferation	TRANSFORMING GROWTH FACTOR-BETA-1; CELL NUCLEAR ANTIGEN; DEVOID DIET; SIMIAN VIRUS-40; T-ANTIGEN; LIVER; DNA; DEATH; INDUCTION; INVITRO	Immortalized CWSV-1 rat hepatocytes, in which p53 protein is inactivated by SV40 large T antigen, had increased numbers of cells with strand breaks in genomic DNA (terminal dUTP end labeling) when grown in 0 mu M choline (67-73% of cells) than when grown in 70 mu M choline (2-3% of cells). Internucleosomal fragmentation of DNA (DNA ladders) was detected in cells grown with 5 mu M and 0 mu M choline for 72 h, Cells treated with 8 or 5 mu M choline for 72 h detached from the substrate in high numbers (58% of choline deficient cells vs, 1.4% of choline sufficient cells detached) exhibited a high incidence of apoptosis (apoptotic bodies were seen in 55-75% of cells; 67-73% had DNA strand breaks), and an absence of mitosis and proliferating cell nuclear antigen (PCNA) expression, Cells undergoing DNA fragmentation had functioning mitochondria, At 24 h, cells grown in 0 or 5 mu M choline synthesized DNA more rapidly than those grown in 70 mu M choline. By 72 h, the cells grown in 0 or 5 mu M choline were forming DNA much more slowly than control cells (assessed by thymidine incorporation, PCNA expression, and mitotic index), Western blot analysis showed that p53 in the nucleus of cells was detected in direct association with SV40 T-antigen, and was therefore likely to be inactive. We conclude that choline deficiency kills CWSV-1 hepatocytes in culture by inducing apoptosis via what may be a p53-independent process, and that this process begins in viable cells before they detach from the culture dish.	UNIV N CAROLINA,DEPT NUTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill								ABANOBI SE, 1982, CANCER RES, V42, P412; ALBRIGHT CD, 1990, CELL BIOL TOXICOL, V6, P379, DOI 10.1007/BF00120804; ALBRIGHT CD, 1991, J TISSUE CULTURE MET, V13, P5; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BIES J, 1995, CANCER RES, V55, P501; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; CHANDAR N, 1987, CARCINOGENESIS, V8, P669, DOI 10.1093/carcin/8.5.669; CHANDAR N, 1988, CARCINOGENESIS, V9, P259, DOI 10.1093/carcin/9.2.259; DONALDSON RW, 1992, P NATL ACAD SCI USA, V89, P8477, DOI 10.1073/pnas.89.18.8477; ELDEIRY WS, 1994, CANCER RES, V54, P1169; GEHRING H, 1991, BIOCHEM BIOPH RES CO, V177, P259, DOI 10.1016/0006-291X(91)91976-J; GERSCHENSON LE, 1992, FASEB J, V6, P2450, DOI 10.1096/fasebj.6.7.1563596; GHOSHAL AK, 1984, CARCINOGENESIS, V5, P1367, DOI 10.1093/carcin/5.10.1367; GHOSHAL AK, 1983, AM J PATHOL, V113, P309; GIAMBARRESI LI, 1982, BRIT J CANCER, V46, P825, DOI 10.1038/bjc.1982.278; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; GRASLKRAUPP B, 1994, P NATL ACAD SCI USA, V91, P9995, DOI 10.1073/pnas.91.21.9995; JAMES SJ, 1994, CANCER RES, V54, P5508; LANE DP, 1994, PHILOS T ROY SOC B, V345, P277, DOI 10.1098/rstb.1994.0106; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LIN JK, 1992, CANCER RES, V52, P385; LOMBARDI B, 1971, FED PROC, V30, P139; MARTIKAINEN P, 1991, CANCER RES, V51, P4693; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MURGIA M, 1992, J BIOL CHEM, V267, P10939; NOSSERI C, 1994, EXP CELL RES, V212, P367, DOI 10.1006/excr.1994.1156; OBERHAMMER F, 1991, CANCER RES, V51, P2478; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; ROBBINS SL, 1984, PATHOLOGIC BASIS DIS, P1; RUSHMORE TH, 1986, CARCINOGENESIS, V7, P1677, DOI 10.1093/carcin/7.10.1677; SHINOMIYA N, 1994, EXP CELL RES, V210, P236, DOI 10.1006/excr.1994.1035; SLATER TF, 1963, BIOCHIM BIOPHYS ACTA, V77, P383, DOI 10.1016/0006-3002(63)90513-4; TAN CK, 1986, J BIOL CHEM, V261, P2310; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; UEDA N, 1994, J LAB CLIN MED, V124, P169; *US DEPT HHS, 1988, DHHS PUBL; WASEEM NH, 1990, J CELL SCI, V96, P121; WEISENTHAL LM, 1983, CANCER RES, V43, P258; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025; WILSON RB, 1973, EXP MOL PATHOL, V18, P357, DOI 10.1016/0014-4800(73)90031-2; WOODWORTH C, 1986, CANCER RES, V46, P4018; WOODWORTH CD, 1987, MOL CELL BIOL, V7, P3740, DOI 10.1128/MCB.7.10.3740; WOODWORTH CD, 1988, MOL CELL BIOL, V8, P4492, DOI 10.1128/MCB.8.10.4492; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; WYLLIE AH, 1987, INT REV CYTOL S, V17, P755; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1989, J BIOL CHEM, V264, P11373; YOKOYAMA S, 1985, CANCER RES, V45, P2834; ZEISEL SH, 1993, FASEB J, V7, P551, DOI 10.1096/fasebj.7.6.8472893; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413; ZEISEL SH, 1990, J NUTR BIOCH, P132	52	91	95	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1996	10	4					510	516		10.1096/fasebj.10.4.8647350	http://dx.doi.org/10.1096/fasebj.10.4.8647350			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UE557	8647350	Green Submitted			2022-12-28	WOS:A1996UE55700015
J	DemmigAdams, B; Gilmore, AM; Adams, WW				DemmigAdams, B; Gilmore, AM; Adams, WW			Carotenoids .3. In vivo functions of carotenoids in higher plants	FASEB JOURNAL			English	Review						photosynthesis; photoprotection; xanthophyll cycle; zeaxanthin	LIGHT-HARVESTING FUNCTION; PHOTOSYSTEM-II; PHOTOSYNTHETIC MEMBRANES; INTACT CHLOROPLASTS; FLUORESCENCE; ZEAXANTHIN; LEAVES; STATES; DARK; SUN	The function of the long-chain, highly unsaturated carotenoids of higher plants in photoprotection is becoming increasingly well understood, while at the same time their function in other processes, such as light collection, needs to be reexamined, Recent progress in this area has been fueled by more accurate determinations of the photophysical properties of these molecules, as well as extensive characterization of the physiology and ecology of a particular group of carotenoids, those of the xanthophyll cycle, that play a key role in the photoprotection of photosynthesis under environmental stress, The deepoxidized xanthophylls zeaxanthin and antheraxanthin, together with a low pH within the photosynthetic membrane, facilitate the harmless dissipation of excess excitation energy directly within the light-collecting chlorophyll antennae, Evidence for this function as well as current contrasting hypotheses concerning its molecular mechanism are reviewed, In addition, the acclimation of the xanthophyll cycle content and composition of leaves to contrasting environments with different demands for photoprotection is summarized.	UNIV ILLINOIS,DEPT PLANT BIOL,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign	DemmigAdams, B (corresponding author), UNIV COLORADO,DEPT ENVIRONM POPULAT & ORGANISM BIOL,BOULDER,CO 80309, USA.		Adams, William/R-2772-2019					ADAMS WW, 1990, PLANT PHYSIOL, V92, P302, DOI 10.1104/pp.92.2.302; ADAMS WW, 1995, AUST J PLANT PHYSIOL, V22, P261, DOI 10.1071/PP9950261; ARSALANE W, 1994, PHOTOCHEM PHOTOBIOL, V60, P237, DOI 10.1111/j.1751-1097.1994.tb05097.x; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; BILGER W, 1991, PLANTA, V184, P226, DOI [10.1007/BF01102422, 10.1007/BF00197951]; BILGER W, 1994, PLANTA, V193, P238, DOI 10.1007/BF00192536; COGDELL RJ, 1992, J PHOTOCH PHOTOBIO B, V15, P105, DOI 10.1016/1011-1344(92)87009-X; CROFTS AR, 1994, FEBS LETT, V352, P265, DOI 10.1016/0014-5793(94)00976-7; DAU H, 1994, PHOTOCHEM PHOTOBIOL, V60, P1; DECOSTER B, 1992, BIOCHIM BIOPHYS ACTA, V1102, P107, DOI 10.1016/0167-4838(92)90504-7; Demmig-Adams B., 1993, CAROTENOIDS PHOTOSYN, P206, DOI [10.1007/978-94-011-2124-8_7, DOI 10.1007/978-94-011-2124-8_7]; DemmigAdams B, 1996, PLANTA, V198, P460, DOI 10.1007/BF00620064; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; DEMMIGADAMS B, 1992, PLANT CELL ENVIRON, V15, P411, DOI 10.1111/j.1365-3040.1992.tb00991.x; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; DEMMIGADAMS B, 1994, AUST J PLANT PHYSIOL, V21, P575, DOI 10.1071/PP9940575; DEMMIGADAMS B, 1995, AUST J PLANT PHYSIOL, V22, P249, DOI 10.1071/PP9950249; Foote C.S, 1976, FREE RADICALS BIOL, P85, DOI DOI 10.1016/B978-0-12-566502-5.50010-X; Frank H. A., 1993, CAROTENOIDS PHOTOSYN, P253; FRANK HA, 1994, PHOTOSYNTH RES, V41, P389, DOI 10.1007/BF02183041; GILMORE AM, 1994, FEBS LETT, V350, P271, DOI 10.1016/0014-5793(94)00784-5; GILMORE AM, 1995, P NATL ACAD SCI USA, V92, P2273, DOI 10.1073/pnas.92.6.2273; GILMORE AM, 1994, PLANTA, V192, P537, DOI 10.1007/BF00203592; GILMORE AM, 1994, PLANTA, V192, P526, DOI 10.1007/BF00203591; GILMORE AM, 1995, PLANTA, V197, P646, DOI 10.1007/BF00191573; GILMORE AM, 1993, PHOTOSYNTH RES, V35, P67, DOI 10.1007/BF02185412; GILMORE AM, 1992, P NATL ACAD SCI USA, V89, P1899, DOI 10.1073/pnas.89.5.1899; GILMORE AM, 1993, PHOTOSYNTHETIC RESPO, P162; GOEDHEER JC, 1969, BIOCHIM BIOPHYS ACTA, V172, P252, DOI 10.1016/0005-2728(69)90068-1; HAGER A, 1994, PLANTA, V192, P581, DOI 10.1007/BF00203597; Hager A., 1980, PIGMENTS PLANTS, P57; HEBER U, 1992, PLANT PHYSIOL, V100, P1621, DOI 10.1104/pp.100.4.1621; HORTON P, 1991, FEBS LETT, V292, P1, DOI 10.1016/0014-5793(91)80819-O; HORTON P, 1994, PLANT PHYSIOL, V106, P415, DOI 10.1104/pp.106.2.415; KANDORI H, 1994, J AM CHEM SOC, V116, P2671, DOI 10.1021/ja00085a078; Krause G.H., 1994, PHOTOINHIBITION PHOT, P331, DOI 10.1017/ S0021859600071434; KRIEGER A, 1992, BIOCHIM BIOPHYS ACTA, V1102, P167, DOI 10.1016/0005-2728(92)90097-L; KRIEGER A, 1993, PHOTOSYNTH RES, V37, P117, DOI 10.1007/BF02187470; KRINSKY NI, 1979, PURE APPL CHEM, V51, P649, DOI 10.1351/pac197951030649; MATHIS P, 1981, CAROTENOID CHEM BIOC, P339; MILLS JD, 1982, BIOCHIM BIOPHYS ACTA, V679, P75, DOI 10.1016/0005-2728(82)90257-2; MIMURO M, 1992, BIOCHIM BIOPHYS ACTA, V1098, P271, DOI 10.1016/S0005-2728(05)80347-0; MOHANTY N, 1995, AUST J PLANT PHYSIOL, V22, P239, DOI 10.1071/PP9950239; NEUBAUER C, 1992, PLANT PHYSIOL, V99, P1354, DOI 10.1104/pp.99.4.1354; Owens T. G., 1994, PHOTOINHIBITION PHOT, P95; OWENS TG, 1992, RES PHOTOSYNTHESIS, V4, P170; RUBAN AV, 1994, PLANT PHYSIOL, V104, P227, DOI 10.1104/pp.104.1.227; SCHREIBER U, 1979, BIOCHIM BIOPHYS ACTA, V546, P436, DOI 10.1016/0005-2728(79)90079-3; Schreiber U, 1994, ECOPHYSIOLOGY PHOTOS, V1, P49, DOI DOI 10.1007/978-3-642-79354-73; SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413; SIEFERMANNHARMS D, 1987, PHYSIOL PLANTARUM, V69, P561, DOI 10.1111/j.1399-3054.1987.tb09240.x; SIEFERMANNHARMS D, 1985, BIOCHIM BIOPHYS ACTA, V811, P325, DOI 10.1016/0304-4173(85)90006-0; THAYER SS, 1990, PHOTOSYNTH RES, V23, P331, DOI 10.1007/BF00034864; WALTERS RG, 1994, EUR J BIOCHEM, V226, P1063, DOI 10.1111/j.1432-1033.1994.01063.x; YAMAMOTO HY, 1979, PURE APPL CHEM, V51, P639, DOI 10.1351/pac197951030639; YAMAMOTO HY, 1996, ADV PHOTOSYNTHESIS, V4; Young A., 1993, CAROTENOIDS PHOTOSYN, P16, DOI DOI 10.1007/978-94-011-2124-8_2	57	544	570	3	82	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1996	10	4					403	412		10.1096/fasebj.10.4.8647339	http://dx.doi.org/10.1096/fasebj.10.4.8647339			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UE557	8647339	Bronze			2022-12-28	WOS:A1996UE55700004
J	Hatefi, Y; Yamaguchi, M				Hatefi, Y; Yamaguchi, M			Nicotinamide nucleotide transhydrogenase: A model for utilization of substrate binding energy for proton translocation	FASEB JOURNAL			English	Review						transhydrogenation; energy transduction; transmembrane proton translocation; conformation change	HEART MITOCHONDRIAL TRANSHYDROGENASE; ESCHERICHIA-COLI TRANSHYDROGENASE; OXYGEN-EXCHANGE REACTIONS; ENZYME; N,N'-DICYCLOHEXYLCARBODIIMIDE; PURIFICATION; SEQUENCE; SITE; N-(ETHOXYCARBONYL)-2-ETHOXY-1,2-DIHYDROQUINOLINE; IDENTIFICATION	The energy-transducing nicotinamide nucleotide transhydrogenases of mammalian mitochondria and bacteria are structurally related membrane-bound enzymes that catalyze the direct transfer of a hydride ion between NAD(H) and NADP(H) in a reaction that is coupled to transmembrane proton translocation. The protonmotive force alters the affinity of the transhydrogenase for substrates, accelerates the rate of hydride ion transfer from NADH to NADP, and shifts the equilibrium of this reaction toward NADPH formation, Transhydrogrenation in the. reverse direction from NADPH to NAD is accompanied by outward proton translocation and formation of a protonmotive force, in reverse transhydrogenation, the enzyme utilizes substrate binding energy for proton pumping, Therefore, with regard to the mechanism of energy transduction, the transhydrogenase works according to the same principles as the ATP synthase complex of mitochondria and bacteria, the proton and cation ATPases, and possibly certain redox-linked proton pumps, However, the relatively simple structure of the transhydrogenase recommends it as a model for study of the utilization of binding energy for vectorial translocation of protons and other cations.			Hatefi, Y (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV BIOCHEM, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024887] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24887] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD S, 1992, EUR J BIOCHEM, V207, P733, DOI 10.1111/j.1432-1033.1992.tb17103.x; BOYER PD, 1973, P NATL ACAD SCI USA, V70, P2837, DOI 10.1073/pnas.70.10.2837; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHOATE GL, 1979, J BIOL CHEM, V254, P286; CLARKE DM, 1985, EUR J BIOCHEM, V149, P517, DOI 10.1111/j.1432-1033.1985.tb08955.x; CLARKE DM, 1986, EUR J BIOCHEM, V158, P647, DOI 10.1111/j.1432-1033.1986.tb09802.x; ENANDER K, 1982, J BIOL CHEM, V257, P4760; FISHER R. R., 1982, PYRIDINE NUCLEOTIDE, P279; FJELLSTROM O, 1995, PROTEINS, V21, P91, DOI 10.1002/prot.340210203; GLAVAS N, 1993, J BIOL CHEM, V268, P14125; GLAVAS NA, 1995, BIOCHEMISTRY-US, V34, P7694, DOI 10.1021/bi00023a016; HANSON RL, 1979, J BIOL CHEM, V254, P888; HATEFI Y, 1980, J BIOL CHEM, V255, P9526; HATEFI Y, 1992, MOL MECHANISMS BIOEN, P265; HOEK JB, 1988, BIOCHEM J, V254, P1; HOLMBERG E, 1994, BIOCHEMISTRY-US, V33, P7691, DOI 10.1021/bi00190a024; HOU C, 1990, BIOCHIM BIOPHYS ACTA, V1018, P61, DOI 10.1016/0005-2728(90)90110-P; HU X, 1995, BBA-BIOENERGETICS, V1229, P64, DOI 10.1016/0005-2728(94)00187-A; HUTTON M, 1994, EUR J BIOCHEM, V219, P1041, DOI 10.1111/j.1432-1033.1994.tb18587.x; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; JENCKS WP, 1989, METHOD ENZYMOL, V171, P145; KAPLAN NO, 1953, J BIOL CHEM, V205, P1; KRAMER RA, 1993, MOL BIOCHEM PARASIT, V60, P327, DOI 10.1016/0166-6851(93)90144-M; LEVER TM, 1991, EUR J BIOCHEM, V197, P247, DOI 10.1111/j.1432-1033.1991.tb15905.x; OLAUSSON T, 1993, BIOCHEMISTRY-US, V32, P13237, DOI 10.1021/bi00211a036; OLSON JA, 1953, J BIOL CHEM, V202, P841; PALMER T, 1993, EUR J BIOCHEM, V211, P663, DOI 10.1111/j.1432-1033.1993.tb17594.x; PENNINGTON RM, 1981, J BIOL CHEM, V256, P8963; PERSSON B, 1984, J BIOL CHEM, V259, P8626; PHELPS DC, 1984, BIOCHEMISTRY-US, V23, P6340, DOI 10.1021/bi00321a008; PHELPS DC, 1980, J BIOL CHEM, V255, P9647; PHELPS DC, 1985, ARCH BIOCHEM BIOPHYS, V243, P298, DOI 10.1016/0003-9861(85)90799-4; RYDSTROM J, 1977, BIOCHIM BIOPHYS ACTA, V463, P155, DOI 10.1016/0304-4173(77)90007-6; Rydstrom J., 1987, PYRIDINE NUCLEOTIDE, P433; TONG RCW, 1991, BIOCHIM BIOPHYS ACTA, V1080, P19, DOI 10.1016/0167-4838(91)90106-A; VANDESTADT RJ, 1971, BIOCHIM BIOPHYS ACTA, V234, P173, DOI 10.1016/0005-2728(71)90143-5; VERMEULEN AN, 1993, FEMS MICROBIOL LETT, V110, P223, DOI 10.1111/j.1574-6968.1993.tb06324.x; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILLIAMS R, 1994, MICROBIOL-UK, V140, P1595, DOI 10.1099/13500872-140-7-1595; WU LNY, 1981, J BIOL CHEM, V256, P7401; YAMAGUCHI M, 1993, J BIOL CHEM, V268, P17871; YAMAGUCHI M, 1991, J BIOL CHEM, V266, P5728; YAMAGUCHI M, 1994, J BIOENERG BIOMEMBR, V26, P435, DOI 10.1007/BF00762784; YAMAGUCHI M, 1988, J BIOL CHEM, V263, P2761; YAMAGUCHI M, 1990, BIOCHEMISTRY-US, V29, P4136, DOI 10.1021/bi00469a017; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P16653, DOI 10.1074/jbc.270.28.16653; YAMAGUCHI M, 1991, J BIOL CHEM, V266, P17020; YAMAGUCHI M, 1989, BIOCHEMISTRY-US, V28, P6050, DOI 10.1021/bi00440a049; YU Y, 1994, MOL BIOCHEM PARASIT, V68, P323, DOI 10.1016/0166-6851(94)90178-3	49	75	78	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1996	10	4					444	452		10.1096/fasebj.10.4.8647343	http://dx.doi.org/10.1096/fasebj.10.4.8647343			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UE557	8647343				2022-12-28	WOS:A1996UE55700008
J	LEE, J; MORGAN, JR; TOMPKINS, RG; YARMUSH, ML				LEE, J; MORGAN, JR; TOMPKINS, RG; YARMUSH, ML			PROLINE-MEDIATED ENHANCEMENT OF HEPATOCYTE FUNCTION IN A COLLAGEN GEL SANDWICH CULTURE CONFIGURATION	FASEB JOURNAL			English	Note						PROLINE; CIS-HYDROXYPROLINE; COLLAGEN; HEPATOCYTES; ALBUMIN; PRIMARY CULTURE	CELL-MATRIX INTERACTIONS; RAT HEPATOCYTES; AMINO-ACIDS; POLYPEPTIDES; LIPOGENESIS; PROCOLLAGEN	Isolated rat primary hepatocytes were cultured between two layers of gelled collagen in a sandwich configuration that reinstates the cellular polarity necessary for long-term function in vitro. Maintenance of hepatocyte function, as measured by the secretion of albumin, was shown to be dependent on both the sandwich gel configuration and the continued presence of L-proline in the culture media. Cis-hydroxyproline, an analog of proline known to prevent the proper folding of triple helical collagen molecules, inhibited the response of sandwiched hepatocytes to proline in a dose-dependent and reversible manner. The addition of cis-hydroxyproline to cultures established for 7 days also resulted in the inhibition of hepatocyte function. These data support the hypothesis that continued collagen synthesis by hepatocytes is critical for hepatocyte function in the sandwich gel configuration.	MASSACHUSETTS GEN HOSP, SURG SERV, BOSTON, MA 02114 USA; SHRINERS BURNS INST, SURG SERV, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital	LEE, J (corresponding author), RUTGERS STATE UNIV, DEPT CHEM & BIOCHEM ENGN, BRETT BOWERS RD, PISCATAWAY, NJ 08854 USA.			Morgan, Jeffrey/0000-0002-7546-3443; Yarmush, Martin/0000-0003-4986-8444	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043371] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43371] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAQUET A, 1991, BIOCHEM J, V273, P57, DOI 10.1042/bj2730057; BENZEEV A, 1988, P NATL ACAD SCI USA, V85, P2161, DOI 10.1073/pnas.85.7.2161; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; CARON JM, 1990, MOL CELL BIOL, V10, P1239, DOI 10.1128/MCB.10.3.1239; DIEGELMANN RF, 1983, SCIENCE, V219, P1343, DOI 10.1126/science.6828863; DUNN JCY, 1989, FASEB J, V3, P174, DOI 10.1096/fasebj.3.2.2914628; DUNN JCY, 1991, BIOTECHNOL PROGR, V7, P237, DOI 10.1021/bp00009a007; EKBLOM P, 1986, ANNU REV CELL BIOL, V2, P27, DOI 10.1146/annurev.cb.02.110186.000331; ELSDALE T, 1972, J CELL BIOL, V54, P626, DOI 10.1083/jcb.54.3.626; FELDHOFF RC, 1977, J BIOL CHEM, V252, P3611; Hay E. D., 1981, CELL BIOL EXTRACELLU; HOUCK KA, 1985, IN VITRO CELL DEV B, V21, P121, DOI 10.1007/BF02620953; HUTSON SM, 1987, AM J PHYSIOL, V252, pE291, DOI 10.1152/ajpendo.1987.252.3.E291; JIMENEZ S, 1974, ARCH BIOCHEM BIOPHYS, V163, P459, DOI 10.1016/0003-9861(74)90502-5; LEE JW, 1992, BIOTECHNOL BIOENG, V40, P298, DOI 10.1002/bit.260400214; MOORE DH, 1982, HEPATOLOGY TXB LIVER, P137; Nakane M. B., 1978, IMMUNOFLUORESCENCE R, P215; NEUMAN RE, 1949, ARCH BIOCHEM, V24, P289; Peterkofsky B, 1982, IMMUNOCHEMISTRY EXTR, VII, P19; RUOSLAHTI E, 1988, LIVER BIOL PATHOBIOL, P739; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SUGDEN MC, 1984, BIOCHIM BIOPHYS ACTA, V798, P368, DOI 10.1016/0304-4165(84)90111-9; UITTO J, 1974, BIOCHIM BIOPHYS ACTA, V336, P234, DOI 10.1016/0005-2795(74)90401-2; UITTO VJ, 1978, ARCH BIOCHEM BIOPHYS, V185, P214, DOI 10.1016/0003-9861(78)90161-3; YARMUSH ML, 1992, ANN NY ACAD SCI, V665, P238, DOI 10.1111/j.1749-6632.1992.tb42588.x; [No title captured]	26	44	47	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 1	1993	7	6					586	591		10.1096/fasebj.7.6.8472895	http://dx.doi.org/10.1096/fasebj.7.6.8472895			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KY009	8472895				2022-12-28	WOS:A1993KY00900013
J	Pollack, R				Pollack, R			Darwin and Mendel versus Watson and Crick	FASEB JOURNAL			English	Editorial Material									Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Pollack, R (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.								0	0	0	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1998	12	2					149	150		10.1096/fasebj.12.2.149	http://dx.doi.org/10.1096/fasebj.12.2.149			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472979	Bronze			2022-12-28	WOS:000071848400002
J	Bezombes, C; Maestre, N; Laurent, G; Levade, T; Bettaieb, A; Jaffrezou, JP				Bezombes, C; Maestre, N; Laurent, G; Levade, T; Bettaieb, A; Jaffrezou, JP			Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the p-glycoprotein blocker PSC833	FASEB JOURNAL			English	Article						TNF-alpha; sphingomyelin asymmetry; sphingomyelinase; ceramide	TUMOR-NECROSIS-FACTOR; PLASMA-MEMBRANE; MULTIDRUG-RESISTANCE; INDUCED CYTOTOXICITY; SPHINGOMYELIN CYCLE; IONIZING-RADIATION; DNA FRAGMENTATION; DEATH; PHOSPHATIDYLCHOLINE; RECEPTOR	Tumor necrosis factor (TNF-alpha) is a cytokine with antitumor activity against several cellular models, TNF-alpha-induced apoptosis seems to be mediated by a signaling pathway termed 'sphingomyelin-ceramide' pathway, which consists of the hydrolysis of sphingomyelin and the production of its breakdown product ceramide, Our study shows that KG1a cells, which are inherently resistant to TNF-alpha and do not produce ceramide upon cytokine stimulation, can be sensitized by the use of the P-glycoprotein inhibitor PSC833, Coincubation with 1 mu M of this cyclosporin derivative restored the apoptotic potential of 10 ng/ml TNF-alpha, This effect was associated with the restoration of ceramide generation (315%) and activation of neutral, but not acid sphingomyelinase activity (143%), Furthermore, we demonstrate that treatment of KG1a cells with 1 mu M PSC833 led to a threefold increase in inner plasma membrane sphingomyelin content and basal neutral sphingomyelinase activity, These results support the hypothesis whereby resistance to TNF-alpha-mediated apoptosis of certain leukemic cells is linked to the disposability of the sphingomyelin pool, These data also suggest a role for P-glycoprotein in sphingomyelin transverse plasma membrane asymmetry.	Ctr Claudius Regaud, INSERM, CJF 9503, F-31052 Toulouse, France; CHU Purpan, Serv Hematol, F-31059 Toulouse, France; CHU Rangueil, INSERM 466, Lab Biochim Med, F-31403 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; CHU de Toulouse; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Jaffrezou, JP (corresponding author), Ctr Claudius Regaud, INSERM, CJF 9503, 20 Rue Pont St Pierre, F-31052 Toulouse, France.	jaffrezou@regaud-tlse.fnclcc.fr	Levade, Thierry/O-8948-2014; Bezombes, christine/X-8479-2019; Bezombes, Christine/G-2743-2017; Bezombes, Christine/AAC-1724-2020	Bezombes, christine/0000-0003-4079-4872; 				Andrieu N, 1996, EUR J BIOCHEM, V236, P738, DOI 10.1111/j.1432-1033.1996.00738.x; ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; BAILLY JD, 1995, LEUKEMIA, V9, P799; Banker DE, 1997, BLOOD, V89, P243, DOI 10.1182/blood.V89.1.243.243_243_255; Bettaieb A, 1996, BLOOD, V88, P1465, DOI 10.1182/blood.V88.4.1465.bloodjournal8841465; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; CHEN M, 1995, CANCER RES, V55, P991; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DEVAUX PF, 1994, CHEM PHYS LIPIDS, V73, P107, DOI 10.1016/0009-3084(94)90177-5; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FILIPSKI J, 1990, EMBO J, V9, P1319, DOI 10.1002/j.1460-2075.1990.tb08241.x; FOLCH J, 1957, J BIOL CHEM, V226, P497; FORD JM, 1990, PHARMACOL REV, V42, P155; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HIGUCHI M, 1994, J IMMUNOL, V152, P4017; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; LEVADE T, 1986, J CLIN CHEM CLIN BIO, V24, P205; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; MCCONKEY DJ, 1991, J IMMUNOL, V146, P1072; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P113; MUNKER R, 1987, BLOOD, V70, P1730; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; PAYRASTRE B, 1988, BIOCHIM BIOPHYS ACTA, V939, P355, DOI 10.1016/0005-2736(88)90081-8; QuilletMary A, 1996, LEUKEMIA, V10, P417; RECORD M, 1985, BIOCHIM BIOPHYS ACTA, V819, P1, DOI 10.1016/0005-2736(85)90188-9; RECORD M, 1984, BIOCHIM BIOPHYS ACTA, V778, P449, DOI 10.1016/0005-2736(84)90393-6; RECORD M, 1982, BIOCHIM BIOPHYS ACTA, V699, P57; RIBBES G, 1985, FEBS LETT, V191, P195, DOI 10.1016/0014-5793(85)80007-7; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SMITH AJ, 1994, FEBS LETT, V354, P263, DOI 10.1016/0014-5793(94)01135-4; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STOFFEL W, 1980, H-S Z PHYSIOL CHEM, V361, P755, DOI 10.1515/bchm2.1980.361.1.755; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TERCE F, 1988, J BIOL CHEM, V263, P3142; TWENTYMAN PR, 1991, EUR J CANCER, V27, P1639, DOI 10.1016/0277-5379(91)90435-G; VALLARI S, 1990, ARCH BIOCHEM BIOPHYS, V71, P538; van Helvoort A, 1997, J CELL SCI, V110, P75; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Weisburg JH, 1996, J EXP MED, V183, P2699, DOI 10.1084/jem.183.6.2699; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Wright SC, 1996, FASEB J, V10, P325, DOI 10.1096/fasebj.10.2.8641566; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	58	121	124	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1998	12	1					101	109		10.1096/fasebj.12.1.101	http://dx.doi.org/10.1096/fasebj.12.1.101			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YR723	9438415				2022-12-28	WOS:000071523800011
J	L'Heureux, N; Paquet, S; Labbe, R; Germain, L; Auger, FA				L'Heureux, N; Paquet, S; Labbe, R; Germain, L; Auger, FA			A completely biological tissue-engineered human blood vessel	FASEB JOURNAL			English	Article						tissue engineering; vascular graft; cultured cells; ascorbate; mechanical strength	SMOOTH-MUSCLE CELLS; HUMAN-ENDOTHELIAL-CELLS; EXPANDED POLYTETRAFLUOROETHYLENE GRAFTS; CULTURED VASCULAR CELLS; UMBILICAL VEINS; SAPHENOUS-VEIN; HUMAN-SKIN; FOLLOW-UP; COLLAGEN; FIBROBLASTS	Mechanically challenged tissue-engineered organs, such as blood vessels, traditionally relied on synthetic or modified biological materials for structural support. In this report, we present a novel approach to tissue-engineered blood vessel (TEBV) production that is based exclusively on the use of cultured human cells, i.e., without any synthetic or exogenous biomaterials. Human vascular smooth muscle cells (SMC) cultured with ascorbic acid produced a cohesive cellular sheet. This sheet was placed around a tubular support to produce the media of the vessel. A similar sheet of human fibroblasts was wrapped around the media to provide the adventitia. After maturation, the tubular support was removed and endothelial cells were seeded in the lumen. This TEBV featured a well-defined, three-layered organization and numerous extracellular matrix proteins, including elastin. In this environment, SMC reexpressed desmin, a differentiation marker known to be lost under standard culture conditions. The endothelium expressed von Willebrand factor, incorporated acetylated LDL, produced PGI(2), and strongly inhibited platelet adhesion in vitro. The complete vessel had a burst strength over 2000 mmHg. This is the first completely biological TEBV to display a burst strength comparable to that of human vessels. Short-term grafting experiment in a canine model demonstrated good handling and suturability characteristics. Taken together, these results suggest that this novel technique can produce completely biological vessels fulfilling the fundamental requirements for grafting: high burst strength, positive surgical handling, and a functional endothelium.	Hop St Sacrement, Lab Angiogenese Expt LOEX, Ste Foy, PQ G1S 4L8, Canada; Univ Laval, Fac Med, Dept Surg, Quebec City, PQ G1S 4L8, Canada	Laval University; Laval University	Auger, FA (corresponding author), Hop St Sacrement, Lab Angiogenese Expt LOEX, 1050 Chemin, Ste Foy, PQ G1S 4L8, Canada.	nheureux@bioeng.ucsd.edu; lucie.germain@chg.ulaval.ca	L'Heureux, Nicolas/K-8669-2015	L'Heureux, Nicolas/0000-0001-8602-3948; Germain, Lucie/0000-0001-8883-6491				ABSHER M, 1989, IN VITRO CELL DEV B, V25, P183; Allaire E, 1996, TRANSPLANTATION, V62, P794, DOI 10.1097/00007890-199609270-00017; AUGER FA, 1995, IN VITRO CELL DEV-AN, V31, P432; BERGAMINI TM, 1988, J VASC SURG, V7, P21, DOI 10.1067/mva.1988.avs0070021; BIRINYI LK, 1987, J VASC SURG, V5, P193, DOI 10.1067/mva.1987.avs0050193; Birk D.E., 1994, EXTRACELL MATRIX ASS, P91, DOI [10.1016/b978-0-12-775170-2.50009-3, DOI 10.1016/B978-0-12-775170-2.50009-3]; BRICKER DL, 1970, CHEST, V58, P566, DOI 10.1378/chest.58.6.566; CHARLESWORTH PM, 1985, BRIT J SURG, V72, P896, DOI 10.1002/bjs.1800721116; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; COATES A, 1995, MELANOMA RES, V5, P107, DOI 10.1097/00008390-199504000-00006; DAVIES AH, 1992, BRIT J SURG, V79, P1019, DOI 10.1002/bjs.1800791011; Drury J K, 1987, Ann Vasc Surg, V1, P542, DOI 10.1016/S0890-5096(06)61437-4; EPPERSON DE, 1994, J IMMUNOL, V153, P5402; FLEISCHMAJER R, 1991, J INVEST DERMATOL, V97, P638, DOI 10.1111/1523-1747.ep12483132; FREISCHLAG J, 1990, ANN VASC SURG, V3, P895; GAMBLE JR, 1993, J CELL BIOL, V121, P931, DOI 10.1083/jcb.121.4.931; Gillis C, 1996, EUR J VASC ENDOVASC, V11, P127, DOI 10.1016/S1078-5884(96)80040-2; Greisler H P, 1990, Ann Vasc Surg, V4, P98, DOI 10.1007/BF02042699; GRINNELL F, 1989, EXP CELL RES, V181, P483, DOI 10.1016/0014-4827(89)90105-5; GUIDOIN R, 1980, BIOMATER ARTIF CELL, V8, P145, DOI 10.3109/10731198009118977; HALLIN RW, 1975, AM SURGEON, V41, P550; HATA R, 1988, EUR J BIOCHEM, V173, P261, DOI 10.1111/j.1432-1033.1988.tb13993.x; HEWETT PW, 1993, IN VITRO CELL DEV-AN, V29A, P325; HILES MC, 1995, J BIOMED MATER RES, V29, P883, DOI 10.1002/jbm.820290714; Hirai J, 1996, CELL TRANSPLANT, V5, P93, DOI 10.1016/0963-6897(95)02002-0; Hoopes C W, 1996, Semin Thorac Cardiovasc Surg, V8, P156; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kent K C, 1992, Ann Vasc Surg, V6, P258, DOI 10.1007/BF02000272; KIELTY CM, 1993, J CELL SCI, V106, P167; KRALING BM, 1994, LAB INVEST, V71, P745; Lantz G C, 1990, J Invest Surg, V3, P217, DOI 10.3109/08941939009140351; Lantz G C, 1993, J Invest Surg, V6, P297, DOI 10.3109/08941939309141619; LATRON Y, 1991, THROMB HAEMOSTASIS, V66, P361; LEE E, 1995, ARTERIOSCL THROM VAS, V15, P2284, DOI 10.1161/01.ATV.15.12.2284; LHEUREUX N, 1993, J VASC SURG, V17, P499, DOI 10.1016/0741-5214(93)90150-K; LU CY, 1994, FASEB J, V8, P1122, DOI 10.1096/fasebj.8.14.7958617; LUSCINSKAS FW, 1994, FASEB J, V8, P929, DOI 10.1096/fasebj.8.12.7522194; MAGOMETSCHNIGG H, 1992, J VASC SURG, V15, P527, DOI 10.1016/0741-5214(92)90192-B; MARGIOTTA MS, 1995, J AM COLL SURGEONS, V181, pA215; MERTENS RA, 1995, J VASC SURG, V21, P782, DOI 10.1016/S0741-5214(05)80009-6; Noishiki Y, 1996, NAT MED, V2, P90, DOI 10.1038/nm0196-90; NORMAND J, 1995, IN VITRO CELL DEV-AN, V31, P447; PASIC M, 1995, CIRCULATION, V92, P2605, DOI 10.1161/01.CIR.92.9.2605; PICKERING JG, 1994, CIRCULATION, V89, P13, DOI 10.1161/01.CIR.89.1.13; Pickering JG, 1997, ARTERIOSCL THROM VAS, V17, P475, DOI 10.1161/01.ATV.17.3.475; POOT M, 1991, CYTOMETRY, V12, P184, DOI 10.1002/cyto.990120214; ROSENMAN JE, 1985, J VASC SURG, V2, P778, DOI 10.1067/mva.1985.avs0020778; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; RUMISEK JD, 1986, J VASC SURG, V4, P136, DOI 10.1067/mva.1986.avs0040136; SELTZER JL, 1994, EXP CELL RES, V213, P365, DOI 10.1006/excr.1994.1211; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; Sparks C H, 1969, Ann Thorac Surg, V8, P104; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; TRUBEL W, 1995, EUR J VASC ENDOVASC, V10, P415, DOI 10.1016/S1078-5884(05)80163-7; VEELKEN H, 1994, HUM GENE THER, V5, P1203, DOI 10.1089/hum.1994.5.10-1203; VEITH FJ, 1986, J VASC SURG, V3, P104; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; WAGNER DD, 1982, J CELL BIOL, V95, P355, DOI 10.1083/jcb.95.1.355; WAGNER E, 1995, J THORAC CARDIOV SUR, V110, P1732, DOI 10.1016/S0022-5223(95)70037-4; WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/science.2934816; WILLIAMS SK, 1994, J BIOMED MATER RES, V28, P203, DOI 10.1002/jbm.820280210; WILLIAMS SK, 1994, J VASC SURG, V19, P916, DOI 10.1016/S0741-5214(94)70019-2; XU XM, 1993, J CLIN INVEST, V91, P1843, DOI 10.1172/JCI116398; YAMAMOTO M, 1993, EXP CELL RES, V204, P121, DOI 10.1006/excr.1993.1016; YANG ZH, 1994, CIRCULATION, V89, P2266, DOI 10.1161/01.CIR.89.5.2266; YEAGER RA, 1982, SURGERY, V91, P99; ZILLA P, 1994, J VASC SURG, V19, P540, DOI 10.1016/S0741-5214(94)70083-4	67	1034	1100	6	266	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1998	12	1					47	56		10.1096/fasebj.12.1.47	http://dx.doi.org/10.1096/fasebj.12.1.47			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YR723	9438410				2022-12-28	WOS:000071523800006
J	Pagano, M				Pagano, M			Cell cycle regulation by the ubiquitin pathway	FASEB JOURNAL			English	Review						cyclins; cdks; cell cycle inhibitors; degradation; ubiquitination; proteasome	SISTER-CHROMATID SEPARATION; ANAPHASE-PROMOTING COMPLEX; FAT-FACETS GENE; SACCHAROMYCES-CEREVISIAE; CONJUGATING ENZYME; PROTEASOME PATHWAY; S-PHASE; DNA-REPLICATION; MITOTIC CYCLINS; BUDDING YEAST	In the past 2 years, two ubiquitin-dependent proteolytic pathways have been established as important players in the regulation of the cell division cycle. In S, cerevisiae, the entry into S phase requires ubiquitin-mediated degradation of a cdk inhibitor, p40(Sic1), in a pathway that involves the E2 enzyme Cdc34, Recent studies reviewed herein show that the Cdc34 pathway targets phosphorylated substrates. A second pathway that regulates chromosome segregation and mitotic exit by degrading anaphase inhibitors and mitotic cyclins involves a different E2 and a large molecular weight E3 complex, called the anaphase-promoting complex or cyclosome. This pathway targets substrates containing one or more destruction box motif.	NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University	Pagano, M (corresponding author), NYU MED CTR,DEPT PATHOL,MSB 548,550 1ST AVE,NEW YORK,NY 10016, USA.			pagano, michele/0000-0003-3210-2442	NCI NIH HHS [CA66229-02] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amon A, 1997, EMBO J, V16, P2693, DOI 10.1093/emboj/16.10.2693; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BARINAGA M, 1995, SCIENCE, V269, P631, DOI 10.1126/science.7624789; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; BASI G, 1995, MOL CELL BIOL, V15, P2028; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; BROWN JP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985; Funabiki H, 1996, EMBO J, V15, P6617, DOI 10.1002/j.1460-2075.1996.tb01052.x; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; FUNABIKI H, 1997, IN PRESS EMBO J; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HAREFORD L, 1974, J MOL BIOL, V84, P445; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Irniger S, 1997, J CELL SCI, V110, P1523; Ishii K, 1996, EMBO J, V15, P6629, DOI 10.1002/j.1460-2075.1996.tb01053.x; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; Jackson PK, 1996, CURR BIOL, V6, P1209, DOI 10.1016/S0960-9822(96)00697-5; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Jentsch S, 1992, Trends Cell Biol, V2, P98, DOI 10.1016/0962-8924(92)90013-D; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; Kalderon D, 1996, CURR BIOL, V6, P662, DOI 10.1016/S0960-9822(09)00443-6; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Koch C, 1996, GENE DEV, V10, P129, DOI 10.1101/gad.10.2.129; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; LI JK, 1995, MOL BIOL CELL, V6, P1111, DOI 10.1091/mbc.6.9.1111; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; MCKINNEY JD, 1993, GENE DEV, V7, P833, DOI 10.1101/gad.7.5.833; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; MURALIDHAR MG, 1993, NEURON, V11, P253, DOI 10.1016/0896-6273(93)90182-Q; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OH CE, 1994, J NEUROSCI, V14, P3166; Osaka F, 1997, MOL CELL BIOL, V17, P3388, DOI 10.1128/MCB.17.6.3388; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1996, CANC GENES FUNCTIONA, V7, P241; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Roest HP, 1996, CELL, V86, P799, DOI 10.1016/S0092-8674(00)80154-3; Rolfe M, 1997, J MOL MED-JMM, V75, P5, DOI 10.1007/s001090050081; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR C, 1996, CELL, V274, P1672; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SKOWYRA D, 1997, IN PRESS CELL; SOLOMON MJ, 1997, CELL CYCLE, V4; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Stankovic T, 1997, GENOMICS, V40, P267, DOI 10.1006/geno.1996.4595; Stemmann O, 1996, EMBO J, V15, P3611, DOI 10.1002/j.1460-2075.1996.tb00730.x; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Sudakin V, 1997, J BIOL CHEM, V272, P18051, DOI 10.1074/jbc.272.29.18051; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; VERMA R, 1997, IN PRESS MOL BIOL CE; VLACH J, 1997, IN PRESS EMBO J; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELKER M, 1996, ONCOGENE, V13, P4191; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; YAMADA H, 1997, IN PRESS J CELL SCI; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; YAMANO H, 1996, EMBO J, V15, P5266; Yamashita YM, 1996, NATURE, V384, P276, DOI 10.1038/384276a0; YEW R, 1997, SCIENCE, V277, P1672; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; 1996, SCIENCE, V274, P1643	121	191	199	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1997	11	13					1067	1075		10.1096/fasebj.11.13.9367342	http://dx.doi.org/10.1096/fasebj.11.13.9367342			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367342				2022-12-28	WOS:A1997YE98300005
J	Gualix, J; Fideu, MD; Pintor, J; Rotllan, P; GarciaCarmona, F; MirasPortugal, MT				Gualix, J; Fideu, MD; Pintor, J; Rotllan, P; GarciaCarmona, F; MirasPortugal, MT			Characterization of diadenosine polyphosphate transport into chromaffin granules from adrenal medulla	FASEB JOURNAL			English	Article						diadenosine polyphosphates; vesicular transport; mnemonic transporter; purinergic transmission	CELLS; PURINOCEPTORS; AP4A; ATP; SYNAPTOSOMES; NUCLEOTIDE; CHANNELS; RECEPTOR; BINDING; RELEASE	The transport of diadenosine polyphosphates into chromaffin granules from bovine adrenal medulla has been studied by using the radiolabeled substrate [H-3]Ap(5)A and the fluorescent substrate analog di(1,N-6-ethenoadenosine)polyphosphate, epsilon-(Ap(n)A) (n=3-5). The vesicular concentration increase was time dependent and the substrates were not metabolized to any extent during the transport experiments. The saturation curve indicates the existence of kinetic and allosteric cooperativity during Ap(n)A (diadenosine polyphosphates) transport and could be the result of the presence of various affinity states of the transporter with K values of 16 +/- 1 mu M and 75 +/- 6 mu M, and corresponding Hill numbers of 2 and 4, when epsilon-(Ap(4)A) was the substrate, The saturation studies for [H-3]Ap(5)A were performed in a broader concentration range; in this case a three-step curve was obtained with K values of 16 +/- 2 mu M, 125 +/- 9 mu M, and 545 +/- 11 mu M; the corresponding Hill numbers were 2, 4, and 6. This kinetic behavior can be explained on the basis of a mnemonic model, as already demonstrated for the vesicular transport of ATP. The nonhydrolyzable adenine nucleotide analogs, ATP gamma S and ADP beta S, inhibited the diadenosine polyphosphate transport at concentrations in the millimolar range. Ap(n)A transport was also inhibited by the P2 receptor antagonist suramin, the mitochondrial ATP/ADP exchange inhibitor atractyloside, the proton translocator FCCP, and N-ethylmaleimide.	UNIV COMPLUTENSE MADRID,FAC VET,DEPT BIOQUIM,E-28040 MADRID,SPAIN; UNIV LA LAGUNA,FAC BIOL,DEPT BIOQUIM,E-38206 TENERIFE,CANARY ISLANDS,SPAIN; UNIV MURCIA,FAC BIOL,DEPT BIOQUIM,MURCIA 30080,SPAIN	Complutense University of Madrid; Universidad de la Laguna; University of Murcia			Garcia-Carmona, Francisco/K-6520-2017; Miras-Portugal, Maria Teresa/L-7137-2014; Gualix, Javier/C-5783-2017	Gualix, Javier/0000-0001-7215-6483; Pintor, Jesus/0000-0002-9191-7679				ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; ABERER W, 1978, BIOCHEM J, V172, P353, DOI 10.1042/bj1720353b; [Anonymous], ALLOSTERIC ENZYMES K; BAILEY SJ, 1994, BRIT J PHARMACOL, V112, P219, DOI 10.1111/j.1476-5381.1994.tb13055.x; BAKER JC, 1986, P NATL ACAD SCI USA, V83, P2350, DOI 10.1073/pnas.83.8.2350; Bankston LA, 1996, J BIOL CHEM, V271, P17132, DOI 10.1074/jbc.271.29.17132; BAXI MD, 1995, BIOCHEMISTRY-US, V34, P9700, DOI 10.1021/bi00030a007; CASILLAS T, 1993, BIOCHEMISTRY-US, V32, P14203, DOI 10.1021/bi00214a020; DELCASTILLO AR, 1988, J NEUROCHEM, V51, P1696, DOI 10.1111/j.1471-4159.1988.tb01147.x; GRUMMT F, 1979, P NATL ACAD SCI USA, V76, P6081, DOI 10.1073/pnas.76.12.6081; GRUNINGER HA, 1983, NEUROSCIENCE, V9, P917, DOI 10.1016/0306-4522(83)90280-4; Gualix J, 1996, J BIOL CHEM, V271, P1957, DOI 10.1074/jbc.271.4.1957; Holden CP, 1996, J NEUROCHEM, V67, P574; IRVING MG, 1973, BIOCHEM J, V131, P287, DOI 10.1042/bj1310287; IRVING MG, 1973, BIOCHEM J, V131, P303, DOI 10.1042/bj1310303; Jovanovic A, 1996, BRIT J PHARMACOL, V117, P233, DOI 10.1111/j.1476-5381.1996.tb15180.x; KAGAN ZS, 1973, BIOCHIM BIOPHYS ACTA, V302, P110, DOI 10.1016/0005-2744(73)90014-4; LAZAROWSKI ER, 1995, BRIT J PHARMACOL, V116, P1619, DOI 10.1111/j.1476-5381.1995.tb16382.x; LEINHARD GE, 1973, J BIOL CHEM, V248, P1121; LUTHJE J, 1983, BIOCHEM BIOPH RES CO, V115, P253, DOI 10.1016/0006-291X(83)90997-X; Mateo J, 1996, BRIT J PHARMACOL, V119, P1; MCLENNAN AG, 1992, APA4A OTHER DINUCLEO; Neet K E, 1980, Methods Enzymol, V64, P139; NELSON N, 1992, J EXP BIOL, V172, P149; NG KME, 1987, NUCLEIC ACIDS RES, V15, P3573, DOI 10.1093/nar/15.8.3573; PINTOR J, 1992, NEUROSCI RES COMMUN, V10, P9; PINTOR J, 1992, ANAL BIOCHEM, V200, P296, DOI 10.1016/0003-2697(92)90469-N; Pintor J, 1997, MOL PHARMACOL, V51, P277, DOI 10.1124/mol.51.2.277; PINTOR J, 1993, BRIT J PHARMACOL, V108, P1094, DOI 10.1111/j.1476-5381.1993.tb13510.x; PINTOR J, 1995, BRIT J PHARMACOL, V115, P895, DOI 10.1111/j.1476-5381.1995.tb15894.x; Pintor J, 1996, BRIT J PHARMACOL, V119, P1006, DOI 10.1111/j.1476-5381.1996.tb15771.x; Pivorun EB, 1996, J NEUROSCI RES, V44, P478, DOI 10.1002/(SICI)1097-4547(19960601)44:5<478::AID-JNR8>3.0.CO;2-C; RAMOS A, 1995, ANAL BIOCHEM, V228, P74, DOI 10.1006/abio.1995.1317; RAMOS A, 1995, BBA-PROTEIN STRUCT M, V1253, P103, DOI 10.1016/0167-4838(95)00154-M; RAPAPORT E, 1976, P NATL ACAD SCI USA, V73, P3984, DOI 10.1073/pnas.73.11.3984; Ripoll C, 1996, DIABETES, V45, P1431, DOI 10.2337/diabetes.45.10.1431; ROTLLAN P, 1985, EUR J BIOCHEM, V151, P365, DOI 10.1111/j.1432-1033.1985.tb09110.x; ROTLLAN P, 1991, FEBS LETT, V280, P371; SCHLUTER H, 1994, NATURE, V367, P186, DOI 10.1038/367186a0; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SILLERO MAG, 1991, EUR J BIOCHEM, V202, P507; SOMERO GN, 1969, NATURE, V223, P194, DOI 10.1038/223194a0; TORRES M, 1992, BIOCHIM BIOPHYS ACTA, V1105, P291, DOI 10.1016/0005-2736(92)90207-3; VARON R, 1991, BIOCHEM J, V178, P91; VARONCASTELLANO.R, 1995, COMPUTERIZED DERIVAT; WINKLER H, 1982, SECRETORY PROCESS, V1, P3; ZAMECNIK PC, 1966, BIOCHEM BIOPH RES CO, V24, P91, DOI 10.1016/0006-291X(66)90415-3	47	24	25	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1997	11	12					981	990		10.1096/fasebj.11.12.9337151	http://dx.doi.org/10.1096/fasebj.11.12.9337151			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YA724	9337151				2022-12-28	WOS:A1997YA72400008
J	Wagner, E; McCaffery, P; Mey, J; Farhangfar, F; Applebury, ML; Drager, UC				Wagner, E; McCaffery, P; Mey, J; Farhangfar, F; Applebury, ML; Drager, UC			Retinoic aid increases arrestin mRNA levels in the mouse retina	FASEB JOURNAL			English	Article						phototransduction; photoreceptors; retinal pigment epithelium; all-trans-retinaldehyde	LIGHT-DARK CYCLE; MESSENGER-RNA; DIFFERENTIAL EXPRESSION; GENE-EXPRESSION; S-ANTIGEN; G-PROTEIN; PHOTORECEPTORS; OPSIN; PATTERNS; CELLS	Arrestin, which plays a role in the termination of the visual transduction cascade, is one of several photoreceptor proteins whose mRNA levels are increased by light, Retinoic acid, a by-product of photoreceptor signaling and a potent modulator of hormonal transcription control, is one candidate for regulating the arrestin mRNA levels, Here we show that retinoic acid, injected intraperitoneally into dark-adapted mice, increases the arrestin mRNA levels and mimics the effect of light. injection of 1 mu mol of retinoic acid produces a maximal increase in arrestin mRNA levels, The mRNA level reaches a maximum 3 h after injection and slowly declines thereafter, The observations suggest that retinoic acid may mediate the increase in arrestin mRNA produced by light.-Wagner, E., McCaffery, P., Mey, J., Farhangfar, F., Applebury, M. L., Driiger, U. C. Retinoic aid increases arrestin mRNA levels in the mouse retina.	EUNICE KENNEDY SHRIVER CTR MENTAL RETARDAT INC,WALTHAM,MA 02254; HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT OPHTHALMOL,HOWE LAB,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School				Drager, Ursula C/0000-0003-1815-190X	NEI NIH HHS [EY01938, EY04801] Funding Source: Medline; NICHD NIH HHS [HD05515] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD005515] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY004801, R01EY001938] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALUBAIDI MR, 1990, J BIOL CHEM, V265, P20563; BOWES C, 1988, EXP EYE RES, V47, P369, DOI 10.1016/0014-4835(88)90049-8; CAHILL GM, 1995, PROG RETIN EYE RES, V14, P267, DOI 10.1016/1350-9462(94)00001-Y; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CRAFT CM, 1990, J NEUROCHEM, V55, P1461, DOI 10.1111/j.1471-4159.1990.tb04927.x; DOWLING JE, 1960, P NATL ACAD SCI USA, V46, P587, DOI 10.1073/pnas.46.5.587; Drager UC, 1997, PROG RETIN EYE RES, V16, P323, DOI 10.1016/S1350-9462(96)00029-8; FARBER DB, 1991, EXP EYE RES, V53, P781, DOI 10.1016/0014-4835(91)90114-T; HALE F., 1937, Texas State Journal of Medicine, V33, P228; Hyatt GA, 1996, DEVELOPMENT, V122, P195; KELLEY MW, 1994, DEVELOPMENT, V120, P2091; KELLEY MW, 1995, DEVELOPMENT, V121, P3777; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; KORENBROT JI, 1989, NATURE, V337, P454, DOI 10.1038/337454a0; LU XP, 1994, MOL ENDOCRINOL, V8, P1774, DOI 10.1210/me.8.12.1774; Mangelsdorf David J., 1994, P319; MCCAFFERY P, 1993, DEV BIOL, V158, P390, DOI 10.1006/dbio.1993.1197; MCCAFFERY P, 1992, DEVELOPMENT, V115, P371; MCCAFFERY P, 1996, P NATL ACAD SCI USA, V63, P1570; MCGINNIS JF, 1994, J NEUROSCI RES, V38, P479, DOI 10.1002/jnr.490380414; PIERCE ME, 1993, NEURON, V10, P579, DOI 10.1016/0896-6273(93)90161-J; Saari John C., 1994, P351; Sambrook J., 2002, MOL CLONING LAB MANU; STRYER L, 1981, BIOCHEMSITRY; TSUDA M, 1988, GENE, V73, P11, DOI 10.1016/0378-1119(88)90308-3; WAGNER M, 1992, DEVELOPMENT, V116, P55; WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0; WARKANY J, 1946, ARCH OPHTHALMOL-CHIC, V35, P150, DOI 10.1001/archopht.1946.00890200155008; WILSON CJ, 1993, CURR BIOL, V3, P683, DOI 10.1016/0960-9822(93)90068-Y; YOSHIDA K, 1993, NEURON, V10, P1049, DOI 10.1016/0896-6273(93)90053-T	30	17	17	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1997	11	4					271	275		10.1096/fasebj.11.4.9068616	http://dx.doi.org/10.1096/fasebj.11.4.9068616			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WM850	9068616				2022-12-28	WOS:A1997WM85000009
J	Stern, B; Denisova, G; Buyaner, D; Raviv, D; Gershoni, JM				Stern, B; Denisova, G; Buyaner, D; Raviv, D; Gershoni, JM			Helical epitopes determined by low-stringency antibody screening of a combinatorial peptide library	FASEB JOURNAL			English	Article						monoclonal antibodies; phage display libraries; protein secondary structure; AIDS; vaccine	HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN-STRUCTURE DETERMINATION; GP120 SURFACE GLYCOPROTEIN; SECONDARY-STRUCTURE; GLOBULAR-PROTEINS; NMR-SPECTROSCOPY; TYPE-1; IDENTIFICATION; HIV; COMPLEMENT	Combinatorial phage display peptide libraries are routinely used to map epitopes of specific monoclonal antibodies. In this study we illustrate that these libraries can be used in the analysis of protein structure, By screening libraries at low stringency, a collection of phages can be obtained, These are characterized by the fact that they are recognized by a given monoclonal antibody yet with various affinities. Comparing the random peptides of these phages indicates the common essential residues necessary for antibody recognition. Aligning the inserts based on the detected homology has revealed structural motifs that correspond to secondary protein structures, The envelope protein of HIV-1 has been studied using this approach, A combinatorial phage display Library containing a 20 mer random peptide III protein III of the filamentous phage fd-tet has been used to analyze two different monoclonal antibodies directed against gp120. Our results provide experimental evidence that indicate that the C1 domain of gp120 contains an alpha helix.	TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT CELL RES & IMMUNOL, IL-69978 TEL AVIV, ISRAEL	Tel Aviv University								BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLORE GM, 1991, PROG NUCL MAG RES SP, V23, P43, DOI 10.1016/0079-6565(91)80002-J; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DECROLY E, 1993, J VIROL, V67, P3552, DOI 10.1128/JVI.67.6.3552-3560.1993; DELORIMIER R, 1994, BIOCHEMISTRY-US, V33, P2055, DOI 10.1021/bi00174a011; Denisova G, 1996, AIDS RES HUM RETROV, V12, P901, DOI 10.1089/aid.1996.12.901; DIERICH MP, 1993, IMMUNOL TODAY, V14, P435, DOI 10.1016/0167-5699(93)90246-H; GALLAHER WR, 1995, AIDS RES HUM RETROV, V11, P191, DOI 10.1089/aid.1995.11.191; GERSHONI JM, 1988, METHOD BIOCHEM ANAL, V33, P1; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GILBRAT JF, 1987, J MOL BIOL, V198, P425; Harlow E., 1988, ANTIBODIES LAB MANUA; HELSETH E, 1991, J VIROL, V65, P2119, DOI 10.1128/JVI.65.4.2119-2123.1991; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; KABSCH W, 1983, FEBS LETT, V155, P179, DOI 10.1016/0014-5793(82)80597-8; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVITT M, 1977, J MOL BIOL, V114, P181, DOI 10.1016/0022-2836(77)90207-8; MATTHEWS BW, 1976, ANNU REV PHYS CHEM, V27, P493, DOI 10.1146/annurev.pc.27.100176.002425; McPherson A, 1982, PREPARATION ANAL PRO; MOORE JP, 1993, J VIROL, V67, P4785, DOI 10.1128/JVI.67.8.4785-4796.1993; MOORE JP, 1994, J VIROL, V68, P469, DOI 10.1128/JVI.68.1.469-484.1994; MOORE JP, 1994, J VIROL, V68, P6836, DOI 10.1128/JVI.68.11.6836-6847.1994; NYGREN A, 1988, P NATL ACAD SCI USA, V85, P6543, DOI 10.1073/pnas.85.17.6543; OLSHEVSKY U, 1990, J VIROL, V64, P5701, DOI 10.1128/JVI.64.12.5701-5707.1990; OSCHKINAT H, 1994, ANGEW CHEM INT EDIT, V33, P277, DOI 10.1002/anie.199402771; PINTER C, 1995, AIDS RES HUM RETROV, V11, P577, DOI 10.1089/aid.1995.11.577; PRESTRELSKI SJ, 1992, PROTEINS, V14, P440, DOI 10.1002/prot.340140405; RAMAKRISHNAN C, 1982, INT J PEPT PROT RES, V20, P218; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P600; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; STERN B, 1997, IN PRESS METHODS MOL; UNGER R, 1989, PROTEINS, V5, P355, DOI 10.1002/prot.340050410; WUTHRICH K, 1989, SCIENCE, V243, P45, DOI 10.1126/science.2911719	35	18	19	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1997	11	2					147	153		10.1096/fasebj.11.2.9039957	http://dx.doi.org/10.1096/fasebj.11.2.9039957			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK509	9039957				2022-12-28	WOS:A1997WK50900007
J	Song, Y; Chan, CWY; Brown, GM; Pang, SF; Silverman, M				Song, Y; Chan, CWY; Brown, GM; Pang, SF; Silverman, M			Studies of the renal action of melatonin: Evidence that the effects are mediated by 37 kDa receptors of the Mel(1a) subtype localized primarily to the basolateral membrane of the proximal tubule	FASEB JOURNAL			English	Article						immunocytochemistry; 2-[I-125]iodomelatonin binding sites; cortex; small intestine; pertussis toxin-sensitive G-protein	IODOMELATONIN-BINDING-SITES; PIG-KIDNEY; EXCRETION; BRAIN	The pineal hormone melatonin controls circadian behavior of a variety of organs in different species, including humans. However, the precise mechanism (or mechanisms) by which this occurs remains largely unknown. At the cellular level its effects are believed to be mediated via interaction with specific melatonin receptors (MR), which have previously been cloned front human brain (Mel(1n)) and retina (Mel(1b)). At the tissue level, MR have been investigated primarily through empirical definition of specific binding sites, but so far there has been little success in biochemical or molecular characterization of native MR. In the kidney, there is strong circumstantial evidence that melatonin affects diurnal variations in renal function,but relatively little is known about the overall glomerular vs. tubular contributions to these effects. The strategy behind the present study was to use a panel of peptide-specific antibodies to identify MR proteins in various tissues, and from a determination of the intrarenal distribution of MR, gain insight into the mechanism by which melatonin might regulate kidney function. We used two peptide-specific antibodies directed against different regions of Mel(1n) to identify MR. Our results show that the native Mel(1a) receptor is a 37 kilodalton (kDa) protein in hunan and rat brain. Further, immunofluorescent studies carried out hi guinea pig kidney have revealed that anti-Mel(1a) antibody is also localized to the basolateral membrane (BLM) of the renal cortical epithelium, especially the early proximal tubule. Immunoblotting of purified BLM fractions from guinea pig renal cortex and small intestine using the two different peptide-specific antibodies reveals the presence of a single peptide-blockable band at 37 kDa. These same BLM fractions also demonstrate the presence of high-affinity 2-[I-125]iodomelatonin (I-125-MEL) binding sites, with the pharmacological specificity of binding expected of the Mel(1a) receptor subtype, inhibited by guanosine 5'-O-(3'-thiotriphosphate) (GTP gamma S) and pertussis toxin. We conclude that functional MR in guinea pig kidney and small intestine are of the Mel(1a) subtype, and are expressed as 37 kDa proteins localized to the BLM and coupled to a pertussis toxin-sensitive G-protein (Gi). This localization strongly suggests that the proximal tubule plays a significant role in mediating the renal action of melatonin.	UNIV TORONTO,MRC,MEMBRANE BIOL GRP,DEPT MED,TORONTO,ON M5S 1A8,CANADA; CLARKE INST PSYCHIAT,TORONTO,ON M5T 1R8,CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada								BLANCO J, 1992, BRIT J PHARMACOL, V107, P671, DOI 10.1111/j.1476-5381.1992.tb14505.x; DOUCET A, 1979, AM J PHYSIOL, V237, pF105, DOI 10.1152/ajprenal.1979.237.2.F105; DUBOCOVICH ML, 1995, TRENDS PHARMACOL SCI, V16, P50, DOI 10.1016/S0165-6147(00)88978-6; EICHHOLZ A, 1967, BIOCHIM BIOPHYS ACTA, V135, P475, DOI 10.1016/0005-2736(67)90037-5; KEMP GJ, 1992, CLIN CHEM, V38, P400; Koopman MC, 1989, BIOL RHYTHMS CLIN PR, V83-98; KOOPMAN MG, 1994, Q J MED, V87, P109; Lee P. P. N., 1993, Biological Signals, V2, P181; PONTOIRE C, 1993, EUR J PHARM-MOLEC PH, V247, P111, DOI 10.1016/0922-4106(93)90067-J; PORTEOUS JW, 1965, BIOCHEM J, V96, P159, DOI 10.1042/bj0960159; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; REITER RJ, 1993, EXPERIENTIA, V49, P654, DOI 10.1007/BF01923947; REPPERT SM, 1995, NEURON, V15, P1003, DOI 10.1016/0896-6273(95)90090-X; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; RIBEIRONETO FAP, 1985, METHOD ENZYMOL, V109, P566; RICHARDSON BA, 1992, J PINEAL RES, V13, P49, DOI 10.1111/j.1600-079X.1992.tb00054.x; SCALERA V, 1981, MEMBRANE BIOCHEM, V4, P49, DOI 10.3109/09687688109065422; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Song Y., 1993, Biological Signals, V2, P207; SONG Y, 1993, J PINEAL RES, V15, P153, DOI 10.1111/j.1600-079X.1993.tb00523.x; SONG Y, 1992, J ENDOCRINOL, V135, P353, DOI 10.1677/joe.0.1350353; SONG Y, 1995, J CLIN ENDOCR METAB, V80, P1560, DOI 10.1210/jc.80.5.1560; Song Y, 1996, EUR J ENDOCRINOL, V135, P128, DOI 10.1530/eje.0.1350128; SONG Y, 1996, IN PRESS FRONTIERS H, V21; Tsuda T, 1995, J PINEAL RES, V19, P166, DOI 10.1111/j.1600-079X.1995.tb00185.x; VAKKURI O, 1984, ANAL BIOCHEM, V142, P284, DOI 10.1016/0003-2697(84)90466-4; WEILAND GA, 1981, LIFE SCI, V29, P313, DOI 10.1016/0024-3205(81)90324-6; YUAN H, 1995, NEUROSCI LETT, V197, P154, DOI 10.1016/0304-3940(95)11904-B; [No title captured]	30	88	93	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1997	11	1					93	100		10.1096/fasebj.11.1.9034171	http://dx.doi.org/10.1096/fasebj.11.1.9034171			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK147	9034171				2022-12-28	WOS:A1997WK14700013
J	Holler, T; Cermak, JM; Blusztajn, JK				Holler, T; Cermak, JM; Blusztajn, JK			Dietary choline supplementation in pregnant rats increases hippocampal phospholipase D activity of the offspring	FASEB JOURNAL			English	Article						development; hippocampus; memory; metabotropic glutamate receptors; phosphatidylcholine	LONG-TERM POTENTIATION; ADP-RIBOSYLATION FACTOR; PROTEIN-KINASE-C; SUBSTRATE-SPECIFICITY; ACTIVATION; MEMORY; SLICES; NUTRITION; MODEL; GRANULOCYTES	Supplementation with choline during pregnancy in rats causes a long-lasting improvement of visuospatial memory of the offspring, The biochemical mechanism of this effect may be related to the function of choline as a precursor of phosphatidylcholine (PC), the substrate of a receptor-stimulated enzyme, phospholipase D (PLD), PLD activation initiates the sequential formation of two intracellular messengers, phosphatidic acid and 1,2-sn-diacylglycerol, We hypothesized that prenatal choline status may cause long-term modulation of PLD-catalyzed PC hydrolysis in the hippocampus, a brain region implicated in visuospatial memory functions, PLD activity was determined in hippocampal slices prelabeled with [H-3]glycerol or [H-3]oleic acid by measuring the PLD-catalyzed formation of [3H]phosphatidylpropanol in the presence of l-propanol, Slices were obtained from male pups born to mothers consuming a control diet, a choline-supplemented diet, or a choline-free diet from days 11 to 17 of pregnancy, The radiolabeling of phospholipid classes was unaffected by the treatments, Prenatal choline supplementation significantly increased basal PLD activity in [H-3]glycerol-labeled slices [by 46% of controls on postnatal day (P) 7 and by 36% on P21], and [H-3] oleate-labeled slices (by 91% on P7), as well as glutamate-stimulated PLD activity in [H-3]oleate-labeled slices (by 60% on P?), Prenatal choline deficiency failed to alter PLD activity, The actions of choline apparently required intact cells because in vitro assays of PLD activity in hippocampal homogenates, using fluorescent NBD-PC as substrate, revealed no differences between groups, The results show that prenatal choline supplementation up-regulates basal and receptor-stimulated PLD activity in the hippocampus during postnatal development.	BOSTON UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02118	Boston University; Boston University				/0000-0001-8438-3122	NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER; NIA NIH HHS [AG09525] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BEHNISCH T, 1993, NEUROSCIENCE, V54, P37, DOI 10.1016/0306-4522(93)90381-O; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BLUSZTAJN JK, 1983, SCIENCE, V221, P614, DOI 10.1126/science.6867732; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BOSS V, 1992, J NEUROCHEM, V59, P2340; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BUCHMAN AL, 1995, HEPATOLOGY, V22, P1399, DOI 10.1002/hep.1840220510; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Crawford M. A., 1993, Nutrition and Health (Bicester), V9, P81; DANIN M, 1993, METH NEUROSCI, V18, P14; Delong G. Robeert, 1993, American Journal of Clinical Nutrition, V57, p286S, DOI 10.1093/ajcn/57.2.286S; EAGLE H, 1955, J EXP MED, V102, P595, DOI 10.1084/jem.102.5.595; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FIBIGER HC, 1991, TRENDS NEUROSCI, V14, P220, DOI 10.1016/0166-2236(91)90117-D; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRICKE R, 1977, J COMP NEUROL, V173, P231, DOI 10.1002/cne.901730203; GRIFFITH WENDELL H., 1939, JOUR BIOL CHEM, V131, P567; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HOLLER T, 1993, J NEUROCHEM, V61, P1569, DOI 10.1111/j.1471-4159.1993.tb13659.x; HOLLER T, 1994, BIOCHEM PHARMACOL, V47, P411, DOI 10.1016/0006-2952(94)90033-7; HORWITZ J, 1993, BIOCHEM J, V295, P793, DOI 10.1042/bj2950793; IZQUIERDO I, 1975, Progress in Neurobiology (Oxford), V5, P37, DOI 10.1016/0301-0082(75)90007-6; KLEIN J, 1995, J NEUROCHEM, V65, P1445; KOBAYASHI M, 1987, J NEUROCHEM, V48, P1597, DOI 10.1111/j.1471-4159.1987.tb05707.x; LEE HC, 1993, P NATL ACAD SCI USA, V90, P10086, DOI 10.1073/pnas.90.21.10086; LINDEN DJ, 1989, BRAIN RES REV, V14, P279, DOI 10.1016/0165-0173(89)90004-0; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LLAHI S, 1992, J BIOL CHEM, V267, P3679; LOY R, 1991, ADV EXP MED BIOL, V295, P373; LOY R, 1977, BRAIN RES, V121, P229, DOI 10.1016/0006-8993(77)90149-4; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; MECK WH, 1989, BEHAV NEUROSCI, V103, P1234, DOI 10.1037/0735-7044.103.6.1234; Minkwitz H G, 1975, J Hirnforsch, V16, P37; Minkwitz H G, 1976, J Hirnforsch, V17, P255; MOHN H, 1992, J BIOL CHEM, V267, P11131; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OTANI S, 1993, BRAIN RES, V613, P1, DOI 10.1016/0006-8993(93)90446-T; OTANI S, 1991, EUR J PHARMACOL, V205, P325, DOI 10.1016/0014-2999(91)90920-L; PAI JK, 1988, J BIOL CHEM, V263, P12472; RIEDER MJ, 1994, CLIN PERINATOL, V21, P483, DOI 10.1016/S0095-5108(18)30328-2; SARRI E, 1995, J NEUROCHEM, V65, P837; SASTRY PS, 1985, PROG LIPID RES, V24, P69, DOI 10.1016/0163-7827(85)90011-6; SHEN Y, 1994, PROG NEUROBIOL, V44, P485, DOI 10.1016/0301-0082(94)90008-6; SINGH SC, 1977, ANAT EMBRYOL, V151, P183, DOI 10.1007/BF00297480; THAL LJ, 1992, NEUROBIOL AGING, V13, P67, DOI 10.1016/0197-4580(92)90011-L; WANG P, 1991, J BIOL CHEM, V266, P14877; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413; ZEISEL SH, 1995, J NUTR, V125, P3049; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061	51	51	51	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1996	10	14					1653	1659		10.1096/fasebj.10.14.9002559	http://dx.doi.org/10.1096/fasebj.10.14.9002559			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WC869	9002559				2022-12-28	WOS:A1996WC86900013
J	Salmivirta, M; Lidholt, K; Lindahl, U				Salmivirta, M; Lidholt, K; Lindahl, U			Heparan sulfate: A piece of information	FASEB JOURNAL			English	Article						heparin; GAG; proteoglycan; enzyme; polysaccharide-protein interactions	FIBROBLAST GROWTH-FACTOR; D-GLUCOSAMINYLTRANSFERASE REACTIONS; CELL-SURFACE; MOLECULAR-CLONING; BINDING DOMAIN; BIOSYNTHESIS; PROTEOGLYCANS; GLYCOSAMINOGLYCANS; SULFOTRANSFERASE; SEQUENCES	he sulfated glycosaminoglycans, heparan sulfate and heparin, are increasingly implicated in cell-biological processes such as cytokine action, cell adhesion, and regulation of enzymic catalysis, These activities generally depend on interactions of the polysaccharides with proteins, mediated by distinct saccharide sequences, and expressed at various levels of specificity, selectivity, and molecular organization. The formation of heparin/heparan sulfate in the cell requires an elaborate biosynthetic machinery, that is conceived in terms of a novel model of glycosaminoglycan assembly and processive modification, Recent advances in the identification and molecular analysis of the enzymes and other proteins involved in the biosynthesis provide novel tools to study the regulation of the process, presently poorly understood, at the subcellular and cellular levels, The potential medical importance of heparin-related compounds is likely to promote the biotechnological exploitation of components of the biosynthetic machinery.	UPPSALA UNIV,CTR BIOMED,DEPT MED & PHYSIOL CHEM,S-75123 UPPSALA,SWEDEN	Uppsala University								BERNFIELD M, 1992, ANN REV CELL BIOL, V8, P333; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; BUSCH SJ, 1992, J CELL BIOL, V116, P31, DOI 10.1083/jcb.116.1.31; CAMPBELL P, 1994, J BIOL CHEM, V269, P26953; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; COLLIECJOUAULT S, 1994, J BIOL CHEM, V269, P24953; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; GROOTENHUIS PDJ, 1995, NAT STRUCT BIOL, V2, P736, DOI 10.1038/nsb0995-736; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; IOZZO RV, 1994, MATRIX BIOL, V14, P203, DOI 10.1016/0945-053X(94)90183-X; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P817, DOI 10.1093/glycob/4.6.817; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KITAGAWA H, 1995, J BIOL CHEM, V270, P22190, DOI 10.1074/jbc.270.38.22190; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KUSCHE M, 1990, J BIOL CHEM, V265, P15403; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LIND T, 1993, J BIOL CHEM, V268, P20705; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; Lindahl U., 1989, HEPARIN, P159; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; NORGARDSUMNICHT K, 1995, J BIOL CHEM, V270, P12012, DOI 10.1074/jbc.270.20.12012; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; RAZI N, 1995, J BIOL CHEM, V270, P11267, DOI 10.1074/jbc.270.19.11267; SALMIVIRTA M, 1992, J BIOL CHEM, V267, P17606; SALMIVIRTA M, 1995, EXPERIENTIA, V51, P863, DOI 10.1007/BF01921737; SANDERSON PN, 1983, BIOCHEM J, V211, P677, DOI 10.1042/bj2110677; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885; WLAD H, 1994, J BIOL CHEM, V269, P24538; ZHANG L, 1995, J BIOL CHEM, V270, P12557, DOI 10.1074/jbc.270.21.12557; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127	50	383	388	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1996	10	11					1270	1279		10.1096/fasebj.10.11.8836040	http://dx.doi.org/10.1096/fasebj.10.11.8836040			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VJ717	8836040				2022-12-28	WOS:A1996VJ71700006
J	Roberts, DD				Roberts, DD			Regulation of tumor growth and metastasis by thrombospondin-1	FASEB JOURNAL			English	Review						tumorigenesis; angiogenesis; cell-matrix interactions	HUMAN SQUAMOUS CARCINOMA; HUMAN BREAST-CARCINOMA; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; FACTOR-BETA; MELANOMA-CELLS; ADHESION MOLECULES; EPITHELIAL-CELLS; IN-VIVO; ANGIOGENESIS	Thrombospondin-1 (TSP1) is an extracellular matrix glycoprotein that influences cell adhesion, motility, and growth, Based on its effects on tumor and endothelial cell behavior, this member of the thrombospondin gene family has attracted interest as a potential regulator of tumor growth and metastasis, Initial studies have confirmed that increased TSP1 expression suppresses growth or metastasis of some tumors in vivo and inhibits angiogenesis. These activities are cell. type specific, however, since overexpression of TSP1 in some tumors causes increased tumor progression. One basis for these apparently conflicting observations may be the complexity of the protein, TSP1 interacts specifically with several cell-surface receptors, heparan sulfate proteoglycans, growth factors, and other matrix components. These multiple binding specificities, combined with the ability of TSP1 to activate latent transforming growth factor beta and inhibit several proteases, suggest; that exposure to TSP1 may initiate several intracellular signals, The integration of these signals may allow varied responses to TSP1, Furthermore, these signals may be received by the tumor cells, endothelial cells responsible for neovascularization, stromal cells, or cells of the host immune system, TSP1 influences specific behaviors of each cell type. Relating these phenomena to the molecular interactions of TSP1 observed in vitro may lead to novel therapeutic strategies for controlling cancer progression and metastasis.	NCI,PATHOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981				ADAMS J, 1993, CURR BIOL, V3, P188, DOI 10.1016/0960-9822(93)90270-X; ALBELDA SM, 1993, LAB INVEST, V68, P4; ARTEAGA CL, 1993, J CLIN INVEST, V92, P2569, DOI 10.1172/JCI116871; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; ASCH AS, 1993, THROMBOSPONDIN, P265; BAGAVANDOSS P, 1993, BIOCHEM BIOPH RES CO, V192, P325, DOI 10.1006/bbrc.1993.1418; BALEY P, 1990, J CELL BIOCHEM, V43, P111, DOI 10.1002/jcb.240430203; BENEZRA D, 1993, INVEST OPHTH VIS SCI, V34, P3601; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; BOUKERCHE H, 1995, BRIT J CANCER, V72, P108, DOI 10.1038/bjc.1995.285; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CAO AG, 1996, J BIOL CHEM, V271, P21; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; CASTLE VP, 1993, J BIOL CHEM, V268, P2899; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLEZARDIN P, 1993, CANCER RES, V53, P1421; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DEFREITAS MF, 1995, NEURON, V15, P333, DOI 10.1016/0896-6273(95)90038-1; DIPIETRO LA, 1994, J VASC RES, V31, P178, DOI 10.1159/000319585; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; HOGG PJ, 1994, THROMB HAEMOSTASIS, V72, P787; HONN KV, 1992, CANCER METAST REV, V11, P325, DOI 10.1007/BF01307186; HOSOKAWA T, 1993, ONCOL RES, V5, P183; INCARDONA F, 1995, CANCER RES, V55, P166; IruelaArispe ML, 1996, J CLIN INVEST, V97, P403, DOI 10.1172/JCI118429; KATAGIRI Y, 1991, CANCER RES, V51, P1286; LAHAV J, 1993, BIOCHIM BIOPHYS ACTA, V1182, P1, DOI 10.1016/0925-4439(93)90146-R; Lahav J, 1993, THROMBOSPONDIN; LAWLER J, 1993, THROMBOSPONDIN, P275; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1993, J BIOL CHEM, V268, P26784; PASSANITI A, 1992, LAB INVEST, V67, P519; PHAN SH, 1989, BIOCHEM BIOPH RES CO, V163, P56, DOI 10.1016/0006-291X(89)92098-6; Pierson BA, 1996, BLOOD, V87, P180, DOI 10.1182/blood.V87.1.180.bloodjournal871180; RAYCHAUDHURY A, 1994, J CELL SCI, V107, P39; RISER BL, 1989, CANCER RES, V49, P6123; RISER BL, 1988, EXP CELL RES, V174, P319, DOI 10.1016/0014-4827(88)90303-5; ROBERTS DD, 1993, THROMBOSPONDIN, P73; SALNIKOW K, 1994, MOL CELL BIOL, V14, P851, DOI 10.1128/MCB.14.1.851; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; Serre CM, 1995, VIRCHOWS ARCH, V427, P365; SHEIBANI N, 1995, P NATL ACAD SCI USA, V92, P6788, DOI 10.1073/pnas.92.15.6788; SI ZY, 1994, PATHOLOGY, V26, P6, DOI 10.1080/00313029400169011; SILVERSTEIN RL, 1992, J BIOL CHEM, V267, P16607; SOUCHELNITSKIY S, 1995, ENDOCRINOLOGY, V136, P5118, DOI 10.1210/en.136.11.5118; Stracke M L, 1994, In Vivo, V8, P49; SUCHARD SJ, 1993, BLOOD CELLS, V19, P197; TARABOLETTI G, 1987, J CELL BIOL, V105, P2409, DOI 10.1083/jcb.105.5.2409; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TSAO PW, 1995, J BIOL CHEM, V270, P23747, DOI 10.1074/jbc.270.40.23747; Tuszynski GP, 1996, BIOESSAYS, V18, P71, DOI 10.1002/bies.950180113; TUSZYNSKI GP, 1994, LAB INVEST, V70, P228; VOGEL T, 1993, J CELL BIOCHEM, V53, P74, DOI 10.1002/jcb.240530109; VOLPERT OV, 1995, BREAST CANCER RES TR, V36, P119, DOI 10.1007/BF00666034; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; WONG SY, 1992, AM J PATHOL, V140, P1473; YABKOWITZ R, 1993, J IMMUNOL, V151, P149; YABKOWITZ R, 1991, CANCER RES, V51, P3648; YABKOWITZ R, 1993, CANCER RES, V53, P378; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209; ZAJCHOWSKI DA, 1990, P NATL ACAD SCI USA, V87, P2314, DOI 10.1073/pnas.87.6.2314	69	248	262	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1996	10	10					1183	1191		10.1096/fasebj.10.10.8751720	http://dx.doi.org/10.1096/fasebj.10.10.8751720			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VD429	8751720				2022-12-28	WOS:A1996VD42900009
J	Komuro, I; Kudo, S; Yamazaki, T; Zou, YZ; Shiojima, I; Yazaki, Y				Komuro, I; Kudo, S; Yamazaki, T; Zou, YZ; Shiojima, I; Yazaki, Y			Mechanical stretch activates the stress-activated protein kinases in cardiac myocytes	FASEB JOURNAL			English	Article						cardiac hypertrophy; mechanical stress; the stress-activated protein kinase; gene expression; angiotensin II	GENE-EXPRESSION; PHOSPHORYLATION; HYPERTROPHY	We have recently shown that mechanical stress activates a phosphorylation cascade of protein kinases including Raf-1 and the extracellular signal-regulated kinases (ERKs) in cultured cardiac: myocytes partially through the enhanced secretion of angiotensin II, Osmotic stress in budding yeast has been shown to activate similar signaling molecules including Hog-1, a distant relative of the ERK family, In the present study, we examined whether mechanical stretch of cardiac myocytes activates the stress-activated protein kinases (SAPKs)/c-Jun NH2-terminal kinase, the mammalian homologs of yeast Hog-1 that regulate gene expression through activation of the transcription factor, AP-1, When cardiac myocytes of neonatal rats cultured on a deformable silicone dish were stretched, activity of SAPKs was increased from 10 min, peaked at 30 min, and gradually decreased thereafter, The increase in activity of SAPKs was proportional to the stretch, Unlike ERKs, the activation of SAPKs by stretching cardiac myocytes was not dependent on the secreted angiotensin II, The chelation of extracellular Ca2+ or down-regulation of protein kinase C did not attenuate activation of SAPKs by stretch, Transfection experiments using an AP-1 binding site-containing reporter gene revealed that stretch increases AP-1 activity in cardiac myocytes, In conclusion, Like osmotic stress in yeast, mechanical stretch activates SAPKs in cardiac myocytes without the participation of angiotensin II, These results suggest that the activation of SAPKs may regulate gene expression during mechanical stress-induced cardiac hypertrophy.			Komuro, I (corresponding author), UNIV TOKYO,SCH MED,DEPT MED 3,MOL CARDIOL DIV,BUNKYO KU,7-3-1 HONGO,TOKYO 113,JAPAN.							BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KOJIMA M, 1994, CIRCULATION, V89, P2204, DOI 10.1161/01.CIR.89.5.2204; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LOKUTA AJ, 1994, J BIOL CHEM, V269, P4832; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; YAMAZAKI T, 1995, CIRC RES, V77, P258, DOI 10.1161/01.RES.77.2.258; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069	27	191	195	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1996	10	5					631	636		10.1096/fasebj.10.5.8621062	http://dx.doi.org/10.1096/fasebj.10.5.8621062			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UJ055	8621062				2022-12-28	WOS:A1996UJ05500011
J	Benschop, RJ; Jacobs, R; Sommer, B; Schurmeyer, TH; Raab, HR; Schmidt, RE; Schedlowski, M				Benschop, RJ; Jacobs, R; Sommer, B; Schurmeyer, TH; Raab, HR; Schmidt, RE; Schedlowski, M			Modulation of the immunologic response to acute stress in humans by beta-blockade or benzodiazepines	FASEB JOURNAL			English	Article						neuroimmunology; beta-adrenoceptor blockade; benzodiazepines; neuroendocrinology; splenectomy	NATURAL-KILLER-CELLS; PSYCHOLOGICAL STRESS; LYMPHOCYTE SUBSETS; PERIPHERAL-BLOOD; ALPRAZOLAM; CATECHOLAMINES; EXERCISE	Acute stress evokes immediate responses in the cardiovascular, endocrine, and immune systems, In particular, the number and activity of natural killer (NK) lymphocytes increase after stress. Here, we investigate the possibility to pharmacologically interfere with these stress-induced immunologic changes. Twenty-five healthy males were subjected to an acute stressor, a first-time tandem parachute jump. Subjects were randomly assigned to a beta-adrenoceptor antagonist (propranolol), a benzodiazepine (alprazolam), or placebo group. To analyze the role of the spleen in lymphocyte redistribution, splenectomized subjects performed a parachute jump. Propranolol, but not alprazolam, inhibited the heart rate increase during jumping. Increases in epinephrine and cortisol in the propranolol group were comparable to placebo, but were attenuated by alprazolam. The number and activity of NK cells significantly increased in the placebo group but not in the propranolol group immediately after stress. Alprazolam treatment did not alter the increase in NK cell numbers but did inhibit the increase in Nh activity. In splenectomized subjects, NK cell numbers, but not NK activity, increased as in placebo subjects. We conclude that stress-induced changes in the immune system are controlled by P-adrenergic mechanisms and only partly depend on the spleen; central interference with alprazolam differentially affects stress-induced changes in the NK cell compartment.	HANNOVER MED SCH,DIV CLIN ENDOCRINOL,D-30623 HANNOVER,GERMANY; HANNOVER MED SCH,DIV SURG,D-30623 HANNOVER,GERMANY; HANNOVER MED SCH,DIV MED PSYCHOL,D-30623 HANNOVER,GERMANY	Hannover Medical School; Hannover Medical School; Hannover Medical School	Benschop, RJ (corresponding author), HANNOVER MED SCH,DEPT CLIN IMMUNOL,DIV CLIN IMMUNOL,D-30623 HANNOVER,GERMANY.		Jacobs, Roland/E-7099-2010	Jacobs, Roland/0000-0003-2942-7924; jacobs, reinhilde/0000-0002-3461-0363				BENSCHOP RJ, 1993, EUR J IMMUNOL, V23, P3242, DOI 10.1002/eji.1830231230; BENSCHOP RJ, 1994, BRIT J PHARMACOL, V113, P1311, DOI 10.1111/j.1476-5381.1994.tb17141.x; BENSCHOP RJ, 1994, CIRCULATION, V89, P762, DOI 10.1161/01.CIR.89.2.762; BOYUM A, 1968, SCAND J CLIN LAB INV, V21, P97; BREIER A, 1992, BIOL PSYCHIAT, V32, P880, DOI 10.1016/0006-3223(92)90177-2; BROSSCHOT JF, 1992, PSYCHOSOM MED, V54, P394, DOI 10.1097/00006842-199207000-00002; BRYANT J, 1992, J IMMUNOL METHODS, V146, P91, DOI 10.1016/0022-1759(92)90052-U; Cannon WB., BODILY CHANGES PAIN, DOI [10.1037/10013-000, DOI 10.1037/10013-000]; CRARY B, 1983, J IMMUNOL, V131, P1178; DIMSDALE JE, 1980, JAMA-J AM MED ASSOC, V243, P340, DOI 10.1001/jama.243.4.340; FREIREGARABAL M, 1993, CANCER LETT, V73, P155, DOI 10.1016/0304-3835(93)90258-B; GREENBLATT DJ, 1993, ARCH GEN PSYCHIAT, V50, P715; GREENBLATT DJ, 1993, CLIN PHARMACOKINET, V24, P453, DOI 10.2165/00003088-199324060-00003; HERCEND T, 1988, IMMUNOL TODAY, V9, P291, DOI 10.1016/0167-5699(88)91317-5; HOFFMAN BB, 1990, PHARMACOL BASIS THER, P221; HOFFMANGOETZ L, 1994, IMMUNOL TODAY, V15, P382, DOI 10.1016/0167-5699(94)90177-5; IRWIN M, 1993, BRAIN RES, V631, P114, DOI 10.1016/0006-8993(93)91194-W; JACOBS R, 1992, BLOOD, V79, P3239; KIPARSKI R V, 1985, Biomedizinische Technik, V30, P76; KNAPP W, 1989, LEUKOCYTE TYPING 4; LANDMANN R, 1992, EUR J CLIN INVEST, V22, P30; MAISEL AS, 1989, CLIN PHARMACOL THER, V46, P429, DOI 10.1038/clpt.1989.161; MURRAY DR, 1992, CIRCULATION, V86, P203, DOI 10.1161/01.CIR.86.1.203; NALIBOFF BD, 1991, PSYCHOSOM MED, V53, P121, DOI 10.1097/00006842-199103000-00002; NESTEL PJ, 1969, LANCET, V1, P692, DOI 10.1016/S0140-6736(69)92645-2; PABST R, 1987, AM REV RESPIR DIS, V136, P1213, DOI 10.1164/ajrccm/136.5.1213; PERUSSIA B, 1983, J IMMUNOL, V130, P2133; RITZ J, 1988, ADV IMMUNOL, V42, P181, DOI 10.1016/S0065-2776(08)60845-7; ROHRER T, 1994, HORM METAB RES, V26, P200, DOI 10.1055/s-2007-1000811; SCHEDLOWSKI M, 1992, LIFE SCI, V50, P1201, DOI 10.1016/0024-3205(92)90319-K; SCHEDLOWSKI M, 1993, J CLIN IMMUNOL, V13, P344, DOI 10.1007/BF00920243; SCHEDLOWSKI M, 1992, PSYCHOPHYSIOLOGY, V29, P95, DOI 10.1111/j.1469-8986.1992.tb02020.x; Schedlowski M, 1996, J IMMUNOL, V156, P93; SCHEDLOWSKI M, 1993, J CLIN IMMUNOL, V13, P118; SCHMIDT RE, 1985, NATURE, V318, P289, DOI 10.1038/318289a0; SHADER RI, 1993, NEW ENGL J MED, V328, P1398; SHERWOOD A, 1986, PSYCHOPHYSIOLOGY, V23, P89, DOI 10.1111/j.1469-8986.1986.tb00602.x; TORPY DJ, 1994, J CLIN ENDOCR METAB, V79, P140, DOI 10.1210/jc.79.1.140; UCIECHOWSKI P, 1992, EUR J IMMUNOL, V22, P1635, DOI 10.1002/eji.1830220643; WHITESIDE TL, 1989, CLIN IMMUNOL IMMUNOP, V53, P1, DOI 10.1016/0090-1229(89)90096-2	40	116	116	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1996	10	4					517	524		10.1096/fasebj.10.4.8647351	http://dx.doi.org/10.1096/fasebj.10.4.8647351			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UE557	8647351				2022-12-28	WOS:A1996UE55700016
J	Fischer, D; Rice, D; Bowie, JU; Eisenberg, D				Fischer, D; Rice, D; Bowie, JU; Eisenberg, D			Assigning amino acid sequences to 3-dimensional protein folds	FASEB JOURNAL			English	Review						fold recognition; inverted protein folding	PROFILE ANALYSIS; DATA-BANK; PREDICTION; IDENTIFICATION; RECOGNITION; INFORMATION; SELECTION	With the advent of genome sequencing projects, the amino acid sequences of thousands of proteins are determined every year, Each of these protein sequences must be identified with its function and its 3-dimensional structure for us to gain a full understanding of the molecular biology of organisms, To meet this challenge, new methods are being developed for fold recognition, the computational assignment of newly determined amino acid sequences to 3-dimensional protein structures, These methods start with a library of known 3-dimensional target protein structures, The new probe sequence is then aligned to each target protein structure in the library and the compatibility of the sequence for that structure is scored, If a target structure is found to have a significantly high compatibility score, it is assumed that the probe sequence folds in much the same way as the target structure, The fundamental assumptions of this approach are that many different sequences fold in similar ways and there is a relatively high probability that a new sequence possesses a previously observed fold. We review various approaches to fold recognition and break down the process into its main steps: creation of a library of target folds; representation of the folds; alignment of the probe sequence to a target fold using a sequence-to-structure compatibility scoring function; and assessment of significance of compatibility. We emphasize that even though this new field of fold recognition has made rapid progress, technical problems remain to be solved in most of the steps. Standard benchmarks may help identify the problem steps and find solutions to the problems.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, UCLA DOE LAB STRUCT BIOL & MOLEC MED, LOS ANGELES, CA 90095 USA	United States Department of Energy (DOE); University of California System; University of California Los Angeles				Rice, Danny/0000-0002-1123-4617				ALTSCHUL SF, 1991, J MOL BIOL, V219, P555, DOI 10.1016/0022-2836(91)90193-A; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOBERG J, 1992, PROTEINS, V14, P265, DOI 10.1002/prot.340140212; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BOWIE JU, 1993, CURR OPIN STRUC BIOL, V3, P437, DOI 10.1016/S0959-440X(05)80118-6; BRYANT SH, 1995, CURR OPIN STRUC BIOL, V5, P236, DOI 10.1016/0959-440X(95)80082-4; BRYANT SH, 1993, PROTEINS, V16, P92, DOI 10.1002/prot.340160110; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DOOLITTLE RF, 1986, URFS ORFS PRIMER HOW; DREXLER KE, 1981, P NATL ACAD SCI USA, V78, P5275, DOI 10.1073/pnas.78.9.5275; FISCHER D, 1995, IN PRESS PROTEIN ENG; FISCHER D, 1996, IN PRESS 1ST P PAC S; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; GODZIK A, 1992, J MOL BIOL, V227, P227, DOI 10.1016/0022-2836(92)90693-E; GOLDSTEIN RA, 1992, P NATL ACAD SCI USA, V89, P9029, DOI 10.1073/pnas.89.19.9029; GONNET GH, 1992, SCIENCE, V256, P1443, DOI 10.1126/science.1604319; GRIBSKOV M, 1990, METHOD ENZYMOL, V183, P146; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; GRIBSKOV M, 1988, COMPUT APPL BIOSCI, V4, P61; HOBOHM U, 1992, PROTEIN SCI, V1, P409; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; JONES D, 1993, J COMPUT AID MOL DES, V7, P439, DOI 10.1007/BF02337560; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; KOCHER JPA, 1994, J MOL BIOL, V235, P1598, DOI 10.1006/jmbi.1994.1109; KROGH A, 1994, J MOL BIOL, V235, P1501, DOI 10.1006/jmbi.1994.1104; LATHROP RH, 1994, PROTEIN ENG, V7, P1059, DOI 10.1093/protein/7.9.1059; LATHROP RH, 1994, 27TH P HAW INT C SYS, V5, P365; LUTHY R, 1991, PROTENIS, V10, P220; MATSUO Y, 1994, PROTEIN SCI, V3, P2055, DOI 10.1002/pro.5560031118; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; ORENGO CA, 1993, PROTEIN ENG, V6, P485, DOI 10.1093/protein/6.5.485; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; ORENGO CA, 1993, CURR BIOL, V3, P131, DOI 10.1016/0960-9822(93)90254-L; OUZOUNIS C, 1993, J MOL BIOL, V232, P805, DOI 10.1006/jmbi.1993.1433; PABBO C, 1973, NATURE, V301, P200; PASTORE A, 1990, PROTEINS, V8, P133, DOI 10.1002/prot.340080204; PEARSON WR, 1995, PROTEIN SCI, V4, P1145, DOI 10.1002/pro.5560040613; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; ROOMAN MJ, 1992, BIOCHEMISTRY-US, V31, P10226, DOI 10.1021/bi00157a009; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SCHIRMER T, 1985, J MOL BIOL, V184, P257, DOI 10.1016/0022-2836(85)90379-1; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SIPPL MJ, 1990, J MOL BIOL, V213, P859, DOI 10.1016/S0022-2836(05)80269-4; SIPPL MJ, 1992, PROTEINS, V13, P258, DOI 10.1002/prot.340130308; SIPPL MJ, 1995, CURR OPIN STRUC BIOL, V5, P229, DOI 10.1016/0959-440X(95)80081-6; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; TAYLOR WR, 1989, J MOL BIOL, V208, P1, DOI 10.1016/0022-2836(89)90084-3; VINGRON M, 1994, J MOL BIOL, V235, P1, DOI 10.1016/S0022-2836(05)80006-3; VOGT G, 1995, J MOL BIOL, V249, P816, DOI 10.1006/jmbi.1995.0340; WILMANNS M, 1993, P NATL ACAD SCI USA, V90, P1379, DOI 10.1073/pnas.90.4.1379; WILMANNS M, 1995, PROTEIN ENG, V8, P627, DOI 10.1093/protein/8.7.627; WODAK SJ, 1993, CURR OPIN STRUC BIOL, V3, P247, DOI 10.1016/S0959-440X(05)80160-5; YI TM, 1994, PROTEIN SCI, V3, P1315, DOI 10.1002/pro.5560030818; ZHANG KYJ, 1994, PROTEIN SCI, V3, P687	54	75	79	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1996	10	1					126	136		10.1096/fasebj.10.1.8566533	http://dx.doi.org/10.1096/fasebj.10.1.8566533			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566533				2022-12-28	WOS:A1996TR32800017
J	WOLOSIUK, RA; BALLICORA, MA; HAGELIN, K				WOLOSIUK, RA; BALLICORA, MA; HAGELIN, K			THE REDUCTIVE PENTOSE-PHOSPHATE CYCLE FOR PHOTOSYNTHETIC CO2 ASSIMILATION - ENZYME MODULATION	FASEB JOURNAL			English	Review						BENSON-CALVIN CYCLE; FERREDOXIN-THIOREDOXIN SYSTEM; ENZYME MODULATION; CHLOROPLASTS	SPINACH CHLOROPLAST FRUCTOSE-1,6-BISPHOSPHATASE; FERREDOXIN-THIOREDOXIN REDUCTASE; PROTEIN DISULFIDE-ISOMERASE; LINKED GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; RIBULOSE BISPHOSPHATE CARBOXYLASE; AMINO-ACID-SEQUENCE; CHAOTROPIC ANIONS; LIGHT-ACTIVATION; OXYGENIC PHOTOSYNTHESIS; RUBISCO ACTIVASE	The reductive pentose phosphate cycle (Benson-Calvin cycle) is the main biochemical pathway for the conversion of atmospheric CO2 to organic compounds. Two unique systems that link light-triggered events in thylakoid membranes with enzyme regulation are located in the soluble portion of chloroplasts (stroma): the ferredoxin-thioredoxin system and ribulose 1,5-bisphosphate carboxylase/oxygenase-Activase (Rubisco-Activase). The ferredoxin-thioredoxin system (ferredoxin, ferredoxin-thioredoxin reductase, and thioredoxin) transforms native (inactive) glyceraldehyde-3-P dehydrogenase, fructose-1,6-bisphosphatase, sedoheptulose-1,7-bisphosphatase, and phosphoribulokinase to catalytically competent forms. However, the comparison of enzymes reveals the absence of common amino acid sequences for the action of reduced thioredoxin. Thiol/disulfide exchanges appear as the underlying mechanism, but chloroplast metabolites and target domains make the activation process peculiar for each enzyme. On the other hand, Rubisco-Activase facilitates the combination of CO2 with a specific epsilon-amino group of ribulose 1,5-bisphosphate carboxylase/oxygenase and the subsequent stabilization of the carbamylated enzyme by Mg2+, in a reaction that depends on ATP and ribulose 1,5-bisphosphate. Most of these studies were carried out in homogenous solutions; nevertheless, a growing body of evidence indicates that several enzymes of the cycle associate either with thylakoid membranes or with other proteins yielding supramolecular complexes in the chloroplast.	UNIV BUENOS AIRES,FAC CIENCIAS EXACTAS & NAT,INST INVEST BIOQUIM,BUENOS AIRES,ARGENTINA	University of Buenos Aires				Ballicora, Miguel/0000-0002-5324-0724				ANDERSON LE, 1987, FEBS LETT, V212, P45, DOI 10.1016/0014-5793(87)81553-3; ANDERSON LE, 1981, PHOTOSYNTHESIS, V4, P373; Andrews T.J., 1987, BIOCH PLANTS, P131, DOI 10.1016/B978-0-12-675410-0.50009-9; BALLICORA MA, 1990, PLANT SCI, V70, P35, DOI 10.1016/0168-9452(90)90029-N; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; BUCHANAN BB, 1991, ARCH BIOCHEM BIOPHYS, V288, P1, DOI 10.1016/0003-9861(91)90157-E; BUCHANAN BB, 1990, PHOTOSYNTH RES, V24, P47, DOI 10.1007/BF00032643; BUCHANAN BB, 1979, TRENDS BIOCHEM SCI, V4, P93, DOI 10.1016/0968-0004(79)90191-9; CADET F, 1988, BIOCHEM J, V253, P243, DOI 10.1042/bj2530243; CAMPBELL WJ, 1990, PLANT PHYSIOL, V94, P479, DOI 10.1104/pp.94.2.479; CERFF R, 1986, MOL GEN GENET, V204, P44, DOI 10.1007/BF00330185; CODD GA, 1987, MICROBIOL SCI, V4, P154; CORLEY E, 1983, BIOCHEM BIOPH RES CO, V115, P707, DOI 10.1016/S0006-291X(83)80202-2; CORLEY E, 1985, J BIOL CHEM, V260, P3978; Crawford N. A., 1989, PHOTOSYNTHESIS, P425; CSEKE C, 1986, BIOCHIM BIOPHYS ACTA, V853, P43, DOI 10.1016/0304-4173(86)90004-2; DROUX M, 1987, ARCH BIOCHEM BIOPHYS, V252, P426, DOI 10.1016/0003-9861(87)90049-X; DROUX M, 1987, ARCH BIOCHEM BIOPHYS, V256, P372, DOI 10.1016/0003-9861(87)90458-9; DROUX M, 1988, CR HEBD ACAD SCI, V305, P335; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; FERRI G, 1990, BIOCHIM BIOPHYS ACTA, V1041, P36, DOI 10.1016/0167-4838(90)90119-Z; FORD DM, 1987, PLANT PHYSIOL, V83, P628, DOI 10.1104/pp.83.3.628; FRIEDEN C, 1970, J BIOL CHEM, V245, P5788; GIBSON JL, 1990, BIOCHEMISTRY-US, V29, P8085, DOI 10.1021/bi00487a014; GONTERO B, 1988, EUR J BIOCHEM, V173, P437, DOI 10.1111/j.1432-1033.1988.tb14018.x; GREER S, 1986, THIOREDOXIN GLUTARED, P121; GUTTERIDGE S, 1990, BIOCHIM BIOPHYS ACTA, V1015, P1, DOI 10.1016/0005-2728(90)90210-U; HANSON RW, 1990, BIOCHEM EDUC, V18, P194, DOI 10.1016/0307-4412(90)90132-8; HARTMAN H, 1990, MOL BIOL EVOL, V7, P247; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HERMOSO R, 1992, PLANT PHYSIOL BIOCH, V30, P39; HERTIG CM, 1983, J BIOL CHEM, V258, P984; HIRASAWA M, 1988, BIOCHIM BIOPHYS ACTA, V935, P1, DOI 10.1016/0005-2728(88)90101-6; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; IWADATE H, 1993, IN PRESS RES PHOTOSY; JORDAN DB, 1983, J BIOL CHEM, V258, P3752; KE H, 1989, J MOL BIOL, V212, P513; KNAFF DB, 1991, BIOCHIM BIOPHYS ACTA, V1056, P93, DOI 10.1016/S0005-2728(05)80277-4; KOBREHEL K, 1991, J BIOL CHEM, V266, P16135; KOBREHEL K, 1992, PLANT PHYSIOL, V99, P919, DOI 10.1104/pp.99.3.919; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; KREIMER G, 1988, PLANT PHYSIOL, V86, P423, DOI 10.1104/pp.86.2.423; LAMOTTEGUERY F, 1991, EUR J BIOCHEM, V196, P287; LAN Y, 1992, Plant Physiology (Rockville), V99, P104; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; MARCUS F, 1991, ARCH BIOCHEM BIOPHYS, V287, P195, DOI 10.1016/0003-9861(91)90406-9; MARCUS F, 1990, ARCH BIOCHEM BIOPHYS, V279, P151, DOI 10.1016/0003-9861(90)90475-E; MCCAIN DC, 1988, PLANT PHYSIOL, V86, P16, DOI 10.1104/pp.86.1.16; MCFARLAN SC, 1989, EUR J BIOCHEM, V179, P389, DOI 10.1111/j.1432-1033.1989.tb14565.x; MILANEZ S, 1991, J BIOL CHEM, V266, P10694; MODEL P, 1986, THIOREDOXIN GLUTARED, P323; MOORE B, 1992, PLANT PHYSIOL, V99, P1551, DOI 10.1104/pp.99.4.1551; MOORE BD, 1992, PLANT PHYSIOL, V99, P1546, DOI 10.1104/pp.99.4.1546; MORI H, 1984, PHOTOSYNTH RES, V5, P17, DOI 10.1007/BF00018372; NICHOLSON S, 1987, EUR J BIOCHEM, V162, P423, DOI 10.1111/j.1432-1033.1987.tb10619.x; OVADI J, 1988, TRENDS BIOCHEM SCI, V13, P486, DOI 10.1016/0968-0004(88)90237-X; PERSSON LO, 1989, BIOCHEM J, V259, P863, DOI 10.1042/bj2590863; PETTERSSON G, 1988, EUR J BIOCHEM, V177, P351, DOI 10.1111/j.1432-1033.1988.tb14383.x; PICKERSGILL RW, 1986, BIOCHEM J, V236, P311, DOI 10.1042/bj2360311; PLA A, 1981, BIOCHIM BIOPHYS ACTA, V636, P113, DOI 10.1016/0005-2728(81)90082-7; PORTER MA, 1988, J BIOL CHEM, V263, P123; PORTIS AR, 1990, BIOCHIM BIOPHYS ACTA, V1015, P15, DOI 10.1016/0005-2728(90)90211-L; PRATGAY G, 1991, J BIOL CHEM, V266, P20913; PRATGAY G, 1989, BIOCHIM BIOPHYS ACTA, V973, P457, DOI 10.1016/S0005-2728(89)80388-3; PREISS J, 1967, J BIOL CHEM, V242, P2292; PUPILLO P, 1975, EUR J BIOCHEM, V51, P475, DOI 10.1111/j.1432-1033.1975.tb03947.x; RAGHAVENDRA AS, 1981, PHOTOSYNTHESIS, V4, P31; RAINES CA, 1992, EUR J BIOCHEM, V205, P1053, DOI 10.1111/j.1432-1033.1992.tb16873.x; REBEILLE F, 1986, ARCH BIOCHEM BIOPHYS, V249, P164, DOI 10.1016/0003-9861(86)90571-0; REICHARD P, 1968, EUR J BIOCHEM, V3, P259, DOI 10.1111/j.1432-1033.1968.tb19525.x; RYAZANOV AG, 1988, FEBS LETT, V237, P1, DOI 10.1016/0014-5793(88)80159-5; SCHEIBE R, 1990, BOT ACTA, V103, P327, DOI 10.1111/j.1438-8677.1990.tb00170.x; SCHEIBE R, 1981, FEBS LETT, V133, P301, DOI 10.1016/0014-5793(81)80529-7; SCHURMANN P, 1985, PHYSIOL VEG, V23, P813; SERVAITES JC, 1990, PLANT PHYSIOL, V92, P867, DOI 10.1104/pp.92.4.867; SHEN JB, 1991, J BIOL CHEM, V266, P8963; SHEN JB, 1992, PLANT PHYSIOL, V99, P1201, DOI 10.1104/pp.99.3.1201; SMEEKENS S, 1989, PLANT PHYSIOL, V89, P1270, DOI 10.1104/pp.89.4.1270; SOMERVILLE CR, 1982, PLANT PHYSIOL, V70, P381, DOI 10.1104/pp.70.2.381; SOULIE JM, 1991, EUR J BIOCHEM, V195, P671, DOI 10.1111/j.1432-1033.1991.tb15752.x; SPECTOR A, 1988, BIOCHEM BIOPH RES CO, V150, P156, DOI 10.1016/0006-291X(88)90499-8; STEIN M, 1987, J BIOL CHEM, V262, P16171; STEIN M, 1989, EUR J BIOCHEM, V185, P425, DOI 10.1111/j.1432-1033.1989.tb15132.x; SZEKERES M, 1991, J BACTERIOL, V173, P1821, DOI 10.1128/jb.173.5.1821-1823.1991; TABITA FR, 1988, MICROBIOL REV, V52, P155, DOI 10.1128/MMBR.52.2.155-189.1988; TABOR S, 1986, THIOREDOXIN GLUTARED, P285; TANAKA K, 1990, AGR BIOL CHEM TOKYO, V54, P2149, DOI 10.1080/00021369.1990.10870258; TSUGITA A, 1991, Protein Sequences and Data Analysis, V4, P9; VU CV, 1984, PLANT PHYSIOL, V76, P843; WALKER DA, 1973, NEW PHYTOL, V72, P209, DOI 10.1111/j.1469-8137.1973.tb02027.x; WALKER DA, 1976, CURR TOP CELL REGUL, V11, P204; WANG ZY, 1992, PLANT PHYSIOL, V99, P1348, DOI 10.1104/pp.99.4.1348; WERNEKE JM, 1989, PLANT CELL, V1, P815, DOI 10.1105/tpc.1.8.815; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WOLOSIUK RA, 1985, FEBS LETT, V189, P212, DOI 10.1016/0014-5793(85)81025-5; WOLOSIUK RA, 1979, J BIOL CHEM, V254, P1627; WOLOSIUK RA, 1976, J BIOL CHEM, V251, P6456; WOLOSIUK RA, 1990, ARCH BIOCHEM BIOPHYS, V279, P70, DOI 10.1016/0003-9861(90)90464-A; WOLOSIUK RA, 1986, ARCH BIOCHEM BIOPHYS, V246, P1, DOI 10.1016/0003-9861(86)90443-1; WOLOSIUK RA, 1978, PLANT PHYSIOL, V61, P669, DOI 10.1104/pp.61.4.669; WOLOSIUK RA, 1982, FEBS LETT, V140, P31, DOI 10.1016/0014-5793(82)80514-0; WOLOSIUK RA, 1986, THIOREDOXIN GLUTARED, P253; WOLOSIUK RA, 1983, THIOREDOXINS STRUCTU, P167; WOLOSIUK RA, 1976, NATURE, V266, P565; WOOD HG, 1986, TRENDS BIOCHEM SCI, V11, P14, DOI 10.1016/0968-0004(86)90223-9; WOODROW IE, 1984, J BIOL CHEM, V259, P3791; ZIELINSKI RE, 1988, PLANT PHYSIOL, V90, P516	109	65	67	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1993	7	8					622	637		10.1096/fasebj.7.8.8500687	http://dx.doi.org/10.1096/fasebj.7.8.8500687			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LE290	8500687				2022-12-28	WOS:A1993LE29000004
J	ROSS, AC				ROSS, AC			CELLULAR-METABOLISM AND ACTIVATION OF RETINOIDS - ROLES OF CELLULAR RETINOID-BINDING PROTEINS	FASEB JOURNAL			English	Review						RETINOIC ACID; CELLULAR RETINOL-BINDING PROTEIN; RETINOL ESTERIFICATION; OXIDATION; NUCLEAR RECEPTOR PROTEINS	RAT SMALL-INTESTINE; VITAMIN-A METABOLISM; ROD OUTER SEGMENTS; ACYL-COENZYME-A; MAMMARY-GLAND MICROSOMES; MESSENGER-RNA LEVELS; HUMAN SKIN INVIVO; ACYLTRANSFERASE ACTIVITY; PIGMENT-EPITHELIUM; LIVER-MICROSOMES	Vitamin A and related molecules-the retinoids-play essential roles in vision, growth, reproduction, and cellular differentiation beginning in early development. Retinoic acid, a key regulatory retinoid formed intracellularly through the oxidation of retinol, functions as ligand for a family of nuclear retinoic acid receptors that regulate transcription from target genes. Metabolic events are critical to maintaining physiological concentrations of retinoic acid. In the cytoplasm, retinol, retinaldehyde, and retinoic acid are associated with retinoid-binding proteins, most of which are approximately 15-kDa proteins belonging to the fatty acid-binding protein/cellular retinol-binding protein family. The ligand binding properties and molecular features of these proteins have been well characterized. Recent experiments have highlighted the importance of the cellular retinoid-binding proteins in controlling the concentration of free retinoids and in directing protein-bound retinoids to key enzymes responsible for their metabolism. For example, the cellular retinol-binding protein, CRBP, has been implicated in retinol uptake, retinol esterification, mobilization of retinyl esters, and the initial oxidation of retinol to retinaldehyde. The ligands bound to other retinoid-binding proteins have also been shown to be available for enzymatic transformation. The new knowledge of the various ways these cytoplasmic proteins buffer the concentration of ligand, control their distribution, and determine their metabolism by specific enzymes is contributing to an improved understanding of the physiological control of retinoid action.	MED COLL PENN, DEPT PEDIAT, PHILADELPHIA, PA 19129 USA	Drexel University	ROSS, AC (corresponding author), MED COLL PENN, DEPT BIOCHEM, DIV NUTR, 2900 QUEENS LANE, PHILADELPHIA, PA 19129 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016484] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-22633] Funding Source: Medline; NICHD NIH HHS [HD-16484] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASTROM A, 1991, J BIOL CHEM, V266, P17662; BALL MD, 1985, BIOCHEM BIOPH RES CO, V128, P7, DOI 10.1016/0006-291X(85)91636-5; BARRY RJ, 1989, J BIOL CHEM, V264, P9231; BASHOR MM, 1973, P NATL ACAD SCI USA, V70, P3483, DOI 10.1073/pnas.70.12.3483; BAVIK CO, 1991, J BIOL CHEM, V266, P14978; BENDICH A, 1989, FASEB J, V3, P1927, DOI 10.1096/fasebj.3.8.2656356; BERMAN ER, 1985, CURR EYE RES, V4, P867, DOI 10.3109/02713688509095254; BERMAN ER, 1980, BIOCHIM BIOPHYS ACTA, V630, P36, DOI 10.1016/0304-4165(80)90135-X; BHAT PV, 1988, BIOCHIM BIOPHYS ACTA, V967, P211, DOI 10.1016/0304-4165(88)90011-6; BLANER WS, 1989, ENDOCR REV, V10, P308, DOI 10.1210/edrv-10-3-308; BLANER WS, 1987, J BIOL CHEM, V262, P53; BLANER WS, 1985, J LIPID RES, V26, P1241; BLOMHOFF R, 1991, FASEB J, V5, P271, DOI 10.1096/fasebj.5.3.2001786; BLOMHOFF R, 1991, PHYSIOL REV, V71, P951, DOI 10.1152/physrev.1991.71.4.951; BOERMAN MHEM, 1991, J BIOL CHEM, V266, P22273; BOLLAG W, 1983, LANCET, V1, P860; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; CANADA FJ, 1990, BIOCHEMISTRY-US, V29, P9690, DOI 10.1021/bi00493a026; CASTAIGNE S, 1990, NOUV REV FR HEMATOL, V32, P297; CHAUDHARY LR, 1987, BIOCHIM BIOPHYS ACTA, V917, P24, DOI 10.1016/0005-2760(87)90279-7; CHYTIL F, 1987, ANNU REV NUTR, V7, P321, DOI 10.1146/annurev.nu.07.070187.001541; COOPER DA, 1990, METHOD ENZYMOL, V189, P490; CREEK KE, 1993, J NUTR, V123, P356, DOI 10.1093/jn/123.suppl_2.356; DE LUCA LM, 1991, FASEB J, V5, P2924; DILLEHAY DL, 1988, J LEUKOCYTE BIOL, V44, P353, DOI 10.1002/jlb.44.5.353; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOWLING JE, 1960, P NATL ACAD SCI USA, V46, P587, DOI 10.1073/pnas.46.5.587; DUELL E, 1991, J INVEST DERMATOL, V96, P533; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEX G, 1987, BIOCHIM BIOPHYS ACTA, V901, P255, DOI 10.1016/0005-2736(87)90122-2; FIORELLA PD, 1991, J BIOL CHEM, V266, P16572; FUTTERMAN S, 1964, J BIOL CHEM, V239, P81; GAD MZ, 1991, J LIPID RES, V32, P685; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GOLDFARB MT, 1987, MAYO CLIN PROC, V62, P1161, DOI 10.1016/S0025-6196(12)62514-2; GOODMAN DS, 1965, J LIPID RES, V6, P390; Goodman DS, 1984, RETINOIDS, V2, P42; GORDON JI, 1991, CURR OPIN LIPIDOL, V2, P125; GUBLER ML, 1990, METHOD ENZYMOL, V189, P525; GUELI MC, 1991, ARCH BIOCHEM BIOPHYS, V288, P572, DOI 10.1016/0003-9861(91)90238-E; HARRISON EH, 1987, J LIPID RES, V28, P973; HARRISON EH, 1990, METHOD ENZYMOL, V189, P459; HARRISON EH, 1989, J BIOL CHEM, V264, P17142; HASHIMOTO Y, 1991, CELL STRUCT FUNCT, V16, P113, DOI 10.1247/csf.16.113; HATCHIGIAN EA, 1989, P SOC EXP BIOL MED, V191, P47; HELGERUD P, 1983, J CLIN INVEST, V71, P747, DOI 10.1172/JCI110822; HELGERUD P, 1982, J LIPID RES, V23, P609; HERR FM, 1992, BIOCHEMISTRY-US, V31, P6748, DOI 10.1021/bi00144a014; HERR FM, 1991, J NUTR BIOCHEM, V2, P503, DOI 10.1016/0955-2863(91)90108-H; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HO MTP, 1989, J BIOL CHEM, V264, P928; HODAM JR, 1991, J INVEST DERMATOL, V97, P298, DOI 10.1111/1523-1747.ep12480562; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HUPERT J, 1991, BIOCHEM CELL BIOL, V69, P509, DOI 10.1139/o91-075; HUSSAIN MM, 1989, J BIOL CHEM, V264, P9571; KAKKAD BP, 1988, J BIOL CHEM, V263, P12916; KATO M, 1985, J BIOL CHEM, V260, P4832; KIM CI, 1992, ARCH BIOCHEM BIOPHYS, V294, P388, DOI 10.1016/0003-9861(92)90700-7; KLAUS M, 1990, METHOD ENZYMOL, V189, P3; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LENICH CM, 1987, J LIPID RES, V28, P183; LEO MA, 1989, ARCH BIOCHEM BIOPHYS, V269, P305, DOI 10.1016/0003-9861(89)90112-4; LEO MA, 1987, ARCH BIOCHEM BIOPHYS, V259, P241, DOI 10.1016/0003-9861(87)90492-9; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; LEWIS KC, 1990, J LIPID RES, V31, P1535; LEWIS KC, 1981, J NUTR, V111, P1135, DOI 10.1093/jn/111.7.1135; LI E, 1986, P NATL ACAD SCI USA, V83, P5779, DOI 10.1073/pnas.83.16.5779; LI E, 1991, J BIOL CHEM, V266, P3622; MACDONALD PN, 1988, BIOCHEM BIOPH RES CO, V156, P157, DOI 10.1016/S0006-291X(88)80818-0; MACDONALD PN, 1987, J BIOL CHEM, V262, P10550; MACDONALD PN, 1988, J BIOL CHEM, V263, P12478; MAKOVER A, 1989, DIFFERENTIATION, V40, P17, DOI 10.1111/j.1432-0436.1989.tb00809.x; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MATA NL, 1992, J BIOL CHEM, V267, P9794; MATSUURA T, 1993, IN PRESS ARCH BIOCH; NAPOLI JL, 1987, ARCH BIOCHEM BIOPHYS, V255, P95, DOI 10.1016/0003-9861(87)90298-0; NAPOLI JL, 1993, J NUTR, V123, P362, DOI 10.1093/jn/123.suppl_2.362; NAPOLI JL, 1991, BIOMED PHARMACOTHER, V45, P131, DOI 10.1016/0753-3322(91)90101-X; NAPOLI JL, 1986, J BIOL CHEM, V261, P3592; NAPOLI JL, 1990, BIOCHIM BIOPHYS ACTA, V1034, P228, DOI 10.1016/0304-4165(90)90081-7; NAPOLI JL, 1989, ARCH BIOCHEM BIOPHYS, V274, P192, DOI 10.1016/0003-9861(89)90430-X; NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012; NOY N, 1991, BIOCHEMISTRY-US, V30, P6380, DOI 10.1021/bi00240a005; NOY N, 1990, BIOCHEMISTRY-US, V29, P3883, DOI 10.1021/bi00468a013; ONG DE, 1993, J NUTR, V123, P351, DOI 10.1093/jn/123.suppl_2.351; ONG DE, 1984, J BIOL CHEM, V259, P1476; ONG DE, 1978, J BIOL CHEM, V253, P828; ONG DE, 1975, NATURE, V255, P74, DOI 10.1038/255074a0; ONG DE, 1991, J LIPID RES, V32, P1521; ONG DE, 1987, J BIOL CHEM, V262, P2729; ONG DE, 1988, J BIOL CHEM, V263, P5789; ORFANOS CE, 1987, DRUGS, V34, P459, DOI 10.2165/00003495-198734040-00003; ORTIZ A, 1992, BIOCHIM BIOPHYS ACTA, V1106, P282, DOI 10.1016/0005-2736(92)90007-9; OTTONELLO S, 1987, J BIOL CHEM, V262, P3975; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; POSCH KC, 1992, BIOCHEM PHARMACOL, V43, P2296; POSCH KC, 1989, ARCH BIOCHEM BIOPHYS, V274, P171, DOI 10.1016/0003-9861(89)90428-1; QUICK TC, 1990, BIOCHEMISTRY-US, V29, P11116, DOI 10.1021/bi00502a015; RAJAN N, 1990, J LIPID RES, V31, P821; RANDO RR, 1982, BIOCHEM BIOPH RES CO, V104, P430, DOI 10.1016/0006-291X(82)90655-6; RANDO RR, 1991, BIOCHEMISTRY-US, V30, P595, DOI 10.1021/bi00217a001; RANDOLPH RK, 1991, J LIPID RES, V32, P809; RANDOLPH RK, 1991, J BIOL CHEM, V266, P16453; RANDOLPH RK, 1991, ARCH BIOCHEM BIOPHYS, V288, P500, DOI 10.1016/0003-9861(91)90227-A; RASK L, 1976, J BIOL CHEM, V251, P6360; RHODES J, 1980, IMMUNOLOGY, V40, P467; RIGTRUP KM, 1992, BIOCHEMISTRY-US, V31, P2920, DOI 10.1021/bi00126a011; ROBERTS ES, 1992, MOL PHARMACOL, V41, P427; ROSS AC, 1982, J BIOL CHEM, V257, P2453; ROSS AC, 1977, J LIPID RES, V18, P169; ROSS AC, 1982, J LIPID RES, V23, P133; SAARI JC, 1989, J BIOL CHEM, V264, P8636; SAARI JC, 1988, J BIOL CHEM, V263, P8084; SAARI JC, 1990, METHOD ENZYMOL, V190, P156; SAARI JC, 1984, VISION RES, V24, P1595, DOI 10.1016/0042-6989(84)90317-1; SAARI JC, 1982, BIOCHIM BIOPHYS ACTA, V716, P266, DOI 10.1016/0304-4165(82)90277-X; SCHWEIGERT FJ, 1990, COMP BIOCHEM PHYS A, V95, P573, DOI 10.1016/0300-9629(90)90741-A; SHIH TW, 1991, DRUG METAB DISPOS, V19, P332; SHINGLETON JL, 1989, BIOCHEMISTRY-US, V28, P9641, DOI 10.1021/bi00451a015; SHINGLETON JL, 1989, BIOCHEMISTRY-US, V28, P9647, DOI 10.1021/bi00451a016; SIEGENTHALER G, 1990, BIOCHEM J, V268, P371, DOI 10.1042/bj2680371; SKREDE B, 1991, EUR J CLIN INVEST, V21, P574, DOI 10.1111/j.1365-2362.1991.tb01411.x; SOPRANO DR, 1986, J LIPID RES, V27, P166; SOPRANO DR, 1993, J NUTR, V123, P367, DOI 10.1093/jn/123.suppl_2.367; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TORMA H, 1990, J INVEST DERMATOL, V94, P132, DOI 10.1111/1523-1747.ep12873990; TORMA H, 1987, J INVEST DERMATOL, V88, P398, DOI 10.1111/1523-1747.ep12469726; TREHAN A, 1990, BIOCHEMISTRY-US, V29, P309, DOI 10.1021/bi00454a001; TSUTSUMI C, 1992, J BIOL CHEM, V267, P1805; UBELS JL, 1990, INVEST OPHTH VIS SCI, V31, P582; Vanden Bossche H, 1988, Skin Pharmacol, V1, P176; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WATHNE KO, 1988, J BIOL CHEM, V263, P8691; WILSON DE, 1987, BIOCHIM BIOPHYS ACTA, V922, P247, DOI 10.1016/0005-2760(87)90047-6; YOST RW, 1988, J BIOL CHEM, V263, P18693; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZILVERSMIT DB, 1982, BIOCHIM BIOPHYS ACTA, V712, P88, DOI 10.1016/0005-2760(82)90088-1; 1985, ASSESSMENT VITAMIN A	145	174	179	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB 1	1993	7	2					317	327		10.1096/fasebj.7.2.8440409	http://dx.doi.org/10.1096/fasebj.7.2.8440409			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KN885	8440409				2022-12-28	WOS:A1993KN88500007
J	NOLLER, HF				NOLLER, HF			TRANSFER RNA-RIBOSOMAL-RNA INTERACTIONS AND PEPTIDYL TRANSFERASE	FASEB JOURNAL			English	Article						FUNCTIONAL RNA; ANTICODON STEM-LOOP; A-SITE; P-SITE	16S RIBOSOMAL-RNA; COLICIN E3; A-SITES; P-SITES; NUCLEOTIDES; SUBUNIT	The extent to which ribosomal RNA is directly involved in the function of ribosomes has important implications for both the mechanism of translation and the molecular origins of life. Detailed evidence has accumulated that places the anticodon and acceptor ends of tRNA in close proximity to conserved features of rRNA in the ribosome. Recent studies are providing evidence that these features are important for ribosomal function.			NOLLER, HF (corresponding author), UNIV CALIF SANTA CRUZ,SINSHEIMER LABS,SANTA CRUZ,CA 95064, USA.							BARTA A, 1984, P NATL ACAD SCI-BIOL, V81, P3607, DOI 10.1073/pnas.81.12.3607; BARTA A, 1990, RIBOSOME, P358; BOWMAN CM, 1971, P NATL ACAD SCI USA, V68, P964, DOI 10.1073/pnas.68.5.964; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; CUNDLIFFE E, 1990, RIBOSOME, P479; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HUTTENHOFER A, 1992, P NATL ACAD SCI USA, V89, P7851, DOI 10.1073/pnas.89.17.7851; MOAZED D, 1991, P NATL ACAD SCI USA, V88, P3725, DOI 10.1073/pnas.88.9.3725; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1987, BIOCHIMIE, V69, P879, DOI 10.1016/0300-9084(87)90215-X; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; NOMURA M, 1969, COLD SPRING HARB SYM, V34, P49, DOI 10.1101/SQB.1969.034.01.009; OFENGAND J, 1986, STRUCTURE FUNCTION G, P473; SENIOR BW, 1971, P NATL ACAD SCI USA, V68, P959, DOI 10.1073/pnas.68.5.959; WOODCOCK J, 1991, EMBO J, V10, P3099, DOI 10.1002/j.1460-2075.1991.tb07863.x	18	31	31	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1993	7	1					87	89		10.1096/fasebj.7.1.8422979	http://dx.doi.org/10.1096/fasebj.7.1.8422979			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422979				2022-12-28	WOS:A1993KH88000013
J	Pankhaniya, R; Jabrane-Ferrat, N; Gaufo, GO; Sreedharan, SP; Dazin, P; Kaye, J; Goetzl, EJ				Pankhaniya, R; Jabrane-Ferrat, N; Gaufo, GO; Sreedharan, SP; Dazin, P; Kaye, J; Goetzl, EJ			Vasoactive intestinal peptide enhancement of antigen-induced differentiation of a cultured line of mouse thymocytes	FASEB JOURNAL			English	Article						neuropeptide; immunology; T lymphocyte; receptor; apoptosis	MODEL BASEMENT-MEMBRANE; T-CELLS; POLYPEPTIDE VIP; IMMUNE-SYSTEMS; EXPRESSION; NEUROPEPTIDES; CHEMOTAXIS; SELECTION; NEUROIMMUNOMODULATION; LYMPHOCYTES	The prominence of vasoactive intestinal peptide (VIP) in rodent thymic neurons suggested that this potent mediator of T cell functions may alter developmental responses of thymocytes to T cell receptor (TCR) -dependent stimulation, CD4(+)8(+) DPK cells derived from a thymic lymphoma of a TCR transgenic mouse respond to pigeon cytochrome C (PCC) antigen in association with distinct I-E MHC II haplotypes on antigen-presenting cells (APCs) by differentiating into CD4(+)8(-) T cells, The specific recognition of VIP by two types of homologous C-protein-coupled receptors (VIPR1 and VIPR2) on DPK cells was attributable predominantly to VIPR1 before and to VIPR2 after exposure to APCs and PCC, as assessed by quantification of the respective mRNAs, PCC-evoked differentiation of DPK cells was enhanced significantly by 1 to 100 nM VIP after 3 to 4 days, The effects of VIP analogs with VIPR type selectivity implied that VIP enhancement of differentiation of DPK cells was mediated principally by VIPR2, Differential reduction in the expression of each type of VIPR by transfection of DPK cells with plasmids encoding the respective antisense mRNAs confirmed the central role of VIPR2 in VIP-enhanced conversion to CD4(+)8(-) T cells. The suppression of DPK cell differentiation by inhibitors of adenylyl cyclase and protein kinase A suggested a transductional role for VIP-elicited increases in [cAMP](i). That the changes in frequency of CD4(+)8(+) and CD4(+)8(-) DPK cells reflected principally differentiation was supported by the lack of consistent differences between the two subsets in the effects of VIP and VIPR2 agonist on cell number, viability, apoptosis, and proliferation, VIP may be one endogenous mediator that explains the unique thymic microenvironment for topographically specific development of T cells.	Univ Calif San Francisco, Dept Med & Microbiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Scripps Res Inst, La Jolla, CA 92037 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Scripps Research Institute	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Dept Med & Microbiol, Room UB8B,Box 0711,533 Parnassus, San Francisco, CA 94143 USA.		Jabrane-Ferrat, Nabila/K-1224-2014; Gaufo, Gary/D-3928-2011	Jabrane-Ferrat, Nabila/0000-0003-4809-7836; Gaufo, Gary/0000-0003-3695-3500; Kaye, Jonathan/0000-0002-1634-9069	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029912, R37AI029912, U01AI034570] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29912, AI34570] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1187, DOI 10.1164/ajrccm/144.5.1187; Bellinger DL, 1996, ADV NEUROIMMUNOL, V6, P5, DOI 10.1016/S0960-5428(96)00008-3; BOIRIVANT M, 1994, GASTROENTEROLOGY, V106, P576, DOI 10.1016/0016-5085(94)90688-2; FINK T, 1988, NEUROSCI LETT, V90, P39, DOI 10.1016/0304-3940(88)90783-5; Fujieda S, 1996, J CLIN INVEST, V98, P1527, DOI 10.1172/JCI118944; GANEA D, 1993, J NEUROIMMUNOL, V47, P147, DOI 10.1016/0165-5728(93)90025-T; GOETZL EJ, 1995, J IMMUNOL, V154, P1041; GOETZL EJ, 1992, FASEB J, V6, P2646, DOI 10.1096/fasebj.6.9.1612288; Grossman Z, 1996, P NATL ACAD SCI USA, V93, P14747, DOI 10.1073/pnas.93.25.14747; Groves T, 1997, J IMMUNOL, V158, P65; HASSNER A, 1993, J ALLERGY CLIN IMMUN, V92, P891, DOI 10.1016/0091-6749(93)90067-P; ICHIKAWA S, 1994, REGUL PEPTIDES, V54, P385, DOI 10.1016/0167-0115(94)90536-3; JOHNSTON JA, 1994, J IMMUNOL, V153, P1762; Kaltreider HB, 1997, AM J RESP CELL MOL, V16, P133, DOI 10.1165/ajrcmb.16.2.9032120; KAYE J, 1992, CELL, V71, P423, DOI 10.1016/0092-8674(92)90512-B; LITWIN DK, 1992, REGUL PEPTIDES, V40, P63, DOI 10.1016/0167-0115(92)90084-8; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; MERRILL JE, 1995, FASEB J, V9, P611, DOI 10.1096/fasebj.9.8.7768352; Metwali A, 1996, J IMMUNOL, V157, P265; MOSIMANN BL, 1993, J ALLERGY CLIN IMMUN, V92, P95, DOI 10.1016/0091-6749(93)90043-F; OTTAWAY CA, 1991, GASTROENTEROL CLIN N, V20, P511; POIRIER G, 1994, IMMUNITY, V1, P385, DOI 10.1016/1074-7613(94)90069-8; SAID SI, 1994, CL ALLER IM, V4, P143; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Shao H, 1997, J EXP MED, V185, P731, DOI 10.1084/jem.185.4.731; SMITH CH, 1993, J IMMUNOL, V151, P3274; STEAD RH, 1987, P NATL ACAD SCI USA, V84, P2975, DOI 10.1073/pnas.84.9.2975; SUN L, 1993, J NEUROIMMUNOL, V48, P59, DOI 10.1016/0165-5728(93)90059-8; VACCHIO MS, 1994, J EXP MED, V179, P1835, DOI 10.1084/jem.179.6.1835; Xia MG, 1997, J PHARMACOL EXP THER, V281, P629; Xia MH, 1996, J CLIN IMMUNOL, V16, P21, DOI 10.1007/BF01540969; Xia MH, 1996, J CELL BIOCHEM, V61, P452, DOI 10.1002/(SICI)1097-4644(19960601)61:3<452::AID-JCB12>3.3.CO;2-9; Xia MH, 1996, J IMMUNOL, V157, P1132; Xia MH, 1996, J IMMUNOL, V156, P160; YU YL, 1991, J CLIN LAB ANAL, V5, P262	35	32	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1998	12	1					119	127		10.1096/fasebj.12.1.119	http://dx.doi.org/10.1096/fasebj.12.1.119			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YR723	9438417				2022-12-28	WOS:000071523800013
J	Hickey, MJ; Sharkey, KA; Sihota, EG; Reinhardt, PH; Macmicking, JD; Nathan, C; Kubes, P				Hickey, MJ; Sharkey, KA; Sihota, EG; Reinhardt, PH; Macmicking, JD; Nathan, C; Kubes, P			Inducible nitric oxide synthase-deficient mice have enhanced leukocyte-endothelium interactions in endotoxemia	FASEB JOURNAL			English	Article						adhesion; selectin; rolling; neutrophil	NF-KAPPA-B; P-SELECTIN; ADHESION MOLECULE-1; MESSENGER-RNA; SEPTIC SHOCK; IN-VIVO; INHIBITION; EXPRESSION; INFLAMMATION; SUPEROXIDE	Nitric oxide (NO) from constitutive NO synthase (NOS) has been postulated to be a homeostatic regulator of leukocyte-endothelial cell interactions. By contrast, the inducible NO synthase (iNOS) isoform has been invoked as a potential pathogenic enzyme in numerous inflammatory diseases. The objective of this study was to determine whether the iNOS isoform is also capable of functioning as a regulator of leukocyte recruitment. Mice received endotoxin (LPS, 30 mu g/kg, i.v.); 2-4 h later, intravital microscopy was used to examine leukocyte rolling and adhesion in postcapillary venules of the cremaster muscle and the sinusoids and postsinusoidal venules of the hepatic microcirculation. Leukocyte recruitment into the lung was also examined. RT-PCR confirmed that this treatment induced iNOS mRNA expression in wild-type mice as early as 2 h after LPS treatment. Between 2 and 4 h after LPS administration, the number of rolling and adherent leukocytes in cremasteric postcapillary venules and of adherent cells in liver postsinusoidal venules of iNOS-deficient mice were significantly higher than in wild-type mice. Leukocyte accumulation in the lung (measured by myeloperoxidase assay) was also significantly elevated in iNOS-deficient animals. These effects could not be attributed to differences in systemic blood pressure, shear rates, circulating leukocyte numbers, or baseline levels of rolling and adhesion because these parameters were not different between the two groups. To establish whether the differences in leukocyte recruitment were related to the leukocytes per se, perfusion of iNOS(+/+) or iNOS(-/-) septic blood over purified E-selectin (using parallel plate flow chambers) revealed much larger recruitment of iNOS(-/-) leukocytes. These results suggest that iNOS induced in response to LPS releases NO that is capable of reducing leukocyte accumulation by affecting leukocytes directly and raises the possibility that induction of iNOS is a homeostatic regulator for leukocyte recruitment.	UNIV CALGARY,HLTH SCI CTR,IMMUNOL RES GRP,CALGARY,AB T2N 4N1,CANADA; UNIV CALGARY,HLTH SCI CTR,GASTROINTESTINAL RES GRP,CALGARY,AB T2N 4N1,CANADA; CORNELL UNIV COLL,DEPT MED,BEATRICE & SAMUEL A SEAVER LAB,NEW YORK,NY 10021	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; Cornell University			Hickey, Michael J./A-5429-2012	Hickey, Michael J./0000-0003-2354-357X; Sharkey, Keith/0000-0001-9560-1711				ASAKO H, 1994, J CLIN INVEST, V93, P1508, DOI 10.1172/JCI117129; AVONTUUR JAM, 1995, CIRC RES, V76, P418, DOI 10.1161/01.RES.76.3.418; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVENPECK KL, 1994, GASTROENTEROLOGY, V107, P1050, DOI 10.1016/0016-5085(94)90229-1; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; Gaboury JP, 1996, CIRCULATION, V93, P318, DOI 10.1161/01.CIR.93.2.318; GAUTHIER TW, 1994, AM J PHYSIOL-GASTR L, V267, pG562, DOI 10.1152/ajpgi.1994.267.4.G562; GUO FH, 1995, P NATL ACAD SCI USA, V92, P7809, DOI 10.1073/pnas.92.17.7809; HARBRECHT BG, 1992, J LEUKOCYTE BIOL, V52, P390, DOI 10.1002/jlb.52.4.390; HENDERSON JL, 1994, ARCH SURG-CHICAGO, V129, P1271; Hickey MJ, 1997, J IMMUNOL, V158, P3391; HOUSE SD, 1987, MICROVASC RES, V34, P363, DOI 10.1016/0026-2862(87)90068-9; Kanwar S, 1997, J EXP MED, V185, P1077, DOI 10.1084/jem.185.6.1077; Khan BV, 1996, P NATL ACAD SCI USA, V93, P9114, DOI 10.1073/pnas.93.17.9114; King JM, 1997, J IMMUNOL, V158, P880; KISHIMOTO TK, 1992, INFLAMMATION BASIC P, P353; KOLLS J, 1994, P SOC EXP BIOL MED, V205, P220; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUBES P, 1992, AM J PHYSIOL, V262, pH611, DOI 10.1152/ajpheart.1992.262.2.H611; Kunkel EJ, 1996, J EXP MED, V183, P57, DOI 10.1084/jem.183.1.57; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; LAWRENCE MB, 1990, BLOOD, V75, P227; Lefer DJ, 1997, J CLIN INVEST, V99, P684, DOI 10.1172/JCI119212; LUSCINSKAS FW, 1995, J EXP MED, V181, P1179, DOI 10.1084/jem.181.3.1179; LUSCINSKAS FW, 1996, J IMMUNOL, V156, P326; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; MORRIS SM, 1994, AM J PHYSIOL, V266, pE829, DOI 10.1152/ajpendo.1994.266.6.E829; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NAVA E, 1991, LANCET, V338, P1555, DOI 10.1016/0140-6736(91)92375-C; NISHIDA J, 1994, AM J PHYSIOL-GASTR L, V267, pG1135, DOI 10.1152/ajpgi.1994.267.6.G1135; NOLTE D, 1994, AM J PHYSIOL-HEART C, V267, pH1637, DOI 10.1152/ajpheart.1994.267.4.H1637; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; VOLLMAR B, 1994, AM J PHYSIOL-GASTR L, V267, pG786, DOI 10.1152/ajpgi.1994.267.5.G786; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; Wheeler MA, 1997, J CLIN INVEST, V99, P110, DOI 10.1172/JCI119121; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95	43	249	252	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1997	11	12					955	964		10.1096/fasebj.11.12.9337148	http://dx.doi.org/10.1096/fasebj.11.12.9337148			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YA724	9337148				2022-12-28	WOS:A1997YA72400005
J	SanchezGongora, E; Ruiz, F; Mingorance, J; An, W; Corrales, FJ; Mato, JM				SanchezGongora, E; Ruiz, F; Mingorance, J; An, W; Corrales, FJ; Mato, JM			Interaction of liver methionine adenosyltransferase with hydroxyl radical	FASEB JOURNAL			English	Article						CHO cell; liver MAT; desferrioxamine; hydrogen peroxide	S-ADENOSYLMETHIONINE SYNTHETASE; B TRANSCRIPTION FACTOR; RAT-LIVER; MOLECULAR-CLONING; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; MESSENGER-RNA; KAPPA-B; CDNA; GLUTATHIONE	Liver methionine adenosyltransferase (MAT) plays a critical role in the metabolism of methionine converting this amino acid, in the presence of ATP, into S-adenosylmethionine. Here we report that hydrogen peroxide (H2O2), via generation of hydroxyl radical, inactivates liver MAT by reversibly and covalently oxidizing an enzyme site, In vitro studies using pure liver recombinant enzyme and mutants of MAT, where each of the 10 cysteine residues of the enzyme subunit were individually changed to serine by site-directed mutagenesis, identified cysteine 121 as the site of molecular interaction between H2O2 and liver MAT, Cysteine 121 is specific to the hepatic enzyme and is localized at a ''flexible loop'' over the active site cleft of MAT, In vivo studies, using wildtype Chinese hamster ovary (CHO) cells and CHO cells stably expressing liver MAT, demonstrate that the inactivation of MAT by H2O2 is specific to the hepatic enzyme, resulting from the modification of the cysteine residue 121, and that this effect is mediated by the generation of the hydroxyl radical, Our results suggest that H2O2-induced MAT inactivation might be the cause of reduced MAT activity and abnormal methionine metabolism observed in patients with alcoholic liver disease.	CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			MATO, JOSE/A-5187-2011; Ruiz, Felix A./B-1032-2008; Mingorance, Jesus/B-7562-2009	MATO, JOSE/0000-0003-1264-3153; Ruiz, Felix A./0000-0003-0748-5015; Mingorance, Jesus/0000-0001-6173-5711; Corrales, Fernando/0000-0002-0231-5159				ALVAREZ L, 1991, FEBS LETT, V290, P142, DOI 10.1016/0014-5793(91)81245-4; ALVAREZ L, 1993, BIOCHEM J, V293, P481, DOI 10.1042/bj2930481; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Avila MA, 1997, HEPATOLOGY, V25, P391; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BERGER R, 1983, CLIN CHIM ACTA, V134, P129, DOI 10.1016/0009-8981(83)90191-2; CABRERO C, 1988, HEPATOLOGY, V8, P1530, DOI 10.1002/hep.1840080610; CABRERO C, 1987, EUR J BIOCHEM, V170, P299, DOI 10.1111/j.1432-1033.1987.tb13699.x; CORRALES F, 1991, HEPATOLOGY, V14, P528, DOI 10.1002/hep.1840140320; CORRALES F, 1992, HEPATOLOGY, V16, P1022, DOI 10.1002/hep.1840160427; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; Gil B, 1996, HEPATOLOGY, V24, P876; GILBERT HF, 1989, GLUTATHIONE CENTENNI, P73; GRIFFITH OW, 1979, J BIOL CHEM, V239, P538; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HARDWICK DF, 1970, METABOLIS, V19, P381, DOI 10.1016/0026-0495(70)90135-6; HORIKAWA S, 1989, EUR J BIOCHEM, V184, P497, DOI 10.1111/j.1432-1033.1989.tb15042.x; HORIKAWA S, 1990, J BIOL CHEM, V265, P13683; HORIKAWA S, 1991, BIOCHEM INT, V25, P81; HORIKAWA S, 1992, FEBS LETT, V312, P37, DOI 10.1016/0014-5793(92)81405-B; HOROWITZ JH, 1981, GASTROENTEROLOGY, V81, P668; Inoue Masayasu, 1994, P443; KINSELL LW, 1947, SCIENCE, V106, P589, DOI 10.1126/science.106.2763.589; Kotb M, 1997, TRENDS GENET, V13, P51, DOI 10.1016/S0168-9525(97)01013-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Lieber C. S., 1992, MED NUTR COMPLICATIO; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; MARTINDUCE C, 1988, HEPATOLOGY, V8, P65; MATO JM, 1997, PHARMACOL THERAPEUT, V73, P1; Mingorance J, 1996, BIOCHEM J, V315, P761, DOI 10.1042/bj3150761; Mingorance J, 1997, INT J BIOCHEM CELL B, V29, P485, DOI 10.1016/S1357-2725(96)00151-3; MUDD SH, 1975, METABOLISM, V24, P721, DOI 10.1016/0026-0495(75)90040-2; OKADA G, 1981, BIOCHEMISTRY-US, V20, P934, DOI 10.1021/bi00507a045; PAJARES MA, 1992, J BIOL CHEM, V267, P17598; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; PINKUS R, 1995, BIOCHEMISTRY-US, V34, P81, DOI 10.1021/bi00001a010; SanchezGongora E, 1996, BIOCHEM J, V319, P767, DOI 10.1042/bj3190767; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; STAAL FJT, 1994, P NATL ACAD SCI USA, V91, P3619, DOI 10.1073/pnas.91.9.3619; Takusagawa F, 1996, J BIOL CHEM, V271, P136, DOI 10.1074/jbc.271.1.136; Takusagawa F, 1996, BIOCHEMISTRY-US, V35, P2586, DOI 10.1021/bi952604z; Weiner Francis R., 1994, P1383; YAN SD, 1994, J BIOL CHEM, V269, P9889	45	69	70	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1997	11	12					1013	1019		10.1096/fasebj.11.12.9337154	http://dx.doi.org/10.1096/fasebj.11.12.9337154			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YA724	9337154				2022-12-28	WOS:A1997YA72400011
J	Sundfors, CH; Collan, YUI				Sundfors, CH; Collan, YUI			Target length and primer concentration affect the gain of c-erbB2 and p53 amplicons	FASEB JOURNAL			English	Article						quantitative polymerase chain reaction; primer; DNA synthesis; optical density; target sequence	POLYMERASE CHAIN-REACTION; AQUATICUS DNA-POLYMERASE; THERMUS-AQUATICUS; PCR; QUANTITATION; PRODUCTS; BASICS	Although quantitative polymerase chain reaction (PCR) using internal standards may perform reproducibly, the calibration of the normal level is problematic, Three test sequences (171, 213, and 260 base pairs [bp]) from the c-erbB2 oncogene were separately coamplified with a 133 bp control sequence from the single copy gene p53 in differential PCR, Sequence length differences between the oncogene and control sequences influenced the ratio estimates, obviously because of less efficient synthesis of the longer sequence, Increase in primer concentration of the longer oncogene sequences adjusted this imbalance, and the expected ratio of 1.0 could be reached, The primer or target sequence also influenced the ratio estimate, since the 171 bp oncogene sequence was as efficiently synthesized as the 133 bp control sequence but with lower primer concentration, The 260 bp oncogene sequence produced the most stable results, probably because of clear band separation in polyacrylamide gel electrophoresis. A ratio estimate of 1.0 was produced by oncogene and control gene printer concentrations of 3.5 pmol/ mu 1 and 0.6 pmol/mu 1, respectively. Calibrated quantitative PCR methodology is applicable to many areas and offers an excellent tool for screening allele deletions, supernumerary alleles, or chromosomes associated with familial diseases or disease syndromes.			Sundfors, CH (corresponding author), UNIV TURKU, DEPT PATHOL, BIOCITY 6TH FLOOR, TYKISTOKATU 6B, FIN-20520 TURKU, FINLAND.							BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BRISCOE WT, 1993, BREAST CANCER RES TR, V28, P45, DOI 10.1007/BF00666355; CHIEN A, 1976, J BACTERIOL, V127, P1550, DOI 10.1128/JB.127.3.1550-1557.1976; CHOU Q, 1992, NUCLEIC ACIDS RES, V20, P1717, DOI 10.1093/nar/20.7.1717; FRYE RA, 1989, ONCOGENE, V4, P1153; KARP C, 1996, CELL MOL BIOL CONCEP, P573; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; SUNDFORS C, 1995, CELL MOL BIOL, V41, P671; Sundfors C, 1996, ELECTROPHORESIS, V17, P44, DOI 10.1002/elps.1150170108; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Zimmermann K, 1996, BIOTECHNIQUES, V21, P480	12	4	4	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1997	11	11					897	903		10.1096/fasebj.11.11.9285488	http://dx.doi.org/10.1096/fasebj.11.11.9285488			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XT790	9285488				2022-12-28	WOS:A1997XT79000009
J	Yeh, P; Perricaudet, M				Yeh, P; Perricaudet, M			Advances in adenoviral vectors: from genetic engineering to their biology	FASEB JOURNAL			English	Review						adenovirus; viral capsid; DNA replication; gutless	DNA; E1A	Ad2 and Ad5 belong to a group of human cytolytic viruses that target the respiratory airways for reproduction, whereas latent infections establish within other tissues. Signals therefore exist that control this dichotomic process in different cell types, perhaps including cis and/or trans elements of viral origin. Since 1993, Ad2- and Ad5-based adenoviruses lacking all or part of the El regulatory region have been undergoing evaluation in phase I trials that target cancer and cystic fibrosis. These viruses are extremely attenuated and actually do not reproduce in most human cells. However, they retain most of the virus genetic program and often promote a significant cytotoxicity after infection, emphasizing the need to further cripple the virus biology to extend the duration of transgene expression, if required. We will review the strategies currently followed to engineer a professional lytic virus for epithelial cells into an innocuous gene delivery vehicle. Potential effects on the transducing properties of the vector that may result from the inactivation of viral activities that normally allow/regulate extrachromosomal gene expression during wild-type infection are discussed.			Yeh, P (corresponding author), RHONE POULENC RORER GENCELL,CNRS,URA 1301,LAB GENET VIRUS ONCOGENES,INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE.							Amalfitano A, 1996, P NATL ACAD SCI USA, V93, P3352, DOI 10.1073/pnas.93.8.3352; Barinaga M, 1996, SCIENCE, V274, P724, DOI 10.1126/science.274.5288.724; Besse S, 1995, GENE EXPRESSION, V5, P79; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Brough DE, 1996, J VIROL, V70, P6497, DOI 10.1128/JVI.70.9.6497-6501.1996; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; CROUZET J, 1997, IN PRESS P NATL ACAD; Dedieu JF, 1997, J VIROL, V71, P4626, DOI 10.1128/JVI.71.6.4626-4637.1997; ENGELHARDT JF, 1994, P NATL ACAD SCI USA, V91, P6196, DOI 10.1073/pnas.91.13.6196; FLOMENBERG P, 1995, J INFECT DIS, V171, P1090, DOI 10.1093/infdis/171.5.1090; Flomenberg P, 1996, J VIROL, V70, P6314, DOI 10.1128/JVI.70.9.6314-6322.1996; FREDMAN JN, 1993, J VIROL, V67, P3384, DOI 10.1128/JVI.67.6.3384-3395.1993; Freimuth P, 1996, J VIROL, V70, P4081, DOI 10.1128/JVI.70.6.4081-4085.1996; Gall J, 1996, J VIROL, V70, P2116, DOI 10.1128/JVI.70.4.2116-2123.1996; Gao GP, 1996, J VIROL, V70, P8934, DOI 10.1128/JVI.70.12.8934-8943.1996; GINSBERG HS, 1991, P NATL ACAD SCI USA, V88, P1651, DOI 10.1073/pnas.88.5.1651; Gorziglia MI, 1996, J VIROL, V70, P4173, DOI 10.1128/JVI.70.6.4173-4178.1996; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Hehir KM, 1996, J VIROL, V70, P8459, DOI 10.1128/JVI.70.12.8459-8467.1996; HIERHOLZER JC, 1992, CLIN MICROBIOL REV, V5, P262, DOI 10.1128/CMR.5.3.262-274.1992; Hong JS, 1996, J VIROL, V70, P7071, DOI 10.1128/JVI.70.10.7071-7078.1996; Huang S, 1996, J VIROL, V70, P4502, DOI 10.1128/JVI.70.7.4502-4508.1996; Imler JL, 1996, GENE THER, V3, P75; Ishov AM, 1996, J CELL BIOL, V134, P815, DOI 10.1083/jcb.134.4.815; KETNER G, 1994, P NATL ACAD SCI USA, V91, P6186, DOI 10.1073/pnas.91.13.6186; Kochanek S, 1996, P NATL ACAD SCI USA, V93, P5731, DOI 10.1073/pnas.93.12.5731; Krougliak V, 1995, HUM GENE THER, V6, P1575, DOI 10.1089/hum.1995.6.12-1575; Lieber A, 1996, J VIROL, V70, P8944, DOI 10.1128/JVI.70.12.8944-8960.1996; MITANI K, 1995, P NATL ACAD SCI USA, V92, P3854, DOI 10.1073/pnas.92.9.3854; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; Pahl HL, 1996, J CELL BIOL, V132, P511, DOI 10.1083/jcb.132.4.511; Parks RJ, 1996, P NATL ACAD SCI USA, V93, P13565, DOI 10.1073/pnas.93.24.13565; Schaack J, 1996, P NATL ACAD SCI USA, V93, P14686, DOI 10.1073/pnas.93.25.14686; SCHAACK J, 1990, GENE DEV, V4, P1197, DOI 10.1101/gad.4.7.1197; SHENK T, 1996, VIROLOGY, P2111; Smith CA, 1996, J VIROL, V70, P6733, DOI 10.1128/JVI.70.10.6733-6740.1996; Sparer TE, 1996, J VIROL, V70, P2431, DOI 10.1128/JVI.70.4.2431-2439.1996; STEVENSON SC, 1995, J VIROL, V69, P2850, DOI 10.1128/JVI.69.5.2850-2857.1995; Thorne TE, 1996, J VIROL, V70, P8502, DOI 10.1128/JVI.70.12.8502-8507.1996; Tollefson AE, 1996, J VIROL, V70, P2296, DOI 10.1128/JVI.70.4.2296-2306.1996; Tursz T, 1996, J NATL CANCER I, V88, P1857, DOI 10.1093/jnci/88.24.1857; Vigne E, 1996, GENETIC APPROACHES TO NONCOMMUNICABLE DISEASES, P113; Wang Q, 1995, GENE THER, V2, P775; Wickham TJ, 1996, NAT BIOTECHNOL, V14, P1570, DOI 10.1038/nbt1196-1570; Wickham TJ, 1995, GENE THER, V2, P750; Yeh P, 1996, J VIROL, V70, P559, DOI 10.1128/JVI.70.1.559-565.1996; ZHANG XL, 1994, J GEN VIROL, V75, P1943, DOI 10.1099/0022-1317-75-8-1943; Zhou HS, 1996, J VIROL, V70, P7030, DOI 10.1128/JVI.70.10.7030-7038.1996	50	137	175	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1997	11	8					615	623		10.1096/fasebj.11.8.9240963	http://dx.doi.org/10.1096/fasebj.11.8.9240963			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XN027	9240963				2022-12-28	WOS:A1997XN02700002
J	Ghosh, S; Strum, JC; Bell, RM				Ghosh, S; Strum, JC; Bell, RM			Lipid biochemistry: Functions of glycerolipids and sphingolipids in cellular signaling	FASEB JOURNAL			English	Review						lipid; second messenger; PKC; Raf; cell cycle	PROTEIN-KINASE-C; PHORBOL ESTER BINDING; PROGESTERONE-INDUCED MATURATION; HIGH-AFFINITY BINDING; CYSTEINE-RICH DOMAIN; REGULATORY DOMAIN; XENOPUS OOCYTES; MIXED MICELLES; MAP KINASE; ACTIVATION	Products of glycerolipid and sphingolipid metabolism are now known to fulfill second messenger functions in a variety of cellular signaling pathways. Evidence for glycerolipid-derived second messengers was first obtained from the ''phosphatidylinositol cycle,'' which involves a signal-dependent hydrolysis of phosphatidylinositol bisphosphate yielding diacylglycerol and inositol trisphosphate, The role of diacylglycerol in the regulation of protein kinase C activity and its site of interaction with PKC are now well known. Recently, another glycerolipid second messenger, phosphatidic acid, was found to interact with the protooncogenic Raf-1 kinase, In cultured cells, a signal-induced generation of phosphatidic acid Tvas critical for Raf-1 translocation to the cell membrane, Thus, different glycerolipid second messengers appear to regulate distinct targets with exquisite specificity, Analogous to the PI cycle, a ''sphingomyelin cycle'' was also found to exist, generating sphingolipid second messengers, Ceramide, derived from the agonist-induced hydrolysis of sphingomyelin, is a potent biomolecule with effects in multiple cell signaling pathways, The steroid hormone progesterone stimulated sphingomyelin hydrolysis in Xenopus oocytes, Ceramide, derived from the ''sphingomyelin cycle,'' was sufficient for meiotic cell cycle progression in the oocytes, These results demonstrate the various effects of lipid-derived second messengers and promise exciting discoveries into the roles of lipids in cell signaling.	GLAXO WELLCOME RES,RES TRIANGLE PK,NC 27709	GlaxoSmithKline			Ghosh, Sujoy/I-3729-2017	Ghosh, Sujoy/0000-0002-7601-165X				AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; Bell R M, 1986, Methods Enzymol, V124, P353; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CARNERO A, 1993, J CELL BIOCHEM, V52, P440, DOI 10.1002/jcb.240520408; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; DAVIS RJ, 1985, J BIOL CHEM, V260, P1562; EDWARDS JS, 1995, BIOCHEM J, V308, P473, DOI 10.1042/bj3080473; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; GANONG BR, 1986, P NATL ACAD SCI USA, V83, P1184, DOI 10.1073/pnas.83.5.1184; GANONG BR, 1987, CELL MEMBRANES METHO, P183; GHOSH S, 1994, J BIOL CHEM, V269, P30785; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; Gorter E, 1925, J EXP MED, V41, P439, DOI 10.1084/jem.41.4.439; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1986, J BIOL CHEM, V261, P9341; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HANNUN YA, 1996, HDB LIPID RES, P177; Hawthorne J.N., 1982, PHOSPHOLIPIDS, P263; HOMMEL U, 1994, NAT STRUCT BIOL, V1, P383, DOI 10.1038/nsb0694-383; KAIBUCHI K, 1981, J BIOL CHEM, V256, P7146; KISHIMOTO A, 1980, J BIOL CHEM, V255, P2273; KONIG B, 1985, J CELL BIOCHEM, V29, P37, DOI 10.1002/jcb.240290105; LEE MH, 1986, J BIOL CHEM, V261, P4867; LEE MH, 1989, J BIOL CHEM, V264, P14797; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MCGOVERN UB, 1995, BRIT J DERMATOL, V132, P892; Merrill Alfred H. Jr., 1993, V25, P1; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OISHI K, 1988, J BIOL CHEM, V263, P6865; Okada T, 1996, J BIOL CHEM, V271, P4671; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; QUEST AFG, 1994, J BIOL CHEM, V269, P2961; QUEST AFG, 1994, PROTEIN KINASE C, P64; QUEST AFG, 1994, J BIOL CHEM, V269, P2000; SHARKEY NA, 1984, P NATL ACAD SCI USA, V81, P697; SIDDIQUI RA, 1995, CELL SIGNAL, V7, P247, DOI 10.1016/0898-6568(94)00083-N; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; STRUM JC, 1995, J BIOL CHEM, V270, P13541, DOI 10.1074/jbc.270.22.13541; TAKAI Y, 1979, J BIOCHEM-TOKYO, V86, P575, DOI 10.1093/oxfordjournals.jbchem.a132557; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; VARNOLD RL, 1990, DEVELOPMENT, V109, P597; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	55	116	121	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1997	11	1					45	50		10.1096/fasebj.11.1.9034165	http://dx.doi.org/10.1096/fasebj.11.1.9034165			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK147	9034165				2022-12-28	WOS:A1997WK14700007
J	Morohashi, KI; Omura, T				Morohashi, KI; Omura, T			Cytochromes P450 .10. Ad4BP/SF-1, a transcription factor essential for the transcription of steroidogenic cytochrome P450 genes and for the establishment of the reproductive function	FASEB JOURNAL			English	Review						differentiation; protein kinase A; gene-disrupted mouse; steroidogenic transcription factor	VENTROMEDIAL HYPOTHALAMIC NUCLEUS; HORMONE-RECEPTOR SUPERFAMILY; CHAIN-CLEAVAGE ENZYME; SEXUAL-DIFFERENTIATION; AD4-BINDING PROTEIN; GONADAL DEVELOPMENT; PROMOTER REGION; KEY REGULATOR; FTZ-F1 GENE; FACTOR-I	Ad4BP/SF-1 Tvas identified as the steroidogenic tissue-specific transcription factor regulating the expression of the steroidogenic cytochrome P450 genes, In addition to the steroidogenic endocrine tissues such as adrenal cortex, testis, and ovary, the factor was found to be expressed in the pituitary gonadotroph and the ventromedial hypothalamic nucleus, Considering the roles of the hypothalamus-pituitary-gonadal axis, it is reasonable to assume that Ad4BP/SF-1 is closely associated with the reproductive function of adult animals, Another fundamental role of Ad4BP/SF-1 in the fetal development was discovered by gene disruption studies, Serious structural and functional defects were observed in the Ad4BP/SF-1-positive tissues of the gene-disrupted mice, Based on the sexually dimorphic expression of Ad4BP/SF-1 in the fetal gonads, the factor is also likely to be involved in the gonadal sex differentiation. Because of this functional significance during the tissue differentiation, the regulatory mechanism of the Ad4BP/SF1 gene, the mammalian Ftz-F1 gene, has been investigated, The gene is controlled by an autoregulatory mechanism in which Ad4BP/SF-1 functions as the dominant transcription transcription factor essential for the transcription of steroidogenic cytochrome P450 genes and for the establishment of the reproductive function.	KYUSHU UNIV, GRAD SCH MED SCI, DEPT MOL BIOL, HIGASHI KU, FUKUOKA 812, JAPAN; VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA	Kyushu University; Vanderbilt University								BARNHART KM, 1994, MOL ENDOCRINOL, V8, P878, DOI 10.1210/me.8.7.878; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CLARK BJ, 1995, MOL ENDOCRINOL, V9, P1346, DOI 10.1210/me.9.10.1346; COHEN RS, 1992, PROG NEUROBIOL, V38, P423, DOI 10.1016/0301-0082(92)90045-G; DORRINGTON JH, 1975, P NATL ACAD SCI USA, V72, P2677, DOI 10.1073/pnas.72.7.2677; DUFAU ML, 1988, ANNU REV PHYSIOL, V50, P483, DOI 10.1146/annurev.ph.50.030188.002411; FENG ZM, 1989, MOL ENDOCRINOL, V3, P1914, DOI 10.1210/mend-3-12-1914; FITZPATRICK SL, 1993, MOL ENDOCRINOL, V7, P341, DOI 10.1210/me.7.3.341; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HACKER A, 1995, DEVELOPMENT, V121, P1603; Halvorson LM, 1996, J BIOL CHEM, V271, P6645, DOI 10.1074/jbc.271.12.6645; HATANO O, 1994, DEVELOPMENT, V120, P2787; HONDA S, 1993, J BIOL CHEM, V268, P7494; HONDA SI, 1990, J BIOCHEM-TOKYO, V108, P1042, DOI 10.1093/oxfordjournals.jbchem.a123303; HORN F, 1992, MOL CELL BIOL, V12, P2143, DOI 10.1128/MCB.12.5.2143; IDEKA Y, 1994, MOL ENDOCRINOL, V8, P654; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; IKEDA Y, 1995, MOL ENDOCRINOL, V9, P478, DOI 10.1210/me.9.4.478; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MICHAEL MD, 1995, J BIOL CHEM, V270, P13561, DOI 10.1074/jbc.270.22.13561; MOROHASHI K, 1994, MOL ENDOCRINOL, V8, P643, DOI 10.1210/me.8.5.643; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; MUNSTERBERG A, 1991, DEVELOPMENT, V113, P613; NINOMIYA Y, 1995, J BIOCHEM-TOKYO, V118, P380, DOI 10.1093/oxfordjournals.jbchem.a124918; Nomura M, 1996, J BIOL CHEM, V271, P8243, DOI 10.1074/jbc.271.14.8243; NOMURA M, 1995, J BIOL CHEM, V270, P7453, DOI 10.1074/jbc.270.13.7453; PARKER KL, 1993, TRENDS ENDOCRIN MET, V4, P46, DOI 10.1016/S1043-2760(05)80014-1; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; RICE DA, 1990, J BIOL CHEM, V265, P11713; RICHARDS JS, 1988, ANNU REV PHYSIOL, V50, P441; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SHINODA K, 1995, DEV DYNAM, V204, P22, DOI 10.1002/aja.1002040104; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; Swain A, 1996, NAT GENET, V12, P404, DOI 10.1038/ng0496-404; TAKAYAMA K, 1995, J CLIN ENDOCR METAB, V80, P2815, DOI 10.1210/jc.80.9.2815; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; TSAIMORIS CH, 1991, J BIOL CHEM, V262, P11355; TSUKIYAMA T, 1992, MOL CELL BIOL, V12, P1286, DOI 10.1128/MCB.12.3.1286; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WATERMAN MR, 1994, J BIOL CHEM, V269, P27783; WEHRENBERG U, 1994, P NATL ACAD SCI USA, V91, P1440, DOI 10.1073/pnas.91.4.1440; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; Zhang PL, 1996, MOL ENDOCRINOL, V10, P147, DOI 10.1210/me.10.2.147	50	184	188	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1996	10	14					1569	1577		10.1096/fasebj.10.14.9002548	http://dx.doi.org/10.1096/fasebj.10.14.9002548			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WC869	9002548				2022-12-28	WOS:A1996WC86900002
J	Estabrook, RW				Estabrook, RW			The remarkable P4150s: A historical overview of these versatile hemeprotein catalysts	FASEB JOURNAL			English	Review							CYTOCHROME-P-450				Estabrook, RW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,CECIL & IDA GREEN CHAIR BIOMED SCI,DALLAS,TX 75235, USA.				NIGMS NIH HHS [GM16488-26] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRODIE BB, 1958, ANNU REV BIOCHEM, V27, P427, DOI 10.1146/annurev.bi.27.070158.002235; CHANCE B, 1951, REV SCI INSTRUM, V22, P619, DOI 10.1063/1.1746019; CONNEY AH, 1967, PHARMACOL REV, V19, P317; COOPER DY, 1965, SCIENCE, V147, P400, DOI 10.1126/science.147.3656.400; ESTABROOK RW, 1963, BIOCHEM Z, V338, P741; ESTABROOK RW, 1968, 19 COLL GES BIOL CHE, P142; FUJIIKURIYAMA Y, 1982, P NATL ACAD SCI-BIOL, V79, P2793, DOI 10.1073/pnas.79.9.2793; GILLETTE JR, 1957, J PHARMACOL EXP THER, V119, P532; HAYAISHI O, 1955, J AM CHEM SOC, V77, P5450, DOI 10.1021/ja01625a095; HODGSON E, 1993, BIOCHEM SOC T, V21, P1060, DOI 10.1042/bst0211060; HOLTON TA, 1993, NATURE, V366, P276, DOI 10.1038/366276a0; KLINGENBERG M, 1958, ARCH BIOCHEM BIOPHYS, V75, P376, DOI 10.1016/0003-9861(58)90436-3; LIEBERMAN S, 1951, ANNU REV BIOCHEM, V20, P227, DOI 10.1146/annurev.bi.20.070151.001303; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; LU AYH, 1969, J BIOL CHEM, V244, P3714; MASON HS, 1955, J AM CHEM SOC, V77, P2914, DOI 10.1021/ja01615a088; MILLER EC, 1959, ANNU REV BIOCHEM, V28, P291, DOI 10.1146/annurev.bi.28.070159.001451; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OMURA T, 1964, J BIOL CHEM, V239, P2370; OMURA T, 1978, CYTOCHROME P450, P1; POULOS TL, 1985, J BIOL CHEM, V260, P6122; PRIESS B, 1964, J BIOL CHEM, V239, P85; REMMER H, 1965, ANN NY ACAD SCI, V123, P79; RUF HH, 1979, J INORG BIOCHEM, V11, P189, DOI 10.1016/S0162-0134(00)80017-3; SHET MS, 1995, ARCH BIOCHEM BIOPHYS, V318, P314, DOI 10.1006/abbi.1995.1235; STEGEMAN JJ, 1991, ENVIRON HEALTH PERSP, V90, P101, DOI 10.2307/3430851; TYNDALE R, 1991, PHARMACOGENETICS, V1, P26, DOI 10.1097/00008571-199110000-00005; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; WILLIAMS RT, 1951, ANNU REV BIOCHEM, V20, P441, DOI 10.1146/annurev.bi.20.070151.002301	29	45	51	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1996	10	2					202	204		10.1096/fasebj.10.2.8641552	http://dx.doi.org/10.1096/fasebj.10.2.8641552			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641552				2022-12-28	WOS:A1996TY96200003
J	RANSOHOFF, RM; HAMILTON, TA; TANI, M; STOLER, MH; SHICK, HE; MAJOR, JA; ESTES, ML; THOMAS, DM; TUOHY, VK				RANSOHOFF, RM; HAMILTON, TA; TANI, M; STOLER, MH; SHICK, HE; MAJOR, JA; ESTES, ML; THOMAS, DM; TUOHY, VK			ASTROCYTE EXPRESSION OF MESSENGER-RNA ENCODING CYTOKINES IP-10 AND JE/MCP-1 IN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS	FASEB JOURNAL			English	Note						CHEMOATTRACTANTS; ASTROCYTES; DEMYELINATION; CYTOKINES; IP-10; JE/MCP-1; INSITU HYBRIDIZATION	MYELIN PROTEOLIPID PROTEIN; HUMAN ENDOTHELIAL-CELLS; MONOCYTE CHEMOATTRACTANT; MULTIPLE-SCLEROSIS; INTERFERON; GENE; IDENTIFICATION; SYNTHESIZE; SECRETION; INDUCTION	Mononuclear leukocytes preferentially accumulate in the central nervous system (CNS) during the course of experimental autoimmune encephalomyelitis (EAE). To address factors that govern leukocyte trafficking in EAE, we monitored expression of mRNAs encoding IP-10 and JE/MCP-1, which are members of a family of chemoattractant cytokines. A transient burst of IP-10 and JE/MCP-1 mRNA accumulation in the CNS occurred, in close relation to the onset of histologic and clinical disease. In situ hybridizations showed, unexpectedly, that astrocytes were the major source of mRNAs encoding IP-10 and JE/MCP-1. These observations implicate astrocyte-derived cytokines as potential chemoattractants for inflammatory cells during EAE.	CLEVELAND CLIN FDN,DIV PATHOL & LAB MED,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,NEUROPATHOL SECT,CLEVELAND,OH 44195	Cleveland Clinic Foundation; Cleveland Clinic Foundation	RANSOHOFF, RM (corresponding author), CLEVELAND CLIN FDN,RES INST,MELLEN CTR MULTIPLE SCLEROSIS TREATMENT & NEUROL,DEPT MOLEC BIOL,CLEVELAND,OH 44195, USA.		Hamilton, Thomas A/A-7756-2009	Hamilton, Thomas/0000-0002-9817-242X	NHLBI NIH HHS [HL29582] Funding Source: Medline; NINDS NIH HHS [NSKO8-01265, NS 29095] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS029095, K08NS001265] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGERER LM, 1987, IN SITU HYBRIDIZATIO, P42; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; BENVENISTE EN, 1990, J NEUROIMMUNOL, V30, P201, DOI 10.1016/0165-5728(90)90104-U; FIERZ W, 1985, J IMMUNOL, V134, P3785; FONTANA A, 1984, NATURE, V307, P273, DOI 10.1038/307273a0; FONTANA A, 1984, LYMPHOKINE RES, V3, P11; FREI K, 1985, J IMMUNOL, V135, P4044; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; Hickey WF, 1991, BRAIN PATHOL, V1, P97, DOI 10.1111/j.1750-3639.1991.tb00646.x; HOFMAN FM, 1986, J IMMUNOL, V136, P3239; KAPLAN G, 1987, J EXP MED, V166, P1098, DOI 10.1084/jem.166.4.1098; KIES MW, 1984, EXPT ALLERGIC ENCEPH; Lassmann H, 1983, COMP NEUROPATHOLOGY; LEE SC, 1990, J NEUROPATH EXP NEUR, V49, P122, DOI 10.1097/00005072-199003000-00005; LEWIS SA, 1984, P NATL ACAD SCI-BIOL, V81, P2743, DOI 10.1073/pnas.81.9.2743; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MERRILL JE, 1992, P NATL ACAD SCI USA, V89, P574, DOI 10.1073/pnas.89.2.574; NARUMI S, 1992, J LEUKOCYTE BIOL, V52, P27, DOI 10.1002/jlb.52.1.27; OHMORI Y, 1990, BIOCHEM BIOPH RES CO, V168, P1261, DOI 10.1016/0006-291X(90)91164-N; OHMORI Y, 1992, IN PRESS AM J PATHOL; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; RANSOHOFF RM, 1991, J NEUROIMMUNOL, V33, P103, DOI 10.1016/0165-5728(91)90054-B; RANSOHOFF RM, 1991, ARCH NEUROL-CHICAGO, V48, P1244, DOI 10.1001/archneur.1991.00530240048017; ROLLINS BJ, 1991, AM J PATHOL, V138, P1315; ROLLINS BJ, 1990, AM J PATHOL, V136, P1229; SAFIRSTEIN R, 1991, AM J PHYSIOL, V261, pF1095, DOI 10.1152/ajprenal.1991.261.6.F1095; SIMMONS RD, 1990, J NEUROL SCI, V100, P37, DOI 10.1016/0022-510X(90)90010-K; SOBEL RA, 1990, J NEUROPATH EXP NEUR, V49, P468, DOI 10.1097/00005072-199009000-00002; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; TUOHY VK, 1989, J IMMUNOL, V142, P1523; VANGURI P, 1990, J BIOL CHEM, V265, P15049; VANGURI P, 1992, 23RD ANN M AM SOC NE; WOLPE SD, 1989, FASEB J, V3, P2565, DOI 10.1096/fasebj.3.14.2687068; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; YOSHIMURA T, 1990, J IMMUNOL, V144, P2377; YOSHIMURA T, 1989, J EXP MED, V169, P1449, DOI 10.1084/jem.169.4.1449	36	478	494	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR 1	1993	7	6					592	600		10.1096/fasebj.7.6.8472896	http://dx.doi.org/10.1096/fasebj.7.6.8472896			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KY009	8472896				2022-12-28	WOS:A1993KY00900014
J	Howl, J; Langel, U; Hawtin, SR; Valkna, A; Yarwood, NJ; Saar, K; Wheatley, M				Howl, J; Langel, U; Hawtin, SR; Valkna, A; Yarwood, NJ; Saar, K; Wheatley, M			Chimeric strategies for the rational design of bioactive analogs of small peptide hormones	FASEB JOURNAL			English	Article						bradykinin; vasopressin; galanin; antagonist; mastoparan	BRADYKININ RECEPTOR ANTAGONISTS; V1A VASOPRESSIN RECEPTOR; ARGININE-VASOPRESSIN; AGONIST; PHARMACOLOGY; GALANIN; LIGANDS; KININS; CELLS; NEUROPEPTIDES	The aim of this study was to evaluate a variety of synthetic strategies pertinent to the development of chimeric analogs of the structurally divergent nonapeptide hormones arginine vasopressin (AW) and bradykinin (BK). Single-chain peptides combining AW and BK directly, AVP(1-9)-BK(1-9) or via a flexible aminohexanoic acid (epsilon Ahx) linker, AVP(1-9)-epsilon Ahx-BK(1-9), bind with relatively high affinity to the bovine kidney medulla B-2a bradykinin receptor (B-2a BKR). Significantly, amino-terminal extended chimeric analogs of BK including AVP(1-9)BK(1-9) and galanin(1-13)-BK(1-9), are functional B-2 BKR agonists. These findings illustrate that chimeric peptides can activate G-protein-coupled receptors (GPCRs) in a manner analogous to that of endogenous monomeric agonists. Further development, combining the sequences of receptor subtype-selective antagonist, produced high-affinity chimeric antagonists of the V-1a vasopressin receptor (V-1a VPR) and the B-2a BKR. We also determined the pharmacological characteristics of high-affinity chimeric hormone analogs derivatized with the membrane targeting function of mastoparan. Homodimers of an amino-terminal extended BK analog and a V-1a-selective antagonist represent the first examples of new classes of B-2 BKR and V-1a VPR antagonists, respectively. These findings are discussed in relation to the GPCR binding site for small peptides and the development of novel biological probes and therapeutic agents.	UNIV STOCKHOLM,ARRHENIUS LABS NAT SCI,DEPT NEUROCHEM & NEUROTOXICOL,S-10691 STOCKHOLM,SWEDEN	Stockholm University	Howl, J (corresponding author), UNIV BIRMINGHAM,SCH BIOCHEM,POB 363,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.			Langel, Ulo/0000-0001-6107-0844; Howl, John/0000-0001-9341-3717; Wheatley, Mark/0000-0001-6261-5682				ACHER R, 1993, REGUL PEPTIDES, V45, P1, DOI 10.1016/0167-0115(93)90174-7; BARTFAI T, 1993, CRIT REV NEUROBIOL, V7, P229; CALLAHAN JF, 1989, J MED CHEM, V32, P391, DOI 10.1021/jm00122a017; CANN JR, 1994, BIOPOLYMERS, V34, P869, DOI 10.1002/bip.360340706; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHERONIS JC, 1994, J MED CHEM, V37, P348, DOI 10.1021/jm00029a006; CHERONIS JC, 1992, J MED CHEM, V35, P1563, DOI 10.1021/jm00087a010; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; CONN PM, 1982, NATURE, V296, P653, DOI 10.1038/296653a0; GITELMAN HJ, 1980, SCIENCE, V207, P893, DOI 10.1126/science.7355269; HOWL J, 1993, EUR J BIOCHEM, V213, P711, DOI 10.1111/j.1432-1033.1993.tb17811.x; HOWL J, 1995, GEN PHARMACOL-VASC S, V26, P1143, DOI 10.1016/0306-3623(95)00016-T; HOWL J, 1991, BIOCHEM J, V276, P189, DOI 10.1042/bj2760189; Howl J, 1996, KIDNEY INT, V50, P586, DOI 10.1038/ki.1996.353; Howl J, 1996, NEUROPEPTIDES, V30, P73, DOI 10.1016/S0143-4179(96)90058-X; Howl J, 1996, BIOCHEM J, V317, P577, DOI 10.1042/bj3170577; HOWL J, 1991, MOL CELL ENDOCRINOL, V77, P123, DOI 10.1016/0303-7207(91)90066-2; HOWL J, 1993, METHODS NEUROSCI, V13, P281; JACKSON TR, 1987, EMBO J, V6, P49, DOI 10.1002/j.1460-2075.1987.tb04717.x; Jard S, 1987, PROG BRAIN RES <D>, V72, P173; JONES PM, 1993, MOL CELL ENDOCRINOL, V94, P97, DOI 10.1016/0303-7207(93)90056-P; Jureus A., 1996, ACTA CHIM SLOV, V43, P51, DOI DOI 10.1007/S008940100045; KIRK CJ, 1986, BIOCHEM J, V240, P197, DOI 10.1042/bj2400197; KYLE DJ, 1994, J MED CHEM, V37, P1347, DOI 10.1021/jm00035a015; LANGEL U, 1992, INT J PEPT PROT RES, V39, P516; Langel U, 1996, REGUL PEPTIDES, V62, P47, DOI 10.1016/0167-0115(96)00002-X; LASZLO FA, 1991, PHARMACOL REV, V43, P73; LONG DLW, 1996, PEPTIDES CHEM STRUCT, P595; MANNING M, 1984, TRENDS NEUROSCI, V7, P6, DOI 10.1016/S0166-2236(84)80179-4; MANNING M, 1992, J MED CHEM, V35, P382, DOI 10.1021/jm00080a027; MANNING M, 1991, PEPTIDES 1990, P665; MANNING M, 1987, NATURE, V329, P839, DOI 10.1038/329839a0; MANNING M, 1987, VASOPRESSIN PRINCIPL, P335; MARGOLIUS HS, 1989, ANNU REV PHARMACOL, V29, P343; Mezna Mokdad, 1997, Biochemical Society Transactions, V25, p450S; MOUILLAC B, 1995, J BIOL CHEM, V270, P25711; MOUSLI M, 1990, TRENDS PHARMACOL SCI, V11, P358, DOI 10.1016/0165-6147(90)90179-C; NOVOTNY EA, 1994, BIOCHEM BIOPH RES CO, V201, P523, DOI 10.1006/bbrc.1994.1733; OSTENSSON CG, 1997, IN PRESS ENDOCRINOLO; OTTER A, 1993, BIOPOLYMERS, V33, P769, DOI 10.1002/bip.360330506; RAYNOR RL, 1991, J BIOL CHEM, V266, P2753; REGOLI D, 1993, CAN J PHYSIOL PHARM, V71, P556, DOI 10.1139/y93-079; REGOLI D, 1994, LIFE SCI, V55, P735, DOI 10.1016/0024-3205(94)00557-5; REGOLI D, 1980, PHARMACOL REV, V32, P1; REGOLI D, 1990, TRENDS PHARMACOL SCI, V11, P156, DOI 10.1016/0165-6147(90)90067-I; Rose JP, 1996, NAT STRUCT BIOL, V3, P163, DOI 10.1038/nsb0296-163; SCHMIDT JM, 1991, EUR J BIOCHEM, V201, P355, DOI 10.1111/j.1432-1033.1991.tb16293.x; Sejbal J, 1996, J MED CHEM, V39, P1281, DOI 10.1021/jm950485f; Sermasi E, 1995, NEUROENDOCRINOLOGY, V62, P634, DOI 10.1159/000127060; SHARMA JN, 1993, GEN PHARMACOL, V24, P267, DOI 10.1016/0306-3623(93)90302-E; STEWART JM, 1995, BIOPOLYMERS, V37, P143, DOI 10.1002/bip.360370208; UFER E, 1995, FEBS LETT, V362, P19, DOI 10.1016/0014-5793(95)00150-8; VALKNA A, 1995, PROTEIN PEPTIDE LETT, V2, P267; WEI CM, 1993, J CLIN INVEST, V92, P2048, DOI 10.1172/JCI116800	54	29	33	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1997	11	7					582	590		10.1096/fasebj.11.7.9212082	http://dx.doi.org/10.1096/fasebj.11.7.9212082			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XH342	9212082				2022-12-28	WOS:A1997XH34200010
J	Varin, L; Marsolais, F; Richard, M; Rouleau, M				Varin, L; Marsolais, F; Richard, M; Rouleau, M			Biochemistry and molecular biology of plant sulfotransferases	FASEB JOURNAL			English	Review						flavonol sulfotransferase; glucosinolate; choline sulfate; flavonoid; gallic acid	LIPO-OLIGOSACCHARIDE SIGNALS; PARTIAL-PURIFICATION; FLAVERIA-BIDENTIS; OILSEED RAPE; FLAVONOL 3-SULFOTRANSFERASE; RHIZOBIUM-MELILOTI; P-LOOP; CLONING; EXPRESSION; BINDING	It is now well established that, in mammals, sulfate conjugation constitutes an important reaction in the transformation of xenobiotics and in the modulation of the biological activity of steroid hormones and neurotransmitter (1, 2). The presence of a sulfate group on some molecules can also be a prerequisite for their biological function. For example, it is well known that the sulfate groups are directly involved in the molecular interaction between heparin and antithrombin III (3). In plants, sulfation also seems to play an important role in the intermolecular recognition and signaling processes, as indicated by the requirement of a sulfate moiety for the biological activity of gallic acid glucoside sulfate in the seismonastic and gravitropic movements of plants (4), and of Nod RM1 in the cortical cell division during early nodule initiation in Rhizobium meliloti-alfalfa interaction (5). In addition, recent studies indicate that flavonoid conjugates, including the sulfate esters, may play a role in the regulation of plant growth by strongly binding the naphthylphthalamic acid receptor, thus blocking the quercetin-stimulated accumulation of the auxin phytohormone (6). Although several sulfated metabolites are known to accumulate in a variety of plant species (7), the study of enzymes that catalyze the sulfation reaction in plants lagged considerably compared to those conducted with their mammalian homologs. This apparent lack of interest may have been because the function of plant-sulfated metabolites is difficult to predict, since their accumulation is often restricted to a limited number of species. Despite this limitation, several plant sulfotransferases (STs) have been characterized at the biochemical level, and the cDNA clones encoding six plant STs have been isolated. Based on sequence homology, the plant ST coding sequences are grouped under the SULT3 family, also known as the flavonol ST family. This review summarizes our current knowledge of the plant STs and focuses on the functional significance of the sulfate conjugation in plant growth, development, and adaptation to stress.	UNIV LAVAL,DEPT BIOL,ST FOY,PQ G1K 7P4,CANADA	Laval University	Varin, L (corresponding author), CONCORDIA UNIV,DEPT BIOL,1455 DE MAISONNEUVE BLVD W,MONTREAL,PQ H3G 1M8,CANADA.			Marsolais, Frederic/0000-0003-3914-141X				ANANVORANICH S, 1994, PLANT PHYSIOL, V106, P485, DOI 10.1104/pp.106.2.485; BARRON D, 1988, PHYTOCHEMISTRY, V27, P2375, DOI 10.1016/0031-9422(88)87003-1; BORCHARDT RT, 1982, BIOCHIM BIOPHYS ACTA, V708, P280, DOI 10.1016/0167-4838(82)90438-1; CHEM ZX, 1995, P NATL ACAD SCI USA, V92, P4134; DOUGHTY KJ, 1991, ANN APPL BIOL, V118, P469, DOI 10.1111/j.1744-7348.1991.tb05648.x; Driscoll WJ, 1995, P NATL ACAD SCI USA, V92, P12328, DOI 10.1073/pnas.92.26.12328; FAULKNER IJ, 1992, PLANTA, V186, P618, DOI 10.1007/BF00198044; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; GLENDENING TM, 1990, PLANT PHYSIOL, V94, P811, DOI 10.1104/pp.94.2.811; HAHLBROCK K, 1989, ANNU REV PLANT PHYS, V41, P339; HANNOUFA A, 1991, PLANT PHYSIOL, V97, P259, DOI 10.1104/pp.97.1.259; HANSON AD, 1991, PLANT PHYSIOL, V97, P1199, DOI 10.1104/pp.97.3.1199; HANSON AD, 1994, P NATL ACAD SCI USA, V91, P306, DOI 10.1073/pnas.91.1.306; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; JAIN JC, 1990, J PLANT PHYSIOL, V136, P356, DOI 10.1016/S0176-1617(11)80062-3; KALLAS P, 1989, Naturwissenschaftliche Rundschau, V42, P309; KALLAS P, 1990, J PLANT PHYSIOL, V136, P225, DOI 10.1016/S0176-1617(11)81670-6; KOBAYASHI DY, 1990, MOL PLANT MICROBE IN, V3, P94, DOI 10.1094/MPMI-3-094; KOMATSU K, 1994, BIOCHEM BIOPH RES CO, V204, P1178, DOI 10.1006/bbrc.1994.2587; KORITSAS VM, 1991, ANN APPL BIOL, V118, P209, DOI 10.1111/j.1744-7348.1991.tb06099.x; Lacomme C, 1996, PLANT MOL BIOL, V30, P995, DOI 10.1007/BF00020810; LONG SR, 1989, CELL, V56, P203, DOI 10.1016/0092-8674(89)90893-3; Marsolais F, 1995, J BIOL CHEM, V270, P30458, DOI 10.1074/jbc.270.51.30458; MITHEN R, 1992, EUPHYTICA, V63, P71, DOI 10.1007/BF00023913; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PETITOU M, 1988, EUR J BIOCHEM, V176, P637, DOI 10.1111/j.1432-1033.1988.tb14324.x; POULTON JE, 1993, METHODS PLANT BIOCH, V9, P209; RICCA U, 1916, ARCH ITAL BIOL, V65, P219; RIVOAL J, 1994, PLANT PHYSIOL, V106, P1187, DOI 10.1104/pp.106.3.1187; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SATISHCHANDRAN C, 1992, BIOCHEMISTRY-US, V31, P11684, DOI 10.1021/bi00162a003; SATTER RL, 1990, PULVINUS MOTOR ORGAN, P1; SCHILDKNECHT H, 1981, CHEM ZTG, V105, P287; Schildknecht H, 1990, PULVINUS MOTOR ORGAN, P101; TRUCHET G, 1991, NATURE, V351, P670, DOI 10.1038/351670a0; VARIN L, 1995, J BIOL CHEM, V270, P12498, DOI 10.1074/jbc.270.21.12498; VARIN L, 1991, PLANT PHYSIOL, V95, P1254, DOI 10.1104/pp.95.4.1254; VARIN L, 1989, PLANT PHYSIOL, V90, P977, DOI 10.1104/pp.90.3.977; VARIN L, 1992, J BIOL CHEM, V267, P1858; VARIN L, 1992, P NATL ACAD SCI USA, V89, P1286, DOI 10.1073/pnas.89.4.1286; VARIN L, 1997, IN PRESS PLANT J; WEINSHILBOUM R, 1994, HDB EXPT PHARM CONJU, V112, P45; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160	44	74	81	1	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1997	11	7					517	525		10.1096/fasebj.11.7.9212075	http://dx.doi.org/10.1096/fasebj.11.7.9212075			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XH342	9212075				2022-12-28	WOS:A1997XH34200003
J	Spycher, SE; TabatabaVakili, S; ODonnell, VB; Palomba, L; Azzi, A				Spycher, SE; TabatabaVakili, S; ODonnell, VB; Palomba, L; Azzi, A			RETRACTED: Aldose reductase induction: A novel response to oxidative stress of smooth muscle cells (Retracted article. See vol. 26, pg. 2719, 2012)	FASEB JOURNAL			English	Article; Retracted Publication						hydrogen peroxide; 4-hydroxynonenal; differential display; gene expression	MESSENGER-RNA EXPRESSION; HUMAN-SKIN FIBROBLASTS; HYDROGEN-PEROXIDE; EPITHELIAL-CELLS; FREE-RADICALS; AUTOXIDATIVE GLYCOSYLATION; DIFFERENTIAL DISPLAY; ARACHIDONIC-ACID; HUMAN-TISSUES; ENZYME FORMS	Hydrogen peroxide (H2O2) or 4-hydroxy-2,3-trans-nonenal (HNE) treatment of rat vascular smooth muscle cells (A7r5) caused induction of aldose reductase mRNA. Induction was dose (10-100 mu M H2O2, 1-10 mu M HNE) and time dependent, reaching a maximum (three- to fourfold) after 7-12 h. Treatment of cells with actinomycin D confirmed de novo synthesis of aldose reductase mRNA. H2O2-induced expression was prevented by catalase but unaffected by Desferal, indicating that metal catalyzed degradation of peroxide was not involved, Induction of enzymatically active aldose reductase by H2O2 and HNE was confirmed using Western blotting and enzyme assays, Aldose reductase can metabolize several aldehyde compounds including HNE, a major toxic product of lipid peroxidation. Inclusion of Sorbinil, an aldose reductase inhibitor, in toxicity assays resulted in a significant (twofold) enhancement of HNE-mediated killing of A7r5 cells, suggesting a protective role of aldose reductase against HNE-induced cell death, These data indicate that the induction of aldose reductase during oxidative stress might represent an important cellular antioxidant defense mechanism.	UNIV URBINO, IST FARMACOL & FARMACOGNOSIA, I-61029 URBINO, ITALY	University of Urbino	Spycher, SE (corresponding author), UNIV BERN, INST BIOCHEM & MOL BIOL, BUHLSTR 28, CH-3012 BERN, SWITZERLAND.		O'Donnell, Valerie/C-6948-2012	/0000-0003-4089-8460				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMERON NE, 1992, DIABETOLOGIA, V35, P1011, DOI 10.1007/BF02221675; CAMMARATA PR, 1992, INVEST OPHTH VIS SCI, V33, P3572; CAPPIELLO M, 1994, EXP EYE RES, V58, P491, DOI 10.1006/exer.1994.1042; CHAUDHRI G, 1986, J IMMUNOL, V137, P2646; Crawford DR, 1996, ARCH BIOCHEM BIOPHYS, V325, P256, DOI 10.1006/abbi.1996.0032; DELCORSO A, 1989, ARCH BIOCHEM BIOPHYS, V270, P604, DOI 10.1016/0003-9861(89)90543-2; DELCORSO A, 1989, J BIOL CHEM, V264, P17653; DELCORSO A, 1993, ARCH BIOCHEM BIOPHYS, V300, P430, DOI 10.1006/abbi.1993.1058; DELCORSO A, 1987, BIOCHEM BIOPH RES CO, V148, P369, DOI 10.1016/0006-291X(87)91120-X; ECKL PM, 1993, MUTAT RES, V290, P183, DOI 10.1016/0027-5107(93)90158-C; FLYNN TG, 1982, METHOD ENZYMOL, V89, P501; GABBAY KH, 1966, SCIENCE, V151, P209, DOI 10.1126/science.151.3707.209; GRAHAM C, 1991, GENE, V107, P259, DOI 10.1016/0378-1119(91)90326-7; Grimshaw CE, 1996, ARCH BIOCHEM BIOPHYS, V327, P89, DOI 10.1006/abbi.1996.0096; HUNT JV, 1990, DIABETES, V39, P1420, DOI 10.2337/diabetes.39.11.1420; JAGT DLV, 1995, BBA-PROTEIN STRUCT M, V1249, P117; JIANG ZY, 1991, BIOCHEM PHARMACOL, V42, P1273, DOI 10.1016/0006-2952(91)90265-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KEYSE SM, 1987, J BIOL CHEM, V262, P14821; KINOSHITA JH, 1988, DIABETES METAB REV, V4, P323, DOI 10.1002/dmr.5610040403; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON R, 1988, J BIOL CHEM, V263, P17452; LEE AYW, 1995, P NATL ACAD SCI USA, V92, P2780, DOI 10.1073/pnas.92.7.2780; LI Y, 1994, EUR J BIOCHEM, V226, P31, DOI 10.1111/j.1432-1033.1994.tb20023.x; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1992, CANCER RES, V52, P6966; MARANO CW, 1992, INVEST OPHTH VIS SCI, V33, P2619; MEARS AB, 1984, DIABETES, V33, P604; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MITCHELL DY, 1991, HEPATOLOGY, V13, P728, DOI 10.1016/0270-9139(91)92572-P; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; MYLARI BL, 1991, J MED CHEM, V34, P1011, DOI 10.1021/jm00107a020; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; NISHIMURA C, 1988, BIOCHEM BIOPH RES CO, V153, P1051, DOI 10.1016/S0006-291X(88)81335-4; OHTAKA M, 1992, DIABETOLOGIA, V35, P730; OWENS GK, 1981, P NATL ACAD SCI-BIOL, V78, P7759, DOI 10.1073/pnas.78.12.7759; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROSSI MA, 1993, INT J TISSUE REACT, V15, P201; SHI ST, 1992, MOL CELL BIOCHEM, V115, P27; Srivastava S, 1995, BIOCHEM BIOPH RES CO, V217, P741, DOI 10.1006/bbrc.1995.2835; TAWATA M, 1992, LIFE SCI, V51, P719, DOI 10.1016/0024-3205(92)90480-D; TESFAMARIAM B, 1994, FREE RADICAL BIO MED, V16, P383, DOI 10.1016/0891-5849(94)90040-X; Ullrich O, 1996, BIOCHEM J, V315, P705, DOI 10.1042/bj3150705; VANDERJAGT DL, 1990, J BIOL CHEM, V265, P10912; VONWARTBURG JP, 1982, METHOD ENZYMOL, V89, P506; WERMUTH B, 1982, METHOD ENZYMOL, V89, P181; WESTERHAUSEN A, 1982, METHOD ENZYMOL, V89, P497; WIESE AG, 1995, ARCH BIOCHEM BIOPHYS, V318, P231, DOI 10.1006/abbi.1995.1225; WOLFF SP, 1991, FREE RADICAL BIO MED, V10, P339, DOI 10.1016/0891-5849(91)90040-A; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243; YOSHIOKA T, 1994, KIDNEY INT, V46, P405, DOI 10.1038/ki.1994.288; ZARKOVIC N, 1993, CELL BIOCHEM FUNCT, V11, P279, DOI 10.1002/cbf.290110409; ZOR U, 1993, BIOCHEM J, V295, P879, DOI 10.1042/bj2950879	59	143	150	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1997	11	2					181	188		10.1096/fasebj.11.2.9039961	http://dx.doi.org/10.1096/fasebj.11.2.9039961			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK509	9039961				2022-12-28	WOS:A1997WK50900011
J	Baldwin, W; McCardle, P				Baldwin, W; McCardle, P			Peer review at NIH in the 21st century	FASEB JOURNAL			English	Editorial Material											Baldwin, W (corresponding author), NIH,OFF EXTRAMURAL RES,BETHESDA,MD 20892, USA.								0	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1996	10	14					1563	1568		10.1096/fasebj.10.14.9002547	http://dx.doi.org/10.1096/fasebj.10.14.9002547			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WC869	9002547				2022-12-28	WOS:A1996WC86900001
J	Edmondson, DG; Roth, SY				Edmondson, DG; Roth, SY			Chromatin and transcription	FASEB JOURNAL			English	Review						nucleosome; histone; regulation; position effects	NUCLEOSOME REMODELING FACTOR; POSITION EFFECT VARIEGATION; HISTONE ACETYLATION; IN-VIVO; DNA-REPLICATION; PHO5 PROMOTER; COMPLEX; YEAST; ACTIVATION; DROSOPHILA	The compaction of DNA into chromatin in the eukaryotic nucleus poses many obstacles to transcription. Individual nucleosomes as well as higher order structures limit access of cis-acting regulatory elements to trans-acting factors. The structural nature of this inhibition and the mechanisms by which chromatin is remodeled to facilitate the regulation of gene expression have remained puzzles for many years. Recent advances highlight the intimate and dynamic interplay between transcription proteins and components of chromatin, providing new clues to long-standing questions. A transcriptional adaptor complex has been discovered to house histone acetylase activity. A chromatin remodeling ''machine'' has been found to be part of the RNA polymerase II holoenzyme. Identification of new factors that affects the organization of functional chromatin domains in yeast, flies, and mammals provides new insights into the organization of higher order chromatin structures, as well as the nature of boundaries that restrict these domains. These compelling discoveries and others define a new and exciting threshold for our understanding of the many connections between chromatin and transcription.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOL BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center				Dent, Sharon/0000-0002-4824-3269; Edmondson, Diane/0000-0003-3702-9715	NCI NIH HHS [CA65098-01] Funding Source: Medline; NIGMS NIH HHS [GM511890] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA065098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P568, DOI 10.1210/me.8.5.568; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; BROWNELL JE, 1996, IN PRESS CELL; BURATOWSKI S, 1995, SCIENCE, V270, P1773, DOI 10.1126/science.270.5243.1773; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; EDMONDSON DG, 1996, IN PRESS GENES DEV; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; GUARENTE L, 1995, TRENDS BIOCHEM SCI, V20, P516; HANSEN JC, 1994, P NATL ACAD SCI USA, V91, P2339, DOI 10.1073/pnas.91.6.2339; HANSEN SK, 1995, CELL, V82, P1; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HIRSCHHORN JN, 1995, MOL CELL BIOL, V15, P1999; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; NIKOLOV DB, 1995, NATURE, V377, P121; ORLANDO V, 1995, CURR OPIN GENET DEV, V5, P174, DOI 10.1016/0959-437X(95)80005-0; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PALLADINO F, 1994, CURR OPIN CELL BIOL, V6, P373, DOI 10.1016/0955-0674(94)90029-9; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PERRY CA, 1991, EXP CELL RES, V196, P337, DOI 10.1016/0014-4827(91)90269-Z; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; RIVIER DH, 1994, CELL, V76, P963, DOI 10.1016/0092-8674(94)90373-5; ROTH SY, 1995, CURR OPIN GENET DEV, V5, P168, DOI 10.1016/0959-437X(95)80004-2; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SAUER F, 1995, SCIENCE, V270, P1825, DOI 10.1126/science.270.5243.1825; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; Strick R, 1995, CELL, V83, P1137, DOI 10.1016/0092-8674(95)90140-X; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; SVAREN J, 1994, EMBO J, V13, P4856, DOI 10.1002/j.1460-2075.1994.tb06812.x; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; van Holde KE., 1989, SPRINGER SERIES MOL; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; VETTESEDADEY M, 1994, MOL CELL BIOL, V14, P970, DOI 10.1128/MCB.14.2.970; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; WEILER KS, 1995, IN PRESS ANN REV GEN; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0	59	46	48	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1996	10	10					1173	1182		10.1096/fasebj.10.10.8751719	http://dx.doi.org/10.1096/fasebj.10.10.8751719			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VD429	8751719				2022-12-28	WOS:A1996VD42900008
J	Bollag, W				Bollag, W			The retinoid revolution	FASEB JOURNAL			English	Editorial Material											Bollag, W (corresponding author), F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES,CH-4070 BASEL,SWITZERLAND.								0	14	15	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1996	10	9					938	939		10.1096/fasebj.10.9.8801175	http://dx.doi.org/10.1096/fasebj.10.9.8801175			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801175				2022-12-28	WOS:A1996UY93200002
J	Murray, M; Butler, AM; Agus, C				Murray, M; Butler, AM; Agus, C			Restoration of cytochrome P450 2C11 in vitamin A-deficient rat liver by exogenous androgen	FASEB JOURNAL			English	Article						vitamin A deficiency; androgen; CYP2C11 regulation; steroid hydroxylation	HORMONAL-REGULATION; MESSENGER-RNA; RETINOIC ACID; HEPATIC CYTOCHROME-P-450; EXPRESSION; DRUG; ISOZYMES; ENZYMES; TESTOSTERONE; SUPPRESSION	Down-regulation of microsomal androgen-dependent CYP2C11 is produced in male rat liver by dietary vitamin A deficiency, Decreased circulating androgen concentrations also occur in vitamin A-deficient male rats, Both effects are prevented by addition of all-trans-retinoic acid to the diet, The present study evaluated directly whether androgen deficiency may be responsible for the down-regulation of 2C11 in vitamin A-deficient male rats, The major finding was that subcutaneous administration of the androgen methyltrienolone (MT) during the final week of the study restored CYP2C11 protein and its associated steroid 16 alpha-hydroxylation activities to control levels; CYP2C11 mRNA was also restored, Despite the efficient restoration of CYP2C11 at a pretranslational level, no alteration in vitamin A status was apparent and animals remained vitamin A deficient after MT treatment, The possibility was assessed that vitamin A can maintain the microsomal content of CYP2C11 in normal Liver, However, in contrast to MT, administration of ATRA to gonadectomized male rats did not restore 2C11 in liver, These findings establish that the major effect of vitamin A deficiency on CYP2C11 in male rat liver is mediated indirectly by androgen deficiency.			Murray, M (corresponding author), UNIV SYDNEY,DEPT MED,WESTMEAD HOSP,STORR LIVER UNIT,WESTMEAD,NSW 2145,AUSTRALIA.							AZAIS V, 1987, TOXICOLOGY, V44, P341, DOI 10.1016/0300-483X(87)90035-7; BEDO G, 1989, NATURE, V339, P231, DOI 10.1038/339231a0; BLOMHOFF R, 1992, ANNU REV NUTR, V12, P37, DOI 10.1146/annurev.nu.12.070192.000345; BREEN JJ, 1995, ENDOCRINOLOGY, V136, P543, DOI 10.1210/en.136.2.543; BUTLER AM, 1993, MOL PHARMACOL, V43, P902; CAMPBELL TC, 1974, PHARMACOL REV, V26, P171; CHAUDHARY LR, 1989, BIOCHEM BIOPH RES CO, V158, P400, DOI 10.1016/S0006-291X(89)80061-0; CHEN JQ, 1995, J BIOL CHEM, V270, P25233, DOI 10.1074/jbc.270.42.25233; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EINARSSON K, 1973, J BIOL CHEM, V248, P4987; GUSTAFSSON JA, 1983, ANNU REV PHYSIOL, V45, P51, DOI 10.1146/annurev.ph.45.030183.000411; JANECZKO R, 1990, MOL ENDOCRINOL, V4, P295, DOI 10.1210/mend-4-2-295; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLANC GA, 1988, J BIOL CHEM, V263, P15732; LEGRAVEREND C, 1992, FASEB J, V6, P711, DOI 10.1096/fasebj.6.2.1537461; LEMOINE A, 1988, EUR J BIOCHEM, V177, P597, DOI 10.1111/j.1432-1033.1988.tb14412.x; LIDDLE C, 1992, ARCH BIOCHEM BIOPHYS, V298, P159, DOI 10.1016/0003-9861(92)90107-8; LOWRY OH, 1951, J BIOL CHEM, V193, P3179; MALLO F, 1992, NEUROENDOCRINOLOGY, V55, P642, DOI 10.1159/000126183; MARTINI R, 1995, J PHARMACOL EXP THER, V273, P427; MARTINI R, 1994, BIOCHEM PHARMACOL, V48, P1305, DOI 10.1016/0006-2952(94)90170-8; MORGAN ET, 1985, J BIOL CHEM, V260, P1895; MURRAY M, 1986, BIOCHEM PHARMACOL, V35, P1817, DOI 10.1016/0006-2952(86)90298-4; MURRAY M, 1983, TOXICOL APPL PHARM, V68, P66, DOI 10.1016/0041-008X(83)90355-1; MURRAY M, 1992, CHEM RES TOXICOL, V5, P60, DOI 10.1021/tx00025a010; NADIN L, 1995, GASTROENTEROLOGY, V109, P198, DOI 10.1016/0016-5085(95)90285-6; OMURA T, 1964, J BIOL CHEM, V239, P2370; RAM PA, 1991, MOL ENDOCRINOL, V5, P13, DOI 10.1210/mend-5-1-13; RENTON KW, 1976, BIOCHEM BIOPH RES CO, V73, P343, DOI 10.1016/0006-291X(76)90713-0; RICH KA, 1979, MOL CELL ENDOCRINOL, V13, P123, DOI 10.1016/0303-7207(79)90013-3; Sambrook J., 2002, MOL CLONING LAB MANU; SKETT P, 1982, BIOCHEM PHARMACOL, V32, P3115; SPORN MB, 1977, NUTR REV, V35, P65, DOI 10.1111/j.1753-4887.1977.tb06541.x; THUMMEL KE, 1990, MOL PHARMACOL, V37, P119; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAXMAN DJ, 1983, J BIOL CHEM, V258, P1937; WAXMAN DJ, 1985, BIOCHEMISTRY-US, V24, P4409, DOI 10.1021/bi00337a023; WAXMAN DJ, 1991, P NATL ACAD SCI USA, V88, P6868, DOI 10.1073/pnas.88.15.6868; YEOWELL HN, 1987, MOL PHARMACOL, V32, P340; YOSHIOKA H, 1987, J BIOL CHEM, V262, P1706	40	10	10	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1996	10	9					1058	1063		10.1096/fasebj.10.9.8801167	http://dx.doi.org/10.1096/fasebj.10.9.8801167			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801167				2022-12-28	WOS:A1996UY93200016
J	Ross, AC; Stephensen, CB				Ross, AC; Stephensen, CB			Vitamin A and retinoids in antiviral responses	FASEB JOURNAL			English	Article						Newcastle disease virus; Herpes simplex virus; natural killer cells; cytokines; retinol binding protein; vitamin A status	DISEASE VIRUS-INFECTION; A-DEFICIENT RATS; KILLER-CELL ACTIVITY; ROTAVIRUS INFECTION; IMMUNE-RESPONSE; CHICKENS; ACID; SERUM; MICE; PATHOGENESIS	Vitamin A deficiency results in multiple derangements that impair the response to infection, This review focuses on experimental models of specific virus infections and on cytokines and cells with cytolytic activity important to antiviral defenses, Altered specific antibody responses and greater epithelial damage in vitamin A-deficient hosts are consistent findings, The cytolytic activity of natural killer cells and various cytokine responses are altered, The inflammatory response to infection may also result in derangements in the transport and metabolism of retinol, We speculate that interaction of several factors may combine to explain the greater severity of infection seen in vitamin A-deficient animals and children, In addition to a preexisting lack of tissue vitamin A, these factors may include reduced mobilization and increased excretion of retinol during the acute phase response to infection, poor innate and specific immune response to virus, and delayed repair of damaged epithelia. Foci of vitamin A-deficient epithelia may be sites of penetration of bacteria and other agents, leading to secondary infections and contributing to an increased severity of infections and poor outcome in vitamin A-deficient animals and humans.	UNIV ALABAMA,SCH PUBL HLTH,DEPT INT HLTH,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham	Ross, AC (corresponding author), PENN STATE UNIV,DEPT NUTR,126 S HENDERSON BLDG,UNIVERSITY PK,PA 16802, USA.		Stephensen, Charles/AAF-1742-2021		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041479, R56DK041479] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-30293] Funding Source: Medline; NIDDK NIH HHS [R01 DK041479, DK-41479] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED F, 1991, BRIT J NUTR, V65, P475, DOI 10.1079/BJN19910106; AHMED F, 1990, BRIT J NUTR, V63, P363, DOI 10.1079/BJN19900122; Alexander D. J., 1991, Diseases of poultry., P496; ALVAREZ JO, 1995, AM J CLIN NUTR, V61, P1273, DOI 10.1093/ajcn/61.6.1273; BANG BG, 1969, P SOC EXP BIOL MED, V132, P50, DOI 10.3181/00379727-132-34146; BANG FB, 1971, JOHNS HOPKINS MED J, V129, P100; BANG FB, 1975, AM J PATHOL, V78, P417; BEATON CH, 1994, FOOD NUTR B, V15, P282; BHATTI L, 1994, IMMUNOLOGY, V81, P273; BLOMHOFF R, 1991, PHYSIOL REV, V71, P951, DOI 10.1152/physrev.1991.71.4.951; BOWMAN TA, 1990, J NUTR, V120, P1264, DOI 10.1093/jn/120.10.1264; CANTORNA MT, 1994, J IMMUNOL, V152, P1515; CANTORNA MT, 1995, EUR J IMMUNOL, V25, P1673, DOI 10.1002/eji.1830250629; CLASZIOU PP, 1993, BRIT MED J, V306, P366; DAVIS CY, 1989, POULTRY SCI, V68, P136, DOI 10.3382/ps.0680136; FELLI MP, 1991, MOL CELL BIOL, V11, P4771, DOI 10.1128/MCB.11.9.4771; GOTTGENS B, 1995, BIOESSAYS, V17, P187, DOI 10.1002/bies.950170302; GRIFFIN DE, 1990, CLIN EXP IMMUNOL, V81, P218; HUAN BF, 1992, P NATL ACAD SCI USA, V89, P9059, DOI 10.1073/pnas.89.19.9059; HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304; KIRKWOOD BR, 1993, LANCET, V342, P7; LEIGH MW, 1991, REV INFECT DIS, V13, pS501; MOSSMAN TR, 1996, IMMUNOL TODAY, V17, P138; NAUSS KM, 1985, J NUTR, V115, P1300, DOI 10.1093/jn/115.10.1300; NAUSS KM, 1985, J NUTR, V115, P1316, DOI 10.1093/jn/115.10.1316; NEUZIL KM, 1994, J PEDIATR-US, V124, P433, DOI 10.1016/S0022-3476(94)70369-8; POLI G, 1992, P NATL ACAD SCI USA, V89, P2689, DOI 10.1073/pnas.89.7.2689; PUENGTOMWATANAKUL S, 1986, P SOC EXP BIOL MED, V182, P437, DOI 10.3181/00379727-182-42362; ROMBOUT JHWM, 1992, BRIT J NUTR, V68, P753, DOI 10.1079/BJN19920131; ROMBOUT JHWM, 1992, VET IMMUNOL IMMUNOP, V31, P155, DOI 10.1016/0165-2427(92)90093-6; Rosales FJ, 1996, J LIPID RES, V37, P962; Ross A. Catharine, 1994, P521; SHINGLETON JL, 1989, BIOCHEMISTRY-US, V28, P9641, DOI 10.1021/bi00451a015; SIDELL N, 1993, CELL IMMUNOL, V146, P28, DOI 10.1006/cimm.1993.1003; SIJTSMA SR, 1990, VET IMMUNOL IMMUNOP, V26, P191, DOI 10.1016/0165-2427(90)90067-3; SIJTSMA SR, 1989, J NUTR, V119, P932, DOI 10.1093/jn/119.6.932; SIJTSMA SR, 1991, DEV COMP IMMUNOL, V15, P349, DOI 10.1016/0145-305X(91)90027-V; SIRISINHA S, 1980, CLIN EXP IMMUNOL, V40, P127; SMITH SM, 1987, P NATL ACAD SCI USA, V84, P5878, DOI 10.1073/pnas.84.16.5878; SMOLIN G, 1979, ARCH OPHTHALMOL-CHIC, V97, P2181; Sommer A, 1995, B WORLD HEALTH ORGAN, V73, P609; SOMMER A, 1992, LANCET, V339, P864, DOI 10.1016/0140-6736(92)90298-H; SQUIBB RL, 1961, POULTRY SCI, V40, P425, DOI 10.3382/ps.0400425; STARR MB, 1981, ARCH OPHTHALMOL-CHIC, V99, P322; STEPHENSEN CB, 1994, AM J CLIN NUTR, V60, P388, DOI 10.1093/ajcn/60.3.388; STEPHENSEN CB, 1993, J NUTR, V123, P823, DOI 10.1093/jn/123.5.823; Stephensen CB, 1996, J NUTR, V126, P94, DOI 10.1093/jn/126.1.94; TOWERS G, 1995, AIDS, V9, P129, DOI 10.1097/00002030-199509020-00003; WATSON RR, 1988, LIFE SCI, V43, P13; WEST CE, 1992, J NUTR, V122, P333, DOI 10.1093/jn/122.2.333; WIEDEMANN U, 1993, INFECT IMMUNOL, V6, P3952; ZHAO ZR, 1994, NAT IMMUN, V13, P280; ZHAO ZR, 1994, NAT IMMUN, V13, P29	53	95	99	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1996	10	9					979	985		10.1096/fasebj.10.9.8801180	http://dx.doi.org/10.1096/fasebj.10.9.8801180			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801180				2022-12-28	WOS:A1996UY93200007
J	Post, GR; Brown, JH				Post, GR; Brown, JH			G protein-coupled receptors and signaling pathways regulating growth responses	FASEB JOURNAL			English	Article						mitogenesis; gene expression; tyrosine phosphorylation; mitogen-activated protein kinases; Ras effectors; transformation; hypertrophy; c-Jun NH2-terminal kinases	GTP-BINDING PROTEIN; SWISS 3T3 CELLS; RAS-DEPENDENT ACTIVATION; STIMULATES DNA-SYNTHESIS; MUTANT ALPHA-SUBUNIT; MAP KINASE KINASE; TYROSINE PHOSPHORYLATION; PERTUSSIS TOXIN; MALIGNANT TRANSFORMATION; HAMSTER FIBROBLASTS	Hormones that interact with seven-transmembrane spanning receptors, generally considered to be involved in acute signaling functions, also induce longer term effects on gene expression and cell growth, These genetic and proliferative effects can be induced by activation of receptors that signal through heterotrimeric GTP-binding proteins (G-proteins) of the G(q) family, pertussis toxin-sensitive G(i)/G(o) proteins, G(s), or G(12)/G(13). Numerous growth-promoting G protein-coupled receptors activate the low molecular weight G-protein Ras and stimulate mitogen-activated protein kinase, Recent data suggest that c-Jun NH2-terminal kinase is also activated, possibly through interaction with low molecular weight G-proteins of the Rho family, Because G protein-coupled receptors lack intrinsic tyrosine kinase activity, the mechanisms by which heterotrimeric G-proteins couple to these kinase cascades remain to be elucidated, By analogy to growth factor receptors, G protein-coupled receptors may access these kinase cascades through binding of adapter proteins or recruitment of cytosolic tyrosine kinases, It is likely that interactions between multiple signaling pathways are required for G protein-coupled receptors to propagate signals to the nucleus.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					NHLBI NIH HHS [HL28143] Funding Source: Medline; NIGMS NIH HHS [GM36927] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028143, R37HL028143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036927, R56GM036927] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; ASHKENAZI A, 1989, NATURE, V340, P146, DOI 10.1038/340146a0; ASUDA J, 1981, P NATL ACAD SCI USA, V78, P1001; AULLO P, 1993, EMBO J, V12, P921, DOI 10.1002/j.1460-2075.1993.tb05733.x; BAFFY G, 1994, J BIOL CHEM, V269, P8483; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BORRELLI E, 1992, Critical Reviews in Oncogenesis, V3, P321; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN YH, 1994, J BIOL CHEM, V269, P27372; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVIVO M, 1994, J BIOL CHEM, V269, P19671; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; FAURE M, 1994, J BIOL CHEM, V269, P7851; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; GUSOVSKY F, 1993, J BIOL CHEM, V268, P7768; GUTKIND JS, 1992, BIOCHEM BIOPH RES CO, V188, P155; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HANSEN CA, 1994, J CELL BIOL, V126, P811, DOI 10.1083/jcb.126.3.811; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HERBERT JM, 1994, BIOCHEM J, V303, P227, DOI 10.1042/bj3030227; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HUANG NN, 1991, J CELL PHYSIOL, V146, P483, DOI 10.1002/jcp.1041460320; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JALINK K, 1994, BBA-REV CANCER, V1198, P185, DOI 10.1016/0304-419X(94)90013-2; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7438; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LAMY F, 1993, J BIOL CHEM, V268, P8398; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LETTERIO JJ, 1986, SCIENCE, V234, P1117, DOI 10.1126/science.3465038; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; MEINKOTH JL, 1992, J BIOL CHEM, V267, P13239; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MURAYAMA T, 1987, J BIOL CHEM, V262, P12463; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEMECEK GM, 1986, P NATL ACAD SCI USA, V83, P674, DOI 10.1073/pnas.83.3.674; NILSSON J, 1985, NATURE, V315, P61, DOI 10.1038/315061a0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PAPAVASSILIOU AG, 1994, ANTICANCER RES, V14, P1801; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PINKASKRAMARSKI R, 1992, J NEUROCHEM, V59, P2158; POLAKIS P, 1992, CANCER SURV, V12, P25; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; PUMIGLIA KM, 1995, J BIOL CHEM, V270, P14251, DOI 10.1074/jbc.270.24.14251; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RAMIREZ MT, 1995, J BIOL CHEM, V270, P8446, DOI 10.1074/jbc.270.15.8446; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SEUWEN K, 1988, NATURE, V335, P254, DOI 10.1038/335254a0; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; SPADA A, 1993, FRONT NEUROENDOCRIN, V14, P214, DOI 10.1006/frne.1993.1007; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STEPHENS EV, 1993, ONCOGENE, V8, P19; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THORBURN J, 1994, BIOCHEM BIOPH RES CO, V202, P1586, DOI 10.1006/bbrc.1994.2113; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VICENTINI LM, 1984, BIOCHEM BIOPH RES CO, V123, P663, DOI 10.1016/0006-291X(84)90280-8; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WEISS RH, 1993, J BIOL CHEM, V268, P5724; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WINITZ S, 1993, J BIOL CHEM, V268, P19196; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, ONCOGENE, V9, P597; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	137	202	204	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1996	10	7					741	749		10.1096/fasebj.10.7.8635691	http://dx.doi.org/10.1096/fasebj.10.7.8635691			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UN798	8635691				2022-12-28	WOS:A1996UN79800008
J	Roberts, SS				Roberts, SS			Blood safety in the age of AIDS	FASEB JOURNAL			English	Editorial Material								This series of essays was developed as part of FASEB's efforts to educate the general public and the legislators whom it elects about the benefits of fundamental biomedical research-particularly how investment in such research leads to scientific progress, improved health, and economic well-being. ''Blood Safety in the Age of AIDS'' examines the effects of the AIDS epidemic on the safety of the blood supply. Just as a pebble tossed in a lake sends out ripples that last long after the pebble sinks, the discovery more than a decade ago that the AIDS virus was in the blood supply is still having repercussions on research and transfusion practices. New screening tests for blood and new ways of using one's own blood during surgery are among the steps that have made blood transfusions much safer. Meanwhile, researchers continue tracking down new threats and devising ways to circumvent them. (This is the second article in the series.)										[Anonymous], 1990, READINGS RISK; *COMM STUD HIV TRA, 1995, HIV BLOOD SUPPL AN C; EDELSON E, 1993, POP SCI, V242, P122; EDELSON E, 1993, POP SCI, V242, P108; GALEL SA, 1995, ANNU REV IMMUNOL, V13, P201; Lederberg J., 1992, I MED US COMMITTEE; REVELLE M, 1995, FDA PUBLICATION	7	1	1	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1996	10	4					391	402		10.1096/fasebj.10.4.8647338	http://dx.doi.org/10.1096/fasebj.10.4.8647338			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UE557	8647338				2022-12-28	WOS:A1996UE55700003
J	Hofer, AM; Curci, S; Machen, TE; Schulz, I				Hofer, AM; Curci, S; Machen, TE; Schulz, I			ATP regulates calcium leak from agonist-sensitive internal calcium stores	FASEB JOURNAL			English	Article						mag-fura-2; vanadate; nucleotides; nonhydrolyzable nucleotide analogs	SMOOTH-MUSCLE CELLS; SARCOPLASMIC-RETICULUM; INOSITOL 1,4,5-TRISPHOSPHATE; FLUORESCENT INDICATOR; ADENINE-NUCLEOTIDES; SKELETAL-MUSCLE; RELEASE; CA-2+; CHANNEL; TRANSPORT	Under resting conditions, steady-state [Ca] in agonist-sensitive Ca stores reflects a balance between active uptake (usually mediated by a thapsigargin-sensitive Ca-ATPase of the SERCA family) and passive efflux of Ca. Even though this pump-leak cycle appears to be a common property of Ca-storing organelles, little is known about the nature of the leak pathway, Ca homeostasis in thapsigargin-sensitive internal Ca stores of single permeabilized BHK-21 fibroblasts was examined using digital image processing of compartmentalized mag-fura-2 (a low-affinity Ca indicator), It is shown here that the leak of Ca from internal stores is regulated specifically by the cytosolic ATP concentration, The rate of leak was 3.6 times slower in 0.375 mM [ATP] than in 4 mM [ATP] (Na or Mg salt), These effects were observed in the presence of 0 Ca/EGTA, thapsigargin, heparin, and ruthenium red, and therefore appear to be independent of the Ca-ATPase, the InsP(3) receptor and the ryanodine receptor, The ATP-stimulated leak was seen in a variety of cell types, including rat basophilic leukemia cells and mouse pancreatic acinar cells, Other nucleotides (ADP, GTP, CTP, and UTP) and nonhydrolyzable ATP analogs (AMP-PNP and ATP gamma S) did not reproduce the action of ATP, Changes in cellular metabolism and ensuing alterations in [ATP] will be expected to influence the filling state of internal Ca stores through effects on the passive leak pathway, potentially leading to modulation of Ca signaling and organellar function.	UNIV BARI, IST FISIOL GEN, I-70126 BARI, ITALY; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	Universita degli Studi di Bari Aldo Moro; University of California System; University of California Berkeley	Hofer, AM (corresponding author), UNIV SAARLAND, INST PHYSIOL 2, D-66421 HOMBURG, GERMANY.				NIDDK NIH HHS [DK19520] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019520] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; CHI WM, 1995, BBA-GEN SUBJECTS, V1243, P513, DOI 10.1016/0304-4165(94)00190-9; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; DEMEIS L, 1992, FEBS LETT, V299, P33, DOI 10.1016/0014-5793(92)80093-V; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; GAMBERUCCI A, 1994, J BIOL CHEM, V269, P23597; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GOULD GW, 1987, BIOCHIM BIOPHYS ACTA, V904, P45, DOI 10.1016/0005-2736(87)90085-X; GUILLEN E, 1995, BIOCHEMISTRY-US, V34, P5472, DOI 10.1021/bi00016a018; HAYNES DH, 1987, PHYSIOL REV, V67, P244, DOI 10.1152/physrev.1987.67.1.244; HIROSE K, 1994, NATURE, V372, P791; HOFER AM, 1994, AM J PHYSIOL, V267, pG442, DOI 10.1152/ajpgi.1994.267.3.G442; HOFER AM, 1995, FASEB J, V9, P788, DOI 10.1096/fasebj.9.9.7601343; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; IINO M, 1991, J GEN PHYSIOL, V98, P681, DOI 10.1085/jgp.98.4.681; LYNN S, 1995, FEBS LETT, V367, P23, DOI 10.1016/0014-5793(95)00499-Y; MARTONOSI AN, 1984, PHYSIOL REV, V64, P1240, DOI 10.1152/physrev.1984.64.4.1240; MISSIAEN L, 1993, BIOCHEM BIOPH RES CO, V193, P6, DOI 10.1006/bbrc.1993.1582; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; NEGULESCU PA, 1990, METHOD ENZYMOL, V192, P38; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; PFEIFFER F, 1995, IN PRESS PFLUEGERS A; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SMITH JB, 1985, J BIOL CHEM, V260, P4413; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; SMITH JS, 1986, BIOPHYS J, V50, P921, DOI 10.1016/S0006-3495(86)83533-0; SMITH PM, 1994, BIOCHEM J, V299, P37, DOI 10.1042/bj2990037; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; THOMAS D, 1994, METHOD CELL BIOL, V40, P65; TRUMP BF, 1995, FASEB J, V9, P219, DOI 10.1096/fasebj.9.2.7781924; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; WANG JS, 1992, J MEMBRANE BIOL, V130, P163; ZHANG GH, 1990, CELL CALCIUM, V11, P397, DOI 10.1016/0143-4160(90)90051-U	42	69	71	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1996	10	2					302	308		10.1096/fasebj.10.2.8641563	http://dx.doi.org/10.1096/fasebj.10.2.8641563			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641563				2022-12-28	WOS:A1996TY96200014
J	Masters, BSS				Masters, BSS			Introduction: Cytochrome P450	FASEB JOURNAL			English	Review											Masters, BSS (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284, USA.							ESTABROOK RW, 1963, BIOCHEM Z, V338, P741; GILLETTE JR, 1957, J PHARMACOL EXP THER, V119, P532; KLINGENBERG M, 1958, ARCH BIOCHEM BIOPHYS, V75, P376, DOI 10.1016/0003-9861(58)90436-3; LU AYH, 1969, J BIOL CHEM, V244, P3714; OMURA T, 1964, J BIOL CHEM, V239, P2370	5	7	7	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1996	10	2					205	205		10.1096/fasebj.10.2.8641553	http://dx.doi.org/10.1096/fasebj.10.2.8641553			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641553	Bronze			2022-12-28	WOS:A1996TY96200004
J	Chalikian, TV; Gindikin, VS; Breslauer, KJ				Chalikian, TV; Gindikin, VS; Breslauer, KJ			Spectroscopic and volumetric investigation of cytochrome c unfolding at alkaline pH: Characterization of the base-induced unfolded state at 25 degrees C	FASEB JOURNAL			English	Article						protein folding; ultrasonics; volume; adiabatic compressibility	PROTON-TRANSFER REACTIONS; GLOBULAR-PROTEINS; ULTRASONIC-ABSORPTION; AQUEOUS-SOLUTIONS; AMINO-ACIDS; STABILITY; COMPRESSIBILITY	We have measured at 25 degrees C the relative specific sound velocity increment, [u], and the partial specific volume, v degrees, of cytochrome c as a function of pH, Our data reveal that the base-induced native to unfolded transition of the protein is accompanied by a volume decrease of 0.014 cm(3) g(-1) and a compressibility decrease of 3.8 x 10(-6) cm(3) g(-1) bar(-1). These results allow us to conclude that, relative to a fully unfolded conformation, the base-denatured state of cytochrome c has only 70 to 80% of its surface area exposed to the solvent. Recently, we reported a similar result for the acid-denatured state of cytochrome c. Thus, insofar as solvent exposure is concerned, both the base- and the acid-induced unfolded states of cytochrome c retain some order, with 20 to 30% of their surface areas remaining solvent-inaccessible. We discuss the implications of this result in terms of defining potential intermediate states in protein folding pathways.	RUTGERS STATE UNIV,DEPT CHEM,WRIGHT & RIEMAN LABS,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick								Brandts J. F., 1969, STRUCTURE STABILITY, V2, P213; CHALIKIAN TV, 1992, J PHYS CHEM-US, V96, P876, DOI 10.1021/j100181a065; CHALIKIAN TV, 1994, BIOPHYS CHEM, V51, P89, DOI 10.1016/0301-4622(94)85007-0; CHALIKIAN TV, 1995, J MOL BIOL, V250, P291, DOI 10.1006/jmbi.1995.0377; CHALIKIAN TV, 1994, BIOPHYS J, V66, pA65; CHALIKIAN TV, 1996, IN PRESS P NATL ACAD; CHO KC, 1985, BIOCHIM BIOPHYS ACTA, V830, P36, DOI 10.1016/0167-4838(85)90128-1; CHOI PK, 1990, J ACOUST SOC AM, V87, P874, DOI 10.1121/1.398897; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; DURCHSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; EGGERS F, 1973, REV SCI INSTRUM, V44, P969, DOI 10.1063/1.1686339; GEKKO K, 1986, BIOCHEMISTRY-US, V25, P6563, DOI 10.1021/bi00369a034; HUSSEY M, 1971, J PHYS CHEM-US, V75, P4012, DOI 10.1021/j100695a017; KANDA H, 1976, BIOPOLYMERS, V15, P785, DOI 10.1002/bip.1976.360150414; KHARAKOZ DP, 1993, BIOPOLYMERS, V33, P11, DOI 10.1002/bip.360330103; LEE B, 1991, P NATL ACAD SCI USA, V88, P5154, DOI 10.1073/pnas.88.12.5154; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; MILLERO FJ, 1977, J ACOUST SOC AM, V61, P1492, DOI 10.1121/1.381449; NIKITIN SY, 1984, MOL BIOL+, V18, P685; NOLTING B, 1993, BIOCHEMISTRY-US, V32, P12319, DOI 10.1021/bi00097a007; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; Richards F. M., 1992, P1; ROBINSON JB, 1983, J BIOL CHEM, V258, P6772; RUPLEY JA, 1964, BIOCHEMISTRY-US, V3, P1648, DOI 10.1021/bi00899a008; SARVAZYAN AP, 1979, J PHYS CHEM-US, V83, P1796, DOI 10.1021/j100476a021; SARVAZYAN AP, 1991, ANNU REV BIOPHYS BIO, V20, P321, DOI 10.1146/annurev.bb.20.060191.001541; SARVAZYAN AP, 1982, ULTRASONICS, V20, P151, DOI 10.1016/0041-624X(82)90032-4; SHORTLE D, 1993, CURR OPIN STRUC BIOL, V3, P66, DOI 10.1016/0959-440X(93)90204-X; STELLWAGEN E, 1964, BIOCHEMISTRY-US, V3, P919, DOI 10.1021/bi00895a011; TAMURA Y, 1995, BIOCHEMISTRY-US, V34, P1878, DOI 10.1021/bi00006a008; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; Theorell H, 1941, J AM CHEM SOC, V63, P1812, DOI 10.1021/ja01852a006; YANG AS, 1993, J MOL BIOL, V231, P459, DOI 10.1006/jmbi.1993.1294; ZANA R, 1972, J PHYS CHEM-US, V76, P1737, DOI 10.1021/j100656a012	35	41	41	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1996	10	1					164	170		10.1096/fasebj.10.1.8566538	http://dx.doi.org/10.1096/fasebj.10.1.8566538			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566538				2022-12-28	WOS:A1996TR32800022
J	Brodsky, B; Shah, NK				Brodsky, B; Shah, NK			Protein motifs .8. The triple-helix motif in proteins	FASEB JOURNAL			English	Review						collagen; collectins	MACROPHAGE SCAVENGER RECEPTORS; COLLAGEN-LIKE REGION; CHAIN CONFORMATION; MOLECULAR PACKING; STRUCTURAL MODEL; COILED COILS; PEPTIDES; BINDING; C1Q; (PRO-HYP-GLY)(10)	The triple helix is an important motif found in the family of collagens as well as a set of host-defense proteins. This conformation may be identified by its strict sequence constraints, including glycine as every third residue and a high content of imino acids. The first high-resolution structure available for a triple helix has confirmed the model of three supercoiled polyproline II-like helices and has defined a highly ordered water network whose regularity depends on the presence of 4-hydroxyproline. The role of the rod-like triple helix lies in its capacity to self-associate in a variety of forms as well as its ability to bind a wide range of ligands. The extensive hydrogen-bonded water network, together with the high content of sterically restricted imino acids, are the major contributors to the stabilization of triple helices, whereas electrostatic and hydrophobic interactions define intermolecular association and ligand binding. Mutations 11 the repeating Gly-X-Y sequences of triple helices have been shown to cause a variety of human diseases.			Brodsky, B (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT BIOCHEM, 675 HOES LANE, PISCATAWAY, NJ 08854 USA.				NIAMS NIH HHS [AR19626] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR019626] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACTON S, 1993, J BIOL CHEM, V268, P3530; ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; ANACHI RB, 1995, FEBS LETT, V368, P551, DOI 10.1016/0014-5793(95)00738-U; ANDRIKOPOULOS K, 1995, NAT GENET, V9, P31, DOI 10.1038/ng0195-31; BANSAL M, 1977, INT J PEPT PROT RES, V9, P224; BARBER HE, 1966, ARCH BIOCHEM BIOPHYS, V117, P466; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; BELLA J, 1995, STRUCTURE, V3, P393; BRODSKYDOYLE B, 1976, BIOCHEM J, V159, P279, DOI 10.1042/bj1590279; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; DOI T, 1993, J BIOL CHEM, V268, P2126; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; ENGEL J, 1977, BIOPOLYMERS, V16, P601, DOI 10.1002/bip.1977.360160310; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; FAN P, 1993, BIOCHEMISTRY-US, V32, P13299, DOI 10.1021/bi00211a043; FERREIRA LR, 1994, J CELL BIOCHEM, V56, P518, DOI 10.1002/jcb.240560412; FIELDS CG, 1993, J BIOL CHEM, V268, P14153; FIELDS CG, 1993, BIOPOLYMERS, V33, P1695, DOI 10.1002/bip.360331107; FIELDS GB, 1991, J THEOR BIOL, V153, P585, DOI 10.1016/S0022-5193(05)80157-2; Fraser R.D.B., 1973, CONFORMATION FIBROUS; FRASER RDB, 1979, J MOL BIOL, V129, P463, DOI 10.1016/0022-2836(79)90507-2; HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143; HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; HULMES DJS, 1973, J MOL BIOL, V79, P137, DOI 10.1016/0022-2836(73)90275-1; JONES EY, 1991, J MOL BIOL, V218, P209, DOI 10.1016/0022-2836(91)90885-A; KADLER K, 1994, PROTEIN PROFILE EXTR, V1, P550; KATZ EP, 1992, J MOL BIOL, V228, P963, DOI 10.1016/0022-2836(92)90878-N; KATZ EP, 1990, BIOPOLYMERS, V29, P791, DOI 10.1002/bip.360290413; Kielty Cay M., 1993, P103; KILCHHERR E, 1985, J MOL BIOL, V186, P403, DOI 10.1016/0022-2836(85)90114-7; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; LI KH, 1993, J BIOL CHEM, V268, P8825; LI MH, 1993, BIOCHEMISTRY-US, V32, P7377, DOI 10.1021/bi00080a007; LI ST, 1975, J MOL BIOL, V98, P835, DOI 10.1016/S0022-2836(75)80015-5; LONG CG, 1993, BIOCHEMISTRY-US, V32, P11688, DOI 10.1021/bi00094a027; MALHOTRA R, 1993, BIOCHEM J, V293, P15, DOI 10.1042/bj2930015; MARINI JC, 1993, J BIOL CHEM, V268, P2667; MILLER MH, 1980, MACROMOLECULES, V13, P470, DOI 10.1021/ma60075a003; MORTON LF, 1987, BIOCHEM J, V248, P483, DOI 10.1042/bj2480483; PARRY DAD, 1984, ULTRASTRUCTURE CONNE, pCH2; PEARSON AM, 1993, J BIOL CHEM, V268, P3516; PIEZ KA, 1984, EXTRACELLULAR MATRIX, P1; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; RAGHUNATH M, 1994, J MOL BIOL, V236, P940, DOI 10.1006/jmbi.1994.1199; RESNICK D, 1993, J BIOL CHEM, V268, P3538; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; RIGBY BJ, 1971, ADV CHEM PHYS, V21, P537; RISTELI J, 1980, EUR J BIOCHEM, V108, P239, DOI 10.1111/j.1432-1033.1980.tb04717.x; SAKAKIBARA S, 1973, BIOCHIM BIOPHYS ACTA, V303, P198, DOI 10.1016/0005-2795(73)90164-5; SALEM G, 1975, FEBS LETT, V51, P94, DOI 10.1016/0014-5793(75)80861-1; SCHMID TM, 1987, STRUCTURE FUNCTION C; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; SIBLEY MH, 1994, EMBO J, V13, P3278, DOI 10.1002/j.1460-2075.1994.tb06629.x; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; SUTOH K, 1974, BIOPOLYMERS, V13, P2461, DOI 10.1002/bip.1974.360131206; SUTOH K, 1974, BIOPOLYMERS, V13, P2477, DOI 10.1002/bip.1974.360131207; TISCHENKO VM, 1993, J MOL BIOL, V234, P654, DOI 10.1006/jmbi.1993.1618; VENUGOPAL MG, 1994, BIOCHEMISTRY-US, V33, P7948, DOI 10.1021/bi00191a023; VITAGLIANO L, 1993, BIOCHEMISTRY-US, V32, P7354, DOI 10.1021/bi00080a004; Woody R. W., 1992, ADV BIOPHYS CHEM, V2, P37; YING SC, 1993, J IMMUNOL, V150, P169	65	114	121	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1995	9	15					1537	1546		10.1096/fasebj.9.15.8529832	http://dx.doi.org/10.1096/fasebj.9.15.8529832			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TM761	8529832				2022-12-28	WOS:A1995TM76100006
J	SESSLER, DI				SESSLER, DI			PERIANESTHETIC THERMOREGULATION AND HEAT-BALANCE IN HUMANS	FASEB JOURNAL			English	Article						SPINAL ANESTHESIA; ISOFLURANE; HALOTHANE; HYPOTHALAMUS; HYPOTHERMIA; THERMOREGULATION; SKIN; SETPOINT; SHIVERING	EPIDURAL-ANESTHESIA; ISOFLURANE ANESTHESIA; BODY-TEMPERATURE; THRESHOLD; HYPOTHERMIA; BUPIVACAINE; METABOLISM; VOLUNTEERS; BLOCKADE	General anesthesia markedly impairs normal control of body temperature, reducing the threshold (triggering core temperature) for thermoregulatory vasoconstriction from almost-equal-to 37 to almost-equal-to 34.5-degrees-C. Sweating and active vasodilation thresholds similarly are increased, widening the range of temperatures not triggering regulatory compensations from almost-equal-to 0.2 to is-approximately-equal-to 4-degrees-C. However, once initiated, the gains (slopes of response intensity vs. core temperature curves) and maximum intensities of thermoregulatory responses are nearly normal. Intraoperative core temperature initially decreases rapidly because anesthetic-induced inhibition of tonic thermoregulatory vasoconstriction causes a core-to-peripheral redistribution of body heat. The subsequent slower, linear decrease in body temperature results from heat loss exceeding metabolic heat production. And finally, after 3-4 h of anesthesia, core temperature stabilizes at an abnormally low value. In patients experiencing minimal heat loss, and therefore not becoming sufficiently hypothermic to trigger vasoconstriction, this plateau can be passive steady state in which heat loss equals production. Conversely, patients becoming sufficiently hypothermic will trigger thermoregulatory vasoconstriction that both decreases cutaneous heat loss and sequesters some metabolic heat in the core. Epidural and spinal anesthesia also cause core hypothermia by inhibiting tonic thermoregulatory vasoconstriction, producing an internal redistribution of heat from the warm core to cooler peripheral tissues. Core hypothermia provokes thermoregulatory responses including vasoconstriction (above the block level) and shivering. Nonetheless, many patients feel warmer after induction of regional anesthesia, apparently because perceived skin temperature is elevated. The following review will focus on anesthetic-induced impairment of normal thermoregulatory control and the resulting alterations in heat balance.			SESSLER, DI (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,ROOM C-214,SAN FRANCISCO,CA 94143, USA.		Sessler, Daniel/D-3504-2011	Sessler, Daniel/0000-0001-9932-3077	NIGMS NIH HHS [R29 GM39723] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039723] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAIR ER, 1977, DRUGS BIOGENIC AMINE, P84; BALDWIN BA, 1967, J PHYSIOL-LONDON, V191, P375, DOI 10.1113/jphysiol.1967.sp008256; BELANI K, IN PRESS ANESTHESIOL; BENZINGER T, 1961, P NATL ACAD SCI USA, V47, P730, DOI 10.1073/pnas.47.5.730; BICKLER PE, 1990, ANESTH ANALG, V71, P415; BISSONNETTE B, 1990, ANESTHESIOLOGY, V73, P1114, DOI 10.1097/00000542-199012000-00008; BISSONNETTE B, 1992, ANESTHESIOLOGY, V76, P387, DOI 10.1097/00000542-199203000-00011; BROWNRIDGE P, 1986, ANAESTH INTENS CARE, V14, P412, DOI 10.1177/0310057X8601400414; BRUCK K, 1978, TEMPERATURE REGULATI, P157; CARLI F, 1989, BRIT J ANAESTH, V63, P276, DOI 10.1093/bja/63.3.276; COLIN J, 1971, J APPL PHYSIOL, V31, P484, DOI 10.1152/jappl.1971.31.3.484; COOPER J O, 1990, Anesthesiology (Hagerstown), V73, pA230; DAWKINS MJR, 1965, NATURE, V206, P201, DOI 10.1038/206201b0; DOWNEY JA, 1969, J APPL PHYSIOL, V27, P209, DOI 10.1152/jappl.1969.27.2.209; DUCHARME MB, 1991, J APPL PHYSIOL, V70, P2682, DOI 10.1152/jappl.1991.70.6.2682; FARR LA, 1986, CHRONOBIOLOGIA, V13, P105; GLOSTEN B, 1992, ANESTHESIOLOGY, V77, P10, DOI 10.1097/00000542-199207000-00003; GLOSTEN B, 1991, ANESTHESIOLOGY, V75, pA854; Guffin A, 1987, J Cardiothorac Anesth, V1, P24, DOI 10.1016/S0888-6296(87)92593-2; HAMMEL HT, 1968, ANNU REV PHYSIOL, V30, P641, DOI 10.1146/annurev.ph.30.030168.003233; Hardy JD, 1936, PHYSICS-J GEN APPL P, V7, P466, DOI 10.1063/1.1745358; HARRIS MM, 1989, REGION ANESTH, V14, P13; HEIER T, 1991, ANESTHESIOLOGY, V74, P815, DOI 10.1097/00000542-199105000-00003; Hynson J M, 1992, J Clin Anesth, V4, P194, DOI 10.1016/0952-8180(92)90064-8; HYNSON JM, 1991, ANESTHESIOLOGY, V74, P680, DOI 10.1097/00000542-199104000-00011; HYNSON JM, 1992, ANESTH ANALG, V75, P947; HYNSON JM, 1991, ANESTH ANALG, V72, pS119; ISRAEL DJ, 1989, J APPL PHYSIOL, V66, P2358, DOI 10.1152/jappl.1989.66.5.2358; JESSEN C, 1971, PFLUG ARCH EUR J PHY, V324, P189, DOI 10.1007/BF00586418; JUST B, 1992, ANESTHESIOLOGY, V76, P60, DOI 10.1097/00000542-199201000-00009; MACINTYRE PE, 1987, ANESTH ANALG, V66, P751; MEKJAVIC IB, 1985, IEEE T BIO-MED ENG, V32, P407, DOI 10.1109/TBME.1985.325467; MEKJAVIC IB, 1991, J APPL PHYSIOL, V71, P1289, DOI 10.1152/jappl.1991.71.4.1289; MERCER JB, 1978, PFLUG ARCH EUR J PHY, V374, P179, DOI 10.1007/BF00581299; MOAYERI A, 1991, ANESTHESIOLOGY, V75, P1004; MORA F, 1983, BRAIN RES BULL, V11, P613, DOI 10.1016/0361-9230(83)90132-6; MORRIS RH, 1972, ANESTHESIOLOGY, V36, P408, DOI 10.1097/00000542-197204000-00020; Ozuna J M, 1978, AORN J, V28, P240, DOI 10.1016/S0001-2092(07)61369-6; PASSIAS TC, 1992, ANESTHESIOLOGY, V76, P550, DOI 10.1097/00000542-199204000-00011; PONTE J, 1986, ACTA ANAESTH SCAND, V30, P584, DOI 10.1111/j.1399-6576.1986.tb02480.x; PONTE J, 1990, BRIT J ANAESTH, V64, P731, DOI 10.1093/bja/64.6.731; QUINTIN L, 1991, ANESTHESIOLOGY, V74, P236, DOI 10.1097/00000542-199102000-00008; ROE CF, 1972, SURG GYNECOL OBSTETR, V135, P577; SATINOFF E, 1978, SCIENCE, V201, P16, DOI 10.1126/science.351802; SESSLER DI, 1991, ANESTHESIOLOGY, V75, P985, DOI 10.1097/00000542-199112000-00010; SESSLER DI, 1990, ANESTHESIOLOGY, V72, P816, DOI 10.1097/00000542-199005000-00008; SESSLER DI, 1991, ANESTHESIOLOGY, V75, P594, DOI 10.1097/00000542-199110000-00009; SESSLER DI, 1991, ANESTHESIOLOGY, V74, P875, DOI 10.1097/00000542-199105000-00012; SESSLER DI, 1992, ANESTHESIOLOGY, V76, P670, DOI 10.1097/00000542-199205000-00002; SESSLER DI, 1991, ANESTHESIOLOGY, V74, P226, DOI 10.1097/00000542-199102000-00006; SESSLER DI, 1988, ANESTHESIOLOGY, V68, P836, DOI 10.1097/00000542-198806000-00002; SESSLER DI, 1988, ANESTHESIOLOGY, V69, P357, DOI 10.1097/00000542-198809000-00012; Sessler DI, 1990, ANESTHESIA, VThird, P1227; SEVARINO FB, 1989, ANESTH ANALG, V68, P530; SHARKEY A, 1987, ANESTHESIOLOGY, V66, P249, DOI 10.1097/00000542-198702000-00029; SIMON E, 1974, REV PHYSIOL BIOCH P, V71, P1, DOI 10.1007/BFb0027660; SOLIMAN MG, 1972, CAN ANAESTH SOC J, V19, P529, DOI 10.1007/BF03005813; STEVENS WC, 1971, ANESTHESIOLOGY, V35, P8, DOI 10.1097/00000542-197107000-00005; STOEN R, 1990, ANESTHESIOLOGY, V72, P822, DOI 10.1097/00000542-199005000-00009; VALERI CR, 1987, ANN SURG, V205, P175, DOI 10.1097/00000658-198702000-00012; VAUGHN LK, 1980, BRAIN RES BULL, V5, P69, DOI 10.1016/0361-9230(80)90285-3; WASHINGTON D, 1993, IN PRESS J APPL PHYS; WASHINGTON DE, 1992, ANESTHESIOLOGY, V77, P286, DOI 10.1097/00000542-199208000-00011; WISSLER EH, 1971, J PHYSIOL-PARIS, V63, P455	64	167	170	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1993	7	8					638	644		10.1096/fasebj.7.8.8500688	http://dx.doi.org/10.1096/fasebj.7.8.8500688			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LE290	8500688				2022-12-28	WOS:A1993LE29000005
J	BERDANIER, CD; PARENTE, JA; MCINTOSH, MK				BERDANIER, CD; PARENTE, JA; MCINTOSH, MK			IS DEHYDROEPIANDROSTERONE AN ANTIOBESITY AGENT	FASEB JOURNAL			English	Review						DEHYDROPIANDROSTERONE; OBESITY; LIPOGENESIS; PEROXISOMES; MITOCHONDRIAL RESPIRATION; ENERGY BALANCE	OBESE ZUCKER RATS; ADIPOSE-TISSUE; NORMAL MICE; METABOLISM; LIVER; DHEA; MEN; CORTISOL; BHE; TRIIODOTHYRONINE	The steroid hormone intermediate, DHEA, has been proposed as a therapeutic agent for the treatment of obesity. Its effects on lipogenesis, substrate cycling, peroxisome proliferation, mitochondrial respiration, protein synthesis, and thyroid hormone function have been reported. The results of these studies suggest that the antiobesity function of DHEA is not simply one of inhibiting fat synthesis and deposition but is one of affecting a number of pathways that contribute to the maintenance of the isoenergetic state rather than the promotion of positive energy balance.	UNIV N CAROLINA,DEPT FOODS & NUTR,GREENSBORO,NC 27412	University of North Carolina; University of North Carolina Greensboro	BERDANIER, CD (corresponding author), UNIV GEORGIA,DEPT FOODS & NUTR,ATHENS,GA 30602, USA.							BELLEI M, 1992, J NUTR, V122, P967, DOI 10.1093/jn/122.4.967; BERDANIER CD, 1989, FASEB J, V3, P2179, DOI 10.1096/fasebj.3.10.2666232; BERDANIER CD, 1989, P SOC EXP BIOL MED, V192, P242, DOI 10.3181/00379727-192-42992; BERDANIER CD, 1988, FRONTIERS DIABETES R, P356; BRADY LJ, 1991, J NUTR, V121, P525, DOI 10.1093/jn/121.4.525; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; BRAY GA, 1991, J NUTR, V121, P1146, DOI 10.1093/jn/121.8.1146; CASAZZA JP, 1986, J NUTR, V116, P304, DOI 10.1093/jn/116.2.304; CAVALIERI RR, 1984, ENDOCRINOLOGY, V114, P215, DOI 10.1210/endo-114-1-215; CLEARY MP, 1988, J NUTR, V118, P382, DOI 10.1093/jn/118.3.382; CLEARY MP, 1982, P SOC EXP BIOL MED, V171, P276; CLEARY MP, 1989, HORMONES, THERMOGENESIS AND OBESITY, P365; CLEARY MP, 1990, P SOC EXP BIOL MED, V196, P8; COLEMAN DL, 1984, DIABETES, V33, P26, DOI 10.2337/diabetes.33.1.26; COLEMAN DL, 1982, DIABETES, V31, P830, DOI 10.2337/diabetes.31.9.830; COLEMAN DL, 1985, ENDOCRINOLOGY, V117, P2279, DOI 10.1210/endo-117-6-2279; COLEMAN DL, 1984, ENDOCRINOLOGY, V115, P239, DOI 10.1210/endo-115-1-239; DEPERGOLA G, 1991, METABOLISM, V40, P187, DOI 10.1016/0026-0495(91)90172-S; DIERSENSCHADE DA, 1989, HORM METAB RES, V21, P356, DOI 10.1055/s-2007-1009236; Drucker W. D., 1980, ADRENAL ANDROGENS, P89; FALANY CN, 1989, BIOCHEM J, V260, P641, DOI 10.1042/bj2600641; FINAN AC, 1988, NUTR RES, V8, P755, DOI 10.1016/S0271-5317(88)80156-8; FRENKEL RA, 1990, J STEROID BIOCHEM, V35, P333, DOI 10.1016/0022-4731(90)90293-2; GANSLER TS, 1985, P SOC EXP BIOL MED, V180, P155; GORDON GB, 1986, CANCER RES, V40, P3389; JENNINGS AS, 1984, ENDOCRINOLOGY, V114, P31, DOI 10.1210/endo-114-1-31; KALIMI M, 1988, BIOCHEM BIOPH RES CO, V156, P22, DOI 10.1016/S0006-291X(88)80800-3; LARDY H, 1989, HORMONES, THERMOGENESIS AND OBESITY, P415; LEIGHTON B, 1987, Journal of Nutrition, V117, P1287; MACEWEN EG, 1989, HORMONES, THERMOGENESIS AND OBESITY, P399; MCINTOSH MK, 1992, J NUTR BIOCHEM, V3, P194, DOI 10.1016/0955-2863(92)90116-Z; MCINTOSH MK, 1991, J NUTR, V121, P2037, DOI 10.1093/jn/121.12.2037; MCINTOSH MK, 1988, P SOC EXP BIOL MED, V187, P216; MCINTOSH MK, 1988, J NUTR, V118, P1011, DOI 10.1093/jn/118.8.1011; MCINTOSH MK, 1993, IN PRESS J NUTR; MCINTOSH MK, 1993, IN PRESS COMP BIOCH; MOHAN PF, 1991, J NUTR, V121, P240, DOI 10.1093/jn/121.2.240; MOHAN PF, 1988, AM J PHYSIOL, V255, pE1, DOI 10.1152/ajpendo.1988.255.1.E1; MOHAN PF, 1990, J NUTR, V120, P1103, DOI 10.1093/jn/120.9.1103; MONTANINI V, 1988, HORM RES, V29, P1, DOI 10.1159/000180956; MULLER S, 1985, METABOLISM, V34, P278, DOI 10.1016/0026-0495(85)90013-7; NESTLER JE, 1988, J CLIN ENDOCR METAB, V66, P57, DOI 10.1210/jcem-66-1-57; PAVLOV EP, 1986, J CLIN ENDOCR METAB, V62, P767, DOI 10.1210/jcem-62-4-767; PHILLIPS RW, 1984, ANIMAL MODELS NUTRIT, P1; PRASANNA HR, 1989, J TOXICOL-TOXIN REV, V8, P121, DOI 10.3109/15569548909059744; PRASANNA HR, 1989, BIOCHEM J, V262, P9485; ROSE DP, 1977, EUR J CANCER, V16, P43; ROTTER JI, 1985, METABOLISM, V34, P731, DOI 10.1016/0026-0495(85)90023-X; SAHU A, 1984, IRCS MED SCI-BIOCHEM, V12, P662; SCHAUER JE, 1990, ARCH BIOCHEM BIOPHYS, V283, P506; SCHWARTZ AG, 1979, CANCER RES, V39, P1129; SCHWARTZ AG, 1983, COMM RES BREAST DIS, V3, P113; SHEPHERD A, 1984, AM J PHYSIOL, V246, pE123, DOI 10.1152/ajpendo.1984.246.2.E123; SILVA JE, 1985, ENDOCRINOLOGY, V116, P1627, DOI 10.1210/endo-116-4-1627; SILVA JE, 1986, J CLIN INVEST, V77, P1214, DOI 10.1172/JCI112424; SONG MKH, 1989, J BIOL CHEM, V264; SONKA J, 1976, ACTA U CAROLINAE M L, V111; TAGLIAFERRO AR, 1986, J NUTR, V116, P1977, DOI 10.1093/jn/116.10.1977; USISKIN KS, 1990, INT J OBESITY, V14, P457; VANDEWELE R, 1980, BIOL ACTIVITIES STER, P93; VANWEERDEN WM, 1992, LIFE SCI, V50, P857, DOI 10.1016/0024-3205(92)90204-3; WELLE S, 1990, J CLIN ENDOCR METAB, V71, P1259, DOI 10.1210/jcem-71-5-1259; YEN TT, 1977, LIPIDS, V12, P409, DOI 10.1007/BF02533624; YEN TT, 1978, EXPERIENTIA, V34, P1542, DOI 10.1007/BF02034660; ZUMOFF B, 1983, J CLIN ENDOCR METAB, V56, P668, DOI 10.1210/jcem-56-4-668	65	65	66	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1993	7	5					414	419		10.1096/fasebj.7.5.8462783	http://dx.doi.org/10.1096/fasebj.7.5.8462783			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KV351	8462783				2022-12-28	WOS:A1993KV35100005
J	Floreani, M; Skaper, SD; Facci, L; Lipartiti, M; Giusti, P				Floreani, M; Skaper, SD; Facci, L; Lipartiti, M; Giusti, P			Melatonin maintains glutathione homeostasis in kainic acid-exposed rat brain tissues	FASEB JOURNAL			English	Article						oxidative stress; neuroprotection; glutathione peroxidase; glutathione reductase; GSH; ROS	KAINATE-INDUCED EXCITOTOXICITY; INDUCED LIPID-PEROXIDATION; SIGNAL-TRANSDUCING SYSTEM; CEREBELLAR GRANULE CELLS; PRIMARY CULTURES; OXIDATIVE STRESS; NEURONS; DAMAGE; PROTECTION; MECHANISMS	Reduced glutathione (GSH) is a key component of the cellular defense cascade against injury caused by reactive oxygen species, Because kainic acid (KA) neurotoxicity is probably mediated at least in part by oxidative stress, we examined the influence of KA treatment on GSH content and GSH-related enzyme activities in adult rats, A single injection of KA (10 mg/kg i.p.) time-dependently decreased forebrain GSH (maximal reduction at 48 h). KA also markedly lowered GSH levels in amygdala and hippocampus, but not in the corpus striatum, which is resistant to KA injury, The pineal secretory product melatonin has been shown to exert neuroprotective effects against KA-induced excitotoxicity in rats, Melatonin (2.5 mp/kg i.p., administered four times) partially prevented all. decreases in GSH of KA-treated rats, These neuroprotective effects of melatonin may result from a sparing of glutathione reductase, which decreased in KA-treated but not in KA/melatonin-treated animals. Moreover, KA caused a rapid decrease in the GSH content of cultured cerebellar granule neurons but not astrocytes, These cell types both express functional KA receptors, but only the former are sensitive to reactive oxygen species-dependent KA injury, Melatonin counteracted the changes in GSH induced by KA in cultured cerebellar granule neurons, Our results suggest that melatonin prevents the neurotoxic effects of reactive oxygen species linked to KA receptor activation by maintaining cellular GSH homeostasis.	Univ Padua, Dept Pharmacol, I-35131 Padua, Italy	University of Padua	Giusti, P (corresponding author), Univ Padua, Dept Pharmacol, Largo E Meneghetti 2, I-35131 Padua, Italy.			GIUSTi, Pietro/0000-0001-9352-4046				ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Antolin I, 1996, FASEB J, V10, P882, DOI 10.1096/fasebj.10.8.8666165; BARLOWWALDEN LR, 1995, NEUROCHEM INT, V26, P497, DOI 10.1016/0197-0186(94)00154-M; BAZAN NG, 1986, BASIC MECH EPILEPSIE, V44, P385; BONDY SC, 1993, BRAIN RES, V610, P229, DOI 10.1016/0006-8993(93)91405-H; CAGNOLI CM, 1995, J PINEAL RES, V18, P222, DOI 10.1111/j.1600-079X.1995.tb00163.x; CARLBERG I, 1975, J BIOL CHEM, V250, P5475; CHENG Y, 1994, NEUROCHEM RES, V19, P1557, DOI 10.1007/BF00969006; CHUANG JI, 1994, J PINEAL RES, V17, P11, DOI 10.1111/j.1600-079X.1994.tb00107.x; Cooper A.J.L., 1993, MOL GENETIC BASIS NE, P209; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DYKENS JA, 1987, J NEUROCHEM, V49, P1222, DOI 10.1111/j.1471-4159.1987.tb10014.x; Floreani M, 1997, FREE RADICAL RES, V26, P449, DOI 10.3109/10715769709084481; GIUSTI P, 1995, EXP NEUROL, V131, P39, DOI 10.1016/0014-4886(95)90005-5; Giusti P, 1996, FASEB J, V10, P891, DOI 10.1096/fasebj.10.8.8666166; Giusti P, 1996, J PINEAL RES, V20, P226, DOI 10.1111/j.1600-079X.1996.tb00263.x; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Huang J, 1996, BRAIN RES, V711, P184, DOI 10.1016/0006-8993(95)01376-8; JAIN A, 1991, P NATL ACAD SCI USA, V88, P1913, DOI 10.1073/pnas.88.5.1913; KATO K, 1991, J PHARMACOL EXP THER, V256, P402; LEBARS D, 1991, NUCL MED BIOL, V18, P357; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANEV H, 1994, NEUROREPORT, V5, P2661, DOI 10.1097/00001756-199412000-00064; Manev H, 1996, FASEB J, V10, P1546, DOI 10.1096/fasebj.10.13.8940301; Maney H., 1995, Society for Neuroscience Abstracts, V21, P1518; Matuszak Z, 1997, FREE RADICAL BIO MED, V23, P367, DOI 10.1016/S0891-5849(96)00614-4; MCCASLIN PP, 1987, BRAIN RES, V417, P380, DOI 10.1016/0006-8993(87)90469-0; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Meister A., 1995, BIOTHIOLS HLTH DIS, P165; Melchiorri D, 1996, BIOCHEM PHARMACOL, V51, P1095, DOI 10.1016/0006-2952(96)00055-X; MELCHIORRI D, 1995, FASEB J, V9, P1205, DOI 10.1096/fasebj.9.12.7672513; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; MILANI D, 1989, GLIA, V2, P161, DOI 10.1002/glia.440020305; NICOLETTI F, 1986, J NEUROSCI, V6, P1905; NORLUND JJ, 1977, J CLIN ENDOCR METAB, V45, P768; OLANOW CW, 1992, ANN NEUROL, V32, P52; OLNEY JW, 1974, BRAIN RES, V77, P507, DOI 10.1016/0006-8993(74)90640-4; PHILLIS JW, 1994, PROG NEUROBIOL, V42, P441, DOI 10.1016/0301-0082(94)90046-9; PIERI C, 1994, LIFE SCI, V55, pPL271, DOI 10.1016/0024-3205(94)00666-0; PIGEOLET E, 1991, FREE RADICAL BIO MED, V11, P191, DOI 10.1016/0891-5849(91)90171-X; PROHASKA JR, 1976, J NEUROCHEM, V27, P1379, DOI 10.1111/j.1471-4159.1976.tb02619.x; PUTTFARCKEN PS, 1993, BRAIN RES, V624, P223, DOI 10.1016/0006-8993(93)90081-W; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; SAIJA A, 1994, GEN PHARMACOL-VASC S, V25, P97, DOI 10.1016/0306-3623(94)90016-7; SEWERYNEK E, 1995, J PINEAL RES, V19, P51, DOI 10.1111/j.1600-079X.1995.tb00170.x; Sewerynek E, 1996, HEPATO-GASTROENTEROL, V43, P898; SKAPER SD, 1990, METHODS NEUROSCIENCE, V2, P17; SPERK G, 1994, PROG NEUROBIOL, V42, P1, DOI 10.1016/0301-0082(94)90019-1; SUN AY, 1992, MOL CHEM NEUROPATHOL, V17, P51, DOI 10.1007/BF03159981; Tan DX, 1993, ENDOCR J, V1, P57; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Uz Tolga, 1997, Croatian Medical Journal, V38, P205	52	88	90	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1997	11	14					1309	1315		10.1096/fasebj.11.14.9409550	http://dx.doi.org/10.1096/fasebj.11.14.9409550			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YN210	9409550				2022-12-28	WOS:000071144100012
J	DeFlora, S; Izzotti, A; Walsh, D; Degan, P; Petrilli, GL; Lewtas, J				DeFlora, S; Izzotti, A; Walsh, D; Degan, P; Petrilli, GL; Lewtas, J			Molecular epidemiology of atherosclerosis	FASEB JOURNAL			English	Article						aging; dyslipidosis; cigarette smoke; hypertension; smooth muscle cells; DNA adducts; oxidative DNA damage	SMOOTH-MUSCLE CELLS; OXIDATIVE DNA-DAMAGE; CANCER BIOMARKERS; ADDUCT FORMATION; ARTERIAL-WALL; IN-VIVO; BENZO<A>PYRENE; PROLIFERATION; RAT; PLAQUES	It has been hypothesized that mutational events may be involved in the atherogenetic process and that at least a portion of atherosclerotic plaques may develop according to an initiation-promotion process of arterial smooth muscle cells, akin to benign tumors. We conducted a study to evaluate the occurrence of oxidative DNA damage and formation of DNA adducts in human atherosclerotic lesions and to assess the relationships of these promutagenic alterations with exposure to atherogenic risk factors. Pure DNA was extracted from the tunica media (composed mainly of smooth muscle cells) of abdominal aorta fragments taken at surgery from 85 patients suffering from severe atherosclerotic lesions. DNA adducts were detected by synchronous fluorescence spectrophotometry and P-32 postlabeling after enrichment of adducts with either butanol or nuclease P1. 8-Hydroxy-2'-deoxguanosine (8-OH-dG), a typical indicator of oxidative DNA damage, was measured by HPLC/electrochemical detection. A complete questionnaire reporting general, clinical, and laboratory characteristics was available for each patient. All 84 samples tested by P-32 postlabeling were positive by displaying the presence of diagonal radioactive zones and up to 9 individual DNA adducts. Of 52 samples tested, 32 (61.5%) yielded typical positive signals at synchronous fluorescence spectrophotometry. All but one of 39 samples tested had very high levels of 8-OH-dG, thus showing a remarkable oxidative DNA damage. Statistically significant correlations were found between the levels of molecular biomarkers and atherogenic risk factors including age, number of currently smoked cigarettes, ratio of total-to-high density lipoprotein blood cholesterol, blood triglycerides, and blood pressure. The DNA alterations detected in our study may be only one component of the genetic basis of atherogenesis. Moreover, no causal role in the atherogenetic process can be inferred from our results. However, DNA alterations, including oxidative damage and adduction of reactive molecules of either endogenous or exogenous source, were systematically present in the smooth muscle cells of human atherosclerotic lesions and their intensity was significantly correlated with the occurrence of atherogenic risk factors in the patients.	UNIV GENOA, INST HYG & PREVENT MED, I-16132 GENOA, ITALY; US EPA, EPIDEMIOL & BIOMARKER BRANCH, RES TRIANGLE PK, NC 27711 USA; GALLIERA HOSP, DIV VASC SURG, GENOA, ITALY; NATL INST CANC RES, GENOA, ITALY	University of Genoa; United States Environmental Protection Agency; Ente Ospedaliero Ospedali Galliera; University of Genoa; IRCCS AOU San Martino IST			degan, paolo/AAB-6713-2019; degan, paolo/AAB-4093-2019	degan, paolo/0000-0003-0855-8896; izzotti, alberto/0000-0002-8588-0347				AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; [Anonymous], 1984, ARCH INTERN MED, V144, P1045; Baik SC, 1996, CANCER RES, V56, P1279; BASHIR S, 1993, ANN RHEUM DIS, V52, P659, DOI 10.1136/ard.52.9.659; BENDITT EP, 1973, P NATL ACAD SCI USA, V70, P1753, DOI 10.1073/pnas.70.6.1753; Bogliolo M, 1996, CHEM-BIOL INTERACT, V102, P55, DOI 10.1016/0009-2797(96)03731-3; BOND JA, 1979, LIFE SCI, V25, P425, DOI 10.1016/0024-3205(79)90574-5; BRIDGES B A, 1990, Mutation Research, V239, P143, DOI 10.1016/0165-1110(90)90002-S; BURCHFIEL CM, 1995, CIRCULATION, V92, P1430, DOI 10.1161/01.CIR.92.6.1430; BUSBEE DL, 1982, CARCINOGENESIS, V3, P1107, DOI 10.1093/carcin/3.10.1107; CHOBANIAN AV, 1990, HYPERTENSION, V15, P666, DOI 10.1161/01.HYP.15.6.666; CLAUSEN J, 1993, CANCER LETT, V72, P163, DOI 10.1016/0304-3835(93)90123-Q; CRAWFORD DW, 1991, ATHEROSCLEROSIS, V89, P97, DOI 10.1016/0021-9150(91)90049-9; DAGOSTINI F, 1995, CANCER EPIDEM BIOMAR, V4, P111; DEGAN P, 1995, CARCINOGENESIS, V16, P735, DOI 10.1093/carcin/16.4.735; DEGAN P, 1991, CARCINOGENESIS, V12, P865, DOI 10.1093/carcin/12.5.865; Duthie G G, 1989, Nutr Res Rev, V2, P51, DOI 10.1079/NRR19890007; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943; GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081; HANSEN ES, 1990, MUTAT RES, V239, P163, DOI 10.1016/0165-1110(90)90004-U; HOGG SI, 1982, COMP BIOCHEM PHYS B, V73, P669, DOI 10.1016/0305-0491(82)90094-3; IMAI H, 1980, SCIENCE, V207, P651, DOI 10.1126/science.7352277; INDOLFI C, 1995, NAT MED, V1, P541, DOI 10.1038/nm0695-541; International Agency for Research on Cancer, 1986, IARC MON EV CARC RIS, V38; IZZOTTI A, 1994, CANCER RES, V54, pS1994; IZZOTTI A, 1991, CARCINOGENESIS, V12, P1281, DOI 10.1093/carcin/12.7.1281; IZZOTTI A, 1995, CANCER EPIDEM BIOMAR, V4, P105; IZZOTTI A, 1992, CARCINOGENESIS, V13, P2187, DOI 10.1093/carcin/13.11.2187; KANNEL WB, 1981, AM HEART J, V101, P319, DOI 10.1016/0002-8703(81)90197-6; KENDALL CW, 1992, CANCER LETT, V66, P241, DOI 10.1016/0304-3835(92)90253-R; LEWTAS J, 1995, P 86 ANN M AM ASS CA, V36, P652; LEWTAS J, 1993, ENV HLTH PERSPECT, V99, P88; MAJESKY MW, 1985, P NATL ACAD SCI USA, V82, P3450, DOI 10.1073/pnas.82.10.3450; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; OU X, 1995, ARCH BIOCHEM BIOPHYS, V760, P354; PAIGEN B, 1986, CANCER RES, V46, P3321; PARK JW, 1992, FREE RADICAL BIO MED, V12, P245, DOI 10.1016/0891-5849(92)90111-S; PARKES JL, 1991, AM J PATHOL, V138, P765; PENG SK, 1978, ARCH PATHOL LAB MED, V102, P57; PENN A, 1986, P NATL ACAD SCI USA, V83, P7951, DOI 10.1073/pnas.83.20.7951; PENN A, 1991, ARTERIOSCLER THROMB, V11, P1053, DOI 10.1161/01.ATV.11.4.1053; PENN A, 1988, CARCINOGENESIS, V9, P2185, DOI 10.1093/carcin/9.12.2185; RAMOS KS, 1996, CASARETT DOULLS TOXI, P487; RANDERATH E, 1989, J NATL CANCER I, V81, P341, DOI 10.1093/jnci/81.5.341; RANDERATH E, 1994, DIETARY RESTRICTION, P299; RANDERATH K, 1995, MCBU, P77; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1993, AM J PATHOL, V143, P987; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SEVANIAN A, 1986, FOOD CHEM TOXICOL, V24, P1103, DOI 10.1016/0278-6915(86)90295-4; SHIMODA R, 1994, CANCER RES, V54, P3171; Smith LL, 1981, CHOLESTEROL AUTOXIDA, P49; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P5397, DOI 10.1073/pnas.91.12.5397; TROSKO JE, 1980, MED HYPOTHESES, V6, P455, DOI 10.1016/0306-9877(80)90098-5; VAHAKANGAS K, 1988, IARC SCI PUBL, V89, P208; *WHO, 1985, WHO TECH REP SERV, V143, P1; YOSHIDA Y, 1990, ANN NY ACAD SCI, V598, P256, DOI 10.1111/j.1749-6632.1990.tb42298.x; Zhang Y, 1997, MUTAT RES-FUND MOL M, V373, P285, DOI 10.1016/S0027-5107(96)00213-8; ZWIJSEN RML, 1992, CARCINOGENESIS, V13, P1913, DOI 10.1093/carcin/13.10.1913; ZWIJSEN RML, 1990, MUTAT RES, V230, P111, DOI 10.1016/0027-5107(90)90048-9	63	132	135	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1997	11	12					1021	1031		10.1096/fasebj.11.12.9337155	http://dx.doi.org/10.1096/fasebj.11.12.9337155			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YA724	9337155				2022-12-28	WOS:A1997YA72400012
J	Chattergoon, M; Boyer, J; Weiner, DB				Chattergoon, M; Boyer, J; Weiner, DB			Genetic immunization: a new era in vaccines and immune therapeutics	FASEB JOURNAL			English	Review						infectious diseases; immunotherapy; DNA vaccine; cancer; human vaccines; genetic immunization	DNA-BASED IMMUNIZATION; PROTECTIVE IMMUNITY; SKELETAL-MUSCLE; SURFACE-ANTIGEN; VIRUS; HEPATITIS; VACCINATION; INFLUENZA; INJECTION; RESPONSES	DNA inoculation represents a novel approach to vaccine and immune therapeutic develop ment, The direct injection of gene expression cassettes into a living host transforms a number of cells into factories for production of the introduced gene products, Expression of these delivered genes has important immunological consequences and may result in the specific immune activation of the host against the novel expressed antigens, The recent demonstration by laboratories that these immune responses are protective in some infectious disease experimental models as well as cancers is viewed with cautious optimism, Further, the relatively short development times, ease of large-scale production, low development, manufacturing, and distribution costs all combine with immunological effectiveness to suggest that this technology will dramatically influence the production of a new generation of experimental vaccines and immune therapies, It is hoped that DNA inoculation will ultimately lead to new vaccines that are immunologically effective and economically accessible to all nations.	UNIV PENN,DEPT PATHOL & LAB MED,STELLAR CHANCE LABS 505,PHILADELPHIA,PA 19104	University of Pennsylvania			Weiner, David B/H-8579-2014					Atanasiu P., 1962, ACAD SCI, V254, P4228; Bright RK, 1995, ANN NY ACAD SCI, V772, P241, DOI 10.1111/j.1749-6632.1995.tb44750.x; CAMPO MS, 1994, CIBA F SYMP, V187, P61; CONRY RM, 1995, CANCER GENE THER, V2, P33; Davis HL, 1996, P NATL ACAD SCI USA, V93, P7213, DOI 10.1073/pnas.93.14.7213; DAVIS HL, 1993, HUM MOL GENET, V2, P1847, DOI 10.1093/hmg/2.11.1847; DAVIS HL, 1993, HUM GENE THER, V4, P151, DOI 10.1089/hum.1993.4.2-151; DAVIS HL, 1994, VACCINE, V12, P1503, DOI 10.1016/0264-410X(94)90073-6; DEBENSKY T, 1984, P NATL ACAD SCI USA, V81, P7529; Donnelly JJ, 1996, J INFECT DIS, V173, P314, DOI 10.1093/infdis/173.2.314; Doolan DL, 1996, J EXP MED, V183, P1739, DOI 10.1084/jem.183.4.1739; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; Gaukroger JM, 1996, J GEN VIROL, V77, P1577, DOI 10.1099/0022-1317-77-7-1577; HUYGEN K, 1996, NTURE MED, V2, P983; ISRAEL MA, 1979, J VIROL, V29, P990, DOI 10.1128/JVI.29.3.990-996.1979; ITO Y, 1960, VIROLOGY, V12, P596, DOI 10.1016/0042-6822(60)90182-3; Khanna R, 1995, VIROLOGY, V214, P633, DOI 10.1006/viro.1995.0076; Kim JJ, 1997, J IMMUNOL, V158, P816; Kirnbauer R, 1996, VIROLOGY, V219, P37, DOI 10.1006/viro.1996.0220; Mancini M, 1996, J BIOTECHNOL, V44, P47, DOI 10.1016/0168-1656(95)00098-4; ORTH G, 1964, P SOC EXP BIOL MED, V115, P1090; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; Regimbald LH, 1996, CANCER RES, V56, P4244; Roth J, 1996, P NATL ACAD SCI USA, V93, P4781, DOI 10.1073/pnas.93.10.4781; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; STASNEY J, 1950, CANCER RES, V10, P775; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; Tascon RE, 1996, NAT MED, V2, P888, DOI 10.1038/nm0896-888; TSANG KY, 1995, J NATL CANCER I, V87, P982, DOI 10.1093/jnci/87.13.982; ULMER JB, 1994, VACCINE, V12, P1541, DOI 10.1016/0264-410X(94)90081-7; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WANG B, 1995, VIROLOGY, V211, P102, DOI 10.1006/viro.1995.1383; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; WANG B, 1995, HUM GENE THER, V6, P407, DOI 10.1089/hum.1995.6.4-407; WANG B, 1994, AIDS RES HUM RETROV, V10, pS35; WANG B, 1994, VACCINES, V94, P83; WILL H, 1982, NATURE, V299, P740, DOI 10.1038/299740a0; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; XIANG ZQ, 1995, IMMUNITY, V2, P129, DOI 10.1016/S1074-7613(95)80001-8; XIANG ZQ, 1994, VIROLOGY, V199, P132, DOI 10.1006/viro.1994.1105; Yasutomi Y, 1996, J VIROL, V70, P678, DOI 10.1128/JVI.70.1.678-681.1996	42	102	138	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1997	11	10					753	763		10.1096/fasebj.11.10.9271360	http://dx.doi.org/10.1096/fasebj.11.10.9271360			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XR105	9271360				2022-12-28	WOS:A1997XR10500005
J	Bilbao, G; Feng, MZ; Rancourt, C; Jackson, WH; Curiel, DT				Bilbao, G; Feng, MZ; Rancourt, C; Jackson, WH; Curiel, DT			Adenoviral/retroviral vector chimeras: a novel strategy to achieve high-efficiency stable transduction in vivo	FASEB JOURNAL			English	Review						vector chimera; gene delivery; adenoviral vector; transgene sequence; retrovirus	MEDIATED GENE-TRANSFER; FIBROSIS AIRWAY EPITHELIA; HUMAN FACTOR-IX; CYSTIC-FIBROSIS; IN-VIVO; RETROVIRAL VECTORS; BRAIN-TUMORS; HUMAN ALPHA-1-ANTITRYPSIN; HEMOPHILIA-B; HUMAN-SERUM	Gene therapy to correct defective genes requires efficient gene delivery and long-term gene expression. Realization of both goals with available vector systems has so far not been achieved. As a novel approach to solve this problem, we have developed a chimeric viral vector system that exploits favorable aspects of both adenoviral and retroviral vectors. In this schema, adenoviral vectors induce target cells to function as transient retroviral producer cells in vivo. The progeny retroviral vector particles can then effectively achieve stable transduction of neighboring cells. In this system, the nonintegrative adenoviral vector is rendered functionally integrative via the intermediate generation of an induced retroviral producer cell. Such chimeric vectors may now allow realization of the requisite goals for specific gene therapy applications.	UNIV ALABAMA,GENE THERAPY PROGRAM,CTR COMPREHENS CANC,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NHLBI NIH HHS [R01-HL50255] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050255] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON WF, 1984, SCIENCE, V226, P401, DOI 10.1126/science.6093246; Baru M, 1995, INTERVIROLOGY, V38, P356, DOI 10.1159/000150464; Bosch A, 1996, J CLIN INVEST, V98, P2683, DOI 10.1172/JCI119091; Bowles NE, 1996, HUM GENE THER, V7, P1735, DOI 10.1089/hum.1996.7.14-1735; CARDOSO JE, 1993, HUM GENE THER, V4, P411, DOI 10.1089/hum.1993.4.4-411; CARUSO M, 1993, P NATL ACAD SCI USA, V90, P7024, DOI 10.1073/pnas.90.15.7024; COUTELLE C, 1995, BIOLOGICALS, V23, P21, DOI 10.1016/1045-1056(95)90006-3; COUTELLE C, 1994, CYSTIC FIBROSIS CURR, P33; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; CURIEL DT, 1994, NAT IMMUN, V13, P141; DAI Y, 1992, P NATL ACAD SCI USA, V89, P10892, DOI 10.1073/pnas.89.22.10892; Douglas JT, 1996, NAT BIOTECHNOL, V14, P1574, DOI 10.1038/nbt1196-1574; DOUGLAS JT, 1995, TUMOR TARGET, V1, P67; DUNCKLEY MG, 1993, HUM MOL GENET, V2, P717, DOI 10.1093/hmg/2.6.717; DUPUIT F, 1995, HUM GENE THER, V6, P1185, DOI 10.1089/hum.1995.6.9-1185; ENGELHARDT JF, 1994, P NATL ACAD SCI USA, V91, P6196, DOI 10.1073/pnas.91.13.6196; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; FASSATI A, 1995, HUM GENE THER, V6, P1177, DOI 10.1089/hum.1995.6.9-1177; Fassati A, 1996, HUM GENE THER, V7, P595, DOI 10.1089/hum.1996.7.5-595; FELGNER PL, 1991, NATURE, V349, P351, DOI 10.1038/349351a0; FERRY N, 1991, P NATL ACAD SCI USA, V88, P8377, DOI 10.1073/pnas.88.19.8377; FINER MH, 1994, BLOOD, V83, P43; Fisher KJ, 1996, HUM GENE THER, V7, P2079, DOI 10.1089/hum.1996.7.17-2079; Fisher KJ, 1996, VIROLOGY, V217, P11, DOI 10.1006/viro.1996.0088; FLAMANT F, 1995, VIROLOGY, V211, P234, DOI 10.1006/viro.1995.1396; FLAMANT F, 1994, INT J DEV BIOL, V38, P751; FLOTTE TR, 1993, P NATL ACAD SCI USA, V90, P10613, DOI 10.1073/pnas.90.22.10613; Fox JC, 1996, THER DRUG MONIT, V18, P410, DOI 10.1097/00007691-199608000-00018; Goldman M, 1996, GENE THER, V3, P811; GOLDMAN MJ, 1995, NAT GENET, V9, P126, DOI 10.1038/ng0295-126; GOLDMAN MJ, 1995, J VIROL, V69, P5951, DOI 10.1128/JVI.69.10.5951-5958.1995; Gorziglia MI, 1996, J VIROL, V70, P4173, DOI 10.1128/JVI.70.6.4173-4178.1996; GRUBB BR, 1994, NATURE, V371, P802, DOI 10.1038/371802a0; HANANIA EG, 1995, AM J MED, V99, P537, DOI 10.1016/S0002-9343(99)80232-0; HATZOGLOU M, 1990, J BIOL CHEM, V265, P17285; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HITT M, 1995, METH MOL G, V7, P13; HURFORD RK, 1995, NAT GENET, V10, P430, DOI 10.1038/ng0895-430; IMLER JL, 1995, VACCINE, V13, P1143, DOI 10.1016/0264-410X(95)00032-V; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JAFFE HA, 1992, NAT GENET, V1, P372, DOI 10.1038/ng0892-372; JOHNSON LG, 1992, NAT GENET, V2, P21, DOI 10.1038/ng0992-21; KALEKO M, 1991, HUM GENE THER, V2, P27, DOI 10.1089/hum.1991.2.1-27; KAY MA, 1995, HEPATOLOGY, V21, P815, DOI 10.1002/hep.1840210331; KAY MA, 1993, SCIENCE, V262, P117, DOI 10.1126/science.8211118; KAY MA, 1992, HUM GENE THER, V3, P641, DOI 10.1089/hum.1992.3.6-641; KLEIN HG, 1994, J CLIN APHERESIS, V9, P139, DOI 10.1002/jca.2920090210; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; KOLODKA TM, 1993, SOMAT CELL MOLEC GEN, V19, P491, DOI 10.1007/BF01233254; KOLODKA TM, 1995, P NATL ACAD SCI USA, V92, P3293, DOI 10.1073/pnas.92.8.3293; KORST RJ, 1995, AM J RESP CRIT CARE, V151, pS75, DOI 10.1164/ajrccm/151.3_Pt_2.S75; KOZARSKY K, 1993, SOMAT CELL MOLEC GEN, V19, P449, DOI 10.1007/BF01233250; Kozarsky KF, 1996, NAT GENET, V13, P54, DOI 10.1038/ng0596-54; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; Krasnykh VN, 1996, J VIROL, V70, P6839, DOI 10.1128/JVI.70.10.6839-6846.1996; KURACHI K, 1993, THROMB HAEMOSTASIS, V70, P193; LEMARCHAND P, 1992, P NATL ACAD SCI USA, V89, P6482, DOI 10.1073/pnas.89.14.6482; LIEBER A, 1995, HUM GENE THER, V6, P1029, DOI 10.1089/hum.1995.6.8-1029; LOZIER JN, 1994, JAMA-J AM MED ASSOC, V271, P47, DOI 10.1001/jama.271.1.47; MICHAEL SI, 1994, GENE THER, V1, P223; MILLER AD, 1992, CURR TOP MICROBIOL, V158, P1; MILLER AD, 1990, BLOOD, V76, P271; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; MILLER N, 1995, FASEB J, V9, P190, DOI 10.1096/fasebj.9.2.7781922; MITTAL SK, 1993, VIRUS RES, V28, P67, DOI 10.1016/0168-1702(93)90090-A; MOORMAN DW, 1994, J SURG ONCOL, V57, P152, DOI 10.1002/jso.2930570304; MORLING FJ, 1995, GENE THER, V2, P504; MORSY MA, 1993, J CLIN INVEST, V92, P1580, DOI 10.1172/JCI116739; MOSCIONI AD, 1993, SURGERY, V113, P304; NABEL EG, 1993, THROMB HAEMOSTASIS, V70, P202; NoguiezHellin P, 1996, P NATL ACAD SCI USA, V93, P4175, DOI 10.1073/pnas.93.9.4175; Nuss HB, 1996, GENE THER, V3, P900; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pensiero MN, 1996, HUM GENE THER, V7, P1095, DOI 10.1089/hum.1996.7.9-1095; Pickles RJ, 1996, HUM GENE THER, V7, P921, DOI 10.1089/hum.1996.7.8-921; RAM Z, 1993, CANCER RES, V53, P83; RAM Z, 1993, J NEUROSURG, V79, P400, DOI 10.3171/jns.1993.79.3.0400; RAM Z, 1994, CANCER RES, V54, P2141; RETTINGER SD, 1994, P NATL ACAD SCI USA, V91, P1460, DOI 10.1073/pnas.91.4.1460; ROEMER K, 1992, EUR J BIOCHEM, V208, P211, DOI 10.1111/j.1432-1033.1992.tb17176.x; Rollins SA, 1996, HUM GENE THER, V7, P619, DOI 10.1089/hum.1996.7.5-619; Rosenfeld MA, 1996, CHEST, V109, P241, DOI 10.1378/chest.109.1.241; ROTHER RP, 1995, J EXP MED, V182, P1345, DOI 10.1084/jem.182.5.1345; ROTHER RP, 1995, HUM GENE THER, V6, P429, DOI 10.1089/hum.1995.6.4-429; RUSSELL DW, 1995, HUM GENE THER, V6, P635, DOI 10.1089/hum.1995.6.5-635; SAJJADI N, 1994, HUM GENE THER, V5, P693, DOI 10.1089/hum.1994.5.6-693; Schulick AH, 1997, J CLIN INVEST, V99, P209, DOI 10.1172/JCI119149; SHERWIN SA, 1978, INT J CANCER, V21, P6, DOI 10.1002/ijc.2910210103; SHORT MP, 1990, J NEUROSCI RES, V27, P427, DOI 10.1002/jnr.490270322; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; STRAUSS M, 1994, GENE THER, V1, P156; TAKAMIYA Y, 1993, J NEUROSURG, V79, P104, DOI 10.3171/jns.1993.79.1.0104; TAKEUCHI Y, 1994, J VIROL, V68, P8001, DOI 10.1128/JVI.68.12.8001-8007.1994; VILE RG, 1995, BRIT MED BULL, V51, P12, DOI 10.1093/oxfordjournals.bmb.a072941; VONRUDEN T, 1995, BIOTECHNIQUES, V18, P484; WAGNER JA, 1995, ANNU REV PHARMACOL, V35, P257; WELSH RM, 1975, NATURE, V257, P612, DOI 10.1038/257612a0; Wickham TJ, 1996, J VIROL, V70, P6831, DOI 10.1128/JVI.70.10.6831-6838.1996; Wilson JM, 1995, J CLIN INVEST, V96, P2547, DOI 10.1172/JCI118318; YANG Y, 1995, IMMUNITY, V1, P433; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YANG YP, 1995, J IMMUNOL, V155, P2564; YANG YP, 1995, P NATL ACAD SCI USA, V92, P7257, DOI 10.1073/pnas.92.16.7257; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; YAO SN, 1991, P NATL ACAD SCI USA, V88, P8101, DOI 10.1073/pnas.88.18.8101; Ye XH, 1996, J BIOL CHEM, V271, P3639; ZABNER J, 1994, HUM GENE THER, V5, P585, DOI 10.1089/hum.1994.5.5-585; Zabner J, 1996, J VIROL, V70, P6994, DOI 10.1128/JVI.70.10.6994-7003.1996; ZEITLIN PL, 1995, GENE THER, V2, P623; ZSENGELLER ZK, 1995, HUM GENE THER, V6, P457, DOI 10.1089/hum.1995.6.4-457	110	62	80	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1997	11	8					624	634		10.1096/fasebj.11.8.9240964	http://dx.doi.org/10.1096/fasebj.11.8.9240964			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XN027	9240964				2022-12-28	WOS:A1997XN02700003
J	Lander, HM				Lander, HM			An essential role for free radicals and derived species in signal transduction	FASEB JOURNAL			English	Review						intracellular messenger; PDGF; reactive oxygen species; specificity regulation; reactive nitrogen species	NECROSIS-FACTOR-ALPHA; VASCULAR SMOOTH-MUSCLE; NITRIC-OXIDE; GROWTH-FACTOR; TRANSCRIPTION FACTOR; IN-VITRO; TYROSINE PHOSPHORYLATION; HYDROGEN-PEROXIDE; OXIDATIVE-STRESS; OXYGEN RADICALS	It is well accepted that extracellular ligands trigger nuclear signals through a cascade of protein-protein interactions, Many of these pathways have been carefully defined and provide an important framework by which we can understand and intervene in the processes they initiate. Recent data in the literature indicate that really extracellular Ligands generate and/or require reactive free radicals or derived species to successfully transmit their signals to the nucleus. Thus, a novel signaling mechanism akin to one solely dependent on protein-protein interactions may exist, Here, TI-e review this information, identify both the sources and targets of free radicals generated by various growth factors and cytokines, discuss how specificity call be achieved, and explore the pathophysiological implications.			Lander, HM (corresponding author), CORNELL UNIV,COLL MED,DEPT BIOCHEM,1300 YORK AVE,NEW YORK,NY 10021, USA.				NIAID NIH HHS [AI37637] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI037637] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ARNONE MI, 1995, J BIOL CHEM, V270, P12048, DOI 10.1074/jbc.270.20.12048; BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; BANDYOPADHYAY S, 1994, J BIOL CHEM, V269, P29949; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BECHEREL PA, 1994, J CLIN INVEST, V93, P2275, DOI 10.1172/JCI117227; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; Buck M, 1996, EMBO J, V15, P1753, DOI 10.1002/j.1460-2075.1996.tb00524.x; BURDON RH, 1995, FREE RADICAL RES, V23, P471, DOI 10.3109/10715769509065268; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CHAUDHRI G, 1986, J IMMUNOL, V137, P2646; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; CLEMENTI E, 1995, J BIOL CHEM, V270, P22277, DOI 10.1074/jbc.270.38.22277; CORBETT JA, 1993, FASEB J, V7, P369, DOI 10.1096/fasebj.7.2.8440413; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DING JM, 1994, SCIENCE, V266, P1713, DOI 10.1126/science.7527589; DONG YJ, 1995, EMBO J, V14, P2700, DOI 10.1002/j.1460-2075.1995.tb07270.x; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; DROGE W, 1994, FASEB J, V8, P1131; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; Fenton H., 1894, J CHEM SOC T, V65, P899, DOI [10.1039/CT8946500899, DOI 10.1039/CT8946500899]; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; GALLE J, 1994, FEBS LETT, V351, P314, DOI 10.1016/0014-5793(94)00853-1; GARDES J, 1992, LIFE SCI, V50, P987, DOI 10.1016/0024-3205(92)90092-4; Golino P, 1996, NAT MED, V2, P35, DOI 10.1038/nm0196-35; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; GUY GR, 1993, J BIOL CHEM, V268, P2141; HAINAUT P, 1993, CANCER RES, V53, P4469; HAJJAR DP, 1995, J AM CHEM SOC, V117, P3340, DOI 10.1021/ja00117a004; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; HUANG LE, 1994, J BIOL CHEM, V269, P30718; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; KELNER MJ, 1994, ARCH BIOCHEM BIOPHYS, V312, P240, DOI 10.1006/abbi.1994.1305; KUO SS, 1993, P NATL ACAD SCI USA, V90, P908, DOI 10.1073/pnas.90.3.908; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; LANDER HM, 1993, J IMMUNOL, V150, P1509; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; LARSSON R, 1989, CANCER RES, V49, P5627; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LIU GH, 1994, J BIOL CHEM, V269, P33028; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MASINI E, 1989, AGENTS ACTIONS, V27, P72, DOI 10.1007/BF02222202; Meffert MK, 1996, NEURON, V16, P1229, DOI 10.1016/S0896-6273(00)80149-X; MEFFERT MK, 1994, NEURON, V12, P1235, DOI 10.1016/0896-6273(94)90440-5; MEHLEN P, 1995, BIOCHEM J, V312, P367, DOI 10.1042/bj3120367; Melville SB, 1996, P NATL ACAD SCI USA, V93, P1226, DOI 10.1073/pnas.93.3.1226; MILLER KJ, 1994, J BIOL CHEM, V269, P27351; MORRIS BJ, 1995, J BIOL CHEM, V270, P24740; Muzykantov VR, 1996, P NATL ACAD SCI USA, V93, P5213, DOI 10.1073/pnas.93.11.5213; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; PATEL KD, 1991, J CELL BIOL, V112, P749, DOI 10.1083/jcb.112.4.749; PERANOVICH TMS, 1995, BIOCHEM J, V305, P613, DOI 10.1042/bj3050613; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; Pratico D, 1996, J BIOL CHEM, V271, P8919, DOI 10.1074/jbc.271.15.8919; RETTORI V, 1993, P NATL ACAD SCI USA, V90, P10130, DOI 10.1073/pnas.90.21.10130; RETTORI V, 1992, P NATL ACAD SCI USA, V89, P11543, DOI 10.1073/pnas.89.23.11543; ROSKAMS AJ, 1994, NEURON, V13, P289; ROY B, 1995, BIOCHEMISTRY-US, V34, P5411, DOI 10.1021/bi00016a012; SAKAI H, 1994, J BIOL CHEM, V269, P23426; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; SATRIANO JA, 1993, J CLIN INVEST, V92, P1564, DOI 10.1172/JCI116737; Schenk H, 1996, J IMMUNOL, V156, P765; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shi MM, 1996, J BIOL CHEM, V271, P5878, DOI 10.1074/jbc.271.10.5878; Shin WS, 1996, J BIOL CHEM, V271, P11317, DOI 10.1074/jbc.271.19.11317; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STEVENSON MA, 1994, CANCER RES, V54, P12; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tetsuka T, 1996, J CLIN INVEST, V97, P2051, DOI 10.1172/JCI118641; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Vallette G, 1996, BIOCHEM J, V313, P35, DOI 10.1042/bj3130035; WAHLER GM, 1995, AM J PHYSIOL-CELL PH, V268, pC45, DOI 10.1152/ajpcell.1995.268.1.C45; WANG GL, 1995, BIOCHEM BIOPH RES CO, V212, P550, DOI 10.1006/bbrc.1995.2005; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; WOLIN MS, 1994, J CARDIOVASC PHARM, V23, P664, DOI 10.1097/00005344-199404000-00022; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	90	782	806	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1997	11	2					118	124		10.1096/fasebj.11.2.9039953	http://dx.doi.org/10.1096/fasebj.11.2.9039953			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK509	9039953				2022-12-28	WOS:A1997WK50900003
J	Cho, MR; Thatte, HS; Lee, RC; Golan, DE				Cho, MR; Thatte, HS; Lee, RC; Golan, DE			Reorganization of microfilament structure induced by ac electric fields	FASEB JOURNAL			English	Article						microfilaments; integral membrane proteins; signal transduction	EMBRYONIC MUSCLE-CELL; INDUCED REDISTRIBUTION; HUMAN-FIBROBLASTS; DNA-SYNTHESIS; SHAPE CHANGES; RECEPTORS; ELECTROPHORESIS; SURFACE; STIMULATION; MEMBRANE	AC electric fields induce redistribution of integral membrane proteins, Cell-surface receptor redistribution does not consistently follow electric field lines and depends critically on the frequency of the applied ac electric fields, suggesting that mechanisms other than electroosmosis are involved, We hypothesized that cytoskeletal reorganization is responsible for electric field-induced cell-surface receptor redistribution, and used fluorescence video microscopy to study the reorganization of microfilaments in human hepatoma (Hep3B) cells exposed to low-frequency electric fields ranging in strength from 25 mV/cm to 20 V/cm (peak to peak), The frequency of the applied electric field was varied from 1 to 120 Hz and the field exposure duration from 1 to 60 min, In control cells, cytoplasmic microfilaments were aligned in the form of continuous parallel cables along the longitudinal axis of the cell, Exposure of cells to ac electric fields induced alterations in microfilament structure in a manner that depended on the frequency of the applied field, A 1 or 10 Hz ac field caused microfilament reorganization from continuous, aligned cable structures to discontinuous globular patches, In contrast, the structure of microfilaments in cells exposed to 20-120 Hz electric fields did not differ from that in control cells, The extent of microfilament reorganization increased nonlinearly with the electric field strength, The characteristic time for microfilament reorganization in cells exposed to a 1 Hz, 20 V/cm electric field was similar to 5 min, Applied ac electric fields could initiate signal transduction cascades, which in turn cause reorganization of cytoskeletal structures.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; UNIV CHICAGO, DEPT SURG, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT ANAT, CHICAGO, IL 60637 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Chicago; University of Chicago				Lee, Raphael C./0000-0002-6628-1867; Cho, Myoung Rae/0000-0002-8191-8045	NHLBI NIH HHS [HL-32854, HL-15157] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032854, R37HL032854, P60HL015157] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADEY WR, 1981, PHYSIOL REV, V61, P435, DOI 10.1152/physrev.1981.61.2.435; ADEY WR, 1983, NONLINEAR ELECTRODYN, P2; BASCH RM, 1988, THESIS MIT BOSTON; BEAR CE, 1991, AM J PHYSIOL, V261, pC1018, DOI 10.1152/ajpcell.1991.261.6.C1018; BOURGUIGNON GJ, 1987, FASEB J, V1, P398, DOI 10.1096/fasebj.1.5.3678699; BRETSCHER A, 1994, J CELL BIOL, V126, P821, DOI 10.1083/jcb.126.4.821; Bretscher A, 1993, CURR OPIN CELL BIOL, V5, P653, DOI 10.1016/0955-0674(93)90136-E; CARPEN O, 1992, J CELL BIOL, V118, P1223, DOI 10.1083/jcb.118.5.1223; CHO MR, 1994, FASEB J, V8, P771, DOI 10.1096/fasebj.8.10.8050677; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; HAHN WC, 1993, J IMMUNOL, V150, P2607; HINKLE L, 1981, J PHYSIOL-LONDON, V314, P121, DOI 10.1113/jphysiol.1981.sp013695; JAFFE LF, 1977, NATURE, V265, P600, DOI 10.1038/265600a0; LAUB F, 1984, BIOCHIM BIOPHYS ACTA, V803, P308, DOI 10.1016/0167-4889(84)90122-8; LEE RC, 1993, BIOPHYS J, V64, P44, DOI 10.1016/S0006-3495(93)81339-0; LIN JC, 1996, BIOL EFFECTS ELECTRO, P337; LUTHER PW, 1983, NATURE, V303, P61, DOI 10.1038/303061a0; MCLEOD KJ, 1987, SCIENCE, V236, P1465, DOI 10.1126/science.3589667; MCLEOD KJ, 1992, BIOELECTROMAGNETICS, P161, DOI 10.1002/bem.2250130716; MELAMED I, 1991, J IMMUNOL, V147, P1139; ONUMA EK, 1985, CELL CALCIUM, V6, P281, DOI 10.1016/0143-4160(85)90012-0; ONUMA EK, 1988, J CELL BIOL, V106, P2067, DOI 10.1083/jcb.106.6.2067; POO MM, 1977, NATURE, V265, P602, DOI 10.1038/265602a0; POO MM, 1978, J CELL BIOL, V76, P483, DOI 10.1083/jcb.76.2.483; POO MM, 1981, ANNU REV BIOPHYS BIO, V10, P245, DOI 10.1146/annurev.bb.10.060181.001333; RAO KMK, 1991, MUTAT RES, V256, P139, DOI 10.1016/0921-8734(91)90007-X; RODAN GA, 1978, SCIENCE, V199, P690, DOI 10.1126/science.625660; RUBIN CT, 1993, J BONE MINER RES, V8, pS573; RYAN TA, 1988, SCIENCE, V239, P61, DOI 10.1126/science.2962287; SAWANOBORI T, 1989, J CELL PHYSIOL, V139, P580, DOI 10.1002/jcp.1041390318; SISKEN BF, 1975, J EMBRYOL EXP MORPH, V33, P29; SMITH BA, 1979, P NATL ACAD SCI USA, V76, P5641, DOI 10.1073/pnas.76.11.5641; STOLPEN AH, 1988, P NATL ACAD SCI USA, V85, P1844, DOI 10.1073/pnas.85.6.1844; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TANK DW, 1985, J CELL BIOL, V101, P148, DOI 10.1083/jcb.101.1.148; THATTE HS, 1994, J CELL PHYSIOL, V160, P345, DOI 10.1002/jcp.1041600216; WALLECZEK J, 1992, FASEB J, V6, P3177, DOI 10.1096/fasebj.6.13.1397839; WEEDS A, 1982, NATURE, V296, P811, DOI 10.1038/296811a0; YANG WP, 1984, EXP CELL RES, V155, P92, DOI 10.1016/0014-4827(84)90770-5	39	59	60	2	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1996	10	13					1552	1558		10.1096/fasebj.10.13.8940302	http://dx.doi.org/10.1096/fasebj.10.13.8940302			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VU982	8940302				2022-12-28	WOS:A1996VU98200013
J	Liu, JK; Wang, XY; Shigenaga, MK; Yeo, HC; Mori, A; Ames, BN				Liu, JK; Wang, XY; Shigenaga, MK; Yeo, HC; Mori, A; Ames, BN			Immobilization stress causes oxidative damage to lipid, protein, and DNA in the brain of rats	FASEB JOURNAL			English	Article						mitochondria; lipid peroxidation; protein oxidation; DNA damage	INDUCED EXTRACELLULAR ACCUMULATION; ANTIOXIDANT DEFENSE CHANGES; EXCITATORY AMINO-ACIDS; REDUCED GLUTATHIONE; BIOLOGICAL-FLUIDS; OXIDIZED PROTEINS; NUCLEAR-DNA; CELL-DEATH; GLUCOCORTICOIDS; HIPPOCAMPUS	Immobilization stress of male Sprague-Dawley rats induces oxidative damage to lipid, protein, and DNA in the brain, Significant increases in lipid peroxidation were found in the cerebral cortex, cerebellum, hippocampus, and midbrain compared to the unstressed controls, Significant increases in levels of protein oxidation were also found in the cortex, hypothalamus, striatum, and medulla oblongata, Oxidative nuclear DNA damage increased after stress in all brain regions, although only the cerebral cortex showed a significant increase, Depletion of glutathione showed some stimulation to oxidative damage in the unstressed control and stressed animals, Further studies of the mitochondrial and cytosol fractions of cerebral cortex demonstrated that mitochondria showed a significantly greater increase in lipid peroxidation and protein oxidation than cytosol, Data from plasma and liver showed oxidative damage similar to that of the brain, These findings provide evidence to support the idea that stress produces oxidants, and that the oxidative damage in stress could contribute to the degenerative diseases of aging, including brain dysfunction.	UNIV CALIF BERKELEY, DIV BIOCHEM & MOL BIOL, BERKELEY, CA 94720 USA; OKAYAMA UNIV, SCH MED, INST MOL & CELLULAR MED, DEPT NEUROSCI, OKAYAMA 700, JAPAN	University of California System; University of California Berkeley; Okayama University			Liu, Jiankang/A-1610-2011		NATIONAL CANCER INSTITUTE [R35CA039910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NCI NIH HHS [CA39910] Funding Source: Medline; NIEHS NIH HHS [ESO1896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADACHI S, 1993, CANCER RES, V53, P4153; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ANDINE P, 1991, J NEUROCHEM, V57, P222, DOI 10.1111/j.1471-4159.1991.tb02119.x; ARMARIO A, 1990, FREE RADICAL RES COM, V9, P113, DOI 10.3109/10715769009148578; BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202; BEAL MF, 1993, TRENDS NEUROSCI, V16, P125, DOI 10.1016/0166-2236(93)90117-5; BONDY SC, 1991, TOXICOL LETT, V58, P13, DOI 10.1016/0378-4274(91)90185-9; BONDY SC, 1994, ALCOHOL ALCOHOLISM, V29, P375; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BULON VV, 1990, B EXP BIOL MED+, V110, P1524, DOI 10.1007/BF00841310; CEREMUZYNSKI L, 1991, EXP PATHOL-JENA, V43, P213, DOI 10.1016/S0232-1513(11)80120-9; CHOI DW, 1992, SCIENCE, V258, P241, DOI 10.1126/science.1357748; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; CHOU YC, 1994, BRAIN RES, V654, P8, DOI 10.1016/0006-8993(94)91565-2; CLARK JB, 1970, J BIOL CHEM, V245, P4724; CLIMENT I, 1989, ANAL BIOCHEM, V182, P226, DOI 10.1016/0003-2697(89)90584-8; FLOYD RA, 1991, ARCH GERONTOL GERIAT, V12, P155, DOI 10.1016/0167-4943(91)90025-L; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; HAGEN TM, 1987, AM J PHYSIOL, V252, pG607, DOI 10.1152/ajpgi.1987.252.5.G607; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; HASEGAWA T, 1993, ANN NY ACAD SCI, V691, P281, DOI 10.1111/j.1749-6632.1993.tb26196.x; HERBACZYNSKACEDRO K, 1990, CLIN EXP PHARMACOL P, V17, P1, DOI 10.1111/j.1440-1681.1990.tb01258.x; HIDALGO J, 1991, HORM METAB RES, V23, P104, DOI 10.1055/s-2007-1003626; ITOH T, 1993, BRAIN RES, V618, P318, DOI 10.1016/0006-8993(93)91283-X; KOVACHEVAIVANOVA S, 1992, B EXP BIOL MED+, V113, P164; LANDFIELD PW, 1994, NEUROBIOL AGING, V15, P579, DOI 10.1016/0197-4580(94)90101-5; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; LIU J, 1996, IN PRESS FREE RADICA; LIU J, 1996, IN PRESS MOL ASPECTS; LIU JK, 1994, INT J STRESS MANAGE, V1, P249, DOI 10.1007/BF01857992; LIU JK, 1994, INT J BIOCHEM, V26, P511, DOI 10.1016/0020-711X(94)90008-6; LOWY MT, 1995, J NEUROCHEM, V65, P268; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MOGHADDAM B, 1994, BRAIN RES, V655, P251, DOI 10.1016/0006-8993(94)91622-5; MOGHADDAM B, 1993, J NEUROCHEM, V60, P1650, DOI 10.1111/j.1471-4159.1993.tb13387.x; MORONI F, 1991, EUR J PHARMACOL, V199, P227, DOI 10.1016/0014-2999(91)90461-X; OLANOW CW, 1992, ANN NEUROL, V32, pS2, DOI 10.1002/ana.410320703; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; PARE WP, 1965, J GERONTOL, V20, P78, DOI 10.1093/geronj/20.1.78; RICHTER C, 1991, CHEM-BIOL INTERACT, V77, P1, DOI 10.1016/0009-2797(91)90002-O; SAPOLSKY RM, 1993, BEHAV BRAIN RES, V57, P175, DOI 10.1016/0166-4328(93)90133-B; SEREDENIN SB, 1992, B EXP BIOL MED, V108, P46; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SHIGENAGA MK, 1994, METHOD ENZYMOL, V234, P16; Shvets V. N., 1993, Ukrainskii Biokhimicheskii Zhurnal, V65, P91; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Sosnovskii A. S., 1992, Byulleten' Eksperimental'noi Biologii i Meditsiny, V113, P486; SOSNOVSKII AS, 1992, B EXP BIOL MED+, V113, P25, DOI 10.1007/BF00787736; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5; STEINBEHRENS BA, 1994, J NEUROCHEM, V63, P596; STEINBEHRENS BA, 1992, J NEUROCHEM, V58, P1730, DOI 10.1111/j.1471-4159.1992.tb10047.x; STEINBEHRENS BA, 1992, AGING-CLIN EXP RES, V4, P197; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; WIECHELMAN KJ, 1988, ANAL BIOCHEM, V175, P231, DOI 10.1016/0003-2697(88)90383-1; YEGEN BC, 1992, AGENTS ACTIONS, V35, P130, DOI 10.1007/BF01990962; YEO HC, 1994, ANAL BIOCHEM, V220, P391, DOI 10.1006/abio.1994.1355	59	308	318	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1996	10	13					1532	1538		10.1096/fasebj.10.13.8940299	http://dx.doi.org/10.1096/fasebj.10.13.8940299			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VU982	8940299				2022-12-28	WOS:A1996VU98200010
J	deHaro, C; Mendez, R; Santoyo, J				deHaro, C; Mendez, R; Santoyo, J			The eIF-2 alpha kinases and the control of protein synthesis	FASEB JOURNAL			English	Review						protein-serine kinase; protein phosphorylation; translational control; eIF-2 alpha; cell cycle	STABILIZED TRANSLATIONAL INHIBITOR; DSRNA BINDING DOMAIN; INITIATION FACTOR-II; NF-KAPPA-B; STRANDED-RNA BINDING; HEAT-SHOCK PROTEINS; MALIGNANT TRANSFORMATION; IN-VIVO; 3T3-F442A CELLS; SUBUNIT KINASE	Protein synthesis is regulated in response to environmental stimuli by covalent modification, primarily phosphorylation, of components of the translational machinery. Phosphorylation of the alpha subunit of eIF-2 is one of the best-characterized mechanisms for down-regulating protein synthesis in higher eukaryotes in response to various stress conditions. Three distinct protein kinases regulate protein synthesis in eukaryotic cells by phosphorylating the alpha subunit of eIF-2 at serine-51. There are two mammalian eIF-2 alpha kinases: the double-stranded RNA-dependent kinase (PKR) and heme-regulated inhibitor kinase (HRI), and the yeast GCN2. The regulatory mechanisms and the molecular sizes of these eIF-2 alpha kinases are different. The expression of PKR is induced by interferon, and the kinase activity is stimulated by low concentrations of double-stranded RNA. HRI is activated under heme-deficient conditions. Yeast GCN2 is activated by amino acid starvation. The phosphorylation of eIF-2 alpha results in the shutdown of protein synthesis. Nevertheless, the eIF-2 alpha kinases can regulate both global as well as specific mRNA translation. inhibition of protein synthesis correlates with eIF-2 alpha phosphorylation in response to a wide variety of different stimuli, including heat shock, serum deprivation, glucose starvation, amino acid starvation, exposure to heavy metal ions, and viral infection. Finally, recent studies suggest a role for eIF-2 alpha phosphorylation in the control of cell growth and differentiation.			deHaro, C (corresponding author), UNIV AUTONOMA MADRID,FAC CIENCIAS,CSIC,CTR BIOL MOL SEVERO OCHOA,E-28049 MADRID,SPAIN.		; Santoyo-Lopez, Javier/C-9714-2012	Mendez, Raul/0000-0002-1952-6905; Santoyo-Lopez, Javier/0000-0003-1988-5059				BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P315, DOI 10.1073/pnas.88.2.315; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CHEN JJ, 1993, TRANSLATIONAL REGULA, V2, P349; CLEMENS MJ, 1994, MOL BIOL REP, V19, P201, DOI 10.1007/BF00986962; COSENTINO GP, 1995, P NATL ACAD SCI USA, V92, P9445, DOI 10.1073/pnas.92.21.9445; DEALDANA CRV, 1995, EMBO J, V14, P3184, DOI 10.1002/j.1460-2075.1995.tb07321.x; DEHARO C, 1983, P NATL ACAD SCI-BIOL, V80, P6843; DEHERREROS AG, 1985, P NATL ACAD SCI USA, V82, P3119, DOI 10.1073/pnas.82.10.3119; DEVER TE, 1995, MOL CELL BIOL, V15, P6351; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; GROSS M, 1994, J BIOL CHEM, V269, P22738; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1993, MOL MICROBIOL, V10, P215, DOI 10.1111/j.1365-2958.1993.tb01947.x; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; ITO T, 1994, P NATL ACAD SCI USA, V91, P7455, DOI 10.1073/pnas.91.16.7455; JUDWARE R, 1992, J BIOL CHEM, V267, P21685; Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0; Kaufman Randal J., 1994, Current Opinion in Biotechnology, V5, P550, DOI 10.1016/0958-1669(94)90073-6; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KOROMILAS AE, 1995, J BIOL CHEM, V270, P25426, DOI 10.1074/jbc.270.43.25426; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LATHROP JT, 1993, SCIENCE, V259, P522, DOI 10.1126/science.8424176; LEE SB, 1994, P NATL ACAD SCI USA, V91, P10551, DOI 10.1073/pnas.91.22.10551; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LI JH, 1991, EUR J BIOCHEM, V195, P41, DOI 10.1111/j.1432-1033.1991.tb15673.x; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MATTS RL, 1992, J BIOL CHEM, V267, P18160; MATTS RL, 1993, BIOCHEMISTRY-US, V32, P7323, DOI 10.1021/bi00080a001; MELLOR H, 1994, J BIOL CHEM, V269, P10201; MELLOR H, 1993, EUR J BIOCHEM, V211, P529, DOI 10.1111/j.1432-1033.1993.tb17579.x; MENDEZ R, 1992, J BIOL CHEM, V267, P11500; MENDEZ R, 1994, J BIOL CHEM, V269, P6170; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MUNDSCHAU LJ, 1995, J BIOL CHEM, V270, P3100, DOI 10.1074/jbc.270.7.3100; OLMSTED EA, 1993, J BIOL CHEM, V268, P12552; PALOMO C, 1985, ARCH BIOCHEM BIOPHYS, V239, P497, DOI 10.1016/0003-9861(85)90718-0; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; ROLFES RJ, 1993, MOL CELL BIOL, V13, P5099, DOI 10.1128/MCB.13.8.5099; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; SALZBERG S, 1995, EXP CELL RES, V219, P223, DOI 10.1006/excr.1995.1222; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SCHEPER GC, 1994, BIOCHIMIE, V76, P801, DOI 10.1016/0300-9084(94)90084-1; SCHMEDT C, 1995, J MOL BIOL, V249, P29, DOI 10.1006/jmbi.1995.0278; THOMIS DC, 1995, J VIROL, V69, P5195, DOI 10.1128/JVI.69.8.5195-5198.1995; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; WEK SA, 1995, MOL CELL BIOL, V15, P4497; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; ZHANG L, 1995, EMBO J, V14, P313, DOI 10.1002/j.1460-2075.1995.tb07005.x	64	230	234	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1996	10	12					1378	1387		10.1096/fasebj.10.12.8903508	http://dx.doi.org/10.1096/fasebj.10.12.8903508			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VP485	8903508				2022-12-28	WOS:A1996VP48500003
J	Chik, CL; Li, B; Ogiwara, T; Ho, AK; Karpinski, E				Chik, CL; Li, B; Ogiwara, T; Ho, AK; Karpinski, E			PACAP modulates L-type Ca2+ channel currents in vascular smooth muscle cells: Involvement of PKC and PKA	FASEB JOURNAL			English	Article						cAMP; L-type Ca2+ current; protein kinase C	CYCLASE-ACTIVATING POLYPEPTIDE; PROTEIN-KINASE-C; SENSITIVE CALCIUM-CHANNEL; ADENYLATE-CYCLASE; CYCLIC-AMP; K+ CHANNEL; SIGNAL-TRANSDUCTION; PARATHYROID-HORMONE; RECEPTOR-BINDING; BLOOD-FLOW	he effect of pituitary adenylate cyclase activating polypeptide (PACAP) on the L-type Ca2+ channel current (L-channel current) was studied in smooth muscle cells prepared from the rat tail artery, PACAP caused an increase in the amplitude of the L-channel current, The maximal increase (56%) occurred at a PACAP concentration of 1 x 10(-8) M; higher concentrations resulted in a smaller increase, Investigation into the intracellular mechanisms of PACAP action revealed that the increase in L-channel currents was blocked by calphostin C and bisindolylmaleimide IV [protein kinase C (PKC) inhibitors] and mimicked by 4 beta-phorbol 12-myristate 13-acetate (PMA), an activator of PKC, PACAP was also found to cause translocation of PKC, suggesting that the increase in the current by PACAP was due to PKC. In contrast, activation of cAMP-dependent protein kinase (PKA) by 8-bromo-cAMP caused an inhibition of the L-channel current. A high concentration of PACAP (1x10(-6) M) had no effect on the L-channel current, The null effect of PACAP on the L-channel current could be converted to an increase by Rp-cAMPs, a cAMP antagonist, and a decrease by calphostin C. PACAP also increased cAMP accumu lation. These observations indicate the effect of PACAP on the L-channel current represents the integration of two signaling mechanisms that involve the activation of PKA and PKC.	UNIV ALBERTA,DEPT PHYSIOL,EDMONTON,AB T6G 2H7,CANADA	University of Alberta	Chik, CL (corresponding author), UNIV ALBERTA,DEPT MED,ROOM 733,MED SCI BLDG,EDMONTON,AB T6G 2H7,CANADA.							ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BRAHA O, 1993, J NEUROSCI, V13, P1839; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHEN Y, 1994, J BIOL CHEM, V269, P7839; CHIK CL, 1995, J NEUROCHEM, V64, P2111; CHRISTOPHE J, 1993, BIOCHIM BIOPHYS ACTA, V1154, P183, DOI 10.1016/0304-4157(93)90011-C; CURTIS BM, 1985, P NATL ACAD SCI USA, V82, P2528, DOI 10.1073/pnas.82.8.2528; DAVIS PD, 1992, J MED CHEM, V35, P177, DOI 10.1021/jm00079a024; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; FISH RD, 1988, CIRC RES, V62, P1049, DOI 10.1161/01.RES.62.5.1049; GALLIZI JP, 1987, J BIOL CHEM, V262, P6947; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HO AK, 1994, BIOCHEM BIOPH RES CO, V200, P569, DOI 10.1006/bbrc.1994.1486; HO AK, 1988, J BIOL CHEM, V263, P9292; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; HUANG M, 1993, PEPTIDES, V14, P755, DOI 10.1016/0196-9781(93)90109-T; MINKES RK, 1992, J APPL PHYSIOL, V72, P212; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; NANDHA KA, 1991, J ENDOCRINOL, V129, P69, DOI 10.1677/joe.0.1290069; NARUSE S, 1993, PEPTIDES, V14, P505, DOI 10.1016/0196-9781(93)90139-8; NOWYCKY MC, 1985, P NATL ACAD SCI USA, V82, P2178, DOI 10.1073/pnas.82.7.2178; PAYET MD, 1992, J BIOL CHEM, V267, P18270; PELECH SL, 1986, BIOCHEMISTRY-US, V25, P8348, DOI 10.1021/bi00374a002; ROSSASCUITTO NT, 1993, PEDIATR RES, V34, P323, DOI 10.1203/00006450-199309000-00017; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; TATSUNO I, 1992, ENDOCRINOLOGY, V131, P73, DOI 10.1210/en.131.1.73; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; UDDMAN R, 1993, J CEREBR BLOOD F MET, V13, P291, DOI 10.1038/jcbfm.1993.36; WANG R, 1991, J PHYSIOL-LONDON, V441, P325, DOI 10.1113/jphysiol.1991.sp018754; WANG R, 1991, FEBS LETT, V282, P331, DOI 10.1016/0014-5793(91)80507-Y; WANG WH, 1991, P NATL ACAD SCI USA, V88, P9722, DOI 10.1073/pnas.88.21.9722; WARREN JB, 1991, EUR J PHARMACOL, V197, P131, DOI 10.1016/0014-2999(91)90511-N; XIONG ZL, 1994, J VASC RES, V31, P271, DOI 10.1159/000159053	38	48	50	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1996	10	11					1310	1317		10.1096/fasebj.10.11.8836045	http://dx.doi.org/10.1096/fasebj.10.11.8836045			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VJ717	8836045				2022-12-28	WOS:A1996VJ71700011
J	Kondo, S; Kondo, Y; Yin, DL; Barnett, GH; Kaakaji, R; Peterson, JW; Morimura, T; Kubo, H; Takeuchi, J; Barna, BP				Kondo, S; Kondo, Y; Yin, DL; Barnett, GH; Kaakaji, R; Peterson, JW; Morimura, T; Kubo, H; Takeuchi, J; Barna, BP			Involvement of interleukin-1 beta-converting enzyme in apoptosis of bFGF-deprived murine aortic endothelial cells	FASEB JOURNAL			English	Article						ICE; MAE cell; cell viability; apoptosis; bFGF deprivation	FIBROBLAST GROWTH-FACTOR; PROTEIN-KINASE-C; CISPLATIN-INDUCED APOPTOSIS; DEATH GENE CED-3; IL-1-BETA-CONVERTING ENZYME; CONVERTING-ENZYME; CYSTEINE PROTEASE; BONE-MARROW; INDUCTION; IDENTIFICATION	Apoptosis (programmed cell death) is an essential physiological process that is genetically regulated and contributes to the balance between cell growth, differentiation, and the maintenance of normal cells. Recent studies show that deprivation of growth factor induces apoptosis in endothelial cells. However, the molecular mechanisms regulating apoptosis remain unclear. In this study, we demonstrate that deprivation of basic fibroblast growth factor (bFGF) increased the expression of interleukin-1 beta-converting enzyme (ICE) protein, and subsequently induced apoptosis in murine aortic endothelial (MAE) cells. In contrast, the proteins of the tumor suppressor p53 and c-myc were undetected during apoptosis. This apoptosis was suppressed by the tetrapeptide ICE inhibitor, Ac-YVAD-CMK. Overexpression of murine ICE, in addition, induced apoptosis in MAE cells using gene transfer techniques. These results strongly suggest that ICE may mediate apoptosis in bFGF-deprived endothelial cells, and the suppression of ICE function could represent a novel approach for the protection of endothelial cells from damages.	CLEVELAND CLIN FDN,CTR CANC,BRAIN TUMOR CTR,DEPT NEUROSCI,CLEVELAND,OH 44195; NATL UTANO HOSP,DEPT NEUROSURG,KYOTO,JAPAN	Cleveland Clinic Foundation	Kondo, S (corresponding author), CLEVELAND CLIN FDN,CTR CANC,BRAIN TUMOR CTR,DEPT NEUROSURG S80,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.			Peterson, John/0000-0002-5528-8561				ARAKI S, 1990, BIOCHEM BIOPH RES CO, V168, P1194, DOI 10.1016/0006-291X(90)91155-L; BECKER CG, 1973, AM J PATHOL, V71, P1; BLACK RA, 1988, J BIOL CHEM, V263, P9437; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DZAU VJ, 1993, CIRCULATION, V87, P705, DOI 10.1161/01.CIR.87.3.705; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIMBRONE MA, 1969, NATURE, V222, P33, DOI 10.1038/222033a0; GOSPODAROWICZ D, 1986, MOL CELL ENDOCRINOL, V46, P187, DOI 10.1016/0303-7207(86)90001-8; Gospodarowicz D, 1976, Prog Clin Biol Res, V9, P1; HAIMOVITZFRIEDMAN A, 1994, CANCER RES, V54, P2591; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOWARD AD, 1991, J IMMUNOL, V147, P2964; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KENT KC, 1995, CIRC RES, V77, P231, DOI 10.1161/01.RES.77.2.231; KONDO S, 1995, CANCER RES, V55, P6166; KONDO S, 1995, BRIT J CANCER, V71, P282, DOI 10.1038/bjc.1995.57; KONDO S, 1994, EXP CELL RES, V213, P428, DOI 10.1006/excr.1994.1219; KONDO S, 1994, BRIT J CANCER, V70, P421, DOI 10.1038/bjc.1994.321; KONDO S, 1995, ONCOGENE, V10, P2001; KONDO S, 1994, CANCER RES, V54, P2928; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MASCARDO RN, 1984, ANN NY ACAD SCI, V435, P451, DOI 10.1111/j.1749-6632.1984.tb13849.x; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; RAJOTTE D, 1992, J BIOL CHEM, V267, P9980; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; STRUM JM, 1972, J CELL BIOL, V54, P456, DOI 10.1083/jcb.54.3.456; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAZQUEZ A, 1991, EUR J IMMUNOL, V21, P2311, DOI 10.1002/eji.1830211004; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1987, INT REV CYTOL S, V17, P755; YIN DL, 1994, FEBS LETT, V339, P73, DOI 10.1016/0014-5793(94)80387-0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZELDIS SM, 1972, SCIENCE, V175, P766, DOI 10.1126/science.175.4023.766	45	32	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1996	10	10					1192	1197		10.1096/fasebj.10.10.8751721	http://dx.doi.org/10.1096/fasebj.10.10.8751721			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VD429	8751721				2022-12-28	WOS:A1996VD42900010
J	Cleary, SF; Du, ZM; Cao, GH; Liu, LM; McCrady, C				Cleary, SF; Du, ZM; Cao, GH; Liu, LM; McCrady, C			Effect of isothermal radiofrequency radiation on cytolytic T lymphocytes	FASEB JOURNAL			English	Article						[H-3]TdR; log phase; CTLL-2; IL-2 receptor; specific absorption rates; T cell proliferation	PHASE-TRANSITION; INTERLEUKIN-2; INVITRO; PERMEABILITY; TEMPERATURE; ERYTHROCYTE; VIABILITY; MICROWAVE	Previous in vitro studies provide evidence that RF electromagnetic radiation modulates proliferation of human glioma, lymphocytes, and other cell types, The mechanism of RF radiation cell proliferation modulation, as well as mechanisms for effects on other cell physiologic endpoints, are not well understood, To obtain insight regarding interaction mechanisms, we investigated effects of RF radiation exposure on interleukin 2 (IL-2)-dependent proliferation of cytolytic T lymphocytes (CTLL-2). After exposure to RF radiation in the presence or absence of IL-2 cells were cultured at various physiological concentrations of IL-2, Treatment effects on CTLL-2 proliferation were determined by tritiated thymidine incorporation immediately or 24 h after exposure, Exposure to 2450 MHz RF radiation at specific absorption rates (SARs) of greater than 25 W/kg (induced E-field strength 98.4 V/m) induced a consistent, statistically significant reduction in CTLL-2 proliferation, especially at low IL-2 concentrations, At lower SARs, 2450 MHz exposure increased CTLL-2 proliferation immediately after exposure but reduced 24 h postexposure proliferation, RF radiation effects depended on the mitotic state of the cells at the time of exposure, Comparison of the effects of temperature elevation and RF radiation indicated significant qualitative and quantitative differences.			Cleary, SF (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHYSIOL & BIOPHYS, BIOELECTROMAGNET LAB, RICHMOND, VA 23298 USA.				NIEHS NIH HHS [ES5417] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BUDD RA, 1985, J MICROWAVE POWER EE, V20, P217; CAO GH, 1995, BIOELECTROCH BIOENER, V37, P131, DOI 10.1016/0302-4598(95)05022-Z; CLEARY SF, 1992, ANN NY ACAD SCI, V649, P166, DOI 10.1111/j.1749-6632.1992.tb49606.x; CLEARY SF, 1985, BIOELECTROMAGNETICS, V6, P53, DOI 10.1002/bem.2250060106; CLEARY SF, 1985, BIOELECTROMAGNETICS, V6, P313, DOI 10.1002/bem.2250060311; CLEARY SF, 1990, BIOELECTROMAGNETICS, V11, P47, DOI 10.1002/bem.2250110107; CLEARY SF, 1990, RADIAT RES, V121, P38, DOI 10.2307/3577561; CLEARY SF, IN PRESS BIOELECTROC; CLEARY SF, 1991, 13 ANN M BIOEL SOC S; CLEARY SF, 1988, ENCY MED DEVICES INS, P274; DINZEO G, 1988, BIOELECTROMAGNETICS, V9, P363, DOI 10.1002/bem.2250090406; FREY AH, 1993, FASEB J, V7, P272, DOI 10.1096/fasebj.7.2.8440406; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; KOLOMITKIN OV, 1994, CHARGE FIELD EFFECTS, V4; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LIBURDY RP, 1984, BIOELECTROMAGNETICS, V5, P283, DOI 10.1002/bem.2250050215; LIBURDY RP, 1988, RADIAT RES, V114, P500, DOI 10.2307/3577121; LIU LM, 1988, BIOELECTROMAGNETICS, V9, P249, DOI 10.1002/bem.2250090306; LIU LM, 1995, BIOELECTROMAGNETICS, V16, P160, DOI 10.1002/bem.2250160304; LIU LM, 1994, CHARGE FIELD EFFECTS, V4; OGARRA A, 1988, IMMUNOL TODAY, V9, P45, DOI 10.1016/0167-5699(88)91259-5; PHILIPPOVA TM, 1988, BIOELECTROMAGNETICS, V9, P347, DOI 10.1002/bem.2250090404; PHILIPPOVA TM, 1994, BIOELECTROMAGNETICS, V15, P183, DOI 10.1002/bem.2250150303; RIEGEL JS, 1992, CHEM IMMUNOL, V51, P266; SISKEN JE, 1965, EXP CELL RES, V39, P103, DOI 10.1016/0014-4827(65)90012-1; SMITH KA, 1983, J IMMUNOL, V131, P1808; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876	27	39	43	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1996	10	8					913	919						7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UQ456	8666169				2022-12-28	WOS:A1996UQ45600014
J	Silberstein, S; Gilmore, R				Silberstein, S; Gilmore, R			Biochemistry, molecular biology, and genetics of the oligosaccharyltransferase	FASEB JOURNAL			English	Review						N-linked glycosylation; endoplasmic reticulum; hypoglycosylation; yeast OST subunits	ASPARAGINE-LINKED GLYCOSYLATION; ENDOPLASMIC-RETICULUM MEMBRANE; N-GLYCOSYLATION; GLYCOPROTEIN-BIOSYNTHESIS; TRYPANOSOMATID PROTOZOA; PROTEIN GLYCOSYLATION; YEAST MUTANTS; RIBOPHORINS-I; AMINO-ACID; SEQUENCE	Asparagine-linked glycosylation is a highly conserved protein modification reaction that occurs in all eukaryotes. The initial stage in the biosynthesis of N-linked glycoproteins, catalyzed by the enzyme oligosaccharyltransferase (OST), involves the transfer of a preassembled high-mannose oligosaccharide from a dolichol-linked oligosaccharide donor onto asparagine acceptor sites in nascent proteins in the lumen of the rough endoplasmic reticulum, Biochemical, molecular biological, and genetic studies conducted during the past 5 years have resulted in an explosive growth in our knowledge concerning the OST, Although the basic biochemical properties of the enzyme were determined more than a decade ago using intact microsomal membranes, recent studies provide novel insight into the catalytic mechanism of the enzyme, The OST was recently purified as a large heteroligomeric membrane protein complex; the sequences of many of the subunits have been determined from both fungal and vertebrate sources, Consistent with the evolutionary conservation of N-linked glycosylation, protein sequence comparisons reveal significant homologies between vertebrate, invertebrate, plant, and fungal OST subunits, Yeast molecular genetic methods have been instrumental in the functional characterization of the OST subunits, and have proven to be powerful tools for the identification of novel gene products that influence oligosaccharide transfer in vivo.			Silberstein, S (corresponding author), UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOLEC BIOL, 55 LAKE AVE N, WORCESTER, MA 01655 USA.							ALLEN S, 1995, J BIOL CHEM, V270, P4797, DOI 10.1074/jbc.270.9.4797; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; BAUSE E, 1981, BIOCHEM J, V195, P639, DOI 10.1042/bj1950639; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BOSCH M, 1988, J BIOL CHEM, V263, P17360; BREUER W, 1995, EUR J BIOCHEM, V228, P689, DOI 10.1111/j.1432-1033.1995.0689m.x; CHALIFOUR RJ, 1988, J BIOL CHEM, V263, P15673; Chi JH, 1996, J BIOL CHEM, V271, P3132, DOI 10.1074/jbc.271.6.3132; CLARK RS, 1990, J ORG CHEM, V55, P6275, DOI 10.1021/jo00313a013; CRIMAUDO C, 1987, EMBO J, V6, P75, DOI 10.1002/j.1460-2075.1987.tb04721.x; DEAN N, 1995, P NATL ACAD SCI USA, V92, P1287, DOI 10.1073/pnas.92.5.1287; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GILMORE R, 1993, CELL, V75, P589, DOI 10.1016/0092-8674(93)90476-7; GLABE CG, 1980, J BIOL CHEM, V255, P9236; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GRINNELL BW, 1991, J BIOL CHEM, V266, P9778; HARNIKORT V, 1987, J CELL BIOL, V104, P855, DOI 10.1083/jcb.104.4.855; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HENDRICKSON TL, 1995, BIOCHEMISTRY-US, V34, P9444, DOI 10.1021/bi00029a020; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; IMPERIALI B, 1991, BIOCHEMISTRY-US, V30, P4374, DOI 10.1021/bi00232a002; IMPERIALI B, 1992, J AM CHEM SOC, V114, P7944, DOI 10.1021/ja00046a069; Imperiali B, 1995, BIOORGAN MED CHEM, V3, P1565, DOI 10.1016/0968-0896(95)00142-5; IMPERIALI B, 1992, J AM CHEM SOC, V114, P7942, DOI 10.1021/ja00046a068; JETHMALANI SM, 1994, J BIOL CHEM, V269, P23603; KARAOGLU D, 1995, J CELL BIOL, V130, P567, DOI 10.1083/jcb.130.3.567; KARAOGLU D, IN PRESS COLD SPRING; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KELLEHER DJ, 1994, J BIOL CHEM, V269, P12908; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; KNAUER R, 1994, FEBS LETT, V344, P83, DOI 10.1016/0014-5793(94)00356-4; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; KUMAR V, 1994, J BIOL CHEM, V269, P13451; KUMAR V, 1995, ARCH BIOCHEM BIOPHYS, V320, P217, DOI 10.1016/0003-9861(95)90003-9; LEE J, 1993, BIOCHEMISTRY-US, V32, P6794, DOI 10.1021/bi00077a034; MARCANTONIO EE, 1984, J CELL BIOL, V99, P2254, DOI 10.1083/jcb.99.6.2254; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MCGINNES LW, 1994, VIROLOGY, V200, P470, DOI 10.1006/viro.1994.1210; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; NAKASHIMA T, 1993, MOL CELL BIOL, V13, P6367, DOI 10.1128/MCB.13.10.6367; NILSSON I, 1993, J BIOL CHEM, V268, P5798; PARODI AJ, 1993, GLYCOBIOLOGY, V3, P193, DOI 10.1093/glycob/3.3.193; PATHAK R, 1995, BIOCHEMISTRY-US, V34, P4179, DOI 10.1021/bi00013a005; PATHAK R, 1995, FEBS LETT, V362, P229, DOI 10.1016/0014-5793(95)00253-6; PICARD V, 1995, BIOCHEMISTRY-US, V34, P8433, DOI 10.1021/bi00026a026; PLESS DD, 1977, P NATL ACAD SCI USA, V74, P134, DOI 10.1073/pnas.74.1.134; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; REDDY VA, 1988, J BIOL CHEM, V263, P6978; ROOS J, 1994, P NATL ACAD SCI USA, V91, P1485, DOI 10.1073/pnas.91.4.1485; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SCHUTZBACH JS, 1993, J BIOL CHEM, V268, P24190; SHAKINESHLEMAN SH, 1993, BIOCHEMISTRY-US, V32, P9465, DOI 10.1021/bi00087a026; SHARMA C, 1981, EUR J BIOCHEM, V116, P101, DOI 10.1111/j.1432-1033.1981.tb05306.x; SILBERSTEIN S, 1995, J CELL BIOL, V131, P371, DOI 10.1083/jcb.131.2.371; SILBERSTEIN S, 1995, J CELL BIOL, V128, P525, DOI 10.1083/jcb.128.4.525; SILBERSTEIN S, 1992, J BIOL CHEM, V267, P23658; STAGLJAR I, 1994, P NATL ACAD SCI USA, V91, P5977, DOI 10.1073/pnas.91.13.5977; STAGLJAR I, 1995, GENE, V158, P209, DOI 10.1016/0378-1119(95)00172-3; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; TRIMBLE RB, 1980, J BIOL CHEM, V255, P1892; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; YU Y, 1990, J CELL BIOL, V111, P1335, DOI 10.1083/jcb.111.4.1335; ZUFFEREY R, 1995, EMBO J, V14, P4949, DOI 10.1002/j.1460-2075.1995.tb00178.x	69	200	205	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1996	10	8					849	858		10.1096/fasebj.10.8.8666161	http://dx.doi.org/10.1096/fasebj.10.8.8666161			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UQ456	8666161				2022-12-28	WOS:A1996UQ45600006
J	Negishi, M; Uno, T; Darden, TA; Sueyoshi, T; Pedersen, LG				Negishi, M; Uno, T; Darden, TA; Sueyoshi, T; Pedersen, LG			Structural flexibility and functional versatility of mammalian P450 enzymes	FASEB JOURNAL			English	Review						DHEA; specificity; polarity; substrate recognition sites; side chains	SITE-DIRECTED MUTAGENESIS; AMINO-ACID; COUMARIN 7-HYDROXYLASE; STEROID 15-ALPHA-HYDROXYLASE; SUBSTRATE-SPECIFICITY; II P-45015-ALPHA; CYTOCHROME-P450; MUTATION; CYTOCHROMES-P450; HYDROXYLATION	P450 enzymes have evolved into a large superfamily that displays great diversity in substrate and product specificities by fixing the natural amino acid substitutions with high frequency. Site-directed mutagenesis has been used to correlate the substitutions with the diverse specificities in various P450s. As a result, the common residues that determine the specificities of various mammalian P450s have been identified and aligned to the corresponding residues in the substrate-heme pocket of the 3-dimensional structures of bacterial P450s. The substrate-heme pocket appears to be structurally variable so that only a minor substitution (Ala -->--> Val, for example) at the critical positions is enough to define the altered specificity. Thus, the structural variability of the P450s provides the inherent versatility in acquiring a novel activity. Recent mutational studies indicate that the side chain size is the major determining factor of specificity, outweighing other factors such as polarity. Further understanding of the paradoxical characteristics observed may provide us with the underlying principles that determine P450 activities, and may lead to the ability to predict P450 activities based on the types of key amino acid residues.	NIEHS, LAB QUANTITAT & COMP BIOL, NIH, RES TRIANGLE PK, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Negishi, M (corresponding author), NIEHS, REPROD & DEV TOXICOL LAB, PHARMACOGENET SECT, NIH, RES TRIANGLE PK, NC 27709 USA.		Negishi, Masahiko/F-7805-2019; Pedersen, Lee G/E-3405-2013	Negishi, Masahiko/0000-0002-2076-8928; Pedersen, Lee G/0000-0003-1262-9861				AIDA K, 1994, GENOMICS, V19, P564, DOI 10.1006/geno.1994.1107; ESTABROOK RW, 1963, BIOCHEM Z, V338, P741; GOTOH O, 1992, J BIOL CHEM, V267, P83; HALPERT JR, 1993, J BIOL CHEM, V268, P4453; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; HE YA, 1994, BIOCHEMISTRY-US, V33, P4419, DOI 10.1021/bi00180a040; HSU MH, 1993, J BIOL CHEM, V268, P6939; IWASAKI M, 1994, J BIOL CHEM, V269, P9079; IWASAKI M, 1995, BIOCHEM J, V306, P29, DOI 10.1042/bj3060029; IWASAKI M, 1993, J BIOL CHEM, V268, P759; IWASAKI M, 1991, J BIOL CHEM, V266, P3380; IWASAKI M, 1995, BIOCHEMISTRY-US, V34, P5054, DOI 10.1021/bi00015a016; IWASAKI M, 1993, BIOCHEM J, V291, P569, DOI 10.1042/bj2910569; JUVONEN RO, 1991, J BIOL CHEM, V266, P16431; KAMINSKY LS, 1993, MOL PHARMACOL, V43, P234; KEDZIE KM, 1991, J BIOL CHEM, V266, P22515; KLAPPER MH, 1971, BIOCHIM BIOPHYS ACTA, V229, P557, DOI 10.1016/0005-2795(71)90271-6; KRONBACH T, 1991, BIOCHEMISTRY-US, V30, P6097, DOI 10.1021/bi00239a003; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; LINDBERG RLP, 1992, PHARMACOGENETICS, V2, P32, DOI 10.1097/00008571-199202000-00006; Luo Zongshu, 1994, Archives of Biochemistry and Biophysics, V309, P52; MATSUNAGA E, 1990, J BIOL CHEM, V265, P17197; NEGISHI M, 1992, J STEROID BIOCHEM, V43, P1031, DOI 10.1016/0960-0760(92)90330-L; NEI M, 1986, MOL BIOL EVOL, V3, P418; NELSON DR, 1989, BIOCHEMISTRY-US, V28, P656, DOI 10.1021/bi00428a036; PELKONEN P, 1994, EUR J PHARM-ENVIRON, V292, P67, DOI 10.1016/0926-6917(94)90027-2; POULOS TL, 1991, METHOD ENZYMOL, V206, P11; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RICHARDSON TH, 1994, J BIOL CHEM, V269, P23937; SCHENKMAN JB, 1992, J STEROID BIOCHEM, V43, P1023, DOI 10.1016/0960-0760(92)90329-H; STRAUB P, 1993, ARCH BIOCHEM BIOPHYS, V306, P521, DOI 10.1006/abbi.1993.1547; VERONESE ME, 1993, BIOCHEM J, V289, P533, DOI 10.1042/bj2890533	34	62	67	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1996	10	7					683	689		10.1096/fasebj.10.7.8635685	http://dx.doi.org/10.1096/fasebj.10.7.8635685			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UN798	8635685				2022-12-28	WOS:A1996UN79800002
J	Engleman, EG				Engleman, EG			Blood safety in the age of AIDS	FASEB JOURNAL			English	Editorial Material											Engleman, EG (corresponding author), STANFORD UNIV,SCH MED,CTR BLOOD,STANFORD,CA 94305, USA.								0	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1996	10	4					390	390		10.1096/fasebj.10.4.8647337	http://dx.doi.org/10.1096/fasebj.10.4.8647337			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UE557	8647337				2022-12-28	WOS:A1996UE55700002
J	Bishop, JM				Bishop, JM			The discovery of proto-oncogenes	FASEB JOURNAL			English	Article							DEPENDENT DNA POLYMERASE; AVIAN-SARCOMA VIRUSES; TRANSFORMING GENE; RNA; VIRIONS				Bishop, JM (corresponding author), UNIV CALIF SAN FRANCISCO,GW HOOPER RES FDN,SAN FRANCISCO,CA 94143, USA.							BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BISHOP JM, 1989, PRIX NOBEL NOBEL PRI, P213; HUEBNER RJ, 1969, P NATL ACAD SCI USA, V64, P1087, DOI 10.1073/pnas.64.3.1087; MARTIN GS, 1970, NATURE, V227, P1021, DOI 10.1038/2271021a0; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SHEINESS D, 1979, J VIROL, V31, P514, DOI 10.1128/JVI.31.2.514-521.1979; SPECTOR DH, 1978, P NATL ACAD SCI USA, V75, P4102, DOI 10.1073/pnas.75.9.4102; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; STEHELIN D, 1976, J MOL BIOL, V101, P349, DOI 10.1016/0022-2836(76)90152-2; STEHELIN D, 1989, COMMUNICATION   1110; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; VARMUS HE, 1989, PRIX NOBLE NOBLE PRI, P190; VOGT PK, 1971, VIROLOGY, V46, P939, DOI 10.1016/0042-6822(71)90092-4	13	2	2	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1996	10	2					362	364		10.1096/fasebj.10.2.8641572	http://dx.doi.org/10.1096/fasebj.10.2.8641572			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641572				2022-12-28	WOS:A1996TY96200023
J	Miranker, A; Robinson, CV; Radford, SE; Dobson, CM				Miranker, A; Robinson, CV; Radford, SE; Dobson, CM			Investigation of protein folding by mass spectrometry	FASEB JOURNAL			English	Review						hydrogen exchange; oxidative refolding; peptide models; molecular chaperone folding intermediate	HYDROGEN-EXCHANGE; CONFORMATIONAL-CHANGES; LYSOZYME	Mass spectrometry is emerging as one of the most exciting new techniques being applied to studies of protein folding, Recent developments in soft ionization techniques enable intact proteins to be generated in the gas phase from aqueous solution, and fragmentation methods are providing a means of obtaining sequence-specific information. These techniques, particularly in combination with established methods such as NMR spectroscopy, allow the investigation of both covalent and noncovalent events that occur during refolding processes, One important type of application involves mass spectrometry in an analytical role, for example, in characterizing the products of oxidative refolding experiments, Mass spectrometry can also be used to reveal fundamentally new information about the conformational properties of folding intermediates, both in isolation and in complexes with molecular chaperones, through the exploitation of hydrogen-deuterium exchange phenomena. Of particular interest is the insight this approach can provide into the cooperativity of structure formation and the distribution of intermediates at different steps along folding pathways. In this paper we describe recent insights into protein folding resulting from the application of mass spectrometry and discuss the future potential of the method for studies in this area.	UNIV OXFORD, NEW CHEM LAB, OXFORD OX1 3QT, ENGLAND; UNIV OXFORD, OXFORD CTR MOLEC SCI, OXFORD OX1 3QT, ENGLAND	University of Oxford; University of Oxford				robinson, carol/0000-0001-7829-5505; Radford, Sheena/0000-0002-3079-8039				ANDEREGG RJ, 1995, J AM CHEM SOC, V117, P1374, DOI 10.1021/ja00109a022; ANDREN PE, 1994, J AM SOC MASS SPECTR, V5, P867, DOI 10.1016/1044-0305(94)87010-1; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BALDWIN RL, 1993, CURR OPIN STRUC BIOL, V3, P84, DOI 10.1016/0959-440X(93)90206-Z; CHAN C, 1995, BIOCHEM J, V308, P585, DOI 10.1042/bj3080585; CHEN RD, 1995, ANAL CHEM, V67, P1159, DOI 10.1021/ac00103a004; CHOWDHURY SK, 1990, J AM CHEM SOC, V112, P9012, DOI 10.1021/ja00180a074; CREIGHTON TE, 1994, BIOCHEMISTRY-US, V33, P1534, DOI 10.1021/bi00172a033; DELEPIERRE M, 1987, J MOL BIOL, V197, P111, DOI 10.1016/0022-2836(87)90613-9; DOBSON CM, 1995, CURR OPIN STRUC BIOL, V5, P56, DOI 10.1016/0959-440X(95)80009-P; DYSON HJ, 1993, CURR OPIN STRUC BIOL, V3, P60, DOI 10.1016/0959-440X(93)90203-W; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; EYLES SJ, 1994, BIOCHEMISTRY-US, V33, P13038, DOI 10.1021/bi00248a013; FENG R, 1993, ANAL CHEM, V65, P645, DOI 10.1021/ac00053a027; FERSHT AR, 1995, CURR OPIN STRUC BIOL, V5, P79, DOI 10.1016/0959-440X(95)80012-P; FREEDMAN RB, 1995, CURR OPIN STRUC BIOL, V5, P85, DOI 10.1016/0959-440X(95)80013-Q; GLOCKER O, 1994, P NATL ACAD SCI USA, V91, P5868; HOOKE SD, 1995, J AM CHEM SOC, V117, P7548, DOI 10.1021/ja00133a030; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; JOHNSON RS, 1994, PROTEIN SCI, V3, P2411, DOI 10.1002/pro.5560031224; KATTA V, 1991, RAPID COMMUN MASS SP, V5, P214, DOI 10.1002/rcm.1290050415; KRAGELUND BB, 1995, BIOCHEMISTRY-US, V34, P7217, DOI 10.1021/bi00021a037; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LEVINTHAL C, 1968, J CHIM PHYS PCB, V65, P44, DOI 10.1051/jcp/1968650044; MANN M, 1995, TRENDS BIOCHEM SCI, V20, P219, DOI 10.1016/S0968-0004(00)89019-2; MIRANKER A, 1993, SCIENCE, V262, P896, DOI 10.1126/science.8235611; MIRANKER A, 1991, NATURE, V349, P633, DOI 10.1038/349633a0; MIRZA UA, 1993, ANAL CHEM, V65, P1, DOI 10.1021/ac00049a003; MORRIS HR, 1990, BIOCHEM J, V268, P803, DOI 10.1042/bj2680803; MUIR TW, 1995, ANAL BIOCHEM, V224, P100, DOI 10.1006/abio.1995.1013; PENG ZY, 1995, PHILOS T ROY SOC B, V348, P43, DOI 10.1098/rstb.1995.0044; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; RADFORD SE, 1992, PROTEINS, V14, P237, DOI 10.1002/prot.340140210; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; SCHNIER PD, 1995, J AM CHEM SOC, V117, P6747, DOI 10.1021/ja00130a015; SEGAWA SI, 1981, BIOPOLYMERS, V20, P1691, DOI 10.1002/bip.1981.360200810; SENKO MW, 1994, ANNU REV BIOPH BIOM, V23, P763, DOI 10.1146/annurev.bb.23.060194.003555; SERRANO L, 1994, CURR OPIN STRUC BIOL, V4, P107, DOI 10.1016/S0959-440X(94)90067-1; SIUZDAK G, 1994, P NATL ACAD SCI USA, V91, P11290, DOI 10.1073/pnas.91.24.11290; SMITH RD, 1994, NATURE, V369, P137, DOI 10.1038/369137a0; SMITH RD, 1993, BIOL MASS SPECTROM, V22, P493, DOI 10.1002/bms.1200220902; TORELLA C, 1994, FEBS LETT, V352, P301; WAGNER DS, 1994, PROTEIN SCI, V3, P1305, DOI 10.1002/pro.5560030817; WOLYNES PG, 1995, P NATL ACAD SCI USA, V92, P2426, DOI 10.1073/pnas.92.7.2426; WOOD TD, 1995, P NATL ACAD SCI USA, V92, P2451, DOI 10.1073/pnas.92.7.2451; ZHANG ZQ, 1993, PROTEIN SCI, V2, P522	47	162	164	1	36	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1996	10	1					93	101		10.1096/fasebj.10.1.8566553	http://dx.doi.org/10.1096/fasebj.10.1.8566553			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566553				2022-12-28	WOS:A1996TR32800013
J	Pace, CN; Shirley, BA; McNutt, M; Gajiwala, K				Pace, CN; Shirley, BA; McNutt, M; Gajiwala, K			Forces contributing to the conformational stability of proteins	FASEB JOURNAL			English	Review						protein stability; protein folding; hydrogen bonding; hydrophobic effect	CAVITY-CREATING MUTATIONS; ACID SIDE-CHAINS; GLOBULAR-PROTEINS; AMINO-ACIDS; STAPHYLOCOCCAL NUCLEASE; HYDROPHOBIC CORE; HYDROGEN-BONDS; ALPHA-HELIX; FREE-ENERGY; SUBSTITUTIONS	For 35 years, the prevailing view has been that the hydrophobic effect is the dominant force in protein folding. The importance of hydrogen bonding was always clear, but whether it made a net favorable contribution to protein stability was not, Studies of mutant proteins have improved our understanding of the forces stabilizing proteins. They suggest that hydrogen bonding and the hydrophobic effect make large but comparable contributions to the stability of globular proteins.	TEXAS A&M UNIV,CTR MACROMOLEC DESIGN,DEPT BIOCHEM & BIOPHYS,DEPT MED BIOCHEM & GENET,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station					NIGMS NIH HHS [GM 37039] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037039] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernal JD, 1939, NATURE, V143, P663, DOI 10.1038/143663a0; BLABER M, 1993, BIOCHEMISTRY-US, V32, P11363, DOI 10.1021/bi00093a013; BRANDTS JF, 1964, J AM CHEM SOC, V86, P4302, DOI 10.1021/ja01074a014; CHAKRABARTTY A, 1995, ADV PROTEIN CHEM, V46, P141, DOI 10.1016/S0065-3233(08)60334-4; CHEN YW, 1993, J MOL BIOL, V234, P1158, DOI 10.1006/jmbi.1993.1667; CREAMER TP, 1992, P NATL ACAD SCI USA, V89, P5937, DOI 10.1073/pnas.89.13.5937; DAMODARAN S, 1986, J BIOL CHEM, V261, P7220; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P321; FREIER SM, 1986, BIOCHEMISTRY-US, V25, P3214, DOI 10.1021/bi00359a020; GREEN SM, 1992, BIOCHEMISTRY-US, V31, P5717, DOI 10.1021/bi00140a005; HAMMEN PK, 1995, PROTEIN SCI, V4, P936; HARPAZ Y, 1994, NATURE, V2, P641; HUGGINS ML, 1971, ANGEW CHEM INT EDIT, V10, P147, DOI 10.1002/anie.197101471; HUYGHUESDESPOINTES BMP, 1995, BIOCHEMISTRY-US, V34, P13267, DOI 10.1021/bi00041a001; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; KARPLUS PA, 1994, CURR OPIN STRUC BIOL, V4, P770, DOI 10.1016/S0959-440X(94)90178-3; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; KAUZMANN W, 1954, MECHANISM ENZYME ACT; KEMMINK J, 1993, J MOL BIOL, V234, P861, DOI 10.1006/jmbi.1993.1631; LEE B, 1993, PROTEIN SCI, V2, P733, DOI 10.1002/pro.5560020505; LEE KH, 1994, PROTEINS, V20, P68, DOI 10.1002/prot.340200108; LEO A, 1971, CHEM REV, V71, P525, DOI 10.1021/cr60274a001; LESSER GJ, 1990, PROTEINS, V8, P6, DOI 10.1002/prot.340080104; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; MAKHATADZE GI, 1994, BIOPHYS CHEM, V51, P291, DOI 10.1016/0301-4622(94)00050-6; MARQUSEE S, 1994, PROTEIN SCI, V3, P2217, DOI 10.1002/pro.5560031207; MATTHEWS BW, 1995, ADV PROTEIN CHEM, V462, P240; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Mirsky AE, 1936, P NATL ACAD SCI USA, V22, P439, DOI 10.1073/pnas.22.7.439; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; PACE CN, 1990, TRENDS BIOCHEM SCI, V15, P14, DOI 10.1016/0968-0004(90)90124-T; Pace CN, 1995, METHOD ENZYMOL, V259, P538; PACE NC, 1968, BIOCHEMISTRY-US, V7, P198; PAKULA AA, 1990, NATURE, V344, P363, DOI 10.1038/344363a0; Radzicka A., 1988, BIOCHEMISTRY-US, V27, P1644; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; SANDBERG WS, 1991, P NATL ACAD SCI USA, V88, P1706, DOI 10.1073/pnas.88.5.1706; SCHEINER S, 1991, REV COMPUTATIONAL CH, V2, P165; SCHELLMAN JOHN A., 1955, COMPT REND TRAV LAB CARLSBERG SER CHIM, V29, P223; SCHOLTZ JM, 1991, P NATL ACAD SCI USA, V88, P2854, DOI 10.1073/pnas.88.7.2854; SERRANO L, 1992, J MOL BIOL, V224, P783, DOI 10.1016/0022-2836(92)90562-X; SHIRLEY BA, 1992, BIOCHEMISTRY-US, V31, P725, DOI 10.1021/bi00118a013; SHORTLE D, 1993, CURR OPIN STRUC BIOL, V3, P66, DOI 10.1016/0959-440X(93)90204-X; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STICKLE DF, 1992, J MOL BIOL, V226, P1143, DOI 10.1016/0022-2836(92)91058-W; TANFORD C, 1962, J AM CHEM SOC, V84, P4240, DOI 10.1021/ja00881a009; VOET D, 1995, BIOCHEMISTRY-US, P176; YUTANI K, 1987, P NATL ACAD SCI USA, V84, P4441, DOI 10.1073/pnas.84.13.4441	52	537	556	2	82	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1996	10	1					75	83		10.1096/fasebj.10.1.8566551	http://dx.doi.org/10.1096/fasebj.10.1.8566551			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566551				2022-12-28	WOS:A1996TR32800011
J	FaberElman, A; Lavie, V; Schvartz, I; Shaltiel, S; Schwartz, M				FaberElman, A; Lavie, V; Schvartz, I; Shaltiel, S; Schwartz, M			Vitronectin overrides a negative effect of TNF-alpha on astrocyte migration	FASEB JOURNAL			English	Article						turner necrosis factor-alpha; nerve injury; wound healing	PLASMINOGEN-ACTIVATOR INHIBITOR-1; PROTEIN KINASE-A; EXTRACELLULAR-MATRIX; NEURITE OUTGROWTH; ENDOTHELIAL-CELLS; OPTIC NERVES; S-PROTEIN; REGENERATION; PLASMA; PHOSPHORYLATION	Morphogenesis and tissue repair require appropriate cross-talk between the cells and their surrounding milieu, which includes extracellular components and soluble factors, e.g., cytokines and growth factors. The present work deals with this communication needed for recovery after axotomy in the central nervous system (CNS). The failure of CNS axons to regenerate after axonal injury Iras been attributed, in part, to astrocyte failure to repopulate the injury site. The goal of this work was to provide an in vitro model to mimic the in vivo response of astrocytes to nerve injury and to find ways to modulate this response and create a milieu that favors astrocyte migration and repopulation of the injury site. In an astrocyte scratch wound model, we blocked astrocyte migration by tumor necrosis factor alpha (TNF-alpha). This effect could not be reversed by astrocyte migration-inducing factors such as transforming growth factor beta(1) (TGF-beta(1)) or by any of the tested extracellular matrix (ECM) components (laminin and fibronectin) except for vitronectin (Vn). Vn, added together with TNF-alpha, counteracted the TNF-alpha blockage and allowed a massive migration of astrocytes (not due to cell proliferation) beyond that allowed by Vn only. Heparan sulfate proteoglycans (HSPG) were shown to be involved in the migration. The results may be relevant to regeneration of CNS axons, and may also provide an example that an extracellular component (Vn) can overcome and neutralize a negative effect of a growth factor/cytokine (TNF-alpha) and can act in synergy with other features of this cytokine to promote a necessary function (e.g., cell migration) that is otherwise inhibited.	WEIZMANN INST SCI, DEPT NEUROBIOL, IL-76100 REHOVOT, ISRAEL; WEIZMANN INST SCI, DEPT REGULAT BIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science								AKIYAMA H, 1991, J NEUROIMMUNOL, V32, P19, DOI 10.1016/0165-5728(91)90067-H; ALOISI F, 1992, J NEUROSCI RES, V32, P494, DOI 10.1002/jnr.490320405; BLAUGRUND E, 1993, J COMP NEUROL, V330, P105, DOI 10.1002/cne.903300109; BLAUGRUND E, 1992, EXP NEUROL, V118, P105, DOI 10.1016/0014-4886(92)90027-N; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; CHAIN D, 1990, FEBS LETT, V269, P221, DOI 10.1016/0014-5793(90)81159-L; CHAIN D, 1991, BIOCHEM J, V274, P387, DOI 10.1042/bj2740387; CHAIN D, 1991, FEBS LETT, V285, P251, DOI 10.1016/0014-5793(91)80810-P; COHEN I, 1993, J COMP NEUROL, V334, P431, DOI 10.1002/cne.903340308; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; FABERELMAN A, 1995, IN PRESS J NEUROCHEM; GECHTMAN Z, 1993, FEBS LETT, V315, P293, DOI 10.1016/0014-5793(93)81181-X; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; GRABHAM PW, 1992, EXP CELL RES, V202, P337, DOI 10.1016/0014-4827(92)90083-K; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; HOLMES R, 1967, J CELL BIOL, V32, P297, DOI 10.1083/jcb.32.2.297; KELLER KM, 1989, BIOCHEMISTRY-US, V28, P8100, DOI 10.1021/bi00446a021; KORCGRODZICKI B, 1988, BIOCHEM BIOPH RES CO, V157, P1131; KORCGRODZICKI B, 1988, P NATL ACAD SCI USA, V85, P7541, DOI 10.1073/pnas.85.20.7541; KORCGRODZICKI B, 1990, ANAL BIOCHEM, V188, P288, DOI 10.1016/0003-2697(90)90608-C; KOST C, 1992, J BIOL CHEM, V267, P12098; LOGAN A, 1993, TRENDS PHARMACOL SCI, V14, P337, DOI 10.1016/0165-6147(93)90007-7; LOTAN M, 1994, FASEB J, V8, P1026, DOI 10.1096/fasebj.8.13.7926367; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MIMURO J, 1989, J BIOL CHEM, V264, P936; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; NEUGEBAUER KM, 1991, NEURON, V6, P345, DOI 10.1016/0896-6273(91)90244-T; PEPPER MS, 1992, J CELL PHYSIOL, V153, P129, DOI 10.1002/jcp.1041530117; PEPPER MS, 1987, J CELL BIOL, V105, P2535, DOI 10.1083/jcb.105.6.2535; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SCHWARTZ M, 1991, BRAIN RES, V545, P334, DOI 10.1016/0006-8993(91)91309-O; SEIFFERT D, 1990, J CELL BIOL, V111, P1283, DOI 10.1083/jcb.111.3.1283; SEIFFERT D, 1990, CELL DIFFER DEV, V32, P287, DOI 10.1016/0922-3371(90)90041-T; SELDEN SC, 1981, J CELL PHYSIOL, V108, P195, DOI 10.1002/jcp.1041080210; SHALTIEL S, 1993, MOL CELL BIOCHEM, V128, P283, DOI 10.1007/BF01076778; SHALTIEL S, 1993, INT CONGR SER, V1042, P311; SINGER SJ, 1986, ANNU REV CELL BIOL, V2, P337, DOI 10.1146/annurev.cb.02.110186.002005; SKERRETT PJ, 1991, SCIENCE, V252, P1064, DOI 10.1126/science.252.5009.1064; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2	45	30	30	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1995	9	15					1605	1613		10.1096/fasebj.9.15.8529840	http://dx.doi.org/10.1096/fasebj.9.15.8529840			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TM761	8529840				2022-12-28	WOS:A1995TM76100014
J	LIBET, B				LIBET, B			BRAIN METABOLISM, FERRIN, AND NONCARBOHYDRATE OXIDATION	FASEB JOURNAL			English	Article											LIBET, B (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143, USA.							Elliott KAC, 1942, J BIOL CHEM, V146, P251; Elliott KAC, 1942, J BIOL CHEM, V143, P227; Elliott KAC, 1944, J BIOL CHEM, V152, P617; ELLIOTT KAC, 1943, FED PROC, V2, P61; Granick S, 1943, J BIOL CHEM, V149, P157; Libet B, 1944, J BIOL CHEM, V152, P613; Panimon F, 1941, J CELL COMPAR PHYSL, V17, P1, DOI 10.1002/jcp.1030170102	7	0	0	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR 1	1993	7	6					601	601		10.1096/fasebj.7.6.8472897	http://dx.doi.org/10.1096/fasebj.7.6.8472897			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KY009	8472897				2022-12-28	WOS:A1993KY00900015
J	CAVARELLI, J; MORAS, D				CAVARELLI, J; MORAS, D			RECOGNITION OF TRANSFER-RNAS BY AMINOACYL-TRANSFER RNA-SYNTHETASES	FASEB JOURNAL			English	Article						TRANSFER RNA; AMINOACYL-TRANSFER RNA SYNTHETASE; RECOGNITION; IDENTITY DETERMINANTS; CRYSTAL STRUCTURE	GLUTAMINYL-TRANSFER RNA; PHENYLALANINE TRANSFER-RNA; ASPARAGINYL-TRANSFER-RNA; YEAST TRANSFER RNAASP; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; TERTIARY STRUCTURE; SEQUENCE; IDENTITY	Our present understanding of the molecular mechanisms responsible for the recognition of tRNAs by their cognate aminoacyl-tRNA synthetases (aaRS) is essentially based on three sources of information: 1) the characterization of tRNA identity determinants using in vivo and in vitro approaches, 2) the classification of synthetases from primary sequence analysis: aaRS can be partitioned into two classes according to the spatial structure of their ATP binding domain, and 3) the structural results of crystallographic investigations and solution studies. The crystal structures of three aaRS and two complexes, one of each class, are known to atomic resolution. tRNA recognition has two structural components. The interaction between the acceptor end and the active site domain is class-specific and the binding mode of the stem observed in the crystal structures of GlnRS-tRNA(Gln) and AspRS-tRNA(Asp) complexes can be generalized to their respective classes. Identity determinants located in other parts of the tRNA molecule are decoded by different domains of the enzyme. These protein modules exhibit a large structural diversity. The recognition process is then system or subgroup specific.			CAVARELLI, J (corresponding author), CNRS, INST BIOL MOLEC & CELLULAIRE, BIOL STRUCT LAB, F-67084 STRASBOURG, FRANCE.		Cavarelli, Jean/P-3566-2016	Cavarelli, Jean/0000-0001-8620-8723				ANSELME J, 1989, GENE, V84, P481, DOI 10.1016/0378-1119(89)90524-6; BASAVAPPA R, 1991, EMBO J, V10, P3105, DOI 10.1002/j.1460-2075.1991.tb07864.x; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; BURBAUM JJ, 1990, PROTEINS, V7, P99, DOI 10.1002/prot.340070202; CAVARELLI J, 1992, IN PRESS NATURE LOND; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DELARUE M, 1992, NUCLEIC ACIDS MOL BI, V6; DOCKBREGEON AC, 1990, EUR J BIOCHEM, V188, P283, DOI 10.1111/j.1432-1033.1990.tb15401.x; EILER S, 1992, J MOL BIOL, V224, P1171, DOI 10.1016/0022-2836(92)90478-3; ERIANI G, 1990, NUCLEIC ACIDS RES, V18, P7109, DOI 10.1093/nar/18.23.7109; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; FRASER TH, 1975, P NATL ACAD SCI USA, V72, P3044, DOI 10.1073/pnas.72.8.3044; FRUGIER M, 1992, P NATL ACAD SCI USA, V89, P3990, DOI 10.1073/pnas.89.9.3990; GIEGE R, 1992, IN PRESS PROG NUCLEI; HAYASE Y, 1992, IN PRESS EMBO J; HECHT SM, 1979, TRANSFER RNA STRUCTU, P345; HOU YM, 1989, TRENDS BIOCHEM SCI, V14, P233, DOI 10.1016/0968-0004(89)90033-9; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; HOUNTONDJI C, 1986, BIOCHIMIE, V68, P1071, DOI 10.1016/S0300-9084(86)80181-X; KERN D, 1980, EUR J BIOCHEM, V106, P137; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAPOINTE J, 1991, TRANSLATION EUKARYOT, P35; LEVEQUE F, 1990, NUCLEIC ACIDS RES, V18, P305, DOI 10.1093/nar/18.2.305; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0; MORAS D, 1992, TRENDS BIOCHEM SCI, V17, P159, DOI 10.1016/0968-0004(92)90326-5; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; MUSIERFORSYTH K, 1992, NATURE, V357, P513, DOI 10.1038/357513a0; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; NORMANLY J, 1992, P NATL ACAD SCI USA, V89, P5680, DOI 10.1073/pnas.89.12.5680; PERONA JJ, 1991, P NATL ACAD SCI USA, V88, P2903, DOI 10.1073/pnas.88.7.2903; PERRET V, 1990, NATURE, V344, P787, DOI 10.1038/344787a0; PUTZ J, 1991, SCIENCE, V252, P1696, DOI 10.1126/science.2047878; RICH A, 1977, NUCLEIC ACIDS RES, V4, P1649, DOI 10.1093/nar/4.5.1649; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; ROMBY P, 1985, J MOL BIOL, V184, P455, DOI 10.1016/0022-2836(85)90294-3; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUDINGER J, 1992, P NATL ACAD SCI USA, V89, P5882, DOI 10.1073/pnas.89.13.5882; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SCHATZ D, 1991, P NATL ACAD SCI USA, V88, P6132, DOI 10.1073/pnas.88.14.6132; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; SCHULMAN LH, 1991, PROG NUCLEIC ACID RE, V41, P23; SHI JP, 1992, BIOCHEMISTRY-US, V31, P4931, DOI 10.1021/bi00136a002; SOLL D, 1990, EXPERIENTIA, V46, P1089; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; SPRINZL M, 1991, NUCLEIC ACIDS RES, V19, P2127, DOI 10.1093/nar/19.suppl.2127; SPRINZL M, 1975, P NATL ACAD SCI USA, V72, P3049, DOI 10.1073/pnas.72.8.3049; STOUT CD, 1978, ACTA CRYSTALLOGR B, V34, P1529, DOI 10.1107/S0567740878006056; Tzagoloff A, 1990, Prog Nucleic Acid Res Mol Biol, V39, P129, DOI 10.1016/S0079-6603(08)60625-X; WOO NH, 1980, NATURE, V286, P346, DOI 10.1038/286346a0; YAREMCHUK AD, 1992, J MOL BIOL, V224, P519, DOI 10.1016/0022-2836(92)91014-G	59	86	87	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1993	7	1					79	86		10.1096/fasebj.7.1.8422978	http://dx.doi.org/10.1096/fasebj.7.1.8422978			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KH880	8422978				2022-12-28	WOS:A1993KH88000012
J	Campana, WM; Hiraiwa, M; O'Brien, JS				Campana, WM; Hiraiwa, M; O'Brien, JS			Prosaptide activates the MAPK pathway by a G-protein-dependent mechanism essential for enhanced sulfatide synthesis by Schwann cells	FASEB JOURNAL			English	Article						prosaposin; saposin C; myelin; MAP kinase; PI3 kinase	INSULIN-LIKE GROWTH-FACTOR-1; BETA-GAMMA-SUBUNITS; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; NEUROTROPHIC FACTOR; SCIATIC-NERVE; IN-VIVO; PROSAPOSIN; RECEPTOR; RAS	Prosaposin, the precursor of saposins A, B, C, and D, was recently reported to be a neurotrophic factor in vivo and in vitro, The neurotrophic region of prosaposin has been localized to a 12-amino acid sequence within the saposin C domain and has been used to derive biologically active synthetic peptides (14-22 residues), called prosaptides, Treatment of primary Schwann cells and an immortalized Schwann cell line, iSC, with a 14-mer prosaptide, TX14(A) (10 nM), enhanced phosphorylation of mitogen-activated kinases ERK1 (p44 MAPK) and ERK2 (p42 MAPK) within 5 min, which was blocked by 4 h pretreatment with pertussis toxin, Furthermore, incubation of Schwann cells with the nonhydrolyzable GDP analog GDP-PS inhibited TX14(A)-induced ERK phosphorylation. TX14(A) enhanced the sulfatide content of primary Schwann cells by 2.5-fold, which was inhibited by pretreatment with pertussis toxin or the synthetic MAP kinase kinase inhibitor PD098059, In addition, TX14(A) increased the tyrosine phosphorylation of all three isoforms of the adapter molecule, Shc, which coincided with the association of p60Src and PI(3)K. Inhibition of PI3(K) by wortmannin blocked TX14(A)-induced ERK phosphorylation, These data demonstrate that TX14(A) uses a pertussis toxin-sensitive G-protein pathway to activate ERKs, which is essential for enhanced sulfatide synthesis in Schwann cells.	Univ Calif San Diego, Sch Med, Ctr Mol Genet 115, Dept Neurosci, La Jolla, CA 92093 USA	University of California System; University of California San Diego	O'Brien, JS (corresponding author), Univ Calif San Diego, Sch Med, Ctr Mol Genet 115, Dept Neurosci, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NIDDK NIH HHS [DK07318-18] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007318] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASSOULINE JG, 1989, DISSECTION TISSUE CU, P247; BERTIMATTERA LN, 1992, J NEUROCHEM, V59, P1729, DOI 10.1111/j.1471-4159.1992.tb11004.x; BOLIN LM, 1992, J NEUROSCI RES, V33, P231, DOI 10.1002/jnr.490330206; Campana WM, 1996, BIOCHEM BIOPH RES CO, V229, P706, DOI 10.1006/bbrc.1996.1869; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Coetzee T, 1996, CELL, V86, P209, DOI 10.1016/S0092-8674(00)80093-8; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fujita N, 1996, HUM MOL GENET, V5, P711, DOI 10.1093/hmg/5.6.711; Garnovskaya MN, 1996, BIOCHEMISTRY-US, V35, P13716, DOI 10.1021/bi961764n; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; HARZER K, 1989, EUR J PEDIATR, V149, P31, DOI 10.1007/BF02024331; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Hiraiwa M, 1997, P NATL ACAD SCI USA, V94, P4778, DOI 10.1073/pnas.94.9.4778; Hiraiwa M, 1997, BIOCHEM BIOPH RES CO, V240, P415, DOI 10.1006/bbrc.1997.7673; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; Kotani Y, 1996, J NEUROCHEM, V66, P2197; Kotani Y, 1996, J NEUROCHEM, V66, P2019; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; OBRIEN JS, 1995, FASEB J, V9, P681, DOI 10.1096/fasebj.9.8.7768361; OBRIEN JS, 1994, P NATL ACAD SCI USA, V91, P9593, DOI 10.1073/pnas.91.20.9593; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; Qi XY, 1996, J BIOL CHEM, V271, P6874, DOI 10.1074/jbc.271.12.6874; SANO A, 1994, BIOCHEM BIOPH RES CO, V204, P994, DOI 10.1006/bbrc.1994.2558; Stariha RL, 1997, J NEUROCHEM, V68, P945; SVENSSON B, 1995, NEUROSCI LETT, V200, P33, DOI 10.1016/0304-3940(95)12066-D; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; TRAVERSE S, 1992, BIOCHEM J, V288, P119; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; YANO H, 1993, J BIOL CHEM, V268, P25846	40	91	97	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1998	12	3					307	314		10.1096/fasebj.12.3.307	http://dx.doi.org/10.1096/fasebj.12.3.307			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YZ898	9506474				2022-12-28	WOS:000072305500019
J	Roloff, B; Fechner, K; Slominski, A; Furkert, J; Botchkarev, VA; Bulfone-Paus, S; Zipper, J; Krause, E; Paus, R				Roloff, B; Fechner, K; Slominski, A; Furkert, J; Botchkarev, VA; Bulfone-Paus, S; Zipper, J; Krause, E; Paus, R			Hair cycle-dependent expression of corticotropin-releasing factor (CRF) and CRF receptors in murine skin	FASEB JOURNAL			English	Article						stress; hair growth; C57BL/6 mouse	HORMONE; GROWTH; MICE; PROOPIOMELANOCORTIN; MELANOGENESIS; CLONING; STRESS; ANAGEN; PLASMA; CELLS	We demonstrate the presence and hair cycle-dependent expression of corticotropin-releasing factor (CRF) and CRF receptors (CRF-R) in C57BL/6 mouse skin. To correlate this with a physiological, developmentally controlled tissue remodeling process, we have analyzed CRF and CRF-R expression during defined stages of the murine hair cycle with its rhythmic changes between growth (anagen), regression (catagen), and resting (telogen). Using reversed-phase HPLC combined with two independent anti-CRF radioimmunoassays, we have identified CRF in murine skin. Maximal CRF levels were found in anagen III-IV skin, and minimal values were detected in catagen and telogen skin. By immunofluorescence, maximal CRF immunoreactivity (CRF-IR) was seen in the basal epidermis, nerve bundles of skin, the outer root sheath and matrix region of anagen IV-VI follicles, and in defined sections of their perifollicular neural network, whereas catagen and telogen skin displayed minimal CRF-IR. Using quantitative autoradiography and I-125-CRF as a tracer, high-affinity binding sites for CRF were detected in murine skin. The highest density of specific binding sites was detected in the panniculus carnosus, the epidermis, and the hair follicle. CRF-R type 1 (CRF-R1) IR was detected by immunohistology mainly in the outer root sheath, hair matrix, and dermal papilla of anagen VI follicles, as well as in the inner and outer root sheaths of early catagen follicles. CRF-RI expression was also hair cycle dependent. Therefore, in normal murine skin, the CRF-CRF-R signaling system may operate as an additional neuroendocrine pathway regulating skin functions, possibly in the context of cutaneous stress responses.	Loyola Univ, Med Ctr, Dept Pathol, Maywood, IL 60153 USA; Inst Mol Pharmacol, Berlin, Germany; Humboldt Univ, Dept Dermatol, Berlin, Germany; Free Univ Berlin, Inst Immunol, D-1000 Berlin, Germany	Loyola University Chicago; Humboldt University of Berlin; Free University of Berlin	Slominski, A (corresponding author), Loyola Univ, Med Ctr, Dept Pathol, 2160 S 1st Ave, Maywood, IL 60153 USA.	aslom@wpo.it.luc.edu		Slominski, Andrzej/0000-0001-8963-3995; Botchkarev, Vladimir/0000-0002-5212-5353				Beyermann M, 1996, J MED CHEM, V39, P3324, DOI 10.1021/jm960116z; Botchkarev VA, 1997, J COMP NEUROL, V386, P379, DOI 10.1002/(SICI)1096-9861(19970929)386:3<379::AID-CNE4>3.0.CO;2-Z; CHASE HB, 1954, PHYSIOL REV, V34, P113, DOI 10.1152/physrev.1954.34.1.113; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; EICHLER J, 1991, PEPTIDES 1990, P156; Eichmuller S, 1996, J IMMUNOL METHODS, V190, P255, DOI 10.1016/0022-1759(95)00281-2; Ermak G, 1997, J INVEST DERMATOL, V108, P160, DOI 10.1111/1523-1747.ep12332925; Furkert J, 1997, BBA-GEN SUBJECTS, V1336, P315, DOI 10.1016/S0304-4165(97)00046-9; GILBERT SF, 1994, DEV BIOL SKIN; Hadley M.E., 1996, ENDOCRINOLOGY; Hofmann U, 1996, J INVEST DERMATOL, V106, P598, DOI 10.1111/1523-1747.ep12345103; KISHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P1108, DOI 10.1073/pnas.92.4.1108; Liaw CW, 1996, ENDOCRINOLOGY, V137, P72, DOI 10.1210/en.137.1.72; LUGER TA, 1997, IN PRESS ANN NY ACAD; MAZURKIEWICZ JE, 1996, J HISTOCHEM CYTOCHEM, V44, pA784; MUELLER WA, 1997, DEV BIOL; Muglia L, 1996, ANN NY ACAD SCI, V780, P49, DOI 10.1111/j.1749-6632.1996.tb15111.x; NISHIOKA T, 1994, ENDOCR J, V41, P453, DOI 10.1507/endocrj.41.453; ORTH DN, 1992, ENDOCR REV, V13, P164, DOI 10.1210/er.13.2.164; Paus R, 1997, J INVEST DERMATOL, V109, P518, DOI 10.1111/1523-1747.ep12336635; PAUS R, 1994, BRIT J DERMATOL, V130, P281, DOI 10.1111/j.1365-2133.1994.tb02922.x; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; Paus R, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P61, DOI 10.1038/jidsymp.1997.13; PAUS R, 1996, CURR OPIN DERMATOL, V3, P248; PLOTSKY PM, 1990, J NEUROENDOCRINOL, V2, P65, DOI 10.1111/j.1365-2826.1990.tb00394.x; Rohde E, 1996, BIOCHEM PHARMACOL, V52, P829, DOI 10.1016/0006-2952(96)00300-0; RUCKERT Y, 1990, EXP CLIN ENDOCRINOL, V96, P129; SHIBAHARA S, 1983, EMBO J, V2, P775, DOI 10.1002/j.1460-2075.1983.tb01499.x; SLOMINSKI A, 1992, EXPERIENTIA, V48, P50, DOI 10.1007/BF01923606; Slominski A, 1996, BBA-GEN SUBJECTS, V1289, P247, DOI 10.1016/0304-4165(95)00159-X; SLOMINSKI A, 1993, MOL CELL ENDOCRINOL, V93, pC1, DOI 10.1016/0303-7207(93)90131-3; Slominski A, 1996, INT J DERMATOL, V35, P849, DOI 10.1111/j.1365-4362.1996.tb05049.x; SLOMINSKI A, 1995, FEBS LETT, V374, P113, DOI 10.1016/0014-5793(95)01090-2; SLOMINSKI A, 1994, J INVEST DERMATOL, V102, P862, DOI 10.1111/1523-1747.ep12382606; SLOMINSKI A, 1993, J INVEST DERMATOL, V101, pS90, DOI 10.1111/1523-1747.ep12362991; Slominski A, 1996, FEBS LETT, V399, P175, DOI 10.1016/S0014-5793(96)01315-4; SLOMINSKI A, 1991, J INVEST DERMATOL, V96, P172, DOI 10.1111/1523-1747.ep12460956; StenzelPoore MP, 1996, ANN NY ACAD SCI, V780, P36, DOI 10.1111/j.1749-6632.1996.tb15110.x; VITA N, 1993, FEBS LETT, V335, P1, DOI 10.1016/0014-5793(93)80427-V	39	85	85	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1998	12	3					287	297		10.1096/fasebj.12.3.287	http://dx.doi.org/10.1096/fasebj.12.3.287			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YZ898	9506472				2022-12-28	WOS:000072305500017
J	Shulman, RG				Shulman, RG			Hard days in the trenches	FASEB JOURNAL			English	Editorial Material									Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA	Yale University	Shulman, RG (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA.							Fell D., 1997, FRONTIERS METABOLISM, V2	1	4	4	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1998	12	3					255	258		10.1096/fasebj.12.3.255	http://dx.doi.org/10.1096/fasebj.12.3.255			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YZ898	9506465	Bronze			2022-12-28	WOS:000072305500002
J	Fabbrini, MS; Carpani, D; BelloRivero, I; Soria, MR				Fabbrini, MS; Carpani, D; BelloRivero, I; Soria, MR			The amino-terminal fragment of human urokinase directs a recombinant chimeric toxin to target cells: internalization is toxin mediated	FASEB JOURNAL			English	Article						ribosome-inactivating proteins; urokinase receptor; LDL-related receptor protein, alpha 2 macroglobulin receptor; cancer therapy	PLASMINOGEN-ACTIVATOR-INHIBITOR; RECEPTOR-RELATED-PROTEIN; RIBOSOME-INACTIVATING PROTEIN; ALPHA(2)-MACROGLOBULIN RECEPTOR; INTRACELLULAR-TRANSPORT; ENDOCYTOSIS; LIPOPROTEIN; COMPLEXES; SAPORIN; EXPRESSION	In contrast to two-chain urokinase (uPA), a chemical conjugate between uPA and native saporin (a cytotoxic plant seed ribosome-inactivating protein) did not require plasminogen activator inhibitors to be internalized, To dissect this pathway, we constructed a chimera consisting of the amino-terminal fragment (ATF) of human urokinase fused to a saporin isoform (SAP-3). The chimeric ATF-SAP toxin was expressed in Escherichia coli, purified, and characterized for its ribosome-inactivating activity. Besides being a potent inhibitor of protein synthesis in cell-free assays, ATF-SAP was specifically cytotoxic toward cells expressing human uPAR. Competition experiments indicated that both the human uPAR and the LDL-related receptor protein are involved in mediating the cell killing ability of ATF-SAP, We conclude that neither plasminogen activator inhibitors nor the catalytic moiety of urokinase are necessary to initiate these internalization pathways, Thus, saporin may play a role similar to plasminogen activator inhibitors in its ability to trigger internalization of uPAR-bound Ligands through endocytic receptors.			Fabbrini, MS (corresponding author), SAN RAFFAELE SCI INST,DIBIT DEPT BIOL & TECHNOL RES,VIA OLGETTINA 58,I-20132 MILAN,ITALY.							ANDREASEN PA, 1994, FEBS LETT, V338, P239, DOI 10.1016/0014-5793(94)80276-9; APPELLA E, 1987, J BIOL CHEM, V262, P4437; ARGRAVES KM, 1995, J BIOL CHEM, V270, P26550, DOI 10.1074/jbc.270.44.26550; BARTHELEMY I, 1993, J BIOL CHEM, V268, P6541; Besser D, 1996, FIBRINOLYSIS, V10, P215, DOI 10.1016/S0268-9499(96)80018-X; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; CAVALLARO U, 1993, J BIOL CHEM, V268, P23186; CAVALLARO U, 1995, EUR J BIOCHEM, V232, P165, DOI 10.1111/j.1432-1033.1995.tb20795.x; Christensen L, 1996, INT J CANCER, V66, P441; CONESE M, 1995, FEBS LETT, V358, P73, DOI 10.1016/0014-5793(94)01399-L; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DEVRIES TJ, 1995, J PATHOL, V175, P59, DOI 10.1002/path.1711750110; ENDO Y, 1987, J BIOL CHEM, V262, P5908; Fabbrini MS, 1997, BIOCHEM J, V322, P719, DOI 10.1042/bj3220719; FAZIOLI F, 1994, TRENDS PHARMACOL SCI, V15, P25, DOI 10.1016/0165-6147(94)90130-9; GrondahlHansen J, 1995, CLIN CANCER RES, V1, P1079; HEEGAARD CW, 1995, J BIOL CHEM, V270, P20855, DOI 10.1074/jbc.270.35.20855; IPPOLITI R, 1995, FASEB J, V9, P1220, DOI 10.1096/fasebj.9.12.7672515; LAPPI DA, 1994, J BIOL CHEM, V269, P12552; MOESTRUP SK, 1993, J BIOL CHEM, V268, P16564; NYKJAER A, 1997, IN PRESS EMBO J; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; Sandvig K, 1996, PHYSIOL REV, V76, P949, DOI 10.1152/physrev.1996.76.4.949; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; VERSPAGET HW, 1995, EUR J CANCER, V31A, P1105, DOI 10.1016/0959-8049(95)00170-N; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	28	44	51	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1997	11	13					1169	1176		10.1096/fasebj.11.13.9367352	http://dx.doi.org/10.1096/fasebj.11.13.9367352			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367352				2022-12-28	WOS:A1997YE98300015
J	Waterman, MR; Bischof, LJ				Waterman, MR; Bischof, LJ			Cytochromes P450 .12. Diversity of ACTH (cAMP)-dependent transcription of bovine steroid hydroxylase genes	FASEB JOURNAL			English	Review						adenocorticotropin; steroid hormone; cycloheximide; adrenal steroidogenesis; adrenal cortex	SIDE-CHAIN CLEAVAGE; PROTEIN-KINASE; DEPENDENT TRANSCRIPTION; CAMP RESPONSIVENESS; CHOLESTEROL; EXPRESSION; CELLS; P-45017-ALPHA; SEQUENCE; ENZYMES	An essential role of ACTH is to assure that optimal steroidogenic capacity is maintained in the adrenal cortex throughout life, This is achieved by maintaining transcriptional pressure on the genes encoding the adrenocortical steroid hydroxylases via the second messenger, cAMP, Even though these genes respond coordinately to cAMP, it has been surprising to discover that each gene uses its own unique cAMP response system during this coordinate response, Thus, different cis elements and sets of transcription factors control the cAMP responsiveness of each different steroid hydroxylase gene, Although the physiological basis of this diversity in biochemical mechanisms of transcriptional regulation is not apparent, a portion of this signaling pathway is common to all of these genes, In particular, the action of cAMP-dependent protein kinase and an as yet uncharacterized cycloheximide-sensitive step are necessary for ACTH-mediated transcription of each gene, Biochemical characterization of these common steps in the ACTH-dependent signaling pathways is essential to an understanding of the maintenance of optimal steroidogenic capacity in the adrenal cortex.			Waterman, MR (corresponding author), VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, 607 LIGHT HALL, NASHVILLE, TN 37232 USA.				NIDDK NIH HHS [DK28350] Funding Source: Medline; NIEHS NIH HHS [P30 ES00267] Funding Source: Medline; NIGMS NIH HHS [T32 GMO7347] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKKE M, 1995, MOL ENDOCRINOL, V9, P327, DOI 10.1210/me.9.3.327; CHEN JY, 1992, BIOCHEMISTRY-US, V31, P2400, DOI 10.1021/bi00123a027; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DARROW AL, 1990, MOL CELL BIOL, V10, P5883, DOI 10.1128/MCB.10.11.5883; Garren L D, 1971, Recent Prog Horm Res, V27, P433; HONDA SI, 1990, J BIOCHEM-TOKYO, V108, P1042, DOI 10.1093/oxfordjournals.jbchem.a123303; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JEFCOATE CR, 1992, J STEROID BIOCHEM, V43, P751, DOI 10.1016/0960-0760(92)90305-3; JOHN ME, 1986, P NATL ACAD SCI USA, V83, P4715, DOI 10.1073/pnas.83.13.4715; KAGAWA N, 1992, J BIOL CHEM, V267, P25213; KAGAWA N, 1994, J BIOL CHEM, V269, P18716; KAGAWA N, 1991, J BIOL CHEM, V266, P11199; KIMURA T, 1969, ENDOCRINOLOGY, V85, P492, DOI 10.1210/endo-85-3-492; LEGOASCOGNE C, 1987, SCIENCE, V237, P1212, DOI 10.1126/science.3306919; Liu Z, 1997, MOL ENDOCRINOL, V11, P127, DOI 10.1210/me.11.2.127; LUND J, 1990, J BIOL CHEM, V265, P3304; LUND J, 1988, J BIOL CHEM, V263, P16195; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MATHEW PA, 1990, MOL CELL ENDOCRINOL, V73, P73, DOI 10.1016/0303-7207(90)90046-B; MATSUYAMA H, 1971, ENDOCRINOLOGY, V88, P692, DOI 10.1210/endo-88-3-692; MOMOI K, 1992, MOL ENDOCRINOL, V6, P1682, DOI 10.1210/me.6.10.1682; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; Morohashi KI, 1996, FASEB J, V10, P1569, DOI 10.1096/fasebj.10.14.9002548; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Ogo A, 1997, ARCH BIOCHEM BIOPHYS, V338, P193, DOI 10.1006/abbi.1996.9838; ORAVA M, 1989, MOL ENDOCRINOL, V3, P887, DOI 10.1210/mend-3-6-887; PERRIN A, 1991, ENDOCRINOLOGY, V128, P357, DOI 10.1210/endo-128-1-357; PURVIS JL, 1973, ANN NY ACAD SCI, V212, P319, DOI 10.1111/j.1749-6632.1973.tb47605.x; PURVIS JL, 1973, ARCH BIOCHEM BIOPHYS, V159, P39, DOI 10.1016/0003-9861(73)90427-X; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; Simpson E.R., 1995, ENDOCRINOLOGY, P1630; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; SIMPSON ER, 1979, MOL CELL ENDOCRINOL, V13, P213, DOI 10.1016/0303-7207(79)90082-0; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; VIARD I, 1992, ENDOCRINOLOGY, V130, P1193, DOI 10.1210/en.130.3.1193; WATERMAN MR, 1994, J BIOL CHEM, V269, P27783; WATERMAN MR, 1989, RECENT PROG HORM RES, V45, P533; WONG M, 1989, ENDOCR RES, V15, P49, DOI 10.1080/07435808909039088; ZANGER UM, 1991, J BIOL CHEM, V266, P11417; Zhang PL, 1996, MOL ENDOCRINOL, V10, P147, DOI 10.1210/me.10.2.147; ZUBER MX, 1986, J BIOL CHEM, V261, P2475	42	36	38	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1997	11	6					419	427		10.1096/fasebj.11.6.9194522	http://dx.doi.org/10.1096/fasebj.11.6.9194522			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XE404	9194522				2022-12-28	WOS:A1997XE40400004
J	Hack, V; Schmid, D; Breitkreutz, R; StahlHenning, C; Drings, P; Kinscherf, R; Taut, F; Holm, E; Droge, W				Hack, V; Schmid, D; Breitkreutz, R; StahlHenning, C; Drings, P; Kinscherf, R; Taut, F; Holm, E; Droge, W			Cystine levels, cystine flux, and protein catabolism in cancer cachexia, HIV/SIV infection, and senescence	FASEB JOURNAL			English	Article						skeletal muscle catabolism; HIV infection; cancer; plasma cystine level; glutamine exchange rate; controlled constructive metabolism	ACQUIRED IMMUNODEFICIENCY SYNDROME; AMINO-ACID-CONCENTRATIONS; VIRUS-INFECTION; METABOLISM; EXERCISE; CYSTEINE; ALANINE; GLUCOSE; UREA	Patients with skeletal muscle catabolism (cachexia) fail to conserve the skeletal muscle protein and release lar re amounts of nitrogen as urea. Previous studies suggest that the threshold for the conversion of amino acids into other forms of chemical energy and the concomitant production of urea are regulated by the plasma cystine level and hepatic cysteine catabolism. Studies of plasma amino acid exchange rates in the lower extremities now show that healthy young subjects regulate their plasma cystine level in a process that may be described as controlled constructive catabolism. The term controlled describes the fact that the release of cystine and other amino acids from the peripheral tissue is negatively correlated with (certain) plasma amino acid levels. The term constructive describes the fact that the release of cystine is correlated with an increase of the plasma cystine level. The regulation of the plasma cystine level is disturbed in conditions with progressive skeletal muscle catabolism including cancer, HIV infection, and old age. These conditions show also a low plasma glutamine:cystine ratio indicative of an impaired hepatic cystine catabolism. In HIV (+) patients and SIV-infected macaques, a decrease of the plasma cystine level was found to coincide with the decrease of CD4(+) T cells.	DEUTSCH KREBSFORSCHUNGSZENTRUM,DIV IMMUNOCHEM,D-69120 HEIDELBERG,GERMANY; UNIV HEIDELBERG,MED CLIN MANNHEIM 1,DEPT PATHOPHYSIOL,D-68167 MANNHEIM,GERMANY; GERMAN PRIMATE CTR,DEPT VIROL & IMMUNOL,D-37077 GOTTINGEN,GERMANY; HOSP THORAX DIS,D-69126 HEIDELBERG,GERMANY; UNIV HEIDELBERG,DEPT ANESTHESIOL,D-69120 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Deutsches Primatenzentrum (DPZ); Ruprecht Karls University Heidelberg			Kinscherf, Ralf/AAV-7164-2021					AOKI T, 1993, CLIN IMMUNOL IMMUNOP, V69, P253, DOI 10.1006/clin.1993.1178; Aoki T T, 1972, Adv Enzyme Regul, V10, P145, DOI 10.1016/0065-2571(72)90011-8; BARBEY K, 1963, Z KREISLAUFFORSCH, V52, P1129; BELLA DL, 1995, AM J PHYSIOL-ENDOC M, V269, pE910, DOI 10.1152/ajpendo.1995.269.5.E910; BRENNAN MF, 1977, CANCER RES, V37, P2359; BRENNAN MF, 1986, DIGEST DIS SCI, V31, pS77, DOI 10.1007/BF01295991; CHAWLA RK, 1984, GASTROENTEROLOGY, V87, P770; CHEN MK, 1993, ANN SURG, V217, P655, DOI 10.1097/00000658-199306000-00007; DEWYS WD, 1980, AM J MED, V69, P491, DOI 10.1016/S0149-2918(05)80001-3; DIAMOND JM, 1992, NATURE, V357, P362, DOI 10.1038/357362a0; DOHM GL, 1986, EXERCISE SPORT SCI R, V14, P143; DROGE W, 1988, BIOL CHEM H-S, V369, P143, DOI 10.1515/bchm3.1988.369.1.143; DROGE W, 1996, ANTIOXIDANTS DIS MEC, V28, P581; ECK HP, 1991, LANCET, V338, P346, DOI 10.1016/0140-6736(91)90482-5; FEIN R, 1985, CANCER, V56, P2512, DOI 10.1002/1097-0142(19851115)56:10<2512::AID-CNCR2820561032>3.0.CO;2-9; FONTANA L, 1986, IMMUNOBIOLOGY, V171, P425, DOI 10.1016/S0171-2985(86)80074-2; FRIEDMAN PJ, 1987, NUTR RES, V7, P707, DOI 10.1016/S0271-5317(87)80101-X; Gross A, 1996, AIDS RES HUM RETROV, V12, P1639, DOI 10.1089/aid.1996.12.1639; GRUNFELD C, 1991, GASTROINTESTINAL NUT, P207; Hack V, 1996, FASEB J, V10, P1219, DOI 10.1096/fasebj.10.10.8751725; HORTIN GL, 1994, CLIN CHEM, V40, P785; Kinscherf R, 1996, J MOL MED-JMM, V74, P393, DOI 10.1007/s001090050040; KOHASHI N, 1978, J BIOCHEM-TOKYO, V84, P159, DOI 10.1093/oxfordjournals.jbchem.a132104; KOTLER DP, 1985, AM J CLIN NUTR, V42, P1255, DOI 10.1093/ajcn/42.6.1255; LAWSON DH, 1982, ANNU REV NUTR, V2, P277, DOI 10.1146/annurev.nu.02.070182.001425; LONG CL, 1976, AM J CLIN NUTR, V29, P380, DOI 10.1093/ajcn/29.4.380; OWEN OE, 1969, J CLIN INVEST, V48, P584; PISTERS PWT, 1993, CRIT REV CL LAB SCI, V30, P223, DOI 10.3109/10408369309084669; POLI G, 1985, CLIN EXP IMMUNOL, V62, P128; SHAW JHF, 1987, SURGERY, V101, P181; SHAW JHF, 1985, SURGERY, V97, P557; STIPANUK MH, 1986, ANNU REV NUTR, V6, P179, DOI 10.1146/annurev.nu.06.070186.001143; STRAIN AJ, 1979, INVEST CELL PATHOL, V2, P181; UBUKA T, 1992, Amino Acids (Vienna), V2, P143, DOI 10.1007/BF00806085; ULLUM H, 1995, J EXP MED, V182, P789, DOI 10.1084/jem.182.3.789; VIRU A, 1987, SPORTS MED, V4, P95, DOI 10.2165/00007256-198704020-00003; Warren S, 1932, AM J MED SCI, V184, P610, DOI 10.1097/00000441-193211000-00002; WATERHOUSE C, 1979, CANCER RES, V39, P1968	38	51	52	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1997	11	1					84	92		10.1096/fasebj.11.1.9034170	http://dx.doi.org/10.1096/fasebj.11.1.9034170			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK147	9034170				2022-12-28	WOS:A1997WK14700012
J	Gaffney, BJ				Gaffney, BJ			Origins of biological magnetic resonance	FASEB JOURNAL			English	Article											Gaffney, BJ (corresponding author), FLORIDA STATE UNIV, NATL HIGH MAGNET FIELD LAB, 1800 E PAUL DIRAC DR, TALLAHASSEE, FL 32306 USA.		Gaffney, Betty J/C-9666-2015		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036232] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD JT, 1951, J CHEM PHYS, V19, P507, DOI 10.1063/1.1748264; BENNETT JE, 1956, NATURE, V177, P275, DOI 10.1038/177275a0; BENNETT JE, 1957, PROC R SOC LON SER-A, V240, P67, DOI 10.1098/rspa.1957.0067; BILLETER M, 1989, J MOL BIOL, V206, P677, DOI 10.1016/0022-2836(89)90575-5; BLOCH F, 1946, PHYS REV, V69, P127, DOI 10.1103/PhysRev.69.127; CHAN SI, 1964, J AM CHEM SOC, V86, P4182, DOI 10.1021/ja01073a055; COHN M, 1960, J BIOL CHEM, V235, P3250; COMMONER B, 1956, P NATL ACAD SCI USA, V42, P710, DOI 10.1073/pnas.42.10.710; COOLEY JW, 1965, MATH COMPUT, V19, P297, DOI 10.2307/2003354; CRESPI HL, 1968, SCIENCE, V161, P796, DOI 10.1126/science.161.3843.795; CUTOWSKY HS, 1954, TECH INF B, V1; EATON G, 1996, IN PRESS EPR 50; EHRENBERG A, 1967, WERN GREN CTR INT S, V9; Ernst RR, 1994, B MAGN RESON, V16, P5; FEHER G, 1971, PHOTOCHEM PHOTOBIOL, V14, P373, DOI 10.1111/j.1751-1097.1971.tb06180.x; Freeman R., 1991, BRIEF HIST HIGH RESO, P1; GRIFFITH OH, 1966, P NATL ACAD SCI USA, V55, P8, DOI 10.1073/pnas.55.1.8; HUBBELL WL, 1968, P NATL ACAD SCI USA, V61, P12, DOI 10.1073/pnas.61.1.12; JARDETZKY CD, 1960, J AM CHEM SOC, V82, P222, DOI 10.1021/ja01486a050; JARDETZKY O, 1958, J BIOL CHEM, V233, P383; Jeener J., 1971, AMPERE INT SUMMER SC; KOWALSKY A, 1964, ANNU REV BIOCHEM, V33, P481, DOI 10.1146/annurev.bi.33.070164.002405; LAUTERBUR PC, 1974, PURE APPL CHEM, V40, P149, DOI 10.1351/pac197440010149; LAUTERBUR PC, 1973, NATURE, V242, P190, DOI 10.1038/242190a0; Lebedev O. L., 1959, T KHIM KHIM TEKHNOL, V3, P649; MANASSEN Y, 1989, PHYS REV LETT, V62, P2531, DOI 10.1103/PhysRevLett.62.2531; MARKLEY JL, 1968, SCIENCE, V161, P1249, DOI 10.1126/science.161.3847.1249; McConnell H M, 1970, Q Rev Biophys, V3, P91; MCCONNELL HM, 1956, J CHEM PHYS, V24, P632, DOI 10.1063/1.1742580; MCCONNELL HM, 1958, J CHEM PHYS, V28, P991, DOI 10.1063/1.1744323; MCDONALD CC, 1967, J AM CHEM SOC, V89, P6332, DOI 10.1021/ja01000a061; MOSHER HS, 1964, SCIENCE, V144, P1100, DOI 10.1126/science.144.3622.1100; NAKANISHI K, 1963, TETRAHEDRON LETT, P2161; OGG RA, 1954, DISCUSS FARADAY SOC, P215, DOI 10.1039/df9541700215; OKAMURA MY, 1992, ANNU REV BIOCHEM, V61, P861; PURCELL EM, 1946, PHYS REV, V69, P127; RUGAR D, 1992, NATURE, V360, P563, DOI 10.1038/360563a0; SAUNDERS M, 1957, J AM CHEM SOC, V79, P3289, DOI 10.1021/ja01569a083; SAUNDERS M, 1958, ANN NY ACAD SCI, V70, P870, DOI 10.1111/j.1749-6632.1958.tb35437.x; SJOBERG BM, 1978, J BIOL CHEM, V253, P6863; STONE TJ, 1965, P NATL ACAD SCI USA, V54, P1010, DOI 10.1073/pnas.54.4.1010; TAKEDA M, 1957, J CHEM PHYS, V26, P1346, DOI 10.1063/1.1743528; Volodarsky LB, 1994, SYNTHETIC CHEM STABL; WAUGH JS, 1958, ANN NY ACAD SCI, V70, P900, DOI 10.1111/j.1749-6632.1958.tb35440.x; Wiithrich K., 1995, NMR STRUCTURAL BIOL; WUTHRICH K, 1969, P NATL ACAD SCI USA, V63, P1071, DOI 10.1073/pnas.63.4.1071; ZAVOISKY EK, 1945, THEORET FIZIKI, V15, P253	47	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1996	10	12					1448	1451		10.1096/fasebj.10.12.8903516	http://dx.doi.org/10.1096/fasebj.10.12.8903516			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VP485	8903516				2022-12-28	WOS:A1996VP48500011
J	Zou, XG; Xian, J; Davies, NP; Popov, AV; Bruggemann, M				Zou, XG; Xian, J; Davies, NP; Popov, AV; Bruggemann, M			Dominant expression of a 1.3 Mb human Ig kappa locus replacing mouse light chain production	FASEB JOURNAL			English	Article						locus introduction; transgenesis; expression control; human antibodies	YEAST ARTIFICIAL CHROMOSOMES; SOMATIC HYPERMUTATION; MONOCLONAL-ANTIBODIES; TRANSGENIC MICE; GENE; REGION; HEAVY; REPERTOIRE; CONSTANT	Expression studies of multigene families, such as the immunoglobulin (Ig) loci, are difficult because of their large size and the necessity to introduce germline configured regions into an animal. Antibody diversity from Ig gene miniloci is limited by the number of variable (V) region genes and the need for distal regulatory elements to control expression, Here, we show germline transfer into mice of a 1300 kb human Ig kappa light chain locus on a yeast artificial chromosome that resulted in early DNA rearrangement and highly efficient human light chain expression, The human locus was assembled from a 300 kb authentic region using contig extension by addition of cosmid multimers to supplement the variable gene cluster. This resulted in the addition of about 100 V region genes in germline configuration from different families. In transgenic animals with Ig kappa disruption, this large human kappa locus replaced the endogenous locus, and subsequent down-regulation of Ig lambda light chain contribution Zed to a dominant expression of the rearranged human genes. Contrary to expectation, rather than providing a solely selective advantage for ensuring repertoire formation controlled by the sheer number of introduced genes, the lambda/kappa ratio in serum appears to be the result of competition for early surface Ig expression maintained in the developing B cell.	BABRAHAM INST, DEPT GENET & DEV, DEV IMMUNOL LAB, CAMBRIDGE CB2 4AT, ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute								BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; BRUGGEMANN M, 1991, Methods (Orlando), V2, P159, DOI 10.1016/S1046-2023(05)80216-6; BRUGGEMANN M, 1989, P NATL ACAD SCI USA, V86, P6709, DOI 10.1073/pnas.86.17.6709; COOK GP, 1995, IMMUNOL TODAY, V16, P237, DOI 10.1016/0167-5699(95)80166-9; DAVIES NP, 1993, BIO-TECHNOL, V11, P911, DOI 10.1038/nbt0893-911; DAVIES NP, 1993, NUCLEIC ACIDS RES, V21, P767, DOI 10.1093/nar/21.3.767; DAVIES NP, 1992, NUCLEIC ACIDS RES, V20, P2693, DOI 10.1093/nar/20.11.2693; DAVIES NP, 1996, ANTIBODY ENG PRACTIC, P59; DAVIES NP, 1994, THESIS U CAMBRIDGE; FRIPPIAT JP, 1995, HUM MOL GENET, V4, P983; GREENMAN L, 1994, NEW STATESMAN SOC, V7, P13, DOI 10.1038/ng0594-13; Guthrie C, 1991, GUIDE YEAST GENETICS; HIETER PA, 1980, CELL, V22, P197, DOI 10.1016/0092-8674(80)90168-3; Hogan B, 1994, MANIPULATING MOUSE E; JAKOBOVITS A, 1993, NATURE, V362, P255, DOI 10.1038/362255a0; KLEIN R, 1993, EUR J IMMUNOL, V23, P3248, DOI 10.1002/eji.1830231231; LAMB BT, 1993, NAT GENET, V5, P22, DOI 10.1038/ng0993-22; LONBERG N, 1994, NATURE, V368, P856, DOI 10.1038/368856a0; NEUBERGER MS, 1995, CURR OPIN IMMUNOL, V7, P248, DOI 10.1016/0952-7915(95)80010-7; PECH M, 1985, J MOL BIOL, V183, P291, DOI 10.1016/0022-2836(85)90001-4; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; STORB U, 1989, MOL CELL BIOL, V9, P711, DOI 10.1128/MCB.9.2.711; TAYLOR LD, 1992, NUCLEIC ACIDS RES, V20, P6287, DOI 10.1093/nar/20.23.6287; ZACHAU HG, 1993, GENE, V135, P167, DOI 10.1016/0378-1119(93)90062-8; ZOU XG, 1995, EUR J IMMUNOL, V25, P2154, DOI 10.1002/eji.1830250806	25	19	52	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1996	10	10					1227	1232		10.1096/fasebj.10.10.8751726	http://dx.doi.org/10.1096/fasebj.10.10.8751726			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VD429	8751726				2022-12-28	WOS:A1996VD42900015
J	Kren, BT; Steer, CJ				Kren, BT; Steer, CJ			Liver regeneration .5. Posttranscriptional regulation of gene expression in liver regeneration: Role of mRNA stability	FASEB JOURNAL			English	Review						cell cycle; partial hepatectomy; posttranscriptional regulation	MESSENGER-RNA STABILITY; RAT-LIVER; C-FOS; DIFFERENTIAL REGULATION; DESTABILIZING ELEMENTS; BINDING-PROTEIN; CODING REGION; MOUSE-LIVER; SEQUENCES; POLY(A)	The rentry of hepatocytes and nonparenchymal cells from the normal quiescent G(0) phase into the cell cycle during liver regeneration after 70% partial hepatectomy results in the discrete modulation of mRNA transcripts for many different genes, The modulation of steady-state levels of transcripts for genes involved in hepatocyte growth and replication during liver regeneration indicates that gene expression is regulated not only transcriptionally but also posttranscriptionally. In fact, posttranscriptional control appears to be the primary mechanism of regulating gene expression after the first 3 h after partial hepatectomy, Alteration in transcript stability is a key posttranscriptional regulatory mechanism used by the regenerating liver to modulate the steady-state transcript levels of multiple genes, Even genes that are transcriptionally activated during liver regeneration exhibit posttranscriptional control at the level of transcript stability, Moreover, the abundance of mRNA binding proteins, as well as translational activity and rate of poly(A) tail removal, are modulated and appear to influence transcript stability during liver regeneration, However, alteration of transcript stability is not the sole posttranscriptional mechanism regulating steady-state levels, Posttranscriptional control also occurs at the level of alternative splicing, stabilization of heterogeneous nuclear (hn) RNA, and hnRNA processing, Moreover, the role of nucleocytoplasmic transport of mature mRNA during liver regeneration is still undefined, Thus, during liver regeneration gene expression is regulated at multiple levels after the initial synthesis of hnRNA, By understanding the role of posttranscriptional mechanisms in regulating steady-state transcript levels in an in vivo model of normal growth, we will begin to appreciate its role in the genesis of abnormal growth.	UNIV MINNESOTA, SCH MED, DEPT CELL BIOL & NEUROANAT, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Kren, BT (corresponding author), UNIV MINNESOTA, SCH MED, DEPT MED, BOX 36 UMHC, 516 DELAWARE ST SE, MINNEAPOLIS, MN 55455 USA.				NIDDK NIH HHS [R01 DK44649] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044649] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGELL N, 1994, HEPATOLOGY, V20, P1002, DOI 10.1002/hep.1840200432; ALBRECHT JH, 1994, ARCH BIOCHEM BIOPHYS, V314, P229, DOI 10.1006/abbi.1994.1434; ALBRECHT JH, 1993, AM J PHYSIOL, V265, pG857, DOI 10.1152/ajpgi.1993.265.5.G857; ALONI R, 1992, MOL CELL BIOL, V12, P2203, DOI 10.1128/MCB.12.5.2203; ASTROM J, 1992, J BIOL CHEM, V267, P18154; BABU N, 1993, FASEB J, V7, P702; BACHURSKI CJ, 1994, MOL CELL BIOL, V14, P4076, DOI 10.1128/MCB.14.6.4076; BAKI L, 1994, EUR J BIOCHEM, V225, P797, DOI 10.1111/j.1432-1033.1994.0797b.x; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BELGRADER P, 1994, MOL CELL BIOL, V14, P8219, DOI 10.1128/MCB.14.12.8219; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BONNIEU A, 1988, ONCOGENE RES, V3, P155; BRAWERMAN G, 1991, CRC CRIT REV BIOCH, V10, P1; CAIRO G, 1994, J BIOL CHEM, V269, P6405; CAPUTI M, 1995, NUCLEIC ACIDS RES, V23, P238, DOI 10.1093/nar/23.2.238; CARUCCIO N, 1994, J BIOL CHEM, V269, P31814; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHEW LJ, 1994, MOL ENDOCRINOL, V8, P603, DOI 10.1210/me.8.5.603; CHRIST B, 1994, HEPATOLOGY, V20, P1577, DOI 10.1002/hep.1840200629; DIAMOND RH, 1993, J BIOL CHEM, V268, P15185; Fausto Nelson, 1994, P1059; FERRERO M, 1994, J CELL PHYSIOL, V158, P263, DOI 10.1002/jcp.1041580208; FLODBY P, 1993, EXP CELL RES, V208, P248, DOI 10.1006/excr.1993.1244; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GALLIE DR, 1994, J BIOL CHEM, V269, P17166; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; GOROSPE M, 1994, J BIOL CHEM, V269, P11845; GOUMAZ MO, 1994, AM J PHYSIOL, V266, pE1001, DOI 10.1152/ajpendo.1994.266.6.E1001; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; Harford J., 1994, IRON METABOLISM HLTH, P123; Harford Joe B., 1994, P69; HARGROVE JL, 1993, FASEB J, V7, P1163, DOI 10.1096/fasebj.7.12.8375615; HELPER JE, 1990, ENDOCRINOLOGY, V127, P1550; HOVLAND R, 1995, BIOCHEM J, V310, P193, DOI 10.1042/bj3100193; INGELBRECHT I, 1994, P NATL ACAD SCI USA, V91, P10502, DOI 10.1073/pnas.91.22.10502; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; JOHNSON TR, 1991, P NATL ACAD SCI USA, V88, P5287, DOI 10.1073/pnas.88.12.5287; JOST JP, 1993, P NATL ACAD SCI USA, V90, P4684, DOI 10.1073/pnas.90.10.4684; KNOPP J, 1992, Endocrine Regulations, V26, P67; Kren BT, 1996, AM J PHYSIOL-GASTR L, V270, pG763, DOI 10.1152/ajpgi.1996.270.5.G763; KREN BT, 1993, J CELL BIOL, V123, P707, DOI 10.1083/jcb.123.3.707; KREN BT, 1994, HEPATOLOGY, V19, P1214, DOI 10.1002/hep.1840190520; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; LAVENU A, 1995, MOL CELL BIOL, V15, P4410; LEE CH, 1995, CELL GROWTH DIFFER, V6, P347; LEE SJ, 1993, BIOCHEM J, V293, P137, DOI 10.1042/bj2930137; LEVY JR, 1992, J BIOL CHEM, V267, P25289; LIM SK, 1992, EMBO J, V11, P3271, DOI 10.1002/j.1460-2075.1992.tb05405.x; LUSCHER B, 1985, P NATL ACAD SCI USA, V82, P4389, DOI 10.1073/pnas.82.13.4389; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MALYANKAR UM, 1994, P NATL ACAD SCI USA, V91, P335, DOI 10.1073/pnas.91.1.335; MASON JO, 1988, GENE DEV, V2, P1003, DOI 10.1101/gad.2.8.1003; MILLAND J, 1990, AM J PHYSIOL, V259, pG340, DOI 10.1152/ajpgi.1990.259.3.G340; MILLER AC, 1993, MOL CELL BIOL, V13, P4416, DOI 10.1128/MCB.13.7.4416; MOORE MA, 1988, NUCLEIC ACIDS RES, V16, P2247, DOI 10.1093/nar/16.5.2247; MORELLO D, 1993, ONCOGENE, V8, P1921; MORELLO D, 1990, ONCOGENE, V5, P1511; MUEGGE K, 1993, P NATL ACAD SCI USA, V90, P7054, DOI 10.1073/pnas.90.15.7054; NAMBU S, 1987, JPN J CANCER RES, V78, P695; NESIC D, 1993, MOL CELL BIOL, V13, P3359, DOI 10.1128/MCB.13.6.3359; NISHIZAWA K, 1994, BIOCHEM BIOPH RES CO, V205, P1380, DOI 10.1006/bbrc.1994.2818; NOGUCHI S, 1992, HEPATOLOGY, V15, P88, DOI 10.1002/hep.1840150117; OHH M, 1994, J BIOL CHEM, V269, P30117; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; PANDURO A, 1990, BIOCHEMISTRY-US, V29, P8430, DOI 10.1021/bi00488a033; PROUDFOOT NJ, 1994, CURR BIOL, V4, P359, DOI 10.1016/S0960-9822(00)00080-4; RAY R, 1994, MOL CELL BIOCHEM, V141, P71, DOI 10.1007/BF00935593; ROSA JL, 1992, P NATL ACAD SCI USA, V89, P3746, DOI 10.1073/pnas.89.9.3746; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; ROSS J, 1994, RNA PROCESSING PRACT, V2, P107; SCHEPER W, 1995, MOL CELL BIOL, V15, P235, DOI 10.1128/MCB.15.1.235; SCHIAVI SC, 1994, J BIOL CHEM, V269, P3441; SHEINESS D, 1973, NATURE-NEW BIOL, V241, P265, DOI 10.1038/newbio241265a0; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SIMONET WS, 1989, J BIOL CHEM, V264, P569; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; SUREAU A, 1994, P NATL ACAD SCI USA, V91, P932, DOI 10.1073/pnas.91.3.932; Tanguay RL, 1996, MOL CELL BIOL, V16, P146; THARUN S, 1995, NUCLEIC ACIDS RES, V23, P641, DOI 10.1093/nar/23.4.641; TREMBLEY JH, 1994, CELL GROWTH DIFFER, V5, P99; Tsui LV, 1995, P NATL ACAD SCI USA, V92, P12398, DOI 10.1073/pnas.92.26.12398; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; WAHLE E, 1995, J BIOL CHEM, V270, P2800, DOI 10.1074/jbc.270.6.2800; WAINFAN E, 1992, CANCER RES, V52, pS2071; WELLINGTON CL, 1993, MOL CELL BIOL, V13, P5034, DOI 10.1128/MCB.13.8.5034; WILLIAMS AS, 1994, NUCLEIC ACIDS RES, V22, P4660, DOI 10.1093/nar/22.22.4660; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WUARIN J, 1994, MOL CELL BIOL, V14, P7219, DOI 10.1128/MCB.14.11.7219; ZAMBETTI G, 1990, J CELL PHYSIOL, V144, P175, DOI 10.1002/jcp.1041440123; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	93	55	57	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1996	10	5					559	573		10.1096/fasebj.10.5.8621056	http://dx.doi.org/10.1096/fasebj.10.5.8621056			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UJ055	8621056				2022-12-28	WOS:A1996UJ05500005
J	Chiang, PK; Gordon, RK; Tal, J; Zeng, GC; Doctor, BP; Pardhasaradhi, K; McCann, PP				Chiang, PK; Gordon, RK; Tal, J; Zeng, GC; Doctor, BP; Pardhasaradhi, K; McCann, PP			S-adenosylmethionine and methylation	FASEB JOURNAL			English	Review						AdoMet synthesis; AdoHcy hydrolase; protein methylation	EUKARYOTIC DNA METHYLATION; ADENOSYL-L-METHIONINE; MESSENGER-RNA; GENE-EXPRESSION; CELL-LINES; TERATOCARCINOMA CELLS; CPG DINUCLEOTIDES; ESCHERICHIA-COLI; VIRUS; METHYLTRANSFERASE	S-Adenosylmethionine (AdoMet or SAM) plays a pivotal role as a methyl donor in a myriad of biological and biochemical events, Although it has been claimed that AdoMet itself has therapeutic benefits, it remains to be established whether it can be taken up intact by cells, S-Adenosylhomocysteine (AdoHcy), formed after donation of the methyl group of AdoMet to a methyl acceptor, is then hydrolyzed to adenosine and homocysteine by AdoHey hydrolase. This enzyme has long been a target for inhibition as its blockade can affect methylation of phospholipids, proteins, DNA, RNA, and other small molecules, Protein carboxymethylation may he involved in repair functions of aging proteins, and heat shock proteins are methylated in response to stress. Bacterial chemotaxis involves carboxymethylation and demethylation in receptor-transducer proteins, although a similar role in mammalian cells is unclear. The precise role of phospholipid methylation remains open, DNA methylation is related to mammalian gene activities, somatic inheritance, and cellular differentiation. Activation of some genes has been ascribed to the demethylation of critical mCpG loci, and silencing of some genes may be related to the methylation of specific CpG loci, Viral DNA genomes exist in cells as extrachromosomal units and are generally not methylated, although once integrated into host chromosomes, different patterns of methylation are correlated with altered paradigms of transcriptional activity, Some viral latency may be related to DNA methylation, Cellular factors have been found to interact with methylated DNA sequences, Methylation of mammalian ribosomal RNAs occurs soon after the synthesis of its 47S precursor RNA in the nucleolus before cleavage to smaller fragments. Inhibition of the methylation of rRNA affects its processing to mature 18S and 28S rRNAs, The methylation of 5'-terminal cap plays an important role in mRNA export from the nucleus, efficient translation, and protection of the integrity of mRNAs, Another important function of AdoMet is that it serves as the sole donor of an aminopropyl group that is conjugated with putrescine to form, first, the polyamine spermidine, and then spermine.	UNIFORMED SERV UNIV HLTH SCI, F EDWARD HEBERT SCH MED, DEPT PHARMACOL, BETHESDA, MD 20814 USA; BRITISH BIOTECH INC, ANNAPOLIS, MD 21401 USA	Uniformed Services University of the Health Sciences - USA	Chiang, PK (corresponding author), WALTER REED ARMY MED CTR, WALTER REED ARMY INST RES, WASHINGTON, DC 20307 USA.							AARBAKKE J, 1986, CANCER RES, V46, P5469; AARBAKKE J, 1981, MOL PHARMACOL, V19, P463; ALIX JH, 1986, BIOL METHYLATION DRU, P175; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; ARAKI K, 1990, JPN J CANCER RES, V81, P1265, DOI 10.1111/j.1349-7006.1990.tb02689.x; ARONDEL V, 1993, J BIOL CHEM, V268, P16002; BANERJEE AK, 1980, MICROBIOL REV, V44, P175, DOI 10.1128/MMBR.44.2.175-205.1980; BANGS JD, 1992, J BIOL CHEM, V267, P9805; BANSAL VS, 1985, BIOCHEM BIOPH RES CO, V128, P411, DOI 10.1016/0006-291X(85)91694-8; BEDNARIK DP, 1987, J VIROL, V61, P1253, DOI 10.1128/JVI.61.4.1253-1257.1987; BENHATTAR J, 1988, GENE, V65, P219, DOI 10.1016/0378-1119(88)90458-1; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BORCHARDT RT, 1976, J MED CHEM, V19, P1099, DOI 10.1021/jm00231a004; BOTTIGLIERI T, 1994, ACTA NEUROL SCAND, V89, P19, DOI 10.1111/j.1600-0404.1994.tb05405.x; BROWN PTH, 1989, GENOME, V31, P717, DOI 10.1139/g89-130; CANTONI GL, 1953, J BIOL CHEM, V204, P403; CHIANG PK, 1977, J BIOL CHEM, V252, P4506; CHIANG PK, 1992, J BIOL CHEM, V267, P4988; CHIANG PK, 1985, METHOD PHARMACOL, V6, P127; COLTORTI M, 1990, METHOD FIND EXP CLIN, V12, P69; COOPER DN, 1983, HUM GENET, V64, P315, DOI 10.1007/BF00292363; CROVELL BG, 1993, BEHAV NEURAL BIOL, V59, P186; CSEPANY T, 1990, J BIOL CHEM, V265, P20117; DECLERCQ E, 1987, BIOCHEM PHARMACOL, V36, P2567, DOI 10.1016/0006-2952(87)90533-8; DING JB, 1994, J BIOL CHEM, V269, P16837; DOERFLER W, 1991, ADV VIRUS RES, V39, P89; ELORANTA TO, 1984, BIOCHEM J, V224, P137, DOI 10.1042/bj2240137; GERMAN DC, 1983, J BIOL CHEM, V258, P997; GUENETTE DK, 1992, BIOCHEM J, V283, P699, DOI 10.1042/bj2830699; HAAF T, 1995, PHARMACOL THERAPEUT, V65, P19, DOI 10.1016/0163-7258(94)00053-6; HANSEN RS, 1990, P NATL ACAD SCI USA, V87, P4174, DOI 10.1073/pnas.87.11.4174; HOEBEN RC, 1991, J VIROL, V65, P904, DOI 10.1128/JVI.65.2.904-912.1991; HOFFMAN JL, 1986, BIOCHEMISTRY-US, V25, P4444, DOI 10.1021/bi00363a041; HRYEYNA CA, 1993, PHARMACOL THERAPEUT, V59, P281; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; JANE SM, 1993, MOL CELL BIOL, V13, P3272, DOI 10.1128/MCB.13.6.3272; JANSSON A, 1992, J VIROL, V66, P62, DOI 10.1128/JVI.66.1.62-69.1992; JOHNSON BA, 1985, J BIOL CHEM, V260, P913; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KAGAN BL, 1990, AM J PSYCHIAT, V147, P591; KANAMORI A, 1987, J GEN VIROL, V68, P1485, DOI 10.1099/0022-1317-68-5-1485; KATZ SL, 1994, DNA CELL BIOL, V13, P321, DOI 10.1089/dna.1994.13.321; KITAMURA Y, 1992, P NATL ACAD SCI USA, V89, P5532, DOI 10.1073/pnas.89.12.5532; KODAKI T, 1991, J BIOCHEM-TOKYO, V109, P276; KUMAGAI I, 1982, J BIOL CHEM, V257, P7388; LADINO CA, 1992, J CELL PHYSIOL, V153, P297, DOI 10.1002/jcp.1041530209; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI N, 1992, FEBS LETT, V306, P103, DOI 10.1016/0014-5793(92)80978-P; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; LUBBERT M, 1989, ONCOGENE, V4, P643; MACNAB JCM, 1988, MOL CELL BIOL, V8, P1443, DOI 10.1128/MCB.8.4.1443; MATSUO K, 1993, SOMAT CELL MOLEC GEN, V19, P543, DOI 10.1007/BF01233381; MAYERS DL, 1995, P NATL ACAD SCI USA, V92, P215, DOI 10.1073/pnas.92.1.215; MCKENZIE RC, 1983, FEBS LETT, V164, P244, DOI 10.1016/0014-5793(83)80294-4; MILLER MW, 1994, EMBO J, V13, P1806, DOI 10.1002/j.1460-2075.1994.tb06449.x; MINAROVITS J, 1992, J GEN VIROL, V73, P1687, DOI 10.1099/0022-1317-73-7-1687; MIURA GA, 1985, ANAL BIOCHEM, V147, P217, DOI 10.1016/0003-2697(85)90030-2; MOORE JP, 1984, BIOCHEM J, V221, P675, DOI 10.1042/bj2210675; NAKAGAWA K, 1991, JPN J CANCER RES, V82, P1277, DOI 10.1111/j.1349-7006.1991.tb01793.x; NISHIMURA S, 1974, BIOCHEM BIOPH RES CO, V57, P702, DOI 10.1016/0006-291X(74)90603-2; NIWA O, 1983, CELL, V32, P1105, DOI 10.1016/0092-8674(83)90294-5; PAJARES MA, 1994, BIOCHEM J, V303, P949, DOI 10.1042/bj3030949; PEGG AE, 1992, PHARMACOL THERAPEUT, V56, P359, DOI 10.1016/0163-7258(92)90025-U; PHILLIPS RL, 1994, P NATL ACAD SCI USA, V91, P5222, DOI 10.1073/pnas.91.12.5222; PIEPER RO, 1991, CANCER COMMUN, V3, P241, DOI 10.3727/095535491820873092; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; RAINIER S, 1994, JNCI-J NATL CANCER I, V86, P753, DOI 10.1093/jnci/86.10.753; REDDY R, 1992, PHARMACOL THERAPEUT, V54, P249, DOI 10.1016/0163-7258(92)90002-H; RENBAUM P, 1992, FEBS LETT, V313, P243, DOI 10.1016/0014-5793(92)81201-V; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; ROSL F, 1993, J GEN VIROL, V74, P791, DOI 10.1099/0022-1317-74-5-791; SAKATA SF, 1993, J BIOL CHEM, V268, P13978; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; SARGENT T, 1992, BIOL PSYCHIAT, V32, P1078, DOI 10.1016/0006-3223(92)90188-6; SCHNIERLE BS, 1992, P NATL ACAD SCI USA, V89, P2897, DOI 10.1073/pnas.89.7.2897; SCHORDERET DF, 1992, P NATL ACAD SCI USA, V89, P957, DOI 10.1073/pnas.89.3.957; SELKER EU, 1993, SCIENCE, V262, P1724, DOI 10.1126/science.8259516; SLANY RK, 1994, BIOCHIMIE, V76, P389, DOI 10.1016/0300-9084(94)90113-9; SMITH JD, 1990, BIOCHIM BIOPHYS ACTA, V1047, P290, DOI 10.1016/0005-2760(90)90528-6; STOCK J, 1987, TRENDS BIOCHEM SCI, V12, P371, DOI 10.1016/0968-0004(87)90172-1; TAMAME M, 1983, MOL CELL BIOL, V3, P2287, DOI 10.1128/MCB.3.12.2287; TERNS MP, 1994, SCIENCE, V264, P959, DOI 10.1126/science.8178154; THEOLOGIS A, 1992, CELL, V70, P181, DOI 10.1016/0092-8674(92)90093-R; THOMPSON JP, 1988, J VIROL, V62, P4680, DOI 10.1128/JVI.62.12.4680-4685.1988; TUCK MT, 1992, INT J BIOCHEM, V24, P379, DOI 10.1016/0020-711X(92)90028-Y; VANBUUL CPJJ, 1983, MOL GEN GENET, V189, P475, DOI 10.1007/BF00325912; VANDOREN K, 1990, MOL CELL BIOL, V10, P1769, DOI 10.1128/MCB.10.4.1769; VANNOORT JM, 1986, EUR J BIOCHEM, V160, P557; VANPHI L, 1982, BIOCHEM J, V206, P481, DOI 10.1042/bj2060481; WANG C, 1992, ARCH BIOCHEM BIOPHYS, V297, P169, DOI 10.1016/0003-9861(92)90656-H; WEISSBACH A, 1989, CURR TOP CELL REGUL, V30, P1; WIESMANN WP, 1985, AM J PHYSIOL, V2468, pF43; WOLF SF, 1985, NATURE, V314, P467, DOI 10.1038/314467a0; WOLFL S, 1991, P NATL ACAD SCI USA, V88, P271, DOI 10.1073/pnas.88.1.271; WOLOS JA, 1993, J IMMUNOL, V150, P3264; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; YAMANE HK, 1993, ANNU REV PHARMACOL, V33, P201, DOI 10.1146/annurev.pharmtox.33.1.201; ZHANG XY, 1990, NUCLEIC ACIDS RES, V18, P6253, DOI 10.1093/nar/18.21.6253	99	696	742	5	106	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1996	10	4					471	480		10.1096/fasebj.10.4.8647346	http://dx.doi.org/10.1096/fasebj.10.4.8647346			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UE557	8647346				2022-12-28	WOS:A1996UE55700011
J	ARCHER, S				ARCHER, S			MEASUREMENT OF NITRIC-OXIDE IN BIOLOGICAL MODELS	FASEB JOURNAL			English	Article						NITRIC OXIDE; CHEMILUMINESCENCE ASSAY; DIAZOTIZATION ASSAY; ELECTRON PARAMAGNETIC RESONANCE (EPR); NITROSYL-HEMOGLOBIN	ARTERIAL SMOOTH-MUSCLE; RELAXING FACTOR; GUANYLATE-CYCLASE; ENDOTHELIAL-CELLS; CYCLIC-GMP; ACETYLCHOLINE; RELEASE; CHEMILUMINESCENCE; RELAXATION; EDRF	Nitric oxide (NO) is a small, gaseous, paramagnetic radical with a high affinity for interaction with ferrous hemoproteins such as soluble guanylate cyclase and hemoglobin. Interest in NO measurement increased exponentially with the discovery that NO or a related compound is the endothelium-derived relaxing factor (EDRF). In addition to being a potent endogenous vasodilator, NO has a role in inflammation, thrombosis, immunity, and neurotransmission. Measurement of NO is important as many of its effects (e.g., vasodilatation, inhibition of platelet aggregation) are similar to those of other substances produced by the endothelium, such as prostacyclin. NO is formed in small amounts in vivo and is rapidly destroyed by interaction with oxygen, making measurement difficult. A computerized search of the past five year's literature found NO measurements reported in fewer than 50 of 955 articles dealing with EDRF. Inhibitors of NO synthesis such as the arginine analogs or agents that inactivate NO, such as reduced hemoglobin, are commonly used as specific probes for NO, in vivo and in vitro; however, none of the NO inhibitors is completely specific. The most widely used assays use one of three strategies to detect NO: 1) NO is ''trapped'' by nitroso compounds, or reduced hemoglobin, forming a stable adduct that is detected by electron paramagnetic resonance (EPR) (detection threshold almost-equal-to 1 nmol); 2) NO oxidizes reduced hemoglobin to methemoglobin, which is detected by spectrophotometry (detection threshold almost-equal-to 1 nmol); 3) NO interacts with ozone producing light, ''chemiluminescence'' (detection threshold almost-equal-to 20 pmol). These assays can be performed to exclusively detect NO, or by adding acid and reducing agents to the sample, can measure NO and related oxides of nitrogen such as nitrite. Several new amperometric microelectrode assays offer the potential to measure smaller amounts of NO (10(-20) M), permitting NO measurement in intact issues and from single cells. This review describes the pharmacology and toxicology of NO and reviews the major techniques for measuring NO in biological models.	UNIV MINNESOTA,DEPT MED,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	ARCHER, S (corresponding author), VET ADM MED CTR,111C,1 VET DR,MINNEAPOLIS,MN 55417, USA.		Archer, Stephen L/C-3621-2013		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045735] Funding Source: NIH RePORTER; NHLBI NIH HHS [1R29-HL45735-1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMEZCUA JL, 1989, BRIT J PHARMACOL, V97, P1019; AOKI T, 1990, BIOMED CHROMATOGR, V4, P128, DOI 10.1002/bmc.1130040311; ARCHER SL, 1992, BIOCHEM BIOPH RES CO, V188, P590, DOI 10.1016/0006-291X(92)91097-A; ARCHER SL, 1990, J APPL PHYSIOL, V68, P735, DOI 10.1152/jappl.1990.68.2.735; ARCHER SL, 1991, CIRC RES, V68, P1569, DOI 10.1161/01.RES.68.6.1569; ARROYO CM, 1991, FREE RADICAL RES COM, V14, P145, DOI 10.3109/10715769109094127; Braker W, 1975, MATHESON UNABRIDGED, V5; BRIEN JF, 1991, J PHARMACOL METHOD, V25, P19, DOI 10.1016/0160-5402(91)90019-2; Budvari S., 1989, MERCK INDEX; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; CHEN G, 1988, BRIT J PHARMACOL, V95, P1165, DOI 10.1111/j.1476-5381.1988.tb11752.x; CHEN WZ, 1989, J VASC MED BIOL, V1, P1; CHUNG SJ, 1990, J PHARMACOL EXP THER, V253, P614; COCKS TM, 1991, J CARDIOVASC PHARM, V17, pS159, DOI 10.1097/00005344-199117003-00030; CRAVEN PA, 1978, J BIOL CHEM, V253, P8433; DOWNES MJ, 1976, ANALYST, V101, P742, DOI 10.1039/an9760100742; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; Furchgott RF, 1988, VASODILATATION VASCU, P410; GREENBERG SS, 1990, CIRC RES, V67, P1446, DOI 10.1161/01.RES.67.6.1446; GRUETTER CA, 1979, J CYCLIC NUCL PROT, V5, P211; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; HECKER M, 1990, BIOCHEM BIOPH RES CO, V167, P1037, DOI 10.1016/0006-291X(90)90627-Y; HENRY Y, 1991, EUR BIOPHYS J, V20, P1; HOEFFNER U, 1989, AM J PHYSIOL, V257, pH330, DOI 10.1152/ajpheart.1989.257.1.H330; IGNARRO LJ, 1984, J PHARMACOL EXP THER, V228, P682; IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KASHEF HA, 1988, AM J PHYSIOL, V251, pH808; KELM M, 1988, EUR J PHARMACOL, V155, P317, DOI 10.1016/0014-2999(88)90522-5; KELM M, 1988, BIOCHEM BIOPH RES CO, V154, P237; KOMORI K, 1988, AM J PHYSIOL, V255, pH207, DOI 10.1152/ajpheart.1988.255.1.H207; KONTOS HA, 1990, AM J PHYSIOL, V258, pH1261, DOI 10.1152/ajpheart.1990.258.5.H1261; KOSTIC MM, 1992, CIRC RES, V70, P208, DOI 10.1161/01.RES.70.1.208; LIU MC, 1987, EUR J BIOCHEM, V169, P253, DOI 10.1111/j.1432-1033.1987.tb13605.x; LONG CJ, 1989, LIFE SCI, V45, P1, DOI 10.1016/0024-3205(89)90429-3; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; MAPLES KR, 1991, AM J RESP CELL MOL, V4, P538, DOI 10.1165/ajrcmb/4.6.538; MARTIN W, 1988, BRIT J PHARMACOL, V93, P579, DOI 10.1111/j.1476-5381.1988.tb10313.x; MATSUNAGA K, 1989, J PHARMACOL EXP THER, V248, P687; MENON NK, 1991, J MOL CELL CARDIOL, V23, P389, DOI 10.1016/0022-2828(91)90162-F; MENON NK, 1989, P SOC EXP BIOL MED, V191, P316; MONCADA S, 1991, PHARMACOL REV, V43, P109; Murad F, 1979, Adv Cyclic Nucleotide Res, V11, P175; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; PAI TG, 1987, ANAL BIOCHEM, V166, P150, DOI 10.1016/0003-2697(87)90557-4; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PEACH MJ, 1987, AM J CARDIOL, V59, pA35, DOI 10.1016/0002-9149(87)90174-3; RAPOPORT RM, 1986, CIRC RES, V58, P407, DOI 10.1161/01.RES.58.3.407; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; SCHMIDT HHH, 1988, EUR J PHARMACOL, V154, P212; SCHROR K, 1991, N-S ARCH PHARMACOL, V344, P240, DOI 10.1007/BF00167225; SHIBUKI K, 1990, NEUROSCI RES, V9, P69, DOI 10.1016/0168-0102(90)90048-J; SHIKANO K, 1988, J PHARMACOL EXP THER, V247, P873; THOMAS G, 1992, J PHARMACOL EXP THER, V260, P676; TRACEY WR, 1990, J PHARMACOL EXP THER, V252, P922; WANG QZ, 1991, LIFE SCI, V49, pPL55, DOI 10.1016/0024-3205(91)90251-6; WENNMALM A, 1990, ANAL BIOCHEM, V4, P128; WESTENBERGER U, 1990, FREE RADICAL RES COM, V11, P167, DOI 10.3109/10715769009109680; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; ZAFIRIOU OC, 1980, ANAL CHEM, V52, P1662, DOI 10.1021/ac50061a029	63	822	851	3	67	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB 1	1993	7	2					349	360		10.1096/fasebj.7.2.8440411	http://dx.doi.org/10.1096/fasebj.7.2.8440411			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KN885	8440411				2022-12-28	WOS:A1993KN88500010
J	Kinscherf, R; Claus, R; Wagner, M; Gehrke, C; Kamencic, H; Hou, D; Nauen, O; Schmiedt, W; Kovacs, G; Pill, J; Metz, J; Deigner, HP				Kinscherf, R; Claus, R; Wagner, M; Gehrke, C; Kamencic, H; Hou, D; Nauen, O; Schmiedt, W; Kovacs, G; Pill, J; Metz, J; Deigner, HP			Apoptosis caused by oxidized LDL is manganese superoxide dismutase and p53 dependent	FASEB JOURNAL			English	Article						atherosclerosis; macrophages; glutathione; TNF-alpha; antibodies; immunohistochemistry	LOW-DENSITY-LIPOPROTEIN; TUMOR-NECROSIS-FACTOR; ATHEROSCLEROTIC LESIONS; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; KAPPA-B; MACROPHAGES; PROTEIN; CELLS; CERAMIDE	Oxidized low density lipoprotein (oxLDL) induces apoptosis in human macrophages (M Phi), a significant feature in atherogenesis. We found that induction of apoptosis in M Phi by oxLDL, C-2-ceramide, tumor necrosis factor alpha (TNF-alpha), and hydrogen peroxide (H2O2) was associated with enhanced expression of manganese superoxide dismutase (MnSOD) and p53. Treatment of cells with p53 or MnSOD antisense oligonucleotides prior to stimulation with oxLDL, C-2-ceramide, TNF-alpha, or H2O2 caused an inhibition of the expression of the respective protein together with a marked reduction of apoptosis. Exposure to N-acetylcysteine before treatment with oxLDL, C-2-ceramide, TNF-alpha, or H2O2 reversed a decrease in cellular glutathione concentrations as well as the enhanced production of p53 and MnSOD mRNA and protein. In apoptotic macrophages of human atherosclerotic plaques, colocalization of MnSOD and p53 immunoreactivity was found. These results indicate that in oxLDL-induced apoptosis, a concomitant induction of p53 and MnSOD is critical, and suggest that it is at least in part due to an enhancement of the sphingomyelin/ceramide pathway.	Heidelberg Univ, Inst Pharmaceut Chem, D-69120 Heidelberg, Germany; Heidelberg Univ, Dept Anat & Cell Biol 3, D-69120 Heidelberg, Germany; Heidelberg Univ, Dept Urol, D-69120 Heidelberg, Germany; Dept Cardiothorac & Vasc Surg, D-55101 Mainz, Germany; Boehringer Mannheim, Dept Preclin Res, D-68298 Mannheim, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Deigner, HP (corresponding author), Heidelberg Univ, Inst Pharmaceut Chem, Neuenheimer Feld 364, D-69120 Heidelberg, Germany.		Kinscherf, Ralf/AAV-7164-2021; Claus, Ralf A./Q-4035-2016	Claus, Ralf A./0000-0001-7232-4088				AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; ARES MPS, 1995, ARTERIOSCL THROM VAS, V15, P1584, DOI 10.1161/01.ATV.15.10.1584; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Auge N, 1996, J BIOL CHEM, V271, P19251, DOI 10.1074/jbc.271.32.19251; Bishop MR, 1996, J CLIN ONCOL, V14, P1320, DOI 10.1200/JCO.1996.14.4.1320; Bjorkerud S, 1996, AM J PATHOL, V149, P367; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Claus R, 1996, BIOCHEMISTRY-US, V35, P4911, DOI 10.1021/bi952036n; CORBETT JT, 1989, J BIOCHEM BIOPH METH, V18, P297, DOI 10.1016/0165-022X(89)90039-0; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; GOTOH N, 1993, BIOCHEM J, V296, P151, DOI 10.1042/bj2960151; GRAND RJA, 1995, EXP CELL RES, V218, P439, DOI 10.1006/excr.1995.1177; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Hardwick SJ, 1996, J PATHOL, V179, P294; HARTUNG HP, 1986, LAB INVEST, V55, P209; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; IOTSOVA V, 1995, EUR J CELL BIOL, V68, P122; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; JOSEPH BZ, 1993, INFLAMMATION, V17, P361, DOI 10.1007/BF00918997; Jovinge S, 1996, ARTERIOSCL THROM VAS, V16, P1573, DOI 10.1161/01.ATV.16.12.1573; Keane J, 1997, INFECT IMMUN, V65, P298, DOI 10.1128/IAI.65.1.298-304.1997; KINSCHERF R, 1995, HISTOCHEM CELL BIOL, V104, P295, DOI 10.1007/BF01464325; Kinscherf R, 1997, FEBS LETT, V405, P55, DOI 10.1016/S0014-5793(97)00157-9; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Lotem J, 1996, P NATL ACAD SCI USA, V93, P9166, DOI 10.1073/pnas.93.17.9166; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Nakano T, 1996, CANCER RES, V56, P2771; REID VC, 1993, J PATHOL, V171, P321, DOI 10.1002/path.1711710413; REID VC, 1993, FEBS LETT, V332, P218, DOI 10.1016/0014-5793(93)80635-8; Rosen B, 1996, CARIES RES, V30, P1, DOI 10.1159/000262129; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SATRIANO JA, 1993, J CLIN INVEST, V92, P1564, DOI 10.1172/JCI116737; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SHACKELFORD RE, 1995, J BIOL CHEM, V270, P3475, DOI 10.1074/jbc.270.8.3475; SIES H, 1986, ANGEW CHEM INT EDIT, V25, P1058, DOI 10.1002/anie.198610581; SIMON G, 1994, CHEM-BIOL INTERACT, V91, P217, DOI 10.1016/0009-2797(94)90042-6; Speir E, 1995, SCAND J INFECT DIS, P78; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Warner BB, 1996, AM J PHYSIOL-LUNG C, V271, pL150, DOI 10.1152/ajplung.1996.271.1.L150; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; Yamashita N, 1996, AM J PHYSIOL-HEART C, V271, pH1356, DOI 10.1152/ajpheart.1996.271.4.H1356; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhong WX, 1996, CELL GROWTH DIFFER, V7, P1175	52	124	129	2	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1998	12	6					461	467		10.1096/fasebj.12.6.461	http://dx.doi.org/10.1096/fasebj.12.6.461			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZG118	9535218				2022-12-28	WOS:000072967300007
J	Watanabe, H; Takahashi, R; Zhang, XX; Goto, Y; Hayashi, H; Ando, J; Isshiki, M; Seto, M; Hidaka, H; Niki, I; Ohno, R				Watanabe, H; Takahashi, R; Zhang, XX; Goto, Y; Hayashi, H; Ando, J; Isshiki, M; Seto, M; Hidaka, H; Niki, I; Ohno, R			An essential role of myosin light-chain kinase in the regulation of agonist- and fluid flow-stimulated Ca2+ influx in endothelial cells	FASEB JOURNAL			English	Article						fluid flow; calcium; bradykinin; thapsigargin	SMOOTH-MUSCLE; PROTEIN-KINASE; SHEAR-STRESS; FREE CALCIUM; INHIBITOR; STORES; PHOSPHORYLATION; DEPLETION; PERMEABILITY; MESSENGER	Cytosolic Ca2+ ([Ca2+](i)) plays an important role in endothelial cell signaling. Although it has been suggested that the influx of Ca2+ can be triggered by depletion of intracellular Ca2+ stores, the mechanism (or mechanisms) underlying this phenomenon needs further elaboration. In the present study, involvement of myosin light-chain kinase (MLCK) in the regulation of Ca2+ signaling was investigated in agonist-and fluid flow-stimulated endothelial cells loaded with Ca2+-sensitive dyes. Bradykinin (BK) and thapsigargin caused an increase in [Ca2+](i) followed by a sustained rise due to Ca2+ influx from extracellular space and shifted total myosin light-chain (MLC) from the unphosphorylated to the diphosphorylated form. ML-9 (100 mu M), an inhibitor of MLCK, abolished Ca2+ influx and prevented MLC diphosphorylation in BK-and thapsigargin-treated cells, but did not affect Ca2+ mobilization from internal stores. Fluid flow stimulation (shear stress=5 dynes/cm(2)) increased [Ca2+](i) and enhanced MLC phosphorylation. ML-9 also inhibited Ca2+ response and MLC phosphorylation in fluid flow-stimulated cells. The Ca2+ influx in response to BK was linearly correlated with the diphosphorylation of MLC in ML-9 treated cells. Effects of ML-5 and ML-7, analogs of ML-9, to inhibit Ca2+ influx paralleled their potencies to inhibit MLCK activity. These findings demonstrate that MLCK plays an essential role in regulating the plasmalemmal Ca2+ influx in agonist-and fluid flow-stimulated endothelial cells. This study is the first to report the close relationship between Ca2+ influx and MLC diphosphorylation.	Hamamatsu Univ Sch Med, Hamamatsu, Shizuoka 43131, Japan; Univ Tokyo, Grad Sch Sci, Dept Biomed Engn, Tokyo, Japan; Asahi Chem Ind Co Ltd, Life Sci Ctr, Shizuoka, Japan; Nagoya Univ, Sch Med, Dept Pharmacol, Nagoya, Aichi 466, Japan	Hamamatsu University School of Medicine; University of Tokyo; Nagoya University	Watanabe, H (corresponding author), Hamamatsu Univ Sch Med, 3600 Handa Cho, Hamamatsu, Shizuoka 43131, Japan.	hwat@hama-med.ac.jp						ADAMS DJ, 1989, FASEB J, V3, P2389, DOI 10.1096/fasebj.3.12.2477294; ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; ANDO J, 1988, IN VITRO CELL DEV B, V24, P871; BYRON KL, 1992, J BIOL CHEM, V267, P108; CURRY FE, 1992, FASEB J, V6, P2456, DOI 10.1096/fasebj.6.7.1563597; FLEMING I, 1995, CIRC RES, V76, P522, DOI 10.1161/01.RES.76.4.522; FLETCHER WH, 1986, J BIOL CHEM, V261, P5504; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; Garcia JGN, 1997, AM J RESP CELL MOL, V16, P489, DOI 10.1165/ajrcmb.16.5.9160829; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; IGNARRO LJ, 1993, THROMB HAEMOSTASIS, V70, P148; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; LAMBERT TL, 1986, J BIOL CHEM, V261, P5288; LI QA, 1987, BIOCHEM BIOPH RES CO, V147, P120; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NOLLERT MU, 1990, BIOCHEM BIOPH RES CO, V170, P281, DOI 10.1016/0006-291X(90)91271-S; NORIS M, 1995, CIRC RES, V76, P536, DOI 10.1161/01.RES.76.4.536; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PERSECHINI A, 1986, J BIOL CHEM, V261, P6293; PRASAD ARS, 1993, CIRC RES, V72, P827, DOI 10.1161/01.RES.72.4.827; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SCHILLING WP, 1992, BIOCHEM J, V284, P521, DOI 10.1042/bj2840521; SETO M, 1991, EUR J PHARMACOL, V195, P267, DOI 10.1016/0014-2999(91)90545-2; Seto M, 1996, PFLUG ARCH EUR J PHY, V432, P7, DOI 10.1007/s004240050099; SHEN J, 1992, AM J PHYSIOL, V262, pC384, DOI 10.1152/ajpcell.1992.262.2.C384; Takahashi R, 1997, BIOCHEM BIOPH RES CO, V235, P657, DOI 10.1006/bbrc.1997.6856; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Watanabe H, 1996, BIOCHEM BIOPH RES CO, V225, P777, DOI 10.1006/bbrc.1996.1250; WATANABE H, 1991, AM J PHYSIOL, V260, pH1344, DOI 10.1152/ajpheart.1991.260.4.H1344; WYSOLMERSKI RB, 1991, AM J PHYSIOL, V261, pC32, DOI 10.1152/ajpcell.1991.261.1.C32	33	75	76	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1998	12	3					341	348		10.1096/fasebj.12.3.341	http://dx.doi.org/10.1096/fasebj.12.3.341			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YZ898	9506478				2022-12-28	WOS:000072305500023
J	Leonarduzzi, G; Scavazza, A; Biasi, F; Chiarpotto, E; Camandola, S; Vogl, S; Dargel, R; Poli, G				Leonarduzzi, G; Scavazza, A; Biasi, F; Chiarpotto, E; Camandola, S; Vogl, S; Dargel, R; Poli, G			The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor beta 1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis	FASEB JOURNAL			English	Article						fibrinogenesis; sclerosis; cytokines; aldehydes; Kupffer cell	I GENE-EXPRESSION; RAT-LIVER; CARBON-TETRACHLORIDE; ALDEHYDIC PRODUCTS; CELLS; ATHEROSCLEROSIS; STIMULATION; ACTIVATION; SEPARATION; CIRRHOSIS	An increasing number of reports underscore the frequent association of fibrosclerotic diseases of lung, liver, arterial wall, brain, etc., with the accumulation of oxidatively modified lipids and proteins. A cause-and-effect relationship has been proposed between cellular oxidative damage and increased fibrogenesis based on the fact that experimental treatment with antioxidants either prevents or quenches the fibrotic process. With some peculiarities in the different organs, fibrosclerosis is essentially the result of the interaction of macrophages and extracellular matrix-producing cells. The cross-talk is mediated by fibrogenic cytokines, among which the most important appears to be transforming growth factor beta 1 (TGF-beta 1). This report describes treatment of different types of macrophage, of both human and murine origin, with 4-hydroxy-2,3-nonenal (HNE) a major aldehyde end product of membrane lipid oxidation found consistently to induce both mRNA expression and synthesis of TGF-beta 1. Since increased HNE levels have been demostrated in the cirrhotic liver and in the oxidatively modified low-density human lipoproteins associated with atherosclerosis, the up-regulation of macrophage TGF-beta 1 by HNE appears to be involved in the pathogenesis of these and similar diseases characterized by fibrosclerosis.	UNIV TURIN,DEPT EXPTL MED & ONCOL,SECT GEN PATHOL,I-10125 TURIN,ITALY; CNR,CTR IMMUNOGENET & EXPTL ONCOL,I-10126 TURIN,ITALY; UNIV JENA,INST PATHOL BIOCHEM,D-07740 JENA,GERMANY	University of Turin; Consiglio Nazionale delle Ricerche (CNR); Friedrich Schiller University of Jena			Leonarduzzi, Gabriella/AAA-6575-2019	LEONARDUZZI, Gabriella Marisa/0000-0002-3422-821X				BEDOSSA P, 1994, HEPATOLOGY, V19, P1262, DOI 10.1016/0270-9139(94)90876-1; BELLOMO G, 1996, P 2 INT C LIP OX ATH; CAMANDOLA S, 1997, BIOFACTORS, V9, P1; CARINI R, 1988, ALCOHOL TOXICITY FRE, P61; Davies K.J.A., 1993, FREE RADICALS BASIC, P18; DIANZANI MU, 1993, CRIT REV ONCOL HEMAT, V15, P125, DOI 10.1016/1040-8428(93)90052-6; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; ESTERBAUER H, 1982, BIOCHEM J, V208, P129, DOI 10.1042/bj2080129; Esterbauer H., 1982, FREE RADICAL LIPID P, P101; EYHORN S, 1988, J HEPATOL, V6, P23, DOI 10.1016/S0168-8278(88)80459-8; KASS GEN, 1989, BIOCHEM J, V260, P499, DOI 10.1042/bj2600499; KIM SJ, 1989, J BIOL CHEM, V264, P19373; LIU SL, 1995, HEPATOLOGY, V22, P1474, DOI 10.1016/0270-9139(95)90155-8; Massague J., 1990, REV CELL BIOL, V6, P597; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PAROLA M, 1992, HEPATOLOGY, V16, P1014, DOI 10.1002/hep.1840160426; Parola M, 1996, BIOCHEM BIOPH RES CO, V222, P261, DOI 10.1006/bbrc.1996.0732; PAROLA M, 1993, BIOCHEM BIOPH RES CO, V194, P1044, DOI 10.1006/bbrc.1993.1927; PAROLA M, 1992, FEBS LETT, V308, P267, DOI 10.1016/0014-5793(92)81290-3; POLI G, 1987, CHEM PHYS LIPIDS, V45, P117, DOI 10.1016/0009-3084(87)90063-6; POLI G, 1985, BIOCHEM J, V227, P629, DOI 10.1042/bj2270629; Poli G, 1997, FREE RADICAL BIO MED, V22, P287, DOI 10.1016/S0891-5849(96)00327-9; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; ROSS R, 1993, AM J PATHOL, V143, P987; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; ZIMMERMANN T, 1986, EXP PATHOL-JENA, V30, P109, DOI 10.1016/S0232-1513(86)80069-X	28	235	250	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1997	11	11					851	857		10.1096/fasebj.11.11.9285483	http://dx.doi.org/10.1096/fasebj.11.11.9285483			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XT790	9285483				2022-12-28	WOS:A1997XT79000004
J	Mari, B; Guerin, S; Maulon, L; Belhacene, N; Far, DF; Imbert, V; Rossi, B; Peyron, JF; Auberger, P				Mari, B; Guerin, S; Maulon, L; Belhacene, N; Far, DF; Imbert, V; Rossi, B; Peyron, JF; Auberger, P			Endopeptidase 24.11 (CD10/NEP) is required for phorbol ester-induced growth arrest in Jurkat T cells	FASEB JOURNAL			English	Article						diacylglycerol; protein kinase C; PMA; cellular proliferation; transfectant	PROTEIN-KINASE-C; BOMBESIN-LIKE PEPTIDES; EL4 THYMOMA CELLS; NEUTRAL ENDOPEPTIDASE; SIGNAL-TRANSDUCTION; HUMAN-NEUTROPHILS; LEUKEMIA ANTIGEN; DOWN-REGULATION; FETAL LUNG; WILD-TYPE	Jurkat T cells express a functional endopeptidase 24.11 that is involved in the regulation of T cell activation. We have analyzed the effect of ectopic CD10 expression in mutant Jurkat cell clones that fail to express CD10 and, unlike wild-type cells, are resistant to the growth-inhibitory effects of the protein kinase C activator, PMA. No differences in the expression of the mRNA encoding the alpha, beta, gamma, delta epsilon, and zeta isoforms of PKC were found in parental vs. PMA-resistant Jurkat cells, ruling out the possibility that the defect could be accounted for by an altered expression of one of these isoforms. Phorbol ester-induced growth arrest was not due to apoptosis since PMA failed to trigger DNA fragmentation in parental and mutant Jurkat T cells. CD10 mRNA expression and activity were abrogated in four independent PMA-resistant Jurkat T cell clones compared to parental cells, whereas the activities of several other peptidases were unaffected. Transfection of one mutant clone with a functional endopeptidase 24.11 restored in a significant manner PMA-induced growth arrest in all the clones selected and tested, whereas transfection of an inactive form of endopeptidase 24.11 had no effect, demonstrating that the enzymatic activity of CD10 is critical in the mediation of the PMA growth arrest. The data presented here demonstrate that a functional CD10 is required for PMA-induced growth arrest in Jurkat cells and provide further evidence for a role of endopeptidase 24.11 in the regulation of tumor cell proliferation.	FAC MED,CJF INSERM 9605,F-06107 NICE 02,FRANCE; FAC MED,INSERM U364,F-06107 NICE 02,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			Jean-Francois, Peyron/AAA-9496-2022; AUBERGER, Patrick/G-1491-2013; Mari, Bernard P/F-8960-2013; Peyron, Jean-Francois/M-5682-2016; Imbert, Véronique/I-6093-2016; Mari, Bernard P/D-7445-2015; Mari, Bernard/Q-5832-2019; Mari, Bernard P/GVS-3100-2022	Jean-Francois, Peyron/0000-0001-6113-916X; AUBERGER, Patrick/0000-0002-2481-8275; Mari, Bernard P/0000-0002-0422-9182; Peyron, Jean-Francois/0000-0001-6113-916X; Imbert, Véronique/0000-0003-2103-6718; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182				BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BIEMANN HPN, 1990, MOL CELL BIOL, V10, P2122, DOI 10.1128/MCB.10.5.2122; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVAULT A, 1988, J BIOL CHEM, V263, P4033; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ERDOS EG, 1989, J BIOL CHEM, V264, P14519; ERDOS EG, 1989, FASEB J, V3, P145, DOI 10.1096/fasebj.3.2.2521610; GANJU RK, 1994, J CLIN INVEST, V94, P1784, DOI 10.1172/JCI117526; GAUSE KC, 1993, J BIOL CHEM, V268, P16124; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; Guerin S, 1997, CELL IMMUNOL, V175, P85, DOI 10.1006/cimm.1996.1045; Guerin S, 1997, FASEB J, V11, P376, DOI 10.1096/fasebj.11.5.9141505; HOMAN EC, 1990, J BIOL CHEM, V266, P5676; HOMMA Y, 1986, P NATL ACAD SCI USA, V83, P7316, DOI 10.1073/pnas.83.19.7316; ISAKOV N, 1990, J BIOL CHEM, V265, P2091; ISHIMARU F, 1995, BLOOD, V85, P3199, DOI 10.1182/blood.V85.11.3199.bloodjournal85113199; Ishimaru F, 1996, EXP HEMATOL, V24, P43; JENSEN DE, 1991, ONCOGENE, V6, P1219; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KALLED SL, 1995, EUR J IMMUNOL, V25, P677, DOI 10.1002/eji.1830250308; KEENAN C, 1995, EUR J IMMUNOL, V25, P13, DOI 10.1002/eji.1830250104; KING KA, 1993, J CLIN INVEST, V91, P1969, DOI 10.1172/JCI116417; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LETARTE M, 1988, J EXP MED, V168, P1247, DOI 10.1084/jem.168.4.1247; MARI B, 1992, EMBO J, V11, P3875, DOI 10.1002/j.1460-2075.1992.tb05480.x; MARI B, 1994, J BIOL CHEM, V269, P8517; MARI B, 1994, IMMUNOLOGY, V82, P433; Mari B, 1996, FASEB J, V10, P309, DOI 10.1096/fasebj.10.2.8641564; MEIER KE, 1991, J BIOL CHEM, V266, P1914; MILHIET PE, 1992, BIOCHEM PHARMACOL, V43, P1711, DOI 10.1016/0006-2952(92)90700-S; PAINTER RG, 1988, J BIOL CHEM, V263, P9456; PEYRON JF, 1991, MOL IMMUNOL, V28, P921, DOI 10.1016/0161-5890(91)90177-L; ROQUES BP, 1993, PHARMACOL REV, V45, P87; SALLES G, 1993, P NATL ACAD SCI USA, V90, P7618, DOI 10.1073/pnas.90.16.7618; SALLES G, 1992, BLOOD, V80, P2021; SHIPP MA, 1991, P NATL ACAD SCI USA, V88, P10662, DOI 10.1073/pnas.88.23.10662; SHIPP MA, 1991, BLOOD, V78, P1834; SHIPP MA, 1989, P NATL ACAD SCI USA, V86, P297, DOI 10.1073/pnas.86.1.297; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; SUNDAY ME, 1992, J CLIN INVEST, V90, P2517, DOI 10.1172/JCI116145; TANAKA T, 1993, P NATL ACAD SCI USA, V90, P4586, DOI 10.1073/pnas.90.10.4586; TCHOUWONG KM, 1992, MOL CELL BIOL, V12, P394, DOI 10.1128/MCB.12.1.394; TSUTSUMI A, 1993, J IMMUNOL, V150, P1746; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WERB Z, 1989, J BIOL CHEM, V264, P9111; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1	47	21	21	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1997	11	11					869	879		10.1096/fasebj.11.11.9285485	http://dx.doi.org/10.1096/fasebj.11.11.9285485			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XT790	9285485				2022-12-28	WOS:A1997XT79000006
J	Forman, HJ; Azzi, A				Forman, HJ; Azzi, A			On the virtual existence of superoxide anions in mitochondria: Thoughts regarding its role in pathophysiology	FASEB JOURNAL			English	Editorial Material							HYDROGEN-PEROXIDE; OXIDATIVE DAMAGE; RADICALS; DECAY		UNIV BERN, INST BIOCHEM & MOL BIOL, CH-3012 BERN, SWITZERLAND; UNIV SO CALIF, DEPT MOL PHARMACOL & TOXICOL, LOS ANGELES, CA 90033 USA	University of Bern; University of Southern California				Forman, Henry Jay/0000-0001-5838-2791				AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; CADENAS E, 1980, BIOCHEM J, V188, P31, DOI 10.1042/bj1880031; Cairo G, 1996, FASEB J, V10, P1326, DOI 10.1096/fasebj.10.11.8836047; CORTOPASSI G, 1995, BBA-MOL BASIS DIS, V1271, P171, DOI 10.1016/0925-4439(95)00025-Y; CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927; FORMAN HJ, 1974, BIOCHEM BIOPH RES CO, V60, P1044, DOI 10.1016/0006-291X(74)90418-5; Liu JK, 1996, FASEB J, V10, P1532, DOI 10.1096/fasebj.10.13.8940299; LOSCHEN G, 1974, FEBS LETT, V42, P68, DOI 10.1016/0014-5793(74)80281-4; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SOHAL RS, 1994, FREE RADICAL BIO MED, V16, P621, DOI 10.1016/0891-5849(94)90062-0; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P401, DOI 10.1016/0003-9861(82)90518-5; WANG ED, 1994, J BIOL CHEM, V269, P22463; WINTERBOURN CC, 1978, FEBS LETT, V94, P269, DOI 10.1016/0014-5793(78)80953-3	16	106	106	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1997	11	5					374	375		10.1096/fasebj.11.5.9141504	http://dx.doi.org/10.1096/fasebj.11.5.9141504			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WX156	9141504				2022-12-28	WOS:A1997WX15600010
J	Suchy, FJ; Sippel, CJ; Ananthanarayanan, M				Suchy, FJ; Sippel, CJ; Ananthanarayanan, M			Hepatic canalicular membrane .3. Bile acid transport across the hepatocyte canalicular membrane	FASEB JOURNAL			English	Article						liver; bile canaliculus; taurocholate	DEPENDENT TAUROCHOLATE TRANSPORT; LIVER PLASMA-MEMBRANE; ECTO-ATPASE PROTEIN; RAT-LIVER; SALT TRANSPORT; HEPATOCELLULAR TRANSPORT; P-GLYCOPROTEIN; VESICLES; SYSTEM; GENE	Transport of bile acids across the canalicular membrane of the hepatocyte provides the primary motive force for generation of bile flow and is rate limiting in the vectorial movement of bile acids from blood to bile, Several distinct carriers for bile acids have been defined based on physiological studies in isolated hepatocytes, membrane vesicles, hepatocyte couplets, and the perfused rat liver including membrane potential-driven and ATP-dependent mechanisms, Several groups have isolated and functionally reconstituted a canalicular bile acid transport protein of M(r) similar to 110 kDa. The ATP-dependent mechanism for secretion of monovalent bile acids appears to be mediated by a yet to be identified protein of the ATP binding cassette family of transporters, However, it remains conjectural whether the ATP-dependent and membrane potential-driven components of canalicular bile acid transport are mediated by one or more transport porteins. Bile acid sulfates and glucuronides are substrates for the canalicular multispecific organic anion transporter whose activity has recently been associated with the multidrug resistance-associated protein.-Suchy, F. J., Sippel, C. J., Ananthanarayanan, M. Bile acid transport across the hepatocyte canalicular membrane.	YALE UNIV,SCH MED,DEPT PEDIAT & CELLULAR & MOL PHYSIOL,NEW HAVEN,CT 06520; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110	Yale University; Washington University (WUSTL)					NICHD NIH HHS [HD20632] Funding Source: Medline; NIDDK NIH HHS [DK47084, DK34989] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020632, R37HD020632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034989, R01DK047084] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI Y, 1991, HEPATOLOGY, V14, P655, DOI 10.1016/0270-9139(91)90053-X; ANWER MS, 1985, AM J PHYSIOL, V249, pG479, DOI 10.1152/ajpgi.1985.249.4.G479; BECKER A, 1993, EUR J BIOCHEM, V214, P539, DOI 10.1111/j.1432-1033.1993.tb17952.x; BROWN RS, 1995, P NATL ACAD SCI USA, V92, P5421, DOI 10.1073/pnas.92.12.5421; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; CHILDS S, 1995, CANCER RES, V55, P2029; ELFERINK RPJO, 1995, BBA-REV BIOMEMBRANES, V1241, P215, DOI 10.1016/0304-4157(95)00006-D; HARDISON WGM, 1981, AM J PHYSIOL, V241, pG337, DOI 10.1152/ajpgi.1981.241.4.G337; HARDISON WGM, 1991, HEPATOLOGY, V13, P68, DOI 10.1002/hep.1840130111; HOFMANN A, 1988, LIVER BIOL PATHOBIOL, P599; INOUE M, 1984, J CLIN INVEST, V73, P659, DOI 10.1172/JCI111257; KAST C, 1994, J BIOL CHEM, V269, P5179; KUHN WF, 1988, AM J PHYSIOL, V254, pG732, DOI 10.1152/ajpgi.1988.254.5.G732; LIN SH, 1988, J BIOL CHEM, V263, P12253; LIN SH, 1989, J BIOL CHEM, V264, P14403; Lomri N., 1995, Hepatology, V22, p312A; MARIN JJG, 1995, AM J PHYSIOL-GASTR L, V268, pG685, DOI 10.1152/ajpgi.1995.268.4.G685; MAYER R, 1995, J CELL BIOL, V131, P137, DOI 10.1083/jcb.131.1.137; MEIER PJ, 1984, J BIOL CHEM, V259, P614; MEIER PJ, 1987, BIOCHEM J, V242, P465, DOI 10.1042/bj2420465; MULLER M, 1991, J BIOL CHEM, V266, P18920; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; NISHIDA T, 1992, AM J PHYSIOL, V262, pG629, DOI 10.1152/ajpgi.1992.262.4.G629; NISHIDA T, 1995, HEPATOLOGY, V21, P1058, DOI 10.1016/0270-9139(95)90255-4; NOVAK DA, 1991, AM J PHYSIOL, V260, pG743, DOI 10.1152/ajpgi.1991.260.5.G743; RUETZ S, 1987, J BIOL CHEM, V262, P11324; RUETZ S, 1988, P NATL ACAD SCI USA, V85, P6147, DOI 10.1073/pnas.85.16.6147; SHNEIDER BL, 1993, J BIOL CHEM, V268, P6985; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SIPPEL CJ, 1994, J BIOL CHEM, V269, P19539; SIPPEL CJ, 1994, J BIOL CHEM, V269, P2820; SIPPEL CJ, 1994, HEPATOLOGY, V20, pA205; SIPPEL CJ, 1990, AM J PHYSIOL, V258, pG728, DOI 10.1152/ajpgi.1990.258.5.G728; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; STIEGER B, 1992, BIOCHEM J, V284, P67, DOI 10.1042/bj2840067; STPIERRE MV, 1994, P NATL ACAD SCI USA, V91, P9476, DOI 10.1073/pnas.91.20.9476; SUCHY FJ, 1993, SEMIN LIVER DIS, V13, P235, DOI 10.1055/s-2007-1007352; THOMAS P, 1990, BIOCHIM BIOPHYS ACTA, V1032, P177, DOI 10.1016/0304-419X(90)90003-J; WEINMAN SA, 1989, AM J PHYSIOL, V256, pG826, DOI 10.1152/ajpgi.1989.256.5.G826; WOLTERS H, 1992, J CLIN INVEST, V90, P2321, DOI 10.1172/JCI116120	41	49	50	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1997	11	4					199	205		10.1096/fasebj.11.4.9068608	http://dx.doi.org/10.1096/fasebj.11.4.9068608			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WM850	9068608				2022-12-28	WOS:A1997WM85000001
J	Elferink, RPJO; Tytgat, GNJ; Groen, AK				Elferink, RPJO; Tytgat, GNJ; Groen, AK			The role of mdr2 P-glycoprotein in hepatobiliary lipid transport	FASEB JOURNAL			English	Review						bile; canaliculus; phospholipid; cholesterol; ABC transporters; bile salts; flippase; multidrug resistance	BILE CANALICULAR MEMBRANE; GPI-ANCHORED PROTEINS; PLASMA-MEMBRANE; PHOSPHOLIPID SECRETION; HOMOZYGOUS DISRUPTION; BILIARY CHOLESTEROL; CELL-SURFACE; MDCK CELLS; PHOSPHATIDYLCHOLINE; RAT	The small apical (canalicular) domains of hepatocytes form a luminal meshwork of tubules between adjacent hepatocytes and are the sites of primary bile formation, Organic compounds are transported across this membrane domain against high concentration gradients, It has been recognized hi recent years that the hepatocyte is harnessed,vith a set of canalicular ATP-dependent transport proteins, specialized in this uphill transport, Bile salts, organic anions, cations, and neutral amphipaths are all pumped into the bile via such primary active transporters, Functionally, these transporters resemble ABC transporters overexpressed in cells with the multidrug resistance phenotype. Indeed, those transporters that have been characterized at the molecular level turn out to be new, or already recognized, members of this family, Phospholipid secretion across the canalicular membrane of the mouse is also mediated by a member of this family, mdr2 P-glycoprotein. This was demonstrated by the absence of phospholipid. secretion into bile of slice with a disrupted mdr2 gene and by subsequent demonstration of phospholipid translocation in cells that overexpress this protein, The recognition of mdr2 P-glycoprotein as a phospholipid flippase sheds new Light on the function of P-glycoproteins and is an important step in understanding the mechanism of biliary Lipid secretion.			Elferink, RPJO (corresponding author), UNIV AMSTERDAM, ACAD MED CTR FO116, DEPT GASTROINTESTINAL & LIVER DIS, MEIBERGDREEF 9, NL-1105 AZ AMSTERDAM, NETHERLANDS.							BERR F, 1993, J BIOL CHEM, V268, P3976; BISHOP WR, 1985, CELL, V42, P51, DOI 10.1016/S0092-8674(85)80100-8; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BUSCHMAN E, 1992, J BIOL CHEM, V267, P18093; CAREY MC, 1978, J CLIN INVEST, V61, P998, DOI 10.1172/JCI109025; COHEN DE, 1994, BIOCHEMISTRY-US, V33, P9975, DOI 10.1021/bi00199a021; COHEN DE, 1989, AM J PHYSIOL, V257, pG1, DOI 10.1152/ajpgi.1989.257.1.G1; COLEMAN R, 1992, BIOCHIM BIOPHYS ACTA, V1125, P113, DOI 10.1016/0005-2760(92)90036-U; COLEMAN R, 1989, BIOCHEM J, V258, P17, DOI 10.1042/bj2580017; CRAWFORD JM, 1995, J LIPID RES, V36, P2147; CRAWFORD JM, 1993, HEPATOLOGY, V22, pA316; CURATOLO W, 1987, BIOCHIM BIOPHYS ACTA, V906, P111, DOI 10.1016/0304-4157(87)90008-6; Deleuze JF, 1996, HEPATOLOGY, V23, P904, DOI 10.1002/hep.510230435; DEVAUX PF, 1993, CURR OPIN STRUC BIOL, V3, P489, DOI 10.1016/0959-440X(93)90072-S; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; ELFERINK RPJO, 1995, J CLIN INVEST, V95, P31, DOI 10.1172/JCI117658; Elferink RPJO, 1996, J LIPID RES, V37, P1065; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V284, P278; GROEN AK, 1995, GASTROENTEROLOGY, V109, P1997, DOI 10.1016/0016-5085(95)90768-8; Hauser Helmut, 1994, V40, P167; HEUMAN DM, 1991, GASTROENTEROLOGY, V100, P203, DOI 10.1016/0016-5085(91)90602-H; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; JOHNSON WJ, 1994, J LIPID RES, V35, P563; KAST C, 1994, J BIOL CHEM, V269, P5179; KASURINEN J, 1990, BIOCHEMISTRY-US, V29, P8548, DOI 10.1021/bi00489a007; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KullakUblick GA, 1996, HEPATOLOGY, V23, P1254; LEE GM, 1994, CURR TOP MEMBR, V40, P111, DOI 10.1016/S0070-2161(08)60979-X; LEE SP, 1987, AM J PHYSIOL, V252, pG374, DOI 10.1152/ajpgi.1987.252.3.G374; LISCUM L, 1992, J LIPID RES, V33, P1239; MAUAD TH, 1994, AM J PATHOL, V145, P1237; MONTET JC, 1987, BIOCHIM BIOPHYS ACTA, V918, P1, DOI 10.1016/0005-2760(87)90002-6; Nies AT, 1996, J LIPID RES, V37, P1125; PATTINSON NR, 1985, FEBS LETT, V181, P339, DOI 10.1016/0014-5793(85)80288-X; PATTON GM, 1994, J LIPID RES, V35, P1211; PORTAL I, 1993, AM J PHYSIOL, V264, pG1052, DOI 10.1152/ajpgi.1993.264.6.G1052; PUGLIELLI L, 1994, GASTROENTEROLOGY, V107, P244, DOI 10.1016/0016-5085(94)90083-3; QUENEAU PE, 1994, J HEPATOL, V21, P260, DOI 10.1016/S0168-8278(05)80406-4; RUETZ S, 1995, J BIOL CHEM, V270, P25388, DOI 10.1074/jbc.270.43.25388; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SAGAWA H, 1993, AM J PHYSIOL, V264, pG835, DOI 10.1152/ajpgi.1993.264.5.G835; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SLOTTE JP, 1994, CURR TOP MEMBR, V40, P483, DOI 10.1016/S0070-2161(08)60993-4; SMIT JJM, 1994, LAB INVEST, V71, P638; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SMITH AJ, 1994, FEBS LETT, V354, P263, DOI 10.1016/0014-5793(94)01135-4; SOMJEN GJ, 1983, FEBS LETT, V156, P265, DOI 10.1016/0014-5793(83)80510-9; ULLOA N, 1987, HEPATOLOGY, V7, P235, DOI 10.1002/hep.1840070206; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; VAN MEER G, 1987, TRENDS BIOCHEM SCI, V12, P375, DOI 10.1016/0968-0004(87)90173-3; VANNIEUWKERK CMJ, 1996, IN PRESS GASTROENTER; VANT HOF W, 1994, CURR TOP MEMBR, V40, P539, DOI 10.1016/S0070-2161(08)60995-8; VELARDI ALM, 1991, GASTROENTEROLOGY, V101, P457, DOI 10.1016/0016-5085(91)90025-G; YOUSEF IM, 1976, CAN J BIOCHEM CELL B, V54, P1040, DOI 10.1139/o76-152	59	120	123	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1997	11	1					19	28		10.1096/fasebj.11.1.9034162	http://dx.doi.org/10.1096/fasebj.11.1.9034162			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK147	9034162	Green Submitted			2022-12-28	WOS:A1997WK14700004
J	Probst, JC; Zetzsche, T; Weber, M; Theilemann, P; Skutella, T; Landgraf, R; Jirikowski, GF				Probst, JC; Zetzsche, T; Weber, M; Theilemann, P; Skutella, T; Landgraf, R; Jirikowski, GF			Human intestinal trefoil factor is expressed in human hypothalamus and pituitary: Evidence for a novel neuropeptide	FASEB JOURNAL			English	Article						cloning; immunohistochemistry; peptides; epithelial cell migration	PANCREATIC SPASMOLYTIC POLYPEPTIDE; PS2 GENE; MOUSE ASTROCYTES; RAT; PEPTIDE; PROTEIN; IDENTIFICATION; SECRETION; MIGRATION; STOMACH	Human intestinal trefoil factor, hITF, a secretory polypeptide found mainly in the human gastrointestinal tract, is a member of the newly characterized trefoil factor or P-domain peptide family representing putative growth factors. Here we describe the identification of this gut peptide in the human brain and pituitary. With reverse transcriptase polymerase chain reaction, we were able to isolate and clone the transcript from human hypothalamus. An antibody generated against a synthetic peptide derived from the carboxyl terminus of hITF was used for immunohistochemical studies of appropriate tissue sections. Neurons expressing hITF were identified in two magnocellular hypothalamic nuclei, the paraventricular and periventricular nuclei. hITF polypeptide was also observed in Herring bodies of the neurohypophysis and in secretory cells of the adenohypophysis. Double immunostaining with antigrowth hormone antibody showed partial coexistence in a selected subpopulation of adenohypophysial cells. Localization of hITF in the hypothalamo-neurohypophysial system may suggest a modulatory action on the classic al magnocellular nonapeptides vasopressin and oxytocin, and further indicates an adenohypophysial importance of this peptide. It is likely that hITF represents a novel neuropeptide of yet unknown function.	MAX PLANCK INST PSYCHIAT, INST CLIN, DEPT NEUROENDOCRINOL, D-80804 MUNICH, GERMANY; UNIV JENA, INST ANAT 2, D-6900 JENA, GERMANY	Max Planck Society; Friedrich Schiller University of Jena								ALISON MR, 1994, CELL BIOL INT, V18, P1, DOI 10.1006/cbir.1994.1001; Ausubel FM, 1988, MOL REPROD DEV; CHINERY R, 1995, PEPTIDES, V16, P749, DOI 10.1016/0196-9781(95)00045-L; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNASS A, 1994, J CLIN INVEST, V94, P376, DOI 10.1172/JCI117332; ENGLERBLUM G, 1993, ANAL BIOCHEM, V210, P235, DOI 10.1006/abio.1993.1189; FALLON JH, 1984, SCIENCE, V224, P1107, DOI 10.1126/science.6144184; FRANDSEN EK, 1988, REGUL PEPTIDES, V20, P45, DOI 10.1016/0167-0115(88)90056-0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAJHEDE M, 1993, DIGESTION, V55, P353; HAUSER F, 1993, P NATL ACAD SCI USA, V90, P6961, DOI 10.1073/pnas.90.15.6961; HENRY JA, 1991, BRIT J CANCER, V64, P677, DOI 10.1038/bjc.1991.380; HIROTA M, 1994, BIOCHEM MOL BIOL INT, V33, P515; HIROTA M, 1994, NEUROSCI LETT, V171, P49, DOI 10.1016/0304-3940(94)90601-7; HIROTA M, 1995, BIOCHEM MOL BIOL INT, V35, P1079; HOOSEIN NM, 1989, FEBS LETT, V247, P303, DOI 10.1016/0014-5793(89)81357-2; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JIRIKOWSKI GF, 1989, CELL TISSUE RES, V256, P411; JORGENSEN KD, 1982, REGUL PEPTIDES, V3, P231, DOI 10.1016/0167-0115(82)90128-8; LUQMANI Y, 1989, INT J CANCER, V44, P806, DOI 10.1002/ijc.2910440510; MASHIMO H, 1995, BIOCHEM BIOPH RES CO, V210, P31, DOI 10.1006/bbrc.1995.1623; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MORRISON RS, 1989, ENZYCLOPEDIA NEURO S, V1; PLAYFORD RJ, 1995, GASTROENTEROLOGY, V108, P108, DOI 10.1016/0016-5085(95)90014-4; PODOLSKY DK, 1993, J BIOL CHEM, V268, P6694; POULSOM R, 1993, J CLIN GASTROENTEROL, V17, pS78, DOI 10.1097/00004836-199312001-00016; PROBST JC, 1995, MOL BRAIN RES, V33, P269, DOI 10.1016/0169-328X(95)00137-H; SANDS BE, 1995, J BIOL CHEM, V270, P9353, DOI 10.1074/jbc.270.16.9353; SKUTELLA T, 1994, MOL BRAIN RES, V23, P179, DOI 10.1016/0169-328X(94)90224-0; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; THIM L, 1989, FEBS LETT, V250, P85, DOI 10.1016/0014-5793(89)80690-8; TOMASETTO C, 1990, EMBO J, V9, P407, DOI 10.1002/j.1460-2075.1990.tb08125.x; Vigh-Teichmann I., 1974, Advances Anat Embryol Cell Biol, V50, P1; von Euler US, 1931, J PHYSIOL-LONDON, V72, P74, DOI 10.1113/jphysiol.1931.sp002763; WRIGHT NA, 1993, GUT, V34, P577, DOI 10.1136/gut.34.5.577; WRIGHT NA, 1992, SCAND J GASTROENTERO, V27, P76, DOI 10.3109/00365529209096010	36	40	48	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1996	10	13					1518	1523		10.1096/fasebj.10.13.8940297	http://dx.doi.org/10.1096/fasebj.10.13.8940297			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VU982	8940297				2022-12-28	WOS:A1996VU98200008
J	Fisher, GJ; Voorhees, JJ				Fisher, GJ; Voorhees, JJ			Molecular mechanisms of retinoid actions in skin	FASEB JOURNAL			English	Article						retinoic acid receptors; activator protein-1; keratinocytes	HUMAN EPIDERMAL-KERATINOCYTES; CULTURED HUMAN KERATINOCYTES; BINDING PROTEIN-II; TREATED HUMAN SKIN; ACID RECEPTORS; GROWTH-FACTOR; VITAMIN-A; FIBROBLASTS INVITRO; TOPICAL APPLICATION; GENE-EXPRESSION	For more than 40 years, it has been appreciated that vitamin A is a critical regulator of growth and differentiation of developing and adult mammalian and avian skin. Vitamin A deficiency and hypervitaminosis A cause disruption of normal cellular homeostatic mechanisms, resulting in impairment of skin barrier function, More recent studies demonstrating ah-trans retinoic acid as the major biologically active form of vitamin A, and nuclear retinoid receptors as the major mediators of all-trans retinoic acid actions, have provided exciting new insights into the molecular basis of vitamin A actions, These recent insights have been the driving force for important advances in the many areas of retinoid research made during the past 6 years, Nowhere has this new knowledge been more extensively applied than toward understanding the molecular basis of retinoid physiology and pharmacology in skin, This article will review these recent findings and attempt to synthesize their meaning to provide a view into the mechanisms whereby retinoids participate in regulation of skin function.			Fisher, GJ (corresponding author), UNIV MICHIGAN, DEPT DERMATOL, MED CTR, KRESGE I, R6558, ANN ARBOR, MI 48109 USA.		Voorhees, John/AAM-9966-2020	Voorhees, John/0000-0003-1856-785X	NIADDK NIH HHS [5T32 AM07197-19] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [T32AM007197] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARONSON SA, 1991, ANN NY ACAD SCI, V638, P62, DOI 10.1111/j.1749-6632.1991.tb49018.x; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; Armstrong Robert B., 1994, P545; ASSELINEAU D, 1990, DIFFERENTIATION, V45, P221, DOI 10.1111/j.1432-0436.1990.tb00476.x; ASTROM A, 1991, J BIOL CHEM, V266, P17662; ASTROM A, 1994, J BIOL CHEM, V269, P22334; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; CHAI XY, 1995, J BIOL CHEM, V270, P28408, DOI 10.1074/jbc.270.47.28408; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CHEN S, 1995, J INVEST DERMATOL, V104, P779, DOI 10.1111/1523-1747.ep12606988; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; DAWSON MI, 1995, J MED CHEM, V38, P3368, DOI 10.1021/jm00017a021; DONOVAN M, 1995, J STEROID BIOCHEM, V53, P459, DOI 10.1016/0960-0760(95)00092-E; Duell EA, 1996, J INVEST DERMATOL, V106, P316, DOI 10.1111/1523-1747.ep12342972; DUELL EA, 1992, J CLIN INVEST, V90, P1269, DOI 10.1172/JCI115990; DUELL EA, 1996, IN PRESS J INVEST DE; ELDER JT, 1992, J INVEST DERMATOL, V98, P673, DOI 10.1111/1523-1747.ep12499896; ELDER JT, 1991, J INVEST DERMATOL, V96, P425, DOI 10.1111/1523-1747.ep12469889; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FIORELLA PD, 1994, J BIOL CHEM, V269, P10538; FISHER GJ, 1994, J BIOL CHEM, V269, P20629; FISHER GJ, 1991, J INVEST DERMATOL, V96, P699, DOI 10.1111/1523-1747.ep12470632; FISHER GJ, 1995, J INVEST DERMATOL, V105, P80, DOI 10.1111/1523-1747.ep12313352; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; FUCHS E, 1981, CELL, V25, P617, DOI 10.1016/0092-8674(81)90169-0; FUTORYAN T, 1994, NUTR REV, V52, P299, DOI 10.1111/j.1753-4887.1994.tb01461.x; GENDIMENICO GJ, 1994, J INVEST DERMATOL, V102, P676, DOI 10.1111/1523-1747.ep12374092; GILFIX BM, 1985, J BIOL CHEM, V260, P4026; GREEN H, 1982, MOL CELL BIOL, V2, P1115, DOI 10.1128/MCB.2.9.1115; GRIFFITHS CEM, 1992, J INVEST DERMATOL, V99, P283, DOI 10.1111/1523-1747.ep12616626; GRIFFITHS CEM, 1993, NEW ENGL J MED, V329, P530, DOI 10.1056/NEJM199308193290803; HARDY MH, 1968, J EMBRYOL EXP MORPH, V19, P157; HIROSE T, 1995, BIOCHEM BIOPH RES CO, V211, P83, DOI 10.1006/bbrc.1995.1781; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; HUSMANN M, 1992, BIOCHEM BIOPH RES CO, V187, P1558, DOI 10.1016/0006-291X(92)90480-9; IMAKADO S, 1995, GENE DEV, V9, P317, DOI 10.1101/gad.9.3.317; JETTEN AM, 1990, J INVEST DERMATOL, V95, pS44, DOI 10.1111/1523-1747.ep12505757; JIANG CK, 1993, P NATL ACAD SCI USA, V90, P6786, DOI 10.1073/pnas.90.14.6786; KANG S, 1996, IN PRESS J INVEST DE; KANG SW, 1995, J INVEST DERMATOL, V105, P549, DOI 10.1111/1523-1747.ep12323445; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KLIGMAN LH, 1986, PHOTODERMATOLOGY, V3, P215; KURLANDSKY SB, 1994, J BIOL CHEM, V269, P32821; KURLANDSKY SB, 1996, IN PRESS J BIOL CHEM; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; MAGNALDO T, 1992, DIFFERENTIATION, V49, P39, DOI 10.1111/j.1432-0436.1992.tb00767.x; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1995, GENE DEV, V9, P1033; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; NAPOLI JL, 1993, J NUTR, V123, P362, DOI 10.1093/jn/123.suppl_2.362; NAVARRO JM, 1995, J BIOL CHEM, V270, P21362, DOI 10.1074/jbc.270.36.21362; ONG DE, 1994, NUTR REV, V52, P24, DOI 10.1111/j.1753-4887.1994.tb01383.x; OTTONELLO S, 1993, J BIOL CHEM, V268, P27133; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; POSCH KC, 1992, J BIOL CHEM, V267, P19676; RAFAL ES, 1992, NEW ENGL J MED, V326, P368, DOI 10.1056/NEJM199202063260603; REDDY AP, 1992, BIOCHEM J, V287, P833, DOI 10.1042/bj2870833; REDFERN CPF, 1992, J CELL SCI, V102, P113; REYNOLDS NJ, 1993, J PHARMACOL EXP THER, V266, P1636; ROSENTHAL DS, 1992, J INVEST DERMATOL, V98, P343, DOI 10.1111/1523-1747.ep12499802; ROSENTHAL DS, 1990, J INVEST DERMATOL, V95, P510, DOI 10.1111/1523-1747.ep12504718; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SANQUER S, 1994, ARCH BIOCHEM BIOPHYS, V311, P86, DOI 10.1006/abbi.1994.1212; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHWARTZ E, 1991, J INVEST DERMATOL, V96, P975, DOI 10.1111/1523-1747.ep12476385; SCHWARTZ E, 1994, J INVEST DERMATOL, V102, P241, DOI 10.1111/1523-1747.ep12371770; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; SIEGENTHALER G, 1990, BIOCHEM J, V268, P371, DOI 10.1042/bj2680371; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; TALWAR HS, 1995, J INVEST DERMATOL, V105, P285, DOI 10.1111/1523-1747.ep12318471; TAVAKKOL A, 1992, J INVEST DERMATOL, V99, P146, DOI 10.1111/1523-1747.ep12616781; TAVAKKOL A, 1992, J INVEST DERMATOL, V99, P343, DOI 10.1111/1523-1747.ep12616668; TORMA H, 1987, J INVEST DERMATOL, V88, P398, DOI 10.1111/1523-1747.ep12469726; VAHLQUIST A, 1982, J INVEST DERMATOL, V79, P89, DOI 10.1111/1523-1747.ep12500032; WEISS JS, 1988, JAMA-J AM MED ASSOC, V259, P527, DOI 10.1001/jama.259.4.527; WLASCHEK M, 1994, PHOTOCHEM PHOTOBIOL, V59, P550, DOI 10.1111/j.1751-1097.1994.tb02982.x; XIAO JH, 1995, J BIOL CHEM, V270, P3001, DOI 10.1074/jbc.270.7.3001; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3	87	326	337	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1996	10	9					1002	1013		10.1096/fasebj.10.9.8801161	http://dx.doi.org/10.1096/fasebj.10.9.8801161			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801161	Green Submitted			2022-12-28	WOS:A1996UY93200010
J	Formelli, F; Barua, AB; Olson, JA				Formelli, F; Barua, AB; Olson, JA			Bioactivities of N-(4-hydroxyphenyl) retinamide and retinoyl beta-glucuronide	FASEB JOURNAL			English	Review						4HPR; RAG; beta-glucuronide; cell; differentiation; cancer; toxicity	BREAST-CANCER PATIENTS; MAMMARY EPITHELIAL-CELLS; VITAMIN-A; BIOLOGICAL-ACTIVITY; CHEMOPREVENTIVE AGENTS; METABOLIZING ENZYMES; 13-CIS-RETINOIC ACID; CHEMICAL SYNTHESIS; RATS INVIVO; PHASE-II	N-(4-Hydroxyphenyl) retinamide (4HPR) and retinoyl beta-glucuronide (RAG) are two derivatives of all-trans retinoic acid (RA) that show properties both similar to as well as different from their parent compound, RA. Both retinoids possess the important property of showing much-reduced toxicity relative to RA while maintaining significant biological activity, 4HPR, a synthetic derivative, is active in the prevention and treatment of a variety of neoplasms in animals, and by inducing apoptosis, shows growth inhibitory activity against many human tumor cell types in vitro. In humans, 4HPR reduces the incidence of new occurrences of leukoplakia and is currently being tested as a preventive agent for breast cancer, RAG, a naturally occurring metabolite of RA, effectively stimulates the growth of vitamin A-deficient animals, induces the differentiation of epithelial cells in vivo and in vitro, and is effective in the topical treatment of acne in humans, Unlike RA, RAG is nontoxic when applied to the skin and is nonteratogenic when given orally to rats, Possible mechanisms of action of both compounds are discussed. These two derivatives of retinoids show interesting physiologic effects and potentially beneficial pharmacologic actions.	IOWA STATE UNIV,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011; IST NAZL STUDIO & CURA TUMORI,DIV EXPTL ONCOL B,I-20133 MILAN,ITALY	Iowa State University; Fondazione IRCCS Istituto Nazionale Tumori Milan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039733] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-39733] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALL MD, 1985, BIOCHEM BIOPH RES CO, V128, P7, DOI 10.1016/0006-291X(85)91636-5; BARUA AB, 1985, J LIPID RES, V26, P258; Barua AB, 1996, SYNTHETIC COMMUN, V26, P1355, DOI 10.1080/00397919608003496; BARUA AB, 1988, BIOCHEM J, V252, P415, DOI 10.1042/bj2520415; BARUA AB, 1994, FASEB J, V8, pA444; BARUA AB, 1990, METHOD ENZYMOL, V189, P136; BARUA AB, 1989, BIOCHEM J, V263, P403, DOI 10.1042/bj2630403; BARUA AB, 1986, AM J CLIN NUTR, V43, P481, DOI 10.1093/ajcn/43.4.481; BARUA AB, 1985, J LIPID RES, V26, P1277; BARUA AB, 1989, Patent No. 4855463; BECKER B, 1993, FASEB J, V7, pA304; Becker B, 1996, BIOCHEM J, V314, P249, DOI 10.1042/bj3140249; BECKER B, 1992, FASEB J, V6, pA1660; BERNI R, 1992, FEBS LETT, V308, P43, DOI 10.1016/0014-5793(92)81046-O; BIESALSKI HK, 1993, RETINOIDS, P329; Blaner William S., 1994, P229; BOLLAG W, 1981, ANN NY ACAD SCI, V359, P9, DOI 10.1111/j.1749-6632.1981.tb12733.x; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; BUNK MJ, 1985, CANCER LETT, V26, P319, DOI 10.1016/0304-3835(85)90056-4; COBLEIGH MA, 1993, J CLIN ONCOL, V11, P474, DOI 10.1200/JCO.1993.11.3.474; COENE MC, 1995, C RETINOIDS 95, P86; COHEN LA, 1994, NUTR CANCER, V21, P271, DOI 10.1080/01635589409514325; Dawson Marcia I., 1994, P5; DECENSI A, 1994, JNCI-J NATL CANCER I, V86, P138, DOI 10.1093/jnci/86.2.138; DECENSI A, 1994, J NATL CANCER I, V86, P105, DOI 10.1093/jnci/86.2.105; DELIA D, 1993, CANCER RES, V53, P6036; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; DEPALO G, 1995, J NATL CANCER I, V87, P146, DOI 10.1093/jnci/87.2.146; DEPALO G, 1995, DRUG SAFETY, V13, P245, DOI 10.2165/00002018-199513040-00004; DEW SE, 1993, CANCER RES, V53, P2965; DILLEHAY DL, 1988, J LEUKOCYTE BIOL, V44, P353, DOI 10.1002/jlb.44.5.353; DIVINCI A, 1994, INT J CANCER, V59, P422, DOI 10.1002/ijc.2910590322; DOOSE DR, 1992, J CLIN PHARMACOL, V32, P1089; FONTANA JA, 1987, EXP CELL BIOL, V55, P136; FORMELLI F, 1993, CANCER RES, V53, P5374; FORMELLI F, 1987, MED SCI RES-BIOCHEM, V15, P843; FORMELLI F, 1989, CANCER RES, V49, P6149; FORMELLI F, 1993, J CLIN ONCOL, V11, P2036, DOI 10.1200/JCO.1993.11.10.2036; FORMELLI F, 1991, ANN ONCOL, V2, P446; FORMELLI F, 1993, PROGR RES CLIN APPL, P473; Furr Harold C., 1994, P179; GABOUREL JD, 1990, J TOXICOL-CUTAN OCUL, V9, P251, DOI 10.3109/15569529009036331; GALLUP JM, 1987, P SOC EXP BIOL MED, V186, P269; GANDER RJ, 1978, Patent No. 4108880; GAREWAL HS, 1989, LEUKEMIA RES, V13, P339, DOI 10.1016/0145-2126(89)90071-4; Genchi G, 1996, BBA-GEN SUBJECTS, V1289, P284, DOI 10.1016/0304-4165(95)00168-9; Genchi Giuseppe, 1996, FASEB Journal, V10, pA525; Gravallese EM, 1996, ARTHRITIS RHEUM-US, V39, P1021, DOI 10.1002/art.1780390620; GUNNING DB, 1993, TERATOLOGY, V47, P29, DOI 10.1002/tera.1420470107; GUNNING DB, 1994, J DERMATOL TREAT, V5, P181; HARAOUI B, 1985, IMMUNOPHARMACOLOGY, V7, P90; IGAWA M, 1994, PROSTATE, V24, P299, DOI 10.1002/pros.2990240605; KAISERKUPFER MI, 1986, ARCH OPHTHALMOL-CHIC, V104, P69; KALEMKERIAN GP, 1995, J NATL CANCER I, V87, P1674, DOI 10.1093/jnci/87.22.1674; KELLOFF GJ, 1994, J CELL BIOCHEM, V10, P176; KENEL MF, 1988, TERATOGEN CARCIN MUT, V8, P1, DOI 10.1002/tcm.1770080102; KINGSTON TP, 1986, CLIN EXP DERMATOL, V11, P624, DOI 10.1111/j.1365-2230.1986.tb00520.x; LEWIS KC, 1994, CANCER RES, V54, P4112; LI S, 1996, IN PRESS J CHROMATOG; LUCIA MS, 1995, CANCER RES, V55, P5621; MALPELI G, 1995, EUR J BIOCHEM, V229, P486, DOI 10.1111/j.1432-1033.1995.0486k.x; MARTH C, 1987, INT J CANCER, V40, P840, DOI 10.1002/ijc.2910400623; MARTH C, 1985, J NATL CANCER I, V75, P871, DOI 10.1093/jnci/75.5.871; MCCARTHY DJ, 1989, TOXICOL APPL PHARM, V97, P300, DOI 10.1016/0041-008X(89)90335-9; MCCARTHY DJ, 1987, CANCER RES, V47, P5014; MEHTA RG, 1992, INT J VITAM NUTR RES, V62, P143; MEHTA RG, 1991, EUR J CANCER, V27, P138, DOI 10.1016/0277-5379(91)90471-O; MEHTA RG, 1991, ONCOLOGY, V48, P505; MEYSKENS FL, 1983, INT J CANCER, V32, P295, DOI 10.1002/ijc.2910320306; MODIANO MR, 1990, INVEST NEW DRUG, V8, P317; MOON RC, 1979, CANCER RES, V39, P1339; Moon Richard C., 1994, P573; Nau H., 1994, Vitamin A in health and disease., P615; NAU H, 1993, PROGR RES CLIN APPLI, P599; OLSON JA, 1992, J NUTR, V122, P615, DOI 10.1093/jn/122.suppl_3.615; OLSON JA, 1994, MODERN NUTR HLTH DIS, P178; ORIDATE N, 1995, INT J ONCOL, V7, P433; PANIGOT MJ, 1994, J CARBOHYD CHEM, V13, P303, DOI 10.1080/07328309408009195; PELLEGRINI R, 1995, CELL GROWTH DIFFER, V6, P863; PENG YM, 1989, INT J CANCER, V43, P22, DOI 10.1002/ijc.2910430106; PIENTA KJ, 1993, CANCER RES, V53, P224; POLLARD M, 1991, CANCER LETT, V59, P159, DOI 10.1016/0304-3835(91)90181-G; PONZONI M, 1995, CANCER RES, V55, P853; Ross A. C., 1994, Retinoids: from basic science to clinical applications., P197; SANI BP, 1995, CARCINOGENESIS, V16, P2531, DOI 10.1093/carcin/16.10.2531; SANI BP, 1992, BIOCHEM PHARMACOL, V43, P919, DOI 10.1016/0006-2952(92)90266-L; SASS JO, 1994, BIOCHEM PHARMACOL, V47, P485, DOI 10.1016/0006-2952(94)90179-1; SASS JO, 1995, C RETINOIDS 95, P99; SASS JO, 1995, C RETINOIDS 95, P97; SCHAFFER EM, 1993, J NUTR, V123, P1497, DOI 10.1093/jn/123.9.1497; SHARMA S, 1994, CANCER RES, V54, P5848; SHEALY YF, 1988, J MED CHEM, V31, P190, DOI 10.1021/jm00396a031; SHEIKH MS, 1995, CARCINOGENESIS, V16, P2477, DOI 10.1093/carcin/16.10.2477; Sporn MB, 1994, RETINOIDS BIOL CHEM, P1; SUPINO R, 1996, INT J CANCER, V65, P1; SWANSON BN, 1981, J PHARMACOL EXP THER, V219, P632; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; Takahashi N., 1994, Vitamin A in health and disease., P257; TOBLER A, 1986, J CLIN INVEST, V78, P303, DOI 10.1172/JCI112565; TORMA H, 1991, SKIN PHARMACOL, V4, P246; TORRISI R, 1993, CANCER RES, V53, P4769; TRADATI N, 1994, CANCER LETT, V76, P109, DOI 10.1016/0304-3835(94)90385-9; TRIZNA Z, 1993, ANTICANCER RES, V13, P355; URBACH J, 1994, BIOCHEM J, V299, P459, DOI 10.1042/bj2990459; VILLA ML, 1993, BRIT J CANCER, V68, P845, DOI 10.1038/bjc.1993.443; Wang W., 1996, FASEB Journal, V10, pA524; ZILE MH, 1987, P NATL ACAD SCI USA, V84, P2208, DOI 10.1073/pnas.84.8.2208; 1987, DRUGS FUTURE, V12, P305	108	114	116	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1996	10	9					1014	1024		10.1096/fasebj.10.9.8801162	http://dx.doi.org/10.1096/fasebj.10.9.8801162			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801162				2022-12-28	WOS:A1996UY93200011
J	Fausto, N; Laird, AD; Webber, EM				Fausto, N; Laird, AD; Webber, EM			Liver regeneration .2. Role of growth factors and cytokines in hepatic regeneration	FASEB JOURNAL			English	Review						liver; hepatocyte replication; priming; TGF alpha	MESSENGER-RNA EXPRESSION; FACTOR HEPATOPOIETIN-A; ALPHA TRANSGENIC MICE; PARTIAL-HEPATECTOMY; RAT HEPATOCYTES; CARBON-TETRACHLORIDE; DNA-SYNTHESIS; MOUSE-LIVER; TGF-ALPHA; INDUCTION	During liver regeneration quiescent hepatocytes undergo one or two rounds of replication and then return to a nonproliferative state. Growth factors regulate this process by providing both stimulatory and inhibitory signals for cell proliferation. EGF, TGF alpha, and HGF stimulate DNA synthesis in hepatocytes in vivo and in culture but the sensitivity of cultured hepatocytes to the mitogenic effects of these factors is much higher than that of quiescent hepatocytes in intact livers. We have proposed that after partial hepatectomy, hepatocytes enter a state of replicative competence (''priming'') before they can fully respond to growth factors. The priming step is an initiating event in liver regeneration that involves the activation and DNA binding of NF-kappa B and other transcription factors, which could be induced by TNF or other cytokines. EGF, TGF alpha, and HGF have major effects on liver growth. TGF alpha expression correlates with hepatocyte DNA synthesis during liver development and growth and the constitutive expression of the factor confers proliferative activity to adult hepatocytes in vivo and in culture. The data indicate that the activity of stimulatory and inhibitory growth factors such as TGF beta 1 and activin is low in normal livers but that the expression of both types of factors increase during liver regeneration.	BROWN UNIV, DEPT PATHOL & LAB MED, PROVIDENCE, RI 02912 USA	Brown University				Webber, Eric/0000-0002-6108-6288				AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; ALBRECHT JH, 1993, AM J PHYSIOL, V265, pG857, DOI 10.1152/ajpgi.1993.265.5.G857; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; BARROS EJG, 1995, P NATL ACAD SCI USA, V92, P4412, DOI 10.1073/pnas.92.10.4412; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1534; Bucher N.L.R., 1971, REGENERATION LIVER K; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; DIEHL AM, 1994, AM J PHYSIOL, V267, pC552; EVARTS RP, 1992, MOL CARCINOGEN, V5, P25, DOI 10.1002/mc.2940050107; Fausto N, 1993, Prog Liver Dis, V11, P115; Fausto N, 1991, Prog Growth Factor Res, V3, P219, DOI 10.1016/0955-2235(91)90008-R; Fausto Nelson, 1994, P1059; FITZGERALD MJ, 1995, CELL GROWTH DIFFER, V6, P417; FRANCAVILLA A, 1991, HEPATOLOGY, V14, P665, DOI 10.1016/0270-9139(91)90055-Z; FUJIWARA K, 1993, HEPATOLOGY, V18, P1443, DOI 10.1016/0270-9139(93)90237-H; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; GEBHARDT R, 1991, BIOCHEM BIOPH RES CO, V181, P1201, DOI 10.1016/0006-291X(91)92066-S; GRILLI M, 1993, INT REV CYTOL, V143, P1; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HOUSLEY RM, 1994, J CLIN INVEST, V94, P1764, DOI 10.1172/JCI117524; ISHIKI Y, 1992, HEPATOLOGY, V16, P1227, DOI 10.1016/0270-9139(92)90019-6; ITO N, 1994, BIOCHEM BIOPH RES CO, V198, P25, DOI 10.1006/bbrc.1994.1004; JAKOWLEW SB, 1991, CELL REGUL, V2, P535, DOI 10.1091/mbc.2.7.535; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JIRTLE RL, 1991, J BIOL CHEM, V266, P22444; JONES DE, 1995, AM J PHYSIOL-GASTR L, V268, pG872, DOI 10.1152/ajpgi.1995.268.5.G872; LEE GH, 1989, CANCER RES, V49, P403; LEE GH, 1992, CANCER RES, V52, P5162; LINDROOS PM, 1991, HEPATOLOGY, V13, P743, DOI 10.1002/hep.1840130422; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIU ML, 1994, HEPATOLOGY, V19, P1521; LOYER P, 1994, J BIOL CHEM, V269, P2491; LU XP, 1992, J BIOL CHEM, V267, P2841; MAHER JJ, 1993, J CLIN INVEST, V91, P2244, DOI 10.1172/JCI116451; MARS WM, 1993, AM J PATHOL, V143, P949; MATSUMOTO K, 1993, HEPATOCYTE GROWTH FA, P226; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; MCGOWAN JA, 1986, RES ISOLATED CULTURE, P14; MEAD JE, 1990, CANCER RES, V50, P7023; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; MICHALOPOULOS GK, 1992, HEPATOLOGY, V15, P149, DOI 10.1002/hep.1840150125; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MITAKA T, 1991, HEPATOLOGY, V13, P21, DOI 10.1016/0270-9139(91)90211-D; MITAKA T, 1992, HEPATOLOGY, V16, P440, DOI 10.1002/hep.1840160224; MULLHAUPT B, 1994, J BIOL CHEM, V269, P19667; NOGUCHI S, 1992, HEPATOLOGY, V15, P88, DOI 10.1002/hep.1840150117; NOGUCHI S, 1991, J ENDOCRINOL, V128, P425, DOI 10.1677/joe.0.1280425; RANA B, 1994, MOL CELL BIOL, V14, P5858, DOI 10.1128/MCB.14.9.5858; ROOS F, 1995, AM J PHYSIOL-GASTR L, V268, pG380, DOI 10.1152/ajpgi.1995.268.2.G380; RUSSELL WE, 1993, ENDOCRINOLOGY, V133, P1731, DOI 10.1210/en.133.4.1731; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; SCHIRMACHER P, 1992, HEPATOLOGY, V15, P5, DOI 10.1002/hep.1840150103; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SHIOTA C, 1995, HEPATOLOGY, V21, P106; SHIOTA G, 1994, HEPATOLOGY, V19, P962, DOI 10.1016/0270-9139(94)90297-6; STRAIN AJ, 1993, J ENDOCRINOL, V137, P1, DOI 10.1677/joe.0.1370001; TAKAGI H, 1992, CANCER RES, V52, P5171; TANAHASHI T, 1994, IN VITRO CELL DEV-AN, V30A, P139; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; UEBARA Y, 1995, NATURE, V373, P702; WEBBER EM, 1993, HEPATOLOGY, V18, P1422, DOI 10.1016/0270-9139(93)90234-E; WEBBER EM, 1994, AM J PATHOL, V145, P398; WEBBER EM, 1994, HEPATOLOGY, V19, P489; WESTWICK JK, 1995, J CLIN INVEST, V95, P803, DOI 10.1172/JCI117730; WU JC, 1994, CANCER RES, V54, P5964; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; YASUDA H, 1993, J CLIN INVEST, V92, P1491, DOI 10.1172/JCI116727	68	555	565	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1995	9	15					1527	1536		10.1096/fasebj.9.15.8529831	http://dx.doi.org/10.1096/fasebj.9.15.8529831			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TM761	8529831				2022-12-28	WOS:A1995TM76100005
J	Shen, JH; Kuhn, H; PethoSchramm, A; Chan, L				Shen, JH; Kuhn, H; PethoSchramm, A; Chan, L			Transgenic rabbits with the integrated human 15-lipoxygenase gene driven by a lysozyme promoter: Macrophage-specific expression and variable positional specificity of the transgenic enzyme	FASEB JOURNAL			English	Article						atherosclerosis; eicosanoids; lipoxygenase; transgenic rabbit; 15-HETE	LOW-DENSITY-LIPOPROTEIN; RETICULOCYTE LIPOXYGENASE; ARACHIDONATE 15-LIPOXYGENASE; MAMMALIAN LIPOXYGENASES; ATHEROSCLEROTIC LESIONS; MESSENGER-RNA; OXYGENATION; ACID; LEUKOTRIENES; PURIFICATION	15-lipoxygenase is expressed in foamy macrophages of atherosclerotic lesions and has been implicated in the oxidative modification of low density lipoprotein during early stages of atherogenesis. To establish an animal model of 15-lipoxygenase overexpression, we created transgenic rabbits that express at high level the human 15-lipoxygenase in monocyte-derived macrophages but not in liver, heart, kidney, lung, or other tissues. The expression level of the enzyme in monocyte-derived macrophages is comparable to that of interleukin 4 (IL4)-treated human monocytes, but more than 20-fold higher than in macrophages of normal rabbits. The transgenic enzyme oxygenates linoleic acid to 13S-hydroperoxy-9, 11 (Z,E)-octadecadienoic acid (13-HODE), and arachidonic acid to a mixture of 12S-hydroperoxy-5, 8, 10, 14 (Z,Z,E,Z)-eicosatetraenoic acid (12S-HETE), and 15S-hydroperoxy-5, 8, 11, 14 (Z,Z,Z,E)-eicosatetraenoic acid (15S-HETE). The 12-HETE/15-HETE ratio varied between 0.3 and 5.4, indicating a remarkable variability in the positional specificity of the transgenic enzyme. Macrophages from normal rabbits consistently produced 12S-HETE as the major oxygenation product. 15-lipoxygenase-overexpressing rabbits may be used for further mechanistic studies on the implication of lipoxygenase in atherogenesis; they are also an ideal model for testing the in vivo action of 15-lipoxygenase inhibitors.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; HUMBOLDT UNIV BERLIN,UNIV CLIN CHARITE,INST BIOCHEM,D-10115 BERLIN,GERMANY	Baylor College of Medicine; Baylor College of Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin					NHLBI NIH HHS [HL-51586] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELKNER J, 1993, EUR J BIOCHEM, V213, P251, DOI 10.1111/j.1432-1033.1993.tb17755.x; BELKNER J, 1991, FEBS LETT, V279, P110, DOI 10.1016/0014-5793(91)80263-3; BENZ DJ, 1995, J BIOL CHEM, V270, P5191, DOI 10.1074/jbc.270.10.5191; BIGBY TD, 1987, J IMMUNOL, V138, P1546; BOEYNAEMS JM, 1980, ANAL BIOCHEM, V104, P259, DOI 10.1016/0003-2697(80)90073-1; BONIFER C, 1990, EMBO J, V9, P2843, DOI 10.1002/j.1460-2075.1990.tb07473.x; BRYANT RW, 1982, J BIOL CHEM, V257, P6050; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; FEUSSNER I, 1995, IN PRESS FEBS LETT; FORDHUTCHINSON AW, 1991, EICOSANOIDS, V4, P65; GARDNER HW, 1989, BIOCHIM BIOPHYS ACTA, V1001, P274, DOI 10.1016/0005-2760(89)90111-2; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HARATS D, 1995, J CLIN INVEST, V95, P1335, DOI 10.1172/JCI117784; Kaplow L. S., 1981, MANUAL MACROPHAGE ME, P199; KISHIMOTO T, 1992, INTERLEUKINS MOL BIO, V51; KUHN H, 1990, J BIOL CHEM, V265, P18351; KUHN H, 1994, J EXP MED, V179, P1903, DOI 10.1084/jem.179.6.1903; KUHN H, 1986, ADV ENZYMOL RAMB, V58, P273; KUHN H, 1990, J BIOL CHEM, V265, P16300; KUHN H, 1993, BIOCHIM BIOPHYS ACTA, V1169, P80, DOI 10.1016/0005-2760(93)90085-N; LEHMANN WD, 1994, FREE RADICAL BIO MED, V16, P241, DOI 10.1016/0891-5849(94)90149-X; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MURRAY JJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P514, DOI 10.1016/0003-9861(88)90156-7; NADEL JA, 1991, J CLIN INVEST, V87, P1139, DOI 10.1172/JCI115110; REGDEL D, 1994, BBA-LIPID LIPID MET, V1210, P297, DOI 10.1016/0005-2760(94)90232-1; ROSSMAN MD, 1986, AM REV RESPIR DIS, V133, P292; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SHIMIZU T, 1984, P NATL ACAD SCI-BIOL, V81, P689, DOI 10.1073/pnas.81.3.689; SIEDOW JN, 1991, ANNU REV PLANT PHYS, V42, P145, DOI 10.1146/annurev.pp.42.060191.001045; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V150, P376, DOI 10.1016/0006-291X(88)90531-1; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; SIGAL E, 1990, J BIOL CHEM, V265, P5113; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; TOH H, 1992, PROSTAGLANDINS, V44, P291, DOI 10.1016/0090-6980(92)90004-D; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959	37	53	58	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1995	9	15					1623	1631		10.1096/fasebj.9.15.8529842	http://dx.doi.org/10.1096/fasebj.9.15.8529842			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TM761	8529842				2022-12-28	WOS:A1995TM76100016
J	CASERO, RA; PEGG, AE				CASERO, RA; PEGG, AE			SPERMIDINE SPERMINE N1-ACETYLTRANSFERASE - THE TURNING-POINT IN POLYAMINE METABOLISM	FASEB JOURNAL			English	Article						POLYAMINE BIOSYNTHESIS; POLYAMINE ACETYLATION; MUTAGENESIS STUDIES; BIOSYNTHETIC ENZYMES	ANALOG-INDUCED INCREASES; COLON CARCINOMA-CELLS; HAMSTER OVARY CELLS; BIS(ETHYL)POLYAMINE ANALOGS; ESCHERICHIA-COLI; LUNG-CARCINOMA; TUMOR-CELLS; GROWTH; INDUCTION; N-1-ACETYLTRANSFERASE	Polyamines are thought to have several vital roles in cell growth and differentiation. The highly regulated polyamine metabolic pathway provides cells with the ability to finely control the intracellular concentration of these ubiquitous polycations. Although earlier studies of regulation of polyamine content were concentrated on the biosynthetic reactions, recently the importance of the catabolic processes, particularly the highly regulated acetylation step in polyamine degradation, has become apparent. This work has led to an understanding of how a cell may, in a tightly controlled manner, facilitate the breakdown, excretion, cycling, and/or intracellular shuttling of the polyamines. This myriad of possibilities appears to be regulated initially at a single rate-limiting enzymatic step, the N1-acetylation of spermidine or spermine, by spermidine/spermine N1-acetyltransferase (SSAT). Recent cloning of the human SSAT gene has facilitated a more detailed study of this enzyme. SSAT appears to have a role in the determination of tumor sensitivity to a new class of antineoplastic agents. The further study of SSAT and the associated polyamine metabolism should provide a better understanding of the regulation and function of these cations.	PENN STATE UNIV, MILTON S HERSHEY MED CTR, COLL MED, DEPT PHARMACOL, HERSHEY, PA 17033 USA; PENN STATE UNIV, MILTON S HERSHEY MED CTR, COLL MED, DEPT CELLULAR & MOLEC PHYSIOL, HERSHEY, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	CASERO, RA (corresponding author), JOHNS HOPKINS UNIV, SCH MED, JOHNS HOPKINS ONCOL CTR LABS, BALTIMORE, MD 21231 USA.			Casero, Robert/0000-0001-5653-3306	NCI NIH HHS [CA-47492, CA-51085] Funding Source: Medline; NIGMS NIH HHS [GM-26290] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051085, R29CA047492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026290] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASU HS, 1990, CANCER RES, V50, P3137; BERGERON RJ, 1988, J MED CHEM, V31, P1183, DOI 10.1021/jm00401a019; BERNACKI RJ, 1992, CANCER RES, V52, P2424; BOLKENIUS FN, 1981, INT J BIOCHEM, V13, P287, DOI 10.1016/0020-711X(81)90080-X; BOLKENIUS FN, 1985, BIOCHIM BIOPHYS ACTA, V838, P69, DOI 10.1016/0304-4165(85)90251-X; BYERS TL, 1989, AM J PHYSIOL, V257, pC545, DOI 10.1152/ajpcell.1989.257.3.C545; CARPER SW, 1991, J BIOL CHEM, V266, P12439; CASERO RA, 1992, CANCER RES, V52, P5359; CASERO RA, 1989, CANCER RES, V49, P639; CASERO RA, 1990, BIOCHEM J, V270, P615, DOI 10.1042/bj2700615; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1987, CANCER RES, V47, P3964; CASERO RA, 1991, J BIOL CHEM, V266, P810; CELANO P, 1989, J BIOL CHEM, V264, P8922; CELANO P, 1989, BIOCHEM BIOPH RES CO, V165, P384, DOI 10.1016/0006-291X(89)91082-6; CHANG BK, 1992, CANCER CHEMOTH PHARM, V30, P179, DOI 10.1007/BF00686308; CHANG BK, 1992, CANCER CHEMOTH PHARM, V30, P183, DOI 10.1007/BF00686309; DAVIDSON NE, 1993, IN PRESS CANCER RES; DELLARAGIONE F, 1983, BIOCHEM J, V213, P707, DOI 10.1042/bj2130707; DELLARAGIONE F, 1983, BIOCHEM J, V213, P701, DOI 10.1042/bj2130701; DESIDERIO MA, 1992, HEPATOLOGY, V15, P928, DOI 10.1002/hep.1840150529; EDWARDS ML, 1990, J MED CHEM, V33, P1369, DOI 10.1021/jm00167a014; ERWIN BG, 1984, BIOCHEMISTRY-US, V23, P4250, DOI 10.1021/bi00313a036; FOGELPETROVIC M, 1992, MOL BIOL CELL, V3, pA21; FULLER DJM, 1990, BIOCHEM J, V267, P601, DOI 10.1042/bj2670601; GRAMZINSKI RA, 1990, DIFFERENTIATION, V43, P59, DOI 10.1111/j.1432-0436.1990.tb00430.x; HUANG TL, 1992, J MED CHEM, V35, P2414, DOI 10.1021/jm00091a009; HYVONEN T, 1989, INT J BIOCHEM, V21, P313, DOI 10.1016/0020-711X(89)90189-4; LEI X, 1992, BIOCHEM BIOPH RES CO, V187, P1493, DOI 10.1016/0006-291X(92)90471-V; LIBBY PR, 1991, ARCH BIOCHEM BIOPHYS, V284, P238, DOI 10.1016/0003-9861(91)90291-P; LIBBY PR, 1989, BIOCHEM PHARMACOL, V38, P1435, DOI 10.1016/0006-2952(89)90182-2; LIBBY PR, 1992, ANTICANCER RES, V12, P1083; MATSUI I, 1982, BIOCHEM BIOPH RES CO, V106, P1155, DOI 10.1016/0006-291X(82)91233-5; MATSUI I, 1981, BIOCHIM BIOPHYS ACTA, V675, P373; MATSUI I, 1980, BIOCHEM BIOPH RES CO, V92, P1009, DOI 10.1016/0006-291X(80)90802-5; MATSUIYUASA I, 1992, CHEM-BIOL INTERACT, V81, P233, DOI 10.1016/0009-2797(92)90080-5; MATSUIYUASA I, 1989, ARCH BIOCHEM BIOPHYS, V268, P209, DOI 10.1016/0003-9861(89)90581-X; MORGAN DML, 1987, ESSAYS BIOCHEM, V23, P82; OBAYASHI M, 1992, BIOCHIM BIOPHYS ACTA, V1131, P41, DOI 10.1016/0167-4781(92)90096-I; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1990, BIOCHEM J, V267, P331, DOI 10.1042/bj2670331; PEGG AE, 1989, J BIOL CHEM, V264, P11744; PEGG AE, 1992, IN PRESS BIOCH BIOPH; PERSSON L, 1984, J BIOL CHEM, V259, P2364; PORTER CW, 1991, CANCER RES, V51, P3715; PORTER CW, 1988, ADV ENZYME REGUL, V27, P57; POULIN R, 1991, J BIOL CHEM, V266, P6142; POULIN R, 1993, IN PRESS J BIOL CHEM; SEILER N, 1990, CANCER RES, V50, P5077; SEILER N, 1987, CAN J PHYSIOL PHARM, V65, P2024, DOI 10.1139/y87-317; SESSA A, 1991, CANCER LETT, V56, P159, DOI 10.1016/0304-3835(91)90091-U; SHAPPELL NW, 1992, ANTICANCER RES, V12, P1083; SHINKI T, 1989, EUR J BIOCHEM, V183, P285, DOI 10.1111/j.1432-1033.1989.tb14926.x; SUGIMOTO H, 1991, CIRC SHOCK, V33, P171; TABOR CW, 1968, BIOCHEM BIOPH RES CO, V30, P339, DOI 10.1016/0006-291X(68)90747-X; Wallace H M, 1988, Adv Exp Med Biol, V250, P331; WITTICH RM, 1990, MOL BIOCHEM PARASIT, V38, P13, DOI 10.1016/0166-6851(90)90199-V; XIAO L, 1991, BIOCHEM BIOPH RES CO, V179, P407, DOI 10.1016/0006-291X(91)91385-P	59	400	431	3	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1993	7	8					653	661		10.1096/fasebj.7.8.8500690	http://dx.doi.org/10.1096/fasebj.7.8.8500690			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LE290	8500690				2022-12-28	WOS:A1993LE29000007
J	Conte, MS				Conte, MS			The ideal small arterial substitute: a search for the Holy Grail?	FASEB JOURNAL			English	Editorial Material							SAPHENOUS-VEIN; GRAFTS; MODEL		Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Vasc Surg, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Conte, MS (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Vasc Surg, Boston, MA 02115 USA.							ARORA S, 1996, SURG TECHNOLOGY INT, V4; Cameron A, 1996, NEW ENGL J MED, V334, P216, DOI 10.1056/NEJM199601253340402; COX JL, 1991, PROG CARDIOVASC DIS, V34, P45, DOI 10.1016/0033-0620(91)90019-I; Faggiolo GL, 1995, ADV VASCULAR SURG, V3; FILLINGER MF, 1994, J VASC SURG, V19, P970, DOI 10.1016/S0741-5214(94)70208-X; GIORDANO JM, 1982, SURGERY, V91, P343; HARRIS RW, 1984, ANN SURG, V200, P785, DOI 10.1097/00000658-198412000-00019; KAKUTA T, 1994, CIRCULATION, V89, P2809, DOI 10.1161/01.CIR.89.6.2809; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; LONDREY GL, 1994, J VASC SURG, V20, P451, DOI 10.1016/0741-5214(94)90145-7; MANN MJ, 1995, P NATL ACAD SCI USA, V92, P4502, DOI 10.1073/pnas.92.10.4502; SPARKS CH, 1973, ANN SURG, V177, P293, DOI 10.1097/00000658-197303000-00009; VEITH FJ, 1986, J VASC SURG, V3, P104; WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/science.2934816; WHITTEMORE AD, 1995, VASCULAR SURG	15	179	190	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1998	12	1					43	45		10.1096/fasebj.12.1.43	http://dx.doi.org/10.1096/fasebj.12.1.43			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YR723	9438409				2022-12-28	WOS:000071523800005
J	Wolosker, H; Kline, D; Bian, Y; Blackshaw, S; Cameron, M; Fralich, TJ; Schnaar, RL; Snyder, SH				Wolosker, H; Kline, D; Bian, Y; Blackshaw, S; Cameron, M; Fralich, TJ; Schnaar, RL; Snyder, SH			Molecularly cloned mammalian glucosamine-6-phosphate deaminase localizes to transporting epithelium and lacks oscillin activity	FASEB JOURNAL			English	Article						metabolism; hexosamines; cloning; sialic acid; GNPDA	REPETITIVE CALCIUM TRANSIENTS; ESCHERICHIA-COLI; MOUSE EGG; SIALIC ACIDS; PROTEIN; SPERM; PURIFICATION; GLUCOSAMINE; CELLS	Glucosamine-6-phosphate deaminase (GNPDA) catalyzes the conversion of glucosamine-6-phosphate to fructose-6-phosphate, a reaction that under physiological conditions proceeds to the formation of fructose-6-phosphate. Though first identified in mammalian tissues in 1956, the enzyme has not previously been molecularly characterized in mammalian tissues, although a bacterial GNPDA has been cloned. Recently, a protein displaying similarity to bacterial GNPDA was purified and cloned from sperm extract. It was proposed that this protein was the factor, found in sperm extracts, that causes calcium oscillations in cells; thus, the protein was named 'oscillin.' We demonstrate that oscillin is the mammalian form of glucosamine 6-phosphate deaminase by showing that cloned oscillin has a robust GNPDA activity and can account for all such activity in mammalian tissues extracts. In situ hybridization and immunohistochemistry localize GNPDA selectively to tissues with high energy requirements such as the apical zone of transporting epithelia in the proximal convoluted tubules of the kidney and the small intestine; to neurons (but not glia) and especially to nerve terminals in the brain; and to motile sperm. Recombinant GNPDA and GNPDA purified to homogeneity from hamster sperm fail to elevate intracellular calcium when injected into mouse eggs over a wide range of concentrations under conditions in which sperm extracts elicit pronounced calcium oscillations. Thus, the calcium-releasing or oscillin activity of sperm extracts is due to a substance other than GNPDA. Since GNPDA is the sole enzyme linking hexosamine systems with glycolytic pathways, we propose that it provides a source of energy in the form of phosphosugar derived from the catabolism of hexosamines found in glycoproteins, glycolipids, and sialic acid-containing macromolecules. Evidence that GNPDA can regulate hexosamine stores comes from our observation that transfection of GNPDA into HEK-293 cells reduces cellular levels of sialic acid.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; Kent State Univ, Dept Biol Sci, Kent, OH 44242 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University System of Ohio; Kent State University; Kent State University Kent; Kent State University Salem	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.		Schnaar, Ronald L/S-8967-2016; Kline, Douglas/AAH-5955-2020	Schnaar, Ronald L/0000-0002-7701-5484; Kline, Douglas/0000-0003-2555-6729; Wolosker, Herman/0000-0001-5508-9194	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R15HD031683] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 31683] Funding Source: Medline; NIDA NIH HHS [DA00074] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		CALCAGNO M, 1984, BIOCHIM BIOPHYS ACTA, V787, P165, DOI 10.1016/0167-4838(84)90076-1; COMB DG, 1958, J BIOL CHEM, V232, P807; CORFIELD AP, 1985, BIOCHEM J, V226, P163, DOI 10.1042/bj2260163; DAVIS JS, 1967, ANAL BIOCHEM, V19, P72, DOI 10.1016/0003-2697(67)90135-2; ERIKSSON G, 1984, ARCH BIOCHEM BIOPHYS, V235, P692, DOI 10.1016/0003-9861(84)90245-5; HARLOW E, 1988, ANTIBODIES; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Kay JE, 1996, BIOCHEM J, V314, P361, DOI 10.1042/bj3140361; KLINE D, 1992, DEV BIOL, V149, P80, DOI 10.1016/0012-1606(92)90265-I; KLINE D, 1992, J BIOL CHEM, V267, P17624; LELOIR LF, 1956, BIOCHIM BIOPHYS ACTA, V20, P30; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MEHLMANN LM, 1994, BIOL REPROD, V51, P1088, DOI 10.1095/biolreprod51.6.1088; Parrington J, 1996, NATURE, V379, P364, DOI 10.1038/379364a0; ROGERS MJ, 1988, GENE, V62, P197; ROME LH, 1986, BIOCHEM J, V268, P707; Sambrook J., 1989, MOL CLONING; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Sette C, 1997, DEVELOPMENT, V124, P2267; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stricker SA, 1997, DEV BIOL, V186, P185, DOI 10.1006/dbio.1997.8594; SUZUKI H, 1989, J BIOL CHEM, V264, P1368; SWANN K, 1990, DEVELOPMENT, V110, P1295; Swann K, 1996, Rev Reprod, V1, P33, DOI 10.1530/ror.0.0010033; WEIDANZ JA, 1995, BRIT J HAEMATOL, V91, P72, DOI 10.1111/j.1365-2141.1995.tb05247.x; Weidanz JA, 1996, BRIT J HAEMATOL, V95, P645, DOI 10.1046/j.1365-2141.1996.d01-1955.x; WU II, 1997, MOL REPROD DEV, V46, P176	27	110	112	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1998	12	1					91	99		10.1096/fasebj.12.1.91	http://dx.doi.org/10.1096/fasebj.12.1.91			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YR723	9438414				2022-12-28	WOS:000071523800010
J	Haas, AL; Siepmann, TJ				Haas, AL; Siepmann, TJ			Pathways of ubiquitin conjugation	FASEB JOURNAL			English	Review						protein specificity; eukaryotes; ligation pathway; E2 superfamily; protease	N-END RULE; ATP-DEPENDENT PROTEOLYSIS; CROSS-REACTIVE PROTEIN; ACTIVATING ENZYME E1; SHORT-LIVED PROTEIN; REPAIR GENE RAD6; CARRIER PROTEIN; MULTIUBIQUITIN CHAIN; BINDING-SITES; AUTOGRAPHA-CALIFORNICA	The covalent attachment of the polypeptide ubiquitin to proteins marks them for degradation by the ubiquitin/26S proteasome-dependent degradation pathway, This pathway functions in regulating many fundamental processes required for cell viability. Phylogenetic analysis of ubiquitin sequences reveals greater variability among lower eukaryotes and defines essential residues, many of which are conserved among the three ubiquitin-like proteins known to undergo parallel Ligation pathways, The hierarchical design of the ubiquitin conjugation mechanism provides great flexibility for the divergent evolution of new functions mediated by this posttranslational modification, Within this hierarchy, a single ubiquitin-activating enzyme provides charged intermediates to multiple targeting pathways defined by cognate ubiquitin carrier protein (E2)/ligase (E3) pairs, Sequence analysis of E2 isozymes shows that the E2 superfamily is composed of distinct function-specific families, The apparent lack of E2/E3 specificity suggested in the literature results from the presence of multiple isozymes within many E2 families and erroneous family assignments based on incomplete data sets, Other apparent inconsistencies are explained by interfamily sequence relationships among some E2 isoforms.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Haas, AL (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047426, R01GM034009] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47426, GM34009] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1989, AM J HUM GENET, V44, P534; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Berleth ES, 1996, BIOCHEMISTRY-US, V35, P1664, DOI 10.1021/bi952105y; Betting J, 1996, J BIOL CHEM, V271, P25790, DOI 10.1074/jbc.271.42.25790; BOHNSACK RN, 1993, THESIS MED COLL WISC; BOND U, 1988, J BIOL CHEM, V263, P2384; BURCH TJ, 1994, BIOCHEMISTRY-US, V33, P7300, DOI 10.1021/bi00189a035; CALLIS J, 1995, GENETICS, V139, P921; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; CIECHANOVER A, 1981, P NATL ACAD SCI-BIOL, V78, P761, DOI 10.1073/pnas.78.2.761; COOK WJ, 1992, J BIOL CHEM, V267, P15116; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; Cook WJ, 1997, BIOCHEMISTRY-US, V36, P1621, DOI 10.1021/bi962639e; DCunha J, 1996, J IMMUNOL, V157, P4100; DCUNHA J, 1996, J BIOL CHEM, V93, P211; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; DURNER J, 1995, J BIOL CHEM, V270, P3720, DOI 10.1074/jbc.270.8.3720; ECKER DJ, 1987, J BIOL CHEM, V262, P14213; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOLDSTEIN G, 1975, P NATL ACAD SCI USA, V72, P11, DOI 10.1073/pnas.72.1.11; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1983, BIOCHEMISTRY-US, V22, P4388, DOI 10.1021/bi00288a007; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1987, J BIOL CHEM, V262, P11315; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1987, J BIOL CHEM, V262, P345; HAAS AL, 1991, J BIOL CHEM, V266, P5104; Haas AL, 1996, BIOCHEMISTRY-US, V35, P5385, DOI 10.1021/bi9524981; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HAAS AL, 1988, UBIQUITIN, P173; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HATEBOER C, 1996, J BIOL CHEM, V271, P25906; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; HATFIELD PM, 1992, J BIOL CHEM, V267, P14799; HELLER H, 1990, J BIOL CHEM, V265, P6532; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HODGINS RRW, 1992, J BIOL CHEM, V267, P8807; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P5249, DOI 10.1073/pnas.92.11.5249-a; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P127, DOI 10.1016/0167-4781(91)90001-3; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; KATZUNG DJ, 1997, THESIS MED COLL WISC; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KUMAR S, 1993, BIOCHEM BIOPH RES CO, V195, P393, DOI 10.1006/bbrc.1993.2056; Lazar GA, 1997, PROTEIN SCI, V6, P1167, DOI 10.1002/pro.5560060605; LEYSER HMO, 1993, NATURE, V364, P161, DOI 10.1038/364161a0; LOEB KR, 1992, J BIOL CHEM, V267, P7806; LOEB KR, 1994, MOL CELL BIOL, V14, P8408, DOI 10.1128/MCB.14.12.8408; LOWE J, 1995, J PATHOL, V177, P163, DOI 10.1002/path.1711770210; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; Narasimhan J, 1996, J BIOL CHEM, V271, P324, DOI 10.1074/jbc.271.1.324; Okura T, 1996, J IMMUNOL, V157, P4277; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1994, J BIOL CHEM, V269, P7115; Reilly LM, 1996, VIROLOGY, V218, P243, DOI 10.1006/viro.1996.0185; REISS Y, 1989, J BIOL CHEM, V264, P10378; REISS Y, 1988, J BIOL CHEM, V263, P2693; REISS Y, 1990, J BIOL CHEM, V265, P3685; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; SAITOH H, 1997, IN PRESS TRENDS BIOC; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SHARP PM, 1987, J MOL EVOL, V25, P58, DOI 10.1007/BF02100041; SIMPSON MV, 1953, J BIOL CHEM, V201, P143; SPENCE J, 1995, MOL CELL BIOL, V15, P1266; Stephen AG, 1997, J BIOL CHEM, V272, P10895; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SULLIVAN ML, 1989, P NATL ACAD SCI USA, V86, P9861, DOI 10.1073/pnas.86.24.9861; SULLIVAN ML, 1991, J BIOL CHEM, V266, P23878; SUNG P, 1991, EMBO J, V10, P2187, DOI 10.1002/j.1460-2075.1991.tb07754.x; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; WEFES I, 1995, P NATL ACAD SCI USA, V92, P4982, DOI 10.1073/pnas.92.11.4982; WILKINSON KD, 1981, J BIOL CHEM, V256, P9235; WILKINSON KD, 1990, BIOCHEMISTRY-US, V29, P7373, DOI 10.1021/bi00484a004; WING SS, 1992, J BIOL CHEM, V267, P6495; WOSTMANN C, 1992, FEBS LETT, V308, P54, DOI 10.1016/0014-5793(92)81049-R; Yasugi T, 1996, NUCLEIC ACIDS RES, V24, P2005, DOI 10.1093/nar/24.11.2005; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4	102	262	277	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1997	11	14					1257	1268						12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YN210	9409544				2022-12-28	WOS:000071144100006
J	Sabbioni, MEE; Bovbjerg, DH; Mathew, S; Sikes, C; Lasley, B; Stokes, PE				Sabbioni, MEE; Bovbjerg, DH; Mathew, S; Sikes, C; Lasley, B; Stokes, PE			Classically conditioned changes induced by dexamethasone in healthy men	FASEB JOURNAL			English	Article						hypothalamic-pituitary-adrenal; central nervous system; conditioned stimulus; double-blind	RAT-BRAIN; RESPONSES; ADRENALECTOMY; CHEMOTHERAPY; CANCER; STRESS; LEVEL; BLOOD	Animal research has indicated that the activity of the hypothalamic-pituitary-adrenal axis: can be influenced by classical (Pavlovian) conditioning procedures. To test the hypothesis that alterations in plasma cortisol levels can be conditioned in humans, the present study used a prospective, randomized, double-blind, placebo-controlled design in which a distinctively flavored beverage was paired with p.o. administration of dexamethasone. Twenty-five healthy men were randomly assigned to one of two groups. During the conditioning phase of the study, subjects in the experimental group received three conditioning trials (pairings of a distinctively flavored beverage with a capsule containing 5 mg dexamethasone) separated by 1 wk recovery periods. Subjects in the control group were treated identically, except that the capsule contained a placebo. During the test phase, all subjects underwent a test day (reexposure to the distinctively flavored beverage before receiving a placebo capsule) and a comparison day (no exposure to the beverage or the capsule). Plasma cortisol was assessed repetitively before and after administration of the beverage and capsule, as were possible confounding factors, including: behavioral variables, psychological distress, aversive reactions to the beverage, and expectations of treatment. After reexposure to the beverage and administration of a placebo capsule (conditioned stimuli), the experimental group had significantly higher levels of plasma cortisol than the control group, after controlling for variability in baseline levels of cortisol (F(5,60) = 3.09; P = 0.015) that could not be explained by differences in other study variables. No differences in cortisol levels were found on the comparison day. These results support the study hypothesis that changes in plasma cortisol levels can be classically conditioned in humans by pairing a distinctive beverage with p.o. administration of dexamethasone.	Cornell Univ, Coll Med, Mem Sloan Kettering Canc Ctr, Dept Psychiat, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Neurosci, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Psychiat, New York, NY 10021 USA; Inselspital Bern, Med Div Lory Haus, CH-3010 Bern, Switzerland	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University; University of Bern; University Hospital of Bern	Sabbioni, MEE (corresponding author), Cornell Univ, Coll Med, Mem Sloan Kettering Canc Ctr, Dept Psychiat, New York, NY 10021 USA.		Sabbioni, Marzio/AAC-2606-2020		NIMH NIH HHS [MH45157] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045157] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADER R, 1976, J COMP PHYSIOL PSYCH, V90, P1156, DOI 10.1037/h0077290; Ader R., 1988, EXPT FDN BEHAV MED C, P47; Berson S A, 1971, R I Med J, V54, P501; BOVBJERG D, 1986, PITUITARY FUNCTION I, P252; BOVBJERG DH, 1992, PSYCHOSOM MED, V54, P623, DOI 10.1097/00006842-199211000-00001; CALOGERO AE, 1991, J ENDOCRINOL INVEST, V14, P277, DOI 10.1007/BF03346812; CARELLA MJ, 1993, J CLIN ENDOCR METAB, V76, P1188, DOI 10.1210/jc.76.5.1188; COOVER GD, 1977, J COMP PHYSIOL PSYCH, V91, P716, DOI 10.1037/h0077363; DEROGATIS LR, 1979, JAMA-J AM MED ASSOC, V242, P1504, DOI 10.1001/jama.242.14.1504; EIKELBOOM R, 1982, PSYCHOL REV, V89, P507, DOI 10.1037/0033-295X.89.5.507; Findling J.W, 1991, BASIC CLIN ENDOCRINO, P79; FINK G, 1988, J PHYSIOL-LONDON, V401, P329, DOI 10.1113/jphysiol.1988.sp017165; FRIM DM, 1990, AM J PHYSIOL, V258, pE686, DOI 10.1152/ajpendo.1990.258.4.E686; HALE C, 1989, ENDOCRINOLOGY, V1, P363; HAYNES R C JR, 1990, P1431; HOUK JC, 1988, FASEB J, V2, P97, DOI 10.1096/fasebj.2.2.3277888; KIRSCHBAUM C, 1992, PSYCHOSOM MED, V54, P648, DOI 10.1097/00006842-199211000-00004; LUGER A, 1987, NEW ENGL J MED, V316, P1309, DOI 10.1056/NEJM198705213162105; MEIKLE AW, 1973, STEROIDS, V22, P193, DOI 10.1016/0039-128X(73)90085-8; MILLER AH, 1992, BIOL PSYCHIAT, V32, P850, DOI 10.1016/0006-3223(92)90175-Y; PEDHAZUR EJ, 1991, MEASUREMENT DESIGN A; Ramsay DS, 1997, PSYCHOL REV, V104, P170, DOI 10.1037/0033-295X.104.1.170; SABBIONI MEE, 1992, ANN ONCOL, V3, P393, DOI 10.1093/oxfordjournals.annonc.a058214; SAPOLSKY RM, 1990, NEUROENDOCRINOLOGY, V51, P328, DOI 10.1159/000125357; SPINEDI E, 1991, NEUROENDOCRINOLOGY, V53, P160, DOI 10.1159/000125713; Stanton M. E., 1988, EXPT F BEHAVIORAL ME, P25; STOKES PE, 1984, ARCH GEN PSYCHIAT, V41, P257; TYRELL JB, 1991, BASIC CLIN ENDOCRINO, P323; WOODS SC, 1976, PSYCHOSOM MED, V38, P201, DOI 10.1097/00006842-197605000-00006; WOODS SC, 1980, COMPREHENSIVE HDB BE, V1, P239	30	23	24	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1997	11	14					1291	1296		10.1096/fasebj.11.14.9409548	http://dx.doi.org/10.1096/fasebj.11.14.9409548			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YN210	9409548				2022-12-28	WOS:000071144100010
J	Sohal, RS				Sohal, RS			Mitochondria generate superoxide anion radicals and hydrogen peroxide	FASEB JOURNAL			English	Editorial Material							OXIDATIVE DAMAGE; DROSOPHILA-MELANOGASTER; HEART-MITOCHONDRIA; LIFE-SPAN; DISMUTASE; OVEREXPRESSION; RESTRICTION; CATALASE; RELEASE; MICE		So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA	Southern Methodist University	Sohal, RS (corresponding author), So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA.							AGARWAL S, 1994, P NATL ACAD SCI USA, V91, P12332, DOI 10.1073/pnas.91.25.12332; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Forman HJ, 1997, FASEB J, V11, P374, DOI 10.1096/fasebj.11.5.9141504; GRISWOLD CM, 1993, GENETICS, V134, P781; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; MUSCARI C, 1990, BASIC RES CARDIOL, V85, P172, DOI 10.1007/BF01906970; NOHL H, 1978, EUR J BIOCHEM, V82, P563, DOI 10.1111/j.1432-1033.1978.tb12051.x; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SETO NOL, 1990, P NATL ACAD SCI USA, V87, P4270, DOI 10.1073/pnas.87.11.4270; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; SOHAL RS, 1995, J BIOL CHEM, V270, P15671, DOI 10.1074/jbc.270.26.15671; SOHAL RS, 1994, FREE RADICAL BIO MED, V16, P621, DOI 10.1016/0891-5849(94)90062-0; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P411, DOI 10.1016/0003-9861(82)90519-7; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0	19	44	45	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1997	11	14					1269	1270		10.1096/fasebj.11.14.9409545	http://dx.doi.org/10.1096/fasebj.11.14.9409545			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YN210	9409545				2022-12-28	WOS:000071144100007
J	Gao, WW; Goldman, E				Gao, WW; Goldman, E			Use of sodium dodecyl sulfate-polyacrylamide gel electrophoresis to resolve mRNA and its protein product in one gel	FASEB JOURNAL			English	Article						codon usage in Escherichia coli; rare arginine codons; translational control	T7 RNA-POLYMERASE; ESCHERICHIA-COLI; CLONED GENES; EXPRESSION; SYSTEM	We demonstrate that it is possible to simultaneously resolve both an mRNA and its protein product by electrophoresis in a single SDS-polyacrylamide gel by using double labeling with [P-32]H3PO4 and [S-35]methionine, and an elongated 5% stacking gel atop the 10% resolving gel, The mRNA is resolved in the 5% gel; the protein, as expected, resolves in the 10% gel. Using a T7 expression system, we show that putative mRNA bands in the 5% gel are: 1) labeled only with P-32 and not with S-35; 2) inducible with isopropylthiogalactopyranoside (needed to induce a T7 RNA polymerase gene under control of a lac promoter); 3) synthesized in the presence of rifampicin (T7 RNA polymerase is not inhibited by rifampicin); 4) degraded by base or RNase treatment; and 5) are largely resistant to DNase treatment, The mRNA bands were also evident in samples not treated with rifampicin, We used this technique to confirm previously published results that inhibition of expression by consecutive low-usage AGG arginine codons inserted near the 5' end of a test message in Escherichia coli is at the level of translation.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT MICROBIOL & MOL GENET,NEWARK,NJ 07103; UNIV MED & DENT NEW JERSEY,GRAD SCH BIOMED SCI,DEPT MICROBIOL & MOL GENET,NEWARK,NJ 07103	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center								AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, V2, pCH10; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; GOLDMAN E, 1982, J MOL BIOL, V158, P619, DOI 10.1016/0022-2836(82)90252-2; GOLDMAN E, 1994, METH MOL G, V3, P159; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSENBERG AH, 1993, J BACTERIOL, V175, P716, DOI 10.1128/JB.175.3.716-722.1993; SAMBROOK J, 1989, MOL CLONING LABORATO, pCH7; SIPLEY J, 1993, P NATL ACAD SCI USA, V90, P2315, DOI 10.1073/pnas.90.6.2315; SIPLEY J, 1991, MOL GEN GENET, V230, P376, DOI 10.1007/BF00280294; STUDIER FW, 1973, J MOL BIOL, V79, P237, DOI 10.1016/0022-2836(73)90003-X; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	15	4	4	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1997	11	13					1153	1156		10.1096/fasebj.11.13.9367350	http://dx.doi.org/10.1096/fasebj.11.13.9367350			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367350				2022-12-28	WOS:A1997YE98300013
J	Singal, PK; Iliskovic, N; Li, TM; Kumar, D				Singal, PK; Iliskovic, N; Li, TM; Kumar, D			Adriamycin cardiomyopathy: pathophysiology and prevention	FASEB JOURNAL			English	Review						oxidative stress; heart failure; antioxidants; probucol	DOXORUBICIN-INDUCED CARDIOTOXICITY; OXYGEN RADICAL FORMATION; DNA TOPOISOMERASE-II; ANTI-CANCER AGENTS; BREAST TUMOR-CELLS; LIPID-PEROXIDATION; CARDIAC TOXICITY; HEART-FAILURE; CYTO-TOXICITY; IRON COMPLEX	Current knowledge about adriamycin cardiomyopathy indicates that the major cause of this condition is increased oxidative stress although the drug's antitumor action in patients may involve other mechanisms, Controversies about the different antioxidants in preventing cardiomyopathy likely stem from the fact that antioxidants must be effective in both the lipid and water phases, and the dose must be optimal, in order to be protective, Probucol, an antioxidant and promoter of endogenous antioxidants, is one such agent, Conducting clinical trials with an optimal dose of probucol is the next step and should make this great anticancer drug safer and more efficient in the fight against the cancer.	UNIV MANITOBA,FAC MED,DEPT PHYSIOL,WINNIPEG,MB,CANADA	University of Manitoba	Singal, PK (corresponding author), ST BONIFACE GEN HOSP,RES CTR,INST CARDIOVASC SCI,351 TACHE AVE,ROOM R3022,WINNIPEG,MB R2H 2A6,CANADA.		Kalra, D/H-6661-2019	Kalra, D/0000-0001-5254-4067				ALEGRIA AE, 1989, BIOCHEMISTRY-US, V28, P8653, DOI 10.1021/bi00447a056; ANAND S, 1995, CANCER LETT, V88, P101, DOI 10.1016/0304-3835(94)03617-R; ARCAMONE F, 1969, BIOTECHNOL BIOENG, V11, P1101, DOI 10.1002/bit.260110607; ARENA E, 1972, INT S ADRIAMYCIN, P96; ARENA E, 1974, INT RES COMMUN SYS M, V2, P1053; BACHUR NR, 1979, P NATL ACAD SCI USA, V76, P954, DOI 10.1073/pnas.76.2.954; BACHUR NR, 1982, CANCER RES, V42, P1078; BALANEHRU S, 1992, BIOCHEM INT, V28, P735; BERLIN V, 1981, J BIOL CHEM, V256, P4747; BONADONNA G, 1970, CANCER RES, V30, P2572; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; BRISTOW MR, 1982, HOSP PRACT, V17, P101; BRISTOW MR, 1978, AM J MED, V65, P823, DOI 10.1016/0002-9343(78)90802-1; BRISTOW MR, 1981, AM HEART J, V102, P709, DOI 10.1016/0002-8703(81)90096-X; BRISTOW MR, 1980, J CARDIOVASC PHARM, V2, P487, DOI 10.1097/00005344-198009000-00002; BUJA LM, 1973, CANCER-AM CANCER SOC, V32, P771, DOI 10.1002/1097-0142(197310)32:4<771::AID-CNCR2820320407>3.0.CO;2-A; CAPRANICO G, 1989, CHEM-BIOL INTERACT, V72, P113, DOI 10.1016/0009-2797(89)90022-7; Cece R, 1996, LAB INVEST, V75, P601; CERVANTES A, 1988, CANCER LETT, V41, P169, DOI 10.1016/0304-3835(88)90113-9; CHALCROFT SC, 1973, PATHOLOGY, V5, P99, DOI 10.3109/00313027309060824; COSTA L, 1988, BIOCHEM BIOPH RES CO, V153, P275, DOI 10.1016/S0006-291X(88)81218-X; DEFFIE AM, 1989, CANCER RES, V49, P58; DIMARCO A, 1969, CANCER CHEMOTH REP 1, V53, P33; DOROSHOW JH, 1983, CANCER RES, V43, P460; DOROSHOW JH, 1979, RES COMMUN CHEM PATH, V26, P285; ELIOT H, 1984, BIOCHEMISTRY-US, V23, P928, DOI 10.1021/bi00300a021; GILLADOGA AC, 1976, CANCER, V37, P1070, DOI 10.1002/1097-0142(197602)37:2+<1070::AID-CNCR2820370814>3.0.CO;2-6; GOSALVEZ M, 1979, CANCER RES, V39, P257; GRAVES DE, 1983, BIOCHEMISTRY-US, V22, P3941, DOI 10.1021/bi00285a033; HERMAN E, 1971, PHARMACOLOGY, V6, P230, DOI 10.1159/000136248; HERMAN EH, 1981, CANCER RES, V41, P3436; HERMANSEN K, 1986, ACTA PHARMACOL TOX, V58, P31; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; Iliskovic N, 1997, AM J PATHOL, V150, P727; JONES SM, 1990, CARDIOVASC RES, V24, P834, DOI 10.1093/cvr/24.10.834; KALYANARAMAN B, 1980, BIOCHIM BIOPHYS ACTA, V630, P119, DOI 10.1016/0304-4165(80)90142-7; Kang YJ, 1996, J BIOL CHEM, V271, P12610, DOI 10.1074/jbc.271.21.12610; KAUL N, 1993, J PHARMACOL TOX MET, V30, P55, DOI 10.1016/1056-8719(93)90008-3; LEFRAK EA, 1973, CANCER-AM CANCER SOC, V32, P302, DOI 10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2; LEGHA SS, 1982, ANN INTERN MED, V96, P133, DOI 10.7326/0003-4819-96-2-133; MAO SJT, 1991, J MED CHEM, V34, P298, DOI 10.1021/jm00105a046; MIMNAUGH EG, 1979, TOXICOL APPL PHARM, V49, P119, DOI 10.1016/0041-008X(79)90284-9; MINOW RA, 1977, CANCER, V39, P1397, DOI 10.1002/1097-0142(197704)39:4<1397::AID-CNCR2820390407>3.0.CO;2-U; MONTI E, 1995, ANTICANCER RES, V15, P193; MUINDI J, 1985, MOL PHARMACOL, V27, P356; MUINDI JRF, 1984, FEBS LETT, V172, P226, DOI 10.1016/0014-5793(84)81130-8; MYERS C, 1983, SEMIN ONCOL, V10, P53; MYERS CE, 1977, SCIENCE, V197, P165, DOI 10.1126/science.877547; NOWAK D, 1995, FREE RADICAL BIO MED, V19, P659, DOI 10.1016/0891-5849(95)00028-V; ODOM AL, 1992, BIOCHEM PHARMACOL, V43, P831, DOI 10.1016/0006-2952(92)90250-M; OLSEN RD, 1980, J PHARMACOL EXP THER, V215, P450; OLSON HM, 1974, AM J PATHOL, V77, P439; PANNEERSELVAM M, 1987, P AM ASSOC CANC RES, V28, P267; POTMESIL M, 1984, BIOCHEM PHARMACOL, V33, P3137, DOI 10.1016/0006-2952(84)90069-8; PRITSOS CR, 1992, BIOCHEM PHARMACOL, V44, P839, DOI 10.1016/0006-2952(92)90427-K; PRYOR WA, 1988, J AM CHEM SOC, V110, P2224, DOI 10.1021/ja00215a036; SEIFERT CF, 1994, ANN PHARMACOTHER, V28, P1063, DOI 10.1177/106002809402800912; SHAPIRA J, 1990, CANCER, V65, P870, DOI 10.1002/1097-0142(19900215)65:4<870::AID-CNCR2820650407>3.0.CO;2-D; SHIMPO K, 1991, AM J CLIN NUTR, V54, pS1298, DOI 10.1093/ajcn/54.6.1298s; Singal P K, 1985, Can J Cardiol, V1, P139; SINGAL PK, 1995, J MOL CELL CARDIOL, V27, P1055, DOI 10.1016/0022-2828(95)90074-8; SINGAL PK, 1986, AM J PHYSIOL, V250, pH419, DOI 10.1152/ajpheart.1986.250.3.H419; SINGAL PK, 1987, J MOL CELL CARDIOL, V19, P817, DOI 10.1016/S0022-2828(87)80392-9; SINGAL PK, 1984, RES COMMUN CHEM PATH, V43, P67; SINGAL PK, 1995, INFORMATION CARDIOLO, V19, P289; SINHA BK, 1979, CHEM-BIOL INTERACT, V28, P301, DOI 10.1016/0009-2797(79)90170-4; SINHA BK, 1987, BIOCHEMISTRY-US, V26, P3776, DOI 10.1021/bi00387a006; SINHA BK, 1987, BIOCHEM PHARMACOL, V36, P793, DOI 10.1016/0006-2952(87)90164-X; SIVESKIILISKOVIC N, 1995, CIRCULATION, V91, P10, DOI 10.1161/01.CIR.91.1.10; SIVESKIILISKOVIC N, 1994, CIRCULATION, V89, P2829, DOI 10.1161/01.CIR.89.6.2829; SIVESKIILISKOVIC N, 1994, CARDIOMYOPATHIC HEART, P277; SKLADANOWSKI A, 1993, BIOCHEM PHARMACOL, V46, P375, DOI 10.1016/0006-2952(93)90512-U; STEINHERZ LJ, 1991, JAMA-J AM MED ASSOC, V266, P1672, DOI 10.1001/jama.266.12.1672; THORNALLEY PJ, 1985, BIOCHEM PHARMACOL, V34, P669, DOI 10.1016/0006-2952(85)90262-X; TONG J, 1991, AM J PHYSIOL, V260, pH909, DOI 10.1152/ajpheart.1991.260.3.H909; vanAcker SABE, 1996, CANCER CHEMOTH PHARM, V38, P95, DOI 10.1007/s002800050453; VANVLEET JF, 1980, AM J PATHOL, V99, P13; VILE GF, 1990, CANCER RES, V50, P2307; VONHOFF DD, 1981, CANCER TREAT REP, V65, P249; VONHOFF DD, 1979, ANN INTERN MED, V91, P710, DOI 10.7326/0003-4819-91-5-710; WEISS RB, 1992, SEMIN ONCOL, V19, P670; YODA Y, 1986, CANCER RES, V46, P2551; Zhang J, 1996, J MOL CELL CARDIOL, V28, P1931, DOI 10.1006/jmcc.1996.0186	83	245	256	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1997	11	12					931	936		10.1096/fasebj.11.12.9337145	http://dx.doi.org/10.1096/fasebj.11.12.9337145			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YA724	9337145				2022-12-28	WOS:A1997YA72400002
J	Gilchrest, BA; Bohr, VA				Gilchrest, BA; Bohr, VA			Aging processes, DNA damage, and repair	FASEB JOURNAL			English	Editorial Material						oxidative damage; mutation; recombination; signal transduction; gene expression	PROGRAMMED CELL-DEATH; V(D)J RECOMBINATION; SENESCENCE; RNA; DIFFERENTIATION; PHOSPHORYLATION; TELOMERASE; MUTATION; AGE	The second triennial FASEB Summer Research Conference on ''Clonal Senescence and Differentiation'' (August 17-22, 1996) focused on the interrelationships between aging processes and DNA damage and repair. The attendees represented a cross section of senior and junior investigators working in fields ranging from classic cellular gerontology to Feast and nematode models of aging to basic mechanisms of DNA damage and repair, The meeting opened with a keynote address by Dr. Bruce Ames that emphasized the documented relationships between oxidative damage, cancer, and aging. This was followed by eight platform sessions, one poster discussion, one featured presentation, and an after-dinner address. The following sections highlight the key points discussed.	NIA,NIH,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Gilchrest, BA (corresponding author), BOSTON UNIV,SCH MED,DEPT DERMATOL,80 E CONCORD ST,BOSTON,MA 02118, USA.		Bohr, Vilhelm/AAP-5931-2020					APRHYS C, 1996, STRESS INDUCIVLE CEL, P289; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BULYCHEV NV, 1996, IN PRESS BIOCHEMISTR; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Cleaver JE, 1995, METABOLIC MOL BASES, VIII, P4393; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11043; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Garcia GG, 1997, CELL IMMUNOL, V175, P51, DOI 10.1006/cimm.1996.1040; GHOSH J, 1995, MECH AGEING DEV, V80, P171, DOI 10.1016/0047-6374(94)01568-7; Gilchrest BA, 1996, BRIT J DERMATOL, V135, P867, DOI 10.1046/j.1365-2133.1996.d01-1088.x; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; Hara E, 1996, DEV GENET, V18, P161; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; MEDRANO EE, 1994, MOL BIOL CELL, V5, P497, DOI 10.1091/mbc.5.4.497; Melov S, 1995, NUCLEIC ACIDS RES, V23, P4938, DOI 10.1093/nar/23.23.4938-a; MELOV S, 1995, NUCLEIC ACIDS RES, V23, P1419, DOI 10.1093/nar/23.8.1419; MELOV S, 1995, NUCLEIC ACIDS RES, V23, P4122, DOI 10.1093/nar/23.20.4122; Moriwaki SI, 1996, MUTAT RES-DNA REPAIR, V364, P117, DOI 10.1016/0921-8777(96)00029-8; Murakami S, 1996, GENETICS, V143, P1207; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PATEL HR, 1992, EUR J IMMUNOL, V22, P253, DOI 10.1002/eji.1830220137; REENSTRA WR, 1993, EXP CELL RES, V209, P118, DOI 10.1006/excr.1993.1291; Reenstra WR, 1996, EXP CELL RES, V227, P252, DOI 10.1006/excr.1996.0274; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; SMULSON ME, 1995, J BIOL CHEM, V270, P119, DOI 10.1074/jbc.270.1.119; TACCIOLI GE, 1994, J BIOL CHEM, V269, P7439; TACCIOLI GE, 1995, CURR OPIN IMMUNOL, V7, P436, DOI 10.1016/0952-7915(95)80085-9; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; UMAR A, 1996, IN PRESS CELL, V87; WANG E, 1994, J CELL BIOCHEM, V54, P432, DOI 10.1002/jcb.240540410; WANG E, 1995, CANCER RES, V55, P2284; Webb DK, 1996, EXP CELL RES, V224, P272, DOI 10.1006/excr.1996.0137; WEI QY, 1993, P NATL ACAD SCI USA, V90, P1614, DOI 10.1073/pnas.90.4.1614; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; WRIGHT WE, 1995, TRENDS CELL BIOL, V5, P293, DOI 10.1016/S0962-8924(00)89044-3	42	72	74	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1997	11	5					322	330		10.1096/fasebj.11.5.9141498	http://dx.doi.org/10.1096/fasebj.11.5.9141498			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WX156	9141498				2022-12-28	WOS:A1997WX15600004
J	Makita, K; Falck, JR; Capdevila, JH				Makita, K; Falck, JR; Capdevila, JH			Cytochrome P450, the arachidonic acid cascade, and hypertension: New vistas for an old enzyme system	FASEB JOURNAL			English	Review						omega/omega 2 oxygenase; omega-alcohols; EETs; epoxyeicosatrienoic acid	20-HYDROXYEICOSATETRAENOIC ACID; EPOXYEICOSATRIENOIC ACIDS; OXIDATIVE-METABOLISM; OMEGA-HYDROXYLATION; FATTY-ACIDS; EPOXYGENASE; RAT; CELLS; VASOCONSTRICTOR; CYCLOOXYGENASE	As a participant of the endogenous arachidonic acid metabolic cascade, microsomal cytochrome P450 metabolizes the fatty acid to biologically active hydroxyeicosatetraenoic and epoxy-eicosatrienoic acids, Studies from several laboratories have documented the powerful vasoactive properties of these P450-derived eicosanoids, Associated changes in cell membrane ion permeability and fluxes may provide the molecular basis underlining their vasoactivity. Furthermore, a role for the P450 arachidonic acid monooxygenase in renal physiology and pathophysiology has been suggested by: 1) an association between the activities of the arachidonic acid pi/pi-1 oxygenase and the development of hypertension in spontaneously hypertensive rats, and 2) a relationship between acquired or inherited abnormalities in the renal epoxygenase activities and/or regulation and salt-sensitive hypertension in Dahl rats. These studies provide significant evidence to indicate that microsomal P450, in addition to its recognized traditional toxicological and pharmacological roles, may also play an important physiological role in the control of tissue and body homeostasis.	VANDERBILT UNIV, MED CTR, DEPT MED, MED CTR N S3223, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; UNIV TEXAS, SW MED CTR, DEPT MOL GENET, DALLAS, TX 75235 USA	Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Falck, John/0000-0002-9219-7845	NICHD NIH HHS [NIHDK 38226] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BURNS KD, 1995, AM J PHYSIOL-CELL PH, V269, pC831, DOI 10.1152/ajpcell.1995.269.4.C831; CAPDEVILA J, 1981, P NATL ACAD SCI-BIOL, V78, P5362, DOI 10.1073/pnas.78.9.5362; CAPDEVILA J, 1981, BIOCHEM BIOPH RES CO, V101, P1357, DOI 10.1016/0006-291X(81)91597-7; CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1992, J BIOL CHEM, V267, P21720; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; Capdevila Jorge H., 1995, P443; CARROLL MA, 1992, J PHARMACOL EXP THER, V260, P104; ESCALANTE B, 1994, AM J PHYSIOL, V266, pC1775, DOI 10.1152/ajpcell.1994.266.6.C1775; GRAIER WF, 1995, J PHYSIOL-LONDON, V482, P259, DOI 10.1113/jphysiol.1995.sp020515; HARDER DR, 1995, J VASC RES, V32, P79, DOI 10.1159/000159080; HARDWICK JP, 1991, METHOD ENZYMOL, V206, P273; HU SL, 1993, EUR J PHARMACOL, V230, P215, DOI 10.1016/0014-2999(93)90805-R; IMAOKA S, 1989, BIOCHEM INT, V18, P731; JACOBSON HR, 1984, PROSTAGLANDINS MEMBR; KARARA A, 1993, J BIOL CHEM, V268, P13565; KATOH T, 1991, AM J PHYSIOL, V261, pF578, DOI 10.1152/ajprenal.1991.261.4.F578; KAWASHIMA H, 1992, BIOCHIM BIOPHYS ACTA, V1123, P156, DOI 10.1016/0005-2760(92)90106-6; KUTSKY P, 1983, PROSTAGLANDINS, V26, P13, DOI 10.1016/0090-6980(83)90070-9; MA YH, 1993, CIRC RES, V72, P126, DOI 10.1161/01.RES.72.1.126; MAKITA K, 1994, J CLIN INVEST, V94, P2414, DOI 10.1172/JCI117608; MATSUKAWA N, 1993, J BIOL CHEM, V268, P9117; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; MERRICK AB, 1995, PHARMACOLOGY, V30, P129; MORRISON AR, 1981, P NATL ACAD SCI-BIOL, V78, P7375, DOI 10.1073/pnas.78.12.7375; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OLIW EH, 1994, PROG LIPID RES, V33, P329, DOI 10.1016/0163-7827(94)90029-9; OLIW EH, 1981, BIOCHIM BIOPHYS ACTA, V666, P327, DOI 10.1016/0005-2760(81)90291-5; OMATA K, 1992, AM J PHYSIOL, V262, pF591, DOI 10.1152/ajprenal.1992.262.4.F591; RAPP JP, 1982, HYPERTENSION, V4, P753, DOI 10.1161/01.HYP.4.6.753; ROMAN LJ, 1993, ARCH BIOCHEM BIOPHYS, V307, P57, DOI 10.1006/abbi.1993.1560; ROMERO MF, 1991, RENAL PHYSIOL BIOCH, V14, P199; SACERDOTI D, 1989, SCIENCE, V243, P388, DOI 10.1126/science.2492116; SAKAIRI Y, 1995, AM J PHYSIOL-RENAL, V268, pF931, DOI 10.1152/ajprenal.1995.268.5.F931; SCHWARTZMAN ML, 1995, J LIPID MEDIAT CELL, V12, P229, DOI 10.1016/0929-7855(95)00021-H; SCHWARTZMAN ML, 1989, J BIOL CHEM, V264, P11658; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; SNYDER G, 1986, BIOCHEM BIOPH RES CO, V139, P1188, DOI 10.1016/S0006-291X(86)80303-5; STAUDINGER R, 1994, J CELL PHYSIOL, V160, P69, DOI 10.1002/jcp.1041600109; Stec DE, 1996, HYPERTENSION, V27, P564, DOI 10.1161/01.HYP.27.3.564; VAINIONPAA V, 1974, PHARMACOL RES COMMUN, V6, P343, DOI 10.1016/S0031-6989(74)80033-0; WADA A, 1988, J STEROID BIOCHEM, V31, P803, DOI 10.1016/0022-4731(88)90289-0	42	115	117	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1996	10	13					1456	1463		10.1096/fasebj.10.13.8940291	http://dx.doi.org/10.1096/fasebj.10.13.8940291			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VU982	8940291				2022-12-28	WOS:A1996VU98200002
J	Thomas, AP; Bird, GSJ; Hajnoczky, G; RobbGaspers, LD; Putney, JW				Thomas, AP; Bird, GSJ; Hajnoczky, G; RobbGaspers, LD; Putney, JW			Spatial and temporal aspects of cellular calcium signaling	FASEB JOURNAL			English	Article						cytosolic calcium; calcium oscillations; calcium waves; inosital 1,4,5-trisphosphate	PANCREATIC ACINAR-CELLS; CA2+-INDUCED CA2+ RELEASE; CYTOPLASMIC FREE CALCIUM; XENOPUS-LAEVIS OOCYTES; SINGLE-RAT HEPATOCYTES; ONE-POOL MODEL; INOSITOL TRISPHOSPHATE; INTRACELLULAR CALCIUM; CYTOSOLIC CALCIUM; FURA-2-LOADED HEPATOCYTES	Cytosolic Ca2+ signals are often organized in complex temporal and spatial patterns, even under conditions of sustained stimulation. In this review we discuss the mechanisms and physiological significance of this behavior in nonexcitable cells, in which the primary mechanism of Ca2+ mobilization is through (1,4,5)IP3-dependent Ca2+ release from intracellular stores. Oscillations of cytosolic free Ca2+ ([Ca2+](i)) are a common form of temporal organization; in the spatial domain, these [Ca2+](i) oscillations may take the form of [Ca2+](i) waves that propagate throughout the cell or they may be restricted to specific subcellular regions. These patterns of Ca2+ signaling result from the limited range of cytoplasmic Ca2+ diffusion and the feedback regulation of the pathways responsible for Ca2+ mobilization. In addition, the spatial organization of [Ca2+](i) changes appears to depend on the strategic distribution of Ca2+ stores within the cell. One type of [Ca2+](i) oscillation is baseline spiking, in which discrete [Ca2+](i) spikes occur with a frequency, but not amplitude, that is determined by agonist dose. Most current evidence favors a model in which baseline [Ca2+](i) spiking results from the complex interplay between [Ca2+](i) and (1,4,5)IP3 in regulating the gating of (1,4,5)IP3-sensitive intracellular Ca2+ channels. Sinusoidal [Ca2+](i) oscillations represent a mechanistically distinct type of temporal organization, in which agonist dose regulates the amplitude but has no effect on oscillation frequency. Sinusoidal [Ca2+](i) oscillations can be explained by a negative feedback effect of protein kinase C on the generation of (1,4,5)IP3 at the level of phospholipase C or its activating G-protein. The physiological significance of [Ca2+](i) oscillations and waves is becoming more established with the observation of this behavior in intact tissues and by the recognition of Ca2+-dependent processes that are adapted to respond to frequency-modulated oscillatory [Ca2+](i) signals. In some cells, these [Ca2+](i) signals are targeted to control processes in limited cytoplasmic domains, and in other systems [Ca2+](i) waves can be propagated through gap junctions to coordinate the function of multicellular systems.	NIEHS,CELLULAR & MOL PHARMACOL LAB,NIH,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Thomas, AP (corresponding author), THOMAS JEFFERSON UNIV,DEPT PATHOL ANAT & CELL BIOL,271 JAH1020 LOCUST ST,PHILADELPHIA,PA 19107, USA.		Bird, Gary/AAI-8186-2021; Gaspers, Lawrence/W-8766-2019; Putney, James W/F-7247-2019; Thomas, Andrew/C-6755-2013	Bird, Gary/0000-0003-1389-8748; Gaspers, Lawrence/0000-0002-5620-3283; Putney, James W/0000-0002-3379-4789; Thomas, Andrew/0000-0002-9026-7467	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038422, R01DK038422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006293] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA07215] Funding Source: Medline; NIDA NIH HHS [DA06293] Funding Source: Medline; NIDDK NIH HHS [DK38422] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLBRITTON NL, 1993, CELL CALCIUM, V14, P691, DOI 10.1016/0143-4160(93)90095-N; ATRI A, 1993, BIOPHYS J, V65, P1727, DOI 10.1016/S0006-3495(93)81191-3; Berridge Michael J., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P211; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1992, J BIOL CHEM, V267, P18382; BIRD GS, 1992, J BIOL CHEM, V267, P17722; BIRD GSJ, 1993, J BIOL CHEM, V268, P8425; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; BRUNDAGE RA, 1991, SCIENCE, V254, P703, DOI 10.1126/science.1948048; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; CHATTON JY, 1995, FEBS LETT, V368, P165, DOI 10.1016/0014-5793(95)00632-J; CHIAVAROLI C, 1994, J BIOL CHEM, V269, P25570; COBBOLD PH, 1991, CELL CALCIUM, V12, P87, DOI 10.1016/0143-4160(91)90011-3; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CUTHBERTSON KSR, 1991, CELL CALCIUM, V12, P61, DOI 10.1016/0143-4160(91)90008-3; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DELISLE S, 1990, J BIOL CHEM, V265, P11726; DEYOUNG GW, 1992, P NATL ACAD SCI USA, V89, P9895, DOI 10.1073/pnas.89.20.9895; DUPONT G, 1993, CELL CALCIUM, V14, P311, DOI 10.1016/0143-4160(93)90052-8; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FOSKETT JK, 1994, J BIOL CHEM, V269, P31525; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; GILKEY JC, 1978, J CELL BIOL, V76, P448, DOI 10.1083/jcb.76.2.448; GIRARD S, 1993, SCIENCE, V260, P229, DOI 10.1126/science.8385801; GRAY PTA, 1988, J PHYSIOL-LONDON, V406, P35, DOI 10.1113/jphysiol.1988.sp017367; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HANSEN CA, 1991, J BIOL CHEM, V266, P18573; HAROOTUNIAN AT, 1988, COLD SPRING HARB SYM, V53, P935, DOI 10.1101/SQB.1988.053.01.108; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; IINO M, 1992, NATURE, V360, P767; ILYIN V, 1994, J PHYSIOL-LONDON, V477, P503, DOI 10.1113/jphysiol.1994.sp020211; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KAWANISHI T, 1989, J BIOL CHEM, V264, P12859; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LIN C, 1994, CELL CALCIUM, V16, P247, DOI 10.1016/0143-4160(94)90088-4; LOESSBERG PA, 1993, J BIOL CHEM, V268, P19769; MENNITI FS, 1991, J BIOL CHEM, V266, P13646; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MIYAZAKI S, 1992, FEBS LETT, V309, P180, DOI 10.1016/0014-5793(92)81090-9; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; NATHANSON MH, 1994, GASTROENTEROLOGY, V106, P1349, DOI 10.1016/0016-5085(94)90030-2; NATHANSON MH, 1994, AM J PHYSIOL, V267, pC338; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PETERSEN CCH, 1991, EMBO J, V10, P527, DOI 10.1002/j.1460-2075.1991.tb07979.x; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; PRENTKI M, 1988, J BIOL CHEM, V263, P11044; PRINCE WT, 1973, J EXP BIOL, V58, P367; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; ROBBGASPERS LD, 1995, J BIOL CHEM, V270, P8102, DOI 10.1074/jbc.270.14.8102; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROONEY TA, 1993, CELL CALCIUM, V14, P674, DOI 10.1016/0143-4160(93)90094-M; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; SANDERSON MJ, 1994, MOL CELL ENDOCRINOL, V98, P173, DOI 10.1016/0303-7207(94)90136-8; SOMOGYI R, 1991, J BIOL CHEM, V266, P11068; STACHOWIAK MK, 1990, J BIOL CHEM, V265, P4694; STOJILKOVIC SS, 1992, ENDOCR REV, V13, P256, DOI 10.1210/er.13.2.256; SUH HH, 1992, J NEUROCHEM, V59, P993, DOI 10.1111/j.1471-4159.1992.tb08340.x; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; Thomas Andrew P., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P225; THOMAS AP, 1991, CELL CALCIUM, V12, P111, DOI 10.1016/0143-4160(91)90013-5; THORN P, 1993, CELL CALCIUM, V14, P746, DOI 10.1016/0143-4160(93)90100-K; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TOESCU EC, 1995, AM J PHYSIOL-GASTR L, V269, pG173, DOI 10.1152/ajpgi.1995.269.2.G173; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSUNODA Y, 1990, AM J PHYSIOL, V258, pC147, DOI 10.1152/ajpcell.1990.258.1.C147; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WERNER MH, 1992, BIOCHEM J, V282, P815, DOI 10.1042/bj2820815; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; WOODS NM, 1987, CELL CALCIUM, V8, P79, DOI 10.1016/0143-4160(87)90038-8; YAO Y, 1995, J PHYSIOL-LONDON, V482, P533, DOI 10.1113/jphysiol.1995.sp020538; YULE DI, 1988, FEBS LETT, V239, P358, DOI 10.1016/0014-5793(88)80951-7; ZHANG BX, 1992, AM J PHYSIOL, V262, pC1125, DOI 10.1152/ajpcell.1992.262.5.C1125; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	94	412	420	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1996	10	13					1505	1517		10.1096/fasebj.10.13.8940296	http://dx.doi.org/10.1096/fasebj.10.13.8940296			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VU982	8940296				2022-12-28	WOS:A1996VU98200007
J	Boyarsky, G; Hanssen, C; Clyne, LA				Boyarsky, G; Hanssen, C; Clyne, LA			Superiority of in vitro over in vivo calibrations of BCECF in vascular smooth muscle cells	FASEB JOURNAL			English	Article						rabbit; intracellular pH; nigericin; buffering power	INTRACELLULAR PH REGULATION; CYTOPLASMIC PH; NA-H; CL/HCO3 EXCHANGE; CL-HCO3 EXCHANGE; FIBROBLASTS; LYMPHOCYTES	We measured intracellular pH (pH(i)) in single vascular smooth muscle cells (VSM) cultured from rabbit abdominal aorta, using 2',7'-biscarboxyethyl-5(6)carboxyfluorescein (BCECF) on a microscope-based fluorimetric system. We previously found substantial errors introduced by using high K+/nigericin to calibrate intracellular BCECF (1). We also previously demonstrated that the necessary correction (pH(cor)) to the high K+/nigericin-calibrated pH(i) was linearly dependent on pH(i), increasing with increasing pH(i) (2), When the nigericin calibration data were corrected using this pH(cor), the new corrected calibration was similar to the result of calibrating BCECF in vitro (higher R(max), lower R(min), and lower pK). Therefore, in this study the possibility is considered that in vitro calibrations might provide better estimates of pH(i). Our best estimate for the absolute level of pH(i) derives from a null method for bracketing steady-state pH(i). In VSM cells, using only in vitro calibrations to estimate steady-state pH(i) leads to less error (only similar to 0.08 different from null estimates) than using nigericin calibrations alone (similar to 0.2 different from null estimates), Unlike high K+/nigericin calibrations, the error, pH(cor), introduced by using an in vitro calibration is pH(i) independent. Using high K+/nigericin or in vitro calibrations, along with the respective pH(cor) on the same experimental days in the same cells, gave the same estimate of pH(i) whether in the steady state, in acid-loaded cells, or in alkali-loaded cells. Similarly, when appropriately corrected, both methods gave indistinguishable calibration curves. Thus, the two methods are entirely equivalent from the stand-point of accuracy, Because nigericin is toxic, expensive, and complicated in its use, we suggest that in vitro calibrations, along with simple null determinations to assess the small, constant correction factor,be used to calibrate intracellular BCECF.			Boyarsky, G (corresponding author), UNIV TEXAS,MED BRANCH,DEPT PHYSIOL & BIOPHYS,GALVESTON,TX 77550, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL048122] Funding Source: NIH RePORTER; NHLBI NIH HHS [R29 HL-48122] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALPERN RJ, 1987, J GEN PHYSIOL, V89, P581, DOI 10.1085/jgp.89.4.581; BERK BC, 1987, J BIOL CHEM, V262, P5057; BORON WF, 1986, ANNU REV PHYSIOL, V48, P377; BOYARSKY G, 1993, GLIA, V8, P241, DOI 10.1002/glia.440080404; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; BOYARSKY G, 1991, AM J PHYSIOL, V260, pC167, DOI 10.1152/ajpcell.1991.260.1.C167; BOYARSKY G, 1996, IN PRESS AM J PHYSL; CHAILLET JR, 1985, J GEN PHYSIOL, V86, P765, DOI 10.1085/jgp.86.6.765; GANZ MB, 1990, AM J PHYSIOL, V259, pF269, DOI 10.1152/ajprenal.1990.259.2.F269; GANZ MB, 1989, NATURE, V337, P648, DOI 10.1038/337648a0; GRINSTEIN S, 1984, J GEN PHYSIOL, V83, P341, DOI 10.1085/jgp.83.3.341; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; HATORI N, 1987, J BIOL CHEM, V262, P5073; KAHN AM, 1990, AM J PHYSIOL, V259, pC134, DOI 10.1152/ajpcell.1990.259.1.C134; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; KORBMACHER C, 1988, PFLUG ARCH EUR J PHY, V412, P29, DOI 10.1007/BF00583728; LITTLE PJ, 1986, AM J PHYSIOL, V251, pC707, DOI 10.1152/ajpcell.1986.251.5.C707; PARADISO AM, 1987, AM J PHYSIOL, V253, pC30, DOI 10.1152/ajpcell.1987.253.1.C30; PARADISO AM, 1986, AM J PHYSIOL, V250, pC524; POUYSSEGUR J, 1985, FEBS LETT, V190, P115, DOI 10.1016/0014-5793(85)80439-7; PUTNAM RW, 1990, AM J PHYSIOL, V258, P470; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VIGNE P, 1988, J BIOL CHEM, V263, P18023; WILDING TJ, 1992, J GEN PHYSIOL, V100, P593, DOI 10.1085/jgp.100.4.593	26	37	37	2	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1996	10	10					1205	1212		10.1096/fasebj.10.10.8751723	http://dx.doi.org/10.1096/fasebj.10.10.8751723			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VD429	8751723				2022-12-28	WOS:A1996VD42900012
J	Chomienne, C; Fenaux, P; Degos, L				Chomienne, C; Fenaux, P; Degos, L			Retinoid differentiation therapy in promyelocytic leukemia	FASEB JOURNAL			English	Article						APL; acute myeloid leukemia; RAR; ATRA therapy; RA efficacy	ACID RECEPTOR-ALPHA; INDUCED GRANULOCYTIC DIFFERENTIATION; POLYMERASE CHAIN-REACTION; RAR-ALPHA; FUSION PROTEINS; BINDING PROTEIN; CELLS; TRANSLOCATION; PML; CHEMOTHERAPY	Acute promyelocytic leukemia (APL) is a specific type of acute myeloid leukemia characterized by the morphology of the blast cells, a specific t(15;17) translocation, and risks of definite coagulopathy, Recently this leukemia was further characterized by an exquisite sensitivity to all-trans retinoic acid's differentiation effect and the production of a fusion gene altering the gene of RAR alpha and a novel gene PML. In vivo differentiation therapy with retinoids in APL patients follows strict guidelines related both to the APL cell and the biodisposal of all-trans retinoic acid.	CHU LILLE, F-59037 LILLE, FRANCE	Universite de Lille - ISITE; CHU Lille	Chomienne, C (corresponding author), HOP ST LOUIS, INST HEMATOL, LAB BIOL CELLULAIRE HEMATOPOIET, 1 AVE CLAUDE VELLEFAUX, F-75010 PARIS, FRANCE.			CHOMIENNE, Christine/0000-0001-5513-5752				ADAMSON PC, 1993, CANCER RES, V53, P472; AGADIR A, 1995, J CLIN ONCOL, V13, P2517, DOI 10.1200/JCO.1995.13.10.2517; AGADIR A, 1995, BIOCHEM BIOPH RES CO, V213, P112, DOI 10.1006/bbrc.1995.2105; AGADIR A, 1995, LEUKEMIA, V9, P139; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; Calabresse C, 1995, LEUKEMIA, V9, P2049; CASTAIGNE S, 1990, BLOOD, V76, P1704; CASTAIGNE S, 1992, BLOOD, V79, P3110; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547; CHOMIENNE C, 1990, BLOOD, V76, P1710; Chomienne C, 1996, LEUKEMIA, V10, P368; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; COMIC M, 1994, LEUKEMIA, V8, P914; DEGENTILE A, 1994, LEUKEMIA, V8, P1758; DEGOS L, 1995, BLOOD, V85, P2643, DOI 10.1182/blood.V85.10.2643.bloodjournal85102643; DEGOS L, 1990, LANCET, V336, P1440, DOI 10.1016/0140-6736(90)93135-C; DELVA L, 1993, BLOOD, V82, P2175; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DIVERIO D, 1994, LEUKEMIA, V8, P1105; DOMBRET H, 1992, LEUKEMIA, V6, P1237; DOMBRET H, 1993, LEUKEMIA, V7, P2; DUBOIS C, 1994, LEUKEMIA, V8, P1750; DUBOIS C, 1994, BLOOD, V83, P3264; EARDLEY AM, 1994, LEUKEMIA, V8, P934; FENAUX P, 1993, BLOOD, V82, P3241; FENAUX P, 1992, BLOOD, V80, P2176; FENAUX P, 1994, LANCET, V343, P1033, DOI 10.1016/S0140-6736(94)90151-1; FENAUX P, 1994, BLOOD, V84, P666; FRANKEL SR, 1992, ANN INTERN MED, V117, P292, DOI 10.7326/0003-4819-117-4-292; FUKUTANI H, 1995, LEUKEMIA, V9, P588; GRATAS C, 1993, LEUKEMIA, V7, P1156; GRIGNANI F, 1995, CANCER RES, V55, P440; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GUIDEZ F, 1994, LEUKEMIA, V8, P312; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUANG W, 1993, BLOOD, V82, P1264, DOI 10.1182/blood.V82.4.1264.bloodjournal8241264; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KANAMARU A, 1995, BLOOD, V85, P1202, DOI 10.1182/blood.V85.5.1202.bloodjournal8551202; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LEFEBVRE P, 1991, LEUKEMIA, V5, P1054; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; Miller J, 1995, BLOOD, V86, P319; MILLER WH, 1993, BLOOD, V82, P1689; MUINDI J, 1992, BLOOD, V79, P299; Napoli JL, 1996, FASEB J, V10, P993, DOI 10.1096/fasebj.10.9.8801182; OHNO R, 1993, LEUKEMIA, V7, P1722; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; RIGAS JR, 1993, J NATL CANCER I, V85, P1921, DOI 10.1093/jnci/85.23.1921; ROUSSELOT P, 1994, ONCOGENE, V9, P545; RUNDE V, 1992, ANN HEMATOL, V64, P270, DOI 10.1007/BF01695469; Seale J, 1996, LEUKEMIA, V10, P95; Takeshita A, 1996, ANN INTERN MED, V124, P893, DOI 10.7326/0003-4819-124-10-199605150-00006; Tallman M. S., 1995, Blood, V86, p125A; TOSI P, 1994, LEUKEMIA LYMPHOMA, V14, P503, DOI 10.3109/10428199409049711; TURHAN AG, 1995, BLOOD, V85, P2154, DOI 10.1182/blood.V85.8.2154.bloodjournal8582154; VAHDAT L, 1994, BLOOD, V84, P3843, DOI 10.1182/blood.V84.11.3843.bloodjournal84113843; VANBOCKSTAELE DR, 1993, ANN HEMATOL, V66, P61, DOI 10.1007/BF01695885; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1994, LEUKEMIA, V8, P929; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WILEY JS, 1995, LEUKEMIA, V9, P774	67	122	125	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1996	10	9					1025	1030		10.1096/fasebj.10.9.8801163	http://dx.doi.org/10.1096/fasebj.10.9.8801163			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801163				2022-12-28	WOS:A1996UY93200012
J	Marshall, H; Morrison, A; Studer, M; Popperl, H; Krumlauf, R				Marshall, H; Morrison, A; Studer, M; Popperl, H; Krumlauf, R			Retinoids and Hox genes	FASEB JOURNAL			English	Article						retinoic acid; Hoxb-1; RARE; rhombomere; transgenic	ACID RESPONSE ELEMENT; HOMEOBOX-CONTAINING GENES; MOUSE HINDBRAIN; CRABP-I; EMBRYONIC EXPRESSION; PATTERN-FORMATION; BRANCHIAL REGION; VERTEBRATE HEAD; NERVOUS-SYSTEM; NEURAL CREST	The vertebrate embryonic body plan is constructed through the interaction of many developmentally regulated genes that supply cells with the essential positional and functional information they require to migrate to their appropriate destination and generate the proper structures, Some molecular cues involved in patterning the central nervous system, particularly in the hindbrain, are interpreted by the Hox homeobox genes, Retinoids can affect the expression of Hox genes in cell lines and embryonic tissues; the hindbrain and branchial region of the head are particularly sensitive to the teratogenic effects of retinoic acid, The presence of endogenous retinoic acid, together with the distribution of retinoid binding proteins and nuclear receptors in the developing embryo, strongly suggest that retinoic acid is a natural morphogen in vertebrate development, The molecular basis for the interaction between retinoic acid and the Hox genes has been aided in-part by approaches using deletion analysis in transgenic mice carrying lacZ reporter constructs, Such studies have identified functional retinoic acid response elements within the flanking sequences of some of the most 3' Hox genes, suggesting a direct interaction between the genes and retinoic acid, Furthermore, as demonstrated using transgenic mice carrying Hoxb-1/lacZ constructs, multiple retinoic acid response elements may cooperate with positive and negative regulatory enhancers to specify pattern formation in the vertebrate embryo, These types of studies strongly support the normal roles of retinoids in patterning vertebrate embryogenesis through the Hox genes.	NATL INST MED RES, DIV DEV NEUROBIOL, LONDON NW7 1AA, ENGLAND	MRC National Institute for Medical Research			Studer, Michele/P-4580-2016; Krumlauf, Robb/AAH-5012-2019	Studer, Michele/0000-0001-7105-2957; Krumlauf, Robb/0000-0001-9102-7927				ALEXANDRE D, 1996, IN PRESS DEVELOPMENT; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; CHOUINARD S, 1991, DEVELOPMENT, V113, P1267; CONLON RA, 1992, DEVELOPMENT, V116, P357; DEKKER EJ, 1992, DEVELOPMENT, P195; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EID R, 1993, DEV DYNAM, V196, P205, DOI 10.1002/aja.1001960307; FRASCH M, 1995, DEVELOPMENT, V121, P957; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; FROHMAN MA, 1992, MECH DEVELOP, V38, P55, DOI 10.1016/0925-4773(92)90038-L; GAUNT SJ, 1989, DEVELOPMENT, V107, P131; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; HOLDER N, 1991, DEVELOPMENT, V113, P1159; HORTON C, 1995, DEV DYNAM, V202, P312, DOI 10.1002/aja.1002020310; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; HUNTER K, 1991, P NATL ACAD SCI USA, V88, P3666, DOI 10.1073/pnas.88.9.3666; KASTNER P, 1994, VITAMIN A HLTH DIS; Kaufman T C, 1990, Adv Genet, V27, P309; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KRUMLAUF R, 1993, TRENDS GENET, V9, P106, DOI 10.1016/0168-9525(93)90203-T; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LYN S, 1994, DEV DYNAM, V199, P280, DOI 10.1002/aja.1001990404; MADEN M, 1992, BIOESSAYS, V14, P431, DOI 10.1002/bies.950140702; MAHAFFEY JW, 1989, DEVELOPMENT, V105, P167; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARK M, 1993, DEVELOPMENT, V119, P319; MARSHALL H, 1994, NATURE, V370, P567, DOI 10.1038/370567a0; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MORRISON A, 1996, IN PRESS DEVELOPMENT; MORRISSKAY GM, 1991, EMBO J, V10, P2985, DOI 10.1002/j.1460-2075.1991.tb07849.x; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; PAPALOPULU N, 1991, DEVELOPMENT, V113, P1145; POPPERL H, 1993, MOL CELL BIOL, V13, P257; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; PRINCE V, 1994, DEVELOPMENT, V120, P911; RUBERTE E, 1991, DEVELOPMENT, V111, P45; RUBERTE E, 1992, DEVELOPMENT, V115, P973; Ruberte E., 1991, SEMIN DEV BIOL, V2, P153; SCHWABE JWR, 1991, TRENDS BIOCHEM SCI, V16, P291, DOI 10.1016/0968-0004(91)90121-B; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAM MH, 1992, EMBO J, V11, P1825, DOI 10.1002/j.1460-2075.1992.tb05234.x; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STUDER M, 1994, SCIENCE, V265, P1728, DOI 10.1126/science.7916164; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WILKINSON DG, 1993, BIOESSAYS, V15, P499, DOI 10.1002/bies.950150802; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WOOD H, 1994, DEVELOPMENT, V120, P2279; ZHANG MB, 1994, DEVELOPMENT, V120, P2431	62	206	210	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1996	10	9					969	978		10.1096/fasebj.10.9.8801179	http://dx.doi.org/10.1096/fasebj.10.9.8801179			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801179				2022-12-28	WOS:A1996UY93200006
J	Neu, J; Shenoy, V; Chakrabarti, R				Neu, J; Shenoy, V; Chakrabarti, R			Glutamine nutrition and metabolism: Where do we go from here?	FASEB JOURNAL			English	Review						critical care; amino acids; critical illness; catabolism; infection	SYNTHETASE GENE; EXPRESSION; CELLS; DIET; RAT	Glutamine, a ''nonessential'' amino acid, is attracting widespread attention because of its relevance to numerous metabolic processes and its potential role in the treatment and prevention of critical illness, In this paper we review some key concepts of glutamine biochemistry, metabolism, and nutrition, We then discuss several studies in the area of glutamine metabolism and nutrition that are primed for further investigation.			Neu, J (corresponding author), UNIV FLORIDA,DEPT PEDIAT,BOX 100296,GAINESVILLE,FL 32610, USA.		Neu, Josef/AAI-2799-2020		NICHD NIH HHS [1 ROI HD-29279] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029279] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARGENZIO RA, 1994, GASTROENTEROLOGY, V106, P1418, DOI 10.1016/0016-5085(94)90393-X; AUSTGEN TR, 1992, J TRAUMA, V32, P600, DOI 10.1097/00005373-199205000-00011; COOPER AJL, 1977, CRC CR REV BIOCH MOL, V4, P281, DOI 10.3109/10409237709102560; CURTHOYS NP, 1995, ANNU REV NUTR, V15, P133, DOI 10.1146/annurev.nu.15.070195.001025; FAHMER J, 1993, EUR J BIOCHEM, V213, P1067; FAIR MJ, 1994, J PARENTER ENTERAL N, V18, P471; FALDUTO MT, 1992, AM J PHYSIOL, V263, pE1157; FENG B, 1990, J BIOL CHEM, V265, P18702; FOX AD, 1988, JPEN-PARENTER ENTER, V12, P325, DOI 10.1177/0148607188012004325; FOX RE, 1994, PEDIATR RES, V35, P589, DOI 10.1203/00006450-199405000-00010; HICKSON RC, 1995, AM J PHYSIOL-ENDOC M, V268, pE730, DOI 10.1152/ajpendo.1995.268.4.E730; HWANG TL, 1987, SURG FORUM, V38, P56; KALEBIC T, 1991, P NATL ACAD SCI USA, V88, P986, DOI 10.1073/pnas.88.3.986; KLIMBERG VS, 1990, ARCH SURG-CHICAGO, V125, P1040, DOI 10.1001/archsurg.1990.01410200104017; KREBS HANS ADOLF, 1935, BIOCHEM JOUR, V29, P1951; KUMADA Y, 1993, P NATL ACAD SCI USA, V90, P3009, DOI 10.1073/pnas.90.7.3009; LACEY JM, 1990, NUTR REV, V48, P297, DOI 10.1111/j.1753-4887.1990.tb02967.x; LACY J, 1995, ASPEN ABSTR, P599; LETOURNELBOULLAND ML, 1994, EUR CYTOKINE NETW, V5, P51; MACBURNEY M, J AM DIET ASSOC, V94, P1263; MAKAREWICZ W, 1991, PLACENTA, V12, P416; MEETZE WH, 1993, BIOL NEONATE, V64, P368; Meister A., 1980, GLUTAMINE METABOLISM, P1; MILL JF, 1991, MOL BRAIN RES, V9, P197, DOI 10.1016/0169-328X(91)90003-G; NUSJHAN N, 1995, J CLIN NUTR, V95, P2723; PARRYBILLINGS M, 1990, LANCET, V336, P523, DOI 10.1016/0140-6736(90)92083-T; PENG L, 1993, DEV NEUROSCI-BASEL, V15, P367, DOI 10.1159/000111357; RIBEIRO H, 1994, J AM COLL NUTR, V13, P251, DOI 10.1080/07315724.1994.10718405; ROIG JC, 1995, JPEN-PARENTER ENTER, V19, P179, DOI 10.1177/0148607195019003179; ROIG JC, 1995, PEDIATR RES, V37, pA285; SARANTOS P, 1994, ARCH SURG-CHICAGO, V129, P59; SARANTOS P, 1994, AM J SURG, V167, P8, DOI 10.1016/0002-9610(94)90047-7; SOUBA WW, 1992, GLUTAMINE PHYSL BIOC, P56; SPITTLER A, 1995, BLOOD, V86, P1564, DOI 10.1182/blood.V86.4.1564.bloodjournal8641564; SULEIMAN MS, 1993, BRIT HEART J, V69, P241; SUZUKI I, 1993, J NUTR SCI VITAMINOL, V39, P405, DOI 10.3177/jnsv.39.405; Swails W S, 1992, Nutr Clin Pract, V7, P77, DOI 10.1177/011542659200700277; VAUGHN PR, 1995, AM J PHYSIOL-ENDOC M, V268, pE705, DOI 10.1152/ajpendo.1995.268.4.E705; WATFORD M, 1984, BIOCHEM J, V224, P207, DOI 10.1042/bj2240207; WELLBOURNE TC, 1995, AM J CLIN NUTR, V61, P1058; Yoshida S, 1993, Nihon Geka Gakkai Zasshi, V94, P1078; ZHAN ZR, 1994, INT J BIOCHEM, V26, P263, DOI 10.1016/0020-711X(94)90155-4; ZIEGLER TR, 1992, ANN INTERN MED, V116, P821, DOI 10.7326/0003-4819-116-10-821	43	120	134	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1996	10	8					829	837		10.1096/fasebj.10.8.8666159	http://dx.doi.org/10.1096/fasebj.10.8.8666159			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UQ456	8666159				2022-12-28	WOS:A1996UQ45600004
J	Series, F; Cote, C; Simoneau, JA; StPierre, S; Marc, I				Series, F; Cote, C; Simoneau, JA; StPierre, S; Marc, I			Upper airway collapsibility, and contractile and metabolic characteristics of musculus uvulae	FASEB JOURNAL			English	Article						upper airway dilator muscle; muscle fatigue; muscle fiber area; metabolic profile; human skeletal muscle	OBSTRUCTIVE SLEEP-APNEA; GENIOGLOSSAL EMG ACTIVITY; MUSCLE-FIBER-TYPE; PHARYNGEAL RESISTANCE; CLOSING PRESSURES; ENZYME-ACTIVITIES; FLOW; UVULOPALATOPHARYNGOPLASTY; STIMULATION; ACTIVATION	Physiologic, metabolic, and histochemical characteristics of one upper airway (UA) dilator muscle (musculus uvulae; MU) differ between sleep apnea hypopnea syndrome (SAPS) and nonapneic snorers, We hypothesized that these differences in MU characteristics could result from the cumulative effects of the diurnal and nocturnal intermittent contractions of UA muscles in order to compensate for a permanent increase in UA collapsibility, The aim of this study was to determine the influence of UA collapsibility on MU characteristics. Seventeen SAHS and three nonapneic snorers, who underwent an uvulo-palato-pharyngoplasty as a treatment for snoring or SAHS, participated in the study, Awake and sleeping UA critical pressure (Pcrit) was measured during continuous positive or negative airway pressure trials by analysis of the relationship between maximal inspiratory flow and the upstream pressure of flow-limited breathing cycles, Maximum isometric twitch (P-t) and tetanic tension (P-o), fatigability measurements, activities of marker enzymes for anaerobic and aerobic-oxidative profile, and fiber type proportions and areas of MU were determined, There was a significant positive relationship between Pt, Po,, and Pcrit measured during wakefulness and sleep, The fatigability index was negatively correlated with awake Pcrit values (r = -0.19), Activity level of the anaerobic enzymes as well as the percentage of surface occupied by type I and type TIA muscle fibers as correlated with awake Pcrit, We conclude that the differences in awake UA collapsibility help to determine the contractile properties and metabolic and histochemical characteristics of MU.	CHU LAVAL,HORMONALE BIOREGULAT LAB,LAVAL,PQ,CANADA; HOP LAVAL,DEPT ORL,LAVAL,PQ G1V 4G5,CANADA; UNIV LAVAL,LAB SCI ACTIV PHYS,LAVAL,PQ,CANADA	Laval University; Laval University; Laval University	Series, F (corresponding author), HOP LAVAL,CTR PNEUMOL,UNITE RECH,2725 CHEMIN STE FOY,ST FOY,PQ G1V 4G5,CANADA.			Marc, Isabelle/0000-0001-6060-8550				ANCH AM, 1982, J APPL PHYSIOL, V53, P1158, DOI 10.1152/jappl.1982.53.5.1158; ANDERSEN P, 1977, ACTA PHYSIOL SCAND, V99, P123, DOI 10.1111/j.1748-1716.1977.tb10361.x; [Anonymous], 1992, SLEEP, V15, P174; BAYDUR A, 1982, AM REV RESPIR DIS, V126, P788; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROUILLETTE RT, 1980, J APPL PHYSIOL, V49, P801, DOI 10.1152/jappl.1980.49.5.801; CHADHA TS, 1982, AM REV RESPIR DIS, V125, P644; COSTILL DL, 1979, J APPL PHYSIOL, V46, P96, DOI 10.1152/jappl.1979.46.1.96; FREMONT P, 1991, AM J PHYSIOL, V260, pR615, DOI 10.1152/ajpregu.1991.260.3.R615; FUJITA S, 1981, OTOLARYNG HEAD NECK, V89, P923, DOI 10.1177/019459988108900609; GAUTHIER JM, 1992, MED SCI SPORT EXER, V24, P1252; GLEADHILL IC, 1991, AM REV RESPIR DIS, V143, P1300, DOI 10.1164/ajrccm/143.6.1300; GONYEA WJ, 1986, EUR J APPL PHYSIOL O, V55, P137, DOI 10.1007/BF00714995; GOULD GA, 1988, AM REV RESPIR DIS, V137, P895, DOI 10.1164/ajrccm/137.4.895; HOWALD H, 1990, INT J SPORTS MED, V11, pS10, DOI 10.1055/s-2007-1024847; ISSA FG, 1984, J APPL PHYSIOL, V57, P520, DOI 10.1152/jappl.1984.57.2.520; LEITER JC, 1992, J APPL PHYSIOL, V73, P584, DOI 10.1152/jappl.1992.73.2.584; LEITER JC, 1992, J APPL PHYSIOL, V73, P576, DOI 10.1152/jappl.1992.73.2.576; MABUCHI K, 1980, MUSCLE NERVE, V3, P227, DOI 10.1002/mus.880030307; MATHEW OP, 1982, J APPL PHYSIOL, V52, P438, DOI 10.1152/jappl.1982.52.2.438; MEZZANOTTE WS, 1992, J CLIN INVEST, V89, P1571, DOI 10.1172/JCI115751; MORRISON DL, 1993, AM REV RESPIR DIS, V148, P606, DOI 10.1164/ajrccm/148.3.606; OLIVEN A, 1989, RESP PHYSIOL, V75, P29, DOI 10.1016/0034-5687(89)90084-4; PEPIN JL, 1992, THORAX, V47, P150, DOI 10.1136/thx.47.3.150; PETROF BJ, 1994, J APPL PHYSIOL, V76, P1746, DOI 10.1152/jappl.1994.76.4.1746; PRINCE FP, 1976, PFLUG ARCH EUR J PHY, V363, P19, DOI 10.1007/BF00587397; Rechtschaffen A., 1968, BRAIN INFORM SERVICE; REMMERS JE, 1978, J APPL PHYSIOL, V44, P931, DOI 10.1152/jappl.1978.44.6.931; ROBERTS JL, 1985, J APPL PHYSIOL, V58, P290, DOI 10.1152/jappl.1985.58.1.290; SCHWARTZ AR, 1992, AM REV RESPIR DIS, V145, P527, DOI 10.1164/ajrccm/145.3.527; SCHWARTZ AR, 1989, J APPL PHYSIOL, V66, P1626, DOI 10.1152/jappl.1989.66.4.1626; SCHWARTZ AR, 1991, AM REV RESPIR DIS, V144, P494, DOI 10.1164/ajrccm/144.3_Pt_1.494; SERIES F, 1995, J CLIN INVEST, V95, P20, DOI 10.1172/JCI117640; SERIES F, 1993, CHEST, V104, P14, DOI 10.1378/chest.104.1.14; SERIES F, 1993, J APPL PHYSIOL, V75, P1222, DOI 10.1152/jappl.1993.75.3.1222; SIMONEAU J A, 1991, Medicine and Science in Sports and Exercise, V23, pS149; SIMONEAU JA, 1988, PFLUG ARCH EUR J PHY, V412, P86, DOI 10.1007/BF00583735; SIMONEAU JA, 1989, AM J PHYSIOL, V257, pE567, DOI 10.1152/ajpendo.1989.257.4.E567; SMIRNE S, 1991, LANCET, V337, P597; STROHL KP, 1980, J APPL PHYSIOL, V49, P638, DOI 10.1152/jappl.1980.49.4.638; SURATT PM, 1988, AM REV RESPIR DIS, V137, P889, DOI 10.1164/ajrccm/137.4.889; SURATT PM, 1984, J APPL PHYSIOL, V57, P140, DOI 10.1152/jappl.1984.57.1.140; THERIAULT R, 1994, J APPL PHYSIOL, V77, P1885, DOI 10.1152/jappl.1994.77.4.1885; VANDERTOUW T, 1994, J APPL PHYSIOL, V76, P424, DOI 10.1152/jappl.1994.76.1.424; WASICKO MJ, 1990, AM REV RESPIR DIS, V141, P1569, DOI 10.1164/ajrccm/141.6.1569; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	46	31	31	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1996	10	8					897	904		10.1096/fasebj.10.8.8666167	http://dx.doi.org/10.1096/fasebj.10.8.8666167			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UQ456	8666167				2022-12-28	WOS:A1996UQ45600012
J	Bloch, K				Bloch, K			The origins of intermediary metabolism at Columbia College of Physicians and Surgeons (P&S)	FASEB JOURNAL			English	Editorial Material											Bloch, K (corresponding author), HARVARD UNIV,DEPT CHEM,12 OXFORD ST,CAMBRIDGE,MA 02138, USA.							CLARKE HT, 1958, ANNU REV BIOCHEM, V27, P1, DOI 10.1146/annurev.bi.27.070158.000245; KAMEN MD, 1940, PHYS REV, V58, P194; LIPMANN F, 1941, ADV ENZYMOL, V1, P100; Schoenheimer R, 1936, J BIOL CHEM, V114, P381; SHEMIN D, 1954, HARVEY LECT, P258; STETTEN D, 1940, J BIOL CHEM, V133, P320; STETTEN D, 1982, RUDI PERSPECTIVES BI, V25, P354	7	1	1	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1996	10	7					802	805		10.1096/fasebj.10.7.8635699	http://dx.doi.org/10.1096/fasebj.10.7.8635699			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UN798	8635699				2022-12-28	WOS:A1996UN79800016
J	Stearns, DM; Wise, JP; Patierno, SR; Wetterhahn, KE				Stearns, DM; Wise, JP; Patierno, SR; Wetterhahn, KE			Chromium(III) picolinate produces chromosome damage in Chinese hamster ovary cells	FASEB JOURNAL			English	Article						chromium; picolinic acid; nicotinic acid; chromosomal aberrations	LEAD CHROMATE PARTICLES; NICOTINIC-ACID; AMINO-ACIDS; PLASMA; METABOLISM; TRYPTOPHAN; COMPLEXES; BINDING; INVIVO; ZINC	Chromium(III) complexes currently being sold as dietary supplements were tested for their ability to cause chromosomal aberrations in Chinese hamster ovary cells. Complexes were tested in soluble and particulate forms. Chromium picolinate was found to produce chromosome damage 3-fold to 18-fold above control levels for soluble doses of 0.050, 0.10, 0.50, and 1.0 mM after 24 h treatment. Particulate chromium picolinate doses of 8.0 mu g/cm(2) (corresponding to a 0.10 mM solubilized dose) and 40 mu g/cm(2) (0.50 mM) produced aberrations 4-fold and 16-fold above control levels, respectively. Toxicity was measured as a decrease in plating efficiency relative to controls. The above treatments produced greater than or equal to 86% survival for all doses except 1.0 mM chromium picolinate, which produced 69 +/- 10% survival. Chromium nicotinate, nicotinic acid, and chromium(III) chloride hexahydrate did not produce chromosome damage at equivalent nontoxic doses. Damage was inferred to he caused by the picolinate ligand because picolinic acid in the absence of chromium was clastogenic. Data are evaluated in terms of their relevance to human exposure based on pharmacokinetic modeling of tissue accumulation and are discussed in terms of literature reporting toxic effects of picolinic acid.	GEORGE WASHINGTON UNIV, MED CTR, DEPT PHARMACOL, WASHINGTON, DC 20037 USA	George Washington University	Stearns, DM (corresponding author), DARTMOUTH COLL, DEPT CHEM, 6128 BURKE LAB, HANOVER, NH 03755 USA.			Wise, John/0000-0002-2587-2855	NATIONAL CANCER INSTITUTE [R01CA034869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005304, R01ES007167] Funding Source: NIH RePORTER; NCI NIH HHS [CA34869] Funding Source: Medline; NIEHS NIH HHS [ES05304, R01 ES005304, ES07167] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BOYNTON H, 1992, Patent No. 5087623; BRIDGEWATER LC, 1994, MOL CARCINOGEN, V9, P122, DOI 10.1002/mc.2940090304; COHEN MD, 1993, CRIT REV TOXICOL, V23, P255, DOI 10.3109/10408449309105012; CONNETT PH, 1983, STRUCT BOND, V54, P93; COOPER JA, 1984, INORG CHIM A-BIOINOR, V91, P1, DOI 10.1016/S0020-1693(00)84211-5; CUPO DY, 1985, CANCER RES, V45, P1146; De Flora S, 1989, LIFE CHEM REPORTS, V7, P169; DEROJASWALKER T, 1995, CHEM RES TOXICOL, V8, P473, DOI 10.1021/tx00045a020; DEVLIN TM, 1986, TXB BIOCH CLIN CORRE, P470; DOBBINS JP, 1991, Patent No. 5013752; DUBBINS JP, 1990, Patent No. 4918102; ETZEL KR, 1988, NUTR RES, V8, P1391, DOI 10.1016/S0271-5317(88)80007-1; EVANS GW, 1993, INT J SPORT NUTR, V3, P117, DOI 10.1123/ijsn.3.1.117; Evans GW, 1982, US Patent, Patent No. [4315927, 4,315,927]; EVANS GW, 1990, Patent No. 1314; FERNANDEZPOL JA, 1977, BIOCHEM BIOPH RES CO, V78, P136, DOI 10.1016/0006-291X(77)91231-1; FERNSTROM JD, 1979, AM J CLIN NUTR, V32, P1912, DOI 10.1093/ajcn/32.9.1912; GARGAS ML, 1994, DRUG METAB DISPOS, V22, P522; GONZALEZVERGARA E, 1981, ISRAEL J CHEM, V21, P18, DOI 10.1002/ijch.198100005; HIRAKU Y, 1995, CARCINOGENESIS, V16, P349, DOI 10.1093/carcin/16.2.349; HURLEY LS, 1981, PEDIATR RES, V15, P166, DOI 10.1203/00006450-198102000-00017; HURLEY LS, 1980, J NUTR, V110, P2536, DOI 10.1093/jn/110.12.2536; HURLEY LS, 1982, NUTR REV, V40, P65, DOI 10.1111/j.1753-4887.1982.tb05268.x; HUSZONEK J, 1993, AM J PSYCHIAT, V150, P1560; ISHIKAWA Y, 1994, BRIT J CANCER, V70, P160, DOI 10.1038/bjc.1994.268; JENSEN NL, 1989, Patent No. 10357; JOHNSON WT, 1982, J NUTR, V112, P914, DOI 10.1093/jn/112.5.914; KORTENKAMP A, 1987, TOXICOL ENVIRON CHEM, V14, P23, DOI 10.1080/02772248709357191; KUZNEZOVA LE, 1969, NATURE, V222, P484, DOI 10.1038/222484a0; LEE NA, 1994, DIABETES CARE, V17, P1449, DOI 10.2337/diacare.17.12.1449; LEFAVI RG, 1992, INT J SPORT NUTR, V2, P111, DOI 10.1123/ijsn.2.2.111; LEVIS AG, 1979, BRIT J CANCER, V40, P523, DOI 10.1038/bjc.1979.217; LIM TH, 1983, AM J PHYSIOL, V244, pR445, DOI 10.1152/ajpregu.1983.244.4.R445; MEHLER AH, 1964, SCIENCE, V145, P817, DOI 10.1126/science.145.3634.817; MEHLER AH, 1958, J BIOL CHEM, V232, P323; MELILLO G, 1994, J BIOL CHEM, V269, P8128; MERTZ W, 1993, J NUTR, V123, P626, DOI 10.1093/jn/123.4.626; MERTZ W, 1969, PHYSIOL REV, V49, P163, DOI 10.1152/physrev.1969.49.2.163; MERTZ W, 1975, NUTR REV, V33, P129, DOI 10.1111/j.1753-4887.1975.tb07105.x; MORITA I, 1990, J CHROMATOGR-BIOMED, V526, P367, DOI 10.1016/S0378-4347(00)82520-7; Nelson S.C., 1973, J NUTR, V103, P1182; NIELSEN FH, 1994, MODERN NUTRITION HLT, V1, P261; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; REBELLO T, 1982, AM J CLIN NUTR, V35, P1; RECORD CO, 1976, EUR J CLIN INVEST, V6, P387, DOI 10.1111/j.1365-2362.1976.tb00533.x; SEAL CJ, 1988, ANN NUTR METAB, V32, P186, DOI 10.1159/000177440; Sidransky H, 1986, Adv Exp Med Biol, V206, P187; SNOW ET, 1991, ENVIRON HEALTH PERSP, V92, P75, DOI 10.2307/3431140; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; STEARNS DM, 1992, INORG CHEM, V31, P5178, DOI 10.1021/ic00051a007; STEARNS DM, 1995, BIOCHEMISTRY-US, V34, P910, DOI 10.1021/bi00003a025; STEARNS DM, 1995, FASEB J, V9, P1649; STELLA M, 1982, MUTAT RES, V101, P151, DOI 10.1016/0165-1218(82)90005-2; SUHADOLNIK RJ, 1957, J BIOL CHEM, V228, P973; VANDERMAST RC, 1991, LANCET, V338, P851, DOI 10.1016/0140-6736(91)91504-N; WISE JP, 1992, MUTAT RES, V278, P69, DOI 10.1016/0165-1218(92)90287-A; WISE JP, 1994, CARCINOGENESIS, V15, P2249, DOI 10.1093/carcin/15.10.2249; WOLF H, 1971, AM J CLIN NUTR, V24, P792; XU JA, 1992, MUTAT RES, V280, P129; 1985, GUIDE SHORT TERM TES, P57	61	182	190	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1995	9	15					1643	1649		10.1096/fasebj.9.15.8529845	http://dx.doi.org/10.1096/fasebj.9.15.8529845			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TM761	8529845				2022-12-28	WOS:A1995TM76100019
J	Collins, MA; Zou, JY; Neafsey, EJ				Collins, MA; Zou, JY; Neafsey, EJ			Brain damage due to episodic alcohol exposure in vivo and in vitro: furosemide neuroprotection implicates edema-based mechanism	FASEB JOURNAL			English	Article						ethanol; neurodegeneration; excitotoxicity; binge intoxication; entorhinal cortex; dentate gyrus; dizocilpine maleate; olfactory bulb; cell swelling; intracranial pressure	ORGANOTYPIC HIPPOCAMPAL CULTURES; EPILEPTIFORM BURSTS; ARACHIDONIC-ACID; ETHANOL EXPOSURE; CELL LOSS; RAT; WITHDRAWAL; NEURONS; CEREBELLAR; SEIZURE	Adult rats intubated with a single dose of ethanol (alcohol; similar to 5 g/kg) for 5 to 10 successive days incur neurodegeneration in the entorhinal cortex, dentate gyrus, and olfactory bulbs accompanied by cerebrocortical edema and electrolyte (Na+, K+) accumulation. The brain damage is not lessened by cotreatment with the NMDA receptor antagonist MK-801; also, as reported elsewhere, MK-801 as well as non-NMDA receptor and Ca2+ channel antagonists are not neuroprotective in a similar, but more compressed, intoxication protocol. However, cotreatment with the electrolyte transport inhibitor/diuretic furosemide reduces alcohol-dependent cerebrocortical damage by 75-85% while preventing brain hydration and electrolyte elevations; olfactory bulb neurodegeneration is not attenuated. in parcel in vitro studies, rat organotypic entorhinal/hippocampal slice cultures exposed to alcohol (50-200 mM) 15 h/day for 6 days, mirroring episodic intoxication in vivo, demonstrate concentration-related release of the cytotoxic indicator, lactate dehydrogenase. Analogous to the in vivo findings, furosemide blocks this alcohol-induced in vitro cytotoxicity. Our results showing neuroprotection by furosemide indicate that brain edema and swelling are essential events in the brain damage induced by episodic alcohol exposure. Furosemide and related agents might be useful as neuroprotective agents in alcohol abuse. We suggest that the neurodegeneration is elicited in part by edema-dependent oxidative stress, but the regional selectivity of the damage may be best explained by physical (mechanical) compression of the limbic cortex against the adjacent tympanic bulla and subsequent neuronal cytoskeletal collapse. A scheme for these apparently nonexcitotoxic metabolic and mechanical pathways initiated by repeated alcohol exposure is proposed.	Loyola Univ, Stritch Sch Med, Dept Mol & Cellular Biochem, Maywood, IL 60153 USA; Loyola Univ, Stritch Sch Med, Dept Cell Biol Neurobiol & Anat, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago	Neafsey, EJ (corresponding author), Loyola Univ, Stritch Sch Med, Dept Mol & Cellular Biochem, Maywood, IL 60153 USA.	mcollin@luc.edu	Neafsey, Edward J./ABG-3419-2021					ADAMS H, 1972, INTRACRANIAL PRESSUR, P250; AHERN KV, 1994, NEUROSCI LETT, V165, P211; ANDREW RD, 1991, J NEUROL SCI, V101, P7, DOI 10.1016/0022-510X(91)90013-W; ASANO T, 1989, MOL CHEM NEUROPATHOL, V10, P101, DOI 10.1007/BF03159717; BAHR BA, 1995, J NEUROSCI RES, V42, P294, DOI 10.1002/jnr.490420303; Bazan N G, 1980, Adv Neurol, V28, P197; BEARD JD, 1968, J AMER MED ASSOC, V204, P135, DOI 10.1001/jama.204.2.135; Becker HC, 1996, ALCOHOL CLIN EXP RES, V20, pA121, DOI 10.1111/j.1530-0277.1996.tb01760.x; Beltramino C A, 1993, NIDA Res Monogr, V136, P101; Bruce AJ, 1996, P NATL ACAD SCI USA, V93, P2312, DOI 10.1073/pnas.93.6.2312; CHAN PH, 1983, ANN NEUROL, V13, P625, DOI 10.1002/ana.410130608; CHANDLER LJ, 1993, J NEUROCHEM, V60, P1578, DOI 10.1111/j.1471-4159.1993.tb03326.x; CLIFFORD DB, 1990, EPILEPSIA, V31, P382, DOI 10.1111/j.1528-1157.1990.tb05492.x; Collins MA, 1996, ALCOHOL CLIN EXP RES, V20, P284, DOI 10.1111/j.1530-0277.1996.tb01641.x; CORSO TD, 1997, IN PRESS ALCOHOL CLI; de Olmos J.S., 1981, NEUROANATOMICAL TRAC, P117, DOI [10.1007/978-1-4613-3189-6_4, DOI 10.1007/978-1-4613-3189-6_4]; Diekmann S, 1994, J Neural Transm Suppl, V44, P61; DUDEK FE, 1990, NEUROSCI LETT, V120, P267, DOI 10.1016/0304-3940(90)90056-F; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122, DOI 10.1152/ajplegacy.1949.157.1.122; Fix AS, 1996, TOXICOL PATHOL, V24, P291, DOI 10.1177/019262339602400305; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P504, DOI 10.1007/BF00310027; GROSS L, 1985, MUCH IS TOO MUCH EFF; HEATON MB, 1994, J NEUROSCI RES, V39, P305, DOI 10.1002/jnr.490390308; HOCHMAN DW, 1995, SCIENCE, V270, P99, DOI 10.1126/science.270.5233.99; HUNT WA, 1993, ALCOHOL, V10, P559, DOI 10.1016/0741-8329(93)90083-Z; HUNT WA, 1993, NIH PUBLICATION; KIMELBERG HK, 1993, J NEUROCHEM, V60, P1682, DOI 10.1111/j.1471-4159.1993.tb13391.x; KNOTT DH, 1968, SO MED J, V62, P485; LAMBIE DG, 1985, MED HYPOTHESES, V16, P377, DOI 10.1016/0306-9877(85)90058-1; LANCASTER FE, 1995, METAB BRAIN DIS, V10, P125, DOI 10.1007/BF01991860; LERMA J, 1992, MOL PHARMACOL, V41, P217; LOVINGER DM, 1993, ALCOHOL CLIN EXP RES, V17, P19, DOI 10.1111/j.1530-0277.1993.tb00720.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lundqvist C, 1995, ALCOHOL ALCOHOLISM, V30, P737; MACVICAR BA, 1991, J NEUROSCI, V11, P1458; MANDER AJ, 1989, DRUG ALCOHOL DEPEN, V24, P23; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; MCCOWN TJ, 1990, ALCOHOL CLIN EXP RES, V14, P394, DOI 10.1111/j.1530-0277.1990.tb00492.x; Meldrum B S, 1994, Neurology, V44, pS14; MENZANO E, 1994, ALCOHOL CLIN EXP RES, V18, P895, DOI 10.1111/j.1530-0277.1994.tb00057.x; MURPHY VA, 1987, ANAL BIOCHEM, V161, P144, DOI 10.1016/0003-2697(87)90664-6; NICHOLS JM, 1993, ALCOHOL, V10, P269, DOI 10.1016/0741-8329(93)90004-8; OLSON JE, 1990, ANN EMERG MED, V19, P1113, DOI 10.1016/S0196-0644(05)81514-8; PANTAZIS NJ, 1993, ALCOHOL CLIN EXP RES, V17, P1014, DOI 10.1111/j.1530-0277.1993.tb05657.x; PAULABARBOSA MM, 1991, ALCOHOL CLIN EXP RES, V15, P834, DOI 10.1111/j.1530-0277.1991.tb00610.x; ROPER SN, 1992, ANN NEUROL, V31, P81, DOI 10.1002/ana.410310115; SATO N, 1991, AM J PHYSIOL, V260, pE946, DOI 10.1152/ajpendo.1991.260.6.E946; SmithSwintosky VL, 1996, J CEREBR BLOOD F MET, V16, P585, DOI 10.1097/00004647-199607000-00008; Snyder AK, 1996, ROLE GLIA NEUROTOXIC, P111; SNYDER H, 1992, Journal of Emergency Medicine, V10, P129, DOI 10.1016/0736-4679(92)90205-8; SPARENBORG S, 1992, NEUROPHARMACOLOGY, V31, P357, DOI 10.1016/0028-3908(92)90068-Z; STAUB F, 1994, J CEREBR BLOOD F MET, V14, P1030, DOI 10.1038/jcbfm.1994.135; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Switzer R. C., 1982, ANAT REC, V202, p186A; SWITZER RC, 1993, ANN NY ACAD SCI, V679, P341, DOI 10.1111/j.1749-6632.1993.tb18319.x; TAVARES MA, 1982, EXP NEUROL, V78, P574, DOI 10.1016/0014-4886(82)90075-9; TRABERT W, 1992, ACTA PSYCHIAT SCAND, V85, P376, DOI 10.1111/j.1600-0447.1992.tb10322.x; TSAI GC, 1995, AM J PSYCHIAT, V152, P332; UNTERBERG A, 1990, ACT NEUR S, V51, P104; UNTERBERG A, 1990, ADV NEUROL, V52, P55; Vallett M, 1997, ALCOHOL CLIN EXP RES, V21, P275; Veatch LM, 1996, ALCOHOL CLIN EXP RES, V20, P262, DOI 10.1111/j.1530-0277.1996.tb01638.x; VORNOV JJ, 1991, EXP NEUROL, V114, P11, DOI 10.1016/0014-4886(91)90079-R; WALKER DW, 1980, SCIENCE, V209, P711, DOI 10.1126/science.7394532; WASTERLAIN CG, 1993, EPILEPSIA, V34, pS37, DOI 10.1111/j.1528-1157.1993.tb05905.x; Zou JY, 1996, ALCOHOL CLIN EXP RES, V20, P1406, DOI 10.1111/j.1530-0277.1996.tb01141.x	66	87	94	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1998	12	2					221	230		10.1096/fasebj.12.2.221	http://dx.doi.org/10.1096/fasebj.12.2.221			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YV644	9472987	Bronze			2022-12-28	WOS:000071848400010
J	Low, SY; Rennie, MJ; Taylor, PM				Low, SY; Rennie, MJ; Taylor, PM			Signaling elements involved in amino acid transport responses to altered muscle cell volume	FASEB JOURNAL			English	Article						skeletal muscle; glutamine transport; phosphatidylinositol 3-kinase	RAT SKELETAL-MUSCLE; GLYCOGEN-SYNTHESIS; GLUTAMINE TRANSPORT; PHOSPHOINOSITIDE 3-KINASE; INTEGRIN; HEPATOCYTES; ACTIVATION; SYNTHASE; INSULIN; KINASE	Skeletal muscle glutamine uptake via the transport system N-m is subject to rapid (t(1/2) = approximate to 1 min) regulation after changes in cell volume by mechanisms that remain to be elucidated. Wortmannin (phosphatidylinositol 3-kinase inhibitor) but not rapamycin (inhibitor of p(70S6) kinase activation) prevents both hypo-osmotic swelling-induced stimulation and hyperosmotic shrinkage-induced inhibition of Na+-dependent glutamine uptake in primary culture of rat skeletal muscle, G-protein inhibitors (cholera, pertussis toxins) also abolished responses of glutamine transport to cell. volume changes whereas these responses were sustained in the presence of G-protein activators (MAS 7, lysophosphatidic acid), Swelling-induced activation of glutamine transport does not seem to involve release of autocrine factors because ''conditioned'' medium from swollen cells has no effect on previously unstimulated cells, System A amino acid transport exhibits responses to cell volume change that are opposite to those of system N-m, but these are also blocked by wortmannin. Active phosphatidylinositol 3-kinase appears to be required to enable muscle cells to exhibit rapid, volume-induced changes in amino acid transport when suitably stimulated.			Low, SY (corresponding author), UNIV DUNDEE,DEPT PHYSIOL & ANAT,DUNDEE DD1 4HN,SCOTLAND.		Taylor, Peter M/A-4667-2010					BAQUET A, 1991, BIOCHEM J, V273, P57, DOI 10.1042/bj2730057; BAQUET A, 1990, J BIOL CHEM, V265, P955; BODE BP, 1991, J BIOL CHEM, V266, P7376; CHEN BM, 1995, SCIENCE, V269, P1578, DOI 10.1126/science.7667637; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; Clarke MSF, 1996, FASEB J, V10, P502, DOI 10.1096/fasebj.10.4.8647349; Flynn A, 1996, FEBS LETT, V389, P162, DOI 10.1016/0014-5793(96)00564-9; Haussinger D, 1996, BIOCHEM J, V313, P697; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; Krause U, 1996, J BIOL CHEM, V271, P16668, DOI 10.1074/jbc.271.28.16668; Low SY, 1996, J PHYSIOL-LONDON, V495, P299, DOI 10.1113/jphysiol.1996.sp021594; Low SY, 1996, J PHYSIOL-LONDON, V492, P877, DOI 10.1113/jphysiol.1996.sp021353; MCCORMICK JI, 1995, BIOCHEM J, V311, P743, DOI 10.1042/bj3110743; MCDOWELL HE, 1995, AM J PHYSIOL-CELL PH, V269, pC1287, DOI 10.1152/ajpcell.1995.269.5.C1287; MEIJER AJ, 1992, J BIOL CHEM, V267, P5823; Neu J, 1996, FASEB J, V10, P829, DOI 10.1096/fasebj.10.8.8666159; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PEAK M, 1992, BIOCHEM J, V282, P797, DOI 10.1042/bj2820797; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; Rennie MJ, 1996, BIOCHEM SOC T, V24, P869, DOI 10.1042/bst0240869; RENNIE MJ, 1989, METABOLISM, V38, P47, DOI 10.1016/0026-0495(89)90140-6; SCHLIESS F, 1995, BIOCHEM J, V309, P13, DOI 10.1042/bj3090013; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; Shimizu Y, 1995, J CELL BIOL, V131, P1867, DOI 10.1083/jcb.131.6.1867; SOLER C, 1993, BIOCHEM J, V289, P653, DOI 10.1042/bj2890653; TADROS LB, 1993, AM J PHYSIOL, V265, pE135, DOI 10.1152/ajpendo.1993.265.1.E135; VARNIER M, 1995, AM J PHYSIOL-ENDOC M, V269, pE309, DOI 10.1152/ajpendo.1995.269.2.E309; WILSON E, 1995, J CLIN INVEST, V96, P2353; Wymann M. P., 1993, BIOCHEM J, V296, P297	30	58	59	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1997	11	13					1111	1117		10.1096/fasebj.11.13.9367345	http://dx.doi.org/10.1096/fasebj.11.13.9367345			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367345				2022-12-28	WOS:A1997YE98300008
J	Montero, M; Barrero, MJ; Alvarez, J				Montero, M; Barrero, MJ; Alvarez, J			[Ca2+] microdomains control agonist-induced Ca2+ release in intact HeLa cells	FASEB JOURNAL			English	Article						endoplasmic reticulum; recombinant aequorin; inositol 1,4,5-trisphosphate receptor	ENDOPLASMIC-RETICULUM; INTRACELLULAR STORES; INOSITOL TRISPHOSPHATE; FLUORESCENT INDICATOR; CELLULAR CALCIUM; AEQUORIN; OSCILLATIONS; MOBILIZATION; DEPENDENCE; RECEPTORS	We have monitored specifically the [Ca2+] in the lumen of the endoplasmic reticulum (ER) of intact HeLa cells using-an ER-targeted low Ca2+-affinity aequorin. The steady-state [Ca2+] in the ER was around 600 mu M Histamine induced a concentration-dependent decrease in lumenal [Ca2+], whose rate increased near one order of magnitude and became ''quantal'' when cytosolic [Ca2+] ([Ca2+](c)) was clamped with the Ca2+ chelator BAPTA. This effect was not due to decreased Ca2+ pumping because simultaneous addition of a SERCA inhibitor produced only additive effects, Given that inhibition by [Ca2+](c) of the inositol 1,4,5-trisphosphate-gated channels requires a [Ca2+](c) much higher than that observed in the bulk cytosol after histamine addition, we conclude that local [Ca2+](c) microdomains at the site of release strongly inhibit agonist-induced Ca2+ mobilization in intact cells, This effect should play a key role in the mechanism controlling cytosolic [Ca2+] oscillations and waves, and therefore in the generation of spatio-temporal Ca2+ patterns.	UNIV VALLADOLID, FAC MED, DEPT BIOQUIM & FISIOL, IBGM, E-47002 VALLADOLID, SPAIN; CSIC, MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid; Consejo Superior de Investigaciones Cientificas (CSIC)			Montero, Mayte/K-8212-2014; Alvarez, Javier/K-8210-2014	Montero, Mayte/0000-0001-7702-6653; Alvarez, Javier/0000-0003-0636-5521				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOOTMAN M, 1994, CURR BIOL, V4, P169, DOI 10.1016/S0960-9822(94)00041-2; BOOTMAN MD, 1994, J BIOL CHEM, V269, P24783; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Button D, 1996, MOL BIOL CELL, V7, P419, DOI 10.1091/mbc.7.3.419; CHATTON JY, 1995, FEBS LETT, V368, P165, DOI 10.1016/0014-5793(95)00632-J; Combettes L, 1996, EMBO J, V15, P2086, DOI 10.1002/j.1460-2075.1996.tb00562.x; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; HANNAERTMERAH Z, 1995, CELL CALCIUM, V18, P390, DOI 10.1016/0143-4160(95)90054-3; Hofer AM, 1996, CELL CALCIUM, V20, P235, DOI 10.1016/S0143-4160(96)90029-9; HOFER AM, 1995, FASEB J, V9, P788, DOI 10.1096/fasebj.9.9.7601343; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; KENDALL JM, 1992, BIOCHEM BIOPH RES CO, V189, P1008, DOI 10.1016/0006-291X(92)92304-G; Kendall JM, 1996, BIOCHEM J, V318, P383, DOI 10.1042/bj3180383; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; MARSHALL ICB, 1994, BIOCHEM J, V301, P591, DOI 10.1042/bj3010591; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; MUALLEM S, 1989, J BIOL CHEM, V264, P205; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; SHIMOMURA O, 1993, CELL CALCIUM, V14, P373, DOI 10.1016/0143-4160(93)90041-4; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; TSE FW, 1994, P NATL ACAD SCI USA, V91, P9750, DOI 10.1073/pnas.91.21.9750; Tse FW, 1997, NEURON, V18, P121, DOI 10.1016/S0896-6273(01)80051-9; VILLALOBOS C, 1995, FASEB J, V9, P815, DOI 10.1096/fasebj.9.9.7601345	32	65	66	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1997	11	11					881	885		10.1096/fasebj.11.11.9285486	http://dx.doi.org/10.1096/fasebj.11.11.9285486			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XT790	9285486				2022-12-28	WOS:A1997XT79000007
J	Ye, JP; Young, HA				Ye, JP; Young, HA			Negative regulation of cytokine gene transcription	FASEB JOURNAL			English	Review						nuclear factor; DNA methylation; T cell	NF-KAPPA-B; INTERFERON-GAMMA PROMOTER; TATA-BINDING PROTEIN; CBP-INDUCED STIMULATION; RNA-POLYMERASE-II; INTERLEUKIN-6 GENE; DNA-BINDING; NUCLEAR FACTOR; T-CELLS; TRANSGENIC MICE	Cytokines are a class of soluble proteins that mediate signals throughout the immune system as well as between immune effector cells and other cell populations, This class of proteins includes interleukins, interferons, and chemokines, The expression of cytokines is tightly controlled in the producing cells, and one of the most important regulatory steps in this control is gene transcription, The transcription of most cytokine genes is silent until a producing cell is activated by extracellular stimuli, It is very common that transcription of these genes initiates immediately upon activation and shuts down quickly even in the continuous presence of the stimulating agent, Work performed over the past decade has revealed much about the molecular mechanism responsible for transcriptional regulation of these genes, Positive and negative transcription factors function in a concerted manner to regulate transcription of a specific cytokine at the promoter or intron region. We focus on recent progress in the field of transcriptional regulation of cytokine genes with an emphasis on the negative regulation of cytokine gene transcription.	NCI, FREDERICK CANC RES & DEV CTR, DIV BASIC SCI, EXPT IMMUNOL LAB, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Ye, JP (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT CELLULAR & STRUCT BIOL, SAN ANTONIO, TX 78284 USA.		Ye, Jianping/N-1998-2017; Young, Howard/A-6350-2008	Ye, Jianping/0000-0003-3875-365X; Young, Howard/0000-0002-3118-5111				ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; ARYA SK, 1984, J IMMUNOL, V133, P273; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; Campbell PM, 1996, TRANSPLANTATION, V61, P933, DOI 10.1097/00007890-199603270-00016; Cantorna MT, 1996, J IMMUNOL, V156, P2674; CASOLARO V, 1995, P NATL ACAD SCI USA, V92, P11623, DOI 10.1073/pnas.92.25.11623; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHRIVIA JC, 1990, J EXP MED, V172, P661, DOI 10.1084/jem.172.2.661; Cippitelli M, 1996, J BIOL CHEM, V271, P26783, DOI 10.1074/jbc.271.43.26783; CIPPITELLI M, 1995, J BIOL CHEM, V270, P12548, DOI 10.1074/jbc.270.21.12548; DEGRAZIA U, 1994, J EXP MED, V180, P1485, DOI 10.1084/jem.180.4.1485; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; DEVOS K, 1992, J INTERFERON RES, V12, P95, DOI 10.1089/jir.1992.12.95; DIJKEMA R, 1985, EMBO J, V4, P761, DOI 10.1002/j.1460-2075.1985.tb03694.x; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Farmer G, 1996, MOL CELL BIOL, V16, P4295; FONG CLW, 1994, NUCLEIC ACIDS RES, V22, P1108, DOI 10.1093/nar/22.6.1108; Foulkes NS, 1996, BBA-REV CANCER, V1288, pF101, DOI 10.1016/S0304-419X(96)00025-X; GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668; GRANELLIPIPERNO A, 1990, J EXP MED, V172, P1869, DOI 10.1084/jem.172.6.1869; GRAY PW, 1987, LYMPHOKINES, V13, P151; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUHL D, 1987, CELL, V50, P1057, DOI 10.1016/0092-8674(87)90172-3; KUNSCH C, 1994, J IMMUNOL, V153, P153; KWOK RP, 1994, NATURE, V370, P177; LANG RA, 1987, CELL, V51, P675, DOI 10.1016/0092-8674(87)90136-X; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Luo C, 1996, MOL CELL BIOL, V16, P3955; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MELVIN AJ, 1995, EUR J IMMUNOL, V25, P426, DOI 10.1002/eji.1830250218; MIN LW, 1992, J IMMUNOL, V148, P1913; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MIYATAKE S, 1991, MOL CELL BIOL, V11, P5894, DOI 10.1128/MCB.11.12.5894; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; NABEL GJ, 1988, P NATL ACAD SCI USA, V85, P2934, DOI 10.1073/pnas.85.9.2934; NIMER S, 1990, MOL CELL BIOL, V10, P6084, DOI 10.1128/MCB.10.11.6084; NIMER SD, 1988, MOL CELL BIOL, V8, P1979, DOI 10.1128/MCB.8.5.1979; NOMIYAMA H, 1993, MOL CELL BIOL, V13, P2787, DOI 10.1128/MCB.13.5.2787; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NOURBAKHSH M, 1993, EMBO J, V12, P451, DOI 10.1002/j.1460-2075.1993.tb05677.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PAGLIOGIANNI F, 1993, J CLIN INVEST, V91, P1481; Parker D, 1996, MOL CELL BIOL, V16, P694; PENIX L, 1993, J EXP MED, V178, P1483, DOI 10.1084/jem.178.5.1483; Penix LA, 1996, J BIOL CHEM, V271, P31964, DOI 10.1074/jbc.271.50.31964; PFEUFFER I, 1994, J IMMUNOL, V153, P5572; POTTRATZ ST, 1994, J CLIN INVEST, V93, P944, DOI 10.1172/JCI117100; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Ray A, 1995, ANN NY ACAD SCI, V762, P79; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; RAY A, 1994, J BIOL CHEM, V269, P12940; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCALA R, 1990, CELL, V62, P1217; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; STEIN B, 1995, MOL CELL BIOL, V15, P4971; SUEMATSU S, 1989, P NATL ACAD SCI USA, V86, P7547, DOI 10.1073/pnas.86.19.7547; SUN PQ, 1995, J BIOL CHEM, V270, P7041, DOI 10.1074/jbc.270.13.7041; TABIBZADEH SS, 1989, J IMMUNOL, V142, P3134; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; YANG Y, 1990, NUCLEIC ACIDS RES, V18, P3083, DOI 10.1093/nar/18.10.3083; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Ye JP, 1996, MOL CELL BIOL, V16, P157; YE JP, 1995, J LEUKOCYTE BIOL, V58, P225, DOI 10.1002/jlb.58.2.225; Ye JP, 1996, MOL CELL BIOL, V16, P4744; YE JP, 1994, J BIOL CHEM, V269, P25728; Young HA, 1997, BLOOD, V89, P583, DOI 10.1182/blood.V89.2.583; YOUNG HA, 1994, J IMMUNOL, V153, P3603; YOUNG HA, 1995, J LEUKOCYTE BIOL, V58, P373, DOI 10.1002/jlb.58.4.373; Young HA, 1996, J INTERF CYTOK RES, V16, P563, DOI 10.1089/jir.1996.16.563; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	99	31	31	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1997	11	11					825	833		10.1096/fasebj.11.11.9285480	http://dx.doi.org/10.1096/fasebj.11.11.9285480			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XT790	9285480				2022-12-28	WOS:A1997XT79000001
J	Argiles, JM; LopezSoriano, J; Busquets, S; LopezSoriano, FJ				Argiles, JM; LopezSoriano, J; Busquets, S; LopezSoriano, FJ			Journey from cachexia to obesity by TNF	FASEB JOURNAL			English	Review						insulin resistance; adipose tissue; thermogenesis; adipostat; diabetes	TUMOR-NECROSIS-FACTOR; LIPOPROTEIN-LIPASE ACTIVITY; FACTOR-ALPHA CACHECTIN; BROWN ADIPOSE-TISSUE; INSULIN-RESISTANCE; CANCER CACHEXIA; GENE-EXPRESSION; GLUCOSE-METABOLISM; 3T3-L1 ADIPOCYTES; DIABETES-MELLITUS	Tumor necrosis factor-alpha (TNF-alpha) is a cytokine involved in the physiological and metabolic abnormalities found in cachectic states, Until very recently, it was inconceivable to think of TNF-alpha in obesity, However, recent studies have shown that TNF-alpha can also play a key role in obesity, the cytokine being overexpressed in adipose tissue of obese rodents and humans, The aim of this review is to reconcile the role of TNF-alpha in these two opposite metabolic situations: obesity and cachexia. It is suggested that TNF-alpha may have a key role in the control of body mass in normal weight-controlled situations and that abnormalities in either its production (during cachexia) or action (during obesity) are responsible for the lack of control of body weight.			Argiles, JM (corresponding author), UNIV BARCELONA,FAC BIOL,DEPT BIOQUIM & BIOL MOL,UNITAT BIOQUIM & BIOL MOL B,DIAGONAL 645,E-08071 BARCELONA,SPAIN.		Busquets, Silvia/C-5544-2017; Lopez-Soriano, Joaquin/AAB-7459-2019; Lopez-Soriano, Francisco J./W-4947-2018	Busquets, Silvia/0000-0002-9319-3555; Lopez-Soriano, Francisco J./0000-0003-1493-3023; Lopez-Soriano, Joaquin/0000-0002-5374-2222				ADERKA D, 1985, LANCET, V2, P1190; Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; ALEMANY M, 1989, PROG FOOD NUTR SCI, V13, P45; ARBOS J, 1992, MOL CELL BIOCHEM, V112, P53, DOI 10.1007/BF00229643; ARGILES JM, 1988, MOL CELL BIOCHEM, V81, P3; Arner P, 1996, DIABETIC MED, V13, pS85; ASTRUP T, 1978, PROGR CHEM FIBRINOLY, P1; BALKWILL F, 1987, LANCET, V2, P1229; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BEUTLER B, 1985, NATURE, V316, P352; BIANCHI A, 1989, HORM METAB RES, V21, P11; BJORNTORP P, 1991, DIABETES CARE, V14, P1132, DOI 10.2337/diacare.14.12.1132; CARBO N, 1994, CLIN SCI, V87, P349, DOI 10.1042/cs0870349; CIANFLONE K, 1994, BIOCHEMISTRY-US, V33, P9489, DOI 10.1021/bi00198a014; CIANFLONE K, 1995, INT J OBESITY, V19, pS34; Cooley W.B., 1893, AM J MED SCI, V105, P487, DOI [10.1097/00000441-189305000-00001, DOI 10.1097/00000441-189305000-00001]; CORNELIUS P, 1988, BIOCHEM J, V249, P765, DOI 10.1042/bj2490765; COSTELLI P, 1993, J CLIN INVEST, V92, P2783, DOI 10.1172/JCI116897; DASCOMBE MJ, 1989, INT J OBESITY, V13, P367; DASCOMBE MJ, 1988, J PHYSIOL-LONDON, V403, pP41; DEFRONZO RA, 1985, J CLIN INVEST, V76, P149, DOI 10.1172/JCI111938; DEVOS P, 1995, J BIOL CHEM, V270, P15958, DOI 10.1074/jbc.270.27.15958; DONNER CC, 1985, DIABETES, V34, P831, DOI 10.2337/diabetes.34.9.831; EVANS RD, 1988, BIOCHEM J, V256, P1055, DOI 10.1042/bj2561055; FARGEAS MJ, 1993, GASTROENTEROLOGY, V104, P377, DOI 10.1016/0016-5085(93)90404-Z; FEINGOLD KR, 1992, ENDOCRINOLOGY, V130, P10, DOI 10.1210/en.130.1.10; FEINGOLD KR, 1987, J CLIN INVEST, V80, P1384; FELIG P, 1979, ENDOCRINOLOGY, V3, P1927; FLORES EA, 1989, J CLIN INVEST, V83, P1614, DOI 10.1172/JCI114059; FRAYN KN, 1992, CLIN SCI, V82, P1, DOI 10.1042/cs0820001; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; FRIED SK, 1989, J LIPID RES, V30, P1917; GARCIAMARTINEZ C, 1993, FEBS LETT, V323, P211, DOI 10.1016/0014-5793(93)81341-V; GOODMAN MN, 1991, AM J PHYSIOL, V260, pE727, DOI 10.1152/ajpendo.1991.260.5.E727; GRAU GE, 1987, SCIENCE, V237, P1210, DOI 10.1126/science.3306918; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; Hamann A, 1996, EXP CLIN ENDOCR DIAB, V104, P293, DOI 10.1055/s-0029-1211457; HAUNER H, 1995, DIABETOLOGIA, V38, P764, DOI 10.1007/s001250050350; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; JUE DM, 1990, BIOCHEMISTRY-US, V29, P8371, DOI 10.1021/bi00488a025; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; KAWAKAMI M, 1987, J BIOCHEM-TOKYO, V101, P331, DOI 10.1093/oxfordjournals.jbchem.a121917; KAWAKAMI M, 1981, J EXP MED, V154, P631, DOI 10.1084/jem.154.3.631; KENNEDY GC, 1953, PROC R SOC SER B-BIO, V140, P578, DOI 10.1098/rspb.1953.0009; KERN PA, 1988, J LIPID RES, V29, P909; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; KRAUSS RM, 1990, ENDOCRINOLOGY, V127, P1016, DOI 10.1210/endo-127-3-1016; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; LANG CH, 1989, AM J PHYSIOL, V257, pE301, DOI 10.1152/ajpendo.1989.257.3.E301; LAWSON DH, 1982, ANNU REV NUTR, V2, P277, DOI 10.1146/annurev.nu.02.070182.001425; LEAHY JL, 1990, DIABETES CARE, V13, P992, DOI 10.2337/diacare.13.9.992; Leroy P, 1996, J BIOL CHEM, V271, P2365, DOI 10.1074/jbc.271.5.2365; Liotta AL, 1989, INFLUENCE TUMOR DEV, P176; LLOVERA M, 1993, J NATL CANCER I, V85, P1334, DOI 10.1093/jnci/85.16.1334; LOPEZSORIANO J, 1995, MOL CELL BIOCHEM, V143, P113, DOI 10.1007/BF01816944; MADEJ T, 1995, FEBS LETT, V373, P13, DOI 10.1016/0014-5793(95)00977-H; MCGILL JB, 1994, DIABETES, V43, P104, DOI 10.2337/diabetes.43.1.104; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MOLDAWER LL, 1988, EUR J CLIN INVEST, V18, P486, DOI 10.1111/j.1365-2362.1988.tb01044.x; NAPOLITANO A, 1994, INT J OBESITY, V18, P213; NICHOLLS DG, 1983, BIOSCIENCE REP, V3, P431, DOI 10.1007/BF01121954; OGIWARA H, 1994, J SURG ONCOL, V57, P129, DOI 10.1002/jso.2930570211; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; OLIFF A, 1987, CELL, V50, P555, DOI 10.1016/0092-8674(87)90028-6; Oudart H, 1995, CAN J PHYSIOL PHARM, V73, P1625, DOI 10.1139/y95-724; PAPE ME, 1988, MOL ENDOCRINOL, V2, P395, DOI 10.1210/mend-2-5-395; PEKALA PH, 1983, P NATL ACAD SCI-BIOL, V80, P2743, DOI 10.1073/pnas.80.9.2743; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; PLATASALAMAN CR, 1994, AM J PHYSIOL, V266, pR1711, DOI 10.1152/ajpregu.1994.266.5.R1711; PRICE SR, 1986, ARCH BIOCHEM BIOPHYS, V251, P738, DOI 10.1016/0003-9861(86)90384-X; RAYFIELD EJ, 1982, AM J MED, V72, P439, DOI 10.1016/0002-9343(82)90511-3; Remesar X, 1997, FEBS LETT, V402, P9, DOI 10.1016/S0014-5793(96)01477-9; ROTHWELL NJ, 1990, NEUROSCI BIOBEHAV R, V14, P263, DOI 10.1016/S0149-7634(05)80037-5; ROTHWELL NJ, 1993, INT J OBESITY, V17, pS98; SAARINEN UM, 1990, CANCER RES, V50, P592; Saghizadeh M, 1996, J CLIN INVEST, V97, P1111, DOI 10.1172/JCI118504; Samad F, 1996, J CLIN INVEST, V97, P37, DOI 10.1172/JCI118404; Sanchis D, 1996, INT J OBESITY, V20, P588; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SCHWARTZ MW, 1995, AM J PHYSIOL-REG I, V269, pR949, DOI 10.1152/ajpregu.1995.269.5.R949; SCUDERI P, 1986, LANCET, V2, P1364; SELBY PJ, 1988, LANCET, V1, P483; SEMB H, 1987, J BIOL CHEM, V262, P8390; SOCHER SH, 1988, J NATL CANCER I, V80, P595, DOI 10.1093/jnci/80.8.595; SPIEGELMAN BM, 1993, CELL, V73, P625, DOI 10.1016/0092-8674(93)90243-J; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; SPRENGERS ED, 1987, BLOOD, V69, P381; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; STOCK MJ, 1986, BIOCHEM SOC T, V14, P2; STOVROFF MC, 1988, ARCH SURG-CHICAGO, V124, P94; TANAKA J, 1993, EXP NEUROL, V119, P235, DOI 10.1006/exnr.1993.1025; Tao YH, 1997, BBA-LIPID LIPID MET, V1344, P221, DOI 10.1016/S0005-2760(96)00144-0; TAYLOR R, 1988, BIOCHEM J, V250, P625, DOI 10.1042/bj2500625; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; VAGUE P, 1989, METABOLISM, V38, P913, DOI 10.1016/0026-0495(89)90241-2; VANDERPOLL T, 1991, AM J PHYSIOL, V261, pE457, DOI 10.1152/ajpendo.1991.261.4.E457; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WAAGE A, 1986, SCAND J IMMUNOL, V24, P739, DOI 10.1111/j.1365-3083.1986.tb02194.x; ZAMIR O, 1992, ARCH SURG-CHICAGO, V127, P170; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; [No title captured]	107	118	125	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1997	11	10					743	751		10.1096/fasebj.11.10.9271359	http://dx.doi.org/10.1096/fasebj.11.10.9271359			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XR105	9271359				2022-12-28	WOS:A1997XR10500004
J	Tjandrawinata, RR; Vincent, VL; HughesFulford, M				Tjandrawinata, RR; Vincent, VL; HughesFulford, M			Vibrational force alters mRNA expression in osteoblasts	FASEB JOURNAL			English	Article						vibration; shear force; mRNA expression; mechanical stress	HUMAN-ENDOTHELIAL-CELLS; MECHANICAL STRAIN; GENES; PATHWAY	Serum-deprived mouse osteoblastic (MC3T3E1) cells were subjected to a vibrational force modeled by NASA to simulate a space shuttle launch (7.83 G rms). The mRNA levels for eight genes were investigated to determine the effect of vibrational force on mRNA expression. The mRNA levels of two growth-related protooncogenes, c-fos and c-myc, were up-regulated significantly within 30 min after vibration, whereas those of osteocalcin as well as transforming growth factor-beta 1 were decreased significantly within 3 h after vibration. No changes were detected in the levels of beta-actin, histone H4, or cytoplasmic phospholipase A2 after vibration. No basal levels of cyclooxygenase-2 expression were detected. Zn addition, the extracellular concentrations of prostaglandin E-2 (PGE(2)), a potent autocrine/paracrine growth factor in bone, were not significantly altered after vibration most likely due to the serum deprivation state of the osteoblasts. In comparison with the gravitational launch profile, vibrational-induced changes in gene expression were greater both in magnitude and number of genes activated. Taken together, these data suggest that the changes in mRNA expression are due to a direct mechanical effect of the vibrational force on the osteoblast cells and not to changes in the local PGE(2) concentrations. The finding that launch forces induce gene expression is of utmost importance since many of the biological experiments do not dampen vibrational loads on experimental samples. This lack of dampening of vibrational forces may partially explain why l-G onboard controls sometimes do not reflect l-G ground controls. These data may also suggest that scientists use extra ground controls that are exposed to launch forces, have these forces dampened on launched samples, or use facilities such as Biorack that provide an onboard 1-G centrufuge in order to control for space shuttle launch forces.	VET AFFAIRS MED CTR,LAB CELL GROWTH 151F,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco			Tjandrawinata, Raymond R/F-1889-2013	Tjandrawinata, Raymond R/0000-0003-0461-9874; Hughes-Fulford, Millie/0000-0002-0756-068X				BACKUP P, 1994, AM J PHYSIOL, V266, pE567, DOI 10.1152/ajpendo.1994.266.4.E567; BANES AJ, 1990, AM BIOTECHNOL LAB, V8, P12; BIRCH MA, 1993, J BONE MINER RES, V8, P1155; BRIGHTON CT, 1992, J ORTHOPAED RES, V10, P385, DOI 10.1002/jor.1100100311; CARTER DR, 1987, J BIOMECH, V20, P1095, DOI 10.1016/0021-9290(87)90027-3; DIAMOND SL, 1989, SCIENCE, V243, P1483, DOI 10.1126/science.2467379; Fitzgerald J, 1996, EXP CELL RES, V228, P168, DOI 10.1006/excr.1996.0313; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; HUGHESFULFORD M, 1992, EXP CELL RES, V203, P150, DOI 10.1016/0014-4827(92)90050-I; HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116; IRVING J, 1992, EXP CELL RES, V202, P161, DOI 10.1016/0014-4827(92)90415-5; MALEK AM, 1993, J CLIN INVEST, V92, P2013, DOI 10.1172/JCI116796; MURRAY DW, 1990, CALCIFIED TISSUE INT, V47, P35, DOI 10.1007/BF02555863; NOSE K, 1994, EXP CELL RES, V211, P168, DOI 10.1006/excr.1994.1073; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; Sambrook J., 2002, MOL CLONING LAB MANU; Tjandrawinata RR, 1997, BRIT J CANCER, V75, P1111, DOI 10.1038/bjc.1997.192; WANG DL, 1995, J CELL PHYSIOL, V163, P400, DOI 10.1002/jcp.1041630220; WIERSBITZKY M, 1994, EXP CELL RES, V210, P52, DOI 10.1006/excr.1994.1008; WIRZ HRW, 1990, SCIENCE, V250, P1266	20	54	60	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1997	11	6					493	497		10.1096/fasebj.11.6.9194530	http://dx.doi.org/10.1096/fasebj.11.6.9194530			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XE404	9194530				2022-12-28	WOS:A1997XE40400012
J	Milzani, A; Dalledonne, I; Vailati, G; Colombo, R				Milzani, A; Dalledonne, I; Vailati, G; Colombo, R			Paraquat induces actin assembly in depolymerizing conditions	FASEB JOURNAL			English	Article						actin polymerization; F-actin; actin cross-linking proteins; FITC-phalloidin; myosin subfragment 1	HUMAN LUNG-CELLS; ALPHA-ACTININ; F-ACTIN; OXIDANT INJURY; SMOOTH-MUSCLE; RAT LUNG; TOXICITY; POLYMERIZATION; BINDING; PROTEIN	The molecular mechanism (or mechanisms) at the basis of paraquat (PQ) (a widely used herbicide) toxicity is far from being fully understood, Until now, two main points of view have emerged: 1) PQ-related cell injuries could be mediated by toxic oxygen free radicals coming from the metabolism of the herbicide by the microsomal enzyme system, and/or 2) PQ, by inducing mitochondrial swelling and breakage, could cause troubles in cell energy charge, then driving the cell to death, Recently, some of cytoskeletal structures (microtubules and microfilaments) have been proposed as further PQ cell targets, The microfilament system in particular seems to be markedly affected by the herbicide, but so far no direct evidence associates PQ to actin damage, In this study, experimental data are presented concerning the direct effect of PQ on actin dynamics in solution, We demonstrate that actin selectively binds PQ; moreover, PQ induces the formation of actin sopramolecular structures in depolymerizing medium (G-buffer), Furthermore, by the interactions with F-actin crosslinking proteins (alpha-actinin and filamin), FITC-phalloidin, and myosin subfragment 1 (S1), it is demonstrated that PQ-induced actin aggregates are undoubtedly built up by F-actin, Electron micrographs showed that PQ-induced actin polymers are very short and tend to aggregate one to another, This mutual cohesion leads to the steric blockage of polymer growing ends as suggested by nucleated actin polymerization assays, Sonication, by releasing F-actin fragments from short polymer aggregates, allows actin polymer ends to regain their growing ability.-Milzani, A., DalleDonne, I., Vailati, G., Colombo, R. Paraquat induces actin assembly in depolymerizing conditions.	UNIV MILAN, DEPT BIOL, LAB BIOCHEM & BIOPHYS CYTOSKELETAL STRUCT, I-20133 MILAN, ITALY	University of Milan			Milzani, Aldo/AHE-3364-2022; Dalle-Donne, Isabella/K-1436-2018; Dalle-Donne, Isabella/AHE-8993-2022	Milzani, Aldo/0000-0002-1496-6872; Dalle-Donne, Isabella/0000-0001-7098-6213				BALDWIN RC, 1975, TOXICOL APPL PHARM, V32, P298, DOI 10.1016/0041-008X(75)90220-3; BERSHADSKY AD, 1980, EXP CELL RES, V127, P421, DOI 10.1016/0014-4827(80)90446-2; BODY MR, 1979, J PHARMACOL EXP THER, V212, P109; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLIVANT CM, 1966, BMJ-BRIT MED J, V1, P1272, DOI 10.1136/bmj.1.5498.1272; BUS JS, 1974, BIOCHEM BIOPH RES CO, V58, P749, DOI 10.1016/S0006-291X(74)80481-X; BUS JS, 1984, ENVIRON HEALTH PERSP, V55, P37, DOI 10.2307/3429690; CAPPELLETTI G, 1993, B ENVIRON CONTAM TOX, V50, P717; Cappelletti G, 1996, EUR J CELL BIOL, V71, P293; CAPPELLETTI G, 1994, CELL BIOL TOXICOL, V10, P255, DOI 10.1007/BF00756765; CHEN T, 1985, BIOCHEMISTRY-US, V24, P137, DOI 10.1021/bi00322a019; CHOU IN, 1984, CELL BIOL INT REP, V8, P441, DOI 10.1016/0309-1651(84)90165-6; CLARK DG, 1966, BRIT J IND MED, V23, P126; COLUCCIO LM, 1984, J CELL BIOL, V99, P529, DOI 10.1083/jcb.99.2.529; CONNING DM, 1969, BRIT MED BULL, V25, P245, DOI 10.1093/oxfordjournals.bmb.a070712; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; DalleDonne I, 1995, BIOPHYS J, V69, P2710, DOI 10.1016/S0006-3495(95)80142-6; DOSTER AR, 1983, AM J PATHOL, V111, P56; EGELMAN EH, 1985, J MUSCLE RES CELL M, V6, P129, DOI 10.1007/BF00713056; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FORKERT PG, 1985, TOXICOLOGY, V35, P143, DOI 10.1016/0300-483X(85)90028-9; FRIEDEN C, 1983, BIOCHEMISTRY-US, V22, P5836, DOI 10.1021/bi00294a023; GORDON DJ, 1976, J BIOL CHEM, V251, P7474; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; GUMUCIO JJ, 1978, AM J PHYSIOL, V3, pC102; HALEY TJ, 1979, CLIN TOXICOL, V14, P1; HARLEY JB, 1977, YALE J BIOL MED, V50, P481; Heath D., 1977, BIOCH MECHANISMS PAR, P39; HINSHAW DB, 1991, ARCH BIOCHEM BIOPHYS, V288, P311, DOI 10.1016/0003-9861(91)90200-3; ILETT KF, 1974, TOXICOL APPL PHARM, V28, P216, DOI 10.1016/0041-008X(74)90007-6; KIMBROUGH RD, 1974, CHEST, V65, P655; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKOWICZ JR, 1988, MODERN PHYSICAL ME B, V11, P1; LI W, 1987, TOXICOL APPL PHARM, V91, P96, DOI 10.1016/0041-008X(87)90197-9; MAHVI D, 1977, AM J PATHOL, V86, P559; MCGOUGH A, 1994, J CELL BIOL, V126, P433, DOI 10.1083/jcb.126.2.433; OMANN GM, 1994, ARCH BIOCHEM BIOPHYS, V308, P407, DOI 10.1006/abbi.1994.1057; POLLARD TD, 1982, METHOD ENZYMOL, V85, P211; RIFKIN DB, 1979, CELL, V18, P361, DOI 10.1016/0092-8674(79)90055-2; ROSE MS, 1976, BIOCHEM PHARMACOL, V25, P419, DOI 10.1016/0006-2952(76)90344-0; ROSE MS, 1974, NATURE, V252, P314, DOI 10.1038/252314b0; *ROY SOC CHEM, 1984, AGR HDB HERB PAR DIC, pA310; SELDEN LA, 1994, ADV EXP MED BIOL, V358, P51; SHARP CW, 1972, TOXICOL APPL PHARM, V22, P241, DOI 10.1016/0041-008X(72)90174-3; SHIZUTA Y, 1976, J BIOL CHEM, V251, P6562; SKILLRUD DM, 1984, AM REV RESPIR DIS, V129, P995; SMITH LL, 1986, TARGET ORGAN TOXICIT, V2, P45; SMITH P, 1976, CRC CR REV TOXICOL, V4, P411, DOI 10.1080/10408447609164020; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUTOH K, 1983, BIOCHEMISTRY-US, V22, P1579, DOI 10.1021/bi00276a009; SUZUKI A, 1976, J BIOL CHEM, V251, P6860; TELLAM R, 1982, BIOCHEMISTRY-US, V21, P6046; WANG GY, 1992, J ELECTRON MICROSC, V41, P181; WANG K, 1975, P NATL ACAD SCI USA, V72, P4483, DOI 10.1073/pnas.72.11.4483; WEGNER A, 1982, BIOCHEMISTRY-US, V21, P1909, DOI 10.1021/bi00537a032; WIELAND T, 1977, NATURWISSENSCHAFTEN, V64, P303, DOI 10.1007/BF00446784; WILKINS JA, 1986, J CELL BIOL, V102, P1085, DOI 10.1083/jcb.102.3.1085; WONG RC, 1985, J TOXICOL ENV HEALTH, V15, P417, DOI 10.1080/15287398509530669; YUEN SH, 1967, ANALYST, V92, P375, DOI 10.1039/an9679200375	60	18	18	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1997	11	4					261	270		10.1096/fasebj.11.4.9068615	http://dx.doi.org/10.1096/fasebj.11.4.9068615			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WM850	9068615				2022-12-28	WOS:A1997WM85000008
J	Herren, B; Raines, EW; Ross, R				Herren, B; Raines, EW; Ross, R			Expression of a disintegrin-like protein in cultured human vascular cells and in vivo	FASEB JOURNAL			English	Article						RGD; endothelium; smooth muscle; atherosclerosis; integrins; metargidin; metalloproteinase	SPERM-EGG FUSION; MATRIX METALLOPROTEINASES; SUBSTRATE-SPECIFICITY; NONHUMAN PRIMATE; FAMILY; SEQUENCES; HYPERCHOLESTEROLEMIA; IDENTIFICATION; PROLIFERATION; INHIBITORS	Metalloproteinase-like, disintegrin-like, and cysteine-rich. proteins (MDCs) are potential novel regulators of cell-cell and cell-matrix interactions, as well as of matrix degradation, We have asked whether MDCs are expressed in cultured diploid vascular cells, and have identified MDC 15 in human aortic smooth muscle (SMC) and umbilical vein endothelium (HUVEC), MDC 15 mRNA is expressed at higher levels in HUVECs than in SMCs. In cultured SMCs, MDC 15 mRNA levels are not regulated by PDGF or IGF-I or by adherence to different extracellular matrices, Nor is regulation of MDC 15 mRNA levels observed in HUVEC monolayers at different cell densities, after multi-scratch wounding, or after treatment with TNF-alpha, LPS, or thrombin, However, differences in proteolytic processing of MDC 15 are observed in different HUVEC strains, In contrast to cultured arterial cells, MDC 15 protein is not expressed in vivo in normal vessels, but is up-regulated in lesions of atherosclerosis, These findings suggest that MDC 15 may be a potential regulator of vascular cell function and may be involved in the development of lesions of atherosclerosis.	UNIV WASHINGTON, SCH MED, DEPT PATHOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL47151, HL18645] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL047151, P01HL018645] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; BARAMOVA EN, 1989, ARCH BIOCHEM BIOPHYS, V275, P63, DOI 10.1016/0003-9861(89)90350-0; BARAMOVA EN, 1991, BIOMED BIOCHIM ACTA, V50, P762; Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; CHANG MY, 1995, ARTERIOSCL THROM VAS, V15, P1631, DOI 10.1161/01.ATV.15.10.1631; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COLLINS T, 1993, TRENDS CARDIOVAS MED, V3, P92, DOI 10.1016/1050-1738(93)90030-A; DELUCA M, 1995, BIOCHEM BIOPH RES CO, V206, P570, DOI 10.1006/bbrc.1995.1081; DOLLERY CM, 1995, CIRC RES, V77, P863, DOI 10.1161/01.RES.77.5.863; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JANG YS, 1994, J AM COLL CARDIOL, V24, P1591, DOI 10.1016/0735-1097(94)90162-7; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KINI RM, 1992, TOXICON, V30, P265, DOI 10.1016/0041-0101(92)90869-7; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; LINDER B, 1995, EXP CELL RES, V221, P66, DOI 10.1006/excr.1995.1353; MARUYAMA M, 1992, TOXICON, V30, P1387, DOI 10.1016/0041-0101(92)90514-6; MURPHY GJP, 1991, FEBS LETT, V289, P4, DOI 10.1016/0014-5793(91)80895-A; NEWBY AC, 1994, BASIC RES CARDIOL, V89, P59; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Rabiet MJP, 1996, ARTERIOSCL THROM VAS, V16, P488, DOI 10.1161/01.ATV.16.3.488; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SHANNON JD, 1989, J BIOL CHEM, V264, P11575; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; VANDERWAL AC, 1994, CARDIOVASC PATHOL, V3, P81, DOI 10.1016/1054-8807(94)90037-X; WESKAMP G, 1994, P NATL ACAD SCI USA, V91, P2748, DOI 10.1073/pnas.91.7.2748; WOLFSBERG TG, 1995, J CELL BIOL, V131, P175; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0	39	101	110	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1997	11	2					173	180		10.1096/fasebj.11.2.9039960	http://dx.doi.org/10.1096/fasebj.11.2.9039960			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WK509	9039960				2022-12-28	WOS:A1997WK50900010
J	Manev, H; Uz, T; Kharlamov, A; Joo, JY				Manev, H; Uz, T; Kharlamov, A; Joo, JY			Increased brain damage after stroke or excitotoxic seizures in melatonin-deficient rats	FASEB JOURNAL			English	Article						kainate; pinealectomy; carotid artery; cerebral artery	PINEAL-GLAND; NUCLEAR RECEPTOR; EXPRESSION; INDUCTION; SECRETION; SUBTYPES; P53	The pineal hormone melatonin is neuroprotective in vitro, and in vivo it is neuroprotective when given in pharmacological doses. Consequently, it has been hypothesized that with aging, as circulating levels of melatonin in mammals normally decrease, the brain might be at increased risk of neurodegeneration. However, direct evidence that melatonin deficiency leads to increased brain vulnerability is still lacking, We created melatonin deficiency in rats by pinealectomy and induced neurodegeneration by two models of focal brain ischemia/stroke and by glutamate receptor-mediated, epilepsy-like seizures, We observed greater neurodegeneration in melatonin-deficient animals than in controls, Our results suggest that endogenous melatonin may play a neuroprotective role, and that melatonin deficiency might be a pathophysiological mechanism in neurodegenerative diseases.	ALLEGHENY SINGER RES INST,PITTSBURGH,PA 15212; MED COLL PENN & HAHNEMANN UNIV,DEPT NEUROSURG,PITTSBURGH,PA 15212	Drexel University	Manev, H (corresponding author), UNIV ILLINOIS,INST PSYCHIAT,1601 W TAYLOR ST,M-C 912,CHICAGO,IL 60612, USA.				NATIONAL INSTITUTE ON AGING [K07AG000532] Funding Source: NIH RePORTER; NIA NIH HHS [KO7AG00532] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ACUNACASTROVIEJO D, 1995, J PINEAL RES, V19, P57; Antolin I, 1996, FASEB J, V10, P882, DOI 10.1096/fasebj.10.8.8666165; BARLOWWALDEN LR, 1995, NEUROCHEM INT, V26, P497, DOI 10.1016/0197-0186(94)00154-M; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; BRUGGER P, 1995, LANCET, V345, P1408, DOI 10.1016/S0140-6736(95)92600-3; CAGNOLI CM, 1995, J PINEAL RES, V18, P222, DOI 10.1111/j.1600-079X.1995.tb00163.x; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512290-00014; DAVIS M, 1995, STROKE, V26, P1072, DOI 10.1161/01.STR.26.6.1072; DUBOCOVICH ML, 1995, TRENDS PHARMACOL SCI, V16, P50, DOI 10.1016/S0165-6147(00)88978-6; GIUSTI P, 1995, EXP NEUROL, V131, P39, DOI 10.1016/0014-4886(95)90005-5; Giusti P, 1996, FASEB J, V10, P891, DOI 10.1096/fasebj.10.8.8666166; GIUSTI P, 1996, IN PRESS J PINEAL RE; HIRAMATSU K, 1993, ACTA NEUROCHIR, V120, P66, DOI 10.1007/BF02001472; MANEV H, 1994, NEUROREPORT, V5, P2661, DOI 10.1097/00001756-199412000-00064; MANEV H, 1996, NEUROL NEUROSCI, V9, P251; MELCHIORRI D, 1995, FASEB J, V9, P1205, DOI 10.1096/fasebj.9.12.7672513; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; Osborne NN, 1996, J NEUROCHEM, V66, pS57; PANG SF, 1990, J PINEAL RES, V9, P193, DOI 10.1111/j.1600-079X.1990.tb00708.x; Paxinos G, 1988, RAT BRAIN STEREOTAXI; REITER RJ, 1995, FRONT NEUROENDOCRIN, V16, P383, DOI 10.1006/frne.1995.1014; REITER RJ, 1973, EXP NEUROL, V38, P386, DOI 10.1016/0014-4886(73)90161-1; REITER RJ, 1972, PHYSIOL BEHAV, V9, P203, DOI 10.1016/0031-9384(72)90236-3; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; REITER RJ, 1991, MOL CELL ENDOCRINOL, V79, pC153, DOI 10.1016/0303-7207(91)90087-9; Reiter Russel J., 1994, Acta Neurobiologiae Experimentalis (Warsaw), V54, P31; REPPERT SM, 1995, NEURON, V15, P1003, DOI 10.1016/0896-6273(95)90090-X; Reppert SM, 1995, CELL, V83, P1059, DOI 10.1016/0092-8674(95)90131-0; ROJDMARK S, 1993, METABOLISM, V42, P1047, DOI 10.1016/0026-0495(93)90021-F; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; Sakhi S, 1996, NEUROREPORT, V7, P493, DOI 10.1097/00001756-199601310-00028; SANDYK R, 1992, INT J NEUROSCI, V62, P243; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; STOKKAN KA, 1991, BRAIN RES, V545, P66, DOI 10.1016/0006-8993(91)91270-B; Tan DX, 1993, ENDOCR J, V1, P57; UNLAP T, 1995, MOL BRAIN RES, V28, P193, DOI 10.1016/0169-328X(94)00202-P; Uz T, 1996, NEUROSCIENCE, V73, P631, DOI 10.1016/0306-4522(96)00155-8; WATSON BD, 1985, ANN NEUROL, V17, P497, DOI 10.1002/ana.410170513	39	196	203	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1996	10	13					1546	1551		10.1096/fasebj.10.13.8940301	http://dx.doi.org/10.1096/fasebj.10.13.8940301			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VU982	8940301				2022-12-28	WOS:A1996VU98200012
J	Sulica, A; Herberman, RB				Sulica, A; Herberman, RB			Cytophilic immunoglobulins revisited via natural killer cells	FASEB JOURNAL			English	Article						Fc receptors; immunoregulation; cytotosic cells; antibodies	LARGE GRANULAR LYMPHOCYTES; HUMAN-IGG; MONOMERIC IGG; CYTO-TOXICITY; BINDING-SITE; FC-RECEPTORS; INHIBITION; EXPRESSION; ANTIBODIES; AFFINITY	Cytophilia is one of the biologic properties of the Fe region of immunoglobulins operationally defined as the ability of an antibody molecule to attach to certain cell types before combination with antigen, By attachment of cytophilic antibody to membrane Fc receptors, cells become ''armed'' with antibodies and able to interact specifically with soluble or particulate antigens, In contrast to this cytophilia, the so-called opsonic antibody binds to FcR of various cell types only after it has complexed with antigen, In spite of knowledge of cytophilic properties of immunoglobulins for more than 30 years and an impressive accumulation of facts regarding the structure and function of cell-surface FcR binding IgG, IgE, or IgA molecules, less progress has been made in understanding the molecular basis of cytophilia. Our extensive studies of the structural and functional aspects of the interaction of IgG in monomeric form with human natural killer cells, via the type IIIA IgG Fc receptor (Fc gamma RIIIA), provide a focal point for revisiting this major pathway of direct and continuous communication between the humoral and cellular compartments of the immune system.	UNIV PITTSBURGH, INST CANC, PITTSBURGH, PA 15213 USA; SOS MIHAI BRAVU, CTR IMMUNOL, BUCHAREST 79650, ROMANIA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Romanian Academy of Sciences; Stefan S. Nicolau Institute of Virology			Institute of Virology, Stefan S Nicolau/HGE-9069-2022					AREND WP, 1973, J IMMUNOL, V110, P1455; BANCU AC, 1988, CELL IMMUNOL, V114, P246, DOI 10.1016/0008-8749(88)90319-X; BERKEN A, 1966, J EXP MED, V123, P119, DOI 10.1084/jem.123.1.119; BOYDEN SV, 1963, CELL BOUND ANTIBODIE, P7; BRODT P, 1981, J RETICULOENDOTH SOC, V30, P283; BURTON DR, 1985, MOL IMMUNOL, V22, P161, DOI 10.1016/0161-5890(85)90151-8; CAPRON M, 1984, CELL IMMUNOL, V83, P60, DOI 10.1016/0008-8749(84)90225-9; CHAPPEL MS, 1991, P NATL ACAD SCI USA, V88, P9036, DOI 10.1073/pnas.88.20.9036; deHaas M, 1996, J IMMUNOL, V156, P2948; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; ENGELHARD D, 1986, J PEDIATR-US, V108, P77, DOI 10.1016/S0022-3476(86)80772-7; FLORES M, 1977, CANCER, V39, P494, DOI 10.1002/1097-0142(197702)39:2<494::AID-CNCR2820390218>3.0.CO;2-8; FORTUNE F, 1990, CLIN EXP IMMUNOL, V82, P326; GALATIUC C, 1995, CELL IMMUNOL, V163, P167, DOI 10.1006/cimm.1995.1113; GHERMAN M, 1987, MOL IMMUNOL, V24, P743, DOI 10.1016/0161-5890(87)90057-5; Herberman RB, 1985, UCLA S MOL CELLULAR, V27, P193; HERMAN R, 1980, INFECT IMMUN, V28, P585; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; IMIR T, 1976, J IMMUNOL, V117, P1938; JAIN S, 1986, Journal of Hygiene Epidemiology Microbiology and Immunology (Prague), V30, P207; JEFFERIS R, 1995, IMMUNOL LETT, V44, P111, DOI 10.1016/0165-2478(94)00201-2; KOREN HS, 1978, J IMMUNOL, V120, P796; KULCZYCK.A, 1974, J EXP MED, V140, P1676, DOI 10.1084/jem.140.6.1676; LANIER LL, 1983, J IMMUNOL, V131, P1789; Leibson PJ, 1995, NAT IMMUN, V14, P117; Leslie R G, 1979, Curr Top Microbiol Immunol, V88, P25; LOBO PI, 1976, J IMMUNOL, V117, P939; LYNCH RG, 1990, FC RECEPTORS ACTION, P305; MANCIULEA M, 1989, MOL IMMUNOL, V26, P1087, DOI 10.1016/0161-5890(89)90052-7; Manciulea M, 1996, CELL IMMUNOL, V167, P63, DOI 10.1006/cimm.1996.0008; METES D, 1994, NAT IMMUN, V13, P289; MITSUNAGA M, 1987, ACTA MED OKAYAMA, V41, P205; MURAYAMA T, 1990, CLIN IMMUNOL IMMUNOP, V55, P297, DOI 10.1016/0090-1229(90)90105-Y; ONICA D, 1988, APMIS, V96, P525, DOI 10.1111/j.1699-0463.1988.tb05339.x; PARISH WE, 1965, NATURE, V208, P594, DOI 10.1038/208594a0; PARRILLO JE, 1977, IMMUNOLOGY, V33, P839; Perlmann P, 1970, Cell Immunol, V1, P300, DOI 10.1016/0008-8749(70)90051-1; PETERSON PK, 1983, J INFECT DIS, V148, P1040, DOI 10.1093/infdis/148.6.1040; PRICOP L, 1993, J IMMUNOL, V151, P3018; RABINOWICH H, 1996, IN PRESS J IMMUNOL; ROSENBLATT J, 1977, J IMMUNOL, V118, P981; SEGAL DM, 1977, J IMMUNOL, V118, P1338; SORKIN E, 1963, IMMUNOLOGICALLY COMP, P38; SULICA A, 1982, J IMMUNOL, V128, P1031; SULICA A, 1976, SCAND J IMMUNOL, V5, P1191; SULICA A, 1979, IMMUNOLOGY, V38, P173; SULICA A, 1993, CELL IMMUNOL, V147, P397, DOI 10.1006/cimm.1993.1079; SULICA A, 1979, EUR J IMMUNOL, V9, P979, DOI 10.1002/eji.1830091212; TAO MH, 1989, J IMMUNOL, V143, P2595; TIZARD IR, 1971, BACTERIOL REV, V35, P365, DOI 10.1128/MMBR.35.4.365-378.1971; TIZARD IR, 1969, INT ARCH ALLER A IMM, V36, P332, DOI 10.1159/000230755; TRINCHIERI G, 1993, NAT IMMUN, V12, P218; TROYE M, 1977, J IMMUNOL, V119, P1061; TRUCCO M, 1981, IMMUNOLOGICAL METHOD, V2, P1; TYLER DS, 1989, AIDS RES HUM RETROV, V5, P557, DOI 10.1089/aid.1989.5.557; VANCE BA, 1993, J IMMUNOL, V151, P6429; WHELEN AC, 1993, J PARASITOL, V79, P908, DOI 10.2307/3283729; WHITESIDE TL, 1989, CLIN IMMUNOL IMMUNOP, V53, P1, DOI 10.1016/0090-1229(89)90096-2; WILSON AB, 1985, CELL IMMUNOL, V90, P196, DOI 10.1016/0008-8749(85)90181-9; WRIGHT JF, 1990, J BIOL CHEM, V265, P10506	60	7	7	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1996	10	13					1495	1504		10.1096/fasebj.10.13.8940295	http://dx.doi.org/10.1096/fasebj.10.13.8940295			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VU982	8940295				2022-12-28	WOS:A1996VU98200006
J	Cairo, G; Castrusini, E; Minotti, G; BernelliZazzera, A				Cairo, G; Castrusini, E; Minotti, G; BernelliZazzera, A			Superoxide and hydrogen peroxide-dependent inhibition of iron regulatory protein activity: A protective stratagem against oxidative injury	FASEB JOURNAL			English	Article						superoxide anion; superoxide dismutase; IRP; intra-cellular stores; iron-responsive element	ELEMENT-BINDING-PROTEIN; FE-S CLUSTER; MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; LIPID-PEROXIDATION; FERRITIN SYNTHESIS; GENE-EXPRESSION; REDOX REACTIONS; STRESS; ACONITASE	Cellular iron homeostasis is regulated by the cytoplasmic iron regulatory protein (IRP), which binds to iron-responsive elements (IRE) of mRNAs, modulating iron uptake and sequestration, respectively. When iron is scarce, IRP binds to IRE and coordinately increases the synthesis of transferrin receptor and decreases that of ferritin, thus providing the cell with readily available free iron. When iron is in excess, IRP does not bind and iron sequestration prevails over iron uptake. We have found that incubation of rat liver lysates with xanthine oxidase (XO), which generates superoxide (O-2(.-)) and hydrogen peroxide (H2O2), caused a remarkable but reversible inhibition of IRP activity, as the formation of IRE-IRP decreased by 70-80% but returned to baseline values upon exposure to a reducing agent like 2-mercaptoethanol. IRP inhibition was prevented by separate or simultaneous addition of superoxide dismutase and catalase, showing that both O-2(.-). and H2O2 were involved. By contrast, iron chelators and hydroxyl radical scavengers did not impede the inhibition of IRP, suggesting that O-2(.-) and H2O2 acted independently of fi ee iron sources. Ferritin enhanced IRP inhibition, but this process involved tightly bound iron centers that shunted reducing equivalents from XO and returned them to oxygen, thus increasing the formation of O-2(.-). In agreement with the exclusive role of O-2(.-) and H2O2, XO also inhibited recombinant human IRP in the absence of iron. These results demonstrate that O2(.-). and H2O2 can directly but reversibly down-regulate the RNA-binding activity of IRP, causing transient decrease of free iron that otherwise would convert them into more potent oxidants such as hydroxyl radicals or equally aggressive iron-peroxo complexes. This establishes a novel protective stratagem against oxidative injury under pathophysiologic conditions characterized by the excessive generation of O2(.-) and H2O2.	UNIV CATTOLICA SACRO CUORE,IST FARMACOL,ROME,ITALY	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Cairo, G (corresponding author), UNIV MILAN,IST PATOL GEN,CNR,CTR STUDIO PATOL CELLULARE,VIA MANGIAGALLI 31,I-20133 MILAN,ITALY.		Cairo, Gaetano/M-5104-2016	Cairo, Gaetano/0000-0002-8147-4720; Minotti, Giorgio/0000-0002-5678-6175				AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; BALLA G, 1992, J BIOL CHEM, V267, P18148; BEINERT H, 1993, FASEB J, V7, P1442, DOI 10.1096/fasebj.7.15.8262329; BIEMOND P, 1986, BIOCHEM J, V239, P169, DOI 10.1042/bj2390169; CAIRO G, 1994, J BIOL CHEM, V269, P6405; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; CHU E, 1994, J BIOL CHEM, V269, P20289; CLERCH LB, 1992, J BIOL CHEM, V267, P2853; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; FLECHA BG, 1991, FREE RADICAL BIO MED, V10, P93; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FLISS HF, 1991, ARCH BIOCHEM BIOPHYS, V293, P195; GORDEUK VR, 1987, ANNU REV NUTR, V7, P485, DOI 10.1146/annurev.nu.07.070187.002413; GUO B, 1994, J BIOL CHEM, V269, P24252; HENDERSON BR, 1993, J BIOL CHEM, V269, P27327; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; KADIR FHA, 1991, BIOCHEM J, V278, P817, DOI 10.1042/bj2780817; KEHRER JP, 1989, FREE RADICAL RES COM, V5, P305, DOI 10.3109/10715768909073412; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; LEVI S, 1992, BIOCHEM J, V288, P591, DOI 10.1042/bj2880591; LIN JJ, 1990, ENZYME, V44, P59, DOI 10.1159/000468747; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MARTINS EAL, 1995, ARCH BIOCHEM BIOPHYS, V316, P128, DOI 10.1006/abbi.1995.1019; MINOTTI G, 1993, CHEM RES TOXICOL, V6, P134, DOI 10.1021/tx00032a001; MINOTTI G, 1987, ARCH BIOCHEM BIOPHYS, V253, P257, DOI 10.1016/0003-9861(87)90659-X; MINOTTI G, 1992, ARCH BIOCHEM BIOPHYS, V297, P189, DOI 10.1016/0003-9861(92)90661-F; MINOTTI G, 1995, J CLIN INVEST, V95, P1595, DOI 10.1172/JCI117833; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1992, EUR J BIOCHEM, V208, P597, DOI 10.1111/j.1432-1033.1992.tb17224.x; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; PHILPOTT CC, 1993, J BIOL CHEM, V268, P17655; POWIS G, 1989, FREE RADICAL BIO MED, V6, P63, DOI 10.1016/0891-5849(89)90162-7; RADY R, 1991, ARCH BIOCHEM BIOPHYS, V286, P117; ROMANIUK PJ, 1985, BIOCHEMISTRY-US, V24, P4239, DOI 10.1021/bi00336a064; RUBIN E, 1994, PATHOLOGY, P11; RYAN TP, 1992, CRIT REV TOXICOL, V22, P119, DOI 10.3109/10408449209146308; STRALIN P, 1994, BIOCHEM J, V298, P347, DOI 10.1042/bj2980347; THEIL EC, 1990, J BIOL CHEM, V265, P4771; THEIL EC, 1994, BIOCHEM J, V304, P1; THOMAS JP, 1986, BIOCHIM BIOPHYS ACTA, V884, P448, DOI 10.1016/0304-4165(86)90195-9; TORCHINSKY YM, 1981, SULFUR PROTEINS, P48; ULVIK R, 1979, BIOCHIM BIOPHYS ACTA, V588, P256, DOI 10.1016/0304-4165(79)90209-5; VILE GF, 1993, J BIOL CHEM, V268, P14678; WATT RK, 1992, BIOCHEMISTRY-US, V31, P9673, DOI 10.1021/bi00155a021; WORWOOD M, 1989, J INT MED, P381; YAMAZAKI I, 1990, J BIOL CHEM, V265, P13589; YAMAZAKI I, 1991, J AM CHEM SOC, V113, P7588, DOI 10.1021/ja00020a021	53	103	105	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1996	10	11					1326	1335		10.1096/fasebj.10.11.8836047	http://dx.doi.org/10.1096/fasebj.10.11.8836047			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VJ717	8836047				2022-12-28	WOS:A1996VJ71700013
J	Hack, V; Gross, A; Kinscherf, R; Bockstette, M; Fiers, W; Berke, G; Droge, W				Hack, V; Gross, A; Kinscherf, R; Bockstette, M; Fiers, W; Berke, G; Droge, W			Abnormal glutathione and sulfate levels after interleukin 6 treatment and in tumor-induced cachexia	FASEB JOURNAL			English	Article						IL-6; cytokines; glutathione, role in cachexia; cysteine catabolism, role in cachexia	AMINO-ACID-CONCENTRATIONS; NECROSIS-FACTOR-ALPHA; CANCER CACHEXIA; METABOLISM; PROTEIN; TRANSPORT; GAMMA; MALNUTRITION; INFLAMMATION; SYNTHETASE	Excessive urea excretion associated with a negative nitrogen balance and massive loss of skeletal muscle mass (cachexia) is a frequent life-threatening complication in malignancies and HIV infection. As these patients have often elevated interleukin-6 (IL-6) and abnormally low cystine levels, we have now determined the intracellular levels of glutathione and other cysteine derivatives in the liver and muscle tissue of IL-6-treated or tumor-bearing C57BL/6 mice, IL-6 treatment or inoculation of the MCA-105 fibrosarcoma caused a significant increase in hepatic gamma-glutamyl-cysteine synthetase activity and a decrease in the sulfate level, glutamine/urea ratio, and glutamine/glutamate ratio, suggesting that a decrease of the proton generating cysteine catabolism in the liver may increase carbamoyl-phosphate synthesis and urea formation at the expense of net glutamine synthesis. Treatment with cysteine, conversely, caused an increase in sulfate, gluzamine/urea ratios, and glutamine/glutamate ratios and may thus be a useful therapeutic tool in clinical medicine, In contrast to the liver, muscle tissue of tumor-bearing mice showed decreased glutathione and increased sulfate levels, suggesting that the cysteine pool may be drained by an increased cysteine catabolism in this tissue, The findings indicate that tumor cachexia is triggered initially by IL-6 and is later sustained by processes driven by an abnormal cysteine metabolism in different organs.	DEUTSCH KREBSFORSCHUNGSZENTRUM,DIV IMMUNOCHEM,D-69120 HEIDELBERG,GERMANY; STATE UNIV GHENT,MOL BIOL LAB,B-9000 GHENT,BELGIUM; WEIZMANN INST SCI,IL-76100 REHOVOT,ISRAEL	Helmholtz Association; German Cancer Research Center (DKFZ); Ghent University; Weizmann Institute of Science			Kinscherf, Ralf/AAV-7164-2021					AUDUS T, 1987, FEBS LETT, V221, P18; BANNAI S, 1986, J MEMBRANE BIOL, V89, P1, DOI 10.1007/BF01870891; BRENNAN MF, 1977, CANCER RES, V37, P2359; BRENNAN MF, 1986, DIGEST DIS SCI, V31, pS77, DOI 10.1007/BF01295991; BROUCKAERT P, 1989, J EXP MED, V169, P2257, DOI 10.1084/jem.169.6.2257; BURT ME, 1983, ANN SURG, V198, P685, DOI 10.1097/00000658-198312000-00003; CAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251; CERRA FB, 1980, ANN SURG, V192, P570, DOI 10.1097/00000658-198010000-00015; CRUNFELD C, 1991, GASTROINTESTINAL NUT, P207; DEWYS WD, 1980, AM J MED, V69, P491, DOI 10.1016/S0149-2918(05)80001-3; DROGE W, 1988, BIOL CHEM H-S, V369, P143, DOI 10.1515/bchm3.1988.369.1.143; DROGE W, 1988, J CANCER RES CLIN, V114, P124, DOI 10.1007/BF00417824; ECK HP, 1989, J CANCER RES CLIN, V115, P571, DOI 10.1007/BF00391360; ECK HP, 1991, LANCET, V338, P346, DOI 10.1016/0140-6736(91)90482-5; FEIN R, 1985, CANCER, V56, P2512, DOI 10.1002/1097-0142(19851115)56:10<2512::AID-CNCR2820561032>3.0.CO;2-9; FOX BA, 1990, J BIOL RESP MODIF, V9, P499; FRIEDMAN PJ, 1987, NUTR RES, V7, P707, DOI 10.1016/S0271-5317(87)80101-X; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Hack V, 1996, J MOL MED-JMM, V74, P337, DOI 10.1007/BF00207511; HAMETT WL, 1952, SURVEY CANC LONDON; HAUSSINGER D, 1985, EUR J BIOCHEM, V152, P381, DOI 10.1111/j.1432-1033.1985.tb09208.x; HEIM ME, 1980, RECENT ADV CLIN NUTR, V1, P185; HORTIN GL, 1994, CLIN CHEM, V40, P785; HUNTER EAL, 1994, J NUTR, V124, P2319, DOI 10.1093/jn/124.12.2319; JABLONS DM, 1989, J IMMUNOL, V142, P1542; LAWSON DH, 1982, ANNU REV NUTR, V2, P277, DOI 10.1146/annurev.nu.02.070182.001425; MAKOWSKE M, 1982, J BIOL CHEM, V257, P5663; OLDENBURG HSA, 1993, EUR J IMMUNOL, V23, P1889, DOI 10.1002/eji.1830230824; OLIFF A, 1988, CELL, V54, P141, DOI 10.1016/0092-8674(88)90543-0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PISTERS PWT, 1993, CRIT REV CL LAB SCI, V30, P223, DOI 10.3109/10408369309084669; PLAITAKIS A, 1987, ANN NEUROL, V22, P575, DOI 10.1002/ana.410220503; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; ROTH E, 1985, SURGERY, V97, P436; SHAW JHF, 1987, SURGERY, V101, P181; SHERRY BA, 1989, FASEB J, V3, P1956, DOI 10.1096/fasebj.3.8.2721856; SHI MM, 1994, J BIOL CHEM, V269, P26512; SIEGEL JH, 1979, SURGERY, V86, P163; STRAIN AJ, 1979, INVEST CELL PATHOL, V2, P181; STRASSMANN G, 1992, J CLIN INVEST, V89, P1681, DOI 10.1172/JCI115767; STRIEBEL JP, 1986, INFUSIONSTHERAPIE, V13, P92; SVANINGER G, 1987, J NATL CANCER I, V78, P913; TALGREN LC, 1980, ACTA MED SCAND S, V640, P1; TAYEK JA, 1992, J AM COLL NUTR, V11, P445; TESSITORE L, 1993, ARCH BIOCHEM BIOPHYS, V306, P52, DOI 10.1006/abbi.1993.1479; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TISDALE MJ, 1991, BRIT J CANCER, V63, P337, DOI 10.1038/bjc.1991.80; TRACEY KJ, 1988, J EXP MED, V167, P1211, DOI 10.1084/jem.167.3.1211; TURKSEN K, 1992, P NATL ACAD SCI USA, V89, P5068, DOI 10.1073/pnas.89.11.5068; Warren S, 1932, AM J MED SCI, V184, P610, DOI 10.1097/00000441-193211000-00002; WATANABE H, 1987, J EXP MED, V165, P628, DOI 10.1084/jem.165.3.628; WATERHOUSE C, 1968, CANCER RES, V39, P1968; ZHANG PC, 1992, CLIN CHEM, V38, P1198	53	49	49	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1996	10	10					1219	1226		10.1096/fasebj.10.10.8751725	http://dx.doi.org/10.1096/fasebj.10.10.8751725			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VD429	8751725				2022-12-28	WOS:A1996VD42900014
J	Serhan, CN; Haeggstrom, JZ; Leslie, CC				Serhan, CN; Haeggstrom, JZ; Leslie, CC			Lipid mediator networks in cell signaling: Update and impact of cytokines	FASEB JOURNAL			English	Article						signal transduction; lipid mediators; phospholipases; inflammation; eicosanoids	PLATELET-ACTIVATING-FACTOR; CYTOSOLIC PHOSPHOLIPASE A(2); LEUKOTRIENE A(4) HYDROLASE; BASOPHILIC LEUKEMIA-CELLS; ENDOPEROXIDE-H SYNTHASE-1; FACTOR ACETYLHYDROLASE; HUMAN NEUTROPHILS; ALVEOLAR MACROPHAGES; NUCLEAR-ENVELOPE; GENE DISRUPTION	Biomembranes serve barrier functions and serve as a store for precursors of rapidly generated, structurally diverse intracellular and extracellular lipid-derived mediators (LM). Cell activation is accompanied by remodeling of membrane components that appear to be essential in signal transduction. Phospholipases (PLA(2), PLC, PLD, sphingomyelinase) are pivotal in the generation of these LM including eicosanoids, platelet activating factor (PAF), diacylglycerides, ceramide, and other newly discovered bioactive autacoids. Cytokines exert a dramatic multilevel impact both in regulating enzymes in individual LM pathways and in generating LM central to their action. Here, we provide an overview and update of recent progress in this area with emphases on the effect of cytokines on LM networks. The generation of eicosanoids (prostaglandins, leukotrienes, and lipoxins), oxygenated lipids, and PAF remain the focus of rational drug design targets given their established roles in cell-cell communication and as mediators in inflammation and pathophysiologic events. Key enzymes in these pathways are cloned, sequenced, and their subcellular organization is investigated with surprising findings implicating involvement of the nuclear membrane at the functional level. Several LM receptors are identified and cloned, and results from transgenic animals have emerged for several key enzymes. Novel bioactive eicosanoids were discovered, including 15-epi-lipoxins, isoprostanes, and isoleukotrienes, that offered new concepts to consider in formation of LM and the actions of nonsteroidal anti-inflammatory drugs. Together, these findings indicate that LM play critical and essential roles in both signal transduction and cell-cell communication and will continue to be important pathways to be considered in novel therapeutic approaches.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,STOCKHOLM,SWEDEN; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV BASIC SCI,DENVER,CO 80206	Harvard University; Harvard Medical School; Karolinska Institutet; National Jewish Health	Serhan, CN (corresponding author), BRIGHAM & WOMENS HOSP,CTR EXPT THERAPEUT & REPERFUS INJURY,DEPT ANESTHESIA,75 FRANCIS ST,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038765, R37GM038765, R01GM038765] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34303] Funding Source: Medline; NIDDK NIH HHS [P01 DK50305] Funding Source: Medline; NIGMS NIH HHS [GM-38765] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; BALLOU LR, 1996, IN PRESS BIOCH BIOPH; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BRADY HR, 1995, TRENDS CARDIOVAS MED, V5, P186, DOI 10.1016/1050-1738(95)00055-E; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; Clemens JA, 1996, STROKE, V27, P527, DOI 10.1161/01.STR.27.3.527; DECARVALHO MS, 1995, J BIOL CHEM, V35, P20439; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FELTENMARK S, 1995, BRIT J HAEMATOL, V90, P585, DOI 10.1111/j.1365-2141.1995.tb05588.x; Fiore S, 1995, BIOCHEMISTRY-US, V34, P16678, DOI 10.1021/bi00051a016; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; FUNK CD, 1993, PROG NUCLEIC ACID RE, V45, P67, DOI 10.1016/S0079-6603(08)60867-3; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GOULET JL, 1994, P NATL ACAD SCI USA, V91, P12852, DOI 10.1073/pnas.91.26.12852; HAEGGSTROM JZ, 1993, J LIPID MEDIATOR, V6, P1; HAMMARBERG T, 1995, EUR J BIOCHEM, V230, P401; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HARRISON KA, 1995, J BIOL CHEM, V270, P17273, DOI 10.1074/jbc.270.29.17273; HATTORI M, 1994, J BIOL CHEM, V269, P23150; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; IZUMI T, 1995, J LIPID MEDIAT CELL, V12, P429, DOI 10.1016/0929-7855(95)00028-O; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V177, P217; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; LHEUREUX GP, 1995, BLOOD, V85, P522, DOI 10.1182/blood.V85.2.522.bloodjournal852522; MANCINI JA, 1995, EUR J BIOCHEM, V231, P65, DOI 10.1111/j.1432-1033.1995.tb20671.x; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; MORROW JD, 1994, J BIOL CHEM, V269, P4317; MUELLER MJ, 1995, P NATL ACAD SCI USA, V92, P8383, DOI 10.1073/pnas.92.18.8383; MURAKAMI M, 1995, J EXP MED, V182, P197, DOI 10.1084/jem.182.1.197; NASSAR GM, 1994, J BIOL CHEM, V269, P27631; NEGISHI M, 1995, BBA-LIPID LIPID MET, V1259, P109, DOI 10.1016/0005-2760(95)00146-4; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; POULIOT M, 1994, J EXP MED, V179, P1225, DOI 10.1084/jem.179.4.1225; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RING WL, 1996, IN PRESS J CLIN INVE; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SERHAN CN, 1995, BIOCHEMISTRY-US, V34, P14609, DOI 10.1021/bi00044a041; SHARP JD, 1994, J BIOL CHEM, V269, P23250; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SMITH WL, 1995, SEMIN NEPHROL, V15, P179; STENKE L, 1994, LEUKEMIA RES, V18, P727, DOI 10.1016/0145-2126(94)90053-1; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; TOH H, 1995, FEBS LETT, V361, P17, DOI 10.1016/0014-5793(95)00129-W; VENABLE ME, 1993, J LIPID RES, V34, P691; WANG LH, 1993, BIOCHEM BIOPH RES CO, V190, P406, DOI 10.1006/bbrc.1993.1062; WETTERHOLM A, 1995, J PHARMACOL EXP THER, V275, P31; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; YEO EJ, 1994, J BIOL CHEM, V269, P27823	62	356	369	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1996	10	10					1147	1158		10.1096/fasebj.10.10.8751717	http://dx.doi.org/10.1096/fasebj.10.10.8751717			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VD429	8751717				2022-12-28	WOS:A1996VD42900006
J	Chambon, P				Chambon, P			A decade of molecular biology of retinoic acid receptors	FASEB JOURNAL			English	Review						RAR alpha, beta, and gamma; RXR alpha, beta, and gamma; RA responseelements; RXR/RAR heterodimers; transactivation; ligand-dependent transcriptional activation; coactivator; corepressor; ligand binding domain structure; ligand-dependent transconformation; cross-modulation API	THYROID-HORMONE RECEPTOR; DNA-BINDING DOMAINS; RAR DOUBLE MUTANTS; NUCLEAR RECEPTORS; X-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; ESTROGEN-RECEPTOR; RESPONSE ELEMENT; SIGNALING PATHWAYS; RXR-BETA	Retinoids play an important role in development, differentiation, and homeostasis, The discovery of retinoid receptors belonging to the superfamily of nuclear ligand-activated transcriptional regulators has revolutionized our molecular understanding as to how these structurally simple molecules exert their pleiotropic effects, Diversity in the control of gene expression by retinoid signals is generated through complexity at different levels of the signaling pathway, A major source of diversity originates from the existence of two families of retinoid acid (RA) receptors (R), the RAR isotypes (alpha, beta, and gamma) and the three RXR isotypes (alpha, beta, and gamma), and their numerous isoforms, which bind as RXR/RAR heterodimers to the polymorphic cis-acting response elements of RA target genes, The possibility of cross-modulation (cross-talk) with cell-surface receptors signaling pathways, as well as the finding that RARs and RXRs interact with multiple putative coactivators and/or corepressors, generates additional levels of complexity for the array of combinatorial effects that underlie the pleiotropic effects of retinoids, This review focuses on recent developments, particularly in the area of structure-function relationships.			Chambon, P (corresponding author), COLL FRANCE, INST GENET & BIOL MOL & CELLULAIRE,CNRS,INSERM,ULP, BP 163, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE.							ALLEGRETTO EA, 1995, J BIOL CHEM, V270, P23906, DOI 10.1074/jbc.270.41.23906; Apfel CM, 1995, J BIOL CHEM, V270, P30765, DOI 10.1074/jbc.270.51.30765; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Blomhoff R., 1994, VITAMIN A HLTH DIS; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CHEN ZP, 1994, J BIOL CHEM, V269, P25770; CLASS CK, 1994, ENDOCR REV, V15, P391; CLIFFORD J, 1996, IN PRESS EMBO J; CRONEMEYER H, 1996, PROTEIN PROFILE, V2; DALMAN FC, 1991, BIOCHEMISTRY-US, V30, P5605, DOI 10.1021/bi00236a038; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DAVIS KD, 1994, MOL CELL BIOL, V14, P7105, DOI 10.1128/MCB.14.11.7105; DE LUCA LM, 1991, FASEB J, V5, P2924; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FOLKERS GE, 1993, MOL ENDOCRINOL, V7, P616, DOI 10.1210/me.7.4.616; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREEN S, 1986, NATURE, V324, P615, DOI 10.1038/324615a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HEERY DM, 1993, P NATL ACAD SCI USA, V90, P4281, DOI 10.1073/pnas.90.9.4281; HEERY DM, 1994, NUCLEIC ACIDS RES, V22, P726, DOI 10.1093/nar/22.5.726; HERRLICH P, 1994, TRENDS ENDOCRIN MET, V5, P341, DOI 10.1016/1043-2760(94)90164-3; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kastner P., 1994, Vitamin A in health and disease., P189; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KATO S, 1995, MOL CELL BIOL, V15, P5858; KEAVENEY M, 1995, INDUCIBLE GENE EXPRE, V2, P187; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; LAMPRON C, 1995, DEVELOPMENT, V121, P539; LEBLANC BP, 1995, GENE DEV, V9, P1811, DOI 10.1101/gad.9.15.1811; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; LIU Q, 1993, MOL ENDOCRINOL, V7, P651, DOI 10.1210/me.7.5.651; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MADER S, 1993, J BIOL CHEM, V268, P591; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MARTIN B, 1994, NUCLEIC ACIDS RES, V22, P4898, DOI 10.1093/nar/22.23.4898; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MorrissKay GM, 1996, FASEB J, V10, P961, DOI 10.1096/fasebj.10.9.8801178; NAGATA T, 1994, GENE, V142, P183, DOI 10.1016/0378-1119(94)90259-3; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; Napoli JL, 1996, FASEB J, V10, P993, DOI 10.1096/fasebj.10.9.8801182; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; ONATE SA, 1995, SCIENCE, V270, P1354; Parker MG, 1993, CURR OPIN CELL BIOL, V5, P499, DOI 10.1016/0955-0674(93)90016-J; PERLMANN T, 1995, NATURE, V377, P387; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; PETKOVICH M, 1992, ANNU REV NUTR, V12, P443, DOI 10.1146/annurev.nu.12.070192.002303; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROSEN ED, 1992, J BIOL CHEM, V267, P22010; ROY DY, 1995, MOL CELL BIOL, V15, P6481; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; SCHWABE JWR, 1993, STRUCTURE, V1, P187, DOI 10.1016/0969-2126(93)90020-H; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SPOM MB, 1994, RETINOIDS BIOL CHEM; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; TANEJA R, 1996, IN PRESS P NATL AC S; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; THUMMEL CS, 1995, CELL, V83, P871, DOI 10.1016/0092-8674(95)90203-1; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; VOEGEL JJ, IN PRESS EMBO J; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WREGGETT KA, 1994, CYTOGENET CELL GENET, V66, P99, DOI 10.1159/000133676; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YANGYEN HF, 1991, NEW BIOL, V3, P1206; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	120	2483	2557	6	161	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1996	10	9					940	954		10.1096/fasebj.10.9.8801176	http://dx.doi.org/10.1096/fasebj.10.9.8801176			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801176				2022-12-28	WOS:A1996UY93200003
J	Collins, JF; Ghishan, FK				Collins, JF; Ghishan, FK			The molecular defect in the renal sodium-phosphate transporter expression pathway of Gyro (Gy) mice is distinct from that of hypophosphatemic (Hyp) mice	FASEB JOURNAL			English	Article						Na+/P-i transporter; Hyp mouse model; Gy mouse model; X-linked hypophosphatemic vitamin D-resistant rickets	D-RESISTANT RICKETS; MOUSE MODEL; MEMBRANES; HYP	Two animal models of the human disorder hypophosphatemic vitamin D-resistant rickets exist, the Hyp and Gy mice, Affected mice and humans both manifest an X-linked phenotype, and show decreased Na+/P-i transport activity in the renal proximal tubules, which is characterized by a decreased maximal velocity (V-max). The defect in Hyp mice is most likely due to a decreased transcription rate of the renal Na+/P-i transporter gene, The current studies were designed to define the molecular defect in the Gy mice, Sodium-dependent uptake of phosphate (P-i) in renal BBMV showed uptake levels of 170.58 +/- 25 and 66.00 +/- 11 pmol . mg protein(-1). 6 s(-1) in normal and Gy mice, respectively (n=3; P=0.0102). Glucose uptake levels in the BBWV were 1.94 +/- 0.81 and 1.91 +/- 0.35 pmol . mg protein .(1)6 s(-1) in normal and Gy mice, respectively (n=3), Northern blot analysis of kidney cortex in both mice revealed nearly equivalent message levels (normal/Gy=1.01 +/- 0.12, n=3), Iu situ hybridization localized the mRNA to the renal cortex in both mice and confirmed equal message levels, Western blot analysis of renal BBM proteins, using a polyclonal antiserum, showed one predominant band at 87 kDa in both mouse samples, with intensities being decreased in the Gy mice (normal/Gy=4.129 +/- 0.70, n=4, P < 0.04), Immunohistochemical analysis localized the protein to the apical membrane of proximal tubules in both mice, These results suggest that the molecular defect in the Gy mice is distinct from that in the Hyp mice, and furthermore, that the manifestation of the diseased phenotype in Gy mice is related to a different defect in the renal Na+/P-i transporter expression pathway, The molecular mechanism of the defect likely relates to protein processing, metabolic turnover rate, or translocation to the brush-border membrane, These results further suggest that two distinct X-linked factors modulate different steps in the expression pathway of the Na+/P-i transporter gene.	UNIV ARIZONA, ARIZONA HLTH SCI CTR, STEELE MEM CHILDRENS RES CTR, DEPT PEDIAT, TUCSON, AZ 85724 USA; UNIV ARIZONA, ARIZONA HLTH SCI CTR, STEELE MEM CHILDRENS RES CTR, DEPT PHYSIOL, TUCSON, AZ 85724 USA	University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033209] Funding Source: NIH RePORTER; NIDDK NIH HHS [2R01 DK33209] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albright F, 1937, AM J DIS CHILD, V54, P529; COLLINS JF, 1995, AM J PHYSIOL-GASTR L, V268, pG917, DOI 10.1152/ajpgi.1995.268.6.G917; COLLINS JF, 1994, FASEB J, V8, P862, DOI 10.1096/fasebj.8.11.8070635; COLLINS JF, 1995, AM J PHYSIOL-RENAL, V269, pF439, DOI 10.1152/ajprenal.1995.269.3.F439; COWGILL LD, 1979, J CLIN INVEST, V63, P1203, DOI 10.1172/JCI109415; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; EICHER EM, 1976, P NATL ACAD SCI USA, V73, P4667, DOI 10.1073/pnas.73.12.4667; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; Ghishan Fayez K., 1994, Pediatric Research, V35, P510, DOI 10.1203/00006450-199404000-00026; GIASSON SD, 1977, PFLUG ARCH EUR J PHY, V371, P33, DOI 10.1007/BF00580769; HAMMERMAN MR, 1983, AM J PHYSIOL, V245, pF701, DOI 10.1152/ajprenal.1983.245.6.F701; LYON MF, 1986, P NATL ACAD SCI USA, V83, P4899, DOI 10.1073/pnas.83.13.4899; MEYER RA, 1980, ENDOCRINOLOGY, V107, P1577, DOI 10.1210/endo-107-5-1577; NAKAGAWA N, 1991, J BIOL CHEM, V266, P13616; NAKAGAWA N, 1994, P SOC EXP BIOL MED, V205, P162, DOI 10.3181/00379727-205-43692; NAKAGAWA N, 1993, P SOC EXP BIOL MED, V203, P328; OHNO S, 1973, NATURE, V244, P259, DOI 10.1038/244259a0; Rasmussen H., 1983, METABOLIC BASIS INHE, V5th, P1743; Sambrook J., 2002, MOL CLONING LAB MANU; SELA J, 1982, METAB BONE DIS RELAT, V4, P129, DOI 10.1016/0221-8747(82)90026-1; SHETTY NS, 1991, TERATOLOGY, V44, P463, DOI 10.1002/tera.1420440412; TENENHOUSE HS, 1994, J CLIN INVEST, V93, P671, DOI 10.1172/JCI117019; VAUGHN LK, 1987, PHYSIOL BEHAV, V40, P131, DOI 10.1016/0031-9384(87)90195-8; WINTERS RW, 1958, MEDICINE, V37, P97, DOI 10.1097/00005792-195805000-00001	24	14	14	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1996	10	7					751	759		10.1096/fasebj.10.7.8635692	http://dx.doi.org/10.1096/fasebj.10.7.8635692			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UN798	8635692				2022-12-28	WOS:A1996UN79800009
J	Wallace, JL; Granger, DN				Wallace, JL; Granger, DN			The cellular and molecular basis of gastric mucosal defense	FASEB JOURNAL			English	Review						stomach; ulcer; prostaglandin; nitric oxide; microcirculation; mucus; restitution	ACID BACK-DIFFUSION; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NITRIC-OXIDE; GROWTH-FACTOR; LEUKOCYTE ADHESION; STRESS-ULCERS; RAT STOMACH; BLOOD-FLOW; MAST-CELLS; SECRETION	The association between colonization of the stomach by Helicobacter pylori and peptic ulcer disease has stimulated a renewal of interest in the factors that render the gastric mucosa resistant to injury induced by endogenous secretions and ingested toxins, Mucosal defense consists of a complex network of components that function in concert with one another, This network includes: 1) the extramucosal components such as acid, mucus, surface-active phospholipids, and bicarbonate; 2) the epithelium itself; 3) the microcirculation and sensory afferent neurons beneath the epithelium; 4) the mucosal immune system; and 5) the ability of the mucosa to undergo repair, In the past two decades, an enormous amount has been learned about the cellular and molecular basis of the various components of mucosal defense, including a better understanding of the chemical substances that coordinate mucosal responses to injury. In this paper, we review the factors that contribute to mucosal defense, the cellular and molecular mechanisms through which mucosal defense is modulated, and the chemical mediators that play key roles in this process.	LOUISIANA STATE UNIV, MED CTR, DEPT PHYSIOL & BIOPHYS, SHREVEPORT, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Wallace, JL (corresponding author), UNIV CALGARY, DEPT PHARMACOL & THERAPEUT, INTESTINAL DIS RES UNIT, 3330 HOSP DR NW, CALGARY, AB T2N 4N1, CANADA.							ANDREWS FJ, 1994, AM J PHYSIOL, V266, pG657, DOI 10.1152/ajpgi.1994.266.4.G657; BAHARI HMM, 1982, GUT, V23, P513, DOI 10.1136/gut.23.6.513; BHASKAR KR, 1992, NATURE, V360, P458, DOI 10.1038/360458a0; BROWN JF, 1993, AM J PHYSIOL, V265, pG418, DOI 10.1152/ajpgi.1993.265.3.G418; BROWN JF, 1994, EUR J PHARM-ENVIRON, V292, P111, DOI 10.1016/0926-6917(94)90033-7; BRUGGEMAN TM, 1979, GASTROENTEROLOGY, V77, P736; CATTOSMITH AG, 1989, AM J PHYSIOL, V257, pG704, DOI 10.1152/ajpgi.1989.257.5.G704; CHEN CM, 1994, AM J PHYSIOL, V267, pG1012; CHEN MC, 1994, GASTROENTEROLOGY, V106, pA803; CURTIS GH, 1992, AM J PHYSIOL, V262, pG1033, DOI 10.1152/ajpgi.1992.262.6.G1033; DIGNASS A, 1994, J CLIN INVEST, V94, P376, DOI 10.1172/JCI117332; DIGNASS AU, 1993, GASTROENTEROLOGY, V105, P1323, DOI 10.1016/0016-5085(93)90136-Z; ELOMAR EM, 1995, GASTROENTEROLOGY, V109, P681, DOI 10.1016/0016-5085(95)90374-7; FERRAZ JGP, 1995, GASTROENTEROLOGY, V108, P1183, DOI 10.1016/0016-5085(95)90218-X; FORSTNER JF, 1978, DIGESTION, V17, P234, DOI 10.1159/000198115; GAMER A, 1984, SCAND J GASTROE S101, V19, P79; GANNON B, 1984, GASTROENTEROLOGY, V86, P866; GIANNELLA RA, 1973, ANN INTERN MED, V78, P271, DOI 10.7326/0003-4819-78-2-271; GODDARD PJ, 1987, AM J PHYSIOL, V252, pG421, DOI 10.1152/ajpgi.1987.252.3.G421; GODDARD PJ, 1990, GASTROENTEROLOGY, V98, P361, DOI 10.1016/0016-5085(90)90826-M; GRAHAM DY, 1993, GASTROENTEROLOGY, V104, P1655, DOI 10.1016/0016-5085(93)90642-P; GRAHAM DY, 1990, AM J GASTROENTEROL, V85, P394; GRAY JDA, 1967, GUT, V8, P574, DOI 10.1136/gut.8.6.574; GRISHAM MB, 1987, AM J PHYSIOL, V253, pG93, DOI 10.1152/ajpgi.1987.253.1.G93; GUTTU K, 1994, AM J PHYSIOL-GASTR L, V267, pG536, DOI 10.1152/ajpgi.1994.267.4.G536; HARDING RK, 1977, GASTROENTEROLOGY, V72, P857; HILLS BA, 1983, AM J PHYSIOL, V244, pG561, DOI 10.1152/ajpgi.1983.244.5.G561; HOGABOAM CM, 1993, GASTROENTEROLOGY, V104, P122, DOI 10.1016/0016-5085(93)90843-2; HOGABOAM CM, 1993, J IMMUNOL, V151, P3767; HOLM L, 1992, GASTROENTEROLOGY, V103, P1797, DOI 10.1016/0016-5085(92)91437-9; HOLZER P, 1991, ADV EXP MED BIOL, V298, P3; JONES DGC, 1985, Q J MED, V54, P253; KANWAR S, 1994, AM J PHYSIOL, V266, pG222, DOI 10.1152/ajpgi.1994.266.2.G222; KAO YCJ, 1993, GASTROENTEROLOGY, V104, P103, DOI 10.1016/0016-5085(93)90841-Y; KATO K, 1995, GASTROENTEROLOGY, V108, pA129, DOI 10.1016/0016-5085(95)23179-X; KINDON H, 1995, GASTROENTEROLOGY, V109, P516, DOI 10.1016/0016-5085(95)90340-2; KUBES P, 1992, AM J PHYSIOL, V262, pG1138, DOI 10.1152/ajpgi.1992.262.6.G1138; KUBES P, 1993, FASEB J, V7, P1293, DOI 10.1096/fasebj.7.13.8405815; LI DS, 1992, GASTROENTEROLOGY, V102, P1124; LICHTENBERGER LM, 1995, NAT MED, V1, P154, DOI 10.1038/nm0295-154; LICHTENBERGER LM, 1995, ANNU REV PHYSIOL, V57, P565, DOI 10.1146/annurev.ph.57.030195.003025; LIPPE IT, 1992, BRIT J PHARMACOL, V105, P708, DOI 10.1111/j.1476-5381.1992.tb09043.x; MACNAUGHTON WK, 1989, LIFE SCI, V45, P1869, DOI 10.1016/0024-3205(89)90540-7; MILLER MJS, 1995, IN PRESS MED INFLAMM; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MORRIS GP, 1984, VIRCHOWS ARCH B, V46, P239, DOI 10.1007/BF02890313; PAIMELA H, 1993, GASTROENTEROLOGY, V104, P1337, DOI 10.1016/0016-5085(93)90342-A; REN JY, 1993, GASTROENTEROLOGY, V104, P485, DOI 10.1016/0016-5085(93)90417-B; ROBERT A, 1979, GASTROENTEROLOGY, V77, P761, DOI 10.1016/0016-5085(79)90235-x; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; SANDERS MJ, 1985, NATURE, V313, P52, DOI 10.1038/313052a0; SCHEIMAN JM, 1992, GASTROENTEROLOGY, V103, P1842, DOI 10.1016/0016-5085(92)91443-8; SILEN W, 1985, ANNU REV PHYSIOL, V47, P217; SKINNER KA, 1981, GASTROENTEROLOGY, V81, P335; SZABO S, 1991, AM J MED, V91, pS158, DOI 10.1016/0002-9343(91)90469-E; TAKEUCHI K, 1992, DIGEST DIS SCI, V37, P737, DOI 10.1007/BF01296432; TARNAWSKI A, 1992, GASTROENTEROLOGY, V102, P695, DOI 10.1016/0016-5085(92)90123-G; TEPPERMAN BL, 1994, CAN J PHYSIOL PHARM, V72, P1308, DOI 10.1139/y94-188; WALDER CE, 1990, P ROY SOC B-BIOL SCI, V241, P195, DOI 10.1098/rspb.1990.0085; WALLACE JL, 1993, CAN J PHYSIOL PHARM, V71, P98, DOI 10.1139/y93-014; WALLACE JL, 1991, GASTROENTEROLOGY, V100, P878, DOI 10.1016/0016-5085(91)90259-N; WALLACE JL, 1994, GASTROENTEROLOGY, V107, P173, DOI 10.1016/0016-5085(94)90074-4; WALLACE JL, 1993, AM J PHYSIOL, V265, pG993, DOI 10.1152/ajpgi.1993.265.5.G993; WALLACE JL, 1990, GASTROENTEROLOGY, V99, P295, DOI 10.1016/0016-5085(90)91009-U; WALLACE JL, 1989, AM J PHYSL F, P31; WALSH JH, 1995, NEW ENGL J MED, V333, P984, DOI 10.1056/NEJM199510123331508; WANG JY, 1990, AM J PHYSIOL, V258, pG78, DOI 10.1152/ajpgi.1990.258.1.G78; WANG JY, 1990, AM J PHYSIOL, V259, pG584; WHITTLE BJR, 1990, BRIT J PHARMACOL, V99, P607, DOI 10.1111/j.1476-5381.1990.tb12977.x; WRIGHT NA, 1990, NATURE, V343, P82, DOI 10.1038/343082a0; WRIGHT NA, 1993, GASTROENTEROLOGY, V104, P12, DOI 10.1016/0016-5085(93)90830-6; WRIGHT NA, 1984, MECHANISMS MUCOSAL P, P15; YOSHIDA N, 1993, GASTROENTEROLOGY, V105, P715, DOI 10.1016/0016-5085(93)90888-J; YOSHIDA N, 1993, GASTROENTEROLOGY, V105, P1431, DOI 10.1016/0016-5085(93)90148-6	74	270	286	2	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1996	10	7					731	740		10.1096/fasebj.10.7.8635690	http://dx.doi.org/10.1096/fasebj.10.7.8635690			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UN798	8635690				2022-12-28	WOS:A1996UN79800007
J	Clarke, MSF; Feeback, DL				Clarke, MSF; Feeback, DL			Mechanical load induces sarcoplasmic wounding and FGF release in differentiated human skeletal muscle cultures	FASEB JOURNAL			English	Article						skeletal muscle hypertrophy; differentiation	FIBROBLAST GROWTH-FACTOR; MDX MOUSE MUSCLE; CARDIAC MYOCYTES; GENE-EXPRESSION; TISSUE-CULTURE; CELLS; HYPERTROPHY; LOCALIZATION; ACTIVATION; MYOFIBERS	The transduction mechanism (or mechanisms) responsible for converting a mechanical load into a skeletal muscle growth response are unclear, In this study we have used a mechanically active tissue culture model of differentiated human skeletal muscle cells to investigate the relationship between mechanical load, sarcolemma wounding, fibroblast growth factor release, and skeletal muscle cell growth, Using the Flexcell Strain Unit we demonstrate that as mechanical load increases, so too does the amount of sarcolemma wounding. A similar relationship was also observed between the level of mechanical load inflicted on the cells and the amount of bFGF (FGF2) released into the surrounding medium. In addition, we demonstrate that the muscle cell growth response induced by chronic mechanical loading in culture can be inhibited by the presence of an antibody capable of neutralizing the biological activity of FGF. This study provides direct evidence that mechanically induced, sarcolemma wound-mediated FGF release is an important autocrine mechanism for transducing the stimulus of mechanical load into a skeletal muscle growth response.			Clarke, MSF (corresponding author), NASA, LYNDON B JOHNSON SPACE CTR, BIOMED OPERAT & RES BRANCH SD4, MUSCLE RES LAB, BLDG 37, HOUSTON, TX 77058 USA.							BAKER KM, 1990, AM J PHYSIOL, V259, pH610, DOI 10.1152/ajpheart.1990.259.2.H610; BANES A, 1987, FASEB J, V46, P2017; BENES AJ, 1985, J CELL SCI, V75, P35; CLARKE MSF, 1994, BIOTECHNIQUES, V17, P1118; CLARKE MSF, 1992, J CELL SCI, V102, P533; CLARKE MSF, 1995, CIRC RES, V76, P927, DOI 10.1161/01.RES.76.6.927; CLARKE MSF, 1993, J CELL SCI, V106, P121; DARR KC, 1987, J APPL PHYSIOL, V63, P1816, DOI 10.1152/jappl.1987.63.5.1816; DAVIES PF, 1993, CIRC RES, V72, P239, DOI 10.1161/01.RES.72.2.239; DEVOL DL, 1990, AM J PHYSIOL, V259, pE89, DOI 10.1152/ajpendo.1990.259.1.E89; DIMARIO J, 1989, SCIENCE, V244, P688, DOI 10.1126/science.2717945; DIMARIO J, 1988, DIFFERENTIATION, V39, P42, DOI 10.1111/j.1432-0436.1988.tb00079.x; FLANAGAN MF, 1991, CIRC RES, V68, P1458, DOI 10.1161/01.RES.68.5.1458; Guthridge M, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209008871; INGJER F, 1979, EUR J APPL PHYSIOL, V40, P197, DOI 10.1007/BF00426942; KU PT, 1993, MOL BIOL CELL, V4, pH39; MacDougall J., 1986, HUMAN MUSCLE POWER, P269; McNeil Paul L., 1993, Trends in Cell Biology, V3, P302, DOI 10.1016/0962-8924(93)90012-P; MCNEIL PL, 1992, AM J PATHOL, V140, P1097; MORROW NG, 1990, J CLIN INVEST, V85, P1816, DOI 10.1172/JCI114640; PADUA RR, 1993, GROWTH FACTORS, V8, P291, DOI 10.3109/08977199308991574; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SPEIR E, 1992, CIRC RES, V71, P251, DOI 10.1161/01.RES.71.2.251; TESCH PA, 1988, MED SCI SPORT EXER, V20, pS132, DOI 10.1249/00005768-198810001-00008; VANDENBURGH HH, 1990, AM J PHYSIOL, V259, pC232, DOI 10.1152/ajpcell.1990.259.2.C232; VANDENBURGH HH, 1989, AM J PHYSIOL, V256, pC674, DOI 10.1152/ajpcell.1989.256.3.C674; VANDENBURGH HH, 1988, IN VITRO CELL DEV B, V24, P166, DOI 10.1007/BF02623542; VANDENBURGH HH, 1991, AM J PHYSIOL, V260, pC475, DOI 10.1152/ajpcell.1991.260.3.C475; YAMADA S, 1989, MED SCI SPORT EXER, V21, pS173; [No title captured]; [No title captured]	34	96	98	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1996	10	4					502	509		10.1096/fasebj.10.4.8647349	http://dx.doi.org/10.1096/fasebj.10.4.8647349			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UE557	8647349				2022-12-28	WOS:A1996UE55700014
J	Coon, MJ; Vaz, ADN; Bestervelt, LL				Coon, MJ; Vaz, ADN; Bestervelt, LL			Cytochrome P450 .2. Peroxidative reactions of diversozymes	FASEB JOURNAL			English	Review						P450 cytochromes; reductive cleavage of lipid hydroperoxides; inactivation of P450 by trans-4-hydroxynonenal; peroxidative deformylation of aldehydes	ASCITES TUMOR-CELLS; LIPID-PEROXIDATION; INDUCIBLE CYTOCHROME-P-450; SUBSTRATE HYDROXYLATION; OLEFIN FORMATION; CLEAVAGE; PRODUCT; HYDROPEROXIDES; DEMETHYLATION; DEFORMYLATION	Cytochrome P450, the most versatile biological catalyst known, was originally named as a pigment having a carbon monoxide difference spectrum at about 450 nm and no known function, Recent progress in many laboratories has revealed that the P450 superfamily has immense diversity in its functions, with hundreds of isoforms in many species catalyzing many types of chemical reactions, We believe it is safe to predict that each mammalian species may be found to have up to a hundred P450 isoforms that respond in tote to a thousand or more inducers and that, along with P450s from other sources, metabolize a million or more potential substrates, Accordingly, the name DIVERSOZYMES is proposed for this remarkable family of hemoproteins. This paper reviews the peroxidative reactions of Diversozymes, including peroxides as oxygen donors in hydroxylation reactions, as substrates for reductive beta-scission, and as peroxyhemiacetal intermediates in the cleavage of aldehydes to formate and alkenes, Lipid hydroperoxides undergo reductive beta-cleavage to give hydrocarbons and aldehydic acids. One of these products, trans-4-hydroxynonenal, inactivates P450, particularly alcohol-inducible 2E1, in what may be a negative regulatory process, Although a P450 iron-oxene species is believed to be the oxygen donor in most hydroxylation reactions, an iron-peroxy species is apparently involved in the deformylation of many aldehydes with desaturation of the remaining structure, as in aromatization reactions.			Coon, MJ (corresponding author), UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109, USA.				NIAAA NIH HHS [AA-06221] Funding Source: Medline; NIDDK NIH HHS [DK-10339] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK010339, R01DK010339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006221] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AKHTAR M, 1982, BIOCHEM J, V201, P569, DOI 10.1042/bj2010569; BENEDETTI A, 1980, BIOCHIM BIOPHYS ACTA, V620, P281, DOI 10.1016/0005-2760(80)90209-X; BESTERVELT LL, 1995, P NATL ACAD SCI USA, V92, P3764, DOI 10.1073/pnas.92.9.3764; BIMBAUM LS, 1993, HDB EXPT PHARM, V105, P477; BLAKE RC, 1981, J BIOL CHEM, V256, P2127; CHIANG JYL, 1983, MOL PHARMACOL, V23, P244; COLE PA, 1990, P NATL ACAD SCI USA, V87, P2999, DOI 10.1073/pnas.87.8.2999; COON MJ, 1992, FASEB J, V6, P669, DOI 10.1096/fasebj.6.2.1537454; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9; EKSTROM G, 1984, BIOCHEM PHARMACOL, V33, P2521, DOI 10.1016/0006-2952(84)90729-9; ESTERBAUER H, 1989, FREE RADICAL BIO MED, V7, P197, DOI 10.1016/0891-5849(89)90015-4; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1985, BIOCHEM J, V228, P363, DOI 10.1042/bj2280363; FISCHER RT, 1991, J BIOL CHEM, V266, P6124; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; HOCHSTEIN P, 1963, BIOCHEM BIOPH RES CO, V12, P388, DOI 10.1016/0006-291X(63)90111-6; KAMIMURA S, 1992, HEPATOLOGY, V16, P448, DOI 10.1002/hep.1840160225; KATO R, 1968, J BIOCHEM-TOKYO, V63, P406; NORDBLOM GD, 1976, ARCH BIOCHEM BIOPHYS, V175, P524, DOI 10.1016/0003-9861(76)90541-5; PERNECKY SJ, 1995, ARCH BIOCHEM BIOPHYS, V318, P446, DOI 10.1006/abbi.1995.1253; PORTER TD, 1991, J BIOL CHEM, V266, P13469; PUFAHL RA, 1995, BIOCHEMISTRY-US, V34, P1930, DOI 10.1021/bi00006a014; REED JR, 1994, P NATL ACAD SCI USA, V91, P10000, DOI 10.1073/pnas.91.21.10000; ROBERTS ES, 1991, P NATL ACAD SCI USA, V88, P8963, DOI 10.1073/pnas.88.20.8963; SAGAI M, 1980, LIFE SCI, V27, P731, DOI 10.1016/0024-3205(80)90326-4; Schauenstein E., 1979, CIBA F S, V67, P225; SCHMUCKER DL, 1985, PHARMACOL REV, V37, P133; SCHMUCKER DL, 1981, MECH AGEING DEV, V15, P189, DOI 10.1016/0047-6374(81)90074-9; STEVENSON DE, 1988, J CHEM SOC P1, V1, P2043; SUTTER MA, 1985, BIOCHEM PHARMACOL, V34, P2983, DOI 10.1016/0006-2952(85)90025-5; SZWEDA LI, 1993, J BIOL CHEM, V268, P3342; UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P4544, DOI 10.1073/pnas.89.10.4544; UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P5611, DOI 10.1073/pnas.89.12.5611; UCHIDA K, 1993, J BIOL CHEM, V268, P6388; VAZ ADN, 1994, BIOCHEMISTRY-US, V33, P13651, DOI 10.1021/bi00250a015; VAZ ADN, 1990, P NATL ACAD SCI USA, V87, P5499, DOI 10.1073/pnas.87.14.5499; VAZ ADN, 1987, P NATL ACAD SCI USA, V84, P1172, DOI 10.1073/pnas.84.5.1172; VAZ ADN, 1991, J AM CHEM SOC, V113, P5886, DOI 10.1021/ja00015a066; WATANABE Y, 1989, J AM CHEM SOC, V111, P410, DOI 10.1021/ja00183a083; WINKLER P, 1984, BIOCHIM BIOPHYS ACTA, V796, P232, DOI 10.1016/0005-2760(84)90122-X; WINKLER P, 1984, BIOCHIM BIOPHYS ACTA, V796, P226, DOI 10.1016/0005-2760(84)90121-8; YOSHIDA Y, 1990, 8TH P INT S MICR DRU, P118	42	67	76	2	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1996	10	4					428	434		10.1096/fasebj.10.4.8647341	http://dx.doi.org/10.1096/fasebj.10.4.8647341			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UE557	8647341	Green Submitted			2022-12-28	WOS:A1996UE55700006
J	Perris, R; Perissinotto, D; Pettway, Z; BronnerFraser, M; Morgelin, M; Kimata, K				Perris, R; Perissinotto, D; Pettway, Z; BronnerFraser, M; Morgelin, M; Kimata, K			Inhibitory effects of PG-H/aggrecan and PG-M/versican on avian neural crest cell migration	FASEB JOURNAL			English	Article						neural crest; cell migration; proteoglycans; aggrecan; versican	CHONDROITIN SULFATE PROTEOGLYCANS; NEURITE OUTGROWTH; CARTILAGE PROTEOGLYCANS; CHICK-EMBRYO; ADHESION; CHONDROGENESIS; COLLAGEN; REGION	Aggrecans and PG-M/versicans represent two newly defined families of hyaluronan-binding proteoglycans for which the function is still poorly understood, Using the avian neural crest as a model system, we have examined the molecular mechanisms entailed in the cell-proteoglycan interaction during embryonic cell motility. Both the primary cartilage aggrecan of the avian embryo (PG-H/aggrecan) and the largest variant of the avian mesenchymal versican (PG-M/versican V0) failed to support neural crest cell adhesion and migration when topographically immobilized onto the substrate, Conversely, solely the PG-H/aggrecan, and similar aggrecans from other species, counteracted the migration-promoting effect of a number of matrix molecules lacking proteoglycan affinity, This inhibitory effect was not reproduced by the isolated glycosaminoglycan chains, the isolated core protein, the reduced and alkylated macromolecule, or the aggrecan in which the G1 hyaluronan-binding domain had been inactivated with hyaluronan fragments or antibodies, Limited depolymerization of the side chains and preincubation of the PG-H/aggrecan with anti-glycosaminoglycan antibodies differentially reduced the inhibitory activity of the proteoglycan on cell motility, The results demonstrate a diverse inhibitory effect of aggrecans and PG-H/versicans on embryonic cell movement and show that the inhibitory action of aggrecans is independent of substrate binding, is depedent on a G1 domain-mediated association of the intact proteoglycan with cell surface-bound hyaluronan, and is differentially mediated by its glycosaminoglycan side chains.	UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92717; LUND UNIV,DEPT MED & PHYSIOL CHEM,S-22100 LUND,SWEDEN; AICHI MED UNIV,INST MOLEC SCI MED,NAGAKUTE,AICHI 48011,JAPAN	University of California System; University of California Irvine; Lund University; Aichi Medical University	Perris, R (corresponding author), REFERENCE CTR ONCOL,DIV EXPT ONCOL 2,VIA PEDEMONTANA OCCIDENTALE 12,I-33081 AVIANO,PN,ITALY.		Pettway Unno, Zoe/J-3020-2013	Bronner, Marianne/0000-0003-4274-1862; Pettway Unno, Zoe/0000-0002-5176-185X	NICHD NIH HHS [HD 15527] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD015527] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BJORNSSON S, 1993, ANAL BIOCHEM, V210, P292, DOI 10.1006/abio.1993.1198; BRENNAN MJ, 1983, CANCER RES, V43, P4302; COLE GJ, 1991, NEURON, V7, P1007, DOI 10.1016/0896-6273(91)90345-Z; DOU CL, 1994, J NEUROSCI, V14, P7616; ERICKSON CA, 1993, DEV BIOL, V159, P60, DOI 10.1006/dbio.1993.1221; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; KIMATA K, 1986, J BIOL CHEM, V261, P3517; KITCHEN JR, 1995, BIOCHEM J, V309, P649, DOI 10.1042/bj3090649; KNOX P, 1979, J CELL SCI, V40, P77; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; LALLIER T, 1994, DEV BIOL, V162, P451, DOI 10.1006/dbio.1994.1101; MORGELIN M, 1992, J BIOL CHEM, V267, P14275; OAKLEY RA, 1994, DEVELOPMENT, V120, P103; OOHIRA A, 1991, J NEUROSCI, V11, P822; PERRIS R, 1990, DEV BIOL, V137, P1, DOI 10.1016/0012-1606(90)90002-Z; PERRIS R, 1991, DEVELOPMENT, V111, P583; PERRIS R, 1987, J CELL BIOL, V105, P2511, DOI 10.1083/jcb.105.6.2511; PERRIS R, 1991, TRENDS GLYCOSCI GLYC, V3, P166; PETTWAY Z, 1990, DEV BIOL, V142, P335, DOI 10.1016/0012-1606(90)90354-L; RICH AM, 1981, NATURE, V293, P224, DOI 10.1038/293224a0; SALEQUE S, 1993, GLYCOBIOLOGY, V3, P185, DOI 10.1093/glycob/3.2.185; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; SHINOMURA T, 1983, J BIOL CHEM, V15, P9316; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; SOMMARIN Y, 1983, BIOCHEM J, V214, P777, DOI 10.1042/bj2140777; SORRELL JM, 1993, MATRIX, V13, P351, DOI 10.1016/S0934-8832(11)80040-5; SUGIURA N, 1993, J BIOL CHEM, V268, P15779; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012	28	75	77	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1996	10	2					293	301		10.1096/fasebj.10.2.8641562	http://dx.doi.org/10.1096/fasebj.10.2.8641562			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641562				2022-12-28	WOS:A1996TY96200013
J	Britton, G				Britton, G			Structure and properties of carotenoids in relation to function	FASEB JOURNAL			English	Review						light absorption; lipid peroxidation; carotenoid-protein interactions; membranes; free-radical reactions	BETA-CAROTENE; FREE-RADICALS; ANTIOXIDANT	The basic principles of structure, stereochemistry, and nomenclature of carotenoids are described and the relationships between structure and the chemical and physical properties on which all the varied biological functions and actions of carotenoids depend are discussed. The conjugated polyene chromophore determines not only the light absorption properties, and hence color, but also the photochemical properties of the molecule and consequent light-harvesting and photoprotective action. The polyene chain is also the feature mainly responsible for the chemical reactivity of carotenoids toward oxidizing agents and free radicals, and hence for any antioxidant role. In vivo, carotenoids are found in precise locations and orientations in subcellular structures, and their chemical and physical properties are strongly influenced by other molecules in their vicinity, especially proteins and membrane lipids. In turn, the carotenoids influence the properties of these subcellular structures. Structural features such as size, shape, and polarity are essential determinants of the ability of a carotenoid to fit correctly into its molecular environment to allow it to function. A role for carotenoids in modifying structure, properties, and stability of cell membranes, and thus affecting molecular processes associated with these membranes, may be an important aspect of their possible beneficial effects on human health.			Britton, G (corresponding author), UNIV LIVERPOOL, DEPT BIOCHEM, POB 147, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND.							BENDICH A, 1989, J NUTR, V119, P112, DOI 10.1093/jn/119.1.112; Britton G., 1995, SPECTROSCOPY-US, V1B, P13; Britton G, 1995, CAROTENOIDS ISOLAT A, V1A; Buchecker R., 1996, SPECTROSCOPY-US, V1B, P63; BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156; Frank H. A., 1993, CAROTENOIDS PHOTOSYN, P252, DOI [10.1007/978-94-011-2124-8_8, DOI 10.1007/978-94-011-2124-8_8]; GRUSZECKI WI, 1990, BIOCHIM BIOPHYS ACTA, V1023, P405, DOI 10.1016/0005-2736(90)90133-9; GUST D, 1994, NATURE, V372, P133, DOI 10.1038/372133a0; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; International Union of Pure and Applied Chemistry- International Union of Biochemistry, 1975, PURE APPL CHEM, V41, P407; Karrer P, 1950, CAROTENOIDS; KRINSKY NI, 1988, ANN NY ACAD SCI, V551, P17, DOI 10.1111/j.1749-6632.1988.tb22317.x; KRINSKY NI, 1989, FREE RADICAL BIO MED, V7, P617, DOI 10.1016/0891-5849(89)90143-3; KULL D, 1995, CAROTENOIDS, V1, P295; LAFFERTY J, 1992, J CHEM SOC F1, V74, P2760; LAZRAK T, 1987, BIOCHIM BIOPHYS ACTA, V903, P132, DOI 10.1016/0005-2736(87)90163-5; LIEBLER DC, 1993, ANN NY ACAD SCI, V691, P20, DOI 10.1111/j.1749-6632.1993.tb26154.x; MATHEWSROTH MM, 1982, CAROTENOID CHEM BIOC, P297; Mo F., 1995, CAROTENOIDS, P321; PACKER JE, 1981, BIOCHEM BIOPH RES CO, V98, P901, DOI 10.1016/0006-291X(81)91196-7; PALOZZA P, 1992, METHOD ENZYMOL, V213, P403; PLATT JR, 1959, SCIENCE, V129, P372, DOI 10.1126/science.129.3346.372; SIMIC MG, 1992, METHOD ENZYMOL, V213, P444; Sitte P, 1980, PIGMENTS PLANTS, P117; Straub O., 1987, KEY CAROTENOIDS; SUBCZYNSKI WK, 1991, BIOCHIM BIOPHYS ACTA, V1068, P68, DOI 10.1016/0005-2736(91)90061-C; Weedon B. C. L., 1995, ISOLATION ANAL, V1A, P27; WEESIE RJ, 1995, FEBS LETT, V362, P34, DOI 10.1016/0014-5793(95)00191-B; WOODALL AA, 1994, THESIS U LIVERPOOL L; YAMAMOTO Y, 1984, B CHEM SOC JPN, V57, P1260, DOI 10.1246/bcsj.57.1260; ZHANG LX, 1991, CARCINOGENESIS, V12, P2109, DOI 10.1093/carcin/12.11.2109	31	1101	1171	8	286	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1995	9	15					1551	1558		10.1096/fasebj.9.15.8529834	http://dx.doi.org/10.1096/fasebj.9.15.8529834			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TM761	8529834				2022-12-28	WOS:A1995TM76100008
J	Cleland, WW; Hengge, AC				Cleland, WW; Hengge, AC			Mechanisms of phosphoryl and acyl transfer	FASEB JOURNAL			English	Review						isotope effect; O-18; O-16	PHENOLATE ION NUCLEOPHILES; TRANSITION-STATE STRUCTURE; BASE-CATALYZED-HYDROLYSIS; ACETYL GROUP TRANSFER; PHOSPHATE-ESTERS; META-PHOSPHATE; ENZYMATIC-REACTIONS; GLUCOSE-6-PHOSPHATE; MONOESTERS; CLEAVAGE	Acyl and phosphoryl transfer are important biochemical reactions. We have been using isotope effects caused by O-18, N-15, C-13, and deuterium substitution to examine the mechanisms and transition-state structures for enzymatic and nonenzymatic transfers of phosphoryl and acyl groups. Phosphoryl transfers from phosphate monoesters are highly dissociative, although not truly stepwise in protic solvents or in enzymatic reactions, Phosphodiesters show A(N)D(N) (S(N)2) reactions, whereas triester hydrolyses involve more associative transition states. Except under acidic conditions, true phosphorane intermediates likely form only when geometry requires (i.e,, when the leaving group cannot he axial until pseudorotation of the phosphorane). Enzymatic phosphoryl transfers appear similar to nonenzymatic ones. The reactions of oxygen or sulfur nucleophiles with p-nitrophenyl acetate are concerted with a tetrahedral transition state, which is more dissociative with sulfur than with oxygen. Enzymatic hydrolyses of p-nitrophenyl acetate are also concerted reactions.	UNIV WISCONSIN,INST ENZYME RES,MADISON,WI 53705; UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53705	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			Hengge, Alvan C/C-8667-2011	Hengge, Alvan C/0000-0002-5696-2087	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047297, R01GM018938, R37GM018938] Funding Source: NIH RePORTER; NIGMS NIH HHS [R29 GM047297, GM 18938] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON CM, 1978, J MOL BIOL, V123, P207, DOI 10.1016/0022-2836(78)90321-2; ANSLYN E, 1989, J AM CHEM SOC, V111, P5972, DOI 10.1021/ja00197a085; BASAIF S, 1987, J AM CHEM SOC, V109, P6362, DOI 10.1021/ja00255a021; BASAIF S, 1989, J AM CHEM SOC, V111, P2647, DOI 10.1021/ja00189a045; Benkovic S. J., 1978, TRANSITION STATES BI, P493; BENTLEY TW, 1985, J CHEM SOC PERK T 2, P983, DOI 10.1039/p29850000983; BRESLOW R, 1993, J AM CHEM SOC, V115, P10705, DOI 10.1021/ja00076a031; BUCHWALD SL, 1984, J AM CHEM SOC, V106, P4911, DOI 10.1021/ja00329a047; BUCHWALD SL, 1982, METHOD ENZYMOL, V87, P279; BUNCEL E, 1989, J AM CHEM SOC, V111, P971, DOI 10.1021/ja00185a029; CALDWELL SR, 1991, BIOCHEMISTRY-US, V30, P7444, DOI 10.1021/bi00244a011; CULP JS, 1986, ARCH BIOCHEM BIOPHYS, V246, P245, DOI 10.1016/0003-9861(86)90470-4; DEJAEGERE A, 1991, J AM CHEM SOC, V113, P4353, DOI 10.1021/ja00011a061; ECKSTEIN F, 1982, METHOD ENZYMOL, V87, P197; FINDLAY D, 1962, BIOCHEM J, V85, P139, DOI 10.1042/bj0850139; FREY PA, 1982, METHOD ENZYMOL, V87, P213; FRIEDMAN JM, 1988, J AM CHEM SOC, V110, P1268, DOI 10.1021/ja00212a040; FUKUTO TR, 1965, J MED CHEM, V8, P759, DOI 10.1021/jm00330a007; GUTHRIE JP, 1991, J AM CHEM SOC, V113, P3941, DOI 10.1021/ja00010a040; HARROWFIELD JM, 1980, J AM CHEM SOC, V102, P7733, DOI 10.1021/ja00546a016; HENGGE AC, 1995, J AM CHEM SOC, V117, P5919, DOI 10.1021/ja00127a003; HENGGE AC, 1994, J AM CHEM SOC, V116, P11256, DOI 10.1021/ja00104a007; HENGGE AC, 1990, J AM CHEM SOC, V112, P7421, DOI 10.1021/ja00176a067; HENGGE AC, 1991, J AM CHEM SOC, V113, P5835, DOI 10.1021/ja00015a043; HENGGE AC, 1991, J ORG CHEM, V56, P1972, DOI 10.1021/jo00005a064; HENGGE AC, 1994, J AM CHEM SOC, V116, P5045, DOI 10.1021/ja00091a003; HORN H, 1990, J AM CHEM SOC, V112, P2121, DOI 10.1021/ja00162a012; JARVINEN P, 1991, J ORG CHEM, V56, P5396, DOI 10.1021/jo00018a037; JONES DR, 1983, J AM CHEM SOC, V105, P7327, DOI 10.1021/ja00363a021; JONES JP, 1991, BIOCHEMISTRY-US, V30, P3634, DOI 10.1021/bi00229a007; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KIRBY AJ, 1967, J AM CHEM SOC, V89, P415, DOI 10.1021/ja00978a044; KLUGER R, 1969, J AM CHEM SOC, V91, P6066, DOI 10.1021/ja01050a023; KNIGHT WB, 1991, BIOCHEMISTRY-US, V30, P4970, DOI 10.1021/bi00234a019; KNIGHT WB, 1986, J AM CHEM SOC, V108, P2759, DOI 10.1021/ja00270a048; KWON DS, 1990, B KOR CHEM SOC, V11, P262; LIM C, 1990, J AM CHEM SOC, V112, P5872, DOI 10.1021/ja00171a033; OLEARY MH, 1979, J AM CHEM SOC, V101, P3300, DOI 10.1021/ja00506a027; PAULING L, 1947, J AM CHEM SOC, V69, P542, DOI 10.1021/ja01195a024; RAJCA A, 1987, J AM CHEM SOC, V109, P4189, DOI 10.1021/ja00248a011; RAY WJ, 1993, BIOCHEMISTRY-US, V32, P12977, DOI 10.1021/bi00211a005; SATTERTH.AC, 1974, J AM CHEM SOC, V96, P7018, DOI 10.1021/ja00829a034; SEM DS, 1991, BIOCHEMISTRY-US, V30, P4978, DOI 10.1021/bi00234a020; SIMOPOULOS TT, 1994, BIOCHEMISTRY-US, V33, P10375, DOI 10.1021/bi00200a018; STEFANIDIS D, 1993, J AM CHEM SOC, V115, P1650, DOI 10.1021/ja00058a006; UM IH, 1991, B KOR CHEM SOC, V12, P406; WEBB MR, 1982, METHOD ENZYMOL, V87, P301; WEISS PM, 1989, J AM CHEM SOC, V111, P1928, DOI 10.1021/ja00187a084; WEISS PM, 1986, J AM CHEM SOC, V108, P2761, DOI 10.1021/ja00270a049; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624	50	108	108	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1995	9	15					1585	1594		10.1096/fasebj.9.15.8529838	http://dx.doi.org/10.1096/fasebj.9.15.8529838			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TM761	8529838				2022-12-28	WOS:A1995TM76100012
J	Mathews, CE; McGraw, RA; Berdanier, CD				Mathews, CE; McGraw, RA; Berdanier, CD			A point mutation in the mitochondrial DNA of diabetes-prone BHE/cdb rats	FASEB JOURNAL			English	Article						F-0-ATPase; mtDNA; NIDDM	ESCHERICHIA-COLI; BHE RATS; PROTON TRANSLOCATION; STRAIN DIFFERENCES; MUTAGENIC ANALYSIS; ALPHA-SUBUNIT; ATP SYNTHESIS; WISTAR RATS; RESPIRATION; LIPOGENESIS	Mitochondrial DNA was extracted from hepatic tissue of 50- and 300-day-old male BHE/cdb and Sprague-Dawley rats. The complete gene for the F(0)ATPase subunits 6 and 8 was sequenced. Four nucleotide substitutions were found: three of the substitutions were silent; the other substitution at position 523 was not. Its codon dictates the substitution of asparagine for aspartic acid in a critical location (in the polar pocket) of the F(0)ATPase. It is possible that this point mutation may explain previously reported decreases in ATP synthesis efficiency in BHE/cdb rats compared to Sprague-Dawley rats.	UNIV GEORGIA,DEPT NUTR & FOODS,ATHENS,GA 30602; UNIV GEORGIA,DEPT VET PHYSIOL & PHARMACOL,ATHENS,GA 30602	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia								BERDANIER CD, 1979, J NUTR, V109, P247, DOI 10.1093/jn/109.2.247; BERDANIER CD, 1986, COMP BIOCHEM PHYS B, V85, P531, DOI 10.1016/0305-0491(86)90042-8; BERDANIER CD, 1992, J NUTR, V122, P1309, DOI 10.1093/jn/122.6.1309; BERDANIER CD, 1982, P SOC EXP BIOL MED, V169, P74; BERDANIER CD, 1993, J NUTR BIOCHEM, V4, P10, DOI 10.1016/0955-2863(93)90014-N; BERDANIER CD, 1980, EXP GERONTOL, V15, P519, DOI 10.1016/0531-5565(80)90004-2; BERDANIER CD, 1991, FASEB J, V5, P2139, DOI 10.1096/fasebj.5.8.2022312; BERDANIER CD, 1993, NUTR LIFE SCI ADV, V12, P103; BERDANIER CD, 1994, RECENT ADV ANIMAL DI, P231; BOUILLON DJ, 1983, J NUTR, V113, P2205, DOI 10.1093/jn/113.11.2205; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BROWN GC, 1992, BIOCHEM J, V284, P1; BROWN GC, 1990, EUR J BIOCHEM, V192, P355, DOI 10.1111/j.1432-1033.1990.tb19234.x; BROWN GC, 1992, FASEB J, V6, P2961, DOI 10.1096/fasebj.6.11.1644259; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIN BD, 1989, J BIOL CHEM, V264, P3292; DEAVER OE, 1986, J NUTR, V116, P1148, DOI 10.1093/jn/116.7.1148; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FOWLER KA, 1993, P SOC EXP BIOL MED, V203, P163; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; GROSSKOPF R, 1981, CURR GENET, V4, P151, DOI 10.1007/BF00365694; HAFNER RP, 1990, EUR J BIOCHEM, V188, P313, DOI 10.1111/j.1432-1033.1990.tb15405.x; HARTZOG PE, 1993, J BACTERIOL, V175, P1337, DOI 10.1128/JB.175.5.1337-1343.1993; HARTZOG PE, 1993, J BIOL CHEM, V268, P12250; LAKSHMANAN MR, 1977, ARCH BIOCHEM BIOPHYS, V183, P355, DOI 10.1016/0003-9861(77)90369-1; LANG PL, 1993, CRL CD REGISTRATION; LIANG Y, 1994, J CLIN INVEST, V93, P2473, DOI 10.1172/JCI117256; MCCUSKER RH, 1983, J NUTR, V113, P1327, DOI 10.1093/jn/113.7.1327; PARK JHY, 1986, J NUTR, V116, P1193, DOI 10.1093/jn/116.7.1193; PAULE CR, 1989, ARCH BIOCHEM BIOPHYS, V274, P270, DOI 10.1016/0003-9861(89)90439-6; Sambrook J, 1989, MOL CLONING LABORATO	31	32	36	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1995	9	15					1638	1642		10.1096/fasebj.9.15.8529844	http://dx.doi.org/10.1096/fasebj.9.15.8529844			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TM761	8529844				2022-12-28	WOS:A1995TM76100018
J	Trojanowski, JQ; Lee, VMY				Trojanowski, JQ; Lee, VMY			Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: Focusing on phosphatases	FASEB JOURNAL			English	Review						microbubules; cytoskeleton; neurodegenerative disease	DEPENDENT PROTEIN-KINASE; MICROTUBULE-BINDING; ABNORMAL PHOSPHORYLATION; A68 PROTEINS; SPINAL-CORD; BRAIN; PATHOLOGY; ISOFORMS; TANGLES; IDENTIFICATION	The major brain abnormalities in patients with Alzheimer's disease (AD) include extracellular deposits of beta-amyloid, intraneuronal neurofibrillary lesions, and the massive loss of specific subsets of telencephalic neurons. Neurofibrillary lesions contain paired helical filaments (PHFs) that accumulate in the perikarya (e.g., neurofibrillary tangles) and processes (e.g., dystrophic neurites, neuropil threads) of selectively vulnerable telencephalic neurons. The subunits of PHFs are derivatized forms of central nervous system (CNS) tau proteins (CNS tau) known collectively as PHFtau. Until very recently it tvas thought that the aberrant phosphorylation of PHFtau was the most salient difference between normal human CNS tau and PHFtau. However, this view required modification when it was shown that fetal and biopsy-derived human CNS tau proteins were phosphorylated at nearly all of the same sites found in PHFtau, albeit to a lesser extent. More significantly, these and other studies may be interpreted to suggest that the abnormal phosphorylation of PHFtau may result front the failure of protein phosphatases (i.e., PP2A and 2B) to dephosphorylate PHFtau. In this review, we summarize current understanding of the role of kinases and phosphatases in pathogenesis of PHFtau. We then consider how the formation PHFtau in neurons could disrupt the microtubule network, impair axonal transport, and compromise the viability of neurons. thereby contributing to the onset and progression of AD.			Trojanowski, JQ (corresponding author), UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,DIV ANATOM PATHOL,HUP,MALONEY BLDG,ROOM A009,PHILADELPHIA,PA 19104, USA.							ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; ARNOLD SE, 1996, IN PRESS J COMP NEUR; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; BANCHER C, 1994, ACTA NEUROPATHOL, V88, P565; BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; BILLINGSLEY ML, 1994, EXP NEUROL, V126, P178, DOI 10.1006/exnr.1994.1056; BRAMBLETT GT, 1992, LAB INVEST, V66, P212; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BRION JP, 1991, BIOCHEM J, V279, P831, DOI 10.1042/bj2790831; BUEESCHERRER V, 1995, AM J PATHOL, V68, P924; BUSEIGLIO J, 1995, NEURON, V14, P879; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; CORDELL B, 1994, ANNU REV PHARMACOL, V34, P69; CROWTHER RA, 1992, FEBS LETT, V309, P199, DOI 10.1016/0014-5793(92)81094-3; CROWTHER RA, 1994, FEBS LETT, V337, P135, DOI 10.1016/0014-5793(94)80260-2; DICKSON DW, 1991, NEUROBIOL AGING, V13, P179; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1147; DREWES G, 1993, FEBS LETT, V336, P425, DOI 10.1016/0014-5793(93)80850-T; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; GARVER TD, 1994, J NEUROCHEM, V63, P2279; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1992, FEBS LETT, V312, P95, DOI 10.1016/0014-5793(92)81418-L; GOEDERT M, 1993, P NATL ACAD SCI USA, V90, P5066, DOI 10.1073/pnas.90.11.5066; Goetz Juergen, 1995, EMBO (European Molecular Biology Organization) Journal, V14, P1304; GONG CX, 1994, J NEUROCHEM, V62, P803; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; HARRIS KA, 1993, ANN NEUROL, V33, P77, DOI 10.1002/ana.410330113; HASAGAWA M, 1992, J BIOL CHEM, V267, P17047; HOCK C, 1995, ANN NEUROL, V37, P414, DOI 10.1002/ana.410370325; HOF PR, 1994, ACTA NEUROPATHOL, V88, P397; HYMAN BT, 1994, AM J PATHOL, V144, P565; ISHIGURO K, 1993, FEBS LETT, V325, P167, DOI 10.1016/0014-5793(93)81066-9; KANEMARU K, 1992, J NEUROCHEM, V58, P1667, DOI 10.1111/j.1471-4159.1992.tb10039.x; KHACHATURIAN ZS, 1994, NEUROBIOL AGING, V15, pS11; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; KHATOON S, 1992, J NEUROCHEM, V59, P750, DOI 10.1111/j.1471-4159.1992.tb09432.x; KSIEZAKREDING H, 1991, NEURON, V6, P717, DOI 10.1016/0896-6273(91)90169-Z; LANG E, 1992, BIOCHEM BIOPH RES CO, V187, P783, DOI 10.1016/0006-291X(92)91264-Q; LEDESMA MD, 1992, FEBS LETT, V308, P218, DOI 10.1016/0014-5793(92)81278-T; LEE JH, 1993, EXP NEUROL, V121, P93, DOI 10.1006/exnr.1993.1074; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEE VMY, 1994, NEUROBIOL AGING, V15, pS87; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; Markesbery W, 1993, CLIN NEUROSCI, V1, P212; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; MATUS A, 1994, TRENDS NEUROSCI, V17, P19, DOI 10.1016/0166-2236(94)90030-2; MAWALDEWAN M, 1994, J BIOL CHEM, V269, P30981; MCKEE AC, 1991, ANN NEUROL, V30, P156, DOI 10.1002/ana.410300206; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; ROBERTSON J, 1993, DEMENTIA, V4, P256, DOI 10.1159/000107331; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHMIDT ML, 1994, FEBS LETT, V344, P69, DOI 10.1016/0014-5793(94)00259-2; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHIN RW, 1994, J NEUROSCI, V14, P7221; SHIN RW, 1992, AM J PATHOL, V140, P937; SHIRAZI SK, 1993, NEUROREPORT, V4, P435, DOI 10.1097/00001756-199304000-00024; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; TOHYAMA T, 1991, J COMP NEUROL, V310, P285, DOI 10.1002/cne.903100302; TROJANOWSKI JQ, 1994, ANN NY ACAD SCI, V747, P92; TROJANOWSKI JQ, 1993, BRAIN RES, V618, P333, DOI 10.1016/0006-8993(93)91286-2; VULLIET R, 1992, J BIOL CHEM, V267, P22570; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISNIEWSKI T, 1994, NEUROBIOL AGING, V15, P143, DOI 10.1016/0197-4580(94)90105-8; WOOD JG, 1993, NEUROSCI LETT, V156, P83, DOI 10.1016/0304-3940(93)90445-Q; YACHNIS AT, 1993, J COMP NEUROL, V334, P356, DOI 10.1002/cne.903340303; YOSHIDA H, 1993, J NEUROCHEM, V61, P1183, DOI 10.1111/j.1471-4159.1993.tb03642.x	77	169	176	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1995	9	15					1570	1576		10.1096/fasebj.9.15.8529836	http://dx.doi.org/10.1096/fasebj.9.15.8529836			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TM761	8529836				2022-12-28	WOS:A1995TM76100010
J	Baggio, G; Donazzan, S; Monti, D; Mari, D; Martini, S; Gabelli, C; Dalla Vestra, M; Previato, L; Guido, M; Pigozzo, S; Cortella, I; Crepaldi, G; Franceschi, C				Baggio, G; Donazzan, S; Monti, D; Mari, D; Martini, S; Gabelli, C; Dalla Vestra, M; Previato, L; Guido, M; Pigozzo, S; Cortella, I; Crepaldi, G; Franceschi, C			Lipoprotein(a) and lipoprotein profile in healthy centenarians: a reappraisal of vascular risk factors	FASEB JOURNAL			English	Article						atherosclerosis; lipoproteins; aging; interleukin 6	CORONARY HEART-DISEASE; SERUM LIPOPROTEIN(A); CHOLESTEROL; TRIGLYCERIDES; PEOPLE	In this study we assessed whether widely accepted risk factors for atherosclerotic vascular diseases such as lipoprotein(a) [Lp(a)], a cholesterol-rich lipoprotein under strict genetical control, and other lipid parameters change with age. The variations of blood levels and the pathophysiological role of Lp(a) in old people, and particularly in the oldest old, are unknown. Accordingly, we measured Lp(a) levels as well as total, LDL, and HDL cholesterol (CT), and triglycerides (TG) in sera from 75 healthy centenarians, 114 randomly selected subjects under 65 years, 73 randomly selected elderly people, and 30 healthy selected elderly people. The results showed that Lp(a) serum levels did not vary by age group, including centenarians. Remarkably, one-quarter of the centenarians had high Lp(a) serum levels even though they never suffered from atherosclerosis-related diseases. At variance with young and aged people, centenarians with high Lp(a) serum levels also had high plasma concentrations of the proinflammatory cytokine IL-6, suggesting that genetic control of the Lp(a) serum level may attenuate with age and that environmental factors such as chronic subclinical inflammatory processes may play a role. We also showed that most centenarians are paradoxically characterized by low HDL-CT and relatively high TG levels, which together are considered to be strong risk factors for coronary heart disease. On the whole, these data support the hypothesis that a continuous and complex reshaping of lipid metabolism occurs in physiological aging, likely contributing to successful aging.	Univ Modena, Dept Biomed Sci, Sect Gen Pathol, I-41100 Modena, Italy; Univ Padua, Inst Internal Med, Padova, Italy; Italian Natl Res Ctr Aging, Ancona, Italy; Univ Milan, Maggiore Hosp, IRCCS, Inst Internal Med, Milano, Italy	Universita di Modena e Reggio Emilia; University of Padua; IRCCS INRCA; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Franceschi, C (corresponding author), Univ Modena, Dept Biomed Sci, Sect Gen Pathol, Via Campi 287, I-41100 Modena, Italy.	francesc@unimo.it	Monti, Daniela/G-9556-2012; Mari, Daniela/K-5663-2016; Franceschi, Claudio/L-4484-2017	Monti, Daniela/0000-0001-8651-8123; Mari, Daniela/0000-0002-6950-0789; Franceschi, Claudio/0000-0001-9841-6386; GUIDO, Marcello/0000-0002-7907-2677				ALLAIN CC, 1974, CLIN CHEM, V20, P470; ASSMANN G, 1992, AM J CARDIOL, V70, P733, DOI 10.1016/0002-9149(92)90550-I; Berglund Lars, 1995, Current Opinion in Lipidology, V6, P48, DOI 10.1097/00041433-199502000-00011; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; Cohen HJ, 1997, J GERONTOL A-BIOL, V52, pM201, DOI 10.1093/gerona/52A.4.M201; Corti MC, 1996, AGING CLIN EXP RES, V8, P75, DOI 10.1007/BF03339560; DAHLEN GH, 1994, ATHEROSCLEROSIS, V108, P111, DOI 10.1016/0021-9150(94)90106-6; FAGIOLO U, 1993, EUR J IMMUNOL, V23, P2375, DOI 10.1002/eji.1830230950; FOSSATI P, 1982, CLIN CHEM, V28, P2077; FRANCESCHI C, 1995, IMMUNOL TODAY, V16, P12, DOI 10.1016/0167-5699(95)80064-6; HELMHOLD M, 1991, J LIPID RES, V32, P1919; HERSHELER WB, 1993, J AM GERIATR SOC, V41, P176; JENNER JL, 1993, CIRCULATION, V87, P1135, DOI 10.1161/01.CIR.87.4.1135; LIGTHART GJ, 1984, MECH AGEING DEV, V28, P47, DOI 10.1016/0047-6374(84)90152-0; Liu Alexander C., 1994, Current Opinion in Lipidology, V5, P269, DOI 10.1097/00041433-199408000-00005; MAEDA S, 1989, ATHEROSCLEROSIS, V78, P145, DOI 10.1016/0021-9150(89)90218-9; MAHER VMG, 1995, CURR OPIN LIPIDOL, V6, P229, DOI 10.1097/00041433-199508000-00007; MARI D, 1995, BLOOD, V85, P3144, DOI 10.1182/blood.V85.11.3144.bloodjournal85113144; Mari D, 1996, LANCET, V347, P1044, DOI 10.1016/S0140-6736(96)90181-6; MARTIN MJ, 1986, LANCET, V2, P933; MIYASHITA Y, 1992, GERONTOLOGY, V38, P258; RANTAPAADAHLQVIST S, 1991, ANN RHEUM DIS, V50, P366, DOI 10.1136/ard.50.6.366; ROSE M. R., 1991, EVOLUTIONARY BIOL AG; SANSONI P, 1993, BLOOD, V82, P2767; SIMONS L, 1993, ATHEROSCLEROSIS, V99, P87, DOI 10.1016/0021-9150(93)90054-X; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; WARNICK GR, 1982, CLIN CHEM, V28, P1379	27	136	138	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1998	12	6					433	437		10.1096/fasebj.12.6.433	http://dx.doi.org/10.1096/fasebj.12.6.433			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZG118	9535215	Green Submitted			2022-12-28	WOS:000072967300004
J	Droge, W; Holm, E				Droge, W; Holm, E			Role of cysteine and glutathione in HIV infection and other diseases associated with muscle wasting and immunological dysfunction	FASEB JOURNAL			English	Article						low CG syndrome; Cori cycle; plasma cystine level; insulin; skeletal muscle; glutathione level; cyst(e)ine catabolism	IMMUNODEFICIENCY-VIRUS-INFECTION; TUMOR NECROSIS FACTOR; NATURAL-KILLER-CELLS; INFLAMMATORY BOWEL-DISEASE; HEPATIC UREA SYNTHESIS; AMINO-ACID-METABOLISM; N-ACETYL-CYSTEINE; IMMUNE-SYSTEM; CANCER CACHEXIA; BODY-COMPOSITION	The combination of abnormally low plasma cystine and glutamine levels, low natural killer (NK) cell activity, skeletal muscle wasting or muscle fatigue, and increased rates of urea production defines a complex of abnormalities that is tentatively called ''low CG syndrome.'' These symptoms are found in patients with HIV infection, cancer, major injuries, sepsis, Crohn's disease, ulcerative colitis, chronic fatigue syndrome, and to some extent in overtrained athletes. The coincidence of these symptoms in diseases of different etiological origin suggests a causal relationship. The low NK cell activity in most cases is not life-threatening, but may be disastrous in HIV infection because it may compromise the initially stable balance between the immune system and virus, and trigger disease progression. This hypothesis is supported by the coincidence observed between the decrease of CD4(+) T cells and a decrease in the plasma cystine level. In addition, recent studies revealed important clues about the role of cysteine and glutathione in the development of skeletal muscle wasting. Evidence suggests that 1) the cystine level is regulated primarily by the normal postabsorptive skeletal muscle protein catabolism, 2) the cystine level itself is a physiological regulator of nitrogen balance and body cell mass, 3) the cyst(e)ine-mediated regulatory circuit is compromised in various catabolic conditions, including old age, and 4) cysteine supplementation may be a useful therapy if combined with disease-specific treatments such as antiviral therapy in HIV infection.	UNIV HEIDELBERG,MED CLIN MANNHEIM 1,DEPT PATHOPHYSIOL,D-68167 MANNHEIM,GERMANY	Ruprecht Karls University Heidelberg	Droge, W (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM,DIV IMMUNOCHEM,NEUENHEIMER FELD 280,D-69120 HEIDELBERG,GERMANY.							ABUMRAD NN, 1983, JPEN-PARENTER ENTER, V7, P163, DOI 10.1177/0148607183007002163; Akerlund B, 1996, EUR J CLIN PHARMACOL, V50, P457, DOI 10.1007/s002280050140; AOKI T, 1993, CLIN IMMUNOL IMMUNOP, V69, P253, DOI 10.1006/clin.1993.1178; Aoki T T, 1972, Adv Enzyme Regul, V10, P145, DOI 10.1016/0065-2571(72)90011-8; BARBUL A, 1986, JPEN-PARENTER ENTER, V10, P227, DOI 10.1177/0148607186010002227; BAUSS F, 1987, INFECT IMMUN, V55, P1622, DOI 10.1128/IAI.55.7.1622-1625.1987; BERGSTROM J, 1981, ANN SURG, V193, P810, DOI 10.1097/00000658-198106000-00017; BLAZAR BA, 1986, J CLIN IMMUNOL, V6, P26, DOI 10.1007/BF00915361; BRENNAN MF, 1977, CANCER RES, V37, P2359; Brittenden J, 1996, CANCER-AM CANCER SOC, V77, P1226, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1226::AID-CNCR2>3.0.CO;2-G; BROUCKAERT P, 1989, J EXP MED, V169, P2257, DOI 10.1084/jem.169.6.2257; BUHL R, 1989, LANCET, V2, P1294; CALDER PC, 1994, CLIN NUTR, V13, P2, DOI 10.1016/0261-5614(94)90003-5; COHEN RD, 1971, CLIN SCI, V41, P159, DOI 10.1042/cs0410159; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DALY JM, 1988, ANN SURG, V208, P512, DOI 10.1097/00000658-198810000-00013; deHaro C, 1996, FASEB J, V10, P1378, DOI 10.1096/fasebj.10.12.8903508; DEWYS WD, 1980, AM J MED, V69, P491, DOI 10.1016/S0149-2918(05)80001-3; Droge W, 1997, Adv Pharmacol, V38, P581; DROGE W, 1988, BIOL CHEM H-S, V369, P143, DOI 10.1515/bchm3.1988.369.1.143; DROGE W, 1988, J CANCER RES CLIN, V114, P124, DOI 10.1007/BF00417824; DROGE W, 1992, IMMUNOL TODAY, V13, P211, DOI 10.1016/0167-5699(92)90156-2; DROGE W, 1994, FASEB J, V8, P1131; Droge W, 1989, PROJECT NEWS, V2, P4; ECK HP, 1991, LANCET, V338, P346, DOI 10.1016/0140-6736(91)90482-5; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; ERIKSSON LS, 1983, GUT, V24, P1161, DOI 10.1136/gut.24.12.1161; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; FEIN R, 1985, CANCER, V56, P2512, DOI 10.1002/1097-0142(19851115)56:10<2512::AID-CNCR2820561032>3.0.CO;2-9; FELIG P, 1969, J CLIN INVEST, V48, P584, DOI 10.1172/JCI106017; FRIEDMAN PJ, 1987, NUTR RES, V7, P707, DOI 10.1016/S0271-5317(87)80101-X; Gross A, 1996, AIDS RES HUM RETROV, V12, P1639, DOI 10.1089/aid.1996.12.1639; Hack V, 1996, FASEB J, V10, P1219, DOI 10.1096/fasebj.10.10.8751725; Hack V, 1997, FASEB J, V11, P84, DOI 10.1096/fasebj.11.1.9034170; Hack V, 1996, J MOL MED-JMM, V74, P337, DOI 10.1007/BF00207511; Hack V, 1997, AM J PHYSIOL-ENDOC M, V272, pE788, DOI 10.1152/ajpendo.1997.272.5.E788; Hall JC, 1996, BRIT J SURG, V83, P305, DOI 10.1002/bjs.1800830306; HANNAFORD MC, 1982, AM J PHYSIOL, V243, pE251, DOI 10.1152/ajpendo.1982.243.3.E251; HAUSSINGER D, 1985, EUR J BIOCHEM, V152, P381, DOI 10.1111/j.1432-1033.1985.tb09208.x; HERBERMAN RB, 1981, SCIENCE, V214, P24, DOI 10.1126/science.7025208; HERZENBERG LA, 1997, IN PRESS P NATL ACAD; HESLIN MJ, 1992, AM J PHYSIOL, V262, pE911, DOI 10.1152/ajpendo.1992.262.6.E911; HESLIN MJ, 1996, PROTEIN AMINO ACID M, P187; HEYMSFIELD SB, 1985, CANCER, V55, P238, DOI 10.1002/1097-0142(19850101)55:1+<238::AID-CNCR2820551306>3.0.CO;2-S; HOMMES MJT, 1991, METABOLISM, V40, P651, DOI 10.1016/0026-0495(91)90059-6; JANSSEN GME, 1988, CAN J SPORT SCI, V13, pP18; KINSCHERF R, 1994, FASEB J, V8, P448, DOI 10.1096/fasebj.8.6.7909525; Kinscherf R, 1996, J MOL MED-JMM, V74, P393, DOI 10.1007/s001090050040; KIRK SJ, 1990, BIOCHEM BIOPH RES CO, V173, P660, DOI 10.1016/S0006-291X(05)80086-5; KOTLER DP, 1985, AM J CLIN NUTR, V42, P1255, DOI 10.1093/ajcn/42.6.1255; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LONG CL, 1976, AM J CLIN NUTR, V29, P380, DOI 10.1093/ajcn/29.4.380; LOW SY, 1994, FASEB J, V8, P127, DOI 10.1096/fasebj.8.1.7905447; Lozano Polo J L, 1990, Rev Esp Enferm Dig, V78, P71; Lundsgaard C, 1996, J HEPATOL, V24, P587, DOI 10.1016/S0168-8278(96)80145-0; Luo JL, 1996, ANN SURG, V223, P420, DOI 10.1097/00000658-199604000-00011; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; MEISTER A, 1995, BBA-MOL BASIS DIS, V1271, P35, DOI 10.1016/0925-4439(95)00007-Q; Newsholme EA, 1996, EXPERIENTIA, V52, P455, DOI 10.1007/BF01919315; NEWSHOLME EA, 1990, JPEN-PARENTER ENTER, V14, pS63, DOI 10.1177/014860719001400406; Nissim I, 1996, J BIOL CHEM, V271, P31234, DOI 10.1074/jbc.271.49.31234; OLIVIER R, 1995, METHOD ENZYMOL, V251, P270, DOI 10.1016/0076-6879(95)51129-6; OTT M, 1993, AM J CLIN NUTR, V57, P15, DOI 10.1093/ajcn/57.1.15; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; Paolicchi A, 1996, J ACQ IMMUN DEF SYND, V13, P94, DOI 10.1097/00042560-199609000-00014; PARK KGM, 1991, LANCET, V337, P645, DOI 10.1016/0140-6736(91)92456-C; PARRYBILLINGS M, 1990, INT J SPORTS MED, V11, pS122, DOI 10.1055/s-2007-1024863; PEDERSEN BK, 1994, INT J SPORTS MED, V15, pS116, DOI 10.1055/s-2007-1021125; PISTERS PWT, 1993, CRIT REV CL LAB SCI, V30, P223, DOI 10.3109/10408369309084669; POLI G, 1985, CLIN EXP IMMUNOL, V62, P128; PUENTE J, 1991, REV MED CHILE, V119, P142; ROEDERER M, 1991, INT IMMUNOL, V3, P933, DOI 10.1093/intimm/3.9.933; ROHDE T, 1995, J APPL PHYSIOL, V79, P146, DOI 10.1152/jappl.1995.79.1.146; Rohde T, 1996, SCAND J IMMUNOL, V44, P648, DOI 10.1046/j.1365-3083.1996.d01-352.x; ROTH E, 1985, SURGERY, V97, P436; SCHMITZ JE, 1994, MODERNE INFUSIONSTHE, P316; SHANAHAN F, 1989, J CLIN IMMUNOL, V9, P55, DOI 10.1007/BF00917128; SHAW JHF, 1987, SURGERY, V101, P181; SIEGEL JH, 1979, SURGERY, V86, P163; SMITH SR, 1974, METABOLISM, V23, P603, DOI 10.1016/S0026-0495(74)80020-X; STRASSMANN G, 1992, J CLIN INVEST, V89, P1681, DOI 10.1172/JCI115767; STRIEBEL JP, 1986, INFUSIONSTHERAPIE, V13, P92; TAYEK JA, 1992, J AM COLL NUTR, V11, P445; TRACEY KJ, 1988, J EXP MED, V167, P1211, DOI 10.1084/jem.167.3.1211; TURINSKY J, 1982, J SURG RES, V33, P337, DOI 10.1016/0022-4804(82)90047-6; TURKSEN K, 1992, P NATL ACAD SCI USA, V89, P5068, DOI 10.1073/pnas.89.11.5068; ULLUM H, 1995, J EXP MED, V182, P789, DOI 10.1084/jem.182.3.789; Warren S, 1932, AM J MED SCI, V184, P610, DOI 10.1097/00000441-193211000-00002; WILMORE DW, 1978, SURG CLIN N AM, V58, P1173; WITSCHI A, 1995, AIDS RES HUM RETROV, V11, P141, DOI 10.1089/aid.1995.11.141; ZHANG PC, 1992, CLIN CHEM, V38, P1198	91	130	138	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1997	11	13					1077	1089		10.1096/fasebj.11.13.9367343	http://dx.doi.org/10.1096/fasebj.11.13.9367343			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367343				2022-12-28	WOS:A1997YE98300006
J	Durand, P; LussierCacan, S; Blache, D				Durand, P; LussierCacan, S; Blache, D			Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats	FASEB JOURNAL			English	Article						atherogenesis; thrombosis; folic acid; lipid peroxidation	ENDOTHELIAL-CELL INJURY; LOW-DENSITY-LIPOPROTEIN; VASCULAR-DISEASE; RISK FACTOR; PLASMA HOMOCYSTEINE; FOLIC-ACID; FOLATE-DEFICIENCY; METHYLENETETRAHYDROFOLATE REDUCTASE; INDUCED ARTERIOSCLEROSIS; COORDINATE REGULATION	A moderate elevation of plasma homocysteine is a risk factor for atherosclerosis and arterial and veinous thrombosis. However, the mechanisms leading to vascular disorders are poorly understood because studies that have investigated the potential atherothrombogenicity of hyperhomocysteinemia in vivo are scarce. Using a rat model, we were the first to show that dietary folic acid deficiency, a major cause of basal hyperhomocysteinemia, is associated with enhanced macrophage-derived tissue factor and platelet activities. We proposed that an homocysteine-induced oxidative stress may account for this hypercoagulable state. To determine the true thrombogenicity of moderate hyperhomocysteinemia and better understand its etiology, we have carried out an acute methionine load in control and folate-deficient animals. When rats were fed the control diet, a transient fourfold increase in plasma homocysteine levels was observed 2 h after the methionine administration. As with prolonged dietary folic acid deficiency, this methionine load potentiated the platelet aggregation in response to thrombin and ADP as well as the thrombin-induced thromboxane synthesis. It also stimulated the basal and lipopolysaccharide-induced tissue factor activity of peritoneal macrophages. These prothrombotic effects were associated with an increased lipid peroxidation characterized by an elevation of plasma conjugated dienes, lipid hydroperoxides, and thiobarbituric acid-reactive substances. When rats were fed a folic acid-deficient diet, the methionine load did not cause any further increase in plasma homocysteine concentration, platelet activation, macrophage tissue factor-dependent coagulation, or lipoperoxidation. Altogether, our data showed that the prethrombotic state due to both the altered remethylation and transsulfuration pathways resulted from the moderate elevation of circulating homocysteine. We conclude that moderate hyperhomocysteinemia plays a role in the development of a thrombogenic state that might be mediated by the occurrence of oxidative stress.	UNIV BOURGOGNE, FAC MED, LAB BIOCHIM LIPOPROT, INSERM, CJF 9310, F-21033 DIJON, FRANCE; CLIN RES INST MONTREAL, MONTREAL, PQ H2W 1R7, CANADA	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal								ANDERSSON A, 1995, CLIN CHEM, V41, P361; BALAGHI M, 1993, BIOCHEM J, V291, P145, DOI 10.1042/bj2910145; BLACHE D, 1995, AM J PHYSIOL-HEART C, V268, pH679, DOI 10.1152/ajpheart.1995.268.2.H679; BLOM HJ, 1995, EUR J CLIN INVEST, V25, P149, DOI 10.1111/j.1365-2362.1995.tb01541.x; BOSTOM AG, 1995, ATHEROSCLEROSIS, V116, P147, DOI 10.1016/0021-9150(95)05529-6; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 1996, J NUTR, V126, pS1276, DOI 10.1093/jn/126.suppl_4.1276S; BRISSEAU GF, 1995, BLOOD, V85, P1025, DOI 10.1182/blood.V85.4.1025.bloodjournal8541025; CIAVATTI M, 1989, ARTERIOSCLEROSIS, V9, P84, DOI 10.1161/01.ATV.9.1.84; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; CRUTCHLEY DJ, 1995, CIRCULATION, V92, P238, DOI 10.1161/01.CIR.92.2.238; DESGRES J, 1979, J CHROMATOGR, V162, P133, DOI 10.1016/S0378-4347(00)81907-6; DIMINNO G, 1993, J CLIN INVEST, V92, P1400, DOI 10.1172/JCI116715; DUDMAN NPB, 1993, ARTERIOSCLER THROMB, V13, P512, DOI 10.1161/01.ATV.13.4.512; Durand P, 1996, CLIN CHIM ACTA, V252, P83, DOI 10.1016/0009-8981(96)06325-5; Durand P, 1996, ATHEROSCLEROSIS, V121, P231, DOI 10.1016/0021-9150(95)06724-8; Durand P, 1996, ATHEROSCLEROSIS, V121, P205, DOI 10.1016/0021-9150(95)05720-X; DURAND P, 1997, IN PRESS THROMB VASC, V17; ELSAADANI M, 1989, J LIPID RES, V30, P627; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; Freedman JE, 1996, CIRCULATION, V94, P2434, DOI 10.1161/01.CIR.94.10.2434; FRONTIERA MS, 1994, J NUTR BIOCHEM, V5, P28, DOI 10.1016/0955-2863(94)90006-X; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; FRYER RH, 1993, ARTERIOSCLER THROMB, V13, P1327, DOI 10.1161/01.ATV.13.9.1327; GUTTORMSEN AB, 1994, J NUTR, V124, P1934, DOI 10.1093/jn/124.10.1934; HARKER LA, 1976, J CLIN INVEST, V58, P731, DOI 10.1172/JCI108520; Harpel PC, 1996, J NUTR, V126, pS1285, DOI 10.1093/jn/126.suppl_4.1285S; HASHIZUME T, 1991, ARCH BIOCHEM BIOPHYS, V289, P47, DOI 10.1016/0003-9861(91)90440-T; HEINECKE JW, 1993, J LIPID RES, V34, P2051; HENNEKENS CH, 1994, AM HEART J, V128, P1333, DOI 10.1016/0002-8703(94)90256-9; Iuliano L, 1996, BRIT J PHARMACOL, V119, P1438, DOI 10.1111/j.1476-5381.1996.tb16056.x; Jacques PF, 1996, CIRCULATION, V93, P7, DOI 10.1161/01.CIR.93.1.7; JAMES SJ, 1992, CARCINOGENESIS, V13, P2471, DOI 10.1093/carcin/13.12.2471; KRITCHEVSKY D, 1993, ANN NY ACAD SCI, V676, P180; Loehrer FMT, 1996, CLIN SCI, V91, P79, DOI 10.1042/cs0910079; MANSOOR MA, 1992, CLIN CHEM, V38, P1316; Matthias D, 1996, ATHEROSCLEROSIS, V122, P201, DOI 10.1016/0021-9150(95)05740-4; MCCULLY KS, 1983, ATHER REV, V11, P157; MILLER JW, 1994, AM J CLIN NUTR, V59, P1033, DOI 10.1093/ajcn/59.5.1033; MILLER JW, 1994, BIOCHEM J, V298, P415, DOI 10.1042/bj2980415; Morrison HI, 1996, JAMA-J AM MED ASSOC, V275, P1893, DOI 10.1001/jama.275.24.1893; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; POLETTE A, 1992, ATHEROSCLEROSIS, V96, P171, DOI 10.1016/0021-9150(92)90063-M; PRATICO D, 1992, J LAB CLIN MED, V119, P364; RICHIE JP, 1994, FASEB J, V8, P1302, DOI 10.1096/fasebj.8.15.8001743; SALONEN JT, 1991, AM J CLIN NUTR, V53, P1222, DOI 10.1093/ajcn/53.5.1222; SCHORER AE, 1985, J LAB CLIN MED, V106, P38; SELHUB J, 1992, AM J CLIN NUTR, V55, P131, DOI 10.1093/ajcn/55.1.131; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; Toborek M, 1996, NUTR RES, V16, P1251, DOI 10.1016/0271-5317(96)00128-5; TOBOREK M, 1995, ATHEROSCLEROSIS, V115, P217, DOI 10.1016/0021-9150(94)05516-L; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; UBBINK JB, 1994, J NUTR, V124, P1927, DOI 10.1093/jn/124.10.1927; Ueland PM, 1996, J NUTR, V126, pS1281, DOI 10.1093/jn/126.suppl_4.1281S; UELAND PM, 1989, J LAB CLIN MED, V114, P473; Verhoef P, 1996, AM J EPIDEMIOL, V143, P845, DOI 10.1093/oxfordjournals.aje.a008828	57	184	195	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1997	11	13					1157	1168		10.1096/fasebj.11.13.9367351	http://dx.doi.org/10.1096/fasebj.11.13.9367351			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367351				2022-12-28	WOS:A1997YE98300014
J	Weiss, JN				Weiss, JN			The Hill equation revisited: uses and misuses	FASEB JOURNAL			English	Review						ligands; receptors; binding; ligand-receptor interaction; ion channels; enzymes		The Hill coefficient is commonly used to estimate the number of ligand molecules that are required to bind to a receptor to produce a functional effect. However, for a receptor dth more than one ligand binding site, the Hill equation does not reflect a physically possible reaction scheme; only under the very specific condition of marked positive cooperativity does the Hill coefficient accurately estimate the number of binding sites. The Hill coefficient is best thought of as an ''interaction'' coefficient, reflecting the extent of cooperativity among multiple ligand binding sites. Several relatively simple, physically plausible reaction schemes are shown here to produce a variety of ligand dose-response curve phenotypes more appropriately suited to modeling ligand-receptor interactions, especially if independent information about the stochiometry of the ligand-receptor interaction is available.			Weiss, JN (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DIV CARDIOL,DEPT MED,3641 MRL BLDG,LOS ANGELES,CA 90095, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052319, R01HL036729] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL52319, R01HL36729] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; ENGEL PC, 1996, NONLINEAR KINETICS C; FROMM HJ, 1996, INITIAL RATE ENZYME, P236; GADSBY DC, 1993, SCIENCE, V260, P100, DOI 10.1126/science.7682009; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; WALZ D, 1988, CELL BIOPHYS, V12, P13, DOI 10.1007/BF02918348	9	654	664	7	123	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1997	11	11					835	841		10.1096/fasebj.11.11.9285481	http://dx.doi.org/10.1096/fasebj.11.11.9285481			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XT790	9285481				2022-12-28	WOS:A1997XT79000002
J	Aspnes, LE; Lee, CM; Weindruch, R; Chung, SS; Roecker, EB; Aiken, JM				Aspnes, LE; Lee, CM; Weindruch, R; Chung, SS; Roecker, EB; Aiken, JM			Caloric restriction reduces fiber loss and mitochondrial abnormalities in aged rat muscle	FASEB JOURNAL			English	Article						aging; sarcopenia; mitochondria; skeletal muscle	CYTOCHROME-C-OXIDASE; ANTIOXIDANT ENZYME-ACTIVITIES; DNA OXIDATIVE DAMAGE; SKELETAL-MUSCLE; DIETARY RESTRICTION; FOOD RESTRICTION; MULTIPLE DELETIONS; RHESUS-MONKEYS; LIFE-SPAN; ATROPHY	The influence of caloric restriction (CR) initiated at 17 months of age was investigated on selected age-associated measures in skeletal muscle. Tissue from young (3-4 months) ad libitum-fed, old (30-32 months) restricted (35% and 50% CR, designated CR35 and CR50, respectively), and old ad libitum-fed rats (29 months) was studied. CR preserved fiber number and fiber type composition in the vastus lateralis muscle of the CR50 rats. In the old rats from all groups, individual fibers were found with either no detectable cytochrome c oxidase activity (COX-), hyperreactivity for succinate dehydrogenase activity (SDH++; also known as ragged red fibers [RRF]), or both COX- and SDH++. Muscle from the CR50 rats contained significantly fewer COX- and SDH++ fibers than did the muscle from CR35 rats. CR50 rats also had significantly lower numbers of mtDNA deletion products in two (adductor longus and soleus) of the four muscles examined compared to CR35 rats. These data indicate that CR begun in late middle age can retard age-associated fiber loss and fiber type changes, as well as increases in the number of skeletal muscle fibers showing mitochondrial enzyme abnormalities. CR also decreased the accumulation of mtDNA deletions.	UNIV WISCONSIN,DEPT NUTR SCI,MADISON,WI 53706; UNIV WISCONSIN,DEPT MED,MADISON,WI 53706; UNIV WISCONSIN,DEPT BIOSTAT,MADISON,WI 53706; WILLIAM S MIDDLETON MEM VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital	Aspnes, LE (corresponding author), UNIV WISCONSIN,DEPT ANIM HLTH & BIOMED SCI,1655 LINDEN DR,MADISON,WI 53706, USA.			Aiken, Judd/0000-0001-6119-4521	NATIONAL INSTITUTE ON AGING [P01AG011915, R01AG011604, R01AG010536] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG10536, P01 AG11915, R01 AG11604] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGARWAL S, 1994, P NATL ACAD SCI USA, V91, P12332, DOI 10.1073/pnas.91.25.12332; ARIANO MA, 1973, J HISTOCHEM CYTOCHEM, V21, P51, DOI 10.1177/21.1.51; ARMSTRONG RB, 1984, AM J ANAT, V171, P259, DOI 10.1002/aja.1001710303; ATTARDI G, 1986, BIOESSAYS, V5, P34, DOI 10.1002/bies.950050111; BASS A, 1975, GERONTOLOGY, V21, P31, DOI 10.1159/000212028; BAUMER A, 1994, AM J HUM GENET, V54, P618; BOREHAM CAG, 1988, J ANAT, V157, P111; BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x; BROSSAS JY, 1994, BIOCHEM BIOPH RES CO, V202, P654, DOI 10.1006/bbrc.1994.1980; CACCIA MR, 1979, MUSCLE NERVE, V2, P202, DOI 10.1002/mus.880020308; CARLSON BM, 1995, J GERONTOL A-BIOL, V50, P96; CARON F, 1979, P NATL ACAD SCI USA, V76, P4265, DOI 10.1073/pnas.76.9.4265; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHUNG SS, 1994, AGING-CLIN EXP RES, V6, P193, DOI 10.1007/BF03324239; CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573; COGGAN AR, 1992, J GERONTOL, V47, pB71, DOI 10.1093/geronj/47.3.B71; CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927; DAW CK, 1988, J APPL PHYSIOL, V64, P2428, DOI 10.1152/jappl.1988.64.6.2428; Desai VG, 1996, ARCH BIOCHEM BIOPHYS, V333, P145, DOI 10.1006/abbi.1996.0375; DiMauro S, 1993, MOL GENETIC BASIS NE, P665; Dubowitz V, 1985, MUSCLE BIOPSY PRACTI, P19; EDRIS W, 1994, MUTAT RES-DNAGING G, V316, P69, DOI 10.1016/0921-8734(94)90009-4; Eimon PM, 1996, DEV GENET, V18, P107, DOI 10.1002/(SICI)1520-6408(1996)18:2&lt;107::AID-DVG3&gt;3.0.CO;2-D; ELHAJ AJ, 1986, COMP BIOCHEM PHYS A, V85, P281, DOI 10.1016/0300-9629(86)90251-3; ENGEL WK, 1963, NEUROLOGY, V13, P919, DOI 10.1212/WNL.13.11.919; FAULKNER JA, 1995, J GERONTOL A-BIOL, V50, P124; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; GADALETA MN, 1992, MUTAT RES, V275, P181, DOI 10.1016/0921-8734(92)90022-H; GARTHWAITE SM, 1986, MECH AGEING DEV, V36, P187, DOI 10.1016/0047-6374(86)90019-9; GUTMANN E, 1972, AGE CHANGES NEUROMUS; HATTORI K, 1991, AM HEART J, V121, P1735, DOI 10.1016/0002-8703(91)90020-I; HAVENITH MG, 1990, HISTOCHEMISTRY, V93, P497, DOI 10.1007/BF00266407; HIGAMI Y, 1994, J GERONTOL, V49, pB239, DOI 10.1093/geronj/49.5.B239; HOLLOSZY JO, 1991, MECH AGEING DEV, V60, P199, DOI 10.1016/0047-6374(91)90131-I; HOLLOSZY JO, 1995, J GERONTOL A, V50; JI LL, 1990, AM J PHYSIOL, V258, pR918, DOI 10.1152/ajpregu.1990.258.4.R918; JOHNSTON W, 1995, ANN NEUROL, V37, P16, DOI 10.1002/ana.410370106; LARSSON L, 1986, J NEUROL SCI, V76, P69, DOI 10.1016/0022-510X(86)90143-7; LARSSON L, 1995, J GERONTOL A-BIOL, V50, P91; LARSSON L, 1978, ACTA PHYSIOL SCAND, V103, P31, DOI 10.1111/j.1748-1716.1978.tb06187.x; LEE CM, 1993, J GERONTOL, V48, pB201, DOI 10.1093/geronj/48.6.B201; LEXELL J, 1983, MUSCLE NERVE, V6, P588, DOI 10.1002/mus.880060809; LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; LUHTALA TA, 1994, J GERONTOL, V49, pB231, DOI 10.1093/geronj/49.5.B231; MCCARTER R, 1987, J GERONTOL, V42, P432, DOI 10.1093/geronj/42.4.432; McCullagh P., 1983, GEN LINEAR MODELS, DOI [10.1007/978-1-4899-3244-0, DOI 10.1007/978-1-4899-3244-0]; MORAES CT, 1992, AM J HUM GENET, V50, P934; MULLERHOCKER J, 1992, MUTAT RES, V275, P115, DOI 10.1016/0921-8734(92)90016-I; MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9; MULLERHOCKER J, 1993, VIRCHOWS ARCH A, V422, P7, DOI 10.1007/BF01605127; MullerHocker J, 1996, MECH AGEING DEV, V86, P197, DOI 10.1016/0047-6374(95)01692-9; NOY N, 1985, MECH AGEING DEV, V29, P63, DOI 10.1016/0047-6374(85)90047-8; OhIshi S, 1995, MECH AGEING DEV, V84, P65, DOI 10.1016/0047-6374(95)01637-F; PRELLE A, 1994, ACTA NEUROPATHOL, V87, P371; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; RIFAI Z, 1995, ANN NEUROL, V37, P24, DOI 10.1002/ana.410370107; Sambrook J., 2002, MOL CLONING LAB MANU; Sanderson JP, 1997, J GERONTOL A-BIOL, V52, pB20, DOI 10.1093/gerona/52A.1.B20; SCHWARZE SR, 1995, MECH AGEING DEV, V83, P91, DOI 10.1016/0047-6374(95)01611-3; SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1; SNECEDOR GW, 1980, STAT METHODS; SNYDER DL, 1990, J GERONTOL, V45, pB52, DOI 10.1093/geronj/45.2.B52; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; SOHAL RS, 1992, MUTAT RES, V275, P295, DOI 10.1016/0921-8734(92)90033-L; SOHAL RS, 1994, MECH AGEING DEV, V76, P215, DOI 10.1016/0047-6374(94)91595-4; SUGIYAMA S, 1993, BIOCHEM MOL BIOL INT, V30, P937; TAKASAWA M, 1993, EXP GERONTOL, V28, P269, DOI 10.1016/0531-5565(93)90034-B; TANHAUSER SM, 1995, J BIOL CHEM, V270, P24769, DOI 10.1074/jbc.270.42.24769; TAUCHI H, 1971, GERONTOLOGY, V17, P219, DOI 10.1159/000211826; TORRI K, 1992, AM J RESP CELL MOL B, V6, P543; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; VanTuyle GC, 1996, MUTAT RES-FUND MOL M, V349, P95, DOI 10.1016/0027-5107(95)00165-4; VERTECHY M, 1989, EXP GERONTOL, V24, P211, DOI 10.1016/0531-5565(89)90012-0; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; WEINDRUCH R, 1995, J GERONTOL A-BIOL, V50, P157; WEINDRUCH R, 1988, RETARDATION AGING DI; WEINDRUCH RH, 1980, MECH AGEING DEV, V12, P375, DOI 10.1016/0047-6374(80)90070-6; Yu BP, 1993, FREE RADICALS AGING; ZHANG C, 1992, FEBS LETT, V297, P34, DOI 10.1016/0014-5793(92)80321-7	82	129	129	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1997	11	7					573	581		10.1096/fasebj.11.7.9212081	http://dx.doi.org/10.1096/fasebj.11.7.9212081			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XH342	9212081				2022-12-28	WOS:A1997XH34200009
J	Turner, AJ; Tanzawa, K				Turner, AJ; Tanzawa, K			Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX	FASEB JOURNAL			English	Review						endothelial cells; regulatory peptides; cardiovascular system; atherosclerosis; hypertension	ENDOTHELIN-CONVERTING ENZYME; NEUTRAL ENDOPEPTIDASE 24.11; BLOOD-GROUP PROTEIN; LEUKEMIA ANTIGEN; BIG ENDOTHELIN-1; FUNCTIONAL EXPRESSION; CLONING; CELLS; GENE; ENKEPHALINASE	Mammalian cell-surface peptidases participate in the postsecretory processing and metabolism of neuropeptides and peptide hormones. Neutral endopeptidase-24.11 (MEP) is the prototype of a family of zinc metallopeptidases that also includes the endothelin-converting enzymes (ECE) and which are structurally related to the bacterial enzymes thermolysin and lactococcal endopeptidase. Two Other mammalian gene products exhibit strong homology with NEP: the erythrocyte cell-surface antigen, KELL; and the putative product of the PEX gene, which has been associated with X-linked hypophosphatemic rickets. No enzymic activity has yet been attributed to KELL and PEX proteins, and they remain peptidases in search of a substrate. A wide range of biologically active peptide substrates has been described for NEP, of which the enkephalins and the atrial natriuretic peptide family have assumed greatest significance. Endothelin-converting enzyme catalyses the final step in the biosynthesis of the vasoconstrictor peptide, endothelin (ET). Like NEP, it is a type II integral membrane protein, but is expressed predominantly in endothelial cells. Isoforms of ECE (ECE-1 alpha, ECE-1 beta, and ECE-2) exist that differ in a number of characteristics. In particular, ECE-1, through the paracrine effects of ET-1, may contribute to the proliferation of smooth muscle after angioplasty and to the development of human atherosclerosis. Inhibitors of ECE and NEP may have important therapeutic applications in cardiovascular and renal medicine.	SANKYO CO LTD,BIOL RES LABS,SHINAGAWA KU,TOKYO 140,JAPAN	Daiichi Sankyo Company Limited	Turner, AJ (corresponding author), UNIV LEEDS,DEPT BIOCHEM & MOL BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.							Albertin G, 1996, BIOCHEM BIOPH RES CO, V221, P682, DOI 10.1006/bbrc.1996.0656; BARKER PE, 1989, J IMMUNOL, V142, P283; Barnes K, 1997, J NEUROCHEM, V68, P570; Barnes K, 1996, J CELL SCI, V109, P919; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; DADAMIO L, 1989, P NATL ACAD SCI USA, V86, P7103, DOI 10.1073/pnas.86.18.7103; DEVAULT A, 1987, EMBO J, V6, P1317, DOI 10.1002/j.1460-2075.1987.tb02370.x; DION N, 1993, FEBS LETT, V318, P301, DOI 10.1016/0014-5793(93)80533-Z; DION N, 1995, BIOCHEM J, V311, P623, DOI 10.1042/bj3110623; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; ERDOS EG, 1989, FASEB J, V3, P145, DOI 10.1096/fasebj.3.2.2521610; HARRISON VJ, 1995, P NATL ACAD SCI USA, V92, P6344, DOI 10.1073/pnas.92.14.6344; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; HOWELL S, 1991, BIOCHEM J, V278, P417, DOI 10.1042/bj2780417; HOWELL S, 1993, BIOCHEM J, V290, P159, DOI 10.1042/bj2900159; *HYP CONS, 1995, NAT GENET, V11, P130; IKURA T, 1994, BIOCHEM BIOPH RES CO, V203, P1417, DOI 10.1006/bbrc.1994.2343; KERR MA, 1974, BIOCHEM J, V137, P477, DOI 10.1042/bj1370477; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; LAPADULA G, 1995, CLIN EXP RHEUMATOL, V13, P143; LEE S, 1995, BLOOD, V85, P1364, DOI 10.1182/blood.V85.5.1364.bloodjournal8551364; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; LEMOUAL H, 1994, EUR J BIOCHEM, V221, P475; LETARTE M, 1988, J EXP MED, V168, P1247, DOI 10.1084/jem.168.4.1247; LI CW, 1995, J BIOL CHEM, V270, P5723, DOI 10.1074/jbc.270.11.5723; LU B, 1995, J EXP MED, V181, P2271, DOI 10.1084/jem.181.6.2271; MATSAS R, 1983, P NATL ACAD SCI-BIOL, V80, P3111, DOI 10.1073/pnas.80.10.3111; Matsuoka R, 1996, CYTOGENET CELL GENET, V72, P322, DOI 10.1159/000134214; MIERAU I, 1993, J BACTERIOL, V175, P2087, DOI 10.1128/JB.175.7.2087-2096.1993; Minamino T, 1997, CIRCULATION, V95, P221, DOI 10.1161/01.CIR.95.1.221; MURPHY LJ, 1994, BRIT J PHARMACOL, V113, P137, DOI 10.1111/j.1476-5381.1994.tb16185.x; NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995-944; OHNAKA K, 1993, J BIOL CHEM, V268, P26759; OPGENORTH TJ, 1992, FASEB J, V6, P2653, DOI 10.1096/fasebj.6.9.1612289; POLLOCK DM, 1995, FASEB J, V9, P1196, DOI 10.1096/fasebj.9.12.7672512; RELTON JM, 1983, BIOCHEM J, V215, P519, DOI 10.1042/bj2150519; ROQUES BP, 1990, TRENDS PHARMACOL SCI, V11, P245; ROQUES BP, 1993, PHARMACOL REV, V45, P87; SCHMIDT M, 1994, FEBS LETT, V356, P238, DOI 10.1016/0014-5793(94)01277-6; Shimada K, 1996, BIOCHEM J, V315, P863, DOI 10.1042/bj3150863; SHIMADA K, 1995, BIOCHEM BIOPH RES CO, V207, P807, DOI 10.1006/bbrc.1995.1258; SHIMADA K, 1994, J BIOL CHEM, V269, P18275; SHIMADA K, 1995, FEBS LETT, V371, P140, DOI 10.1016/0014-5793(95)00886-E; SHIPP MA, 1991, BLOOD, V78, P1834; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; SPENCERDENE B, 1994, DEVELOPMENT, V120, P3213; TAKAHASHI M, 1993, J BIOL CHEM, V268, P21394; TAKAHASHI M, 1995, BIOCHEM J, V311, P657, DOI 10.1042/bj3110657; TSURUMI Y, 1995, J ANTIBIOT, V48, P1066, DOI 10.7164/antibiotics.48.1066; Turner AJ, 1996, BIOCHEM PHARMACOL, V51, P91, DOI 10.1016/0006-2952(95)02036-5; VALDENAIRE O, 1995, J BIOL CHEM, V270, P29794; Wang XK, 1996, CIRC RES, V78, P322, DOI 10.1161/01.RES.78.2.322; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YAMAGISAWA M, 1988, NATURE, V332, P411; YANAGISAWA M, 1995, COE INT S OS JAP; YORIMITSU K, 1995, BIOCHEM BIOPH RES CO, V208, P721, DOI 10.1006/bbrc.1995.1397	56	353	367	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1997	11	5					355	364		10.1096/fasebj.11.5.9141502	http://dx.doi.org/10.1096/fasebj.11.5.9141502			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	WX156	9141502				2022-12-28	WOS:A1997WX15600008
J	Spiegel, S; Merrill, AH				Spiegel, S; Merrill, AH			Sphingolipid metabolism and cell growth regulation	FASEB JOURNAL			English	Review						sphingosine; sphingosine-1-phosphate; fumonisins; cell growth/death; signal transduction	PROTEIN-KINASE-C; RADIOACTIVE ACETIC-ANHYDRIDE; FREE SPHINGOSINE LEVELS; SWISS 3T3 FIBROBLASTS; NIEMANN-PICK DISEASE; DNA-BINDING ACTIVITY; SIGNAL-TRANSDUCTION; SERINE PALMITOYLTRANSFERASE; INTRACELLULAR CALCIUM; PHORBOL DIBUTYRATE	Sphingolipids have been implicated in the regulation of cell growth, differentiation, and programmed cell death. The current paradigm for their action is that complex sphingolipids such as gangliosides interact with growth factor receptors, the extracellular matrix, and neighboring cells, whereas the backbones-sphingosine and other long-chain or ''sphingoid'' bases, ceramides, and sphingosine 1-phosphate-activate or inhibit protein kinases and phosphatases, ion transporters, and other regulatory machinery. Tumor necrosis factor-alpha, interleukin Ip, and nerve growth factor, for example, induce sphingomyelin hydrolysis to ceramide. Other agonists, such as platelet-derived growth factor, trigger further hydrolysis of ceramide to sphingosine and activate sphingosine kinase to form sphingosine 1-phosphate. These metabolites either stimulate or inhibit growth and may be cytotoxic (in some cases via induction of apoptosis), depending on which products are formed (or added exogenously), the cellular levels (and possibly intracellular localization), and the cell type. In Swiss 3T3 cells, for example, sphingosine and sphingosine 1-phosphate are growth stimulatory at low concentrations via calcium mobilization from intracellular stores and activation of the mitogen-activated protein kinase (MAP kinase) pathway and transcription factors (AP-1), but are toxic at high concentrations. High levels of endogenous sphingoid bases are also produced by inhibition of ceramide synthase by fumonisins, mycotoxins produced by Fusarium moniliforme, resulting in growth stimulation or toxicity. Thus, sphingolipid metabolites appear to serve as second messengers for growth factors, cytokines, and other ''physiological'' agonists and, when elevated abnormally, to lead to disease.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ROLLINS RES CTR 4113,ATLANTA,GA 30322; GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOL BIOL,WASHINGTON,DC 20007	Emory University; Georgetown University				Merrill, Alfred/0000-0002-6673-968X	NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043880, R01GM046368] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA61774] Funding Source: Medline; NIGMS NIH HHS [1R01 GM46368, 1R01 GM43880] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSENKO A, 1995, MOL CELL BIOCHEM, V143, P169, DOI 10.1007/BF01816950; ARNOLD RS, 1991, BIOCHEMISTRY-US, V30, P7747, DOI 10.1021/bi00245a011; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BALLOU LR, 1990, J IMMUNOL, V145, P4245; BELL R, 1993, ADV LIPID RES SPHING, V26; BELL RM, 1993, ADV LIPID RES SPHING, V25; BENAV P, 1989, FEBS LETT, V259, P64, DOI 10.1016/0014-5793(89)81495-4; BERGER A, 1995, P NATL ACAD SCI USA, V92, P5885, DOI 10.1073/pnas.92.13.5885; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZUIDENHOUT SC, 1988, J CHEM SOC CHEM COMM, P743, DOI 10.1039/c39880000743; BOREK C, 1991, P NATL ACAD SCI USA, V88, P1953, DOI 10.1073/pnas.88.5.1953; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; BUCKLEY NE, 1990, EXP CELL RES, V189, P13, DOI 10.1016/0014-4827(90)90250-E; BUEHRER BM, 1993, ADV LIPID RES, V26, P59; CHAO CP, 1994, J BIOL CHEM, V269, P5849; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; DAVIS RJ, 1988, J BIOL CHEM, V263, P5373; DESAI NN, 1992, J BIOL CHEM, V267, P23122; DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385; DILLEHAY DL, 1994, J NUTR, V124, P615, DOI 10.1093/jn/124.5.615; ENDO K, 1991, CANCER RES, V51, P1613; EXTON JH, 1990, J BIOL CHEM, V65, P1; Fatatis A, 1996, J BIOL CHEM, V271, P295, DOI 10.1074/jbc.271.1.295; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; GOLDIN E, 1992, BIOCHIM BIOPHYS ACTA, V1127, P303, DOI 10.1016/0005-2760(92)90236-O; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; GOMEZMUNOZ A, 1995, J BIOL CHEM, V270, P26313; GOODEMOTE KA, 1995, J BIOL CHEM, V270, P10272, DOI 10.1074/jbc.270.17.10272; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HASSLER DF, 1993, ADV LIPID RES, V26, P49; HAUSER JM, 1994, J BIOL CHEM, V69, P6803; HELLER RA, 1994, J CELL BIOL, V26, P5; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HUANG CX, 1995, CANCER RES, V55, P1655; HUDSON PL, 1994, J BIOL CHEM, V269, P21885; IGARASHI Y, 1990, J BIOL CHEM, V265, P5385; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; JACOBS LS, 1993, AM J PHYSIOL, V265, pC740, DOI 10.1152/ajpcell.1993.265.3.C740; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; Jarvis WD, 1996, J BIOL CHEM, V271, P8275, DOI 10.1074/jbc.271.14.8275; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JEFFERSON AB, 1988, J BIOL CHEM, V263, P15241; JOHNSON JA, 1990, J BIOL CHEM, V265, P9333; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KIM S, 1995, J BIOL CHEM, V270, P5266, DOI 10.1074/jbc.270.10.5266; KISS Z, 1990, J BIOL CHEM, V65, P7188; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LAVIE Y, 1990, BIOCHEM BIOPH RES CO, V67, P607; LAVIE Y, 1990, FED EUR BIOL SOC, V77, P7; MANDALA SM, 1995, J ANTIBIOT, V48, P349, DOI 10.7164/antibiotics.48.349; MARU M, 1993, INT J CANCER, V53, P645, DOI 10.1002/ijc.2910530420; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MAZUREK N, 1994, BIOCHEM BIOPH RES CO, V198, P1, DOI 10.1006/bbrc.1994.1001; MCDONALD O, 1991, J BIOL CHEM, V66, P21773; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1993, ADV LIPID RES, V26, P215; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; Merrill AH, 1996, TRENDS CELL BIOL, V6, P218, DOI 10.1016/0962-8924(96)10021-0; MERRILL AH, 1995, J NUTR, V125, pS1677, DOI 10.1093/jn/125.suppl_6.1677S; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; MERRILL AH, 1995, HDB LIPID RES, V8, P205; MICCHELI A, 1991, BIOCHIM BIOPHYS ACTA, V1095, P90, DOI 10.1016/0167-4889(91)90049-4; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; Nakamura S, 1996, J BIOL CHEM, V271, P1255, DOI 10.1074/jbc.271.3.1255; NATARAJAN V, 1994, AM J RESP CELL MOL, V11, P221, DOI 10.1165/ajrcmb.11.2.8049083; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHTA H, 1994, ANAL BIOCHEM, V222, P489, DOI 10.1006/abio.1994.1522; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1994, J BIOL CHEM, V269, P17924; OLIVERA A, 1994, ANAL BIOCHEM, V223, P306, DOI 10.1006/abio.1994.1589; OLIVERA A, 1992, GLYCOCONJUGATE J, V9, P109; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PERRY DK, 1992, J IMMUNOL, V149, P2749; PUSHKAREVA M, 1995, BIOCHEMISTRY-US, V34, P1885, DOI 10.1021/bi00006a009; PUSHKAREVA MY, 1992, J BIOL CHEM, V267, P15246; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RICCIOLINI R, 1994, BBA-MOL CELL RES, V1221, P103, DOI 10.1016/0167-4889(94)90001-9; RILEY RT, 1994, J FOOD PROTECT, V57, P638, DOI 10.4315/0362-028X-57.7.638; RILEY RT, 1994, J AOAC INT, V77, P533; RITCHIE T, 1992, BIOCHEM BIOPH RES CO, V86, P790; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SABBADINI RA, 1992, J BIOL CHEM, V267, P15475; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SADAHIRA Y, 1994, FEBS LETT, V340, P99, DOI 10.1016/0014-5793(94)80180-0; Sakakura C, 1996, FEBS LETT, V379, P177, DOI 10.1016/0014-5793(95)01508-6; SANDHOFF K, 1993, ADV LIPID RES, V26, P119; SCHROEDER JJ, 1994, J BIOL CHEM, V269, P3475; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; SPENCE MW, 1993, ADV LIPID RES, V26, P3; SPIEGEL S, 1993, ADV LIPID RES, V25, P105; SPIEGEL S, 1994, BREAST CANC RES TREA, V1, P195; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; STEVENS VL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P37, DOI 10.1016/0167-4889(90)90171-9; SU Y, 1994, J BIOL CHEM, V269, P16512; SUGIYA H, 1991, FEBS LETT, V286, P113, DOI 10.1016/0014-5793(91)80953-Z; TAYLOR W, 1992, TRENDS BIOCHEM SCI, V7, P403; Tolleson WH, 1996, CARCINOGENESIS, V17, P239, DOI 10.1093/carcin/17.2.239; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; vanKoppen CJ, 1996, J BIOL CHEM, V271, P2082, DOI 10.1074/jbc.271.4.2082; VANVELDHOVEN PP, 1994, BIOCHEM J, V299, P597, DOI 10.1042/bj2990597; VANVELDHOVEN PP, 1993, ADV LIPID RES, V26, P69; VANVELDHOVEN PP, 1994, FEBS LETT, V350, P91, DOI 10.1016/0014-5793(94)00739-X; WAHL M, 1988, J BIOL CHEM, V263, P7581; WANG E, 1991, J BIOL CHEM, V266, P14486; WILSON E, 1988, J BIOL CHEM, V263, P9304; WONG K, 1993, CELL CALCIUM, V14, P493, DOI 10.1016/0143-4160(93)90008-T; WRIGHT SC, 1996, FASEB J, V70, P325; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; WU WI, 1993, J BIOL CHEM, V268, P13830; YAMADA K, 1993, BIOCHIM BIOPHYS ACTA, V1169, P211; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193; YATOMI Y, 1995, ANAL BIOCHEM, V230, P315, DOI 10.1006/abio.1995.1480; YOO HS, 1992, TOXICOL APPL PHARM, V114, P9, DOI 10.1016/0041-008X(92)90090-F; YULE DI, 1993, J BIOL CHEM, V268, P12353; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZHANG H, 1990, J BIOL CHEM, V265, P21309; ZWEERINK MM, 1992, J BIOL CHEM, V267, P25032	131	622	643	0	33	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1996	10	12					1388	1397		10.1096/fasebj.10.12.8903509	http://dx.doi.org/10.1096/fasebj.10.12.8903509			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VP485	8903509				2022-12-28	WOS:A1996VP48500004
J	Columbano, A; Shinozuka, H				Columbano, A; Shinozuka, H			Liver regeneration .8. Liver regeneration versus direct hyperplasia	FASEB JOURNAL			English	Review							TUMOR-NECROSIS-FACTOR; TRANSFORMING GROWTH FACTOR-BETA-1; PROLIFERATOR-ACTIVATED RECEPTOR; PROGRAMMED CELL-DEATH; ENZYME-ALTERED FOCI; MYC MESSENGER-RNA; RAT-LIVER; FACTOR-ALPHA; PEROXISOME PROLIFERATORS; PARTIAL-HEPATECTOMY	In this, the penultimate article to appear in the series on liver regeneration, Columbano and Shinozuka review the role of primary mitogens as inducers of hepatic growth without cell. loss. Cell proliferation by direct hyperplasia in the absence of compensatory regeneration represents another unique ability of hepatic cells to proliferate. Throughout the series we have dealt primarily with liver regeneration after two-thirds partial hepatectomy or chemical toxicity. We are now introduced to a type of hepatocyte proliferation that does not necessarily require expression of certain immediate early genes or growth factors or even exhibits the same patterns of signal transduction associated with compensatory hyperplasia. The mechanisms involved in transition through the G1 phase of the cell cycle are quite different for the two types of liver regeneration. However, once the hepatocyte is committed to replication, progression through the cell cycle appears to be the same for both types of growth. The characteristics of mitogen-induced direct hyperplasia also appear to depend on the type of mitogen involved. For example, the pattern of ploidy, the perturbation in cytokinesis, and the incidence of multinucleate cells are very different in direct hyperplasia induced by lead nitrate vs. that induced by the peroxisome proliferator nafenopin. However, one common characteristic remains intact: as soon as the mitogenic stimulus is withdrawn, liver mass and DNA content return to their original values, regressing through what appears to be the well-controlled process of apoptosis. In liver regeneration by direct hyperplasia, we become aware of a host of new players, including nuclear receptors for peroxisome proliferators such as clofibrate and the retinoid X receptor for 9-cis retinoic acid. We are also reintroduced to a set of old players including nonparenchymal cells and TNF-alpha. If it begins to seem logical, try to explain why direct hyperplasia is far less effective in initiation of chemical hepatocarcinogenesis than compensatory regeneration. The hepatic cell is truly a remarkable entity, with its myriad of ways to replicate, regress, and remain quiescent. Just when the subject of liver regeneration was beginning to make sense!.	UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Columbano, A (corresponding author), UNIV CAGLIARI,IST PATOL SPERIMENTALE,VIA PORCELL 4,I-09124 CAGLIARI,ITALY.		Columbano, Amedeo/C-7463-2011	Columbano, Amedeo/0000-0002-6956-9030	NCI NIH HHS [CA 53453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BEYER HS, 1993, BIOCHEM MOL BIOL INT, V29, P1; BEYER HS, 1990, BIOCHEM INT, V22, P405; BUCHER NLR, 1963, INT REV CYTOL, V15, P245, DOI 10.1016/S0074-7696(08)61119-5; BURSCH W, 1984, CARCINOGENESIS, V5, P453, DOI 10.1093/carcin/5.4.453; CHEN ZY, 1994, CANCER RES, V54, P2622; COLUMBANO A, 1985, LAB INVEST, V52, P670; COLUMBANO A, 1987, CANCER RES, V47, P5557; Columbano A, 1996, CARCINOGENESIS, V17, P395, DOI 10.1093/carcin/17.3.395; COLUMBANO A, 1990, CARCINOGENESIS, V11, P771, DOI 10.1093/carcin/11.5.771; COLUMBANO A, 1981, CANCER RES, V41, P2079; CONI P, 1990, CARCINOGENESIS, V11, P835, DOI 10.1093/carcin/11.5.835; CONI P, 1993, HEPATOLOGY, V17, P1109, DOI 10.1002/hep.1840170626; CORNELL RP, 1985, AM J PHYSIOL, V249, pR563, DOI 10.1152/ajpregu.1985.249.5.R563; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DRAGAN YP, 1994, CARCINOGENESIS, V15, P1451, DOI 10.1093/carcin/15.7.1451; DRAGANI TA, 1986, CANCER LETT, V31, P171, DOI 10.1016/0304-3835(86)90008-X; EVARTS RP, 1995, AM J PATHOL, V147, P699; FARBER E, 1987, LAB INVEST, V56, P4; FARRANTS AKO, 1993, BIOCHIM BIOPHYS ACTA, V1168, P100, DOI 10.1016/0005-2760(93)90272-B; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; FEINGOLD KR, 1991, HEPATOLOGY, V13, P773, DOI 10.1016/0270-9139(91)92578-V; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FRANCAVILLA A, 1994, HEPATOLOGY, V20, P1237, DOI 10.1002/hep.1840200521; FUASTO N, 1994, LIVER BIOL PATHOBIOL, P1059; GERLYNG P, 1994, CARCINOGENESIS, V15, P371, DOI 10.1093/carcin/15.2.371; GOLDSWORTHY TL, 1994, CELL PROLIFERAT, V27, P269, DOI 10.1111/j.1365-2184.1994.tb01424.x; GOYETTE M, 1983, SCIENCE, V219, P510, DOI 10.1126/science.6297003; GRASLKRAUPP B, 1994, P NATL ACAD SCI USA, V91, P9995, DOI 10.1073/pnas.91.21.9995; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; HELVERING LM, 1993, CANCER LETT, V71, P133, DOI 10.1016/0304-3835(93)90108-L; HERBST H, 1991, LAB INVEST, V65, P324; HERTZ R, 1992, BIOCHEM J, V281, P41, DOI 10.1042/bj2810041; Higgins GM, 1931, ARCH PATHOL, V12, P186; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; ISSEMANN I, 1993, BIOCHIMIE, V75, P251, DOI 10.1016/0300-9084(93)90084-6; JAMES SJ, 1994, CANCER RES, V54, P5508; KASPER P, 1995, CARCINOGENESIS, V16, P2309, DOI 10.1093/carcin/16.10.2309; KINOSHITA T, 1991, BIOCHEM BIOPH RES CO, V177, P330, DOI 10.1016/0006-291X(91)91987-N; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; Kubo Y, 1996, HEPATOLOGY, V23, P104, DOI 10.1002/hep.510230115; LABRECQUE D, 1994, AM J GASTROENTEROL, V89, pS86; LEDDACOLUMBANO GM, 1994, AM J PATHOL, V145, P951; LEDDACOLUMBANO GM, 1994, ARCH TOX S, V16, P271; LEDDACOLUMBANO GM, 1991, APOPTOSIS MOL BASIS, P101; LEE SST, 1995, MOL CELL BIOL, V15, P3012; MAHER JJ, 1993, SEMIN LIVER DIS, V13, P13, DOI 10.1055/s-2007-1007334; Mangelsdorf David J., 1994, P319; MASUHARA M, 1992, HEPATOLOGY, V16, P1241, DOI 10.1002/hep.1840160522; MASUHARA M, 1993, CARCINOGENESIS, V14, P1579, DOI 10.1093/carcin/14.8.1579; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; MEALY K, 1991, BRIT J SURG, V78, P331, DOI 10.1002/bjs.1800780320; MELCHIORRI C, 1993, CARCINOGENESIS, V14, P1825, DOI 10.1093/carcin/14.9.1825; MICHALOPOULOS GK, 1990, FASEB J, V4, P240; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NADAL C, 1966, EXP CELL RES, V42, P99, DOI 10.1016/0014-4827(66)90324-7; NADAL C, 1975, VIRCHOWS ARCH B, V18, P273; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Ohmura T, 1996, LIFE SCI, V58, pPL211, DOI 10.1016/0024-3205(96)00039-2; Ohmura T, 1996, AM J PATHOL, V148, P815; PERERA MIR, 1984, CARCINOGENESIS, V5, P1193, DOI 10.1093/carcin/5.9.1193; POUND AW, 1978, BRIT J CANCER, V37, P585, DOI 10.1038/bjc.1978.88; RAO MS, 1987, CARCINOGENESIS, V8, P631; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; RIJHSINGHANI K, 1993, HEPATOLOGY, V17, P685, DOI 10.1002/hep.1840170424; ROBERTS RA, 1995, CARCINOGENESIS, V16, P1693, DOI 10.1093/carcin/16.8.1693; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SATOH M, 1991, Molecular Biotherapy, V3, P136; SATOH M, 1993, J CELL PHYSIOL, V157, P104, DOI 10.1002/jcp.1041570114; SATTERWHITE LL, 1992, J CELL BIOL, V118, P595, DOI 10.1083/jcb.118.3.595; SCEARCE LM, 1996, CELL DEATH DIFFER, V3, P51; Schulte-Hermann R, 1995, Prog Liver Dis, V13, P1; SCHULTEHERMANN R, 1980, CHEM-BIOL INTERACT, V31, P301, DOI 10.1016/0009-2797(80)90018-6; SCHULTEHERMANN R, 1983, ENVIRON HEALTH PERSP, V50, P185, DOI 10.2307/3429549; SELYE H, 1966, J BACTERIOL, V91, P884, DOI 10.1128/JB.91.2.884-890.1966; SHIMAOKA S, 1987, EXP CELL RES, V172, P228, DOI 10.1016/0014-4827(87)90109-1; SHINOZUKA H, 1994, LAB INVEST, V71, P35; SHORT J, 1972, J BIOL CHEM, V247, P1757; STAUBLI W, 1984, CARCINOGENESIS, V5, P41, DOI 10.1093/carcin/5.1.41; TUGWOOD JD, 1992, EMBO J, V11, P432; WEBBER EM, 1993, HEPATOLOGY, V14, P489; WHEATLEY DN, 1972, EXP CELL RES, V74, P445; Wyllie A H, 1980, Int Rev Cytol, V68, P251	88	151	154	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1996	10	10					1118	1128		10.1096/fasebj.10.10.8751714	http://dx.doi.org/10.1096/fasebj.10.10.8751714			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VD429	8751714				2022-12-28	WOS:A1996VD42900003
J	vanBreemen, RB; Huang, CR				vanBreemen, RB; Huang, CR			High-performance liquid chromatography electrospray mass spectrometry of retinoids	FASEB JOURNAL			English	Article						LC-MS; reversed phase (C-30) HPLC; limit of detection	HUMAN PLASMA; SEPARATION; ACITRETIN	High-performance liquid chromatography (HPLC)-electrospray mass spectrometry (LC-MS) was used to analyze vitamin A-active retinoids including retinoic acid, retinol, retinal, and retinyl acetate. Unlike previous LC-MS methods such as negative ion electron capture chemical ionization, no derivatization of retinoic acid was required, HPLC separations were carried out on a C-30 reversed phase column with gradient elution using mobile phases containing water, methanol, and methyl-tert-butyl ether, Ammonium acetate (5 mM) was added to the mobile phase to facilitate ion pair formation during reversed phase HPLC of retinoic acid, and acetic acid (0.5% v/v) was added to the mobile phase to enhance protonation during LC-RIS analysis of nonacidic retinoids, During negative ion electrospray, retinoic acid formed abundant deprotonated molecules, [M-H](-), of m/z 299 without significant fragmentation, Although retinol, retinal, and retinyl acetate did not ionize during negative ion electrospray, the positive ion electrospray mass spectra of these retinoids showed an abundant protonated molecule of m/z 285 for retinal and base peaks of m/z 269 corresponding to elimination of water or acetic acid from the protonated molecules of retinol or retinyl acetate, respectively. No ions from retinoic acid were detected during positive ion electrospray. Limits of detection for retinoic acid, retinal, retinol, and retinyl acetate were 23 pg, 1.0 ng, 0.5 ng, and 10 ng, respectively.			vanBreemen, RB (corresponding author), UNIV ILLINOIS,DEPT MED CHEM & PHARMACOGNOSY,COLL PHARM,833 S WOOD ST,M-C 781,CHICAGO,IL 60612, USA.		van Breemen, Richard/AAO-2875-2020	van Breemen, Richard/0000-0003-2016-0063				COTLER S, 1992, XENOBIOTICA, V22, P1229, DOI 10.3109/00498259209053151; DUFFIN KL, 1992, ANAL CHEM, V64, P61, DOI 10.1021/ac00025a012; FAYER BE, 1991, J CHROMATOGR-BIOMED, V568, P135, DOI 10.1016/0378-4347(91)80347-F; Furr Harold C., 1994, P179; OLSON J, 1994, AMODERN NUTR HUMAN H, P287; RANALDER UB, 1993, J CHROMATOGR-BIOMED, V617, P129, DOI 10.1016/0378-4347(93)80431-3; SALYERS KL, 1993, BIOCHIM BIOPHYS ACTA, V1152, P328, DOI 10.1016/0005-2736(93)90265-2; SANDER LC, 1994, ANAL CHEM, V66, P1667, DOI 10.1021/ac00082a012; Sporn M.B., 1994, RETINOIDS BIOL CHEM; VANBREEMEN RB, 1995, ANAL CHEM, V67, P2004, DOI 10.1021/ac00109a016; WYSS R, 1995, J CHROMATOGR B, V671, P381, DOI 10.1016/0378-4347(95)00154-B	11	36	36	5	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1996	10	9					1098	1101		10.1096/fasebj.10.9.8801173	http://dx.doi.org/10.1096/fasebj.10.9.8801173			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UY932	8801173				2022-12-28	WOS:A1996UY93200022
J	Pistoi, S; Morello, D				Pistoi, S; Morello, D			Liver regeneration .7. Prometheus' myth revisited: Transgenic mice as a powerful tool to study liver regeneration	FASEB JOURNAL			English	Review						growth factors; gene targeting; proto-oncogene; hepatectomy	GROWTH-FACTOR-ALPHA; NULL MUTATION; PARTIAL-HEPATECTOMY; C-FOS; CELL; JUN; DISEASE; GENE; PROTOONCOGENES; APOPTOSIS	In this review, we present examples of the contribution of transgenic mice to our knowledge concerning the type of cells that are able to repopulate a damaged liver and information on the factors and mechanisms involved in postnatal liver growth and regeneration, The transgenic technology offers the opportunity to evaluate the physiological consequences of perturbating expression of a given gene in vivo, It has provided insights into the concerted action of extracellular (HGF/SF, TGF-alpha, EGF, TGF-beta) and intracellular factors (c-myc, c-fos, c-jun, p53, c-met, and others) in Liver regeneration, Transgenic mice can also contribute to the dissection of the molecular mechanisms responsible for the regulated expression of these factors, both at the transcriptional and the posttranscriptional level. An illustration of such a strategy is given by the study of the sequences involved in the posttranscriptional regulation of the c-myc proto-oncogene. The recent improvement of gene targeting, in which endogenous genes are inactivated by homologous recombination, represents a further step toward the study of the function of a particular gene, Inactivation of most of the factors described in this review has been undertaken, However, further studies of their role in liver growth control are impeded by the fact that the corresponding knockout mice die prematurely, This problem could be overcome by the advent of new techniques, which will be briefly presented, aimed at turning genes on and off at will and in a tissue-specific manner.	INST PASTEUR,DEPT IMMUNOL,UNITE BIOL DEV,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								ARBER N, 1988, LIVER, V8, P80; BABINET C, 1989, GENOME, V31, P938, DOI 10.1139/g89-165; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BRALET MP, 1994, AM J PATHOL, V144, P896; BRANDON EP, 1995, CURR BIOL, V5, P873, DOI 10.1016/S0960-9822(95)00177-1; BRANDON EP, 1995, CURR BIOL, V5, P625, DOI 10.1016/S0960-9822(95)00127-8; BRANDON EP, 1995, CURR BIOL, V5, P758, DOI 10.1016/S0960-9822(95)00152-7; BURSCH W, 1992, TRENDS PHARMACOL SCI, V13, P245, DOI 10.1016/0165-6147(92)90077-J; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHEN L, 1994, HEPATOLOGY, V19, P989, DOI 10.1016/0270-9139(94)90300-X; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; FAUSTO N, 1989, LAB INVEST, V60, P4; Fausto Nelson, 1994, P1059; FRANCAVILLA A, 1991, HEPATOLOGY, V14, P665, DOI 10.1016/0270-9139(91)90055-Z; FUJIMARA K, 1994, HEPATOLOGY, V20, P552; FUJIWARA K, 1993, HEPATOLOGY, V18, P1443, DOI 10.1016/0270-9139(93)90237-H; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; GUPTA S, 1994, HUM GENE THER, V5, P959, DOI 10.1089/hum.1994.5.8-959; Gupta Sanjeev, 1994, P1519; Higgins GM, 1931, ARCH PATHOL, V12, P186; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JIRTLE RL, 1991, J BIOL CHEM, V266, P22444; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KENNEDY S, 1995, HEPATOLOGY, V22, P160, DOI 10.1016/0270-9139(95)90369-0; KESAVAN P, 1990, ONCOGENE, V5, P483; KLINMAN NR, 1963, P SOC EXP BIOL MED, V112, P338; KUN R, 1995, SCIENCE, V269, P1427; LAVENU A, 1995, MOL CELL BIOL, V15, P4410; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; LIU ML, 1994, HEPATOLOGY, V19, P1521; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MATSUMOTO K, 1993, HEPATOCYTE GROWTH FA, P224; MEAD JE, 1990, CANCER RES, V50, P7023; Merlino Glenn, 1994, P1579; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MORELLO D, 1993, ONCOGENE, V8, P1921; MORELLO D, 1990, ONCOGENE, V5, P1511; MUGHUL A, 1994, ONCOGENE, V9, P2045; PONDER KP, 1991, P NATL ACAD SCI USA, V88, P1217, DOI 10.1073/pnas.88.4.1217; RHIM JA, 1995, SCIENCE, V92, P4942; ROOS F, 1995, AM J PHYSIOL-GASTR L, V268, pG380, DOI 10.1152/ajpgi.1995.268.2.G380; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; SANDGREN EP, 1991, CELL, V66, P245, DOI 10.1016/0092-8674(91)90615-6; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SANDGREN EP, 1995, LIVER REGENERATION C, P257; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SHIBILIA M, 1995, SCIENCE, V269, P230; SHIOTA G, 1994, HEPATOLOGY, V19, P962, DOI 10.1016/0270-9139(94)90297-6; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SIGAL SH, 1992, AM J PHYSIOL, V263, pG139, DOI 10.1152/ajpgi.1992.263.2.G139; STROMBLAD S, 1993, EXP CELL RES, V204, P321, DOI 10.1006/excr.1993.1039; TAKAGI H, 1992, CANCER RES, V52, P5171; TESSITORE L, 1989, INT J CANCER, V44, P697, DOI 10.1002/ijc.2910440424; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; TREMBLEY JH, 1994, CELL GROWTH DIFFER, V5, P99; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WEBBER EM, 1994, AM J PATHOL, V145, P398; WEBBER EM, 1994, HEPATOLOGY, V19, P489; WIGHT DC, 1994, MUTAT RES, V307, P429, DOI 10.1016/0027-5107(94)90254-2; WOODMAN AC, 1992, J CELL PHYSIOL, V151, P405, DOI 10.1002/jcp.1041510222	68	30	31	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1996	10	8					819	828		10.1096/fasebj.10.8.8666158	http://dx.doi.org/10.1096/fasebj.10.8.8666158			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UQ456	8666158				2022-12-28	WOS:A1996UQ45600003
J	Sato, M; Rippy, MK; Bryant, HU				Sato, M; Rippy, MK; Bryant, HU			Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats	FASEB JOURNAL			English	Article						osteoporosis; uterus; bone; cholesterol; osteoclast	LONG-TERM ESTROGEN; BONE-MINERAL DENSITY; REPLACEMENT THERAPY; BREAST-CANCER; POSTMENOPAUSAL WOMEN; ENDOMETRIAL CARCINOMA; ELDERLY WOMEN; BODY-WEIGHT; FOOD-INTAKE; OSTEOPOROSIS	For the first time, four wen-characterized compounds from four distinct chemical classes were directly compared for efficacy and potency in bone, uteri, lipids, and adipose tissues in an ovariectomized model with 6 month old rats. Five weeks of oral dosing confirmed that ethynyl estradiol, tamoxifen, and raloxifene are potent inhibitors of the loss in volumetric bone mineral density (BMD, mg/cc) induced by ovariectomy, as measured by computed tomography. In the metaphysis of distal femora from ovariectomized rats, analysis showed a significant 12-20% decrease (P < 0.01) in the BMD. Linear regression analysis was used to calculate half-maximal efficacious doses for ethynyl estradiol ED(50) = 0.04 mg/kg, which was threefold more potent than tamoxifen, which in turn was threefold more potent than raloxifene, which was more efficacious than nafoxidine. In the uterus, raloxifene had minimal effects on the endometrium and smaller effects on uterine eosinophil peroxidase activity than nafoxidine, tamoxifen, or estrogen, respectively, Estrogen was the most potent in reducing cholesterol levels in ovariectomized rats, whereas tamoxifen and nafoxidine were more effective than raloxifene in blocking gain in body weight. Distinct compounds had advantages in the management of bone, uterine, serum cholesterol, and adipose tissues after ovariectomy. Tire distinct pattern of pharmacological effects may be best understood in terms of their respective chemical structure, specifically estrogens, benzothiophenes (raloxifene), dihydronapthylenes (nafoxidine), and triphenylethylenes (tamoxifen). These data point to advantages of separate compounds in the management of bone, uterine, serum cholesterol, and adipose tissues after estrogen deficiency, and show that the benzothiophene raloxifene has potentially important advantages over estrogen, tamoxifen, or nafoxidine in the uterus.			Sato, M (corresponding author), ELI LILLY & CO,LILLY CORP CTR,DEPT ENDOCRINE RES,INDIANAPOLIS,IN 46285, USA.							BLACK LJ, 1994, J CLIN INVEST, V93, P63, DOI 10.1172/JCI116985; BLACK LJ, 1983, LIFE SCI, V32, P1031, DOI 10.1016/0024-3205(83)90935-9; BURCH JC, 1974, AM J OBSTET GYNECOL, V118, P778, DOI 10.1016/0002-9378(74)90487-6; CHRISTIANSEN C, 1992, BONE, V13, pS35, DOI 10.1016/S8756-3282(09)80008-2; DEMPSTER DW, 1993, LANCET, V341, P797, DOI 10.1016/0140-6736(93)90570-7; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; DRAPER MW, 1993, 4TH P INT S OST, P119; DUKES M, 1994, J ENDOCRINOL, V141, P335, DOI 10.1677/joe.0.1410335; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; FROST HM, 1992, BONE MINER, V18, P227, DOI 10.1016/0169-6009(92)90809-R; FUCHSYOUNG Y, 1995, 77 ANN M END SOC WAS, P57; GALAND P, 1984, J STEROID BIOCHEM, V21, P43, DOI 10.1016/0022-4731(84)90058-X; GRAY JM, 1981, AM J PHYSIOL, V240, pE474, DOI 10.1152/ajpendo.1981.240.5.E474; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P525, DOI 10.1016/0002-9378(79)90288-6; JORDAN VC, 1980, CANCER TREAT REP, V64, P745; KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169-6009(91)90124-I; KALU DN, 1991, BONE MINER, V14, P175, DOI 10.1016/0169-6009(91)90021-Q; KALU DN, 1991, BONE MINER, V15, P109, DOI 10.1016/0169-6009(91)90002-H; Katzenellenbogen B S, 1979, Recent Prog Horm Res, V35, P259; KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X; LINDSAY R, 1980, LANCET, V2, P1151; LINDSAY R, 1993, LANCET, V341, P801, DOI 10.1016/0140-6736(93)90571-W; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; LOVE RR, 1991, ANN INTERN MED, V115, P860, DOI 10.7326/0003-4819-115-11-860; LYTTLE CR, 1977, P NATL ACAD SCI USA, V74, P3162, DOI 10.1073/pnas.74.8.3162; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MOON LY, 1991, ENDOCRINOLOGY, V129, P1568, DOI 10.1210/endo-129-3-1568; MOORE M, 1990, J BONE MINER RES, V5, P659; QUIGLEY MET, 1987, AM J OBSTET GYNECOL, V156, P1516; SATO M, 1995, J PHARMACOL EXP THER, V272, P1252; SATO M, 1994, J BONE MINER RES, V9, P715; SATO M, 1995, BONE, V17, pS157, DOI 10.1016/8756-3282(95)00288-O; SMITH DC, 1975, NEW ENGL J MED, V293, P1164, DOI 10.1056/NEJM197512042932302; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; SUNDERLAND MC, 1991, J CLIN ONCOL, V9, P1283, DOI 10.1200/JCO.1991.9.7.1283; TURNER RT, 1988, ENDOCRINOLOGY, V122, P1146, DOI 10.1210/endo-122-3-1146; VESEY MP, 1984, J ROY SOC MED, V77, P542; WADE GN, 1993, AM J PHYSIOL, V264, pR1219, DOI 10.1152/ajpregu.1993.264.6.R1219; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; WHITE SR, 1991, J IMMUNOL METHODS, V44, P257; Wronski TJ., 1992, CELLS MAT, V1, P69; ZIEL HK, 1975, NEW ENGL J MED, V293, P1167, DOI 10.1056/NEJM197512042932303	45	236	243	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1996	10	8					905	912		10.1096/fasebj.10.8.8666168	http://dx.doi.org/10.1096/fasebj.10.8.8666168			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UQ456	8666168				2022-12-28	WOS:A1996UQ45600013
J	Sykes, M				Sykes, M			Immunobiology of transplantation	FASEB JOURNAL			English	Article						T cell; tolerance; T cell repertoire; chimerism; anergy; suppression; thymus; bone marrow transplantation	T-CELLS; CLONAL ANERGY; TRANSGENIC MICE; HOST DISEASE; TOLERANCE; INDUCTION; LYMPHOCYTES; SUPPRESSION; MECHANISMS; ALLOGRAFTS	Despite major advances resulting from the development of new immunosuppressive drugs in recent years, the field of clinical transplantation is currently limited by inadequate organ availability, chronic: rejection, and complications of chronic, nonspecific immunosuppressive therapy, Because of the organ shortage, extensive research has recently focused on the potential to use donors from other species, i.e., xenotransplantation, The best way to avoid the problems of chronic rejection and complications of immunosuppressive therapy, and to overcome the considerable immunologic barriers to xenotransplantation, would be to induce a state of systemic tolerance to the donor in the recipient, Recent developments in the understanding of mechanisms of central and peripheral T cell tolerance have led to new strategies for inducing tolerance in experimental models, some of which are already being evaluated clinically.			Sykes, M (corresponding author), HARVARD UNIV, MASSACHUSETTS GEN HOSP,SCH MED, TRANSPLANTAT BIOL RES CTR,MGH E,BLDG 149, 13TH ST, BOSTON, MA 02129 USA.				NATIONAL CANCER INSTITUTE [R01CA064912] Funding Source: NIH RePORTER; NCI NIH HHS [CA64912] Funding Source: Medline; NHLBI NIH HHS [HL49915] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUS DB, 1991, J EXP MED, V173, P1039, DOI 10.1084/jem.173.5.1039; ALFREY EJ, 1995, TRANSPLANTATION, V59, P1171, DOI 10.1097/00007890-199504270-00016; ANTIN JH, 1992, BLOOD, V80, P2964; AUCHINCLOSS H, 1995, XENO, V3, P19; BEVAN MJ, 1995, J EXP MED, V182, P639, DOI 10.1084/jem.182.3.639; BLAKELY ML, 1994, TRANSPLANTATION, V58, P1059, DOI 10.1097/00007890-199411270-00001; BLAZAR BR, 1995, BLOOD, V85, P2607, DOI 10.1182/blood.V85.9.2607.bloodjournal8592607; BURLINGHAM WJ, 1995, TRANSPLANTATION, V59, P1147, DOI 10.1097/00007890-199504270-00013; BYRNE MC, 1993, ANN NY ACAD SCI, V685, P611, DOI 10.1111/j.1749-6632.1993.tb35924.x; CHAHINE AA, 1995, TRANSPLANTATION, V59, P1313, DOI 10.1097/00007890-199505150-00016; CHAN SY, 1995, TRANSPLANTATION, V59, P1155, DOI 10.1097/00007890-199504270-00014; CHARLTON B, 1994, ANNU REV IMMUNOL, V12, P707, DOI 10.1146/annurev.immunol.12.1.707; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; DOODY DP, 1994, J EXP MED, V179, P1645, DOI 10.1084/jem.179.5.1645; DURIE FH, 1994, RES IMMUNOL, V145, P200, DOI 10.1016/S0923-2494(94)80184-3; FOWLER DH, 1994, BLOOD, V84, P3540; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; Gjertson D W, 1991, Clin Transpl, P225; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; KHAN A, IN PRESS TRANSPLANTA; KOBATA T, 1993, BLOOD, V82, P176, DOI 10.1182/blood.V82.1.176.bloodjournal821176; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; LAFFERTY KJ, 1994, CLIN TRANSPLANT, V8, P181; LEE RS, 1994, J EXP MED, V179, P865, DOI 10.1084/jem.179.3.865; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LOMBARDI G, 1994, SCIENCE, V264, P1587, DOI 10.1126/science.8202711; LOWRY RP, 1994, TH1 TH2 PARADIGM TRA; MILLER RG, 1986, IMMUNOL TODAY, V7, P112, DOI 10.1016/0167-5699(86)90151-9; MURRAY AG, 1994, IMMUNITY, V1, P57, DOI 10.1016/1074-7613(94)90009-4; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OLUWOLE SF, 1994, TRANSPLANTATION, V58, P1077, DOI 10.1097/00007890-199411270-00004; PEARCE NW, 1989, J IMMUNOL, V143, P499; PEARSON TC, 1994, TRANSPLANTATION, V57, P1701, DOI 10.1097/00007890-199457120-00002; PLATT JL, 1994, IMMUNOL REV, V141, P127, DOI 10.1111/j.1600-065X.1994.tb00875.x; POSSELT AM, 1990, SCIENCE, V249, P1293, DOI 10.1126/science.2119056; QIN LH, 1995, TRANSPLANTATION, V59, P809, DOI 10.1097/00007890-199503270-00002; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; REMUZZI G, 1994, J EXP MED, V180, P1967, DOI 10.1084/jem.180.5.1967; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; ROLLINS SA, 1994, TRANSPLANTATION, V57, P1709, DOI 10.1097/00007890-199406270-00004; ROSENBERG AS, 1992, ANNU REV IMMUNOL, V10, P333, DOI 10.1146/annurev.immunol.10.1.333; SACHS DH, 1992, SWINE AS MODELS IN BIOMEDICAL RESEARCH, P3; SACHS DH, 1993, EXP NEPHROL, V1, P128; SAYEGH MH, 1995, J EXP MED, V181, P1869, DOI 10.1084/jem.181.5.1869; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHAPIRO R, 1995, TRANSPLANTATION, V59, P306, DOI 10.1097/00007890-199501270-00026; SHOSKES DA, 1994, IMMUNOL TODAY, V15, P32, DOI 10.1016/0167-5699(94)90023-X; SPRENT J, 1994, J EXP MED, V180, P307, DOI 10.1084/jem.180.1.307; STEWART FM, 1993, BLOOD, V81, P2566; SYKES M, 1995, BLOOD, V86, P2429, DOI 10.1182/blood.V86.6.2429.bloodjournal8662429; SYKES M, 1994, IMMUNOL REV, V141, P245, DOI 10.1111/j.1600-065X.1994.tb00880.x; SYKES M, 1995, IMMUNOTHERAPY BONE M, P87; SYKES M, 1994, BONE MARROW TRANSPL, P204; SYKES M, 1996, IN PRESS CLIN TRANSP; SYKES M, 1996, IN PRESS XENOTRANSPL; THIELE DL, 1987, J IMMUNOL, V138, P51; THOMAS JM, 1995, TRANSPLANTATION, V59, P245, DOI 10.1097/00007890-199501270-00017; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TOMITA Y, 1994, BLOOD, V83, P939; TULLIUS SG, 1995, TRANSPLANTATION, V59, P313, DOI 10.1097/00007890-199502150-00001; VERBANAC KKM, 1994, TRANSPLANTATION, V57, P893, DOI 10.1097/00007890-199403270-00022; Wood K J, 1990, Semin Immunol, V2, P389; WREN SM, 1993, TRANSPLANTATION, V56, P905, DOI 10.1097/00007890-199310000-00025; ZHENG XX, 1995, J IMMUNOL, V154, P5590	69	30	35	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1996	10	7					721	730		10.1096/fasebj.10.7.8635689	http://dx.doi.org/10.1096/fasebj.10.7.8635689			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UN798	8635689				2022-12-28	WOS:A1996UN79800006
J	Macara, IG; Lounsbury, KM; Richards, SA; McKiernan, C; BarSagi, D				Macara, IG; Lounsbury, KM; Richards, SA; McKiernan, C; BarSagi, D			The Ras superfamily of GTPases	FASEB JOURNAL			English	Review						cytoskeleton; secretion; signal transduction; GTP binding proteins; nuclear transport	PROTEINS	The Ras superfamily of small GTPases comprises a group of molecular switches that regulate an astonishing diversity of cellular functions, A deep understanding of mitogenesis, cytoskeletal organization, vesicle traffic, and nuclear transport now requires the inclusion of the small GTPases as essential components of the molecular machines that drive these processes, The rich complexity of the control mechanisms involved is evidenced by the recent discoveries of GTPase cascades, multiple downstream effecters, and interconnected networks of GTPase-regulated protein kinase cascades, The 1995 FASEB Summer Conference at Snowmass Village, Colorado, on the Ras GTPase superfamily provided testimony to the broad impact that the study of these proteins continues to exert on cell biology.	SUNY STONY BROOK, DEPT MOLEC GENET & MICROBIOL, NEW YORK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Macara, IG (corresponding author), UNIV VERMONT, DEPT PATHOL, MED ALUMNI BLDG, BURLINGTON, VT 05405 USA.			Bar-Sagi, Dafna/0000-0003-2597-8948				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BEDDOW AL, 1995, P NATL ACAD SCI USA, V92, P3328, DOI 10.1073/pnas.92.8.3328; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lounsbury KM, 1996, J BIOL CHEM, V271, P2357, DOI 10.1074/jbc.271.5.2357; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; SODATI T, 1994, NATURE, V369, P76; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	45	198	202	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1996	10	5					625	630		10.1096/fasebj.10.5.8621061	http://dx.doi.org/10.1096/fasebj.10.5.8621061			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UJ055	8621061				2022-12-28	WOS:A1996UJ05500010
J	Mano, H; Yamashita, Y; Miyazato, A; Miura, Y; Ozawa, K				Mano, H; Yamashita, Y; Miyazato, A; Miura, Y; Ozawa, K			Tec protein-tyrosine kinase is an effector molecule of Lyn protein-tyrosine kinase	FASEB JOURNAL			English	Article						Src homology-3 domain; Tec homology domain	X-LINKED AGAMMAGLOBULINEMIA; HEMATOPOIETIC-CELLS; GENE; EXPRESSION; P60C-SRC; YEAST; SITE; SRC	The Tec family is a recently emerging subfamily among nonreceptor type protein-tyrosine kinases (PTKs) consisting of Tee, Txk, Btk, Bmx, and Itk/Tsk/Emt. They have a long amino-terminal unique region containing a pleckstrin homology domain and a Tec-homology domain, We could previously show that, through the Tec-homology domain, Tee is bound to Lyn kinase both in vitro and in vivo. Because Tec is coexpressed with Lyn in many hematopoietic cell types, it has been intriguing to investigate the biological role of the Tec-Lyn association, Here we demonstrate that Lyn can phosphorylate tyrosine residues of the Tee protein, and thereby activate Tec in 3T3 fibroblasts, However, coexpression of Tec has little effect on the phosphotyrosine-contents of Lyn. By using the in vitro kinase assay and the yeast system, we could prove that the Tec protein is a direct substrate of the Lyn kinase both in vitro and in vivo, From this evidence we conclude that Tec acts downstream of Lyn in intracellular signaling pathways, This is a novel case where one PTK is phosphorylated and regulated by another.	JICHI MED SCH,DEPT HEMATOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN	Jichi Medical University	Mano, H (corresponding author), JICHI MED SCH,DEPT MOLEC BIOL,YAKUSHIJI 3311-1,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.							BOLEN JB, 1993, ONCOGENE, V8, P2025; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COOPER JA, 1987, ONCOGENE RES, V1, P297; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Harlow E., 1988, ANTIBODIES LAB MANUA; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACHIDE M, 1995, ONCOGENE, V11, P619; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1995, BLOOD, V85, P343; MANO H, 1994, ONCOGENE, V9, P3205; MANO H, 1993, ONCOGENE, V8, P417; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SOMMERS CL, 1995, ONCOGENE, V11, P245; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404	31	44	51	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1996	10	5					637	642		10.1096/fasebj.10.5.8621063	http://dx.doi.org/10.1096/fasebj.10.5.8621063			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UJ055	8621063				2022-12-28	WOS:A1996UJ05500012
J	Armstrong, GA; Hearst, JE				Armstrong, GA; Hearst, JE			Carotenoids .2. Genetics and molecular biology of carotenoid pigment biosynthesis	FASEB JOURNAL			English	Review						phytoene; lycopene cyclization; cyclic xanthophylls; xanthophyll glycosides; beta-carotene; provitamin A	GERANYLGERANYL PYROPHOSPHATE SYNTHASE; ERWINIA-HERBICOLA; NEUROSPORA-CRASSA; ESCHERICHIA-COLI; RHODOBACTER-CAPSULATUS; PHYTOENE DESATURASE; NUCLEOTIDE-SEQUENCE; BETA-CAROTENE; ZETA-CAROTENE; CLONING	The crucial roles of carotenoids and their metabolites in photooxidative protection and photosynthesis, not to mention nutrition, vision, and cellular differentiation, make them an important and complex class of biological pigments, Significant advances within the last few years have enhanced our understanding of the genetics and molecular biology of carotenoid biosynthesis in bacteria, fungi, algae, and plants, All of the genes involved in carotenoid biosynthesis from Rhodobacter capsulatus, an anoxygenic photosynthetic bacterium, and from several species of Erwinia, nonphotosynthetic bacteria, have been molecularly characterized, Recent studies have revealed that two early enzymes of carotenoid biosynthesis, geranylgeranyl pyrophosphate synthase and phytoene synthase, are structurally and functionally related in all carotenogenic organisms, In contrast, the subsequent conversion of phytoene, the first C-40 carotenoid, to beta-carotene requires two desaturases and one cyclase in oxygenic photosynthetic organisms (cyanobacteria, algae, and higher plants) but only one structurally distinct desaturase and a structurally distinct cyclase in other carotenogenic bacteria and in fungi, Studies of the enzymes that introduce oxygen-containing functional groups into carotenes to produce xanthophylls, the vast majority of all carotenoids, are still in their infancy, This review summarizes the most recent developments in carotenoid biosynthesis from a molecular genetic standpoint.	LAWRENCE BERKELEY LAB,STRUCT BIOL DIV,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Armstrong, GA (corresponding author), ETH ZURICH,INST PLANT SCI,CH-8092 ZURICH,SWITZERLAND.							ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; ARMSTRONG GA, 1994, J BACTERIOL, V176, P4795, DOI 10.1128/jb.176.16.4795-4802.1994; ARMSTRONG GA, 1990, P NATL ACAD SCI USA, V87, P9975, DOI 10.1073/pnas.87.24.9975; ARMSTRONG GA, 1993, METHOD ENZYMOL, V214, P297; ARMSTRONG GA, 1995, ADV PHOTOSYNTH, V2, P1135; BADILLO A, 1995, PLANT MOL BIOL, V27, P425, DOI 10.1007/BF00020196; BARTLEY GE, 1994, ANNU REV PLANT PHYS, V45, P287, DOI 10.1146/annurev.pp.45.060194.001443; BARTLEY GE, 1992, J BIOL CHEM, V267, P5036; BARTLEY GE, 1991, P NATL ACAD SCI USA, V88, P6532, DOI 10.1073/pnas.88.15.6532; BARTLEY GE, 1990, J BIOL CHEM, V265, P16020; BENAMOTZ A, 1988, PLANT PHYSIOL, V86, P1286, DOI 10.1104/pp.86.4.1286; BIRD CR, 1991, BIO-TECHNOL, V9, P635, DOI 10.1038/nbt0791-635; BOUVIER F, 1994, PLANT J, V6, P45, DOI 10.1046/j.1365-313X.1994.6010045.x; BRAMLEY PM, 1988, CURR TOP CELL REGUL, V29, P291; Britton G., 1988, Plant pigments., P133; BUCKNER B, 1990, PLANT CELL, V2, P867, DOI 10.1105/tpc.2.9.867; Cerda-Olmedo E., 1989, BIOTECHNOLOGY VITAMI, P27; CHAMOVITZ D, 1991, PLANT MOL BIOL, V16, P9647; CHEN AJ, 1994, ARCH BIOCHEM BIOPHYS, V314, P399, DOI 10.1006/abbi.1994.1459; CHEN AJ, 1994, PROTEIN SCI, V3, P600; COGDELL RJ, 1993, METHOD ENZYMOL, V214, P185; CUNNINGHAM FX, 1994, PLANT CELL, V6, P1107, DOI 10.1105/tpc.6.8.1107; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; DOGBO O, 1988, P NATL ACAD SCI USA, V85, P7054, DOI 10.1073/pnas.85.19.7054; EHRENSHAFT M, 1994, APPL ENVIRON MICROB, V60, P2766, DOI 10.1128/AEM.60.8.2766-2771.1994; FRASER PD, 1992, J BIOL CHEM, V267, P19891; GARI E, 1992, FEMS MICROBIOL LETT, V93, P103, DOI 10.1016/0378-1097(92)90497-C; GOODWIN TW, 1980, BIOCH CAROTENOIDS, V1, P1; Hodgson D, 1993, MYXOBACTERIA, VII, P157; HOUSSAINIIRAQUI M, 1993, CURR MICROBIOL, V27, P317, DOI 10.1007/BF01568954; HUGUENEY P, 1992, EUR J BIOCHEM, V209, P399, DOI 10.1111/j.1432-1033.1992.tb17302.x; HUNDLE B, 1994, MOL GEN GENET, V245, P406, DOI 10.1007/BF00302252; HUNDLE BS, 1993, FEBS LETT, V315, P329, DOI 10.1016/0014-5793(93)81188-6; HUNDLE BS, 1992, P NATL ACAD SCI USA, V89, P9321, DOI 10.1073/pnas.89.19.9321; HUNDLE BS, 1991, PHOTOCHEM PHOTOBIOL, V54, P89, DOI 10.1111/j.1751-1097.1991.tb01989.x; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; KUNTZ M, 1992, PLANT J, V2, P25; LANG HP, 1994, J BACTERIOL, V176, P3859, DOI 10.1128/JB.176.13.3859-3869.1994; LINDEN H, 1994, PLANT MOL BIOL, V24, P369, DOI 10.1007/BF00020174; LOTAN T, 1995, FEBS LETT, V364, P125, DOI 10.1016/0014-5793(95)00368-J; MAITS B, 1981, J BACTERIOL, V146, P1003; MATH SK, 1992, P NATL ACAD SCI USA, V89, P6761, DOI 10.1073/pnas.89.15.6761; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; MISAWA N, 1995, BIOCHEM BIOPH RES CO, V209, P867, DOI 10.1006/bbrc.1995.1579; MISAWA N, 1990, J BACTERIOL, V172, P6704, DOI 10.1128/jb.172.12.6704-6712.1990; OHNUMA S, 1994, J BIOL CHEM, V269, P14792; OLSON JA, 1993, ANN NY ACAD SCI, V691, P156, DOI 10.1111/j.1749-6632.1993.tb26167.x; OLSON JA, 1993, J NUTR SCI VITAMINOL, V39, pS57, DOI 10.3177/jnsv.39.Supplement_S57; PECKER I, 1992, P NATL ACAD SCI USA, V89, P4962, DOI 10.1073/pnas.89.11.4962; PERRY KL, 1986, J BACTERIOL, V168, P607, DOI 10.1128/jb.168.2.607-612.1986; QUINNOES MA, 1994, SCIENCE, V26, P558; RAY J, 1987, NUCLEIC ACIDS RES, V15, P10587, DOI 10.1093/nar/15.24.10587; ROCK CD, 1991, P NATL ACAD SCI USA, V88, P7496, DOI 10.1073/pnas.88.17.7496; RUIZVAZQUEZ R, 1993, MOL MICROBIOL, V10, P25, DOI 10.1111/j.1365-2958.1993.tb00900.x; SANDMANN G, 1993, J PHOTOCH PHOTOBIO B, V18, P245, DOI 10.1016/1011-1344(93)80071-G; SCHMIDHAUSER TJ, 1994, J BIOL CHEM, V269, P12060; SCHMIDHAUSER TJ, 1990, MOL CELL BIOL, V10, P5064, DOI 10.1128/MCB.10.10.5064; STRAUB O, 1987, KEY CAROTENOIDS, P11; TABATA K, 1994, FEBS LETT, V341, P251, DOI 10.1016/0014-5793(94)80466-4; TAYLOR RF, 1984, MICROBIOL REV, V48, P181, DOI 10.1128/MMBR.48.3.181-198.1984; TO KY, 1994, J GEN MICROBIOL, V140, P331; Tswett M., 1911, BER DEUT BOT GES, V29, P630; WIELAND B, 1994, J BACTERIOL, V176, P7719, DOI 10.1128/JB.176.24.7719-7726.1994; [No title captured]	64	233	250	3	44	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1996	10	2					228	237		10.1096/fasebj.10.2.8641556	http://dx.doi.org/10.1096/fasebj.10.2.8641556			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TY962	8641556				2022-12-28	WOS:A1996TY96200007
J	Sauer, RT; Milla, ME; Waldburger, CD; Brown, BM; Schildbach, JF				Sauer, RT; Milla, ME; Waldburger, CD; Brown, BM; Schildbach, JF			Sequence determinants of folding and stability for the P22 Arc repressor dimer	FASEB JOURNAL			English	Review						side chain information; hydrophobic core; transition state; buried polar interactions; combinatorial mutagenesis	DISSOCIATION; EQUILIBRIUM; PRESSURE; DNA	The Arc repressor is a small, homodimeric protein, Studies of mutant proteins show that the side chains that form the hydrophobic core are the most important determinants of structure, A variety of hydrogen bonds and salt bridges also contribute to stabilization of the native structure, but these can often be replaced by hydrophobic interactions, The transition state for folding/unfolding is dimeric and contains a large amount of buried hydrophobic surface, but the beta-sheet of native Arc is not formed, Moreover, relatively little side chain information appears to be used in the transition state, suggesting that tight packing of the hydrophobic core and optimization of hydrogen-bond geometry are events that occur later in folding.			Sauer, RT (corresponding author), MIT,DEPT BIOL,77 MASSACHUSETTS AVE,68-571,CAMBRIDGE,MA 02139, USA.			Sauer, Robert/0000-0002-1719-5399; Schildbach, Joel/0000-0002-3038-9745	NIAID NIH HHS [AI-15706] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015706, R01AI015706] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BONVIN AMJJ, 1994, J MOL BIOL, V236, P328, DOI 10.1006/jmbi.1994.1138; BOWIE JU, 1989, P NATL ACAD SCI USA, V86, P2152, DOI 10.1073/pnas.86.7.2152; BOWIE JU, 1989, BIOCHEMISTRY-US, V28, P7139, DOI 10.1021/bi00444a001; BREG JN, 1990, NATURE, V346, P586, DOI 10.1038/346586a0; BURGERING MJM, 1995, BIOPOLYMERS, V35, P217, DOI 10.1002/bip.360350210; FERSHT AR, 1994, P NATL ACAD SCI USA, V91, P10426, DOI 10.1073/pnas.91.22.10426; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P964; MILLA ME, 1994, NAT STRUCT BIOL, V1, P518, DOI 10.1038/nsb0894-518; MILLA ME, 1995, BIOCHEMISTRY-US, V34, P3344, DOI 10.1021/bi00010a025; MILLA ME, 1994, BIOCHEMISTRY-US, V33, P1125, DOI 10.1021/bi00171a011; MILLA ME, 1995, BIOCHEMISTRY-US, V34, P1394; PENG XD, 1993, P NATL ACAD SCI USA, V90, P1776, DOI 10.1073/pnas.90.5.1776; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; SCHILDBACH JF, 1995, BIOCHEMISTRY-US, V34, P1405, DOI 10.1021/bi00004a035; SILVA JL, 1992, J MOL BIOL, V223, P545, DOI 10.1016/0022-2836(92)90669-B; SUSSKIND MM, 1983, LAMBDA, V2, P347; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; VERSHON A K, 1986, Proteins Structure Function and Genetics, V1, P302, DOI 10.1002/prot.340010404; VERSHON AK, 1987, J MOL BIOL, V195, P323, DOI 10.1016/0022-2836(87)90653-X; WALDBURGER CD, 1995, NAT STRUCT BIOL, V2, P122, DOI 10.1038/nsb0295-122	21	41	41	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1996	10	1					42	48		10.1096/fasebj.10.1.8566546	http://dx.doi.org/10.1096/fasebj.10.1.8566546			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566546				2022-12-28	WOS:A1996TR32800007
J	MAYER, RJ; MARSHALL, LA				MAYER, RJ; MARSHALL, LA			NEW INSIGHTS ON MAMMALIAN PHOSPHOLIPASE-A2(S) - COMPARISON OF ARACHIDONOYL-SELECTIVE AND ARACHIDONOYL-NONSELECTIVE ENZYMES	FASEB JOURNAL			English	Review						TYPE-II 14-KDA PHOSPHOLIPASE-A2; 85-KDA PHOSPHOLIPASE-A2; EICOSANOIDS; ARACHIDONIC ACID; LIPID METABOLISM	GROUP-II PHOSPHOLIPASE-A2; HUMAN SYNOVIAL-FLUID; CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; CALCIUM-INDEPENDENT PHOSPHOLIPASE-A2; HYDROLYZING PHOSPHOLIPASE-A2; RHEUMATOID-ARTHRITIS; EXTRACELLULAR PHOSPHOLIPASE-A2; INFLAMMATORY RESPONSE; MEMBRANE ASSOCIATION; GENE-EXPRESSION	With the recent discoveries of novel forms of phospholipases A2 (PLA2s),2 new schemes for the roles of various PLA2s in lipid metabolism must be considered. The type II 14-kDa PLA2 isolated from human synovial fluid or platelet has many of the biochemical characteristics of the homologous snake venom and mammalian pancreatic PLA2s. It appears to function both as a cell-associated enzyme and extracellularly, where its expression and/or release is regulated by a variety of mediators such as cytokines or growth factors. The mammalian 85-kDa PLA2 purified from monocytic cells or platelets has no sequence homology to the 14-kDa PLA2 and exhibits biochemically different characteristics. It translocates from cytosol to particulate cell fractions in the presence of submicromolar levels of Ca2+ and has a substrate preference for sn-2-arachidonoyl-containing phospholipids. The cellular function and relative importance of these two enzymes in lipid metabolism remain to be determined. In this review, the biochemistry, localization, function, and regulation of these two distinct mammalian Ca2+-dependent PLA2 are compared.	SMITHKLINE BEECHAM PHARMACEUT, DEPT PHARMACOL, 709 SWEDELAND RD, KING OF PRUSSIA, PA 19406 USA	GlaxoSmithKline								ANDO M, 1992, BIOCHEM BIOPH RES CO, V183, P708, DOI 10.1016/0006-291X(92)90540-2; AXELROD J, 1990, BIOCHEM SOC T, V18, P503, DOI 10.1042/bst0180503; BALSINDE J, 1988, J BIOL CHEM, V263, P1929; BOMALASKI JS, 1991, J IMMUNOL, V146, P3904; BOMALASKI JS, 1990, J LAB CLIN MED, V116, P814; BUHL WJ, 1991, EUR J CELL BIOL, V56, P381; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CLARK MA, 1991, P NATL ACAD SCI USA, V88, P5418, DOI 10.1073/pnas.88.12.5418; CLARK MA, 1987, J BIOL CHEM, V262, P4402; COCKCROFT S, 1991, BIOCHEM SOC T, V19, P333, DOI 10.1042/bst0190333; CROWL RM, 1991, J BIOL CHEM, V266, P2647; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DIEZ E, 1992, J BIOL CHEM, V267, P18342; DIEZ E, 1990, J BIOL CHEM, V265, P14654; DUVAL D, 1992, PROSTAG LEUKOTR ESS, V45, P85, DOI 10.1016/0952-3278(92)90225-8; FAWZY AA, 1987, INFLAMMATION, V11, P389, DOI 10.1007/BF00915983; FORST S, 1987, BIOCHIM BIOPHYS ACTA, V920, P221, DOI 10.1016/0005-2760(87)90098-1; FUJIMORI Y, 1992, J BIOCHEM-TOKYO, V111, P54, DOI 10.1093/oxfordjournals.jbchem.a123718; GALBRAITH W, 1989, AGENTS ACTIONS, V27, P422, DOI 10.1007/BF01972840; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GREEN JA, 1991, INFLAMMATION, V15, P355, DOI 10.1007/BF00917352; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; HARA S, 1989, J BIOCHEM-TOKYO, V105, P395, DOI 10.1093/oxfordjournals.jbchem.a122675; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HAZEN SL, 1991, J BIOL CHEM, V266, P5629; HAZEN SL, 1992, CIRC RES, V70, P486, DOI 10.1161/01.RES.70.3.486; JAIN MK, 1989, BIOCHEMISTRY-US, V28, P4135, DOI 10.1021/bi00436a002; KORTESUO PT, 1991, BIOCHEM J, V278, P263, DOI 10.1042/bj2780263; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KRAUSE H, 1991, EUR J BIOCHEM, V199, P355, DOI 10.1111/j.1432-1033.1991.tb16131.x; LANNI C, 1983, AM J PATHOL, V113, P90; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; MARSHALL LA, 1992, BIOCHEM PHARMACOL, V44, P1849, DOI 10.1016/0006-2952(92)90081-S; MARSHALL LA, 1991, J RHEUMATOL, V18, P59; MARSHALL LA, 1991, AGENTS ACTIONS, V34, P106, DOI 10.1007/BF01993251; MEERS P, 1991, BIOCHEMISTRY-US, V30, P2903, DOI 10.1021/bi00225a025; MOBILIO D, 1989, ANNU REP MED CHEM, V24, P157; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; MURAKAMI M, 1992, J BIOCHEM-TOKYO, V111, P175, DOI 10.1093/oxfordjournals.jbchem.a123733; MURAKAMI M, 1990, FEBS LETT, V268, P113, DOI 10.1016/0014-5793(90)80986-S; NAKANO T, 1990, J BIOL CHEM, V265, P12745; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; NARASIMHAN V, 1990, J BIOL CHEM, V265, P1459; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OGAWA M, 1992, RES COMMUN CHEM PATH, V75, P109; OKA S, 1991, J BIOL CHEM, V266, P9956; PERNAS P, 1991, BIOCHEM BIOPH RES CO, V178, P1298, DOI 10.1016/0006-291X(91)91035-B; PIERIK AJ, 1988, BIOCHIM BIOPHYS ACTA, V962, P345, DOI 10.1016/0005-2760(88)90264-0; POTTS BCM, 1992, J AM CHEM SOC, V114, P5093, DOI 10.1021/ja00039a021; PRUZANSKI W, 1991, IMMUNOL TODAY, V12, P143, DOI 10.1016/0167-5699(91)90077-7; RAMIREZ F, 1991, PROTEINS, V9, P229, DOI 10.1002/prot.340090402; RECKLIES AD, 1991, ARTHRITIS RHEUM, V34, P1106, DOI 10.1002/art.1780340906; REHFELDT W, 1991, BIOCHEM J, V276, P631, DOI 10.1042/bj2760631; RODORF G, 1991, J NEUROSCI, V11, P1829; ROSS MI, 1985, ARCH BIOCHEM BIOPHYS, V238, P247, DOI 10.1016/0003-9861(85)90162-6; SAKATA T, 1989, BIOCHIM BIOPHYS ACTA, V1007, P124, DOI 10.1016/0167-4781(89)90141-3; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SHARP JD, 1991, J BIOL CHEM, V266, P14850; STASI M, 1992, BIOCHIM BIOPHYS ACTA, V1124, P279, DOI 10.1016/0005-2760(92)90140-Q; STEINER MR, 1991, J CELL BIOL, V115, P1445; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X; VADAS P, 1985, LIFE SCI, V36, P579, DOI 10.1016/0024-3205(85)90640-X; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N; WILKERSON W, 1991, EUR J MED CHEM, V26, P667, DOI 10.1016/0223-5234(91)90116-5; YU L, 1990, J BIOL CHEM, V265, P2657; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	76	498	502	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB 1	1993	7	2					339	348		10.1096/fasebj.7.2.8440410	http://dx.doi.org/10.1096/fasebj.7.2.8440410			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KN885	8440410	Bronze			2022-12-28	WOS:A1993KN88500009
